PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zhang, L; Wang, P; Qin, Y; Cong, Q; Shao, C; Du, Z; Ni, X; Li, P; Ding, K				Zhang, L.; Wang, P.; Qin, Y.; Cong, Q.; Shao, C.; Du, Z.; Ni, X.; Li, P.; Ding, K.			RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-2; CLINICOPATHOLOGICAL SIGNIFICANCE; ACTIVATOR PROTEIN-1; FACTOR RECEPTOR; EXPRESSION; TRANSDUCTION; ANGIOGENESIS; METASTASIS; APOPTOSIS; GCS-100	Galectin-3 (Gal-3) has been implicated in pancreatic ductal adenocarcinoma (PDAC), and its candidacy as a therapeutic target has been evaluated. Gal-3 is widely upregulated in tumors, and its expression is associated with the development and malignancy of PDAC. In the present study, we demonstrate that a polysaccharide, RN1, purified from the flower of Panax notoginseng binds to Gal-3 and suppresses its expression. In addition, RN1 markedly inhibits PDAC cells growth in vitro, in vivo and in patient-derived xenografts. Mechanistically, RN1 binds to epidermal growth factor receptor (EGFR) and Gal-3, thereby disrupting the interaction between Gal-3 and EGFR and downregulating extracellular-related kinase (ERK) phosphorylation and the transcription factor of Gal-3, Runx1 expression. Inhibiting the expression of Runx1 by RN1, suppresses Gal-3 expression and inactivates Gal-3-associated signaling pathways, including the EGFR/ERK/Runx1, BMP/smad/Id-3 and integrin/FAK/JNK signaling pathways. In addition, RN1 can also bind to bone morphogenetic protein receptors (BMPR1A and BMPR2) and block the interaction between Gal-3 and the BMPRs. Thus, our results suggest that a novel Gal-3 inhibitor RN1 may be a potential candidate for human PDAC treatment via multiple targets and multiple signaling pathways.	[Zhang, L.; Wang, P.; Qin, Y.; Cong, Q.; Du, Z.; Ni, X.; Ding, K.] Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China; [Zhang, L.; Li, P.] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjia Lane, Nanjing 210009, Jiangsu, Peoples R China; [Shao, C.] Second Mil Med Univ, Changzheng Hosp, Dept Gen Surg, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; China Pharmaceutical University; Naval Medical University	Ding, K (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.; Li, P (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjia Lane, Nanjing 210009, Jiangsu, Peoples R China.	liping2004@126.com; dingkan@simm.ac.cn	Li, Ping/GYV-4914-2022	Cong, Qifei/0000-0002-4446-7222; Ding, Kan/0000-0002-8140-9259	National Natural Science Foundation of China [31230022]; New Drug Creation and Manufacturing Program [2012ZX09301001-003]; National Science Foundation of China [81421005]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010302]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Drug Creation and Manufacturing Program; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from National Natural Science Foundation of China (31230022), New Drug Creation and Manufacturing Program (2012ZX09301001-003), Innovative Research Groups of the National Science Foundation of China (81421005), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010302).	Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Blanchard H, 2014, EXPERT OPIN THER PAT, V24, DOI 10.1517/13543776.2014.947961; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chauhan D, 2005, CANCER RES, V65, P8350, DOI 10.1158/0008-5472.CAN-05-0163; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Di Lella S, 2011, BIOCHEMISTRY-US, V50, P7842, DOI 10.1021/bi201121m; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Iurisci I, 2000, CLIN CANCER RES, V6, P1389; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kobayashi T, 2011, INT J CANCER, V129, P2775, DOI 10.1002/ijc.25946; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Merlin J, 2011, ONCOGENE, V30, P2514, DOI 10.1038/onc.2010.631; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nangia-Makker P, 2002, JNCI-J NATL CANCER I, V94, P1854, DOI 10.1093/jnci/94.24.1854; Ochieng J, 2002, GLYCOCONJUGATE J, V19, P527, DOI 10.1023/B:GLYC.0000014082.99675.2f; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Shimamura T, 2002, CLIN CANCER RES, V8, P2570; Shin S, 2009, MOL CANCER RES, V7, P745, DOI 10.1158/1541-7786.MCR-08-0462; Sorme P, 2005, J AM CHEM SOC, V127, P1737, DOI 10.1021/ja043475p; Stegmayr J, 2016, J BIOL CHEM, V291, P13318, DOI 10.1074/jbc.M116.721464; Streetly MJ, 2010, BLOOD, V115, P3939, DOI 10.1182/blood-2009-10-251660; Tellez-Sanz R, 2013, CURR MED CHEM, V20, P2979, DOI 10.2174/09298673113209990163; Tobita K, 2003, INT J MOL MED, V11, P305; Uegaki K, 1997, ANTICANCER RES, V17, P3841; Wang PP, 2015, CARBOHYD POLYM, V121, P328, DOI 10.1016/j.carbpol.2014.11.073; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; YAMANAKA Y, 1993, ANTICANCER RES, V13, P565; Zhang HY, 2009, ENDOCRINE, V35, P101, DOI 10.1007/s12020-008-9129-z	44	45	46	5	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1297	1308		10.1038/onc.2016.306	http://dx.doi.org/10.1038/onc.2016.306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27617577				2023-01-03	WOS:000395861300013
J	Dzau, VJ; Ginsburg, GS				Dzau, Victor J.; Ginsburg, Geoffrey S.			Realizing the Full Potential of Precision Medicine in Health and Health Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERSONALIZED MEDICINE; PROMISE		[Dzau, Victor J.] Natl Acad Med, 500 Fifth St NW, Washington, DC 20001 USA; [Ginsburg, Geoffrey S.] Duke Univ, Durham, NC USA	National Academies of Sciences, Engineering & Medicine; Duke University	Dzau, VJ (corresponding author), Natl Acad Med, 500 Fifth St NW, Washington, DC 20001 USA.; Ginsburg, GS (corresponding author), Duke Ctr Appl Genom & Precis Med, 101 Sci Dr,Box 3382, Durham, NC 27708 USA.	vdzau@nas.edu; geoffrey.ginsburg@duke.edu						Aspinall MG, 2007, HARVARD BUS REV, V85, P108; Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Dzau VJ, 2015, LANCET, V385, P2118, DOI 10.1016/S0140-6736(15)60722-X; Ginsburg G, 2014, NATURE, V508, P451, DOI 10.1038/508451a	4	57	58	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2016	316	16					1659	1660		10.1001/jama.2016.14117	http://dx.doi.org/10.1001/jama.2016.14117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ8GB	27669484				2023-01-03	WOS:000386107800022
J	Green, AK; Wood, WA; Basch, EM				Green, Angela K.; Wood, William A.; Basch, Ethan M.			Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Green, Angela K.; Wood, William A.; Basch, Ethan M.] Univ N Carolina, Canc Outcomes Res Program, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill	Basch, EM (corresponding author), Univ N Carolina, Canc Outcomes Res Program, 170 Manning Dr,CB 7305, Chapel Hill, NC 27599 USA.	ebasch@med.unc.edu						Abernethy AP, 2009, ANN INTERN MED, V150, P336, DOI 10.7326/0003-4819-150-5-200903030-00107; [Anonymous], 2015, ERL AM HOSP FORM SER; [Anonymous], 2015, ERL HYDR; Conti RM, 2013, J CLIN ONCOL, V31, P1134, DOI 10.1200/JCO.2012.42.7252; Gold Standard, 2015, ERL HYDR CLIN PHARM; Institute of Medicine, 2011, CLIN PRACTICE GUIDEL; McKinney R, 2009, 290200710066I HHSA A; Micromedex, 2015, DRUGDEX ERL TRUV HLT; Mitchell AP, 2016, JAMA ONCOL, V2, P1628, DOI 10.1001/jamaoncol.2016.2710	9	16	17	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2016	316	15					1541	1542		10.1001/jama.2016.12770	http://dx.doi.org/10.1001/jama.2016.12770			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ0KM	27561002				2023-01-03	WOS:000385527600011
J	Zhang, L; Huang, Y; Hong, SD; Yang, YP; Yu, GS; Jia, J; Peng, PJ; Wu, X; Lin, Q; Xi, XP; Peng, JW; Xu, MJ; Chen, DP; Lu, XJ; Wang, RS; Cao, XL; Chen, XZ; Lin, ZX; Xiong, JP; Lin, Q; Xie, CH; Li, ZH; Pan, JJ; Li, JG; Wu, SX; Lian, YN; Yang, QL; Zhao, C				Zhang, Li; Huang, Yan; Hong, Shaodong; Yang, Yunpeng; Yu, Gengsheng; Jia, Jun; Peng, Peijian; Wu, Xuan; Lin, Qing; Xi, Xuping; Peng, Jiewen; Xu, Mingjun; Chen, Dongping; Lu, Xiaojun; Wang, Rensheng; Cao, Xiaolong; Chen, Xiaozhong; Lin, Zhixiong; Xiong, Jianping; Lin, Qin; Xie, Conghua; Li, Zhihua; Pan, Jianji; Li, Jingao; Wu, Shixiu; Lian, Yingni; Yang, Quanlie; Zhao, Chong			Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial	LANCET			English	Article							DISTANT METASTASIS; CHEMOTHERAPY; RADIOTHERAPY; VINORELBINE; MANAGEMENT; PATTERNS; SURVIVAL; REGIMENS	Background Outcomes are poor for patients with recurrent or metastatic nasopharyngeal carcinoma and no well established first-line chemotherapy is available for the disease. We compared the efficacy and safety of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Methods In this multicentre, randomised, open-label, phase 3 trial, patients with recurrent or metastatic nasopharyngeal carcinoma were recruited from 22 hospitals in China. Key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ function, and measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1. Patients were randomly assigned in a 1: 1 ratio to receive either gemcitabine (1 g/m(2) intravenously on days 1 and 8) and cisplatin (80 mg/m(2) intravenously on day 1), or fluorouracil (4 g/m(2) in continuous intravenous infusion over 96 h) and cisplatin (80 mg/m(2) on day 1 given intravenously) once every 3 weeks for a maximum of six cycles. The randomisation was done centrally via an interactive phone response system using block randomisation with a size of six. The primary endpoint was progression-free survival assessed by the independent image committee in the intention-to-treat population. Safety analyses were done in patients who received at least one cycle of study drug. This study is ongoing and is registered with ClinicalTrials. gov, number NCT01528618. Findings Between Feb 20, 2012, and Oct 30, 2015, 362 patients were randomly assigned to a group (181 to the gemcitabine [ plus cisplatin] group and 181 to the fluorouracil [plus cisplatin] group). Median follow-up time for progression-free survival was 19.4 months (IQR 12.1-35.6). The median progression-free survival was 7.0 months (4.4-10.9) in the gemcitabine group and 5.6 months (3.0-7.0) in the fl uorouracil group (hazard ratio [HR] 0.55 [ 95% CI 0.44-0.68]; p< 0.0001). A total of 180 patients in the gemcitabine group and 173 patients in the fl uorouracil group were included in the safety analysis. Significantly different treatment-related grade 3 or 4 adverse events between the gemcitabine and fl uorouracil groups were leucopenia (52 [29%] vs 15 [9%]; < 0.0001), neutropenia (41 [23%] vs 23 [13%]; p= 0.0251), thrombocytopenia (24 [13%] vs three [2%]; p= 0.0007), and mucosal inflammation (0 vs 25 [14%]; < 0.0001). Serious treatment-related adverse events occurred in seven (4%) patients in the gemcitabine group and ten (6%) in the fluorouracil group. Six (3%) patients in the gemcitabine group and 14 (8%) patients in the fluorouracil group discontinued treatment because of drug-related adverse events. No treatment-related deaths occurred in either group. Interpretation Gemcitabine plus cisplatin prolongs progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The results establish gemcitabine plus cisplatin as the standard first-line treatment option for this population.	[Zhang, Li; Huang, Yan; Hong, Shaodong; Yang, Yunpeng; Wu, Xuan] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China; [Zhao, Chong] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Radiotherapy, Guangzhou, Guangdong, Peoples R China; [Yu, Gengsheng] Jiangmen Cent Hosp, Dept Med Oncol, Jiangmen, Peoples R China; [Jia, Jun] Dongguan Peoples Hosp, Dept Med Oncol, Dongguan, Peoples R China; [Peng, Peijian] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 5, Zhuhai, Peoples R China; [Lin, Qing] Shunde Hosp Tradit Chinese Med, Dept Oncol, Foshan, Peoples R China; [Xi, Xuping] Canc Hosp Hunan Prov, Dept Radiotherapy, Changsha, Hunan, Peoples R China; [Peng, Jiewen] Zhongshan Peoples Hosp, Dept Med Oncol, Zhongshan, Peoples R China; [Lu, Xiaojun] Zhongshan Peoples Hosp, Dept Radiotherapy, Zhongshan, Peoples R China; [Xu, Mingjun] Gangnan Med Coll, Affiliated Hosp 1, Dept Oncol, Gangnan, Peoples R China; [Chen, Dongping] Guangzhou Med Univ, Dept Radiotherapy, Affiliated Canc Hosp, Guangzhou, Guangdong, Peoples R China; [Wang, Rensheng] Guangxi Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Nanning, Peoples R China; [Cao, Xiaolong] Panyu Cent Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Chen, Xiaozhong] Canc Hosp Zhejiang Prov, Dept Radiotherapy, Hangzhou, Zhejiang, Peoples R China; [Lin, Zhixiong] Shantou Univ, Affiliated Canc Hosp, Dept Med Oncol, Shantou, Peoples R China; [Xiong, Jianping] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Peoples R China; [Lin, Qin] Xiamen Univ, Affiliated Hosp 1, Dept Radiotherapy, Xiamen, Peoples R China; [Xie, Conghua] Wuhan Univ, Dept Oncol, Zhongnan Hosp, Wuhan, Peoples R China; [Li, Zhihua] Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Pan, Jianji] Fujian Prov Canc Hosp, Dept Radiotherapy, Fuzhou, Peoples R China; [Li, Jingao] Jiangxi Prov Canc Hosp, Dept Radiotherapy, Nanchang, Peoples R China; [Wu, Shixiu] Canc Hosp Hangzhou City, Dept Radiotherapy, Hangzhou, Zhejiang, Peoples R China; [Lian, Yingni] First Peoples Hosp Zhaoqing City, Dept Med Oncol, Zhaoqing, Peoples R China; [Yang, Quanlie] Peoples Hosp Meizhou, Dept Chemotherapy, Meizhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Guangxi Medical University; Shantou University; Nanchang University; Xiamen University; Wuhan University; Sun Yat Sen University	Zhang, L (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China.	zhangli6@mail.sysu.edu.cn	Wu, Xuan/AAE-4778-2020	Pan, Jianji/0000-0002-3211-7874; Lin, Zhixiong/0000-0003-4898-7441; Xiong, Jianping/0000-0002-9856-7747	Sun Yat-Sen University Clinical Research Programme [5010]; Chinese National Natural Science Foundation [81372502, 81201917]; National High Technology Research and Development Program of China (863 program) [2012AA02A501, 2012AA02A502]; Natural Science Foundation of Guangdong [S2013010016564]	Sun Yat-Sen University Clinical Research Programme; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863 program)(National High Technology Research and Development Program of China); Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province)	Sun Yat-Sen University Clinical Research 5010 Programme, Chinese National Natural Science Foundation project (grant numbers 81372502 and 81201917), the National High Technology Research and Development Program of China (863 program numbers 2012AA02A501 and 2012AA02A502), and the Natural Science Foundation of Guangdong (grant number S2013010016564).	AU E, 1994, ANN ONCOL, V5, P87, DOI 10.1093/oxfordjournals.annonc.a058703; Bergman AM, 1996, CLIN CANCER RES, V2, P521; Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Chen C, 2012, ORAL ONCOL, V48, P1146, DOI 10.1016/j.oraloncology.2012.05.021; Chen YP, 2015, RADIOTHER ONCOL, V116, P157, DOI 10.1016/j.radonc.2015.07.030; CHOO R, 1991, CANCER, V68, P2120, DOI 10.1002/1097-0142(19911115)68:10<2120::AID-CNCR2820681005>3.0.CO;2-7; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Foo KF, 2002, ANN ONCOL, V13, P150, DOI 10.1093/annonc/mdf002; Her C, 2001, AM FAM PHYSICIAN, V63, P1776; Hsieh JCH, 2015, JPN J CLIN ONCOL, V45, P819, DOI 10.1093/jjco/hyv083; Hui EP, 2004, CANCER-AM CANCER SOC, V101, P300, DOI 10.1002/cncr.20358; Jiang Y, 2005, CANCER INVEST, V23, P123, DOI 10.1081/CNV-200050438; Jin Y, 2012, J CANCER RES CLIN, V138, P1717, DOI 10.1007/s00432-012-1219-x; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Li AC, 2015, ONCOTARGET, V6, P24511, DOI 10.18632/oncotarget.4312; Ma BBY, 2009, ANN ONCOL, V20, P1854, DOI 10.1093/annonc/mdp065; Ma BBY, 2005, CANCER-AM CANCER SOC, V103, P22, DOI 10.1002/cncr.20768; Ma BBY, 2002, CANCER-AM CANCER SOC, V95, P2516, DOI 10.1002/cncr.10995; Ngan RKC, 2002, ANN ONCOL, V13, P1252, DOI 10.1093/annonc/mdf200; Pan CC, 2012, EXP THER MED, V4, P334, DOI 10.3892/etm.2012.584; Peng PJ, 2016, THER ADV MED ONCOL, V8, P153, DOI 10.1177/1758834016637592; Tang LQ, 2013, J CLIN ONCOL, V31, P2861, DOI 10.1200/JCO.2012.46.0816; Wang CC, 2006, HEAD NECK-J SCI SPEC, V28, P74, DOI 10.1002/hed.20310; Wang JL, 2008, ORAL ONCOL, V44, P464, DOI 10.1016/j.oraloncology.2007.06.004; Wang T L, 1991, Ann Acad Med Singap, V20, P601; Wang Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep10534; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Zhang L, 2008, CANCER CHEMOTH PHARM, V61, P33, DOI 10.1007/s00280-007-0441-8	30	296	325	5	68	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2016	388	10054					1883	1892		10.1016/S0140-6736(16)31388-5	http://dx.doi.org/10.1016/S0140-6736(16)31388-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ0AM	27567279				2023-01-03	WOS:000385499000032
J	Hinman, RS; Wrigley, TV; Metcalf, BR; Campbell, PK; Paterson, KL; Hunter, DJ; Kasza, J; Forbes, A; Bennell, KL				Hinman, Rana S.; Wrigley, Tim V.; Metcalf, Ben R.; Campbell, Penny K.; Paterson, Kade L.; Hunter, David J.; Kasza, Jessica; Forbes, Andrew; Bennell, Kim L.			Unloading Shoes for Self-management of Knee Osteoarthritis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							ADDUCTION MOMENT; BASE-LINE; DISEASE PROGRESSION; CLINICAL-TRIALS; FLEXION MOMENTS; WALKING SHOES; PAIN; VALIDATION; GAIT; HIP	Background: Appropriate footwear is recommended for self-management of knee osteoarthritis. Shoes that reduce harmful knee loads are available, but symptomatic effects are uncertain. Objective: To evaluate the efficacy of unloading shoes in alleviating knee osteoarthritis symptoms. Design: Participant-and assessor-blinded comparative effectiveness randomized, controlled trial. (Australian New Zealand Clinical Trials Registry: ACTRN12613000851763) Setting: Community. Participants: 164 persons with medial knee osteoarthritis. Intervention: Walking shoes with triple-density, variable-stiffness midsoles and mild lateral-wedge insoles designed to unload the medial knee and worn daily (intervention) versus conventional walking shoes (comparator). Measurements: Primary outcomes were pain with walking (assessed on a numerical rating scale [NRS]) and physical function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) at 6 months. Secondary outcomes were knee pain and stiffness (WOMAC), average pain (NRS), intermittent and constant knee pain (Intermittent and Constant Osteoarthritis Pain questionnaire), quality of life (Assessment of Quality of Life instrument), physical activity (Physical Activity Scale for the Elderly), and global change in pain and function (Likert scales). Results: A total of 160 participants (98%) completed primary outcome measures at 6 months. Changes in pain (mean difference, 0.0 units [95% CI, -0.9 to 0.8 unit]) and function (mean difference, 0.3 unit [CI, -3.2 to 3.7 units]) did not differ between groups at 6 months, with both groups showing clinically relevant improvements in function and the intervention group showing clinically relevant improvements in pain. There were no differences in secondary outcomes. Pain was globally improved in 54% of participants, and function was globally improved in 44% to 48%. Unloading shoes were not associated with increased probability of improvement (odds ratios, 0.99 [CI, 0.53 to 1.86] for pain and 0.85 [CI, 0.45 to 1.61] for function). Limitation: Effects on joint structure were not evaluated. Conclusion: Shoes with modified midsoles to unload the medial knee conferred no additional benefit over conventional walking shoes. Both improved pain and function by clinically relevant amounts.	[Hinman, Rana S.; Wrigley, Tim V.; Metcalf, Ben R.; Campbell, Penny K.; Paterson, Kade L.; Bennell, Kim L.] Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Level 7,Alan Gilbert Bldg,161 Barry St, Melbourne, Vic 3010, Australia; [Kasza, Jessica; Forbes, Andrew] Monash Univ, Dept Epidemiol & Prevent Med, Alfred Ctr, 99 Commercial Rd, Melbourne, Vic 3004, Australia; [Hunter, David J.] Univ Sydney, Sydney, NSW, Australia; [Hunter, David J.] Royal North Shore Hosp, Dept Rheumatol, St Leonards, NSW 2065, Australia	University of Melbourne; Monash University; University of Sydney; Royal North Shore Hospital	Hinman, RS (corresponding author), Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Level 7,Alan Gilbert Bldg,161 Barry St, Melbourne, Vic 3010, Australia.	ranash@unimelb.edu.au; Andrew.Forbes@monash.edu	/AAB-3060-2019; Paterson, Kade L/G-4715-2012; Bennell, Kim/C-7022-2014	Paterson, Kade L/0000-0002-0323-6129; Forbes, Andrew/0000-0003-4269-914X; WRIGLEY, TIM/0000-0003-3222-4706; Hinman, Rana/0000-0001-6368-9456; Metcalf, Ben/0000-0002-4945-3217; Bennell, Kim/0000-0003-4982-5639	National Health and Medical Research Council [1044396]; Australian Research Council [FT130100175]; National Health and Medical Research Council Practitioner Fellowship [1079777]; National Health and Medical Research Council Fellowship [1058440]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); National Health and Medical Research Council Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	The trial was funded by the National Health and Medical Research Council (project #1044396). Dr. Hinman is supported by an Australian Research Council Future Fellowship (FT130100175). Dr. Hunter is supported by a National Health and Medical Research Council Practitioner Fellowship (#1079777). Dr. Bennell is supported by a National Health and Medical Research Council Fellowship (#1058440).	Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, pA1, DOI 10.1016/j.joca.2006.11.009; Amin S, 2004, ARTHRIT RHEUM-ARTHR, V51, P371, DOI 10.1002/art.20396; Andriacchi TP, 2006, CURR OPIN RHEUMATOL, V18, P514, DOI 10.1097/01.bor.0000240365.16842.4e; Angst F, 2002, J RHEUMATOL, V29, P131; BELLAMY N, 1992, J RHEUMATOL, V19, P451; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bennell KL, 2013, ARTHRITIS RHEUM-US, V65, P701, DOI 10.1002/art.37788; Bennell KL, 2011, ANN RHEUM DIS, V70, P1770, DOI 10.1136/ard.2010.147082; Bennell KL, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2912; Chang AH, 2015, OSTEOARTHR CARTILAGE, V23, P1099, DOI 10.1016/j.joca.2015.02.005; Chehab EF, 2014, OSTEOARTHR CARTILAGE, V22, P1833, DOI 10.1016/j.joca.2014.08.009; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Erhart JC, 2008, J BIOMECH, V41, P2720, DOI 10.1016/j.jbiomech.2008.06.016; Erhart JC, 2010, J ORTHOP RES, V28, P1548, DOI 10.1002/jor.21183; Erhart JC, 2010, J ORTHOP RES, V28, P873, DOI 10.1002/jor.21077; Erhart-Hledik JC, 2012, J ORTHOP RES, V30, P514, DOI 10.1002/jor.21563; Fernandes L, 2013, ANN RHEUM DIS, V72, P1125, DOI 10.1136/annrheumdis-2012-202745; Foroughi N, 2009, KNEE, V16, P303, DOI 10.1016/j.knee.2008.12.007; Gierisch JM, 2014, ANN INTERN MED, V160, P836, DOI 10.7326/M14-0318; Hatfield GL, 2015, ARTHRIT CARE RES, V67, P1004, DOI 10.1002/acr.22564; Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P409, DOI 10.1016/j.joca.2007.12.015; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660; Hinman RS, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-48; Hinman RS, 2006, ARTHRIT RHEUM-ARTHR, V55, P306, DOI 10.1002/art.21836; James KE, 1996, STAT MED, V15, P1421; Kean CO, 2013, J BIOMECH, V46, P2060, DOI 10.1016/j.jbiomech.2013.05.011; Kellgren JH, 1963, EPIDEMIOLOGY CHRONIC; Kemp G, 2008, ARTHRIT RHEUM-ARTHR, V59, P609, DOI 10.1002/art.23578; Kim WY, 2004, KNEE, V11, P225, DOI 10.1016/S0968-0160(03)00068-1; Kito N, 2010, CLIN BIOMECH, V25, P914, DOI 10.1016/j.clinbiomech.2010.06.008; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P520, DOI 10.1136/ard.52.7.520; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Martin KA, 1999, MED SCI SPORT EXER, V31, P627, DOI 10.1097/00005768-199905000-00001; McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Miyazaki T, 2002, ANN RHEUM DIS, V61, P617, DOI 10.1136/ard.61.7.617; Osborne RH, 2003, J CLIN EPIDEMIOL, V56, P138, DOI 10.1016/S0895-4356(02)00601-7; Paterson KL, 2014, J FOOT ANKLE RES, V7, DOI 10.1186/s13047-014-0043-8; PRODROMOS CC, 1985, J BONE JOINT SURG AM, V67A, P1188, DOI 10.2106/00004623-198567080-00007; Redmond AC, 2006, CLIN BIOMECH, V21, P89, DOI 10.1016/j.clinbiomech.2005.08.002; Scarpignato C, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0285-8; Shakoor N, 2006, ARTHRITIS RHEUM, V54, P2923, DOI 10.1002/art.22123; Singh JA, 2014, J RHEUMATOL, V41, P509, DOI 10.3899/jrheum.130609; St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020; Strauss VY, 2012, RHEUMATOLOGY, V51, P2075, DOI 10.1093/rheumatology/kes179; Thorlund JB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2747; Trombini-Souza F, 2015, CLIN BIOMECH, V30, P1194, DOI 10.1016/j.clinbiomech.2015.08.004; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Zhao D, 2007, J ORTHOP RES, V25, P789, DOI 10.1002/jor.20379; Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis-2015-208387	54	31	32	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 20	2016	165	6					381	+		10.7326/M16-0453	http://dx.doi.org/10.7326/M16-0453			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DW9FR	27398991				2023-01-03	WOS:000383962000013
J	Dance, A				Dance, Amber			Medical histories	NATURE			English	Editorial Material																			0	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	2016	537	7619					S52	S53		10.1038/537S52a	http://dx.doi.org/10.1038/537S52a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH2UI	27602739	Bronze			2023-01-03	WOS:000452224700001
J	Moon, RE; Potter, JVF				Moon, Richard E.; Potter, Jennifer V. F.			Follow-up to Nonfatal Opioid Overdoses	ANNALS OF INTERNAL MEDICINE			English	Letter									[Moon, Richard E.] Duke Univ, Med Ctr, Durham, NC 27708 USA; [Potter, Jennifer V. F.] Univ Virginia, Charlottesville, VA USA	Duke University; University of Virginia	Moon, RE (corresponding author), Duke Univ, Med Ctr, Durham, NC 27708 USA.		Moon, Richard/AAF-2170-2019	Moon, Richard/0000-0003-4432-0332				Bates ML, 2014, NEW ENGL J MED, V370, P584, DOI 10.1056/NEJMc1311092; Gregg J, 2016, ANN INTERN MED, V164, P62, DOI 10.7326/M15-2687; Nelson James A, 2011, J Emerg Med, V40, pe67, DOI 10.1016/j.jemermed.2007.12.022; Potter JVF, 2015, J APPL PHYSIOL, V119, P420, DOI 10.1152/japplphysiol.00034.2015; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x	5	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 6	2016	165	5					377	378		10.7326/L16-0110	http://dx.doi.org/10.7326/L16-0110			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV3BC	27595220				2023-01-03	WOS:000382795000012
J	Fernandez, O; Arroyo, R; Martinez-Yelamos, S; Marco, M; Merino, JAG; Munoz, D; Merino, E; Roque, A				Fernandez, O.; Arroyo, R.; Martinez-Yelamos, S.; Marco, M.; Garcia Merino, J. A.; Munoz, D.; Merino, E.; Roque, A.		RELOAD Study Grp	Long-Term Adherence to IFN Beta-1 alpha Treatment when Using RebiSmart (R) Device in Patients with Relapsing-Remitting Multiple Sclerosis	PLOS ONE			English	Article							DISEASE-MODIFYING THERAPIES; INJECTION-SITE REACTIONS; MS; MULTICENTER; TOLERABILITY; INTERFERONS; PROGRESSION; PREVALENCE; TRIAL; DRUGS	The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart (R) electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) beta-1 alpha (Rebif (R)). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing-remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN beta-1 alpha (Rebif (R)) treatment by using RebiSmart (R) until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart (R). Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6%(95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN beta-1 alpha administration facilitated by RebiSmart (R) could lead to high rates of adherence to a prescribed dose regimen over 36 months.	[Fernandez, O.] Univ Malaga, Hosp Univ Reg Malaga & Virgen Victoria, IBIMA, E-29071 Malaga, Spain; [Arroyo, R.] Hosp Univ Clin San Carlos, Madrid, Spain; [Martinez-Yelamos, S.] Hosp Univ Bellvitge, Barcelona, Spain; [Marco, M.] Corporacio Sanitaria Parc Tauli, Barcelona, Spain; [Garcia Merino, J. A.] Hosp Univ Puerta de Hierro, Madrid, Spain; [Munoz, D.] Hosp Xeral Cies, Vigo, Spain; [Merino, E.; Roque, A.] Merck SL, Dept Med, Barcelona, Spain	Universidad de Malaga; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Hospital Puerta de Hierro-Majadahonda; Complexo Hospitalario Universitario de Vigo	Fernandez, O (corresponding author), Univ Malaga, Hosp Univ Reg Malaga & Virgen Victoria, IBIMA, E-29071 Malaga, Spain.	oscar.fernandez.sspa@gmail.com	MARTÍNEZ-YÉLAMOS, Sergio/ABH-3087-2020; Merino, Esperanza/AAV-3244-2021; Merino de Lucas, Esperanza/AFQ-1126-2022	Merino de Lucas, Esperanza/0000-0003-3854-4874	Biogen Idec; Teva; Sanofi-Aventis; Merck-Serono; Novartis; Bayer-Schering	Biogen Idec(Biogen); Teva(Teva Pharmaceutical Industries); Sanofi-Aventis(Sanofi-Aventis); Merck-Serono(Merck & Company); Novartis(Novartis); Bayer-Schering(Bayer AG)	OF and RA have received honoraria as consultants in advisory boards, and as chairmen or lecturer in meetings, and have also participated in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering, Merck-Serono, Teva, Novartis, Genzyme, Roche, Allergan, and Almirall; SM-Y has received honoraria compensation to participate in advisory boards, collaborations as a consultant and scientific communications from Biogen-Idec, Teva, Sanofi-Aventis, Merck-Serono, Novartis, and Bayer-Schering, and has received research support, funding for travel, and congress expenses from Biogen Idec, Teva, Sanofi-Aventis, Merck-Serono, Novartis, and Bayer-Schering; MM declares no conflict of interest; JAGM has received compensations for travel, lecturing or advisory work from Merck-Serono, Biogen-Idec, Bayer, Novartis, Almirall, Sanofi-Aventis, and research grants from Novartis and Biogen-Idec; DM has received honoraria as consultant in advisory boards, has participated and collaborated in meetings, and has also participated in clinical trials and other research projects promoted by Bayer-Schering, Merck-Serono, Novartis, Biogen-Idec, and Genzyme; EM and AR are employees at Merck-Serono. The authors received no specific funding for this work. The funder provided support in the form of salaries for authors [EM and AR], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	AL-Sabbagh A, 2008, J NEUROL, V255, P79; Bartulos Iglesias M, 2014, NEUROLOGIA; Bayas A, 2013, EXPERT OPIN DRUG DEL, V10, P285, DOI 10.1517/17425247.2013.763793; Beer K, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-144; Brochet B, 2006, REV NEUROL-FRANCE, V162, P735, DOI 10.1016/S0035-3787(06)75071-8; Brown MG, 2007, NEUROLOGY, V69, P1498, DOI 10.1212/01.wnl.0000271884.11129.f3; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Costello Kathleen, 2008, Medscape J Med, V10, P225; Cox Darcy, 2006, J Neurosci Nurs, V38, P167; Cramer JA, 2006, ACTA NEUROL SCAND, V113, P156, DOI 10.1111/j.1600-0404.2005.00568.x; de Sa J, 2010, CURR MED RES OPIN, V26, P2237, DOI 10.1185/03007995.2010.508688; Devonshire V, 2011, EUR J NEUROL, V18, P69, DOI 10.1111/j.1468-1331.2010.03110.x; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Exell S, 2011, EXPERT REV MED DEVIC, V8, P543, DOI [10.1586/ERD.11.29, 10.1586/erd.11.29]; Fernandez O, 2012, MULT SCLER J, V18, P372, DOI 10.1177/1352458511421917; Fernandez O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035600; IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Lugaresi A, 2013, EXPERT OPIN DRUG DEL, V10, P273, DOI 10.1517/17425247.2013.746311; Lugaresi A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-7; Mikol D, 2005, MULT SCLER J, V11, P585, DOI 10.1191/1352458505ms1197oa; Mohr DC, 2001, ANN BEHAV MED, V23, P125, DOI 10.1207/S15324796ABM2302_7; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Seddighzadeh A, 2014, EXPERT OPIN DRUG DEL, V11, P1713, DOI 10.1517/17425247.2014.944159; Steinberg SC, 2010, CLIN DRUG INVEST, V30, P89, DOI 10.2165/11533330-000000000-00000; Treadaway K, 2009, J NEUROL, V256, P568, DOI 10.1007/s00415-009-0096-y; Tremlett HL, 2003, NEUROLOGY, V61, P551, DOI 10.1212/01.WNL.0000078885.05053.7D; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; Willis H, 2014, PATIENT PREFER ADHER, V8, P843, DOI 10.2147/PPA.S54986	30	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2016	11	8							e0160313	10.1371/journal.pone.0160313	http://dx.doi.org/10.1371/journal.pone.0160313			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4SL	27526201	Green Published, gold, Green Submitted			2023-01-03	WOS:000381471100013
J	Kermode-Scott, B				Kermode-Scott, Barbara			Canadians authorised to use cannabis for medical purposes to be allowed to grow their own again	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Government of Canada, 2016, INF B SAF SEC CONS P; Health Canada, DRUGS HLTH PROD MARK; Health Canada, 2016, MED US CANN INF NEW; Spurgeon D, 2001, BMJ-BRIT MED J, DOI [10.1136/bmj.323.7304.68/b, DOI 10.1136/BMJ.323.7304.68/B]	4	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	2016	354								i4480	10.1136/bmj.i4480	http://dx.doi.org/10.1136/bmj.i4480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT9GR	27527731				2023-01-03	WOS:000381805400017
J	Teofili, L; Valentini, CG; Di Blasi, R; Orlando, N; Fianchi, L; Zini, G; Sica, S; De Stefano, V; Pagano, L				Teofili, Luciana; Valentini, Caterina Giovanna; Di Blasi, Roberta; Orlando, Nicoletta; Fianchi, Luana; Zini, Gina; Sica, Simona; De Stefano, Valerio; Pagano, Livio			Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia	PLOS ONE			English	Article							RHG-CSF; INFECTIONS; DONORS; EFFICACY; IMMUNOSUPPRESSION; IMMUNOMODULATION; ASSOCIATION; SEPSIS; ADULTS; FEVER	It is still under debate whether granulocyte transfusions (GTs) substantially increase survival in patients with febrile neutropenia. We retrospectively examined data relative to 96 patients with hematological malignancies receiving 491 GTs during 114 infectious episodes (IE). Patients were grouped according to the median doses of granulocytes transfused during the infectious episode (low-dose group: < 1.5-x108 cells/Kg; standard-dose group: 1.53.0x10(8) cells/Kg and high-dose group: > 3.0x10(8) cells/Kg). The impact of clinical, microbiological and GT-related variables on the infection-related mortality (IRM) was investigated. The IRM was not influenced by the number of GTs or by the total amount of granulocytes received, whereas a dose-related effect of the median dose received for IE was detected at univariate analysis (IRM of 18.4% in the standard-dose group, 44.4% in the low-dose group and 48.4% in the high-dose group, p = 0.040) and confirmed at multivariate analysis (OR 3.7, IC 95% 1.5-8.9; 0.004 for patients not receiving standard doses of GTs). Moreover, patients receiving GTs at doses lower or greater than standard had increased risk for subsequent ICU admission and reduced overall survival. The dose-related effect of GTs was confirmed in bacterial but not in fungal infections. Preliminary findings obtained from a subgroup of patients candidate to GTs revealed that levels of inflammatory response mediators increase in a dose-related manner after GTs, providing a possible explanation for the detrimental effect exerted by high-dose transfusions. GTs can constitute a valuable tool to improve the outcome of infections in neutropenic patients, provided that adequate recipient-tailored doses are supplied. Further investigations of the immunomodulatory effects of GTs are recommended.	[Teofili, Luciana; Valentini, Caterina Giovanna; Di Blasi, Roberta; Orlando, Nicoletta; Fianchi, Luana; Zini, Gina; Sica, Simona; De Stefano, Valerio; Pagano, Livio] Catholic Univ, Inst Hematol, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Teofili, L (corresponding author), Catholic Univ, Inst Hematol, Rome, Italy.	luciana.teofili@unicatt.it	pagano, livio/J-3020-2018; Valentini, Caterina Giovanna/J-3746-2018; Teofili, Luciana/K-7278-2016; sica, simona/AAC-3679-2020; Orlando, Nicoletta N/P-5061-2017	pagano, livio/0000-0001-8287-928X; Valentini, Caterina Giovanna/0000-0002-7022-5366; Teofili, Luciana/0000-0002-7214-1561; Zini, Gina/0000-0003-0782-294X; sica, simona/0000-0003-2426-3465; Fianchi, Luana/0000-0002-7113-7202	"Centro di ricerca sulle cellule staminali emopoietiche e terapie cellulari" of Universita Cattolica del Sacro Cuore; Grant Linea D1	"Centro di ricerca sulle cellule staminali emopoietiche e terapie cellulari" of Universita Cattolica del Sacro Cuore; Grant Linea D1	The study was funded by "Centro di ricerca sulle cellule staminali emopoietiche e terapie cellulari" of Universita Cattolica del Sacro Cuore, and by Grant Linea D1 to Luciana Teofili and Livio Pagano.	BENSINGER WI, 1993, BLOOD, V81, P1883, DOI 10.1182/blood.V81.7.1883.1883; Blumberg N, 1996, SEMIN HEMATOL, V33, P329; Blumberg N, 2010, TRANSFUSION, V50, P2738, DOI 10.1111/j.1537-2995.2010.02748.x; BRECHER G, 1953, P SOC EXP BIOL MED, V84, P54; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Cata JP, 2013, BRIT J ANAESTH, V110, P690, DOI 10.1093/bja/aet068; Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024; Estcourt LJ, 2015, COCHRANE DB SYST REV, V29; Flowers CR, 2013, J CLIN ONCOL, V31, P794, DOI 10.1200/JCO.2012.45.8661; Freifeld AG, 2011, CLIN INFECT DIS, V52, P427, DOI 10.1093/cid/ciq147; Gea-Banacloche J, 2013, HEMATOL-AM SOC HEMAT, P414, DOI 10.1182/asheducation-2013.1.414; Gustot T, 2011, CURR OPIN CRIT CARE, V17, P153, DOI 10.1097/MCC.0b013e328344b446; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Italian Ministry of Health's, 2015, QUAL SAF BLOOD BLOOD; Klastersky J, 2000, J CLIN ONCOL, V18, P3038, DOI 10.1200/JCO.2000.18.16.3038; Lannan KL, 2013, BLOOD CELL MOL DIS, V50, P61, DOI 10.1016/j.bcmd.2012.08.009; Legrand M, 2012, CRIT CARE MED, V40, P43, DOI 10.1097/CCM.0b013e31822b50c2; Marfin AA, 2015, J INTENSIVE CARE MED, V30, P79, DOI 10.1177/0885066613498045; Peters C, 1999, BRIT J HAEMATOL, V106, P689, DOI 10.1046/j.1365-2141.1999.01619.x; Price TH, 2000, BLOOD, V95, P3302, DOI 10.1182/blood.V95.11.3302.010k35_3302_3309; Price TH, 2015, BLOOD, V126, P2153, DOI 10.1182/blood-2015-05-645986; Roubinian NH, 2015, TRANSFUSION, V55, P1838, DOI 10.1111/trf.13021; Rutella S, 2003, CYTOTHERAPY, V5, P19, DOI 10.1080/14653240310000047; Rutella S, 1997, BONE MARROW TRANSPL, V20, P355, DOI 10.1038/sj.bmt.1700899; Sachs UJ, 2003, TRANSFUSION, V43, P1683, DOI 10.1111/j.0041-1132.2003.00568.x; Schulte W, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/165974; Seidel MG, 2008, BONE MARROW TRANSPL, V42, P679, DOI 10.1038/bmt.2008.237; Seidel MG, 2009, J PEDIAT HEMATOL ONC, V31, P166, DOI 10.1097/MPH.0b013e318196a6f9; Stanworth SJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005339; TALCOTT JA, 1988, ARCH INTERN MED, V148, P2561, DOI 10.1001/archinte.148.12.2561; Vamvakas EC, 1996, J CLIN APHERESIS, V11, P1; WINSTON DJ, 1982, ANN INTERN MED, V97, P509, DOI 10.7326/0003-4819-97-4-509; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	33	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2016	11	8							e0159569	10.1371/journal.pone.0159569	http://dx.doi.org/10.1371/journal.pone.0159569			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3GA	27487075	Green Published, gold, Green Submitted			2023-01-03	WOS:000381367800034
J	Tap, WD; Jones, RL; Van Tine, BA				Tap, W. D.; Jones, R. L.; Van Tine, A. B.			Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial (vol 388, pg 488, 2016)	LANCET			English	Correction													Jones, Robin L/AAO-3738-2020; van+Tine, Brain/AAI-1919-2019	Jones, Robin L/0000-0003-4173-3844; 	NATIONAL CANCER INSTITUTE [P50CA140146, P30CA008748] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Tap WD, 2016, LANCET, V388, P464, DOI 10.1016/S0140-6736(16)30587-6	1	401	421	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	2016	388	10043					464	464						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS2EK	27291997	Green Accepted			2023-01-03	WOS:000380559400025
J	Zhang, QM; Morgan, SP; O'Shea, P; Mather, ML				Zhang, Qimei; Morgan, Stephen P.; O'Shea, Paul; Mather, Melissa L.			Ultrasound Induced Fluorescence of Nanoscale Liposome Contrast Agents	PLOS ONE			English	Article							TRANSBILAYER MOVEMENT; PHASE-TRANSITION; IN-VIVO; PYRENE; MICROBUBBLES; VESICLES; PROBES; PHOSPHOLIPIDS	A new imaging contrast agent is reported that provides an increased fluorescent signal upon application of ultrasound (US). Liposomes containing lipids labelled with pyrene were optically excited and the excimer fluorescence emission intensity was detected in the absence and presence of an ultrasound field using an acousto-fluorescence setup. The acousto-fluorescence dynamics of liposomes containing lipids with pyrene labelled on the fatty acid tail group (PyPC) and the head group (PyPE) were compared. An increase in excimer emission intensity following exposure to US was observed for both cases studied. The increased intensity and time constants were found to be different for the PyPC and PyPE systems, and dependent on the applied US pressure and exposure time. The greatest change in fluorescence intensity (130%) and smallest rise time constant (0.33 s) are achieved through the use of PyPC labelled liposomes. The mechanism underlying the observed increase of the excimer emission intensity in PyPC labelled liposomes is proposed to arise from the "wagging" of acyl chains which involves fast response and requires lower US pressure. This is accompanied by increased lipid lateral diffusivity at higher ultrasound pressures, a mechanism that is also active in the PyPE labelled liposomes.	[Zhang, Qimei; Morgan, Stephen P.; Mather, Melissa L.] Univ Nottingham, Adv Opt Grp, Fac Engn, Nottingham, England; [O'Shea, Paul] Univ Nottingham, Sch Life Sci, Cell Biophys Grp, Nottingham, England; [Mather, Melissa L.] Keele Univ, Inst Sci & Technol Med, Stoke On Trent, Staffs, England	University of Nottingham; University of Nottingham; Keele University	Mather, ML (corresponding author), Univ Nottingham, Adv Opt Grp, Fac Engn, Nottingham, England.; Mather, ML (corresponding author), Keele Univ, Inst Sci & Technol Med, Stoke On Trent, Staffs, England.	m.mather@keele.ac.uk		Zhang, Qimei/0000-0001-5811-8034; Mather, Melissa/0000-0002-5551-1321; O'Shea, paul/0000-0001-9313-8313; Morgan, Stephen/0000-0003-4069-3801	China Scholarship Council; Career Acceleration Fellowship from the Engineering and Physical Sciences Research Council [EP/J001953/1]; National Centre for the Replacement, Refinement and Reduction of Animals in Research [NC/L00187X/1]; Engineering and Physical Sciences Research Council [EP/J017566/1]; BBSRC [BB/F004826/1] Funding Source: UKRI; EPSRC [EP/J001953/2, EP/J017566/1, EP/J001953/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F004826/1] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/J001953/2, EP/J001953/1] Funding Source: researchfish; National Centre for the Replacement [NC/L00187X/1] Funding Source: researchfish	China Scholarship Council(China Scholarship Council); Career Acceleration Fellowship from the Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Centre for the Replacement, Refinement and Reduction of Animals in Research(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Centre for the Replacement	QZ is partially funded by the China Scholarship Council (http://en.csc.edu.cn/). MLM is supported by a Career Acceleration Fellowship from the Engineering and Physical Sciences Research Council (EP/J001953/1, https://www.epsrc.ac.uk/). SPM is supported by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/L00187X/1, https://www.nc3rs.org.uk/) and PO is supported by the Engineering and Physical Sciences Research Council (EP/J017566/1, https://www.epsrc.ac.uk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102; Benchimol MJ, 2013, SOFT MATTER, V9, P2384, DOI 10.1039/c2sm26900g; Castile JD, 1999, INT J PHARM, V188, P87, DOI 10.1016/S0378-5173(99)00207-0; Cheng BB, 2014, IEEE J SEL TOP QUANT, V20, DOI 10.1109/JSTQE.2013.2280997; COMBS CA, 2010, CURRENT PROTOCOLS NE, V50, P1; DAEMS D, 1985, EUR BIOPHYS J BIOPHY, V12, P97, DOI 10.1007/BF00260432; Dayton PA, 2006, MOL IMAGING, V5, P160, DOI 10.2310/7290.2006.00019; Deshpande N, 2010, CLIN RADIOL, V65, P567, DOI 10.1016/j.crad.2010.02.013; Ducros N, 2011, IRBM, V32, P243, DOI 10.1016/j.irbm.2011.04.001; Hillman EMC, 2011, PHILOS T R SOC A, V369, P4620, DOI 10.1098/rsta.2011.0264; Hillman EMC, 2009, LASER PHOTONICS REV, V3, P159, DOI 10.1002/lpor.200810031; Huynh NT, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.076008; Immordino ML, 2006, INT J NANOMED, V1, P297; Jiao LJ, 2010, ORG BIOMOL CHEM, V8, P2517, DOI 10.1039/c001068e; John K, 2002, BIOPHYS J, V83, P3315, DOI 10.1016/S0006-3495(02)75332-0; Johns LD, 2002, J ATHL TRAINING, V37, P293; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; Kobayashi M, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2364600; Kulkarni PR, 2011, INT J CURR PHARM RES, V3, P10; Lai PX, 2013, LASER PHYS LETT, V10, DOI 10.1088/1612-2011/10/7/075604; Leblond F, 2010, J PHOTOCH PHOTOBIO B, V98, P77, DOI 10.1016/j.jphotobiol.2009.11.007; Lehrer S S, 1995, Subcell Biochem, V24, P115; Lin YT, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3681378; Liu J, 2004, J AM CHEM SOC, V126, P8376, DOI 10.1021/ja048245p; Liu Y, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.3.036012; Liu Y, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.085005; Liu Y, 2012, INT J OPT, V2012, DOI 10.1155/2012/260709; Maenpaa K, 2009, SCI TOTAL ENVIRON, V407, P2666, DOI 10.1016/j.scitotenv.2009.01.019; Makrigiorgos GM, 1997, J BIOCHEM BIOPH METH, V35, P23, DOI 10.1016/S0165-022X(97)00020-1; Marks DL, 2008, HISTOCHEM CELL BIOL, V130, P819, DOI 10.1007/s00418-008-0509-5; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Muller P, 2000, CHEM PHYS LIPIDS, V106, P89, DOI 10.1016/S0009-3084(00)00134-1; O'Brien WD, 2007, PROG BIOPHYS MOL BIO, V93, P212, DOI 10.1016/j.pbiomolbio.2006.07.010; Ozawa T, 2013, ANAL CHEM, V85, P590, DOI 10.1021/ac3031724; Paul S, 2014, COMPUT MECH, V53, P413, DOI 10.1007/s00466-013-0962-4; Pei YB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04690; Rao JH, 2007, CURR OPIN BIOTECH, V18, P17, DOI 10.1016/j.copbio.2007.01.003; Richardson ES, 2007, BIOPHYS J, V93, P4100, DOI 10.1529/biophysj.107.104042; SASSAROLI M, 1990, BIOPHYS J, V57, P281, DOI 10.1016/S0006-3495(90)82530-3; Schutt CE, 2014, SMALL, V10, P3316, DOI 10.1002/smll.201302786; Si K, 2012, NAT PHOTONICS, V6, P657, DOI [10.1038/NPHOTON.2012.205, 10.1038/nphoton.2012.205]; Sundararajan V., 2011, COMPUTATIONAL MODELL, P105; Swerdlow AJ, 2010, HLTH EFFECTS EXPOSUR; Traikia M, 2000, EUR BIOPHYS J BIOPHY, V29, P184, DOI 10.1007/s002490000077; Valeur B., 2002, MOL FLUORESCENCE PRI, P94; VAUHKONEN M, 1990, BIOPHYS J, V57, P291, DOI 10.1016/S0006-3495(90)82531-5; Wang YM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1925; Yang J, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4867385; Yuan BH, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4737211	49	2	2	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2016	11	7							e0159742	10.1371/journal.pone.0159742	http://dx.doi.org/10.1371/journal.pone.0159742			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IL	27467748	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000381516100051
J	Moneim, AEA				Moneim, Ahmed E. Abdel			Indigofera oblongifolia Prevents Lead Acetate-Induced Hepatotoxicity, Oxidative Stress, Fibrosis and Apoptosis in Rats	PLOS ONE			English	Article							FLAXSEED OIL; LIVER; EXPRESSION; REVERSAL; CADMIUM; KIDNEY; TESTES; ASSAY; NRF2	The current study was aimed to evaluate the preventive effects of Indigofera oblongifolia leaf extract (IOLE) on lead acetate (PbAc)-induced hepatotoxicity in adult male Wistar rats. PbAc was intraperitoneally injected at a dose of 20 mg/kg body weight for 5 days alone or in combination with the IOLE (100 mg/kg). Liver lead concentration and oxidative stress markers such as lipid peroxidation, hydrogen peroxide, nitric oxide, and glutathione content were investigated in addition to the enzymatic antioxidant activities. PbAc injection caused a significant elevation in the liver function parameters, lead level, lipid peroxidation, hydrogen peroxide, and nitric oxide, with a concomitant decline in the glutathione content compared with the control, accompanied by a significant inhibition of antioxidant enzyme activities. The induction of oxidative stress, lead accumulation, and histological alterations in the liver were successfully minimized by pre-administration of IOLE. In addition, the PbAc group showed increase in the levels of Bax, caspase-3, and matrix metalloproteinase-9 proteins, while the expression of Bcl-2 protein was decreased. Prior administration of IOLE significantly mitigated apoptosis and fibrosis in the liver. Finally, the major components in I. oblongifolia extract were identified as polyphenols, flavonoids, and organic acids using liquid chromatography coupled mass spectroscopy. Thus, the findings of the current study revealed that I. oblongifolia had protective, anti-fibrotic, antioxidant, and anti-apoptotic activities on PbAc-induced hepatotoxicity. The beneficial effects of I. oblongifolia were in part mediated by Nrf2/HO-1 pathway.	[Moneim, Ahmed E. Abdel] Helwan Univ, Fac Sci, Dept Zool & Entomol, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Helwan University	Moneim, AEA (corresponding author), Helwan Univ, Fac Sci, Dept Zool & Entomol, Cairo, Egypt.	aest1977@hotmail.com	Moneim, Ahmed E. Abdel/C-7461-2012	Moneim, Ahmed E. Abdel/0000-0002-2654-2591				Moneim AEA, 2012, BIOL TRACE ELEM RES, V148, P363, DOI 10.1007/s12011-012-9370-4; Abdel-Moneim AE, 2011, BIOL TRACE ELEM RES, V143, P457, DOI 10.1007/s12011-010-8882-z; Abdou HM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/435857; Aggarwal BB, 2011, CURR DRUG TARGETS, V12, P1595; Al-Olayan EM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-164; Al-Olayan E, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/381413; Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Aykin-Burns N, 2003, ARCH ENVIRON CON TOX, V44, P417, DOI 10.1007/s00244-002-2023-4; BELFIELD A, 1971, ENZYME, V12, P561, DOI 10.1159/000459586; Berrahal AA, 2011, ENVIRON TOXICOL, V26, P68, DOI 10.1002/tox.20530; Dkhil MA, 2016, BIOL TRACE ELEM RES, V173, P354, DOI 10.1007/s12011-016-0689-0; Dkhil MA, 2016, DRUG DES DEV THER, V10, P1847, DOI 10.2147/DDDT.S105511; El-Nekeety AA, 2009, FOOD CHEM TOXICOL, V47, P2209, DOI 10.1016/j.fct.2009.06.019; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Flora Gagan, 2012, Interdiscip Toxicol, V5, P47, DOI 10.2478/v10102-012-0009-2; Flora SJS, 2008, INDIAN J MED RES, V128, P501; Flora SJS, 2007, J PHARMACOL EXP THER, V322, P108, DOI 10.1124/jpet.107.121996; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Jia QH, 2012, TOXICOL MECH METHOD, V22, P705, DOI 10.3109/15376516.2012.718811; Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750; Lahat N, 2002, J NEUROIMMUNOL, V132, P123, DOI 10.1016/S0165-5728(02)00323-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubbad MY, 2015, PARASITOL RES, V114, P3431, DOI 10.1007/s00436-015-4568-y; Mohamed OI, 2016, PHARM BIOL, V54, P1164, DOI 10.3109/13880209.2015.1057651; Mudipalli A, 2007, INDIAN J MED RES, V126, P518; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oyagbemi A, 2014, FASEB J, V28; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Parola M, 2001, J HEPATOL, V35, P297, DOI 10.1016/S0168-8278(01)00142-8; Ponce-Canchihuaman JC, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-35; REITMAN S, 1957, AM J CLIN PATHOL, V28, P56, DOI 10.1093/ajcp/28.1.56; Reyes JL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/730789; Schmidt M, 1975, Fortschr Med, V93, P1461; Sethi G, 2006, J BIOL CHEM, V281, P23425, DOI 10.1074/jbc.M602627200; Shahjahan M, 2005, J MED FOOD, V8, P261, DOI 10.1089/jmf.2005.8.261; Sharif A, 2005, ARCH PHARM RES, V28, P761, DOI 10.1007/BF02977339; Sternberger LA., 1979, IMMUNOCYTOCHEMISTRY; Szkoda J, 2005, B VET I PULAWY, V49, P89; Tantawy EI- WH, 2015, J TRADIT COMPLEMENT; Wang Y, 2013, ENVIRON TOXICOL PHAR, V35, P109, DOI 10.1016/j.etap.2012.12.001; Wang Y, 2013, NEURAL REGEN RES, V8, P2021, DOI 10.3969/j.issn.1673-5374.2013.22.001; Ye F, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2075915; Yu CL, 2016, MOL NEUROBIOL, V53, P6489, DOI 10.1007/s12035-015-9555-x; Yuan GP, 2014, INT J CLIN EXP PATHO, V7, P2905	44	88	89	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158965	10.1371/journal.pone.0158965	http://dx.doi.org/10.1371/journal.pone.0158965			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27391413	Green Published, gold			2023-01-03	WOS:000380005400174
J	Groot, E; Kouyoumdjian, FG; Kiefer, L; Madadi, P; Gross, J; Prevost, B; Jhirad, R; Huyer, D; Snowdon, V; Persaud, N				Groot, Emily; Kouyoumdjian, Fiona G.; Kiefer, Lori; Madadi, Parvaz; Gross, Jeremy; Prevost, Brittany; Jhirad, Reuven; Huyer, Dirk; Snowdon, Victoria; Persaud, Navindra			Drug Toxicity Deaths after Release from Incarceration in Ontario, 2006-2013: Review of Coroner's Cases	PLOS ONE			English	Review							THERAPEUTIC-COMMUNITY TREATMENT; OPIOID SUBSTITUTION THERAPY; MORTALITY; PRISON; RISK; INMATES; OFFENDERS; OVERDOSE; SCOTLAND; IMPACT	Background There is an increased risk of death due to drug toxicity after release from incarceration. The purpose of this study was to describe the timing, rate and circumstances of drug toxicity deaths following release from incarceration. This information can be used to help design potential preventive interventions. Methods and Findings We reviewed coroner's files to identify deaths in adults in Ontario between 2006 and 2013 caused by drug toxicity (n = 6,978) and these records were matched with provincial correctional records to identify individuals who died within one year of being released from incarceration (n = 702). Twenty percent (n = 137) of the 702 deaths occurred within one week of release. The majority (77%, n = 538) of deaths after release involved one or more opioids. Of the deaths involving opioids, intervention by another person may have been possible in 318 cases. Conclusions Between 2006 and 2013 in Ontario, one in ten drug toxicity deaths in adults occurred within one year of release from provincial incarceration. These findings may help to inform the implemention and assessment of interventions aimed at reducing drug toxicity deaths following release from incarceration.	[Groot, Emily] Queens Univ, Dept Family Med, Kingston, ON, Canada; [Kouyoumdjian, Fiona G.; Persaud, Navindra] St Michaels Hosp, Toronto, ON, Canada; [Kiefer, Lori] Ontario Minist Community Safety & Correct Serv, Toronto, ON, Canada; [Kiefer, Lori] Unviers Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Madadi, Parvaz] Ctr Forens Sci, Toronto, ON, Canada; [Gross, Jeremy; Prevost, Brittany] Univ Toronto, Fac Med, Toronto, ON, Canada; [Jhirad, Reuven; Huyer, Dirk; Snowdon, Victoria; Persaud, Navindra] Off Chief Coroner Ontario, Toronto, ON, Canada; [Persaud, Navindra] Univ Toronto, Toronto, ON, Canada	Queens University - Canada; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto	Persaud, N (corresponding author), St Michaels Hosp, Toronto, ON, Canada.; Persaud, N (corresponding author), Off Chief Coroner Ontario, Toronto, ON, Canada.; Persaud, N (corresponding author), Univ Toronto, Toronto, ON, Canada.	nav.persaud@utoronto.ca	Cuscó, Xavier Garcia/S-7576-2019	Cuscó, Xavier Garcia/0000-0001-7199-6931				Andrews JY, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-270; [Anonymous], 2010, MICR EXC; Beswick T, 2002, J DRUG ISSUES, V32, P1103, DOI 10.1177/002204260203200406; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Binswanger IA, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-3; Bird SM, 2015, ADDICTION, V110, P1617, DOI 10.1111/add.12969; Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x; Christensen PB, 2006, INT J PRISON HEALTH, V2, P13, DOI 10.1080/17449200600743644; Degenhardt L, 2014, ADDICTION, V109, P1306, DOI 10.1111/add.12536; Farrell M, 2008, ADDICTION, V103, P251, DOI 10.1111/j.1360-0443.2007.02081.x; Forsberg LG, 2011, SUBST USE MISUSE, V46, P1477, DOI 10.3109/10826084.2011.591880; Freudenberg N, 2010, J ADOLESCENT HEALTH, V47, P448, DOI 10.1016/j.jadohealth.2010.01.008; Grommon E, 2013, J OFFENDER REHABIL, V52, P287, DOI 10.1080/10509674.2013.782775; HARDINGPINK D, 1988, BRIT MED J, V297, P596, DOI 10.1136/bmj.297.6648.596; Information Services Division of the NHS National Services Scotland [Internet], 2014, NAT NAL PROGR SCOTL; Joukamaa M, 1998, FORENSIC SCI INT, V96, P11, DOI 10.1016/S0379-0738(98)00098-X; Kariminia A, 2007, INT J EPIDEMIOL, V36, P310, DOI 10.1093/ije/dyl225; Kouyoumdjian Fiona G, 2016, CMAJ Open, V4, pE153, DOI 10.9778/cmajo.20150098; Kouyoumdjian FG, 2015, AM J PUBLIC HEALTH, V105, pE13, DOI 10.2105/AJPH.2014.302498; Kouyoumdjian FG, 2014, CAN J PUBLIC HEALTH, V105, pE198, DOI 10.17269/cjph.105.4193; Krinsky CS, 2009, AM J FOREN MED PATH, V30, P6, DOI 10.1097/PAF.0b013e3181873784; Lattimore PK, 1997, J RES CRIME DELINQ, V34, P187, DOI 10.1177/0022427897034002002; Luce J, 2011, CROSS CANADA SCAN ME; Lyons S, 2010, INT J PRISON HLTH, V35, P26; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Needels K, 2005, J URBAN HEALTH, V82, P420, DOI 10.1093/jurban/jti092; Prendergast M, 2011, J EXP CRIMINOL, V7, P225, DOI 10.1007/s11292-011-9123-y; Putkonen H, 2001, FORENSIC SCI INT, V119, P221, DOI 10.1016/S0379-0738(00)00431-X; Sacks JY, 2012, J ADDICT DIS, V31, P258, DOI 10.1080/10550887.2012.694601; Statistics Canada, 2014, POP AG SEX POP EST A; Stewart LM, 2004, AUST NZ J PUBL HEAL, V28, P32, DOI 10.1111/j.1467-842X.2004.tb00629.x; Strang J, 2013, J URBAN HEALTH, V90, P983, DOI 10.1007/s11524-013-9803-1; Sullivan CJ, 2007, AM J DRUG ALCOHOL AB, V33, P823, DOI 10.1080/00952990701653800; Verger P, 2003, J FORENSIC SCI, V48, P614; WHO, 2014, PREV OV DEATHS CRIM; World Health Organization (WHO), 2014, COMM MAN OP OV; Zakaria D., 2010, SUMMARY EMERGING FIN; Zlotnick C, 2009, BEHAV THER, V40, P325, DOI 10.1016/j.beth.2008.09.004	40	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2016	11	7							e0157512	10.1371/journal.pone.0157512	http://dx.doi.org/10.1371/journal.pone.0157512			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR3NH	27384044	gold, Green Published, Green Submitted			2023-01-03	WOS:000379809400014
J	Kay-Stacey, M; Attarian, H				Kay-Stacey, Margaret; Attarian, Hrayr			Advances in the management of chronic insomnia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; OREXIN RECEPTOR ANTAGONIST; SUBLINGUAL ZOLPIDEM TARTRATE; PLACEBO-CONTROLLED TRIAL; DWELLING OLDER-ADULTS; TERM-CARE FACILITIES; SLEEP QUALITY; TAI-CHI	Chronic insomnia is a common condition that affects people worldwide and has negative effects on patients' health and wellbeing. The treatment of insomnia can be complex and time consuming for patients and providers. Although behavioral interventions are the first line therapy, there are barriers to access for these treatments. However, in recent years, alternative ways of providing these behavioral therapies that make them more widely available have been investigated. Drugs also play an important role in the treatment of insomnia and new drugs have been introduced as options for treating patients with sleep initiation and sleep maintenance insomnia. In this review, we will discuss advances in the past six years in both non-pharmacologic and pharmacologic treatments for patients with chronic insomnia. We will also review the controversies surrounding some of the current drug treatments, as well as the role that technology and personal activity monitoring devices may play in treating insomnia.	[Kay-Stacey, Margaret; Attarian, Hrayr] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Kay-Stacey, M (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.	margaret-stacey@northwestern.edu						Afonso RF, 2012, MENOPAUSE, V19, P186, DOI 10.1097/gme.0b013e318228225f; Amaral Odete, 2014, Aten Primaria, V46 Suppl 5, P191, DOI 10.1016/S0212-6567(14)70090-3; American Academy of Sleep Medicine, 2014, INTERNATIONAL CLASSI; Bakken MS, 2014, EUR J CLIN PHARMACOL, V70, P873, DOI 10.1007/s00228-014-1684-z; Bei B, 2015, J CLIN SLEEP MED, V11, P1021, DOI 10.5664/jcsm.5018; Benbir G, 2015, PSYCHIAT CLIN NEUROS, V69, P543, DOI 10.1111/pcn.12252; Blank M, 2015, SLEEP, V38, P197, DOI 10.5665/sleep.4396; Blom K, 2015, BEHAV RES THER, V70, P47, DOI 10.1016/j.brat.2015.05.002; Borison R., 2014, WEARABLES AWARENESS; Bostock ECS, 2015, J AFFECT DISORDERS, V183, P57, DOI 10.1016/j.jad.2015.04.057; Bothelius K, 2013, J SLEEP RES, V22, P688, DOI 10.1111/jsr.12067; Bower JE, 2012, CANCER-AM CANCER SOC, V118, P3766, DOI 10.1002/cncr.26702; Brand S, 2014, SLEEP MED, V15, P1031, DOI 10.1016/j.sleep.2014.05.016; Buman MP, 2014, SLEEP MED, V15, P755, DOI 10.1016/j.sleep.2014.01.008; Canivet C, 2014, J PSYCHOSOM RES, V76, P292, DOI 10.1016/j.jpsychores.2014.02.001; Cape J, 2016, PSYCHOL MED, V46, P1015, DOI 10.1017/S0033291715002561; Castro LS, 2013, ANN NEUROL, V74, P537, DOI 10.1002/ana.23945; Cervena K, 2004, J SLEEP RES, V13, P385, DOI 10.1111/j.1365-2869.2004.00431.x; Chen HC, 2013, SLEEP, V36, P1187, DOI 10.5665/sleep.2884; Chen KM, 2009, INT J NURS STUD, V46, P154, DOI 10.1016/j.ijnurstu.2008.09.005; Chen MC, 2012, INT J NURS STUD, V49, P265, DOI 10.1016/j.ijnurstu.2011.09.009; Cheng SK, 2012, PSYCHOTHER PSYCHOSOM, V81, P206, DOI 10.1159/000335379; Chung KF, 2015, SLEEP MED, V16, P477, DOI 10.1016/j.sleep.2014.10.018; Citrome L, 2014, INT J CLIN PRACT, V68, P1429, DOI 10.1111/ijcp.12568; Clancy Megan, 2015, Int J MS Care, V17, P261, DOI 10.7224/1537-2073.2014-071; Clarke G, 2015, BEHAV RES THER, V69, P111, DOI 10.1016/j.brat.2015.04.009; Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236; Connor KM, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw022; Constantino Michael J, 2007, Behav Sleep Med, V5, P210; de Bruin EJ, 2014, BEHAV SLEEP MED, V12, P235, DOI 10.1080/15402002.2013.784703; de Gage SB, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6231; de Zambotti M, 2015, SLEEP, V38, P1461, DOI 10.5665/sleep.4990; Dhruva A, 2012, J ALTERN COMPLEM MED, V18, P473, DOI 10.1089/acm.2011.0555; Dubey AK, 2015, J PHARMACOL PHARMACO, V6, P118, DOI 10.4103/0976-500X.155496; Ellis JG, 2012, J PSYCHIATR RES, V46, P1278, DOI 10.1016/j.jpsychires.2012.07.001; Equihua AC, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00163; Espie CA, 2007, SLEEP, V30, P574, DOI 10.1093/sleep/30.5.574; Espie CA, 2014, SLEEP MED, V15, P913, DOI 10.1016/j.sleep.2014.03.001; Espie CA, 2012, SLEEP, V35, P769, DOI 10.5665/sleep.1872; Falloon K, 2015, BRIT J GEN PRACT, V65, pE508, DOI 10.3399/bjgp15X686137; Ferguson T, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0201-9; Fernandez-Mendoza J, 2015, J SLEEP RES, V24, P390, DOI 10.1111/jsr.12285; Finan PH, 2014, SLEEP MED CLIN, V9, P261, DOI 10.1016/j.jsmc.2014.02.007; Ford ES, 2015, SLEEP MED, V16, P372, DOI 10.1016/j.sleep.2014.12.008; Garde AH, 2013, SCAND J WORK ENV HEA, V39, P550, DOI 10.5271/sjweh.3372; Garland SN, 2015, EXPLORE-NY, V11, P445, DOI 10.1016/j.explore.2015.08.004; Gindin J, 2014, J AM GERIATR SOC, V62, P2033, DOI 10.1111/jgs.13099; Godet-Cayre V, 2006, SLEEP, V29, P179, DOI 10.1093/sleep/29.2.179; Greenblatt DJ, 2014, DRUG AGING, V31, P731, DOI 10.1007/s40266-014-0211-3; Greenblatt DJ, 2014, J CLIN PHARMACOL, V54, P282, DOI 10.1002/jcph.220; Greenblatt DJ, 2013, CLIN THER, V35, P604, DOI 10.1016/j.clinthera.2013.03.007; Gross CR, 2011, EXPLORE-NY, V7, P76, DOI 10.1016/j.explore.2010.12.003; Haaramo P, 2014, J SLEEP RES, V23, P281, DOI 10.1111/jsr.12116; Halpern J, 2014, ALTERN THER HEALTH M, V20, P37; Hariprasad VR, 2013, INDIAN J PSYCHIAT, V55, pS364, DOI 10.4103/0019-5545.116310; Heckler CE, 2016, SUPPORT CARE CANCER, V24, P2059, DOI 10.1007/s00520-015-2996-y; Heidenreich T, 2006, PSYCHOTHER PSYCHOSOM, V75, P188, DOI 10.1159/000091778; Herring WJ, 2016, BIOL PSYCHIAT, V79, P136, DOI 10.1016/j.biopsych.2014.10.003; Herring WJ, 2012, NEUROLOGY, V79, P2265, DOI 10.1212/WNL.0b013e31827688ee; Holmqvist M, 2014, SLEEP MED, V15, P187, DOI 10.1016/j.sleep.2013.10.013; Horoszok L, 2014, HUM PSYCHOPHARM CLIN, V29, P266, DOI 10.1002/hup.2395; Hsu HM, 2015, BEHAV RES THER, V73, P143, DOI 10.1016/j.brat.2015.07.016; Hsu YW, 2013, SLEEP MED, V14, P843, DOI 10.1016/j.sleep.2013.02.017; Irwin MR, 2015, BIOL PSYCHIAT, V78, P721, DOI 10.1016/j.biopsych.2015.01.010; Irwin MR, 2014, SLEEP, V37, P1543, DOI 10.5665/sleep.4008; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Jarnefelt H, 2014, BEHAV RES THER, V56, P16, DOI 10.1016/j.brat.2014.02.007; Jarnefelt H, 2012, J OCCUP REHABIL, V22, P511, DOI 10.1007/s10926-012-9365-1; Jaussent I, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-212; Jiang XL, 2015, PUBLIC HEALTH, V129, P1579, DOI 10.1016/j.puhe.2015.07.030; Johnson JA, 2016, SLEEP MED REV, V27, P20, DOI 10.1016/j.smrv.2015.07.001; Jones KD, 2012, CLIN RHEUMATOL, V31, P1205, DOI 10.1007/s10067-012-1996-2; Kao CH, 2012, MAYO CLIN PROC, V87, P430, DOI 10.1016/j.mayocp.2012.02.012; Kapella MC, 2011, INT J CHRONIC OBSTR, V6, P625, DOI 10.2147/COPD.S24858; Kaplan KA, 2013, AM J PSYCHIAT, V170, P716, DOI 10.1176/appi.ajp.2013.12050708; Karlin BE, 2013, J CONSULT CLIN PSYCH, V81, P912, DOI 10.1037/a0032554; Kishi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136910; Kolla BP, 2013, J HOSP MED, V8, P1, DOI 10.1002/jhm.1985; Kriegbaum M, 2015, PHARMACOEPIDEM DR S, V24, P779, DOI 10.1002/pds.3745; Kripke DF, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000850; Kronholm E, 2016, J SLEEP RES, V25, P454, DOI 10.1111/jsr.12398; Krystal AD, 2011, SLEEP, V34, P1433, DOI 10.5665/SLEEP.1294; Krystal AD, 2010, SLEEP, V33, P1553, DOI 10.1093/sleep/33.11.1553; Lallukka T, 2015, J SLEEP RES; Lancee J, 2016, SLEEP, V39, P183, DOI 10.5665/sleep.5344; Lancee J, 2015, COGN BEHAV THERAPY, V44, P406, DOI 10.1080/16506073.2015.1026386; Lankford A, 2012, SLEEP MED, V13, P133, DOI 10.1016/j.sleep.2011.09.006; Larkey LK, 2015, ANN BEHAV MED, V49, P165, DOI 10.1007/s12160-014-9645-4; Larouche M, 2014, PATHOL BIOL, V62, P284, DOI 10.1016/j.patbio.2014.07.002; Laugsand LE, 2014, EUR HEART J, V35, P1382, DOI 10.1093/eurheartj/eht019; LeBlanc M, 2009, SLEEP, V32, P1027, DOI 10.1093/sleep/32.8.1027; Lee J, 2015, STUD HEALTH TECHNOL, V210, P458, DOI 10.3233/978-1-61499-512-8-458; Leger D, 2014, J SLEEP RES, V23, P143, DOI 10.1111/jsr.12104; Leger D, 2010, SLEEP MED, V11, P987, DOI 10.1016/j.sleep.2010.04.019; Li FZ, 2004, J AM GERIATR SOC, V52, P892, DOI 10.1111/j.1532-5415.2004.52255.x; Li Y, 2015, HYPERTENSION, V65, P644, DOI 10.1161/HYPERTENSIONAHA.114.04604; Lichstein KL, 2013, J CLIN PSYCHOL, V69, P1056, DOI 10.1002/jclp.22030; Lovato N, 2013, SLEEP MED, V14, P888, DOI 10.1016/j.sleep.2013.05.008; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; MCCLUSKY HY, 1991, AM J PSYCHIAT, V148, P121; Michelson D, 2014, LANCET NEUROL, V13, P461, DOI 10.1016/S1474-4422(14)70053-5; Min Y, 2016, DRUG AGING, V33, P151, DOI 10.1007/s40266-015-0339-9; Montgomery P, 2002, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858; Morgenthaler T, 2006, SLEEP, V29, P1415; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Mustian KM, 2013, J CLIN ONCOL, V31, P3233, DOI 10.1200/JCO.2012.43.7707; Nicolau ZFM, 2014, CONTEMP CLIN TRIALS, V39, P166, DOI 10.1016/j.cct.2014.08.006; Norell-Clarke A, 2015, BEHAV RES THER, V74, P80, DOI 10.1016/j.brat.2015.09.005; Okajima I, 2012, J CLIN PSYCHIAT, V73, P377, DOI 10.4088/JCP.10m06286; Omvik S, 2008, BEHAV RES THER, V46, P623, DOI 10.1016/j.brat.2008.02.013; Ong J, 2010, J CLIN PSYCHOL, V66, P1175, DOI 10.1002/jclp.20736; Ong JC, 2008, BEHAV THER, V39, P171, DOI 10.1016/j.beth.2007.07.002; Ong JC, 2008, J PSYCHOSOM RES, V64, P419, DOI 10.1016/j.jpsychores.2007.10.009; Ong JC, 2014, SLEEP, V37, P1553, DOI 10.5665/sleep.4010; Ong JC, 2009, EXPLORE-NY, V5, P30, DOI 10.1016/j.explore.2008.10.004; Parthasarathy S, 2015, AM J MED, V128, P268, DOI 10.1016/j.amjmed.2014.10.015; Passos GS, 2010, J CLIN SLEEP MED, V6, P270; Passos GS, 2011, SLEEP MED, V12, P1018, DOI 10.1016/j.sleep.2011.02.007; Pergolizzi Joseph V Jr, 2014, Sleep Disord, V2014, P527109, DOI 10.1155/2014/527109; Perlis ML, 2008, J CLIN SLEEP MED, V4, P11; Reid KJ, 2010, SLEEP MED, V11, P934, DOI 10.1016/j.sleep.2010.04.014; Ritterband LM, 2012, PSYCHO-ONCOLOGY, V21, P695, DOI 10.1002/pon.1969; Rosenberger ME, 2016, MED SCI SPORT EXER, V48, P457, DOI 10.1249/MSS.0000000000000778; Roth T, 2014, HUM PSYCHOPHARM CLIN, V29, P25, DOI 10.1002/hup.2364; Roth T, 2013, SLEEP, V36, P189, DOI 10.5665/sleep.2370; Sarsour K, 2011, SLEEP, V34, P443, DOI 10.1093/sleep/34.4.443; SCHARF MB, 1994, J CLIN PSYCHIAT, V55, P192; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Sivertsen B, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-720; Sivertsen B, 2014, J SLEEP RES, V23, P124, DOI [10.1111/jsr.12102, 10.1111/jsr.12254]; Smith MT, 2015, ARTHRITIS RHEUMATOL, V67, P1221, DOI 10.1002/art.39048; Smitherman TA, 2016, HEADACHE, V56, P276, DOI 10.1111/head.12760; Sun H, 2013, SLEEP, V36, P259, DOI 10.5665/sleep.2386; Taipale HT, 2009, DRUG AGING, V26, P871, DOI 10.2165/11317080-000000000-00000; Talbot LS, 2014, SLEEP, V37, P327, DOI 10.5665/sleep.3408; Taylor-Piliae RE, 2014, ARCH PHYS MED REHAB, V95, P816, DOI 10.1016/j.apmr.2014.01.001; Thorndike FP, 2013, J CLIN PSYCHOL, V69, P1078, DOI 10.1002/jclp.22032; Trauer JM, 2015, ANN INTERN MED, V163, P191, DOI 10.7326/M14-2841; Uemura N, 2015, J CLIN PHARMACOL, V55, P1093, DOI 10.1002/jcph.523; Valente KD, 2013, SLEEP MED, V14, P20, DOI 10.1016/j.sleep.2012.09.003; Vermeeren A, 2014, SLEEP, V37, P489, DOI 10.5665/sleep.3482; Verster JC, 2014, CURR DRUG SAF, V9, P205, DOI 10.2174/1574886309666140601210422; Vitiello MV, 2013, J AM GERIATR SOC, V61, P947, DOI 10.1111/jgs.12275; Vozoris NT, 2014, J CLIN PSYCHIAT, V75, P616, DOI 10.4088/JCP.13m08818; Walsh JK, 2009, SLEEP MED, V10, P859, DOI 10.1016/j.sleep.2008.10.005; Wang F, 2016, SLEEP MED REV, V30, P43, DOI 10.1016/j.smrv.2015.12.001; Wilson SJ, 2010, J PSYCHOPHARMACOL, V24, P1577, DOI 10.1177/0269881110379307; Wong MY, 2016, CLIN PSYCHOL PSYCHOT, V23, P377, DOI 10.1002/cpp.1980; Wu JQ, 2015, JAMA INTERN MED, V175, P1461, DOI 10.1001/jamainternmed.2015.3006; Wu MP, 2014, STROKE, V45, P1349, DOI 10.1161/STROKEAHA.113.003675; Wu RG, 2006, PSYCHOTHER PSYCHOSOM, V75, P220, DOI 10.1159/000092892; Yamadera W, 2013, SLEEP BIOL RHYTHMS, V11, P176, DOI 10.1111/sbr.12019; Ye YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142258; Yeung WF, 2015, SLEEP MED REV, V19, P75, DOI 10.1016/j.smrv.2014.06.001; Zachariae R, 2016, SLEEP MED REV, V30, P1, DOI 10.1016/j.smrv.2015.10.004; Zhan YQ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1050; Zhang JX, 2015, EXPLORE-NY, V11, P180, DOI 10.1016/j.explore.2015.02.005; Zhuang J, 2016, CLIN EXP HYPERTENS, V38, P51, DOI 10.3109/10641963.2015.1060983; Zisapel N, 2015, EXPERT OPIN INV DRUG, V24, P401, DOI 10.1517/13543784.2015.987340	159	72	79	1	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2016	354								i2123	10.1136/bmj.i2123	http://dx.doi.org/10.1136/bmj.i2123			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DR0EP	27383400				2023-01-03	WOS:000379581100001
J	Wong, MH; Chan, DL; Lee, A; Li, BT; Lumba, S; Clarke, SJ; Samra, J; Pavlakis, N				Wong, Matthew H.; Chan, David L.; Lee, Adrian; Li, Bob T.; Lumba, Sumit; Clarke, Stephen J.; Samra, Jaswinder; Pavlakis, Nick			Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)	PLOS ONE			English	Article							ENETS CONSENSUS GUIDELINES; ISLET-CELL-CARCINOMA; STREPTOZOCIN PLUS FLUOROURACIL; PROGNOSTIC-FACTORS; MANAGEMENT; TEMOZOLOMIDE; DOXORUBICIN; NEOPLASMS; INTERFERON; PANCREAS	Background/Objectives In the era of somatostatin analogues and targeted therapies, the role of chemotherapy in NET remains largely undefined. This systematic review aimed to assess the effect of chemotherapy on response rates (RR), progression-free survival (PFS), overall survival (OS) and toxicity compared to other chemotherapies/systemic therapies or best supportive care in patients with advanced or metastatic NET. Methods Randomised controlled trials (RCTs) from 1946 to 2015 were identified from MEDLINE, EMBASE, other databases and conference proceedings. Review of abstracts, quality assessment and data abstraction were performed independently by two investigators. Meta-analyses were conducted using Mantel-Haenszel analysis with random-effects modelling. Results Six RCTs comparing standard streptozotocin plus 5-fluorouacil (STZ/5FU) chemotherapy to other chemotherapy regimens, and 2 comparing this to interferon (IFN) were included. Only 1 study was considered at low risk of bias. STZ/5-FU was no different to other chemotherapies in response rate [RR 0.96; 95% confidence interval (CI) 0.72-1.27], PFS (RR 0.95; CI 0.81-1.13), or OS (RR 1.03; CI 0.77-1.39). IFN may produce higher response than STZ/5FU (RR 0.20; CI 0.04-1.13), but event rates were small and survival was no different. Interferon was associated with higher overall haematological (RR 0.47; CI 0.27-0.82) and lower overall renal toxicity (RR 3.61; CI 1.24-10.51). Conclusion Strong evidence is lacking in the area of chemotherapy in neuroendocrine tumors. There is currently no evidence that one chemotherapeutic regimen is significantly better than the other, nor is interferon better than chemotherapy. There is an urgent need to design RCTs comparing modern chemotherapy to other agents in NET.	[Wong, Matthew H.] Gosford Hosp, Dept Med Oncol, Gosford, Australia; [Wong, Matthew H.; Chan, David L.; Lee, Adrian; Clarke, Stephen J.; Pavlakis, Nick] Univ Sydney, Kolling Inst Med Res, Sydney, NSW, Australia; [Chan, David L.; Lee, Adrian; Lumba, Sumit; Clarke, Stephen J.; Pavlakis, Nick] Royal N Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia; [Lee, Adrian] Northern Canc Inst, Sydney, NSW, Australia; [Li, Bob T.] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, 1275 York Ave, New York, NY 10021 USA; [Li, Bob T.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Samra, Jaswinder] Royal N Shore Hosp, Dept Gastrointestinal Surg, Sydney, NSW, Australia; [Samra, Jaswinder] Macquarie Univ Hosp, Dept Gastrointestinal Surg, Sydney, NSW, Australia	University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital; University of Sydney; Memorial Sloan Kettering Cancer Center; University of Sydney; Royal North Shore Hospital; University of Sydney; Macquarie University	Wong, MH (corresponding author), Gosford Hosp, Dept Med Oncol, Gosford, Australia.; Wong, MH (corresponding author), Univ Sydney, Kolling Inst Med Res, Sydney, NSW, Australia.	matt.wong@health.nsw.gov.au	Chan, David L/E-7149-2017	Chan, David/0000-0002-7773-3144; Clarke, Stephen/0000-0001-5817-1222; Lee, Adrian/0000-0001-5345-5226	Roche; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Roche(Roche Holding); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DLC has received honoraria from Ipsen and travel support from Novartis. NP has received honoraria from Bayer, Roche and Sanofi; provided advice to Roche, Merck, Bayer, Sanofi and Amgen; and received a travel grant from Roche. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Barakat MT, 2004, ENDOCR-RELAT CANCER, V11, P1, DOI 10.1677/erc.0.0110001; BRODER LE, 1973, ANN INTERN MED, V79, P108, DOI 10.7326/0003-4819-79-1-108; Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI 10.1056/NEJMoa1316158; Dahan L, 2009, ENDOCR-RELAT CANCER, V16, P1351, DOI 10.1677/ERC-09-0104; Delaunoit T, 2009, ACTA GASTRO-ENT BELG, V72, P49; Dhall D, 2012, HUM PATHOL, V43, P489, DOI 10.1016/j.humpath.2011.06.011; Dixon E, 2007, CURR OPIN ONCOL, V19, P30, DOI 10.1097/CCO.0b013e328011a236; Ekeblad S, 2007, CLIN CANCER RES, V13, P2986, DOI 10.1158/1078-0432.CCR-06-2053; ENGSTROM PF, 1984, J CLIN ONCOL, V2, P1255, DOI 10.1200/JCO.1984.2.11.1255; Falconi M, 2012, NEUROENDOCRINOLOGY, V95, P120, DOI 10.1159/000335587; Gustafsson BI, 2008, CURR OPIN ONCOL, V20, P1, DOI 10.1097/CCO.0b013e3282f1c595; HEAL JM, 1979, CANCER RES, V39, P82; Higgins J, 2011, HDB SYSTEMATIC REV I; Jensen RT, 2012, NEUROENDOCRINOLOGY, V95, P98, DOI 10.1159/000335591; Kloppel G, 2004, ANN NY ACAD SCI, V1014, P13, DOI 10.1196/annals.1294.002; Kulke MH, 2011, J CLIN ONCOL, V29, P934, DOI 10.1200/JCO.2010.33.2056; Kulke MH, 2010, PANCREAS, V39, P735, DOI 10.1097/MPA.0b013e3181ebb168; Kulke MH, 2006, J CLIN ONCOL, V24, P401, DOI 10.1200/JCO.2005.03.6046; Meyer T, 2014, EUR J CANCER, V50, P902, DOI 10.1016/j.ejca.2013.12.011; Modlin IM, 2008, EXPERT OPIN PHARMACO, V9, P2617, DOI 10.1517/14656566.9.15.2617 ; Modlin IM, 2008, LANCET ONCOL, V9, P61, DOI 10.1016/S1470-2045(07)70410-2; Moertel C G, 1979, Cancer Clin Trials, V2, P327; MOERTEL CG, 1992, NEW ENGL J MED, V326, P519, DOI 10.1056/NEJM199202203260804; MOERTEL CG, 1975, CANCER, V36, P675, DOI 10.1002/1097-0142(197508)36:2+<675::AID-CNCR2820360810>3.0.CO;2-A; MOERTEL CG, 1980, NEW ENGL J MED, V303, P1189, DOI 10.1056/NEJM198011203032101; MURRAYLY.IM, 1968, LANCET, V2, P895; OBERG K, 1989, EUR J CANCER CLIN ON, V25, P1475, DOI 10.1016/0277-5379(89)90107-7; Pape UF, 2012, NEUROENDOCRINOLOGY, V95, P135, DOI 10.1159/000335629; Ramage JK, 2012, GUT, V61, P6, DOI 10.1136/gutjnl-2011-300831; Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510; Seregni E, 2001, ANN ONCOL, V12, pS69, DOI 10.1093/annonc/12.suppl_2.S69; Sorbye H, 2013, ANN ONCOL, V24, P152, DOI 10.1093/annonc/mds276; Strosberg JR, 2011, CANCER-AM CANCER SOC, V117, P268, DOI 10.1002/cncr.25425; Sun WJ, 2005, J CLIN ONCOL, V23, P4897, DOI 10.1200/JCO.2005.03.616; Wolin E, 2015, LANCET; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290	37	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2016	11	6							e0158140	10.1371/journal.pone.0158140	http://dx.doi.org/10.1371/journal.pone.0158140			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0CH	27362760	Green Published, Green Submitted, gold			2023-01-03	WOS:000378865200044
J	Charalambous, A; Giannakopoulou, M; Bozas, E; Marcou, Y; Kitsios, P; Paikousis, L				Charalambous, Andreas; Giannakopoulou, Margarita; Bozas, Evaggelos; Marcou, Yiola; Kitsios, Petros; Paikousis, Lefkios			Guided Imagery And Progressive Muscle Relaxation as a Cluster of Symptoms Management Intervention in Patients Receiving Chemotherapy: A Randomized Control Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; BREAST-CANCER PATIENTS; EORTC QLQ-C30; PAIN; FATIGUE; EFFICACY; ANXIETY; NAUSEA; TRANSPLANTATION; DEPRESSION	Objective Patients receiving chemotherapy often experience many different symptoms that can be difficult to alleviate and ultimately negatively influence their quality of life. Such symptoms include pain, fatigue, nausea, vomiting and retching, anxiety and depression. There is a gap in the relevant literature on the effectiveness of cognitive-behavioural and relaxation techniques in symptom clusters. The study reflects this gap in the literature and aimed to test the effectiveness of Guided Imagery (GI) and Progressive Muscle Relaxation (PMR) on a cluster of symptoms experienced by patients undergoing chemotherapy. Methods This was a randomized control trial with 208 patients equally assigned either in the intervention or the control group. Measurements in both groups were collected at baseline and at completion of intervention (4 weeks). Patients were assessed for pain, fatigue, nausea, vomiting and retching, anxiety and depression. The overall management of the cluster was also assessed based on the patients' self-reported health related quality of life-HRQoL. Chi-square tests (X-2), independent T-tests and Linear Mixed Models were calculated. Results Patients in the intervention group experienced lower levels of Fatigue (p < 0.0.0225), and Pain (p = 0.0003) compared to those in the control group and experienced better HRQoL (p < 0.0001) [PRE-POST: Intervention: Pain 4.2(2.5) -2.5(1.6), Fatigue 27.6(4.1) - 19.3(4.1), HRQoL 54.9(22.7) - 64.5(23), Control: Pain 3.5(1.7) - 4.8(1.5), Fatigue 28.7(4.1) - 32.5(3.8), HRQoL 51.9(22.3)-41.2(24.1)]. Nausea, vomiting and retching occurred significantly less often in the intervention group [pre-post: 25.4(5.9)-20.6(5.6) compared to the control group (17.8(6.5)-22.7(5.3) (F = 58.50 p < 0.0001). More patients in the control group (pre:n = 33-post: n = 47) were found to be moderately depressed compared to those in the intervention group (pre:n = 35-post: n = 15) (X-2 = 5.93; p = 0.02). Conclusion This study provided evidence that the combination of GI and PMR can be effective in the management of a cluster of symptoms in cancer patients receiving chemotherapy. These techniques can complement existing management measures to achieve a comprehensive management of this symptom cluster and increase patients HRQoL.	[Charalambous, Andreas] Cyprus Univ Technol, Limassol, Cyprus; [Charalambous, Andreas] Univ Turku, Turku, Finland; [Giannakopoulou, Margarita; Bozas, Evaggelos] Univ Athens, Athens, Greece; [Marcou, Yiola; Kitsios, Petros] Bank Cyprus Oncol Ctr, Nicosia, Cyprus; [Paikousis, Lefkios] Improvast Analyt Serv Co, Nicosia, Cyprus	Cyprus University of Technology; University of Turku; National & Kapodistrian University of Athens	Charalambous, A (corresponding author), Cyprus Univ Technol, Limassol, Cyprus.; Charalambous, A (corresponding author), Univ Turku, Turku, Finland.	andreas.charalambous@cut.ac.cy	Giannakopoulou, Margarita/AAD-7314-2019; Charalambous, Andreas/R-5753-2018	Giannakopoulou, Margarita/0000-0001-8781-0070; 	Cyprus University of Technology; Improvast; Cyprus University's Open Access Fund	Cyprus University of Technology; Improvast; Cyprus University's Open Access Fund	This study was supported by Cyprus University of Technology. Improvast provided support in the form of salaries for author LP, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.; The authors would like to thank the patients who participated in the study and provided their valuable perspective in adequately evaluating the interventional methods tested within this study. Furthermore, we would like to thank Melanie Charalambous and Theologia Tsitsi who were involved in the delivery of the Guided Imagery and Progressive Muscle Relaxation supervised sessions and Elena Fotiou and PA.SY.KA.F and the Cyprus Anticancer Society for their involvement in the acquisition of the data. The paper is supported by the Cyprus University's Open Access Fund.	American Pain Society, 2005, GUID MAN CANC PAIN A; Arakawa S, 1997, CANCER NURS, V20, P342, DOI 10.1097/00002820-199710000-00005; Armstrong TS, 2004, J NURS SCHOLARSHIP, V36, P197, DOI 10.1111/j.1547-5069.2004.04038.x; Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725; Beck A.T., 1996, BDI 2 BECK DEPRESSIO, V10; Berry DL, 2006, J CLIN ONCOL, V24, P2828, DOI 10.1200/JCO.2005.04.8207; Burns DS, 2001, J MUSIC THER, V38, P51, DOI 10.1093/jmt/38.1.51; Charalambous A, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/270876; Cheung YL, 2003, PSYCHO-ONCOLOGY, V12, P254, DOI 10.1002/pon.638; Dodd M J, 2001, Oncol Nurs Forum, V28, P465; European Medicines Agency, EMACHMP2950502013; Fu MR, 2002, CANCER NURS, V25, P134, DOI 10.1097/00002820-200204000-00010; Gaston-Johansson F, 2000, CANCER NURS, V23, P277, DOI 10.1097/00002820-200008000-00004; Given B, 2001, NURS RES, V50, P222, DOI 10.1097/00006199-200107000-00006; Golan-Vered Y, 2013, PAIN PRACT, V13, P46, DOI 10.1111/j.1533-2500.2012.00554.x; Jacobsen PB, 2002, J CLIN ONCOL, V20, P2851, DOI 10.1200/JCO.2002.08.301; Kim SD, 2005, J CLIN NURS, V14, P51, DOI 10.1111/j.1365-2702.2004.00938.x; Kim SH, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-151; Kincaid Chuck, SAS SOFTWARE P; Kontodimopoulos N, 2011, EUR J CANCER CARE, V20, P354, DOI 10.1111/j.1365-2354.2009.01170.x; Kwekkeboom Kristine L, 2008, Complement Ther Clin Pract, V14, P185, DOI 10.1016/j.ctcp.2008.04.002; Lagopoulos J, 2009, J ALTERN COMPLEM MED, V15, P1187, DOI 10.1089/acm.2009.0113; Lee J, 2005, CANCER NURS, V28, P249; Leon-Pizarro C, 2007, PSYCHO-ONCOLOGY, V16, P971, DOI 10.1002/pon.1171; Liu LQ, 2009, PSYCHO-ONCOLOGY, V18, P187, DOI 10.1002/pon.1412; Molassiotis A, 2000, EUR J CANCER CARE, V9, P230, DOI 10.1046/j.1365-2354.2000.00220.x; Morrow G R, 1993, Oncology (Williston Park), V7, P83; Mosby, 2008, MOSBY MED DICT; Okuyama T, 2000, J PAIN SYMPTOM MANAG, V19, P5, DOI 10.1016/S0885-3924(99)00138-4; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Paice Judith A, 2004, J Natl Cancer Inst Monogr, P98; Pathak P., 2013, INT J ADV NURSING ST, V2, P58; Potthoff K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-162; Rhodes V A, 1984, Cancer Nurs, V7, P33; Rhodes V A, 1999, Oncol Nurs Forum, V26, P889; Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889; Roscoe JA, 2007, ONCOLOGIST, V12, P35, DOI 10.1634/theoncologist.12-S1-35; Sakamoto Y., 1986, J AM STAT ASSOC; Scott DW, 1986, CANC NURS, V9, P178; Shek DTL, 2011, THESCIENTIFICWORLDJO, V11, P42, DOI 10.1100/tsw.2011.2; SLOMAN R, 1995, NURS CLIN N AM, V30, P697; Sloman R, 2002, CANCER NURS, V25, P432, DOI 10.1097/00002820-200212000-00005; Trakhtenberg EC, 2008, INT J NEUROSCI, V118, P839, DOI 10.1080/00207450701792705; Troesch L M, 1993, Oncol Nurs Forum, V20, P1179; Turner JA, 2007, PAIN, V127, P276, DOI 10.1016/j.pain.2006.09.005; Venables W.N., 2002, MODERN APPL STAT S; West BT., 2007, LINEAR MIXED MODELS; Yoo HJ, 2005, SUPPORT CARE CANCER, V13, P826, DOI 10.1007/s00520-005-0806-7; Zung WWK, 1980, NORMAL IS ANXIETY CU	49	51	55	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2016	11	6							e0156911	10.1371/journal.pone.0156911	http://dx.doi.org/10.1371/journal.pone.0156911			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DP3KZ	27341675	Green Submitted, Green Published, gold			2023-01-03	WOS:000378393600004
J	Enewold, L; Thomas, A				Enewold, Lindsey; Thomas, Anish			Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; 1ST-LINE TREATMENT; OPEN-LABEL; AMERICAN SOCIETY; MUTATIONS; CHEMOTHERAPY; GEFITINIB; MULTICENTER; SMOKING; KRAS	Despite being the basis of one of the most effective interventions in lung cancer, little is known about the patterns of epidermal growth factor receptor (EGFR) mutation testing in the general population. We assessed the frequencies and determinants of EGFR testing and erlotinib treatment among a population-based sample. A random sample (n = 1,358) of patients diagnosed in 2010 with histologically-confirmed NSCLC, as reported to the Surveillance Epidemiology and End Results (SEER) program, had their medical records abstracted and treating physicians queried. Logistic regression was used to identify factors associated with EGFR testing and erlotinib treatment. Survival was examined using Cox proportional hazards regression. The frequency of EGFR testing was 16.8% overall and 22.6% for stage IV adenocarcinoma patients. Given an EGFR mutation, 33.6% of all patients and 48.3% of stage IV patients received erlotinib. Among stage IV patients, increased age, Medicaid/no/unknown insurance status, death within 2 months of diagnosis and comorbidity were inversely associated with EGFR testing; erlotinib treatment was less likely among smokers and patients with non-adenocarcinomas. EGFR-mutation was associated with improved survival, albeit only among stage IV adenocarcinomas. Less than a quarter of NSCLC patients diagnosed in 2010 received EGFR testing and less than half of the patients with EGFR-mutant stage IV tumors received erlotinib. Significant disparities were observed in EGFR mutation testing by health insurance status, comorbidity and age. A national strategy is imperative to ensure that resources and processes are in place to efficiently implement molecular testing of cancer.	[Enewold, Lindsey] NCI, Healthcare Assessment Res Branch, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA; [Thomas, Anish] NCI, Thorac & Gastrointestinal Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Enewold, L (corresponding author), NCI, Healthcare Assessment Res Branch, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.	lindsey.enewold@nih.gov			National Cancer Institute [HHSN261201000024C, HHSN261201000025C, HHSN261201000032C, HHSN261201000027C, HHSN261201000026C, HHSN261201000140C, HHSN261201000037C, HHSN261201000033C, HHSN261201000034C, HHSN261201000035C, HHSN261201000029C, HHSN261201000031C, HHSN261201000028C, HHSN261201000030C]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Intramural Research Program of the National Cancer Institute and National Cancer Institute contracts: HHSN261201000024C; HHSN261201000025C, HHSN261201000032C, HHSN261201000027C, HHSN261201000026C, HHSN261201000140C, HHSN261201000037C, HHSN261201000033C, HHSN261201000034C, HHSN261201000035C, HHSN261201000029C, HHSN261201000031C, HHSN261201000028C, and HHSN261201000030C.	American Cancer Society, 2015, CANC FACTS FIG 2015; Araujo LH, 2015, J CLIN ONCOL, V33, P1966, DOI 10.1200/JCO.2014.59.2444; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Ellis PM, 2013, J THORAC ONCOL, V8, P1136, DOI 10.1097/JTO.0b013e31829f6a43; Ettinger DS, 2014, J NATL COMPR CANC NE, V12, P1738, DOI 10.6004/jnccn.2014.0176; Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P1236, DOI 10.6004/jnccn.2012.0130; Hamilton M, 2006, CLIN CANCER RES, V12, P2166, DOI 10.1158/1078-0432.CCR-05-2235; Harlan LC, 2005, J CLIN ONCOL, V23, P9079, DOI 10.1200/JCO.2004.00.1297; Inoue A, 2009, J CLIN ONCOL, V27, P1394, DOI 10.1200/JCO.2008.18.7658; Keedy VL, 2011, J CLIN ONCOL, V29, P2121, DOI 10.1200/JCO.2010.31.8923; Leighl NB, 2014, J CLIN ONCOL, V32, P3673, DOI 10.1200/JCO.2014.57.3055; Lindeman NI, 2013, J THORAC ONCOL, V8, P1343, DOI 10.1097/JTO.0000000000000003; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McQuitty E, 2014, ARCH PATHOL LAB MED, V138, P390, DOI 10.5858/arpa.2013-0225-OA; Miller FA, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-131; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Moreira AL, 2012, CLIN LUNG CANCER, V13, P334, DOI 10.1016/j.cllc.2012.01.004; National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pan IW, 2013, LUNG CANCER, V82, P469, DOI 10.1016/j.lungcan.2013.09.018; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Reinersman JM, 2011, J THORAC ONCOL, V6, P28, DOI 10.1097/JTO.0b013e3181fb4fe2; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sasaki H, 2006, INT J CANCER, V118, P180, DOI 10.1002/ijc.21301; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sequist LV, 2007, ONCOLOGIST, V12, P90, DOI 10.1634/theoncologist.12-1-90; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Yang SH, 2005, CLIN CANCER RES, V11, P2106, DOI 10.1158/1078-0432.CCR-04-1853; Zhang W, 2014, ARCH PATHOL LAB MED, V138, P543, DOI 10.5858/arpa.2013-0311-OA; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	33	48	49	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2016	11	6							e0156728	10.1371/journal.pone.0156728	http://dx.doi.org/10.1371/journal.pone.0156728			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KF	27294665	Green Submitted, Green Published, gold			2023-01-03	WOS:000377821300011
J	Kristensen, HK; Tistad, M; von Koch, L; Ytterberg, C				Kristensen, Hanne Kaae; Tistad, Malin; von Koch, Lena; Ytterberg, Charlotte			The Importance of Patient Involvement in Stroke Rehabilitation	PLOS ONE			English	Article							LONG-TERM NEEDS; SURVIVORS EXPERIENCES; IMPACT; SELF; CARE; PEOPLE; VIEWS	Objective To investigate the perceived needs for health services by persons with stroke within the first year after rehabilitation, and associations between perceived impact of stroke, involvement in decisions regarding care/treatment, and having health services needs met. Method Data was collected, through a mail survey, from patients with stroke who were admitted to a university hospital in 2012 and had received rehabilitation after discharge from the stroke unit. The rehabilitation lasted an average of 2 to 4.6 months. The Stroke Survivor Needs Survey Questionnaire was used to assess the participants' perceptions of involvement in decisions on care or treatment and needs for health services in 11 problem areas: mobility, falls, incontinence, pain, fatigue, emotion, concentration, memory, speaking, reading, and sight. The perceived impact of stroke in eight areas was assessed using the Stroke Impact Scale (SIS) 3.0. Eleven logistic regression models were created to explore associations between having health services needs met in each problem area respectively (dependent variable) and the independent variables. In all models the independent variables were: age, sex, SIS domain corresponding to the dependent variable, or stroke severity in cases when no corresponding SIS domain was identified, and involvement in decisions on care and treatment. Results The 63 participants who returned the questionnaires had a mean age of 72 years, 33 were male and 30 were female. Eighty percent had suffered a mild stroke. The number of participants who reported problems varied between 51 (80%, mobility) and 24 (38%, sight). Involvement in decisions on care and treatment was found to be associated with having health services needs met in six problem areas: falls, fatigue, emotion, memory, speaking, and reading. Conclusions The results highlight the importance of involving patients in making decisions on stroke rehabilitation, as it appears to be associated with meeting their health services needs.	[Kristensen, Hanne Kaae] Univ Coll Lillebaelt, Hlth Sci Res Ctr, Odense, Denmark; [Kristensen, Hanne Kaae; Ytterberg, Charlotte] Univ Southern Denmark, Res Unit Rehabil, Inst Clin Res, Odense, Denmark; [Tistad, Malin; von Koch, Lena; Ytterberg, Charlotte] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden; [Tistad, Malin] Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden; [von Koch, Lena] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden	University of Southern Denmark; Karolinska Institutet; Dalarna University; Karolinska Institutet; Karolinska University Hospital	Kristensen, HK (corresponding author), Univ Coll Lillebaelt, Hlth Sci Res Ctr, Odense, Denmark.; Kristensen, HK (corresponding author), Univ Southern Denmark, Res Unit Rehabil, Inst Clin Res, Odense, Denmark.	hkkr@ucl.dk	von Koch, Lena/P-2310-2018	von Koch, Lena/0000-0002-8560-3016; Ytterberg, Charlotte/0000-0003-3704-8887; Kristensen, Hanne Kaae/0000-0002-9596-5571	Danish Regions; Danish Health Cartel	Danish Regions; Danish Health Cartel	The authors acknowledge Danish Regions and the Danish Health Cartel for funding the study. The funders had no role in study design, datacollection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank The UK Stroke Association for providing the Stroke Survivor Needs Survey Questionnaire. Moreover, we thank Danish Regions and the Danish Health Cartel for funding the study.	Brown M, 2014, DISABIL REHABIL, V36, P1020, DOI 10.3109/09638288.2013.825653; Constand MK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-271; Danish Board of Health, 2011, BRAIN INJURY REHABIL; Danish Health and Medicines Authority, 2014, DISEASE MANAGEMENT P; de Port IGLV, 2007, DISABIL REHABIL, V29, P1841, DOI 10.1080/09638280601129157; Docteur E., 2012, PATIENT CENTREDNESS; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Duxbury S, 2012, OCCUP THER HEALTH CA, V26, P16, DOI 10.3109/07380577.2011.621514; Dworzynski K, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3615; Flink M, 2015, CLIN REHABIL; Godolphin William, 2009, Healthc Q, V12 Spec No Patient, pe186; Govan L, 2009, STROKE, V40, P3396, DOI 10.1161/STROKEAHA.109.557645; Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725; Jones F, 2011, DISABIL REHABIL, V33, P797, DOI 10.3109/09638288.2010.511415; Kasner SE, 2006, LANCET NEUROL, V5, P603, DOI 10.1016/S1474-4422(06)70495-1; Kersten P, 2002, DISABIL REHABIL, V24, P860, DOI 10.1080/09638280210142167; Kristensen HK, 2015, INT J THER REHABIL, V22, P460, DOI 10.12968/ijtr.2015.22.10.460; Kristensen HK, 2015, DISABIL REHABIL IN P; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Leach E, 2010, DISABIL REHABIL, V32, P159, DOI 10.3109/09638280903036605; Levack William M M, 2015, Cochrane Database Syst Rev, pCD009727, DOI 10.1002/14651858.CD009727.pub2; Lindsay MP, 2010, CANADIAN BEST PRACTI; Luker J, 2015, ARCH PHYS MED REHAB, V96, P1698, DOI 10.1016/j.apmr.2015.03.017; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; Momsen AM, 2012, J REHABIL MED, V44, P901, DOI 10.2340/16501977-1040; National Institute For Health And Care Excellence [NICE], 2013, STROKE REHABILITATIO; Nordin NAM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-118; Peoples H, 2011, SCAND J OCCUP THER, V18, P163, DOI 10.3109/11038128.2010.509887; Robison J, 2009, DISABIL REHABIL, V31, P1555, DOI 10.1080/09638280802639327; Rosewilliam S, 2015, CLIN REHABIL; Rosewilliam S, 2015, REHABILITATION GOAL, P345; Salter K, 2008, J REHABIL MED, V40, P595, DOI 10.2340/16501977-0238; Satink T, 2013, ARCH PHYS MED REHAB, V94, P1171, DOI 10.1016/j.apmr.2013.01.011; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Sugavanam T, 2013, DISABIL REHABIL, V35, P177, DOI 10.3109/09638288.2012.690501; Sumathipala K, 2012, CHRONIC ILLN, V8, P31, DOI 10.1177/1742395311423848; Sumsion Thelma, 2006, Can J Occup Ther, V73, P153; Talbot Lise R, 2004, Health Qual Life Outcomes, V2, P53, DOI 10.1186/1477-7525-2-53; Tang WK, 2015, TOP STROKE REHABIL, V22, P194, DOI 10.1179/1074935714Z.0000000024; Tistad M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-40; Tistad M, 2012, J NEUROL SCI, V313, P160, DOI 10.1016/j.jns.2011.08.038; Turner-Stokes L, 2015, INT J THER REHABIL, V22, P210, DOI 10.12968/ijtr.2015.22.5.210; Vincent Claude, 2007, BMC Geriatr, V7, P20; Walsh ME, 2015, DISABIL REHABIL, V37, P1599, DOI 10.3109/09638288.2014.974834; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Zimmermann L, 2014, PATIENT EDUC COUNS, V96, P98, DOI 10.1016/j.pec.2014.04.015	46	37	38	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2016	11	6							e0157149	10.1371/journal.pone.0157149	http://dx.doi.org/10.1371/journal.pone.0157149			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DO1UG	27285997	gold, Green Published, Green Submitted			2023-01-03	WOS:000377564000041
J	Hsu, CL; Hsu, CW; Chang, PC; Huang, WH; Weng, CH; Yang, HY; Liu, SH; Chen, KH; Weng, SM; Chang, CC; Wang, IK; Tsai, AI; Yen, TH				Hsu, Chia-Lin; Hsu, Ching-Wei; Chang, Pei-Ching; Huang, Wen-Hung; Weng, Cheng-Hao; Yang, Huang-Yu; Liu, Shou-Hsuan; Chen, Kuan-Hsing; Weng, Shu-Man; Chang, Chih-Chun; Wang, I-Kuan; Tsai, Aileen I.; Yen, Tzung-Hai			Oral Tori in Chronic Peritoneal Dialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; CLINICAL CHARACTERISTICS; PREVALENCE; PALATINUS; MANDIBULARIS; CONCURRENCE; ASSOCIATION; POPULATION; EXOSTOSES	Background The pathogenesis of oral tori has long been debated and is thought to be the product of both genetic and environmental factors, including occlusal forces. Another proposed mechanism for oral tori is the combination of biomechanical forces, particularly in the oral cavity, combined with cortical bone loss and trabecular expansion, as one might see in the early stages of primary hyperparathyroidism. This study investigated the epidemiology of torus palatinus (TP) and torus mandibularis (TM) in peritoneal dialysis patients, and analyzed the influences of hyperparathyroidism on the formation of oral tori. Method In total, 134 peritoneal dialysis patients were recruited between July 1 and December 31, 2015 for dental examinations for this study. Patients were categorized into two subgroups based on the presence or absence of oral tori. Demographic, hematological, biochemical, and dialysis-related data were obtained for analysis. Results The prevalence of oral tori in our sample group was high at 42.5%(57 of 134), and most patients with oral tori were female (61.4%). The most common location of tori was TP (80.7%), followed by TP and TM (14.0%), then TM (5.3%). All 54 TP cases were at the midline, and most were <2 cm (59.3%), flat (53.7%), and located in the premolar region (40.7%). Of the 11 TM cases, all were bilateral and symmetric, mostly <2 cm (81.9%), lobular (45.4%), and located at premolar region (63.6%). Interestingly, patients with oral tori had slightly lower serum levels of intact parathyroid hormones than those without oral tori, but the difference was not statistically significant (317.3 +/- 292.0 versus 430.1 +/- 492.6 pg/mL, P = 0.126). In addition, patients with oral tori did not differ from patients without tori in inflammatory variables such as serum high sensitivity C-reactive protein levels (6.6 +/- 8.2 versus 10.3 +/- 20.2 mg/L, P = 0.147) or nutritional variables such as serum albumin levels (3.79 +/- 0.38 versus 3.77 +/- 0.45 g/dL, P = 0.790). Furthermore, there were no differences between patients with and without oral tori in dialysis adequacy (weekly Kt/V-urea, 2.14 +/- 0.39 versus 2.11 +/- 0.33, P = 0.533; weekly creatinine clearance rate, 59.31 +/- 17.58 versus 58.57 +/- 13.20 L/1.73 m(2), P = 0.781), or peritoneal membrane transporter characteristics (P = 0.098). Conclusion Secondary hyperparathyroidism does not contribute to the formation of tori in peritoneal dialysis patients. Further studies are warranted.	[Hsu, Chia-Lin; Chang, Pei-Ching; Tsai, Aileen I.] Chang Gung Mem Hosp, Dept Pediat Dent, Linkou, Taiwan; [Hsu, Ching-Wei; Huang, Wen-Hung; Weng, Cheng-Hao; Yang, Huang-Yu; Liu, Shou-Hsuan; Chen, Kuan-Hsing; Weng, Shu-Man; Yen, Tzung-Hai] Chang Gung Univ, Chang Gung Mem Hosp, Dept Nephrol, Linkou, Taiwan; [Hsu, Ching-Wei; Huang, Wen-Hung; Weng, Cheng-Hao; Yang, Huang-Yu; Liu, Shou-Hsuan; Chen, Kuan-Hsing; Weng, Shu-Man; Yen, Tzung-Hai] Chang Gung Univ, Coll Med, Linkou, Taiwan; [Huang, Wen-Hung; Weng, Cheng-Hao; Yang, Huang-Yu; Liu, Shou-Hsuan; Chen, Kuan-Hsing; Yen, Tzung-Hai] Chang Gung Mem Hosp, Kidney Res Ctr, Linkou, Taiwan; [Chang, Chih-Chun] Far Eastern Mem Hosp, Dept Clin Pathol, New Taipei, Taiwan; [Wang, I-Kuan] China Med Univ, China Med Univ Hosp, Dept Nephrol, Taichung, Taiwan; [Wang, I-Kuan] China Med Univ, Coll Med, Taichung, Taiwan; [Yen, Tzung-Hai] Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Far Eastern Memorial Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Chang Gung Memorial Hospital	Tsai, AI (corresponding author), Chang Gung Mem Hosp, Dept Pediat Dent, Linkou, Taiwan.; Yen, TH (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Dept Nephrol, Linkou, Taiwan.; Yen, TH (corresponding author), Chang Gung Univ, Coll Med, Linkou, Taiwan.; Yen, TH (corresponding author), Chang Gung Mem Hosp, Kidney Res Ctr, Linkou, Taiwan.; Yen, TH (corresponding author), Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou, Taiwan.	ait001@adm.cgmh.org.tw; m19570@adm.cgmh.org.tw	huang, wen/GXW-0661-2022; Yen, Tzung-Hai/AAQ-4525-2020	Yen, Tzung-Hai/0000-0002-0907-1505; YANG, HUANG-YU/0000-0001-6826-9717	Ministry of Science and Technology, Taiwan (MST) [104-2221-E182A-003]; Chang Gung Memorial Hospital, Linkou, Taiwan (CMRP) [G3D0012, G3E0361, G3D0072, G3F0601, C3F1161, G3F0371]	Ministry of Science and Technology, Taiwan (MST); Chang Gung Memorial Hospital, Linkou, Taiwan (CMRP)	Support was provided by the Ministry of Science and Technology, Taiwan (MST 104-2221-E182A-003) and Chang Gung Memorial Hospital, Linkou, Taiwan (CMRP G3D0012, G3E0361, G3D0072, G3F0601, C3F1161, G3F0371). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Quran Firas A M, 2006, J Contemp Dent Pract, V7, P112; Al-Bayaty HF, 2001, INT DENT J, V51, P300, DOI 10.1002/j.1875-595X.2001.tb00842.x; Antoniades DZ, 1998, ORAL SURG ORAL MED O, V85, P552, DOI 10.1016/S1079-2104(98)90290-6; Auskalnis A, 2015, MEDICINA-LITHUANIA, V51, P228, DOI 10.1016/j.medici.2015.07.001; Bruce I, 2004, INT DENT J, V54, P78, DOI 10.1111/j.1875-595X.2004.tb00259.x; Chao PJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/897674; Chiang ML, 2014, J DENT SCI, V9, P69, DOI 10.1016/j.jds.2013.06.004; EGGEN S, 1994, SCAND J DENT RES, V102, P60; EGGEN S, 1986, SCAND J DENT RES, V94, P233; EGGEN S, 1994, SCAND J DENT RES, V102, P54; Garcia-Garcia AS, 2010, MED ORAL PATOL ORAL, V15, pE353, DOI 10.4317/medoral.15.e353; Gorsky M, 1996, ARCH ORAL BIOL, V41, P623, DOI 10.1016/0003-9969(96)00149-5; Gorsky M, 1998, AM J MED GENET, V75, P138, DOI 10.1002/(SICI)1096-8628(19980113)75:2<138::AID-AJMG3>3.0.CO;2-P; HAUGEN LK, 1992, ACTA ODONTOL SCAND, V50, P65, DOI 10.3109/00016359209012748; Hiremath VK, 2011, J INT SOC PREV COMMU, V1, P60, DOI 10.4103/2231-0762.97704; Hsu CW, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-17; Jainkittivong A, 2007, SURG RADIOL ANAT, V29, P125, DOI 10.1007/s00276-007-0184-6; Jorgetti V, 2009, NEPHROLOGY, V14, P404, DOI 10.1111/j.1440-1797.2009.01148.x; Lin JL, 2010, NEPHROL DIAL TRANSPL, V25, P1627, DOI 10.1093/ndt/gfp663; Miller PD, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.44; Padbury AD, 2006, J CLIN ENDOCR METAB, V91, P3439, DOI 10.1210/jc.2005-2282; Rai Sachin, 2012, Indian J Dent Res, V23, P384, DOI 10.4103/0970-9290.102236; REICHART PA, 1988, COMMUNITY DENT ORAL, V16, P61, DOI 10.1111/j.1600-0528.1988.tb00557.x; Romanos Georgios E, 2013, N Y State Dent J, V79, P25; Sathya K, 2012, J Oral Biol Craniofac Res, V2, P15, DOI 10.1016/S2212-4268(12)60005-0; Sawair FA, 2009, SAUDI MED J, V30, P1557; Simunkovic SK, 2011, COLLEGIUM ANTROPOL, V35, P637; Sisman Y, 2012, J DENT SCI, V7, P154, DOI 10.1016/j.jds.2012.03.012; Sisman Yildiray, 2008, Eur J Dent, V2, P269; Sprague SM, 2016, AM J KIDNEY DIS, V67, P559, DOI 10.1053/j.ajkd.2015.06.023; United States Renal Data System, 2015, 2015 USRDS ANN DAT R; Wang TY, 2011, NEPHROLOGY, V16, P225, DOI 10.1111/j.1440-1797.2010.01366.x; Yildiz E, 2005, SURG RADIOL ANAT, V27, P368, DOI 10.1007/s00276-005-0003-x; Yoshinaka M, 2010, J ORAL REHABIL, V37, P848, DOI 10.1111/j.1365-2842.2010.02100.x; Yoshinaka M, 2014, GERODONTOLOGY, V31, P117, DOI 10.1111/ger.12017	35	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2016	11	6							e0156988	10.1371/journal.pone.0156988	http://dx.doi.org/10.1371/journal.pone.0156988			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TJ	27275607	gold, Green Published, Green Submitted			2023-01-03	WOS:000377561700054
J	Goette, A; Merino, JL; Ezekowitz, MD; Zamoryakhin, D; Melino, M; Jin, J; Mercuri, MF; Grosso, MA; Fernandez, V; Al-Saady, N; Pelekh, N; Zenin, S; Kushnir, M; Spinar, J; Batushkin, V; Lip, GYH; Weitz, J; Freemantle, N; Klein, H; Buller, H; Segers, A; Roos, Y; Slagboom, T; Thijs, V; van Mechelen, R; Larrey, D; Laleman, W; Huber, K; Heidbuchel, H; Goudev, A; Kautzner, J; Rasmussen, L; Cohen, A; Le Heuzey, JY; Glikson, M; Themistoclakis, S; De Caterina, R; Banach, M; Dan, GA; Ruda, M; Lundqvist, CB; Sychov, O; Ellenbogen, K; Ezekowitz, M; Gwechenberger, M; Huber, K; Purerfellner, H; Roithinger, F; Scherr, D; Stuhlinger, M; Delforge, M; Rivero-Ayerza, M; Thoeng, J; Vervoort, G; Vijgen, J; Willems, R; Benov, H; Dimov, B; Nikolov, F; Godev, A; Jorgova-Makedonska, J; Lazov, P; Marchev, S; Mihov, L; Petranov, S; Raev, D; Stoyanov, M; Tarnovska-Kadreva, R; Todorov, G; Tumbev, H; Cermak, O; Slany, N; Jarkovsky, P; Kautzner, J; Lukac, B; Nadenickova, P; Peterka, K; Slaby, J; Spinar, J; Vesely, J; Vitovec, M; Zavada, F; Al-Hashimi, S; Bronnum-Schou, J; Egstrup, K; Frost, L; Gislason, G; Lomholdt, J; Malczynski, J; Moller, DS; Nielsen, T; Raymond, I; Riahi, S; Tuxen, C; Cohen, A; Cottin, Y; Defaye, P; Deharo, JC; Depuis, JM; Elbaz, M; Ferrari, E; Gosse, P; Goube, P; Paganelli, F; Pineau, J; Piot, O; Biermann, J; Bosch, R; Brachmann, J; Darius, H; Dengler, T; Hartmann, A; Kreis, I; Lamparter, S; Licka, M; Maier, L; Schellong, S; Schmitt, J; Stellbrink, C; Walkili, R; Willems, S; vom Dahl, J; Dezsi, A; Edes, I; Laszlo, S; Lupkovics, G; Matoltsy, A; Merkely, B; Nagy, A; Nagy, L; Palinkas, A; Simor, T; Tomcsanyi, J; Toth, L; Alcalai, R; Hayek, T; Katz, A; Mazen, E; Shechter, M; Shochat, M; Zeltser, D; Zimlichman, R; Boriani, G; De Caterina, R; Di Pasquale, G; Fattore, L; Grimaldi, M; Gulizia, M; Mazzone, C; Themistoclakis, S; Volpe, M; Allaart, C; de Groot, J; Elvan, A; Folkeringa, R; Hazeleger, R; Jansen, W; Nierop, P; Willems, A; de Ruiter, G; Czarnecka, D; Gniot, J; Januszewicz, A; Jaworska, K; Loboz-Grudzien, K; Niezgoda, K; Ptaszynski, P; Wysokinski, A; Bartos, D; Bengus, C; Bolohan, R; Chioncel, O; Coman, IM; Crisu, D; Dan, GA; Dobreanu, D; Dumitrescu, S; Gurghean, A; Lighezan, D; Militaru, C; Minescu, B; Podoleanu, CCG; Pop, C; Popescu, MI; Rosu, RO; Tase, A; Voicu, OC; Belenky, D; Bolshakova, O; Chumakova, G; Demko, A; Goloshchekin, B; Kostenko, V; Kuznetsov, V; Libov, I; Nevzorova, V; Nikolaev, K; Popov, S; Shubik, Y; Staroverov, I; Timofeev, A; Zrazhevskiy, K; Valladares, FA; Lopez, MA; Arenal, A; Gonzalez, VB; Cosin-Sales, J; Gonzalez-Juanatey, JR; Rubio, AM; Martinez, JG; Falconi, E; Mont, L; Bermejo, MAP; Sabate, X; Camano, MV; Vida, M; Vinolas, X; Gomez, JLZ; Lindquist, CB; Fredholm, O; Savelieva, I; Haywood, G; Aggarwal, R; Bakhai, A; Balasubramaniam, R; Betts, T; Campbell, P; Choy, AM; Davis, G; Izzat, L; Kadr, H; Lindsay, S; Lip, G; More, R; Ng, GA; Payne, G; Schilling, R; Senior, R; Tayebjee, M; Travill, C; Rishko, M; Batushkin, V; Fushtey, I; Karpenko, O; Karpenko, Y; Klantsa, A; Kraiz, I; Kushnir, M; Kutniy, O; Parkhomenko, A; Petrovskyy, R; Reshotko, D; Stanislavchuk, M; Sychov, O; Tseluyko, V; Vasylets, V; Minakova, PO; Volkov, D; Zharinov, O; Zhurba, S; Aggarwal, R; Bahu, M; Bashir, F; Berk, M; Cheirif, J; Clay, A; Crenshaw, J; Ellenbogen, K; Ganeshram, V; Halpern, S; Heiman, M; Henderson, D; Ho, A; Kovach, T; Mckenzie, M; Nadar, V; Penny-Peterson, E; Rao, S; Sawhney, N; Shaoulian, E; Sheikh, K; Torres-Heisecke, R; Weiss, R				Goette, Andreas; Merino, Jose L.; Ezekowitz, Michael D.; Zamoryakhin, Dmitry; Melino, Michael; Jin, James; Mercuri, Michele F.; Grosso, Michael A.; Fernandez, Victor; Al-Saady, Naab; Pelekh, Natalya; Zenin, Sergey; Kushnir, Mykola; Spinar, Jindrich; Batushkin, Valeriy; Lip, Gregory Y. H.; Weitz, Jeffrey; Freemantle, Nicholas; Klein, Helmut; Buller, Harry; Segers, Annelise; Roos, Yvo; Slagboom, Ton; Thijs, Vincent; van Mechelen, Rob; Larrey, Dominique; Laleman, Wim; Huber, Kurt; Heidbuchel, Hein; Goudev, Assen; Kautzner, Josef; Rasmussen, Lars; Cohen, Ariel; Le Heuzey, Jean-Yves; Glikson, Michael; Themistoclakis, Sakis; De Caterina, Raffaele; Banach, Maciej; Dan, Gheorghe-Andrei; Ruda, Mikhail; Lundqvist, Carina Blomstrom; Sychov, Oleg; Ellenbogen, Kenneth; Ezekowitz, Michael; Gwechenberger, Marianne; Huber, Kurt; Purerfellner, Helmut; Roithinger, Franz; Scherr, Daniel; Stuhlinger, Markus; Delforge, Marc; Rivero-Ayerza, Maximo; Thoeng, John; Vervoort, Geert; Vijgen, Johan; Willems, Rik; Benov, Haralambi; Dimov, Bojidar; Nikolov, Fedya; Godev, Assen; Jorgova-Makedonska, Julia; Lazov, Petar; Marchev, Sotir; Mihov, Lenko; Petranov, Stanislav; Raev, Dimitar; Stoyanov, Miroslav; Tarnovska-Kadreva, Rumiana; Todorov, Georgi; Tumbev, Haralin; Cermak, Ondrej; Slany, Nemocnice; Jarkovsky, Patrik; Kautzner, Josef; Lukac, Bohdan; Nadenickova, Pavla; Peterka, Karel; Slaby, Josef; Spinar, Jindrich; Vesely, Jiri; Vitovec, Miroslav; Zavada, Filip; Al-hashimi, Souhad; Bronnum-Schou, Jens; Egstrup, Kenneth; Frost, Lars; Gislason, Gunnar; Lomholdt, Jens; Malczynski, Jerzy; Moller, Dorthe Svendstrup; Nielsen, Tonni; Raymond, Ilan; Riahi, Sam; Tuxen, Christian; Cohen, Ariel; Cottin, Yves; Defaye, Pascal; Deharo, Jean-Claude; Depuis, Jean-Marc; Elbaz, Meyer; Ferrari, Emile; Gosse, Philippe; Goube, Pascal; Paganelli, Franck; Pineau, Julien; Piot, Olivier; Biermann, Jurgen; Bosch, Ralph; Brachmann, Johannes; Darius, Harald; Dengler, Thomas; Hartmann, Andreas; Kreis, Ingo; Lamparter, Steffen; Licka, Manuela; Maier, Lars; Schellong, Sebastian; Schmitt, Jorn; Stellbrink, Christoph; Walkili, Reza; Willems, Stephan; vom Dahl, Juergen; Dezsi, Andras; Edes, Istvan; Laszlo, Saghy; Lupkovics, Geza; Matoltsy, Andras; Merkely, Bela; Nagy, Andras; Nagy, Lajos; Palinkas, Attila; Simor, Tamas; Tomcsanyi, Janos; Toth, Laszlo; Alcalai, Ronny; Hayek, Tony; Katz, Amos; Mazen, Elias; Shechter, Michael; Shochat, Michael; Zeltser, David; Zimlichman, Reuven; Boriani, Guiseppe; De Caterina, Raffaele; Di Pasquale, Giuseppe; Fattore, Luciano; Grimaldi, Massimo; Gulizia, Michele; Mazzone, Carmine; Themistoclakis, Sakis; Volpe, Massimo; Allaart, Cornelis; de Groot, Joris; Elvan, Arif; Folkeringa, Richard; Hazeleger, Ronald; Jansen, Ward; Nierop, Pieter; Willems, Albert; de Ruiter, Gijsbert; Czarnecka, Danuta; Gniot, Jacek; Januszewicz, Andrzey; Jaworska, Krystyna; Loboz-Grudzien, Krystyna; Niezgoda, Krzysztof; Ptaszynski, Pawel; Wysokinski, Andrzej; Bartos, Daniela; Bengus, Cristina; Bolohan, Romi; Chioncel, Ovidiu; Coman, Ioan-Mircea; Crisu, Daniela; Dan, Gheorghe-Andrei; Dobreanu, Dan; Dumitrescu, Silviu; Gurghean, Adriana; Lighezan, Daniel; Militaru, Constantin; Minescu, Bogdan; Podoleanu, Cristian Calin Gheorghe; Pop, Calin; Popescu, Mircea Ioachim; Rosu, Radu Ovidiu; Tase, Adrian; Voicu, Olga Cristina; Belenky, Dmitry; Bolshakova, Olga; Chumakova, Galina; Demko, Arkadiy; Goloshchekin, Boris; Kostenko, Viktor; Kuznetsov, Vadim; Libov, Igor; Nevzorova, Vera; Nikolaev, Konstantin; Popov, Sergey; Shubik, Yuriy; Staroverov, Ilya; Timofeev, Alexander; Zrazhevskiy, Konstantin; Alonso Valladares, Francisco; Alvarez Lopez, Miguel; Arenal, Angel; Bertomeu Gonzalez, Vicente; Cosin-Sales, Juan; Ramon Gonzalez-Juanatey, Jose; Martinez Rubio, Antoni; Gabriel Martinez, Juan; Falconi, Estela; Mont, Lluis; Paz Bermejo, Marco Antonio; Sabate, Xavier; Vazquez Camano, Maria; Vida, Manuel; Vinolas, Xavier; Zamorano Gomez, Jose Luis; Lindquist, Carina Blomstrom; Fredholm, Olle; Savelieva, Irina; Haywood, Guy; Aggarwal, Rajesh; Bakhai, Ameet; Balasubramaniam, Richard; Betts, Tim; Campbell, Phillip; Choy, Anna Maria; Davis, Gershan; Izzat, Lena; Kadr, Honer; Lindsay, Steven; Lip, Gregory; More, Ranjit; Ng, Ghulam Andre; Payne, Gillian; Schilling, Richard; Senior, Roxy; Tayebjee, Muzahir; Travill, Chris; Rishko, Mykola; Batushkin, Valerii; Fushtey, Ivan; Karpenko, Oleksandr; Karpenko, Yuriy; Klantsa, Andriy; Kraiz, Igor; Kushnir, Mykola; Kutniy, Oles; Parkhomenko, Aleksander; Petrovskyy, Roman; Reshotko, Dmytro; Stanislavchuk, Mykola; Sychov, Oleg; Tseluyko, Vira; Vasylets, Victoria; Minakova, Prof. O. I.; Volkov, Dmytro; Zharinov, Oleg; Zhurba, Svitlana; Aggarwal, Rahul; Bahu, Marwan; Bashir, Faran; Berk, Martin; Cheirif, Jorge; Clay, Anthony; Crenshaw, James; Ellenbogen, Kenneth; Ganeshram, Vedampattu; Halpern, Stephen; Heiman, Mark; Henderson, David; Ho, Andrew; Kovach, Todd; Mckenzie, Marcus; Nadar, Venkatesh; Penny-Peterson, Erica; Rao, Sunder; Sawhney, Navinder; Shaoulian, Emanuel; Sheikh, Khalid; Torres-Heisecke, Raul; Weiss, Robert		ENSURE-AF Investigators	Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial	LANCET			English	Article							ORAL ANTICOAGULANTS; EFFICACY; SAFETY	Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about edoxaban in patients undergoing electrical cardioversion are available. Methods We did a multicentre, prospective, randomised, open-label, blinded-endpoint evaluation trial in 19 countries with 239 sites comparing edoxaban 60 mg per day with enoxaparin-warfarin in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. The dose of edoxaban was reduced to 30 mg per day if one or more factors (creatinine clearance 15-50 mL/min, low bodyweight [<= 60 kg], or concomitant use of P-glycoprotein inhibitors) were present. Block randomisation (block size four)-stratified by cardioversion approach (transoesophageal echocardiography [TEE] or not), anticoagulant experience, selected edoxaban dose, and region-was done through a voice-web system. The primary efficacy endpoint was a composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular mortality, analysed by intention to treat. The primary safety endpoint was major and clinically relevant non-major (CRNM) bleeding in patients who received at least one dose of study drug. Follow-up was 28 days on study drug after cardioversion plus 30 days to assess safety. This trial is registered with ClinicalTrials.gov, number NCT02072434. Findings Between March 25, 2014, and Oct 28, 2015, 2199 patients were enrolled and randomly assigned to receive edoxaban (n= 1095) or enoxaparin-warfarin (n= 1104). The mean age was 64 years (SD 10 . 54) and mean CHA(2)DS(2)-VASc score was 2.6 (SD 1.4). Mean time in therapeutic range on warfarin was 70.8% (SD 27.4). The primary efficacy endpoint occurred in five (<1%) patients in the edoxaban group versus 11 (1%) in the enoxaparin-warfarin group (odds ratio [OR] 0.46, 95% CI 0.12-1.43). The primary safety endpoint occurred in 16 (1%) of 1067 patients given edoxaban versus 11 (1%) of 1082 patients given enoxaparin-warfarin (OR 1.48, 95% CI 0.64-3.55). The results were independent of the TEE-guided strategy and anticoagulation status. Interpretation ENSURE-AF is the largest prospective randomised clinical trial of anticoagulation for cardioversion of patients with non-valvular atrial fibrillation. Rates of major and CRNM bleeding and thromboembolism were low in the two treatment groups. Funding Daiichi Sankyo provided financial support for the study.	[Goette, Andreas] St Vincenz Hosp, Cardiol & Intens Care Med, D-33098 Paderborn, Nordrhein Westf, Germany; [Goette, Andreas] Univ Hosp Magdeburg, Working Grp Mol Electrophysiol, Magdeburg, Germany; [Merino, Jose L.] Univ Europea, Hosp Univ La Paz, Arrhythmia & Robot Electrophysiol Unit, Madrid, Spain; [Ezekowitz, Michael D.] Thomas Jefferson Univ, Sidney Kimmel Jefferson Med Coll, Dept Cardiovasc Med, Broomall, PA USA; [Zamoryakhin, Dmitry] Lankenau Med Ctr, Broomall, PA USA; [Melino, Michael; Mercuri, Michele F.; Grosso, Michael A.; Fernandez, Victor] Daiichi Sankyo Pharma Dev, Clin Dev Cardiovas & Metab, Edison, NJ USA; [Jin, James] Daiichi Sankyo Pharma Dev, Biostat, Edison, NJ USA; [Al-Saady, Naab] Cardiovasc Metab Covance, Maidenshead, England; [Pelekh, Natalya] Covance, Clin Res, Kiev, Ukraine; [Merkely, Bela] Semmelweis Univ, Heart & Vasc Ctr, Budapest, Hungary; [Zenin, Sergey] Novosibirsk Reg Clin Cardiol Hosp, State Budget Healthcare Inst Novosibirsk Reg, Novosibirsk, Russia; [Kushnir, Mykola] Zhytomyr Reg Clin Hosp, Dept Cardiol, Chervonogo Khresta Str, Zhytomyr, Ukraine; [Spinar, Jindrich] Fak Nemocnice Brno, Brno, Czech Republic; [Batushkin, Valeriy] Kiev City Clin Hosp 5, Cardiol & Intens Care Dept, Kiev, Ukraine; [de Groot, Joris] Acad Med Ctr, Ctr Heart, Dept Cardiol, Clin Electrophysiol, Amsterdam, Netherlands; [Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Inst Cardiovasc Sci, Birmingham, W Midlands, England; [Lip, Gregory Y. H.] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark; [Gwechenberger, Marianne] Univ Vet Med Vienna, Vienna, Austria; [Huber, Kurt] Wilhelminenspital Stadt Wien, Vienna, Austria; [Purerfellner, Helmut] Krankenhaus Elisabethinen Linz, Linz, Austria; [Roithinger, Franz] Landesklinikum Modling, Modling, Austria; [Scherr, Daniel] Med Univ Graz, Graz, Austria; [Stuhlinger, Markus] Med Univ Innsbruck, Innsbruck, Austria; [Delforge, Marc] Ctr Hosp Reg de Huy, Huy, Belgium; [Rivero-Ayerza, Maximo] Ziekenhuis Oost Limburg, Limburg, Belgium; [Thoeng, John] AZ Turnhout VZW, Turnhout, Belgium; [Vervoort, Geert] AZ Sint Maarten, Mechelen, Belgium; [Vijgen, Johan] Jessa Ziekenhuis, Hasselt, Belgium; [Willems, Rik] UZ Leuven, Leuven, Belgium; [Benov, Haralambi] Multiprofile Dist Hosp Act Treatment Dr Stefan Ch, Veliko Tarnovo, Bulgaria; [Dimov, Bojidar] Fifth Multiprofile Hosp Act Treatment Sofia EAD, Sofia, Bulgaria; [Nikolov, Fedya] Univ Multiprofile Hosp Act Treatment Sveti Georgi, Sofia, Bulgaria; [Godev, Assen] Univ Multiprofile Hosp Act Treatment Tsaritsa Joa, Sofia, Bulgaria; [Jorgova-Makedonska, Julia] Univ Multiprofile Hosp Act Treatment Sveta Ekater, Sofia, Bulgaria; [Lazov, Petar] Multiprofile Hosp Act Treatment Pazardzhik AD, Sofia, Bulgaria; [Marchev, Sotir] Specialized Hosp Act Treatment Cardiol EAD, Sofia, Bulgaria; [Mihov, Lenko] Multiprofile Hosp Act Treatment Sveti Ivan Rilski, Sofia, Bulgaria; [Petranov, Stanislav] Multiprofile Hosp Act Treatment Burgas AD, Sofia, Bulgaria; [Raev, Dimitar] Diagnost Consultat Ctr Sveta Anna EOOD, Sofia, Bulgaria; [Stoyanov, Miroslav] Multiprofile Hosp Act Treatment Dr Tota Venkova J, Sofia, Bulgaria; [Tarnovska-Kadreva, Rumiana] Univ Multiprofile Hosp Act Treatment Alexandrovsk, Sofia, Bulgaria; [Todorov, Georgi] Second Multiprofile Hosp Act Treatment Sofia EAD, Sofia, Bulgaria; [Tumbev, Haralin] Specialized Hosp Act Cardiol Treatment Cardiolife, Sofia, Bulgaria; [Cermak, Ondrej] Nemocnice Slany, Slany, Czech Republic; [Jarkovsky, Patrik] Ustoedni Vojenska Nemocnice Vojenska Fak Nemocnic, Prague, Czech Republic; [Kautzner, Josef] Inst Klin Expt Med, Prague, Czech Republic; [Lukac, Bohdan] Nemocnice Eesky Krumlov As, Prague, Czech Republic; [Nadenickova, Pavla] Kromioizska Nemocnice As, Prague, Czech Republic; [Peterka, Karel] Nemocnice Havliekuv Brod, Prague, Czech Republic; [Slaby, Josef] Oblastni Nemocnice Kolin As, Prague, Czech Republic; [Spinar, Jindrich] Fak Nemocnice Brno, Brno, Czech Republic; [Vesely, Jiri] Oblastni Nemocnice Nachod As, Brno, Czech Republic; [Vitovec, Miroslav] Affidea Praha Sro, Brno, Czech Republic; [Zavada, Filip] Oblastni Nemocnice Pribram As, Brno, Czech Republic; [Al-hashimi, Souhad] Holbaek Sygehus, Holbaek, Denmark; [Bronnum-Schou, Jens] Amager Hosp, Glostrup, Denmark; [Egstrup, Kenneth] Odense Univ Hosp, Svendborg Sygehus, Odense, Denmark; [Frost, Lars] Regionshosp Silkeborg, Silkeborg, Denmark; [Gislason, Gunnar] Gentofte Univ Hosp, Gentofte, Denmark; [Lomholdt, Jens] Slagelse Sygehus, Slagelse, Denmark; [Malczynski, Jerzy] Herning Reg Hosp, Herning, Denmark; [Moller, Dorthe Svendstrup] Reg Hosp Viborg, Viborg, Denmark; [Nielsen, Tonni] Koge Sygehus, Koge, Denmark; [Raymond, Ilan] Frederiksberg Univ Hosp, Frederiksberg, Denmark; [Riahi, Sam] Aalborg Univ, Aalborg, Denmark; [Tuxen, Christian] Bispebjerg Hosp, Bispebjerg, Denmark; [Cohen, Ariel] Hop St Antoine, St Antoine, France; [Cottin, Yves] Hop Bocage, CHU Dijon, Dijon, France; [Defaye, Pascal] CHU Grenoble, Grenoble, France; [Deharo, Jean-Claude] CHU Hop Timone, Marseille, France; [Depuis, Jean-Marc] CHU Angers, Angers, France; [Elbaz, Meyer] Hop Rangueil, Rangueil, France; [Ferrari, Emile] Hop Louis Pasteur, CHU Nice, Nice, France; [Gosse, Philippe] Hop St Andre, CHU Hop Bordeaux, St Andre, France; [Goube, Pascal] Ctr Hosp Sud Francilien, Corbeil Essonnes, France; [Paganelli, Franck] Hop Nord, Nord, France; [Pineau, Julien] Ctr Hosp St Joseph St Luc, St Luc, France; [Piot, Olivier] Ctr Cardiol Nord, Nord, France; [Biermann, Jurgen] Univ Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany; [Bosch, Ralph] Cardio Ctr Ludwigsburg Bietigheim, Bietigheim, Germany; [Brachmann, Johannes] Klinikum Coburg GmbH, Coburg, Germany; [Darius, Harald] Vivantes Klinikum Neukolln, Berlin, Germany; [Dengler, Thomas] SLK Kliniken Heilbronn GmbH, Heilbronn, Germany; [Goette, Andreas] St Vincenz Hosp, Paderborn, Germany; [Hartmann, Andreas] Klinikum St Georg GmbH, Leipzig, Germany; [Kreis, Ingo] St Johannes Hosp, Dortmund, Germany; [Lamparter, Steffen] Diakonie Krankenhaus Wehrda, Marburg, Germany; [Licka, Manuela] Univ Klinikum Heidelberg, Heidelberg, Germany; [Maier, Lars] Univ Hosp Regensburg, Regensburg, Germany; [Schellong, Sebastian] Krankenhaus Dresden Friedrichstadt, Friedrichstadt, Germany; [Schmitt, Jorn] Univ Giessen & Marburg GmbH, Giessen, Germany; [Stellbrink, Christoph] Klinikum Bielefeld Mitte, Bielefeld, Germany; [Walkili, Reza] Klinikum Univ Munchen, Munich, Germany; [Willems, Stephan] Univ Hamburg Eppendorf, Hamburg, Germany; [vom Dahl, Juergen] Kliniken Maria Hilf GmbH, Monchengladbach, Germany; [Dezsi, Andras] Petz Aladar Cty Teaching Hosp, Gyor, Hungary; [Edes, Istvan] Debreceni Egyet Klin Kozpont, Kozpont, Hungary; [Laszlo, Saghy] Szegedi Tudomanyegyet, Belgyogyaszati Klin, Szeged, Hungary; [Lupkovics, Geza] Zala Megyei Korhaz, Zalaegerszeg, Hungary; [Matoltsy, Andras] Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary; [Merkely, Bela] Semmelweis Univ, Budapest, Hungary; [Nagy, Andras] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary; [Nagy, Lajos] Vas Megyei Markusovszky Korhaz Nonprofit Zrt, Szombathely, Hungary; [Palinkas, Attila] CSMEK Hodmezovasarhel, Hodmezovasarhely, Hungary; [Simor, Tamas] Pecsi Tudomanyegyetem Klin Kozpont, Pecs, Hungary; [Tomcsanyi, Janos] Budai Irgalmasrendi Korhaz, Budapest, Hungary; [Toth, Laszlo] Fejer Megyei Szent Gyorgy Egyet Oktato Korhaz, Szekesfehervar, Hungary; [Alcalai, Ronny] Hadassah Univ Med Ctr, Jerusalem, Israel; [Hayek, Tony] Rambam Med Ctr, Haifa, Israel; [Katz, Amos] Barzilai Govt Hosp, Ashqelon, Israel; [Mazen, Elias] Emek Med Ctr, Afula, Israel; [Shechter, Michael] Chaim Sheba Med Ctr, Ramat Gan, Israel; [Shochat, Michael] Hillel Yaffe Med Ctr, Hadera, Israel; [Zeltser, David] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Zimlichman, Reuven] Edith Wolfson Med Ctr, Holon, Israel; [Boriani, Guiseppe] Azienda Osped Univ Bologna Policlin S Orsola Malp, Bologna, Italy; [De Caterina, Raffaele] Osped SS Annunziata, Naples, Italy; [Di Pasquale, Giuseppe] Osped Maggiore CA Pizzardi, Bologna, Italy; [Fattore, Luciano] Osped San Giuseppe Melorio, Santa Maria Capua Vetere, Italy; [Grimaldi, Massimo] Ente Ecclesiastico Osped Gen Reg F Miulli, Acquaviva Delle Fonti, Italy; [Gulizia, Michele] Presidio Osped Garibaldi Nesima, Catania, Italy; [Mazzone, Carmine] Ctr Cardiovasc, Catania, Italy; [Themistoclakis, Sakis] Osped dellAngelo, Venice, Italy; [Volpe, Massimo] Azienda Osped St Andrea, Rome, Italy; [Allaart, Cornelis] VU Univ Med Ctr, Leiden, Netherlands; [de Groot, Joris] Acad Med Ctr AMC, Amsterdam, Netherlands; [Elvan, Arif] Isala, Zwolle, Netherlands; [Folkeringa, Richard] Med Ctr Leeuwarden, Leeuwarden, Netherlands; [Hazeleger, Ronald] VieCuri, Venray, Netherlands; [Jansen, Ward] Tergooi Hilversum, Hilversum, Netherlands; [Nierop, Pieter] St Franciscus Gasthuis, Rotterdam, Netherlands; [Willems, Albert] Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands; [de Ruiter, Gijsbert] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; [Czarnecka, Danuta] Univ Hosp Krakow, Krakow, Poland; [Gniot, Jacek] Samodzielny Publ Zaklad Opieki Zdrowotnej Pulawac, Pulawy, Poland; [Januszewicz, Andrzey] Inst Kardiol, Krakow, Poland; [Jaworska, Krystyna] Wojewodzki Szpital Zespolony Ludwika Rydygiera To, Torun, Poland; [Loboz-Grudzien, Krystyna] Lower Silesian Specialist Hosp Tadeusz Marciniak, Ctr Emergency Med, Wroclaw, Poland; [Niezgoda, Krzysztof] Elblaski Szpital Specjalisty Przychodnia Elblagu, Elblag, Poland; [Ptaszynski, Pawel] Med Univ Lodz, Lodz, Poland; [Wysokinski, Andrzej] Samodzielny Publ Szpital Klin 4 SPSK4, Lublin, Poland; [Bartos, Daniela] Spitalul Clin Urgenta Bucuresti, Bucharest, Romania; [Bengus, Cristina] Spitalul Clin Urgenta Sfantul Pantelimon, Bucharest, Romania; [Bolohan, Romi; Dumitrescu, Silviu] Ctr Clin Urgenta Boli Cardiovasc Armatei, Bucharest, Romania; [Chioncel, Ovidiu; Coman, Ioan-Mircea] Inst Urgenta Pentru Boli Cardiovasc Prof Dr CC Il, Bucharest, Romania; [Crisu, Daniela] Ctr Med Consultmed, Bucharest, Romania; [Dan, Gheorghe-Andrei] Spitalul Clin Colentina, Bucharest, Romania; [Dobreanu, Dan] Inst Urgenta Pentru Boli Cardiovasc & Transplant, Targu Mures, Romania; [Gurghean, Adriana] Spitalul Clin Coltea, Bucharest, Romania; [Lighezan, Daniel] Spitalul Clin Municipal Urgenta Timisoara, Timisoara, Romania; [Militaru, Constantin] Spitalul Clin Judetean Urgenta Craiova, Craiova, Romania; [Minescu, Bogdan] Spitalul Judetean Urgenta Braila, Urgenta Braila, Romania; [Podoleanu, Cristian Calin Gheorghe] Spitalul Clin Judetean Mures, Targu Mures, Romania; [Pop, Calin] Spitalul Judetean Urgenta Dr Constantin Opris Bai, Baia Mare, Romania; [Popescu, Mircea Ioachim] Spitalul Clin Judetean Urgenta Oradea, Urgenta Oradea, Romania; [Rosu, Radu Ovidiu] Spitalul Clin Recuperare Cluj Napoca, Cluj Napoca, Romania; [Tase, Adrian] Spitalul Judetean Urgenta Arges, Urgenta Arges, Romania; [Voicu, Olga Cristina] Spitalul Judetean Urgenta Targoviste, Urgenta Targoviste, Romania; [Belenky, Dmitry] City Hosp Ambulance 2, State Budget Inst Hlth Novosibirsk Oblast, Novosibirsk, Russia; [Bolshakova, Olga] Fed Almazov Med Res Ctr, St Petersburg, Russia; [Chumakova, Galina] Altai Reg Clin Hosp, Barnaul, Russia; [Demko, Arkadiy] Sci Clin Ctr Russian Railways JSC, Moscow, Russia; [Goloshchekin, Boris] City Hosp 15, St Petersburg State Budget Inst Healthcare, St Petersburg, Russia; [Kostenko, Viktor] St Petersburg II Dzhanelidze Res Inst Emergency M, St Petersburg, Russia; [Kuznetsov, Vadim] Tyumen Cardiol Ctr, Tyumen, Russia; [Libov, Igor; Timofeev, Alexander] SBHI Clin Oncol Dispensary 1 Minist Healthcare Kr, Krasnodar, Russia; [Nevzorova, Vera] Vladivostok Clin Hosp 1, Vladivostok, Russia; [Nikolaev, Konstantin] City Clin Hosp 34, State Budgetary Inst Healthcare, Novosibirsk, Russia; [Popov, Sergey] Res Inst Cardiol, Tomsk, Russia; [Shubik, Yuriy] Natl Med Surg Ctr, Moscow, Russia; [Staroverov, Ilya] Yaroslavl Reg Clin Hosp, Yaroslavl, Russia; [Zenin, Sergey] Novosibirsk Reg Clin Cardiol Clin, Novosibirsk, Russia; [Alonso Valladares, Francisco] Complejo Hosp Univ Ourense, Orense, Spain; [Alvarez Lopez, Miguel] Hosp Virgen Nieves, Granada, Spain; [Arenal, Angel] Hosp Gen Univ Gregorio Maranon, Madrid, Spain; [Bertomeu Gonzalez, Vicente] San Juan Alicante Univ Hosp, Alicante, Spain; [Cosin-Sales, Juan] Hosp Arnau Vilanova, Lleida, Spain; [Ramon Gonzalez-Juanatey, Jose] CHUS, Hosp Clin Univ, Santiago De Compostela, Spain; [Martinez Rubio, Antoni] Parc Tauli Sabadell Hosp Univ, Barcelona, Spain; [Gabriel Martinez, Juan] Hosp Gen Univ Alicante, Alicante, Spain; [Falconi, Estela] Hosp Univ La Paz, Madrid, Spain; [Mont, Lluis] Hosp Clin Barcelona, Barcelona, Spain; [Paz Bermejo, Marco Antonio] Hosp Santa Caterina, Girona, Spain; [Sabate, Xavier] Hosp Univ Bellvitge, Barcelona, Spain; [Vazquez Camano, Maria] Povisa Hosp, Vigo, Spain; [Vida, Manuel] Hosp Torrecardenas, Almeria, Spain; [Vinolas, Xavier] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Zamorano Gomez, Jose Luis] Hosp Univ Ramon & Cajal, Madrid, Spain; [Lindquist, Carina Blomstrom] Univ Uppsala Hosp, Uppsala, Sweden; [Fredholm, Olle] Helsingborgs Lasaret, Helsingborg, Sweden; [Savelieva, Irina] St Georges Univ Hosp NHS Fdn Trust, St Georges Hosp, London, England; [Haywood, Guy] Plymouth Hosp NHS Trust, Derriford Hosp, Plymouth, Devon, England; [Aggarwal, Rajesh] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Basildon, England; [Bakhai, Ameet] Barnet & Chase Farm Hosp NHS Trust, Barnet Hosp, Barnet, England; [Balasubramaniam, Richard] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Bournemouth, Dorset, England; [Betts, Tim] Oxford Univ Hosp NHS Trust, John Radcliffe Hosp, Oxford, England; [Campbell, Phillip] Royal Gwent Hosp, Newport, Gwent, Wales; [Choy, Anna Maria] NHS Tayside, Dundee, Scotland; [Davis, Gershan] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Izzat, Lena] Prince Philip Hosp, Llanelli, Wales; [Kadr, Honer] Barking Havering & Redbridge Univ Hosp NHS Trust, Queens Hosp, London, England; [Lindsay, Steven] Bradford Teaching Hosp NHS Fdn Trust, Bradford Royal Infirm, Bradford, W Yorkshire, England; [Lip, Gregory] Sandwell & West Birmingham Hosp NHS Trust, Birmingham City Hosp, Birmingham, W Midlands, England; [More, Ranjit] Blackpool Teaching Hosp NHS Fdn Trust, Blackpool Victoria Hosp, Blackpool, England; [Ng, Ghulam Andre] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Leicester, Leics, England; [Payne, Gillian] Doncaster Royal Infirm, Doncaster, England; [Schilling, Richard] Barts Hlth NHS Trust, Whipps Cross Univ Hosp, London, England; London North West Healthcare NHS Trust, Northwick Park Hosp, London, England; [Tayebjee, Muzahir] Leeds Teaching Hosp NHS Trust, Leeds Gen Infirm, Leeds, W Yorkshire, England; [Travill, Chris] Luton & Dunstable Univ Hosp NHS Fdn Trust, Luton, Beds, England; [Rishko, Mykola] Uzhgorod Natl Univ, Uzhgorod, Ukraine; [Batushkin, Valerii] Kiev City Clin Hosp 5, Kiev, Ukraine; [Fushtey, Ivan] Ordzhonikidze Dist Cent Hosp, Pokrov, Ukraine; [Karpenko, Oleksandr] Kyiv City Clin Hosp 1, Kiev, Ukraine; [Karpenko, Yuriy] Odessa Reg Cardiol Dispensary, Odessa, Ukraine; [Klantsa, Andriy] Khmelnytskyi Reg Hosp, Khmelnytskyi, Ukraine; [Kraiz, Igor] Tsentralnaya Klinicheskaya Bolnitsa, Donetsk, Ukraine; [Kushnir, Mykola] Zhitomir Reg Clin Hosp, Zhytomyr, Ukraine; [Kutniy, Oles] Municipal Inst Cent City Hosp 2, Zhytomyr, Ukraine; [Sychov, Oleg; Parkhomenko, Aleksander] MAS Ukraine, Natl Sci Ctr MD Strazhesko Inst Cardiol, Kiev, Ukraine; [Petrovskyy, Roman] Ivano Frankivsk Reg Clin Hosp, Ivano Frankivsk, Ukraine; [Reshotko, Dmytro] Oleksandrivska Clin Hosp, Kiev, Ukraine; [Stanislavchuk, Mykola] Vinnitsa Reg Clin Hosp NI Pirogov, Vinnitsa, Ukraine; [Tseluyko, Vira] Kharkiv City Clin Hosp 8, Kharkov, Ukraine; [Vasylets, Victoria] City Clin Hosp 9, Dnipro, Ukraine; [Minakova, Prof. O. I.; Volkov, Dmytro] Inst Gen & Emergency Surg, Kharkov, Ukraine; [Zharinov, Oleg] Kyiv City Heart Ctr, Kiev, Ukraine; [Zhurba, Svitlana] Cherkasy Reg Cardiol Ctr, Cherkassy, Ukraine; [Aggarwal, Rahul] Siteman Canc Ctr, Ctr Adv Med, St Louis, MO USA; [Bahu, Marwan] Phoenix Cardiovasc Res Grp LLC, Phoenix, AZ USA; [Bashir, Faran] Affiliated Cardiologists Arizona, Phoenix, AZ USA; [Berk, Martin] Cardiovasc Res Inst Dallas, Dallas, TX USA; [Cheirif, Jorge] Texas Hlth Presbyterian Hosp Dallas, Dallas, TX USA; [Clay, Anthony] Cardiol Physicians PA, Newark, DE USA; [Crenshaw, James] Jackson Clin, Jackson, TN USA; [Ellenbogen, Kenneth] Virginia Commonwealth Univ VCU Med Ctr, Richmond, VA USA; [Ganeshram, Vedampattu] Wichita Falls Heart Clin PLLC, Wichita, KS USA; [Halpern, Stephen] Radiant Res Ctr, Phoenix, AZ USA; [Heiman, Mark] Cardiol Associates Fairfield Cty P C, Fairfield, CT USA; [Henderson, David] Cardiol Res Associates, Daytona Beach, FL USA; [Ho, Andrew] Riverside Community Hosp, Riverside, CA USA; [Kovach, Todd] Heart & Vasc Inst Florida, Clearwater, FL USA; [Mckenzie, Marcus] Baylor Univ Med Ctr, Dallas, TX USA; [Nadar, Venkatesh] Capital Area Res LLC, Camp Hill, PA 17011 USA; [Penny-Peterson, Erica] Penn State Milton S Hershey Med Ctr, Hershey, PA USA; [Rao, Sunder] Butler Hlth Providers, Butler, PA USA; [Sawhney, Navinder] Arch Hlth Partners, Poway, CA USA; [Shaoulian, Emanuel] Pacific Coast Cardiol & Res, Newport Beach, CA USA; [Sheikh, Khalid] Brevard Cardiovasc Res Associates Inc, Rockledge, FL USA; [Torres-Heisecke, Raul] Tyler Cardiovasc Consultants PA, Tyler, TX USA; [Weiss, Robert] Maine Res Associates, Auburn, ME USA	University Hospital Magdeburg; Hospital Universitario La Paz; Jefferson University; Lankenau Medical Center; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Semmelweis University; University Hospital Brno; University of Amsterdam; Academic Medical Center Amsterdam; University of Birmingham; Aalborg University; University of Veterinary Medicine Vienna; Wilhelminenspital; Ordensklinikum Linz Elisabethinen; Medical University of Graz; Medical University of Innsbruck; East Limburg Hospital; KU Leuven; Medical University Sofia; Institute for Clinical & Experimental Medicine (IKEM); University Hospital Brno; Holbaek Hospital; University of Southern Denmark; Odense University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Aarhus University; Aalborg University; University of Copenhagen; Bispebjerg Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Dijon Bourgogne; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Toulouse; CHU Nice; CHU Bordeaux; Centre Hospitalier Sud Francilien; Universitats Herzzentrum Freiburg; Klinikum Coburg; VIivantes Klinikum Neukolln; SLK-Kliniken Heilbronn GmbH; St. Johannes Hospital; Ruprecht Karls University Heidelberg; University of Regensburg; Technische Universitat Dresden; Municipal Hospital Dresden; University Hospital of Giessen & Marburg; University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; Szeged University; Semmelweis University; University of Pecs; Hebrew University of Jerusalem; Rambam Health Care Campus; Technion Israel Institute of Technology; Ben Gurion University; Barzilai Medical Center; Emek Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; AUSL di Bologna; Presidio Ospedaliero Garibaldi-Nesima; ULSS 3 Serenissima; Ospedale dell'Angelo Mestre; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Amsterdam; Academic Medical Center Amsterdam; Medical Center Leeuwarden; Franciscus Gasthuis; Sint Lucas Andreas Hospital; Onze Lieve Vrouwe Gasthuis Hospital; Medical University Lodz; Almazov National Medical Research Centre; Tyumen Cardiology Research Center; Russian Academy of Sciences; Tomsk National Research Medical Center; Cardiology Research Institute - Tomsk; Complexo Hospitalario Universitario de Ourense, Verin e O Barco de Valdeorras; Hospital Universitario Virgen de las Nieves; General University Gregorio Maranon Hospital; University Hospital Arnau de Vilanova; Complexo Hospitalario Universitario de Santiago de Compostela; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; General University Hospital of Alicante; Hospital Universitario La Paz; University of Barcelona; Hospital Clinic de Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Hospital Torrecardenas; Hospital of Santa Creu i Sant Pau; Hospital Universitario Ramon y Cajal; Uppsala University; Uppsala University Hospital; Helsingborgs Hospital; St Georges University London; Derriford Hospital; University of Plymouth; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Royal Gwent Hospital; Aintree University Hospitals NHS Foundation Trust; Bradford Royal Infirmary; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Barts Health NHS Trust; University of London; Queen Mary University London; Leeds General Infirmary; University of Leeds; Ministry of Education & Science of Ukraine; Uzhgorod National University; National Academy of Medical Sciences of Ukraine; National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine; National Academy of Medical Sciences of Ukraine; Zaycev V.T. Institute of General & Urgent Surgery of National Academy of Medical Sciences of Ukraine; Siteman Cancer Center; Baylor University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Goette, A (corresponding author), St Vincenz Hosp, Cardiol & Intens Care Med, D-33098 Paderborn, Nordrhein Westf, Germany.	andreas.goette@vincenz.de	Ezekowitz, Michael/AAJ-2543-2021; Weitz, Jeffrey/AAD-1929-2019; Shochat, Michael Kleiner/ABI-2898-2020; Banach, Maciej/A-1271-2009; Licka, Manuela/AAA-7609-2020; Thijs, Vincent/C-3647-2009; Marchev, Sotir/AAH-6529-2020; VIJGEN, Johan M/AFQ-1297-2022; Ptaszynski, Pawel Andrzej/S-9684-2016; Stanislavchuk, Mykola/GRX-8902-2022; Stellbrink, Christoph/AAX-7701-2021; Pop, Calin/HJB-1034-2022; Ellenbogen, Kenneth/AAJ-3992-2021; Puererfellner, Helmut/AAJ-2367-2020; Gislason, Gunnar/B-7561-2009; Grimaldi, Massimo/AAX-9576-2021; Willems, Rik/AAM-2392-2020; Dan, G.Andrei/N-6744-2015; Podoleanu, Cristian/E-2850-2010; COTTIN, YVES/ABA-4622-2020; Libov, Igor/GRN-8152-2022; Chioncel, Ovidiu/R-7556-2017; Volpe, Massimo/K-5240-2016; de Groot, Joris R/M-3282-2017; Zharinov, Oleg J/U-8033-2018; Gurghean, Adriana/AAN-1243-2021; Nikolaev, Konstantin/P-4750-2017; Staroverov, Ilya/M-8174-2014; Brachmann, Johannes/AAD-1499-2021; Riahi, Sam/AAI-5298-2021; Heidbuchel, Hein/AAU-2711-2021; Scherr, Daniel/D-4098-2019; Mircea Ioachim, Popescu/AAD-2887-2022	Weitz, Jeffrey/0000-0002-1092-7550; Banach, Maciej/0000-0001-6690-6874; Thijs, Vincent/0000-0002-6614-8417; Marchev, Sotir/0000-0001-9250-510X; Ptaszynski, Pawel Andrzej/0000-0001-6084-7324; Pop, Calin/0000-0003-0267-3199; Gislason, Gunnar/0000-0002-0548-402X; Willems, Rik/0000-0002-5469-9609; Dan, G.Andrei/0000-0001-9867-2582; Podoleanu, Cristian/0000-0001-9987-2519; Chioncel, Ovidiu/0000-0002-3197-3628; Volpe, Massimo/0000-0002-9642-8380; de Groot, Joris R/0000-0002-8122-7017; Nikolaev, Konstantin/0000-0003-4601-6203; Riahi, Sam/0000-0003-1849-9463; Heidbuchel, Hein/0000-0001-9301-8127; Scherr, Daniel/0000-0001-5868-5493; Mircea Ioachim, Popescu/0000-0002-8273-4416; Ng, G. Andre/0000-0001-5965-0671; Merino, Jose Luis/0000-0002-1737-1903; Merkely, Bela/0000-0001-6514-0723; Laleman, Wim/0000-0002-0842-7813	Daiichi Sankyo; Daiichi Sankyo Pharma Development; Daiichi Sankyo Development	Daiichi Sankyo(Daiichi Sankyo Company Limited); Daiichi Sankyo Pharma Development(Daiichi Sankyo Company Limited); Daiichi Sankyo Development(Daiichi Sankyo Company Limited)	Daiichi Sankyo provided financial support for the study.r The ENSURE-AF study was sponsored and funded by Daiichi Sankyo Pharma Development and Daiichi Sankyo Development. We thank Ming Sun (Covance), for support with statistical analyses and Shannon Winters (Daiichi Sankyo) for editorial assistance in the preparation of the report.	Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/europace/eus305, 10.1093/eurheartj/ehs253]; Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367; Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Goette A., 2016, EUROPACE; Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083; Lip GYH, 2015, AM HEART J, V169, P597, DOI 10.1016/j.ahj.2015.02.009; Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546; Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025; Plitt A, 2016, CLIN CARDIOL, V39, P345, DOI 10.1002/clc.22537; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Sjogren V, 2015, THROMB HAEMOSTASIS, V113, P1370, DOI 10.1160/TH14-10-0859; You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304	13	176	177	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2016	388	10055					1995	2003		10.1016/S0140-6736(16)31474-X	http://dx.doi.org/10.1016/S0140-6736(16)31474-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ6EQ	27590218				2023-01-03	WOS:000385954800029
J	Mulvenna, P; Nankivell, M; Barton, R; Faivre-Finn, C; Wilson, P; McColl, E; Moore, B; Brisbane, I; Ardron, D; Holt, T; Morgan, S; Lee, C; Waite, K; Bayman, N; Pugh, C; Sydes, B; Stephens, R; Parmar, MK; Langley, RE				Mulvenna, Paula; Nankivell, Matthew; Barton, Rachael; Faivre-Finn, Corinne; Wilson, Paula; McColl, Elaine; Moore, Barbara; Brisbane, Iona; Ardron, David; Holt, Tanya; Morgan, Sally; Lee, Caroline; Waite, Kathryn; Bayman, Neil; Pugh, Cheryl; Sydes, Benjamin; Stephens, Richard; Parmar, Mahesh K.; Langley, Ruth E.			Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial	LANCET			English	Article							PARTITIONING ANALYSIS RPA; THERAPY-ONCOLOGY-GROUP; QUALITY-OF-LIFE; RADIATION-THERAPY; PROGNOSTIC-FACTORS; MOTEXAFIN GADOLINIUM; CEREBRAL METASTASES; CONSENSUS WORKSHOP; 1ST 2; MANAGEMENT	Background Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life. Methods The Quality of Life after Treatment for Brain Metastases (QUARTZ) study is a non-inferiority, phase 3 randomised trial done at 69 UK and three Australian centres. NSCLC patients with brain metastases unsuitable for surgical resection or stereotactic radiotherapy were randomly assigned (1: 1) to optimal supportive care (OSC) including dexamethasone plus WBRT (20 Gy in five daily fractions) or OSC alone (including dexamethasone). The dose of dexamethasone was determined by the patients' symptoms and titrated downwards if symptoms improved. Allocation to treatment group was done by a phone call from the hospital to the Medical Research Council Clinical Trials Unit at University College London using a minimisation programme with a random element and stratification by centre, Karnofsky Performance Status (KPS), gender, status of brain metastases, and the status of primary lung cancer. The primary outcome measure was quality-adjusted life-years (QALYs). QALYs were generated from overall survival and patients' weekly completion of the EQ-5D questionnaire. Treatment with OSC alone was considered noninferior if it was no more than 7 QALY days worse than treatment with WBRT plus OSC, which required 534 patients (80% power, 5% [one-sided] significance level). Analysis was done by intention to treat for all randomly assigned patients. The trial is registered with ISRCTN, number ISRCTN3826061. Findings Between March 2, 2007, and Aug 29, 2014, 538 patients were recruited from 69 UK and three Australian centres, and were randomly assigned to receive either OSC plus WBRT (269) or OSC alone (269). Baseline characteristics were balanced between groups, and the median age of participants was 66 years (range 38-85). Significantly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported while patients were receiving WBRT, although there was no evidence of a difference in the rate of serious adverse events between the two groups. There was no evidence of a difference in overall survival (hazard ratio 1.06, 95% CI 0.90-1.26), overall quality of life, or dexamethasone use between the two groups. The difference between the mean QALYs was 4.7 days (46.4 QALY days for the OSC plus WBRT group vs 41.7 QALY days for the OSC group), with two-sided 90% CI of -12.7 to 3.3. Interpretation Although the primary outcome measure result includes the prespecified non-inferiority margin, the combination of the small difference in QALYs and the absence of a difference in survival and quality of life between the two groups suggests that WBRT provides little additional clinically significant benefit for this patient group. Funding Cancer Research UK, Medical Research Council Clinical Trials Unit at University College London, and the National Health and Medical Research Council in Australia. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.	[Mulvenna, Paula] Newcastle Hosp NHS Fdn Trust, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [Nankivell, Matthew; Pugh, Cheryl; Sydes, Benjamin; Stephens, Richard; Parmar, Mahesh K.; Langley, Ruth E.] UCL, Med Res Council Clin Trials Unit, London, England; [Barton, Rachael] Castle Hill Hosp, Queens Ctr Oncol & Haematol, Kingston Upon Hull, N Humberside, England; [Faivre-Finn, Corinne; Bayman, Neil] Univ Manchester, Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Inst Canc Sci, Manchester, Lancs, England; [Wilson, Paula] Bristol Haematol & Oncol Ctr, Bristol, Avon, England; [McColl, Elaine] Newcastle Univ, Newcastle Clin Trials Unit, Newcastle Upon Tyne, Tyne & Wear, England; [McColl, Elaine] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Moore, Barbara] Wales Canc Res Network, Cardiff, S Glam, Wales; [Brisbane, Iona] Greater Glasgow Hlth Board & Clyde, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Holt, Tanya] Trans Tasman Radiat Oncol Grp, Waratah, NSW, Australia; [Holt, Tanya] Univ Queensland, Brisbane, Qld 4072, Australia; [Morgan, Sally] Univ Nottingham Hosp, Nottingham, England; [Lee, Caroline] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Waite, Kathryn] Queen Elizabeth Hosp, Kings Lynn, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Medical Research Council Clinical Trials Unit; University of London; University College London; University of Hull; Christie NHS Foundation Trust; University of Manchester; Bristol Haematology & Oncology Centre; Newcastle University - UK; Newcastle University - UK; Beatson Oncology Centre; University of Queensland; University of Nottingham; Weston Park Hospital	Langley, RE (corresponding author), UCL, Inst Clin Trials & Methodol, Med Res Council Clin Trials Unit, London WC2B 6NH, England.	ruth.langley@ucl.ac.uk	McColl, Elaine/V-9906-2019	McColl, Elaine/0000-0001-8300-3204; Faivre-Finn, Corinne/0000-0001-5617-9781	Cancer Research UK; Medical Research Council Clinical Trials Unit at University College London; National Health and Medical Research Council in Australia; Cancer Research UK [C17956/A6414]; Medical Research Council in the UK; Trans Tasman Radiation Oncology Group in Australia; National Health and Medical Research Council Australia (NHMRC) [441402]; MRC [MC_UU_12023/28] Funding Source: UKRI; Cancer Research UK [6414, 20465] Funding Source: researchfish; Medical Research Council [MC_UU_12023/28] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Medical Research Council Clinical Trials Unit at University College London(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Health and Medical Research Council in Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Research UK(Cancer Research UK); Medical Research Council in the UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Trans Tasman Radiation Oncology Group in Australia; National Health and Medical Research Council Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Cancer Research UK, Medical Research Council Clinical Trials Unit at University College London, and the National Health and Medical Research Council in Australia.; Funding was provided by Cancer Research UK (C17956/A6414). The trial sponsor was the Medical Research Council in the UK, and the Trans Tasman Radiation Oncology Group in Australia. Funding for Australia sites was provided by the National Health and Medical Research Council Australia (NHMRC 441402). The trial was done and analysed at the MRC CTU at UCL. We thank all patients, their families, and carers who agreed to participate in QUARTZ, and the investigators and research staff at the trial centres and the MRC CTU at UCL.	American College of Radiology, 2014, ACR APPR CRIT; Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8; Barnholtz-Sloan JS, 2004, J CLIN ONCOL, V22, P2865, DOI 10.1200/JCO.2004.12.149; Billingham LJ, 2002, STAT METHODS MED RES, V11, P25, DOI 10.1191/0962280202sm269ra; BORGELT B, 1981, INT J RADIAT ONCOL, V7, P1633, DOI 10.1016/0360-3016(81)90184-X; BORGELT B, 1980, INT J RADIAT ONCOL, V6, P1, DOI 10.1016/0360-3016(80)90195-9; Brown PD, 2015, ASCO M S, V33, pLBA4; CHAO JH, 1954, CANCER, V7, P682, DOI 10.1002/1097-0142(195407)7:4<682::AID-CNCR2820070409>3.0.CO;2-S; Chen AM, 2007, CANCER-AM CANCER SOC, V109, P1668, DOI 10.1002/cncr.22565; COIA LR, 1992, INT J RADIAT ONCOL, V23, P223, DOI 10.1016/0360-3016(92)90566-Z; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0; Gerrard GE, 2003, CLIN ONCOL-UK, V15, P422, DOI 10.1016/S0936-6555(03)00148-1; HORTON J, 1971, AMER J ROENTGENOL RA, V111, P334, DOI 10.2214/ajr.111.2.334; Hoskin PJ, 2001, CLIN ONCOL-UK, V13, P91, DOI 10.1053/clon.2001.9226; Kaal EC, 2005, LANCET NEUROL, V4, P289, DOI 10.1016/S1474-4422(05)70072-7; Khuntia D, 2006, J CLIN ONCOL, V24, P1295, DOI 10.1200/JCO.2005.04.6185; Langer CJ, 2005, J CLIN ONCOL, V23, P6207, DOI 10.1200/JCO.2005.03.145; Langley RE, 2013, CLIN ONCOL-UK, V25, pE23, DOI 10.1016/j.clon.2012.11.002; Law A, 2001, CANCER, V92, P160, DOI 10.1002/1097-0142(20010701)92:1<160::AID-CNCR1304>3.0.CO;2-X; Lee SM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju151; Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503; Lutterbach J, 2002, RADIOTHER ONCOL, V63, P339, DOI 10.1016/S0167-8140(02)00119-6; Mehta M, 2011, J CLIN ONCOL, V29, P121, DOI 10.1200/JCO.2010.33.3294; Mehta MP, 2009, INT J RADIAT ONCOL, V73, P1069, DOI 10.1016/j.ijrobp.2008.05.068; Mehta MP, 2003, J CLIN ONCOL, V21, P2529, DOI 10.1200/JCO.2003.12.122; Mulvenna PM, 2010, CLIN ONCOL-UK, V22, P365, DOI 10.1016/j.clon.2010.03.011; Nieder C, 2000, INT J RADIAT ONCOL, V46, P297, DOI 10.1016/S0360-3016(99)00416-2; ORDER SE, 1968, RADIOLOGY, V91, P149, DOI 10.1148/91.1.149; Owen S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00248; Priestman T J, 1996, Clin Oncol (R Coll Radiol), V8, P308, DOI 10.1016/S0936-6555(05)80717-4; Rades D, 2007, CANCER, V110, P1077, DOI 10.1002/cncr.22877; Sneed PK, 1996, NEUROSURG CLIN N AM, V7, P505; Soffietti R, 2005, J NEURO-ONCOL, V75, P31, DOI 10.1007/s11060-004-8096-3; Sperduto PW, 2010, INT J RADIAT ONCOL, V77, P655, DOI 10.1016/j.ijrobp.2009.08.025; Stuschke M, 1999, J CLIN ONCOL, V17, P2700, DOI 10.1200/JCO.1999.17.9.2700; Taphoorn MJB, 2010, EUR J CANCER, V46, P1033, DOI 10.1016/j.ejca.2010.01.012; Tsao MN, 2012, CLIN ONCOL-UK, V24, pE81, DOI 10.1016/j.clon.2012.03.008; Tsao MN, 2012, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003869.PUB3; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Yamamoto M, 2014, LANCET ONCOL, V15, P387, DOI 10.1016/S1470-2045(14)70061-0; ZIMM S, 1981, CANCER, V48, P384, DOI 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8	42	381	397	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2016	388	10055					2004	2014		10.1016/S0140-6736(16)30825-X	http://dx.doi.org/10.1016/S0140-6736(16)30825-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ6EQ	27604504	Green Published, hybrid			2023-01-03	WOS:000385954800030
J	Das, A; Srinivasan, M; Ghosh, TS; Mande, SS				Das, Anubhav; Srinivasan, Meenakshi; Ghosh, Tarini Shankar; Mande, Sharmila S.			Xenobiotic Metabolism and Gut Microbiomes	PLOS ONE			English	Article							METAGENOMIC ANALYSIS; INTESTINAL BACTERIA; FLORA; DRUG; ENZYMES; MICROFLORA; SEQUENCE; RATS; ATHEROSCLEROSIS; BIOACTIVATION	Humans are exposed to numerous xenobiotics, a majority of which are in the form of pharmaceuticals. Apart from human enzymes, recent studies have indicated the role of the gut bacterial community (microbiome) in metabolizing xenobiotics. However, little is known about the contribution of the plethora of gut microbiome in xenobiotic metabolism. The present study reports the results of analyses on xenobiotic metabolizing enzymes in various human gut microbiomes. A total of 397 available gut metagenomes from individuals of varying age groups from 8 nationalities were analyzed. Based on the diversities and abundances of the xenobiotic metabolizing enzymes, various bacterial taxa were classified into three groups, namely, least versatile, intermediately versatile and highly versatile xenobiotic metabolizers. Most interestingly, specific relationships were observed between the overall drug consumption profile and the abundance and diversity of the xenobiotic metabolizing repertoire in various geographies. The obtained differential abundance patterns of xenobiotic metabolizing enzymes and bacterial genera harboring them, suggest their links to pharmacokinetic variations among individuals. Additional analyses of a few well studied classes of drug modifying enzymes (DMEs) also indicate geographic as well as age specific trends.	[Das, Anubhav; Ghosh, Tarini Shankar; Mande, Sharmila S.] Tata Consultancy Serv Ltd, TCS Res, Pune, Maharashtra, India; [Srinivasan, Meenakshi] Manipal Univ, Manipal Coll Pharmaceut Sci, Manipal, Karnataka, India	Tata Sons; Tata Consultancy Services Limited (TCS); Manipal Academy of Higher Education (MAHE)	Mande, SS (corresponding author), Tata Consultancy Serv Ltd, TCS Res, Pune, Maharashtra, India.	sharmila.mande@tcs.com	Ghosh, Tarini/AAW-5456-2020	Ghosh, Tarini/0000-0001-9570-0365				Al-Asmakh M, 2012, GUT MICROBES, V3, P366, DOI 10.4161/gmic.21287; Alomar MJ, 2014, SAUDI PHARM J, V22, P83, DOI 10.1016/j.jsps.2013.02.003; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Arrieta MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00427; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Bhattacharya T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142038; Bowey E, 2003, FOOD CHEM TOXICOL, V41, P631, DOI 10.1016/S0278-6915(02)00324-1; Brunton LL, 2011, GOODMAN GILMANS PHAR, V12th; Caesar R, 2010, J INTERN MED, V268, P320, DOI 10.1111/j.1365-2796.2010.02270.x; Cardona S, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-158; Claus SP, 2011, MBIO, V2, DOI 10.1128/mBio.00271-10; Devos D, 2000, PROTEINS, V41, P98, DOI 10.1002/1097-0134(20001001)41:1<98::AID-PROT120>3.3.CO;2-J; DRASAR BS, 1972, BIOCHEM J, V129, P881, DOI 10.1042/bj1290881; Forslund K, 2013, GENOME RES, V23, P1163, DOI 10.1101/gr.155465.113; Ghosh TS, 2011, BIOINFORMATION, V6, P91, DOI 10.6026/97320630006091; Ghosh TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095547; Ghosh TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083823; Ghosh TS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S7-S14; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Grilo NM, 2014, TOXICOL LETT, V224, P416, DOI 10.1016/j.toxlet.2013.10.036; Grundmann O., 2010, J DRUG METAB TOXICOL, V1, P104, DOI DOI 10.4172/2157-7609.1000104; Hajjar Emily R, 2003, Am J Geriatr Pharmacother, V1, P82; Haque MM, 2009, BIOINFORMATICS, V25, P1722, DOI 10.1093/bioinformatics/btp317; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Hu YF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3151; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ishizuka T, 2010, J BIOL CHEM, V285, P11892, DOI 10.1074/jbc.M109.072629; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; Jancova P, 2010, BIOMED PAP, V154, P103, DOI 10.5507/bp.2010.017; Jung Lee Woo, 2015, Gastroenterol Hepatol (N Y), V11, P24; Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198; Kazui M, 2010, DRUG METAB DISPOS, V38, P92, DOI 10.1124/dmd.109.029132; KOCH RL, 1980, BIOCHEM PHARMACOL, V29, P3281, DOI 10.1016/0006-2952(80)90304-4; KOCH RL, 1979, BIOCHEM PHARMACOL, V28, P3611, DOI 10.1016/0006-2952(79)90407-6; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Laine JE, 2009, XENOBIOTICA, V39, P11, DOI [10.1080/00498250802512830, 10.1080/00498250802512830 ]; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Lhoste EF, 2003, FOOD CHEM TOXICOL, V41, P695, DOI 10.1016/S0278-6915(03)00010-3; Li H, 2013, NATURE, V94, P1; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; MATHAN VI, 1989, GUT, V30, P971, DOI 10.1136/gut.30.7.971; Nash DB, 2012, AM HEALTH DRUG BENEF, V5, P423; Parks DH, 2010, BIOINFORMATICS, V26, P715, DOI 10.1093/bioinformatics/btq041; Peabody MA, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0788-5; Penner N., 2012, ADME ENABLING TECHNO, V1st ed., P545; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rafii F, 2007, COMPARATIVE MED, V57, P282; ROWLAND IR, 1988, TOXICOL PATHOL, V16, P147, DOI 10.1177/019262338801600207; Saad R, 2012, GUT PATHOG, V4, DOI 10.1186/1757-4749-4-16; Selma MV, 2009, J AGR FOOD CHEM, V57, P6485, DOI 10.1021/jf902107d; Sen Gupta S, 2011, GUT PATHOG, V3, DOI 10.1186/1757-4749-3-7; Shah RR, 2007, PHARMACOGENOMICS ADM, P180; SHU YZ, 1991, XENOBIOTICA, V21, P737, DOI 10.3109/00498259109039513; Smith HF, 2013, CR PALEVOL, V12, P339, DOI 10.1016/j.crpv.2012.12.001; Smyth RMD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024061; Springael D, 2004, TRENDS MICROBIOL, V12, P53, DOI 10.1016/j.tim.2003.12.010; STRONG HA, 1987, XENOBIOTICA, V17, P685, DOI 10.3109/00498258709043976; Suicide, 2012, HLTH GLANC EUR 2012, P28; Tamames J, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-85; Tedjo DI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126685; Nguyen TLA, 2015, DIS MODEL MECH, V8, P1, DOI 10.1242/dmm.017400; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Wilson CA, 2000, J MOL BIOL, V297, P233, DOI 10.1006/jmbi.2000.3550; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; Yasuda SU, 2008, CLIN PHARMACOL THER, V84, P417, DOI 10.1038/clpt.2008.141; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	70	31	33	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2016	11	10							e0163099	10.1371/journal.pone.0163099	http://dx.doi.org/10.1371/journal.pone.0163099			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0TR	27695034	Green Submitted, Green Published, gold			2023-01-03	WOS:000385553100024
J	Bentzer, P; Griesdale, DE; Boyd, J; MacLean, K; Sirounis, D; Ayas, NT				Bentzer, Peter; Griesdale, Donald E.; Boyd, John; MacLean, Kelly; Sirounis, Demetrios; Ayas, Najib T.			Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PULSE-PRESSURE VARIATION; STROKE VOLUME VARIATION; CRITICALLY-ILL PATIENTS; CENTRAL VENOUS-PRESSURE; INTERNATIONAL CONSENSUS DEFINITIONS; SPONTANEOUSLY BREATHING PATIENTS; VENA-CAVA DIAMETER; ABDOMINAL COMPARTMENT SYNDROME; ACUTE CIRCULATORY FAILURE; END-EXPIRATORY OCCLUSION	IMPORTANCE Fluid overload occurring as a consequence of overly aggressive fluid resuscitation may adversely affect outcome in hemodynamically unstable critically ill patients. Therefore, following the initial fluid resuscitation, it is important to identify which patients will benefit from further fluid administration. OBJECTIVE To identify predictors of fluid responsiveness in hemodynamically unstable patients with signs of inadequate organ perfusion. DATA SOURCES AND STUDY SELECTION Search of MEDLINE and EMBASE (1966 to June 2016) and reference lists from retrieved articles, previous reviews, and physical examination textbooks for studies that evaluated the diagnostic accuracy of tests to predict fluid responsiveness in hemodynamically unstable adult patients who were defined as having refractory hypotension, signs of organ hypoperfusion, or both. Fluid responsiveness was defined as an increase in cardiac output following intravenous fluid administration. DATA EXTRACTION Two authors independently abstracted data (sensitivity, specificity, and likelihood ratios [LRs]) and assessed methodological quality. A bivariate mixed-effects binary regression model was used to pool the sensitivities, specificities, and LRs across studies. RESULTS A total of 50 studies (N = 2260 patients) were analyzed. In all studies, indices were measured before assessment of fluid responsiveness. The mean prevalence of fluid responsiveness was 50% (95% CI, 42%-56%). Findings on physical examination were not predictive of fluid responsiveness with LRs and 95% CIs for each finding crossing 1.0. A low central venous pressure (CVP) (mean threshold < 8 mm Hg) was associated with fluid responsiveness (positive LR, 2.6 [95% CI, 1.4-4.6]; pooled specificity, 76%), but a CVP greater than the threshold made fluid responsiveness less likely (negative LR, 0.50 [95% CI, 0.39-0.65]; pooled sensitivity, 62%). Respiratory variation in vena cava diameter measured by ultrasound (distensibility index > 15%) predicted fluid responsiveness in a subgroup of patients without spontaneous respiratory efforts (positive LR, 5.3 [95% CI, 1.1-27]; pooled specificity, 85%). Patients with less vena cava distensibility were not as likely to be fluid responsive (negative LR, 0.27 [95% CI, 0.08-0.87]; pooled sensitivity, 77%). Augmentation of cardiac output or related parameters following passive leg raising predicted fluid responsiveness (positive LR, 11 [95% CI, 7.6-17]; pooled specificity, 92%). Conversely, the lack of an increase in cardiac output with passive leg raising identified patients unlikely to be fluid responsive (negative LR, 0.13 [95% CI, 0.07-0.22]; pooled sensitivity, 88%). CONCLUSIONS AND RELEVANCE Passive leg raising followed by measurement of cardiac output or related parameters may be the most useful test for predicting fluid responsiveness in hemodynamically unstable adults. The usefulness of respiratory variation in the vena cava requires confirmatory studies.	[Bentzer, Peter] Helsingborg Hosp, Anesthesiol & Intens Care, Dept Clin Sci Lund, Helsingborg, Sweden; [Bentzer, Peter] Lund Univ, Lund, Sweden; [Bentzer, Peter; Boyd, John; Sirounis, Demetrios] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Griesdale, Donald E.; Sirounis, Demetrios] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC, Canada; [Griesdale, Donald E.; Ayas, Najib T.] Vancouver Coastal Hlth, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada; [Griesdale, Donald E.; Boyd, John; Sirounis, Demetrios; Ayas, Najib T.] Univ British Columbia, Div Crit Care Med, Dept Med, Vancouver, BC, Canada; [MacLean, Kelly] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada; [Ayas, Najib T.] Providence Healthcare, Dept Med, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Ayas, Najib T.] Univ British Columbia, Div Resp, Dept Med, Vancouver, BC, Canada; [Boyd, John; Ayas, Najib T.] St Pauls Hosp, Div Crit Care Med, Dept Med, Vancouver, BC V6Z 1Y6, Canada; [Griesdale, Donald E.] Vancouver Gen Hosp, Program Crit Care Med, Vancouver, BC, Canada; [Sirounis, Demetrios] St Pauls Hosp, Dept Anesthesiol, Vancouver, BC V6Z 1Y6, Canada	Helsingborgs Hospital; Lund University; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; University of British Columbia; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Ayas, NT (corresponding author), St Pauls Hosp, Div Crit Care Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	nayas@providencehealth.bc.ca	Griesdale, Donald/AAT-7762-2021	Griesdale, Donald/0000-0001-5985-8624				Airapetian N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1100-9; de Oliveira-Costa CDA, 2012, CLINICS, V67, P773, DOI 10.6061/clinics/2012(07)12; Angappan S, 2015, INDIAN J CRIT CARE M, V19, P394, DOI 10.4103/0972-5229.160278; Arikan AA, 2012, PEDIATR CRIT CARE ME, V13, P253, DOI 10.1097/PCC.0b013e31822882a3; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; Barbier C, 2004, INTENS CARE MED, V30, P1740, DOI 10.1007/s00134-004-2259-8; Biais M, 2008, BRIT J ANAESTH, V101, P761, DOI 10.1093/bja/aen277; Biais M, 2012, CRIT CARE MED, V40, P1186, DOI 10.1097/CCM.0b013e31823bc632; Biais M, 2009, CRIT CARE, V13, DOI 10.1186/cc8195; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Cecconi M, 2012, MINERVA ANESTESIOL, V78, P527; Charbonneau H, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0473-5; Charron C, 2006, ANESTH ANALG, V102, P1511, DOI 10.1213/01.ane.0000209015.21418.f4; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; De Backer D, 2005, INTENS CARE MED, V31, P517, DOI 10.1007/s00134-005-2586-4; De Backer D, 2009, ANESTHESIOLOGY, V110, P1092, DOI 10.1097/ALN.0b013e31819db2a1; Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016; Eskesen TG, 2016, INTENS CARE MED, V42, P324, DOI 10.1007/s00134-015-4168-4; FEINBERG MS, 1995, CHEST, V107, P769, DOI 10.1378/chest.107.3.769; Feissel M, 2004, INTENS CARE MED, V30, P1834, DOI 10.1007/s00134-004-2233-5; Feissel M, 2007, INTENS CARE MED, V33, P993, DOI 10.1007/s00134-007-0602-6; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Freitas FGR, 2013, BRIT J ANAESTH, V110, P402, DOI 10.1093/bja/aes398; Hanson J, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-348; Heenen S, 2006, CRIT CARE, V10, DOI 10.1186/cc4970; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Holodinsky JK, 2013, CRIT CARE, V17, DOI 10.1186/cc13075; Huang CC, 2008, CRIT CARE MED, V36, P2810, DOI 10.1097/CCM.0b013e318186b74e; HUNTSMAN LL, 1983, CIRCULATION, V67, P593, DOI 10.1161/01.CIR.67.3.593; Khwannimit B, 2012, EUR J ANAESTH, V29, P64, DOI 10.1097/EJA.0b013e32834b7d82; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Kupersztych-Hagege E, 2013, BRIT J ANAESTH, V111, P961, DOI 10.1093/bja/aet282; Lafanechere A, 2006, CRIT CARE, V10, DOI 10.1186/cc5044; Lakhal K, 2012, Ann Fr Anesth Reanim, V31, pe67, DOI 10.1016/j.annfar.2012.01.032; Lakhal K, 2011, CRIT CARE, V15, DOI 10.1186/cc10083; Lakhal K, 2010, INTENS CARE MED, V36, P940, DOI 10.1007/s00134-010-1755-2; Lamia B, 2007, INTENS CARE MED, V33, P1125, DOI 10.1007/s00134-007-0646-7; Lansdorp B, 2014, CRIT CARE MED, V42, P1983, DOI 10.1097/CCM.0000000000000345; Levy B, 2010, INTENS CARE MED, V36, P2019, DOI 10.1007/s00134-010-2045-8; Liu Y, 2016, CRIT CARE MED, V44, P342, DOI 10.1097/CCM.0000000000001371; Machare-Delgado Enrique, 2011, J Intensive Care Med, V26, P116; Magder S, 2006, CURR OPIN CRIT CARE, V12, P219, DOI 10.1097/01.ccx.0000224866.01453.43; Mahjoub Y, 2010, CRIT CARE MED, V38, P1824, DOI 10.1097/CCM.0b013e3181eb3c21; Maizel J, 2007, INTENS CARE MED, V33, P1133, DOI 10.1007/s00134-007-0642-y; Marcelino Paulo, 2006, Acta Med Port, V19, P197; Marik PE, 2013, CRIT CARE MED, V41, P1774, DOI 10.1097/CCM.0b013e31828a25fd; Marik PE, 2013, CHEST, V143, P364, DOI 10.1378/chest.12-1274; Marik PE, 2011, ANN INTENSIVE CARE, V1, DOI [10.1186/2110-5820-1-1, 10.1186/2110-5820-1-17]; Michard F, 2002, CHEST, V121, P2000, DOI 10.1378/chest.121.6.2000; Michard F, 2000, AM J RESP CRIT CARE, V162, P134, DOI 10.1164/ajrccm.162.1.9903035; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; Garcia MIM, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-9; Garcia MIM, 2009, CRIT CARE, V13, DOI 10.1186/cc8027; Monnet X, 2005, INTENS CARE MED, V31, P1195, DOI 10.1007/s00134-005-2731-0; Monnet X, 2006, CRIT CARE MED, V34, P1402, DOI 10.1097/01.CCM.0000215453.11735.06; Monnet X, 2012, BRIT J ANAESTH, V109, P330, DOI 10.1093/bja/aes182; Monnet X, 2013, CRIT CARE, V17, DOI 10.1186/cc12526; Monnet X, 2013, INTENS CARE MED, V39, P93, DOI 10.1007/s00134-012-2693-y; Monnet X, 2012, CRIT CARE MED, V40, P152, DOI 10.1097/CCM.0b013e31822f08d7; Monnet X, 2009, CRIT CARE MED, V37, P951, DOI 10.1097/CCM.0b013e3181968fe1; Moretti R, 2010, NEUROCRIT CARE, V13, P3, DOI 10.1007/s12028-010-9356-z; Muller L, 2009, ANN FR ANESTH, V28, P531, DOI 10.1016/j.annfar.2009.04.003; Muller L, 2008, ANESTH ANALG, V107, P607, DOI 10.1213/ane.0b013e31817e6618; Muller L, 2012, CRIT CARE, V16, DOI 10.1186/cc11672; Muller L, 2010, INTENS CARE MED, V36, P496, DOI 10.1007/s00134-009-1686-y; Murphy CV, 2009, CHEST, V136, P102, DOI 10.1378/chest.08-2706; Osman D, 2007, CRIT CARE MED, V35, P64, DOI 10.1097/01.CCM.0000249851.94101.4F; Patterson SW, 1914, J PHYSIOL-LONDON, V48, P357; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Perner A, 2006, ACTA ANAESTH SCAND, V50, P1068, DOI 10.1111/j.1399-6576.2006.01120.x; Preau S, 2010, CRIT CARE MED, V38, P819, DOI 10.1097/CCM.0b013e3181c8fe7a; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rubenfeld GD, 2007, JAMA-J AM MED ASSOC, V298, P458, DOI 10.1001/jama.298.4.458; Rudiger A, 2007, CRIT CARE MED, V35, P1599, DOI 10.1097/01.CCM.0000266683.64081.02; RUTLEN DL, 1981, CIRCULATION, V64, P146, DOI 10.1161/01.CIR.64.1.146; Sakka SG, 2007, BRIT J ANAESTH, V99, P337, DOI 10.1093/bja/aem177; Sakka SG, 1999, INTENS CARE MED, V25, P843, DOI 10.1007/s001340050962; Saugel B, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.10.008; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Simel DL, 2009, RATIONAL CLIN EXAMIN; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; Thiel SW, 2009, CRIT CARE, V13, DOI 10.1186/cc7955; Trepte CJC, 2013, BRIT J ANAESTH, V111, P736, DOI 10.1093/bja/aet204; Vallee F, 2009, INTENS CARE MED, V35, P1004, DOI 10.1007/s00134-009-1478-4; Vieillard-Baron A, 2004, INTENS CARE MED, V30, P1734, DOI 10.1007/s00134-004-2361-y; Vincent JL, 2006, CRIT CARE MED, V34, P1333, DOI 10.1097/01.CCM.0000214677.76535.A5; von Ballmoos MW, 2010, CRIT CARE, V14, DOI 10.1186/cc9060; Wagner JG, 1998, CHEST, V113, P1048, DOI 10.1378/chest.113.4.1048; WEIL MH, 1979, ANESTH ANALG, V58, P124; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	94	136	143	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	2016	316	12					1298	1309		10.1001/jama.2016.12310	http://dx.doi.org/10.1001/jama.2016.12310			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DW9EW	27673307				2023-01-03	WOS:000383959800021
J	Gunderman, R				Gunderman, Richard			Hospitalists and the Decline of Comprehensive Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gunderman, Richard] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Gunderman, R (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46202 USA.							Bryant DC, 1999, J GEN INTERN MED, V14, P182, DOI 10.1046/j.1525-1497.1999.00310.x; Meltzer D, 2001, J LEGAL STUD, V30, P589, DOI 10.1086/339294; Pham HH, 2008, HEALTH AFFAIR, V27, P1315, DOI 10.1377/hlthaff.27.5.1315; Taub Ben, 2016, NEW YORKER	4	13	14	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	2016	375	11					1011	1013		10.1056/NEJMp1608289	http://dx.doi.org/10.1056/NEJMp1608289			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DV6ZG	27509007	Green Published			2023-01-03	WOS:000383085000002
J	Nakazono, H; Ogata, K; Kuroda, T; Tobimatsu, S				Nakazono, Hisato; Ogata, Katsuya; Kuroda, Tsuyoshi; Tobimatsu, Shozo			Phase and Frequency-Dependent Effects of Transcranial Alternating Current Stimulation on Motor Cortical Excitability	PLOS ONE			English	Article							OSCILLATORY ACTIVITY; CORTICOMUSCULAR COHERENCE; NEURONAL POPULATIONS; SENSORIMOTOR CORTEX; BRAIN OSCILLATIONS; ALPHA; SYNCHRONIZATION; PERFORMANCE; POTENTIALS; NETWORK	Transcranial alternating current stimulation (tACS) can entrain ongoing brain oscillations and modulate the motor system in a frequency-dependent manner. Recent animal studies have demonstrated that the phase of a sinusoidal current also has an important role in modulation of neuronal activity. However, the phase effects of tACS on the human motor system are largely unknown. Here, we systematically investigated the effects of tACS phase and frequency on the primary motor cortex (M1) by using motor evoked potentials (MEPs) with transcranial magnetic stimulation (TMS). First, we compared the phase effects (90 degrees, 180 degrees, 270 degrees or 360 degrees) of 10 and 20 Hz tACS on MEPs. The 20 Hz tACS significantly increased M1 excitability compared with the 10 Hz tACS at 90 degrees phase only. Second, we studied the 90 degrees phase effect on MEPs at different tACS frequencies (5, 10, 20 or 40 Hz). The 20 vs. 10 Hz difference was again observed, but the 90 degrees phase in 5 and 40 Hz tACS did not influence M1 excitability. Third, the 90 degrees phase effects of 10 and 20 Hz tACS were compared with sham stimulation. The 90 degrees phase of 20 Hz tACS enhanced MEP amplitudes compared with sham stimulation, but there was no significant effect of 10 Hz tACS. Taken together, we assume that the differential 90 degrees phase effects on 20 Hz and 10 Hz tACS can be attributed to the neural synchronization modulated by tACS. Our results further underline that phase and frequency are the important factors in the effects of tACS on M1 excitability.	[Nakazono, Hisato; Ogata, Katsuya; Tobimatsu, Shozo] Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Clin Neurophysiol, Fukuoka, Japan; [Kuroda, Tsuyoshi] Shizuoka Univ, Fac Informat, Shizuoka, Japan	Kyushu University; Shizuoka University	Nakazono, H (corresponding author), Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Clin Neurophysiol, Fukuoka, Japan.	nakazono@med.kyushu-u.ac.jp	Kuroda, Tsuyoshi/H-8369-2019; l_l, CuteBlock/L-4348-2018	l_l, CuteBlock/0000-0002-7559-9615; Nakazono, Hisato/0000-0002-5076-8953	 [15J03164];  [15K21195];  [15H05875]; Grants-in-Aid for Scientific Research [15H05871] Funding Source: KAKEN	; ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid for JSPS KAKENHI 15J03164 to HN, and a Grant-in-Aid for JSPS KAKENHI 15K21195 to TK, and a Grant-in-Aid for Scientific Research on Innovative Areas MEXT KAKENHI 15H05875 to ST.	Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; Antal A, 2008, BRAIN STIMUL, V1, P97, DOI 10.1016/j.brs.2007.10.001; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cancelli A, 2015, BRAIN STIMUL, V8, P555, DOI 10.1016/j.brs.2015.01.398; Cecere R, 2015, CURR BIOL, V25, P231, DOI 10.1016/j.cub.2014.11.034; Chen DF, 2005, J NEUROPHYSIOL, V94, P2713, DOI 10.1152/jn.00024.2005; Conway BA, 1995, J PHYSIOL-LONDON, V489, P917, DOI 10.1113/jphysiol.1995.sp021104; Datta Abhishek, 2012, Front Psychiatry, V3, P91, DOI 10.3389/fpsyt.2012.00091; Feurra M, 2013, J NEUROSCI, V33, P17483, DOI 10.1523/JNEUROSCI.1414-13.2013; Feurra M, 2011, J NEUROSCI, V31, P12165, DOI 10.1523/JNEUROSCI.0978-11.2011; Frohlich F, 2010, NEURON, V67, P129, DOI 10.1016/j.neuron.2010.06.005; Gross J, 2002, P NATL ACAD SCI USA, V99, P2299, DOI 10.1073/pnas.032682099; Haegens S, 2011, P NATL ACAD SCI USA, V108, P19377, DOI 10.1073/pnas.1117190108; Haegens S, 2010, HUM BRAIN MAPP, V31, P26, DOI 10.1002/hbm.20842; Helfrich RF, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002031; Helfrich RF, 2014, CURR BIOL, V24, P333, DOI 10.1016/j.cub.2013.12.041; Herrmann CS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00279; Jensen O, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00186; Joundi RA, 2012, CURR BIOL, V22, P403, DOI 10.1016/j.cub.2012.01.024; Keil J, 2014, J NEUROPHYSIOL, V111, P513, DOI 10.1152/jn.00387.2013; Krause V, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00004; Kristeva R, 2007, NEUROIMAGE, V36, P785, DOI 10.1016/j.neuroimage.2007.03.025; Kutchko KM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003304; Lepage JF, 2008, J NEUROSCI METH, V175, P17, DOI 10.1016/j.jneumeth.2008.07.021; Maki H, 2010, CLIN NEUROPHYSIOL, V121, P492, DOI 10.1016/j.clinph.2009.11.078; Mitchell WK, 2007, J PHYSIOL-LONDON, V583, P567, DOI 10.1113/jphysiol.2007.134031; Muller NG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143533; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; Neuling T, 2012, NEUROIMAGE, V63, P771, DOI 10.1016/j.neuroimage.2012.07.024; Neuling T, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00161; Neuling Toralf, 2012, Front Psychiatry, V3, P83; Nielsen J. F., 1996, CLIN NEUROPHYSIOL, V101, P404; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ozen S, 2010, J NEUROSCI, V30, P11476, DOI 10.1523/JNEUROSCI.5252-09.2010; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Pogosyan A, 2009, CURR BIOL, V19, P1637, DOI 10.1016/j.cub.2009.07.074; Pollok B, 2015, BEHAV BRAIN RES, V293, P234, DOI 10.1016/j.bbr.2015.07.049; Raco V, 2014, BRAIN STIMUL, V7, P823, DOI 10.1016/j.brs.2014.08.005; Reato D, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00687; Reato D, 2010, J NEUROSCI, V30, P15067, DOI 10.1523/JNEUROSCI.2059-10.2010; Reimer J, 2010, J NEUROSCI, V30, P11506, DOI 10.1523/JNEUROSCI.5947-09.2010; Riecke L, 2015, BRAIN STIMUL, V8, P777, DOI 10.1016/j.brs.2015.04.004; Salenius S, 2003, CURR OPIN NEUROBIOL, V13, P678, DOI 10.1016/j.conb.2003.10.008; SALMELIN R, 1994, NEUROSCIENCE, V60, P537, DOI 10.1016/0306-4522(94)90263-1; Salmelin R, 1995, NEUROIMAGE, V2, P237, DOI 10.1006/nimg.1995.1031; Sauseng P, 2009, NEUROPSYCHOLOGIA, V47, P284, DOI 10.1016/j.neuropsychologia.2008.07.021; Schnitzler A, 1997, NEUROIMAGE, V6, P201, DOI 10.1006/nimg.1997.0286; Schulz H, 2014, CEREB CORTEX, V24, P1708, DOI 10.1093/cercor/bht024; Schutter DJLG, 2011, BRAIN STIMUL, V4, P97, DOI 10.1016/j.brs.2010.07.002; Schutter DJLG, 2010, CLIN NEUROPHYSIOL, V121, P1080, DOI 10.1016/j.clinph.2009.10.038; Tamura Y, 2005, EUR J NEUROSCI, V21, P2555, DOI 10.1111/j.1460-9568.2005.04096.x; Thut G, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00170; Thut G, 2009, TRENDS COGN SCI, V13, P182, DOI 10.1016/j.tics.2009.01.004; Turi Z, 2013, RESTOR NEUROL NEUROS, V31, P275, DOI 10.3233/RNN-120297; van Elswijk G, 2010, J NEUROSCI, V30, P4481, DOI 10.1523/JNEUROSCI.2794-09.2010; Voss U, 2014, NAT NEUROSCI, V17, P810, DOI 10.1038/nn.3719; Vossen A, 2015, BRAIN STIMUL, V8, P499, DOI 10.1016/j.brs.2014.12.004; Wach C, 2013, BEHAV BRAIN RES, V241, P1, DOI 10.1016/j.bbr.2012.11.038; Wetmore DZ, 2004, J PHYSIOL-LONDON, V555, P831, DOI 10.1113/jphysiol.2003.048918; Zaehle T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013766; Zarkowski P, 2006, CLIN EEG NEUROSCI, V37, P247, DOI 10.1177/155005940603700316	61	37	38	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2016	11	9							e0162521	10.1371/journal.pone.0162521	http://dx.doi.org/10.1371/journal.pone.0162521			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JB	27607431	Green Published, gold, Green Submitted			2023-01-03	WOS:000383255600055
J	Oldham, M; Yoon, P; Fathi, Z; Beyer, WF; Adamson, J; Liu, LH; Alcorta, D; Xia, WL; Osada, T; Liu, CX; Yang, XY; Dodd, RD; Herndon, JE; Meng, BY; Kirsch, DG; Lyerly, HK; Dewhirst, MW; Fecci, P; Walder, H; Spector, NL				Oldham, Mark; Yoon, Paul; Fathi, Zak; Beyer, Wayne F.; Adamson, Justus; Liu, Leihua; Alcorta, David; Xia, Wenle; Osada, Takuya; Liu, Congxiao; Yang, Xiao Y.; Dodd, Rebecca D.; Herndon, James E., II; Meng, Boyu; Kirsch, David G.; Lyerly, H. Kim; Dewhirst, Mark W.; Fecci, Peter; Walder, Harold; Spector, Neil L.			X-Ray Psoralen Activated Cancer Therapy (X-PACT)	PLOS ONE			English	Article							T-CELL LYMPHOMA; TERM-FOLLOW-UP; EXTRACORPOREAL PHOTOCHEMOTHERAPY; PUVA; TRANSIMMUNIZATION; APOPTOSIS; PSORIASIS; PHOTOBIOLOGY; MONOCYTE	This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative disease and extracorporeal photopheresis (ECP) of cutaneous T Cell Lymphoma. An immunogenic role for light-activated psoralen has been reported, contributing to long-term clinical responses. Psoralen therapies have to-date been limited to superficial or extracorporeal scenarios due to the requirement for psoralen activation by UVA light, which has limited penetration in tissue. X-PACT solves this challenge by activating psoralen with UV light emitted from novel non-tethered phosphors (co-incubated with psoralen) that absorb x-rays and re-radiate (phosphoresce) at UV wavelengths. The efficacy of X-PACT was evaluated in both in-vitro and in-vivo settings. In-vitro studies utilized breast (4T1), glioma (CT2A) and sarcoma (KP-B) cell lines. Cells were exposed to X-PACT treatments where the concentrations of drug (psoralen and phosphor) and radiation parameters (energy, dose, and dose rate) were varied. Efficacy was evaluated primarily using flow cell cytometry in combination with complimentary assays, and the in-vivo mouse study. In an in-vitro study, we show that X-PACT induces significant tumor cell apoptosis and cytotoxicity, unlike psoralen or phosphor alone (p<0.0001). We also show that apoptosis increases as doses of phosphor, psoralen, or radiation increase. Finally, in an in-vivo pilot study of BALBc mice with syngeneic 4T1 tumors, we show that the rate of tumor growth is slower with X-PACT than with saline or AMT + X-ray (p<0.0001). Overall these studies demonstrate a potential therapeutic effect for X-PACT, and provide a foundation and rationale for future studies. In summary, X-PACT represents a novel treatment approach in which well-tolerated low doses of x-ray radiation are delivered to a specific tumor site to generate UVA light which in-turn unleashes both short- and potentially long-term antitumor activity of photo-active therapeutics like psoralen.	[Oldham, Mark; Yoon, Paul; Adamson, Justus; Dodd, Rebecca D.; Meng, Boyu; Kirsch, David G.; Dewhirst, Mark W.; Walder, Harold] Duke Univ, Dept Radiat Oncol, Med Ctr, Durham, NC USA; [Fathi, Zak] Immunolight LLC, Detroit, MI USA; [Beyer, Wayne F.] QNS Grp LLC, Bahama, NC USA; [Liu, Leihua; Alcorta, David; Xia, Wenle; Spector, Neil L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Osada, Takuya; Liu, Congxiao; Yang, Xiao Y.; Lyerly, H. Kim] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Herndon, James E., II] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA; [Fecci, Peter] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University	Oldham, M (corresponding author), Duke Univ, Dept Radiat Oncol, Med Ctr, Durham, NC USA.	Mark.Oldham@Duke.edu	Dewhirst, Mark/Q-1302-2019; Adamson, Justus/AAM-5335-2021; Lyerly, Herbert Kim/AAX-4925-2020; Lyerly, Herbert K/B-6528-2014	Dewhirst, Mark/0000-0003-3459-6546; Lyerly, Herbert Kim/0000-0002-0063-4770; Lyerly, Herbert K/0000-0002-0063-4770; Adamson, Justus/0000-0002-7868-5631; Dodd, Rebecca/0000-0001-7295-1882; Yoon, Suk Whan "Paul"/0000-0002-0313-8131; Fecci, Peter/0000-0002-2912-8695	Duke University, Immunolight LLC [P50 CA190991]; Duke SPORE in Brain Cancer [P50 CA190991]; NATIONAL CANCER INSTITUTE [P50CA190991] Funding Source: NIH RePORTER	Duke University, Immunolight LLC; Duke SPORE in Brain Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MO received Brainspore funding from Duke University P50 CA190991, Immunolight LLC funding was provided to MO MD NS and KL. Immunolight personnel (HW ZF WB) provided the energy converters and psoralen.; Funding support was received from P50 CA190991-Duke SPORE in Brain Cancer. We are very grateful to Dr Kathleen Ashcraft and Dr Kelly Lee for discussions and technical assistance arising from related work to that presented here.	Berger CL, 2002, TRANSFUS APHER SCI, V26, P205, DOI 10.1016/S1473-0502(02)00014-9; Bethea D, 1999, J DERMATOL SCI, V19, P78, DOI 10.1016/S0923-1811(98)00064-4; Bourke FA, 2014, US Patent Number, Patent No. [US20140323946 A1, 20140323946]; Bourke FA, 2014, US Patent Number, Patent No. [US20140272030 A1, 20140272030]; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; Edelson RL, 2014, TRANSFUS APHER SCI, V50, P322, DOI 10.1016/j.transci.2013.07.031; El-Domyati M, 2013, PHOTODERMATOL PHOTO, V29, P18, DOI 10.1111/phpp.12012; Gasparro F P, 1997, Recent Results Cancer Res, V143, P101; Girardi M, 2003, HEMATOL ONCOL CLIN N, V17, P1391, DOI 10.1016/S0889-8588(03)00106-0; Girardi M, 2002, TRANSFUS APHER SCI, V26, P181, DOI 10.1016/S1473-0502(02)00011-3; Girardi M, 2006, LEUKEMIA LYMPHOMA, V47, P1495, DOI 10.1080/10428190600581419; Gonzalez AL, 2014, CLIN EXP IMMUNOL, V175, P449, DOI 10.1111/cei.12231; HERRMANN JJ, 1995, J AM ACAD DERMATOL, V33, P234, DOI 10.1016/0190-9622(95)90241-4; Holtick U, 2012, TRANSPLANTATION, V94, pE31, DOI 10.1097/TP.0b013e31825f4454; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Knobler R, 2012, PHOTODERMATOL PHOTO, V28, P250, DOI 10.1111/j.1600-0781.2012.00689.x; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Maves RC, 2011, VACCINE, V29, P2691, DOI 10.1016/j.vaccine.2011.01.077; Morse MA, 2010, INT J CANCER, V126, P2893, DOI 10.1002/ijc.24995; Panno ML, 2014, WORLD J CLIN ONCOL, V5, P348, DOI 10.5306/wjco.v5.i3.348; Sachdeva M, 2014, J CLIN INVEST, V124, P4305, DOI 10.1172/JCI77116; Scaffidi JP, 2011, ACS NANO, V5, P4679, DOI 10.1021/nn200511m; SCHMITT IM, 1995, J PHOTOCH PHOTOBIO B, V27, P101, DOI 10.1016/1011-1344(94)07101-S; Shenoi SD, 2014, INDIAN J DERMATOL VE, V80, P497, DOI 10.4103/0378-6323.144143; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; THORNES RD, 1994, J CANCER RES CLIN, V120, pS32, DOI 10.1007/BF01377122; Valbuena MC, 2007, PHOTODERMATOL PHOTO, V23, P126, DOI 10.1111/j.1600-0781.2007.00294.x; Wang Y, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen087; Xia WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088983	29	18	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2016	11	9							e0162078	10.1371/journal.pone.0162078	http://dx.doi.org/10.1371/journal.pone.0162078			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV3WN	27583569	Green Published, gold			2023-01-03	WOS:000382855600099
J	Hunt, J; Murrell, J; Knazovicky, D; Harris, J; Kelly, S; Knowles, TG; Lascelles, BDX				Hunt, James; Murrell, Jo; Knazovicky, David; Harris, John; Kelly, Sara; Knowles, Toby G.; Lascelles, B. Duncan X.			Alfaxalone Anaesthesia Facilitates Electrophysiological Recordings of Nociceptive Withdrawal Reflexes in Dogs (Canis familiaris)	PLOS ONE			English	Article							SPINAL-CORD; CENTRAL SENSITIZATION; OSTEOARTHRITIS PAIN; CONSCIOUS DOGS; RATE-INFUSION; ISOFLURANE; STIMULI; LIMB; ORGANIZATION; HEAT	Naturally occurring canine osteoarthritis represents a welfare issue for affected dogs (Canis familiaris), but is also considered very similar to human osteoarthritis and has therefore been proposed as a model of disease in humans. Central sensitisation is recognized in human osteoarthritis sufferers but identification in dogs is challenging. Electromyographic measurement of responses to nociceptive stimulation represents a potential means of investigating alterations in central nociceptive processing, and has been evaluated in conscious experimental dogs, but is likely to be aversive. Development of a suitable anaesthetic protocol in experimental dogs, which facilitated electrophysiological nociceptive withdrawal reflex assessment, may increase the acceptability of using the technique in owned dogs with naturally occurring osteoarthritis. Seven purpose bred male hound dogs underwent electromyographic recording sessions in each of three states: acepromazine sedation, alfaxalone sedation, and alfaxalone anaesthesia. Electromyographic responses to escalating mechanical and electrical, and repeated electrical, stimuli were recorded. Subsequently the integral of both early and late rectified responses was calculated. Natural logarithms of the integral values were analysed within and between the three states using multi level modeling. Alfaxalone increased nociceptive thresholds and decreased the magnitude of recorded responses, but characteristics of increasing responses with increasing stimulus magnitude were preserved. Behavioural signs of anxiety were noted in two out of seven dogs during recordings in the acepromazine sedated state. There were few significant differences in response magnitude or nociceptive threshold between the two alfaxalone states. Following acepromazine premedication, induction of anaesthesia with 1-2 mg kg(-1) alfaxalone, followed by a continuous rate infusion in the range 0.075-0.1 mg kg(-1) min(-1) produced suitable conditions to enable assessment of spinal nociceptive processing in dogs, without subjecting them to potentially aversive experiences. This methodology may be appropriate for obtaining electrophysiological nociceptive withdrawal reflex data in client-owned dogs with naturally occurring osteoarthritis.	[Hunt, James; Murrell, Jo; Knowles, Toby G.] Univ Bristol, Sch Vet Sci, Bristol, Avon, England; [Knazovicky, David; Lascelles, B. Duncan X.] North Carolina State Univ, Coll Vet Med, Comparat Pain Res Lab, Raleigh, NC 27695 USA; [Harris, John; Kelly, Sara] Univ Nottingham, Sch Biosci, Div Anim Sci, Sutton Bonington Campus, Loughborough, Leics, England; [Lascelles, B. Duncan X.] UNC Sch Dent, Ctr Pain Res & Innovat, Chapel Hill, NC 27599 USA; [Lascelles, B. Duncan X.] North Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA; [Knazovicky, David] Oregon State Univ, Coll Vet Med, Corvallis, OR 97331 USA	University of Bristol; University of North Carolina; North Carolina State University; University of Nottingham; University of North Carolina; North Carolina State University; Oregon State University	Lascelles, BDX (corresponding author), North Carolina State Univ, Coll Vet Med, Comparat Pain Res Lab, Raleigh, NC 27695 USA.; Lascelles, BDX (corresponding author), UNC Sch Dent, Ctr Pain Res & Innovat, Chapel Hill, NC 27599 USA.; Lascelles, BDX (corresponding author), North Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA.	dxlascel@ncsu.edu	Knowles, Toby G/A-2026-2008; Hunt, James/AAK-2854-2020	Knowles, Toby G/0000-0002-3845-0942; Harris, John/0000-0001-7815-5385; Lascelles, B. Duncan X./0000-0002-2950-9009	Comparative Pain Research Laboratory, North Carolina State University; BBSRC [BB/L00240X/1]; BBSRC [BB/L001349/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/L001349/1, BB/L00240X/1] Funding Source: researchfish	Comparative Pain Research Laboratory, North Carolina State University; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funding for the study was received from the Comparative Pain Research Laboratory, North Carolina State University. Travel and accommodation expenses for J. Hunt and JM, and salary costs of J. Hunt were met from BBSRC grant BB/L00240X/1, for which Zoetis is the Industry Partner. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali Z, 1996, PAIN, V68, P401, DOI 10.1016/S0304-3959(96)03199-5; Arendt-Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003; Banic B, 2004, PAIN, V107, P7, DOI 10.1016/j.pain.2003.05.001; Baron R, 2013, ANN NEUROL, V74, P630, DOI 10.1002/ana.24017; Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5; Bergadano A, 2006, AM J VET RES, V67, P882, DOI 10.2460/ajvr.67.5.882; Bergadano A, 2007, AM J VET RES, V68, P899, DOI 10.2460/ajvr.68.8.899; Bergadano A, 2009, VET J, V182, P252, DOI 10.1016/j.tvjl.2008.06.003; Bergadano A, 2009, VET ANAESTH ANALG, V36, P261, DOI 10.1111/j.1467-2995.2009.00447.x; Briley JD, 2014, VET J, V199, P245, DOI 10.1016/j.tvjl.2013.10.025; Brydges NM, 2012, VET J, V193, P545, DOI 10.1016/j.tvjl.2012.01.019; CARSTENS E, 1993, J NEUROPHYSIOL, V70, P621, DOI 10.1152/jn.1993.70.2.621; Clarke RW, 2004, BRAIN RES REV, V46, P163, DOI 10.1016/j.brainresrev.2004.07.005; du Sert NP, 2014, BRIT J PHARMACOL, V171, P2951, DOI 10.1111/bph.12645; FANSELOW MS, 1986, ANN NY ACAD SCI, V467, P40, DOI 10.1111/j.1749-6632.1986.tb14617.x; Frahm KS, 2013, BMC NEUROSCI, V14, P1; Harris J, 2003, J PHYSIOL-LONDON, V546, P251, DOI 10.1113/jphysiol.2002.025023; Harris J, 2007, BRAIN RES, V1131, P106, DOI 10.1016/j.brainres.2006.11.003; Jennings EM, 2014, PROG NEUROBIOL, V121, P1, DOI 10.1016/j.pneurobio.2014.06.003; Jinks SL, 2003, ANESTHESIOLOGY, V98, P1128, DOI 10.1097/00000542-200305000-00015; Kelly S, 2013, OSTEOARTHR CARTILAGE, V21, P1327, DOI 10.1016/j.joca.2013.07.002; Kim J, 2007, ANESTH ANALG, V105, P1020, DOI 10.1213/01.ane.0000280483.17854.56; Knazovicky D, 2015, PEERJ, V3, DOI 10.7717/peerj.772; Lascelles BDX, 2008, J VET INTERN MED, V22, P53, DOI 10.1111/j.1939-1676.2007.0014.x; Lascelles BDX, 2002, J AM VET MED ASSOC, V221, P215, DOI 10.2460/javma.2002.221.215; Lervik A, 2012, VET ANAESTH ANALG, V39, P414, DOI 10.1111/j.1467-2995.2012.00713.x; MEYER RA, 1991, BRAIN RES, V561, P252, DOI 10.1016/0006-8993(91)91601-V; Moore SA, 2013, VET J, V197, P216, DOI 10.1016/j.tvjl.2012.11.003; Morch CD, 2011, MED BIOL ENG COMPUT, V49, P385, DOI 10.1007/s11517-010-0725-8; Nijland ML, 2010, PUBLIC HEALTH NUTR, V13, P102, DOI 10.1017/S136898000999022X; PETERSENFELIX S, 1995, BRIT J ANAESTH, V75, P55, DOI 10.1093/bja/75.1.55; Rasbash J., 2009, MLWIN VERSION 2 1; Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9; SCHOUENBORG J, 1994, NEWS PHYSIOL SCI, V9, P261; Sherrington CS, 1910, J PHYSIOL-LONDON, V40, P28; Sorensen J, 1998, J RHEUMATOL, V25, P152; Spadavecchia C, 2006, AM J VET RES, V67, P762, DOI 10.2460/ajvr.67.5.762; Tomas A, 2014, VET SURG, V43, P542, DOI 10.1111/j.1532-950X.2014.12160.x; TORRING J, 1981, J NEUROL NEUROSUR PS, V44, P129, DOI 10.1136/jnnp.44.2.129; Vainio O, 2012, SCAND J PAIN, V3, P84, DOI 10.1016/j.sjpain.2011.11.007; Weerasinghe NS, 2014, EUR J PAIN, V18, P1199, DOI 10.1002/j.1532-2149.2014.00469.x; Williams MD, 2014, VET J, V199, P63, DOI 10.1016/j.tvjl.2013.11.003; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Yeates J, 2014, J AWSELVA, V18, P9	44	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2016	11	7							e0158990	10.1371/journal.pone.0158990	http://dx.doi.org/10.1371/journal.pone.0158990			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TG	27433936	gold, Green Published, Green Submitted			2023-01-03	WOS:000380169600028
J	Blanchette, ML				Blanchette, Melanie L.			The measure of success	SCIENCE			English	Editorial Material									[Blanchette, Melanie L.] Edith Cowan Univ, Perth, WA, Australia	Edith Cowan University	Blanchette, ML (corresponding author), Edith Cowan Univ, Perth, WA, Australia.	SciCareerEditor@aaas.org		Blanchette, Melanie/0000-0003-2138-2864					0	0	0	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2016	353	6294					94	94		10.1126/science.353.6294.94	http://dx.doi.org/10.1126/science.353.6294.94			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DP9KX	27365451				2023-01-03	WOS:000378816200042
J	Saleem, A; Masood, I				Saleem, Ahsan; Masood, Imran			Pattern and Predictors of Medication Dosing Errors in Chronic Kidney Disease Patients in Pakistan: A Single Center Retrospective Analysis	PLOS ONE			English	Article							DRUG-DOSAGE ADJUSTMENTS; RENAL IMPAIRMENT; HOSPITALIZED-PATIENTS; CREATININE CLEARANCE; SERUM CREATININE; ELDERLY-PATIENTS; EPIDEMIOLOGY; PREVALENCE; GUIDELINES; COMMUNITY	Background Chronic kidney disease (CKD) alters the pharmacokinetic and pharmacodynamic response of various drugs and increases the risk of toxicity. The data regarding the pattern and predictors of medication dosing errors is scare from the developing countries. Therefore, the present study was conducted to assess the pattern and predictors of medication dosing errors in CKD patients in a tertiary care setting in Pakistan. Methods A retrospective study design was employed and medical charts of all those CKD patients who had an eGFR <= 60ml/min/1.73m(2), hospitalization >= 24 hours, and admitted in the nephrology unit during January 2013 to December 2014 were assessed. Descriptive statistics and the logistic regression analysis were done using IBM SPSS version 20. Results In total, 205 medical charts were assessed. The mean age of patients was 38.64 (+/- 16.82) years. Overall, 1534 drugs were prescribed to CKD patients, of which, nearly 34.0% drugs required dose adjustment. Among those drugs, only 41.8% were properly adjusted, and the remaining 58.2% were unadjusted. The logistic regression analysis revealed that the medication dosing errors were significantly associated with the CKD stages, i.e. stage 4 (OR 0.054; 95% CI [0.017-0.177]; p < 0.001) and stage 5 (OR 0.098; 95% CI [0.040-0.241]; p < 0.001), the number of prescribed medicines >= 5 (OR 0.306; 95% CI [0.133-0.704]; p 0.005), and the presence of a comorbidity (OR 0.455; 95% CI [0.226-0.916]; p 0.027) such as the hypertension (OR 0.453; 95% CI [0.231-0.887]; p 0.021). Conclusions It is concluded that more than half drugs prescribed to CKD patients requiring dose adjustment were unadjusted. The predictors of medication dosing errors were the severe-to-end stages of chronic kidney disease, the presence of a comorbidity such as hypertension, and a higher number of prescribed medicines. Therefore, attention should be paid to these risk factors.	[Saleem, Ahsan; Masood, Imran] Islamia Univ Bahawalpur, Dept Pharm, Bahawalpur, Punjab, Pakistan	Islamia University of Bahawalpur	Saleem, A; Masood, I (corresponding author), Islamia Univ Bahawalpur, Dept Pharm, Bahawalpur, Punjab, Pakistan.	saleemahsan77@gmail.com; drimranmasoodppiub@gmail.com	Saleem, Ahsan/P-4760-2014	Saleem, Ahsan/0000-0003-1710-3578				Alahdal AM, 2012, SAUDI PHARM J, V20, P217, DOI 10.1016/j.jsps.2011.12.005; Alam Ashar, 2014, BMC Res Notes, V7, P179, DOI 10.1186/1756-0500-7-179; Bassetti M, 2016, EXPERT OPIN DRUG SAF, V15, P467, DOI 10.1517/14740338.2016.1142528; BENNETT WM, 1983, AM J KIDNEY DIS, V3, P155, DOI 10.1016/S0272-6386(83)80060-2; British Medical Association Royal Pharmaceutical Society of Great Britain, 2009, BRIT NATL FORMULARY; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; de Brito-Ashurst I, 2009, J AM SOC NEPHROL, V20, P2075, DOI 10.1681/ASN.2008111205; Decloedt E, 2010, SAMJ S AFR MED J, V100, P304, DOI 10.7196/SAMJ.3955; Drenth-van Maanen AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128237; Erler A, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-91; Getachew H, 2015, BMC NEPHROL, V15, P1; Gilani SI, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-16; Haider SI, 2014, VALUE HEALTH, V17, pA129, DOI 10.1016/j.jval.2014.03.747; Hallan SI, 2006, J AM SOC NEPHROL, V17, P2275, DOI 10.1681/ASN.2005121273; Hanlon JT, 2011, J AM MED DIR ASSOC, V12, P377, DOI 10.1016/j.jamda.2010.04.008; Hartmann B, 2010, DTSCH ARZTEBL INT, V107, P647, DOI 10.3238/arztebl.2010.0647; Hu KT, 2001, AM J MED SCI, V322, P133, DOI 10.1097/00000441-200109000-00004; Hug BL, 2009, KIDNEY INT, V76, P1192, DOI 10.1038/ki.2009.353; Khanal A, 2015, DRUG AGING, V32, P391, DOI 10.1007/s40266-015-0261-1; Lassiter J, 2013, CLIN GERIATR MED, V29, P657, DOI 10.1016/j.cger.2013.05.008; Leendertse AJ, 2012, ANN PHARMACOTHER, V46, P625, DOI 10.1345/aph.1Q633; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Marasinghe KM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006539; Markota NP, 2009, J NEPHROL, V22, P497; Munar MY, 2007, AM FAM PHYSICIAN, V75, P1487; Papaioannou A, 2000, J AM GERIATR SOC, V48, P1470, DOI 10.1111/j.1532-5415.2000.tb02639.x; Pillans PI, 2003, INTERN MED J, V33, P10, DOI 10.1046/j.1445-5994.2003.00330.x; Prajapati Arpit, 2013, J Pharm Bioallied Sci, V5, P136, DOI 10.4103/0975-7406.111829; Sah S K, 2014, J Nepal Health Res Counc, V12, P54; Salomon L, 2003, INT J QUAL HEALTH C, V15, P331, DOI 10.1093/intqhc/mzg046; Schieppati A, 2005, KIDNEY INT, V68, pS7, DOI 10.1111/j.1523-1755.2005.09801.x; Soetikno V, 2009, MED J INDONES, V18, P108; Stevens LA, 2009, CLIN PHARMACOL THER, V86, P465, DOI 10.1038/clpt.2009.124; Sweileh WM, 2007, PHARMACOEPIDEM DR S, V16, P908, DOI 10.1002/pds.1412; Tamizuddin S, 2010, J PAK MED ASSOC, V60, P342; Ullah K, 2015, SAUDI J KIDNEY DIS T, V26, P1307, DOI 10.4103/1319-2442.168694; van Dijk EA, 2006, ANN PHARMACOTHER, V40, P1254, DOI 10.1345/aph.1G742; Verbeeck RK, 2009, EUR J CLIN PHARMACOL, V65, P757, DOI 10.1007/s00228-009-0678-8; WHO, PAK STAT 2013	41	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2016	11	7							e0158677	10.1371/journal.pone.0158677	http://dx.doi.org/10.1371/journal.pone.0158677			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0TX	27367594	Green Published, Green Submitted, gold			2023-01-03	WOS:000378914900048
J	Morris, PE; Berry, MJ; Files, DC; Thompson, JC; Hauser, J; Flores, L; Dhar, S; Chmelo, E; Lovato, J; Case, LD; Bakhru, RN; Sarwal, A; Parry, SM; Campbell, P; Mote, A; Winkelman, C; Hite, RD; Nicklas, B; Chatterjee, A; Young, MP				Morris, Peter E.; Berry, Michael J.; Files, D. Clark; Thompson, J. Clifton; Hauser, Jordan; Flores, Lori; Dhar, Sanjay; Chmelo, Elizabeth; Lovato, James; Case, L. Douglas; Bakhru, Rita N.; Sarwal, Aarti; Parry, Selina M.; Campbell, Pamela; Mote, Arthur; Winkelman, Chris; Hite, Robert D.; Nicklas, Barbara; Chatterjee, Arjun; Young, Michael P.			Standardized Rehabilitation and Hospital Length of Stay Among Patients With Acute Respiratory Failure A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; PHYSICAL-THERAPY; CRITICAL ILLNESS; DISTRESS-SYNDROME; POINT-PREVALENCE; MORTALITY; VENTILATION; DISABILITY	IMPORTANCE Physical rehabilitation in the intensive care unit (ICU) may improve the outcomes of patients with acute respiratory failure. OBJECTIVE To compare standardized rehabilitation therapy (SRT) to usual ICU care in acute respiratory failure. DESIGN, SETTING, AND PARTICIPANTS Single-center, randomized clinical trial at Wake Forest Baptist Medical Center, North Carolina. Adult patients (mean age, 58 years; women, 55%) admitted to the ICU with acute respiratory failure requiring mechanical ventilation were randomized to SRT (n = 150) or usual care (n = 150) from October 2009 through May 2014 with 6-month follow-up. INTERVENTIONS Patients in the SRT group received daily therapy until hospital discharge, consisting of passive range of motion, physical therapy, and progressive resistance exercise. The usual care group received weekday physical therapy when ordered by the clinical team. For the SRT group, the median (interquartile range [IQR]) days of delivery of therapy were 8.0 (5.0-14.0) for passive range of motion, 5.0 (3.0-8.0) for physical therapy, and 3.0 (1.0-5.0) for progressive resistance exercise. The median days of delivery of physical therapy for the usual care group was 1.0 (IQR, 0.0-8.0). MAIN OUTCOMES AND MEASURES Both groups underwent assessor-blinded testing at ICU and hospital discharge and at 2, 4, and 6 months. The primary outcome was hospital length of stay (LOS). Secondary outcomes were ventilator days, ICU days, Short Physical Performance Battery (SPPB) score, 36-item Short-Form Health Surveys (SF-36) for physical and mental health and physical function scale score, Functional Performance Inventory (FPI) score, Mini-Mental State Examination (MMSE) score, and handgrip and handheld dynamometer strength. RESULTS Among 300 randomized patients, the median hospital LOS was 10 days (IQR, 6 to 17) for the SRT group and 10 days (IQR, 7 to 16) for the usual care group (median difference, 0 [95% CI, -1.5 to 3], P=.41). There was no difference in duration of ventilation or ICU care. There was no effect at 6 months for handgrip (difference, 2.0 kg [95% CI, -1.3 to 5.4], P=.23) and handheld dynamometer strength (difference, 0.4 lb [95% CI, -2.9 to 3.7], P=.82), SF-36 physical health score (difference, 3.4 [95% CI, -0.02 to 7.0], P=.05), SF-36 mental health score (difference, 2.4 [95% CI, -1.2 to 6.0], P=.19), or MMSE score (difference, 0.6 [95% CI, -0.2 to 1.4], P=.17). There were higher scores at 6 months in the SRT group for the SPPB score (difference, 1.1 [95% CI, 0.04 to 2.1, P =.04), SF-36 physical function scale score (difference, 12.2 [95% CI, 3.8 to 20.7], P=.001), and the FPI score (difference, 0.2 [95% CI, 0.04 to 0.4], P=.02). CONCLUSIONS AND RELEVANCE Among patients hospitalized with acute respiratory failure, SRT compared with usual care did not decrease hospital LOS.	[Morris, Peter E.] Univ Kentucky, Div Pulm Crit Care & Sleep Med, Lexington, KY 40536 USA; [Berry, Michael J.; Hauser, Jordan] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA; [Files, D. Clark; Thompson, J. Clifton; Flores, Lori; Dhar, Sanjay; Chmelo, Elizabeth; Bakhru, Rita N.; Campbell, Pamela; Mote, Arthur; Chatterjee, Arjun; Young, Michael P.] Wake Forest Univ, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27109 USA; [Lovato, James; Case, L. Douglas] Wake Forest Univ, Dept Biostat Sci, Winston Salem, NC 27109 USA; [Sarwal, Aarti] Wake Forest Univ, Dept Neurol, Winston Salem, NC 27109 USA; [Parry, Selina M.] Univ Melbourne, Physiotherapy Dept, Melbourne, Vic, Australia; [Winkelman, Chris] Case Western Reserve Univ, Francis Payne Bolton Sch Nursing, Cleveland, OH 44106 USA; [Hite, Robert D.] Cleveland Clin, Resp Inst, Dept Crit Care, Cleveland, OH 44106 USA; [Nicklas, Barbara] Wake Forest Univ, Div Geriatr, Winston Salem, NC 27109 USA	University of Kentucky; Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; University of Melbourne; Case Western Reserve University; Cleveland Clinic Foundation; Wake Forest University	Morris, PE (corresponding author), Univ Kentucky, Div Pulm Crit Care & Sleep Med, Kentucky Clin, 740 S Limestone,L-543, Lexington, KY 40536 USA.	peter.morris@uky.edu	Winkelman, Chris/AAB-7818-2019; Sarwal, A./I-2139-2019; chatterjee, arjun B/H-2689-2013; Nicklas, Barbara/AAA-2781-2020	Winkelman, Chris/0000-0002-2988-9304; chatterjee, arjun B/0000-0001-8221-873X; Hite, Robert Duncan/0000-0002-2625-8750; Parry, Selina/0000-0003-2204-3143; Files, Daniel Clark/0000-0002-1595-4080	National Institutes of Health; National Institute of Nursing Research; National Heart, Lung, and Blood Institute; NATIONAL INSTITUTE ON AGING [P30AG021332] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the National Institutes of Health, National Institute of Nursing Research, and National Heart, Lung, and Blood Institute.	Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Berney SC, 2013, CRIT CARE RESUSC, V15, P260; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brummel NE, 2014, INTENS CARE MED, V40, P370, DOI 10.1007/s00134-013-3136-0; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Elliott D, 2014, CRIT CARE MED, V42, P2518, DOI 10.1097/CCM.0000000000000525; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; Hermans G, 2014, AM J RESP CRIT CARE, V190, P410, DOI 10.1164/rccm.201312-2257OC; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hodgin KE, 2009, CRIT CARE MED, V37, P561, DOI 10.1097/CCM.0b013e3181957449; Hudson LD, 2003, NEW ENGL J MED, V348, P745, DOI 10.1056/NEJMe020180; Iwashyna TJ, 2012, AM J RESP CRIT CARE, V186, P302, DOI 10.1164/rccm.201206-1138ED; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Leidy NK, 2012, INT J CHRONIC OBSTR, V7, P543, DOI 10.2147/COPD.S32032; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Moss M, 2016, AM J RESP CRIT CARE, V193, P1101, DOI 10.1164/rccm.201505-1039OC; Needham DM, 2010, ARCH PHYS MED REHAB, V91, P536, DOI 10.1016/j.apmr.2010.01.002; Nydahl P, 2014, CRIT CARE MED, V42, P1178, DOI 10.1097/CCM.0000000000000149; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Parry SM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001891; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Ratitch B, IMPLEMENTATION PATTE; SAS Institute, 2011, SAS STAT 9 3 SAS US; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; TEAM Study Investigators, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0765-4; Walsh TS, 2015, JAMA INTERN MED, V175, P901, DOI 10.1001/jamainternmed.2015.0822	36	192	211	4	53	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2016	315	24					2694	2702		10.1001/jama.2016.7201	http://dx.doi.org/10.1001/jama.2016.7201			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP7WG	27367766	Bronze, Green Accepted			2023-01-03	WOS:000378709300020
J	Lambie, M; Chess, J; Do, JY; Noh, H; Lee, HB; Kim, YL; Summers, A; Williams, PF; Davison, S; Dorval, M; Topley, N; Davies, SJ				Lambie, Mark; Chess, James; Do, Jun-Young; Noh, Hyunjin; Lee, Hi-Bahl; Kim, Yong-Lim; Summers, Angela; Williams, Paul Ford; Davison, Sara; Dorval, Marc; Topley, Nick; Davies, Simon John		Global Fluid Study Investigators	Peritoneal Dialysate Glucose Load and Systemic Glucose Metabolism in Non-Diabetics: Results from the GLOBAL Fluid Cohort Study	PLOS ONE			English	Article							HYPERGLYCEMIA; ASSOCIATION; DEFINITION; ICODEXTRIN; TRANSPORT; DISEASE	Background and Objectives Glucose control is a significant predictor of mortality in diabetic peritoneal dialysis (PD) patients. During PD, the local toxic effects of intra-peritoneal glucose are well recognized, but despite large amounts of glucose being absorbed, the systemic effects of this in non-diabetic patients are not clear. We sought to clarify whether dialysate glucose has an effect upon systemic glucose metabolism. Methods and Materials We analysed the Global Fluid Study cohort, a prospective, observational cohort study initiated in 2002. A subset of 10 centres from 3 countries with high data quality were selected (368 incident and 272 prevalent non-diabetic patients), with multilevel, multivariable analysis of the reciprocal of random glucose levels, and a stratified-by-centre Cox survival analysis. Results The median follow up was 5.6 and 6.4 years respectively in incident and prevalent patients. On multivariate analysis, serum glucose increased with age (beta = -0.007, 95% CI -0.010, -0.004) and decreased with higher serum sodium (beta = 0.002, 95% CI 0.0005, 0.003) in incident patients and increased with dialysate glucose (beta = -0.0002, 95% CI -0.0004, -0.00006) in prevalent patients. Levels suggested undiagnosed diabetes in 5.4% of prevalent patients. Glucose levels predicted death in unadjusted analyses of both incident and prevalent groups but in an adjusted survival analysis they did not (for random glucose 6-10 compared with <6, Incident group HR 0.92, 95% CI 0.58, 1.46, Prevalent group HR 1.42, 95% CI 0.86, 2.34). Conclusions In prevalent non-diabetic patients, random glucose levels at a diabetic level are under-recognised and increase with dialysate glucose load. Random glucose levels predict mortality in unadjusted analyses, but this association has not been proven in adjusted analyses.	[Lambie, Mark; Davies, Simon John] Keele Univ, Inst Appl Clin Res, Stoke On Trent, Staffs, England; [Chess, James; Topley, Nick] Cardiff Univ, Sch Med, Inst Nephrol, Heath Pk, Cardiff CF10 3AX, S Glam, Wales; [Chess, James] Morriston Hosp, Renal Unit, Swansea, W Glam, Wales; [Do, Jun-Young] Yeungnam Univ Hosp, Div Nephrol, Daegu, South Korea; [Noh, Hyunjin; Lee, Hi-Bahl] Soonchunhyang Univ, Hyonam Kidney Lab, Seoul, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ Hosp, Div Nephrol, Daegu, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ Hosp, Clin Res Ctr ESRD Korea, Daegu, South Korea; [Summers, Angela] Manchester Royal Infirm, Manchester Inst Nephrol & Transplantat, Oxford Rd, Manchester M13 9WL, Lancs, England; [Williams, Paul Ford] Ipswich Hosp NHS Trust Ipswich Hosp, Heath Rd, Ipswich, Suffolk, England; [Davison, Sara] Univ Alberta, Div Nephrol & Immunol, Edmonton, AB, Canada; [Dorval, Marc] Dr Georges L Dumont Univ Hosp Ctr, Div Nephrol, Moncton, NB, Canada	Keele University; Cardiff University; Morriston Hospital; Yeungnam University; Yeungnam University Hospital; Soonchunhyang University; Kyungpook National University; Kyungpook National University Hospital; Kyungpook National University; Kyungpook National University Hospital; University of Manchester; Ipswich Hospital NHS Trust; Ipswich Hospital; University of Alberta	Davies, SJ (corresponding author), Keele Univ, Inst Appl Clin Res, Stoke On Trent, Staffs, England.; Topley, N (corresponding author), Cardiff Univ, Sch Med, Inst Nephrol, Heath Pk, Cardiff CF10 3AX, S Glam, Wales.	topley@cf.ac.uk; simondavies1@compuserve.com	Dorval, Marc/M-7219-2015; Lambie, Mark/AAA-9104-2020; Summers, Angela/AAC-9038-2019	Dorval, Marc/0000-0002-9548-978X; Lambie, Mark/0000-0002-6285-5368; Davies, Simon/0000-0001-5127-4755	Baxter Healthcare Renal Division; International Society for Peritoneal Dialysis	Baxter Healthcare Renal Division; International Society for Peritoneal Dialysis	Infrastructure support for the establishment of the GLOBAL fluid study was provided as unrestricted educational grants from Baxter Healthcare Renal Division (www.baxter.com) and the International Society for Peritoneal Dialysis (www.ispd.org). This study was officially endorsed by the ISPD (www.ispd.org) and by the British Renal Society (BRS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Infrastructure support for the establishment of the GLOBAL fluid study was provided as unrestricted educational grants from Baxter Healthcare Renal Division and the International Society for Peritoneal Dialysis. This study was officially endorsed by the ISPD (www.ispd.org) and by the British Renal Society (BRS) (www.britishrenal.org). The authors would like to acknowledge the support of Anna-Clare Smith, Kathryn Craig, Maureen Fallon and Charlotte James in the co-ordination of the GLOBAL study, Christopher Huckvale in the development of PDDB, and the following clinical staff in the centres for co-ordination of sample and clinical data collection; Hilary Huxtable SRN., Renal Unit, Morriston Hospital, Swansea, UK; Gill Gilbert RGN BSc (Hons), Ipswich Hospital NHS Trust; Catherine Jones RGN, John Torode RGN and Jane Hollis RGN BSc (Hons), Cambridge University Hospitals NHS Foundation Trust; Jung-Ju Seo, RN, MS., Kyungpook National University Hospital, Daegu, South Korea; Kei-Lim Shin, RN., Yeungnam University Hospital, Daegu, South Korea; Sung Hee Chung, R.N., Ph.D., Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, South Korea; Joanne Leblanc-Chiasson, RN, Rachel Belliveau, RN, Regina Arsenault, RN, research assistant, Dr Georges-L.-Dumont Hospital, Moncton, New-Brunswick, Canada; Kathy Yetzer RN and Donna Hackman RN, Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Canada and the nursing teams on the PD Units of the University Hospital of Wales, Cardiff and University Hospital of North Staffordshire, Stoke-on-Trent.	Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x; [Anonymous], 2005, DIABETES CARE, V28, pS4; Borch-Johnsen K, 1999, LANCET, V354, P617; BOYER J, 1967, ANN INTERN MED, V67, P568, DOI 10.7326/0003-4819-67-3-568; Bremer AA, 2012, PEDIATRICS, V129, P557, DOI 10.1542/peds.2011-2912; Caduff A, 2011, DIABETOLOGIA, V54, P2678, DOI 10.1007/s00125-011-2210-9; Chou CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087891; Chung SH, 2015, INT UROL NEPHROL, V47, P1017, DOI 10.1007/s11255-015-0987-z; Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046; Garcia-Lopez E, 2005, PERITON DIALYSIS INT, V25, P181; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jiang N, 2008, BLOOD PURIFICAT, V26, P423, DOI 10.1159/000153248; Lambie M, 2013, J AM SOC NEPHRO 0905; Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057762; Li PKT, 2013, J AM SOC NEPHROL, V24, P1889, DOI 10.1681/ASN.2012100987; Paniagua R, 2009, PERITON DIALYSIS INT, V29, P422; RASBASH J, 2005, MLWIN VERSION 2 02; Shai I, 2006, DIABETES CARE, V29, P1585, DOI 10.2337/dc06-0057; Szeto CC, 2007, AM J KIDNEY DIS, V49, P524, DOI 10.1053/j.ajkd.2007.01.018; Wong TYH, 2003, KIDNEY INT, V63, P1404, DOI 10.1046/j.1523-1755.2003.00883.x; Woodward RS, 2003, AM J TRANSPLANT, V3, P590, DOI 10.1034/j.1600-6143.2003.00082.x	22	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2016	11	6							e0155564	10.1371/journal.pone.0155564	http://dx.doi.org/10.1371/journal.pone.0155564			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN6KZ	27249020	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000377184700018
J	Marron, B; Ostrowski, J; Torok, M; Timofte, D; Orosz, A; Kosicki, A; Calka, A; Moro, D; Kosa, D; Redl, J; Qureshi, AR; Divino, JC				Marron, Belen; Ostrowski, Janusz; Torok, Marietta; Timofte, Delia; Orosz, Attila; Kosicki, Andrzej; Calka, Alicja; Moro, Daniela; Kosa, Dezider; Redl, Jeno; Qureshi, Abdul Rashid; Divino-Filho, Jose Carolino		PD Clin Eastern Europe	Type of Referral, Dialysis Start and Choice of Renal Replacement Therapy Modality in an International Integrated Care Setting	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; LONG-TERM SURVIVAL; PREDIALYSIS EDUCATION; PERITONEAL-DIALYSIS; ESRD; INITIATION; PROGRAMS; IMPACT; PROGRESSION; NEPHROLOGY	Introduction Integrated Care Settings (ICS) provide a holistic approach to the transition from chronic kidney disease into renal replacement therapy (RRT), offering at least both types of dialysis. Objectives To analyze which factors determine type of referral, modality provision and dialysis start on final RRT in ICS clinics. Methods Retrospective analysis of 626 patients starting dialysis in 25 ICS clinics in Poland, Hungary and Romania during 2012. Scheduled initiation of dialysis with a permanent access was considered as planned RRT start. Results Modality information (80% of patients) and renal education (87%) were more frequent (p<0.001) in Planned (P) than in Non-Planned (NP) start. Median time from information to dialysis start was 2 months. 89% of patients started on hemodialysis, 49% were referred late to ICS (<3 months from referral to RRT) and 58% were NP start. Late referral, non-vascular renal etiology, worse clinical status, shorter time from information to RRT and less peritoneal dialysis (PD) were associated with NP start (p<0.05). In multivariate logistic regression analysis, P start (p <= 0.05) was associated with early referral, eGFR >8.2 ml/min, >2 months between information and RRT initiation and with vascular etiology after adjustment for age and gender. "Optimal care," defined as ICS follow-up > 12 months plus modality information and P start, occurred in 23%. Conclusions Despite the high rate of late referrals, information and education were widely provided. However, NP start was high and related to late referral and may explain the low frequency of PD.	[Marron, Belen] Diaverum Home Therapies, Med Off, Munich, Germany; [Ostrowski, Janusz] Wloclawek Diaverum Clin, Wloclawek, Poland; [Torok, Marietta] Szeged Diaverum Clin, Szeged, Hungary; [Timofte, Delia] Semaparc Diaverum Clin, Bucharest, Romania; [Orosz, Attila] Bajcsy Diaverum Clin, Budapest, Hungary; [Kosicki, Andrzej] Przemysl Diaverum Clin, Przemysl, Poland; [Calka, Alicja] Olsztyn Diaverum Clin, Olsztyn, Poland; [Moro, Daniela] Sibiu Distributei Diaverum Clin, Sibiu, Romania; [Kosa, Dezider] Zalaegerszeg Diaverum Clin, Zalaegerszeg, Hungary; [Redl, Jeno] Szolnok Diaverum Clin, Szolnok, Hungary; [Qureshi, Abdul Rashid; Divino-Filho, Jose Carolino] Karolinska Inst, CLINTEC, Div Renal Med, Stockholm, Sweden	Diaverum; Diaverum; Diaverum; Szeged University; Diaverum; Diaverum; Diaverum; Diaverum; Diaverum; Diaverum; Diaverum; Karolinska Institutet	Marron, B (corresponding author), Diaverum Home Therapies, Med Off, Munich, Germany.	belen.marron@diaverum.com	Divino-Filho, Jose/V-5425-2019; Timofte, Delia/AAC-7954-2019	Timofte, Delia/0000-0002-0579-6349; Ostrowski, Janusz/0000-0003-1847-512X				Baer G, 2010, CLIN KIDNEY J, V3, P17, DOI 10.1093/ndtplus/sfp050; Bagnis CI, 2015, NEPHROL DIAL TRANSPL, V30, P1058, DOI 10.1093/ndt/gfu225; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Buck J, 2007, NEPHROL DIAL TRANSPL, V22, P3240, DOI 10.1093/ndt/gfm387; Cass A, 2003, AM J KIDNEY DIS, V42, P1043, DOI 10.1016/j.ajkd.2003.07.006; Cerqueira DC, 2014, CLIN J AM SOC NEPHRO, V9, P728, DOI 10.2215/CJN.06630613; Covic A, 2010, NEPHROL DIAL TRANSPL, V25, P1757, DOI 10.1093/ndt/gfq206; Curtis BM, 2005, NEPHROL DIAL TRANSPL, V20, P147, DOI 10.1093/ndt/gfh585; De Vecchi AF, 1999, NEPHROL DIAL TRANSPL, V14, P31, DOI 10.1093/ndt/14.suppl_6.31; Gayoso-Diz P, 2013, NEFROLOGIA, V33, P223, DOI 10.3265/Nefrologia.pre2013.Jan.11792; Golper TA, 2013, PERITON DIALYSIS INT, V33, P596, DOI 10.3747/pdi.2013.00212; Goovaerts T, 2015, J RENAL CARE, V41, P62, DOI 10.1111/jorc.12106; Gorriz JL, 2005, NEPHROL DIAL TRANSPL, V20, pV17; Gorriz JL, 2002, NEPHROL DIAL TRANSPL, V17, P1354, DOI 10.1093/ndt/17.7.1354-a; Gorriz JL, 2002, NEFROLOGIA, V22, P49; Vilaplana JMG, 2009, J RENAL CARE, V35, P159, DOI 10.1111/j.1755-6686.2009.00113.x; Hanko J, 2011, NEPHROL DIAL TRANSPL, V26, P2302, DOI 10.1093/ndt/gfq669; Heaf J, 2004, JAMA-J AM MED ASSOC, V291, P740, DOI 10.1001/jama.291.6.740; Heatley SA, 2009, PERITON DIALYSIS INT, V29, pS128; Hughes SA, 2013, NEPHROL DIAL TRANSPL, V28, P392, DOI 10.1093/ndt/gfs431; Julian-Mauro JC, 2013, NEFROLOGIA, V33, P333, DOI 10.3265/Nefrologia.pre2012.Dec.11767; Kainer G, 2010, NEPHROLOGY, V15, pS12, DOI 10.1111/j.1440-1797.2010.01225.x; Karkar A, 2011, SAUDI J KIDNEY DIS T, V22, P419; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Lameire N, 2012, CONTRIB NEPHROL, V178, P47, DOI 10.1159/000337808; Levey AS, 2007, AM J NEPHROL, V27, P108, DOI 10.1159/000099801; Levin A, 1997, AM J KIDNEY DIS, V29, P533, DOI 10.1016/S0272-6386(97)90334-6; Levin Adeera, 2005, Kidney Int Suppl, pS7; Lorenzo V, 2004, AM J KIDNEY DIS, V43, P999, DOI 10.1053/j.ajkd.2004.02.012; Marron B, 2005, PERITON DIALYSIS INT, V25, pS56; Marron B, 2015, 12 EUR PER DIAL M KR; Marron B, 2006, NEPHROL DIAL TRANSPL, V21, pii51; Marron B, 2010, CLIN KIDNEY J, V3, P431, DOI 10.1093/ndtplus/sfq116; Mendelssohn DC, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-22; Navaneethan SD, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-3; Nugent RA, 2011, NEPHRON CLIN PRACT, V118, pC269, DOI 10.1159/000321382; Orte-Martinez L, 2008, GUIAS SEN NEFROLOGIA, V28, P49; Otero EB, 2008, NEFROLOGIA, V28, P53; Prichard SS, 1996, PERITON DIALYSIS INT, V16, P69; Prieto-Velasco M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138811; Prieto-Velasco Mario, 2014, BMC Res Notes, V7, P730, DOI 10.1186/1756-0500-7-730; Ramos R, 2013, NEFROLOGIA, V33, P301, DOI 10.3265/Nefrologia.pre2013.Feb.11638; Ravani P, 2003, J NEPHROL, V16, P862; Ravani P, 2003, J NEPHROL, V16, P870; Rubin HR, 2004, JAMA-J AM MED ASSOC, V291, P697, DOI 10.1001/jama.291.6.697; Smart NA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007333.pub2; Sprangers B, 2006, MAYO CLIN PROC, V81, P1487, DOI 10.4065/81.11.1487; Stewart JH, 2006, AM J KIDNEY DIS, V48, P183, DOI 10.1053/j.ajkd.2006.04.067; Van Biesen W, 2000, J AM SOC NEPHROL, V11, P116, DOI 10.1681/ASN.V111116; Van Biesen W, 2009, NEPHROL DIAL TRANSPL, V24, P3277, DOI 10.1093/ndt/gfp448; Villa G, 2012, PERITON DIALYSIS INT, V32, P192, DOI 10.3747/pdi.2011.00037; Wu IW, 2009, NEPHROL DIAL TRANSPL, V24, P3426, DOI 10.1093/ndt/gfp259; Yu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112820; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6	54	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0155987	10.1371/journal.pone.0155987	http://dx.doi.org/10.1371/journal.pone.0155987			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27228101	Green Published, gold, Green Submitted			2023-01-03	WOS:000376882500049
J	Kinoshita, T; Mitamura, Y; Mori, T; Akaiwa, K; Semba, K; Egawa, M; Mori, J; Sonoda, S; Sakamoto, T				Kinoshita, Takamasa; Mitamura, Yoshinori; Mori, Terumi; Akaiwa, Kei; Semba, Kentaro; Egawa, Mariko; Mori, Junya; Sonoda, Shozo; Sakamoto, Taiji			Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy	PLOS ONE			English	Article							OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; KOYANAGI-HARADA DISEASE; STROMAL AREAS; VISUAL-ACUITY; BINARIZATION; VERTEPORFIN; IMAGES; THICKNESS; ASSOCIATION	Purpose To determine the structural changes in the choroid after half-dose photodynamic therapy (hPDT) in eyes with chronic central serous chorioretinopathy (CSC). Methods This was a retrospective interventional study of 29 eyes of 29 patients who underwent hPDT for chronic CSC with serous retinal detachment (SRD) and were followed for >= 3 months. Enhanced depth imaging optical coherence tomographic (EDI-OCT) images of the subfoveal choroid were converted to binary images. The central choroidal thickness (CCT), the cross sectional subfoveal choroidal area, the hyporeflective and hyperreflective areas of the inner, outer, and whole choroid were determined at the baseline, and at 1, 3, and 12 months after the hPDT. Results The SRDs were resolved in 26 (89.7%) eyes at 3 months after the hPDT. The mean CCT (P = 0.001), the total choroidal area (P = 0.001), and the hypo-reflective area (P = 0.003) of the whole choroid were significantly decreased from the baseline at 3 months. The hyperreflective area of whole choroid was not significantly changed during the study period (P = 0.083). The hyperreflective but not the hyporeflective area of the inner choroid was significantly decreased at 3 months (P = 0.001, P = 1.000, respectively). The hyporeflective but not the hyperreflective area of the outer choroid was significantly decreased at 3 months (P = 0.001, P = 1.000, respectively). Conclusions The hyperreflective area of the inner choroid and hyporeflective area of the outer choroid were significantly decreased after hPDT for chronic CSC. Because the hyperreflective and hyporeflective area correspond to the choroidal stroma and vessels, respectively, the decreased CCT and subfoveal choroidal area after hPDT may be attributed to a decrease in the exudative changes in the inner choroidal stroma and the reduction of the dilation of the outer choroidal vessels.	[Kinoshita, Takamasa; Mitamura, Yoshinori; Mori, Terumi; Akaiwa, Kei; Semba, Kentaro; Egawa, Mariko] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Ophthalmol, Tokushima, Japan; [Kinoshita, Takamasa; Mori, Junya] Sapporo City Gen Hosp, Dept Ophthalmol, Sapporo, Hokkaido, Japan; [Sonoda, Shozo; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan	Tokushima University; Sapporo City General Hospital; Kagoshima University	Kinoshita, T (corresponding author), Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Ophthalmol, Tokushima, Japan.; Kinoshita, T (corresponding author), Sapporo City Gen Hosp, Dept Ophthalmol, Sapporo, Hokkaido, Japan.	knst129@gmail.com	Kinoshita, Takamasa/S-9174-2019	Kinoshita, Takamasa/0000-0002-0465-2140	Ministry of Education, Culture, Sports, Science and Technology, Japan [16K11288]	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by grant-in-aid 16K11288 (to YM) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, http://www.mext.go.jp/english/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal R, 2016, RETINA; Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066; Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014; Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453; Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012; Egawa M, 2016, BRIT J OPHTHALMOL, V100, P1646, DOI 10.1136/bjophthalmol-2015-307734; Egawa M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0127-7; Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034; GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023; Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005; Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325; Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83; Inoue R, 2010, AM J OPHTHALMOL, V149, P441, DOI 10.1016/j.ajo.2009.10.011; Iwata A, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0014-2; Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021; Kawano H, 2016, GRAEF ARCH CLIN EXP, V254, P421, DOI 10.1007/s00417-016-3283-4; Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594; Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282; Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004; Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023; Nakayama M, 2012, RETINA-J RET VIT DIS, V32, P2061, DOI 10.1097/IAE.0b013e318256205a; Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022; Nicolo M, 2012, AM J OPHTHALMOL, V153, P474, DOI 10.1016/j.ajo.2011.08.015; PICCOLINO FC, 1995, EYE, V9, P324, DOI 10.1038/eye.1995.63; Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002; Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037; Prunte C, 1996, AM J OPHTHALMOL, V121, P26; Razavi S, 2014, AM J OPHTHALMOL, V157, P852, DOI 10.1016/j.ajo.2013.12.029; Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0b013e31822f5678, 10.1097/IAE.0B013E31822F5678]; Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026; Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835; Smretschnig E, 2013, RETINA-J RET VIT DIS, V33, P316, DOI 10.1097/IAE.0b013e318280769c; Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631; Sonoda S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157190; Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005; Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447; Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2; Spaide RF, 2015, AM J OPHTHALMOL, V160, P1211, DOI 10.1016/j.ajo.2015.08.018; Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991; Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002; YOSHIOKA H, 1982, JPN J OPHTHALMOL, V26, P397	41	27	30	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2016	11	9							e0163104	10.1371/journal.pone.0163104	http://dx.doi.org/10.1371/journal.pone.0163104			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5YN	27636093	gold, Green Submitted, Green Published			2023-01-03	WOS:000383723700033
J	Selby, MJ; Engelhardt, JJ; Johnston, RJ; Lu, LS; Han, MH; Thudium, K; Yao, DP; Quigley, M; Valle, J; Wang, CY; Chen, B; Cardarelli, PM; Blanset, D; Korman, AJ				Selby, Mark J.; Engelhardt, John J.; Johnston, Robert J.; Lu, Li-Sheng; Han, Minhua; Thudium, Kent; Yao, Dapeng; Quigley, Michael; Valle, Jose; Wang, Changyu; Chen, Bing; Cardarelli, Pina M.; Blanset, Diann; Korman, Alan J.			Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology	PLOS ONE			English	Article							FC-GAMMA RECEPTORS; REGULATORY T; PD-1 BLOCKADE; PROGRAMMED DEATH-1; ANTITUMOR-ACTIVITY; CTLA-4; CELLS; CANCER; ANTIBODY; STIMULATION	The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients with metastatic melanoma (CHECKMATE-067). Here we describe the preclinical development strategy that predicted these clinical results. Synergistic antitumor activity in mouse MC38 and CT26 colorectal tumor models was observed with concurrent, but not sequential CTLA-4 and PD1 blockade. Significant antitumor activity was maintained using a fixed dose of anti-CTLA-4 antibody with decreasing doses of anti-PD-1 antibody in the MC38 model. Immunohistochemical and flow cytometric analyses confirmedthat CD3(+) T cells accumulated at the tumor margin and infiltrated the tumor mass in response to the combination therapy, resulting in favorable effector and regulatory T-cell ratios, increased pro-inflammatory cytokine secretion, and activation of tumor-specific T cells. Similarly, in vitro studies with combined ipilimumab and nivolumab showed enhanced cytokine secretion in superantigen stimulation of human peripheral blood lymphocytes and in mixed lymphocyte response assays. In a cynomolgus macaque toxicology study, dose-dependent immune-related gastrointestinal inflammation was observed with the combination therapy; this response had not been observed in previous single agent cynomolgus studies. Together, these in vitro assays and in vivo models comprise a preclinical strategy for the identification and development of highly effective antitumor combination immunotherapies.	[Selby, Mark J.; Engelhardt, John J.; Johnston, Robert J.; Lu, Li-Sheng; Han, Minhua; Thudium, Kent; Yao, Dapeng; Quigley, Michael; Valle, Jose; Wang, Changyu; Chen, Bing; Cardarelli, Pina M.; Blanset, Diann; Korman, Alan J.] Bristol Myers Squibb, Redwood City, CA 94063 USA	Bristol-Myers Squibb	Korman, AJ (corresponding author), Bristol Myers Squibb, Redwood City, CA 94063 USA.	alan.korman@bms.com			Bristol-Myers Squibb	Bristol-Myers Squibb(Bristol-Myers Squibb)	The studies described in this manuscript were sponsored by Bristol-Myers Squibb. The funder provided support in the form of salaries for all authors (MJS JJE RJJ LL MH KT DY MQ JV CW BC PMC DB AJK) and was involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the Authors' Contributions section. In addition, the funder provided support in the form of salaries to individuals listed in the Acknowledgements section (LW MS IC CB).	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Antonia S., 2016, LANCET ONCOL; Brahmer JR, 2015, FUTURE ONCOL, V11, P1307, DOI 10.2217/fon.15.52; Bulliard Y, 2013, J EXP MED, V210, P1685, DOI 10.1084/jem.20130573; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Corse E, 2012, J IMMUNOL, V189, P1123, DOI 10.4049/jimmunol.1200695; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Dahan R, 2015, CANCER CELL, V28, P285, DOI 10.1016/j.ccell.2015.08.004; Dasari A, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3563; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Duraiswamy J, 2013, CANCER RES, V73, P3591, DOI 10.1158/0008-5472.CAN-12-4100; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Grosso Joseph F, 2013, Cancer Immun, V13, P5; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hellman MD, 2016, J CLIN ONCOL S, V34; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Keler T, 2003, J IMMUNOL, V171, P6251, DOI 10.4049/jimmunol.171.11.6251; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; LEBELBINAY S, 1995, EUR J IMMUNOL, V25, P2340, DOI 10.1002/eji.1830250833; Li B, 2009, CLIN CANCER RES, V15, P1623, DOI 10.1158/1078-0432.CCR-08-1825; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973; Mumm JB, 2011, CANCER CELL, V20, P781, DOI 10.1016/j.ccr.2011.11.003; Nakamoto N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000313; Ngiow SF, 2015, CANCER RES, V75, P3800, DOI 10.1158/0008-5472.CAN-15-1082; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Peggs KS, 2008, IMMUNOL REV, V224, P141, DOI 10.1111/j.1600-065X.2008.00649.x; Peng WY, 2012, CANCER RES, V72, P5209, DOI 10.1158/0008-5472.CAN-12-1187; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ueha S, 2015, CANCER IMMUNOL RES, V3, P631, DOI 10.1158/2326-6066.CIR-14-0190; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Walker LSK, 2015, TRENDS IMMUNOL, V36, P63, DOI 10.1016/j.it.2014.12.001; Wang CY, 2014, CANCER IMMUNOL RES, V2, P846, DOI 10.1158/2326-6066.CIR-14-0040; Wang CJ, 2012, J IMMUNOL, V189, P1118, DOI 10.4049/jimmunol.1200972; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wolchok JD, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9505; Wolchok JD, 2013, ANN NY ACAD SCI, V1291, P1, DOI 10.1111/nyas.12180; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	56	145	156	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0161779	10.1371/journal.pone.0161779	http://dx.doi.org/10.1371/journal.pone.0161779			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JE	27610613	Green Submitted, Green Published, gold			2023-01-03	WOS:000383255900029
J	Sullivan, CT				Sullivan, Charles T.			Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose	ANNALS OF INTERNAL MEDICINE			English	Letter									[Sullivan, Charles T.] North Florida South Georgia Vet Hlth Syst, Gainesville, FL 32608 USA		Sullivan, CT (corresponding author), North Florida South Georgia Vet Hlth Syst, Gainesville, FL 32608 USA.							Beyersmann J, 2006, AM STAT, V60, P295; Larochelle MR, 2016, ANN INTERN MED, V164, P1, DOI 10.7326/M15-0038; Vigen R, 2013, JAMA-J AM MED ASSOC, V310, P1829, DOI 10.1001/jama.2013.280386	3	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 6	2016	165	5					376	376		10.7326/L16-0169	http://dx.doi.org/10.7326/L16-0169			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV3BC	27595219				2023-01-03	WOS:000382795000010
J	Stempel, DA; Szefler, SJ; Pedersen, S; Zeiger, RS; Yeakey, AM; Lee, LA; Liu, AH; Mitchell, H; Kral, KM; Raphiou, IH; Prillaman, BA; Buaron, KS; Kirby, SY; Pascoe, SJ				Stempel, David A.; Szefler, Stanley J.; Pedersen, Soren; Zeiger, Robert S.; Yeakey, Anne M.; Lee, Laurie A.; Liu, Andrew H.; Mitchell, Herman; Kral, Kenneth M.; Raphiou, Ibrahim H.; Prillaman, Barbara A.; Buaron, Kathleen S.; Kirby, Suyong Yun; Pascoe, Steven J.		VESTRI Investigators	Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-AGONISTS; MORTALITY; THERAPY; RISKS; DEATH	BACKGROUND Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children. METHODS We randomly assigned, in a 1: 1 ratio, children 4 to 11 years of age who required daily asthma medications and had a history of asthma exacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization), as assessed in a time-to-event analysis. The statistical design specified that noninferiority would be shown if the upper boundary of the 95% confidence interval of the hazard ratio for the primary safety end point was less than 2.675. The main efficacy end point was the first severe asthma exacerbation that led to treatment with systemic glucocorticoids, as assessed in a time-to-event analysis. RESULTS Among the 6208 patients, 27 patients in the fluticasone-salmeterol group and 21 in the fluticasone-alone group had a serious asthma-related event (all were hospitalizations); the hazard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28 (95% confidence interval [CI], 0.73 to 2.27), which showed the noninferiority of fluticasone-salmeterol (P = 0.006). A total of 265 patients (8.5%) in the fluticasone-salmeterol group and 309 (10.0%) in the fluticasone-alone group had a severe asthma exacerbation (hazard ratio, 0.86; 95% CI, 0.73 to 1.01). CONCLUSIONS In this trial involving children with asthma, salmeterol in a fixed-dose combination with fluticasone was associated with the risk of a serious asthma-related event that was similar to the risk with fluticasone alone. (Funded by GlaxoSmithKline; VESTRI ClinicalTrials.gov number, NCT01462344.)	[Stempel, David A.; Yeakey, Anne M.; Lee, Laurie A.; Raphiou, Ibrahim H.; Buaron, Kathleen S.; Kirby, Suyong Yun; Pascoe, Steven J.] GlaxoSmithKline, Resp Clin Dev, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA; [Kral, Kenneth M.] GlaxoSmithKline, Res & Dev, Clin Platforms & Sci, Clin Stat, Res Triangle Pk, NC USA; [Mitchell, Herman] Rho, Chapel Hill, NC USA; [Prillaman, Barbara A.] Parexel Internatl, Biostat, Durham, NC USA; [Szefler, Stanley J.; Liu, Andrew H.] Childrens Hosp Colorado, Dept Pediat, Breathing Inst, Pediat Pulm Sect, Aurora, CO USA; [Szefler, Stanley J.; Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [Pedersen, Soren] Fredericia & Kolding Hosp, Ctr Lillebaelt, Dept Pediat, Odense, Denmark; [Zeiger, Robert S.] Kaiser Permanente Res, Dept Allergy & Res & Evaluat, San Diego, CA USA	GlaxoSmithKline; GlaxoSmithKline; Rho; Parexel International; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Kolding Hospital	Stempel, DA (corresponding author), GlaxoSmithKline, Resp Clin Dev, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.	david.a.stempel@gsk.com	La Grutta, Stefania/N-3615-2014; Craiu, Mihai C/V-5025-2017; Kryuchko, T. A./W-4506-2017; Bullens, Dominique M A/T-6211-2017	La Grutta, Stefania/0000-0001-8026-0715; Craiu, Mihai C/0000-0001-6194-6797; Kryuchko, T. A./0000-0002-5034-4181; Bullens, Dominique M A/0000-0002-4595-9579; Barkai, Laszlo Lajos/0000-0003-2970-3263; /0000-0002-8537-9165; Pavlov, Neven/0000-0002-3580-4020; Teper, Alejandro/0000-0002-7835-9713; Szefler, Stanley/0000-0002-6911-3199; Zeiger, Robert/0000-0001-5788-5063; Seddon, Paul/0000-0003-2136-958X; Bozek, Andrzej/0000-0003-2263-2263; Robinson, Paul/0000-0001-7397-105X	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	Funded by GlaxoSmithKline; VESTRI ClinicalTrials.gov number, NCT01462344.	[Anonymous], [No title captured]; [Anonymous], 2014, PRESCR INF ADV DISK; [Anonymous], 2007, CYT E 5 US MAN; Bauman LJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e6; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CRANE J, 1989, LANCET, V1, P917; Drazen JM, 2009, NEW ENGL J MED, V360, P1671, DOI 10.1056/NEJMe0902057; ERNST P, 1993, AM REV RESPIR DIS, V148, P75, DOI 10.1164/ajrccm/148.1.75; Global Initiative for Asthma, 2021, GLOB STRAT ASTHM MAN; Jennison C, 1999, GROUP SEQUENTIAL MET; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; McMahon AW, 2011, PEDIATRICS, V128, pE1147, DOI 10.1542/peds.2010-1720; Moorman J.E., 2012, VITAL HEALTH STAT, V3, P1; National Institute of Health, 2007, GUID DIAGN MAN ASTHM; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; RUSSELL G, 1995, ANN ALLERG ASTHMA IM, V75, P423; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stempel DA, 2016, NEW ENGL J MED, V374, P1822, DOI 10.1056/NEJMoa1511049; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Vaessen-Verberne AAPH, 2010, AM J RESP CRIT CARE, V182, P1221, DOI 10.1164/rccm.201002-0193OC; Voorend-van Bergen S, 2014, J ALLERGY CLIN IMMUN, V133, P1599; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; Zimmerman B, 2004, PEDIATR PULM, V37, P122, DOI 10.1002/ppul.10404	25	91	93	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2016	375	9					840	849		10.1056/NEJMoa1606356	http://dx.doi.org/10.1056/NEJMoa1606356			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU9HA	27579634	Bronze, Green Published			2023-01-03	WOS:000382526000007
J	O'Dowd, EL; McKeever, TM; Baldwin, DR; Hubbard, RB				O'Dowd, Emma L.; McKeever, Tricia M.; Baldwin, David R.; Hubbard, Richard B.			Place of Death in Patients with Lung Cancer: A Retrospective Cohort Study from 2004-2013	PLOS ONE			English	Article							OF-LIFE CARE; RANDOMIZED-TRIAL; PALLIATIVE-CARE; MENTAL-HEALTH; ENGLAND; DISCUSSIONS; PREDICTORS; HOME	Introduction Many patients with cancer die in an acute hospital bed, which has been frequently identified as the least preferred location, with psychological and financial implications. This study looks at place and cause of death in patients with lung cancer and identifies which factors are associated with dying in an acute hospital bed versus at home. Methods and Findings We used the National Lung Cancer Audit linked to Hospital Episode Statistics and Office for National Statistics data to determine cause and place of death in those with lung cancer; both overall and by cancer Network. We used multivariate logistic regression to compare features of those who died in an acute hospital versus those who died at home. Results Of 143627 patients identified 40% (57678) died in an acute hospital, 29% (41957) died at home and 17% (24108) died in a hospice. Individual factors associated with death in an acute hospital bed compared to home were male sex, increasing age, poor performance status, social deprivation and diagnosis via an emergency route. There was marked variation between cancer Networks in place of death. The proportion of patients dying in an acute hospital ranged from 28% to 48%, with variation most notable in provision of hospice care (9% versus 33%). Cause of death in the majority was lung cancer (86%), with other malignancies, chronic obstructive pulmonary disease (COPD) and ischaemic heart disease (IHD) comprising 9% collectively. Conclusions A substantial proportion of patients with lung cancer die in acute hospital beds and this is more likely with increasing age, male sex, social deprivation and in those with poor performance status. There is marked variation between Networks, suggesting a need to improve end-of-life planning in those at greatest risk, and to review the allocation of resources to provide more hospice beds, enhanced community support and ensure equal access.	[O'Dowd, Emma L.; McKeever, Tricia M.; Hubbard, Richard B.] Div Publ Hlth & Epidemiol, Clin Sci Bldg,Nottingham City Campus,Hucknall Rd, Nottingham, England; [Baldwin, David R.] City Hosp Nottingham, Dept Resp Med, David Evans Bldg,Hucknall Rd, Nottingham, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital	O'Dowd, EL (corresponding author), Div Publ Hlth & Epidemiol, Clin Sci Bldg,Nottingham City Campus,Hucknall Rd, Nottingham, England.	emma.o'dowd@nottingham.ac.uk		McKeever, Tricia/0000-0003-0914-0416	Roy Castle Lung Cancer Foundation [RB08F1]; British Lung Foundation [C05/01] Funding Source: researchfish	Roy Castle Lung Cancer Foundation; British Lung Foundation	This work was supported by the Roy Castle Lung Cancer Foundation, grant number RB08F1. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coupland VH, 2011, PALLIATIVE MED, V25, P314, DOI 10.1177/0269216310395986; Davies E, 2006, BRIT J CANCER, V95, P593, DOI 10.1038/sj.bjc.6603305; Elliss-Brookes L, 2012, BRIT J CANCER, V107, P1220, DOI 10.1038/bjc.2012.408; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; Gatrell AC, 2012, HEALTH PLACE, V18, P832, DOI 10.1016/j.healthplace.2012.03.009; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Gomes B, 2012, PALLIATIVE MED, V26, P102, DOI 10.1177/0269216311432329; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Kawaguchi T, 2010, J THORAC ONCOL, V5, P620, DOI 10.1097/JTO.0b013e3181d2dcd9; Mack JW, 2012, ANN INTERN MED, V156, P204, DOI 10.7326/0003-4819-156-3-201202070-00008; Macmillan Cancer Support, 2014, CANC UN BURD REAL IM; Marie Curie Cancer Care, 2012, UND COST END LIF CAR; Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X; Morden NE, 2012, HEALTH AFFAIR, V31, P786, DOI 10.1377/hlthaff.2011.0650; O'Dowd E, 2014, LUNG CANCER, V83, pS34, DOI 10.1016/S0169-5002(14)70092-3; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Prigerson H G, 1991, Home Health Care Serv Q, V12, P81; Rich AL, 2011, LUNG CANCER, V72, P16, DOI 10.1016/j.lungcan.2010.07.002; Sleeman KE, 2016, PALLIATIVE MED, V30, P45, DOI DOI 10.1177/0269216315585064; Townsend PP., 1988, HLTH DEPRIVATION INE; World Health Organization, 2010, INT STAT CLASS DIS R, V2; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	25	16	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2016	11	8							e0161399	10.1371/journal.pone.0161399	http://dx.doi.org/10.1371/journal.pone.0161399			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TR	27551922	Green Published, gold, Green Submitted			2023-01-03	WOS:000381768800037
J	Rega, D; Pecori, B; Scala, D; Avallone, A; Pace, U; Petrillo, A; Aloj, L; Tatangelo, F; Delrio, P				Rega, Daniela; Pecori, Biagio; Scala, Dario; Avallone, Antonio; Pace, Ugo; Petrillo, Antonella; Aloj, Luigi; Tatangelo, Fabiana; Delrio, Paolo			Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer	PLOS ONE			English	Article							PREOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; RANDOMIZED-TRIAL; CHEMORADIOTHERAPY; INTERVAL	Purpose Neoadjuvant therapy is able to reduce local recurrence in rectal cancer. Immediate surgery after short course radiotherapy allows only for minimal downstaging. We investigated the effect of delayed surgery after short-course radiotherapy at different time intervals before surgery, in patients affected by rectal cancer. Methods From January 2003 to December 2013 sixty-seven patients with the following characteristics have been selected: clinical (c) stage T3N0 <= 12 cm from the anal verge and with circumferential resection margin >5 mm (by magnetic resonance imaging); cT2, any N, <5 cm from anal verge; and patients facing tumors with enlarged nodes and/or CRM+ve who resulted unfit for chemo-radiation, were also included. Patients underwent preoperative short-course radiotherapy with different interval to surgery were divided in three groups: A (within 6 weeks), B (between 6 and 8 weeks) and C (after more than 8 weeks). Hystopatolgical response to radiotherapy was measured by Mandard's modified tumor regression grade (TRG). Results All patients completed the scheduled treatment. Sixty-six patients underwent surgery. Fifty-three of which (80.3%) received a sphincter saving procedure. Downstaging occurred in 41 cases (62.1%). The analysis of subgroups showed an increasing prevalence of TRG 1-2 prolonging the interval to surgery (group A-16.7%, group B-36.8% and 54.3% in group C; p value 0.023). Conclusions Preoperative short-course radiotherapy is able to downstage rectal cancer if surgery is delayed. A higher rate of TRG 1-2 can be obtained if interval to surgery is prolonged to more than 8 weeks.	[Rega, Daniela; Scala, Dario; Pace, Ugo; Delrio, Paolo] Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Colorectal Surg Oncol, Naples, Italy; [Pecori, Biagio] Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Div Radiotherapy, Dept Diagnost Imaging Radiant & Metab Therapy, Naples, Italy; [Avallone, Antonio] Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Div Gastrointestinal Med Oncol, Naples, Italy; [Petrillo, Antonella] Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Div Radiol, Dept Diagnost Imaging Radiant & Metab Therapy, Naples, Italy; [Aloj, Luigi] Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Nucl Med Unit, Naples, Italy; [Tatangelo, Fabiana] Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Pathol Unit, Naples, Italy	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Rega, D (corresponding author), Fdn Giovanni Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Colorectal Surg Oncol, Naples, Italy.	daniela.rega@gmail.com	Tatangelo, Fabiana/AAA-8413-2020; Aloj, Luigi/AAK-5104-2020; Rega, Daniela/K-4876-2018; Scala, Dario/ABA-3610-2020; Petrillo, Antonella/J-5450-2018; Avallone, Antonio/K-4662-2016	Tatangelo, Fabiana/0000-0002-9943-6079; Petrillo, Antonella/0000-0003-2465-5370; Rega, Daniela/0000-0001-8326-050X; Avallone, Antonio/0000-0001-6188-5664; Aloj, Luigi/0000-0002-7452-4961				Avallone A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-875; Avallone A, 2011, INT J RADIAT ONCOL, V79, P670, DOI 10.1016/j.ijrobp.2009.12.007; Berger C, 1997, INT J RADIAT ONCOL, V37, P619, DOI 10.1016/S0360-3016(96)00577-9; Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; de Campos-Lobato LF, 2011, J GASTROINTEST SURG, V15, P444, DOI 10.1007/s11605-010-1197-8; Evans J, 2011, DIS COLON RECTUM, V54, P1251, DOI 10.1097/DCR.0b013e3182281f4b; Foster JD, 2013, DIS COLON RECTUM, V56, P921, DOI 10.1097/DCR.0b013e31828aedcb; Francois Y, 1999, J CLIN ONCOL, V17, P2396, DOI 10.1200/JCO.1999.17.8.2396; Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629; Graf W, 1997, RADIOTHER ONCOL, V43, P133, DOI 10.1016/S0167-8140(96)01867-1; Guillerme F, 2014, INT J COLORECTAL DIS, V29, P157, DOI 10.1007/s00384-013-1778-6; Hatfield P, 2009, RADIOTHER ONCOL, V92, P210, DOI 10.1016/j.radonc.2009.04.007; Latkauskas T, 2012, COLORECTAL DIS, V14, P294, DOI 10.1111/j.1463-1318.2011.02815.x; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Pach R, 2012, LANGENBECK ARCH SURG, V397, P801, DOI 10.1007/s00423-011-0890-8; Petrelli F, 2016, ANN SURG, V263, P458, DOI 10.1097/SLA.0000000000000368; Pettersson D, 2012, BRIT J SURG, V99, P577, DOI 10.1002/bjs.7796; Pettersson D, 2010, BRIT J SURG, V97, P580, DOI 10.1002/bjs.6914; Radu C, 2008, RADIOTHER ONCOL, V87, P343, DOI 10.1016/j.radonc.2007.11.025; Tulchinsky H, 2008, ANN SURG ONCOL, V15, P2661, DOI 10.1245/s10434-008-9892-3; Wasserberg N, 2014, WORLD J GASTROENTERO, V20, P4256, DOI 10.3748/wjg.v20.i15.4256; Yeo SG, 2013, INT J RADIAT ONCOL, V86, P34, DOI 10.1016/j.ijrobp.2012.11.018; 1997, SWEDISH RECTAL CANC, V336, P980	25	19	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2016	11	8							e0160732	10.1371/journal.pone.0160732	http://dx.doi.org/10.1371/journal.pone.0160732			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TP	27548058	gold, Green Published, Green Submitted			2023-01-03	WOS:000381768400019
J	Tandon, P; James, MT; Abraldes, JG; Karvellas, CJ; Ye, F; Pannu, N				Tandon, Puneeta; James, Matthew T.; Abraldes, Juan G.; Karvellas, Constantine J.; Ye, Feng; Pannu, Neesh			Relevance of New Definitions to Incidence and Prognosis of Acute Kidney Injury in Hospitalized Patients with Cirrhosis: A Retrospective Population-Based Cohort Study	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; SERUM CREATININE VALUE; RIFLE CRITERIA; 1.5 MG/DL; MORTALITY; OUTCOMES; RISK; CLASSIFICATION; INCREASES; NETWORK	Background The implementation of new serum creatinine (SCr)-based criteria for acute kidney injury (AKI) has brought to light several areas of uncertainty in patients with cirrhosis. Study Design Population-based cohort study. Setting & Participants Adults with cirrhosis hospitalized between 2002-2012. Predictor We aimed to address the prognostic implications of the new AKI criteria in cirrhosis. Outcomes Baseline kidney function was defined from all outpatient SCr within 3 months before hospitalization. Cox proportional hazards models were fit to examine associations between AKI, renal recovery and all-cause mortality. Results 4,733 patients were studied. The 30-day mortality was higher for participants with AKI (43.9% vs 8.5%; p-value<0.001), and increased with AKI severity. The highest incidence of AKI occurred when the lowest SCr within the three months prior to admission was used to define baseline. The hazard ratio for mortality using the lowest SCr within 3 months and the closest pre-admission SCr (definition suggested by the recent consensus guideline) were similar, validating the use of the latter measure. As compared to patients without AKI, stage 1 AKI with maximum SCr <= 132 mmol/L remained associated with a 3.5-fold increased hazard of death at 30 days (95% CI 2.6 to 4.7). Limitations As an observational study, the results were vulnerable to residual confounding and ascertainment bias in the use of laboratory data to identify AKI. We did not have access to liver function or disease etiology variables and were unable to adjust for these in our analyses. Conclusions These results confirm the graded relationship between AKI severity, renal recovery, and mortality and further clarify previously discordant reports about the prognostic relevance of new AKI criteria in patients with cirrhosis.	[Tandon, Puneeta; Abraldes, Juan G.; Karvellas, Constantine J.] Univ Alberta, Div Gastroenterol, Cirrhosis Care Clin, Edmonton, AB, Canada; [Tandon, Puneeta; Abraldes, Juan G.; Karvellas, Constantine J.] Univ Alberta, Dept Med, CEGIIR, Edmonton, AB, Canada; [James, Matthew T.] Univ Calgary, Div Nephrol, Calgary, AB, Canada; [Karvellas, Constantine J.] Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada; [Ye, Feng; Pannu, Neesh] Univ Alberta, Div Nephrol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Calgary; University of Alberta; University of Alberta	Pannu, N (corresponding author), Univ Alberta, Div Nephrol, Edmonton, AB, Canada.	neesh.pannu@ualberta.ca		Gonzalez-Abraldes, Juan/0000-0003-3421-937X; Karvellas, Constantine/0000-0002-1555-1089	Canadian Institutes of Health Research (CIHR); CRIO team grant from Alberta Innovates-Health Solutions	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CRIO team grant from Alberta Innovates-Health Solutions	This study was funded by an operating grant from the Canadian Institutes of Health Research (CIHR). The Interdisciplinary Chronic Disease Collaboration (ICDC) is funded through a CRIO team grant from Alberta Innovates-Health Solutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angeli P, 2015, J HEPATOL; Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122; Belcher JM, 2013, CLIN GASTROENTEROL H, V11, P1550, DOI 10.1016/j.cgh.2013.03.018; Belcher JM, 2013, HEPATOLOGY, V57, P753, DOI 10.1002/hep.25735; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Fagundes C, 2015, J HEPATOL, V62, P743, DOI 10.1016/j.jhep.2014.11.039; Fagundes C, 2013, J HEPATOL, V59, P474, DOI 10.1016/j.jhep.2013.04.036; Fede G, 2012, J HEPATOL, V56, P810, DOI 10.1016/j.jhep.2011.10.016; Garcia-Tsao G, 2008, HEPATOLOGY, V48, P2064, DOI 10.1002/hep.22605; Hemmelgarn BR, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-30; Hoste EA, 2004, CONTRIB NEPHROL, V144, P1; Ishani A, 2009, J AM SOC NEPHROL, V20, P223, DOI 10.1681/ASN.2007080837; Israelsen ME, 2015, J GASTROEN HEPATOL, V30, P236, DOI 10.1111/jgh.12709; Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Nehra MS, 2013, J CLIN GASTROENTEROL, V47, pE50, DOI 10.1097/MCG.0b013e3182688d2f; Newsome BB, 2008, ARCH INTERN MED, V168, P609, DOI 10.1001/archinte.168.6.609; Pannu N, 2013, CLIN J AM SOC NEPHRO, V8, P194, DOI 10.2215/CJN.06480612; Pannu N, 2011, AM J KIDNEY DIS, V58, P206, DOI 10.1053/j.ajkd.2011.01.028; Piano S, 2015, J HEPATOL, V62, P744, DOI 10.1016/j.jhep.2014.12.001; Piano S, 2013, J HEPATOL, V59, P482, DOI 10.1016/j.jhep.2013.03.039; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Sawhney S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006497; Siew ED, 2010, KIDNEY INT, V77, P536, DOI 10.1038/ki.2009.479; Thakar CV, 2013, ADV CHRONIC KIDNEY D, V20, P67, DOI 10.1053/j.ackd.2012.10.003; Thakar CV, 2009, CRIT CARE MED, V37, P2552, DOI 10.1097/CCM.0b013e3181a5906f; Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F; Wong F, 2015, J HEPATOL, V62, P741, DOI 10.1016/j.jhep.2014.10.047; Wong F, 2013, GASTROENTEROLOGY, V145, P1280, DOI 10.1053/j.gastro.2013.08.051; Wong F, 2011, GUT, V60, P702, DOI 10.1136/gut.2010.236133	35	41	44	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2016	11	8							e0160394	10.1371/journal.pone.0160394	http://dx.doi.org/10.1371/journal.pone.0160394			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3IK	27504876	Green Published, Green Submitted, gold			2023-01-03	WOS:000381374200034
J	Okuda, K; Fu, HY; Matsuzaki, T; Araki, R; Tsuchida, S; Thanikachalam, PV; Fukuta, T; Asai, T; Yamato, M; Sanada, S; Asanuma, H; Asano, Y; Asakura, M; Hanawa, H; Hao, H; Oku, N; Takashima, S; Kitakaze, M; Sakata, Y; Minamino, T				Okuda, Keiji; Fu, Hai Ying; Matsuzaki, Takashi; Araki, Ryo; Tsuchida, Shota; Thanikachalam, Punniyakoti V.; Fukuta, Tatsuya; Asai, Tomohiro; Yamato, Masaki; Sanada, Shoji; Asanuma, Hiroshi; Asano, Yoshihiro; Asakura, Masanori; Hanawa, Haruo; Hao, Hiroyuki; Oku, Naoto; Takashima, Seiji; Kitakaze, Masafumi; Sakata, Yasushi; Minamino, Tetsuo			Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats	PLOS ONE			English	Article							GIANT-CELL MYOCARDITIS; CARDIAC DYSFUNCTION; GENE-EXPRESSION; MODEL; ACTIVATION; IMMUNOSUPPRESSION; RECEPTOR	Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the need to develop a more effective therapeutic approach remains. Nano-sized liposomes may accumulate in and selectively deliver drugs to an inflammatory lesion with enhanced vascular permeability. The aims of this study were to investigate the distribution of liposomal FK506, an immunosuppressive drug encapsulated within liposomes, and the drug's effects on cardiac function in a rat experimental autoimmune myocarditis (EAM) model. We prepared polyethylene glycol-modified liposomal FK506 (mean diameter: 109.5 +/- 4.4 nm). We induced EAM by immunization with porcine myosin and assessed the tissue distribution of the nano-sized beads and liposomal FK506 in this model. After liposomal or free FK506 was administered on days 14 and 17 after immunization, the cytokine expression in the rat hearts along with the histological findings and hemodynamic parameters were determined on day 21. Ex vivo fluorescent imaging revealed that intravenously administered fluorescent-labeled nano-sized beads had accumulated in myocarditic but not normal hearts on day 14 after immunization and thereafter. Compared to the administration of free FK506, FK506 levels were increased in both the plasma and hearts of EAM rats when liposomal FK506 was administered. The administration of liposomal FK506 markedly suppressed the expression of cytokines, such as interferon-gamma and tumor necrosis factor-alpha, and reduced inflammation and fibrosis in the myocardium on day 21 compared to free FK506. The administration of liposomal FK506 also markedly ameliorated cardiac dysfunction on day 21 compared to free FK506. Nano-sized liposomes may be a promising drug delivery system for targeting myocarditic hearts with cardioprotective agents.	[Okuda, Keiji; Fu, Hai Ying; Matsuzaki, Takashi; Araki, Ryo; Tsuchida, Shota; Yamato, Masaki; Sanada, Shoji; Asano, Yoshihiro; Sakata, Yasushi] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka, Japan; [Thanikachalam, Punniyakoti V.] Int Med Univ, Dept Pharmaceut Chem, Kuala Lumpur, Malaysia; [Fukuta, Tatsuya; Asai, Tomohiro; Oku, Naoto] Univ Shizuoka, Grad Sch Pharmaceut Sci, Dept Med Biochem, Shizuoka, Japan; [Asanuma, Hiroshi] Meiji Univ Integrat Med, Dept Internal Med, Nantan, Kyoto, Japan; [Asakura, Masanori; Kitakaze, Masafumi] Natl Cerebral & Cardiovasc Ctr, Res Inst, Clin Res & Dev, Suita, Osaka, Japan; [Hanawa, Haruo] Niigata Univ, Grad Sch Med & Dent Sci, Dept Cardiovasc Biol & Med, Niigata, Japan; [Hao, Hiroyuki] Nihon Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Takashima, Seiji] Osaka Univ, Grad Sch Med, Dept Med Biochem, Suita, Osaka, Japan; [Minamino, Tetsuo] Kagawa Univ, Fac Med, Dept Cardiorenal & Cerebrovasc Med, Miki, Kagawa, Japan	Osaka University; International Medical University Malaysia; University of Shizuoka; National Cerebral & Cardiovascular Center - Japan; Niigata University; Nihon University; Osaka University; Kagawa University	Minamino, T (corresponding author), Kagawa Univ, Fac Med, Dept Cardiorenal & Cerebrovasc Med, Miki, Kagawa, Japan.	minamino@med.kagawa-u.ac.jp		Sakata, Yasushi/0000-0002-5618-4721; Thanikachalam, Punniyakoti Veeraveedu/0000-0002-4249-7962; Fukuta, Tatsuya/0000-0001-8878-8602	Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science (JSPS)	Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This research was supported by a grant from Japan Science and Technology Agency (JST) and a Grant-in-Aid for Challenging Exploratory Research from Japan Society for the Promotion of Science (JSPS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afanasyeva M, 2004, AUTOIMMUN REV, V3, P476, DOI 10.1016/j.autrev.2004.08.009; Barbarino JM, 2013, PHARMACOGENET GENOM, V23, P563, DOI 10.1097/FPC.0b013e328364db84; Chang H, 2008, CIRC J, V72, P813, DOI 10.1253/circj.72.813; Cooper LT, 1997, NEW ENGL J MED, V336, P1860, DOI 10.1056/NEJM199706263362603; Daniels MD, 2008, AUTOIMMUNITY, V41, P490, DOI 10.1080/08916930802167902; Fairweather D, 2009, J AUTOIMMUN, V33, P222, DOI 10.1016/j.jaut.2009.09.012; Francis GE, 1996, J DRUG TARGET, V3, P321, DOI 10.3109/10611869608996824; Fu HY, 2010, CIRCULATION, V122, P361, DOI 10.1161/CIRCULATIONAHA.109.917914; Fuse K, 2001, CLIN EXP IMMUNOL, V124, P346, DOI 10.1046/j.1365-2249.2001.01510.x; Hanawa H, 2002, CLIN SCI, V103, P623, DOI 10.1042/cs1030623; HANAWA H, 1992, CLIN IMMUNOL IMMUNOP, V62, P321, DOI 10.1016/0090-1229(92)90110-A; Ishii T, 2013, FASEB J, V27, P1362, DOI 10.1096/fj.12-221325; Ishii T, 2013, BIOCHEM BIOPH RES CO, V430, P1201, DOI 10.1016/j.bbrc.2012.12.080; Kandolin R, 2013, CIRC-HEART FAIL, V6, P15, DOI 10.1161/CIRCHEARTFAILURE.112.969261; Kindermann I, 2012, J AM COLL CARDIOL, V59, P779, DOI 10.1016/j.jacc.2011.09.074; Kinugasa F, 2008, BIOL PHARM BULL, V31, P1723, DOI 10.1248/bpb.31.1723; KODAMA M, 1993, AM HEART J, V126, P1385, DOI 10.1016/0002-8703(93)90538-K; KODAMA M, 1990, CLIN IMMUNOL IMMUNOP, V57, P250, DOI 10.1016/0090-1229(90)90039-S; KODAMA M, 1991, CIRC RES, V69, P1042, DOI 10.1161/01.RES.69.4.1042; Kumar A, 1999, AM J PHYSIOL-REG I, V276, pR265, DOI 10.1152/ajpregu.1999.276.1.R265; Madni A, 2014, J PHARM PHARM SCI, V17, P401, DOI 10.18433/J3CP55; Matia I, 2010, EUR J VASC ENDOVASC, V39, P478, DOI 10.1016/j.ejvs.2009.11.016; Matsumoto Y, 2012, CELL IMMUNOL, V279, P70, DOI 10.1016/j.cellimm.2012.09.011; Moffatt SD, 1999, TRANSPLANTATION, V67, P1205, DOI 10.1097/00007890-199905150-00001; Muller LK, 2015, BIOCHEM BIOPH RES CO, V468, P411, DOI 10.1016/j.bbrc.2015.08.088; Nehoff H, 2014, INT J NANOMED, V9, P2539, DOI 10.2147/IJN.S47129; Noutsias M, 2011, EUR J HEART FAIL, V13, P611, DOI 10.1093/eurjhf/hfr014; Okura Y, 1997, J MOL CELL CARDIOL, V29, P491, DOI 10.1006/jmcc.1996.0293; Sagar S, 2012, LANCET, V379, P738, DOI 10.1016/S0140-6736(11)60648-X; Sakuma S, 2000, BRIT J PHARMACOL, V130, P1655, DOI 10.1038/sj.bjp.0703472; Takahama H, 2013, CARDIOVASC DRUG THER, V27, P125, DOI 10.1007/s10557-012-6437-6; Takahama H, 2009, J AM COLL CARDIOL, V53, P709, DOI 10.1016/j.jacc.2008.11.014; Watanabe K, 2001, CIRCULATION, V104, P1098, DOI 10.1161/hc3501.096190; Watanabe R, 2008, TRANSL RES, V152, P119, DOI 10.1016/j.trsl.2008.07.006; Yang WI, 2014, CIRC J, V78, P1197, DOI 10.1253/circj.CJ-13-1235	35	10	10	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2016	11	8							e0160944	10.1371/journal.pone.0160944	http://dx.doi.org/10.1371/journal.pone.0160944			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3IE	27501378	Green Published, gold			2023-01-03	WOS:000381373500068
J	Cerciello, A; Auriemma, G; Morello, S; Aquino, RP; Del Gaudio, P; Russo, P				Cerciello, Andrea; Auriemma, Giulia; Morello, Silvana; Aquino, Rita P.; Del Gaudio, Pasquale; Russo, Paola			Prednisolone Delivery Platforms: Capsules and Beads Combination for a Right Timing Therapy	PLOS ONE			English	Article							IMMEDIATE-RELEASE PREDNISONE; RHEUMATOID-ARTHRITIS; MORNING STIFFNESS; CIRCADIAN-RHYTHMS; ALGINATE BEADS; DOSAGE FORMS; IN-VITRO; KETOPROFEN; SYSTEMS; DRUG	In this work, a platform of alginate beads loaded with Prednisolone in hypromellose/gellan gum capsules (F6/Cps) able to delay steroidal anti-inflammatory drug (SAID) release as needed for chronotherapy of rheumatoid arthritis is proposed. Rheumatoid arthritis, showing a worsening in symptoms in the morning upon waking, is a pathology that can benefit from chronotherapy. With the aim to maximize prednisolone therapeutic action allowing the right timing of glucocorticoid therapy, different engineered microparticles (gel-beads) were manufactured using prilling (laminar jet break-up) as micro-encapsulation technique and Zn-alginate as gastroresistant carrier. Starting from various feed solutions and process parameters, the effect of the variables on particles size, morphology, solid state properties and drug release was studied. The optimization of operative and prilling/ionotropic gelation variables led to microspheres with almost spherical shape and a narrow dimensional range. The feed solution with the highest alginate (2.5% w/v) amount and drug/polymer ratio (1: 5 w/w) gave rise to the highest encapsulation efficiency (78.5%) as in F6 formulation. As to drug release, F6 exhibited an interesting dissolution profile, releasing about 24% of the drug in simulated gastric fluid followed by a more sustained profile in simulated intestinal fluid. #F6, acting as a gastro-resistant and delayed release formulation, was selected for in vivo studies on male Wistar rats by means of a carrageenan-induced oedema model. Finally, this efficacious formulation was used as core material for the development of a final dosage form: F6/Cps allowed to significantly reduce prednisolone release in simulated gastric fluid (12.6%) and delayed drug release up to about 390 minutes.	[Cerciello, Andrea; Auriemma, Giulia; Morello, Silvana; Aquino, Rita P.; Del Gaudio, Pasquale; Russo, Paola] Univ Salerno, Dept Pharm, Fisciano, Italy; [Cerciello, Andrea] Univ Salerno, PhD Program Drug Discovery & Dev, Fisciano, Italy	University of Salerno; University of Salerno	Russo, P (corresponding author), Univ Salerno, Dept Pharm, Fisciano, Italy.	paorusso@unisa.it	Auriemma, Giulia/P-9709-2016; Morello, Silvana/E-9328-2012; RUSSO, Paola/A-3931-2011; Del Gaudio, Pasquale/B-6833-2011	Auriemma, Giulia/0000-0001-9547-0969; Morello, Silvana/0000-0002-6541-0997; RUSSO, Paola/0000-0002-4362-4388; Del Gaudio, Pasquale/0000-0003-3852-4523; aquino, rita patrizia/0000-0002-9754-4244				Almeida-Prieto S, 2004, J PHARM SCI-US, V93, P621, DOI 10.1002/jps.10572; Alten R, 2015, SCAND J RHEUMATOL, V44, P354, DOI 10.3109/03009742.2015.1038582; Alten R, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2015-000134; Auriemma G, 2013, CARBOHYD POLYM, V92, P367, DOI 10.1016/j.carbpol.2012.09.056; Auriemma G, 2011, INT J PHARMACEUT, V415, P196, DOI 10.1016/j.ijpharm.2011.05.077; Bijlsma JWJ, 2008, LANCET, V371, P183, DOI 10.1016/S0140-6736(08)60114-2; Buttgereit F, 2008, LANCET, V371, P205, DOI 10.1016/S0140-6736(08)60132-4; Buttgereit F, 2015, BULL HOSP JT DIS, V73, P168; Cerciello A, 2016, DRUG DEV IND PHARM, V30, P1; Cerciello A, 2016, J DRUG DELIV SCI TEC, V32, P126, DOI 10.1016/j.jddst.2015.07.017; Cerciello A, 2015, J PHARM SCI-US, V104, P3451, DOI 10.1002/jps.24554; Chakraborty S, 2010, ACTA PHARMACEUT, V60, P255, DOI 10.2478/v10007-010-0026-7; Cicala C, 2007, EUR J PHARMACOL, V577, P156, DOI 10.1016/j.ejphar.2007.08.007; DAVIS M, 1978, BRIT J CLIN PHARMACO, V5, P501, DOI 10.1111/j.1365-2125.1978.tb01664.x; Del Gaudio P, 2005, INT J PHARMACEUT, V302, P1, DOI 10.1016/j.ijpharm.2005.05.041; Del Gaudio P, 2014, EUR J PHARM BIOPHARM, V87, P541, DOI 10.1016/j.ejpb.2014.02.010; Di Colo G, 2006, INT J PHARMACEUT, V310, P154, DOI 10.1016/j.ijpharm.2005.12.002; Gibbs JE, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4146; Haus E, 2012, BULL HOSP JT DIS, V70, pS3; Lau ETL, 2012, J MICROENCAPSUL, V29, P706, DOI 10.3109/02652048.2012.686527; MADSBAD S, 1980, GUT, V21, P52, DOI 10.1136/gut.21.1.52; Mazurek S, 2012, J AOAC INT, V95, P744, DOI 10.5740/jaoacint.SGE_Mazurek; Okimoto K, 1998, PHARMACEUT RES, V15, P1562, DOI 10.1023/A:1011955117026; Palanisamy M, 2011, DRUG DEV IND PHARM, V37, P373, DOI 10.3109/03639045.2010.513984; Papageorgiou SK, 2010, CARBOHYD RES, V345, P469, DOI 10.1016/j.carres.2009.12.010; PICKUP ME, 1979, CLIN PHARMACOKINET, V4, P111, DOI 10.2165/00003088-197904020-00004; Skowyra J, 2015, EUR J PHARM SCI, V68, P11, DOI 10.1016/j.ejps.2014.11.009; Spies CM, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4687; Straub RH, 2007, ARTHRITIS RHEUM, V56, P399, DOI 10.1002/art.22368; SUGAWARA S, 1994, PHARMACEUT RES, V11, P272, DOI 10.1023/A:1018963626248; Vogt M, 2007, J PHARM SCI-US, V96, P27, DOI 10.1002/jps.20768	31	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2016	11	7							e0160266	10.1371/journal.pone.0160266	http://dx.doi.org/10.1371/journal.pone.0160266			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IM	27472446	Green Published, gold, Green Submitted			2023-01-03	WOS:000381516300039
J	Hey, SP; Kesselheim, AS				Hey, Spencer Phillips; Kesselheim, Aaron S.			Countering imprecision in precision medicine	SCIENCE			English	Editorial Material									[Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, PORTAL, Boston, MA 02120 USA; Harvard Med Sch, Boston, MA 02120 USA; Harvard Med Sch, Ctr Bioeth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, PORTAL, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Andre F, 2011, NAT REV CLIN ONCOL, V8, P171, DOI 10.1038/nrclinonc.2011.4; Ballman KV, 2015, J CLIN ONCOL, V33, P3968, DOI 10.1200/JCO.2015.63.3651; de Gramont A, 2015, NAT REV CLIN ONCOL, V12, P197, DOI 10.1038/nrclinonc.2014.202; FDA, 2012, GUID IND ENR STRAT C; Febbo PG, 2011, J NATL COMPR CANC NE, V9, pS1, DOI 10.6004/jnccn.2011.0137; Hayes DF, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005950; Hey S. P., 2015, THEORIA, V30; Mallett S, 2010, BRIT J CANCER, V102, P173, DOI 10.1038/sj.bjc.6605462; National Academies of Sciences, 2016, BIOM TESTS MOL TARG; Office of Public Health Strategy and Analysis FDA, 2015, PUBL HLTH EV FDA OV; Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112; Schmidt Charlie, 2011, J Natl Cancer Inst, V103, P87, DOI 10.1093/jnci/djq557	12	24	24	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	2016	353	6298					448	449		10.1126/science.aaf5101	http://dx.doi.org/10.1126/science.aaf5101			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DS2HC	27471295				2023-01-03	WOS:000380583600023
J	Li, F; Zhou, XF; Zhou, HY; Jia, JB; Li, LW; Zhai, SM; Yan, B				Li, Fei; Zhou, Xiaofei; Zhou, Hongyu; Jia, Jianbo; Li, Liwen; Zhai, Shumei; Yan, Bing			Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates	PLOS ONE			English	Article							MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PHOTOTHERMAL ABLATION; CANCER; NANOPARTICLES; DELIVERY; CELLS; NANOCARRIERS; CYCLODEXTRINS; CHEMOTHERAPY	Repeated administrations of anti-cancer drugs to patients often induce drug resistance. P-glycoprotein (Pgp) facilitates an efficient drug efflux, preventing cellular accumulation of drugs and causing multi-drug resistance (MDR). In this study, we developed a gold-paclitaxel nanoconjugate system to overcome MDR. Gold nanoparticles (GNPs) were conjugated with beta-cyclodextrin enclosing paclitaxel (PTX) molecules and PEG molecules. GNP conjugates were effectively endocytosed by both drug-sensitive human lung cancer H460 cells and Pgp-overexpressed drug-resistant H460(PTX) cells. Compared with PTX, PGNPs did not induce the Pgp overexpression in drug-sensitive H460 cells after long-term treatment and also avoided being pumped out of cells by overexpressed Pgp molecules in H460(PTX) with a 17-fold lower EC50 compared to PTX. Fluorescent microscopy and flow cytometry further confirmed that fluorescent labeled PGNPs (f-PGNPs) maintained a high cellular PTX level in both H460 and H460(PTX) cells. These results demonstrated that nano-drug conjugates were able to avoid the development of drug resistance in sensitive cells and evade Pgp-mediated drug resistance and to maintain a high cytotoxicity in drug-resistant cancer cells. These findings exemplify a powerful nanotechnological approach to the long-lasting issue of chemotherapy-induced drug resistance.	[Li, Fei; Zhou, Xiaofei; Zhou, Hongyu; Jia, Jianbo; Li, Liwen; Zhai, Shumei; Yan, Bing] Shandong Univ, Sch Chem & Chem Engn, Jinan 250100, Peoples R China	Shandong University	Zhai, SM; Yan, B (corresponding author), Shandong Univ, Sch Chem & Chem Engn, Jinan 250100, Peoples R China.	smzhai@sdu.edu.cn; bingyan@yahoo.com	ZHOU, HONGYU/E-7031-2011	Jia, Jianbo/0000-0002-1703-6734	National Natural Science Foundation of China [21137002, 91543204]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB14030401]; Natural Science Foundation of Shandong Province [ZR2014BM026]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This work was supported by the National Natural Science Foundation of China (grant numbers: 21137002 and 91543204 to BY) (http://www.nsfc.gov.cn), the Strategic Priority Research Program of the Chinese Academy of Sciences (grant numbers: XDB14030401 to BY) (http://www.cas.cn) and the Natural Science Foundation of Shandong Province (grant numbers: ZR2014BM026 to SZ) (http://www.sdnsf.gov.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aykac A, 2014, LANGMUIR, V30, P234, DOI 10.1021/la403454p; Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Brewster ME, 2002, PHARMAZIE, V57, P94; Challa R, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060243; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Chavanpatil MD, 2006, INT J PHARMACEUT, V320, P150, DOI 10.1016/j.ijpharm.2006.03.045; Chen Y, 2015, RSC ADV, V5, P8938, DOI 10.1039/c4ra13135e; Chithrani DB, 2010, RADIAT RES, V173, P719, DOI 10.1667/RR1984.1; Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576; Dong XW, 2010, NANOMEDICINE-UK, V5, P597, DOI 10.2217/NNM.10.35; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Groneberg DA, 2006, CURR DRUG TARGETS, V7, P643, DOI 10.2174/138945006777435245; Gu YJ, 2012, NANOMED-NANOTECHNOL, V8, P204, DOI 10.1016/j.nano.2011.06.005; Guo R, 2010, LANGMUIR, V26, P5428, DOI 10.1021/la903893n; He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065; Heo DN, 2012, BIOMATERIALS, V33, P856, DOI 10.1016/j.biomaterials.2011.09.064; Higgins C F, 1992, ANN REV CELL BIOL; Ho EA, 2007, J CONTROL RELEASE, V117, P20, DOI 10.1016/j.jconrel.2006.10.007; Horcajada P, 2010, NAT MATER, V9, P172, DOI [10.1038/nmat2608, 10.1038/NMAT2608, 10.1038/NMAT260B]; Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x; Jain R, 2009, J CONTROL RELEASE, V138, P90, DOI 10.1016/j.jconrel.2009.05.010; Jiang DH, 2013, CANCER LETT, V335, P404, DOI 10.1016/j.canlet.2013.02.059; Jiao PF, 2011, J AM CHEM SOC, V133, P13918, DOI 10.1021/ja206118a; Khurana V., 2014, RECENT PATENTS NANOM, V4, P57, DOI DOI 10.2174/1877912304999140930143244; Kulkarni SA, 2013, PHARM RES-DORDR, V30, P2512, DOI 10.1007/s11095-012-0958-3; Kumar A, 2013, BIOTECHNOL ADV, V31, P593, DOI 10.1016/j.biotechadv.2012.10.002; Lamendola DE, 2003, CANCER RES, V63, P2200; LEE JS, 1994, MOL PHARMACOL, V46, P627; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Li RB, 2010, ACS NANO, V4, P1399, DOI 10.1021/nn9011225; Libutti SK, 2010, CLIN CANCER RES, V16, P6139, DOI 10.1158/1078-0432.CCR-10-0978; Liu XW, 2011, BIOMATERIALS, V32, P144, DOI 10.1016/j.biomaterials.2010.08.096; Lowery AR, 2006, INT J NANOMED, V1, P149, DOI 10.2147/nano.2006.1.2.149; Mellor HR, 2008, PHARMACOLOGY, V81, P275, DOI 10.1159/000115967; Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]; O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004; Park C, 2009, J MATER CHEM, V19, P2310, DOI 10.1039/b816209c; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Qiu LP, 2015, NANO LETT, V15, P457, DOI 10.1021/nl503777s; Shanker M, 2010, LUNG CANCER-TARGETS, V1, P23; Sharma AK, 2008, J CONTROL RELEASE, V131, P220, DOI 10.1016/j.jconrel.2008.07.031; Shi Q, 2015, BIOMATERIALS, V67, P169, DOI 10.1016/j.biomaterials.2015.07.023; Shi Y, 2013, INORG CHEM, V52, P9418, DOI 10.1021/ic400989v; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sierpe R, 2015, ACS APPL MATER INTER, V7, P15177, DOI 10.1021/acsami.5b00186; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Vigderman L, 2013, ADV DRUG DELIVER REV, V65, P663, DOI 10.1016/j.addr.2012.05.004; Wang F, 2011, ACS NANO, V5, P3679, DOI 10.1021/nn200007z; Wong HL, 2006, J PHARMACOL EXP THER, V317, P1372, DOI 10.1124/jpet.106.101154; Yergeri M, 2014, NANODRUG DELIVERY RE; Zahreddine H, 2013, FRONT PHARMACOL, V4; Zhang XD, 2012, BIOMATERIALS, V33, P6408, DOI 10.1016/j.biomaterials.2012.05.047; Zhang XQ, 2011, ACS NANO, V5, P6962, DOI 10.1021/nn201446c; Zhou HY, 2008, J MED CHEM, V51, P1242, DOI 10.1021/jm7012024	59	14	14	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2016	11	7							e0160042	10.1371/journal.pone.0160042	http://dx.doi.org/10.1371/journal.pone.0160042			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IL	27467397	gold, Green Submitted, Green Published			2023-01-03	WOS:000381516100097
J	Robinson, BM; Akizawa, T; Jager, KJ; Kerr, PG; Saran, R; Pisoni, RL				Robinson, Bruce M.; Akizawa, Tadao; Jager, Kitty J.; Kerr, Peter G.; Saran, Rajiv; Pisoni, Ronald L.			Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices	LANCET			English	Article							QUALITY-OF-LIFE; FREQUENT NOCTURNAL HEMODIALYSIS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; VASCULAR ACCESS; MAINTENANCE HEMODIALYSIS; MORTALITY RISK; UNITED-STATES; CONVENTIONAL HEMODIALYSIS; INTERNATIONAL COMPARISONS	More than 2 million people worldwide are being treated for end-stage kidney disease (ESKD). This Series paper provides an overview of incidence, modality use (in-centre haemodialysis, home dialysis, or transplantation), and mortality for patients with ESKD based on national registry data. We also present data from an international cohort study to highlight differences in haemodialysis practices that affect survival and the experience of patients who rely on this therapy, which is both life-sustaining and profoundly disruptive to their quality of life. Data illustrate disparities in access to renal replacement therapy of any kind and in the use of transplantation or home dialysis, both of which are widely considered preferable to in-centre haemodialysis for many patients with ESKD in settings where infrastructure permits. For most patients with ESKD worldwide who are treated with in-centre haemodialysis, overall survival is poor, but longer in some Asian countries than elsewhere in the world, and longer in Europe than in the USA, although this gap has reduced. Commendable haemodialysis practice includes exceptionally high use of surgical vascular access in Japan and in some European countries, and the use of longer or more frequent dialysis sessions in some countries, allowing for more effective volume management. Mortality is especially high soon after ESKD onset, and improved preparation for ESKD is needed including alignment of decision making with the wishes of patients and families.	[Robinson, Bruce M.; Pisoni, Ronald L.] Arbor Res Collaborat Hlth, Ann Arbor, MI 48104 USA; [Robinson, Bruce M.; Saran, Rajiv] Univ Michigan, Dept Internal Med & Nephrol, Ann Arbor, MI 48109 USA; [Akizawa, Tadao] Showa Univ, Sch Med, Shinagawa Ku, Tokyo, Japan; [Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ERA EDTA Registry, Amsterdam, Netherlands; [Kerr, Peter G.] Monash Med Ctr, Clayton, Vic, Australia; [Kerr, Peter G.] Monash Univ Clayton, Clayton, Vic, Australia	Arbor Research Collaborative for Health; University of Michigan System; University of Michigan; Showa University; University of Amsterdam; Academic Medical Center Amsterdam; Monash University; Monash University	Robinson, BM (corresponding author), Arbor Res Collaborat Hlth, Ann Arbor, MI 48104 USA.	Bruce.Robinson@ArborResearch.org	Kerr, Peter G/I-1461-2013	Jager, Kitty/0000-0003-0444-8569; Robinson, Bruce/0000-0003-0749-1714	US National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services [HHSN276201400001C]; European Renal Association-European Dialysis and Transplant Association (ERA-EDTA Registry); Amgen; Kyowa Hakko Kirin; AbbVie; Sanofi Renal; Baxter Healthcare; Vifor Fresenius Medical Care Renal Pharma; Keryx Biopharmaceuticals; Merck Sharp Dohme; Proteon Therapeutics; Relypsa; F Hoffmann-LaRoche; BHC Medical; Janssen; Takeda; Kidney Foundation of Canada; Hexal; DGfN; Shire; WiNe Institute; Japanese Society for Peritoneal Dialysis	US National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services; European Renal Association-European Dialysis and Transplant Association (ERA-EDTA Registry); Amgen(Amgen); Kyowa Hakko Kirin(Kyowa Kirin Ltd); AbbVie(AbbVie); Sanofi Renal; Baxter Healthcare; Vifor Fresenius Medical Care Renal Pharma; Keryx Biopharmaceuticals; Merck Sharp Dohme(Merck & Company); Proteon Therapeutics; Relypsa; F Hoffmann-LaRoche(Hoffmann-La Roche); BHC Medical; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Takeda(Takeda Pharmaceutical Company Ltd); Kidney Foundation of Canada; Hexal; DGfN; Shire; WiNe Institute; Japanese Society for Peritoneal Dialysis	Information regarding registry data in this Series paper are supported in whole or partly by funds from the US National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services (Contract number HHSN276201400001C; US Renal Data System), and from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA Registry). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health. The DOPPS programme is supported by Amgen, Kyowa Hakko Kirin, AbbVie, Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma. Additional support for specific projects and countries is also provided by Keryx Biopharmaceuticals, Merck Sharp & Dohme, Proteon Therapeutics, Relypsa, and F Hoffmann-LaRoche; in Canada by Amgen, BHC Medical, Janssen, Takeda, and Kidney Foundation of Canada (for logistics support); in Germany by Hexal, DGfN, Shire, and WiNe Institute; for PDOPPS in Japan by the Japanese Society for Peritoneal Dialysis. All support is provided without restrictions on publications. Grants are made to Arbor Research Collaborative for Health and not to individual investigators. We thank Brian Bieber, Alan Leichtman, Keith McCullough, Friedrich Port, Sarah White, and Lindsay Zepel for their supportive contributions to this Series paper, and Shauna Leighton for editorial assistance.	Abma I, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004249; Allon M, 2006, AM J KIDNEY DIS, V47, P469, DOI 10.1053/j.ajkd.2005.11.023; Allon M, 2011, J AM SOC NEPHROL, V22, P426, DOI 10.1681/ASN.2010121219; ANZDATA Registry, 2014, 37 ANN REP ANZDATA R; Asano M, 2013, NEPHRON CLIN PRACT, V124, P23, DOI 10.1159/000353733; Astor BC, 2005, J AM SOC NEPHROL, V16, P1449, DOI 10.1681/ASN.2004090748; Bailie GR, 2015, KIDNEY INT, V87, P162, DOI 10.1038/ki.2014.275; Bieber B, 2014, NEPHROL DIAL TRANSPL, V29, P1770, DOI 10.1093/ndt/gft472; Bikbov BT, NEPHROL DIA IN PRESS; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Bradbury BD, 2009, AM J KIDNEY DIS, V53, P804, DOI 10.1053/j.ajkd.2008.11.031; Brunelli SM, 2010, KIDNEY INT, V77, P630, DOI 10.1038/ki.2009.523; Caskey FJ, 2011, NEPHROL DIAL TRANSPL, V26, P2604, DOI 10.1093/ndt/gfq781; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Combe C, 2009, AM J KIDNEY DIS, V54, P680, DOI 10.1053/j.ajkd.2009.04.035; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Crews DC, 2014, AM J KIDNEY DIS, V63, P806, DOI 10.1053/j.ajkd.2013.12.010; Crews DC, 2014, J AM SOC NEPHROL, V25, P370, DOI 10.1681/ASN.2013050567; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Daugirdas JT, 2015, AM J KIDNEY DIS, V66, P884, DOI 10.1053/j.ajkd.2015.07.015; Daugirdas JT, 2013, KIDNEY INT, V83, P9, DOI 10.1038/ki.2012.365; Depner T, 2004, KIDNEY INT, V65, P1386, DOI 10.1111/j.1523-1755.2004.00519.x; Engemann JJ, 2005, INFECT CONT HOSP EP, V26, P534, DOI 10.1086/502580; *ERA EDTA REG, 2007, ERA EDTA REG 2005 AN; ERA EDTA Registry, 2015, ERA EDTA REG ANN REP; Fissell RB, 2013, J VASC ACCESS, V14, P264, DOI 10.5301/jva.5000140; Flythe JE, 2013, KIDNEY INT, V83, P104, DOI 10.1038/ki.2012.346; Foley RN, 2014, KIDNEY INT, V86, P392, DOI 10.1038/ki.2014.15; Foley RN, 2011, NEW ENGL J MED, V365, P1099, DOI 10.1056/NEJMoa1103313; Fuller DS, 2016, J AM SOC NEPHROL, V27, P2205, DOI 10.1681/ASN.2015060673; Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; Gillespie BW, 2015, CLIN KIDNEY J, V8, P772, DOI 10.1093/ckj/sfv103; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Hasegawa T, 2011, KIDNEY INT, V79, P340, DOI 10.1038/ki.2010.382; Hasegawa T, 2009, CLIN J AM SOC NEPHRO, V4, P595, DOI 10.2215/CJN.03540708; Hecking M, 2012, CLIN J AM SOC NEPHRO, V7, P92, DOI 10.2215/CJN.05440611; Hecking M, 2012, AM J KIDNEY DIS, V59, P238, DOI 10.1053/j.ajkd.2011.07.013; Herrington W, 2015, SEMIN DIALYSIS, V28, P35, DOI 10.1111/sdi.12281; Inrig JK, 2014, AM J KIDNEY DIS, V63, P771, DOI 10.1053/j.ajkd.2013.10.043; Jadoul M, 2012, CLIN J AM SOC NEPHRO, V7, P765, DOI 10.2215/CJN.08850811; Jha V, 2015, NEPHROLOGY, V20, P329, DOI 10.1111/nep.12404; Kalantar-Zadeh K, 2014, AM J KIDNEY DIS, V64, P181, DOI 10.1053/j.ajkd.2014.04.019; Kelley-Hedgepeth A, 2008, CLIN CHEM, V54, P1027, DOI 10.1373/clinchem.2007.098996; Kleophas W, 2013, KIDNEY INT, V84, P578, DOI 10.1038/ki.2013.143; Kopp JB, 2011, J AM SOC NEPHROL, V22, P2129, DOI 10.1681/ASN.2011040388; Kruzel-Davila E, 2016, NEPHROL DIAL TRANSPL, V31, P349, DOI 10.1093/ndt/gfu391; Kumwenda M, 2015, CLIN PRACTICE GUIDEL, V6th; Lacson E, 2011, AM J KIDNEY DIS, V58, P235, DOI 10.1053/j.ajkd.2011.04.015; Lacson E, 2009, AM J KIDNEY DIS, V53, P79, DOI 10.1053/j.ajkd.2008.07.031; Lee H, 2002, AM J KIDNEY DIS, V40, P611, DOI 10.1053/ajkd.2002.34924; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Lok CE, 2012, J AM SOC NEPHROL, V23, p268A; Lopes AA, 2012, AM J KIDNEY DIS, V60, P90, DOI 10.1053/j.ajkd.2011.12.025; Lopes AA, 2009, NEPHROL DIAL TRANSPL, V24, P2809, DOI 10.1093/ndt/gfp212; Mapes DL, 2003, KIDNEY INT, V64, P339, DOI 10.1046/j.1523-1755.2003.00072.x; Marshall MR, 2011, AM J KIDNEY DIS, V58, P782, DOI 10.1053/j.ajkd.2011.04.027; Masakane I, 2015, THER APHER DIAL, V19, P540, DOI 10.1111/1744-9987.12378; McIntyre CW, 2008, CLIN J AM SOC NEPHRO, V3, P19, DOI 10.2215/CJN.03170707; Mehrotra R, 2013, SEMIN DIALYSIS, V26, P644, DOI 10.1111/sdi.12127; Mendelssohn DC, 2008, NEPHROL DIAL TRANSPL, V23, P3227, DOI 10.1093/ndt/gfn195; National Kidney Foundation, 1997, AM J KIDNEY DIS, V30, pS67; National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI), 2006, GUID COMM; Nesrallah GE, 2012, J AM SOC NEPHROL, V23, P696, DOI 10.1681/ASN.2011070676; Ok E, 2016, LANCET, V388, P285, DOI 10.1016/S0140-6736(16)30389-0; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Pippias M, 2016, NEPHROL DIAL TRANSPL, V31, P831, DOI 10.1093/ndt/gfv327; Pisoni R, 2015, J AM SOC NEPHROL, V26, p285A; Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005; Pisoni RL, 2002, KIDNEY INT, V61, P305, DOI 10.1046/j.1523-1755.2002.00117.x; Pisoni RL, 2015, AM J KIDNEY DIS, V65, P905, DOI 10.1053/j.ajkd.2014.12.014; Pisoni RL, 2009, AM J KIDNEY DIS, V53, P475, DOI 10.1053/j.ajkd.2008.10.043; Polkinghorne KR, 2004, J AM SOC NEPHROL, V15, P477, DOI 10.1097/01.ASN.0000109668.05157.05; Port FK, 2004, AM J KIDNEY DIS, V43, P1014, DOI 10.1053/j.ajkd.2004.02.014; Port FK, 2003, BLOOD PURIFICAT, V21, P85, DOI 10.1159/000067859; Port FK, 2014, AM J KIDNEY DIS, V64, P969, DOI 10.1053/j.ajkd.2014.05.025; Ramirez SPB, 2009, J AM SOC NEPHROL, V20, P1094, DOI 10.1681/ASN.2008060579; Rayner HC, 2010, SEMIN DIALYSIS, V23, P6, DOI 10.1111/j.1525-139X.2009.00675.x; Remuzzi G, 2013, LANCET, V382, P353, DOI 10.1016/S0140-6736(13)60438-9; Renal Physicians Association, 2010, SHAR DEC MAK APPR IN; Robinson BM, 2006, J AM SOC NEPHROL, V17, P2910, DOI 10.1681/ASN.2005101078; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; Robinson BM, 2012, CLIN J AM SOC NEPHRO, V7, P1897, DOI 10.2215/CJN.04940512; Robinson BM, 2012, KIDNEY INT, V82, P570, DOI 10.1038/ki.2012.136; Rocco MV, 2015, AM J KIDNEY DIS, V66, P459, DOI 10.1053/j.ajkd.2015.02.331; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Roderick P, 2009, NEPHROL DIAL TRANSPL, V24, P3774, DOI 10.1093/ndt/gfp348; Rosset S, 2011, NAT REV NEPHROL, V7, P313, DOI 10.1038/nrneph.2011.52; Saran R, 2008, ANN SURG, V247, P885, DOI 10.1097/SLA.0b013e31816c4044; Sehulster Lynne, 2003, MMWR Recomm Rep, V52, P1; Seng WH, 2014, 21 REPORT MALAYSIAN; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213; Tentori F, 2012, NEPHROL DIAL TRANSPL, V27, P4180, DOI 10.1093/ndt/gfs021; The Japanese Society for Dialysis Therapy, 2011, J JPN SOC DIAL THER, V44, P855; Thodis ED, 2011, J NEPHROL, V24, P398, DOI 10.5301/JN.2011.8374; Thomas B, 2015, J AM SOC NEPHROL, V26, P2621, DOI 10.1681/ASN.2014101017; Ueshima H, 2008, CIRCULATION, V118, P2702, DOI 10.1161/CIRCULATIONAHA.108.790048; UK NHS, END LIF CAR ADV KIDN; UK NHS Department of Health, PAYM RES GUID 2011 1; United States Renal Data System U, 2015, 2015 USRDS ANN DAT R, V2; US Centers for Medicare & Medicaid Services, TECHN SPEC ESRD QIP; US Renal Data System, 2010, USRDS 2010 ANN DAT R; van de Luijtgaarden MWM, 2013, NEPHROL DIAL TRANSPL, V28, P2604, DOI 10.1093/ndt/gft287; van den Beukel TO, 2008, NEPHROL DIAL TRANSPL, V23, P3571, DOI 10.1093/ndt/gfn336; van Dijk PCW, 2007, KIDNEY INT, V71, P53, DOI 10.1038/sj.ki.5002008; van Manen JG, 2007, NEPHROL DIAL TRANSPL, V22, P187, DOI 10.1093/ndt/gfl502; Vassalotti JA, 2012, SEMIN DIALYSIS, V25, P303, DOI 10.1111/j.1525-139X.2012.01069.x; Watanabe Y, 2015, THER APHER DIAL, V19, P108, DOI 10.1111/1744-9987.12295; Watanabe Y, 2015, THER APHER DIAL, V19, P67, DOI 10.1111/1744-9987.12294; Watanabe Y, 2015, THER APHER DIAL, V19, P93, DOI 10.1111/1744-9987.12293; Wu M-S, 2012, ACTA NEPHROLOGICA, V26, P104; Xue JL, 2003, AM J KIDNEY DIS, V42, P1013, DOI 10.1016/j.ajkd.2003.07.004; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x; Zhang H, 2012, KIDNEY INT, V81, P1108, DOI 10.1038/ki.2011.481	115	214	225	10	53	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	2016	388	10041					294	306		10.1016/S0140-6736(16)30448-2	http://dx.doi.org/10.1016/S0140-6736(16)30448-2			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DR2LN	27226132	Green Accepted			2023-01-03	WOS:000379736100034
J	Johnson, GR; Knibbs, LD; Kidd, TJ; Wainwright, CE; Wood, ME; Ramsay, KA; Bell, SC; Morawska, L				Johnson, Graham R.; Knibbs, Luke D.; Kidd, Timothy J.; Wainwright, Claire E.; Wood, Michelle E.; Ramsay, Kay A.; Bell, Scott C.; Morawska, Lidia			A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; HYGROSCOPIC BEHAVIOR; ROTATING DRUM; INFLUENZA-A; AEROSOLS; SIZE; TRANSMISSION; MECHANISMS; BACTERIA; OXYGEN	This work aimed to develop an in vivo approach for measuring the duration of human bioaerosol infectivity. To achieve this, techniques designed to target short-term and long-term bioaerosol aging, were combined in a tandem system and optimized for the collection of human respiratory bioaerosols, without contamination. To demonstrate the technique, cough aerosols were sampled from two persons with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Measurements and cultures from aerosol ages of 10, 20, 40, 900 and 2700 seconds were used to determine the optimum droplet nucleus size for pathogen transport and the airborne bacterial biological decay. The droplet nuclei containing the greatest number of colony forming bacteria per unit volume of airborne sputum were between 1.5 and 2.6 mu m. Larger nuclei of 3.9 mu m, were more likely to produce a colony when impacted onto growth media, because the greater volume of sputum comprising the larger droplet nuclei, compensated for lower concentrations of bacteria within the sputum of larger nuclei. Although more likely to produce a colony, the larger droplet nuclei were small in number, and the greatest numbers of colonies were instead produced by nuclei from 1.5 to 5.7 mu m. Very few colonies were produced by smaller droplet nuclei, despite their very large numbers. The concentration of viable bacteria within the dried sputum comprising the droplet nuclei exhibited an orderly dual decay over time with two distinct half-lives. Nuclei exhibiting a rapid biological decay process with a 10 second half-life were quickly exhausted, leaving only a subset characterized by a half-life of greater than 10 minutes. This finding implied that a subset of bacteria present in the aerosol was resistant to rapid biological decay and remained viable in room air long enough to represent an airborne infection risk.	[Johnson, Graham R.; Morawska, Lidia] Queensland Univ Technol, ILAQH, Brisbane, Qld, Australia; [Knibbs, Luke D.] Univ Queensland, Sch Publ Hlth, Herston, Qld, Australia; [Kidd, Timothy J.] Univ Queensland, Child Hlth Res Ctr, Herston, Qld, Australia; [Kidd, Timothy J.] Queens Univ, Ctr Med Expt, Belfast, Antrim, North Ireland; [Wainwright, Claire E.; Ramsay, Kay A.; Bell, Scott C.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Wainwright, Claire E.] Royal Lady Cilento Childrens Hosp, Dept Resp & Sleep Med, South Brisbane, Qld, Australia; [Wood, Michelle E.; Ramsay, Kay A.; Bell, Scott C.] QIMR Berghofer Med Res Inst, Lung Bacteria Res Grp, Herston, Qld, Australia; [Wood, Michelle E.; Bell, Scott C.] Prince Charles Hosp, Dept Thorac Med, Chermside, Qld, Australia	Queensland University of Technology (QUT); University of Queensland; University of Queensland; Queens University Belfast; University of Queensland; QIMR Berghofer Medical Research Institute; Prince Charles Hospital	Johnson, GR (corresponding author), Queensland Univ Technol, ILAQH, Brisbane, Qld, Australia.	g.johnson@qut.edu.au	Kidd, Timothy/F-2149-2010; Wainwright, Claire E/G-4218-2013; Bell, Scott C/A-7241-2011; Johnson, Graham/B-4128-2011; Knibbs, Luke/C-7865-2012; Bell, Scott/AAJ-4298-2020; Morawska, Lidia/B-4140-2011	Kidd, Timothy/0000-0002-6135-6364; Wainwright, Claire E/0000-0001-8389-3809; Bell, Scott C/0000-0001-8651-7139; Johnson, Graham/0000-0001-6874-0230; Bell, Scott/0000-0001-8651-7139; Morawska, Lidia/0000-0002-0594-9683; Knibbs, Luke/0000-0002-0399-2370	Prince Charles Hospital Foundation [MS2010-42]; Children's Health Foundation Queensland [50005]; Institute of Health and Biomedical Innovation-Queensland University of Technology (IHBI) (Collaborative Research Development Grants) [2010002239]; Institute of Health and Biomedical Innovation-Queensland University of Technology (IHBI) (Collaborative Research Development Grants) (IHBI Early Career Researcher's Grant) [2009001211]; Australian Research Council Discovery Grant [DP0558410]; Perpetual Philanthropy; Queensland Health Office of Health and Medical Research (Health Fellowships) [QCOS012808, QCOS013795]; National Health and Medical Research Council (NHMRC) Early Career (Australian Public Health) Fellowship [1036620]; ERS-EU RESPIRE2 Marie Sklodowska-Curie Postdoctoral Research Fellowship [4571-2013]	Prince Charles Hospital Foundation; Children's Health Foundation Queensland; Institute of Health and Biomedical Innovation-Queensland University of Technology (IHBI) (Collaborative Research Development Grants); Institute of Health and Biomedical Innovation-Queensland University of Technology (IHBI) (Collaborative Research Development Grants) (IHBI Early Career Researcher's Grant); Australian Research Council Discovery Grant(Australian Research Council); Perpetual Philanthropy; Queensland Health Office of Health and Medical Research (Health Fellowships); National Health and Medical Research Council (NHMRC) Early Career (Australian Public Health) Fellowship(National Health and Medical Research Council (NHMRC) of Australia); ERS-EU RESPIRE2 Marie Sklodowska-Curie Postdoctoral Research Fellowship	The study was funded by grants from The Prince Charles Hospital Foundation (#MS2010-42), Children's Health Foundation Queensland (#50005), Institute of Health and Biomedical Innovation-Queensland University of Technology (IHBI) (Collaborative Research Development Grants to LM, LDK, and GRJ (#2010002239), IHBI Early Career Researcher's Grant to GRJ (#2009001211)), Australian Research Council Discovery Grant to LM (DP0558410), Perpetual Philanthropy, Queensland Health Office of Health and Medical Research (Health Fellowships CEW (QCOS012808) and SCB (QCOS013795)), National Health and Medical Research Council (NHMRC) Early Career (Australian Public Health) Fellowship to LDK (#1036620), and a ERS-EU RESPIRE2 Marie Sklodowska-Curie Postdoctoral Research Fellowship to TJK (#4571-2013).	Agranovski V, 2003, J AEROSOL SCI, V34, P1711, DOI 10.1016/S0021-8502(03)00191-5; [American Society of Heating R Air-Conditioning Engineers], 2015, ASHRAE POS DOC FILTR; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; ASGHARIAN B, 1992, AEROSOL SCI TECH, V17, P263, DOI 10.1080/02786829208959575; BENBOUGH JE, 1967, J GEN MICROBIOL, V47, P325, DOI 10.1099/00221287-47-3-325; Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; Clifton IJ, 2010, J CYST FIBROS, V9, P64, DOI 10.1016/j.jcf.2009.11.004; Cox C. S., 1995, BIOAEROSOLS HDB; Cox CS., 1987, AEROBIOLOGICAL PATHW; DAHL TA, 1989, J BACTERIOL, V171, P2188, DOI 10.1128/jb.171.4.2188-2194.1989; Edwards DA, 2004, P NATL ACAD SCI USA, V101, P17383, DOI 10.1073/pnas.0408159101; Frostling H., 1973, J AEROSOL SCI, V4, P411, DOI [10.1016/0021-8502(73)90030-x, DOI 10.1016/0021-8502(73)90030-X]; GOLDBERG LJ, 1971, APPL MICROBIOL, V21, P244, DOI 10.1128/AEM.21.2.244-252.1971; GOLDBERG LJ, 1958, AM J HYG, V68, P85, DOI 10.1093/oxfordjournals.aje.a119954; GRUEL RL, 1987, J AEROSOL SCI, V18, P17, DOI 10.1016/0021-8502(87)90004-8; Hairston PP, 1997, J AEROSOL SCI, V28, P471, DOI 10.1016/S0021-8502(96)00448-X; HALLIWELL B, 1978, CELL BIOL INT REP, V2, P113, DOI 10.1016/0309-1651(78)90032-2; HESS GE, 1965, APPL MICROBIOL, V13, P781, DOI 10.1128/AEM.13.5.781-787.1965; Hinds W.C, 1999, AEROSOL TECHNOLOGY P; Holmgren H, 2010, J AEROSOL SCI, V41, P439, DOI 10.1016/j.jaerosci.2010.02.011; JANNING B, 1994, J APPL BACTERIOL, V77, P319, DOI 10.1111/j.1365-2672.1994.tb03080.x; Johnson G, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020126; Johnson GR, 2008, J AEROSOL SCI, V39, P850, DOI 10.1016/j.jaerosci.2008.05.005; Johnson GR, 2011, J AEROSOL SCI, V42, P839, DOI 10.1016/j.jaerosci.2011.07.009; Johnson GR, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005657; Johnson GR, 2004, J AEROSOL SCI, V35, P443, DOI 10.1016/j.jaerosci.2003.10.008; Johnson GR, 2009, J AEROSOL MED PULM D, V22, P229, DOI 10.1089/jamp.2008.0720; Kidd TJ, 2011, J CLIN MICROBIOL, V49, P263, DOI 10.1128/JCM.01421-10; Kidd TJ, 2009, J CLIN MICROBIOL, V47, P1503, DOI 10.1128/JCM.00014-09; Kim J, 2009, J ANTIMICROB CHEMOTH, V63, P129, DOI 10.1093/jac/dkn462; Knibbs LD, 2014, THORAX, V69, P740, DOI 10.1136/thoraxjnl-2014-205213; KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.micro.47.1.855; Kramer A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-130; Kreidenweis SM, 2005, ATMOS CHEM PHYS, V5, P1357, DOI 10.5194/acp-5-1357-2005; Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582; MACHER JM, 1989, AM IND HYG ASSOC J, V50, P561, DOI 10.1080/15298668991375164; MCMURRY PH, 1989, ATMOS ENVIRON, V23, P497, DOI 10.1016/0004-6981(89)90593-3; Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002; Morawska L, 2009, ENVIRON SCI TECHNOL, V43, P1015, DOI 10.1021/es802193n; Neidhardt FC, 1992, PHYSL BACTERIAL CELL, P124; Nicas M, 2005, J OCCUP ENVIRON HYG, V2, P143, DOI 10.1080/15459620590918466; REYNOLDS HY, 1984, DM-DIS MON, V30, P1, DOI 10.1016/0011-5029(84)90008-7; SATTAR SA, 1987, CRIT REV ENV CONTR, V17, P89, DOI 10.1080/10643388709388331; Sutton TA, 2005, ANAL AEROSOL AGING R; TANG IN, 1993, ATMOS ENVIRON A-GEN, V27, P467, DOI 10.1016/0960-1686(93)90204-C; Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426; Todar K, 2015, TXB BACTERIOLOGY; Verreault D, 2011, APPL ENVIRON MICROB, V77, P491, DOI 10.1128/AEM.01391-10; Wainwright CE, 2009, THORAX, V64, P926, DOI 10.1136/thx.2008.112466; Wexler A. S., 2002, J GEOPHYS RES-ATMOS, V7, DOI [10.1029/ 2001jd000451, 2002., DOI 10.1029/2001JD000451]; Yang W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021481; Yao M., 2008, REMOVAL VOLATILE ORG	53	12	12	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158763	10.1371/journal.pone.0158763	http://dx.doi.org/10.1371/journal.pone.0158763			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3OC	27388489	Green Published, Green Submitted, gold			2023-01-03	WOS:000379811500044
J	Nath, K; Nelson, DS; Putt, ME; Leeper, DB; Garman, B; Nathanson, KL; Glickson, JD				Nath, Kavindra; Nelson, David S.; Putt, Mary E.; Leeper, Dennis B.; Garman, Bradley; Nathanson, Katherine L.; Glickson, Jerry D.			Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice	PLOS ONE			English	Article							INTRACELLULAR PH; INDUCED ACIDIFICATION; TUMOR; BRAF; CYTOTOXICITY; INHIBITION; METABOLISM; BREAST; MELANOGENESIS; ENHANCEMENT	Previous NMR studies demonstrated that lonidamine (LND) selectively diminishes the intracellular pH (pHi) of DB-1 melanoma and mouse xenografts of a variety of other prevalent human cancers while decreasing their bioenergetic status (tumor beta NTP/Pi ratio) and enhancing the activities of melphalan and doxorubicin in these cancer models. Since melphalan and doxorubicin are highly toxic agents, we have examined three other nitrogen (N)-mustards, chlorambucil, cyclophosphamide and bendamustine, to determine if they exhibit similar potentiation by LND. As single agents LND, melphalan and these N-mustards exhibited the following activities in DB-1 melanoma xenografts; LND: 100% tumor surviving fraction (SF); chlorambucil: 100% SF; cyclophosphamide: 100% SF; bendamustine: 79% SF; melphalan: 41% SF. When combined with LND administered 40 min prior to administration of the N-mustard (to maximize intracellular acidification) the following responses were obtained; chlorambucil: 62% SF; cyclophosphamide: 42% SF; bendamustine: 36% SF; melphalan: 10% SF. The effect of LND on the activities of these N-mustards is generally attributed to acid stabilization of the aziridinium active intermediate, acid inhibition of glutathione-S-transferase, which acts as a scavenger of aziridinium, and acid inhibition of DNA repair by O-6-alkyltransferase. Depletion of ATP by LND may also decrease multidrug resistance and increase tumor response. At similar maximum tolerated doses, our data indicate that melphalan is the most effective N-mustard in combination with LND when treating DB-1 melanoma in mice, but the choice of N-mustard for coadministration with LND will also depend on the relative toxicities of these agents, and remains to be determined.	[Nath, Kavindra; Nelson, David S.; Glickson, Jerry D.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Putt, Mary E.] Univ Penn, Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Garman, Bradley; Nathanson, Katherine L.] Univ Penn, Div Translat Med & Human Genet, Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Nathanson, Katherine L.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Leeper, Dennis B.] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Jefferson University	Nath, K (corresponding author), Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA.	kavindra.nath@uphs.upenn.edu	Glickson, Jerry/AAR-7116-2021		NIH [R01-CA129544, R01-CA172820]; NATIONAL CANCER INSTITUTE [R01CA129544, R01CA172820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by NIH grants R01-CA129544 and R01-CA172820.; Jeff Roman and Kevin Muriuki are acknowledged for their help to perform this study. Support for this project was provided in part by NIH grants R01-CA129544 and R01-CA172820.	ATEMA A, 1993, INT J CANCER, V54, P166, DOI 10.1002/ijc.2910540126; Barnouin K, 1998, BRIT J CANCER, V77, P201, DOI 10.1038/bjc.1998.34; Ben-Yoseph O, 1998, J NEURO-ONCOL, V36, P149, DOI 10.1023/A:1005819604858; BENHORIN H, 1995, CANCER RES, V55, P2814; BERD D, 1989, CANCER RES, V49, P6840; Bro AYAA, 2016, ONCOTARGET, DOI 10.18632/oncotarget.7528; Brozyna AA, 2008, INT J CANCER, V123, P1448, DOI 10.1002/ijc.23664; Brozyna AA, 2013, HUM PATHOL, V44, P2071, DOI 10.1016/j.humpath.2013.02.022; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; de Andrade LF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998119; Demidenko E, 2010, INT J RADIAT BIOL, V86, P164, DOI 10.3109/09553000903419304; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Efron B., 1986, STAT SCI, P54; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Gerweck LE, 1996, CANCER RES, V56, P1194; Guo LL, 2016, J BIOL CHEM, V291, P42, DOI 10.1074/jbc.M115.697516; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; HILL LL, 1991, CANCER RES, V51, P4937; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; JAHDE E, 1989, CANCER RES, V49, P2965; JAHDE E, 1991, CANCER CHEMOTH PHARM, V27, P440, DOI 10.1007/BF00685157; JAHDE E, 1993, EUR J CANCER, V29A, P116, DOI 10.1016/0959-8049(93)90587-6; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang YC, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1363; Kuin A, 1999, BRIT J CANCER, V79, P793, DOI 10.1038/sj.bjc.6690127; Leoni LM, 2008, CLIN CANCER RES, V14, P309, DOI 10.1158/1078-0432.CCR-07-1061; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu S, 2006, J IMMUNOTHER, V29, P284, DOI 10.1097/01.cji.0000190168.53793.6b; Lutzky J, 2014, CHIN CLIN ONCOL, V3, DOI 10.3978/j.issn.2304-3865.2014.05.13; Mardor Y, 2000, CANCER RES, V60, P5179; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Nancolas B, 2016, BIOCHEM J, V473, P929, DOI 10.1042/BJ20151120; Nath K, 2015, NMR BIOMED, V28, P395, DOI 10.1002/nbm.3260; Nath K, 2015, NMR BIOMED, V28, P281, DOI 10.1002/nbm.3240; Nath K, 2013, NMR BIOMED, V26, P98, DOI 10.1002/nbm.2824; Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440; Raghunand N, 1999, BRIT J CANCER, V80, P1005, DOI 10.1038/sj.bjc.6690455; Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P309, DOI 10.1016/S0006-2952(98)00306-2; Raghunand N, 2003, BIOCHEM PHARMACOL, V66, P1219, DOI 10.1016/S0006-2952(03)00468-4; Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575; Shestov AA, 2013, ADV EXP MED BIOL, V765, P265, DOI 10.1007/978-1-4614-4989-8_37; Shestov AA, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00135; Shestov AA, 2016, J BIOL CHEM, V291, P5157, DOI 10.1074/jbc.M115.701862; Silva AS, 2009, CANCER RES, V69, P2677, DOI 10.1158/0008-5472.CAN-08-2394; SKARSGARD LD, 1995, ANTICANCER RES, V15, P219; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2009, INT J CANCER, V124, P1470, DOI 10.1002/ijc.24005; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; TANNOCK IF, 1989, CANCER RES, V49, P4373; Thompson JA, 2012, J IMMUNOTHER, V35, P73, DOI 10.1097/CJI.0b013e31823735d6; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wahl ML, 2002, MOL CANCER THER, V1, P617; Wang AX, 2013, IUBMB LIFE, V65, P748, DOI 10.1002/iub.1193; Warburg, 1930, METABOLISM TUMORS; Wong P, 2005, CLIN CANCER RES, V11, P3553, DOI 10.1158/1078-0432.CCR-04-2472; Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105; Zhou R, 2001, ACAD RADIOL, V8, P571, DOI 10.1016/S1076-6332(03)80681-5	63	7	7	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2016	11	6							e0157125	10.1371/journal.pone.0157125	http://dx.doi.org/10.1371/journal.pone.0157125			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1UG	27285585	Green Published, Green Submitted, gold			2023-01-03	WOS:000377564000039
J	Hosker, CMG; Bennett, MI				Hosker, Christian M. G.; Bennett, Michael I.			Delirium and agitation at the end of life	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONFUSION ASSESSMENT METHOD; HOSPITALIZED-PATIENTS; ADVANCED CANCER; CARE; HALOPERIDOL; ANTIPSYCHOTICS; RECOGNITION; PREVALENCE; MANAGEMENT; SETTINGS		[Hosker, Christian M. G.] Leeds & York Partnership Fdn Trust, Leeds Liaison Psychiat Serv, Leeds LS9 7BE, W Yorkshire, England; [Bennett, Michael I.] Univ Leeds, Sch Med, Leeds Inst Hlth Sci, Acad Unit Palliat Care, Leeds LS2 9LJ, W Yorkshire, England	University of Leeds	Hosker, CMG (corresponding author), Leeds & York Partnership Fdn Trust, Leeds Liaison Psychiat Serv, Leeds LS9 7BE, W Yorkshire, England.	christian.hosker@nhs.net	Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349				Agar M, 2015, J AM GERIATR SOC, V63, pS99; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Breitbart W, 2002, PSYCHOSOMATICS, V43, P183, DOI 10.1176/appi.psy.43.3.183; Bush SH, 2014, J PAIN SYMPTOM MANAG, V48, P215, DOI 10.1016/j.jpainsymman.2014.05.009; Bush SH, 2014, J PAIN SYMPTOM MANAG, V48, P231, DOI 10.1016/j.jpainsymman.2013.07.018; Canadian Coalition for Seniors Mental Health, 2010, GUID ASS TREATM DEL; Candy B, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004770.pub2; Cobb JL, 2000, CANCER PRACT, V8, P172, DOI 10.1046/j.1523-5394.2000.84006.x; Cohen MZ, 2009, J PALLIAT CARE, V25, P164, DOI 10.1177/082585970902500303; Crawford GB, 2013, J PALLIAT MED, V16, P1335, DOI 10.1089/jpm.2013.0230; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Dev R, 2012, CURR OPIN SUPPORT PA, V6, P365, DOI 10.1097/SPC.0b013e328356ab4a; Douglas IJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1227; Fang CK, 2008, JPN J CLIN ONCOL, V38, P56, DOI 10.1093/jjco/hym155; Gaudreau JD, 2005, J PAIN SYMPTOM MANAG, V29, P368, DOI 10.1016/j.jpainsymman.2004.07.009; Hosie A, 2014, INT J NURS STUD, V51, P1353, DOI 10.1016/j.ijnurstu.2014.02.005; Hosie A, 2013, PALLIATIVE MED, V27, P486, DOI 10.1177/0269216312457214; Inouye SK, 2014, LANCET PSYCHIAT, V1, P312, DOI 10.1016/S2215-0366(14)70263-9; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Kurita GP, 2011, J CLIN ONCOL, V29, P1297, DOI 10.1200/JCO.2010.32.6884; Lawlor PG, 2014, J PAIN SYMPTOM MANAG, V48, P159, DOI 10.1016/j.jpainsymman.2013.12.245; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; LeGrand SB, 2012, J PAIN SYMPTOM MANAG, V44, P583, DOI 10.1016/j.jpainsymman.2011.10.013; Leonard M, 2008, PALLIATIVE MED, V22, P848, DOI 10.1177/0269216308094520; Leonard MM, 2014, J PAIN SYMPTOM MANAG, V48, P176, DOI 10.1016/j.jpainsymman.2013.10.024; Maltoni M, 2012, J CLIN ONCOL, V30, P1378, DOI 10.1200/JCO.2011.37.3795; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Morita T, 2001, J PAIN SYMPTOM MANAG, V22, P997, DOI 10.1016/S0885-3924(01)00360-8; National Cancer Institute, 2015, DEL PDQ HLTH PROF VE; National Institute for Health and Care Excellence, 2010, DEL PREV DIAGN MAN; Sands MB, 2010, PALLIATIVE MED, V24, P561, DOI 10.1177/0269216310371556; Scotland NHS, 2014, PALL CAR GUID DEL; Seitz DP, 2007, J CLIN PSYCHIAT, V68, P11, DOI 10.4088/JCP.v68n0102; Siddiqi N, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005563.pub3; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229	38	28	29	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 9	2016	353								i3085	10.1136/bmj.i3085	http://dx.doi.org/10.1136/bmj.i3085			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DO5YQ	27283962	Green Submitted			2023-01-03	WOS:000377859500003
J	Moscatelli, F; Messina, G; Valenzano, A; Monda, V; Viggiano, A; Messina, A; Petito, A; Triggiani, AI; Ciliberti, MAP; Monda, M; Capranica, L; Cibelli, G				Moscatelli, Fiorenzo; Messina, Giovanni; Valenzano, Anna; Monda, Vincenzo; Viggiano, Andrea; Messina, Antonietta; Petito, Annamaria; Triggiani, Antonio Ivano; Ciliberti, Michela Anna Pia; Monda, Marcellino; Capranica, Laura; Cibelli, Giuseppe			Functional Assessment of Corticospinal System Excitability in Karate Athletes	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MUSCLE FATIGUE; HUMAN MOTOR CORTEX; ELECTRICAL-STIMULATION; VOLUNTARY CONTRACTION; SOCCER PLAYERS; PLASTICITY; HAND; COORDINATION; RESPONSES	Objectives To investigate the involvement of the primary motor cortex (M1) in the coordination performance of karate athletes through transcranial magnetic stimulation (TMS). Methods Thirteen right-handed male karate athletes (25.0 +/- 5.0 years) and 13 matched non-athlete controls (26.7 +/- 6.2 years) were enrolled. A single-pulse TMS was applied using a figure-eight coil stimulator. Resting motor threshold (rMT) was determined. Surface electromyography was recorded from the first dorsal interosseous muscle. Motor evoked potential (MEP) latencies and amplitudes at rMT, 110%, and 120% of rMT were considered. Functional assessment of the coordination performance was assessed by in-phase (IP) and antiphase (AP) homolateral hand and foot coordination tasks performed at 80, 120, and 180 bpm. Results Compared to controls, athletes showed lower rMT (p<0.01), shorter MEP latency (p<0.01) and higher MEP amplitude (p<0.01), with a significant correlation (r = 0.50, p<0.01) between rMT and MEP latency. Coordination decreased with increasing velocity, and better IP performances emerged compared to AP ones (p<0.001). In general, a high correlation between rMT and coordination tasks was found for both IP and AP conditions. Conclusion With respect to controls, karate athletes present a higher corticospinal excitability indicating the presence of an activity-dependent alteration in the balance and interactions between inhibitory and facilitatory circuits determining the final output from the M1. Furthermore, the high correlation between corticospinal excitability and coordination performance could support sport-specific neurophysiological arrangements.	[Moscatelli, Fiorenzo; Messina, Giovanni; Valenzano, Anna; Petito, Annamaria; Triggiani, Antonio Ivano; Ciliberti, Michela Anna Pia; Cibelli, Giuseppe] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy; [Moscatelli, Fiorenzo; Capranica, Laura] Univ Rome Foro Ital, Dept Motor Human & Hlth Sci, Rome, Italy; [Messina, Giovanni; Monda, Vincenzo; Messina, Antonietta; Monda, Marcellino] Univ Naples 2, Dept Expt Med, Naples, Italy; [Viggiano, Andrea] Univ Salerno, Dept Med & Surg, I-84100 Salerno, Italy	University of Foggia; Foro Italico University of Rome; Universita della Campania Vanvitelli; University of Salerno	Cibelli, G (corresponding author), Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.	giuseppe.cibelli@unifg.it	Messina, Giovanni/AAE-8668-2022; Triggiani, Antonio Ivano/M-6252-2015; MESSINA, ANTONIETTA/K-9366-2016; Messina, Antonietta/AHH-2383-2022; Laura, Capranica/AFW-3460-2022; triggiani, antonio ivano/Q-4701-2019; Cibelli, Giuseppe/AAC-2635-2019; Moscatelli, Fiorenzo/ABC-9536-2020	Messina, Giovanni/0000-0002-0011-867X; Messina, Antonietta/0000-0001-8343-432X; triggiani, antonio ivano/0000-0003-3291-9452; Moscatelli, Fiorenzo/0000-0003-1274-0332; Monda, Vincenzo/0000-0002-6083-5814; Monda, Marcellino/0000-0002-7184-218X; CIBELLI, GIUSEPPE/0000-0002-5371-2584; Capranica, Laura/0000-0003-3073-7655				Adkins DL, 2006, NEURAL CHANGES ASS T, P1776; Babiloni C, 2011, INT J PSYCHOPHYSIOL, V82, P153, DOI 10.1016/j.ijpsycho.2011.08.001; Borckardt JJ, 2006, J ECT, V22, P169, DOI 10.1097/01.yct.0000235923.52741.72; Capranica L, 2005, GERONTOLOGY, V51, P309, DOI 10.1159/000086367; Capranica L, 2004, GERONTOLOGY, V50, P399, DOI 10.1159/000080178; Chaabene H, 2012, SPORTS MED, V42, P829, DOI 10.2165/11633050-000000000-00000; Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0; Cirillo J, 2011, EUR J NEUROSCI, V34, P1847, DOI 10.1111/j.1460-9568.2011.07870.x; Cortis C, 2013, J STRENGTH COND RES, V27, P2989, DOI 10.1519/JSC.0b013e3182897a46; Cortis C, 2011, J STRENGTH COND RES, V25, P135, DOI 10.1519/JSC.0b013e3181bde2ec; Cortis C, 2009, J STRENGTH COND RES, V23, P2458, DOI 10.1519/JSC.0b013e3181bc1b39; Di Russo F, 2006, NEUROSCI LETT, V408, P113, DOI 10.1016/j.neulet.2006.08.085; Golaszewski SM, 2004, NEUROLOGY, V62, P2262, DOI 10.1212/WNL.62.12.2262; Graziano M, 2006, ANNU REV NEUROSCI, V29, P105, DOI 10.1146/annurev.neuro.29.051605.112924; Jensen JL, 2005, J APPL PHYSIOL, V99, P1558, DOI 10.1152/japplphysiol.01408.2004; Kim HS, 1998, PERCEPT MOTOR SKILL, V87, P96, DOI 10.2466/pms.1998.87.1.96; Lee M, 2010, J PHYSIOL-LONDON, V588, P201, DOI 10.1113/jphysiol.2009.183855; Ljubisavljevic M, 1996, ELECTROMYOGR MOTOR C, V101, P281, DOI 10.1016/0924-980X(96)95627-1; Manto M, 2006, J NEUROSCI RES, V83, P177, DOI 10.1002/jnr.20733; McIntyre-Robinson AJK, 2013, J NEUROPHYSIOL, V110, P1039, DOI 10.1152/jn.00266.2013; McKay WB, 1996, MUSCLE NERVE, V19, P1017, DOI 10.1002/mus.880190803; McNevin NH, 2000, PHYS THER, V80, P373, DOI 10.1093/ptj/80.4.373; MILL KR, 1995, NEUROREPORT, V6, P1966, DOI 10.1097/00001756-199510010-00004; Missitzi J, 2011, J PHYSIOL-LONDON, V589, P297, DOI 10.1113/jphysiol.2010.200600; Monfils MH, 2005, NEUROSCIENTIST, V11, P471, DOI 10.1177/1073858405278015; Mori S, 2002, HUM MOVEMENT SCI, V21, P213, DOI 10.1016/S0167-9457(02)00103-3; Moscatelli F, 2015, BIOL MED ALIGARH, V1, DOI [10.4172/0974-8369.1000s3008, DOI 10.4172/0974-8369.1000S3008]; Nielsen JB, 2008, J PHYSIOL-LONDON, V586, P65, DOI 10.1113/jphysiol.2007.142661; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Pearce AJ, 2000, EXP BRAIN RES, V130, P238, DOI 10.1007/s002219900236; Perez MA, 2004, EXP BRAIN RES, V159, P197, DOI 10.1007/s00221-004-1947-5; Pesce C, 2001, J PSYCHOPHYSIOL, V15, P256, DOI 10.1027//0269-8803.15.4.256; Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967; Roberts RE, 2013, NEUROSCIENTIST, V19, P8, DOI 10.1177/1073858411421218; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Schieber MH, 2001, J NEUROPHYSIOL; Selvanayagam VS, 2011, J APPL PHYSIOL, V111, P367, DOI 10.1152/japplphysiol.00064.2011; Serrien DJ, 2000, J GERONTOL B-PSYCHOL, V55, pP295, DOI 10.1093/geronb/55.5.P295; Svensson P, 2006, EXP BRAIN RES, V173, P165, DOI 10.1007/s00221-006-0380-3; Tan KSY, 2004, J SPORT SOC ISSUES, V28, P169, DOI 10.1177/0193723504264772; Taylor JL, 1996, J PHYSIOL-LONDON, V490, P519, DOI 10.1113/jphysiol.1996.sp021163; Tergau F, 2000, MED SCI SPORT EXER, V32, P1942, DOI 10.1097/00005768-200011000-00019; Tessitore A, 2011, J STRENGTH COND RES, V25, P3059, DOI 10.1519/JSC.0b013e318212e3e3; Todd G, 2009, J APPL PHYSIOL, V106, P1593, DOI 10.1152/japplphysiol.91364.2008; Tyc F, 2005, EUR J NEUROSCI, V21, P259, DOI 10.1111/j.1460-9568.2004.03835.x; Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035; Veldman MP, 2015, EUR J APPL PHYSIOL, V115, P2505, DOI 10.1007/s00421-015-3248-z; Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wu CWH, 2005, NEUROIMAGE, V27, P872, DOI 10.1016/j.neuroimage.2005.05.055	51	40	41	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2016	11	5							e0155998	10.1371/journal.pone.0155998	http://dx.doi.org/10.1371/journal.pone.0155998			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2FY	27218465	Green Published, gold, Green Submitted			2023-01-03	WOS:000376880700034
J	Hart, JL; Halpern, SD				Hart, Joanna L.; Halpern, Scott D.			Between a Rock and a Hard Place: Terminating Cardiopulmonary Resuscitation and Preserving Opportunities for Organ Donation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CIRCULATORY DETERMINATION; UNCONTROLLED DONATION; DEATH; GUIDELINES		Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Hart, JL (corresponding author), Univ Penn, Blockley Hall 734,423 Guardian Dr, Philadelphia, PA 19104 USA.							Bernat JL, 2010, CRIT CARE MED, V38, P963, DOI 10.1097/CCM.0b013e3181c58916; Gries CJ, 2013, AM J RESP CRIT CARE, V188, P103, DOI 10.1164/rccm.201304-0714ST; Halpern SD, 2014, ANN EMERG MED, V63, P401, DOI 10.1016/j.annemergmed.2013.09.020; Halpern SD, 2010, CRIT CARE MED, V38, P1011, DOI 10.1097/CCM.0b013e3181cc1228; Hart JL, 2015, JAMA INTERN MED, V175, P1019, DOI 10.1001/jamainternmed.2015.0372; Jabre P, 2016, ANN INTERN MED, V165, P770, DOI 10.7326/M16-0402; Mancini ME, 2015, CIRCULATION, V132, pS383, DOI 10.1161/CIR.0000000000000254; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Ortega-Deballon I, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0985-7; Wall SP, 2016, ANN EMERG MED, V67, P531, DOI 10.1016/j.annemergmed.2015.09.017	10	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 6	2016	165	11					820	+		10.7326/M16-2056	http://dx.doi.org/10.7326/M16-2056			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EE0KO	27617432				2023-01-03	WOS:000389263900015
J	Sayah, MY; Chabir, R; Benyahia, H; Kandri, YR; Chahdi, FO; Touzani, H; Errachidi, F				Sayah, Mohamed Yassine; Chabir, Rachida; Benyahia, Hamid; Kandri, Youssef Rodi; Chahdi, Fouad Ouazzani; Touzani, Hanan; Errachidi, Faouzi			Yield, Esterification Degree and Molecular Weight Evaluation of Pectins Isolated from Orange and Grapefruit Peels under Different Conditions	PLOS ONE			English	Article							MODIFIED CITRUS PECTIN; RHEOLOGICAL PROPERTIES; EXTRACTION; VISCOSITY; ACID; FRUIT; MICROWAVE; GROWTH; SUGARS; CONFORMATION	Orange (Citrus sinensis) and grapefruit (Citrus paradise) peels were used as a source of pectin, which was extracted under different conditions. The peels are used under two states: fresh and residual (after essential oil extraction). Organic acid (citric acid) and mineral acid (sulfuric acid) were used in the pectin extraction. The aim of this study is the evaluation the effect of extraction conditions on pectin yield, degree of esterification "DE" and on molecular weight "Mw". Results showed that the pectin yield was higher using the residual peels. Moreover, both peels allow the obtainment of a high methoxyl pectin with DE >50%. The molecular weight was calculated using Mark-Houwink-Sakurada equation which describes its relationship with intrinsic viscosity. This later was determined using four equations; Huggins equation, kramer, Schulz-Blaschke and Martin equation. The molecular weight varied from 1.538x10(05) to 2.47x10(05) g/mol for grapefruit pectin and from 1.639x10(05) to 2.471x10(05) g/mol for orange pectin.	[Sayah, Mohamed Yassine; Kandri, Youssef Rodi; Chahdi, Fouad Ouazzani; Touzani, Hanan] Univ Sidi Mohamed Ben Abdellah, Fac Sci & Technol, Lab Appl Organ Chem, Fes, Morocco; [Chabir, Rachida] Univ Sidi Mohamed Ben Abdellah, Fac Med & Pharm, Lab Pathophysiol & Nutr, Fes, Morocco; [Benyahia, Hamid] INRA, Lab Ameliorat & Biotechnol Agrumes, Kenitra, Morocco; [Errachidi, Faouzi] Univ Hassan II Ain Chock, Fac Sci, Lab Physiol & Mol Genet, Casablanca, Morocco	Sidi Mohamed Ben Abdellah University of Fez; Mohammed First University of Oujda; Sidi Mohamed Ben Abdellah University of Fez; Hassan II University of Casablanca	Sayah, MY (corresponding author), Univ Sidi Mohamed Ben Abdellah, Fac Sci & Technol, Lab Appl Organ Chem, Fes, Morocco.	mohamedyassine.sayah@usmba.ac.ma						Bagherian H, 2011, CHEM ENG PROCESS, V50, P1237, DOI 10.1016/j.cep.2011.08.002; BATISSE C, 1994, J FOOD SCI, V59, P389, DOI 10.1111/j.1365-2621.1994.tb06974.x; Brain C, 1985, US patents, Patent No. [4,532,143, 4532143]; Brown L, 1999, AM J CLIN NUTR, V69, P30; Chamberlain EK, 2000, FOOD HYDROCOLLOID, V14, P163, DOI 10.1016/S0268-005X(99)00063-6; Chen CH, 2006, BIOCHEM PHARMACOL, V72, P1001, DOI 10.1016/j.bcp.2006.07.001; CHEN TS, 1967, J COLLOID INTERF SCI, V25, P346, DOI 10.1016/0021-9797(67)90040-9; CHOU TD, 1987, J FOOD SCI, V52, P1658, DOI 10.1111/j.1365-2621.1987.tb05900.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Eddy NO, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/254347; El Madani, 2014, INT J INNOV RES SCI, V03, P15658, DOI DOI 10.15680/IJIRSET.2014.0308078; Eliaz I, 2006, PHYTOTHER RES, V20, P859, DOI 10.1002/ptr.1953; Evageliou V, 2005, FOOD HYDROCOLLOID, V19, P1032, DOI 10.1016/j.foodhyd.2005.01.004; Fishman ML, 2003, BIOMACROMOLECULES, V4, P880, DOI 10.1021/bm020122e; Fishman ML, 2000, CARBOHYD RES, V323, P126; Guo XF, 2012, CARBOHYD POLYM, V88, P441, DOI 10.1016/j.carbpol.2011.12.026; HARDING SE, 1991, CARBOHYD POLYM, V16, P1, DOI 10.1016/0144-8617(91)90069-O; Higiro J, 2007, FOOD RES INT, V40, P435, DOI 10.1016/j.foodres.2006.02.002; HM Shekhar Pandharipande, 2012, ENG RES STUD; Hua X, 2015, FOOD HYDROCOLLOID, V44, P122, DOI 10.1016/j.foodhyd.2014.09.026; Hwang J, 1998, J FOOD SCI, V63, P10, DOI [10.1111/j.1365-2621.1998.tb17911.x, DOI 10.1111/J.1365-2621]; Iacomini M, 2005, FITOTERAPIA, V76, P676, DOI 10.1016/j.fitote.2005.08.017; Kanmani P., 2014, IRANICA J ENERGY ENV, V5, P303, DOI DOI 10.5829/IDOSI.IJEE.2014.05.03.10; Kar F, 1999, CARBOHYD POLYM, V40, P285, DOI 10.1016/S0144-8617(99)00063-6; Kar F, 1999, CARBOHYD POLYM, V40, P277, DOI 10.1016/S0144-8617(99)00062-4; KRATCHANOVA M, 1994, CARBOHYD POLYM, V25, P141, DOI 10.1016/0144-8617(94)90197-X; Kurita O, 2008, CARBOHYD POLYM, V74, P725, DOI 10.1016/j.carbpol.2008.04.033; Kuuva T, 2003, FOOD HYDROCOLLOID, V17, P679, DOI 10.1016/S0268-005X(03)00034-1; Lapasin R., 1995, RHEOLOGY IND POLYSAC, P134, DOI DOI 10.1007/978-1-4615-2185-3_2; Liu Y, 2002, J SCI FOOD AGR, V82, P469, DOI 10.1002/jsfa.1037; Liu Y, 2001, J AGR FOOD CHEM, V49, P3051, DOI 10.1021/jf001020n; Methacanon P, 2014, FOOD HYDROCOLLOID, V35, P383, DOI 10.1016/j.foodhyd.2013.06.018; Minjares-Fuentes R, 2014, CARBOHYD POLYM, V106, P179, DOI 10.1016/j.carbpol.2014.02.013; Morris E. R., 1981, Carbohydrate Polymers, V1, P5, DOI 10.1016/0144-8617(81)90011-4; Morris GA, 2000, FOOD HYDROCOLLOID, V14, P227, DOI 10.1016/S0268-005X(00)00007-2; Morris GA, 2008, FOOD HYDROCOLLOID, V22, P1435, DOI 10.1016/j.foodhyd.2007.09.005; Nangia-Makker P, 2002, JNCI-J NATL CANCER I, V94, P1854, DOI 10.1093/jnci/94.24.1854; Nangia-Makker P, 2002, TRENDS MOL MED, V8, P187, DOI 10.1016/S1471-4914(02)02295-5; Niture S. K., 2013, American Journal of Pharmacology and Toxicology, V8, P9; PANCHEV I, 1988, INT J FOOD SCI TECH, V23, P337; PHATAK L, 1988, J FOOD SCI, V53, P830, DOI 10.1111/j.1365-2621.1988.tb08964.x; PLATT D, 1992, J NATL CANCER I, V84, P438, DOI 10.1093/jnci/84.6.438; Popov SV, 1999, INT J IMMUNOPHARMACO, V21, P617, DOI 10.1016/S0192-0561(99)00032-6; Ralet MC, 2001, CARBOHYD RES, V336, P117, DOI 10.1016/S0008-6215(01)00248-8; Rao DG, 1993, J FOOD SCI TECHNOLOG, P66; Rlcxiillan DE, 1974, COMP 5 METHODS OBTAI, V13, P1367; Ross-Murphy S.B., 1994, PHYS TECHNIQUES STUD, DOI [10.1007/978-1-4615-2101-3, DOI 10.1007/978-1-4615-2101-3]; SABIR MA, 1976, J AGR FOOD CHEM, V24, P348, DOI 10.1021/jf60204a049; Santos JDG, 2013, CARBOHYD POLYM, V92, P1997, DOI 10.1016/j.carbpol.2012.11.089; Sayah M. Y., 2014, International Journal of Innovation and Applied Studies, V7, P1642; SMIDSROD O, 1971, BIOPOLYMERS, V10, P1213, DOI 10.1002/bip.360100711; Thakur BR, 1997, CRIT REV FOOD SCI, V37, P47, DOI 10.1080/10408399709527767; Wai WW, 2010, FOOD BIOPROD PROCESS, V88, P209, DOI 10.1016/j.fbp.2010.01.010; Wanchoo RK, 2003, EUR POLYM J, V39, P1481, DOI 10.1016/S0014-3057(02)00386-5; Wang XS, 2005, CARBOHYD POLYM, V60, P95, DOI 10.1016/j.carbpol.2004.11.031; Yapo BM, 2009, J AGR FOOD CHEM, V57, P1572, DOI 10.1021/jf802969m; Yoo SH, 2006, FOOD HYDROCOLLOID, V20, P62, DOI 10.1016/j.foodhyd.2005.03.003; Zhou JH, 2008, J CENT SOUTH UNIV T, V15, P520, DOI 10.1007/s11771-008-0413-0	58	60	61	6	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2016	11	9							e0161751	10.1371/journal.pone.0161751	http://dx.doi.org/10.1371/journal.pone.0161751			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW8GC	27644093	Green Submitted, gold, Green Published			2023-01-03	WOS:000383891900004
J	Tian, W; Yuan, JF; Yang, D; Zhang, LJ				Tian, Wei; Yuan, Jiangfan; Yang, Dong; Zhang, Lanjing			Descriptive Analysis on the Impacts of Universal Zero-Markup Drug Policy on a Chinese Urban Tertiary Hospital	PLOS ONE			English	Article							PRESCRIBING ERRORS; MEDICINES; PROVINCE; IMPLEMENTATION; INPATIENTS; WORKLOAD	Background Universal Zero-Markup Drug Policy (UZMDP) mandates no price mark-ups on any drug dispensed by a healthcare institution, and covers the medicines not included in the China's National Essential Medicine System. Five tertiaryhospitals in Beijing, China implemented UZMDP in 2012. Its impacts on these hospitals are unknown. We described the effects of UZMDP on a participating hospital, Jishuitan Hospital, Beijing, China (JST). Methods This retrospective longitudinal study examined the hospital-level data of JST and city-level data of tertiaryhospitals of Beijing, China (BJT) 2009-2015. Rank-sum tests and join-point regression analyses were used to assess absolute changes and differences in trends, respectively. Results In absolute terms, after the UZDMP implementation, there were increased annual patient-visits and decreased ratios of medicine-to-healthcare-charges(RMOH) in JST outpatient and inpatient services; however, in outpatient service, physician work-days decreased and physician- workload and inflation-adjusted per-visit healthcare charges increased, while the inpatient physician work-days increased and inpatient mortality-ratereduced. Interestingly, the decreasing trend in inpatient mortality-ratewas neutralized after UZDMP implementation. Compared with BJT and under influence of UZDMP, JST outpatient and inpatient services both had increasing trends in annual patient-visits (annual percentage changes[APC] = 8.1% and 6.5%, respectively) and decreasing trends in RMOH (APC = -4.3% and -5.4%,respectively), while JST outpatient services had increasing trend in inflation-adjusted per-visit healthcare charges (APC = 3.4%) and JST inpatient service had decreasing trend in inflation-adjusted per-visit medicine-charges (APC = -5.2%). Conclusion Implementation of UZMDP seems to increase annual patient- visits, reduce RMOH and have different impacts on outpatient and inpatient services in a Chinese urban tertiary hospital.	[Tian, Wei] Jishuitan Hosp, Dept Spine Surg, Beijing, Peoples R China; [Yuan, Jiangfan] Jishuitan Hosp, Off Patient Phys Relationship, Beijing, Peoples R China; [Yang, Dong] Jishuitan Hosp, Off Performance Management, Beijing, Peoples R China; [Zhang, Lanjing] Univ Med Ctr Princeton, Dept Pathol, Plainsboro, NJ 08536 USA; [Zhang, Lanjing] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA; [Zhang, Lanjing] Rutgers State Univ, RobertWood Johnson Med Sch, Dept Pathol, New Brunswick, NJ 08854 USA; [Zhang, Lanjing] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Zhang, LJ (corresponding author), Univ Med Ctr Princeton, Dept Pathol, Plainsboro, NJ 08536 USA.; Zhang, LJ (corresponding author), Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.; Zhang, LJ (corresponding author), Rutgers State Univ, RobertWood Johnson Med Sch, Dept Pathol, New Brunswick, NJ 08854 USA.; Zhang, LJ (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA.	ljzhang@hotmail.com	Zhang, Lanjing/GZB-0260-2022; Zhang, Lanjing/AGY-7838-2022	Zhang, Lanjing/0000-0001-5436-887X				BIHM, 2013, BRIEFINGS ON THE HEA; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Deveugele M, 2002, BRIT MED J, V325, P472, DOI 10.1136/bmj.325.7362.472; Elliott DJ, 2014, JAMA INTERN MED, V174, P786, DOI 10.1001/jamainternmed.2014.300; Fang Y, 2013, LANCET GLOB HEALTH, V1, pE227, DOI 10.1016/S2214-109X(13)70072-X; Gong YH, 2016, HEALTH POLICY PLANN, V31, P21, DOI 10.1093/heapol/czv008; Gong YH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0103242, 10.1371/journal.pone.0095597]; Kee F, 1999, BRIT MED J, V318, P1381, DOI 10.1136/bmj.318.7195.1381; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Ma XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140568; Meng Q, 2012, LANCET, V379, P805, DOI 10.1016/S0140-6736(12)60278-5; Michtalik HJ, 2013, JAMA INTERN MED, V173, P375, DOI 10.1001/jamainternmed.2013.1864; NBSC, 2015, ANN STAT STAT CHIN; Pannick S, 2015, JAMA INTERN MED, V175, P1288, DOI 10.1001/jamainternmed.2015.2421; Ross S, 2013, BMJ QUAL SAF, V22, P97, DOI 10.1136/bmjqs-2012-001175; Song Yan, 2014, J Pharm Policy Pract, V7, P12, DOI 10.1186/2052-3211-7-12; Starmer AJ, 2013, JAMA-J AM MED ASSOC, V310, P2262, DOI 10.1001/jama.2013.281961; Valentino L, 2022, RSF-RUS SAGE J SOC S, V8, P89, DOI [10.18311/ti/2021/v28i1/24809, 10.1097/QAD.0000000000003368, 10.1016/j.vaccine.2022.07.056, 10.7758/RSF.2022.8.7.05]; Wang J, 2013, CHINA PHARM, V23, P2982, DOI DOI 10.6039/J.ISSN.1001-0408.2012.32.03; Wang JY, 2015, INDIAN J PHARMACOL, V47, P535, DOI 10.4103/0253-7613.165192; Xu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138948; Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1; Yang LP, 2013, HEALTH POLICY PLANN, V28, P750, DOI 10.1093/heapol/czs116; Yi HM, 2015, HEALTH AFFAIR, V34, P1391, DOI 10.1377/hlthaff.2014.1114; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Zhang X, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006471; Zhou ZL, 2015, J ASIAN PUBLIC POLIC, V8, P102, DOI 10.1080/17516234.2015.1005561; Zhou ZL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121630	28	13	16	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2016	11	9							e0162795	10.1371/journal.pone.0162795	http://dx.doi.org/10.1371/journal.pone.0162795			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5JO	27627811	Green Published, Green Submitted, gold			2023-01-03	WOS:000383680600054
J	Powell, MK; Benkova, K; Selinger, P; Dogosi, M; Lunackova, IK; Koutnikova, H; Lastikova, J; Roubickova, A; Spurkova, Z; Laclova, L; Eis, V; Sach, J; Heneberg, P				Powell, Marta K.; Benkova, Kamila; Selinger, Pavel; Dogosi, Marek; Lunackova, Iva Kinkorova; Koutnikova, Hana; Lastikova, Jarmila; Roubickova, Alena; Spurkova, Zuzana; Laclova, Lucie; Eis, Vaclav; Sach, Josef; Heneberg, Petr			Opportunistic Infections in HIV-Infected Patients Differ Strongly in Frequencies and Spectra between Patients with Low CD4(+) Cell Counts Examined Postmortem and Compensated Patients Examined Antemortem Irrespective of the HAART Era	PLOS ONE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS-DEFINING ILLNESSES; POSITIVE PATIENTS; VIRUS-INFECTION; AUTOPSIED PATIENTS; CHANGING PATTERNS; NECROPSY FINDINGS; DEATH; MORTALITY; BACTEREMIA	Objective AIDS-related mortality has changed dramatically with the onset of highly active antiretroviral therapy (HAART), which has even allowed compensated HIV-infected patients to withdraw from secondary therapy directed against opportunistic pathogens. However, in recently autopsied HIV-infected patients, we observed that associations with a broad spectrum of pathogens remain, although detailed analyses are lacking. Therefore, we focused on the possible frequency and spectrum shifts in pathogens associated with autopsied HIV-infected patients. Design We hypothesized that the pathogens frequency and spectrum changes found in HIV-infected patients examined postmortem did not recapitulate the changes found previously in HIV-infected patients examined antemortem in both the pre-and post-HAART eras. Because this is the first comprehensive study originating from Central and Eastern Europe, we also compared our data with those obtained in the West and Southwest Europe, USA and Latin America. Methods We performed autopsies on 124 HIV-infected patients who died from AIDS or other co-mor-bidities in the Czech Republic between 1985 and 2014. The pathological findings were retrieved from the full postmortem examinations and autopsy records. Results We collected a total of 502 host-pathogen records covering 82 pathogen species, a spectrum that did not change according to patients' therapy or since the onset of the epidemics, which can probably be explained by the fact that even recently deceased patients were usually decompensated (in 95% of the cases, the last available CD4(+) cell count was falling below 200 cells*mu l-1) regardless of the treatment they received. The newly identified pathogen taxa in HIV-infected patients included Acinetobacter calcoaceticus, Aerococcus viridans and Escherichia hermannii. We observed a very limited overlap in both the spectra and frequencies of the pathogen species found postmortem in HIV-infected patients in Europe, the USA and Latin America. Conclusions The shifts documented previously in compensated HIV-infected patients examined antemortem in the post-HAART era are not recapitulated in mostly decompensated HIV-infected patients examined postmortem.	[Powell, Marta K.; Eis, Vaclav; Sach, Josef; Heneberg, Petr] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Powell, Marta K.; Benkova, Kamila; Selinger, Pavel; Dogosi, Marek; Lunackova, Iva Kinkorova; Koutnikova, Hana; Lastikova, Jarmila; Roubickova, Alena; Spurkova, Zuzana; Laclova, Lucie] Na Bulovce Hosp, Pathol Anat Dept, Prague, Czech Republic; [Selinger, Pavel; Laclova, Lucie] Charles Univ Prague, Fac Med 2, Dept Forens Med, Prague, Czech Republic; [Dogosi, Marek] Charles Univ Prague, Fac Med 1, Dept Forens Med & Toxicol, Prague, Czech Republic; [Lunackova, Iva Kinkorova] Biopticka Lab Sro, Plzen, Czech Republic; [Eis, Vaclav; Sach, Josef] Teaching Hosp Kralovske Vinohrady, Dept Pathol, Prague, Czech Republic	Charles University Prague; Bulovka University Hospital; Charles University Prague; Charles University Prague; University Hospital Vinohrady	Heneberg, P (corresponding author), Charles Univ Prague, Fac Med 3, Prague, Czech Republic.	petr.heneberg@lf3.cuni.cz	Heneberg, Petr/C-1881-2012; Powell, Marta/E-1317-2017; Walmsley, Alena/G-7471-2018	Heneberg, Petr/0000-0002-0703-951X; Powell, Marta/0000-0002-3277-0873; Walmsley, Alena/0000-0001-7316-6472	Charles University in Prague [UNCE 204015, PRVOUK P31/2012, GAUK 235215, 260276/SVV/2016]; Czech Science Foundation [15-03834Y]	Charles University in Prague; Czech Science Foundation(Grant Agency of the Czech Republic)	This study was supported by the Charles University in Prague projects UNCE 204015, PRVOUK P31/2012, GAUK 235215 and 260276/SVV/2016, and by the Czech Science Foundation project 15-03834Y. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; BRENNER DJ, 1982, J CLIN MICROBIOL, V15, P703, DOI 10.1128/JCM.15.4.703-713.1982; Cox JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033685; Cox JA, 2010, AIDS REV, V12, P183; Cury PM, 2003, PATHOL RES PRACT, V199, P811, DOI 10.1078/0344-0338-00500; Dang AT, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-153; Eza D, 2006, PATHOL RES PRACT, V202, P767, DOI 10.1016/j.prp.2006.07.005; Garcia-Jardon M, 2010, TROP DOCT, V40, P81, DOI 10.1258/td.2010.090465; Guerra I, 2001, PATHOL RES PRACT, V197, P165, DOI 10.1078/0344-0338-00028; Guimaraes LC, 2012, REV INST MED TROP SP, V54, P89, DOI 10.1590/S0036-46652012000200006; HARVEY RL, 1991, REV INFECT DIS, V13, P139; Hofman P, 1999, PATHOL RES PRACT, V195, P209, DOI 10.1016/S0344-0338(99)80037-5; HUI AN, 1984, HUM PATHOL, V15, P670; Iroezindu M. O., 2013, Journal of AIDS and Clinical Research, P002; Ives NJ, 2001, J INFECTION, V42, P134, DOI 10.1053/jinf.2001.0810; Katano H, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-229; Li P, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0870-7; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; Manfredi R, 1997, Infez Med, V5, P23; Martinelli F, 1999, J CLIN MICROBIOL, V37, P2042, DOI 10.1128/JCM.37.6.2042-2044.1999; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; MICHALANY J, 1987, ANN PATHOL, V7, P15; Mocroft A, 2013, CLIN INFECT DIS, V57, P1038, DOI 10.1093/cid/cit423; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MOHAR A, 1992, AIDS, V6, P467, DOI 10.1097/00002030-199205000-00005; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PILLAY D, 1993, AIDS, V7, P969, DOI 10.1097/00002030-199307000-00010; Popescu GA, 2004, EMERG INFECT DIS, V10, P1335, DOI 10.3201/eid1007.030567; Razeq JH, 1999, EMERG INFECT DIS, V5, P838, DOI 10.3201/eid0506.990622; Soriano V, 2000, AIDS, V14, P282; Tong YQ, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.18138; Uh Y, 2002, J KOREAN MED SCI, V17, P113, DOI 10.3346/jkms.2002.17.1.113; Weber R, 2013, HIV MED, V14, P195, DOI 10.1111/j.1468-1293.2012.01051.x; WILKES MS, 1988, LANCET, V2, P85	34	12	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0162704	10.1371/journal.pone.0162704	http://dx.doi.org/10.1371/journal.pone.0162704			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JE	27611681	Green Published, Green Submitted, gold			2023-01-03	WOS:000383255900152
J	Couzin-Frankel, J				Couzin-Frankel, Jennifer			SECOND CHAPTER	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	2016	353	6303					983	985		10.1126/science.353.6303.983	http://dx.doi.org/10.1126/science.353.6303.983			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU9SU	27701099				2023-01-03	WOS:000382558900017
J	Chang, MT; Tang, H; Liu, D; Li, Y; Zhang, LY				Chang, Mingtao; Tang, Hao; Liu, Dong; Li, Yang; Zhang, Lianyang			Comparison of Melatonin, Hypertonic Saline, and Hydroxyethyl Starch for Resuscitation of Secondary Intra-Abdominal Hypertension in an Animal Model	PLOS ONE			English	Article							ABDOMINAL COMPARTMENT SYNDROME; RATS IN-VIVO; INTERNATIONAL-CONFERENCE; REPERFUSION INJURY; HEMORRHAGIC-SHOCK; INTESTINAL EDEMA; PERMEABILITY; INFLAMMATION; DEFINITIONS; ACTIVATION	A variety of agents may have a beneficial effect in reducing injury-induced intestinal edema of fluid, but studies confirming the efficacy and mechanisms of these agents in secondary intra-abdominal hypertension (IAH) are lacking. This study was to compare the effectiveness of melatonin, 7.5% hypertonic saline (HS), and hydroxyethyl starch 130/0.4 (HES) on the resuscitation of secondary IAH in a rat model. Female SD rats were divided into: sham group, shock group, lactated Ringer solution (LR) group, melatonin group, HS group, and HES group. Except for the sham group, all rats underwent a combination of inducing portal hypertension, hemorrhaging to a MAP of 40 mmHg for 2 hr, and using an abdominal restraint device. The collected blood was reinfused and the rats were treated with LR (30ml/h), melatonin (50 mg/kg) + LR, HS (6 ml/kg) + LR, and HES (30 ml/kg) + LR, respectively. The shock group received no fluids. LR was continuously infused for 6hr. The intestinal permeability, immunofluorescence of tight junction proteins, transmission electron microscopy, level of inflammatory mediators (TNF-a, IL-1 beta, IL-6) and of biochemical markers of oxidative stress (malondialdehyde, myeloperoxidase activity, and glutathione peroxidase) were assessed. Expressions of the protein kinase B (Akt) and of tight junction proteins were detected by Western blot. Compared with LR, HS, and HES, melatonin was associated with less inflammatory and oxidative injury, less intestinal permeability and injury, and lower incidence of secondary IAH in this model. The salutary effect of melatonin in this model was associated with the upregulation of intestinal Akt phosphorylation.	[Chang, Mingtao; Tang, Hao; Liu, Dong; Li, Yang; Zhang, Lianyang] Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Surg Res, Trauma Ctr,Daping Hosp, Chongqing, Peoples R China	Army Medical University	Zhang, LY (corresponding author), Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Surg Res, Trauma Ctr,Daping Hosp, Chongqing, Peoples R China.	dpzhangly@163.com			grant from "New Techniques of Trauma Care" [2012BAI11B01]; grant from "Twelfth-Five-Year Military Vehicle Traffic Safety and Prevention" [BWS12J033]	grant from "New Techniques of Trauma Care"; grant from "Twelfth-Five-Year Military Vehicle Traffic Safety and Prevention"	This work was supported by grants from "New Techniques of Trauma Care" (2012BAI11B01) and "Twelfth-Five-Year Military Vehicle Traffic Safety and Prevention" (BWS12J033).	Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; [Anonymous], 2013, BMJ, V346, pf1222, DOI 10.1136/bmj.f1222; Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Balogh ZJ, 2011, AM SURGEON, V77, pS31; Chang MT, 2014, J SURG RES, V187, P244, DOI 10.1016/j.jss.2013.09.038; Cheatham ML, 2007, INTENS CARE MED, V33, P951, DOI 10.1007/s00134-007-0592-4; Chen G, 2013, CRIT CARE, V17, DOI 10.1186/cc12820; De Keulenaer BL, 2011, AM SURGEON, V77, pS34; HARMAN PK, 1982, ANN SURG, V196, P594, DOI 10.1097/00000658-198211000-00015; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Holodinsky JK, 2013, CRIT CARE, V17, DOI 10.1186/cc13075; Huang Wenxiang, 2015, Zhonghua Yi Xue Za Zhi, V95, P943; Kai-Ian W, 2015, TRANSPL P, V47, P1639, DOI 10.1016/j.transproceed.2015.02.023; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Leng YX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109350; Lima Ricardo Antonio Correia, 2011, Rev Col Bras Cir, V38, P417; Malbrain MLNG, 2006, INTENS CARE MED, V32, P1722, DOI 10.1007/s00134-006-0349-5; Marx G, 2006, CRIT CARE MED, V34, P3005, DOI 10.1097/01.CCM.0000242755.74063.ED; Meier C, 2007, J SURG RES, V139, P209, DOI 10.1016/j.jss.2006.08.002; Miki K, 1996, CLIN CHEM, V42, P71; Oda J, 2006, J TRAUMA, V60, P64, DOI 10.1097/01.ta.0000199431.66938.99; Radhakrishnan RS, 2007, CRIT CARE MED, V35, P538, DOI 10.1097/01.CCM.0000254330.39804.9C; Radhakrishnan RS, 2006, CRIT CARE MED, V34, P1713, DOI 10.1097/01.CCM.0000218811.39686.3D; Reintam A, 2008, INTENS CARE MED, V34, P1624, DOI 10.1007/s00134-008-1134-4; Santa-Teresa P, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-S1-S3; Schachtrupp A, 2007, ACTA CLIN BELG, V62, P225, DOI 10.1179/acb.2007.62.s1.031; Sehajpal J, 2014, J SURG RES, V191, P441, DOI 10.1016/j.jss.2014.04.025; Sehirli AO, 2013, J PINEAL RES, V55, P138, DOI 10.1111/jpi.12054; Sener G, 2003, J PINEAL RES, V35, P163, DOI 10.1034/j.1600-079X.2003.00070.x; Sommansson A, 2013, AM J PHYSIOL-GASTR L, V305, pG95, DOI 10.1152/ajpgi.00074.2013; Sommansson A, 2013, J PINEAL RES, V54, P282, DOI 10.1111/jpi.12013; Urbano J, 2012, RESUSCITATION, V83, P1159, DOI 10.1016/j.resuscitation.2012.02.003; Wisselink W, 1998, J VASC SURG, V27, P109, DOI 10.1016/S0741-5214(98)70297-6; Yu GF, 2012, PULM PHARMACOL THER, V25, P27, DOI 10.1016/j.pupt.2011.10.003; Zhang X, 2015, J HUAZHONG U SCI-MED, V35, P378, DOI 10.1007/s11596-015-1441-2; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254	36	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2016	11	8							e0161688	10.1371/journal.pone.0161688	http://dx.doi.org/10.1371/journal.pone.0161688			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU5NN	27560478	gold, Green Published, Green Submitted			2023-01-03	WOS:000382258600080
J	Mohammed, Y; Teixido, M; Namjoshi, S; Giralt, E; Benson, H				Mohammed, Yousuf; Teixido, Meritxell; Namjoshi, Sarika; Giralt, Ernest; Benson, Heather			Cyclic Dipeptide Shuttles as a Novel Skin Penetration Enhancement Approach: Preliminary Evaluation with Diclofenac	PLOS ONE			English	Article							SOLID-PHASE SYNTHESIS; BRAIN-BARRIER BBB; H-II MESOPHASES; TRANSDERMAL DELIVERY; 5-AMINOLEVULINIC ACID; POTENTIAL USE; AMINO-ACIDS; PEPTIDES; TAT; DIKETOPIPERAZINES	This study demonstrates the effectiveness of a peptide shuttle in delivering diclofenac into and through human epidermis. Diclofenac was conjugated to a novel phenylalanyl-Nmethyl- naphthalenylalanine-derived diketopiperazine (DKP) shuttle and to TAT (a classical cell penetrating peptide), and topically applied to human epidermis in vitro. DKP and TAT effectively permeated into and through human epidermis. When conjugated to diclofenac, both DKP and TAT enhanced delivery into and through human epidermis, though DKP was significantly more effective. Penetration of diclofenac through human epidermis (to receptor) was increased by conjugation to the peptide shuttle and cell penetrating peptide with enhancement of 6x by DKP-diclofenac and 3x by TAT-diclofenac. In addition, the amount of diclofenac retained within the epidermis was significantly increased by peptide conjugation. COX-2 inhibition activity of diclofenac was retained when conjugated to DKP. Our study suggests that the peptide shuttle approach may offer a new strategy for targeted delivery of small therapeutic and diagnostic molecules to the skin.	[Mohammed, Yousuf; Benson, Heather] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm, Perth, WA, Australia; [Mohammed, Yousuf; Namjoshi, Sarika] Univ Queensland, Sch Med, Therapeut Res Ctr, Translat Res Inst, Brisbane, Qld, Australia; [Teixido, Meritxell; Giralt, Ernest] Barcelona Sci & Technol Inst BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain	Curtin University; University of Queensland; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Benson, H (corresponding author), Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm, Perth, WA, Australia.; Giralt, E (corresponding author), Barcelona Sci & Technol Inst BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain.	ernest.giralt@irbbarcelona.org; h.benson@curtin.edu.au	giralt, ernest/N-1669-2014; teixido, meritxell/I-3282-2015; Namjoshi, Sarika/O-1049-2019	giralt, ernest/0000-0001-8381-1797; teixido, meritxell/0000-0002-7825-3695; Namjoshi, Sarika/0000-0002-2697-153X; Mohammed, Yousuf/0000-0002-7825-7557	Institute for Research in Biomedicine and Curtin University	Institute for Research in Biomedicine and Curtin University	Institute for Research in Biomedicine and Curtin University funded the research including materials and a scholarship to YM.	Ali M, 2014, CLIN IMMUNOL, V150, P121, DOI 10.1016/j.clim.2013.10.005; Benson Heather A. E., 2005, Current Drug Delivery, V2, P23, DOI 10.2174/1567201052772915; Biron E, 2006, J PEPT SCI, V12, P213, DOI 10.1002/psc.711; Blobaum AL, 2007, J BIOL CHEM, V282, P16379, DOI 10.1074/jbc.M609883200; Blobaum AL, 2007, J MED CHEM, V50, P1425, DOI 10.1021/jm0613166; Cevc G, 2010, J CONTROL RELEASE, V141, P277, DOI 10.1016/j.jconrel.2009.10.016; Chan LY, 2013, CHEMBIOCHEM, V14, P617, DOI 10.1002/cbic.201300034; Clark RJ, 2010, ANGEW CHEM INT EDIT, V49, P6545, DOI 10.1002/anie.201000620; Cohen-Avrahami M, 2014, COLLOID SURFACE B, V122, P231, DOI 10.1016/j.colsurfb.2014.04.026; Cohen-Avrahami M, 2014, J PHYS CHEM B, V118, P6277, DOI 10.1021/jp412739p; Cohen-Avrahami M, 2012, J CONTROL RELEASE, V159, P419, DOI 10.1016/j.jconrel.2012.01.025; Cohen-Avrahami M, 2011, J PHYS CHEM B, V115, P10189, DOI 10.1021/jp112067v; Cohen-Avrahami M, 2010, COLLOID SURFACE B, V77, P131, DOI 10.1016/j.colsurfb.2010.01.013; Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gan TJ, 2010, CURR MED RES OPIN, V26, P1715, DOI 10.1185/03007995.2010.486301; Gentilucci L, 2010, CURR PHARM DESIGN, V16, P3185, DOI 10.2174/138161210793292555; Goh CF, 2014, INT J PHARMACEUT, V473, P607, DOI 10.1016/j.ijpharm.2014.07.052; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Huang RM, 2014, MAR DRUGS, V12, P6213, DOI 10.3390/md12126213; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; Krishnan G, 2011, BIOPOLYMERS, V96, P166, DOI 10.1002/bip.21520; Krishnan G, 2010, J PHARM SCI-US, V99, P2724, DOI 10.1002/jps.22024; Lopes LB, 2005, PHARM RES-DORDR, V22, P750, DOI 10.1007/s11095-005-2591-x; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Madder A, 1999, EUR J ORG CHEM, V1999, P2787; Manosroi J, 2013, DRUG DEV IND PHARM, V39, P520, DOI 10.3109/03639045.2012.684388; Margus H, 2012, MOL THER, V20, P525, DOI 10.1038/mt.2011.284; Martin GM, 2012, J DRUGS DERMATOL, V11, P600; Martin I, 2013, CURR PHARM DESIGN, V19, P2924; Martins MB, 2007, TETRAHEDRON, V63, P9923, DOI 10.1016/j.tet.2007.04.105; Namjoshi S, 2008, BIOPOLYMERS, V90, P655, DOI 10.1002/bip.21033; Namjoshi S, 2007, J CHROMATOGR B, V852, P49, DOI 10.1016/j.jchromb.2006.12.040; Namjoshi S, 2010, BIOPOLYMERS, V94, P673, DOI 10.1002/bip.21476; Nelson CG, 2011, THER CLIN RISK MANAG, V7, P207, DOI 10.2147/TCRM.S12498; Nohynek GJ, 2007, CRIT REV TOXICOL, V37, P251, DOI 10.1080/10408440601177780; OECD Environment HaSP, 2011, GUID NOT DERM ASS; Oller-Salvia B, 2016, ANGEW CHEM INT EDIT, V55, P572, DOI 10.1002/anie.201508445; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Shah PP, 2012, J CONTROL RELEASE, V161, P735, DOI 10.1016/j.jconrel.2012.05.011; Teixido M, 2005, J PEPT RES, V65, P153, DOI 10.1111/j.1399-3011.2004.00213.x; Teixido M, 2007, J AM CHEM SOC, V129, P11802, DOI 10.1021/ja073522o; Teixido M, 2009, ADV EXP MED BIOL, V611, P227, DOI 10.1007/978-0-387-73657-0_105; Uchida T, 2011, J PHARMACOL EXP THER, V338, P443, DOI 10.1124/jpet.111.180042; Vasconcelos L, 2013, THER DELIV, V4, P573, DOI [10.4155/tde.13.22, 10.4155/TDE.13.22]; Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020; Wang Y, 2013, INT J PHARMACEUT, V441, P748, DOI 10.1016/j.ijpharm.2012.10.019; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yang LH, 1997, TETRAHEDRON LETT, V38, P7307, DOI 10.1016/S0040-4039(97)01774-7; Zane C, 2014, BRIT J DERMATOL, V170, P1143, DOI 10.1111/bjd.12844	50	8	8	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2016	11	8							e0160973	10.1371/journal.pone.0160973	http://dx.doi.org/10.1371/journal.pone.0160973			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TP	27548780	Green Published, Green Submitted, gold			2023-01-03	WOS:000381768400026
J	Ueberschlag, SL; Seay, JR; Roberts, AH; DeSpirito, PC; Stith, JM; Folz, RJ; Carter, KA; Weiss, EP; Zavorsky, GS				Ueberschlag, Seteena L.; Seay, James R.; Roberts, Alexandra H.; DeSpirito, Pamela C.; Stith, Jeremy M.; Folz, Rodney J.; Carter, Kathleen A.; Weiss, Edward P.; Zavorsky, Gerald S.			The Effect of Protandim (R) Supplementation on Athletic Performance and Oxidative Blood Markers in Runners	PLOS ONE			English	Article							LIPID-PEROXIDATION; STRESS; RESPONSES; CARCINOGENESIS; INDUCTION; ENZYMES; MUSCLE; TRIAL; TIME	The purpose of this study determined if oral supplementation of Protandim (R) (a nutraceutical) for 90 days improved 5-km running performance and reduced serum thiobarbituric acid-reacting substances (TBARS) at rest, an indicator of oxidative stress. Secondary objectives were to measure whole blood superoxide dismutase (SOD), glutathione (GSH), and glutathione peroxidase (GPX), at rest and 10 minutes after completion of the race before and after supplementation as well as quality of life. In a double-blind, randomized, placebo controlled trial, 38 runners [mean (SD) = 34 (7) yrs; BMI = 22 (2) kg/m(2)] received either 90 days of Protandim (R) [1 pill a day, n = 19)] or placebo (n = 19). Randomization was done in blocks of two controlling for sex and 5-km baseline performance. A 5-km race was performed at baseline and after 90 days of supplementation, with blood samples taken before and 10-min after each race. Fasting blood samples were acquired at baseline, after 30, 60, and 90 days of supplementation. TBARS, SOD, GPX, and GSH were assayed in an out-of-state accredited lab. Running performance was not altered by Protandim (R) or placebo [20.3 (2.1) minutes, with an -8 (33) seconds change in 5-km time regardless of group]. There was no change in TBARS, SOD, or GPX (at rest) after three months of Protandim (R) supplementation compared to placebo. However, in a subgroup >= 35 years of age, there was a 2-fold higher increase in SOD in those taking Protandim (R) for three months compared to those on placebo (p = 0.038). The mean post-race change in TBARS (compared to pre-race) increased by about 20% in half of the subjects, but was not altered between groups, even after three months of supplementation. Quality of life was also not different between the two conditions. In conclusion, Protandim (R) did not (1) alter 5-km running time, (2) lower TBARS at rest (3) raise antioxidant enzyme concentrations compared to placebo (with exception of SOD in those >= 35 years old) or, (4) affect quality of life compared to placebo.	[Ueberschlag, Seteena L.; Seay, James R.; Roberts, Alexandra H.; Carter, Kathleen A.] Univ Louisville, Dept Hlth & Sport Sci, Louisville, KY 40292 USA; [DeSpirito, Pamela C.] Univ Louisville, Dept Med, Louisville, KY 40292 USA; [Stith, Jeremy M.] Univ Kentucky, Dept Clin Sci, Lexington, KY USA; [Folz, Rodney J.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Weiss, Edward P.] St Louis Univ, Dept Nutr & Dietet, St Louis, MO 63103 USA; [Zavorsky, Gerald S.] Georgia State Univ, Dept Resp Therapy, Atlanta, GA 30303 USA	University of Louisville; University of Louisville; University of Kentucky; Case Western Reserve University; Saint Louis University; University System of Georgia; Georgia State University	Zavorsky, GS (corresponding author), Georgia State Univ, Dept Resp Therapy, Atlanta, GA 30303 USA.	zavorsky@gsu.edu	Zavorsky, Gerald S./I-7753-2013; Weiss, Edward P/P-1682-2017; Zavorsky, Gerald S./AAI-1422-2021; Roberts, Alexandra/AAD-8422-2020; Roberts, Alexandra H/I-5763-2017	Zavorsky, Gerald S./0000-0002-4473-1601; Zavorsky, Gerald S./0000-0002-4473-1601; Roberts, Alexandra/0000-0003-4823-9718; Roberts, Alexandra H/0000-0003-4823-9718	LifeVantage	LifeVantage	GSZ was the principal investigator for the grant from LifeVantage that funded graduate student stipends. LifeVantage also paid for equipment, supplies, independent blood analyses, conferences, and publication fees. LifeVantage had no role in study design or data collection. They did, however, have access to the de-identified raw data of which an independent statistician hired by them verified our analyses. In a sub-analysis that their statistician performed, they showed that SOD increased in subjects equal to and greater than 35 years of age. While age related changes in SOD with supplementation was not made a priori, we added the results to the manuscript and discuss the ramifications of performing unplanned statistical tests in the manuscript. LifeVantage also received the manuscript draft as per agreement and provided some suggestions for improvement. GSZ accepted some of their suggestions on improvement, including the reporting of the unplanned age-related changes in SOD with supplementation.	Arent SM, 2010, J STRENGTH COND RES, V24, P1117, DOI 10.1519/JSC.0b013e3181cb70b8; Arent SM, 2010, J INT SOC SPORT NUTR, V7, DOI 10.1186/1550-2783-7-11; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654; Burnham EL, 2012, AM J PHYSIOL-LUNG C, V302, P1688, DOI [10.1152/ajplung.00171.2011, 10.1152/ajplung.00297.2011]; Chandwaney R, 1998, AGE, V21, P109, DOI 10.1007/s11357-998-0017-5; CLEMENS MR, 1987, CHEM PHYS LIPIDS, V45, P251, DOI 10.1016/0009-3084(87)90068-5; EINSELE H, 1987, ARCH TOXICOL, V60, P163, DOI 10.1007/BF00296972; Fatouros IG, 2004, MED SCI SPORT EXER, V36, P2065, DOI 10.1249/01.MSS.0000147632.17450.FF; Feairheller Deborah L, 2011, J Exerc Physiol Online, V14, P49; Hadley M, 2013, MAXIMUM PERFORMANCE; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Jeukendrup AE, 2005, MED SCI SPORT EXER, V37, P1820, DOI 10.1249/01.mss.0000175095.56646.4b; Ji L, 2000, FREE RADICALS EXERCI, P35; Joddar B, 2011, FREE RADICAL BIO MED, V50, P700, DOI 10.1016/j.freeradbiomed.2010.12.008; Liu JF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005284; Margonis K, 2007, FREE RADICAL BIO MED, V43, P901, DOI 10.1016/j.freeradbiomed.2007.05.022; Marzatico F, 1997, J SPORT MED PHYS FIT, V37, P235; MATSUO M, 2000, FREE RADICALS EXERCI, P1; Michailidis Y, 2007, MED SCI SPORT EXER, V39, P1107, DOI 10.1249/01.mss.0b013e318053e7ba; Mullins AL, 2013, BIOMARKERS, V18, P446, DOI 10.3109/1354750X.2013.810668; Nelson SK, 2006, FREE RADICAL BIO MED, V40, P341, DOI 10.1016/j.freeradbiomed.2005.08.043; Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a; Qureshi Muhammad Muddasir, 2010, Journal of Dietary Supplements, V7, P159, DOI 10.3109/19390211.2010.482041; Scalzo R, 2014, FASEB J, V28, pLB399; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Slattery KM, 2014, MED SCI SPORT EXER, V46, P1114, DOI 10.1249/MSS.0000000000000222; Tan XL, 2009, LUNG CANCER, V65, P129, DOI 10.1016/j.lungcan.2009.01.002; Velmurugan K, 2009, FREE RADICAL BIO MED, V46, P430, DOI 10.1016/j.freeradbiomed.2008.10.050; Veskoukis AS, 2009, FREE RADICAL BIO MED, V47, P1371, DOI 10.1016/j.freeradbiomed.2009.07.014	30	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2016	11	8							e0160559	10.1371/journal.pone.0160559	http://dx.doi.org/10.1371/journal.pone.0160559			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3KY	27513339	Green Submitted, Green Published, gold			2023-01-03	WOS:000381381100045
J	Stillman, MD; Williams, SR				Stillman, Michael D.; Williams, Steve R.			It's Rough Out There for Us	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACCESSIBILITY		[Stillman, Michael D.] Univ Washington, Sch Med, Dept Internal Med, Seattle, WA 98195 USA; [Williams, Steve R.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stillman, MD (corresponding author), Univ Washington, Sch Med, Dept Internal Med, Seattle, WA 98195 USA.	michael.stillman1972@gmail.com	Williams, Steve C/D-6979-2011	Williams, Steve C/0000-0003-4299-1941				Frost KL, 2015, J REHABIL RES DEV, V52, P653, DOI 10.1682/JRRD.2015.01.0002; Graham CL, 2008, DISABIL HEALTH J, V1, P209, DOI 10.1016/j.dhjo.2008.06.001; McNeal MAL., 2002, PROVIDING PRIMARY HL; Stillman MD, 2014, ARCH PHYS MED REHAB, V95, P1114, DOI 10.1016/j.apmr.2014.02.005	4	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2016	316	6					585	586		10.1001/jama.2016.4460	http://dx.doi.org/10.1001/jama.2016.4460			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS7TK	27532911				2023-01-03	WOS:000380985600009
J	Slofstra, C; Nauta, MH; Holmes, EA; Bockting, CLH				Slofstra, Christien; Nauta, Maaike H.; Holmes, Emily A.; Bockting, Claudi L. H.			Imagery Rescripting: The Impact of Conceptual and Perceptual Changes on Aversive Autobiographical Memories	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; MENTAL-IMAGERY; EYE-MOVEMENTS; WORKING-MEMORY; PROLONGED EXPOSURE; EMOTIONALITY; VIVIDNESS; PTSD; METAANALYSIS	Background Imagery rescripting (ImRs) is a process by which aversive autobiographical memories are rendered less unpleasant or emotional. ImRs is thought only to be effective if a change in the meaning-relevant (semantic) content of the mental image is produced, according to a cognitive hypothesis of ImRs. We propose an additional hypothesis: that ImRs can also be effective by the manipulation of perceptual features of the memory, without explicitly targeting meaning-relevant content. Methods In two experiments using a within-subjects design (both N = 48, community samples), both Conceptual-ImRs-focusing on changing meaning-relevant content-and Perceptual-ImRs-focusing on changing perceptual features-were compared to Recall-only of aversive autobiographical image-based memories. An active control condition, Recall + Attentional Breathing (Recall+AB) was added in the first experiment. In the second experiment, a Positive-ImRs condition was added-changing the aversive image into a positive image that was unrelated to the aversive autobiographical memory. Effects on the aversive memory's unpleasantness, vividness and emotionality were investigated. Results In Experiment 1, compared to Recall-only, both Conceptual-ImRs and Perceptual-ImRs led to greater decreases in unpleasantness, and Perceptual-ImRs led to greater decreases in emotionality of memories. In Experiment 2, the effects on unpleasantness were not replicated, and both Conceptual-ImRs and Perceptual-ImRs led to greater decreases in emotionality, compared to Recall-only, as did Positive-ImRs. There were no effects on vividness, and the ImRs conditions did not differ significantly from Recall+AB. Conclusions Results suggest that, in addition to traditional forms of ImRs, targeting the meaning-relevant content of an image during ImRs, relatively simple techniques focusing on perceptual aspects or positive imagery might also yield benefits. Findings require replication and extension to clinical samples.	[Slofstra, Christien; Nauta, Maaike H.; Bockting, Claudi L. H.] Univ Groningen, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands; [Holmes, Emily A.] MRC, Cognit & Brain Sci Unit, Cambridge, England; [Holmes, Emily A.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Bockting, Claudi L. H.] Univ Utrecht, Dept Clin Psychol, Utrecht, Netherlands	University of Groningen; Karolinska Institutet; Utrecht University	Bockting, CLH (corresponding author), Univ Groningen, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands.; Bockting, CLH (corresponding author), Univ Utrecht, Dept Clin Psychol, Utrecht, Netherlands.	c.l.h.bockting@uu.nl	Bockting, Claudi L/K-3768-2019; Holmes, Emily/ABD-4367-2020	Bockting, Claudi L/0000-0002-9220-9244; Holmes, Emily/0000-0001-7319-3112; Nauta, Maaike H./0000-0001-7694-1382	NWO the Netherlands Organisation for Scientific Research [022.003.038]; Medical Research Council (United Kingdom) intramural programme [MC-A060-5PR50]; National Institute for Health Research Oxford Biomedical Research Centre Programme; UK Medical Research Council.	NWO the Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Medical Research Council (United Kingdom) intramural programme; National Institute for Health Research Oxford Biomedical Research Centre Programme(National Institute for Health Research (NIHR)); UK Medical Research Council.(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was funded by grant 022.003.038 from NWO (http://www.nwo.nl/) the Netherlands Organisation for Scientific Research, awarded to the Dutch-Flemish Research School Experimental Psychopathology. EAH is supported by the Medical Research Council (http://www.mrc.ac.uk/) (United Kingdom) intramural programme (MC-A060-5PR50) and the National Institute for Health Research (www.nihr.ac.uk) Oxford Biomedical Research Centre Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Funding to pay the Open Access publication charges for this article was also provided by the UK Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrade J, 1997, BRIT J CLIN PSYCHOL, V36, P209, DOI 10.1111/j.2044-8260.1997.tb01408.x; Arntz A., 2014, WORKING EMOTION COGN, P203; Arntz A, 2015, MEMORY, P1; Arntz A., 2012, J EXP PSYCHOPATHOL, V3, P189, DOI [10.5127/jep.024211, DOI 10.5127/JEP.024211]; Arntz A, 2007, J BEHAV THER EXP PSY, V38, P345, DOI 10.1016/j.jbtep.2007.10.006; Arntz A, 2011, COGN BEHAV PRACT, V18, P466, DOI 10.1016/j.cbpra.2011.04.006; Bisson JI, 2007, BRIT J PSYCHIAT, V190, P97, DOI 10.1192/bjp.bp.106.021402; Blackwell SE, 2013, PSYCHIAT RES, V206, P56, DOI 10.1016/j.psychres.2012.09.047; Brewin CR, 2009, BEHAV RES THER, V47, P569, DOI 10.1016/j.brat.2009.03.008; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Cooper MJ, 2011, COGN BEHAV PRACT, V18, P454, DOI 10.1016/j.cbpra.2010.08.003; Dunn BD, 2012, CLIN PSYCHOL PSYCHOT, V19, P326, DOI 10.1002/cpp.1799; Engelhard IM, 2010, BEHAV RES THER, V48, P442, DOI 10.1016/j.brat.2010.01.003; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Grunert BK, 2003, COGN BEHAV PRACT, V10, P333, DOI 10.1016/S1077-7229(03)80051-2; Grunert BK, 2007, J BEHAV THER EXP PSY, V38, P317, DOI 10.1016/j.jbtep.2007.10.005; Hagenaars MA, 2012, J BEHAV THER EXP PSY, V43, P808, DOI 10.1016/j.jbtep.2011.09.005; Hirsch C.R., 2007, PSYCHIATRY, V6, P161, DOI [10.1016/j.mppsy.2007.01.005, DOI 10.1016/J.MPPSY.2007.01.005]; Holmes E., 2003, IMAGINATION COGNITIO, V23, P147, DOI [10.2190/HJG1-7UPH-B3K0-P9H5, DOI 10.2190/HJG1-7UPH-B3K0-P9H5]; Holmes EA, 2005, EMOTION, V5, P489, DOI 10.1037/1528-3542.5.4.489; Holmes EA, 2008, BEHAV RES THER, V46, P976, DOI 10.1016/j.brat.2008.04.009; Holmes EA, 2008, EMOTION, V8, P395, DOI 10.1037/1528-3542.8.3.395; Holmes EA, 2007, J BEHAV THER EXP PSY, V38, P297, DOI 10.1016/j.jbtep.2007.10.007; Holmes EA, 2008, BEHAV RES THER, V46, P1251, DOI 10.1016/j.brat.2008.09.005; Jung K, 2013, PSYCHOTHER PSYCHOSOM, V82, P213, DOI 10.1159/000348450; Lee CW, 2013, J BEHAV THER EXP PSY, V44, P231, DOI 10.1016/j.jbtep.2012.11.001; Leer A, 2014, J BEHAV THER EXP PSY, V45, P396, DOI 10.1016/j.jbtep.2014.04.004; Long ME, 2011, J CLIN PSYCHOL, V67, P1008, DOI 10.1002/jclp.20804; Long ME, 2011, J ANXIETY DISORD, V25, P531, DOI 10.1016/j.janxdis.2010.12.007; Morina N, 2011, J ANXIETY DISORD, V25, P1032, DOI 10.1016/j.janxdis.2011.06.012; Ohanian V, 2002, INT J EAT DISORDER, V31, P352, DOI 10.1002/eat.10044; Raabe S, 2015, J BEHAV THER EXP PSY, V9, P48; Rubin DC, 2008, PSYCHOL REV, V115, P985, DOI 10.1037/a0013397; Seebauer L, 2014, J BEHAV THER EXP PSY, V45, P20, DOI 10.1016/j.jbtep.2013.07.003; Segal Z. V., 2013, MINDFULNESS BASED CO, V2nd; Shapiro F., 2018, EYE MOVEMENT DESENSI, V3rd; Sheppes G, 2014, J EXP PSYCHOL GEN, V143, P163, DOI 10.1037/a0030831; Smeets MAM, 2012, MEMORY, V20, P346, DOI 10.1080/09658211.2012.665462; Stopa L, 2011, COGN BEHAV PRACT, V18, P421, DOI 10.1016/j.cbpra.2011.05.001; Tadmor A, 2014, J BEHAV THER EXP PSY; Tsai C, 2014, J BEHAV THER EXP PSY, V45, P15, DOI 10.1016/j.jbtep.2013.07.004; van den Hout M, 2001, BRIT J CLIN PSYCHOL, V40, P121; van den Hout MA, 2012, J EXP PSYCHOPATHOL, V3, P724; van den Hout MA, 2011, J BEHAV THER EXP PSY, V42, P423, DOI 10.1016/j.jbtep.2011.03.004; van den Hout MA, 2011, BEHAV RES THER, V49, P92, DOI 10.1016/j.brat.2010.11.003; Wesslau C, 2014, CLIN PSYCHOL REV, V34, P273, DOI DOI 10.1016/J.CPR.2014.03.001; Wheatley J, 2007, J BEHAV THER EXP PSY, V38, P371, DOI 10.1016/j.jbtep.2007.08.005; Wheatley J, 2011, COGN BEHAV PRACT, V18, P444, DOI 10.1016/j.cbpra.2010.06.004	48	15	15	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2016	11	8							e0160235	10.1371/journal.pone.0160235	http://dx.doi.org/10.1371/journal.pone.0160235			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT3GA	27486966	Green Published, Green Submitted, gold			2023-01-03	WOS:000381367800062
J	Dunlap, B; Cifu, AS				Dunlap, Beth; Cifu, Adam S.			Clinical Management of Opioid Use Disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Dunlap, Beth] Northwestern Univ, Chicago, IL USA; [Cifu, Adam S.] Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA	Northwestern University; University of Chicago	Cifu, AS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu						Lofwall MR, 2012, DRUG ALCOHOL DEPEN, V126, P379, DOI 10.1016/j.drugalcdep.2012.05.025; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Rosenblatt RA, 2015, ANN FAM MED, V13, P23, DOI 10.1370/afm.1735; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Smyth B P, 2010, Ir Med J, V103, P176; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2015, BEH HLTH TRENDS US R; Wood E, 2015, GUIDELINE CLIN MANAG	9	42	42	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2016	316	3					338	339		10.1001/jama.2016.9795	http://dx.doi.org/10.1001/jama.2016.9795			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DR3LN	27434445				2023-01-03	WOS:000379804800021
J	Marchant, J				Marchant, Jo			PLACEBOS Honest fakery	NATURE			English	Editorial Material							ANALGESIA											Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Benedetti F, 2016, J PHYSL; Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005; DeGrazia D., 2016, PAIN; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Schafer SM, 2015, J PAIN, V16, P412, DOI 10.1016/j.jpain.2014.12.008; Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976	10	13	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2016	535	7611					S14	S15		10.1038/535S14a	http://dx.doi.org/10.1038/535S14a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR4ZN	27410526	Bronze			2023-01-03	WOS:000379912600010
J	Lehmann, BD; Jovanovic, B; Chen, X; Estrada, MV; Johnson, KN; Shyr, Y; Moses, HL; Sanders, ME; Pietenpol, JA				Lehmann, Brian D.; Jovanovic, Bojana; Chen, Xi; Estrada, Monica V.; Johnson, Kimberly N.; Shyr, Yu; Moses, Harold L.; Sanders, Melinda E.; Pietenpol, Jennifer A.			Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection	PLOS ONE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; PROGNOSTIC VALUE; SURVIVAL; IDENTIFICATION; IXABEPILONE; EXPRESSION; PACLITAXEL; WOMEN; RATES	Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy. Given the complexity of the varying histological landscape of tumor specimens, we used histopathological quantification and laser-capture microdissection to determine that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, we refined TNBC molecular subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathology. Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches. Combined analysis of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathological complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], respectively). Collectively, we provide pre-clinical data that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.	[Lehmann, Brian D.; Johnson, Kimberly N.; Pietenpol, Jennifer A.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; [Jovanovic, Bojana] Harvard Univ, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Chen, Xi] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Div Biostat, Miami, FL 33136 USA; [Chen, Xi] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Estrada, Monica V.] Vanderbilt Univ, Breast Canc Res Program, Dept Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Shyr, Yu] Vanderbilt Univ, Dept Biostat, Div Canc Biostat, Ctr Quantitat Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Moses, Harold L.; Pietenpol, Jennifer A.] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Sanders, Melinda E.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; University of Miami; University of Miami; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Lehmann, BD; Pietenpol, JA (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.; Pietenpol, JA (corresponding author), Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.	brian.d.lehmann@vanderbilt.edu; j.pietenpol@vanderbilt.edu	Lehmann, Brian D./H-8464-2019	Lehmann, Brian D./0000-0003-0407-5248; Estrada, Monica Valeria/0000-0001-9846-8223	NCI/NCI grants [CA105436, CA068485, CA085492, CA102162]; Komen for the Cure Foundation grants [SAC110030, CCR13262005]; Vanderbilt-Ingram Cancer Center [P30 CA068485]; Vanderbilt Vision Center [P30 EY08126]; NIH/NCRR [G20 RR030956]; Specialized Program of Research Excellence in Breast Cancer [CA098131]; NATIONAL CANCER INSTITUTE [R01CA085492, P30CA068485, P50CA098131, R01CA102162, R01CA105436] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR030956] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER	NCI/NCI grants; Komen for the Cure Foundation grants; Vanderbilt-Ingram Cancer Center; Vanderbilt Vision Center; NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Specialized Program of Research Excellence in Breast Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This research was supported by: NCI/NCI grants CA105436 (JAP), CA068485 (JAP), CA085492 (HLM) and CA102162 (HLM); and Komen for the Cure Foundation grants SAC110030 (JAP) and CCR13262005 (BDL). The authors would like to thank Vanderbilt Technologies for Advanced Genomics (VANTAGE) and the Translational Pathology Shared Resources supported by the Vanderbilt-Ingram Cancer Center (P30 CA068485), the Vanderbilt Vision Center (P30 EY08126) and NIH/NCRR (G20 RR030956). Grant support for the histopathological analyses was provided by CA098131 (Specialized Program of Research Excellence in Breast Cancer).; We thank members of the Pietenpol lab and Robert Seitz for critical review of the manuscript. This research was supported by: NCI/NCI grants CA105436 (JAP), CA068485 (JAP), CA085492 (HLM) and CA102162 (HLM); and Komen for the Cure Foundation grants SAC110030 (JAP) and CCR13262005 (BDL). We would like to thank Vanderbilt Technologies for Advanced Genomics (VANTAGE) and the Translational Pathology Shared Resources supported by the Vanderbilt-Ingram Cancer Center (P30 CA068485), the Vanderbilt Vision Center (P30 EY08126) and NIH/NCRR (G20 RR030956). Grant support for the histopathological analyses was provided by CA098131 (Specialized Program of Research Excellence in Breast Cancer).	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Allred DC, 1998, MODERN PATHOL, V11, P155; Amirikia KC, 2011, CANCER-AM CANCER SOC, V117, P2747, DOI 10.1002/cncr.25862; [Anonymous], 2015, CANCER DISCOV, V5, P570, DOI 10.1158/2159-8290.CD-NB2015-059; [Anonymous], 2015, CANCER DISCOV, V5, P100, DOI 10.1158/2159-8290.CD-NB2014-184; Asano Y, 2016, BRIT J CANCER, V114, P14, DOI 10.1038/bjc.2015.434; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chen X, 2012, CANCER INFORM, V11, P147, DOI 10.4137/CIN.S9983; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Esserman LJ, 2012, BREAST CANCER RES TR, V132, P1049, DOI 10.1007/s10549-011-1895-2; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Horak CE, 2013, CLIN CANCER RES, V19, P1587, DOI 10.1158/1078-0432.CCR-12-1359; Ibrahim EM, 2014, BREAST CANCER RES TR, V148, P467, DOI 10.1007/s10549-014-3185-2; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyake T, 2012, CANCER SCI, V103, P913, DOI 10.1111/j.1349-7006.2012.02231.x; Rahim F, 2014, BONE MARROW RES, DOI 10.1155/2014/405920; Ring BZ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2198-0; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Saura C, 2013, ONCOLOGIST, V18, P787, DOI 10.1634/theoncologist.2013-0075; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Timms KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0475-x; Tutt A, 2014, SAN ANTONIO BREAST C, V2014, pS3	35	622	647	9	66	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157368	10.1371/journal.pone.0157368	http://dx.doi.org/10.1371/journal.pone.0157368			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27310713	Green Submitted, Green Published, gold			2023-01-03	WOS:000378029800062
J	Garin, N; Felix, G; Chuard, C; Genne, D; Carballo, S; Hugli, O; Lamy, O; Marti, C; Nendaz, M; Rutschmann, O; Harbarth, S; Perrier, A				Garin, Nicolas; Felix, Garance; Chuard, Christian; Genne, Daniel; Carballo, Sebastian; Hugli, Olivier; Lamy, Olivier; Marti, Christophe; Nendaz, Mathieu; Rutschmann, Olivier; Harbarth, Stephan; Perrier, Arnaud			Predictors and Implications of Early Clinical Stability in Patients Hospitalized for Moderately Severe Community-Acquired Pneumonia	PLOS ONE			English	Article							TREATMENT FAILURE; THROMBOCYTOSIS; EUROPE; TIME; PROCALCITONIN; INFECTIONS; MANAGEMENT; MORTALITY; CHILDREN; ETIOLOGY	Background Assessment of early response to treatment is crucial for the management of community-acquired pneumonia (CAP). Objective To describe the predictors and the outcomes of early clinical stability Methods We did a secondary analysis of a multicentre randomized controlled trial on CAP treatment in which 580 patients hospitalized for moderately severe CAP were included. The association between demographic, clinical and biological variables available at inclusion and early clinical stability (stabilization of vital signs within 72 hours with predetermined cut-offs) was assessed by multivariate logistic regression. The association between early clinical stability and mortality, severe adverse events, and length of stay was also tested. Results Younger age (OR 0.98, 95% CI 0.96-0.99), lower platelet count (OR per 10 G/L increment 0.96, 95% CI 0.94-0.98), lower respiratory rate (OR 0.94, 95% CI 0.90-0.97), absence of hypoxemia (OR 0.58, 95% CI 0.40-0.85), lower numbers of co-morbid conditions (OR 0.82, 95% CI 0.69-0.98) and signs or symptoms (OR 0.78, 95% CI 0.68-0.90) were significantly associated with early clinical stability. Patients with early clinical stability had lower 90-days mortality (3.4% vs. 11.9%, p<0.001), fewer admissions to the intensive care unit (2.7% vs. 8.0%, p = 0.005) and a shorter length of stay (6.0 days, IQR 4.0-10.0 vs. 10.0 days, IQR 7.0-15.0, p<0.001). Conclusions Patients with younger age, less co-morbidity, fewer signs or symptoms, less respiratory compromise, and a lower platelet count are more likely to reach early clinical stability. Patients without early clinical stability have a worse prognosis and warrant close scrutiny.	[Garin, Nicolas; Felix, Garance; Carballo, Sebastian; Marti, Christophe; Nendaz, Mathieu; Perrier, Arnaud] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland; [Garin, Nicolas; Felix, Garance; Carballo, Sebastian; Marti, Christophe; Nendaz, Mathieu; Rutschmann, Olivier; Harbarth, Stephan; Perrier, Arnaud] Fac Med, Geneva, Switzerland; [Garin, Nicolas] Reg Hosp Riviera Chablais, Div Internal Med, Monthey, Switzerland; [Chuard, Christian] Hop Cantonal Fribourg, Div Internal Med, Fribourg, Switzerland; [Genne, Daniel] Ctr Hosp Bienne, Div Internal Med, Biel, Switzerland; [Hugli, Olivier] CHU Vaudois, Dept Emergency Med, CH-1011 Lausanne, Switzerland; [Lamy, Olivier] CHU Vaudois, Div Internal Med, CH-1011 Lausanne, Switzerland; [Rutschmann, Olivier] Univ Hosp Geneva, Emergency Dept, Geneva, Switzerland; [Harbarth, Stephan] Univ Hosp Geneva, Infect Control Programme, Geneva, Switzerland	University of Geneva; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva	Garin, N (corresponding author), Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland.; Garin, N (corresponding author), Fac Med, Geneva, Switzerland.; Garin, N (corresponding author), Reg Hosp Riviera Chablais, Div Internal Med, Monthey, Switzerland.	Nicolas.Garin@hopitalrivierachablais.ch	Hugli, Olivier/AAA-7057-2020; Genne, Daniel/O-2305-2014; Nendaz, Mathieu R/X-6786-2019	Nendaz, Mathieu R/0000-0003-3795-3254; Hugli, Olivier/0000-0003-2312-1625	Swiss National Science Foundation [3200BO-120074]; Clinical Trial Unit; Department of Internal Medicine of Geneva University Hospitals	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Clinical Trial Unit; Department of Internal Medicine of Geneva University Hospitals	The original study (BICAP trial) was supported by grant 3200BO-120074 from the Swiss National Science Foundation (AP) and grants from the Clinical Trial Unit and the Department of Internal Medicine of Geneva University Hospitals (AP, NG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akram AR, 2013, CLIN MICROBIOL INFEC, V19, P1174, DOI 10.1111/1469-0691.12173; Aliberti S, 2008, CHEST, V134, P955, DOI 10.1378/chest.08-0334; Aliberti S, 2013, EUR RESPIR J, V42, P742, DOI 10.1183/09031936.00100812; Arancibia F, 2000, AM J RESP CRIT CARE, V162, P154, DOI 10.1164/ajrccm.162.1.9907023; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; Blasi F, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-6; Blasi F, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-44; Brogly N, 2007, J INFECTION, V55, P136, DOI 10.1016/j.jinf.2007.01.011; Chalmers JD, 2008, AM J MED, V121, P219, DOI 10.1016/j.amjmed.2007.10.033; Cretikos MA, 2008, MED J AUSTRALIA, V188, P657; Dodig S, 2005, ARCH MED RES, V36, P124, DOI 10.1016/j.arcmed.2004.12.011; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Garin N, 2014, JAMA INTERN MED, V174, P1894, DOI 10.1001/jamainternmed.2014.4887; Genne D, 2006, EUR J CLIN MICROBIOL, V25, P159, DOI 10.1007/s10096-006-0113-3; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; Harrison MT, 2014, THORAX, V69, P609, DOI 10.1136/thoraxjnl-2013-203996; Hillman K, 2005, LANCET, V365, P2091; Hoogewerf M, 2006, CLIN MICROBIOL INFEC, V12, P1097, DOI 10.1111/j.1469-0691.2006.01535.x; Huang DT, 2008, ANN EMERG MED, V52, P48, DOI 10.1016/j.annemergmed.2008.01.003; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Lodise TP, 2015, ANTIMICROB AGENTS CH, V59, P1119, DOI 10.1128/AAC.03643-14; Marti C, 2012, CRIT CARE, V16, DOI 10.1186/cc11447; Menendez R, 2004, CLIN INFECT DIS, V39, P1783, DOI 10.1086/426028; Menendez R, 2009, THORAX, V64, P987, DOI 10.1136/thx.2009.118612; Menendez R, 2007, CHEST, V132, P1348, DOI 10.1378/chest.06-1995; Mirsaeidi M, 2010, CHEST, V137, P416, DOI 10.1378/chest.09-0998; Mortensen EM, 2002, ARCH INTERN MED, V162, P1059, DOI 10.1001/archinte.162.9.1059; Ott SR, 2012, EUR RESPIR J, V39, P611, DOI 10.1183/09031936.00098411; Prina E, 2013, CHEST, V143, P767, DOI 10.1378/chest.12-1235; Ramirez JA, 2011, J ANTIMICROB CHEMOTH, V66, pIII3, DOI 10.1093/jac/dkr094; Roson B, 2004, ARCH INTERN MED, V164, P502, DOI 10.1001/archinte.164.5.502; Schuetz P, 2011, EUR RESPIR J, V37, P384, DOI 10.1183/09031936.00035610; Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956; Talbot GH, 2012, CLIN INFECT DIS, V55, P1114, DOI 10.1093/cid/cis566; Torres A, 2014, EUR J CLIN MICROBIOL, V33, P1065, DOI 10.1007/s10096-014-2067-1; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502; WOLACH B, 1990, PEDIATR INFECT DIS J, V9, P718, DOI 10.1097/00006454-199010000-00007	37	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2016	11	6							e0157350	10.1371/journal.pone.0157350	http://dx.doi.org/10.1371/journal.pone.0157350			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5LO	27305046	Green Published, gold, Green Submitted			2023-01-03	WOS:000377824800050
J	Kesavan, K; Frank, P; Cordero, DM; Benharash, P; Harper, RM				Kesavan, Kalpashri; Frank, Paul; Cordero, Daniella M.; Benharash, Peyman; Harper, Ronald M.			Neuromodulation of Limb Proprioceptive Afferents Decreases Apnea of Prematurity and Accompanying Intermittent Hypoxia and Bradycardia	PLOS ONE			English	Article							CENTRAL HYPOVENTILATION SYNDROME; OBSTRUCTIVE SLEEP-APNEA; BIRTH-WEIGHT INFANTS; RANDOMIZED CLINICAL-TRIAL; EARLY CAFFEINE THERAPY; PRETERM INFANTS; BRONCHOPULMONARY DYSPLASIA; NEURAL ALTERATIONS; OXIDATIVE STRESS; RISK-FACTORS	Background Apnea of Prematurity (AOP) is common, affecting the majority of infants born at <34 weeks gestational age. Apnea and periodic breathing are accompanied by intermittent hypoxia (IH). Animal and human studies demonstrate that IH exposure contributes to multiple pathologies, including retinopathy of prematurity (ROP), injury to sympathetic ganglia regulating cardiovascular action, impaired pancreatic islet cell and bone development, cerebellar injury, and neurodevelopmental disabilities. Current standard of care for AOP/IH includes prone positioning, positive pressure ventilation, and methylxanthine therapy; these interventions are inadequate, and not optimal for early development. Objective The objective is to support breathing in premature infants by using a simple, non-invasive vibratory device placed over limb proprioceptor fibers, an intervention using the principle that limb movements trigger reflexive facilitation of breathing. Methods Premature infants (23-34 wks gestational age), with clinical evidence of AOP/IH episodes were enrolled 1 week after birth. Caffeine treatment was not a reason for exclusion. Small vibration devices were placed on one hand and one foot and activated in 6 hour ON/OFF sequences for a total of 24 hours. Heart rate, respiratory rate, oxygen saturation (SpO(2)), and breathing pauses were continuously collected. Results Fewer respiratory pauses occurred during vibration periods, relative to baseline (p<0.005). Significantly fewer SpO(2) declines occurred with vibration (p<0.05), relative to control periods. Significantly fewer bradycardic events occurred during vibration periods, relative to no vibration periods (p<0.05). Conclusions In premature neonates, limb proprioceptive stimulation, simulating limb movement, reduces breathing pauses and IH episodes, and lowers the number of bradycardic events that accompany aberrant breathing episodes. This low-cost neuromodulatory procedure has the potential to provide a non-invasive intervention to reduce apnea, bradycardia and intermittent hypoxia in premature neonates.	[Kesavan, Kalpashri; Cordero, Daniella M.] Univ Calif Los Angeles, Pediat, Los Angeles, CA USA; [Frank, Paul] Univ Calif Los Angeles, Cardiothorac Surg, Los Angeles, CA USA; [Benharash, Peyman] Harbor UCLA, Surg, Los Angeles, CA USA; [Harper, Ronald M.] Univ Calif Los Angeles, Neurobiol, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles	Kesavan, K (corresponding author), Univ Calif Los Angeles, Pediat, Los Angeles, CA USA.	KKesavan@mednet.ucla.edu			UCLA Children's Discovery and Innovation Institute's Seed Grant award	UCLA Children's Discovery and Innovation Institute's Seed Grant award	This work was supported by grants from the UCLA Children's Discovery and Innovation Institute's Seed Grant award (KK). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants from the UCLA Children's Discovery and Innovation Institute's Seed Grant award.	Bass JL, 2004, PEDIATRICS, V114, P805, DOI 10.1542/peds.2004-0227; Bland JM, 1996, BRIT MED J, V312, P770; Bloch-Salisbury E, 2009, J APPL PHYSIOL, V107, P1017, DOI 10.1152/japplphysiol.00058.2009; Brown RE, 2012, PHYSIOL REV, V92, P1087, DOI 10.1152/physrev.00032.2011; BUCHER HU, 1988, EUR J PEDIATR, V147, P288, DOI 10.1007/BF00442697; Cohen G, 2007, PEDIATR RES, V61, P329, DOI 10.1203/pdr.0b013e318030d0ef; Cross RL, 2008, SLEEP, V31, P1103; Curzi-Dascalova L, 2002, J PEDIATR-US, V140, P766, DOI 10.1067/mpd.2002.124383; Darnall RA, 1997, PEDIATRICS, V100, P795, DOI 10.1542/peds.100.5.795; Darnall RA, 2010, RESP PHYSIOL NEUROBI, V173, P201, DOI 10.1016/j.resp.2010.04.009; Di Fiore JM, 2010, J PEDIATR-US, V157, P69, DOI 10.1016/j.jpeds.2010.01.046; Dobson NR, 2014, J PEDIATR-US, V164, P992, DOI 10.1016/j.jpeds.2013.12.025; Eichenwald EC, 1997, PEDIATRICS, V100, P354, DOI 10.1542/peds.100.3.354; ELDRIDGE FL, 1985, RESP PHYSIOL, V59, P313, DOI 10.1016/0034-5687(85)90136-7; Fadda P, 1997, PHARMACOL RES, V35, P443, DOI 10.1006/phrs.1997.0155; Fink GR, 1995, J PHYSIOL-LONDON, V489, P663, DOI 10.1113/jphysiol.1995.sp021081; Forster HV, 2014, J PHYSIOL-LONDON, V592, P429, DOI 10.1113/jphysiol.2013.262162; FRANTZ ID, 1976, J APPL PHYSIOL, V41, P41, DOI 10.1152/jappl.1976.41.1.41; Gizzi C, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/301818; Gozal D, 1996, AM J RESP CRIT CARE, V153, P761, DOI 10.1164/ajrccm.153.2.8564130; Gozal D, 2000, AM J RESP CRIT CARE, V162, P1747, DOI 10.1164/ajrccm.162.5.2005012; Grimaldi D, 2014, DIABETES CARE, V37, P355, DOI 10.2337/dc13-0933; GUTHRIE RD, 1980, J APPL PHYSIOL, V48, P347, DOI 10.1152/jappl.1980.48.2.347; Hayes MJ, 2007, J PERINATOL, V27, P782, DOI 10.1038/sj.jp.7211820; Henderson-Smart DJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000432.pub2; Henderson-Smart DJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000140.pub2; HENDERSONSMART DJ, 1986, ARCH DIS CHILD, V61, P227, DOI 10.1136/adc.61.3.227; Hibbs AM, 2008, J PEDIATR-US, V153, P176, DOI 10.1016/j.jpeds.2008.01.040; ISCOE S, 1976, J APPL PHYSIOL, V40, P138, DOI 10.1152/jappl.1976.40.2.138; ISHIDA K, 1993, EUR J APPL PHYSIOL, V66, P507, DOI 10.1007/BF00634300; Iwamoto E, 2010, RESP PHYSIOL NEUROBI, V173, P23, DOI 10.1016/j.resp.2010.06.002; Janvier Annie, 2004, J Perinatol, V24, P763, DOI 10.1038/sj.jp.7211182; JONES RAK, 1981, ARCH DIS CHILD, V56, P889, DOI 10.1136/adc.56.11.889; KEENS TG, 1978, J APPL PHYSIOL, V44, P909, DOI 10.1152/jappl.1978.44.6.909; Kim G, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00015; Koroglu OA, 2014, NEONATOLOGY, V106, P235, DOI 10.1159/000363217; KORNER AF, 1975, PEDIATRICS, V56, P361; Kumar R, 2009, DEPRESS ANXIETY, V26, P480, DOI 10.1002/da.20531; Lehtonen Liisa, 2004, Semin Neonatol, V9, P229, DOI 10.1016/j.siny.2003.09.002; Lin M, 2008, J COMP NEUROL, V509, P103, DOI 10.1002/cne.21732; Lodha A, 2015, JAMA PEDIATR, V169, P33, DOI 10.1001/jamapediatrics.2014.2223; Malcolm WF, 2009, J PERINATOL, V29, P372, DOI 10.1038/jp.2008.234; Marcus CL, 2014, AM J RESP CRIT CARE, V190, P791, DOI 10.1164/rccm.201406-1092OC; Martin Richard J, 2004, Paediatr Respir Rev, V5 Suppl A, pS377, DOI 10.1016/S1526-0542(04)90067-X; Martin RJ, 2015, CLIN PERINATOL, V42, P825, DOI 10.1016/j.clp.2015.08.009; Martin RJ, 2011, NEONATOLOGY, V100, P303, DOI 10.1159/000329922; Moriette G, 2010, ARCH PEDIATRIE, V17, P186, DOI 10.1016/j.arcped.2009.09.016; Nanduri J, 2009, P NATL ACAD SCI USA, V106, P1199, DOI 10.1073/pnas.0811018106; Olini N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072539; Osborn DA, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000502, DOI 10.1002/14651858.CD000502, 10.1002/14651858.cd000502]; Paavonen EJ, 2007, PEDIATRICS, V120, P778, DOI 10.1542/peds.2007-0540; Pae EK, 2005, NEUROSCI LETT, V375, P123, DOI 10.1016/j.neulet.2004.10.091; Pae EK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090192; Pae EK, 2013, BIOCHEM BIOPH RES CO, V441, P637, DOI 10.1016/j.bbrc.2013.10.102; Pae EK, 2011, INT J DEV NEUROSCI, V29, P819, DOI 10.1016/j.ijdevneu.2011.09.003; PAN LG, 1986, J APPL PHYSIOL, V60, P1016, DOI 10.1152/jappl.1986.60.3.1016; Pantalitschka T, 2009, ARCH DIS CHILD-FETAL, V94, pF245, DOI 10.1136/adc.2008.148981; PAPE KE, 1976, PEDIATRICS, V58, P473; Patel RM, 2013, J PERINATOL, V33, P134, DOI 10.1038/jp.2012.52; PATON JY, 1993, AM REV RESPIR DIS, V147, P1185, DOI 10.1164/ajrccm/147.5.1185; Pillekamp F, 2007, NEONATOLOGY, V91, P155, DOI 10.1159/000097446; POETS CF, 1993, PEDIATR RES, V34, P144, DOI 10.1203/00006450-199308000-00007; POETS CF, 1991, EARLY HUM DEV, V26, P1, DOI 10.1016/0378-3782(91)90038-5; Potts JT, 2005, J NEUROSCI, V25, P1965, DOI 10.1523/JNEUROSCI.3881-04.2005; Pozo ME, 2012, NEONATOLOGY, V102, P107, DOI 10.1159/000338096; Ratner V, 2009, NEONATOLOGY, V95, P299, DOI 10.1159/000178798; Rhein LM, 2014, JAMA PEDIATR, V168, P250, DOI 10.1001/jamapediatrics.2013.4371; Robertson CMT, 2009, PEDIATR NEUROL, V40, P189, DOI 10.1016/j.pediatrneurol.2008.09.017; Rosen CL, 2003, J PEDIATR-US, V142, P383, DOI 10.1067/mpd.2003.28; Ryan S, 2005, CIRCULATION, V112, P2660, DOI 10.1161/CIRCULATIONAHA.105.556746; SAIGAL S, 1986, J PEDIATR-US, V109, P857, DOI 10.1016/S0022-3476(86)80714-4; Schmidt B, 2012, JAMA-J AM MED ASSOC, V307, P275, DOI 10.1001/jama.2011.2024; Schmolzer GM, 2008, J PEDIATR-US, V153, P741, DOI 10.1016/j.jpeds.2008.08.016; Schussler P, 2006, PSYCHONEUROENDOCRINO, V31, P915, DOI 10.1016/j.psyneuen.2006.05.002; Sunderram J., 2012, Critical Reviews in Biomedical Engineering, V40, P265; Taha D, 2014, J MATERN-FETAL NEO M, V27, P1698, DOI 10.3109/14767058.2014.885941; Tibballs J, 2003, PEDIATR PULM, V36, P544, DOI 10.1002/ppul.10392; Veasey SC, 2004, SLEEP, V27, P194, DOI 10.1093/sleep/27.2.194; Xie HG, 2011, J CLIN PHARMACOL, V51, P502, DOI 10.1177/0091270010370587; Xu W, 2004, NEUROSCIENCE, V126, P313, DOI 10.1016/j.neuroscience.2004.03.055	80	20	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2016	11	6							e0157349	10.1371/journal.pone.0157349	http://dx.doi.org/10.1371/journal.pone.0157349			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5LO	27304988	gold, Green Published, Green Submitted			2023-01-03	WOS:000377824800049
J	Ren, W; Zuo, R; Wang, YN; Wang, HJ; Yang, J; Xin, SK; Han, LY; Zhao, HY; Han, SY; Gao, B; Hu, H; Hu, YJ; Bian, BL; Si, N				Ren, Wei; Zuo, Ran; Wang, Yao-Nan; Wang, Hong-Jie; Yang, Jian; Xin, Shao-Kun; Han, Ling-Yu; Zhao, Hai-Yu; Han, Shu-Yan; Gao, Bo; Hu, Hao; Hu, Yuan-Jia; Bian, Bao-Lin; Si, Nan			Pharmacokinetic-Pharmacodynamic Analysis on Inflammation Rat Model after Oral Administration of Huang Lian Jie Du Decoction	PLOS ONE			English	Article							COLLAGEN-INDUCED ARTHRITIS; PERFORMANCE LIQUID-CHROMATOGRAPHY; RADIX-SCUTELLARIAE EXTRACT; TANDEM MASS-SPECTROMETRY; TYPE-2 DIABETIC-RATS; DU-TANG HLJDT; LOW BIOAVAILABILITY; INTEGRATED PHARMACOKINETICS; LIPOXYGENASE PATHWAY; BIOACTIVE COMPONENTS	Huang-Lian-Jie-Du Decoction (HLJDD) is a classical Traditional Chinese Medicine (TCM) formula with heat-dissipating and detoxifying effects. It is used to treat inflammation-associated diseases. However, no systematic pharmacokinetic (PK) and pharmacodynamic (PD) data concerning the activity of HLJDD under inflammatory conditions is available to date. In the present study, the concentration-time profiles and the hepatic clearance rates (HCR) of 41 major components in rat plasma in response to the oral administration of a clinical dose of HLJDD were investigated by LC-QqQ-MS using a dynamic multiple reaction monitoring (DMRM) method. Additionally, the levels of 7 cytokines (CKs) in the plasma and the body temperature of rats were analyzed. Furthermore, a PK-PD model was established to describe the time course of the hemodynamic and anti-inflammatory effects of HLJDD. As one of the three major active constituents in HLJDD, iridoids were absorbed and eliminated more easily and quickly than alkaloids and flavonoids. Compared with the normal controls, the flavonoids, alkaloids and iridoids in inflamed rats exhibited consistently changing trends of PK behaviors, such as higher bioavailability, slower elimination, delays in reaching the maximum concentration (T-max) and longer substantivity. The HCR of iridoids was different from that of alkaloids and flavonoids in inflamed rats. Furthermore, excellent pharmacodynamic effects of HLJDD were observed in inflamed rats. The levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1 beta, IL-10, and macrophage inflammatory protein-2 (MIP2) and body temperature significantly decreased after the administration of HLJDD. Based on PK-PD modeling with the three-phase synchronous characterization of time-concentration-effect, flavonoids exhibited one mechanism of action in the anti-inflammatory process, while iridoids and alkaloids showed another mechanism of action. Taken together, the results demonstrated that HLJDD may restrain inflammation synergistically via its major constituents alkaloids, flavonoids and iridoids). A correlation between the exposure concentration of different types of compounds and their anti-inflammatory effects in the body was shown. This study provides a comprehensive understanding of the anti-inflammatory activity of HLJDD.	[Ren, Wei; Wang, Hong-Jie; Yang, Jian; Xin, Shao-Kun; Han, Ling-Yu; Zhao, Hai-Yu; Bian, Bao-Lin; Si, Nan] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China; [Ren, Wei; Wang, Yao-Nan; Xin, Shao-Kun] Capital Med Univ, Beijing 100069, Peoples R China; [Zuo, Ran] Li Kang Hosp, Beijing 102609, Peoples R China; [Hu, Hao; Hu, Yuan-Jia] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Zhuhai, Macao, Peoples R China; [Han, Shu-Yan] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Integrat Chinese & Western Med, Minist Educ,Sch Oncol,Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China; [Gao, Bo] Anhui Jinchan Biochem Co Ltd, Huaibei 235000, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS; Capital Medical University; University of Macau; Peking University	Zhao, HY; Si, N (corresponding author), China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.	hyzhao@icmm.ac.cn; nsi@icmm.ac.cn	Wei, Ren/J-7185-2019; Hu, Yuanjia/AAW-7721-2021; HU, Hao/H-7813-2018	Wei, Ren/0000-0002-5245-451X; HU, Hao/0000-0001-9441-106X; yuanjia, Hu/0000-0001-5244-8577	National Natural Science Fund Project [81202904]; National Basic Research Program of China [2014CB543003]; Fundamental Research Funds for the Central public welfare research institutes [ZZ070832]; Key Project at Central Government Level for Regulating Funds [2060302]	National Natural Science Fund Project(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central public welfare research institutes; Key Project at Central Government Level for Regulating Funds	The work was aided financially by National Natural Science Fund Project (NO. 81202904), National Basic Research Program of China (NO. 2014CB543003), Fundamental Research Funds for the Central public welfare research institutes (NO. ZZ070832) and Key Project at Central Government Level for Regulating Funds (NO. 2060302). Anhui Jinchan Biochemistry Company Ltd. had a role in data collection and analysis and preparation of the manuscript. Anhui Jinchan Biochemistry Company Ltd. has no role in the study design or decision to publish. The other funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Akao T, 2000, J PHARM PHARMACOL, V52, P1563, DOI 10.1211/0022357001777621; Akao T, 2007, J PHARM PHARMACOL, V59, P87, DOI 10.1211/jpp.59.1.0012; Bae SK, 2009, J PHARM SCI-US, V98, P1587, DOI 10.1002/jps.21511; Cai ZX, 2008, J CHROMATOGR A, V1200, P144, DOI 10.1016/j.chroma.2008.05.095; Chaudhry H, 2013, IN VIVO, V27, P669; Chung HJ, 2006, EUR J PHARM SCI, V27, P363, DOI 10.1016/j.ejps.2005.11.008; Dai Y, 1999, LIFE SCI, V66, P19, DOI 10.1016/S0024-3205(99)00557-3; Deng YT, 2008, J CHROMATOGR B, V863, P195, DOI 10.1016/j.jchromb.2007.12.028; Deng YX, 2006, BIOMED CHROMATOGR, V20, P1098, DOI 10.1002/bmc.649; Deng YX, 2012, FITOTERAPIA, V83, P1435, DOI 10.1016/j.fitote.2012.08.007; Dou SS, 2009, CHROMATOGRAPHIA, V69, P659, DOI 10.1365/s10337-008-0945-3; Durairajan SSK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092954; Fang HY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/245357; Flierl MA, 2008, FASEB J, V22, P2198, DOI 10.1096/fj.07-105221; He MY, 2014, J ETHNOPHARMACOL, V155, P334, DOI 10.1016/j.jep.2014.05.033; Hu YH, 2013, J ETHNOPHARMACOL, V150, P1137, DOI 10.1016/j.jep.2013.10.038; Jiang HQ, 2009, GUANGMING J CHIN MED, V24, P480; Jin Dan, 2007, Zhong Xi Yi Jie He Xue Bao, V5, P541, DOI 10.3736/jcim20070513; Kang HE, 2009, XENOBIOTICA, V39, P465, DOI 10.1080/00498250902890151; Kim J, 1997, J PHARM PHARMACOL, V49, P878, DOI 10.1111/j.2042-7158.1997.tb06129.x; Lan MH, 2001, J HENAN COLL TRADIT, V16, P58; Li CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067530; Li Guofu, 2011, Zhongguo Zhong Yao Za Zhi, V36, P644; Lin Liang-Tzung, 2013, J Tradit Complement Med, V3, P227, DOI 10.4103/2225-4110.119732; Lin SC, 1996, AM J CHINESE MED, V24, P219, DOI 10.1142/S0192415X96000281; Liu GJ, 2005, JIANGXI J TRADIT CHI, V36, P19; Liu L, 2010, PLANTA MED, V76, P70, DOI 10.1055/s-0029-1185946; Lu J, 2011, J ETHNOPHARMACOL, V134, P911, DOI 10.1016/j.jep.2011.01.049; Lu T, 2007, J ETHNOPHARMACOL, V110, P412, DOI 10.1016/j.jep.2006.09.036; Ma ST, 2015, CHIN J NAT MEDICINES, V13, P30, DOI 10.1016/S1875-5364(15)60004-8; Ma Z, 2005, BLOOD, V105, P3312, DOI 10.1182/blood-2004-10-3915; Ma ZT, 2014, J ASIAN NAT PROD RES, V16, P483, DOI 10.1080/10286020.2014.913577; Miura N, 2007, BIOL PHARM BULL, V30, P495, DOI 10.1248/bpb.30.495; Nishigaki J, 1998, BIOL PHARM BULL, V21, P735; Ohura K, 2012, J PHARM SCI-US, V101, P3264, DOI 10.1002/jps.23182; Penney M, 2014, BRIT J CLIN PHARMACO, V77, P740, DOI 10.1111/bcp.12225; Sharma R, 2007, J PEDIATR SURG, V42, P454, DOI 10.1016/j.jpedsurg.2006.10.038; Sun Jian, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1526; Sun Jian, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1461; Swartz ME, 2005, J LIQ CHROMATOGR R T, V28, P1253, DOI 10.1081/JLC-200053046; Tang YH, 2006, BIOMED CHROMATOGR, V20, P1116, DOI 10.1002/bmc.655; Tsai TH, 2002, BRIT J PHARMACOL, V137, P1314, DOI 10.1038/sj.bjp.0704959; Wang LM, 1997, J PHARM PHARMACOL, V49, P102, DOI 10.1111/j.2042-7158.1997.tb06760.x; Wang N, 2015, J ETHNOPHARMACOL, V164, P309, DOI 10.1016/j.jep.2015.02.025; Wang PR, 2014, J PHARMACEUT BIOMED, V88, P106, DOI 10.1016/j.jpba.2013.08.025; Wei YF, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/909624; Wen T, 2012, ARTHRITIS RHEUM-US, V64, P2896, DOI 10.1002/art.34528; Wu YH, 2012, J ETHNOPHARMACOL, V140, P55, DOI 10.1016/j.jep.2011.12.002; Xiao Yan-ling, 2005, Zhongguo Zhong Yao Za Zhi, V30, P1767; Xing J, 2005, LIFE SCI, V78, P140, DOI 10.1016/j.lfs.2005.04.072; Yang Y, 2013, LISHIZHEN MED MAT ME, V24, P1599; Yang Y, 2013, J CHROMATOGR A, V1321, P88, DOI 10.1016/j.chroma.2013.10.072; Yi Q, 2012, CURR THER RES CLIN E, V73, P174, DOI 10.1016/j.curtheres.2012.09.002; Yu KH, 2009, J PHARM PHARMACOL, V61, P1197, DOI 10.1211/jpp/61.09.0009; Yue RC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/439690; Yue RC, 2013, J ETHNOPHARMACOL, V145, P465, DOI 10.1016/j.jep.2012.11.010; Zeng HW, 2011, J ETHNOPHARMACOL, V135, P561, DOI 10.1016/j.jep.2011.03.055; Zeng H, 2009, J PHARM PHARMACOL, V61, P1699, DOI [10.1211/jpp/61.12.0016, 10.1211/jpp.61.12.0016]; Zeng MF, 2010, FITOTERAPIA, V81, P490, DOI 10.1016/j.fitote.2010.01.004; Zhang HW, 2014, J ETHNOPHARMACOL, V154, P55, DOI 10.1016/j.jep.2014.03.007; Zhang L, 2005, PHARM RES-DORDR, V22, P1050, DOI 10.1007/s11095-005-5303-7; Zhang XJ, 2014, PHYTOMEDICINE, V21, P615, DOI 10.1016/j.phymed.2013.11.004; Zhu Hua-Xu, 2013, Zhongguo Zhong Yao Za Zhi, V38, P2033; Zhu HX, 2013, PHYTOMEDICINE, V20, P767, DOI 10.1016/j.phymed.2012.11.012; Zhu HX, 2012, J ETHNOPHARMACOL, V141, P158, DOI 10.1016/j.jep.2012.02.014; Zuo R, 2016, XENOBIOTICA, V46, P65, DOI 10.3109/00498254.2015.1048541; Zuo Ran, 2014, Yaoxue Xuebao, V49, P237	67	18	22	3	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0156256	10.1371/journal.pone.0156256	http://dx.doi.org/10.1371/journal.pone.0156256			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TW	27280291	Green Submitted, Green Published, gold			2023-01-03	WOS:000377563000023
J	Niu, YH; Meng, QX; Li, SL; Ren, LP; Zhou, B; Schonewille, T; Zhou, ZM				Niu, Yuhong; Meng, Qingxiang; Li, Shengli; Ren, Liping; Zhou, Bo; Schonewille, Thomas; Zhou, Zhenming			Effects of Diets Supplemented with Ensiled Mulberry Leaves and Sun-Dried Mulberry Fruit Pomace on the Ruminal Bacterial and Archaeal Community Composition of Finishing Steers	PLOS ONE			English	Article							DAIRY-COWS; MICROBIAL-POPULATIONS; METHANE PRODUCTION; MORUS-ALBA; RUMEN; DIVERSITY; SHEEP; FERMENTATION; ABUNDANCE; METHANOGENESIS	This study investigated the effects of ensiled mulberry leaves (EML) and sun-dried mulberry fruit pomace (SMFP) on the ruminal bacterial and archaeal community composition of finishing steers. Corn grain- and cotton meal-based concentrate was partially replaced with EML or SMFP. The diets had similar crude protein (CP), neutral detergent fiber (NDF), and metabolizable energy. Following the feeding trial, the steers were slaughtered and ruminal liquid samples were collected to study the ruminal microbiome. Extraction of DNA, amplification of the V4 region of the 16S rRNA gene, and Illumina MiSeq pyrosequencing were performed for each sample. Following sequence de-noising, chimera checking, and quality trimming, an average of 209,610 sequences were generated per sample. Quantitative real-time PCR was performed to examine the selected bacterial species in the rumen. Our results showed that the predominant phyla were Bacteroidetes (43.90%), Firmicutes (39.06%), Proteobacteria (4.31%), and Tenericutes (2.04%), and the predominant genera included Prevotella (13.82%), Ruminococcus (2.51%), Butyrivibrio (2.38%), and Succiniclasticum (2.26%). Compared to the control group, EML and SMFP groups had a higher abundance of total bacteria (p < 0.001); however, the bacterial community composition was similar among the three groups. At the phylum level, there were no significant differences in Firmicutes (p = 0.7932), Bacteroidetes (p = 0.2330), Tenericutes (p = 0.2811), or Proteobacteria (p = 0.0680) levels among the three groups; however, Fibrobacteres decreased in EML (p = 0.0431). At the genus level, there were no differences in Prevotella (p = 0.4280), Ruminococcus (p = 0.2639), Butyrivibrio (p = 0.4433), or Succiniclasticum (p = 0.0431) levels among the groups. Additionally, the dietary treatments had no significant effects on the archaeal community composition in the rumen. Therefore, EML and SMFP supplementation had no significant effects on the ruminal bacterial or archaeal community composition of finishing steers.	[Niu, Yuhong; Meng, Qingxiang; Li, Shengli; Ren, Liping; Zhou, Bo; Zhou, Zhenming] State Key Lab Anim Nutr, Beijing 100193, Peoples R China; [Niu, Yuhong; Meng, Qingxiang; Li, Shengli; Ren, Liping; Zhou, Bo; Zhou, Zhenming] China Agr Univ, Coll Anim Sci & Technol, Beijing 100193, Peoples R China; [Niu, Yuhong] China Agr Univ, Coll Agron & Biotechnol, Beijing 100193, Peoples R China; [Schonewille, Thomas] Univ Utrecht, Dept Farm Anim Hlth, NL-3584 CL Utrecht, Netherlands	China Agricultural University; China Agricultural University; Utrecht University	Zhou, ZM (corresponding author), State Key Lab Anim Nutr, Beijing 100193, Peoples R China.; Zhou, ZM (corresponding author), China Agr Univ, Coll Anim Sci & Technol, Beijing 100193, Peoples R China.	zhouzm@cau.edu.cn	Meng, Q./GSI-6185-2022		China Agricultural Research System [CARS-38]; National Natural Science Foundation of China [31372335]; Special Fund for Agro-scientific Research in the Public Interest [201503134]	China Agricultural Research System; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Fund for Agro-scientific Research in the Public Interest	This work was supported by grants from the China Agricultural Research System (CARS-38), the National Natural Science Foundation of China (31372335), and Special Fund for Agro-scientific Research in the Public Interest (201503134). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Castro-Carrera T, 2014, J DAIRY SCI, V97, P1661, DOI 10.3168/jds.2013-7243; Cheong SH, 2012, ANIM PROD SCI, V52, P240, DOI 10.1071/AN11087; Denman SE, 2007, FEMS MICROBIOL ECOL, V62, P313, DOI 10.1111/j.1574-6941.2007.00394.x; Denman SE, 2006, FEMS MICROBIOL ECOL, V58, P572, DOI 10.1111/j.1574-6941.2006.00190.x; Ding GZ, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-24; Doran MP, 2007, ANIM FEED SCI TECH, V138, P239, DOI 10.1016/j.anifeedsci.2006.11.016; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Henderson G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14567; Hook SE, 2009, APPL ENVIRON MICROB, V75, P374, DOI 10.1128/AEM.01672-08; Hook SE, 2011, MICROB ECOL, V62, P94, DOI 10.1007/s00248-011-9881-0; Huo WJ, 2014, WORLD J MICROB BIOT, V30, P669, DOI 10.1007/s11274-013-1489-8; Jami E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085423; Janssen PH, 2008, APPL ENVIRON MICROB, V74, P3619, DOI 10.1128/AEM.02812-07; Jewell KA, 2015, APPL ENVIRON MICROB, V81, P4697, DOI 10.1128/AEM.00720-15; Kim M, 2011, FEMS MICROBIOL ECOL, V76, P49, DOI 10.1111/j.1574-6941.2010.01029.x; Kobayashi Y, 2008, FOLIA MICROBIOL, V53, P195, DOI 10.1007/s12223-008-0024-z; Liu C, 2012, ARCH MICROBIOL, V194, P353, DOI 10.1007/s00203-011-0757-y; Liu JX, 2001, SMALL RUMINANT RES, V39, P131, DOI 10.1016/S0921-4488(00)00180-2; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Mao SY, 2016, ENVIRON MICROBIOL, V18, P525, DOI 10.1111/1462-2920.12724; Mosoni P, 2011, J ANIM SCI, V89, P783, DOI 10.2527/jas.2010-2947; Patra AK, 2010, PHYTOCHEMISTRY, V71, P1198, DOI 10.1016/j.phytochem.2010.05.010; Petri RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083424; Pitta DW, 2014, ANAEROBE, V30, P11, DOI 10.1016/j.anaerobe.2014.07.008; Popova M, 2013, APPL ENVIRON MICROB, V79, P1777, DOI 10.1128/AEM.03115-12; Purushe J, 2010, MICROB ECOL, V60, P721, DOI 10.1007/s00248-010-9692-8; Sahoo A, 2011, LIVEST SCI, V136, P175, DOI 10.1016/j.livsci.2010.08.019; Salinas-Chavira J, 2011, TROP ANIM HEALTH PRO, V43, P995, DOI 10.1007/s11250-011-9797-1; Sharma SK, 2010, RANGE MANAG AGROFOR, V31, P97; Shinkai T, 2010, ANIM SCI J, V81, P72, DOI 10.1111/j.1740-0929.2009.00698.x; Singh KM, 2015, MOL BIOL REP, V42, P95, DOI 10.1007/s11033-014-3746-9; Stevenson DM, 2007, APPL MICROBIOL BIOT, V75, P165, DOI 10.1007/s00253-006-0802-y; Suen G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018814; Todaro M, 2007, J ANIM VET ADV, V6, P509; Tymensen LD, 2012, APPL ENVIRON MICROB, V78, P4051, DOI 10.1128/AEM.07994-11; Vu CC, 2011, ASIAN AUSTRAL J ANIM, V24, P1233, DOI 10.5713/ajas.2011.90328; Weimer PJ, 2008, APPL MICROBIOL BIOT, V80, P135, DOI 10.1007/s00253-008-1528-9; Weimer PJ, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00296; Wetzels SU, 2015, J DAIRY SCI, V98, P5572, DOI 10.3168/jds.2014-9166; WOJCIECHOWICZ M, 1979, APPL ENVIRON MICROB, V37, P136, DOI 10.1128/AEM.37.1.136-142.1979; Wright ADG, 2008, MICROB ECOL, V56, P390, DOI 10.1007/s00248-007-9351-x; Yu ZT, 2004, BIOTECHNIQUES, V36, P808, DOI 10.2144/04365ST04; Zhang RY, 2014, J SCI FOOD AGR, V94, P1886, DOI 10.1002/jsfa.6508; Zhou B, 2012, J ANIM FEED SCI, V21, P188, DOI 10.22358/jafs/66063/2012; Zhou M, 2011, J APPL MICROBIOL, V111, P1148, DOI 10.1111/j.1365-2672.2011.05126.x; Zhou M, 2009, APPL ENVIRON MICROB, V75, P6524, DOI 10.1128/AEM.02815-08; Zhou ZM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085406; Zhou ZM, 2012, BIORESOURCE TECHNOL, V103, P173, DOI 10.1016/j.biortech.2011.10.013; ZIOLECKI A, 1980, APPL ENVIRON MICROB, V39, P919	51	14	15	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2016	11	6							e0156836	10.1371/journal.pone.0156836	http://dx.doi.org/10.1371/journal.pone.0156836			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN8ZV	27258373	Green Published, gold, Green Submitted			2023-01-03	WOS:000377369700143
J	Kasteridis, P; Mason, A; Goddard, M; Jacobs, R; Santos, R; Rodriguez-Sanchez, B; McGonigal, G				Kasteridis, Panagiotis; Mason, Anne; Goddard, Maria; Jacobs, Rowena; Santos, Rita; Rodriguez-Sanchez, Beatriz; McGonigal, Gerard			Risk of Care Home Placement following Acute Hospital Admission: Effects of a Pay-for-Performance Scheme for Dementia	PLOS ONE			English	Article								Introduction The Quality and Outcomes Framework, or QOF, rewards primary care doctors (GPs) in the UK for providing certain types of care. Since 2006, GPs have been paid to identify patients with dementia and to conduct an annual review of their mental and physical health. During the review, the GP also assesses the carer's support needs, including impact of caring, and ensures that services are co-ordinated across care settings. In principle, this type of care should reduce the risk of admission to long-term residential care directly from an acute hospital ward, a phenomenon considered to be indicative of poor quality care. However, this potential effect has not previously been tested. Methods Using English data from 2006/07 to 2010/11, we ran multilevel logit models to assess the impact of the QOF review on the risk of care home placement following emergency admission to acute hospital. Emergency admissions were defined for (a) people with a primary diagnosis of dementia and (b) people with dementia admitted for treatment of an ambulatory care sensitive condition. We adjusted for a wide range of potential confounding factors. Results Over the study period, 19% of individuals admitted to hospital with a primary diagnosis of dementia (N = 31,120) were discharged to a care home; of those admitted for an ambulatory care sensitive condition (N = 139,267), the corresponding figure was 14%. Risk factors for subsequent care home placement included older age, female gender, vascular dementia, incontinence, fall, hip fracture, and number of comorbidities. Better performance on the QOF review was associated with a lower risk of care home placement but only when the admission was for an ambulatory care sensitive condition. Conclusions The QOF dementia review may help to reduce the risk of long-term care home placement following acute hospital admission.	[Kasteridis, Panagiotis; Mason, Anne; Goddard, Maria; Jacobs, Rowena; Santos, Rita] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Rodriguez-Sanchez, Beatriz] Univ Groningen, SOM Res Inst, Dept Econ Econometr & Finance, NL-9700 AV Groningen, Netherlands; [McGonigal, Gerard] York Teaching Hosp NHS Fdn Trust, Dept Med Elderly, York, N Yorkshire, England	University of York - UK; University of Groningen	Mason, A (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	anne.mason@york.ac.uk		RODRIGUEZ SANCHEZ, BEATRIZ/0000-0002-6146-068X; Mason, Anne/0000-0002-5823-3064; Santos, Rita/0000-0001-7953-1960; Jacobs, Rowena/0000-0001-5225-6321; Goddard, Maria Karen/0000-0002-1517-7461	Department of Health (England) [103/0001]	Department of Health (England)	This work was supported by the Department of Health (England) to the Policy Research Unit in the Economics of Social and Health Care [grant number: 103/0001]. The sponsors played no role in the design, execution, analysis or interpretation of the data. The views expressed are those of the authors and not necessarily those of the sponsors.	Aguero-Torres H, 2001, J CLIN EPIDEMIOL, V54, P795, DOI 10.1016/S0895-4356(00)00371-1; Andel R, 2007, J AGING HEALTH, V19, P213, DOI 10.1177/0898264307299359; ANDERSEN R, 1978, MED CARE, V16, P533, DOI 10.1097/00005650-197807000-00001; [Anonymous], 2006, SUPP PEOPL DEM THEIR; Bardsley M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002007; British Medical Association, 2006, REV GMS CONTR 2006 0; British Medical Association, 2011, QUAL OUTC FRAM GUID; Department of Health, 2009, INT CAR HALFW HOM UP; Department of Health, 2010, GMS STAT FIN ENT; Department of Health, 2009, LIVING WELL DEMENTIA; Department of Health, 2015, PRIM MIN CHALL DEM D; Health and Social Care Information Centre, 2014, COMM CAR STAT SOC SE; Heij C, 2004, ECONOMETRIC METHODS, V1st Edn; Holroyd-Leduc JM, 2004, J AM GERIATR SOC, V52, P712, DOI 10.1111/j.1532-5415.2004.52207.x; Kane M., 2013, DEMENTIA 2013 HIDDEN; Lewis F., 2014, TRAJECTORY DEMENTIA; Lievesley N, 2011, CHANGING ROLE CARE H; Moise P., 2004, OECD HLTH WORKING PA, DOI [10.1787/485700737071, DOI 10.1787/485700737071]; NHS Commissioning Board, 2013, ENH SERV SPEC FAC TI; NHS England, 2014, 02374 NHS ENGL; Tampi RR, 2011, CLIN GERIATR MED, V19, P41; Young J, 2013, REPORT NATL AUDIT DE	22	10	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0155850	10.1371/journal.pone.0155850	http://dx.doi.org/10.1371/journal.pone.0155850			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27227403	Green Published, Green Accepted, gold			2023-01-03	WOS:000376882500038
J	Salvalaio, M; Rigon, L; Belletti, D; D'Avanzo, F; Pederzoli, F; Ruozi, B; Marin, O; Vandelli, MA; Forni, F; Scarpa, M; Tomanin, R; Tosi, G				Salvalaio, Marika; Rigon, Laura; Belletti, Daniela; D'Avanzo, Francesca; Pederzoli, Francesca; Ruozi, Barbara; Marin, Oriano; Vandelli, Maria Angela; Forni, Flavio; Scarpa, Maurizio; Tomanin, Rosella; Tosi, Giovanni			Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; DRUG-DELIVERY; HUNTER-SYNDROME; MOUSE MODELS; BARRIER; THERAPY; INFLAMMATION; CONVECTION; TRANSPORT; DISEASES	Lysosomal Storage Disorders (LSDs) are a group of metabolic syndromes, each one due to the deficit of one lysosomal enzyme. Many LSDs affect most of the organ systems and overall about 75% of the patients present neurological impairment. Enzyme Replacement Therapy, although determining some systemic clinical improvements, is ineffective on the CNS disease, due to enzymes' inability to cross the blood-brain barrier (BBB). With the aim to deliver the therapeutic enzymes across the BBB, we here assayed biodegradable and biocompatible PLGA-nanoparticles (NPs) in two murine models for LSDs, Mucopolysaccharidosis type I and II (MPS I and MPS II). PLGA-NPs were modified with a 7-aminoacid glycopeptide (g7), yet demonstrated to be able to deliver low molecular weight (MW) molecules across the BBB in rodents. We specifically investigated, for the first time, the g7-NPs ability to transfer a model drug (FITC-albumin) with a high MW, comparable to the enzymes to be delivered for LSDs brain therapy. In vivo experiments, conducted on wild-type mice and knockout mouse models for MPS I and II, also included a whole series of control injections to obtain a broad preliminary view of the procedure efficiency. Results clearly showed efficient BBB crossing of albumin in all injected mice, underlying the ability of NPs to deliver high MW molecules to the brain. These results encourage successful experiments with enzyme-loaded g7-NPs to deliver sufficient amounts of the drug to the brain district on LSDs, where exerting a corrective effect on the pathological phenotype.	[Salvalaio, Marika; Rigon, Laura; D'Avanzo, Francesca; Scarpa, Maurizio; Tomanin, Rosella] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy; [Belletti, Daniela; Pederzoli, Francesca; Ruozi, Barbara; Vandelli, Maria Angela; Forni, Flavio; Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Life Sci, Modena, Italy; [Marin, Oriano] Univ Padua, Dept Biomed Sci, Padua, Italy; [Salvalaio, Marika; Pederzoli, Francesca] Pediat Res Inst Citta Speranza, Padua, Italy; [Marin, Oriano] Univ Padua, CRIBI Biotechnol Ctr, Padua, Italy; [D'Avanzo, Francesca; Scarpa, Maurizio] Brains Brain Fdn Onlus, Padua, Italy	University of Padua; Universita di Modena e Reggio Emilia; University of Padua; Fondazione Citta della Speranza; University of Padua	Tomanin, R (corresponding author), Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy.; Tosi, G (corresponding author), Univ Modena & Reggio Emilia, Dept Life Sci, Modena, Italy.	rosella.tomanin@unipd.it; gtosi@unimore.it	Salvalaio, Marika/G-9538-2014; Rigon, Laura/D-2853-2016; D'Avanzo, Francesca/H-5081-2016; Scarpa, Maurizio/AAC-1467-2019; Belletti, Daniela/L-5288-2016; Tosi, Giovanni/D-4547-2011	Rigon, Laura/0000-0002-0233-1677; D'Avanzo, Francesca/0000-0002-2790-6481; Belletti, Daniela/0000-0003-2872-445X; SCARPA, MAURIZIO/0000-0002-0382-3251; Salvalaio, Marika/0000-0002-0221-1237; Tosi, Giovanni/0000-0001-8318-667X	Fondazione Cassa di Risparmio di Padova e Rovigo-Fondazione Istituto di Ricerca Pediatrica "Citta della Speranza" (Bando Ricerca Pediatrica) [13/09]; Brains for Brain Foundation-Onlus	Fondazione Cassa di Risparmio di Padova e Rovigo-Fondazione Istituto di Ricerca Pediatrica "Citta della Speranza" (Bando Ricerca Pediatrica); Brains for Brain Foundation-Onlus	The project was partly funded by Fondazione Cassa di Risparmio di Padova e Rovigo-Fondazione Istituto di Ricerca Pediatrica "Citta della Speranza" (Bando Ricerca Pediatrica 2012/2014, grant #13/09) and by the Brains for Brain Foundation-Onlus. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We wish to thank Dr. Neufeld (UCLA, CA, USA) and Dr. Heard (Pasteur Institute, Paris, France) for kindly providing the MPS I mouse model and Dr. Muenzer (UCLA, CA, USA) for kindly providing the MPS II mouse model. The project was partly funded by Fondazione Cassa di Risparmio di Padova e Rovigo-Fondazione Istituto di Ricerca Pediatrica "Citta della Speranza" (Bando Ricerca Pediatrica 2012/2014, grant #13/09) and by the Brains For Brain Foundation Onlus.	Begley DJ, 2008, CURR PHARM DESIGN, V14, P1566, DOI 10.2174/138161208784705504; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; Bondioli L, 2011, PARASITOLOGY, V138, P1384, DOI 10.1017/S0031182011001119; Bondioli L, 2010, BIOMATERIALS, V31, P3395, DOI 10.1016/j.biomaterials.2010.01.049; BOVE KE, 1995, HUM PATHOL, V26, P1040, DOI 10.1016/0046-8177(95)90097-7; Boyle J, BIND THERAPEUTICS RE; Cardone M, 2006, HUM MOL GENET, V15, P1225, DOI 10.1093/hmg/ddl038; Chhabra R, 2014, INT J PHARMACEUT, V471, P349, DOI 10.1016/j.ijpharm.2014.05.054; Clarke L.A., 1993, GENEREVIEWS R; Date PV, 2010, AAPS PHARMSCITECH, V11, P304, DOI 10.1208/s12249-010-9382-3; Friso A, 2005, J GENE MED, V7, P1482, DOI 10.1002/jgm.790; Fuller M, 2006, FABRY DIS PERSPECTIV; Garbuzova-Davis S, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-174; Garbuzova-Davis S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016601; Garcia AR, 2007, J INHERIT METAB DIS, V30, P924, DOI 10.1007/s10545-007-0641-8; Jeyakumar M, 2003, BRAIN, V126, P974, DOI 10.1093/brain/awg089; Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsci.2007.05.014; Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008; Kroll RA, 1996, NEUROSURGERY, V38, P746, DOI 10.1227/00006123-199604000-00024; Liu YT, 2010, BIOMATERIALS, V31, P330, DOI 10.1016/j.biomaterials.2009.09.036; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Nobs L, 2004, EUR J PHARM BIOPHARM, V58, P483, DOI 10.1016/j.ejpb.2004.04.006; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Pardridge William M, 2005, NeuroRx, V2, P3; Rosca ID, 2004, J CONTROL RELEASE, V99, P271, DOI 10.1016/j.jconrel.2004.07.007; Ruozi B, 2014, CNS NEUROL DISORD-DR, V13, P1475, DOI 10.2174/1871527313666140806145540; Sands MS, 2008, ACTA PAEDIATR, V97, P22, DOI 10.1111/j.1651-2227.2008.00660.x; Scarpa M., 1993, GENEREVIEWS R; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Siegal T, 2000, J NEUROSURG, V92, P599, DOI 10.3171/jns.2000.92.4.0599; Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022; Tosi G, 2011, J NEURAL TRANSM, V118, P145, DOI 10.1007/s00702-010-0497-1; Tosi G, 2008, EXPERT OPIN DRUG DEL, V5, P155, DOI 10.1517/17425247.5.2.155; Tosi G, 2014, J CONTROL RELEASE, V177, P96, DOI 10.1016/j.jconrel.2014.01.004; Tosi G, 2013, NANOMEDICINE-UK, V8, P1373, DOI [10.2217/nnm.12.172, 10.2217/NNM.12.172]; Tosi G, 2011, NANOMEDICINE-UK, V6, P423, DOI [10.2217/nnm.11.11, 10.2217/NNM.11.11]; Valencia PM, 2011, BIOMATERIALS, V32, P6226, DOI 10.1016/j.biomaterials.2011.04.078; Vilella A, 2014, J CONTROL RELEASE, V174, P195, DOI 10.1016/j.jconrel.2013.11.023; Vitner EB, 2012, BRAIN, V135, P1724, DOI 10.1093/brain/aws095; Wang DR, 2013, P NATL ACAD SCI USA, V110, P2999, DOI 10.1073/pnas.1222742110; Werner ME, 2013, INT J RADIAT ONCOL, V86, P463, DOI 10.1016/j.ijrobp.2013.02.009; Wohlfart S, 2012, J CONTROL RELEASE, V161, P264, DOI 10.1016/j.jconrel.2011.08.017	43	53	54	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0156452	10.1371/journal.pone.0156452	http://dx.doi.org/10.1371/journal.pone.0156452			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27228099	Green Published, gold, Green Submitted			2023-01-03	WOS:000376882500139
J	Chouaib, S; Noman, MZ; Kosmatopoulos, K; Curran, MA				Chouaib, S.; Noman, M. Z.; Kosmatopoulos, K.; Curran, M. A.			Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer	ONCOGENE			English	Review							CYTOTOXIC T-LYMPHOCYTES; REGULATORY T; INDUCIBLE FACTOR-1-ALPHA; TUMOR MICROENVIRONMENT; INDUCED AUTOPHAGY; INTRATUMORAL INFILTRATION; CELL CYTOTOXICITY; SUPPRESSOR-CELLS; EXTRACELLULAR PH; GENE-EXPRESSION	Tumors use several strategies to evade the host immune response, including creation of an immune-suppressive and hostile tumor environment. Tissue hypoxia due to inadequate blood supply is reported to develop very early during tumor establishment. Hypoxic stress has a strong impact on tumor cell biology. In particular, tissue hypoxia contributes to therapeutic resistance, heterogeneity and progression. It also interferes with immune plasticity, promotes the differentiation and expansion of immune-suppressive stromal cells, and remodels the metabolic landscape to support immune privilege. Therefore, tissue hypoxia has been regarded as a central factor for tumor aggressiveness and metastasis. In this regard, manipulating host-tumor interactions in the context of the hypoxic tumor microenvironment may be important in preventing or reverting malignant conversion. We will discuss how tumor microenvironmentdriven transient compositional tumor heterogeneity involves hypoxic stress. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of conventional therapies as well as cancer immunotherapy. Thus, understanding how tumor and stromal cells respond to hypoxia will allow for the design of innovative cancer therapies that can overcome these barriers. A better understanding of hypoxia-dependent mechanisms involved in the regulation of immune tolerance could lead to new strategies to enhance antitumor immunity. Therefore, discovery and validation of therapeutic targets derived from the hypoxic tumor microenvironment is of major importance. In this context, critical hypoxia-associated pathways are attractive targets for immunotherapy of cancer. In this review, we summarize current knowledge regarding the molecular mechanisms induced by tumor cell hypoxia with a special emphasis on therapeutic resistance and immune suppression. We emphasize mechanisms of manipulating hypoxic stress and its associated pathways, which may support the development of more durable and successful cancer immunotherapy approaches in the future.	[Chouaib, S.; Noman, M. Z.] INSERM, UMR1186, Lab Integrat Tumor Immunol & Genet Oncol, Villejuif, France; [Chouaib, S.; Noman, M. Z.] Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, INSERM, Villejuif, France; [Kosmatopoulos, K.] Vaxon Biotech, Paris, France; [Curran, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U1186, 39 Camille Desmoulins, F-94805 Villejuif, Ile De France, France.	salem.chouaib@gustaveroussy.fr	NOMAN, Muhammmad Zaeem/AAJ-1465-2021; Noman, Muhammad zaeem/AAF-8483-2020; NOMAN, Muhammmad Zaeem/AAJ-1466-2021; Chouaib, Salem/F-7939-2016	NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; Curran, Michael/0000-0003-4996-7207	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allavena P, 2012, CLIN EXP IMMUNOL, V167, P195, DOI 10.1111/j.1365-2249.2011.04515.x; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Becker JC, 2013, CANCER IMMUNOL IMMUN, V62, P1137, DOI 10.1007/s00262-013-1434-6; Bellone M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00231; Ben-Shoshan J, 2008, EUR J IMMUNOL, V38, P2412, DOI 10.1002/eji.200838318; Blay J, 1997, CANCER RES, V57, P2602; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Caldwell CC, 2001, J IMMUNOL, V167, P6140, DOI 10.4049/jimmunol.167.11.6140; Cary, 2014, NEURO-ONCOLOGY, V16, pII3; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Chafe SC, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1048955; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Doedens AL, 2013, NAT IMMUNOL, V14, P1173, DOI 10.1038/ni.2714; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; DROGE W, 1987, CELL IMMUNOL, V108, P405, DOI 10.1016/0008-8749(87)90223-1; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Hamai A, 2010, TISSUE ANTIGENS, V75, P1, DOI 10.1111/j.1399-0039.2009.01401.x; Hasmim M, 2013, J IMMUNOL, V191, P5802, DOI 10.4049/jimmunol.1302140; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; Hoskin DW, 2008, INT J ONCOL, V32, P527; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Kobie JJ, 2006, J IMMUNOL, V177, P6780, DOI 10.4049/jimmunol.177.10.6780; Kotsakis A, 2012, ANN ONCOL, V23, P442, DOI 10.1093/annonc/mdr396; Kryczek I, 2011, J IMMUNOL, V186, P4388, DOI 10.4049/jimmunol.1003251; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Lee JH, 2015, IMMUNITY, V42, P1062, DOI 10.1016/j.immuni.2015.05.016; Lin Q, 2010, CANCER BIOL THER, V9, P949, DOI 10.4161/cbt.9.12.12347; Lin SS, 2012, CANCER SCI, V103, P904, DOI 10.1111/j.1349-7006.2012.02259.x; Lugini L, 2006, CANCER RES, V66, P3629, DOI 10.1158/0008-5472.CAN-05-3204; Lukashev D, 2007, CANCER METAST REV, V26, P273, DOI 10.1007/s10555-007-9054-2; Lukashev D, 2001, J BIOL CHEM, V276, P48754, DOI 10.1074/jbc.M104782200; Lukashev D, 2006, J IMMUNOL, V177, P4962, DOI 10.4049/jimmunol.177.8.4962; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mellor AL, 2008, NAT REV IMMUNOL, V8, P74, DOI 10.1038/nri2233; Messai Y, 2015, AUTOPHAGY; Messai Y, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985951; Messai Y, 2014, CANCER RES, V74, P6820, DOI 10.1158/0008-5472.CAN-14-0303; Metelo AM, 2015, ONCOTARGET, V6, P23036, DOI 10.18632/oncotarget.4564; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Nagaraj S, 2007, NAT MED, V13, P828, DOI 10.1038/nm1609; Nakagawa Y, 2015, IMMUNOL LETT, V167, P72, DOI 10.1016/j.imlet.2015.07.003; Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592; Noman MZ, 2016, CANCER LETT, V380, P257, DOI 10.1016/j.canlet.2015.10.026; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Noman MZ, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954463; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Noman MZ, 2012, AUTOPHAGY, V8, P704, DOI 10.4161/auto.19572; Noman MZ, 2011, CRIT REV IMMUNOL, V31, P357, DOI 10.1615/CritRevImmunol.v31.i5.10; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Noman MZ, 2011, B CANCER, V98, pE19, DOI 10.1684/bdc.2010.1295; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Ohta A, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00027; Palazon A, 2012, CANCER DISCOV, V2, P608, DOI 10.1158/2159-8290.CD-11-0314; Payen VL, 2016, CELL MOL LIFE SCI, V73, P1333, DOI 10.1007/s00018-015-2098-5; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; RATNER S, 1990, J NATL CANCER I, V82, P612, DOI 10.1093/jnci/82.7.612; REDEGELD F, 1991, J IMMUNOL, V147, P3638; Robbins JR, 2005, J PHYSIOL-LONDON, V564, P131, DOI 10.1113/jphysiol.2004.081893; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Saggar JK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00154; Sarkar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064835; Scardino A, 2002, J IMMUNOL, V168, P5900, DOI 10.4049/jimmunol.168.11.5900; Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Semenza GL, 2009, CURR PHARM DESIGN, V15, P3839, DOI 10.2174/138161209789649402; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sitkovsky MV, 2008, BLOOD, V111, P5424, DOI 10.1182/blood-2008-03-143990; Takehara H, 2006, DIGEST DIS SCI, V51, P2188, DOI 10.1007/s10620-006-9436-2; Tan S, 1998, J NEUROPATH EXP NEUR, V57, P544, DOI 10.1097/00005072-199806000-00002; Terry Stephane, 2015, Oncoscience, V2, P841; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thiel M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000853; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924; Widmer DS, 2013, J INVEST DERMATOL, V133, P2436, DOI 10.1038/jid.2013.115; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wolter F, 2015, J HEPATOL, V63, P1334, DOI 10.1016/j.jhep.2015.08.008; Xia Y, 2012, EUR J MED CHEM, V49, P24, DOI 10.1016/j.ejmech.2012.01.033; Yamada N, 2012, INT J ONCOL, V41, P2005, DOI 10.3892/ijo.2012.1630; Yeung TM, 2011, P NATL ACAD SCI USA, V108, P4382, DOI 10.1073/pnas.1014519107; Zhang JJ, 2016, J AM SOC NEPHROL, V27, P92, DOI 10.1681/ASN.2014121248	100	200	204	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					439	445		10.1038/onc.2016.225	http://dx.doi.org/10.1038/onc.2016.225			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345407	Green Accepted			2023-01-03	WOS:000394166700001
J	Gerdle, B; Ernberg, M; Mannerkorpi, K; Larsson, B; Kosek, E; Christidis, N; Ghafouri, B				Gerdle, Bjorn; Ernberg, Malin; Mannerkorpi, Kaisa; Larsson, Britt; Kosek, Eva; Christidis, Nikolaos; Ghafouri, Bijar			Increased Interstitial Concentrations of Glutamate and Pyruvate in Vastus Lateralis of Women with Fibromyalgia Syndrome Are Normalized after an Exercise Intervention - A Case-Control Study	PLOS ONE			English	Article							MUSCLE BLOOD-FLOW; CHRONIC WIDESPREAD PAIN; TRAPEZIUS MUSCLE; SKELETAL-MUSCLE; NITRIC-OXIDE; LACTATE CONCENTRATIONS; MASSETER MUSCLE; REGIONAL PAIN; MICRODIALYSIS; METABOLISM	Background Fibromyalgia syndrome (FMS) is associated with central alterations, but controversies exist regarding the presence and role of peripheral factors. Microdialysis (MD) can be used in vivo to study muscle alterations in FMS. Furthermore for chronic pain conditions such as FMS, the mechanisms for the positive effects of exercise are unclear. This study investigates the interstitial concentrations of algesics and metabolites in the vastus lateralis muscle of 29 women with FMS and 28 healthy women before and after an exercise intervention. Methods All the participants went through a clinical examination and completed a questionnaire. In addition, their pressure pain thresholds (PPTs) in their upper and lower extremities were determined. For both groups, MD was conducted in the vastus lateralis muscle before and after a 15-week exercise intervention of mainly resistance training of the lower limbs. Muscle blood flow and interstitial muscle concentrations of lactate, pyruvate, glutamate, glucose, and glycerol were determined. Results FMS was associated with significantly increased interstitial concentrations of glutamate, pyruvate, and lactate. After the exercise intervention, the FMS group exhibited significant decreases in pain intensity and in mean interstitial concentrations of glutamate, pyruvate, and glucose. The decrease in pain intensity in FMS correlated significantly with the decreases in pyruvate and glucose. In addition, the FMS group increased their strength and endurance. Conclusion This study supports the suggestion that peripheral metabolic and algesic muscle alterations are present in FMS patients and that these alterations contribute to pain. After an exercise intervention, alterations normalized, pain intensity decreased (but not abolished), and strength and endurance improved, all findings that suggest the effects of exercise are partially peripheral.	[Gerdle, Bjorn; Larsson, Britt; Ghafouri, Bijar] Linkoping Univ, Pain & Rehabil Ctr, Linkoping, Sweden; [Gerdle, Bjorn; Larsson, Britt; Ghafouri, Bijar] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Ernberg, Malin; Christidis, Nikolaos] Karolinska Inst, Dept Dent Med, Sect Orofacial Pain & Jaw Funct, Stockholm, Sweden; [Ernberg, Malin; Christidis, Nikolaos] SCON, Stockholm, Sweden; [Mannerkorpi, Kaisa] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Sect Physiotherapy, Gothenburg, Sweden; [Mannerkorpi, Kaisa] Univ Gothenburg, Sahlgrenska Acad, Ctr Person Ctr Care GPCC, Gothenburg, Sweden; [Kosek, Eva] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Kosek, Eva] Karolinska Inst, Osher Ctr Integrat Med, Stockholm, Sweden	Linkoping University; Linkoping University; Karolinska Institutet; University of Gothenburg; University of Gothenburg; Karolinska Institutet; Karolinska Institutet	Gerdle, B (corresponding author), Linkoping Univ, Pain & Rehabil Ctr, Linkoping, Sweden.; Gerdle, B (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.	bjorn.gerdle@liu.se	Ernberg, Malin/AAR-5588-2020; Christidis, Nikolaos/AAB-7471-2020	Christidis, Nikolaos/0000-0002-8199-7863; Kosek, Eva/0000-0003-0488-8177; Mannerkorpi, Kaisa/0000-0003-4997-9523	Swedish Rheumatism Association; Swedish Research Council; Health and Medical Care Executive Board of Vastra Gotaland Region; ALF-LUA at Sahlgrenska University Hospital and Linkbping University Hospital, Linkbping University, Gothenburg Centre for Person Centred Care (GPCC); AFA Insurance	Swedish Rheumatism Association; Swedish Research Council(Swedish Research CouncilEuropean Commission); Health and Medical Care Executive Board of Vastra Gotaland Region; ALF-LUA at Sahlgrenska University Hospital and Linkbping University Hospital, Linkbping University, Gothenburg Centre for Person Centred Care (GPCC); AFA Insurance	This work was funded by the Swedish Rheumatism Association, the Swedish Research Council, the Health and Medical Care Executive Board of Vastra Gotaland Region, ALF-LUA at Sahlgrenska University Hospital and Linkbping University Hospital, Linkbping University, Gothenburg Centre for Person Centred Care (GPCC) and AFA Insurance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn AH, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0379-y; Alfredson H, 2001, J ORTHOPAED RES, V19, P881, DOI 10.1016/S0736-0266(01)00016-X; Allen M, 2011, PEDIATR CRIT CARE ME, V12, pS43, DOI 10.1097/PCC.0b013e3182211aed; Barbieri Elena, 2012, J Signal Transduct, V2012, P982794, DOI 10.1155/2012/982794; Bazzichi L, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-36; Benarroch EE, 2011, NEUROLOGY, V77, P1568, DOI 10.1212/WNL.0b013e318233b3e4; BENGTSSON A, 1986, SCAND J RHEUMATOL, V15, P1; Bengtsson A, 2002, RHEUMATOLOGY, V41, P721, DOI 10.1093/rheumatology/41.7.721; Bennett RM, 1999, MAYO CLIN PROC, V74, P385, DOI 10.4065/74.4.385; Birdsong WT, 2010, NEURON, V68, P739, DOI 10.1016/j.neuron.2010.09.029; Birklein F, 2000, NEUROLOGY, V55, P1213, DOI 10.1212/WNL.55.8.1213; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bradley Laurence A, 2009, Am J Med, V122, pS22, DOI 10.1016/j.amjmed.2009.09.008; Brodin E, 2008, SCAND J UROL NEPHROL, V42, P293, DOI 10.1080/00365590701797556; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Busch A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003786.pub2; Busch AJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010884; Cairns BE, 2008, J MUSCULOSKELET PAIN, V16, P85, DOI 10.1080/10582450801960388; Chalaye P, 2012, CLIN J PAIN, V28, P519, DOI 10.1097/AJP.0b013e31823ae69e; Coggeshall RE, 1998, J COMP NEUROL, V391, P78; Cury Y, 2011, NITRIC OXIDE-BIOL CH, V25, P243, DOI 10.1016/j.niox.2011.06.004; Das UN, 2006, NUTRITION, V22, P965, DOI 10.1016/j.nut.2006.05.009; Cruz RSD, 2012, SCI WORLD J, DOI 10.1100/2012/420984; de Paoli FV, 2010, J PHYSIOL-LONDON, V588, P4785, DOI 10.1113/jphysiol.2010.196568; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; Draoui N, 2011, DIS MODEL MECH, V4, P727, DOI 10.1242/dmm.007724; Eisenhut M, 2011, PFLUG ARCH EUR J PHY, V461, P401, DOI 10.1007/s00424-010-0917-y; Elert J, 2001, J RHEUMATOL, V28, P1361; Elvin A, 2006, EUR J PAIN, V10, P137, DOI 10.1016/j.ejpain.2005.02.001; Eriksson L., 2006, MULTI MEGAVARIATE DA, DOI DOI 10.1016/j.arabjc.2013.10.006; Ernberg M, 1999, LIFE SCI, V65, P313, DOI 10.1016/S0024-3205(99)00250-7; Ernberg M, 2013, EUR J PAIN, V17, P539, DOI 10.1002/j.1532-2149.2012.00216.x; Falla D, 2010, J ELECTROMYOGR KINES, V20, P457, DOI 10.1016/j.jelekin.2009.07.002; Fan WG, 2012, NITRIC OXIDE-BIOL CH, V26, P32, DOI 10.1016/j.niox.2011.11.003; Fink MP, 2007, J INTERN MED, V261, P349, DOI 10.1111/j.1365-2796.2007.01789.x; Gerdle B, 2013, EUR J PAIN, V17, P1205, DOI 10.1002/j.1532-2149.2013.00284.x; Gerdle B, 2012, POTENTIAL MUSCLE BIO; Gerdle B, 2014, J PAIN RES, V7, P313, DOI 10.2147/JPR.S59144; Gerdle B, 2014, CLIN J PAIN, V30, P409, DOI 10.1097/AJP.0b013e31829e9d2a; Gerdle B, 2010, J REHABIL MED, V42, P679, DOI 10.2340/16501977-0581; Gerdle B, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-42; Ghafouri N, 2014, PAIN MED, V15, P1379, DOI 10.1111/pme.12486; Ghafouri N, 2013, PAIN, V154, P1649, DOI 10.1016/j.pain.2013.05.002; Gjedsted J, 2011, ACTA PHYSIOL, V202, P641, DOI 10.1111/j.1748-1716.2011.02316.x; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Hannibal KE, 2014, PHYS THER, V94, P1816, DOI 10.2522/ptj.20130597; Hassett AL, 2011, BEST PRACT RES CL RH, V25, P299, DOI 10.1016/j.berh.2011.01.005; Herren-Gerber R, 2004, PAIN MED, V5, P366, DOI 10.1111/j.1526-4637.2004.04055.x; HICKNER RC, 1994, CLIN SCI, V86, P15, DOI 10.1042/cs0860015; Hurley BF, 2011, SPORTS MED, V41, P289, DOI 10.2165/11585920-000000000-00000; Immke D C, 2001, ScientificWorldJournal, V1, P510; Jansen JJ, 2012, METABOLOMICS, V8, P422, DOI 10.1007/s11306-011-0316-1; Jensen KB, 2012, NEUROSCI LETT, V520, P156, DOI 10.1016/j.neulet.2012.03.010; Jensen KB, 2009, PAIN, V144, P95, DOI 10.1016/j.pain.2009.03.018; Kallenborn-Gerhardt W, 2012, NOXIOUS SIGNALING PA; Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007; Karlsson L, 2015, EUR J PAIN, V19, P1075, DOI 10.1002/ejp.630; Kim TJ, 2007, J PAIN, V8, P59, DOI 10.1016/j.jpain.2006.06.003; Kosek E, 1996, PAIN, V64, P415, DOI 10.1016/0304-3959(95)00112-3; Kristensen J, 2012, BRIT J SPORT MED, V46, P719, DOI 10.1136/bjsm.2010.079376; Kulshreshtha P, 2013, CLIN PHYSIOL FUNCT I, V33, P83, DOI 10.1111/cpf.12000; Lam David K, 2005, Pain Res Manag, V10, P145; Lannersten L, 2010, PAIN, V151, P77, DOI 10.1016/j.pain.2010.06.021; Lanza IR, 2008, DIABETES, V57, P2933, DOI 10.2337/db08-0349; Lanza IR, 2010, PFLUG ARCH EUR J PHY, V459, P277, DOI 10.1007/s00424-009-0724-5; Lanza IR, 2009, AM J CLIN NUTR, V89, p467S, DOI 10.3945/ajcn.2008.26717D; Larsson A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0679-1; Lee Y, 2005, MOL CELLS, V20, P315; Leggin B G, 1996, J Shoulder Elbow Surg, V5, P18, DOI 10.1016/S1058-2746(96)80026-7; Louca S, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-89; LUND N, 1986, SCAND J RHEUMATOL, V15, P165, DOI 10.3109/03009748609102084; Mannerkorpi K, 1999, ARTHRIT CARE RES, V12, P193, DOI 10.1002/1529-0131(199906)12:3<193::AID-ART6>3.0.CO;2-N; Mannerkorpi K, 2009, J REHABIL MED, V41, P751, DOI 10.2340/16501977-0409; Mantyselka P, 2008, RHEUMATOLOGY, V47, P1235, DOI 10.1093/rheumatology/ken220; Mantyselka P, 2008, PAIN, V137, P34, DOI 10.1016/j.pain.2007.08.007; McIver KL, 2006, PAIN, V120, P161, DOI 10.1016/j.pain.2005.10.032; Miller KE, 2011, PHARMACOL THERAPEUT, V130, P283, DOI 10.1016/j.pharmthera.2011.01.005; NORREGAARD J, 1994, J NEUROL NEUROSUR PS, V57, P1106, DOI 10.1136/jnnp.57.9.1106; Oaklander AL, 2013, PAIN, V154, P2310, DOI 10.1016/j.pain.2013.06.001; Olausson P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052560; Ortega E, 2009, EXERC IMMUNOL REV, V15, P42; Palstam A, 2014, J REHABIL MED, V46, P773, DOI 10.2340/16501977-1843; Park JH, 1998, ARTHRITIS RHEUM, V41, P406, DOI 10.1002/1529-0131(199803)41:3<406::AID-ART5>3.3.CO;2-C; Peolsson M, 2007, J REHABIL MED, V39, P260, DOI 10.2340/16501977-0052; Petersel DL, 2011, J NEUROSCI RES, V89, P29, DOI 10.1002/jnr.22512; Philp A, 2005, J EXP BIOL, V208, P4561, DOI 10.1242/jeb.01961; Pohjanen E, 2007, J PROTEOME RES, V6, P2113, DOI 10.1021/pr070007g; Pollak KA, 2014, EXP PHYSIOL, V99, P368, DOI 10.1113/expphysiol.2013.075812; Ren G, 2009, EUR SPINE J, V18, P1604, DOI 10.1007/s00586-009-1021-x; Robergs RA, 2004, AM J PHYSIOL-REG I, V287, pR502, DOI 10.1152/ajpregu.00114.2004; Sandberg M, 2004, EUR J PAIN, V8, P163, DOI 10.1016/S1090-3801(03)00090-9; Schaible HG, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3305; Schaufelberger M, 1997, EUR HEART J, V18, P971; SCHELLER D, 1991, J NEUROSCI METH, V40, P31, DOI 10.1016/0165-0270(91)90114-F; Schmidt-Wilcke T, 2011, NAT REV RHEUMATOL, V7, P518, DOI 10.1038/nrrheum.2011.98; Schneider GM, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-29; Serra J, 2014, ANN NEUROL, V75, P196, DOI 10.1002/ana.24065; Shang Y, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4079; Sjogaard G, 2010, EUR J APPL PHYSIOL, V108, P657, DOI 10.1007/s00421-009-1268-2; Sjors A, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-230; Smith HS, 2011, PAIN PHYSICIAN, V14, pE217; Stallknecht B, 1999, J APPL PHYSIOL, V86, P1054, DOI 10.1152/jappl.1999.86.3.1054; Staud R, 2008, J MUSCULOSKELET PAIN, V16, P67, DOI 10.1080/10582450801960339; Staud R, 2011, BEST PRACT RES CL RH, V25, P155, DOI 10.1016/j.berh.2010.01.010; Staud R, 2010, J PAIN, V11, P1376, DOI 10.1016/j.jpain.2010.03.011; Staud R, 2009, PAIN, V145, P96, DOI 10.1016/j.pain.2009.05.020; Steiger F, 2012, EUR SPINE J, V21, P575, DOI 10.1007/s00586-011-2045-6; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Tegeder I, 2002, INFLAMM RES, V51, P393, DOI 10.1007/PL00000320; Uceyler N, 2013, BRAIN, V136, P1857, DOI 10.1093/brain/awt053; Valkeinen H, 2006, ARTHRITIS RHEUM, V54, P1334, DOI 10.1002/art.21751; van Hall G, 2010, ACTA PHYSIOL, V199, P499, DOI 10.1111/j.1748-1716.2010.02122.x; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Zhang YJ, 2013, PAIN MED, V14, P1291, DOI 10.1111/pme.12158; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	116	21	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2016	11	10							e0162010	10.1371/journal.pone.0162010	http://dx.doi.org/10.1371/journal.pone.0162010			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0TR	27695113	Green Submitted, gold, Green Published			2023-01-03	WOS:000385553100010
J	Roberts, CT; Owen, LS; Manley, BJ; Froisland, DH; Donath, SM; Dalziel, KM; Pritchard, MA; Cartwright, DW; Collins, CL; Malhotra, A; Davis, PG; Investigators, HT				Roberts, Calum T.; Owen, Louise S.; Manley, Brett J.; Froisland, Dag H.; Donath, Susan M.; Dalziel, Kim M.; Pritchard, Margo A.; Cartwright, David W.; Collins, Clare L.; Malhotra, Atul; Davis, Peter G.; Investigators, H. I. P. S. T. E. R. Trial			Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; CANNULAE; CPAP	BACKGROUND Treatment with nasal high-flow therapy has efficacy similar to that of nasal continuous positive airway pressure (CPAP) when used as postextubation support in neonates. The efficacy of high-flow therapy as the primary means of respiratory support for preterm infants with respiratory distress has not been proved. METHODS In this international, multicenter, randomized, noninferiority trial, we assigned 564 preterm infants (gestational age, >= 28 weeks 0 days) with early respiratory distress who had not received surfactant replacement to treatment with either nasal high-flow therapy or nasal CPAP. The primary outcome was treatment failure within 72 hours after randomization. Noninferiority was determined by calculating the absolute difference in the risk of the primary outcome; the chosen margin of noninferiority was 10 percentage points. Infants in whom high-flow therapy failed could receive rescue CPAP; infants in whom CPAP failed were intubated and mechanically ventilated. RESULTS Trial recruitment stopped early at the recommendation of the independent data and safety monitoring committee because of a significant difference in the primary outcome between treatment groups. Treatment failure occurred in 71 of 278 infants (25.5%) in the high-flow group and in 38 of 286 infants (13.3%) in the CPAP group (risk difference, 12.3 percentage points; 95% confidence interval [CI], 5.8 to 18.7; P<0.001). The rate of intubation within 72 hours did not differ significantly between the high-flow and CPAP groups (15.5% and 11.5%, respectively; risk difference, 3.9 percentage points; 95% CI, -1.7 to 9.6; P = 0.17), nor did the rate of adverse events. CONCLUSIONS When used as primary support for preterm infants with respiratory distress, high-flow therapy resulted in a significantly higher rate of treatment failure than did CPAP. (Funded by the National Health and Medical Research Council and others; Australian New Zealand Clinical Trials Registry number, ACTRN12613000303741.)	[Roberts, Calum T.; Owen, Louise S.; Manley, Brett J.; Froisland, Dag H.; Davis, Peter G.] Royal Womens Hosp, Neonatal Serv & Newborn Res Ctr, Melbourne, Vic, Australia; [Roberts, Calum T.; Owen, Louise S.; Manley, Brett J.; Davis, Peter G.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Donath, Susan M.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Dalziel, Kim M.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Owen, Louise S.; Davis, Peter G.] Mercy Hosp Women, Murdoch Childrens Res Inst, Neonatal Serv, Crit Care & Neurosci, Melbourne, Vic, Australia; [Donath, Susan M.] Mercy Hosp Women, Murdoch Childrens Res Inst, Neonatal Serv, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; [Malhotra, Atul] Monash Childrens Hosp, Monash Newborn, Melbourne, Vic, Australia; [Malhotra, Atul] Monash Univ, Dept Paediat, Melbourne, Vic, Australia; [Pritchard, Margo A.] Australian Catholic Univ, Sch Nursing Midwifery & Paramed, Sydney, NSW 2059, Australia; [Pritchard, Margo A.] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia; [Cartwright, David W.] Univ Queensland, Dept Paediat, Brisbane, Qld, Australia; [Cartwright, David W.] Royal Brisbane & Womens Hosp, Womens Serv, Brisbane, Qld, Australia; [Cartwright, David W.] Royal Brisbane & Womens Hosp, Newborn Serv, Brisbane, Qld, Australia; [Froisland, Dag H.] Innlandet Hosp Trust, Dept Pediat, Lillehammer, Norway	University of Melbourne; University of Melbourne; University of Melbourne; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Monash University; Australian Catholic University; Mater Research; University of Queensland; University of Queensland; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; Innlandet Hospital Trust	Owen, LS (corresponding author), Royal Womens Hosp, Newborn Res Ctr, Level 7,Locked Bag 300, Parkville, Vic 3052, Australia.	louise.owen@thewomens.org.au	Cartwright, David W/M-3202-2016; Roberts, Calum/AAW-9110-2020; Cartwright, David W/M-7330-2013; Pritchard, Margo/G-5188-2010	Roberts, Calum/0000-0002-9111-5027; Manley, Brett/0000-0003-0212-7956; Malhotra, Atul/0000-0001-9664-4182; Pritchard, Margo/0000-0002-1058-9117; O'Shea, Joyce/0000-0002-3286-3500; Dalziel, Kim/0000-0003-4972-8871; Donath, Susan/0000-0003-2489-3977	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Funded by the National Health and Medical Research Council and others; Australian New Zealand Clinical Trials Registry number, ACTRN12613000303741.	Chess PR, 2006, SEMIN PERINATOL, V30, P171, DOI 10.1053/j.semperi.2006.05.003; Ciuffini F, 2014, Pediatr Med Chir, V36, P88, DOI 10.4081/pmc.2014.88; Collins CL, 2013, J PEDIATR-US, V162, P949, DOI 10.1016/j.jpeds.2012.11.016; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Hamilton Brady E, 2015, Natl Vital Stat Rep, V64, P1; Hochwald OO H, 2010, J NEONATAL PERINATAL, V3, P187; Hough JL, 2012, J PAEDIATR CHILD H, V48, P106, DOI 10.1111/j.1440-1754.2011.02070.x; Iranpour R, 2011, J ISFAHAN MED SCH, V29, P761; Klingenberg C, 2014, ARCH DIS CHILD-FETAL, V99, pF134, DOI 10.1136/archdischild-2013-304525; Kubicka ZJ, 2008, PEDIATRICS, V121, P82, DOI 10.1542/peds.2007-0957; Manley BJ, 2013, NEW ENGL J MED, V369, P1425, DOI 10.1056/NEJMoa1300071; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Nair G, 2005, PED AC SOC M BALT MA; Osman M, 2015, J PERINATOL, V35, P263, DOI 10.1038/jp.2014.206; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Roberts CT, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008483; Roberts CT, 2014, J PAEDIATR CHILD H, V50, P806, DOI 10.1111/jpc.12636; Spence KL, 2007, J PERINATOL, V27, P772, DOI 10.1038/sj.jp.7211828; Wilkinson DJ, 2008, J PERINATOL, V28, P42, DOI 10.1038/sj.jp.7211879; Wilkinson D, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006405.pub3; Yoder BA, 2013, PEDIATRICS, V131, pE1482, DOI 10.1542/peds.2012-2742	22	130	146	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	2016	375	12					1142	1151		10.1056/NEJMoa1603694	http://dx.doi.org/10.1056/NEJMoa1603694			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DW3JE	27653564				2023-01-03	WOS:000383537100007
J	Beard, E; West, R; Michie, S; Brown, J				Beard, Emma; West, Robert; Michie, Susan; Brown, Jamie			Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TOBACCO CONTROL POLICIES; MASS-MEDIA CAMPAIGNS; PREVALENCE; IMPACT; ABSTINENCE; HYPOTHESIS; MORTALITY; HEALTH; GROWTH; ADULTS	OBJECTIVES To estimate how far changes in the prevalence of electronic cigarette (e-cigarette) use in England have been associated with changes in quit success, quit attempts, and use of licensed medication and behavioural support in quit attempts. DESIGN Time series analysis of population trends. PARTICIPANTS Participants came from the Smoking Toolkit Study, which involves repeated, cross sectional household surveys of individuals aged 16 years and older in England. Data were aggregated on about 1200 smokers quarterly between 2006 and 2015. Monitoring data were also used from the national behavioural support programme; during the study, 8 029 012 quit dates were set with this programme. SETTING England. MAIN OUTCOME MEASURES Prevalence of e-cigarette use in current smokers and during a quit attempt were used to predict quit success. Prevalence of e-cigarette use in current smokers was used to predict rate of quit attempts. Percentage of quit attempts involving e-cigarette use was also used to predict quit attempts involving use of prescription treatments, nicotine replacement therapy (NRT) on prescription and bought over the counter, and use of behavioural support. Analyses involved adjustment for a range of potential confounders. RESULTS The success rate of quit attempts increased by 0.098% (95% confidence interval 0.064 to 0.132; P<0.001) and 0.058% (0.038 to 0.078; P<0.001) for every 1% increase in the prevalence of e-cigarette use by smokers and e-cigarette use during a recent quit attempt, respectively. There was no clear evidence for an association between e-cigarette use and rate of quit attempts (beta 0.025; 95% confidence interval -0.035 to 0.085; P=0.41), use of NRT bought over the counter (beta 0.006; -0.088 to 0.077; P=0.89), use of prescription treatment (beta -0.070; -0.152 to 0.013; P=0.10), or use of behavioural support (beta -0.013; -0.102 to 0.077; P=0.78). A negative association was found between e-cigarette use during a recent quit attempt and use of NRT obtained on prescription (beta -0.098; -0.189 to -0.007; P=0.04). CONCLUSION Changes in prevalence of e-cigarette use in England have been positively associated with the success rates of quit attempts. No clear association has been found between e-cigarette use and the rate of quit attempts or the use of other quitting aids, except for NRT obtained on prescription, where the association has been negative.	[Beard, Emma; Michie, Susan; Brown, Jamie] UCL, Res Dept Clin Educ & Hlth Psychol, London WC1E 7HB, England; [Beard, Emma; West, Robert; Brown, Jamie] UCL, Canc Res UK Hlth Behav Res Ctr, Dept Epidemiol & Publ Hlth, London, England	University of London; University College London; Cancer Research UK; University of London; University College London	Beard, E (corresponding author), UCL, Res Dept Clin Educ & Hlth Psychol, London WC1E 7HB, England.; Beard, E (corresponding author), UCL, Canc Res UK Hlth Behav Res Ctr, Dept Epidemiol & Publ Hlth, London, England.	e.beard@ucl.ac.uk	Brown, Jamie/F-4413-2011; West, Robert/B-5414-2009	Brown, Jamie/0000-0002-2797-5428; West, Robert/0000-0001-6398-0921	Cancer Research UK [C1417/A14135, C36048/A11654, C44576/ A19501]; Pfizer; GlaxoSmithKline; Department of Health; Society for the Study of Addiction; National Institute for Health Research's (NIHR) School for Public Health Research (SPHR) [SPHR-SWP-ALC-WP5]; SPHR [SPHR-SWP-ALC-WP5]; Cancer Research UK [14135] Funding Source: researchfish; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; Medical Research Council [MR/K023195/1] Funding Source: researchfish; Versus Arthritis [19501] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); Department of Health; Society for the Study of Addiction; National Institute for Health Research's (NIHR) School for Public Health Research (SPHR)(National Institute for Health Research (NIHR)); SPHR; Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Versus Arthritis(Versus Arthritis)	The Smoking Toolkit Study is currently primarily funded by Cancer Research UK (C1417/A14135; C36048/A11654; C44576/ A19501), and has previously also been funded by Pfizer, GlaxoSmithKline, and the Department of Health. JB's post is funded by a fellowship from the Society for the Study of Addiction, and Cancer Research UK also provide support (C1417/A14135); RW is funded by Cancer Research UK (C1417/A14135). EB is funded by a fellowship from the National Institute for Health Research's (NIHR) School for Public Health Research (SPHR) (SPHR-SWP-ALC-WP5), and Cancer Research UK also provide support (C1417/A14135). SW is funded by Cancer Research UK (C1417/A14135), and the SPHR (SPHR-SWP-ALC-WP5) also provide support. The SPHR is a partnership between the Universities of Sheffield, Bristol, Cambridge, and Exeter; University College London (UCL); London School for Hygiene and Tropical Medicine; LiLaC collaboration between the Universities of Liverpool and Lancaster and Fuse; and the Centre for Translational Research in Public Health, a collaboration between Newcastle, Durham, Northumbria, Sunderland, and Teesside Universities. The views expressed are those of the authors(s) and not necessarily those of the NHS, NIHR, or Department of Health. No funders had any involvement in the design of the study, the analysis or interpretation of the data, the writing of the report, or the decision to submit the paper for publication.	Adkison SE, 2013, AM J PREV MED, V44, P207, DOI 10.1016/j.amepre.2012.10.018; [Anonymous], 2015, BBC; Beard E, 2015, THORAX, V70, P974, DOI 10.1136/thoraxjnl-2015-206801; Beard E, 2014, PATIENT EDUC COUNS, V94, P276, DOI 10.1016/j.pec.2013.10.022; Berg Carla J, 2014, Open J Prev Med, V4, P789; Box G. E. P., 1970, Time series analysis, forecasting and control; Brown J, 2014, ADDICTION, V109, P1531, DOI 10.1111/add.12623; Carter BD, 2015, NEW ENGL J MED, V372, P631, DOI 10.1056/NEJMsa1407211; Cho JH, 2011, J ADOLESCENT HEALTH, V49, P542, DOI 10.1016/j.jadohealth.2011.08.001; Christensen T, 2014, PREV MED, V69, P90, DOI 10.1016/j.ypmed.2014.09.005; Dienes Z, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00781; Dockrell M, 2013, NICOTINE TOB RES, V15, P1737, DOI 10.1093/ntr/ntt057; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Fidler JA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-479; Fidler JA, 2010, ADDICTION, V105, P1984, DOI 10.1111/j.1360-0443.2010.03039.x; Gallus S, 2006, TOB CONTROL, V15, P114, DOI 10.1136/tc.2005.012468; Glass GV, 1975, DESIGN ANAL TIME SER; Hackshaw L, 2010, TOB CONTROL, V19, P160, DOI 10.1136/tc.2009.032656; Health and Social Care Information Centre, 2015, NHS STOP SMOK SERV C; Health and Social Care Information Centre, 2015, STAT NHS STOP SMOK S; Hiscock R, 2015, INT J ENV RES PUB HE, V12, P16157, DOI 10.3390/ijerph121215048; Hughes JR, 2011, DRUG ALCOHOL DEPEN, V117, P111, DOI 10.1016/j.drugalcdep.2011.02.009; Hughes JR, 2004, ADDICTION, V99, P29, DOI 10.1111/j.1360-0443.2004.00540.x; Jensen L., 1989, INTERVENTION EFFECT; Kalkhoran S, 2016, LANCET RESP MED, V4, P116, DOI 10.1016/S2213-2600(15)00521-4; Kamalu N, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA4130; Karanikolos M, 2013, LANCET, V381, P1323, DOI 10.1016/S0140-6736(13)60102-6; Kotz D, 2014, ADDICTION, V109, P491, DOI 10.1111/add.12429; Langley T, 2014, ADDICTION, V109, P995, DOI 10.1111/add.12448; Langley TE, 2011, ADDICTION, V106, P1319, DOI 10.1111/j.1360-0443.2011.03426.x; Lee S, 2014, J ADOLESCENT HEALTH, V54, P684, DOI 10.1016/j.jadohealth.2013.11.003; McLeod AI, 2005, TECHNOMETRICS, V47, P174, DOI 10.1198/004017005000000094; McMillen RC, 2015, NICOTINE TOB RES, V17, P1195, DOI 10.1093/ntr/ntu213; McRobbie Hayden, 2014, Cochrane Database Syst Rev, pCD010216, DOI 10.1002/14651858.CD010216.pub2; Pearson JL, 2015, NICOTINE TOB RES, V17, P1219, DOI 10.1093/ntr/ntu269; Popova L, 2013, AM J PUBLIC HEALTH, V103, P923, DOI 10.2105/AJPH.2012.301070; Pulvers K, 2015, NICOTINE TOB RES, V17, P1085, DOI 10.1093/ntr/ntu241; Regan AK, 2013, TOB CONTROL, V22, P19, DOI 10.1136/tobaccocontrol-2011-050044; Shubber K., 2014, SALES ECIGARETTES SU; Vickerman KA, 2013, NICOTINE TOB RES, V15, P1787, DOI 10.1093/ntr/ntt061; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wakefield MA, 2008, AM J PUBLIC HEALTH, V98, P1443, DOI 10.2105/AJPH.2007.128991; Wakefield MA, 2014, B WORLD HEALTH ORGAN, V92, P413, DOI 10.2471/BLT.13.118448; West R, 2016, MONTHLY TRACKING KEY; West R., 2015, SMOKING PIPE MODEL 2; West RBJ, 2015, SMOKING ENGLAND 2007; West R, 2007, ADDICTION, V102, P506, DOI 10.1111/j.1360-0443.2007.01750.x; West R, 2016, ADDICTION, V111, P1118, DOI 10.1111/add.13343; West R, 2016, ADDICTION, V111, P3, DOI 10.1111/add.13053; West R, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4921	50	172	173	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2016	354								i4645	10.1136/bmj.i4645	http://dx.doi.org/10.1136/bmj.i4645			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DW3NG	27624188	Green Published, hybrid			2023-01-03	WOS:000383547700004
J	Sprigg, N; O'Connor, R; Woodhouse, L; Krishnan, K; England, TJ; Connell, LA; Walker, MF; Bath, PM				Sprigg, Nikola; O'Connor, Rebecca; Woodhouse, Lisa; Krishnan, Kailash; England, Timothy J.; Connell, Louise A.; Walker, Marion F.; Bath, Philip M.			Granulocyte Colony Stimulating Factor and Physiotherapy after Stroke: Results of a Feasibility Randomised Controlled Trial: Stem Cell Trial of Recovery EnhanceMent after Stroke-3 (STEMS-3 ISRCTN16714730)	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; THERAPY; METAANALYSIS; EFFICACY; DONORS; SCALE	Background Granulocyte-colony stimulating factor (G-CSF) mobilises endogenous haematopoietic stem cells and enhances recovery in experimental stroke. Recovery may also be dependent on an enriched environment and physical activity. G-CSF may have the potential to enhance recovery when used in combination with physiotherapy, in patients with disability late after stroke. Methods A pilot 2 x 2 factorial randomised (1:1) placebo-controlled trial of G-CSF (double-blind), and/or a 6 week course of physiotherapy, in 60 participants with disability (mRS > 1), at least 3 months after stroke. Primary outcome was feasibility, acceptability and tolerability. Secondary outcomes included death, dependency, motor function and quality of life measured 90 and 365 days after enrolment. Results Recruitment to the trial was feasible and acceptable; of 118 screened patients, 92 were eligible and 32 declined to participate. 60 patients were recruited between November 2011 and July 2013. All participants received some allocated treatment. Although 29 out of 30 participants received all 5 G-CSF/placebo injections, only 7 of 30 participants received all 18 therapy sessions. G-CSF was well tolerated but associated with a tendency to more adverse events than placebo (16 vs 10 patients, p = 0.12) and serious adverse events (SAE) (9 vs 3, p = 0.10). On average, patients received 14 (out of 18 planned) therapy sessions, interquartile range [12, 17]. Only a minority (23%) of participants completed all physiotherapy sessions, a large proportion of sessions (114 of 540, 21%) were cancelled due to patient (94, 17%) and therapist factors (20, 4%). No significant differences in functional outcomes were detected in either the G-CSF or physiotherapy group at day 90 or 365. Conclusions Delivery of G-CSF is feasible in chronic stroke. However, the study failed to demonstrate feasibility for delivering additional physiotherapy sessions late after stroke therefore a definitive study using this trial design is not supported. Future work should occur earlier after stroke, alongside on-going clinical rehabilitation.	[Sprigg, Nikola; O'Connor, Rebecca; Woodhouse, Lisa; Krishnan, Kailash; Bath, Philip M.] Univ Nottingham, Div Clin Neurosci, Stroke Trials Unit, Nottingham, England; [England, Timothy J.] Univ Nottingham, Div Med Sci & GEM, Nottingham, England; [Walker, Marion F.] Univ Nottingham, Div Rehabil & Ageing, Nottingham, England; [Connell, Louise A.] Univ Cent Lancashire, Sch Hlth, Preston, Lancs, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Central Lancashire	Sprigg, N (corresponding author), Univ Nottingham, Div Clin Neurosci, Stroke Trials Unit, Nottingham, England.	nikola.sprigg@nottingham.ac.uk	Connell, Louise/C-9133-2016; England, Timothy J/AAD-3100-2021; Bath, Philip/F-9020-2011	Connell, Louise/0000-0002-0629-2919; England, Timothy J/0000-0001-5330-8584; Krishnan, Kailash/0000-0002-6486-3783; Woodhouse, Lisa/0000-0002-4472-1999; Bath, Philip/0000-0003-2734-5132	NIHR Research for Patient Benefit [PB-PG-0909-19113]; MRC [G0501997] Funding Source: UKRI; Medical Research Council [G0501997] Funding Source: researchfish; National Institute for Health Research [PB-PG-0909-19113, NF-SI-0512-10092] Funding Source: researchfish	NIHR Research for Patient Benefit; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	STEMS3 is funded by NIHR Research for Patient Benefit (PB-PG-0909-19113), http://www.nihr.ac.uk/funding/research-for-patient-benefit.htm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Health and Technology Assessment Programme, NIHR, NHS or the Department of Health.	Allen R, 2013, INT J STROKE, V8, P12; Anderlini P, 2009, CURR OPIN HEMATOL, V16, P35, DOI 10.1097/MOH.0b013e328319913c; Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Aziz N, 2009, THERAPY BASED REHABI, V2009; Bath PMW, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005207.pub4; Brockmann F, 2013, TRANSFUS MED HEMOTH, V40, P258, DOI 10.1159/000354093; Brown E, 2007, MED DICT REGULATORY, P168, DOI [10.1002/9780470059210.CH13, DOI 10.1002/9780470059210.CH13]; Byl NN, 2008, NEUROREHAB NEURAL RE, V22, P494, DOI 10.1177/1545968308317431; Cavallaro AM, 2000, BONE MARROW TRANSPL, V25, P85, DOI 10.1038/sj.bmt.1702072; Chollet F, 2014, J NEUROL, V261, P1461, DOI 10.1007/s00415-013-7172-z; Clarke J, 2009, NEUROREHAB NEURAL RE, V23, P886, DOI 10.1177/1545968309341067; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; England TJ, 2009, BRAIN RES REV, V62, P71, DOI 10.1016/j.brainresrev.2009.09.002; Floel A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019767; Floel A, 2010, NEUROBIOL DIS, V37, P243, DOI 10.1016/j.nbd.2009.05.027; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fraser C, 2002, NEURON, V34, P831, DOI 10.1016/S0896-6273(02)00705-5; Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033; Janssen H, 2010, NEUROREHAB NEURAL RE, V24, P802, DOI 10.1177/1545968310372092; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Legg L, 2004, LANCET, V363, P352; Logan PA, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18290; MAHONEY F I, 1965, Md State Med J, V14, P61; Mead GE, 2013, JAMA-J AM MED ASSOC, V310, P1066, DOI 10.1001/jama.2013.107828; Minnerup J, 2008, STROKE, V39, P1855, DOI 10.1161/STROKEAHA.107.506816; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; NUDO RJ, 2003, PHYS MED REHABILITAT, V14, P57; Pafford RN, 2015, STROKE, V46; Ringelstein EB, 2013, STROKE, V44, P2681, DOI 10.1161/STROKEAHA.113.001531; Sackley CM, 1990, CLIN REHABIL, V4, P301; Schabitz WR, 2010, STROKE, V41, P2545, DOI 10.1161/STROKEAHA.110.579508; Sprigg N, 2006, STROKE, V37, P2979, DOI 10.1161/01.STR.0000248763.49831.c3; Sprigg N, 2009, J NEUROL SCI, V285, P3, DOI 10.1016/j.jns.2009.04.040; Sulter G, 1999, STROKE, V30, P1538, DOI 10.1161/01.STR.30.8.1538; van Vliet P, 2015, PHYSIOTHERAPY S1, V101; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Wagner DC, 2014, STROKE, V45, P623, DOI 10.1161/STROKEAHA.113.003812; Walsh K, 2007, BRIT J PSYCHIAT, V190, P142, DOI 10.1192/bjp.bp.106.023960; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zhao LR, 2007, STROKE, V38, P2804, DOI 10.1161/STROKEAHA.107.486217; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	42	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0161359	10.1371/journal.pone.0161359	http://dx.doi.org/10.1371/journal.pone.0161359			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JE	27610616	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000383255900016
J	Burns, JP; Truog, RD				Burns, Jeffrey P.; Truog, Robert D.			HISTORY OF MEDICINE The DNR Order after 40 Years	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESUSCITATE		[Burns, Jeffrey P.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Div Crit Care Med, Boston, MA 02115 USA; Harvard Med Sch, Dept Anaesthesia, Boston, MA 02115 USA; Harvard Med Sch, Ctr Bioeth, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Burns, JP (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Div Crit Care Med, Boston, MA 02115 USA.		Burns, Jeffrey P/AAW-8474-2021					*AM MED ASS, 1974, JAMA-J AM MED ASSOC, V227, P864; Bosslet GT, 2015, AM J RESP CRIT CARE, V191, P1318, DOI 10.1164/rccm.201505-0924ST; Burns JP, 2003, CRIT CARE MED, V31, P1543, DOI 10.1097/01.CCM.0000064743.44696.49; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705	5	31	31	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2016	375	6					504	506		10.1056/NEJMp1605597	http://dx.doi.org/10.1056/NEJMp1605597			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU4OT	27509098				2023-01-03	WOS:000382193100002
J	Lin, TT; Wu, CC; Yang, YH; Lin, LY; Lin, JL; Chen, PC; Hwang, JJ				Lin, Ting-Tse; Wu, Chih-Chen; Yang, Yao-Hsu; Lin, Lian-Yu; Lin, Jiunn-Lee; Chen, Pau-Chung; Hwang, Juey-Jen			Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis	PLOS ONE			English	Article							INTENSIVE GLYCEMIC CONTROL; GLUCOSE CONTROL; KIDNEY-DISEASE; TYPE-2; INSULIN; PHARMACOKINETICS; ASSOCIATION; STATEMENT; COMPLICATIONS; EPIDEMIOLOGY	Background Diabetes and chronic kidney disease (CKD) are a high-stakes combination for cardiovascular disease. Patients with decreased kidney function and end-stage renal disease ( ESRD) have increased risk of hypoglycemia when attaining better glycemic control, leading to higher risk of myocardial infarction (MI). For these patients, which kinds of anti-hyperglycemic agents would be associated with higher risk of MI is not clear. Methods We identified patients from a nation-wide database called Registry for Catastrophic Illness, which encompassed almost 100% of the patients receiving dialysis therapy in Taiwan from 1995 to 2008. Patients with diabetes and ESRD were selected as the study cohort. Propensity score adjustment and Cox's proportional hazards regression model were used to estimate the hazard ratios (HRs) for new-onset MI. Results Among 15,161 patients, 39% received insulin, 40% received sulfonylureas, 18% received meglitinides and 3% received thiazolidinedione (TZD). After a median follow-up of 1,357 days, the incidence of MI was significant increase in patients taking sulfonylureas (HR =1.523, 95% confidence interval [CI]=1.331-1.744), meglitinides ( HR=1.251, 95% CI=1.048-1.494) and TZD (HR=1.515, 95% CI=1.071-2.145) by using patients receiving insulin therapy as the reference group. The risk of MI remains higher in other three groups in subgroup analyses. Conclusions In conclusion, among diabetic patients with ESRD undergoing dialysis, the use of sulfonylureas, meglitinides and TZD are associated with higher risk of new-onset MI as compared with insulin.	[Lin, Ting-Tse; Wu, Chih-Chen] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Internal Med, Hsinchu, Taiwan; [Lin, Ting-Tse] Natl Chiao Tung Univ, Inst Biomed Engn, Hsinchu, Taiwan; [Yang, Yao-Hsu] Chang Gung Mem Hosp, Dept Tradit Chinese Med, Chiayi, Taiwan; [Yang, Yao-Hsu; Chen, Pau-Chung] Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei, Taiwan; [Yang, Yao-Hsu] Chang Gung Mem Hosp, Ctr Excellence Chang Gung Res Datalink, Chiayi, Taiwan; [Yang, Yao-Hsu] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Taoyuan, Taiwan; [Lin, Lian-Yu; Lin, Jiunn-Lee; Hwang, Juey-Jen] Natl Taiwan Univ, Coll Med & Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital; National Taiwan University; Chang Gung Memorial Hospital; Chang Gung University; National Taiwan University	Lin, LY; Hwang, JJ (corresponding author), Natl Taiwan Univ, Coll Med & Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan.	hspenos@gmail.com; jueyhwang@ntu.edu.tw	Chen, Pau-Chung/H-5686-2011; 楊, 曜旭/A-3450-2019	Chen, Pau-Chung/0000-0002-6242-5974; 楊, 曜旭/0000-0002-8080-0504; WU, CHIH-CHENG/0000-0002-9690-6573; Hwang, Juey-Jen/0000-0001-6437-0455; LIN, TING-TSE/0000-0002-8810-5127; LIN, LIAN-YU/0000-0001-7505-6429				Abe M, 2011, CURR DRUG METAB, V12, P57, DOI 10.2174/138920011794520053; ADROGUE HJ, 1992, KIDNEY INT, V42, P1266, DOI 10.1038/ki.1992.414; Alvestrand A, 1997, KIDNEY INT, V52, pS48; Berkowitz SA, 2014, JAMA INTERN MED, V174, P1955, DOI 10.1001/jamainternmed.2014.5294; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Chou MT, 2013, INT J CARDIOL, V167, P2719, DOI 10.1016/j.ijcard.2012.06.108; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Goff DC, 2007, AM J CARDIOL, V99, p4I, DOI 10.1016/j.amjcard.2007.03.002; Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hasslacher C, 2003, DIABETES CARE, V26, P886, DOI 10.2337/diacare.26.3.886; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Inoue T, 2003, CLIN NEPHROL, V60, P90; Ismail-Beigi F, 2010, LANCET, V376, P419, DOI 10.1016/S0140-6736(10)60576-4; Jonsson A, 1998, EUR J CLIN PHARMACOL, V53, P429, DOI 10.1007/s002280050403; Levin A, 2007, AM J KIDNEY DIS, V49, pS10, DOI 10.1053/j.ajkd.2006.12.004; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Levin SR, 2000, DIABETES CARE, V23, P1478, DOI 10.2337/diacare.23.10.1478; Lin TT, 2015, KIDNEY INT, V88, P378, DOI 10.1038/ki.2015.96; Nagai T, 2003, DIABETES RES CLIN PR, V59, P191, DOI 10.1016/S0168-8227(02)00242-5; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Nye HJ, 2011, NEPHRON CLIN PRACT, V118, pC380, DOI 10.1159/000323739; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Salpeter SR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002967.pub4; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; Skyler JS, 2009, DIABETES CARE, V32, P187, DOI 10.2337/dc08-9026; Snyder RW, 2004, SEMIN DIALYSIS, V17, P365, DOI 10.1111/j.0894-0959.2004.17346.x; Sobngwi E, 2010, DIABETES CARE, V33, P1409, DOI 10.2337/dc09-2176; Thompson-Culkin K, 2002, J INT MED RES, V30, P391, DOI 10.1177/147323000203000405; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WEINRAUCH LA, 1978, ARCH INTERN MED, V138, P399, DOI 10.1001/archinte.138.3.399; White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	35	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2016	11	8							e0160436	10.1371/journal.pone.0160436	http://dx.doi.org/10.1371/journal.pone.0160436			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3KY	27513562	gold, Green Published, Green Submitted			2023-01-03	WOS:000381381100038
J	Olie, E; Courtet, P				Olie, Emilie; Courtet, Philippe			The Controversial Issue of Euthanasia in Patients With Psychiatric Illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; DISORDERS; ATTITUDES	IMPORTANCE Euthanasia or assisted suicide (EAS) of psychiatric patients is increasing in some jurisdictions such as Belgium and the Netherlands. However, little is known about the practice, and it remains controversial. OBJECTIVES To describe the characteristics of patients receiving EAS for psychiatric conditions and how the practice is regulated in the Netherlands. DESIGN, SETTING, AND PARTICIPANTS This investigation reviewed psychiatric EAS case summaries made available online by the Dutch regional euthanasia review committees as of June 1, 2015. Two senior psychiatrists used directed content analysis to review and code the reports. In total, 66 cases from 2011 to 2014 were reviewed. MAIN OUTCOMES AND MEASURES Clinical and social characteristics of patients, physician review process of the patients' requests, and the euthanasia review committees' assessments of the physicians' actions. RESULTS Of the 66 cases reviewed, 70%(n = 46) werewomen. In total, 32%(n = 21) were 70 years or older, 44%(n = 29) were 50 to 70 years old, and 24%(n = 16) were 30 to 50 years old. Most had chronic, severe conditions, with histories of attempted suicides and psychiatric hospitalizations. Most had personality disorders andwere described as socially isolated or lonely. Depressive disorderswere the primary psychiatric issue in 55% (n = 36) of cases. Other conditions representedwere psychotic, posttraumatic stress or anxiety, somatoform, neurocognitive, and eating disorders, aswell as prolonged grief and autism. Comorbidities with functional impairmentswere common. Forty-one percent (n = 27) of physicians performing EASwere psychiatrists. Twenty-seven percent (n = 18) of patients received the procedure from physicians new to them, 14 of whomwere physicians from the End-of-Life Clinic, a mobile euthanasia clinic. Consultation with other physicianswas extensive, but 11% (n = 7) of cases had no independent psychiatric input, and 24% (n = 16) of cases involved disagreement among consultants. The euthanasia review committees found that one case failed to meet legal due care criteria. CONCLUSIONS AND RELEVANCE Persons receiving EAS for psychiatric disorders in the Netherlands are mostly women and of diverse ages, with complex and chronic psychiatric, medical, and psychosocial histories. The granting of their EAS requests appears to involve considerable physician judgment, usually involving multiple physicians who do not always agree (sometimes without independent psychiatric input), but the euthanasia review committees generally defer to the judgments of the physicians performing the EAS.	[Olie, Emilie; Courtet, Philippe] Univ Montpellier, CHU Montpellier, Lapeyronie Hosp, Dept Psychiat Emergency & Acute Care,INSERM U1061, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Courtet, P (corresponding author), CHU Montpellier, Lapeyronie Hosp, Dept Psychiat Emergency & Acute Care, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	p-courtet@chu-montpellier.fr						Blank K, 2001, GEN HOSP PSYCHIAT, V23, P326, DOI 10.1016/S0163-8343(01)00160-8; Ducasse D, 2014, PSYCHOTHER PSYCHOSOM, V83, P374, DOI 10.1159/000365974; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; Insel TR, 2006, MOL PSYCHIATR, V11, P11, DOI 10.1038/sj.mp.4001777; Kim SYH, 2016, JAMA PSYCHIAT, V73, P362, DOI 10.1001/jamapsychiatry.2015.2887; Olie E, 2010, J AFFECT DISORDERS, V120, P226, DOI 10.1016/j.jad.2009.03.013; Richard-Devantoy S, 2014, PSYCHOL MED, V44, P1663, DOI 10.1017/S0033291713002304; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; Thienpont L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007454; Yovell Y, 2016, AM J PSYCHIAT, V173, P491, DOI 10.1176/appi.ajp.2015.15040535	10	25	25	1	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2016	316	6					656	+		10.1001/jama.2016.9883	http://dx.doi.org/10.1001/jama.2016.9883			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DS7TK	27532920				2023-01-03	WOS:000380985600018
J	Cooney, L; Sinha, I; Hawcutt, D				Cooney, Lewis; Sinha, Ian; Hawcutt, Daniel			Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; IV AMINOPHYLLINE; INTRAVENOUS THEOPHYLLINE; EFFICACY; TOXICITY; HETEROGENEITY; SALBUTAMOL; INFUSION; THERAPY; BOLUS	Background Adequate asthma treatment of childhood exacerbations with IV aminophylline depends on appropriate dosage. Recommendations to aim for a target therapeutic range may be inappropriate as serum concentrations correlate poorly with clinical improvement. This review aims to evaluate the evidence for the optimum dosage strategy of intravenous aminophylline in children suffering an exacerbation of asthma. Methods A systematic review comparing dosage regimens of intravenous aminophylline in children suffering an exacerbation of asthma. Primary outcomes were time until resolution of symptoms, mortality and need for mechanical ventilation. Secondary outcomes were date until discharge criteria are met, actual discharge and adverse effects. Data sources CENTRAL, CINAHL, MEDLINE and Web of Science. Search performed in March 2016 Eligibility criteria Studies using intravenous aminophylline in children with an acute exacerbation of asthma which reported the dosage and clinical outcomes. Findings 14 RCTs were included. There is a poor relationship between the dosage administered to children and symptom resolution, length of stay or need for mechanical ventilation. This study is limited due to its use of indirect evidence. Conclusion The currently recommended dosage regimens may not represent the optimum safety and efficacy of intravenous aminophylline. There is a need to develop the evidence base correlating dosage with patient centered clinical outcomes, to improve prescribing practices.	[Cooney, Lewis; Hawcutt, Daniel] Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England; [Sinha, Ian; Hawcutt, Daniel] Alder Hey Childrens Hosp, Natl Inst Hlth Res, Alder Hey Clin Res Facil, Liverpool, Merseyside, England	University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool	Hawcutt, D (corresponding author), Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England.; Hawcutt, D (corresponding author), Alder Hey Childrens Hosp, Natl Inst Hlth Res, Alder Hey Clin Res Facil, Liverpool, Merseyside, England.	dhawcutt@liverpool.ac.uk		Hawcutt, Dan/0000-0002-8120-6507	NIHR	NIHR(National Institute for Health Research (NIHR))	DH is part funded by the NIHR alder hey clinical research facility. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, THORAX, V69, P1; BIEN JP, 1995, CLIN PEDIATR, V34, P475, DOI 10.1177/000992289503400905; CARTER E, 1993, J PEDIATR-US, V122, P470, DOI 10.1016/S0022-3476(05)83443-2; Clarke M, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-39; Cooling David S., 1993, Journal of Emergency Medicine, V11, P415, DOI 10.1016/0736-4679(93)90244-2; Cooney L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153877; D'Avila RS, 2008, RESP MED, V102, P156, DOI 10.1016/j.rmed.2007.07.030; DIGIULIO GA, 1993, J PEDIATR-US, V122, P464, DOI 10.1016/S0022-3476(05)83442-0; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; ELLIS EF, 1985, J ALLERGY CLIN IMMUN, V76, P297, DOI 10.1016/0091-6749(85)90645-1; GLEESON JGA, 1989, EUR J PEDIATR, V148, P577, DOI 10.1007/BF00441563; HAMBLETON G, 1979, ARCH DIS CHILD, V54, P391, DOI 10.1136/adc.54.5.391; Hawcutt DB, 2016, EXPERT REV PRECIS ME, V1, P69, DOI 10.1080/23808993.2016.1138845; Hendeles L, 2006, ANN PHARMACOTHER, V40, P1417, DOI 10.1345/aph.140027; KUBO M, 1986, J PEDIATR-US, V108, P1011, DOI 10.1016/S0022-3476(86)80951-9; Kukreti R, 2009, PHARMACOGENOMICS, V10, P327, DOI 10.2217/14622416.10.3.327; LOUGHNAN PM, 1976, J PEDIATR-US, V88, P874, DOI 10.1016/S0022-3476(76)81136-5; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; Morris I, 2015, THORAX, V70, P88, DOI 10.1136/thoraxjnl-2014-206041; NEEDLEMAN JP, 1995, ARCH PEDIAT ADOL MED, V149, P206, DOI 10.1001/archpedi.1995.02170140088016; Nuhoglu Y, 1998, ANN ALLERG ASTHMA IM, V80, P395, DOI 10.1016/S1081-1206(10)62990-0; Paediatric Formulary Comittee, 2014, BNF CHILDR BNFC 2014; Ream RS, 2001, CHEST, V119, P1480, DOI 10.1378/chest.119.5.1480; Roberts G, 2003, THORAX, V58, P306, DOI 10.1136/thorax.58.4.306; SESSLER CN, 1990, AM J MED, V88, P567, DOI 10.1016/0002-9343(90)90519-J; Singhi S, 2014, ACTA PAEDIATR, V103, P1301, DOI 10.1111/apa.12780; Sinha IP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000393; STRAUSS RE, 1994, PEDIATRICS, V93, P205; Tamesis GP, 2007, CURR OPIN ALLERGY CL, V7, P185, DOI 10.1097/ACI.0b013e32807fafe7; Vieira SE, 2000, PULM PHARMACOL THER, V13, P189, DOI 10.1006/pupt.1999.0225; Visser K, 2009, ANN RHEUM DIS, V68, P1094, DOI 10.1136/ard.2008.092668; WEINBERGER MW, 1976, JAMA-J AM MED ASSOC, V235, P2110, DOI 10.1001/jama.235.19.2110; Wheeler Derek S, 2005, Pediatr Crit Care Med, V6, P142, DOI 10.1097/01.PCC.0000154943.24151.58; Yung M, 1998, ARCH DIS CHILD, V79, P405, DOI 10.1136/adc.79.5.405	34	12	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2016	11	8							e0159965	10.1371/journal.pone.0159965	http://dx.doi.org/10.1371/journal.pone.0159965			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS9NS	27483163	Green Published, gold, Green Submitted			2023-01-03	WOS:000381110700019
J	Meneses, ME; Martinez-Carrera, D; Torres, N; Sanchez-Tapia, M; Aguilar-Lopez, M; Morales, P; Sobal, M; Bernabe, T; Escudero, H; Granados-Portillo, O; Tovar, AR				Meneses, Maria E.; Martinez-Carrera, Daniel; Torres, Nimbe; Sanchez-Tapia, Monica; Aguilar-Lopez, Miriam; Morales, Porfirio; Sobal, Mercedes; Bernabe, Teodoro; Escudero, Helios; Granados-Portillo, Omar; Tovar, Armando R.			Hypocholesterolemic Properties and Prebiotic Effects of Mexican Ganoderma lucidum in C57BL/6 Mice	PLOS ONE			English	Article							BETA-GLUCANS; CHOLESTEROL; GUT; SUPPLEMENTATION; MODULATION; MICROBIOTA; MUSHROOMS; STEROLS; OBESITY; FIBER	Edible and medicinal mushrooms contain bioactive compounds with promising effects on several cardiovascular risk biomarkers. However, strains of Ganoderma lucidum of Mexican origin have not yet been studied. Standardized extracts of G. lucidum (Gl) were given to C57BL/6 mice fed a high-cholesterol diet compared with the drug simvastatin. The effects of the extracts on serum biochemical parameters, liver lipid content, cholesterol metabolism, and the composition of gut microbiota were assessed. Acetylsalicylic acid (10 mM) added to the cultivation substrate modulated properties of Gl extracts obtained from mature basidiomata. Compared to the high-cholesterol diet group, the consumption of Gl extracts significantly reduced total serum cholesterol (by 19.2% to 27.1%), LDL-C (by 4.5% to 35.1%), triglyceride concentration (by 16.3% to 46.6%), hepatic cholesterol (by 28.7% to 52%) and hepatic triglycerides (by 43.8% to 56.6%). These effects were associated with a significant reduction in the expression of lipogenic genes (Hmgcr, Srebp1c, Fasn, and Acaca) and genes involved in reverse cholesterol transport (Abcg5 and Abcg8), as well as an increase in Ldlr gene expression in the liver. No significant changes were observed in the gene expression of Srebp2, Abca1 or Cyp7a1. In several cases, Gl-1 or Gl-2 extracts showed better effects on lipid metabolism than the drug simvastatin. A proposed mechanism of action for the reduction in cholesterol levels is mediated by alpha-glucans and beta-glucans from Gl, which promoted decreased absorption of cholesterol in the gut, as well as greater excretion of fecal bile acids and cholesterol. The prebiotic effects of Gl-1 and Gl-2 extracts modulated the composition of gut microbiota and produced an increase in the Lactobacillaceae family and Lactobacillus genus level compared to the control group, high-cholesterol diet group and group supplemented with simvastatin. Mexican genetic resources of Gl represent a new source of bioactive compounds showing hypocholesterolemic properties and prebiotic effects.	[Meneses, Maria E.] CONACYT Colegio Postgrad, Campus Puebla, Puebla, Puebla, Mexico; [Martinez-Carrera, Daniel; Morales, Porfirio; Sobal, Mercedes; Bernabe, Teodoro; Escudero, Helios] CP, Biotecnol Hongos Comestibles Func & Med, Campus Puebla, Puebla, Puebla, Mexico; [Torres, Nimbe; Sanchez-Tapia, Monica; Aguilar-Lopez, Miriam; Granados-Portillo, Omar; Tovar, Armando R.] INCMNSZ, Dept Fisiol Nutr, Ciudad De Mexico, Mexico		Martinez-Carrera, D (corresponding author), CP, Biotecnol Hongos Comestibles Func & Med, Campus Puebla, Puebla, Puebla, Mexico.; Tovar, AR (corresponding author), INCMNSZ, Dept Fisiol Nutr, Ciudad De Mexico, Mexico.	dcarrera@colpos.mx; tovar.ar@gmail.com	González, Teodoro Bernabé/AAQ-4183-2020; Aguilar-Lopez, Miriam/CJH-4026-2022; Torres, Nimbe/AAY-8821-2020; Torres, Nimbe/AAI-4340-2020; Meneses, María E./HHN-1339-2022	González, Teodoro Bernabé/0000-0003-1428-7332; Aguilar-Lopez, Miriam/0000-0003-2010-1653; Torres, Nimbe/0000-0002-1741-0984; Meneses, María E./0000-0002-7689-7024; Sanchez-Tapia, Monica/0000-0001-9748-5734	National Council of Science and Technology (CONACYT) in Mexico, through Research Project "105 Genomica de las Propiedades Funcionales y Medicinales de los Hongos Comestibles de Mexico"; CONACYT [290754]; Dannon Institute of Mexico	National Council of Science and Technology (CONACYT) in Mexico, through Research Project "105 Genomica de las Propiedades Funcionales y Medicinales de los Hongos Comestibles de Mexico"; CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Dannon Institute of Mexico	The research work was supported by the National Council of Science and Technology (CONACYT; www.conacyt.mx) in Mexico, through the Research Project "105 Genomica de las Propiedades Funcionales y Medicinales de los Hongos Comestibles de Mexico," directed by DMC; CONACYT also supported the Postdoctoral Position for MEM (agreement no. 290754). A grant from Dannon Institute of Mexico was received by NT. The funders had no role in study design, data collection	Batta AK, 1999, J LIPID RES, V40, P1148; Berger A, 2004, Lipids Health Dis, V3, P2, DOI 10.1186/1476-511X-3-2; Brownawell AM, 2010, NUTR REV, V68, P355, DOI 10.1111/j.1753-4887.2010.00294.x; Caesar R, 2010, J INTERN MED, V268, P320, DOI 10.1111/j.1365-2796.2010.02270.x; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Caz V, 2015, J AGR FOOD CHEM, V63, P7371, DOI 10.1021/acs.jafc.5b02942; Chang CJ, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms8489, 10.1038/ncomms8216]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; FOLCH J, 1957, J BIOL CHEM, V226, P497; Freckmann G, 2014, DIABETES TECHNOL THE, V16, P113, DOI 10.1089/dia.2013.0208; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Guillamon E, 2010, FITOTERAPIA, V81, P715, DOI 10.1016/j.fitote.2010.06.005; Gutierrez J.P., 2012, ENCUESTA NACL SALUD; Hajjaj H, 2005, APPL ENVIRON MICROB, V71, P3653, DOI 10.1128/AEM.71.7.3653-3658.2005; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jones ML, 2012, BRIT J NUTR, V107, P1505, DOI 10.1017/S0007114511004703; Keller S, 2004, J CHROMATOGR B, V813, P199, DOI 10.1016/j.jchromb.2004.09.046; Koren O, 2011, P NATL ACAD SCI USA, V108, P4592, DOI 10.1073/pnas.1011383107; Lindequist U, 2005, EVID-BASED COMPL ALT, V2, P285, DOI 10.1093/ecam/neh107; Martinez I, 2009, APPL ENVIRON MICROB, V75, P4175, DOI 10.1128/AEM.00380-09; Nicolosi R, 1999, AM J CLIN NUTR, V70, P208; Pagidipati NJ, 2013, CIRCULATION, V127, P749, DOI 10.1161/CIRCULATIONAHA.112.128413; Pan D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068332; Ramuirez JuuYrez J., 2016, CIENCIA TECNOLOGIA I; Reeves PG, 1997, J NUTR, V127, pS838; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rop O, 2009, NUTR REV, V67, P624, DOI 10.1111/j.1753-4887.2009.00230.x; Snart J, 2006, APPL ENVIRON MICROB, V72, P1925, DOI 10.1128/AEM.72.3.1925-1931.2006; Theuwissen E, 2008, PHYSIOL BEHAV, V94, P285, DOI 10.1016/j.physbeh.2008.01.001; Torres N, 2015, ARCH MED RES, V46, P408, DOI 10.1016/j.arcmed.2015.05.010; Vetvicka V, 2009, J IMMUNOTOXICOL, V6, P30, DOI 10.1080/15476910802604317; Wachtel-Galor S, 2004, INT J FOOD SCI NUTR, V55, P75, DOI 10.1080/09637480310001642510; Wang CD, 2012, BRIT J NUTR, V108, P2014, DOI 10.1017/S0007114512000153; Wang LX, 2013, WORLD J GASTROENTERO, V19, P3150, DOI 10.3748/wjg.v19.i20.3150; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wasser SP, 1999, CRIT REV IMMUNOL, V19, P65	37	36	39	2	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2016	11	7							e0159631	10.1371/journal.pone.0159631	http://dx.doi.org/10.1371/journal.pone.0159631			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TL	27438015	gold, Green Submitted, Green Published			2023-01-03	WOS:000380170100058
J	Ritchey, M; Tsipas, S; Loustalot, F; Wozniak, G				Ritchey, Matthew; Tsipas, Stavros; Loustalot, Fleetwood; Wozniak, Gregory			Use of Pharmacy Sales Data to Assess Changes in Prescription- and Payment-Related Factors that Promote Adherence to Medications Commonly Used to Treat Hypertension, 2009 and 2014	PLOS ONE			English	Article							BLOOD-PRESSURE CONTROL; IMPROVING ADHERENCE; UNITED-STATES; HEALTH; TRENDS; THERAPIES; OUTCOMES; AGENTS; ADULTS	Background Effective hypertension management often necessitates patients' adherence to the blood pressure (BP)-lowering medication regimen they are prescribed. Patients' adherence to that regimen can be affected by prescription- and payment-related factors that are typically controlled by prescribers, filling pharmacies, pharmacy benefit managers, and/or patients' health insurance plans. This study describes patterns and changes from 2009 to 2014 in factors that the literature reports are associated with increased adherence to BP-lowering medication. Methods and Findings We use a robust source of United States prescription sales data-IMS Health's National Prescription Audit-to describe BP-lowering medication fill counts and spending in 2009 compared with 2014. Moreover, we describe patterns and changes in adherence-promoting factors across age groups, payment sources, and medication classes. From 2009 to 2014, the BP-lowering medication prescription fill count increased from 613.7 million to 653.0 million. Encouraging changes in adherence-promoting factors included: the share of generic fills increased from 82.5% to 95.0%; average days' supply per fill increased from 45.9 to 51.8 days; and average total (patient contribution) spending per years' supply decreased from $359 ($54) to $311 ($37). Possibly undesirable changes included: the percentage of fills for fixed-dose combinations decreased from 17.1% to 14.2% and acquired via mail order decreased from 10.7% to 8.2%. In 2014: 653.0 million fills occurred accounting for $28.81B in spending; adults aged 45-64 years had the highest percentage of fixed-dose combinations fills (16.9%); and fills with Medicaid as the payment source had the lowest average patient spending per fill ($1.19). Conclusions We identified both encouraging and possibly undesirable patterns and changes from 2009 to 2014 in factors that promote adherence to BP-lowering medications during this period. Continued tracking of these metrics using pharmacy sales data can help identify areas that can be addressed by clinical and policy interventions to improve adherence for medications commonly used to treat hypertension.	[Ritchey, Matthew; Loustalot, Fleetwood] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; [Tsipas, Stavros; Wozniak, Gregory] Amer Med Assoc, Hlth Outcomes Grp, 515 N State St, Chicago, IL 60610 USA	Centers for Disease Control & Prevention - USA; American Medical Association	Ritchey, M (corresponding author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.	hha7@cdc.gov			Centers for Disease Control and Prevention; American Medical Association	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); American Medical Association	This study was entirely supported by the Centers for Disease Control and Prevention and American Medical Association.	American Medical Association, IMPR HLTH OUTC; Bangalore S, 2007, AM J MED, V120, P713, DOI 10.1016/j.amjmed.2006.08.033; Bitton A, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.09.004; Burnier M, 2006, AM J HYPERTENS, V19, P1190, DOI 10.1016/j.amjhyper.2006.04.006; Campbell NRC, 2009, HYPERTENSION, V53, P128, DOI 10.1161/HYPERTENSIONAHA.108.119784; Chernew M, 2008, J GEN INTERN MED, V23, P1131, DOI 10.1007/s11606-008-0614-0; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Choudhry NK, 2011, ARCH INTERN MED, V171, P814, DOI 10.1001/archinternmed.2010.495; Danaei G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000058; Domino FJ, 2005, AM FAM PHYSICIAN, V71, P2089; Dragomir A, 2010, MED CARE, V48, P418, DOI 10.1097/MLR.0b013e3181d567bd; Duru OK, 2010, AM J MANAG CARE, V16, P33; El Azizi GB, 2012, PHARMACOEPIDEM DR S, V21, P1067, DOI 10.1002/pds.3288; Frieden TR, 2014, JAMA-J AM MED ASSOC, V311, P21, DOI 10.1001/jama.2013.282615; Frieden TR, 2011, NEW ENGL J MED, V365, DOI [10.1056/NEJMp1110421, 10.1056/NEJMP1110421]; Gellad WF, 2009, REV BARRIERS MED ADH; Gu QP, 2012, CIRCULATION, V126, P2105, DOI 10.1161/CIRCULATIONAHA.112.096156; Gu Qiuping, 2010, NCHS Data Brief, P1; Guide to Community Preventive Services, 2019, CARD DIS PREV CONTR; He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996; Hicks LA, 2013, NEW ENGL J MED, V368, P1461, DOI 10.1056/NEJMc1212055; Hill SC, 2014, HEALTH AFFAIR, V33, P691, DOI 10.1377/hlthaff.2013.0743; Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986; IMS Institute for Healthcare Informatics, HSRN DAT BRIEF NAT P; Iskedjian M, 2002, CLIN THER, V24, P302, DOI 10.1016/S0149-2918(02)85026-3; Jaffe MG, 2013, JAMA-J AM MED ASSOC, V310, P699, DOI 10.1001/jama.2013.108769; Kettani FZ, 2009, STROKE, V40, P213, DOI 10.1161/STROKEAHA.108.522193; Mazzaglia G, 2009, CIRCULATION, V120, P1598, DOI 10.1161/CIRCULATIONAHA.108.830299; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; National Conference of State Legislatures, 2009, 4 FREE DRUG PROM LAR; Neal B, 2000, LANCET, V356, P1955; Nieuwlaat R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub4; Nwankwo Tatiana, 2013, NCHS Data Brief, P1; Ogden LG, 2000, HYPERTENSION, V35, P539, DOI 10.1161/01.HYP.35.2.539; Olfson M, 2015, JAMA PSYCHIAT, V72, P136, DOI 10.1001/jamapsychiatry.2014.1763; Paulozzi LJ, 2014, J SAFETY RES, V51, P125, DOI 10.1016/j.jsr.2014.09.001; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; PWC, 2013, MED COST TREND NUMBE; Sabat E, 2003, ADHERENCE LONG TERM; Schmittdiel JA, 2011, J GEN INTERN MED, V26, P1396, DOI 10.1007/s11606-011-1805-7; Schroeder K, 2004, Cochrane Database Syst Rev, pCD004804; Sherrill B, 2011, J CLIN HYPERTENS, V13, P898, DOI 10.1111/j.1751-7176.2011.00550.x; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Walker RL, 2011, CAN J CARDIOL, V27, P461, DOI 10.1016/j.cjca.2010.12.071; Wozniak G, 2016, J CLIN HYPERTENS, V18, P232, DOI 10.1111/jch.12654; Yang QH, 2012, JAMA-J AM MED ASSOC, V307, P1273, DOI 10.1001/jama.2012.339	46	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2016	11	7							e0159366	10.1371/journal.pone.0159366	http://dx.doi.org/10.1371/journal.pone.0159366			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TD	27428008	Green Submitted, gold, Green Published			2023-01-03	WOS:000380169300057
J	Igarashi, M; Guarente, L				Igarashi, Masaki; Guarente, Leonard			mTORC1 and SIRT1 Cooperate to Foster Expansion of Gut Adult Stem Cells during Calorie Restriction	CELL			English	Article							S6 KINASE; LIFE-SPAN; PHOSPHORYLATION; NAD(+); DIFFERENTIATION; METABOLISM; ACTIVATION; EXPRESSION; STRATEGIES; P70(S6K)	Longevity-promoting caloric restriction is thought to trigger downregulation of mammalian target of rapamycin complex 1 ( mTORC1) signaling and upregulation of SIRT1 activity with associated health benefits. Here, we show that mTORC1 signaling in intestinal stem cells ( ISCs) is instead upregulated during calorie restriction ( CR). SIRT1 deacetylates S6K1, thereby enhancing its phosphorylation by mTORC1, which leads to an increase in protein synthesis and an increase in ISC number. Paneth cells in the ISC niche secrete cyclic ADP ribose that triggers SIRT1 activity and mTORC1 signaling in neighboring ISCs. Notably, the mTOR inhibitor rapamycin, previously reported to mimic effects of CR, abolishes this expansion of ISCs. We suggest that Paneth cell signaling overrides any direct nutrient sensing in ISCs to sculpt the observed response to CR. Moreover, drugs that modulate pathways important in CR may exert opposing effects on different cell types.	[Igarashi, Masaki; Guarente, Leonard] MIT, Dept Biol, Glenn Labs Sci Aging, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Igarashi, Masaki; Guarente, Leonard] MIT, Koch Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, Glenn Labs Sci Aging, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Guarente, L (corresponding author), MIT, Koch Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu			Manpei Suzuki Diabetes Foundation; NIH; Glenn Foundation for Medical Research	Manpei Suzuki Diabetes Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Glenn Foundation for Medical Research	We wish to thank Angeliki Chalkiadaki and Eric Williams for comments on the manuscript. We also thank Dr. Inoki (University of Michigan) for S6K1 acetylation mutant expression vector. M.I. was supported by the Manpei Suzuki Diabetes Foundation. L.G. was supported by grants from NIH and the Glenn Foundation for Medical Research. L.G. is a founder of Elysium Health and consults for GSK, Sibelius, and Segterra.	Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Barker N, 2012, CELL STEM CELL, V11, P452, DOI 10.1016/j.stem.2012.09.009; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Brandauer J, 2013, J PHYSIOL-LONDON, V591, P5207, DOI 10.1113/jphysiol.2013.259515; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Calvanese V, 2010, P NATL ACAD SCI USA, V107, P13736, DOI 10.1073/pnas.1001399107; Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; De Flora A, 2004, ANN NY ACAD SCI, V1028, P176, DOI 10.1196/annals.1322.021; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Faller WJ, 2015, NATURE, V517, P497, DOI 10.1038/nature13896; Fenton TR, 2010, INT J BIOCHEM CELL B, V42, P359, DOI 10.1016/j.biocel.2009.11.022; Fenton TR, 2010, BIOCHEM BIOPH RES CO, V398, P400, DOI 10.1016/j.bbrc.2010.06.081; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gregorieff A, 2010, CURR PROTOC STEM CEL; Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hasty P, 2014, CANCER PREV RES, V7, P169, DOI 10.1158/1940-6207.CAPR-13-0299; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hong SK, 2014, J BIOL CHEM, V289, P13132, DOI 10.1074/jbc.M113.520734; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Iwabu M, 2010, NATURE, V464, P1313, DOI 10.1038/nature08991; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; De Bonis ML, 2014, STEM CELL REP, V2, P690, DOI 10.1016/j.stemcr.2014.03.002; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Roth S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038965; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Saunders LR, 2010, AGING-US, V2, P415, DOI 10.18632/aging.100176; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Simons BD, 2011, CELL, V145, P851, DOI 10.1016/j.cell.2011.05.033; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Wen L, 2013, P NATL ACAD SCI USA, V110, pE2420, DOI 10.1073/pnas.1309354110; Yilmaz OH, 2012, NATURE, V486, P490, DOI 10.1038/nature11163; Yin XL, 2014, NAT METHODS, V11, P106, DOI 10.1038/nmeth.2737; Yoshino J, 2011, CELL METAB, V14, P528, DOI 10.1016/j.cmet.2011.08.014	44	166	176	1	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	2016	166	2					436	450		10.1016/j.cell.2016.05.044	http://dx.doi.org/10.1016/j.cell.2016.05.044			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DR9ZR	27345368	Bronze			2023-01-03	WOS:000380255400020
J	Zeng, CY; Yu, FL; Yang, Y; Cheng, XH; Liu, Y; Zhang, H; Zhao, SQ; Yang, ZB; Li, MY; Li, ZP; Mei, XG				Zeng, Chunying; Yu, Fanglin; Yang, Yang; Cheng, Xiaohui; Liu, Yan; Zhang, Hui; Zhao, Shiqing; Yang, Zhenbo; Li, Mingyuan; Li, Zhiping; Mei, Xingguo			Preparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability	PLOS ONE			English	Article							TARGETED DRUG-DELIVERY; IN-VITRO; TUMOR; DOXORUBICIN; TEMPERATURE; EFFICACY; CANCER; PHARMACOKINETICS; CYTOTOXICITY; HYPERTHERMIA	Oxaliplatin (OXP) was reported to show low anti-tumor activity when used alone and to display side effects; this low activity was attributed to high partitioning to erythrocytes and low accumulation in tumors. Thermosensitive liposomes (TSL) were considered able to specifically deliver drugs to heated tumors and to resolve the OXP distribution problem. Regretfully, TSL encapsulating doxorubicin did not demonstrate significant improvement in progression-free survival. Drug release below 41 degrees C and significant leakage were considered major reasons for the failure. The purpose of this study was to acquire OXP TSL with rapid release at the triggered temperature and high stability at body temperature and at storage temperatures. A small quantity of poloxamer 188 was introduced into the TSL formulation to stabilize the encapsulated drug. It was shown that the addition of poloxamer 188 had no influence on the TSL characteristics. More than 90% of OXP was released within 10 min at 42 degrees C, and less than 15% was released within 60 min at temperatures below 39 degrees C. TSL were stable at 37 degrees C for 96 h and at 4 degrees C for 6 months. The anti-tumor activity of TSL at the dose of 2.5 mg/kg was certified to be equal to those of OXP injection and non-thermosensitive liposomes (NTSL) at the dose of 5 mg/kg, and significant improvement of tumor inhibition was observed in TSL compared with injection and NTSL at the same dose. It was also shown from the histological transmutation of tumors that TSL had stronger anti-tumor activity. Therefore, it could be concluded that TSL composed of a proper amount of poloxamer had rapid release and high stability, and OXP TSL would be anticipated to exert prominent anti-tumor activity in the clinic.	[Zeng, Chunying] Capital Med Univ, Fu Xing Hosp, Dept Pharm, Beijing, Peoples R China; [Yu, Fanglin; Yang, Yang; Cheng, Xiaohui; Liu, Yan; Zhang, Hui; Zhao, Shiqing; Li, Mingyuan; Li, Zhiping; Mei, Xingguo] Beijing Inst Pharmacol & Toxicol, Dept Pharmaceut, Beijing, Peoples R China; [Yang, Zhenbo] 261 Hosp PLA, Dept Pharm, Beijing, Peoples R China	Capital Medical University; Academy of Military Medical Sciences - China	Li, ZP; Mei, XG (corresponding author), Beijing Inst Pharmacol & Toxicol, Dept Pharmaceut, Beijing, Peoples R China.	dearwood2010@126.com; newdds@126.com			Natural Science Foundation of China [81502675]; National Key Technologies R&D Program for New Drugs [2012ZX09301003-001-009]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technologies R&D Program for New Drugs(National Key Technology R&D Program)	This work was supported by Natural Science Foundation of China (No. 81502675; Zhiping Li; http://www.nsfc.gov.cn/) and the National Key Technologies R&D Program for New Drugs (No. 2012ZX09301003-001-009; Xingguo Mei, Zhiping Li, Yang Yang, Fanglin Yu).	Abu Lila AS, 2012, INT J PHARMACEUT, V438, P176, DOI 10.1016/j.ijpharm.2012.08.030; Abu-Lila A, 2009, J CONTROL RELEASE, V134, P18, DOI 10.1016/j.jconrel.2008.10.018; Andresen TL, 2005, PROG LIPID RES, V44, P68, DOI 10.1016/j.plipres.2004.12.001; Charrois GJR, 2004, BBA-BIOMEMBRANES, V1663, P167, DOI 10.1016/j.bbamem.2004.03.006; Chen D, 2013, INT J PHARMACEUT, V449, P1, DOI 10.1016/j.ijpharm.2013.04.002; Chen J, 2014, INT J PHARMACEUT, V475, P408, DOI 10.1016/j.ijpharm.2014.09.009; Church Jeffrey W., 2014, 2014 AM SOC IN PRESS, V5, P16; Dewhirst MW, 1997, SEMIN ONCOL, V24, P616; Di Francesco AM, 2002, CELL MOL LIFE SCI, V59, P1914, DOI 10.1007/PL00012514; Dicheva BM, 2015, PHARM RES-DORDR, V32, P3862, DOI 10.1007/s11095-015-1746-7; Dromi S, 2007, CLIN CANCER RES, V13, P2722, DOI 10.1158/1078-0432.CCR-06-2443; Franzena U, 2010, J PHARM BIOMED ANAL, V55, P16; Judson I, 2001, EUR J CANCER, V37, P870, DOI 10.1016/S0959-8049(01)00050-8; Kong G, 2000, CANCER RES, V60, P6950; Kwon HJ, 2015, J CONTROL RELEASE, V216, P132, DOI 10.1016/j.jconrel.2015.08.002; Li Y, 2015, BIOMATERIALS, V41, P1, DOI 10.1016/j.biomaterials.2014.11.010; Lu T, 2015, J CONTROL RELEASE, V220, P425, DOI 10.1016/j.jconrel.2015.10.056; Mady MM, 2012, PHYS MEDICA, V28, P48, DOI 10.1016/j.ejmp.2011.02.003; May JP, 2013, MOL PHARMACEUT, V10, P4499, DOI 10.1021/mp400321e; Monsky WL, 1999, CANCER RES, V59, P4129; Mosquera M, 2014, FOOD CHEM, V156, P144, DOI 10.1016/j.foodchem.2014.02.011; Nie SF, 2011, INT J NANOMED, V6, P151, DOI 10.2147/IJN.S15057; PENDYALA L, 1993, CANCER RES, V53, P5970; Ponce AM, 2007, J NATL CANCER I, V99, P53, DOI 10.1093/jnci/djk005; Poon RTP, 2009, EXPERT OPIN PHARMACO, V10, P333, DOI [10.1517/14656560802677874 , 10.1517/14656560802677874]; Quinteros D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110344; Romberg B, 2007, BBA-BIOMEMBRANES, V1768, P737, DOI 10.1016/j.bbamem.2006.12.005; Suzuki R, 2008, INT J PHARM, V346, P143, DOI 10.1016/j.ijpharm.2007.06.010; Tagami T, 2015, J PHARM SCI-US, V104, P3824, DOI 10.1002/jps.24593; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Wang M, 2014, INT J PHARMACEUT, V468, P243, DOI 10.1016/j.ijpharm.2014.04.014; Yang C, 2014, BIOMED REP, V2, P335, DOI 10.3892/br.2014.249; Yang CA, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-21; Yang YF, 2014, BIOMATERIALS, V35, P4368, DOI 10.1016/j.biomaterials.2014.01.076; Yuba E, 2013, BIOMATERIALS, V34, P3042, DOI 10.1016/j.biomaterials.2012.12.031; Zalba S, 2012, EUR J PHARM BIOPHARM, V81, P273, DOI 10.1016/j.ejpb.2012.02.007; Zhang B, 2013, INT J PHARMACEUT, V455, P276, DOI 10.1016/j.ijpharm.2013.07.020; Zhang H, 2011, ANAL BIOCHEM, V417, P292, DOI 10.1016/j.ab.2011.06.025; Zhang WL, 2015, J CONTROL RELEASE, V203, P161, DOI 10.1016/j.jconrel.2015.02.026	39	22	22	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2016	11	7							e0158517	10.1371/journal.pone.0158517	http://dx.doi.org/10.1371/journal.pone.0158517			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR0DZ	27415823	Green Submitted, Green Published, gold			2023-01-03	WOS:000379579500024
J	Samson, S; Basri, M; Masoumi, HRF; Malek, EA; Karjiban, RA				Samson, Shazwani; Basri, Mahiran; Masoumi, Hamid Reza Fard; Malek, Emilia Abdul; Karjiban, Roghayeh Abedi			An Artificial Neural Network Based Analysis of Factors Controlling Particle Size in a Virgin Coconut Oil-Based Nanoemulsion System Containing Copper Peptide	PLOS ONE			English	Article							ZNO NANOPARTICLES; NANO-EMULSIONS; OPTIMIZATION; FORMULATION; DELIVERY; EXTRACT; DESIGN; ACID	A predictive model of a virgin coconut oil (VCO) nanoemulsion system for the topical delivery of copper peptide (an anti-aging compound) was developed using an artificial neural network (ANN) to investigate the factors that influence particle size. Four independent variables including the amount of VCO, Tween 80:Pluronic F68 (T80:PF68), xanthan gum and water were the inputs whereas particle size was taken as the response for the trained network. Genetic algorithms (GA) were used to model the data which were divided into training sets, testing sets and validation sets. The model obtained indicated the high quality performance of the neural network and its capability to identify the critical composition factors for the VCO nanoemulsion. The main factor controlling the particle size was found out to be xanthan gum (28.56%) followed by T80:PF68 (26.9%), VCO (22.8%) and water (21.74%). The formulation containing copper peptide was then successfully prepared using optimum conditions and particle sizes of 120.7 nm were obtained. The final formulation exhibited a zeta potential lower than -25 mV and showed good physical stability towards centrifugation test, freeze-thaw cycle test and storage at temperature 25 degrees C and 45 degrees C.	[Samson, Shazwani; Basri, Mahiran; Masoumi, Hamid Reza Fard; Malek, Emilia Abdul; Karjiban, Roghayeh Abedi] Univ Putra Malaysia, Fac Sci, Dept Chem, Upm Serdang, Selangor, Malaysia	Universiti Putra Malaysia	Samson, S; Basri, M (corresponding author), Univ Putra Malaysia, Fac Sci, Dept Chem, Upm Serdang, Selangor, Malaysia.	dorawanie_89@yahoo.com; mahiran@science.upm.edu.my						Abdollahi Y, 2015, J IND ENG CHEM, V25, P168, DOI 10.1016/j.jiec.2014.10.029; Aghaeinejad-Meybodi A, 2015, J TAIWAN INST CHEM E, V48, P40, DOI 10.1016/j.jtice.2014.10.022; Arenillo SA, 2008, J HIGHER ED RES, V5, P190; Ba-Abbad MM, 2013, J IND ENG CHEM, V19, P99, DOI 10.1016/j.jiec.2012.07.010; Badhani B, 2015, RSC ADV, V5, P27540, DOI 10.1039/c5ra01911g; Catalogna M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044587; Chen SM, 2013, J EARTH SYST SCI, V122, P399, DOI 10.1007/s12040-013-0289-8; Choudhury AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077071; Ribeiro RCD, 2015, MOLECULES, V20, P2492, DOI 10.3390/molecules20022492; de Carvalho SM, 2013, IND CROP PROD, V49, P278, DOI 10.1016/j.indcrop.2013.04.054; Fadare DA, 2007, AFR J BIOTECHNOL, V6, P2184; Gibbs MS, 2003, MODSIM 2003: INTERNATIONAL CONGRESS ON MODELLING AND SIMULATION, VOLS 1-4, P789; Hadzir NM, 2013, AAPS PHARMSCITECH, V14, P456, DOI 10.1208/s12249-013-9929-1; Hamman JH, 2005, BIODRUGS, V19, P165, DOI 10.2165/00063030-200519030-00003; Kamariah L, 2008, J TROP AGR FOOD SCI, V36, P1; Kamble Meghana S., 2013, J BIOMED PHARM RES, V2, P100; Kiransan M, 2015, SPECTROCHIM ACTA A, V140, P465, DOI 10.1016/j.saa.2014.12.100; Kumar SN, 2015, EUR J PHARM SCI, V67, P97, DOI 10.1016/j.ejps.2014.10.014; Kumar P, 2014, TRANSPORT RES C-EMER, V40, P111, DOI 10.1016/j.trc.2014.01.006; Leelapornpisid P., 2014, INT J PHARM PHARM SC, V6, P313; Loong NC, 2014, IND CROP PROD, V59, P309, DOI 10.1016/j.indcrop.2014.05.042; Lupo MP, 2005, DERMATOL SURG, V31, P832; Mahdi ES, 2011, INT J NANOMED, V6, P2499, DOI 10.2147/IJN.S22337; Mansor T. S. T., 2012, International Food Research Journal, V19, P837; Marina AM, 2009, TRENDS FOOD SCI TECH, V20, P481, DOI 10.1016/j.tifs.2009.06.003; Marinkovski M, 2014, J SUPERCRIT FLUID, V92, P242; Masoumi HRF, 2013, SCI WORLD J, DOI 10.1155/2013/962083; Moghaddam MG, 2010, J BIOTECHNOL, V13, DOI [10.2225/vol13-issue3-fulltext-9, DOI 10.2225/VOL13-ISSUE3-FULLTEXT-9]; Mukherjee PK, 2011, PHYTOMEDICINE, V19, P64, DOI 10.1016/j.phymed.2011.10.003; Musharavati F., 2010, J ADV MAT MANUFACT E, V41, P140; Ngan CL, 2014, SCI WORLD J, DOI 10.1155/2014/219035; Pickart L, 2010, SOFW-J, V136, P10; Pickart L., 2012, J AGING RES CLIN PRA, V1, P13; Rebolleda S, 2015, FOOD CHEM, V167, P16, DOI 10.1016/j.foodchem.2014.06.097; Rezaee M, 2014, IND CROP PROD, V52, P506, DOI 10.1016/j.indcrop.2013.10.046; Sarkar A, 2015, AQUAT PR, V4, P1070, DOI 10.1016/j.aqpro.2015.02.135; Setya S, 2014, WORLD J, V3, P2214; Shilin M, 2013, INT J NANOMED, V8, P4045, DOI [10.2147/IJN.S47956, DOI 10.2147/IJN.S47956]; Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023; Tsai MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102850	40	16	16	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2016	11	7							e0157737	10.1371/journal.pone.0157737	http://dx.doi.org/10.1371/journal.pone.0157737			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3NH	27383135	Green Submitted, Green Published, gold			2023-01-03	WOS:000379809400024
J	Wang, YL; Zhao, XQ; Lin, JX; Li, H; Johnston, SC; Lin, Y; Pan, YS; Liu, LP; Wang, D; Wang, CX; Meng, X; Xu, JF; Wang, YJ				Wang, Yilong; Zhao, Xingquan; Lin, Jinxi; Li, Hao; Johnston, S. Claiborne; Lin, Yi; Pan, Yuesong; Liu, Liping; Wang, David; Wang, Chunxue; Meng, Xia; Xu, Jianfeng; Wang, Yongjun		CHANCE Investigators	Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPLEMENTATION CONSORTIUM GUIDELINES; ANTIPLATELET TREATMENT; PLATELET-FUNCTION; POLYMORPHISMS; GENOTYPE; METABOLISM; PREVALENCE; GENE	IMPORTANCE Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated with clopidogrel. OBJECTIVE To estimate the association between CYP2C19 genetic variants and clinical outcomes of clopidogrel-treated patients with minor stroke or transient ischemic attack. DESIGN, SETTING, AND PARTICIPANTS Three CYP2C19 major alleles (*2, *3, *17) were genotyped among 2933 Chinese patients from 73 sites who were enrolled in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted from January 2, 2010, to March 20, 2012. INTERVENTIONS Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone. MAIN OUTCOMES AND MEASURES The primary efficacy outcome was new stroke. The secondary efficacy outcome was a composite of new composite vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). Bleeding was the safety outcome. RESULTS Among 2933 patients, 1948 (66.4%) were men, with a mean age of 62.4 years. Overall, 1207 patients (41.2%) were noncarriers and 1726 patients (58.8%) were carriers of loss-of-function alleles (*2, *3). After day 90 follow-up, clopidogrel-aspirin reduced the rate of new stroke in the noncarriers but not in the carriers of the loss-of-function alleles (P = .02 for interaction; events among noncarriers, 41 [6.7%] with clopidogrel-aspirin vs 74 [12.4%] with aspirin; hazard ratio [HR], 0.51 [95% CI, 0.35-0.75]; events among carriers, 80 [9.4%] with clopidogrel-aspirin vs 94 [10.8%] with aspirin; HR, 0.93 [95% CI, 0.69 to 1.26]). Similar results were observed for the secondary composite efficacy outcome (noncarriers: 41 [6.7%] with clopidogrel-aspirin vs 75 [12.5%] with aspirin; HR, 0.50 [95% CI, 0.34-0.74]; carriers: 80 [9.4%] with clopidogrel-aspirin vs 95 [10.9%] with aspirin; HR, 0.92 [95% CI, 0.68-1.24]; P = .02 for interaction). The effect of treatment assignment on bleeding did not vary significantly between the carriers and the noncarriers of the loss-of-function alleles (2.3% for carriers and 2.5% for noncarriers in the clopidogrel-aspirin group vs 1.4% for carriers and 1.7% for noncarriers in the aspirin only group; P = .78 for interaction). CONCLUSIONS AND RELEVANCE Among patients with minor ischemic stroke or transient ischemic attack, the use of clopidogrel plus aspirin compared with aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not carriers of the CYP2C19 loss-of-function alleles. These findings support a role of CYP2C19 genotype in the efficacy of this treatment.	[Wang, Yilong; Zhao, Xingquan; Lin, Jinxi; Li, Hao; Pan, Yuesong; Liu, Liping; Wang, Chunxue; Meng, Xia; Wang, Yongjun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China; [Wang, Yilong; Zhao, Xingquan; Lin, Jinxi; Li, Hao; Pan, Yuesong; Liu, Liping; Wang, Chunxue; Meng, Xia; Wang, Yongjun] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China; [Wang, Yilong; Zhao, Xingquan; Lin, Jinxi; Li, Hao; Pan, Yuesong; Liu, Liping; Wang, Chunxue; Meng, Xia; Wang, Yongjun] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China; [Wang, Yilong; Zhao, Xingquan; Lin, Jinxi; Li, Hao; Pan, Yuesong; Liu, Liping; Wang, Chunxue; Meng, Xia; Wang, Yongjun] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China; [Johnston, S. Claiborne] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA; [Lin, Yi] Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, Fuzhou, Peoples R China; [Lin, Yi] Fujian Med Univ, Affiliated Hosp 1, Inst Neurol, Fuzhou, Peoples R China; [Wang, David] Univ Illinois, Coll Med, Illinois Neurol Inst Stroke Network, OSF Healthcare Syst, Peoria, IL 61656 USA; [Xu, Jianfeng] Fudan Univ, Hushan Hosp, Fudan Inst Urol, Shanghai 200433, Peoples R China; [Xu, Jianfeng] NorthShore Univ HealthSyst, Program Personalized Canc Care, Evanston, IL USA	Capital Medical University; University of Texas System; University of Texas Austin; Fujian Medical University; Fujian Medical University; University of Illinois System; University of Illinois Peoria; Fudan University; NorthShore University Health System	Wang, YJ (corresponding author), 6 Tiantanxili, Beijing 100050, Peoples R China.	yongjunwang1962@gmail.com	Pan, Yuesong/AAI-6303-2020; Li, Hao/GPS-9834-2022	Pan, Yuesong/0000-0003-3082-6789; Wang, Yilong/0000-0003-2725-2788	Ministry of Science and Technology of the People's Republic of China [2006BAI01A11, 2011BAI08B01, 2011BAI08B02, 2012ZX09303-005-001, 2013BAI09B03]; Beijing Biobank of Cerebral Vascular Disease [D131100005313003]; Beijing Institute for Brain Disorders [BIBD-PXM2013_014226_07_000084]; National Natural Science Foundation of China [81322019]; China Postdoctoral Science Foundation [2014T70093]; Natural Science Foundation of Fujian Province [2015J01394]; Beijing Municipal Science and Technology Commission [Z141107002514125]; Shanghai Municipal Commission of Health and Family Planning [20124035]; Ellrodt-Schweighauser Family Chair of Cancer Genomic Research of NorthShore University HealthSystem	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); Beijing Biobank of Cerebral Vascular Disease; Beijing Institute for Brain Disorders; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Beijing Municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission); Shanghai Municipal Commission of Health and Family Planning; Ellrodt-Schweighauser Family Chair of Cancer Genomic Research of NorthShore University HealthSystem	The study is supported by grants from the Ministry of Science and Technology of the People's Republic of China (2006BAI01A11, 2011BAI08B01, 2011BAI08B02, 2012ZX09303-005-001, and 2013BAI09B03), the Beijing Biobank of Cerebral Vascular Disease (D131100005313003), the Beijing Institute for Brain Disorders (BIBD-PXM2013_014226_07_000084), the National Natural Science Foundation of China (No. 81322019), the China Postdoctoral Science Foundation (No. 2014T70093), the Natural Science Foundation of Fujian Province (No. 2015J01394), the Beijing Municipal Science and Technology Commission (No. Z141107002514125), and the Shanghai Municipal Commission of Health and Family Planning (No. 20124035) and supported from the Ellrodt-Schweighauser Family Chair of Cancer Genomic Research of NorthShore University HealthSystem (Dr Xu).	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Bauer T, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4588; Collet JP, 2009, J CARDIOVASC PHARM T, V14, P157, DOI 10.1177/1074248409339309; Hasan MS, 2013, INT J NEUROSCI, V123, P143, DOI 10.3109/00207454.2012.744308; Holmes MV, 2011, JAMA-J AM MED ASSOC, V306, P2704, DOI 10.1001/jama.2011.1880; Hulot JS, 2006, BLOOD, V108, P2244, DOI 10.1182/blood-2006-04-013052; Jia DM, 2013, STROKE, V44, P1717, DOI 10.1161/STROKEAHA.113.000823; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kitzmiller JP, 2011, CLEV CLIN J MED, V78, P243, DOI 10.3949/ccjm.78a.10145; Li ZX, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003038; McDonough CW, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001652; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Osnabrugge RL, 2015, GENET MED, V17, P3, DOI 10.1038/gim.2014.76; Pare G, 2010, NEW ENGL J MED, V363, P1704, DOI 10.1056/NEJMoa1008410; Roberts JD, 2012, LANCET, V379, P1705, DOI 10.1016/S0140-6736(12)60161-5; Scott SA, 2013, CLIN PHARMACOL THER, V94, P317, DOI 10.1038/clpt.2013.105; Scott SA, 2011, CLIN PHARMACOL THER, V90, P328, DOI 10.1038/clpt.2011.132; Sim SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/j.clpt.2005.10.002; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Sun WS, 2015, PLATELETS, V26, P558, DOI 10.3109/09537104.2014.953044; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Trenk D, 2014, BRIT J CLIN PHARMACO, V77, P642, DOI 10.1111/bcp.12230; Wang YL, 2007, INT J STROKE, V2, P211, DOI 10.1111/j.1747-4949.2007.00142.x; Wang YL, 2015, NEUROLOGY, V84, P2354, DOI 10.1212/WNL.0000000000001665; Wang YJ, 2014, CHIN J NEUROL, V48, P258; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Wei Wei, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P420, DOI 10.3760/cma.j.issn.1003-9406.2012.04.009; Yang J, 2013, PHARMAZIE, V68, P183, DOI 10.1691/ph.2013.2703; Zhao D, 2008, STROKE, V39, P1668, DOI 10.1161/STROKEAHA.107.502807	29	195	208	7	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2016	316	1					70	78		10.1001/jama.2016.8662	http://dx.doi.org/10.1001/jama.2016.8662			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ2MY	27348249	Bronze			2023-01-03	WOS:000379037600020
J	Chadha, AS; Skinner, HD; Gunther, JR; Munsell, MF; Das, P; Minsky, BD; Delclos, ME; Chatterjee, D; Wang, HM; Clemons, M; George, G; Singh, PK; Katz, MH; Fleming, JB; Javle, MM; Wolff, RA; Varadhachary, GR; Crane, CH; Krishnan, S				Chadha, Awalpreet S.; Skinner, Heath D.; Gunther, Jillian R.; Munsell, Mark F.; Das, Prajnan; Minsky, Bruce D.; Delclos, Marc E.; Chatterjee, Deyali; Wang, Huamin; Clemons, Marilyn; George, Geena; Singh, Pankaj K.; Katz, Matthew H.; Fleming, Jason B.; Javle, Milind M.; Wolff, Robert A.; Varadhachary, Gauri R.; Crane, Christopher H.; Krishnan, Sunil			Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CONTINUAL REASSESSMENT METHOD; FACTOR RECEPTOR; RADIATION-THERAPY; CLINICAL-TRIALS; TUMOR RESPONSE; EXPRESSION; GEMCITABINE; BLOCKADE; IRRADIATION	Purpose To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. Methods Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer were enrolled between 3/2008 and 10/2010. Prior chemotherapy was permitted. Two patients each were enrolled at dose levels (DLs) 1-4 and 9 patients at DL 5. All patients received 50.4 Gy (GTV only) in 28 fractions with concurrent capecitabine, bevacizumab and erlotinib. Dose of each drug was escalated in 5 DLs using the continual reassessment method. Bevacizumab was escalated from 5mg/Kg q2weeks (DLs 1-4) to 10mg/Kg q2weeks (DL 5); daily erlotinib from 100mg/day (DLs 1-2) to 150 mg/Kg (DLs 3-5); and capecitabine from 400mg/m(2) twice daily on days of radiation (DL 1) to 650mg/m(2) (DLs 2-3) to 825 mg/m(2) (DLs 4-5). Reassessment for potential resection was performed 6-8 weeks later. Results Sixteen patients received gemcitabine-based chemotherapy prior to CRT. With a median clinical follow-up of 10 months, no grade 3 toxicities were observed in DLs 1-4. Three (33%) patients at DL 5 developed a grade 3 acute toxicity (2 diarrhea, 1 rash). No grade 4 or 5 toxicities were seen. DL 4 was selected as the MTD; therefore, the recommended doses in combination with radiation are: bevacizumab, 5mg/Kg q2weeks; erlotinib, 150 mg/Kg daily; and capecitabine, 825mg/m(2) BID. Median survival was 17.4 months. Of the five patients who underwent resection, 4 were originally deemed locally advanced and 1 was borderline resectable. Three patients had excellent pathological response (2 complete response and 20% viable tumor) at surgery, and the 2 patients with complete response are still alive at 61 and 67 months of follow up with no local or distant failures. Conclusions This chemoradiation regimen at the recommended dose levels is safe and tolerable for patients with unresectable pancreatic cancer and merits further evaluation.	[Chadha, Awalpreet S.; Skinner, Heath D.; Gunther, Jillian R.; Das, Prajnan; Minsky, Bruce D.; Delclos, Marc E.; Clemons, Marilyn; George, Geena; Singh, Pankaj K.; Crane, Christopher H.; Krishnan, Sunil] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Munsell, Mark F.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Chatterjee, Deyali; Wang, Huamin] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Katz, Matthew H.; Fleming, Jason B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Javle, Milind M.; Wolff, Robert A.; Varadhachary, Gauri R.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Krishnan, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.	skrishnan@mdanderson.org	; Skinner, Heath/A-1669-2012	Chadha, Awalpreet/0000-0002-8072-2243; Skinner, Heath/0000-0003-1836-151X	Genentech, Inc.; Cancer Center Support (Core) [P30 CA16672]; John E. and Dorothy J. Harris Endowed Professorship; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Genentech, Inc.(Roche HoldingGenentech); Cancer Center Support (Core); John E. and Dorothy J. Harris Endowed Professorship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Genentech, Inc. funded SK. The funder approved the phase I concept but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported in part by Cancer Center Support (Core) Grant P30 CA16672 to The University of Texas MD Anderson Cancer Center for use of the Clinical Trials Support Resource and the John E. and Dorothy J. Harris Endowed Professorship to SK.	Bozec A, 2008, BRIT J CANCER, V99, P93, DOI 10.1038/sj.bjc.6604429; Crane CH, 2006, J CLIN ONCOL, V24, P1145, DOI 10.1200/JCO.2005.03.6780; Crane CH, 2009, J CLIN ONCOL, V27, P4096, DOI 10.1200/JCO.2009.21.8529; Das P, 2014, INT J RADIAT ONCOL, V88, P301, DOI 10.1016/j.ijrobp.2013.10.034; Duffy A, 2008, ANN ONCOL, V19, P86, DOI 10.1093/annonc/mdm441; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Falchook GS, 2013, ONCOTARGET, V4, P118, DOI 10.18632/oncotarget.763; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fjallskog MLH, 2003, CLIN CANCER RES, V9, P1469; Fujita H, 2011, INT J ONCOL, V38, P629, DOI 10.3892/ijo.2011.908; Gorski DH, 1999, CANCER RES, V59, P3374; Gutt R, 2010, NAT REV GASTRO HEPAT, V7, P437, DOI 10.1038/nrgastro.2010.98; Herman JM, 2013, INT J RADIAT ONCOL, V86, P678, DOI 10.1016/j.ijrobp.2013.03.032; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Lee CG, 2000, CANCER RES, V60, P5565; Mahipal A, 2012, MED ONCOL, V29, P134, DOI 10.1007/s12032-010-9802-y; Martin ST, 2012, BRIT J SURG, V99, P918, DOI 10.1002/bjs.8702; Milas L, 2004, INT J RADIAT ONCOL, V58, P966, DOI 10.1016/j.ijrobp.2003.08.035; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; OQUIGLEY J, 1990, BIOMETRICS, V46, P33, DOI 10.2307/2531628; OQuigley JO, 1996, BIOMETRICS, V52, P673, DOI 10.2307/2532905; Pryczynicz A, 2008, ANTICANCER RES, V28, P1399; Rich T, 2004, AM J CLIN ONCOL-CANC, V27, P51, DOI 10.1097/01.coc.0000046300.88847.BF; Schicher N, 2009, CLIN CANCER RES, V15, P3495, DOI 10.1158/1078-0432.CCR-08-2407; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Tobita K, 2003, INT J MOL MED, V11, P305; Tortora G, 2008, NAT CLIN PRACT ONCOL, V5, P521, DOI 10.1038/ncponc1161; Willett CG, 2005, J CLIN ONCOL, V23, P4538, DOI 10.1200/JCO.2005.23.911; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004	34	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0156910	10.1371/journal.pone.0156910	http://dx.doi.org/10.1371/journal.pone.0156910			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27336466	gold, Green Submitted, Green Published			2023-01-03	WOS:000378389200005
J	Ou, SH; Chen, MY; Huang, CW; Chen, NC; Wu, CH; Hsu, CY; Chou, KJ; Lee, PT; Fang, HC; Chen, CL				Ou, Shih-Hsiang; Chen, Mei-Yin; Huang, Chien-Wei; Chen, Nai-Ching; Wu, Chien-Hsing; Hsu, Chih-Yang; Chou, Kang-Ju; Lee, Po-Tsang; Fang, Hua-Chang; Chen, Chien-Liang			Potential Role of Vegetarianism on Nutritional and Cardiovascular Status in Taiwanese Dialysis Patients: A Case-Control Study	PLOS ONE			English	Article							PULSE-WAVE VELOCITY; NONTRADITIONAL RISK-FACTORS; CORONARY-HEART-DISEASE; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; ARTERIAL STIFFNESS; MAINTENANCE HEMODIALYSIS; OXIDATIVE STRESS; INFLAMMATION; METAANALYSIS	Background & Objectives Cardiovascular disease remains the most common cause of death for patients on chronic dialysis. End stage renal disease patients undergoing dialysis imposed to reduce phosphorus intake, which likely contributes to development of vegetarian diet behaviors. Vegetarian diets are often lower in protein content, in contradiction to the recommendation that a high protein diet is followed by patients undergoing dialysis. The purpose of the study was to investigate the effects of a vegetarian diet on the nutritional and cardiovascular status of dialysis patients. Design, Setting, Participants, Measurements A study of 21 vegetarian dialysis patients and 42 age-and sex-matched non-vegetarian dialysis patients selected as controls was conducted in the Kaohsiung Veterans General Hospital. Brachial-ankle pulse wave velocity and biochemistry data including total homocysteine levels, serum lipid profiles, high-sensitivity C-reactive protein, vitamin D levels, albumin, and normalized protein catabolic rate were measured. Results Compared with the non-vegetarian control group, vegetarian subjects had lower body weight, body mass index, serum phosphate, blood urea nitrogen, serum creatinine, vitamin D, uric acid, albumin, and normalized protein catabolic rate (p < 0.05). The vegetarian group showed higher brachial-ankle pulse wave velocity than the non-vegetarian group (1926.95 +/- 456.45 and 1684.82 +/- 309.55 cm/sec, respectively, p < 0.05). After adjustment for age, albumin, pre-dialysis systolic blood pressure, and duration of dialysis, vegetarian diet remained an independent risk factor for brachial-ankle pulse wave velocity. Conclusions The present study revealed that patients on dialysis who follow vegetarian diets may experience subclinical protein malnutrition and vitamin D deficiency that could offset the beneficial cardiovascular effects of vegetarianism.	[Ou, Shih-Hsiang; Huang, Chien-Wei; Hsu, Chih-Yang; Chou, Kang-Ju; Lee, Po-Tsang; Fang, Hua-Chang; Chen, Chien-Liang] Kaohsiung Vet Gen Hosp, Div Nephrol, Kaohsiung, Taiwan; [Chen, Mei-Yin] Kaohsiung Vet Gen Hosp, Div Nutr, Kaohsiung, Taiwan; [Ou, Shih-Hsiang; Huang, Chien-Wei; Hsu, Chih-Yang; Chou, Kang-Ju; Lee, Po-Tsang; Fang, Hua-Chang; Chen, Chien-Liang] Natl Yang Ming Univ, Sch Med, Dept Med, Taipei 112, Taiwan; [Chen, Nai-Ching] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Kaohsiung, Taiwan	Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital; Chang Gung University	Chen, CL (corresponding author), Kaohsiung Vet Gen Hosp, Div Nephrol, Kaohsiung, Taiwan.; Chen, CL (corresponding author), Natl Yang Ming Univ, Sch Med, Dept Med, Taipei 112, Taiwan.	cclchen@seed.net.tw	chen, chien-liang/I-6192-2015; Wu, Chien-Hsing/ABI-4006-2020; Huang, Chien-Wei/AAN-9838-2020	chen, chien-liang/0000-0002-9508-8396; Huang, Chien-Wei/0000-0001-5753-9654; Ou, Shih-Fu/0000-0001-5294-3113				Andrukhova O, 2014, MOL ENDOCRINOL, V28, P53, DOI 10.1210/me.2013-1252; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; Danielski M, 2003, AM J KIDNEY DIS, V42, P286, DOI 10.1016/S0272-6386(03)00653-X; Davis BC, 2003, AM J CLIN NUTR, V78, p640S, DOI 10.1093/ajcn/78.3.640S; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Hansen TW, 2006, CIRCULATION, V113, P664, DOI 10.1161/CIRCULATIONAHA.105.579342; Hung CJ, 2002, J NUTR, V132, P152, DOI 10.1093/jn/132.2.152; Ingenbleek Y, 2012, NUTRITION, V28, P148, DOI 10.1016/j.nut.2011.04.009; Kahleova H, 2011, DIABETIC MED, V28, P549, DOI 10.1111/j.1464-5491.2010.03209.x; Kalantar-Zadeh K, 2005, CURR OPIN CLIN NUTR, V8, P388, DOI 10.1097/01.mco.0000172578.56396.9e; Kim Eun-Young, 2008, Electrolyte Blood Press, V6, P61, DOI 10.5049/EBP.2008.6.2.61; Kitahara T, 2005, AM J KIDNEY DIS, V46, P688, DOI 10.1053/j.ajkd.2005.06.016; Kuang DW, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-143; LAMBERG-ALLARDT C, 1993, AM J CLIN NUTR, V58, P684, DOI 10.1093/ajcn/58.5.684; Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236; London GM, 2001, J AM SO NEPHROL, V18, P613; Muntner P, 2005, J AM SOC NEPHROL, V16, P529, DOI 10.1681/ASN.2004080656; Muntner P, 2004, ANN INTERN MED, V140, P9, DOI 10.7326/0003-4819-140-1-200401060-00006; Noori N, 2011, AM J KIDNEY DIS, V58, P248, DOI 10.1053/j.ajkd.2011.03.017; Noori N, 2010, AM J CLIN NUTR, V92, P1060, DOI 10.3945/ajcn.2010.29188; Obersby D, 2013, BRIT J NUTR, V109, P785, DOI 10.1017/S000711451200520X; Pase MP, 2011, BRIT J NUTR, V106, P974, DOI 10.1017/S0007114511002819; Tanaka H, 2009, J HYPERTENS, V27, P2022, DOI 10.1097/HJH.0b013e32832e94e7; US Renal Data System, 2010, USRDS 2010 ANN DAT R; Wang AYM, 2008, AM J CLIN NUTR, V87, P1631, DOI 10.1093/ajcn/87.6.1631; Wu TT, 2011, NEPHROLOGY, V16, P582, DOI 10.1111/j.1440-1797.2011.01464.x; Yamada S, 2015, AM J PHYSIOL-RENAL, V309, pF744, DOI 10.1152/ajprenal.00017.2015; Yamashina A, 2002, HYPERTENS RES, V25, P359, DOI 10.1291/hypres.25.359	28	13	13	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2016	11	6							e0156297	10.1371/journal.pone.0156297	http://dx.doi.org/10.1371/journal.pone.0156297			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KF	27295214	Green Published, gold, Green Submitted			2023-01-03	WOS:000377821300005
J	Sun, X; Qian, HN				Sun, Xin; Qian, Huinan			Chinese Herbal Medicine Image Recognition and Retrieval by Convolutional Neural Network	PLOS ONE			English	Article								Chinese herbal medicine image recognition and retrieval have great potential of practical applications. Several previous studies have focused on the recognition with hand-crafted image features, but there are two limitations in them. Firstly, most of these hand-crafted features are low-level image representation, which is easily affected by noise and background. Secondly, the medicine images are very clean without any backgrounds, which makes it difficult to use in practical applications. Therefore, designing high-level image representation for recognition and retrieval in real world medicine images is facing a great challenge. Inspired by the recent progress of deep learning in computer vision, we realize that deep learning methods may provide robust medicine image representation. In this paper, we propose to use the Convolutional Neural Network (CNN) for Chinese herbal medicine image recognition and retrieval. For the recognition problem, we use the softmax loss to optimize the recognition network; then for the retrieval problem, we fine-tune the recognition network by adding a triplet loss to search for the most similar medicine images. To evaluate our method, we construct a public database of herbal medicine images with cluttered back-grounds, which has in total 5523 images with 95 popular Chinese medicine categories. Experimental results show that our method can achieve the average recognition precision of 71% and the average retrieval precision of 53% over all the 95 medicine categories, which are quite promising given the fact that the real world images have multiple pieces of occluded herbal and cluttered backgrounds. Besides, our proposed method achieves the state-of-the-art performance by improving previous studies with a large margin.	[Sun, Xin; Qian, Huinan] Beijing Univ Chinese Med, Acad Basic Med Sci, Beijing, Peoples R China; [Sun, Xin; Qian, Huinan] 11 Beisanhuan East Rd, Beijing, Peoples R China	Beijing University of Chinese Medicine	Qian, HN (corresponding author), Beijing Univ Chinese Med, Acad Basic Med Sci, Beijing, Peoples R China.; Qian, HN (corresponding author), 11 Beisanhuan East Rd, Beijing, Peoples R China.	huinan.qian@gmail.com			Natural Science Foundation of China [30171188]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project is supported by the Natural Science Foundation of China (Grant No. 30171188). The funders provide the data and GPU computer servers.	Abdel-Hakim A. E., 2006, COMPUTER VISION PATT; CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851; Chatfield K, 2011, PROCEEDINGS OF THE BRITISH MACHINE VISION CONFERENCE 2011, DOI 10.5244/C.25.76; Chen X., 2013, INT C COMP VIS; Cinbis R. G., 2014, COMPUTER VISION PATT; Dalal N.B.T., 2005, COMPUTER VISION PATT; Girshick R., 2014, P IEEE C COMP VIS PA, P23; He K., 2014, ARXIV150201852; Huang J, 2015, ARXIV150507922; Huang Y., 2011, COMPUTER VISION PATT; Ke Y., 2004, COMPUTER VISION PATT; Krizhevsky A., 2012, NEURAL INFORM POCESS; Laiy H., 2014, ARXIV150403410; LeCun Y., 1995, HDB BRAIN THEORY NEU, V3361, P1995; LeCun Y., 1990, P ADV NEUR INF PROC, V2; LeCun Y, 2010, IEEE INT SYMP CIRC S, P253, DOI 10.1109/ISCAS.2010.5537907; Lee H., 2007, NEURAL INFORM POCESS; Li Z. F., 2013, THESIS; Lin K., 2015, COMP VIS PATT REC WO; Lin Y., 2011, INT C COMP VIS; Liu L., 2011, INT C COMP VIS; Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94; Ma L., 2011, COMPUTER ENG APPL; Mikolajczyk K., 2003, COMPUTER VISION PATT; Morioka N., 2011, INT C COMP VIS; Ng J. Yue-Hei, 2015, COMPUTER VISION PATT; Shabou A., 2012, COMPUTER VISION PATT; Szegedy C., 2015, P CVPR BOST MA US 7, P1, DOI DOI 10.1109/CVPR.2015.7298594; Tao O., 2011, WORLD SCI TECHNOLOGY; Tao O., 2014, WORLD SCI TECHNOLOGY; Wan J., 2015, INT C MULT; Wang C, 2014, LECT NOTES COMPUT SC, V8694, P431, DOI 10.1007/978-3-319-10599-4_28; Wang J., 2014, HASHING SIMILARITY S; Wang J., 2010, COMPUTER VISION PATT; Yang J.C., 2010, COMPUTER VISION PATT; Yang TT, 2014, THESIS; Yao F., 2011, GUIDE CHINESE MED; Yue- Hei J., 2015, COMP VIS PATT REC WO; Zhai G., 2011, J LANZHOU POLYTECHNI; Zhang J., 2011, COMPUTER VISION PATT; Zhao F., 2015, COMPUTER VISION PATT; Zisserman A., 2015, ARXIV14091556	42	9	9	5	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2016	11	6							e0156327	10.1371/journal.pone.0156327	http://dx.doi.org/10.1371/journal.pone.0156327			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN8ZV	27258404	Green Submitted, Green Published, gold			2023-01-03	WOS:000377369700054
J	McKenzie, KC				McKenzie, Katherine C.			A Modern Ars Moriendi	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[McKenzie, Katherine C.] Yale Sch Med, New Haven, CT 06510 USA	Yale University	McKenzie, KC (corresponding author), Yale Sch Med, New Haven, CT 06510 USA.			McKenzie, Katherine/0000-0002-7621-9741				Dugdale LS, 2015, DYING 21 CENTURY NEW	1	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2016	374	22					2107	2109		10.1056/NEJMp1601820	http://dx.doi.org/10.1056/NEJMp1601820			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EB2RP	27248618				2023-01-03	WOS:000387209900003
J	Slama, S; Kim, HJ; Roglic, G; Boulle, P; Hering, H; Varghese, C; Rasheed, S; Tonelli, M				Slama, Slim; Kim, Hyo-Jeong; Roglic, Gojka; Boulle, Philippa; Hering, Heiko; Varghese, Cherian; Rasheed, Shahnawaz; Tonelli, Marcello			Care of non-communicable diseases in emergencies	LANCET			English	Editorial Material							DISASTER PREPAREDNESS; HEALTH; MANAGEMENT; NEEDS		[Slama, Slim] World Hlth Org, Reg Off Eastern Mediterranean, Cairo, Egypt; [Kim, Hyo-Jeong; Roglic, Gojka; Varghese, Cherian] World Hlth Org, Geneva, Switzerland; [Boulle, Philippa] Med Sans Frontieres, Geneva, Switzerland; [Hering, Heiko] United Nations High Commiss Refugees, Geneva, Switzerland; [Rasheed, Shahnawaz] Imperial Coll London, Dept Surg, London, England; [Rasheed, Shahnawaz] Royal Marsden Hosp, London, England; [Tonelli, Marcello] Univ Calgary, Dept Med, Calgary, AB, Canada	Egyptian Knowledge Bank (EKB); World Health Organization Egypt; World Health Organization; World Health Organization; Doctors Without Borders; Imperial College London; Royal Marsden NHS Foundation Trust; University of Calgary	Tonelli, M (corresponding author), Univ Calgary, TRW Bldg, Calgary, AB T2N 4Z6, Canada.	cello@ucalgary.ca	Tonelli, Marcello/B-3028-2009	Tonelli, Marcello/0000-0002-0846-3187; Roglic, Gojka/0000-0003-0872-0689; Hering, Heiko/0000-0003-2678-5064	David Freeze Chair in health services research	David Freeze Chair in health services research	MT was supported by a the David Freeze Chair in health services research.	Aldrich Nancy, 2008, Prev Chronic Dis, V5, pA27; Arrieta MI, 2008, AM J MED SCI, V336, P128, DOI 10.1097/MAJ.0b013e318180f209; Bell Christopher, 2014, Hosp Pharm, V49, P398, DOI 10.1310/hjp4904-398; Brown DW, 2008, PREHOSP DISASTER MED, V23, P447, DOI 10.1017/S1049023X0000618X; Bukhari S K S, 2010, East Mediterr Health J, V16 Suppl, pS106; Chan E Y Y, 2007, Asia Pac J Public Health, V19 Spec No, P45; Committee on Lessons Learned from the Fukushima Nuclear Accident for Improving Safety and Security of U.S. Nuclear Plants, 2014, LESS LEARN FUK NUCL; Doocy S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150088; Duong DB., 2015, THESIS; Friel S, 2011, ANNU REV PUBL HEALTH, V32, P133, DOI 10.1146/annurev-publhealth-071910-140612; IASC Needs Assessment Task Force, 2012, MULT SECT IN RAP ASS; IASC Needs Assessment Task Force, 2015, MULT IN RAP ASS GUID; Korteweg HA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-295; Martel N., 2015, ANN GLOB HEALTH, V81, P115, DOI [10.1016/j.aogh.2015.02.765, DOI 10.1016/J.AOGH.2015.02.765]; Motoki E, 2010, PREHOSP DISASTER MED, V25, P354, DOI 10.1017/S1049023X00008347; Nicholls Keith J., 2015, J APPL SOCIAL SCI, V9, P191; OCHA Needs Assessment Task Force, 2012, GUID NOT HUM IND REG; Peck R, 2014, LANCET GLOB HEALTH, V2, pE285, DOI 10.1016/S2214-109X(14)70033-6; Pimenta-de-Souza P, 2014, CIENC SAUDE COLETIVA, V19, P3731, DOI 10.1590/1413-81232014199.01412014; Sahay BS, 2016, SPR PROC BUS ECON, P3, DOI 10.1007/978-81-322-2416-7_1; Spiegel P, 2014, LANCET ONCOL, V15, pE290, DOI 10.1016/S1470-2045(14)70067-1; The Sphere Project, 2011, SPER HDB HUM CHART M; Tomio J., 2015, ADV ANTHR, V4, P68, DOI [10.4236/aa.2014.42010, DOI 10.4236/AA.2014.42010]; Tomio J, 2014, OPEN ACCESS EMERG M, V6, P69, DOI 10.2147/OAEM.S48532; UNHCR, 2008, UNHCRS PRINC GUID RE; UNICEF, 2014, GUID DEL ANT THER MI; Verity A., 2013, OCHAS 3W PURPOSE TAR; WHO, 2011, GLOB STAT REP NONC D; WHO, 2011, INT EM HLTH KIT 2011, V4; WHO, 2013, LYB POSTC HLTH SERV; Wilkinson AM, 2015, J CONTIN EDUC NURS, V46, P65, DOI [10.3928/00220124-20150126-01, 10.3928/00220124-20150121-15]; World Health Organization, SERV AV READ ASS SAR; World Health Organization, 2011, HOSP EMERGENCY RESPO; World Health Organization, NONC DIS COUNTR PROF; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization, 2010, PACK ESS NONC PEN DI; World Health Organization, 2009, HLTH RES AV MAPP SYS; World Health Organization (WHO), 2008, MAN WHO HUM RESP FIE	38	57	57	2	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2017	389	10066					326	330		10.1016/S0140-6736(16)31404-0	http://dx.doi.org/10.1016/S0140-6736(16)31404-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EI9BC	27637675				2023-01-03	WOS:000392801200034
J	Pei, SS; Minhajuddin, M; D'Alessandro, A; Nemkov, T; Stevens, BM; Adane, B; Khan, N; Hagen, FK; Yadav, VK; De, S; Ashton, JM; Hansen, KC; Gutman, JA; Pollyea, DA; Crooks, PA; Smith, C; Jordan, CT				Pei, Shanshan; Minhajuddin, Mohammad; D'Alessandro, Angelo; Nemkov, Travis; Stevens, Brett M.; Adane, Biniam; Khan, Nabilah; Hagen, Fred K.; Yadav, Vinod K.; De, Subhajyoti; Ashton, John M.; Hansen, Kirk C.; Gutman, Jonathan A.; Pollyea, Daniel A.; Crooks, Peter A.; Smith, Clayton; Jordan, Craig T.			Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						anticancer drug; drug development; drug resistance; endoplasmic reticulum stress (ER stress); leukemia; oxidative stress; 2-deoxyglucose; drug combination; parthenolide; temsirolimus	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; SESQUITERPENE LACTONES; PROGENITOR CELLS; HUMAN CANCERS; EXPRESSION; INHIBITION; STRESS; HETEROGENEITY; PROTEOSTASIS	Although multidrug approaches to cancer therapy are common, few strategies are based on rigorous scientific principles. Rather, drug combinations are largely dictated by empirical or clinical parameters. In the present study we developed a strategy for rational design of a regimen that selectively targets human acute myelogenous leukemia (AML) stem cells. As a starting point, we used parthenolide, an agent shown to target critical mechanisms of redox balance in primary AML cells. Next, using proteomic, genomic, and metabolomic methods, we determined that treatment with parthenolide leads to induction of compensatory mechanisms that include up-regulated NADPH production via the pentose phosphate pathway as well as activation of the Nrf2-mediated oxidative stress response pathway. Using this knowledge we identified 2-deoxyglucose and temsirolimus as agents that can be added to a parthenolide regimen as a means to inhibit such compensatory events and thereby further enhance eradication of AML cells. We demonstrate that the parthenolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a potent means of targeting AML stem cells but has little to no effect on normal stem cells. Taken together our findings illustrate a comprehensive approach to designing combination anticancer drug regimens.	[Pei, Shanshan; Minhajuddin, Mohammad; Stevens, Brett M.; Adane, Biniam; Khan, Nabilah; Gutman, Jonathan A.; Pollyea, Daniel A.; Smith, Clayton; Jordan, Craig T.] Univ Colorado Denver, Div Hematol, Aurora, CO 80045 USA; [D'Alessandro, Angelo; Nemkov, Travis; Hansen, Kirk C.] Univ Colorado Denver, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; [Hagen, Fred K.] Univ Rochester, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA; [Ashton, John M.] Univ Rochester, Dept Microbiol & Immunol, 601 Elmwood Ave, Rochester, NY 14642 USA; [Yadav, Vinod K.; De, Subhajyoti] Univ Colorado, Dept Med, Sch Med, Aurora, CO 80045 USA; [Crooks, Peter A.] Univ Arkansas, Dept Pharmaceut Sci, Little Rock, AR 72205 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Rochester; University of Rochester; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Jordan, CT (corresponding author), Univ Colorado, Anschutz Med Campus,12700 E 19th Ave,Rm 10016, Aurora, CO 80045 USA.	craig.jordan@ucdenver.edu	PEI, SHANSHAN/D-8200-2016; Minhajuddin, Mohammad/AAC-9227-2022; D'Alessandro, Angelo/AAA-4695-2019; Stevens, Brett/AAL-1800-2021; jordan, craig/D-7666-2014	PEI, SHANSHAN/0000-0001-9619-2614; D'Alessandro, Angelo/0000-0002-2258-6490; jordan, craig/0000-0003-0869-3465; Ashton, John/0000-0001-9875-5994	National Institutes of Health [R01 CA158275, R33 CA183685]; Leukemia and Lymphoma Society [TRP 6230-11, 6133-12]; NATIONAL CANCER INSTITUTE [R33CA183685, T32CA082086, R01CA158275] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 CA158275 (to P. A. C.) and R33 CA183685 (to K. C. H.). This work was also supported by Leukemia and Lymphoma Society Grants TRP 6230-11 and 6133-12 (to C. T. J.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aiken CT, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006924; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; Buescher JM, 2015, CURR OPIN BIOTECH, V34, P189, DOI 10.1016/j.copbio.2015.02.003; Catenacci DVT, 2015, MOL ONCOL, V9, P967, DOI 10.1016/j.molonc.2014.09.011; D'Alessandro A, 2015, TRANSFUSION, V55, P1155, DOI 10.1111/trf.12975; D'Alessandro A, 2014, ONCOTARGET, V5, P7722, DOI 10.18632/oncotarget.2300; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Dalle-Donne I, 2009, TRENDS BIOCHEM SCI, V34, P85, DOI 10.1016/j.tibs.2008.11.002; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Engreitz JM, 2010, J BIOMED INFORM, V43, P932, DOI 10.1016/j.jbi.2010.07.001; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Er TK, 2007, CLIN BIOCHEM, V40, P1015, DOI 10.1016/j.clinbiochem.2007.05.013; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Ghantous A, 2013, DRUG DISCOV TODAY, V18, P894, DOI 10.1016/j.drudis.2013.05.005; Goodarzi H, 2009, MOL CELL, V36, P900, DOI 10.1016/j.molcel.2009.11.016; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; Hassane DC, 2010, BLOOD, V116, P5983, DOI 10.1182/blood-2010-04-278044; Hipp MS, 2014, TRENDS CELL BIOL, V24, P506, DOI 10.1016/j.tcb.2014.05.003; Hoey T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001056; Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Jordan CT, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000914; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Krause DS, 1996, BLOOD, V87, P1; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Marcucci G, 2011, J CLIN ONCOL, V29, P475, DOI 10.1200/JCO.2010.30.2554; Mathema VB, 2012, INFLAMMATION, V35, P560, DOI 10.1007/s10753-011-9346-0; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Nasim S, 2011, BIOORGAN MED CHEM, V19, P1515, DOI 10.1016/j.bmc.2010.12.045; Nemkov T, 2015, AMINO ACIDS, V47, P2345, DOI 10.1007/s00726-015-2019-9; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Pei SS, 2013, J BIOL CHEM, V288, P33542, DOI 10.1074/jbc.M113.511170; Ralser M, 2008, P NATL ACAD SCI USA, V105, P17807, DOI 10.1073/pnas.0803090105; Sahasrabuddhe AA, 2015, IMMUNOL REV, V263, P224, DOI 10.1111/imr.12236; Salk JJ, 2010, ANNU REV PATHOL-MECH, V5, P51, DOI 10.1146/annurev-pathol-121808-102113; Sallmyr A, 2008, CANCER LETT, V270, P1, DOI 10.1016/j.canlet.2008.03.036; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Spaans SK, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00742; Stincone A, 2015, BIOL REV, V90, P927, DOI 10.1111/brv.12140; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Zhang Q, 2012, J MED CHEM, V55, P8757, DOI 10.1021/jm301064b; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	60	26	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2016	291	42					21984	22000		10.1074/jbc.M116.750653	http://dx.doi.org/10.1074/jbc.M116.750653			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EA1DL	27573247	Green Published, hybrid			2023-01-03	WOS:000386332600014
J	Zhou, ZM; Hu, Z; Li, M; Zhu, FX; Zhang, H; Nie, J; Ai, J				Zhou, Zhanmei; Hu, Zheng; Li, Mei; Zhu, Fengxin; Zhang, Hao; Nie, Jing; Ai, Jun			QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of beta-Catenin	PLOS ONE			English	Article							GROWTH-FACTOR-BETA; CHRONIC KIDNEY-DISEASE; UNILATERAL URETERAL OBSTRUCTION; P38 MAP KINASE; TGF-BETA; TUBULOINTERSTITIAL FIBROSIS; EPITHELIAL-CELLS; UNITED-STATES; NEPHROPATHY; SMAD3	Chronic kidney disease (CKD) is becoming a worldwide problem. However, current treatment options are limited. In the current study we showed that QiShenYiQi (QSYQ), a water-ethanol extract from several Chinese medicines, is a potent inhibitor of renal interstitial fibrosis. QSYQ inhibited transforming growth factor-beta 1 (TGF-beta 1)-responsive alpha-smoothmuscle actin (alpha-SMA), collagen I, and fibronectin up-regulation in obstructive nephropathy and cultured cells. Administration of QSYQ also inhibited the established renal interstitial fibrosis in obstructive nephropathy. Interestingly, QSYQ selectively inhibited TGF-beta 1-induced beta-catenin up-regulation and downstream gene transcription. Taken together, our study suggests that QSYQ selectively inhibits TGF-beta 1-induced beta-catenin up-regulation and might have significant therapeutic potential for the treatment of renal fibrosis.	[Zhou, Zhanmei; Hu, Zheng; Li, Mei; Zhu, Fengxin; Nie, Jing; Ai, Jun] Southern Med Univ, Nanfang Hosp, Natl Clin Res Ctr Kidney Dis, Div Nephrol,State Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China; [Zhang, Hao] Tasly R&D Inst, Tianjin, Peoples R China	Southern Medical University - China	Ai, J (corresponding author), Southern Med Univ, Nanfang Hosp, Natl Clin Res Ctr Kidney Dis, Div Nephrol,State Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China.	aij1980@163.com			Nanfang Hospital Fundation, Southern Medical University [2012C08]; Tasly RD Institute; Nanfang Hospital Foundation of Southern Medical University [2012C08]	Nanfang Hospital Fundation, Southern Medical University; Tasly RD Institute; Nanfang Hospital Foundation of Southern Medical University	This work was supported by the Nanfang Hospital Fundation, Southern Medical University (2012C08) to Dr. Ai. Tasly R&D Institute provided support in the form of salaries for author HZ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.; This work was supported by the Nanfang Hospital Foundation of Southern Medical University (2012C08) to Dr. Ai.	Ai J, 2015, J AM SOC NEPHROL, V26, P1827, DOI 10.1681/ASN.2014040363; Boor P, 2010, NAT REV NEPHROL, V6, P643, DOI 10.1038/nrneph.2010.120; Cassidy Hilary, 2012, J Signal Transduct, V2012, P463617, DOI 10.1155/2012/463617; Chevalier RL, 1999, PEDIATR NEPHROL, V13, P612, DOI 10.1007/s004670050756; Chevalier RL, 2009, KIDNEY INT, V75, P1145, DOI 10.1038/ki.2009.86; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; Crews DC, 2010, HYPERTENSION, V55, P1102, DOI 10.1161/HYPERTENSIONAHA.110.150722; Ely JJ, 2010, COMPARATIVE MED, V60, P154; Grande MT, 2009, NAT REV NEPHROL, V5, P319, DOI 10.1038/nrneph.2009.74; Hao S, 2011, J AM SOC NEPHROL, V22, P1642, DOI 10.1681/ASN.2010101079; He WC, 2011, J AM SOC NEPHROL, V22, P90, DOI 10.1681/ASN.2009121236; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hong Chengtao, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1018; Hough C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042513; Ina K, 2011, HISTOL HISTOPATHOL, V26, P855, DOI 10.14670/HH-26.855; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Kolosova I, 2011, J CELL PHYSIOL, V226, P1248, DOI 10.1002/jcp.22448; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Langham RG, 2006, DIABETES CARE, V29, P2670, DOI 10.2337/dc06-0911; Li YC, 2012, CLIN HEMORHEOL MICRO, V51, P177, DOI 10.3233/CH-2011-1523; Lin SQ, 2013, INT J CARDIOL, V168, P967, DOI 10.1016/j.ijcard.2012.10.042; Lin SL, 2005, J AM SOC NEPHROL, V16, P2702, DOI 10.1681/ASN.2005040435; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Lv SC, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/415068; Meran S, 2011, INT J EXP PATHOL, V92, P158, DOI 10.1111/j.1365-2613.2011.00764.x; Moll S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056575; Moon JA, 2006, KIDNEY INT, V70, P1234, DOI 10.1038/sj.ki.5001775; Ning XH, 2013, INT IMMUNOPHARMACOL, V15, P406, DOI 10.1016/j.intimp.2012.12.019; Radford MG, 1997, J AM SOC NEPHROL, V8, P199; Schmidt-Ott KM, 2008, KIDNEY INT, V74, P1004, DOI 10.1038/ki.2008.322; Shang HC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/738391; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420; Surendran K, 2005, J AM SOC NEPHROL, V16, P2373, DOI 10.1681/ASN.2004110949; Suwanabol PA, 2012, AM J PHYSIOL-HEART C, V302, pH2211, DOI 10.1152/ajpheart.00966.2011; Thornhill Barbara A, 2012, Methods Mol Biol, V886, P381, DOI 10.1007/978-1-61779-851-1_33; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; VIEDT C, 1995, KIDNEY INT, V48, P1810, DOI 10.1038/ki.1995.479; Wang WS, 2005, NEPHROLOGY, V10, P48, DOI 10.1111/j.1440-1797.2005.00334.x; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yu J, 2009, DEVELOPMENT, V136, P161, DOI 10.1242/dev.022087; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zeisberg M, 2005, METH MOLEC MED, V117, P261; Zeisberg M, 2010, J AM SOC NEPHROL, V21, P1819, DOI 10.1681/ASN.2010080793	44	8	8	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2016	11	9							e0162873	10.1371/journal.pone.0162873	http://dx.doi.org/10.1371/journal.pone.0162873			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5YN	27636716	Green Published, gold, Green Submitted			2023-01-03	WOS:000383723700019
J	Buijze, GA; Sierevelt, IN; van der Heijden, BCJM; Dijkgraaf, MG; Frings-Dresen, MHW				Buijze, Geert A.; Sierevelt, Inger N.; van der Heijden, Bas C. J. M.; Dijkgraaf, Marcel G.; Frings-Dresen, Monique H. W.			The Effect of Cold Showering on Health and Work: A Randomized Controlled Trial	PLOS ONE			English	Article							WHOLE-BODY CRYOTHERAPY; INNATE IMMUNE-RESPONSE; NERVOUS-SYSTEM; INITIAL RESPONSES; WATER IMMERSION; EXPOSURE; HUMANS; SF-36; INFECTION; RECOVERY	Purpose The aim of this study was to determine the cumulative effect of a routine (hot-to-) cold shower on sickness, quality of life and work productivity. Methods Between January and March 2015, 3018 participants between 18 and 65 years without severe comorbidity and no routine experience of cold showering were randomized (1: 1: 1: 1) to a (hot-to-) cold shower for 30, 60, 90 seconds or a control group during 30 consecutive days followed by 60 days of showering cold at their own discretion for the intervention groups. The primary outcome was illness days and related sickness absence from work. Secondary outcomes were quality of life, work productivity, anxiety, thermal sensation and adverse reactions. Results 79% of participants in the interventions groups completed the 30 consecutive days protocol. A negative binomial regression model showed a 29% reduction in sickness absence for (hot-to-) cold shower regimen compared to the control group (incident rate ratio: 0.71, P = 0.003). For illness days there was no significant group effect. No related serious advents events were reported. Conclusion A routine (hot-to-) cold shower resulted in a statistical reduction of self-reported sickness absence but not illness days in adults without severe comorbidity.	[Buijze, Geert A.] Acad Med Ctr, Dept Orthopaed Surg, Amsterdam, Netherlands; [Sierevelt, Inger N.] Med Ctr Slotervaart, Dept Orthopaed Surg, Amsterdam, Netherlands; [van der Heijden, Bas C. J. M.] Achmea, Risk Management, Zeist, Netherlands; [Dijkgraaf, Marcel G.] Acad Med Ctr, Clin Res Unit, Amsterdam, Netherlands; [Frings-Dresen, Monique H. W.] Acad Med Ctr, Inst Occupat Hlth, Dept Coronel, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Buijze, GA (corresponding author), Acad Med Ctr, Dept Orthopaed Surg, Amsterdam, Netherlands.	g.a.buijze@amc.nl						Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; [Anonymous], 2004, GEDRAG ORGAN, DOI DOI 10.5117/2004.017.002.002; Banerjee SK, 1999, J PARASITOL, V85, P442, DOI 10.2307/3285776; Banfi G, 2010, SPORTS MED, V40, P509, DOI 10.2165/11531940-000000000-00000; Bleakley CM, 2014, OPEN ACCESS J SPORTS, V5, P25, DOI 10.2147/OAJSM.S41655; Brenner IKM, 1999, J APPL PHYSIOL, V87, P699, DOI 10.1152/jappl.1999.87.2.699; Castellani JW, 2002, MED SCI SPORT EXER, V34, P2013, DOI 10.1097/00005768-200212000-00023; Centraal Bureau voor de Statistiek (CBS), 2016, NATIONAL STATISTICS; Claridge RT, 1843, HYDROPATHY OR THE CO; Cold Showers, THE DEFINITIVE GUIDE; Costello JT, 2013, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD010789; Crowe MJ, 2007, INT J SPORTS MED, V28, P994, DOI 10.1055/s-2007-965118; de Beurs E, 2006, MAANDBLAD GEESTELIJK, P120; Demerouti E, 2001, SCAND J WORK ENV HEA, V27, P279, DOI 10.5271/sjweh.615; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Eglin CM, 2005, EUR J APPL PHYSIOL, V93, P624, DOI 10.1007/s00421-004-1239-6; Evans JDR, 2013, COMPANION ARCHAEOLOG; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Gagnon DD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110774; Hendriksen IJM, 2010, PREV MED, V51, P132, DOI 10.1016/j.ypmed.2010.05.007; Huffman GR, 2008, J BONE JOINT SURG AM, V90A, P471, DOI 10.2106/JBJS.G.00325; Jansky L, 1996, EUR J APPL PHYSIOL O, V72, P445, DOI 10.1007/BF00242274; Jastrzabek R, 2013, RHEUMATOL INT, V33, P2053, DOI 10.1007/s00296-013-2692-5; Juliff LE, 2014, J STRENGTH COND RES, V28, P2353, DOI 10.1519/JSC.0000000000000417; Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023; Kox M, 2014, P NATL ACAD SCI USA, V111, P7379, DOI 10.1073/pnas.1322174111; Kox M, 2012, PSYCHOSOM MED, V74, P489, DOI 10.1097/PSY.0b013e3182583c6d; Lee HK, 2014, KOREAN J FAM MED, V35, P119, DOI 10.4082/kjfm.2014.35.3.119; Leppaluoto J, 2008, SCAND J CLIN LAB INV, V68, P145, DOI 10.1080/00365510701516350; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Nieman DC, 2011, BRIT J SPORT MED, V45, P987, DOI 10.1136/bjsm.2010.077875; Shephard RJ, 1998, CAN J PHYSIOL PHARM, V76, P828, DOI 10.1139/cjpp-76-9-828; Sramek P, 2000, EUR J APPL PHYSIOL, V81, P436, DOI 10.1007/s004210050065; Teirlinck AC, 2015, REPORT OF THE NATION, P1; Tiessen-Raaphorst A, 2015, REPORT OF THE NETHER, P1; Tipton MJ, 1998, J PHYSIOL-LONDON, V512, P621, DOI 10.1111/j.1469-7793.1998.621be.x; van Middendorp H, 2016, CLIN RHEUMATOL, V35, P1081, DOI 10.1007/s10067-015-3009-8; VASWANI KK, 1988, PHARMACOL BIOCHEM BE, V29, P163, DOI 10.1016/0091-3057(88)90290-0; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	39	8	10	10	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2016	11	9							e0161749	10.1371/journal.pone.0161749	http://dx.doi.org/10.1371/journal.pone.0161749			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5SJ	27631616	Green Published, gold, Green Submitted			2023-01-03	WOS:000383706900022
J	Liu, JC; Hsu, YP; Wu, SY				Liu, Ju-Chi; Hsu, Yi-Ping; Wu, Szu-Yuan			Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CONVERTING ENZYME-INHIBITORS; COA REDUCTASE INHIBITORS; RENAL-DISEASE; TASK-FORCE; CARDIOVASCULAR-DISEASE; PERITONEAL-DIALYSIS; AMERICAN-COLLEGE; HEART-FAILURE; PROGRESSION	Background Taiwan has the highest renal disease incidence and prevalence in the world. We evaluated the association of statin and renin-angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001-2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins. We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose-response relationship, we categorized only statin or RASI use into four groups in each cohort: < 28 (nonusers), 28-90, 91-365, and > 365 cumulative defined daily doses (cDDDs). Results In the main model, PS-adjusted hazard ratios (aHRs; 95% confidence intervals [CIs]) for dialysis risk were 0.57 (0.50-0.65), 0.72 (0.53-0.98), and 0.47 (0.41-0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at > 365 cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95% CI: 0.54-0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirin was used. Conclusion Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk.	[Liu, Ju-Chi; Hsu, Yi-Ping] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Div Cardiovasc Med, New Taipei, Taiwan; [Wu, Szu-Yuan] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan; [Wu, Szu-Yuan] Taipei Med Univ, Wan Fang Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Liu, Ju-Chi; Wu, Szu-Yuan] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei, Taiwan; [Wu, Szu-Yuan] Hungkuang Univ, Dept Biotechnol, Taichung, Taiwan	Taipei Medical University; Shuang Ho Hospital; National Taiwan University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Hungkuang University	Wu, SY (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan.; Wu, SY (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Radiat Oncol, Taipei, Taiwan.; Wu, SY (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei, Taiwan.; Wu, SY (corresponding author), Hungkuang Univ, Dept Biotechnol, Taichung, Taiwan.	szuyuanwu5399@gmail.com		Wu, Szu-Yuan/0000-0001-5637-558X	Wan Fang Hospital	Wan Fang Hospital	This work was supported by Wan Fang Hospital.	Atthobari J, 2006, NEPHROL DIAL TRANSPL, V21, P3106, DOI 10.1093/ndt/gfl244; Bakris GL, 2009, KIDNEY INT, V75, P449, DOI 10.1038/ki.2008.694; Bianchi S, 2003, AM J KIDNEY DIS, V41, P565, DOI 10.1053/ajkd.2003.50140; Blacher J, 2002, CURR OPIN NEPHROL HY, V11, P629, DOI 10.1097/00041552-200211000-00010; Campese VM, 2007, CLIN J AM SOC NEPHRO, V2, P1100, DOI 10.2215/CJN.04060907; Casas JP, 2005, LANCET, V366, P2026, DOI 10.1016/S0140-6736(05)67814-2; Catapano F, 2008, AM J KIDNEY DIS, V52, P475, DOI 10.1053/j.ajkd.2008.03.008; Chang YK, 2012, MEDICINE, V91, P144, DOI 10.1097/MD.0b013e318256538e; Chawla V, 2010, CLIN J AM SOC NEPHRO, V5, P1582, DOI 10.2215/CJN.01450210; CHEN JH, 2016, MEDICINE, V95, DOI DOI 10.1097/MD; Chen JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002845; Chiang CE, 2015, J CHIN MED ASSOC, V78, P1, DOI 10.1016/j.jcma.2014.11.005; Cordell HJ, 2004, AM J HUM GENET, V74, P1294, DOI 10.1086/421476; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; de Zeeuw D, 2015, LANCET DIABETES ENDO, V3, P181, DOI 10.1016/S2213-8587(14)70246-3; DIAMOND JR, 1987, KIDNEY INT, V32, P671, DOI 10.1038/ki.1987.259; Douglas K, 2006, ANN INTERN MED, V145, P117, DOI 10.7326/0003-4819-145-2-200607180-00009; Fink HA, 2012, ANN INTERN MED, V156, P570, DOI [10.7326/0003-4819-156-8-201204170-00008, 10.7326/0003-4819-156-8-201204170-00004]; Fried LF, 2008, KIDNEY INT, V74, P571, DOI 10.1038/ki.2008.231; Grone EF, 2008, NAT CLIN PRACT NEPHR, V4, P424, DOI 10.1038/ncpneph0863; Hwang SJ, 2010, NEPHROLOGY, V15, P3, DOI 10.1111/j.1440-1797.2010.01304.x; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Jayatilake N, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-180; Kao TW, 2013, PERITON DIALYSIS INT, V33, P671, DOI 10.3747/pdi.2012.00081; KEANE WF, 1994, KIDNEY INT, V46, P910, DOI 10.1038/ki.1994.349; Kent DM, 2007, J AM SOC NEPHROL, V18, P1959, DOI 10.1681/ASN.2006101081; KIM SY, 1995, KIDNEY INT, V48, P363, DOI 10.1038/ki.1995.304; Konstadinidou I, 2003, TRANSPLANT P, V35, P1364, DOI 10.1016/S0041-1345(03)00376-2; Landray MJ, 2001, AM J KIDNEY DIS, V38, P537, DOI 10.1053/ajkd.2001.26850; Levey AS, 2007, KIDNEY INT, V72, P247, DOI 10.1038/sj.ki.5002343; Levey AS, 1999, NEPHROL DIAL TRANSPL, V14, P828, DOI 10.1093/ndt/14.4.828; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; MANTTARI M, 1995, HYPERTENSION, V26, P670, DOI 10.1161/01.HYP.26.4.670; McCullough PA, 2010, AM J KIDNEY DIS, V55, pS1, DOI 10.1053/j.ajkd.2009.12.017; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Michel O, 1997, KIDNEY INT, V52, P1532, DOI 10.1038/ki.1997.483; Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x; Navaneethan SD, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007784; Neumann J, 2004, KIDNEY INT, V65, P1568, DOI 10.1111/j.1523-1755.2004.00552.x; Ozsoy RC, 2007, NEPHROL DIAL TRANSPL, V22, P1578, DOI 10.1093/ndt/gfl790; Parfrey PS, 1999, J AM SOC NEPHROL, V10, P1606; PARRA G, 1988, CLIN NEPHROL, V29, P58; Rahman M, 2008, AM J KIDNEY DIS, V52, P412, DOI 10.1053/j.ajkd.2008.05.027; Rahman M, 2014, CLIN J AM SOC NEPHRO, V9, P1190, DOI 10.2215/CJN.09320913; RODRIGUEZITURBE B, 1990, KIDNEY INT, V38, P512, DOI 10.1038/ki.1990.233; RUBIN R, 1994, HYPERTENSION, V23, P92, DOI 10.1161/01.HYP.23.1.92; Ruggenenti P, 2010, CLIN J AM SOC NEPHRO, V5, P1928, DOI 10.2215/CJN.03380410; Sandhu S, 2006, J AM SOC NEPHROL, V17, P2006, DOI 10.1681/ASN.2006010012; Sarafidis PA, 2009, ANN INTERN MED, V150, P731, DOI 10.7326/0003-4819-150-10-200905190-00014; Schaeffner ES, 2003, J AM SOC NEPHROLOGY, V14, P2084; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Shao JYH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001801; Shepherd J, 2007, CLIN J AM SOC NEPHRO, V2, P1131, DOI 10.2215/CJN.04371206; Singh S, 2014, HEPATOLOGY, V59, P735, DOI [10.1002/hep.26614, 10.1002/hep.26575]; Strippoli GFM, 2008, BMJ-BRIT MED J, V336, P645, DOI 10.1136/bmj.39472.580984.AE; Tonelli M, 2003, ANN INTERN MED, V138, P98, DOI 10.7326/0003-4819-138-2-200301210-00010; Weiner DE, 2004, J GEN INTERN MED, V19, P1045, DOI 10.1111/j.1525-1497.2004.40049.x; Whaley-Connell AT, 2008, AM J KIDNEY DIS, V51, pS13, DOI 10.1053/j.ajkd.2007.12.016; Wu M-S, 2012, ACTA NEPHROLOGICA, V26, P04; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	60	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2016	11	9							e0162588	10.1371/journal.pone.0162588	http://dx.doi.org/10.1371/journal.pone.0162588			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5SJ	27632175	Green Published, Green Submitted, gold			2023-01-03	WOS:000383706900055
J	Ibinda, F; Zarnack, HC; Newton, CR				Ibinda, Fredrick; Zarnack, Hans-Christoph; Newton, Charles R.			Sodium Disturbances in Children Admitted to a Kenyan Hospital: Magnitude, Outcome and Associated Factors	PLOS ONE			English	Article							DEMOGRAPHIC SURVEILLANCE SYSTEM; SEVERE FALCIPARUM-MALARIA; KILIFI HEALTH; HYPONATREMIA; HYPERNATREMIA; DEHYDRATION; VASOPRESSIN; PREVALENCE; SEIZURES; DEATH	Background Perturbations of blood sodium are the most frequently encountered electrolyte disorder in sick children, and may influence fluid therapy. We examined the frequency of blood sodium perturbations, and factors and outcomes associated with hyponatremia in children admitted to a rural Kenyan hospital and investigated the risk factors associated with deaths in hyponatremic children. Methods Plasma sodium levels and other laboratory parameters were measured in children admitted to a rural Kenyan hospital. Clinical measurements were collected using standard forms and entered into a computer database. The proportion of children admitted with hyponatremia was determined. Logistic regression models were used to investigate factors associated with hyponatremia, and death in those with hyponatremia. Results Abnormal plasma sodium occurred in 46.6%(95% confidence interval (95% CI) 43.5-49.6%) of 1026 pediatric admissions. Hyponatremia occurred in 44.4% (95% CI 41.4-47.5%) and hypernatremia in 2.1% (95% CI 1.3-3.0%). Malaria (40.8%) was the most common underlying primary diagnosis in hyponatremic children. Malaria, hyperglycemia, wasting, high creatinine levels and preserved consciousness were associated with hyponatremia. Pallor and seizures were associated with increased mortality in hyponatremic children. Conclusions Sodium disturbances are common in pediatric admissions to a County hospital in rural Kenya. Seizures and pallor were predictors of mortality in hyponatremic children.	[Ibinda, Fredrick; Zarnack, Hans-Christoph; Newton, Charles R.] Ctr Geog Med Res Coast, KEMRI Wellcome Trust Res Programme, POB 230-80108, Kilifi, Kenya; [Newton, Charles R.] Univ Oxford, Dept Psychiat, Oxford, England	University of Oxford	Newton, CR (corresponding author), Ctr Geog Med Res Coast, KEMRI Wellcome Trust Res Programme, POB 230-80108, Kilifi, Kenya.; Newton, CR (corresponding author), Univ Oxford, Dept Psychiat, Oxford, England.	cnewton@kemri-wellcome.org	Newton, Charles RJC/B-7578-2014	Newton, Charles RJC/0000-0002-6999-5507	Wellcome Trust Senior Clinical Fellowship [083744]; Wellcome Trust masters training fellowship [101140]	Wellcome Trust Senior Clinical Fellowship(Wellcome Trust); Wellcome Trust masters training fellowship	This study was supported by the Wellcome Trust Senior Clinical Fellowship to Professor Charles Newton (No. 083744). Fredrick Ibinda was supported by the Wellcome Trust masters training fellowship (101140).	ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; Ayus JC, 2008, AM J PHYSIOL-RENAL, V295, pF619, DOI 10.1152/ajprenal.00502.2007; Carter JA, 2004, EPILEPSIA, V45, P978, DOI 10.1111/j.0013-9580.2004.65103.x; Day NPJ, 2000, CRIT CARE MED, V28, P1833, DOI 10.1097/00003246-200006000-00025; Dunn K, 1997, J PAEDIATR CHILD H, V33, P26, DOI 10.1111/j.1440-1754.1997.tb00986.x; Ellison DH, 2007, NEW ENGL J MED, V356, P2064, DOI 10.1056/NEJMcp066837; English MC, 1996, ARCH DIS CHILD, V74, P201, DOI 10.1136/adc.74.3.201; FINBERG L, 1955, PEDIATRICS, V16, P1; Foster BA, 2014, J PEDIATR-US, V165, P163, DOI 10.1016/j.jpeds.2014.01.040; GORDILLO G, 1957, PEDIATRICS, V20, P303; Halawa I, 2011, EPILEPSIA, V52, P410, DOI 10.1111/j.1528-1167.2010.02939.x; Hanson J, 2009, AM J TROP MED HYG, V80, P141, DOI 10.4269/ajtmh.2009.80.141; Hoorn EJ, 2006, NEPHROL DIAL TRANSPL, V21, P70, DOI 10.1093/ndt/gfi082; Ibinda F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122606; Kariuki SM, 2015, NEUROLOGY, V84, P1838, DOI 10.1212/WNL.0000000000001542; Kariuki SM, 2011, BRAIN, V134, P1519, DOI 10.1093/brain/awr051; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; MACAULAY D, 1961, ARCH DIS CHILD, V36, P543, DOI 10.1136/adc.36.189.543; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Mcnab S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009457.pub2; Mcnab S, 2015, LANCET, V385, P1190, DOI 10.1016/S0140-6736(14)61459-8; MILLER LH, 1967, ANN TROP MED PARASIT, V61, P265, DOI 10.1080/00034983.1967.11686487; Mishra SK, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-24; Moritz ML, 1999, PEDIATRICS, V104, P435, DOI 10.1542/peds.104.3.435; Mung'Ala-Odera V, 2004, AM J TROP MED HYG, V71, P64, DOI 10.4269/ajtmh.2004.71.64; Ndila C, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25593; R Core Team, 2021, R LANG ENV STAT COMP; Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062; Sharf R E, 1993, Arch Fam Med, V2, P647, DOI 10.1001/archfami.2.6.647; Sodarangani M, 2008, LANCET NEUROL, V7, P145, DOI [10.1016/S1474-4422(07)70331-9, 10.1016/SI474-4422(07)70331-9]; Sowunmi A, 2000, J TROP PEDIATRICS, V46, P195, DOI 10.1093/tropej/46.4.195; Thwaites CL, 2015, LANCET, V385, P362, DOI 10.1016/S0140-6736(14)60236-1; WHO, 2013, GUID MAN COMM CHILDH; Zilberberg Marya D, 2008, BMC Pulm Med, V8, P16, DOI 10.1186/1471-2466-8-16	35	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2016	11	9							e0161320	10.1371/journal.pone.0161320	http://dx.doi.org/10.1371/journal.pone.0161320			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9IX	27603309	Green Published, gold, Green Submitted			2023-01-03	WOS:000383255200012
J	Chochinov, HM; Frazee, C				Chochinov, Harvey Max; Frazee, Catherine			Finding a balance: Canada's law on medical assistance in dying	LANCET			English	Editorial Material									[Chochinov, Harvey Max] Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada; [Chochinov, Harvey Max] CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB R3E 0V9, Canada; Ryerson Univ, Sch Disabil Studies, Toronto, ON, Canada	University of Manitoba; CancerCare Manitoba Foundation; Toronto Metropolitan University	Chochinov, HM (corresponding author), Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada.; Chochinov, HM (corresponding author), CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB R3E 0V9, Canada.	hchochinov@cancercare.mb.ca		Chochinov, Harvey/0000-0003-2656-4704				[Anonymous], 2016, RT QUESTION MOR 0618; Department of Justice Government of Canada., 2015, CONS PHYS ASS DYING; Parliament of Canada, 2016, MED ASS DYING PAT CT; Provincial Territorial Expert Advisory Group on Physician Assisted Dying, 2015, FIN REP NOV 30 PROV; Stone L, 2016, GLOBE MAIL	5	13	13	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2016	388	10044					543	545		10.1016/S0140-6736(16)31254-5	http://dx.doi.org/10.1016/S0140-6736(16)31254-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DS4NA	27511771				2023-01-03	WOS:000380756600009
J	Yarnoff, BO; Hoerger, TJ; Simpson, SA; Pavkov, ME; Burrows, NR; Shrestha, SS; Williams, DE; Zhuo, XH				Yarnoff, Benjamin O.; Hoerger, Thomas J.; Simpson, Siobhan A.; Pavkov, Meda E.; Burrows, Nilka R.; Shrestha, Sundar S.; Williams, Desmond E.; Zhuo, Xiaohui			The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease	PLOS ONE			English	Article							ERYTHROPOIESIS-STIMULATING AGENTS; QUALITY-OF-LIFE; DARBEPOETIN ALPHA; HEMODIALYSIS; CKD; MORTALITY; THERAPY; STROKE; TRIAL; LEVEL	Background Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating agents (ESAs) for managing chronic anemia in persons with chronic kidney disease (CKD), there are differences in the recommended hemoglobin (Hb) treatment target and no guidelines consider the costs or cost-effectiveness of treatment. In this study, we explored the most cost-effective Hb target for anemia treatment in persons with CKD stages 3-4. Methods and Findings The CKD Health Policy Model was populated with a synthetic cohort of persons over age 30 with prevalent CKD stages 3-4 (i.e., not on dialysis) and anemia created from the 19992010 National Health and Nutrition Examination Survey. Incremental cost-effectiveness ratios (ICERs), computed as incremental cost divided by incremental quality adjusted life years (QALYs), were assessed for Hb targets of 10 g/dl to 13 g/dl at 0.5 g/dl increments. Targeting a Hb of 10 g/dl resulted in an ICER of $32,111 compared with no treatment and targeting a Hb of 10.5 g/dI resulted in an ICER of $32,475 compared with a Hb target of 10 g/dl. QALYs increased to 4.63 for a Hb target of 10 g/dl and to 4.75 for a target of 10.5 g/dl or 11 g/dl. Any treatment target above 11 g/dl increased medical costs and decreased QALYs. Conclusions In persons over age 30 with CKD stages 3-4, anemia treatment is most cost-effective when targeting a Hb level of 10.5 g/dl. This study provides important information for framing guidelines related to treatment of anemia in persons with CKD.	[Yarnoff, Benjamin O.; Hoerger, Thomas J.; Simpson, Siobhan A.] RTI Int, Res Triangle Pk, NC 27709 USA; [Pavkov, Meda E.; Burrows, Nilka R.; Shrestha, Sundar S.; Williams, Desmond E.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Zhuo, Xiaohui] Merck Res Labs, N Wales, PA USA	Research Triangle Institute; Centers for Disease Control & Prevention - USA; Merck & Company	Yarnoff, BO (corresponding author), RTI Int, Res Triangle Pk, NC 27709 USA.	byarnoff@rti.org		Yarnoff, Benjamin/0000-0002-5147-1588; Hoerger, Thomas/0000-0003-4154-7806	Centers for Disease Control and Prevention (CDC) [200-2008-27958]	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This research was supported by funding (Contract #200-2008-27958) from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. Xiaohui Zhuo is now employed by Merck Laboratories, but was employed by the Centers for Disease Control and Prevention while working on this project. The funder provided support in the form of salaries for authors BOY, TJH, SAS, MEP, NRB, SSS, DEW, and XZ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Ara R, 2008, VALUE HEALTH, V11, P1131, DOI 10.1111/j.1524-4733.2008.00352.x; Astor BC, 2002, ARCH INTERN MED, V162, P1401, DOI 10.1001/archinte.162.12.1401; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Blumberg N, 1996, AM J SURG, V171, P324, DOI 10.1016/S0002-9610(97)89635-3; Boulware LE, 2003, JAMA-J AM MED ASSOC, V290, P3101, DOI 10.1001/jama.290.23.3101; Centers for Medicare and Medicaid Services, 2012, MED PART B DRUG AV S; Clement FM, 2010, AM J KIDNEY DIS, V56, P1050, DOI 10.1053/j.ajkd.2010.07.015; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Finkelstein FO, 2009, CLIN J AM SOC NEPHRO, V4, P33, DOI 10.2215/CJN.00630208; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Hoerger TJ, 2015, AM J KIDNEY DIS, V65, P403, DOI 10.1053/j.ajkd.2014.09.023; Hoerger TJ, 2012, J AM SOC NEPHROL, V23, P2035, DOI 10.1681/ASN.2012040347; Hoerger TJ, 2010, AM J KIDNEY DIS, V55, P452, DOI 10.1053/j.ajkd.2009.11.016; Hoerger TJ, 2010, AM J KIDNEY DIS, V55, P463, DOI 10.1053/j.ajkd.2009.11.017; Kopple JD, 2001, AM J KIDNEY DIS, V37, pS66, DOI 10.1053/ajkd.2001.20748; Koulouridis I, 2013, AM J KIDNEY DIS, V61, P44, DOI 10.1053/j.ajkd.2012.07.014; Lawer EV, 2010, CLIN J AM SOC NEPHRO, V5, P667, DOI 10.2215/CJN.06020809; Leaf DE, 2009, KIDNEY INT, V75, P15, DOI 10.1038/ki.2008.414; Locatelli F, 2009, NEPHROL DIAL TRANSPL, V24, P348, DOI 10.1093/ndt/gfn653; Lu M, 2010, AM J HEMATOL, V85, P315, DOI 10.1002/ajh.21656; Meenan RT, 2007, MED DECIS MAKING, V27, P161, DOI 10.1177/0272989X06297388; National Institute for Health and Clinical Excellence, 2011, AN MAN PEOPL CHRON K; Nishio A, 2013, BLOOD PURIFICAT, V36, P29, DOI 10.1159/000350583; Palmer SC, 2010, ANN INTERN MED, V153, P23, DOI 10.7326/0003-4819-153-1-201007060-00252; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Quon P, 2012, HLTH OUTCOMES RES ME, V3, pe79, DOI DOI 10.1016/J.EHRM.2012.03.004; Singh AK, 2010, CURR OPIN NEPHROL HY, V19, P420, DOI 10.1097/MNH.0b013e32833cf1d6; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Skali H, 2011, CIRCULATION, V124, P2903, DOI 10.1161/CIRCULATIONAHA.111.030411; Tonelli M, 2003, KIDNEY INT, V64, P295, DOI 10.1046/j.1523-1755.2003.00079.x; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; Vlagopoulos PT, 2005, J AM SOC NEPHROL, V16, P3403, DOI 10.1681/ASN.2005030226; Weinstein MC, 1996, COST EFFECTIVENESS H	34	2	2	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2016	11	7							e0157323	10.1371/journal.pone.0157323	http://dx.doi.org/10.1371/journal.pone.0157323			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ9CO	27404556	gold, Green Published, Green Submitted			2023-01-03	WOS:000379508200002
J	Li, YH; Zhang, JG; Xu, YF; Han, YL; Jiang, BB; Huang, L; Zhu, H; Xu, YH; Yang, WL; Qin, C				Li, Yanhong; Zhang, Jigang; Xu, Yanfeng; Han, Yunlin; Jiang, Binbin; Huang, Lan; Zhu, Hua; Xu, Yuhuan; Yang, Weiling; Qin, Chuan			The Histopathological Investigation of Red and Blue Light Emitting Diode on Treating Skin Wounds in Japanese Big-Ear White Rabbit	PLOS ONE			English	Article							THERAPY; MODEL	The biological effects of different wavelengths of light emitting diode (LED) light tend to vary from each other. Research into use of photobiomodulation for treatment of skin wounds and the underlying mechanisms has been largely lacking. We explored the histopathological basis of the therapeutic effect of photobiomodulation and the relation between duration of exposure and photobiomodulation effect of different wavelengths of LED in a Japanese big-ear white rabbit skin- wound model. Skin wound model was established in 16 rabbits (three wounds per rabbit: one served as control, the other two wounds were irradiated by red and blue LED lights, respectively). Rabbits were then divided into 2 equal groups based on the duration of exposure to LED lights (15 and 30 min/exposure). The number of wounds that showed healing and the percentage of healed wound area were recorded. Histopathological examination and skin expression levels of fibroblast growth factor (FGF), epidermal growth factor (EGF), endothelial marker (CD31), proliferating cell nuclear antigen (Ki67) and macrophagocyte (CD68) infiltration, and the proliferation of skin collagen fibers was assessed. On days 16 and 17 of irradiation, the healing rates in red (15 min and 30 min) and blue (15 min and 30 min) groups were 50%, 37.5%, 25% and 37.5%, respectively, while the healing rate in the control group was 12.5%. The percentage healed area in the red light groups was significantly higher than those in other groups. Collagen fiber and skin thickness were significantly increased in both red light groups; expression of EGF, FGF, CD31 and Ki67 in the red light groups was significantly higher than those in other groups; the expression of FGF in red (30 min) group was not significantly different from that in the blue light and control groups. The effect of blue light on wound healing was poorer than that of red light. Red light appeared to hasten wound healing by promoting fibrous tissue, epidermal and endothelial cell proliferation. An increase in the exposure time to 30 min did not confer any additional benefit in both red and blue light groups. This study provides a theoretical basis for the potential therapeutic application of LED light in clinical settings.	[Li, Yanhong; Xu, Yanfeng; Han, Yunlin; Huang, Lan; Zhu, Hua; Xu, Yuhuan; Qin, Chuan] Chinese Acad Med Sci, Inst Med Lab Anim Sci, Key Lab Human Dis Comparat Med, Minist Hlth, Beijing 100730, Peoples R China; [Li, Yanhong; Xu, Yanfeng; Han, Yunlin; Zhu, Hua; Xu, Yuhuan; Qin, Chuan] Peking Union Med Coll, State Adm Tradit Chinese Med, Key Lab Human Dis Anim Models, Beijing 100021, Peoples R China; [Zhang, Jigang; Yang, Weiling] Gen Hosp PLA Rocket Force, Dept Dermatol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Qin, C (corresponding author), Chinese Acad Med Sci, Inst Med Lab Anim Sci, Key Lab Human Dis Comparat Med, Minist Hlth, Beijing 100730, Peoples R China.; Qin, C (corresponding author), Peking Union Med Coll, State Adm Tradit Chinese Med, Key Lab Human Dis Anim Models, Beijing 100021, Peoples R China.; Yang, WL (corresponding author), Gen Hosp PLA Rocket Force, Dept Dermatol, Beijing, Peoples R China.	ywlderma@sina.com; qinchuan@pumc.edu.cn			National Major Scientific and Technological Special Project [2012ZX10004-501]; National High Technology Research and Development Program of China (853 Plan) [2003AA123310]	National Major Scientific and Technological Special Project; National High Technology Research and Development Program of China (853 Plan)	Support was provided by National Major Scientific and Technological Special Project during the Twelfth Five-year Plan Period (2012ZX10004-501) and National High Technology Research and Development Program of China (853 Plan) (2003AA123310).; This study was supported by National Major Scientific and Technological Special Project during the Twelfth Five-year Plan Period (2012ZX10004-501); National High Technology Research and Development Program of China (853 Plan) (2003AA123310). This manuscript has been edited and proofread by Medjaden Bioscience Limited.	Adamskaya N, 2011, INJURY, V42, P917, DOI 10.1016/j.injury.2010.03.023; Bashkatov AN, 2005, J PHYS D APPL PHYS, V38, P2543, DOI 10.1088/0022-3727/38/15/004; Becker D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020566; de Sousa APC, 2013, LASER MED SCI, V28, P981, DOI 10.1007/s10103-012-1187-z; Chen J, 2006, PATHOLOGY, P57; Cicchi R, 2016, J BIOPHOTONICS, V9, P645, DOI 10.1002/jbio.201500191; Dai TH, 2012, DRUG RESIST UPDATE, V15, P223, DOI 10.1016/j.drup.2012.07.001; Fang ZL, 2003, PHYS HIGH TECHNOLOGY, V23, P295; Figurova M, 2016, PHOTOMED LASER SURG, V34, P53, DOI 10.1089/pho.2015.4013; Kleinpenning MM, 2010, PHOTODERMATOL PHOTO, V26, P16, DOI 10.1111/j.1600-0781.2009.00474.x; Lau P, 2015, J PHOTOCH PHOTOBIO B, V151, P201, DOI 10.1016/j.jphotobiol.2015.08.009; Li Q, 2011, PLAST RECONSTR SURG, V127, P2255, DOI 10.1097/PRS.0b013e3182131bb5; [李勤 LI Qin], 2008, [光学技术, Optical Technology], V34, P265; Middelkoop E, 2004, BIOMATERIALS, V25, P1559, DOI 10.1016/S0142-9612(03)00502-7; Morton CA, 2005, J DERMATOL TREAT, V16, P219, DOI 10.1080/09546630500283664; Niemz M.H., 2019, LASER TISSUE INTERAC, V4th ed.; Opel Daniel R, 2015, J Clin Aesthet Dermatol, V8, P36; Park KY, 2013, ANN DERMATOL, V25, P400, DOI 10.5021/ad.2013.25.3.400; Qin QH, 2000, FASCICULE BASIC PROB, V21, P33; [任为 Ren Wei], 2013, [第三军医大学学报, Journal of Third Military Medical University], V35, P981; Shi PN, 2014, ZHEJIANG MED, V36, P1349; Simpson CR, 1998, PHYS MED BIOL, V43, P2465, DOI 10.1088/0031-9155/43/9/003; Wang BY, 2000, PATHOLOGICAL TECHNIQ, P131; Weiss RA, 2005, DERMATOL SURG, V31, P1199; Whelan HT, 2001, AIP CONF PROC, V552, P35, DOI 10.1063/1.1357902; Zhao F., 2008, STUDY WOUND HEALING; [赵飞 ZHAO Fei], 2007, [第四军医大学学报, Journal of the Fourth Military Medical University], V28, P1976	27	17	18	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2016	11	6							e0157898	10.1371/journal.pone.0157898	http://dx.doi.org/10.1371/journal.pone.0157898			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP9FD	27347879	Green Published, Green Submitted, gold			2023-01-03	WOS:000378801200019
J	Haeckel, A; Appler, F; de Schellenberger, AA; Schellenberger, E				Haeckel, Akvile; Appler, Franziska; de Schellenberger, Angela Ariza; Schellenberger, Eyk			XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic	PLOS ONE			English	Article							CELL-PENETRATING PEPTIDES; BREAST-CANCER; DOXORUBICIN; PROTEINS; DNA; CARCINOMA; GERMLINE; GROWTH; LINES; KLLN	Increased effectiveness and reduced side effects are general goals in drug research, especially important in cancer therapy. The aim of this study was to design a long-circulating, activatable cytostatic drug that is completely producible in E. coli. Crucial for this goal was the novel unstructured polypeptide XTEN, which acts like polyethylene glycol (PEG) but has many important advantages. Most importantly, it can be produced in E. coli, is less immunogenic, and is biodegradable. We tested constructs containing a fragment of Killin as cytostatic/cytotoxic element, a cell-penetrating peptide, an MMP-2 cleavage site for specific activation, and XTEN for long blood circulation and deactivation of Killin. One of three sequence variants was efficiently expressed in E. coli. As typical for XTEN, it allowed efficient purification of the E. coli lysate by a heat step (10 min 75 degrees C) and subsequent anion exchange chromatography using XTEN as purification tag. After 24 h XTEN-Killin reduced the number of viable cells of HT-1080 tumor cell line to 3.8 +/- 2.0% (p<0.001) compared to untreated controls. In contrast, liver derived non-tumor cells (BRL3A) did not show significant changes in viability. Our results demonstrate the feasibility of completely producing a complex protease-activatable, potentially long-circulating cytostatic/cytotoxic prodrug in E. coli-a concept that could lead to efficient production of highly multifunctional drugs in the future.	[Haeckel, Akvile; de Schellenberger, Angela Ariza; Schellenberger, Eyk] Charite, Dept Radiol, D-13353 Berlin, Germany; [Appler, Franziska] NanoPET Pharma, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schellenberger, E (corresponding author), Charite, Dept Radiol, D-13353 Berlin, Germany.	eyk.schellenberger@charite.de		Schellenberger, Eyk/0000-0003-4096-6865; Ariza de Schellenberger, Angela/0000-0002-1005-5780	German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) [KFO 213: SCHE 1416/2-2]	German Research Foundation, Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) in the form of salaries for FA and AH (KFO 213: SCHE 1416/2-2). nanoPET Pharma is the current employer of FA. Her contribution for this manuscript was during her PhD program when she was employed in our group at the Charite - University Medicine Berlin. nanoPET Pharma did not support this project, was not involved, and has no rights. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Bettina Herwig for language editing. The work was supported by the Deutsche Forschungsgemeinschaft DFG (KFO 213: SCHE 1416/2-2).	Albright CF, 2005, MOL CANCER THER, V4, P751, DOI 10.1158/1535-7163.MCT-05-0006; Alters SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050630; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031; Bennett KL, 2011, GENE CHROMOSOME CANC, V50, P654, DOI 10.1002/gcc.20887; Cho YJ, 2008, P NATL ACAD SCI USA, V105, P5396, DOI 10.1073/pnas.0705410105; Choi KY, 2012, THERANOSTICS, V2, P156, DOI 10.7150/thno.4068; El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2; Erazo-Oliveras A, 2012, PHARMACEUTICALS-BASE, V5, P1177, DOI 10.3390/ph5111177; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; Garay RP, 2012, EXPERT OPIN DRUG DEL, V9, P1319, DOI 10.1517/17425247.2012.720969; Geething NC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010175; Haeckel A, 2014, J NUCL MED, V55, P508, DOI 10.2967/jnumed.113.128108; Jevsevar S, 2010, BIOTECHNOL J, V5, P113, DOI 10.1002/biot.200900218; Lee GY, 2007, EUR J PHARM BIOPHARM, V67, P646, DOI 10.1016/j.ejpb.2007.03.023; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Mahdi H, 2015, CANCER-AM CANCER SOC, V121, P688, DOI 10.1002/cncr.29106; Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002; Ng EK, 2014, ONCOTARGETS THER, V7, P2085, DOI 10.2147/OTT.S53597; Olson ES, 2009, INTEGR BIOL-UK, V1, P382, DOI 10.1039/b904890a; Qian ZQ, 2015, CHEM COMMUN, V51, P2162, DOI 10.1039/c4cc09441g; Roomi MW, 2014, INT J ONCOL, V44, P986, DOI 10.3892/ijo.2013.2235; Roomi MW, 2009, ONCOL REP, V22, P1283, DOI 10.3892/or_00000566; Schellenberger V, 2009, NAT BIOTECHNOL, V27, P1186, DOI 10.1038/nbt.1588; Suzuki T, 2012, INT J PHARMACEUT, V436, P636, DOI 10.1016/j.ijpharm.2012.07.049; Taurin S, 2012, J CONTROL RELEASE, V164, P265, DOI 10.1016/j.jconrel.2012.07.013; Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang Y, 2014, ENDOCR-RELAT CANCER, V21, P579, DOI 10.1530/ERC-14-0148; Wang Y, 2013, HUM MOL GENET, V22, P2263, DOI 10.1093/hmg/ddt077	30	14	14	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2016	11	6							e0157193	10.1371/journal.pone.0157193	http://dx.doi.org/10.1371/journal.pone.0157193			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KF	27295081	Green Submitted, Green Published, gold			2023-01-03	WOS:000377821300027
J	Javalkar, P; Prakash, R; Isac, S; Washington, R; Halli, SS				Javalkar, Prakash; Prakash, Ravi; Isac, Shajy; Washington, Reynold; Halli, Shiva S.			An Estimation of Mortality Risks among People Living with HIV in Karnataka State, India: Learnings from an Intensive HIV/AIDS Care and Support Programme	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; ADHERENCE; SURVIVAL; DEATH; COUNTRIES; OUTCOMES; TRENDS; ADULTS; HAART	Background In Indian context, limited attempts have been made to estimate the mortality risks among people living with HIV (PLHIV). We estimated the rates of mortality among PLHIV covered under an integrated HIV-prevention cum care and support programme implemented in Karnataka state, India, and attempted to identify the key programme components associated with the higher likelihood of their survival. Methods Retrospective programme data of 55,801 PLHIV registered with the Samastha programme implemented in Karnataka state during 2006-11 was used. Kaplan-Meier survival methods were used to estimate the ten years expected survival probabilities and Cox-proportional hazard model was used to examine the factors associated with risk of mortality among PLHIV. We also calculated mortality rates (per 1000 person-year) across selected demographic and clinical parameters. Results Of the total PLHIV registered with the programme, about nine percent died within the 5-years of programme period with an overall death rate of 38 per 1000 person-years. The mortality rate was higher among males, aged 18 and above, among illiterates, and those residing in rural areas. While the presence of co-infections such as Tuberculosis leads to higher mortality rate, adherence to ART was significantly associated with reduction in overall death rate. Cox proportional hazard model revealed that increase in CD4 cell counts and exposure to intensive care and support programme for at least two years can bring significant reduction in risk of death among PLHIV [(hazard ratio: 0.234; CI: 0.211-0.260) & (hazard ratio: 0.062; CI: 0.054-0.071), respectively] even after adjusting the effect of other sociodemographic, economic and health related confounders. Conclusion Study confirms that while residing in rural areas and presence of co-infection significantly increases the mortality risk among PLHIV, adherence to ART and improvement in CD4 counts led to significant reduction in their mortality risk. Longer exposure to the intervention contributed significantly to reduce mortality among PLHIV.	[Javalkar, Prakash; Prakash, Ravi; Isac, Shajy; Washington, Reynold] Karnataka Hlth Promot Trust, Bangalore, Karnataka, India; [Isac, Shajy; Washington, Reynold; Halli, Shiva S.] Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba	Javalkar, P (corresponding author), Karnataka Hlth Promot Trust, Bangalore, Karnataka, India.	prakashj@khpt.org	Prakash, Ravi/ABB-8711-2020; Washington, Reynold/AAD-7447-2020	Javalkar, Prakash/0000-0001-5569-5792; Prakash, Ravi/0000-0003-3715-5789	USAID	USAID(United States Agency for International Development (USAID))	This paper was written as a part of an evaluation of Samastha project funded by USAID and implemented by KHPT. However the project funding does not relates to this manuscript. The views expressed herein are those of the authors and do not necessarily represent the official policy or position of the USAID. We are grateful to the our colleagues of KHPT and University of Manitoba for providing the necessary inputs while preparing this paper. We appreciate the comments of the academic editor and anonymous reviewers for providing valuable suggestions that helped in improving the quality of the paper.	Abaasa AM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-241; Aggarwal Pravesh, 2009, J Assoc Physicians India, V57, P745; Arrivillaga M, 2009, REV PANAM SALUD PUBL, V26, P502, DOI 10.1590/S1020-49892009001200005; Avert, 2013, HIV AIDS IND; Bachani D, 2010, NATL MED J INDIA, V23, P7; Bajpai R. C., 2014, PUBLIC HLTH RES, V4, P31; Banandur P, 2011, SEX TRANSM INFECT, V87, pA340, DOI 10.1136/sextrans-2011-050108.592; Bhattacharjya C, 2015, WORLD J AIDS, V5, P90, DOI [10.4236/wja.2015.52011, DOI 10.4236/WJA.2015.52011]; Cain KP, 2009, EMERG INFECT DIS, V15, P258, DOI 10.3201/eid1502.080942; Cauldbeck MB, 2009, AIDS RES THER, V6, P7, DOI DOI 10.1186/1742-6405-6-7; Chakraborty N, 2008, JPN J INFECT DIS, V61, P49; Chi BH, 2009, INT J EPIDEMIOL, V38, P746, DOI 10.1093/ije/dyp004; Doherty MC, 2000, AIDS, V14, P717, DOI 10.1097/00002030-200004140-00011; Georgia A., 2011, HIV AIDS HAITI ANAL; Ghate Manisha, 2009, Int J Infect Dis, V13, pe1, DOI 10.1016/j.ijid.2008.03.029; Gonzalez MA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-605; Halli SS, 2015, J HIV AIDS IN PRESS; Hambisa Mitiku Teshome, 2013, ISRN AIDS, V2013, P491601, DOI 10.1155/2013/491601; Hosegood V, 2004, AIDS, V18, P663, DOI 10.1097/00002030-200403050-00011; Kee MK, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-128; Krentz HB, 2005, HIV MED, V6, P99, DOI 10.1111/j.1468-1293.2005.00271.x; Lifson AR, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-4; Mills EJ, 2011, ANN INTERN MED, V155, P209, DOI 10.7326/0003-4819-155-4-201108160-00358; NACO N, 2012, TECHN REP IND HIV ES; National AIDS Control Organisation (NACO), 2014, NAT AIDS CONTR PROGR; National Health Mission, 2014, COMPR AB CAR PROV MA; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Pandey A, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000926; Rai S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066860; Raj Y, 2016, INT J STD AIDS, V27, P1257, DOI 10.1177/0956462415612650; Rajagopalan N, 2009, AM J INFECT DIS, V5, P219, DOI 10.3844/ajidsp.2009.219.224; Reda AA, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/574656; Ryavanki SP, 2013, NATL J COMMUNITY MED, P4; Shaboltas AV, 2006, JAIDS-J ACQ IMM DEF, V41, P657; StataCorp, 2015, STAT STAT SOFTW REL; Taylor-Smith K, 2010, MALAWI MED J, V22, P49; UNAIDS, 2014, GLOB FACT SHEET; UNAIDS, 2010, UNAIDS REP GLOB AIDS; USAID, 2011, SAM PROJ USAID INDIA; Venkatesh KK, 2012, INDIAN J CANCER, V49, P176, DOI 10.4103/0019-509X.98947; Venkatesh KK, 2010, AIDS PATIENT CARE ST, V24, P795, DOI 10.1089/apc.2010.0153; Washington RG, 2014, ASIA-PAC J PUBLIC HE, V26, P349, DOI 10.1177/1010539514537677; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008	44	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2016	11	6							e0156611	10.1371/journal.pone.0156611	http://dx.doi.org/10.1371/journal.pone.0156611			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN6XB	27253974	Green Published, gold, Green Submitted			2023-01-03	WOS:000377218700043
J	Van Aelst, B; Devloo, R; Zachee, P; t'Kindt, R; Sandra, K; Vandekerckhove, P; Compernolle, V; Feys, HB				Van Aelst, Britt; Devloo, Rosalie; Zachee, Pierre; t'Kindt, Ruben; Sandra, Koen; Vandekerckhove, Philippe; Compernolle, Veerle; Feys, Hendrik B.			Psoralen and Ultraviolet A Light Treatment Directly Affects Phosphatidylinositol 3-Kinase Signal Transduction by Altering Plasma Membrane Packing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET ACTIVATION; LIPID PACKING; EXTRACORPOREAL PHOTOPHERESIS; PHOTOCHEMICAL INACTIVATION; IMMUNE SUPPRESSION; THROMBUS FORMATION; MASS-SPECTROMETRY; NUCLEIC-ACID; PUVA THERAPY; IN-VITRO	Psoralen and ultraviolet A light (PUNTA) are used to kill pathogens in blood products and as a treatment of aberrant cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft versus-host disease. DNA damage is well described, but the direct effects of PUVA on cell signal transduction are poorly understood. Because platelets are anucleate and contain archetypal signal transduction machinery, they are ideally suited to address this. Lipidomics on platelet membrane extracts showed that psoralen forms adducts with unsaturated carbon bonds of fatty acyls in all major phospholipid classes after PUVA. Such adducts increased lipid packing as measured by a blue shift of an environment-sensitive fluorescent probe in model liposomes. Furthermore, the interaction of these liposomes with lipid order-sensitive proteins like amphipathic lipid-packing sensor and a-synuclein was inhibited by PUVA. In platelets, PUVA caused poor membrane binding of Akt and Bruton's tyrosine kinase effectors following activation of the collagen glycoprotein VI and thrombin protease-activated receptor (PAR) 1. This resulted in defective Akt phosphorylation despite unaltered phosphatidylinositol 3,4,5-trisphosphate levels. Downstream integrin activation was furthermore affected similarly by PUVA following PAR1 (effective half-maximal concentration (EC), 8.4 +/- 1.1 versus 4.3 +/- 1.1 mu M) and glycoprotein VI (EC50, 1.61 +/- 0.85 versus 0.26 +/- 0.21 mu g/ml) but not PAR4 (EC50, 50 +/- 1 versus 58 +/- 1 mu m) signal transduction. Our findings were confirmed in T-cells ftom graft-versus-host disease patients treated with extracorporeal photopheresis, a form of systemic PUVA. In conclusion, PUVA increases the order of lipid phases by covalent modification of phospholipids, thereby inhibiting membrane recruitment of effector kinases.	[Van Aelst, Britt; Devloo, Rosalie; Compernolle, Veerle; Feys, Hendrik B.] Belgian Red Cross Flanders, Transfus Res Ctr, Ottergemsesteenweg 413, B-9000 Ghent, Belgium; [Zachee, Pierre] Hosp Network Antwerp, Dept Hematol, B-2000 Antwerp, Belgium; [t'Kindt, Ruben; Sandra, Koen] Res Inst Chromatog, B-8500 Kortrijk, Belgium; [Vandekerckhove, Philippe; Compernolle, Veerle] Belgian Red Cross Flanders, Blood Serv, B-2800 Mechelen, Belgium; [Vandekerckhove, Philippe] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, B-3000 Leuven, Belgium; [Vandekerckhove, Philippe; Compernolle, Veerle] Univ Ghent, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	KU Leuven; Ghent University	Feys, HB (corresponding author), Belgian Red Cross Flanders, Transfus Res Ctr, Ottergemsesteenweg 413, B-9000 Ghent, Belgium.	hendrik.feys@rodekruis.be	Zachee, Pierre/B-5391-2018	Zachee, Pierre/0000-0002-2275-5143; Feys, Hendrik/0000-0003-0052-8852	Foundation for Research and Development of the Belgian Red Cross-Flanders Blood Service	Foundation for Research and Development of the Belgian Red Cross-Flanders Blood Service	This work was supported by the Foundation for Research and Development of the Belgian Red Cross-Flanders Blood Service. The authors declare that they have no conflicts of interest with the contents of this article.	Anthony FA, 1997, PHOTODERMATOL PHOTO, V13, P9, DOI 10.1111/j.1600-0781.1997.tb00101.x; Badolia R, 2015, BLOOD, V125, P175, DOI 10.1182/blood-2014-05-576306; Bernal-Perez LF, 2012, ANAL BIOCHEM, V428, P13, DOI 10.1016/j.ab.2012.05.026; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2012, DEV CELL, V23, P886, DOI 10.1016/j.devcel.2012.10.009; BOHM F, 1986, ARCH DERMATOL RES, V279, P16, DOI 10.1007/BF00404352; Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376; Caffieri S, 1996, ACTA BIOCHIM POL, V43, P241; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Cazenave Jean-Pierre, 2004, Methods Mol Biol, V272, P13; Chen X, 2013, BLOOD, V121, P3718, DOI 10.1182/blood-2012-10-461897; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.biochem.54.1.1151; Clark J, 2011, NAT METHODS, V8, P267, DOI [10.1038/nmeth.1564, 10.1038/NMETH.1564]; Dardare N, 2002, PHOTOCHEM PHOTOBIOL, V75, P561, DOI 10.1562/0031-8655(2002)075<0561:BAOCES>2.0.CO;2; Darwich Z, 2012, BBA-BIOMEMBRANES, V1818, P3048, DOI 10.1016/j.bbamem.2012.07.017; Del Fante C, 2016, BONE MARROW TRANSPL, V51, P728, DOI 10.1038/bmt.2015.324; dos Santos DJVA, 2011, PHYS CHEM CHEM PHYS, V13, P10174, DOI 10.1039/c0cp02245d; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Fahy E, 2009, J LIPID RES, V50, pS9, DOI 10.1194/jlr.R800095-JLR200; Flesch FM, 2005, BIOCHEM J, V389, P435, DOI 10.1042/BJ20041721; Frank S, 1998, J PHOTOCH PHOTOBIO B, V44, P39, DOI 10.1016/S1011-1344(98)00103-1; Gilio K, 2009, J BIOL CHEM, V284, P33750, DOI 10.1074/jbc.M109.048439; Goodall Alison H, 2004, Methods Mol Biol, V272, P225; Greinix HT, 2012, EXTRACORPOREAL PHOTOPHERESIS: CELLULAR PHOTOIMMUNOTHERAPY, P1, DOI 10.1515/9783110276138; Hardwick J, 2008, ISBT SCI SER, V3, P148, DOI 10.1111/j.1751-2824.2008.00195.x; Infante C, 1999, J CELL BIOL, V145, P83, DOI 10.1083/jcb.145.1.83; Irsch J, 2011, TRANSFUS MED HEMOTH, V38, P19, DOI 10.1159/000323937; Kaiser HJ, 2009, P NATL ACAD SCI USA, V106, P16645, DOI 10.1073/pnas.0908987106; Klymchenko AS, 2014, CHEM BIOL, V21, P97, DOI 10.1016/j.chembiol.2013.11.009; Knutson F, 2000, VOX SANG, V78, P209, DOI 10.1159/000031183; Lai CF, 2008, ANAL CHEM, V80, P8790, DOI 10.1021/ac801520m; LASKIN JD, 1985, P NATL ACAD SCI USA, V82, P6158, DOI 10.1073/pnas.82.18.6158; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Li XY, 2005, PHOTOCHEM PHOTOBIOL, V81, P1153, DOI 10.1562/2005-03-21-RA-467; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; Ling TC, 2016, BRIT J DERMATOL, V174, P24, DOI 10.1111/bjd.14317; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; Lumb CN, 2011, STRUCTURE, V19, P1338, DOI 10.1016/j.str.2011.04.010; Mischnik M, 2013, MOL BIOSYST, V9, P1326, DOI 10.1039/c3mb25597b; Pathak MA, 1992, AD J PHOTOCHEM PHO B, V14, P3, DOI DOI 10.1016/1011-1344(92)85080-E; Pranke IM, 2011, J CELL BIOL, V194, P88, DOI 10.1083/jcb.201011118; Riehle RD, 2013, ADV EXP MED BIOL, V991, P105, DOI 10.1007/978-94-007-6331-9_7; Sandra K, 2010, J CHROMATOGR A, V1217, P4087, DOI 10.1016/j.chroma.2010.02.039; Sanford KW, 2012, J CLIN APHERESIS, V27, P126, DOI 10.1002/jca.21217; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; t'kindt R, 2015, ANAL CHEM, V87, P4957, DOI 10.1021/acs.analchem.5b00732; Van Aelst B, 2015, VOX SANG, V108, P328, DOI 10.1111/vox.12231; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; VANHENEGOUWEN GMJB, 1989, J PHOTOCH PHOTOBIO B, V3, P631, DOI 10.1016/1011-1344(89)80086-7; vanIperen HP, 1996, PHOTOCHEM PHOTOBIOL, V63, P577, DOI 10.1111/j.1751-1097.1996.tb05659.x; Vanni S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5916; WAKSVIK H, 1977, HUM GENET, V38, P195, DOI 10.1007/BF00527403; Wolf P, 2016, BRIT J DERMATOL, V174, P11, DOI 10.1111/bjd.14341; Wolf P, 2006, AM J PATHOL, V169, P795, DOI 10.2353/ajpath.2006.060079; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; ZAREBSKA Z, 1994, J PHOTOCH PHOTOBIO B, V23, P101, DOI 10.1016/1011-1344(94)06944-1	57	20	20	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2016	291	47					24364	24376		10.1074/jbc.M116.735126	http://dx.doi.org/10.1074/jbc.M116.735126			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ED5EX	27687726	Green Published, hybrid			2023-01-03	WOS:000388875500004
J	Sykes, DB; Kfoury, YS; Mercier, FE; Wawer, MJ; Law, JM; Haynes, MK; Lewis, TA; Schajnovitz, A; Jain, ES; Lee, D; Meyer, H; Pierce, KA; Tolliday, NJ; Waller, A; Ferrara, SJ; Eheim, AL; Stoeckigt, D; Maxcy, KL; Cobert, JM; Bachand, J; Szekely, BA; Mukherjee, S; Sklar, LA; Kotz, JD; Clish, CB; Sadreyev, RI; Clemons, PA; Janzer, A; Schreiber, SL; Scadden, DT				Sykes, David B.; Kfoury, Youmna S.; Mercier, Francois E.; Wawer, Mathias J.; Law, Jason M.; Haynes, Mark K.; Lewis, Timothy A.; Schajnovitz, Amir; Jain, Esha; Lee, Dongjun; Meyer, Hanna; Pierce, Kerry A.; Tolliday, Nicola J.; Waller, Anna; Ferrara, Steven J.; Eheim, Ashley L.; Stoeckigt, Detlef; Maxcy, Katrina L.; Cobert, Julien M.; Bachand, Jacqueline; Szekely, Brian A.; Mukherjee, Siddhartha; Sklar, Larry A.; Kotz, Joanne D.; Clish, Clary B.; Sadreyev, Ruslan I.; Clemons, Paul A.; Janzer, Andreas; Schreiber, Stuart L.; Scadden, David T.			Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia	CELL			English	Article							PHASE-I; A77 1726; DUP 785; EXPRESSION; HOXA9; CELLS; METABOLISM; GENES; ACID	While acute myeloid leukemia (AML) comprises many disparate genetic subtypes, one shared hallmark is the arrest of leukemic myeloblasts at an immature and self-renewing stage of development. Therapies that overcome differentiation arrest represent a powerful treatment strategy. We leveraged the observation that the majority of AML, despite their genetically heterogeneity, share in the expression of HoxA9, a gene normally downregulated during myeloid differentiation. Using a conditional HoxA9 model system, we performed a high-throughput phenotypic screen and defined compounds that overcame differentiation blockade. Target identification led to the unanticipated discovery that inhibition of the enzyme dihydroorotate dehydrogenase (DHODH) enables myeloid differentiation in human and mouse AML models. In vivo, DHODH inhibitors reduced leukemic cell burden, decreased levels of leukemia-initiating cells, and improved survival. These data demonstrate the role of DHODH as a metabolic regulator of differentiation and point to its inhibition as a strategy for overcoming differentiation blockade in AML.	[Sykes, David B.; Kfoury, Youmna S.; Mercier, Francois E.; Schajnovitz, Amir; Jain, Esha; Lee, Dongjun; Maxcy, Katrina L.; Cobert, Julien M.; Bachand, Jacqueline; Szekely, Brian A.; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA; [Sykes, David B.; Scadden, David T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Wawer, Mathias J.; Tolliday, Nicola J.; Ferrara, Steven J.] Broad Inst MIT & Harvard, Ctr Dev Therapeut, Cambridge, MA 02142 USA; [Law, Jason M.; Lewis, Timothy A.; Kotz, Joanne D.; Clemons, Paul A.; Schreiber, Stuart L.] Broad Inst, Ctr Sci Therapeut, Cambridge, MA 02142 USA; [Haynes, Mark K.; Waller, Anna; Sklar, Larry A.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA; [Meyer, Hanna; Eheim, Ashley L.; Janzer, Andreas] Bayer Pharma AG, D-13353 Berlin, Germany; [Pierce, Kerry A.; Clish, Clary B.] Broad Inst, Metabolite Profiling Platform, Cambridge, MA 02142 USA; [Mukherjee, Siddhartha] Columbia Univ, Sch Med, Irving Canc Res Ctr, New York, NY 10032 USA; [Sadreyev, Ruslan I.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Sadreyev, Ruslan I.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Sadreyev, Ruslan I.] Harvard Med Sch, Boston, MA 02114 USA; [Sykes, David B.; Kfoury, Youmna S.; Mercier, Francois E.; Schajnovitz, Amir; Lee, Dongjun; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Sykes, David B.; Kfoury, Youmna S.; Mercier, Francois E.; Schajnovitz, Amir; Lee, Dongjun; Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Schreiber, Stuart L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Schreiber, Stuart L.] Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of New Mexico; Bayer AG; Bayer Healthcare Pharmaceuticals; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Columbia University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University; Howard Hughes Medical Institute	Sykes, DB; Scadden, DT (corresponding author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.; Sykes, DB; Scadden, DT (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.; Sykes, DB; Scadden, DT (corresponding author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.; Sykes, DB; Scadden, DT (corresponding author), Harvard Stem Cell Inst, Cambridge, MA 02138 USA.	dbsykes@mgh.harvard.edu; dscadden@mgh.harvard.edu	Clish, Clary/AAB-7124-2019; Jain, Esha/AAB-9234-2020; Clish, Clary B/ABB-9374-2021; Lee, Dongjun/ABF-4381-2021; Cobert, Julien/ABC-9168-2020	Jain, Esha/0000-0003-1201-2052; Clish, Clary B/0000-0001-8259-9245; Hawley, Katrina/0000-0002-5305-2272; Bachand, Jacqueline/0000-0001-9603-5707; Lee, Dongjun/0000-0001-6828-401X; Lewis, Timothy/0000-0001-9748-9575; Waller, Anna/0000-0003-3676-2501	HSCI-CRM Flow Cytometry Facility; Scott Mordecai in the Department of Pathology Flow and Image Cytometry Core [NIH 1S10OD012027-01A1]; Partners HealthCare Personalized Medicine Translational Genomics Core; Genomics Platform at the Broad Institute; NIH [1R03DA032471-01]; NIH Molecular Library Program [U54 HG005032-1, U54 MH084690-1]; American Society of Hematology; Alex's Lemonade Stand Foundation; Leukemia and Lymphoma Society; Harvard Catalyst; American Cancer Society Institutional Research Grant; Harvard Stem Cell Institute; Ludwig Center at Harvard; Amelia Peabody Charitable Fund; Gerald and Darlene Jordan Chair of Medicine at Harvard University; Bayer Pharma AG; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG005032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA032471] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD012027] Funding Source: NIH RePORTER	HSCI-CRM Flow Cytometry Facility; Scott Mordecai in the Department of Pathology Flow and Image Cytometry Core; Partners HealthCare Personalized Medicine Translational Genomics Core; Genomics Platform at the Broad Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Molecular Library Program; American Society of Hematology; Alex's Lemonade Stand Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Harvard Catalyst; American Cancer Society Institutional Research Grant(American Cancer Society); Harvard Stem Cell Institute; Ludwig Center at Harvard; Amelia Peabody Charitable Fund; Gerald and Darlene Jordan Chair of Medicine at Harvard University; Bayer Pharma AG; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors would like to thank Alexa Carver at Massachusetts General Hospital (MGH); Michael Churchill at Columbia University; and Anthony Arvanites, Lance Davidow, and Lee Rubin at the Harvard Stem Cell Institute for their help in optimizing the primary small-molecule screen. We thank Thomas Graf for the lysozyme GFP knockin mouse; Timothy Ley for providing the murine myeloid differentiation microarray data; David Tan, who created the mouse graphic; and Mark Kamps, who provided insight and support throughout the project. We thank Kathleen Higgins and Scott Vafai of the Broad Institute for their help with the Seahorse oxygen consumption experiment. We thank Amir Schajnovitz for sharing his model of MLL/AF9 leukemia for the in vivo comparison of brequinar with standard chemotherapy. We thank Sven Christian for his work profiling the human AML cell lines and their response to DHODH inhibition. We were supported by the HSCI-CRM Flow Cytometry Facility, by Scott Mordecai in the Department of Pathology Flow and Image Cytometry Core (NIH 1S10OD012027-01A1), by the Partners HealthCare Personalized Medicine Translational Genomics Core, and by the Genomics Platform at the Broad Institute. The small-molecule screen was supported by NIH grant 1R03DA032471-01 (to D.B.S.) and the NIH Molecular Library Program (U54 HG005032-1 awarded to S.L.S. and U54 MH084690-1 awarded to L.A.S.). D.B.S. was supported by grants from the American Society of Hematology, Alex's Lemonade Stand Foundation, the Leukemia and Lymphoma Society, Harvard Catalyst, and an American Cancer Society Institutional Research Grant. D.T.S. was supported by the Harvard Stem Cell Institute and the Ludwig Center at Harvard, as well as the Amelia Peabody Charitable Fund, and the Gerald and Darlene Jordan Chair of Medicine at Harvard University. H.M., A.L.E., D.S., and A.J. are employees of Bayer Pharma AG. The work was supported in part by a collaboration with Bayer Pharma AG.	Adamaki M, 2015, LEUKEMIA RES, V39, P874, DOI 10.1016/j.leukres.2015.04.012; ARTEAGA CL, 1989, CANCER RES, V49, P4648; Bond MR, 2015, J CELL BIOL, V208, P869, DOI 10.1083/jcb.201501101; Bourgon R, 2010, P NATL ACAD SCI USA, V107, P9546, DOI 10.1073/pnas.0914005107; Burris HA, 1998, INVEST NEW DRUG, V16, P19; Chattopadhyay S, 2015, CELL REP, V10, P755, DOI 10.1016/j.celrep.2015.01.017; Collins CT, 2016, ONCOGENE, V35, P1090, DOI 10.1038/onc.2015.174; CRAMER DV, 1995, PEDIATR NEPHROL, V9, pS52, DOI 10.1007/BF00867685; DIX DE, 1979, CANCER RES, V39, P4485; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Doscas ME, 2014, NEOPLASIA, V16, P824, DOI 10.1016/j.neo.2014.08.006; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Hanover JA, 2012, NAT REV MOL CELL BIO, V13, P312, DOI 10.1038/nrm3334; Haynes MK, 2009, J BIOMOL SCREEN, V14, P596, DOI 10.1177/1087057109335671; Hesson D. P., 1987, U. S. patent, Patent No. [4680299, US4680299 A]; Huang M, 2002, MOL PHARMACOL, V62, P463, DOI 10.1124/mol.62.3.463; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jozwiak P, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00145; Knecht W, 1998, BIOCHEM PHARMACOL, V56, P1259, DOI 10.1016/S0006-2952(98)00145-2; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Loffler M, 1997, MOL CELL BIOCHEM, V174, P125, DOI 10.1023/A:1006859115450; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; MILLER RW, 1968, CAN J BIOCHEM CELL B, V46, P1099, DOI 10.1139/o68-164; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; NOE DA, 1990, CANCER RES, V50, P4595; Novershtern N, 2011, CELL, V144, P296, DOI 10.1016/j.cell.2011.01.004; O'Donnell EF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013128; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Schreiber SL, 2015, CELL, V161, P1252, DOI 10.1016/j.cell.2015.05.023; SCHWARTSMANN G, 1990, CANCER CHEMOTH PHARM, V25, P345, DOI 10.1007/BF00686235; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sykes D. B., 2015, DISCOVERING SMALL MO; Tedeschi FA, 2006, LEUKEMIA RES, V30, P1453, DOI 10.1016/j.leukres.2006.02.022; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; WISCH JS, 1983, NEW ENGL J MED, V309, P1599, DOI 10.1056/NEJM198312293092602; Wolf C, 2006, J ORG CHEM, V71, P3270, DOI 10.1021/jo060034a; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; YATES JW, 1973, CANCER CHEMOTH REP 1, V57, P485; Yuan W, 2007, BLOOD, V109, P961, DOI 10.1182/blood-2006-07-036640; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	48	256	261	4	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	2016	167	1					171	+		10.1016/j.cell.2016.08.057	http://dx.doi.org/10.1016/j.cell.2016.08.057			31	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EA1GW	27641501	Bronze, Green Accepted			2023-01-03	WOS:000386341500023
J	Guensch, DP; Yu, J; Nadeshalingam, G; Fischer, K; Shearer, J; Friedrich, MG				Guensch, Dominik P.; Yu, Janelle; Nadeshalingam, Gobinath; Fischer, Kady; Shearer, Jane; Friedrich, Matthias G.			Evidence for Acute Myocardial and Skeletal Muscle Injury after Serial Transthoracic Shocks in Healthy Swine	PLOS ONE			English	Article							ACID-BINDING PROTEIN; CARDIOVASCULAR-MAGNETIC-RESONANCE; DEFIBRILLATION; RECOVERY; ELECTROPORATION; CARDIOVERSION; MEMBRANE	Background Previous serological studies have shown controversial results whether defibrillation or cardioversion can cause myocardial injury. Cardiovascular Magnetic Resonance (CMR) can be used to detect myocardial edema, hyperemia and capillary leak as features of acute myocardial injury. The aim of this study was to assess for myocardial and skeletal muscle injury in swine following transthoracic shocks. Methods Seventeen anaesthetized swine were examined, with 11 undergoing five synchronized transthoracic shocks (200J). Myocardial and skeletal muscle injury were assessed at baseline and up to 5h post-shock employing T1 mapping, T2 mapping, early and late gadolinium enhancement. Serologic markers (cFABP, TnI, CK, and CK-MB) and myocardial tissue were assessed by standard histology methods. Results In myocardial regions within the shock path, T1 and T2 were significantly increased compared to remote myocardium in the same animals. The early gadolinium enhancement ratio between the left-ventricular myocardium and the right pectoral muscle was also increased compared to control animals. After the shocks cFABP and CK were significantly elevated. After shock application, the regions identified as abnormal by CMR showed significantly increased interstitial and myocardial cell areas in histological analysis. This increased cell area suggests significant cellular and interstitial edema. Conclusion Our pilot study data indicate that serial defibrillator shocks lead to acute skeletal muscle and myocardial injury. CMR is a useful tool to detect and localize myocardial and skeletal muscle injury early after transthoracic shocks in vivo. In the future the technique could potentially be used as an additional tool for quality control such as verifying insufficient local shock application in non-responders after cardioversion or to develop safer shock forms.	[Guensch, Dominik P.; Yu, Janelle; Nadeshalingam, Gobinath; Fischer, Kady; Friedrich, Matthias G.] Montreal Heart Inst, Philippa & Marvin Carsley CMR Ctr, Montreal, PQ, Canada; [Guensch, Dominik P.; Fischer, Kady] Univ Bern, Univ Hosp Bern, Dept Anaesthesiol & Pain Therapy, Inselspital, Bern, Switzerland; [Guensch, Dominik P.] Univ Bern, Univ Hosp Bern, Inst Diagnost Intervent & Paediat Radiol, Inselspital, Bern, Switzerland; [Friedrich, Matthias G.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Friedrich, Matthias G.] McGill Univ, Dept Radiol, Montreal, PQ, Canada; [Shearer, Jane] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada	Universite de Montreal; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; McGill University; McGill University; University of Calgary	Guensch, DP (corresponding author), Montreal Heart Inst, Philippa & Marvin Carsley CMR Ctr, Montreal, PQ, Canada.; Guensch, DP (corresponding author), Univ Bern, Univ Hosp Bern, Dept Anaesthesiol & Pain Therapy, Inselspital, Bern, Switzerland.; Guensch, DP (corresponding author), Univ Bern, Univ Hosp Bern, Inst Diagnost Intervent & Paediat Radiol, Inselspital, Bern, Switzerland.	dominik.guensch@gmail.com	; Friedrich, Matthias/H-8474-2015	Gunsch, Dominik/0000-0003-4127-4086; Friedrich, Matthias/0000-0003-1204-5647; Fischer, Kady/0000-0002-7765-4550	Montreal Heart Institute Foundation; Canadian Foundation for Innovation; Fonds de Recherche Sante Quebec	Montreal Heart Institute Foundation; Canadian Foundation for Innovation(Canada Foundation for Innovation); Fonds de Recherche Sante Quebec	Funding was provided by the Montreal Heart Institute Foundation, the Canadian Foundation for Innovation and the Fonds de Recherche Sante Quebec. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaiti MA, 2009, PACE, V32, P800, DOI 10.1111/j.1540-8159.2009.02370.x; Allan JJ, 1997, J AM COLL CARDIOL, V30, P1052, DOI 10.1016/S0735-1097(97)00260-X; Azzazy HME, 2006, CLIN CHEM, V52, P19, DOI 10.1373/clinchem.2005.056143; Berg MD, 2008, PEDIATR CRIT CARE ME, V9, P429, DOI 10.1097/PCC.0b013e318172e9f8; Bunai Yasuo, 2003, Leg Med (Tokyo), V5 Suppl 1, pS302, DOI 10.1016/S1344-6223(02)00156-6; Daidoji H, 2012, J CARD FAIL, V18, P556, DOI 10.1016/j.cardfail.2012.04.006; de Caen AR, 2015, CIRCULATION, V132, pS526, DOI 10.1161/CIR.0000000000000266; del Rey Sanchez JM, 2002, REV ESP CARDIOL, V55, P227; Ferreira VM, 2013, JACC-CARDIOVASC IMAG, V6, P1048, DOI 10.1016/j.jcmg.2013.03.008; Ferreira VM, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-42; Friedrich MG, 2009, J AM COLL CARDIOL, V53, P1475, DOI 10.1016/j.jacc.2009.02.007; Friedrich MG, 1998, CIRCULATION, V97, P1802, DOI 10.1161/01.CIR.97.18.1802; Giri S, 2009, J CARDIOVASC MAGN R, V11, DOI 10.1186/1532-429X-11-56; Gissel H, 2005, ANN NY ACAD SCI, V1066, P272, DOI 10.1196/annals.1363.024; Hendel RC, 2006, J AM COLL CARDIOL, V48, P1475, DOI 10.1016/j.jacc.2006.07.003; Kellman P, 2014, J CARDIOVASC MAGN R, V16, DOI 10.1186/1532-429X-16-2; Mazove OL, 2006, KARDIOLOGIYA, V46, P43; Messroghli DR, 2004, MAGN RESON MED, V52, P141, DOI 10.1002/mrm.20110; Santos Elizabete Silva dos, 2006, Arq Bras Cardiol, V86, P191; Skulec R, 2006, RESUSCITATION, V70, P423, DOI 10.1016/j.resuscitation.2006.02.003; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; TOVAR O, 1992, AM J PHYSIOL, V263, pH1128, DOI 10.1152/ajpheart.1992.263.4.H1128; Vogel U, 1998, INTENS CARE MED, V24, P743, DOI 10.1007/s001340050656; Wang YT, 2012, AM J PHYSIOL-HEART C, V303, pH439, DOI 10.1152/ajpheart.01121.2011	24	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0162245	10.1371/journal.pone.0162245	http://dx.doi.org/10.1371/journal.pone.0162245			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JE	27611090	Green Published, gold			2023-01-03	WOS:000383255900069
J	Kandeel, A; Dawson, P; Labib, M; Said, M; El-Refai, S; El-Gohari, A; Talaat, M				Kandeel, Amr; Dawson, Patrick; Labib, Manal; Said, Mayar; El-Refai, Samir; El-Gohari, Amani; Talaat, Maha			Morbidity, Mortality, and Seasonality of Influenza Hospitalizations in Egypt, November 2007-November 2014	PLOS ONE			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; A H1N1 VIRUS; PREGNANT-WOMEN; INFECTIONS; SURVEILLANCE; CHILDREN; EPIDEMICS; DISEASE; ILLNESS; BURDEN	Background Influenza typically comprises a substantial portion of acute respiratory infections, a leading cause of mortality worldwide. However, influenza epidemiology data are lacking in Egypt. We describe seven years of Egypt's influenza hospitalizations from a multi-site influenza surveillance system. Methods Syndromic case definitions identified individuals with severe acute respiratory infection (SARI) admitted to eight hospitals in Egypt. Standardized demographic and clinical data were collected. Nasopharyngeal and oropharyngeal swabs were tested for influenza using real-time reverse transcription polymerase chain reaction and typed as influenza A or B, and influenza A specimens subtyped. Results From November 2007-November 2014, 2,936/17,441 (17%) SARI cases were influenza-positive. Influenza-positive patients were more likely to be older, female, pregnant, and have chronic condition(s) (all p<0.05). Among them, 53 (2%) died, and death was associated with older age, five or more days from symptom onset to hospitalization, chronic condition(s), and influenza A (all p<0.05). An annual seasonal influenza pattern occurred from July-June. Each season, the proportion of the season's influenza-positive cases peaked during November-May (19-41%). Conclusions In Egypt, influenza causes considerable morbidity and mortality and influenza SARI hospitalization patterns mirror those of the Northern Hemisphere. Additional assessment of influenza epidemiology in Egypt may better guide disease control activities and vaccine policy.	[Kandeel, Amr; Labib, Manal; El-Refai, Samir; El-Gohari, Amani] Egypt Minist Hlth, Cairo, Egypt; [Dawson, Patrick; Said, Mayar; Talaat, Maha] US Naval Med Res Unit 3, Cairo, Egypt; [Dawson, Patrick; Talaat, Maha] US Ctr Dis Control & Prevent, Global Dis Detect Ctr, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3)	Dawson, P (corresponding author), US Naval Med Res Unit 3, Cairo, Egypt.; Dawson, P (corresponding author), US Ctr Dis Control & Prevent, Global Dis Detect Ctr, Cairo, Egypt.	ptd2103@cumc.columbia.edu			Global Emerging Infections Surveillance Program (GEIS) [GEIS847705.821000.25GB.E0018]; U.S. Centers for Disease Control and Prevention	Global Emerging Infections Surveillance Program (GEIS); U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The study was funded through the Global Emerging Infections Surveillance Program (GEIS) GEIS847705.821000.25GB.E0018 and by the U.S. Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwhab EM, 2015, VIRULENCE, V6, P6, DOI 10.4161/21505594.2014.992662; Al-Abdallat M, 2016, INFLUENZA OTHER RESP, V10, P91, DOI 10.1111/irv.12354; Al-Awaidy S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144186; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P161; [Anonymous], AV CAND VACC VIR POT; Azziz-Baumgartner E, 2012, B WHO, V90; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Baumgartner EA, 2012, J INFECT DIS, V206, P838, DOI 10.1093/infdis/jis467; Cox S, 2006, OBSTET GYNECOL, V107, P1315, DOI 10.1097/01.AOG.0000218702.92005.bb; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; Echevarria-Zuno S, 2009, LANCET, V374, P2072, DOI 10.1016/S0140-6736(09)61638-X; El Kholy AA, 2014, J INFECT DEV COUNTR, V8, P1285, DOI 10.3855/jidc.4682; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; Gomaa M. R., 2014, J INFECT DIS; Horimoto T, 2001, CLIN MICROBIOL REV, V14, P129, DOI 10.1128/CMR.14.1.129-149.2001; Khattab A, 2013, ASIAN PAC J TROP MED, V6, P693, DOI 10.1016/S1995-7645(13)60120-0; Lee N, 2010, THORAX, V65, P510, DOI 10.1136/thx.2009.130799; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MCKINNEY WP, 1990, ARCH INTERN MED, V150, P213, DOI 10.1001/archinte.150.1.213; MULLOOLY JP, 1986, PUBLIC HEALTH REP, V101, P205; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Periolo N, 2015, J CLIN VIROL, V64, P52, DOI 10.1016/j.jcv.2015.01.009; Radin JM, 2012, J INFECT DIS, V206, pS14, DOI 10.1093/infdis/jis606; Rowlinson E, 2013, J INFECT DIS, V208, pS189, DOI 10.1093/infdis/jit457; Schluger NW, ACUTE RESP INFECT MA; Schroedl A, 2010, EMERG INFECT DIS, V16, P161, DOI 10.3201/eid1601.090560; Shafik CF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-350; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Tallo VL, 2014, INFLUENZA OTHER RESP, V8, P159, DOI 10.1111/irv.12223; Tamfum JJM, 2012, J INFECT DIS, V206, pS36, DOI 10.1093/infdis/jis537; Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; U.S. Centers for Disease Control and Prevention, 2005, SEAS INFL VACC EFF; U.S. Centers for Disease Control and Prevention International Emerging Infections Program (IEIP): Thailand, DESCR CLIN PNEUM; U.S. Central Intelligence Agency, EG WORLD FACTB; United Nations Development Program, HUM DEV REP 2014; Viboud C, 2004, EUR J EPIDEMIOL, V19, P1055, DOI 10.1007/s10654-004-2450-9; WHO/GIP, 2003, CUM NUMB CONF HUM CA; World Health Organization, PAHO CDC GEN PROT IN; World Health Organization, GLOB EP SURV STAND I; World Health Organization, INT SURV REC HUM INF; World Health Organization, GLOB HLTH OBS DAT RE; World Health Organization, WORLD HLTH STAT 2014; World Health Organization (WHO), WHO GLOB TECHN CONS; World Lung Foundation, INFLUENZA	48	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2016	11	9							e0161301	10.1371/journal.pone.0161301	http://dx.doi.org/10.1371/journal.pone.0161301			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JB	27607330	gold, Green Submitted, Green Published			2023-01-03	WOS:000383255600004
J	Lei, W; Browning, JD; Eichen, PA; Folk, WR; Sun, GY; Lubahn, DB; Fritsche, KL				Lei, Wei; Browning, Jimmy D., Jr.; Eichen, Peggy A.; Folk, William R.; Sun, Grace Y.; Lubahn, Dennis B.; Fritsche, Kevin L.			An Investigation into the Immunomodulatory Activities of Sutherlandia frutescens in Healthy Mice	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE; INFLAMMATION; INNATE; POLYSACCHARIDES; INTERLEUKIN-6; TUBERCULOSIS; LISTERIOSIS; INFECTION; RESPONSES	Sutherlandia frutescens is a medicinal plant that has been traditionally used in southern Africa for cancers, infections, and inflammatory conditions. We recently published experiments demonstrating that an aqueous extract of S. frutescens possessed potent immune-stimulatory activity. This work was carried out with murine macrophages, an immune cell type that plays a pivotal role in host defense from infection and in shaping host inflammatory and immune responses. Here, we conducted a series of follow-up experiments to explore the impact of consuming S. frutescens on host response to bacterial challenge using healthy mice. We found that feeding mice a diet containing S. frutescens failed to significantly alter host response to systemic infection by either a gram-positive or gram-negative bacterium (i.e., L. monocytogenes and E.coli, respectively). In contrast to the in vitro observations, we found no evidence that S. frutescens consumption stimulated in vivo inflammatory responses; instead, consumption of S. frutescens tended to diminish in vivo inflammatory responses. Several possible reasons for this are discussed.	[Lei, Wei; Browning, Jimmy D., Jr.; Eichen, Peggy A.; Fritsche, Kevin L.] Univ Missouri, Div Anim Sci, Columbia, MO 65211 USA; [Folk, William R.; Sun, Grace Y.; Lubahn, Dennis B.] Univ Missouri, Dept Biochem, Columbia, MO 65201 USA; [Fritsche, Kevin L.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO 65203 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Fritsche, KL (corresponding author), Univ Missouri, Div Anim Sci, Columbia, MO 65211 USA.; Fritsche, KL (corresponding author), Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO 65203 USA.	fritschek@missouri.edu		Lei, Wei/0000-0002-0374-8642; Fritsche, Kevin/0000-0002-0740-3801; Folk, William/0000-0003-2216-3233	National Center for Complementary & Alternative Medicine (NCCAM) [P50AT006273]; Office of Dietary Supplements (ODS); National Cancer Institute (NCI); University of Missouri's College of Agriculture, Food, and Natural Resources; Food-for-the-21st Century Program	National Center for Complementary & Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Missouri's College of Agriculture, Food, and Natural Resources; Food-for-the-21st Century Program	This publication or project was made possible by Grant Number P50AT006273 from the National Center for Complementary & Alternative Medicine (NCCAM), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI) and the support of the University of Missouri's College of Agriculture, Food, and Natural Resources, and the Food-for-the-21st Century Program. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, ODS, NCI, or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Africa LD, 2015, J NEGAT RESULTS BIOM, V14, DOI 10.1186/s12952-015-0031-y; [Anonymous], 2013, Ann Emerg Med, V62, P536; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; Campbell P A, 1994, Immunol Ser, V60, P313; CHEERS C, 1978, INFECT IMMUN, V19, P763, DOI 10.1128/IAI.19.3.763-770.1978; Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567-5769(01)00086-8; Couzin-Frankel J, 2010, SCIENCE, V330, P1621, DOI 10.1126/science.330.6011.1621; Di Paolo NC, 2015, IMMUNITY, V43, P1125, DOI 10.1016/j.immuni.2015.11.016; Eitel J, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2010.00149; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Feng C, 1999, J INTERF CYTOK RES, V19, P41, DOI 10.1089/107999099314405; Jia T, 2008, J IMMUNOL, V180, P6846, DOI 10.4049/jimmunol.180.10.6846; Johnson RW, 2002, VET IMMUNOL IMMUNOP, V87, P443, DOI 10.1016/S0165-2427(02)00069-7; Kohchi C, 2009, ANTICANCER RES, V29, P817; Lam GY, 2010, SEMIN IMMUNOPATHOL, V32, P415, DOI 10.1007/s00281-010-0221-0; Laroux FS, 2004, FRONT BIOSCI-LANDMRK, V9, P3156, DOI 10.2741/1468; Lei W, 2015, INT IMMUNOPHARMACOL, V29, P254, DOI 10.1016/j.intimp.2015.11.012; Lei W, 2015, J ETHNOPHARMACOL, V172, P247, DOI 10.1016/j.jep.2015.06.013; LIU Z, 1995, IMMUNOLOGY, V85, P562; Mills E, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-19; Montero D, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00384; NAKANE A, 1992, INFECT IMMUN, V60, P523, DOI 10.1128/IAI.60.2.523-528.1992; Poulsen KP, 2013, MICROB PATHOGENESIS, V56, P47, DOI 10.1016/j.micpath.2012.11.003; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Rigato O, 1996, INFECTION, V24, P314, DOI 10.1007/BF01743367; Rucker RB, 2007, J ANIM PHYSIOL AN N, V91, P148, DOI 10.1111/j.1439-0396.2007.00681.x; Salgadon E, 2011, EXPERT REV CLIN IMMU, V7, P329, DOI [10.1586/ECI.11.6, 10.1586/eci.11.6]; Schepetkin IA, 2006, INT IMMUNOPHARMACOL, V6, P317, DOI 10.1016/j.intimp.2005.10.005; Sharma V, 2009, BRIT J PHARMACOL, V157, P907, DOI 10.1111/j.1476-5381.2009.00267.x; Shiloh MU, 1997, INFECT IMMUN, V65, P3193, DOI 10.1128/IAI.65.8.3193-3198.1997; Spiers DE, 2005, J ANIM SCI, V83, P1423; Tripp CS, 1995, RES IMMUNOL, V146, P515, DOI 10.1016/0923-2494(96)83025-2; Vujanovic NL, 2011, IMMUNOL RES, V50, P159, DOI 10.1007/s12026-011-8228-8; Wilson D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128522; Zhang BZ, 2014, J ETHNOPHARMACOL, V152, P340, DOI 10.1016/j.jep.2014.01.017	36	0	0	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2016	11	8							e0160994	10.1371/journal.pone.0160994	http://dx.doi.org/10.1371/journal.pone.0160994			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EE	27575007	Green Submitted, gold, Green Published			2023-01-03	WOS:000382877200013
J	Fox, J; Barfield, W				Fox, Jared; Barfield, Wanda			Decreasing Unintended Pregnancy Opportunities Created by the Affordable Care Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; CONTRACEPTION; TEENS; COST		[Fox, Jared] Ctr Dis Control & Prevent, Policy, 1600 Clifton Rd NE,MS D-28, Atlanta, GA 30329 USA; [Barfield, Wanda] Ctr Dis Control & Prevent, Div Reprod Hlth, 1600 Clifton Rd NE,MS D-28, Atlanta, GA 30329 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Fox, J (corresponding author), Ctr Dis Control & Prevent, Policy, 1600 Clifton Rd NE,MS D-28, Atlanta, GA 30329 USA.	jaredfox@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575; Gavin L, 2013, MMWR-MORBID MORTAL W, V62, P249; Gostin LO, 2014, JAMA-J AM MED ASSOC, V312, P785, DOI 10.1001/jama.2014.9455; Romero L, 2015, MMWR-MORBID MORTAL W, V64, P363; Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506; Sobel L, COVERAGE CONTRACEPTI; Trussell J, 2007, CONTRACEPTION, V75, P168, DOI 10.1016/j.contraception.2006.11.009	7	21	21	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2016	316	8					815	816		10.1001/jama.2016.8800	http://dx.doi.org/10.1001/jama.2016.8800			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT8JL	27455194	Green Accepted			2023-01-03	WOS:000381736200007
J	Kesselheim, AS; Avorn, J; Sarpatwari, A				Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet			The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RESEARCH-AND-DEVELOPMENT; OF-POCKET COSTS; HEALTH-CARE; PEDIATRIC EXCLUSIVITY; MARKET EXCLUSIVITY; PATIENT OUTCOMES; MEDICARE; US; PATENT; MEDICATIONS	IMPORTANCE The increasing cost of prescription drugs in the United States has become a source of concern for patients, prescribers, payers, and policy makers. OBJECTIVES To review the origins and effects of high drug prices in the US market and to consider policy options that could contain the cost of prescription drugs. EVIDENCE We reviewed the peer-reviewed medical and health policy literature from January 2005 to July 2016 for articles addressing the sources of drug prices in the United States, the justifications and consequences of high prices, and possible solutions. FINDINGS Per capita prescription drug spending in the United States exceeds that in all other countries, largely driven by brand-name drug prices that have been increasing in recent years at rates far beyond the consumer price index. In 2013, per capita spending on prescription drugs was $858 compared with an average of $400 for 19 other industrialized nations. In the United States, prescription medications now comprise an estimated 17% of overall personal health care services. The most important factor that allows manufacturers to set high drug prices is market exclusivity, protected by monopoly rights awarded upon Food and Drug Administration approval and by patents. The availability of generic drugs after this exclusivity period is the main means of reducing prices in the United States, but access to them may be delayed by numerous business and legal strategies. The primary counterweight against excessive pricing during market exclusivity is the negotiating power of the payer, which is currently constrained by several factors, including the requirement that most government drug payment plans cover nearly all products. Another key contributor to drug spending is physician prescribing choices when comparable alternatives are available at different costs. Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear. CONCLUSIONS AND RELEVANCE High drug prices are the result of the approach the United States has taken to granting government-protected monopolies to drug manufacturers, combined with coverage requirements imposed on government-funded drug benefits. The most realistic short-term strategies to address high prices include enforcing more stringent requirements for the award and extension of exclusivity rights; enhancing competition by ensuring timely generic drug availability; providing greater opportunities for meaningful price negotiation by governmental payers; generating more evidence about comparative cost-effectiveness of therapeutic alternatives; and more effectively educating patients, prescribers, payers, and policy makers about these choices.	[Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA; [Kesselheim, Aaron S.] Harvard Med Sch, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.; Kesselheim, AS (corresponding author), Harvard Med Sch, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Liles, Nathan W/C-9819-2018; Kesselheim, Aaron/R-6793-2017	Liles, Nathan W/0000-0002-3710-7296; Kesselheim, Aaron/0000-0002-8867-2666	Laura and John Arnold Foundation; Engelberg Foundation	Laura and John Arnold Foundation; Engelberg Foundation	This work was funded by a grant from the Laura and John Arnold Foundation. Additional support was provided by the Engelberg Foundation.	Allan GM, 2007, PLOS MED, V4, P1486, DOI 10.1371/journal.pmed.0040283; Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; Altman D, 2015, WASHINGTON POST; Anell A., 2008, INT PROFILES HLTH CA, P46; [Anonymous], 2012, CONSUMER REPORTS; [Anonymous], 2015, WALL STREET J; Arno Peter S., 2001, TULANE LAW REV, V75, P631; ASPE, 2016, OBS TRENDS PRESCR DR; Avorn J, 2015, NEW ENGL J MED, V373, P967, DOI 10.1056/NEJMhle1506365; Avorn J, 2015, NEW ENGL J MED, V372, P1877, DOI 10.1056/NEJMp1500848; Azoulay P, 2002, J ECON MANAGE STRAT, V11, P551, DOI 10.1111/j.1430-9134.2002.00551.x; Bach PB, 2015, JAMA-J AM MED ASSOC, V314, P2503, DOI 10.1001/jama.2015.16843; Bach PB, 2014, JAMA-J AM MED ASSOC, V312, P1629, DOI 10.1001/jama.2014.13235; Barua S, 2015, ANN INTERN MED, V163, P215, DOI 10.7326/M15-0406; Brekke KR, 2016, J HLTH EC, P30021; Bureau of Consumer Protection, 1979, STAFF REP FED TRAD C; Bureau of Labor Statistics, 2016, DAT TABL CALC SUBJ; Burns LR, 2009, HEALTH AFFAIR, V28, pW76, DOI 10.1377/hlthaff.28.1.w76; Canary LA, 2015, ANN INTERN MED, V163, P226, DOI 10.7326/M15-0320; Chalkidou K, 2009, COMP EFFECTIVENESS R; Chandra A, 2016, JAMA-J AM MED ASSOC, V315, P2069, DOI 10.1001/jama.2016.4915; Chokshi DA, 2014, NEW ENGL J MED, V371, P297, DOI 10.1056/NEJMp1406868; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Choudhry NK, 2010, HEALTH AFFAIR, V29, P1995, DOI 10.1377/hlthaff.2010.0336; Claxton G, 2015, HEALTH AFFAIR, V34, P1779, DOI 10.1377/hlthaff.2015.0885; Cohen RA, 2015, EARLY RELEASE SELECT; Community Catalyst, 2005, RE NEX CONS PAYOR AD; Conti RM, 2016, NEW ENGL J MED, V374, P703, DOI 10.1056/NEJMp1515068; Daniel H, 2016, ANN INTERN MED, V165, P50, DOI 10.7326/M15-2768; DiJulio B, 2015, KAISER HLTH TRACKING; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; DiMasi JA, 2015, NEW ENGL J MED, V372, P1972, DOI 10.1056/NEJMc1504317; Directorate-General for Internal Policies, 2011, DIFF COSTS ACC PHARM; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Dusetzina SB, 2016, JAMA ONCOL, V2, P960, DOI 10.1001/jamaoncol.2016.0648; Express Scripts, 2015, 2015 DRUG TREND REP; Federal Trade Commission, 2010, PAY FOR DEL DRUG CO; Findlay SD, 2006, HEALTH AFFAIR, V25, pW283, DOI 10.1377/hlthaff.25.w283; Fischer MA, 2012, HEALTH AFFAIR, V31, P2206, DOI 10.1377/hlthaff.2012.0817; Fisher LM, 1994, NY TIMES; Food and Drug Administration, 2016, PED EXCL GRANT; Frakt AB, 2008, J HEALTH POLIT POLIC, V33, P1079, DOI 10.1215/03616878-2008-032; Fung V, 2013, HEALTH SERV RES, V48, P1653, DOI 10.1111/1475-6773.12062; Gabble R, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-3; Gagne JJ, 2014, ANN INTERN MED, V161, P400, DOI 10.7326/M13-2942; Gastala NM, 2016, HEALTH AFFAIR, V35, P1237, DOI 10.1377/hlthaff.2016.0146; Generic Pharmaceutical Association, 2015, GEN DRUG SAV US; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Government Accountability Office, 2012, DRUG PRIC RES SAV GE; Grabowski H, 2016, J MED ECON, V20, P1; Greene JA, 2016, JAMA-J AM MED ASSOC, V315, P461, DOI 10.1001/jama.2015.18720; Hawkins N, 2011, HEALTH ECON, V20, P688, DOI 10.1002/hec.1625; Hayes JM, 2005, JAMA-J AM MED ASSOC, V294, P427, DOI 10.1001/jama.294.4.427-b; Hemphill CS, 2006, NEW YORK U LAW REV, V81, P1553; Hennessy S, 2010, CLIN PHARMACOL THER, V87, P157, DOI 10.1038/clpt.2009.249; Henry J Kaiser Family Foundation, 2015, 2015 EMPL HLTH BEN S; Henry J Kaiser Family Foundation, 2016, TOT MONTHL MED CHIP; Herefordshire CCG., 2016, USE MED ASSURANCE SC; Hirschler B., 2015, REUTERS; Hollis A, 2016, PHARMACOECONOMICS, V34, P971, DOI 10.1007/s40273-016-0416-x; Howard DH, 2015, J ECON PERSPECT, V29, P139, DOI 10.1257/jep.29.1.139; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Hua XY, 2016, JAMA-J AM MED ASSOC, V315, P1400, DOI 10.1001/jama.2016.0126; IMS Institute for Health Informatics, 2014, ASS BIOS UPT COMP EU; IMS Institute for Healthcare Informatics, 2013, AV COSTS US HEALTHC; Jacobs DB, 2015, NEW ENGL J MED, V372, P399, DOI 10.1056/NEJMp1411376; Jena AB, 2015, JAMA INTERN MED, V175, P1171, DOI 10.1001/jamainternmed.2015.1665; Jung K, 2014, HEALTH SERV RES, V49, P910, DOI 10.1111/1475-6773.12145; Kaitin KI, 2011, CLIN PHARMACOL THER, V89, P183, DOI 10.1038/clpt.2010.286; Kanavos P, 2013, HEALTH AFFAIR, V32, P753, DOI 10.1377/hlthaff.2012.0920; Kantarjian H, 2015, MAYO CLIN PROC, V90, P500, DOI 10.1016/j.mayocp.2015.01.014; Kapczynski A, 2016, HEALTH AFFAIR, V35, P791, DOI 10.1377/hlthaff.2015.1120; Kapczynski A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049470; Keehan SP, 2015, HEALTH AFFAIR, V34, P1407, DOI 10.1377/hlthaff.2015.0600; Kesselheim AS, 2015, J GEN INTERN MED, V30, P1633, DOI 10.1007/s11606-015-3285-7; Kesselheim AS, 2015, HEALTH AFFAIR, V34, P286, DOI 10.1377/hlthaff.2014.1038; Keyhani S, 2006, HEALTH AFFAIR, V25, P461, DOI 10.1377/hlthaff.25.2.461; Keyhani S, 2010, AM J PUBLIC HEALTH, V100, P1075, DOI 10.2105/AJPH.2009.178491; Kneller R, 2010, NAT REV DRUG DISCOV, V9, P867, DOI 10.1038/nrd3251; LaMattina J., 2016, FORBES          0518; Langreth R., 2015, BLOOMBERG BUSINESS; Lee TH, 2008, NEW ENGL J MED, V359, P333, DOI 10.1056/NEJMp0804261; Leonard K., 2015, US NEWS WORLD REPORT; Li JS, 2007, JAMA-J AM MED ASSOC, V297, P480, DOI 10.1001/jama.297.5.480; Lichtenberg FR, 2002, J LAW ECON, V45, P643, DOI 10.1086/374703; Light DW, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4348; Loftus P., 2014, WALL STREET J; Love J., 2014, NONVOLUNTARY USE PAT; Mailankody S, 2016, JAMA-J AM MED ASSOC, V316, P271, DOI 10.1001/jama.2016.5998; Mailankody S, 2015, JAMA ONCOL, V1, P539, DOI 10.1001/jamaoncol.2015.0373; Martinez B, WALL STREET J; Megerlin F, 2013, HEALTH AFFAIR, V32, P1803, DOI 10.1377/hlthaff.2009.0196; Menges Group, 2015, AN MED COSTS US SEL; Mintzes B, 2003, CAN MED ASSOC J, V169, P405; Moses H, 2015, JAMA-J AM MED ASSOC, V313, P174, DOI 10.1001/jama.2014.15939; Najafzadeh M, 2015, ANN INTERN MED, V162, P407, DOI 10.7326/M14-1152; Neumann PJ, 2006, HEALTH AFFAIR, V25, pW262, DOI 10.1377/hlthaff.25.w262; Neumann PJ, 2015, NEW ENGL J MED, V373, P2595, DOI 10.1056/NEJMp1512009; Newcomer LN, 2012, HEALTH AFFAIR, V31, P780, DOI 10.1377/hlthaff.2012.0002; Niederdeppe J, 2013, J GEN INTERN MED, V28, P886, DOI 10.1007/s11606-013-2379-3; O'Brien E., 2015, WHY DRUG PRICES REMA; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; O'Donnell JC, 2009, VALUE HEALTH, V12, pS1, DOI 10.1111/j.1524-4733.2009.00550.x; Obama B, 2016, JAMA-J AM MED ASSOC, V316, P525, DOI 10.1001/jama.2016.9797; Office of the Assistant Secretary for Planning and Evaluation Department of Health and Human Services, 2015, SOM OBS REL GEN DRUG; Oliver TR, 2004, MILBANK Q, V82, P283, DOI 10.1111/j.0887-378X.2004.00311.x; Organisation for Economic Co-operation and Development, 2015, HLTH GLANC 2015 OECD; Outterson K, 2009, HEALTH AFFAIR, V28, pW832, DOI 10.1377/hlthaff.28.5.w832; Pollack A., 2014, NY TIMES; Pollack A, 2015, NY TIMES, pB2; Pollack Andrew, 2016, NY TIMES; Quon BS, 2005, ANN INTERN MED, V143, P397, DOI 10.7326/0003-4819-143-6-200509200-00004; Ramsey SD, 2015, HEALTH AFFAIR, V34, P571, DOI 10.1377/hlthaff.2015.0112; Reinhardt U, 2015, JAMA-J AM MED ASSOC, V314, P981, DOI 10.1001/jama.2015.9593; Reinke T, 2012, FREE STATINS DISRUPT; Robinson J. C., 2013, Annales Pharmaceutiques Francaises, V71, P285, DOI 10.1016/j.pharma.2013.08.003; Rockoff Jonathan D., 2015, WALL STREET J; Ross JS, 2013, NEW ENGL J MED, V369, P1188, DOI 10.1056/NEJMp1301993; Sachs J, 2015, HUFFINGTON POST; Saku K, 2011, CIRC J, V75, P1493, DOI 10.1253/circj.CJ-10-1281; Saltz LB, 2016, JAMA ONCOL, V2, P19, DOI 10.1001/jamaoncol.2015.4191; Sarpatwari A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001955; Sarpatwari A, 2014, NEW ENGL J MED, V370, P1476, DOI 10.1056/NEJMp1400488; Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681; Schnipper LE, 2015, J CLIN ONCOL, V33, P2563, DOI 10.1200/JCO.2015.61.6706; Schulte F., 2015, OBAMACARE RES I PLAN; Selby JV, 2012, JAMA-J AM MED ASSOC, V307, P1583, DOI 10.1001/jama.2012.500; Shajarizadeh A, 2015, HEALTH ECON, V24, P966, DOI 10.1002/hec.3075; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; Silverman E., 2012, FORBES; Sorenson C, 2014, J HEALTH POLIT POLIC, V39, P139, DOI 10.1215/03616878-2395199; Stabile M, 2013, HEALTH AFFAIR, V32, P643, DOI 10.1377/hlthaff.2012.1252; Starner CI, 2014, HEALTH AFFAIR, V33, P1761, DOI 10.1377/hlthaff.2014.0497; Treasure CL, 2015, MILBANK Q, V93, P761, DOI 10.1111/1468-0009.12164; Tucker RJ, 2015, MONDAQ          0519; Ubel PA, 2013, NEW ENGL J MED, V369, P1484, DOI 10.1056/NEJMp1306826; US Congressional Budget Office, 2005, PRIC BRAND NAM DRUGS; US Senate Committee on Finance, 2015, PRIC SOV ITS IMP US; Vogler S, 2016, LANCET ONCOL, V17, P39, DOI 10.1016/S1470-2045(15)00449-0; Walker J, 2016, WALL STREET J; Wang B, 2015, JAMA INTERN MED, V175, P635, DOI 10.1001/jamainternmed.2014.7968; Weisman R, 2014, BOSTON GLOBE; Wharton GT, 2014, PEDIATRICS, V134, pE512, DOI 10.1542/peds.2013-2987; Wiske CP, 2015, JAMA-J AM MED ASSOC, V314, P2129, DOI 10.1001/jama.2015.13498; Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220	147	381	383	4	186	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2016	316	8					858	871		10.1001/jama.2016.11237	http://dx.doi.org/10.1001/jama.2016.11237			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DT8JL	27552619				2023-01-03	WOS:000381736200016
J	Schuckit, MA				Schuckit, Marc A.			Treatment of Opioid-Use Disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXTENDED-RELEASE NALTREXONE; RANDOMIZED CONTROLLED-TRIAL; MAINTENANCE TREATMENT; METHADONE-MAINTENANCE; HEROIN USERS; SUBSTITUTION TREATMENT; ORAL NALTREXONE; DRUG-USE; BUPRENORPHINE; MORTALITY		[Schuckit, Marc A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Schuckit, MA (corresponding author), Univ Calif San Diego, 8950 Villa La Jolla Dr,B-218, La Jolla, CA 92037 USA.	mschuckit@ucsd.edu						Amato L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003409.pub4; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, P541; [Anonymous], 2009, BUPR RES GUID; [Anonymous], 2011, METH MAINT TREATM PR; Bell JR, 2009, DRUG ALCOHOL DEPEN, V104, P73, DOI 10.1016/j.drugalcdep.2009.03.020; Bentzley BS, 2015, J SUBST ABUSE TREAT, V52, P48, DOI 10.1016/j.jsat.2014.12.011; Brady KT, 2016, AM J PSYCHIAT, V173, P18, DOI 10.1176/appi.ajp.2015.15020262; Center for Behavioral Health Statistics and Quality, 2015, BEH HLTH TRENDS US R, P7; Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, V61, P133; Chavkin C, 2011, NEUROPSYCHOPHARMACOL, V36, P369, DOI 10.1038/npp.2010.137; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Cousins G, 2016, ADDICTION, V111, P73, DOI 10.1111/add.13087; D'Aunno T, 2014, J SUBST ABUSE TREAT, V47, P245, DOI 10.1016/j.jsat.2014.06.001; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Darke S, 2015, J STUD ALCOHOL DRUGS, V76, P909, DOI 10.15288/jsad.2015.76.909; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Degenhardt L, 2015, DRUG ALCOHOL REV, V34, P90, DOI 10.1111/dar.12205; Degenhardt L, 2014, ADDICTION, V109, P1306, DOI 10.1111/add.12536; Degenhardt L, 2014, DRUG ALCOHOL REV, V33, P4, DOI 10.1111/dar.12088; Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851; Evans E, 2015, ADDICTION, V110, P996, DOI 10.1111/add.12863; Faggiano F., 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002208, DOI 10.1002/14651858.CD002208]; Fareed A, 2010, AM J DRUG ALCOHOL AB, V36, P332, DOI 10.3109/00952990.2010.505991; Friedmann PD, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-10; Gowing L, 2014, COCHRANE DB SYST REV, V3; Gowing L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub4; Heit HA, 2008, CLIN J PAIN, V24, P93, DOI 10.1097/AJP.0b013e31815ca2b4; Hser YI, 2014, ADDICTION, V109, P79, DOI 10.1111/add.12333; Huang CLC, 2013, J SUBST ABUSE TREAT, V44, P295, DOI 10.1016/j.jsat.2012.08.003; Hulse GK, 2010, BIOL PSYCHIAT, V68, P296, DOI 10.1016/j.biopsych.2010.04.003; Humphreys K, 2014, ALCOHOL CLIN EXP RES, V38, P2688, DOI 10.1111/acer.12557; Johansson BA, 2006, ADDICTION, V101, P491, DOI 10.1111/j.1360-0443.2006.01369.x; Johnson B, 2015, INT J DRUG POLICY, V26, P183, DOI 10.1016/j.drugpo.2014.10.003; Kowalczyk WJ, 2015, AM J PSYCHIAT, V172, P760, DOI 10.1176/appi.ajp.2014.14081014; Krantz MJ, 2009, ANN INTERN MED, V150, P387, DOI 10.7326/0003-4819-150-6-200903170-00103; Krupitsky E, 2012, ARCH GEN PSYCHIAT, V69, P973, DOI 10.1001/archgenpsychiatry.2012.1a; Lapham SC, 2011, J ADDICT MED, V5, P163, DOI 10.1097/ADM.0b013e3181eb3b89; Launonen E, 2015, INT J DRUG POLICY, V26, P875, DOI 10.1016/j.drugpo.2015.03.007; Lavonas EJ, 2014, J SUBST ABUSE TREAT, V47, P27, DOI 10.1016/j.jsat.2014.02.003; Lee JD, 2015, ADDICTION, V110, P1008, DOI 10.1111/add.12894; Leece P, 2015, J SUBST ABUSE TREAT, V57, P30, DOI 10.1016/j.jsat.2015.04.008; Lintzeris N, 2013, DRUG ALCOHOL DEPEN, V131, P119, DOI 10.1016/j.drugalcdep.2012.12.009; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mitchell MC, 2012, J STUD ALCOHOL DRUGS, V73, P991, DOI 10.15288/jsad.2012.73.991; Nielsen S, 2015, J SUBST ABUSE TREAT, V48, P70, DOI 10.1016/j.jsat.2014.06.006; Nosyk B, 2014, DRUG ALCOHOL DEPEN, V143, P149, DOI 10.1016/j.drugalcdep.2014.07.020; O'Connor PG, 2005, JAMA-J AM MED ASSOC, V294, P961, DOI 10.1001/jama.294.8.961; OBrien CP, 2011, GOODMAN GILMANS PHAR, P649; Park TW, 2015, ADDICTION, V110, P1476, DOI 10.1111/add.13020; Pierce M, 2016, ADDICTION, V111, P298, DOI 10.1111/add.13193; Pinto H, 2010, J SUBST ABUSE TREAT, V39, P340, DOI 10.1016/j.jsat.2010.07.009; Pollack HA, 2008, HEALTH SERV RES, V43, P2143, DOI 10.1111/j.1475-6773.2008.00870.x; Potter JS, 2013, J STUD ALCOHOL DRUGS, V74, P605, DOI 10.15288/jsad.2013.74.605; Schuckit MA, 2009, LANCET, V373, P492, DOI 10.1016/S0140-6736(09)60009-X; SENAY EC, 1977, ARCH GEN PSYCHIAT, V34, P361; Sigmon SC, 2013, JAMA PSYCHIAT, V70, P1347, DOI 10.1001/jamapsychiatry.2013.2216; Sigmon SC, 2012, AM J DRUG ALCOHOL AB, V38, P187, DOI 10.3109/00952990.2011.653426; Soyka M, 2015, SUBST ABUSE REHABIL, V6, P1, DOI 10.2147/SAR.S45585; Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment, 2004, CLIN GUID US BUPR TR; Substance Abuse and Mental Health Services Administration (SAMHSA), 2015, FED GUID OP TREATM P; Sullivan LE, 2008, ANN INTERN MED, V148, P662, DOI 10.7326/0003-4819-148-9-200805060-00006; Teesson M, 2015, ADDICTION, V110, P986, DOI 10.1111/add.12860; Vasilaki EI, 2006, ALCOHOL ALCOHOLISM, V41, P328, DOI 10.1093/alcalc/agl016; Wesson DR, 2003, J PSYCHOACTIVE DRUGS, V35, P253, DOI 10.1080/02791072.2003.10400007; Whiteside GT, 2013, RES DEV OPIOID RELAT, P326; Wright NMJ, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X613106; Yaksh T., 2011, GOODMAN GILMANS PHAR, P481	67	281	283	1	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2016	375	4					357	368		10.1056/NEJMra1604339	http://dx.doi.org/10.1056/NEJMra1604339			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS0UV	27464203	Bronze, Green Published			2023-01-03	WOS:000380313200009
J	Ignatiadis, M; Zardavas, D; Lemort, M; Wilke, C; Vanderbeeken, MC; D'Hondt, V; De Azambuja, E; Gombos, A; Lebrun, F; Dal Lago, L; Bustin, F; Maetens, M; Ameye, L; Veys, I; Michiels, S; Paesmans, M; Larsimont, D; Sotiriou, C; Nogaret, JM; Piccart, M; Awada, A				Ignatiadis, Michail; Zardavas, Dimitrios; Lemort, Marc; Wilke, Celine; Vanderbeeken, Marie-Catherine; D'Hondt, Veronique; De Azambuja, Evandro; Gombos, Andrea; Lebrun, Fabienne; Dal Lago, Lissandra; Bustin, Fanny; Maetens, Marion; Ameye, Lieveke; Veys, Isabelle; Michiels, Stefan; Paesmans, Marianne; Larsimont, Denis; Sotiriou, Christos; Nogaret, Jean-Marie; Piccart, Martine; Awada, Ahmad			Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer	PLOS ONE			English	Article							SURGICAL ADJUVANT BREAST; NEOADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; PATHOLOGICAL RESPONSE; SYSTEMIC TREATMENT; TRIAL; MRI; DISEASE; B-18	Background EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) in combination with paclitaxel. Methods HER2-negative BC patients candidates for neoadjuvant chemotherapy were scheduled to receive 12 cycles of weekly EndoTAG-1 22mg/m(2) plus paclitaxel 70mg/m(2) followed by 3 cycles of FEC (Fluorouracil 500mg/m(2), Epirubicin 100mg/m(2), Cyclophosphamide 500mg/m(2)) every 3 weeks followed by surgery. Primary endpoint was percent (%) reduction in Magnetic Resonance Imaging (MRI) estimated Gadolinium (Gd) enhancing tumor volume at the end of EndoTAG-1 plus paclitaxel administration as compared to baseline. Safety, pathological complete response (pCR) defined as no residual tumor in breast and axillary nodes at surgery and correlation between % reduction in MRI estimated tumor volume and pCR were also evaluated. Results Fifteen out of 20 scheduled patients were included: Six patients with estrogen receptor (ER)-negative/HER2-negative and 9 with ER-positive/HER2-negative BC. Nine patients completed treatment as per protocol. Despite premedication and slow infusion rates, grade 3 hypersensitivity reactions to EndoTAG-1 were observed during the 1st, 2nd, 3rd and 6th weekly infusion in 4 patients, respectively, and required permanent discontinuation of the EndoTAG-1. Moreover, two additional patients stopped EndoTAG-1 plus paclitaxel after 8 and 9 weeks due to clinical disease progression. Two patients had grade 3 increases in transaminases and 1 patient grade 4 neutropenia. pCR was achieved in 5 of the 6 ER-/HER2- and in none of the 9 ER+/HER2-BC patients. The mean % reduction in MRI estimated tumor volume at the end of EndoTAG-1 plus paclitaxel treatment was 81% (95% CI, 66% to 96%, p<0.001) for the 15 patients that underwent surgery; 96% for patients with pCR and 73% for patients with no pCR (p = 0.04). Conclusions The EndoTAG-1 and paclitaxel combination showed promising preliminary activity as pre-operative treatment, especially in ER-/HER2- patients. Further studies are warranted with need of premedication optimization.	[Ignatiadis, Michail; Vanderbeeken, Marie-Catherine; D'Hondt, Veronique; De Azambuja, Evandro; Gombos, Andrea; Lebrun, Fabienne; Dal Lago, Lissandra; Bustin, Fanny; Sotiriou, Christos; Piccart, Martine; Awada, Ahmad] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium; [Ignatiadis, Michail; Maetens, Marion; Sotiriou, Christos; Piccart, Martine] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium; [Zardavas, Dimitrios; Piccart, Martine] Breast Int Grp BIG Aisbl, Brussels, Belgium; [Lemort, Marc; Paesmans, Marianne] Univ Libre Bruxelles, Inst Jules Bordet, Dept Radiol, Brussels, Belgium; [Wilke, Celine] Medigene AG, Planegg, Germany; [Ameye, Lieveke] Univ Libre Bruxelles, Inst Jules Bordet, Dept Biostat, Brussels, Belgium; [Veys, Isabelle; Nogaret, Jean-Marie] Univ Libre Bruxelles, Inst Jules Bordet, Dept Surg, Brussels, Belgium; [Michiels, Stefan] Univ Paris 11, Serv Biostat & Epidemiol, Gustave Roussy, Villejuif, France; [Larsimont, Denis] Univ Libre Bruxelles, Inst Jules Bordet, Dept Pathol, Brussels, Belgium	Institut Jules Bordet; Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles; Breast International Group; Institut Jules Bordet; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Institut Jules Bordet; Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut Jules Bordet; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles	Ignatiadis, M (corresponding author), Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium.; Ignatiadis, M (corresponding author), Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium.	michail.ignatiadis@bordet.be	AWADA, AHMAD/ABF-1137-2020; Michiels, Stefan/L-1516-2013	Michiels, Stefan/0000-0002-6963-2968; de Azambuja, Evandro/0000-0001-9501-4509; D'Hondt, Veronique/0000-0001-5238-4032	Medigene AG; IJB	Medigene AG; IJB	IJB was the sponsor of this study and Medigene AG provided the EndoTAG-1 and an educational grant. Medigene AG provided support in the form of salaries for author CW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Ades F, 2014, CURR OPIN ONCOL, V26, P334, DOI 10.1097/CCO.0000000000000076; Awada A, 2014, ANN ONCOL, V25, P824, DOI 10.1093/annonc/mdu025; Chollet P, 2002, BRIT J CANCER, V86, P1041, DOI 10.1038/sj/bjc/6600210; Cortazar P, 2014, LANCET; De los Santos JF, 2013, CANCER-AM CANCER SOC, V119, P1776, DOI 10.1002/cncr.27995; Delille JP, 2003, RADIOLOGY, V228, P63, DOI 10.1148/radiol.2281011303; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Gralow JR, 2008, J CLIN ONCOL, V26, P814, DOI 10.1200/JCO.2007.15.3510; Hylton NM, 2012, RADIOLOGY, V263, P663, DOI 10.1148/radiol.12110748; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014; Li X, 2014, MAGN RESON MED, V71, P1592, DOI 10.1002/mrm.24782; Loo CE, 2011, J CLIN ONCOL, V29, P660, DOI 10.1200/JCO.2010.31.1258; Pickles MD, 2005, BREAST CANCER RES TR, V91, P1, DOI 10.1007/s10549-004-5819-2; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Wolmark N, 2001, J Natl Cancer Inst Monogr, P96; Zardavas D, ANN REV MED	23	17	18	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2016	11	7							e0154009	10.1371/journal.pone.0154009	http://dx.doi.org/10.1371/journal.pone.0154009			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5ID	27454930	Green Published, gold, Green Submitted			2023-01-03	WOS:000381515200001
J	Wong, FSY; Wong, CCH; Chan, BP; Lo, ACY				Wong, Francisca S. Y.; Wong, Calvin C. H.; Chan, Barbara P.; Lo, Amy C. Y.			Sustained Delivery of Bioactive GDNF from Collagen and Alginate-Based Cell-Encapsulating Gel Promoted Photoreceptor Survival in an Inherited Retinal Degeneration Model	PLOS ONE			English	Article							CILIARY NEUROTROPHIC FACTOR; RAT MODEL; GENE-THERAPY; PIGMENT-EPITHELIUM; GANGLION-CELLS; STEM-CELLS; SECRETION; DYSTROPHY; NEUROPROTECTION; MICROSPHERES	Encapsulated-cell therapy (ECT) is an attractive approach for continuously delivering freshly synthesized therapeutics to treat sight-threatening posterior eye diseases, circumventing repeated invasive intravitreal injections and improving local drug availability clinically. Composite collagen-alginate (CAC) scaffold contains an interpenetrating network that integrates the physical and biological merits of its constituents, including biocompatibility, mild gelling properties and availability. However, CAC ECT properties and performance in the eye are not well-understood. Previously, we reported a cultured 3D CAC system that supported the growth of GDNF-secreting HEK293 cells with sustainable GDNF delivery. Here, the system was further developed into an intravitreally injectable gel with 1x10(4) or 2x10(5) cells encapsulated in 2mg/ml type I collagen and 1% alginate. Gels with lower alginate concentration yielded higher initial cell viability but faster spheroid formation while increasing initial cell density encouraged cell growth. Continuous GDNF delivery was detected in culture and in healthy rat eyes for at least 14 days. The gels were well-tolerated with no host tissue attachment and contained living cell colonies. Most importantly, gel-implanted in dystrophic Royal College of Surgeons rat eyes for 28 days retained photoreceptors while those containing higher initial cell number yielded better photoreceptor survival. CAC ECT gels offers flexible system design and is a potential treatment option for posterior eye diseases.	[Wong, Francisca S. Y.; Wong, Calvin C. H.; Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China; [Chan, Barbara P.] Univ Hong Kong, Fac Engn, Dept Mech Engn, Tissue Engn Lab, Hong Kong, Hong Kong, Peoples R China; [Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Lo, ACY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.; Lo, ACY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China.	amylo@hku.hk	Chan, Barbara Pui/AAM-7767-2020; Lo, Amy C. Y./C-1195-2009	Lo, Amy C. Y./0000-0003-4239-6851; Chan, BP/0000-0001-5419-2472	Hong Kong Research Grant Council, GRF [HKU773613M]; University of Hong Kong Seed Funding Programme for Basic Research [201011159005]	Hong Kong Research Grant Council, GRF(Hong Kong Research Grants Council); University of Hong Kong Seed Funding Programme for Basic Research(University of Hong Kong)	Funded by Hong Kong Research Grant Council, http://www.ugc.edu.hk/eng/rgc/, Grant number: GRF #HKU773613M and The University of Hong Kong Seed Funding Programme for Basic Research, http://www.rss.hku.hk/fund/seed-basic, Grant number: 201011159005. Both funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberch J, 2002, BRAIN RES BULL, V57, P817, DOI 10.1016/S0361-9230(01)00775-4; Andrieu-Soler C, 2005, MOL VIS, V11; Baniasadi M, 2015, MATERIALS, V8, P799, DOI 10.3390/ma8020799; Baruch L, 2006, BIOPOLYMERS, V82, P570, DOI 10.1002/bip.20509; Bohari SPM, 2011, BIO-MED MATER ENG, V21, P159, DOI 10.3233/BME-2011-0665; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; Brun-Graeppi AKAS, 2011, J CONTROL RELEASE, V149, P209, DOI 10.1016/j.jconrel.2010.09.023; Brundin P, 2002, BRAIN, V125, P2149, DOI 10.1093/brain/awf217; Buch PK, 2006, MOL THER, V14, P700, DOI 10.1016/j.ymthe.2006.05.019; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; Capone SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062032; CHANG TMS, 1968, NATURE, V218, P243, DOI 10.1038/218243a0; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; da Cunha CB, 2014, BIOMATERIALS, V35, P8927, DOI 10.1016/j.biomaterials.2014.06.047; de Guzman RC, 2008, J MICROENCAPSUL, V25, P487, DOI 10.1080/02652040802054745; Durrschmid M, 2003, BIOTECHNOL BIOENG, V83, P681, DOI 10.1002/bit.10700; Ejstrup R, 2010, EXP EYE RES, V91, P890, DOI 10.1016/j.exer.2010.09.016; Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338; Gregory-Evans K, 2009, MOL VIS, V15, P962; Ikeda T, 2002, INT J DEV NEUROSCI, V20, P555, DOI 10.1016/S0736-5748(02)00082-5; Ishikawa H, 2005, GENE THER, V12, P289, DOI 10.1038/sj.gt.3302277; Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371; Jiang C, 2007, MOL VIS, V13, P1783; Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970; Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004; Kyhn MV, 2009, EXP EYE RES, V89, P1012, DOI 10.1016/j.exer.2009.08.014; Lawrence JM, 2004, INVEST OPHTH VIS SCI, V45, P267, DOI 10.1167/iovs.03-0093; Lee M, 2009, BIOMATERIALS, V30, P1214, DOI 10.1016/j.biomaterials.2008.11.017; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Marsich E, 2008, J BIOMED MATER RES A, V84A, P364, DOI 10.1002/jbm.a.31307; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539; Patel NK, 2007, ACTA NEUROCHIR SUPPL, V97, P135; Read SP, 2010, MOL THER, V18, P1917, DOI 10.1038/mt.2010.167; Rokstad AMA, 2014, ADV DRUG DELIVER REV, V67-68, P111, DOI 10.1016/j.addr.2013.07.010; Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498; Sang L, 2010, J MATER SCI-MATER M, V21, P2561, DOI 10.1007/s10856-010-4117-2; Santos E, 2012, J CONTROL RELEASE, V158, P443, DOI 10.1016/j.jconrel.2011.09.079; Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135; Thanos CG, 2007, J BIOMED MATER RES A, V83A, P216, DOI 10.1002/jbm.a.31472; Thanos CG, 2004, TISSUE ENG, V10, P1617, DOI 10.1089/ten.2004.10.1617; Touchard E, 2012, GENE THER, V19, P886, DOI 10.1038/gt.2011.154; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; Ward MS, 2007, J PHARM SCI-US, V96, P558, DOI 10.1002/jps.20629; Wong FSY, 2014, INT J MOL SCI, V15, P10669, DOI 10.3390/ijms150610669; Wong FSY, CURRENT TISSUE ENG, V4; Wong HL, 2007, BIOMATERIALS, V28, P5369, DOI 10.1016/j.biomaterials.2007.08.016; Wu WC, 2004, MOL VIS, V10, P93; Wu WC, 2002, INVEST OPHTH VIS SCI, V43, P3480; Yang K, 2012, BIOMATERIALS, V33, P6952, DOI 10.1016/j.biomaterials.2012.06.067	51	14	14	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2016	11	7							e0159342	10.1371/journal.pone.0159342	http://dx.doi.org/10.1371/journal.pone.0159342			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS5CG	27441692	Green Published, gold, Green Submitted			2023-01-03	WOS:000380797500057
J	Greene, AC; Henderson, IM; Gomez, A; Paxton, WF; VanDelinder, V; Bachand, GD				Greene, Adrienne C.; Henderson, Ian M.; Gomez, Andrew; Paxton, Walter F.; VanDelinder, Virginia; Bachand, George D.			The Role of Membrane Fluidization in the Gel-Assisted Formation of Giant Polymersomes	PLOS ONE			English	Article							UNILAMELLAR VESICLES; DRUG-DELIVERY; MODEL SYSTEMS; LIPOSOMES; COPOLYMERS; NETWORKS; FILMS	Polymersomes are being widely explored as synthetic analogs of lipid vesicles based on their enhanced stability and potential uses in a wide variety of applications in (e.g., drug delivery, cell analogs, etc.). Controlled formation of giant polymersomes for use in membrane studies and cell mimetic systems, however, is currently limited by low-yield production methodologies. Here, we describe for the first time, how the size distribution of giant poly(ethylene glycol)-poly(butadiene) (PEO-PBD) polymersomes formed by gel-assisted rehydration may be controlled based on membrane fluidization. We first show that the average diameter and size distribution of PEO-PBD polymersomes may be readily increased by increasing the temperature of the rehydration solution. Further, we describe a correlative relationship between polymersome size and membrane fluidization through the addition of sucrose during rehydration, enabling the formation of PEO-PBD polymersomes with a range of diameters, including giant-sized vesicles (>100 mu m). This correlative relationship suggests that sucrose may function as a small molecule fluidizer during rehydration, enhancing polymer diffusivity during formation and increasing polymersome size. Overall the ability to easily regulate the size of PEO-PBD polymersomes based on membrane fluidity, either through temperature or fluidizers, has broadly applicability in areas including targeted therapeutic delivery and synthetic biology.	[Greene, Adrienne C.; Henderson, Ian M.; Paxton, Walter F.; VanDelinder, Virginia; Bachand, George D.] Sandia Natl Labs, Ctr Integrated Nanotechnol, POB 5800, Albuquerque, NM 87185 USA; [Gomez, Andrew] Sandia Natl Labs, Ctr Mat Sci & Engn, Albuquerque, NM USA	United States Department of Energy (DOE); Sandia National Laboratories; United States Department of Energy (DOE); Sandia National Laboratories	Bachand, GD (corresponding author), Sandia Natl Labs, Ctr Integrated Nanotechnol, POB 5800, Albuquerque, NM 87185 USA.	gdbacha@sandia.gov	Paxton, Walter/AAP-8682-2021	Paxton, Walter/0000-0002-2438-4542; Greene, Adrienne/0000-0003-0270-3351; Bachand, George/0000-0002-3169-9980	U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering (BES-MSE); U.S. Department of Energy (DOE) Office of Science [RA2015A0004]; U.S. Department of Energy's National Nuclear Security Administration [DE-AC04-94AL85000]	U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering (BES-MSE); U.S. Department of Energy (DOE) Office of Science(United States Department of Energy (DOE)); U.S. Department of Energy's National Nuclear Security Administration(National Nuclear Security Administration)	This work was supported by the U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering (BES-MSE). The funder provided support in the form of salaries for authors [ACG, AG, WFP, GDB], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. This work was performed, in part, at the Center for Integrated Nanotechnologies, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science (user project number RA2015A0004). The funder provided support in the form of salaries for authors [IMH and VV], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000.	Amos RC, 2012, SOFT MATTER, V8, P5947, DOI 10.1039/c2sm25172h; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Bermudez H, 2002, MACROMOLECULES, V35, P8203, DOI 10.1021/ma020669l; Christian DA, 2009, NAT MATER, V8, P843, DOI [10.1038/NMAT2512, 10.1038/nmat2512]; Dimova R, 2002, EUR PHYS J E, V7, P241, DOI [10.1007/s10189-002-8236-8, 10.1140/epje/i200101032]; Ding LP, 2010, LANGMUIR, V26, P5544, DOI 10.1021/la9038045; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Discher DE, 2006, ANNU REV BIOMED ENG, V8, P323, DOI 10.1146/annurev.bioeng.8.061505.095838; Egli S, 2011, J AM CHEM SOC, V133, P4476, DOI 10.1021/ja110275f; Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017; Hansen JS, 2013, J AM CHEM SOC, V135, P17294, DOI 10.1021/ja409708e; Henderson IM, 2014, ANGEW CHEM INT EDIT, V53, P3372, DOI 10.1002/anie.201309433; Hickey RJ, 2014, ACS NANO, V8, P495, DOI 10.1021/nn405012h; Horger KS, 2009, J AM CHEM SOC, V131, P1810, DOI 10.1021/ja805625u; Howse JR, 2009, NAT MATER, V8, P507, DOI [10.1038/NMAT2446, 10.1038/nmat2446]; Jang WS, 2016, SOFT MATTER, V12, P1014, DOI 10.1039/c5sm01881a; Jonsson P, 2008, BIOPHYS J, V95, P5334, DOI 10.1529/biophysj.108.134874; Kim KT, 2009, ADV MATER, V21, P2787, DOI 10.1002/adma.200900300; Lee JCM, 2002, MACROMOLECULES, V35, P323, DOI 10.1021/ma0112063; Liu GY, 2012, SOFT MATTER, V8, P8811, DOI 10.1039/c2sm25721a; Mabrouk E, 2009, SOFT MATTER, V5, P1870, DOI 10.1039/b815817g; Marquardt D, 2015, MEMBRANES, V5, P180, DOI 10.3390/membranes5020180; Moodley K, 2012, INT J MOL SCI, V13, P18, DOI 10.3390/ijms13010018; Najer A, 2016, CHIMIA, V70, P288, DOI 10.2533/chimia.2016.288; Pata V, 2003, BIOPHYS J, V85, P2111, DOI 10.1016/S0006-3495(03)74639-6; Paxton WF, 2015, NANOSCALE, V7, P10998, DOI 10.1039/c5nr00826c; Paxton WF, 2013, SOFT MATTER, V9, P11295, DOI 10.1039/c3sm51575c; Rodriguez-Garcia R, 2011, SOFT MATTER, V7, P1532, DOI 10.1039/c0sm00823k; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmaljohann D, 2006, ADV DRUG DELIVER REV, V58, P1655, DOI 10.1016/j.addr.2006.09.020; Streicher P, 2009, BBA-BIOMEMBRANES, V1788, P2291, DOI 10.1016/j.bbamem.2009.07.025; Tsai FC, 2011, LANGMUIR, V27, P10061, DOI 10.1021/la201604z; Tsumoto K, 2009, COLLOID SURFACE B, V68, P98, DOI 10.1016/j.colsurfb.2008.09.023; Walde P, 2010, CHEMBIOCHEM, V11, P848, DOI 10.1002/cbic.201000010; Weinberger A, 2013, BIOPHYS J, V105, P154, DOI 10.1016/j.bpj.2013.05.024; Wesolowska O, 2009, ACTA BIOCHIM POL, V56, P33	37	22	22	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2016	11	7							e0158729	10.1371/journal.pone.0158729	http://dx.doi.org/10.1371/journal.pone.0158729			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ9CP	27410487	gold, Green Published, Green Submitted			2023-01-03	WOS:000379508300033
J	Shi, YH; Quan, RF; Xie, SJ; Li, Q; Cao, GP; Zhuang, W; Zhang, L; Shao, RX; Yang, DS				Shi, Yihui; Quan, Renfu; Xie, Shangju; Li, Qiang; Cao, Guoping; Zhuang, Wei; Zhang, Liang; Shao, Rongxue; Yang, Disheng			Evaluation of a Novel HA/ZrO2-Based Porous Bioceramic Artificial Vertebral Body Combined with a rhBMP-2/Chitosan Slow-Release Hydrogel	PLOS ONE			English	Article							BONE MORPHOGENETIC PROTEIN-2; ZIRCONIA; COMPOSITE; DELIVERY; RHBMP-2; MICROSPHERES; FUSION; BMP-2	A new HA/ZrO2-based porous bioceramic artificial vertebral body (AVB), carried a recombinant human bone morphogenetic protein-2 (rhBMP-2)/chitosan slow-release hydrogel was prepared to repair vertebral bone defect in beagles. An ionic cross-linking was used to prepare the chitosan hydrogel (CS gel) as the rhBMP-2 slow-release carrier. The vertebral body defects were implanted with the rhBMP-2-loaded AVB in group A, or a non-drug-loaded AVB in group B, or autologous iliac in group C. The encapsulation rate of rhBMP-2 in rhBMP-2-loaded CS gel was 91.88 +/- 1.53%, with a drug load of 39.84 +/- 2.34 ng/mg. At 6, 12, 24 weeks postoperatively, radiography showed that the bone calluses gradually increased with time in group A, where the artificial vertebral body had completely fused with host-bone at 24 weeks after surgery. In group C, an apparent bone remodeling was occurred in the early stages, and the graft-bone and host-bone had also fused completely at 24 weeks postoperatively. In group B, fusion occurred less than in groups A and C. At 24 weeks after surgery, micro-computed tomography (Micro-CT) revealed that the volume of newly-formed bone in group A was significantly more than in group B (p<0.05). At 24 weeks after surgery, ultra-compressive strengths of the operated segments were 14.03 +/- 1.66 MPa in group A, 8.62 +/- 1.24 MPa in group B, and 13.78 +/- 1.43 MPa in group C. Groups A and C were both significantly higher than group B (p<0.05). At 24 weeks postoperatively, the hard tissue sections showed that the AVB of group A had tightly fused with host bone, and that pores of the AVB had been filled with abundant nearly mature bone, and that the new bone structured similarly to a trabecular framework, which was similar to that in group C. In contrast, implant fusion of the AVB in group B was not as apparent as group A. In conclusion, the novel HA/ZrO2-based porous bioceramic AVB carried the rhBMP-2-loaded CS gel can promote the repair of bony defect, and induce bone tissue to grow into the pores, which may replace iliac bone grafts as commonly applied in clinical practice.	[Shi, Yihui; Zhang, Liang] Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China; [Quan, Renfu; Xie, Shangju; Li, Qiang; Cao, Guoping; Zhuang, Wei] Zhejiang Chinese Med Univ, Affiliated JiangNan Hosp, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China; [Shao, Rongxue] Zhejiang Chinese Med Univ, Guangxing Hosp, Hangzhou, Zhejiang, Peoples R China; [Yang, Disheng] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang University	Quan, RF (corresponding author), Zhejiang Chinese Med Univ, Affiliated JiangNan Hosp, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.	quanrenfu@126.com			Zhejiang Key Science and Technology Project [2014CO3031]; Public Welfare Technology and Social Development Project Zhejing Science and Technology Department [2012C33114]; Hanghou Key Science and Technology Project [20122513A14]	Zhejiang Key Science and Technology Project; Public Welfare Technology and Social Development Project Zhejing Science and Technology Department; Hanghou Key Science and Technology Project	The study of "Evaluation of a novel HA/ZrO<INF>2</INF>-based porous bioceramic artificial vertebral body combined with a rhBMP-2/chitosan slow-release hydrogel" was supported by Zhejiang Key Science and Technology Project (2014CO3031); Public Welfare Technology and Social Development Project (2012C33114) Zhejing Science and Technology Department and Hanghou Key Science and Technology Project (20122513A14). All funders above were belonging to government public welfare funder. There was no author and individual employed or contracted by the funders involved in this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarrategi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034117; Abarrategi A, 2009, ACTA BIOMATER, V5, P2633, DOI 10.1016/j.actbio.2009.02.031; Alt V, 2009, EUR SPINE J, V18, P800, DOI 10.1007/s00586-009-0935-7; Branemark PI, 1985, TISSUE INTEGRATED PR, P11; Chen L, 2014, J MATER SCI-MATER M, V25, P1709, DOI 10.1007/s10856-014-5194-4; Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003-4819-158-12-201306180-00006; Hannink G, 2013, J MATER SCI-MATER M, V24, P325, DOI 10.1007/s10856-012-4802-4; Jun SH, 2013, J MATER SCI-MATER M, V24, P773, DOI 10.1007/s10856-012-4822-0; Kim H, 2012, EUR SPINE J, V21, P1324, DOI 10.1007/s00586-011-2092-z; Kim S, 2012, ACTA BIOMATER, V8, P1768, DOI 10.1016/j.actbio.2012.01.009; Matsuno T, 2000, J MATER SCI LETT, V19, P573, DOI 10.1023/A:1006722110462; MOSEKILDE L, 1986, BONE, V7, P207, DOI 10.1016/8756-3282(86)90019-0; Muller U, 2006, EUR CELLS MATER, V11, P8, DOI 10.22203/eCM.v011a02; Nayak Y, 2008, J MATER SCI-MATER M, V19, P2437, DOI 10.1007/s10856-008-3371-z; OHGUSHI H, 1993, J BIOMED MATER RES, V27, P1401, DOI 10.1002/jbm.820271107; Patel ZS, 2008, ACTA BIOMATER, V4, P1126, DOI 10.1016/j.actbio.2008.04.002; Piva RH, 2015, SCANNING, V37, P372, DOI 10.1002/sca.21221; Quan R, 2006, JOURNAL OF BIOMATERI, V23, P123; Quan RF, 2008, J MATER SCI-MATER M, V19, P183, DOI 10.1007/s10856-006-0025-x; [全仁夫 Quan Renfu], 2012, [中华创伤杂志, Chinese Journal of Trauma], V28, P946; [全仁夫 QUAN RenJu], 2006, [中华创伤杂志, Chinese Journal of Traumatology], V22, P852; Rodgers MA, 2013, BMJ-BRIT MED J, V346, P398; Ruhe PQ, 2006, J MATER SCI-MATER M, V17, P919, DOI 10.1007/s10856-006-0181-z; Seeherman H, 2005, CYTOKINE GROWTH F R, V16, P329, DOI 10.1016/j.cytogfr.2005.05.001; Shi SS, 2009, J BIOMATER APPL, V23, P331, DOI 10.1177/0885328208090013; Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72; Smucker JD, 2006, SPINE, V31, P2813, DOI 10.1097/01.brs.0000245863.52371.c2; Sollazzo V, 2008, DENT MATER, V24, P357, DOI 10.1016/j.dental.2007.06.003; Vaidya R, 2008, J SPINAL DISORD TECH, V21, P557, DOI 10.1097/BSD.0b013e31815ea897; Wang AH, 2009, J MICROENCAPSUL, V26, P593, DOI 10.3109/02652040802586167; [王玮 Wang Wei], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P4611; Woo EJ, 2011, SPINE, V36, P1817, DOI 10.1097/BRS.0b013e31822e6028; Xie SJ, 2015, COMPOS INTERFACE, V22, P151, DOI 10.1080/15685543.2015.997174; Yusop A. H., 2012, INT J BIOMATER, DOI DOI 10.1155/2012/641430; [张敏 Zhang Min], 2006, [复合材料学报, Acta Materiae Compositae Sinica], V23, P115; Zhou S.H., 2007, CHINESE J TISSUE ENG, V11, P9688	36	4	5	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2016	11	7							e0157698	10.1371/journal.pone.0157698	http://dx.doi.org/10.1371/journal.pone.0157698			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ9CN	27400197	Green Published, gold, Green Submitted			2023-01-03	WOS:000379508100003
J	Dorling, L; Kar, S; Michailidou, K; Hiller, L; Vallier, AL; Ingle, S; Hardy, R; Bowden, SJ; Dunn, JA; Twelves, C; Poole, CJ; Caldas, C; Earl, HM; Pharoah, PDP; Abraham, JE				Dorling, Leila; Kar, Siddhartha; Michailidou, Kyriaki; Hiller, Louise; Vallier, Anne-Laure; Ingle, Susan; Hardy, Richard; Bowden, Sarah J.; Dunn, Janet A.; Twelves, Chris; Poole, Christopher J.; Caldas, Carlos; Earl, Helena M.; Pharoah, Paul D. P.; Abraham, Jean E.			The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; SENSORY NEUROPATHY; PACLITAXEL; LOCI; CYCLOPHOSPHAMIDE; EPIRUBICIN; LISTS	Ninety-four common genetic variants are confirmed to be associated with breast cancer. This study tested the hypothesis that breast cancer susceptibility variants may also be associated with chemotherapy-induced toxicity through shared mechanistic pathways such as DNA damage response, an association that, to our knowledge, has not been previously investigated. The study included breast cancer patients who received neoadjuvant/adjuvant chemotherapy from the Pharmacogenetic SNPs (PGSNPS) study. For each patient, a breast cancer polygenic risk score was created from the 94 breast cancer risk variants, all of which were genotyped or successfully imputed in PGSNPS. Logistic regression was performed to test the association with two clinically important toxicities: taxane-related neuropathy (n = 1279) and chemotherapy-induced neutropenia (n = 1676). This study was well powered (>= 96%) to detect associations between polygenic risk score and chemotherapy toxicity. Patients with high breast cancer risk scores experienced less neutropenia compared to those with low risk scores (adjusted p-value = 0.06). Exploratory functional pathway analysis was performed and no functional pathways driving this trend were identified. Polygenic risk was not associated with taxane neuropathy (adjusted p-value = 0.48). These results suggest that breast cancer patients with high genetic risk of breast cancer, conferred by common variants, can safely receive standard chemotherapy without increased risk of taxane-related sensory neuropathy or chemotherapy-induced neutropenia and may experience less neutropenia. As neutropenia has previously been associated with improved survival and may reflect drug efficacy, these patients may be less likely to benefit from standard chemotherapy treatment.	[Dorling, Leila; Kar, Siddhartha; Michailidou, Kyriaki; Pharoah, Paul D. P.; Abraham, Jean E.] Univ Cambridge, Strangeways Res Lab, Ctr Canc Genet Epidemiol, Cambridge, England; [Vallier, Anne-Laure; Ingle, Susan; Hardy, Richard; Caldas, Carlos; Earl, Helena M.; Abraham, Jean E.] Univ Cambridge NHS Fdn Hosp, Cambridge Breast Unit, Cambridge, England; [Vallier, Anne-Laure; Ingle, Susan; Hardy, Richard; Caldas, Carlos; Earl, Helena M.; Abraham, Jean E.] Univ Cambridge NHS Fdn Hosp, NIHR Cambridge Biomed Res Ctr, Cambridge, England; [Caldas, Carlos; Earl, Helena M.; Abraham, Jean E.] Cambridge Expt Canc Med Ctr, Cambridge, England; [Caldas, Carlos] Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge, England; [Hiller, Louise; Dunn, Janet A.; Poole, Christopher J.] Univ Warwick, Warwick Clin Trials Unit, Coventry, W Midlands, England; [Bowden, Sarah J.] Univ Birmingham, Canc Res UK Clin Trials Unit CRCTU, Birmingham, W Midlands, England; [Twelves, Chris] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England; [Twelves, Chris] Leeds Expt Canc Med Ctr, Leeds, W Yorkshire, England; [Michailidou, Kyriaki] Cyprus Inst Neurol & Genet, Dept Electron Microscopy Mol Pathol, Nicosia, Cyprus	University of Cambridge; University of Cambridge; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Warwick; Cancer Research UK; University of Birmingham	Dorling, L (corresponding author), Univ Cambridge, Strangeways Res Lab, Ctr Canc Genet Epidemiol, Cambridge, England.	ld429@medschl.cam.ac.uk	Pharoah, Paul/V-6658-2019; Caldas, Carlos/U-7250-2019; Michailidou, Kyriaki/ABD-5122-2020	Pharoah, Paul/0000-0001-8494-732X; Caldas, Carlos/0000-0003-3547-1489; Michailidou, Kyriaki/0000-0001-7065-1237; Earl, Helena/0000-0003-1549-8094; Bowden, Sarah/0000-0001-7506-1340; Kar, Siddhartha P./0000-0002-2314-1426; Abraham, Jean/0000-0003-0688-4807; Dunn, Janet/0000-0001-7313-4446	Cancer Research UK [C507/A6306, C10097/A7484, C57/A4180, NEAT/BR9601]; Eli Lilly Limited; Bristol Myers Squibb Ltd [2004-002356-34, ISRCTN 78234870, NCT00070278]; Eli Lilly (GemzarTM); Bristol Myers Squibb (TaxolTM); NIHR Cambridge Biomedical Research Centre; Addenbrookes Charitable Trust; Medical Research Council; Cancer Research UK Research Grant [C57/A4180]; Cancer Research Campaign; Cancer Research UK [16942, 16561] Funding Source: researchfish; Medical Research Council [1366822, MR/M008975/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0515-10090, NF-SI-0507-10244, NF-SI-0611-10154] Funding Source: researchfish; The Francis Crick Institute [10119] Funding Source: researchfish; MRC [MR/M008975/1] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Eli Lilly Limited; Bristol Myers Squibb Ltd(Bristol-Myers Squibb); Eli Lilly (GemzarTM)(Eli Lilly); Bristol Myers Squibb (TaxolTM); NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Addenbrookes Charitable Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK Research Grant; Cancer Research Campaign(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); The Francis Crick Institute; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by 1) PGSNPS: project and fellowship grants received by Jean Abraham from Cancer Research UK, C507/A6306 and C10097/A7484, http://www.cancerresearchuk.org/; 2) Neo-tAnGo funding: Cancer Research UK Research Grant (C57/A4180) and an additional unrestricted educational grant from Eli Lilly Limited who also provided free Gemzar (R)/gemcitabine; Bristol Myers Squibb Ltd provided free Taxol (R)/paclitaxel from January 2005 to June 2006 [EudraCT No: 2004-002356-34, ISRCTN 78234870, ClinicalTrials.gov number: NCT00070278]; 3) tAnGo funding: Unrestricted educational grants and free drug from Eli Lilly (GemzarTM) and Bristol Myers Squibb (TaxoITM); and 4) NEAT/BR9601 funding: Project grant from Cancer Research UK (formerly Cancer Research Campaign) 1996-2003: Unrestricted educational grant Pfizer (formerly Pharmacia). HME, JEA, and CC acknowledge funding from the NIHR Cambridge Biomedical Research Centre. JEA acknowledges funding from Addenbrookes Charitable Trust. LD acknowledges funding from Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham J, BMC MED; Abraham JE, 2014, CLIN CANCER RES, V20, P2466, DOI 10.1158/1078-0432.CCR-13-3232; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Baldwin RM, 2012, CLIN CANCER RES, V18, P5099, DOI 10.1158/1078-0432.CCR-12-1590; Bergh J, 2016, ASCO ANN M P S, V34; Cameron DA, 2003, BRIT J CANCER, V89, P1837, DOI 10.1038/sj.bjc.6601366; Comen EA, 2010, CANCER J, V16, P48, DOI 10.1097/PPO.0b013e3181cf01eb; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Earl HM, 2014, LANCET ONCOL, V15, P201, DOI 10.1016/S1470-2045(13)70554-0; Fernandez-Rozadilla C, 2013, PHARMACOGENOMICS J, V13, P209, DOI 10.1038/tpj.2012.2; Han JY, 2013, PHARMACOGENOMICS J, V13, P417, DOI 10.1038/tpj.2012.24; Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Leandro-Garcia LJ, 2013, J MED GENET, V50, P599, DOI 10.1136/jmedgenet-2012-101466; Mavaddat N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv036; Michailidou K, 2015, NAT GENET, V47, P373, DOI 10.1038/ng.3242; Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563; Milne RL, 2014, HUM MOL GENET, V23, P6096, DOI 10.1093/hmg/ddu311; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Poole CJ, 2008, J CLIN ONCOL, V26, P506; Schneider BP, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1000; Schneider BP, 2015, CLIN CANC RES; Shitara K, 2011, CANCER CHEMOTH PHARM, V68, P301, DOI 10.1007/s00280-010-1487-6	24	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158984	10.1371/journal.pone.0158984	http://dx.doi.org/10.1371/journal.pone.0158984			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27392074	Green Published, gold			2023-01-03	WOS:000380005400180
J	You, H; Gu, H; Ning, WQ; Zhou, H; Dong, HJ				You, Hua; Gu, Hai; Ning, Weiqing; Zhou, Hua; Dong, Hengjin			Comparing Maternal Services Utilization and Expense Reimbursement before and after the Adjustment of the New Rural Cooperative Medical Scheme Policy in Rural China	PLOS ONE			English	Article							HEALTH-CARE; MORTALITY	Background The New Rural Cooperative Medical Scheme (NCMS) includes a maternal care benefits package that is associated with increasing maternal health services. The local compensation policies have been frequently adjusted in recent years. This study examined the association between the NCMS maternal-services policy adjustment and expense reimbursement in Yuyao, China. Methods Two household surveys were conducted in Yuyao in 2008 and 2011 (before and after the NCMS policy adjustment, respectively). Local women (N = 154) who had delivery history in the past three years were recruited. A questionnaire was used to collect information about delivery history, maternal health services utilization (prenatal care, postnatal care, and the grade of delivery institutions), NCMS participation, and reimbursement status. Logistic regression analyses were used to predict the association between policy adjustment and maternal health utilization and the association between policy adjustment and out-of-pocket proportion. Next, t-tests and covariance analyses adjusting for household income were used to compare the out-of-pocket proportion between 2008 and 2011. Results Results revealed that compensation policy adjustment was associated with an increase in postnatal visits (adjusted OR = 3.32, p = 0.009) and the use of second level or above institutions for delivery (adjusted OR = 2.32, p = 0.03) among participants. In 2008, only 9.1% of pregnant women received reimbursement from the NCMS; however, this rate increased to 36.8% in 2011. After policy adjustment, there were no significant changes in the proportion of out-of-pocket expenses shared in delivery fee (F = 0.24, p = 0.63) and in household income (F = 0.46, p = 0.50). Conclusions Financial compensation increase improved maternal health services utilization; however, this effect was limited. Although the reimbursement rate was raised, the out-of-pocket proportion was not significant changed; therefore, the compensation design scheme must be adjusted in practice.	[You, Hua] Nanjing Med Univ, Sch Publ Hlth, Dept Social Med & Hlth Educ, Nanjing, Jiangsu, Peoples R China; [You, Hua; Gu, Hai] Nanjing Univ, Sch Govt, Ctr Hlth Management & Care Secur Policy Res, Nanjing, Jiangsu, Peoples R China; [Ning, Weiqing] Nanjing Med Univ, Affiliated Hosp 1, Dept Women Hlth Care, Nanjing, Jiangsu, Peoples R China; [Zhou, Hua] Maternal & Child Hlth Hosp Changzhou, Dept Child Hlth Care, Changzhou, Jiangsu, Peoples R China; [Dong, Hengjin] Zhejiang Univ, Sch Med, Ctr Hlth Policy Studies, Hangzhou, Zhejiang, Peoples R China	Nanjing Medical University; Nanjing University; Nanjing Medical University; Zhejiang University	Dong, HJ (corresponding author), Zhejiang Univ, Sch Med, Ctr Hlth Policy Studies, Hangzhou, Zhejiang, Peoples R China.	donghj@zju.edu.cn			Enlarging the risk pool of NCMS [09-989]; National Natural Science Foundation of China [71373102]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	Enlarging the risk pool of NCMS; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported by Enlarging the risk pool of NCMS to improve sustainability of rural health insurance in Zhejiang province 09-989, National Natural Science Foundation of China 71373102, and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Celik Y, 2000, SOC SCI MED, V50, P1797, DOI 10.1016/S0277-9536(99)00418-9; Chen Y, 2006, MED PHILOS HUMANISTI, V27, P4; Cheng B, 2008, MATERN CHILD HLTH J, V23, P1323; Chinese Ministry of Health, CHIN HLTH SERV DEV S; Criel B, 1999, SOC SCI MED, V48, P897, DOI 10.1016/S0277-9536(98)00391-8; Cui Y, 2007, RES SITUATION PRENAT; Dong LJ, 2007, CHINESE RURAL HLTH S, V27, P550; Fatmi Z, 2002, J Pak Med Assoc, V52, P138; Goodburn E, 2001, BRIT MED J, V322, P917, DOI 10.1136/bmj.322.7291.917; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Hu Y, 2009, SUSTAINABILITY CHINA; Lei XL, 2002, ZHEJIANG J PREVENTIV, V14, P32; Li CR, 2006, ELEMENTARY STUDY SOC; Li WJ, 2009, MATERN CHILD HLTH J, V24, P4645; Li WJ, 2009, IMPACT NEW COOPERATI; Long QA, 2011, B WORLD HEALTH ORGAN, V89, P144, DOI 10.2471/BLT.10.079434; Long QA, 2010, TROP MED INT HEALTH, V15, P1210, DOI 10.1111/j.1365-3156.2010.02602.x; Luo GH, 2007, RES INFLUENCE RURAL; Saga S, 2008, SOC SCI MED, V66, P2460, DOI DOI 10.1016/J; Shi QL, 2008, MATERN CHILD HLTH J, V23, P2491; Shuval J., 1992, SOCIAL DIMENSIONS HL; Song AH, 2008, MATERN CHILD HLTH J, V23, P299; Sun XY, 2007, CHINESE HLTH EC, V26, P14	24	5	5	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158473	10.1371/journal.pone.0158473	http://dx.doi.org/10.1371/journal.pone.0158473			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR3OC	27388439	gold, Green Published			2023-01-03	WOS:000379811500023
J	Sanghavi, P; Jena, AB; Newhouse, JP; Zaslavsky, AM				Sanghavi, Prachi; Jena, Anupam B.; Newhouse, Joseph P.; Zaslavsky, Alan M.			Is Prehospital Advanced Life Support Harmful?	ANNALS OF INTERNAL MEDICINE			English	Letter									[Sanghavi, Prachi] Univ Chicago, Chicago, IL 60637 USA; [Jena, Anupam B.; Newhouse, Joseph P.; Zaslavsky, Alan M.] Harvard Univ, Cambridge, MA 02138 USA	University of Chicago; Harvard University	Sanghavi, P (corresponding author), Univ Chicago, Chicago, IL 60637 USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					Sanghavi P, 2015, ANN INTERN MED, V163, P681, DOI 10.7326/M15-0557; Sasson C, 2015, ANN INTERN MED, V163, P721, DOI 10.7326/M15-2192	2	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2016	165	1					70	71		10.7326/L16-0010	http://dx.doi.org/10.7326/L16-0010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ5AD	27380157				2023-01-03	WOS:000379215800020
J	Park, SM; Jeong, IS; Jun, SS				Park, Soon Mi; Jeong, Ihn Sook; Jun, Seong Sook			Identification of Risk Factors for Intravenous Infiltration among Hospitalized Children: A Retrospective Study	PLOS ONE			English	Article							EXTRAVASATION	This retrospective study was aimed to identify risk factors of intravenous (IV) infiltration for hospitalized children. The participants were 1,174 children admitted to a general hospital, who received peripheral intravenous injection therapy at least once, and had complete records. Data were analyzed with frequency and percentage or mean and standard deviation were calculated, and odds ratio (OR) from univariate and multiple logistic regressions. The number and % of infiltrations were 92 and 7.8%, respectively. IV infiltration risk factors were lower limb (OR = 1.72), phenytoin (OR = 11.03), 10% dextrose (OR = 6.55), steroids (OR = 6.21), vancomycin (OR = 4.10), high-concentration electrolytes (OR = 3.49), and ampicillin/sulbactam combination (OR = 3.37). Nurses working at children's hospitals should consider the risk of IV infiltration for children receiving IV infusion therapy and make a preventive effort to identify IV infiltration in high-risk children at an early stage.	[Park, Soon Mi] Pusan Natl Univ, Yangsan Hosp, Dept Nursing, Yangsan, South Korea; [Jeong, Ihn Sook; Jun, Seong Sook] Pusan Natl Univ, Coll Nursing, Yangsan, South Korea	Pusan National University; Pusan National University Hospital; Pusan National University	Jeong, IS; Jun, SS (corresponding author), Pusan Natl Univ, Coll Nursing, Yangsan, South Korea.	jeongis@pusan.ac.kr; jss@pusan.ac.kr						Ahn H. S., 2012, PEDIATRICS; Amjad I, 2011, J INFUS MURS, V34, P242, DOI 10.1097/NAN.0b013e31821da1b3; Badimon L, 2014, J INTERN MED, V276, P618, DOI 10.1111/joim.12296; Clark E, 2013, J INFUS MURS, V36, P37, DOI 10.1097/NAN.0b013e3182798844; Clifton-Koeppel R, 2006, NEWBORN INFANT NURS, V6, P202, DOI 10.1053/j.nainr.2006.10.001; Jacinto AKD, 2011, J INFUS MURS, V34, P391, DOI 10.1097/NAN.0b013e3182306491; Doellman D, 2009, J INFUS MURS, V32, P203, DOI 10.1097/NAN.0b013e3181aac042; Dougherty Lisa, 2008, Br J Nurs, V17, pS3; Earhart A, 2011, J INFUS MURS, V34, P97, DOI 10.1097/NAN.0b013e31820b4a11; Fang L, 2011, J INFUS MURS, V34, P366, DOI 10.1097/NAN.0b013e31823061c1; Flemmer L, 1993, Pediatr Nurs, V19, P355; Glueck CJ, 2014, CLIN APPL THROMB-HEM, V20, P244, DOI 10.1177/1076029613499819; Goolsby TV, 2006, SEMIN ONCOL, V33, P139, DOI 10.1053/j.seminoncol.2005.11.007; Hadaway L, 2007, AM J NURS, V107, P64, DOI 10.1097/01.NAJ.0000282299.03441.c7; Hetzler R, 2011, J PEDIATR NURS, V26, P143, DOI 10.1016/j.pedn.2010.12.008; Infusion Nurses Society, 2006, J Infus Nurs, V29, pS1; Ji-Soo Kim，, 2012, Child Health Nursing Research, V18, P135, DOI 10.4094/jkachn.2012.18.3.135; 성세희, 2007, [Journal of Korean Clinical Nursing Research, 임상간호연구], V13, P61; Kumar RJ, 2001, ANZ J SURG, V71, P285, DOI 10.1046/j.1440-1622.2001.02104.x; Le A, 2014, ANN PHARMACOTHER, V48, P870, DOI 10.1177/1060028014527820; McCullen KL, 2006, J WOUND OSTOMY CONT, V33, P133, DOI 10.1097/00152192-200603000-00006; McDonnell PJ, 2004, PENNSYLVANIA PATIENT, V3, P1; Montgomery L A, 1999, Pediatr Nurs, V25, P167; Patient Safety Advisory, 2004, PENNSYLVANIA PATIENT, V1, P1; Payne AS, 2013, EXTRAVASATION INJURY; Sarovath A., 2006, THAI J SURG, V27, P19; Sauerland C, 2006, ONCOL NURS FORUM, V33, P1134, DOI 10.1188/06.ONF.1134-1141; Talbot SG, 2011, ANN PLAS SURG, V67, P531, DOI 10.1097/SAP.0b013e3182085915; Wilson J., 2006, INFECT CONTROL CLIN; Woody G, 2013, J INFUS MURS, V36, P413, DOI 10.1097/NAN.0000000000000013; YOSOWITZ P, 1975, ANN SURG, V182, P553, DOI 10.1097/00000658-197511000-00003	31	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2016	11	6							e0158045	10.1371/journal.pone.0158045	http://dx.doi.org/10.1371/journal.pone.0158045			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AH	27351488	Green Published, Green Submitted, gold			2023-01-03	WOS:000378858900028
J	Hu, RF; Ren, GM; Sun, GB; Sun, XB				Hu, Ruifeng; Ren, Guomin; Sun, Guibo; Sun, Xiaobo			TarNet: An Evidence-Based Database for Natural Medicine Research	PLOS ONE			English	Article							PROTEIN INTERACTION NETWORKS; INSULIN-RESISTANCE; DRUG DISCOVERY; ADIPOSE-TISSUE; PHARMACOLOGY; DISEASE; SUPPRESSOR; OBESITY; POLYMORPHISMS; ASSOCIATION	Background Complex diseases seriously threaten human health. Drug discovery approaches based on "single genes, single drugs, and single targets" are limited in targeting complex diseases. The development of new multicomponent drugs for complex diseases is imperative, and the establishment of a suitable solution for drug group-target protein network analysis is a key scientific problem that must be addressed. Herbal medicines have formed the basis of sophisticated systems of traditional medicine and have given rise to some key drugs that remain in use today. The search for new molecules is currently taking a different route, whereby scientific principles of ethnobotany and ethnopharmacognosy are being used by chemists in the discovery of different sources and classes of compounds. Results In this study, we developed TarNet, a manually curated database and platform of traditional medicinal plants with natural compounds that includes potential bio-target information. We gathered information on proteins that are related to or affected by medicinal plant ingredients and data on protein-protein interactions (PPIs). TarNet includes in-depth information on both plant-compound-protein relationships and PPIs. Additionally, TarNet can provide researchers with network construction analyses of biological pathways and protein-protein interactions (PPIs) associated with specific diseases. Researchers can upload a gene or protein list mapped to our PPI database that has been manually curated to generate relevant networks. Multiple functions are accessible for network topological calculations, sub-network analyses, pathway analyses, and compound-protein relationships. Conclusions TarNet will serve as a useful analytical tool that will provide information on medicinal plant compound-affected proteins (potential targets) and system-level analyses for systems biology and network pharmacology researchers. TarNet is freely available at http://www.herbbol.org:8001/tarnet, and detailed tutorials on the program are also available.	[Hu, Ruifeng; Ren, Guomin; Sun, Guibo; Sun, Xiaobo] Peking Union Med Coll, Beijing Key Lab Innovat Drug Discovery Tradit Chi, Inst Med Plant Dev, Beijing 100021, Peoples R China; [Hu, Ruifeng; Ren, Guomin; Sun, Guibo; Sun, Xiaobo] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Hu, Ruifeng; Ren, Guomin; Sun, Guibo; Sun, Xiaobo] Minist Educ, Key Lab Bioact Subst & Resource Utilizat Chinese, Beijing, Peoples R China; [Hu, Ruifeng; Ren, Guomin; Sun, Guibo; Sun, Xiaobo] Zhongguancun Open Lab Res & Dev Nat Med & Hlth Pr, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Plant Development - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Sun, XB (corresponding author), Peking Union Med Coll, Beijing Key Lab Innovat Drug Discovery Tradit Chi, Inst Med Plant Dev, Beijing 100021, Peoples R China.; Sun, XB (corresponding author), Chinese Acad Med Sci, Beijing 100730, Peoples R China.; Sun, XB (corresponding author), Minist Educ, Key Lab Bioact Subst & Resource Utilizat Chinese, Beijing, Peoples R China.; Sun, XB (corresponding author), Zhongguancun Open Lab Res & Dev Nat Med & Hlth Pr, Beijing, Peoples R China.	xbsun@implad.ac.cn	Hu, Ruifeng/AAF-8619-2019	Hu, Ruifeng/0000-0001-5549-3082	Major Scientific and Technological Special Project [2015ZX09501001-001-003, 2012ZX09501001]; National Natural Science Foundation of China [81374011]; Special Project for National traditional Chinese medicine industry of China [201507004]	Major Scientific and Technological Special Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Project for National traditional Chinese medicine industry of China	This work was supported by the Major Scientific and Technological Special Project for 'Significant New Drugs Formulation' (Grant Numbers: 2015ZX09501001-001-003, 2012ZX09501001), the National Natural Science Foundation of China (Grant Numbers: 81374011), and the Special Project for National traditional Chinese medicine industry of China (Grant Numbers: 201507004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-320; Arikoglu H, 2014, META GENE, V2, P579, DOI 10.1016/j.mgene.2014.07.008; Arrell DK, 2010, CLIN PHARMACOL THER, V88, P120, DOI 10.1038/clpt.2010.91; Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Costello JC, 2014, NAT BIOTECHNOL, V32, P1202, DOI 10.1038/nbt.2877; Davis D, 2015, BIOINFORMATICS, V31, P1632, DOI 10.1093/bioinformatics/btv026; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Fleischman A, 2008, DIABETES CARE, V31, P289, DOI 10.2337/dc07-1338; Gu HL, 2009, ENDOCRINE, V36, P546, DOI 10.1007/s12020-009-9253-4; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hulbert EM, 2007, NUCLEIC ACIDS RES, V35, pD742, DOI 10.1093/nar/gkl933; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Ideker T, 2008, GENOME RES, V18, P644, DOI 10.1101/gr.071852.107; Jiang XY, 2011, BIOMETRICS, V67, P958, DOI 10.1111/j.1541-0420.2010.01519.x; Jorgensen SB, 2013, DIABETES, V62, P56, DOI 10.2337/db12-0443; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.1016/S1875-5364(13)60037-0, 10.3724/SP.J.1009.2013.00110]; Liberman M, 2008, PENNBIOLE ONCOLOGY 1; Liu H, 2011, NUCLEIC ACIDS RES, V39, pD991, DOI 10.1093/nar/gkq1106; Loos RJF, 2007, DIABETES, V56, P1943, DOI 10.2337/db07-0055; Lopes CT, 2010, BIOINFORMATICS, V26, P2347, DOI 10.1093/bioinformatics/btq430; Lopez-Alarcon M, 2012, GENE, V511, P404, DOI 10.1016/j.gene.2012.09.057; Narayana Y, 2009, MOL IMMUNOL, V46, P2947, DOI 10.1016/j.molimm.2009.06.019; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Pizzuti A, 1999, DIABETES, V48, P1881, DOI 10.2337/diabetes.48.9.1881; Pyysalo S, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-50; Reed AS, 2010, DIABETES, V59, P894, DOI 10.2337/db09-1024; Ren GM, 2013, BIOINFORMATICS, V29, P279, DOI 10.1093/bioinformatics/bts666; Sachithanandan N, 2010, HEPATOLOGY, V52, P1632, DOI 10.1002/hep.23861; Seebacher J, 2011, CELL, V144, P1000, DOI 10.1016/j.cell.2011.02.025; Shi H, 2006, DIABETES, V55, P699, DOI 10.2337/diabetes.55.03.06.db05-0841; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Tanabe L, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S1-S3; Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051; Tong Y, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-15; Wang Z, 2013, DRUG DISCOV TODAY, V18, P560, DOI 10.1016/j.drudis.2013.01.009; Weedon MN, 2006, PLOS MED, V3, P1877, DOI 10.1371/journal.pmed.0030374; Xia JG, 2014, NUCLEIC ACIDS RES, V42, pW167, DOI 10.1093/nar/gku443; Xiong JH, 2010, CANCER INFORM, V9, P61; Yamada T, 2009, NAT REV MOL CELL BIO, V10, P791, DOI 10.1038/nrm2787; Yamanishi Y, 2014, NUCLEIC ACIDS RES, V42, pW39, DOI 10.1093/nar/gku337; Yang DC, 2012, IEEE PES TRANSM DIST, V2012, P7, DOI [DOI 10.1371/J0URNAL.P0NE.0042076, DOI 10.1371/J0URNAL.P0NE.0033596]; Yang ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047493; Yang ZZ, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat052; Yaspelkis BB, 2009, AM J PHYSIOL-REG I, V296, pR1709, DOI 10.1152/ajpregu.00117.2009; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang LF, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S11-S18; Zhao J, 2010, BRIEF BIOINFORM, V11, P417, DOI 10.1093/bib/bbp063; Zhao S, 2012, ANNU REV PHARMACOL, V52, P505, DOI 10.1146/annurev-pharmtox-010611-134520; Zheng MY, 2013, TRENDS PHARMACOL SCI, V34, P549, DOI 10.1016/j.tips.2013.08.004	55	10	10	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157222	10.1371/journal.pone.0157222	http://dx.doi.org/10.1371/journal.pone.0157222			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27337171	Green Published, Green Submitted, gold			2023-01-03	WOS:000378389200012
J	Mazzola, G; Murphy, K; Ross, RP; Di Gioia, D; Biavati, B; Corvaglia, LT; Faldella, G; Stanton, C				Mazzola, Giuseppe; Murphy, Kiera; Ross, R. Paul; Di Gioia, Diana; Biavati, Bruno; Corvaglia, Luigi T.; Faldella, Giacomo; Stanton, Catherine			Early Gut Microbiota Perturbations Following Intrapartum Antibiotic Prophylaxis to Prevent Group B Streptococcal Disease	PLOS ONE			English	Article							INTESTINAL MICROBIOTA; VERTICAL TRANSMISSION; BIFIDOBACTERIA; GENERATION; SEARCH; TOOL	The faecal microbiota composition of infants born to mothers receiving intrapartum antibiotic prophylaxis with ampicillin against group B Streptococcus was compared with that of control infants, at day 7 and 30 of life. Recruited newborns were both exclusive breastfed and mixed fed, in order to also study the effect of dietary factors on the microbiota composition. Massive parallel sequencing of the V3-V4 region of the 16S rRNA gene and qPCR analysis were performed. Antibiotic prophylaxis caused the most marked changes on the microbiota in breastfed infants, mainly resulting in a higher relative abundance of Enterobacteriaceae, compared with control infants (52% vs. 14%, p = 0.044) and mixed-fed infants (52% vs. 16%, p = 0.13 NS) at day 7 and in a lower bacterial diversity compared to mixed- fed infants and controls. Bifidobacteria were also particularly vulnerable and abundances were reduced in breastfed (p = 0.001) and mixed- fed antibiotic treated groups compared to nontreated groups. Reductions in bifidobacteria in antibiotic treated infants were also confirmed by qPCR. By day 30, the bifidobacterial population recovered and abundances significantly increased in both breastfed (p = 0.025) and mixed-fed (p = 0.013) antibiotic treated groups, whereas Enterobacteriaceae abundances remained highest in the breastfed antibiotic treated group (44%), compared with control infants (16%) and mixed-fed antibiotic treated group (28%). This study has therefore demonstrated the short term consequences of maternal intrapartum antibiotic prophylaxis on the infant faecal microbial population, particularly in that of breastfed infants.	[Mazzola, Giuseppe; Di Gioia, Diana; Biavati, Bruno] Univ Bologna, Dept Agr Sci, Bologna, Italy; [Murphy, Kiera; Stanton, Catherine] Teagasc Food Res Ctr, Food Biosci Dept, Fermoy, Cork, Ireland; [Murphy, Kiera] Natl Univ Ireland Univ Coll Cork, Sch Microbiol, Cork, Ireland; [Murphy, Kiera; Ross, R. Paul; Stanton, Catherine] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland; [Corvaglia, Luigi T.; Faldella, Giacomo] St Orsola Marcello Malpighi Hosp, Neonatal Intens Care Unit, Bologna, Italy	University of Bologna; Teagasc; University College Cork; University College Cork; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Di Gioia, D (corresponding author), Univ Bologna, Dept Agr Sci, Bologna, Italy.	diana.digioia@unibo.it	Stanton, Catherine/A-9549-2015; Ross, Paul/A-7584-2015	Stanton, Catherine/0000-0002-6724-7011; Ross, Paul/0000-0003-4876-8839; Di Gioia, Diana/0000-0002-0181-1572; Murphy, Kiera/0000-0002-6543-5158	Irish Department of Agriculture Food and Marine INFANTMET Project [10FDairy]; Science Foundation of Ireland; Global Grant Spinner project; Teagasc Walsh Fellowship; Alimentary Pharmabiotic Centre; EU FP7 MyNewGut project [613979]	Irish Department of Agriculture Food and Marine INFANTMET Project; Science Foundation of Ireland(Science Foundation Ireland); Global Grant Spinner project; Teagasc Walsh Fellowship; Alimentary Pharmabiotic Centre(Science Foundation Ireland); EU FP7 MyNewGut project	This work was part funded by the Irish Department of Agriculture Food and Marine INFANTMET Project (RefNo 10FDairy), Science Foundation of Ireland-funded Centre for Science, Engineering and Technology, the Alimentary Pharmabiotic Centre and by EU FP7 MyNewGut project (No.: 613979; www.mynewgut.eu). The research activity of GM and KM were supported by the Global Grant Spinner project 2013 and a Teagasc Walsh Fellowship, respectively.; The authors wish to thank Dr. Paul Cotter, Dr. Fiona Crispie and Ms. Vicki Murray for their technical assistance with MiSeq sequencing. This work was part funded by the Irish Department of Agriculture Food and Marine INFANTMET Project (RefNo 10FDairy), Science Foundation of Ireland-funded Centre for Science, Engineering and Technology, the Alimentary Pharmabiotic Centre and by EU FP7 MyNewGut project (No.: 613979; www.mynewgut.eu). The research activity of GM and KM were supported by the Global Grant Spinner project 2013 and a Teagasc Walsh Fellowship, respectively. Ethical Approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee as indicated in the text and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.	Adlerberth I, 2009, ACTA PAEDIATR, V98, P229, DOI 10.1111/j.1651-2227.2008.01060.x; Aloisio I, 2014, APPL MICROBIOL BIOT, V98, P6051, DOI 10.1007/s00253-014-5712-9; Aloisio I, 2012, APPL MICROBIOL BIOT, V96, P1561, DOI 10.1007/s00253-012-4138-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arboleya S, 2015, J PEDIATR-US, V166, P538, DOI 10.1016/j.jpeds.2014.09.041; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Di Gioia D, 2014, APPL MICROBIOL BIOT, V98, P563, DOI 10.1007/s00253-013-5405-9; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Edwards RK, 2002, OBSTET GYNECOL, V100, P534, DOI 10.1016/S0029-7844(02)02096-3; El Aidy S, 2015, CURR OPIN BIOTECH, V32, P14, DOI 10.1016/j.copbio.2014.09.005; Fouhy F, 2012, ANTIMICROB AGENTS CH, V56, P5811, DOI 10.1128/AAC.00789-12; Guo XL, 2008, ANAEROBE, V14, P224, DOI 10.1016/j.anaerobe.2008.04.001; Ishizeki S, 2013, ANAEROBE, V23, P38, DOI 10.1016/j.anaerobe.2013.08.002; Jacquot A, 2011, J PEDIATR-US, V158, P390, DOI 10.1016/j.jpeds.2010.09.007; Johri AK, 2006, NAT REV MICROBIOL, V4, P932, DOI 10.1038/nrmicro1552; Kelly D, 2007, MUTAT RES-FUND MOL M, V622, P58, DOI 10.1016/j.mrfmmm.2007.03.011; Keski-Nisula L, 2013, ACTA PAEDIATR, V102, P480, DOI 10.1111/apa.12186; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Marques TM, 2010, CURR OPIN BIOTECH, V21, P149, DOI 10.1016/j.copbio.2010.03.020; Martin R, 2009, APPL ENVIRON MICROB, V75, P965, DOI 10.1128/AEM.02063-08; Mathew JL, 2004, POSTGRAD MED J, V80, P196, DOI 10.1136/pgmj.2003.011973; Milani C, 2015, APPL ENVIRON MICROB, V81, P7078, DOI 10.1128/AEM.02037-15; Morelli L, 2008, J NUTR, V138, p1791S, DOI 10.1093/jn/138.9.1791S; Oddie S, 2002, BRIT MED J, V325, P308, DOI 10.1136/bmj.325.7359.308; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Stapleton PJM, 2016, ARCH DIS CHILD-FETAL, V101, P72, DOI 10.1136/archdischild-2015-308707; Tanaka S, 2009, FEMS IMMUNOL MED MIC, V56, P80, DOI 10.1111/j.1574-695X.2009.00553.x; Vazquez-Baeza Y, 2013, GIGASCIENCE, V2, DOI 10.1186/2047-217X-2-16; Yamasaki C, 2012, PEDIATR INT, V54, P651, DOI 10.1111/j.1442-200X.2012.03649.x	33	66	67	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2016	11	6							e0157527	10.1371/journal.pone.0157527	http://dx.doi.org/10.1371/journal.pone.0157527			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WX	27332552	Green Published, gold, Green Submitted			2023-01-03	WOS:000378212800032
J	Amoakoh-Coleman, M; Agyepong, IA; Zuithoff, NPA; Kayode, GA; Grobbee, DE; Klipstein-Grobusch, K; Ansah, EK				Amoakoh-Coleman, Mary; Agyepong, Irene Akua; Zuithoff, Nicolaas P. A.; Kayode, Gbenga A.; Grobbee, Diederick E.; Klipstein-Grobusch, Kerstin; Ansah, Evelyn K.			Client Factors Affect Provider Adherence to Clinical Guidelines during First Antenatal Care	PLOS ONE			English	Article							QUALITY-OF-CARE; HYPERTENSION GUIDELINES; MATERNAL MORTALITY; MULTICENTER; PREVENTION; MANAGEMENT; SURVIVAL; REGION; PARITY	Background The first antenatal clinic (ANC) visit helps to distinguish pregnant women who require standard care, from those with specific problems and so require special attention. There are protocols to guide care providers to provide optimal care to women during ANC. Our objectives were to determine the level of provider adherence to first antenatal visit guidelines in the Safe Motherhood Protocol (SMP), and assess patient factors that determine complete provider adherence. Methods This cross-sectional study is part of a cohort study that recruited women who delivered in eleven health facilities and who had utilized antenatal care services during their pregnancy in the Greater Accra region of Ghana. A record review of the first antenatal visit of participants was carried out to assess the level of adherence to the SMP, using a thirteen-point checklist. Information on their socio-demographic characteristics and previous pregnancy history was collected using a questionnaire. Percentages of adherence levels and baseline characteristics were estimated and cluster-adjusted odds ratios (OR) calculated to identify determinants. Results A total of 948 women who had delivered in eleven public facilities were recruited with a mean age (SD) of 28.2 (5.4) years. Overall, complete adherence to guidelines pertained to only 48.1% of pregnant women. Providers were significantly more likely to completely adhere to guidelines when caring for multiparous women [OR = 5.43 (1.69-17.44), p<0.01] but less likely to do so when attending to women with history of previous pregnancy complications [OR = 0.50 (0.33-0.75), p<0.01]. Conclusion Complete provider adherence to first antenatal visit guidelines is low across different facility types in the Greater Accra region of Ghana and is determined by parity and history of previous pregnancy complication. Providers should be trained and supported to adhere to the guidelines during provision of care to all pregnant women.	[Amoakoh-Coleman, Mary; Zuithoff, Nicolaas P. A.; Kayode, Gbenga A.; Grobbee, Diederick E.; Klipstein-Grobusch, Kerstin] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Julius Global Hlth, Utrecht, Netherlands; [Amoakoh-Coleman, Mary; Agyepong, Irene Akua] Univ Ghana, Sch Publ Hlth, Legon, Ghana; [Klipstein-Grobusch, Kerstin] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Div Epidemiol & Biostat, Johannesburg, South Africa; [Ansah, Evelyn K.] Ghana Hlth Serv, Div Res & Dev, Accra, Ghana	Utrecht University; Utrecht University Medical Center; University of Ghana; University of Witwatersrand; Ghana Health Service	Amoakoh-Coleman, M (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Julius Global Hlth, Utrecht, Netherlands.; Amoakoh-Coleman, M (corresponding author), Univ Ghana, Sch Publ Hlth, Legon, Ghana.	menba19@yahoo.com	Klipstein-Grobusch, Kerstin/F-5555-2016; Kayode, Gabenga A./C-8992-2015	Klipstein-Grobusch, Kerstin/0000-0002-5462-9889; Kayode, Gabenga A./0000-0001-6313-010X; Ansah, Evelyn/0000-0003-0401-8606; AMOAKOH-COLEMAN, MARY/0000-0002-0320-0396; Agyepong, Irene Akua/0000-0002-0193-5882	Netherlands Organization for Scientific Research (NWO) Global Health Policy; 396 Health Systems Research Program, Netherlands [07.45.102.00]; FOGARTY INTERNATIONAL CENTER [D43TW009140] Funding Source: NIH RePORTER	Netherlands Organization for Scientific Research (NWO) Global Health Policy(Netherlands Organization for Scientific Research (NWO)); 396 Health Systems Research Program, Netherlands(Netherlands Government); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The Netherlands Organization for Scientific Research (NWO) Global Health Policy and 396 Health Systems Research Program, Netherlands, provided funds for the conduct of the study (Grant number: 07.45.102.00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Advani A, 2001, J AM MED INFORM ASSN, P2; [Anonymous], 2013, DEF ADH GUID; Babinszki A, 1999, AM J OBSTET GYNECOL, V181, P669, DOI 10.1016/S0002-9378(99)70511-9; Bai J, 2002, AM J OBSTET GYNECOL, V186, P274, DOI 10.1067/mob.2002.119639; Burstin HR, 1999, AM J MED, V107, P437, DOI 10.1016/S0002-9343(99)00269-7; Burua A, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0521-5; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Cruz-Correa M, 2001, ARCH INTERN MED, V161, P2588, DOI 10.1001/archinte.161.21.2588; Cuspidi C, 2002, J HUM HYPERTENS, V16, P699, DOI 10.1038/sj.jhh.1001468; de la Sierra A, 2009, J HYPERTENS, V27, pS27, DOI 10.1097/01.hjh.0000356769.32130.95; Ghana Health Service, 2007, NAT SAF MOTH SERV PR; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Halm EA, UNDERSTANDING PHYS A; Howe LD, 2011, PAEDIATR PERINAT EP, V25, P192, DOI 10.1111/j.1365-3016.2010.01178.x; Issah K, 2011, INT J GYNECOL OBSTET, V113, P208, DOI 10.1016/j.ijgo.2011.01.007; Kersley, 2007, METHODS OBSERVATIONA; Komajda M, 2005, EUR HEART J, V26, P1653, DOI 10.1093/eurheartj/ehi251; Lawler FH, 1997, J FAM PRACTICE, V44, P369; Lin N D, 2006, AMIA Annu Symp Proc, P494; Lugtenberg M, 2009, QUAL SAF HEALTH CARE, V18, P385, DOI 10.1136/qshc.2008.028043; Malone DC, 2001, ANN PHARMACOTHER, V35, P1180; Mangin D, 2012, J PRIM HEALTH CARE, V4, P158, DOI 10.1071/HC12158; McKinlay JB, 2007, J GEN INTERN MED, V22, P289, DOI 10.1007/s11606-006-0075-2; Measure DHS, 2008, GHAN DEM HLGH SURV 2; Ministry of Health/Ghana Health Service RHU, 2013, MAT HLTH REC BOOK; Papaevangelou V, ADHERENCE SCREENING; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003; Sales AE, 2009, J GEN INTERN MED, V24, P1205, DOI 10.1007/s11606-009-1096-4; Schuster MA, 1997, ARCH PEDIAT ADOL MED, V151, P1085, DOI 10.1001/archpedi.1997.02170480015003; Scribano PV, 2001, ACAD EMERG MED, V8, P1147, DOI 10.1111/j.1553-2712.2001.tb01131.x; Shih TY, 2011, SEX TRANSM DIS, V38, P299, DOI 10.1097/OLQ.0b013e31820b8bb4; Styles M, 2011, MIDWIFERY, V27, P104, DOI 10.1016/j.midw.2009.12.003; Theodorou M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/503821; Van Fenema E, 2012, INT J QUAL HEALTH C, V24, P72, DOI 10.1093/intqhc/mzr076; Villar J, 1997, ACTA OBSTET GYN SCAN, V76, P1, DOI 10.3109/00016349709047778; Worrall G, 1997, J FAM PRACTICE, V44, P374; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	40	19	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2016	11	6							e0157542	10.1371/journal.pone.0157542	http://dx.doi.org/10.1371/journal.pone.0157542			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WR	27322643	Green Published, Green Submitted, gold			2023-01-03	WOS:000378212000022
J	Detsky, AS; Gropper, MA				Detsky, Allan S.; Gropper, Michael A.			Why Physician Leaders of Health Care Organizations Should Participate in Direct Patient Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Mt Sinai Hosp, Room 429,600 Univ Ave, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Toronto, ON, Canada; [Gropper, Michael A.] Univ Calif San Francisco, 500 Parnassus Ave,MUE 410, San Francisco, CA 94143 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of California System; University of California San Francisco	Detsky, AS (corresponding author), Mt Sinai Hosp, Room 429,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						Annals of Internal Medicine, 2016, INF READ COMM; Cain DM, 2008, JAMA-J AM MED ASSOC, V299, P2893, DOI 10.1001/jama.299.24.2893; Detsky AS, 2011, J GEN INTERN MED, V26, P88, DOI 10.1007/s11606-010-1486-7; Schwendimann R, 2013, AM J MED QUAL, V28, P414, DOI 10.1177/1062860612473635; Teirstein PS, 2015, NEW ENGL J MED, V372, P106, DOI 10.1056/NEJMp1407422	5	5	5	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2016	165	7					519	+		10.7326/M16-0820	http://dx.doi.org/10.7326/M16-0820			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DY0EY	27399305				2023-01-03	WOS:000384771300011
J	de Wit, NJW; Hulst, M; Govers, C; van der Meulen, J; van Hoef, A; Stoopen, G; Hamers, A; Hoekman, A; de Vos, R; Bovee, TFH; Smits, M; Mes, JJ; Hendriksen, PJM				de Wit, Nicole J. W.; Hulst, Marcel; Govers, Coen; van der Meulen, Jan; van Hoef, Angeline; Stoopen, Geert; Hamers, Astrid; Hoekman, Arjan; de Vos, Ric; Bovee, Toine F. H.; Smits, Mari; Mes, Jurriaan J.; Hendriksen, Peter J. M.			Effects of Digested Onion Extracts on Intestinal Gene Expression: An Interspecies Comparison Using Different Intestine Models	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; CELL-LINE; DIGESTIBILITY; HUMANS; NRF2; INFLAMMATION; RESISTANCE; ENZYMES; PROTEIN; ILEAL	Human intestinal tissue samples are barely accessible to study potential health benefits of nutritional compounds. Numbers of animals used in animal trials, however, need to be minimalized. Therefore, we explored the applicability of in vitro (human Caco-2 cells) and ex vivo intestine models (rat precision cut intestine slices and the pig in-situ small intestinal segment perfusion (SISP) technique) to study the effect of food compounds. In vitro digested yellow (YOd) and white onion extracts (WOd) were used as model food compounds and transcriptomics was applied to obtain more insight into which extent mode of actions depend on the model. The three intestine models shared 9,140 genes which were used to compare the responses to digested onions between the models. Unsupervised clustering analysis showed that genes up-or down-regulated by WOd in human Caco-2 cells and rat intestine slices were similarly regulated by YOd, indicating comparable modes of action for the two onion species. Highly variable responses to onion were found in the pig SISP model. By focussing only on genes with significant differential expression, in combination with a fold change > 1.5, 15 genes showed similar onion-induced expression in human Caco-2 cells and rat intestine slices and 2 overlapping genes were found between the human Caco-2 and pig SISP model. Pathway analyses revealed that mainly processes related to oxidative stress, and especially the Keap1-Nrf2 pathway, were affected by onions in all three models. Our data fit with previous in vivo studies showing that the beneficial effects of onions are mostly linked to their antioxidant properties. Taken together, our data indicate that each of the in vitro and ex vivo intestine models used in this study, taking into account their limitations, can be used to determine modes of action of nutritional compounds and can thereby reduce the number of animals used in conventional nutritional intervention studies.	[de Wit, Nicole J. W.; Govers, Coen; Mes, Jurriaan J.] Univ Wageningen & Res Ctr, Food & Biobased Res, Wageningen, Netherlands; [Hulst, Marcel; van der Meulen, Jan; Hoekman, Arjan; Smits, Mari] Univ Wageningen & Res Ctr, Wageningen Livestock Res, Wageningen, Netherlands; [van Hoef, Angeline; Stoopen, Geert; Hamers, Astrid; Bovee, Toine F. H.; Hendriksen, Peter J. M.] Univ Wageningen & Res Ctr, RIKILT Inst Food Safety, Wageningen, Netherlands; [de Vos, Ric] Univ Wageningen & Res Ctr, Plant Res Int, Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research; Wageningen University & Research; Wageningen University & Research	Hendriksen, PJM (corresponding author), Univ Wageningen & Res Ctr, RIKILT Inst Food Safety, Wageningen, Netherlands.	peter.hendriksen@wur.nl		van der Meulen, Jan/0000-0002-9451-2335	Dutch Ministry of Economic Affairs, Agriculture and Innovation	Dutch Ministry of Economic Affairs, Agriculture and Innovation	This work was supported by the Dutch Ministry of Economic Affairs, Agriculture and Innovation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelmalek MF, 2010, HEPATOLOGY, V51, P1961, DOI 10.1002/hep.23535; [Anonymous], 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2481; Boddupalli Sekhar, 2012, Frontiers in Genetics, V3, P7, DOI 10.3389/fgene.2012.00007; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; de Graaf IAM, 2010, NAT PROTOC, V5, P1540, DOI 10.1038/nprot.2010.111; de Wit NJW, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-14; Deglaire A, 2012, BRIT J NUTR, V108, pS273, DOI 10.1017/S0007114512002346; Deglaire A, 2009, BRIT J NUTR, V102, P1752, DOI 10.1017/S0007114509991267; El-Demerdash FM, 2005, FOOD CHEM TOXICOL, V43, P57, DOI 10.1016/j.fct.2004.08.012; Eldin IMT, 2010, ENVIRON HEALTH INSIG, V4, P71, DOI 10.4137/EHI.S5540; Galeone C, 2006, AM J CLIN NUTR, V84, P1027, DOI 10.1093/ajcn/84.5.1027; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Griffiths G, 2002, PHYTOTHER RES, V16, P603, DOI 10.1002/ptr.1222; Helen A, 2000, TOXICOL LETT, V116, P61, DOI 10.1016/S0378-4274(00)00208-3; Hendriks WH, 2012, BRIT J NUTR, V108, pS247, DOI 10.1017/S0007114512002395; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hulst M, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-18; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jansman AJM, 2012, J ANIM SCI, V90, P161, DOI 10.2527/jas.53848; Jung JY, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-18; Kalthoff S, 2010, J BIOL CHEM, V285, P5993, DOI 10.1074/jbc.M109.075770; KARARLI TT, 1995, BIOPHARM DRUG DISPOS, V16, P351, DOI 10.1002/bdd.2510160502; Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09; Li M, 2016, DRUG METAB DISPOS, V44, P683, DOI 10.1124/dmd.115.068684; Lin K, 2011, J INTEGR BIOINFORMAT, V8, DOI 10.2390/biecoll-jib-2011-160; Lippmann D, 2014, FOOD FUNCT, V5, P1073, DOI 10.1039/c3fo60676g; Lisanti A, 2016, PHARM BIOL, V54, P799, DOI 10.3109/13880209.2015.1080733; Loos M, 2013, VET IMMUNOL IMMUNOP, V152, P82, DOI 10.1016/j.vetimm.2012.09.014; Minekus M, 2014, FOOD FUNCT, V5, P1113, DOI 10.1039/c3fo60702j; Park J, 2007, J NUTR SCI VITAMINOL, V53, P21, DOI 10.3177/jnsv.53.21; Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6; Schokker D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100040; Tremblay E, 2006, J CELL BIOCHEM, V99, P1175, DOI 10.1002/jcb.21015; van der Meulen J, 2010, BENEF MICROBES, V1, P439, DOI 10.3920/BM2010.0025; van Kol SWM, 2011, TOXICOL APPL PHARM, V250, P299, DOI 10.1016/j.taap.2010.11.001; Vreeburg RAM, 2011, FOOD FUNCT, V2, P124, DOI 10.1039/c0fo00068j; Wan Hasan WN, 2014, BMC COMPLEM ALTERN M, V14, P1; Wang XJ, 2006, CANCER RES, V66, P10983, DOI 10.1158/0008-5472.CAN-06-2298; Yang J, 2004, J AGR FOOD CHEM, V52, P6787, DOI 10.1021/jf0307144	40	5	5	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2016	11	9							e0160719	10.1371/journal.pone.0160719	http://dx.doi.org/10.1371/journal.pone.0160719			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5SJ	27631494	Green Published, Green Submitted, gold			2023-01-03	WOS:000383706900011
J	Im, SJ; Hashimoto, M; Gerner, MY; Lee, J; Kissick, HT; Urger, MCB; Shan, Q; Hale, JS; Lee, J; Nasti, TH; Sharpe, AH; Freeman, GJ; Germain, RN; Nakaya, HI; Xue, HH; Ahmed, R				Im, Se Jin; Hashimoto, Masao; Gerner, Michael Y.; Lee, Junghwa; Kissick, Haydn T.; Urger, Matheus C. B.; Shan, Qiang; Hale, J. Scott; Lee, Judong; Nasti, Tahseen H.; Sharpe, Arlene H.; Freeman, Gordon J.; Germain, Ronald N.; Nakaya, Helder I.; Xue, Hai-Hui; Ahmed, Rafi			Defining CD8(+) T cells that provide the proliferative burst after PD-1 therapy	NATURE			English	Article							CHRONIC VIRAL-INFECTION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TRANSCRIPTION FACTOR; LYMPHOID ORGANS; MEMORY; PERSISTENCE; EFFECTOR; FH; DIFFERENTIATION; EXHAUSTION	Chronic viral infections are characterized by a state of CD8(+) T-cell dysfunction that is associated with expression of the programmed cell death 1 (PD-1) inhibitory receptor(1-4). A better understanding of the mechanisms that regulate CD8(+) T-cell responses during chronic infection is required to improve immunotherapies that restore function in exhausted CD8(+) T cells. Here we identify a population of virus-specific CD8(+) T cells that proliferate after blockade of the PD-1 inhibitory pathway in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). These LCMV-specific CD8(+) T cells expressed the PD-1 inhibitory receptor, but also expressed several costimulatory molecules such as ICOS and CD28. This CD8(+) T-cell subset was characterized by a unique gene signature that was related to that of CD4(+) T follicular helper (T-FH) cells, CD8(+) T cell memory precursors and haematopoietic stem cell progenitors, but that was distinct from that of CD4(+) T(H)1 cells and CD8(+) terminal effectors. This CD8(+) T-cell population was found only in lymphoid tissues and resided predominantly in the T-cell zones along with naive CD8(+) T cells. These PD-1(+) CD8(+) T cells resembled stem cells during chronic LCMV infection, undergoing self-renewal and also differentiating into the terminally exhausted CD8(+) T cells that were present in both lymphoid and non-lymphoid tissues. The proliferative burst after PD-1 blockade came almost exclusively from this CD8(+) T-cell subset. Notably, the transcription factor TCF1 had a cell-intrinsic and essential role in the generation of this CD8(+) T-cell subset. These findings provide a better understanding of T-cell exhaustion and have implications in the optimization of PD-1-directed immunotherapy in chronic infections and cancer.	[Im, Se Jin; Hashimoto, Masao; Lee, Junghwa; Kissick, Haydn T.; Hale, J. Scott; Lee, Judong; Nasti, Tahseen H.; Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; [Im, Se Jin; Hashimoto, Masao; Lee, Junghwa; Kissick, Haydn T.; Hale, J. Scott; Lee, Judong; Nasti, Tahseen H.; Ahmed, Rafi] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; [Gerner, Michael Y.; Germain, Ronald N.] NIAID, Lymphocyte Biol Sect, Lab Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gerner, Michael Y.] Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98109 USA; [Kissick, Haydn T.] Emory Univ, Dept Urol, Sch Med, Atlanta, GA 30322 USA; [Urger, Matheus C. B.; Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508 Sao Paulo, Brazil; [Shan, Qiang; Xue, Hai-Hui] Univ Iowa, Dept Microbiol, Carver Coll Med, Iowa City, IA 52242 USA; [Sharpe, Arlene H.] Harvard Med Sch, Dept Microbiol & Immunol, Boston, MA 02115 USA; [Sharpe, Arlene H.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Freeman, Gordon J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Dept Med, Boston, MA 02115 USA; [Xue, Hai-Hui] Univ Iowa, Carver Coll Med, Interdisciplinary Immunol Grad Program, Iowa City, IA 52242 USA	Emory University; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; Emory University; Universidade de Sao Paulo; University of Iowa; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Iowa	Ahmed, R (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.; Ahmed, R (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.	rahmed@emory.edu	Kissick, Haydn/AAS-6292-2021; Nakaya, Helder/AAF-1738-2020; Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020; Nakaya, Helder I/A-1397-2010; Hashimoto, Masao/AAC-9225-2020; Freeman, Gordon/AAC-5380-2019	Kissick, Haydn/0000-0001-7624-5598; Nakaya, Helder/0000-0001-5297-9108; Nakaya, Helder I/0000-0001-5297-9108; Hashimoto, Masao/0000-0002-7120-1390; Freeman, Gordon/0000-0002-7210-5616; Gerner, Michael/0000-0001-5406-8308; Shan, Qiang/0000-0002-7089-0278; Xue, Hai-Hui/0000-0002-9163-7669	National Institutes of Health [R01 AI30048, P01 AI056299, R01 AI112579, R01 AI121080]; Intramural Research Program of NIAID, NIH; Prostate Cancer Foundation; Swim Across America; CNPq; NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001034, P01AI080192, P01AI056299, R01AI112579, R01AI030048, R01AI121080] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Prostate Cancer Foundation; Swim Across America; CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health grants R01 AI30048 (R.A.), P01 AI056299 (R.A. and A.H.S.), R01 AI112579 (H.H.X.) and R01 AI121080 (H.-H.X.) and also by the Intramural Research Program of NIAID, NIH (R.N.G. and M.Y.G.). H.T.K. is supported by funding from the Prostate Cancer Foundation and Swim Across America. H.I.N. receives a CNPq research fellowship. The authors acknowledge technical support from R. Karaffa and S. Durham for cell sorting.	Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Blackburn SD, 2008, P NATL ACAD SCI USA, V105, P15016, DOI 10.1073/pnas.0801497105; Choi YS, 2015, NAT IMMUNOL, V16, P980, DOI 10.1038/ni.3226; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cui GL, 2015, CELL, V161, P750, DOI 10.1016/j.cell.2015.03.021; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Jung YW, 2010, J IMMUNOL, V185, P5315, DOI 10.4049/jimmunol.1001948; Kim HJ, 2010, NATURE, V467, P328, DOI 10.1038/nature09370; Masopust D, 2010, J EXP MED, V207, P553, DOI 10.1084/jem.20090858; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; Miyazaki M, 2015, GENE DEV, V29, P409, DOI 10.1101/gad.255331.114; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Mueller SN, 2007, P NATL ACAD SCI USA, V104, P15430, DOI 10.1073/pnas.0702579104; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Quigley MF, 2007, EUR J IMMUNOL, V37, P3352, DOI 10.1002/eji.200636746; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wu JQ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002565; Xu LF, 2015, NAT IMMUNOL, V16, P991, DOI 10.1038/ni.3229; Yamazaki C, 2013, J IMMUNOL, V190, P6071, DOI 10.4049/jimmunol.1202798; Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	37	897	921	13	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2016	537	7620					417	+		10.1038/nature19330	http://dx.doi.org/10.1038/nature19330			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV7EC	27501248	Green Accepted			2023-01-03	WOS:000383098000057
J	Creanga, AA; Odhiambo, GA; Odera, B; Odhiambo, FO; Desai, M; Goodwin, M; Laserson, K; Goldberg, H				Creanga, Andreea A.; Odhiambo, George Awino; Odera, Benjamin; Odhiambo, Frank O.; Desai, Meghna; Goodwin, Mary; Laserson, Kayla; Goldberg, Howard			Pregnant Women's Intentions and Subsequent Behaviors Regarding Maternal and Neonatal Service Utilization: Results from a Cohort Study in Nyanza Province, Kenya	PLOS ONE			English	Article							FACILITY-BASED DELIVERY; OF-THE-LITERATURE; PLANNED BEHAVIOR; DEVELOPING-COUNTRIES; HOME DELIVERY; CARE; BARRIERS; HEALTH; METAANALYSIS; CHILDBIRTH	Higher use of maternal and neonatal health (MNH) services may reduce maternal and neonatal mortality in Kenya. This study aims to: 1) prospectively explore women's intentions to use MNH services (antenatal care, delivery in a facility, postnatal care, neonatal care) at < 20 and 30-35 weeks' gestation and their actual use of these services; 2) identify predictors of intention-behavior discordance among women with positive service use intentions; 3) examine associations between place of delivery, women's reasons for choosing it, and birthing experiences. We used data from a 2012-2013 population-based cohort of pregnant women in the Demographic Surveillance Site in Nyanza province, Kenya. Of 1,056 women completing the study (89.1% response rate), 948 had live-births and 22 stillbirths, and they represent our analytic sample. Logistic regression analysis identified predictors of intention-behavior discordance regarding delivery in a facility and use of postnatal and neonatal care. At < 20 and 30-35 weeks' gestation, most women intended to seek MNH services (>= 93.9% and >= 87.5%, respectively, for all services assessed). Actual service use was high for antenatal (98.1%) and neonatal (88.5%) care, but lower for delivery in a facility (76.9%) and postnatal care (51.8%). Woman's age > 35 and high-school education were significant predictors of intention-behavior discordance regarding delivery in a facility; several delivery-related factors were significantly associated with intention-behavior discordance regarding use of postnatal and neonatal care. Delivery facilities were chosen based on proximity to women's residence, affordability, and service quality; among women who delivered outside a health facility, 16.3% could not afford going to a facility. Good/very good birth experiences were reported by 93.6% of women who delivered in a facility and 32.6% of women who did not. We found higher MNH service utilization than previously documented in Nyanza province. Further increasing the number of facility deliveries and use of postnatal care may improve MNH in Kenya.	[Creanga, Andreea A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Creanga, Andreea A.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Ctr Maternal & Newborn Hlth, Baltimore, MD 21205 USA; [Odhiambo, George Awino; Odera, Benjamin; Odhiambo, Frank O.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya; [Desai, Meghna; Laserson, Kayla] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA; [Goodwin, Mary; Goldberg, Howard] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; [Laserson, Kayla] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Kenya Medical Research Institute; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Creanga, AA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.; Creanga, AA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Ctr Maternal & Newborn Hlth, Baltimore, MD 21205 USA.	acreanga@jhu.edu			US Centers for Disease Control and Prevention	US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The study was funded by the US Centers for Disease Control and Prevention; authors have received no funding to prepare the manuscript.	Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2012, KENYA COUNTRY STAT; Audo M O, 2005, East Afr Med J, V82, P547; Bell J, 2003, BIRTH-ISS PERINAT C, V30, P227, DOI 10.1046/j.1523-536X.2003.00252.x; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; Conner M, 1998, J APPL SOC PSYCHOL, V28, P1429, DOI 10.1111/j.1559-1816.1998.tb01685.x; Conner M., 1996, PREDICTING HLTH BEHA; de Bernis L, 2003, BRIT MED BULL, V67, P39, DOI 10.1093/bmb/ldg017; Doctor HV, 2012, REPROD HEALTH MATTER, V20, P104, DOI 10.1016/S0968-8080(12)39615-8; Dogba M, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-7; Gebrehiwot T, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-113; Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87; Hounton S, 2008, TROP MED INT HEALTH, V13, P44, DOI 10.1111/j.1365-3156.2008.02086.x; Iyengar SD, 2008, J PERINATOL, V28, pS23, DOI 10.1038/jp.2008.174; Izugbara CO, 2009, PUBLIC HEALTH REP, V124, P585, DOI 10.1177/003335490912400416; Kenya National Bureau of Statistics Nairobi Kenya and MEASURE DHS ICF Macro Calverton Maryland USA, 2009, NAIR KEN MEASURE DHS; Loundon I, 1992, DEATH CHILD BIRTH IN; Magoma M, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-13; Mrisho M, 2007, TROP MED INT HEALTH, V12, P862, DOI 10.1111/j.1365-3156.2007.01855.x; Mwangome FK, 2012, RURAL REMOTE HEALTH, V12; Nair M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004749; Ono M, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-214; Ouma PO, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-1; Oyerinde K, 2012, J COMMUN MED HLTH ED, V2, P1, DOI DOI 10.4172/2161-0711.1000149; Parkhurst JO, 2006, J HEALTH POPUL NUTR, V24, P438; Pembe Andrea B, 2008, Afr J Reprod Health, V12, P120; RANDALL DM, 1994, BRIT J SOC PSYCHOL, V33, P405, DOI 10.1111/j.2044-8309.1994.tb01037.x; Seljeskog Line, 2006, Afr J Reprod Health, V10, P66; Sheeran P, 1998, BRIT J SOC PSYCHOL, V37, P231, DOI 10.1111/j.2044-8309.1998.tb01167.x; Shiferaw S, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-5; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Sorensen BL, 2011, AFR J REPROD HEALTH, V15, P2; Story WT, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-28; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-43; Turan JM, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001295; van Eijk Anna M, 2006, Reprod Health, V3, P2, DOI 10.1186/1742-4755-3-2; WHO UNICEF, 2013, TRENDS MAT MORT 1990; World Bank, 2014, KEN COUNTR EST	41	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2016	11	9							e0162017	10.1371/journal.pone.0162017	http://dx.doi.org/10.1371/journal.pone.0162017			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DW5JR	27622496	Green Published, gold, Green Submitted			2023-01-03	WOS:000383681000013
J	Bahler, C; Signorell, A; Reich, O				Bahler, Caroline; Signorell, Andri; Reich, Oliver			Health Care Utilisation and Transitions between Health Care Settings in the Last 6 Months of Life in Switzerland	PLOS ONE			English	Article							SMALL-AREA ANALYSIS; OLDER-PEOPLE; RETROSPECTIVE ANALYSIS; END; PLACE; DEATH; PATIENT; HOSPITALIZATIONS; PREFERENCES; POPULATION	Background Many efforts are undertaken in Switzerland to enable older and/or chronically ill patients to stay home longer at the end-of-life. One of the consequences might be an increased need for hospitalisations at the end-of-life, which goes along with burdensome transitions for patients and higher health care costs for the society. Aim We aimed to examine the health care utilisation in the last six months of life, including transitions between health care settings, in a Swiss adult population. Methods The study population consisted of 11'310 decedents of 2014 who were insured at the Helsana Group, the leading health insurance in Switzerland. Descriptive statistics were used to analyse the health care utilisation by age group, taking into account individual and regional factors. Zero-inflated Poisson regression model was used to predict the number of transitions. Results Mean age was 78.1 in men and 83.8 in women. In the last six months of life, 94.7% of the decedents had at least one consultation; 61.6% were hospitalised at least once, with a mean length of stay of 28.3 days; and nursing home stays were seen in 47.4% of the decedents. Over the same time period, 64.5% were transferred at least once, and 12.9% experienced at least one burdensome transition. Main predictors for transitions were age, sex and chronic conditions. A high density of home care nurses was associated with a decrease, whereas a high density of ambulatory care physicians was associated with an increase in the number of transitions. Conclusions Health care utilisation was high in the last six months of life and a considerable number of decedents were being transferred. Advance care planning might prevent patients from numerous and particularly from burdensome transitions.	[Bahler, Caroline; Signorell, Andri; Reich, Oliver] Helsana Insurance Grp, Dept Hlth Sci, CH-8081 Zurich, Switzerland		Reich, O (corresponding author), Helsana Insurance Grp, Dept Hlth Sci, CH-8081 Zurich, Switzerland.	oliver.reich@helsana.ch			Helsana Group	Helsana Group	Helsana Group provided support in the form of salaries for authors [CB, OR, AS] but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abarshi E, 2010, PALLIATIVE MED, V24, P166, DOI 10.1177/0269216309351381; Abel J, 2009, PALLIATIVE MED, V23, P616, DOI 10.1177/0269216309106460; Bach PB, 2004, JAMA-J AM MED ASSOC, V292, P2765, DOI 10.1001/jama.292.22.2765; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Beernaert K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137251; Berlin C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-289; Bundesamt fur Gesundheit und Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren, 2012, NAT STRAT PALL CAR 2; Bundesamt fur Statistik [Swiss Federal Statistical Office], 2013, STAT HILF PFLEG HAUS; Bundesamt fur Statistik [Swiss Federal Statistical Office], 2015, NOM RAUML GLIED; Bundesamt fur Statistik [Swiss Federal Statistical Office], 2013, STAT SOZ I SOMED; Burge Frederick I, 2005, BMC Palliat Care, V4, P3, DOI 10.1186/1472-684X-4-3; Chitnis XA, 2013, BMJ SUPPORT PALLIAT, V3, P422, DOI 10.1136/bmjspcare-2012-000424; Dowling-Castronovo A, 2002, GERONTOLOGIST, V42, P82, DOI 10.1093/geront/42.suppl_3.54; Evans G, 2011, J EVAL CLIN PRACT, V17, P1045, DOI 10.1111/j.1365-2753.2010.01471.x; FMH [Swiss Medical Association], 2013, ARZTESTATISTIK; Fried TR, 1999, ANN INTERN MED, V131, P109, DOI 10.7326/0003-4819-131-2-199907200-00006; Gielen B, 2010, HEALTH POLICY, V97, P53, DOI 10.1016/j.healthpol.2010.03.002; Gomez-Batiste X, 2007, J PAIN SYMPTOM MANAG, V33, P584, DOI 10.1016/j.jpainsymman.2007.02.019; Hedinger D, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0111-3; Hedinger D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113236; Hollander MJ, 2007, CAN J AGING, V26, P149, DOI 10.3138/cja.26.suppl_1.149; Huber CA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1030; JACOB JA, 2015, JAMA J AM MED ASSOC, V314, P761; Kardamanidis K, 2007, MED J AUSTRALIA, V187, P383, DOI 10.5694/j.1326-5377.2007.tb01306.x; Kaspers PJ, 2013, PALLIATIVE MED, V27, P544, DOI 10.1177/0269216312457212; Klauss G, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-33; Klinkenberg M, 2005, HEALTH SOC CARE COMM, V13, P420, DOI 10.1111/j.1365-2524.2005.00567.x; Ko W, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-960; Lawson Beverley, 2006, BMC Palliat Care, V5, P4, DOI 10.1186/1472-684X-5-4; Matter-Walstra K, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-119; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Organisation for Economic Co-operation and Development (OECD), 2013, LIF EXP BIRTH; Perrels AJ, 2014, PALLIATIVE MED, V28, P220, DOI 10.1177/0269216313510341; Pollock K, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4855; Reich O, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-116; Simoens S, 2010, J PALLIAT MED, V13, P1365, DOI 10.1089/jpm.2010.0212; Switzerland GfK, 2009, BEV PALL CAR; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Van den Block L, 2007, JAMA-J AM MED ASSOC, V298, P1638, DOI 10.1001/jama.298.14.1638; Van den Block Lieve, 2007, BMC Palliat Care, V6, P6; van den Block L, 2015, EUR J PUBLIC HEALTH, V25, P569, DOI 10.1093/eurpub/ckv039; Zeileis A, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i08	43	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2016	11	9							e0160932	10.1371/journal.pone.0160932	http://dx.doi.org/10.1371/journal.pone.0160932			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DV9IT	27598939	Green Published, gold, Green Submitted			2023-01-03	WOS:000383254800004
J	Zaretsky, JM; Garcia-Diaz, A; Shin, DS; Escuin-Ordinas, H; Hugo, W; Hu-Lieskovan, S; Torrejon, DY; Abril-Rodriguez, G; Sandoval, S; Barthly, L; Saco, J; Moreno, BH; Mezzadra, R; Chmielowski, B; Ruchalski, K; Shintaku, IP; Sanchez, PJ; Puig-Saus, C; Cherry, G; Seja, NPE; Kong, XJ; Pang, J; Berent-Maoz, B; Comin-Anduix, B; Graeber, TG; Tumeh, PC; Schumacher, TNM; Lo, RS; Ribas, A				Zaretsky, Jesse M.; Garcia-Diaz, Angel; Shin, Daniel S.; Escuin-Ordinas, Helena; Hugo, Willy; Hu-Lieskovan, Siwen; Torrejon, Davis Y.; Abril-Rodriguez, Gabriel; Sandoval, Salemiz; Barthly, Lucas; Saco, Justin; Moreno, Blanca Homet; Mezzadra, Riccardo; Chmielowski, Bartosz; Ruchalski, Kathleen; Shintaku, I. Peter; Sanchez, Phillip J.; Puig-Saus, Cristina; Cherry, Grace; Seja, N. P. Elizabeth; Kong, Xiangju; Pang, Jia; Berent-Maoz, Beata; Comin-Anduix, Begona; Graeber, Thomas G.; Tumeh, Paul C.; Schumacher, Ton N. M.; Lo, Roger S.; Ribas, Antoni			Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM SURVIVAL; ADAPTIVE IMMUNE RESISTANCE; GAMMA SIGNAL-TRANSDUCTION; METASTATIC MELANOMA; CANCER-IMMUNOTHERAPY; GENE-EXPRESSION; IPILIMUMAB; CELLS; PEMBROLIZUMAB; RESPONSES	BACKGROUND Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this context are unknown. METHODS We analyzed biopsy samples from paired baseline and relapsing lesions in four patients with metastatic melanoma who had had an initial objective tumor regression in response to anti-PD-1 therapy (pembrolizumab) followed by disease progression months to years later. RESULTS Whole-exome sequencing detected clonal selection and outgrowth of the acquired resistant tumors and, in two of the four patients, revealed resistance-associated loss-of-function mutations in the genes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the wild-type allele. A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient. JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, including insensitivity to its antiproliferative effects on cancer cells. The B2M truncating mutation led to loss of surface expression of major histocompatibility complex class I. CONCLUSIONS In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation. (Funded by the National Institutes of Health and others.)	[Zaretsky, Jesse M.; Garcia-Diaz, Angel; Shin, Daniel S.; Escuin-Ordinas, Helena; Hugo, Willy; Hu-Lieskovan, Siwen; Torrejon, Davis Y.; Abril-Rodriguez, Gabriel; Sandoval, Salemiz; Barthly, Lucas; Saco, Justin; Moreno, Blanca Homet; Chmielowski, Bartosz; Ruchalski, Kathleen; Shintaku, I. Peter; Sanchez, Phillip J.; Puig-Saus, Cristina; Cherry, Grace; Seja, N. P. Elizabeth; Kong, Xiangju; Pang, Jia; Berent-Maoz, Beata; Comin-Anduix, Begona; Graeber, Thomas G.; Tumeh, Paul C.; Lo, Roger S.; Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA USA; [Chmielowski, Bartosz; Comin-Anduix, Begona; Graeber, Thomas G.; Tumeh, Paul C.; Lo, Roger S.; Ribas, Antoni] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA; [Mezzadra, Riccardo; Schumacher, Ton N. M.] Netherlands Canc Inst, Div Immunol, Amsterdam, Netherlands	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; Netherlands Cancer Institute	Ribas, A (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	aribas@mednet.ucla.edu	Schumacher, Ton/Y-2432-2019; Garcia-Diaz, Angel/AAT-9213-2020; Torrejon, Davis/ABC-5589-2020	Schumacher, Ton/0000-0003-0517-8804; Garcia-Diaz, Angel/0000-0001-6139-6764; Torrejon, Davis/0000-0002-4864-6236; Hugo, Willy/0000-0002-1426-7190; Puig Saus, Cristina/0000-0002-3014-3649; Graeber, Thomas/0000-0001-8574-9181; Mezzadra, Riccardo/0000-0002-7737-8461	National Institutes of Health; NATIONAL CANCER INSTITUTE [U54CA199090, T32CA009297, T32CA009120, R35CA197633, P01CA168585, R01CA170689, P30CA016042] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124, UL1TR001881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by the National Institutes of Health and others.	Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Atefi M, 2014, CLIN CANCER RES, V20, P3446, DOI 10.1158/1078-0432.CCR-13-2797; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Corrales L, 2016, CYTOKINE, V77, P245, DOI 10.1016/j.cyto.2015.08.258; Dunn GP, 2005, CANCER RES, V65, P3447, DOI 10.1158/0008-5472.CAN-04-4316; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Eroglu Z, 2015, EUR J CANCER, V51, P2689, DOI 10.1016/j.ejca.2015.08.012; FINKE JH, 1993, CANCER RES, V53, P5613; Fish EN, 2014, MOL CANCER RES, V12, P1691, DOI 10.1158/1541-7786.MCR-14-0450; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Sucker A, 2014, CLIN CANCER RES, V20, P6593, DOI 10.1158/1078-0432.CCR-14-0567; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	37	1813	1883	9	174	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2016	375	9					819	829		10.1056/NEJMoa1604958	http://dx.doi.org/10.1056/NEJMoa1604958			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU9HA	27433843	Green Published, Green Accepted			2023-01-03	WOS:000382526000005
J	Frelinger, AL; Gerrits, AJ; Garner, AL; Torres, AS; Caiafa, A; Morton, CA; Berny-Lang, MA; Carmichael, SL; Neculaes, VB; Michelson, AD				Frelinger, Andrew L., III; Gerrits, Anja J.; Garner, Allen L.; Torres, Andrew S.; Caiafa, Antonio; Morton, Christine A.; Berny-Lang, Michelle A.; Carmichael, Sabrina L.; Neculaes, V. Bogdan; Michelson, Alan D.			Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma	PLOS ONE			English	Article							IRREVERSIBLE ELECTROPORATION; MEMBRANE PERMEABILIZATION; NANOSECOND PULSES; EPITHELIAL-CELLS; BOVINE THROMBIN; ELECTROPERMEABILIZATION; DURATION; IMPACT; GROWTH; GEL	Background Activated autologous platelet-rich plasma (PRP) used in therapeutic wound healing applications is poorly characterized and standardized. Using pulsed electric fields (PEF) to activate platelets may reduce variability and eliminate complications associated with the use of bovine thrombin. We previously reported that exposing PRP to sub-microsecond duration, high electric field (SMHEF) pulses generates a greater number of platelet-derived microparticles, increased expression of prothrombotic platelet surfaces, and differential release of growth factors compared to thrombin. Moreover, the platelet releasate produced by SMHEF pulses induced greater cell proliferation than plasma. Aims To determine whether sub-microsecond duration, low electric field (SMLEF) bipolar pulses results in differential activation of PRP compared to SMHEF, with respect to profiles of activation markers, growth factor release, and cell proliferation capacity. Methods PRP activation by SMLEF bipolar pulses was compared to SMHEF pulses and bovine thrombin. PRP was prepared using the Harvest SmartPreP2 System from acid citrate dextrose anticoagulated healthy donor blood. PEF activation by either SMHEF or SMLEF pulses was performed using a standard electroporation cuvette preloaded with CaCl2 and a prototype instrument designed to take into account the electrical properties of PRP. Flow cytometry was used to assess platelet surface P-selectin expression, and annexin V binding. Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), endothelial growth factor (EGF) and platelet factor 4 (PF4), and were measured by ELISA. The ability of supernatants to stimulate proliferation of human epithelial cells in culture was also evaluated. Controls included vehicle-treated, unactivated PRP and PRP with 10 mM CaCl2 activated with 1 U/mL bovine thrombin. Results PRP activated with SMLEF bipolar pulses or thrombin had similar light scatter profiles, consistent with the presence of platelet-derived microparticles, platelets, and platelet aggregates whereas SMHEF pulses primarily resulted in platelet-derived microparticles. Microparticles and platelets in PRP activated with SMLEF bipolar pulses had significantly lower annexin V-positivity than those following SMHEF activation. In contrast, the% P-selectin positivity and surface P-selectin expression (MFI) for platelets and microparticles in SMLEF bipolar pulse activated PRP was significantly higher than that in SMHEF-activated PRP, but not significantly different from that produced by thrombin activation. Higher levels of EGF were observed following either SMLEF bipolar pulses or SMHEF pulses of PRP than after bovine thrombin activation while VEGF, PDGF, and PF4 levels were similar with all three activating conditions. Cell proliferation was significantly increased by releasates of both SMLEF bipolar pulse and SMHEF pulse activated PRP compared to plasma alone. Conclusions PEF activation of PRP at bipolar low vs. monopolar high field strength results in differential platelet-derived microparticle production and activation of platelet surface procoagulant markers while inducing similar release of growth factors and similar capacity to induce cell proliferation. Stimulation of PRP with SMLEF bipolar pulses is gentler than SMHEF pulses, resulting in less platelet microparticle generation but with overall activation levels similar to that obtained with thrombin. These results suggest that PEF provides the means to alter, in a controlled fashion, PRP properties thereby enabling evaluation of their effects on wound healing and clinical outcomes.	[Frelinger, Andrew L., III; Gerrits, Anja J.; Berny-Lang, Michelle A.; Carmichael, Sabrina L.; Michelson, Alan D.] Harvard Med Sch, Boston Childrens Hosp, Dana Farber Canc Inst, Ctr Platelet Res Studies,Div Hematol Oncol, Boston, MA 02115 USA; [Garner, Allen L.] Purdue Univ, Sch Nucl Engn, W Lafayette, IN 47907 USA; [Torres, Andrew S.; Caiafa, Antonio; Morton, Christine A.; Neculaes, V. Bogdan] GE Global Res Ctr, Niskayuna, NY 12309 USA; [Torres, Andrew S.] Regeneron Pharmaceut Inc, Rensselaer, NY USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Purdue University System; Purdue University; Purdue University West Lafayette Campus; General Electric; Regeneron	Frelinger, AL (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Dana Farber Canc Inst, Ctr Platelet Res Studies,Div Hematol Oncol, Boston, MA 02115 USA.; Neculaes, VB (corresponding author), GE Global Res Ctr, Niskayuna, NY 12309 USA.	Andrew.Frelinger@childrens.harvard.edu; Neculaes@research.ge.com	Michelson, Alan/ABE-8487-2021; Caiafa, Antonio/AAI-7593-2020	Michelson, Alan/0000-0002-1746-4819; Berny-Lang, Michelle/0000-0001-5889-4295; Frelinger, Andrew/0000-0002-6871-7441	GE Healthcare	GE Healthcare(General ElectricGE Healthcare)	This work was funded by a research grant from GE Healthcare to Boston Children's Hospital, Principal Investigator, ALF. The funders participated in study design, data collection, and preparation of the manuscript, but had no role in data analysis or the decision to publish.	Alexander W, 2009, P T, V34, P688; [Anonymous], 2014, THROMBIN JMI THROMB; Barnes R, 2015, FINITE ELEMENT METHO; Beebe SJ, 2015, BIOELECTROCHEMISTRY, V103, P52, DOI 10.1016/j.bioelechem.2014.08.014; Beebe Stephen J, 2013, Cells, V2, P136, DOI 10.3390/cells2010136; Beier HT, 2012, BIOCHEM BIOPH RES CO, V423, P863, DOI 10.1016/j.bbrc.2012.06.055; Berney-Lang MA, 2013, PLATELETS, P581; Berny-Lang MA, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000026; Bielecki TM, 2007, J BONE JOINT SURG BR, V89B, P417, DOI 10.1302/0301-620X.89B3.18491; Breton M, 2012, J AM CHEM SOC, V134, P13938, DOI 10.1021/ja3052365; Breton M, 2012, BIOELECTROMAGNETICS, V33, P106, DOI 10.1002/bem.20692; Bundy L, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-43; CADA DJ, 2008, HOSP PHARM, V43, P43; Caiafa A, 2014, IEEE INT POWER MODUL, P35, DOI 10.1109/IPMHVC.2014.7287201; Chapman WC, 2007, J AM COLL SURGEONS, V205, P252, DOI 10.1016/j.jamcollsurg.2007.03.020; Diesen DL, 2008, VASCULAR, V16, pS29, DOI 10.2310/6670.2008.00031; Driver VR, 2006, OSTOMY WOUND MANAG, V52, P68; Frelinger AL, 2008, J THROMB HAEMOST, V6, P359; Frelinger AL, 2006, CIRCULATION, V113, P2888, DOI 10.1161/CIRCULATIONAHA.105.596627; Frelinger III AL, 2015, PLATELETS, P1; Garner AL, 2007, BIOCHEM BIOPH RES CO, V362, P139, DOI 10.1016/j.bbrc.2007.07.159; Garner AL, 2015, C ELECT INSUL DIEL P, P632, DOI 10.1109/CEIDP.2015.7352148; Gunaydin S, 2008, PERFUSION-UK, V23, P179, DOI 10.1177/0267659108097783; Haase I, 2003, J CELL SCI, V116, P3227, DOI 10.1242/jcs.00610; Ibey BL, 2014, BIOCHEM BIOPH RES CO, V443, P568, DOI 10.1016/j.bbrc.2013.12.004; Jiang CL, 2015, IEEE T BIO-MED ENG, V62, P4, DOI 10.1109/TBME.2014.2367543; Joshi R. P., 2010, Critical Reviews in Biomedical Engineering, V38, P255, DOI 10.1615/CritRevBiomedEng.v38.i3.20; Kotnik T, 2001, BIOELECTROCHEMISTRY, V54, P83, DOI 10.1016/S1567-5394(01)00114-1; Lacci Kathleen M., 2010, Yale Journal of Biology and Medicine, V83, P1; Lakka Klement G, 2013, PLATELETS, P487; Lambricht L, 2016, EXPERT OPIN DRUG DEL, V13, P295, DOI 10.1517/17425247.2016.1121990; LaPlante N, 2013, EX VIVO PLATELET ACT, P202; Lawson JH, 2006, SEMIN THROMB HEMOST, V32, P98, DOI 10.1055/s-2006-939559; Mahnic-Kalamiza S, 2014, J MEMBRANE BIOL, V247, P1279, DOI 10.1007/s00232-014-9737-x; Miklavcic D, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475-925X-13-29; Napotnik TB, 2012, BIOELECTROMAGNETICS, V33, P257, DOI 10.1002/bem.20707; Nuccitelli R, 2006, BIOCHEM BIOPH RES CO, V343, P351, DOI 10.1016/j.bbrc.2006.02.181; Ofosu FA, 2009, CLIN THER, V31, P679, DOI 10.1016/j.clinthera.2009.04.021; Pakhomov AG, 2007, ARCH BIOCHEM BIOPHYS, V465, P109, DOI 10.1016/j.abb.2007.05.003; Pakhomov AG, 2015, BBA-BIOMEMBRANES, V1848, P958, DOI 10.1016/j.bbamem.2014.12.026; Pakhomov AG, 2014, CELL MOL LIFE SCI, V71, P4431, DOI 10.1007/s00018-014-1626-z; Rogers WR, 2004, IEEE T PLASMA SCI, V32, P1587, DOI 10.1109/TPS.2004.831758; ROSA JP, 1987, J CLIN INVEST, V80, P1138, DOI 10.1172/JCI113171; Roth CC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15063; Scheffer HJ, 2014, J VASC INTERV RADIOL, V25, P997, DOI 10.1016/j.jvir.2014.01.028; Schoenbach KH, 2007, IEEE T DIELECT EL IN, V14, P1088, DOI 10.1109/TDEI.2007.4339468; Schoenbach KH, 2015, BIOELECTROCHEMISTRY, V103, P44, DOI 10.1016/j.bioelechem.2014.08.015; Schoenbach KH, 2004, P IEEE, V92, P1122, DOI 10.1109/JPROC.2004.829009; Semenov I, 2013, CELL CALCIUM, V54, P145, DOI 10.1016/j.ceca.2013.05.008; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Stadelmann WK, 1998, AM J SURG, V176, p26S, DOI 10.1016/S0002-9610(98)00183-4; TEKLE E, 1991, P NATL ACAD SCI USA, V88, P4230, DOI 10.1073/pnas.88.10.4230; Torres AS, 2014, J TRAUMA ACUTE CARE, V77, pS94, DOI 10.1097/TA.0000000000000322; Velnar T, 2009, J INT MED RES, V37, P1528, DOI 10.1177/147323000903700531; Vernier PT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-37; Vernier PT, 2006, J AM CHEM SOC, V128, P6288, DOI 10.1021/ja0588306; Vernier PT, 2003, BIOCHEM BIOPH RES CO, V310, P286, DOI 10.1016/j.bbrc.2003.08.140; Wasungu L, 2014, BIOELECTROCHEMISTRY, V100, P36, DOI 10.1016/j.bioelechem.2014.06.011; Weaver JC, 2012, BIOELECTROCHEMISTRY, V87, P236, DOI 10.1016/j.bioelechem.2012.02.007; Weaver JC, 1996, BIOELECTROCH BIOENER, V41, P135, DOI 10.1016/S0302-4598(96)05062-3; White JA, 2004, J BIOL CHEM, V279, P22964, DOI 10.1074/jbc.M311135200; Yarmush ML, 2014, ANNU REV BIOMED ENG, V16, P295, DOI 10.1146/annurev-bioeng-071813-104622; Zhang J, 2008, ARCH BIOCHEM BIOPHYS, V471, P240, DOI 10.1016/j.abb.2007.12.009	63	16	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2016	11	8							e0160933	10.1371/journal.pone.0160933	http://dx.doi.org/10.1371/journal.pone.0160933			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU5NI	27556645	Green Published, gold, Green Submitted			2023-01-03	WOS:000382258100023
J	Cao, LL; Zhang, LJ; Zhao, X; Zhang, Y				Cao, Lili; Zhang, Lijun; Zhao, Xiang; Zhang, Ye			A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells	PLOS ONE			English	Article							CANCER-CELLS; TUBULIN POLYMERIZATION; BIOLOGICAL EVALUATION; MUTATIONAL LANDSCAPE; MOLECULAR THERAPIES; ANTITUBULIN AGENTS; NUCLEOLIN; KINASE; IDENTIFICATION; DERIVATIVES	Small molecule inhibitors that can simultaneously inhibit multiple oncogenic proteins in essential pathways are promising therapeutic chemicals for hepatocellular carcinoma (HCC). To combine the anticancer effects of combretastatins, chalcones and isatins, we synthesized a novel hybrid molecule 3', 4', 5'-trimethoxy-5-chloro-isatinylchalcone (3MCIC). 3MCIC inhibited proliferation of cultured HepG2 cells, causing rounding-up of the cells and massive vacuole accumulation in the cytoplasm. Paxillin and focal adhesion plaques were downregulated by 3MCIC. Surprisingly, unlike the microtubule (MT)-targeting agent CA-4 that inhibits tubulin polymerization, 3MCIC stabilized tubulin polymers both in living cells and in cell lysates. 3MCIC treatment reduced cyclin B1, CDK1, p-CDK1/2, and Rb, but increased p53 and p21. Moreover, 3MCIC caused GSK3 beta degradation by promoting GSK3 beta-Ser9 phosphorylation. Nevertheless, 3MCIC inhibited the Wnt/beta-catenin pathway by downregulating beta-catenin, c-Myc, cyclin D1 and E2F1. 3MCIC treatment not only activated the caspase-3-dependent apoptotic pathway, but also caused massive autophagy evidenced by rapid and drastic changes of LC3 and p62. 3MCIC also promoted cleavage and maturation of the lysosomal protease cathepsin D. Using ligand-affinity chromatography (LAC), target proteins captured onto the Sephacryl S1000-C-12-3MCIC resins were isolated and analyzed by mass spectrometry (MS). Some of the LAC-MS identified targets, i.e., septin-2, vimentin, pan-cytokeratin, nucleolin, EF1 alpha 1/2, EBP1 (PA2G4), cyclin B1 and GSK3 beta, were further detected by Western blotting. Moreover, both septin-2 and HIF-1 alpha decreased drastically in 3MCIC-treated HepG2 cells. Our data suggest that 3MCIC is a promising anticancer lead compound with novel targeting mechanisms, and also demonstrate the efficiency of LAC-MS based target identification in anticancer drug development.	[Cao, Lili; Zhao, Xiang; Zhang, Ye] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing, Peoples R China; [Zhang, Lijun] Peking Univ, Sch Life Sci, Beijing, Peoples R China	Peking University; Peking University	Zhang, Y (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing, Peoples R China.	zhangye@bjmu.edu.cn			National Natural Science Foundation of China [31171296]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The work was supported by the National Natural Science Foundation of China (No. 31171296). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075; Angelis D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096390; Bai Y, 2009, NEUROSCIENCE, V160, P371, DOI 10.1016/j.neuroscience.2009.01.076; Bai Y, 2009, NEUROREPORT, V20, P918, DOI 10.1097/WNR.0b013e32832c92d7; Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008; Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Bilsland AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006459; Bupathi M, 2014, ONCOTARGETS THER, V7, P1927, DOI 10.2147/OTT.S46457; Chen C, 2015, WORLD J HEPATOL, V7, P1964, DOI 10.4254/wjh.v7.i15.1964; Cheng DD, 2014, BIOCHEM BIOPH RES CO, V443, P598, DOI 10.1016/j.bbrc.2013.12.020; Cinghu S, 2014, P NATL ACAD SCI USA, V111, pE1581, DOI 10.1073/pnas.1318598111; Cleary SP, 2013, HEPATOLOGY, V58, P1693, DOI 10.1002/hep.26540; Delire B, 2015, EUR J CLIN INVEST, V45, P609, DOI 10.1111/eci.12441; Deng GL, 2015, WORLD J HEPATOL, V7, P787, DOI 10.4254/wjh.v7.i5.787; Dolat L, 2014, J CELL BIOL, V207, P225, DOI 10.1083/jcb.201405050; Dolat L, 2014, BIOL CHEM, V395, P123, DOI 10.1515/hsz-2013-0233; Galuppo R, 2014, DIGEST DIS SCI, V59, P1688, DOI 10.1007/s10620-014-3058-x; Gangjee A, 2014, ACS MED CHEM LETT, V5, P480, DOI 10.1021/ml4004793; Germano D, 2014, WORLD J GASTROENTERO, V20, P3087, DOI 10.3748/wjg.v20.i12.3087; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Guo XD, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0175-y; Kamal A, 2015, ORG BIOMOL CHEM, V13, P3963, DOI 10.1039/c4ob02606c; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kanda M, 2015, WORLD J GASTROENTERO, V21, P10584, DOI 10.3748/wjg.v21.i37.10584; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Karim MR, 2014, ANAL BIOCHEM, V465, P28, DOI 10.1016/j.ab.2014.07.007; Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004; Kremer BE, 2005, MOL BIOL CELL, V16, P4648, DOI 10.1091/mbc.E05-03-0267; Krishnegowda G, 2011, BIOORGAN MED CHEM, V19, P6006, DOI 10.1016/j.bmc.2011.08.044; Kuo CC, 2004, CANCER RES, V64, P4621, DOI 10.1158/0008-5472.CAN-03-3474; Kuzuya T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138776; Lee WC, 2015, EJSO-EUR J SURG ONC, V41, P1144, DOI 10.1016/j.ejso.2015.05.024; Li JF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0105508, 10.1371/journal.pone.0090225]; Liu M, 2010, MOL BIOL REP, V37, P3601, DOI 10.1007/s11033-010-0009-2; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Lomenick B, 2011, ACS CHEM BIOL, V6, P34, DOI 10.1021/cb100294v; Mahapatra DM, 2015, EUR J MED CHEM, V98, P69, DOI 10.1016/j.ejmech.2015.05.004; Marks EI, 2016, CURR CANCER DRUG TAR, V16, P53, DOI 10.2174/1568009615666150916092903; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Mostowy S, 2012, NAT REV MOL CELL BIO, V13, P183, DOI 10.1038/nrm3284; Mukhtar E, 2014, MOL CANCER THER, V13, P275, DOI 10.1158/1535-7163.MCT-13-0791; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Negi AS, 2015, BIOORGAN MED CHEM, V23, P373, DOI 10.1016/j.bmc.2014.12.027; Nepali K, 2014, EUR J MED CHEM, V77, P422, DOI 10.1016/j.ejmech.2014.03.018; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; Pakravan P, 2013, PHARMACOL REP, V65, P313, DOI 10.1016/S1734-1140(13)71007-7; Palmer DH, 2015, CANCER METAST REV, V34, P497, DOI 10.1007/s10555-015-9580-2; Palmieri D, 2015, P NATL ACAD SCI USA, V112, P9418, DOI 10.1073/pnas.1507087112; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel A, 2014, CURR TREAT OPTION ON, V15, P380, DOI 10.1007/s11864-014-0291-7; Poruchynsky MS, 2015, P NATL ACAD SCI USA, V112, P1571, DOI 10.1073/pnas.1416418112; Renz C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148340; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Sato S, 2010, CHEM BIOL, V17, P616, DOI 10.1016/j.chembiol.2010.05.015; Siemann DW, 2011, CANCER TREAT REV, V37, P63, DOI 10.1016/j.ctrv.2010.05.001; Singh P, 2014, EUR J MED CHEM, V85, P758, DOI 10.1016/j.ejmech.2014.08.033; Smith C, 2015, J MOL BIOL, V427, P3273, DOI 10.1016/j.jmb.2015.07.026; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Toivola DM, 2015, CURR OPIN CELL BIOL, V32, P73, DOI 10.1016/j.ceb.2014.12.008; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tsubota A, 2010, CARCINOGENESIS, V31, P504, DOI 10.1093/carcin/bgp313; Ursu A, 2015, BIOORG MED CHEM LETT, V25, P3079, DOI 10.1016/j.bmcl.2015.06.023; Vardi-Oknin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073179; Villanueva A, 2014, NAT REV CLIN ONCOL, V11, P73, DOI [10.1038/nrclinonc.2013.227, 10.1038/nrclinonc.2013.243]; Villanueva A, 2013, J HEPATOL, V59, P392, DOI 10.1016/j.jhep.2013.03.025; Vine KL, 2009, ANTI-CANCER AGENT ME, V9, P397; Wei H, 2016, RSC ADV, V6, P10846, DOI 10.1039/c5ra26294a; Yang F, 2011, ACS CHEM BIOL, V6, P252, DOI 10.1021/cb100287q; Yang J, 2010, J CELL SCI, V123, P861, DOI 10.1242/jcs.060475; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; Zhang L, 2000, J CELL BIOL, V151, P1; Zhang L, 2015, RSC ADV, V5, P97816, DOI 10.1039/c5ra21217k; Zhao P, 2014, EUR J MED CHEM, V86, P165, DOI 10.1016/j.ejmech.2014.08.049	76	6	6	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2016	11	8							e0161025	10.1371/journal.pone.0161025	http://dx.doi.org/10.1371/journal.pone.0161025			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4SL	27525972	Green Submitted, Green Published, gold			2023-01-03	WOS:000381471100031
J	Wise, J				Wise, Jacqui			Prescription drug misuse in Europe is higher than previously thought	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Novak SP, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0909-3	1	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 4	2016	354								i4304	10.1136/bmj.i4304	http://dx.doi.org/10.1136/bmj.i4304			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS9CY	27492387				2023-01-03	WOS:000381081300006
J	Loc-Carrillo, C; Wang, C; Canden, A; Burr, M; Agarwal, J				Loc-Carrillo, Catherine; Wang, Caroline; Canden, Ahranee; Burr, Michael; Agarwal, Jayant			Local Intramedullary Delivery of Vancomycin Can Prevent the Development of Long Bone Staphylococcus aureus Infection	PLOS ONE			English	Article							SURGICAL-SITE INFECTIONS; RAT MODEL; IN-VITRO; CHRONIC OSTEOMYELITIS; JOINT INFECTIONS; OPEN FRACTURES; PROPHYLAXIS; PHARMACOKINETICS; EPIDEMIOLOGY; ANTIBIOTICS	Current treatments for methicillin-resistant Staphylococcus aureus (MRSA) infections require intravenously delivered vancomycin; however, systemically delivered vancomycin has its problems. To determine the feasibility and safety of locally delivering vancomycin hydrochloride (similar to 25 mg/Kg) to the medullary canal of long bones, we conducted a pharmacokinetics study using a rat tibia model. We found that administering the vancomycin intraosseously resulted in very low concentrations of vancomycin in the blood plasma and the muscle surrounding the tibia, reducing the risk for systemic toxicity, which is often seen with traditional intravenous administration of vancomycin. Additionally, we were able to inhibit the development of osteomyelitis in the tibia if the treatment was administered locally at the same time as a bacterial inoculum (i.e., Log(10) 7.82 CFU/mL or 6.62x10(7) CFU/mL), when compared to an untreated group. These findings suggest that local intramedullary vancomycin delivery can achieve sufficiently high local concentrations to prevent development of osteomyelitis while minimizing systemic toxicity.	[Loc-Carrillo, Catherine; Wang, Caroline; Canden, Ahranee; Agarwal, Jayant] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA; [Loc-Carrillo, Catherine; Agarwal, Jayant] Univ Utah, Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Salt Lake City, UT 84112 USA; [Burr, Michael] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA	US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Loc-Carrillo, C (corresponding author), VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA.; Loc-Carrillo, C (corresponding author), Univ Utah, Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Salt Lake City, UT 84112 USA.	c.loc.carrillo@hsc.utah.edu	Loc-Carrillo, Catherine/B-5461-2014	Loc-Carrillo, Catherine/0000-0002-7265-1203; Wang-Crocker, Caroline/0000-0002-4233-1110	University of Utah Research Foundation	University of Utah Research Foundation	This work was supported by the University of Utah Research Foundation to JA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Antoci V, 2007, CLIN ORTHOP RELAT R, P200, DOI 10.1097/BLO.0b013e31811ff866; Ball AP, 2004, J CHEMOTHERAPY, V16, P419, DOI 10.1179/joc.2004.16.5.419; Bhattacharya R, 2013, MAT SCI ENG C-MATER, V33, P3986, DOI 10.1016/j.msec.2013.05.036; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; Crawford T, 2012, CLIN INFECT DIS; Darley ESR, 2004, J ANTIMICROB CHEMOTH, V53, P928, DOI 10.1093/jac/dkh191; De Smet E, 2006, EUR J ORAL SCI, V114, P232, DOI 10.1111/j.1600-0722.2006.00355.x; DWORKIN R, 1990, ANTIMICROB AGENTS CH, V34, P1014, DOI 10.1128/AAC.34.6.1014; Edin ML, 1996, CLIN ORTHOP RELAT R, P245; EVANS RS, 1990, DICP ANN PHARMAC, V24, P351, DOI 10.1177/106002809002400401; Folsch C, 2015, INT ORTHOP, V39, P981, DOI 10.1007/s00264-014-2582-9; Francis KP, 2000, INFECT IMMUN, V68, P3594, DOI 10.1128/IAI.68.6.3594-3600.2000; GERHART TN, 1988, J ORTHOPAED RES, V6, P585, DOI 10.1002/jor.1100060417; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; Hanssen AD, 1999, CLIN ORTHOP RELAT R, P124; Harbarth S, 2008, JAMA-J AM MED ASSOC, V299, P1149, DOI 10.1001/jama.299.10.1149; Kavanagh KT, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/2047-2994-3-18; Korol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083743; Lazzarini L, 2004, J BONE JOINT SURG AM, V86A, P2305, DOI 10.2106/00004623-200410000-00028; Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086/491709; Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140-6736(04)16727-5; Lucke M, 2005, BONE, V36, P770, DOI 10.1016/j.bone.2005.01.008; MARRE R, 1984, J ANTIMICROB CHEMOTH, V14, P253, DOI 10.1093/jac/14.3.253; MATZKE GR, 1986, CLIN PHARMACOKINET, V11, P257, DOI 10.2165/00003088-198611040-00001; McHugh SM, 2011, J ANTIMICROB CHEMOTH, V66, P693, DOI 10.1093/jac/dkr009; McKinnon PS, 2004, EUR J CLIN MICROBIOL, V23, P271, DOI 10.1007/s10096-004-1107-7; McNamara DR, 2005, J AM ACAD ORTHOP SUR, V13, P89, DOI 10.5435/00124635-200503000-00001; O'Neill KR, 2011, SPINE J, V11, P641, DOI 10.1016/j.spinee.2011.04.025; Peel TN, 2012, ANTIMICROB AGENTS CH, V56, P2386, DOI 10.1128/AAC.06246-11; Pritchard L, 2010, AM J MED, V123, P1143, DOI 10.1016/j.amjmed.2010.07.025; Quintiliani R, 2004, INFECT MED, V21, P219; Rodvold KA, 2001, PHARMACOTHERAPY, V21, p319S, DOI 10.1592/phco.21.18.319S.33904; Rubinstein E, 2014, FRONTIERS PUBLIC HLT, V2; Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI 10.2146/ajhp080434; Rybak MJ, 2006, CLIN INFECT DIS, V42, pS35, DOI 10.1086/491712; Sakoulas G, 2004, J CLIN MICROBIOL, V42, P2398, DOI 10.1128/JCM.42.6.2398-2402.2004; Sjollema J, 2010, BIOMATERIALS, V31, P1984, DOI 10.1016/j.biomaterials.2009.11.068; Solberg BD, 1999, J ORTHOP TRAUMA, V13, P102, DOI 10.1097/00005131-199902000-00006; Stefani S, 2012, INT J ANTIMICROB AG, V39, P273, DOI 10.1016/j.ijantimicag.2011.09.030; Whitehouse JD, 2002, INFECT CONT HOSP EP, V23, P183, DOI 10.1086/502033; Yoeruek E, 2008, J CATARACT REFR SURG, V34, P2139, DOI 10.1016/j.jcrs.2008.08.022; Zalavras CG, 2004, CLIN ORTHOP RELAT R, P86, DOI 10.1097/01.blo.0000143571.18892.8d	43	19	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2016	11	7							e0160187	10.1371/journal.pone.0160187	http://dx.doi.org/10.1371/journal.pone.0160187			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IM	27472197	gold, Green Published, Green Submitted			2023-01-03	WOS:000381516300036
J	Drepper, VJ; Kihm, LP; Kalble, F; Diekmann, C; Seckinger, J; Sommerer, C; Zeier, M; Schwenger, V				Drepper, Valerie Jotterand; Kihm, Lars P.; Kaelble, Florian; Diekmann, Christian; Seckinger, Joerg; Sommerer, Claudia; Zeier, Martin; Schwenger, Vedat			Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients-Independently of Cardiac Failure	PLOS ONE			English	Article							WHOLE-BODY BIOIMPEDANCE; RESIDUAL RENAL-FUNCTION; HEMODIALYSIS-PATIENTS; INCIDENT PERITONEAL; NATRIURETIC PEPTIDE; TROPONIN-T; SPECTROSCOPY; SURVIVAL; RISK; INFLAMMATION	Background Overhydration is a common problem in peritoneal dialysis patients and has been shown to be associated with mortality. However, it still remains unclear whether overhydration per se is predictive of mortality or whether it is mainly a reflection of underlying comorbidities. The purpose of our study was to assess overhydration in peritoneal dialysis patients using bioimpedance spectroscopy and to investigate whether overhydration is an independent predictor of mortality. Methods We analyzed and followed 54 peritoneal dialysis patients between June 2008 and December 2014. All patients underwent bioimpedance spectroscopy measurement once and were allocated to normohydrated and overhydrated groups. Overhydration was defined as an absolute overhydration/extracellular volume ratio > 15%. Simultaneously, clinical, echocardiographic and laboratory data were assessed. Heart failure was defined either on echocardiography, as a reduced left ventricular ejection fraction, or clinically according to the New York Heart Association functional classification. Patient survival was documented up until December 31st 2014. Factors associated with mortality were identified and a multivariable Cox regression model was used to identify independent predictors of mortality. Results Apart from higher daily peritoneal ultrafiltration rate and cumulative diuretic dose in overhydrated patients, there were no significant differences between the 2 groups, in particular with respect to gender, body mass index, comorbidity and cardiac medication. Mortality was higher in overhydrated than in euvolemic patients. In the univariate analysis, increased age, overhydration, low diastolic blood pressure, raised troponin and NTproBNP, hypoalbuminemia, heart failure but not CRP were predictive of mortality. After adjustment, only overhydration, increased age and low diastolic blood pressure remained statistically significant in the multivariate analysis. Conclusions Overhydration remains an independent predictor of mortality even after adjustment for heart failure in peritoneal dialysis patients and should therefore be actively sought and managed in order to improve survival in this population.	[Drepper, Valerie Jotterand] Univ Hosp Geneva, Dept Nephrol, Geneva, Switzerland; [Drepper, Valerie Jotterand; Kihm, Lars P.; Kaelble, Florian; Diekmann, Christian; Seckinger, Joerg; Sommerer, Claudia; Zeier, Martin; Schwenger, Vedat] Univ Heidelberg Hosp, Dept Nephrol, Heidelberg, Germany; [Seckinger, Joerg] Zug Cantonal Hosp, Dept Nephrol, Zug, Switzerland; [Schwenger, Vedat] Klinikum Stuttgart, Dept Nephrol, Stuttgart, Germany	University of Geneva; Ruprecht Karls University Heidelberg; Klinikum Stuttgart	Drepper, VJ (corresponding author), Univ Hosp Geneva, Dept Nephrol, Geneva, Switzerland.; Drepper, VJ (corresponding author), Univ Heidelberg Hosp, Dept Nephrol, Heidelberg, Germany.	Valerie.JotterandDrepper@hcuge.ch						Afshinnia F, 2015, PERIT DIAL INT; Chamney PW, 2002, KIDNEY INT, V61, P2250, DOI 10.1046/j.1523-1755.2002.00377.x; Chung SH, 2003, NEPHROL DIAL TRANSPL, V18, P590, DOI 10.1093/ndt/18.3.590; Cox-Reijven PL, 2001, AM J KIDNEY DIS, V38, P832, DOI 10.1053/ajkd.2001.27703; Devolder I, 2010, PERITON DIALYSIS INT, V30, P208, DOI 10.3747/pdi.2008.00284; Duman D, 2005, NEPHROL DIAL TRANSPL, V20, P962, DOI 10.1093/ndt/gfh741; Ellis KJ, 1998, J APPL PHYSIOL, V85, P1056, DOI 10.1152/jappl.1998.85.3.1056; Fahim MA, 2015, CLIN J AM SOC NEPHRO, V10, P620, DOI 10.2215/CJN.09060914; Franklin SS, 1997, CIRCULATION; Heaf JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090119; Hickman PE, 2015, AM J CARDIOL, V115, P1601, DOI 10.1016/j.amjcard.2015.02.066; Jovanovic DB, 2015, RENAL FAILURE, V37, P230, DOI 10.3109/0886022X.2014.982478; Kang SH, 2012, RENAL FAILURE, V34, P149, DOI 10.3109/0886022X.2011.646808; Kraemer M, 2006, KIDNEY INT, V69, P1609, DOI 10.1038/sj.ki.5000286; Kumar VA, 2014, KIDNEY INT, V86, P1016, DOI 10.1038/ki.2014.224; Leinig CE, 2011, J RENAL NUTR, V21, P176, DOI 10.1053/j.jrn.2010.06.026; Mathew S, 2015, RENAL FAILURE, V37, P66, DOI 10.3109/0886022X.2014.964147; Mehrotra R, 2011, AM J KIDNEY DIS, V58, P418, DOI 10.1053/j.ajkd.2011.03.018; Moissl UM, 2006, PHYSIOL MEAS, V27, P921, DOI 10.1088/0967-3334/27/9/012; Noh H, 1998, PERITON DIALYSIS INT, V18, P387; O'Lone EL, 2014, NEPHROL DIAL TRANSPL, V29, P1430, DOI 10.1093/ndt/gfu049; Paniagua R, 2008, CLIN J AM SOC NEPHRO, V3, P407, DOI 10.2215/CJN.03820907; Paniagua R, 2010, NEPHROL DIAL TRANSPL, V25, P551, DOI 10.1093/ndt/gfp395; Ronco C, 2015, NEPHROL DIAL TRANSPL, V30, P849, DOI 10.1093/ndt/gfv013; Van Biesen W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017148; Wabel P, 2009, BLOOD PURIFICAT, V27, P75, DOI 10.1159/000167013; Wang AYM, 2007, CLIN CHEM, V53, P882, DOI 10.1373/clinchem.2006.078378; Wang AYM, 2007, J AM SOC NEPHROL, V18, P321, DOI 10.1681/ASN.2005121299; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Xie Q, 2015, PERIT DIAL INT	30	29	29	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2016	11	7							e0158741	10.1371/journal.pone.0158741	http://dx.doi.org/10.1371/journal.pone.0158741			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR0DZ	27415758	Green Published, gold, Green Submitted			2023-01-03	WOS:000379579500034
J	Dong, MX; Hu, QC; Shen, P; Pan, JX; Wei, YD; Liu, YY; Ren, YF; Liang, ZH; Wang, HY; Zhao, LB; Xie, P				Dong, Mei-Xue; Hu, Qing-Chuan; Shen, Peng; Pan, Jun-Xi; Wei, You-Dong; Liu, Yi-Yun; Ren, Yi-Fei; Liang, Zi-Hong; Wang, Hai-Yang; Zhao, Li-Bo; Xie, Peng			Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; BRAIN-BARRIER PERMEABILITY; THERAPEUTIC TIME WINDOW; TPA-DEFICIENT MICE; HEMORRHAGIC TRANSFORMATION; INTRACEREBRAL HEMORRHAGE; RT-PA; POLY(ADP-RIBOSE)POLYMERASE INHIBITOR; DELAYED TREATMENT; ARTERY OCCLUSION	Background and Purpose Recombinant tissue plasminogen activator (rtPA) is the only effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic effects besides thrombolysis. We performed a meta-analysis to clarify effect of tissue plasminogen activator (tPA) on cerebral infarction besides its thrombolysis property in mechanical animal stroke. Methods Relevant studies were identified by two reviewers after searching online databases, including Pubmed, Embase, and ScienceDirect, from 1979 to 2016. We identified 6, 65, 17, 12, 16, 12 and 13 comparisons reporting effect of endogenous tPA on infarction volume and effects of rtPA on infarction volume, blood-brain barrier, brain edema, intracerebral hemorrhage, neurological function and mortality rate in all 47 included studies. Standardized mean differences for continuous measures and risk ratio for dichotomous measures were calculated to assess the effects of endogenous tPA and rtPA on cerebral infarction in animals. The quality of included studies was assessed using the Stroke Therapy Academic Industry Roundtable score. Subgroup analysis, meta-regression and sensitivity analysis were performed to explore sources of heterogeneity. Funnel plot, Trim and Fill method and Egger's test were obtained to detect publication bias. Results We found that both endogenous tPA and rtPA had not enlarged infarction volume, or deteriorated neurological function. However, rtPA would disrupt blood-brain barrier, aggravate brain edema, induce intracerebral hemorrhage and increase mortality rate. Conclusions This meta-analysis reveals rtPA can lead to neurological side effects besides thrombolysis in mechanical animal stroke, which may account for clinical exacerbation for stroke patients that do not achieve vascular recanalization with rtPA.	[Dong, Mei-Xue; Shen, Peng; Wei, You-Dong; Liu, Yi-Yun; Ren, Yi-Fei; Liang, Zi-Hong; Xie, Peng] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China; [Dong, Mei-Xue; Xie, Peng] Chongqing Med Univ, Inst Neurosci, Chongqing, Peoples R China; [Dong, Mei-Xue; Xie, Peng] Chongqing Med Univ, Collaborat Innovat Ctr Brain Sci, Chongqing, Peoples R China; [Dong, Mei-Xue; Hu, Qing-Chuan; Pan, Jun-Xi; Wang, Hai-Yang; Xie, Peng] Chongqing Key Lab Neurobiol, Chongqing, Peoples R China; [Zhao, Li-Bo] Chongqing Med Univ, Dept Neurol, Yongchuan Hosp, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Xie, P (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.; Xie, P (corresponding author), Chongqing Med Univ, Inst Neurosci, Chongqing, Peoples R China.; Xie, P (corresponding author), Chongqing Med Univ, Collaborat Innovat Ctr Brain Sci, Chongqing, Peoples R China.; Xie, P (corresponding author), Chongqing Key Lab Neurobiol, Chongqing, Peoples R China.	xiepeng@cqmu.edu.cn		Liang, Zihong/0000-0002-7466-0832; dong, meixue/0000-0001-5853-7861	National Key Clinical Specialties Construction Program of China; National Basic Research Program of China (973 Program) [2009CB918300]	National Key Clinical Specialties Construction Program of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China)	This work was supported by the National Key Clinical Specialties Construction Program of China and National Basic Research Program of China (973 Program, grant no. 2009CB918300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu Fanne R, 2010, NEUROPHARMACOLOGY, V58, P972, DOI 10.1016/j.neuropharm.2009.12.017; Allahtavakoli M, 2015, BASIC CLIN PHARMACOL, V117, P335, DOI 10.1111/bcpt.12413; Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; Armstead WM, 2012, J NEUROTRAUM, V29, P1794, DOI 10.1089/neu.2012.2328; Armugam A, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-120; Balami JS, 2013, CNS NEUROL DISORD-DR, V12, P155; Benchenane K, 2007, J CELL SCI, V120, P578, DOI 10.1242/jcs.03354; Berny-Lang MA, 2011, STROKE, V42, P1736, DOI 10.1161/STROKEAHA.110.603811; Bertrand T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.296; Burggraf D, 2007, BRAIN RES, V1164, P55, DOI 10.1016/j.brainres.2007.05.066; Burggraf D, 2010, THROMB HAEMOSTASIS, V103, P891, DOI 10.1160/TH09-07-0500; Cechmanek BK, 2015, THER HYPOTHERMIA TEM, V5, P203, DOI 10.1089/ther.2015.0010; Cheng PF, 2015, MENOPAUSE, V22, P198, DOI [10.1097/gme.0000000000000290, 10.1097/GME.0000000000000290]; Cheng PF, 2015, CELL MOL NEUROBIOL, V35, P1149, DOI 10.1007/s10571-015-0208-4; Cheng PF, 2015, SCI REP-UK, V5, DOI 10.1038/srep14161; Chevilley A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00415; Copin JC, 2011, EUR J NEUROSCI, V34, P1085, DOI 10.1111/j.1460-9568.2011.07843.x; Crawley JTB, 2013, J THROMB HAEMOST, V11, P64; Crumrine RC, 2012, EXPERIMENTAL AND TRA, V4; Crumrine RC, 2011, EXPERIMENTAL AND TRA, V3; Deguchi K, 2012, BRAIN RES, V1436, P168, DOI 10.1016/j.brainres.2011.12.016; Dhillon S, 2012, CNS DRUGS, V26, P899, DOI 10.2165/11209940-000000000-00000; ElAli A, 2016, NEUROPSYCHOPHARMACOL, V41, P1297, DOI 10.1038/npp.2015.279; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fraser PA, 2011, FREE RADICAL BIO MED, V51, P967, DOI 10.1016/j.freeradbiomed.2011.06.003; Gautier S, 2003, STROKE, V34, P2975, DOI 10.1161/01.STR.0000101914.62066.7B; Grobholz K, 2005, NEUROL RES, V27, P212, DOI 10.1179/016164105X35576; Haddad M, 2013, FUND CLIN PHARMACOL, V27, P393, DOI 10.1111/j.1472-8206.2012.01036.x; Haile WB, 2012, J CEREBR BLOOD F MET, V32, P57, DOI 10.1038/jcbfm.2011.106; Harston GWJ, 2010, J CEREBR BLOOD F MET, V30, P1804, DOI 10.1038/jcbfm.2010.149; Hu L, 2016, EUR J NEUROL, V23, P1195, DOI 10.1111/ene.13013; Ishiguro M, 2012, NEUROSCIENCE, V220, P302, DOI 10.1016/j.neuroscience.2012.06.015; Ishiguro M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015178; Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008; Kikuchi K, 2014, CNS DRUGS, V28, P929, DOI 10.1007/s40263-014-0199-6; Kilic E, 1999, NEUROREPORT, V10, P107, DOI 10.1097/00001756-199901180-00021; Kilic E, 2005, STROKE, V36, P332, DOI 10.1161/01.STR.0000152273.24063.f7; Kilic E, 2001, STROKE, V32, P2641, DOI 10.1161/hs1101.097381; Kilic E, 2005, NEURODEGENER DIS, V2, P49, DOI 10.1159/000089283; Klein GM, 1999, NEUROLOGY, V52, P1381, DOI 10.1212/WNL.52.7.1381; Kocic I, 2015, N-S ARCH PHARMACOL, V388, P79, DOI 10.1007/s00210-014-1061-6; Kumar G, 2015, CNS DRUGS, V29, P659, DOI 10.1007/s40263-015-0265-8; Lee SR, 2007, NEUROSCIENCE, V150, P50, DOI 10.1016/j.neuroscience.2007.06.029; Lee SH, 2014, MOL NEUROBIOL, V49, P199, DOI 10.1007/s12035-013-8511-x; Lemarchand E, 2016, CELL DEATH DIFFER, V23, P123, DOI 10.1038/cdd.2015.76; Lenglet S, 2014, J CEREBR BLOOD F MET, V34, P802, DOI 10.1038/jcbfm.2014.9; Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185; Li Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep11357; Liang J, 2015, STROKE, V46, P1344, DOI 10.1161/STROKEAHA.114.008599; Liu B., 2015, J UNCERTAIN ANAL APP, V3, P10, DOI [DOI 10.1186/S40467-015-0036-6, 10.1186/s40467-015-0036-6]; Liu B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15771; Lu AG, 2009, NEUROL RES, V31, P209, DOI 10.1179/174313209X393933; Lyden P, 2015, EXPERT REV NEUROTHER, V15, P571, DOI 10.1586/14737175.2015.1041510; Machado LS, 2009, STROKE, V40, P3028, DOI 10.1161/STROKEAHA.109.556852; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mendis S, 2015, STROKE, V46, pE121, DOI 10.1161/STROKEAHA.115.008097; Meng W, 1999, J CEREBR BLOOD F MET, V19, P1316, DOI 10.1097/00004647-199912000-00004; Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097; Nakano T, 2015, BRAIN RES, V1624, P330, DOI 10.1016/j.brainres.2015.07.027; Niego B, 2012, BLOOD, V119, P4752, DOI 10.1182/blood-2011-07-369512; Oka F, 2009, J NEUROTRAUM, V26, P1577, DOI [10.1089/neu.2008.0768, 10.1089/neu.2008-0768]; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Parcq J, 2012, CELL DEATH DIFFER, V19, P1983, DOI 10.1038/cdd.2012.86; Roussel BD, 2009, BRAIN, V132, P2219, DOI 10.1093/brain/awp162; Sena ES, 2010, J CEREBR BLOOD F MET, V30, P1905, DOI 10.1038/jcbfm.2010.116; Shen LH, 2011, STROKE, V42, P459, DOI 10.1161/STROKEAHA.110.593863; Siao CJ, 2003, J NEUROSCI, V23, P3234; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Sutherland Brad A, 2013, J Cereb Blood Flow Metab, V33, pe1, DOI 10.1038/jcbfm.2013.148; Tabrizi P, 1999, ARTERIOSCL THROM VAS, V19, P2801, DOI 10.1161/01.ATV.19.11.2801; Tang J, 2010, NEUROL RES, V32, P541, DOI 10.1179/174313209X414560; Tang J, 2009, NEUROL RES, V31, P189, DOI 10.1179/174313209X393898; Tang XN, 2013, THER HYPOTHERMIA TEM, V3, P74, DOI 10.1089/ther.2013.0010; Teng F, 2013, EXP NEUROL, V248, P416, DOI 10.1016/j.expneurol.2013.07.007; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsuji K, 2005, STROKE, V36, P1954, DOI 10.1161/01.STR.0000177517.01203.eb; Tucker HM, 2000, J NEUROSCI, V20, P3937; Turner RJ, 2012, NEUROSCIENCE, V220, P1, DOI 10.1016/j.neuroscience.2012.06.047; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213; Wardlaw JM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub3; Won S, 2014, J CEREBR BLOOD F MET, V34, P72, DOI 10.1038/jcbfm.2013.163; Wu F, 2013, J CEREBR BLOOD F MET, V33, P1761, DOI 10.1038/jcbfm.2013.124; Wu F, 2012, J NEUROSCI, V32, P9848, DOI 10.1523/JNEUROSCI.1241-12.2012; Wu JL, 2010, AM J PATHOL, V177, P2576, DOI 10.2353/ajpath.2010.100466; Yagi K, 2009, STROKE, V40, P626, DOI 10.1161/STROKEAHA.108.520262; Yepes M, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00304, 10.3389/fncel.2015.00304]; Yepes M, 2013, ANN NEUROL, V74, pS7; Yepes M, 2009, TRENDS NEUROSCI, V32, P48, DOI 10.1016/j.tins.2008.09.006; Zechariah A, 2010, J NEUROL, V257, pS193; Zhang WR, 2004, NEUROL RES, V26, P342, DOI 10.1179/016164104225014058; Zhou XY, 2015, WORLD PSYCHIATRY, V14, P207, DOI 10.1002/wps.20217; Zhou XY, 2015, ADDICTION, V110, P38, DOI 10.1111/add.12698; Zhou XY, 2012, STROKE, V43, P2923, DOI 10.1161/STROKEAHA.112.667535; Zhu WB, 2014, TRANSL STROKE RES, V5, P612, DOI 10.1007/s12975-014-0348-8; Zuo W, 2014, EUR J NEUROSCI, V39, P2107, DOI 10.1111/ejn.12551	97	33	34	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158848	10.1371/journal.pone.0158848	http://dx.doi.org/10.1371/journal.pone.0158848			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3OC	27387385	Green Submitted, gold, Green Published			2023-01-03	WOS:000379811500056
J	Park, JW; Liu, MC; Yee, D; Yau, C; van 't Veer, LJ; Symmans, WF; Paoloni, M; Perlmutter, J; Hylton, NM; Hogarth, M; DeMichele, A; Buxton, MB; Chien, AJ; Wallace, AM; Boughey, JC; Haddad, TC; Chui, SY; Kemmer, KA; Kaplan, HG; Isaacs, C; Nanda, R; Tripathy, D; Albain, KS; Edmiston, KK; Elias, AD; Northfelt, DW; Pusztai, L; Moulder, SL; Lang, JE; Viscusi, RK; Euhus, DM; Haley, BB; Khan, QJ; Wood, WC; Melisko, M; Schwab, R; Helsten, T; Lyandres, J; Davis, SE; Hirst, GL; Sanil, A; Esserman, LJ; Berry, DA				Park, J. W.; Liu, M. C.; Yee, D.; Yau, C.; van 't Veer, L. J.; Symmans, W. F.; Paoloni, M.; Perlmutter, J.; Hylton, N. M.; Hogarth, M.; DeMichele, A.; Buxton, M. B.; Chien, A. J.; Wallace, A. M.; Boughey, J. C.; Haddad, T. C.; Chui, S. Y.; Kemmer, K. A.; Kaplan, H. G.; Isaacs, C.; Nanda, R.; Tripathy, D.; Albain, K. S.; Edmiston, K. K.; Elias, A. D.; Northfelt, D. W.; Pusztai, L.; Moulder, S. L.; Lang, J. E.; Viscusi, R. K.; Euhus, D. M.; Haley, B. B.; Khan, Q. J.; Wood, W. C.; Melisko, M.; Schwab, R.; Helsten, T.; Lyandres, J.; Davis, S. E.; Hirst, G. L.; Sanil, A.; Esserman, L. J.; Berry, D. A.		I-SPY 2 Investigators	Adaptive Randomization of Neratinib in Early Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; OPEN-LABEL; TRASTUZUMAB; COMBINATION; SAFETY; EFFICACY; MULTICENTER; PERTUZUMAB; PACLITAXEL; LAPATINIB	BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time of surgery). METHODS We used adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibitor neratinib with control. Eligible women were categorized according to eight biomarker subtypes on the basis of human epidermal growth factor receptor 2 (HER2) status, hormone-receptor status, and risk according to a 70-gene profile. Neratinib was evaluated against control with regard to 10 biomarker signatures (prospectively defined combinations of subtypes). The primary end point was pathological complete response. Volume changes on serial magnetic resonance imaging were used to assess the likelihood of such a response in each patient. Adaptive assignment to experimental groups within each disease subtype was based on Bayesian probabilities of the superiority of the treatment over control. Enrollment in the experimental group was stopped when the 85% Bayesian predictive probability of success in a confirmatory phase 3 trial of neoadjuvant therapy reached a pre-specified threshold for any biomarker signature ("graduation"). Enrollment was stopped for futility if the probability fell to below 10% for every biomarker signature. RESULTS Neratinib reached the prespecified efficacy threshold with regard to the HER2-positive, hormone-receptor-negative signature. Among patients with HER2-positive, hormone-receptor-negative cancer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability interval [PI], 37 to 73%) among 115 patients in the neratinib group, as compared with 33% among 78 controls (95% PI, 11 to 54%). The final predictive probability of success in phase 3 testing was 79%. CONCLUSIONS Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer.	[Park, J. W.; Yau, C.; van 't Veer, L. J.; Hylton, N. M.; Buxton, M. B.; Chien, A. J.; Melisko, M.; Lyandres, J.; Davis, S. E.; Hirst, G. L.; Esserman, L. J.] Univ Calif San Francisco, 1600 Divisadero St,Box 1710, San Francisco, CA 94115 USA; [Paoloni, M.] QuantumLeap Healthcare Collaborat, San Francisco, CA USA; [Yau, C.] Buck Inst Res & Aging, Novato, CA USA; [Hogarth, M.] Univ Calif Davis, Davis, CA 95616 USA; [Wallace, A. M.; Schwab, R.; Helsten, T.] Univ Calif San Diego, San Diego, CA 92103 USA; [Tripathy, D.] Univ So Calif, Los Angeles, CA USA; [Liu, M. C.; Isaacs, C.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA; [Yee, D.; Haddad, T. C.] Univ Minnesota, Minneapolis, MN USA; [Boughey, J. C.] Mayo Clin, Rochester, MN USA; [Symmans, W. F.; Pusztai, L.; Moulder, S. L.; Berry, D. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Euhus, D. M.; Haley, B. B.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Sanil, A.; Berry, D. A.] Berry Consultants, Austin, TX USA; [Perlmutter, J.] Gemini Grp, Ann Arbor, MI USA; [DeMichele, A.] Univ Penn, Philadelphia, PA 19104 USA; [Chui, S. Y.; Kemmer, K. A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kaplan, H. G.] Swedish Med Ctr, Seattle, WA USA; [Nanda, R.] Univ Chicago, Chicago, IL 60637 USA; [Albain, K. S.] Loyola Univ, Chicago, IL 60611 USA; [Edmiston, K. K.] Inova Fairfax Hosp, Falls Church, VA USA; [Elias, A. D.] Univ Denver, Denver, CO USA; [Northfelt, D. W.] Mayo Clin, Scottsdale, AZ USA; [Lang, J. E.; Viscusi, R. K.] Univ Arizona, Tucson, AZ USA; [Khan, Q. J.] Univ Kansas, Lawrence, KS 66045 USA; [Wood, W. C.] Emory Univ, Atlanta, GA 30322 USA	University of California System; University of California San Francisco; Buck Institute for Research on Aging; University of California System; University of California Davis; University of California System; University of California San Diego; University of Southern California; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; Oregon Health & Science University; Swedish Medical Center; University of Chicago; Loyola University Chicago; Inova Fairfax Hospital; University of Denver; Mayo Clinic; Mayo Clinic Phoenix; University of Arizona; University of Kansas; Emory University	Esserman, LJ (corresponding author), Univ Calif San Francisco, UCSF Carol Franc Buck Breast Care Ctr, 1600 Divisadero St,Box 1710, San Francisco, CA 94115 USA.	laura.esserman@ucsf.edu	kaplan, henry/ABI-4845-2020; Lang, Julie Eileen/J-9764-2019; Pusztai, Lajos/AAB-2901-2019; Hylton, Nola/AAF-7861-2019	Lang, Julie Eileen/0000-0002-7534-6124; McDonald, Elizabeth/0000-0002-7209-4216; Diamond, Jennifer/0000-0002-0703-2772; Hirst, Gillian/0000-0002-4502-0035; Hui, Jane Yuet Ching/0000-0002-2628-0720; Lynce, Filipa/0000-0001-6615-7076; Yee, Douglas/0000-0002-3387-4009	QuantumLeap Healthcare Collaborative; NATIONAL CANCER INSTITUTE [P30CA023100, P30CA016672] Funding Source: NIH RePORTER	QuantumLeap Healthcare Collaborative; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.	Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927; Berry DA, 2015, MOL ONCOL, V9, P951, DOI 10.1016/j.molonc.2015.02.011; Berry DA, 2012, NAT REV CLIN ONCOL, V9, P199, DOI 10.1038/nrclinonc.2011.165; Bria E, 2014, CANCER TREAT REV, V40, P847, DOI 10.1016/j.ctrv.2014.05.001; Chan AW, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.22; Chow LWC, 2013, BRIT J CANCER, V108, P1985, DOI 10.1038/bjc.2013.178; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779; Esserman LJ, 2011, JAMA-J AM MED ASSOC, V306, P2608, DOI 10.1001/jama.2011.1837; Feldinger K, 2015, BREAST CANCER-TARGET, V7, P147, DOI 10.2147/BCTT.S54414; Gandhi L, 2014, J CLIN ONCOL, V32, P68, DOI 10.1200/JCO.2012.47.2787; Gelmon KA, 2015, J CLIN ONCOL, V33, P1574, DOI 10.1200/JCO.2014.56.9590; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Glas AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-278; Gradishar WJ, 2015, J NATL COMPR CANC NE, V13, P1475, DOI 10.6004/jnccn.2015.0176; Hortobagyi GN, 2013, J CLIN ONCOL, V31; Jankowitz RC, 2013, CANCER CHEMOTH PHARM, V72, P1205, DOI 10.1007/s00280-013-2262-2; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Mullooly M, 2015, J CLIN ONCOL S, V33; Piccart M, 2016, AM ASS CANC RES ANN; Prowell TM, 2012, NEW ENGL J MED, V366, P2438, DOI 10.1056/NEJMp1205737; Roepman P, 2009, CLIN CANCER RES, V15, P7003, DOI 10.1158/1078-0432.CCR-09-0449; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; Sanchez-Martin M, 2012, INT J CANCER, V131, P244, DOI 10.1002/ijc.26358; Saura C, 2014, J CLIN ONCOL, V32, P3626, DOI 10.1200/JCO.2014.56.3809; Schneeweiss A, 2013, ANN ONCOL, V24, P2278, DOI 10.1093/annonc/mdt182; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; TRIPATHY D, 2015, J CLIN ONCOL S, V33; Viale G, 2014, ANN ONCOL, V25, P816, DOI 10.1093/annonc/mdu026; Wasiuk A, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-4949; Wolf DM, 2013, CANCER RES, V73, P24	33	220	227	1	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2016	375	1					11	22		10.1056/NEJMoa1513750	http://dx.doi.org/10.1056/NEJMoa1513750			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ1ZP	27406346	Bronze, Green Accepted			2023-01-03	WOS:000379000200001
J	Sundstrom, C; Gajecki, M; Johansson, M; Blankers, M; Sinadinovic, K; Stenlund-Gens, E; Berman, AH				Sundstrom, Christopher; Gajecki, Mikael; Johansson, Magnus; Blankers, Matthijs; Sinadinovic, Kristina; Stenlund-Gens, Erik; Berman, Anne H.			Guided and Unguided Internet-Based Treatment for Problematic Alcohol Use - A Randomized Controlled Pilot Trial	PLOS ONE			English	Article							COGNITIVE-BEHAVIOR THERAPY; IDENTIFICATION TEST DUDIT; USE DISORDERS; SELF-HELP; PSYCHOMETRIC PROPERTIES; HOSPITAL ANXIETY; DRUG-USE; PSYCHOLOGICAL TREATMENTS; DEPRESSION SCALE; INTERVENTION	Background The Internet has increasingly been studied as mode of delivery for interventions targeting problematic alcohol use. Most interventions have been fully automated, but some research suggests that adding counselor guidance may improve alcohol consumption outcomes. Methods An eight-module Internet-based self-help program based on cognitive behavioral therapy (CBT) was tested among Internet help-seekers. Eighty participants with problematic alcohol use according to the Alcohol Use Disorders Identification Test (AUDIT; scores of >= 6 for women and >= 8 for men) were recruited online from an open access website and randomized into three different groups. All groups were offered the same self-help program, but participants in two of the three groups received Internet-based counselor guidance in addition to the self-help program. One of the guidance groups was given a choice between guidance via asynchronous text messages or synchronous text-based chat, while the other guidance group received counselor guidance via asynchronous text messages only. Results In the choice group, 65% (13 of 20 participants) chose guidance via asynchronous text messages. At the 10-week post-treatment follow-up, an intention-to-treat (ITT) analysis showed that participants in the two guidance groups (choice and messages) reported significantly lower past week alcohol consumption compared to the group without guidance; 10.8 (SD = 12.1) versus 22.6 (SD = 18.4); p = 0.001; Cohen's d = 0.77. Participants in both guidance groups reported significantly lower scores on the AUDIT at follow-up compared to the group without guidance, with a mean score of 14.4 (SD = 5.2) versus 18.2 (SD = 5.9); p = 0.003; Cohen's d = 0.68. A higher proportion of participants in the guidance groups said that they would recommend the program compared to the group without guidance (81% for choice; 93% for messages versus 47% for self-help). Conclusion Self-help programs for problematic alcohol use can be more effective in reducing alcohol consumption over a 10-week period when counselor guidance is added.	[Sundstrom, Christopher; Gajecki, Mikael; Johansson, Magnus; Sinadinovic, Kristina; Berman, Anne H.] Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden; [Johansson, Magnus] Karolinska Inst, Dept Publ Hlth, Stockholm, Sweden; [Johansson, Magnus; Sinadinovic, Kristina; Berman, Anne H.] Stockholm Ctr Dependency Disorders, Stockholm, Sweden; [Blankers, Matthijs] Arkin Mental Hlth Care, Amsterdam, Netherlands; [Blankers, Matthijs] Netherlands Inst Mental Hlth & Addict, Trimbos, Amsterdam, Netherlands; [Blankers, Matthijs] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Stenlund-Gens, Erik] Stockholm Univ, Dept Psychol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Trimbos Institute; University of Amsterdam; Academic Medical Center Amsterdam; Stockholm University	Sundstrom, C (corresponding author), Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden.	christopher.sundstrom@ki.se	Berman, Anne H/C-4636-2011; Sundström, Christopher/ABH-5379-2020	Berman, Anne H/0000-0002-7709-0230; Sundström, Christopher/0000-0003-4237-7159; Johansson, Magnus/0000-0001-8583-2620	Swedish Research Council [K2012-61X-22132-01-6]; AFA Insurance grant [110248]; Swedish FORTE research council [2013-1793]; Stockholm Center for Dependency Disorders for technical development; Karolinska Institutet/Center for Psychiatry Research doctoral grant	Swedish Research Council(Swedish Research CouncilEuropean Commission); AFA Insurance grant; Swedish FORTE research council; Stockholm Center for Dependency Disorders for technical development; Karolinska Institutet/Center for Psychiatry Research doctoral grant	This study was supported by the Swedish Research Council grant no. K2012-61X-22132-01-6; AFA Insurance grant no. 110248; Swedish FORTE research council, grant no. 2013-1793; the Stockholm Center for Dependency Disorders for technical development; Karolinska Institutet/Center for Psychiatry Research doctoral grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; Andersson G, 2003, J PSYCHOSOM RES, V55, P259, DOI 10.1016/S0022-3999(02)00575-5; Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd ed.; Tran BX, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-132; Bergman H, 2002, ALCOHOL ALCOHOLISM, V37, P245, DOI 10.1093/alcalc/37.3.245; Bergman H, 2003, LAKARTIDNINGEN, V100, P1027; Berman AH, 2005, EUR ADDICT RES, V11, P22, DOI 10.1159/000081413; Berman AH, 2015, PSYCHOL ADDICT BEHAV, V29, P97, DOI 10.1037/a0038420; Bertholet N, 2009, ADDICT BEHAV, V34, P636, DOI 10.1016/j.addbeh.2009.03.034; Bewick BM, 2013, J MED INTERNET RES, V15, P106, DOI 10.2196/jmir.2581; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blankers M, 2011, J CONSULT CLIN PSYCH, V79, P330, DOI 10.1037/a0023498; Blankers M, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1448; Crutzen R, 2015, PSYCHOL HEALTH, V30, P122, DOI 10.1080/08870446.2014.953526; Cuijpers P, 2010, PSYCHOL MED, V40, P1943, DOI 10.1017/S0033291710000772; Cunningham JA, 2004, ADDICT BEHAV, V29, P221, DOI 10.1016/S0306-4603(03)00077-7; Cunningham JA, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-21; Cunningham JA, 2009, ADDICTION, V104, P2023, DOI 10.1111/j.1360-0443.2009.02726.x; Dedert EA, 2015, ANN INTERN MED, V163, P205, DOI 10.7326/M15-0285; Donoghue K, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3193; Eysenbach G, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.1.e11; Folkhalsoinstitutet [Swedish Public Health Agency], 2010, ALK KUNSK FOLKH RAPP; Forsberg L, 2003, ALCOHOL ALCOHOLISM, V38, P276, DOI 10.1093/alcalc/agg067; Gainsbury S, 2011, CLIN PSYCHOL REV, V31, P490, DOI 10.1016/j.cpr.2010.11.007; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hedman E, 2014, J AFFECT DISORDERS, V155, P49, DOI 10.1016/j.jad.2013.10.023; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Honaker J, 2011, J STAT SOFTW, V45, P1; Horton NJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-9; Newman MG, 2011, CLIN PSYCHOL REV, V31, P178, DOI 10.1016/j.cpr.2010.10.002; Postel MG, 2010, J MED INTERNET RES, V12, P11, DOI 10.2196/jmir.1642; Richards D, 2012, CLIN PSYCHOL REV, V32, P329, DOI 10.1016/j.cpr.2012.02.004; Riper H, 2008, ADDICTION, V103, P218, DOI 10.1111/j.1360-0443.2007.02063.x; Riper H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099912; Riper H, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1691; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; Shawver Z, 2016, COMPUT HUM BEHAV, V55, P446, DOI 10.1016/j.chb.2015.09.030; Sinadinovic K, 2014, EUR ADDICT RES, V20, P305, DOI 10.1159/000362406; Sinadinovic K, 2011, DRUG ALCOHOL DEPEN, V114, P55, DOI 10.1016/j.drugalcdep.2010.09.004; Sinadinovic K, 2010, ADDICT BEHAV, V35, P464, DOI 10.1016/j.addbeh.2009.12.021; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Sobell L. C, 1992, MEASURING ALCOHOL CO; Sobell LC, 1996, DRUG ALCOHOL DEPEN, V42, P49, DOI 10.1016/0376-8716(96)01263-X; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; Thomas BA, 2008, DRUG ALCOHOL DEPEN, V96, P121, DOI 10.1016/j.drugalcdep.2008.02.010; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Vitesnikova J, 2014, INJURY, V45, P1440, DOI 10.1016/j.injury.2014.01.004; Voluse AC, 2012, ADDICT BEHAV, V37, P36, DOI 10.1016/j.addbeh.2011.07.030; Wallace P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014740; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	36	36	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2016	11	7							e0157817	10.1371/journal.pone.0157817	http://dx.doi.org/10.1371/journal.pone.0157817			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR3NH	27383389	Green Published, gold, Green Submitted			2023-01-03	WOS:000379809400027
J	Carson, SS; Cox, CE; Wallenstein, S; Hanson, LC; Danis, M; Tulsky, JA; Chai, E; Nelson, JE				Carson, Shannon S.; Cox, Christopher E.; Wallenstein, Sylvan; Hanson, Laura C.; Danis, Marion; Tulsky, James A.; Chai, Emily; Nelson, Judith E.			Effect of Palliative Care-Led Meetings for Families of Patients With Chronic Critical Illness A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLONGED MECHANICAL VENTILATION; RESOURCE UTILIZATION; COMMUNICATION; UNIT; VALIDATION; ICU; OUTCOMES; CONSULTATION; INFORMATION; DEPRESSION	IMPORTANCE Family caregivers of patients with chronic critical illness experience significant psychological distress. OBJECTIVE To determine whether family informational and emotional support meetings led by palliative care clinicians improve family anxiety and depression. DESIGN, SETTING, AND PARTICIPANTS A multicenter randomized clinical trial conducted from October 2010 through November 2014 in 4 medical intensive care units (ICUs). Adult patients (aged >= 21 years) requiring 7 days of mechanical ventilation were randomized and their family surrogate decision makers were enrolled in the study. Observers were blinded to group allocation for the measurement of the primary outcomes. INTERVENTIONS At least 2 structured family meetings led by palliative care specialists and provision of an informational brochure (intervention) compared with provision of an informational brochure and routine family meetings conducted by ICU teams (control). There were 130 patients with 184 family surrogate decision makers in the intervention group and 126 patients with 181 family surrogate decision makers in the control group. MAIN OUTCOMES AND MEASURES The primary outcome was Hospital Anxiety and Depression Scale symptom score (HADS; score range, 0[best] to 42[worst]; minimal clinically important difference, 1.5) obtained during 3-month follow-up interviews with the surrogate decision makers. Secondary outcomes included posttraumatic stress disorder experienced by the family and measured by the Impact of Events Scale-Revised (IES-R; total score range, 0 [best] to 88 [worst]), discussion of patient preferences, hospital length of stay, and 90-day survival. RESULTS Among 365 family surrogate decision makers (mean age, 51 years; 71% female), 312 completed the study. At 3 months, there was no significant difference in anxiety and depression symptoms between surrogate decision makers in the intervention group and the control group (adjusted mean HADS score, 12.2 vs 11.4, respectively; between-group difference, 0.8 [95% CI, -0.9 to 2.6]; P = .34). Posttraumatic stress disorder symptoms were higher in the intervention group (adjusted mean IES-R score, 25.9) compared with the control group (adjusted mean IES-R score, 21.3) (between-group difference, 4.60 [95% CI, 0.01 to 9.10]; P = .0495). There was no difference between groups regarding the discussion of patient preferences (intervention, 75%; control, 83%; odds ratio, 0.63[95% CI, 0.34 to 1.16; P = .14]). The median number of hospital days for patients in the intervention vs the control group (19 days vs 23 days, respectively; between-group difference, -4 days [95% CI, -6 to 3 days]; P = .51) and 90-day survival (hazard ratio, 0.95 [95% CI, 0.65 to 1.38], P = .96) were not significantly different. CONCLUSIONS AND RELEVANCE Among families of patients with chronic critical illness, the use of palliative care-led informational and emotional support meetings compared with usual care did not reduce anxiety or depression symptoms and may have increased posttraumatic stress disorder symptoms. These findings do not support routine or mandatory palliative care-led discussion of goals of care for all families of patients with chronic critical illness.	[Carson, Shannon S.; Hanson, Laura C.] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Cox, Christopher E.] Duke Univ, Med Ctr, Durham, NC USA; [Wallenstein, Sylvan; Chai, Emily] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Danis, Marion] NIH, Bldg 10, Bethesda, MD 20892 USA; [Tulsky, James A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA; [Tulsky, James A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; [Nelson, Judith E.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Nelson, Judith E.] Weill Cornell Med Coll, New York, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Cornell University	Carson, SS (corresponding author), Univ N Carolina, Sch Med, Div Pulm & Crit Care Med, Marsico Lung Inst,Cecil B Sheps Ctr Hlth Serv Res, 4125 Bioinformat Bldg,CB 7020, Chapel Hill, NC 27599 USA.	scarson@med.unc.edu	Cox, Christopher/ABH-7957-2020	Cox, Christopher/0000-0002-4486-0681; , Laura/0000-0003-3737-9926; Hanson, Laura/0000-0001-5120-6058	National Institute of Nursing Research [R01-NR012413]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012413] Funding Source: NIH RePORTER	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This project was funded by grant R01-NR012413 from the National Institute of Nursing Research.	Arnold RM, 2015, J CRIT CARE, V30, P250, DOI 10.1016/j.jcrc.2014.11.016; Aslakson R, 2014, J PALLIAT MED, V17, P219, DOI 10.1089/jpm.2013.0409; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Cameron JI, 2016, NEW ENGL J MED, V374, P1831, DOI 10.1056/NEJMoa1511160; Carson SS, 2012, CRIT CARE MED, V40, P73, DOI 10.1097/CCM.0b013e31822d7901; Cox CE, 2007, CRIT CARE, V11, DOI 10.1186/cc5667; Cox CE, 2009, CRIT CARE MED, V37, P2888, DOI 10.1097/CCM.0b013e3181ab86ed; Curtis JR, 2008, CHEST, V134, P835, DOI 10.1378/chest.08-0235; Curtis JR, 2016, AM J RESP CRIT CARE, V193, P154, DOI 10.1164/rccm.201505-0900OC; Curtis JR, 2013, JAMA-J AM MED ASSOC, V310, P2271, DOI 10.1001/jama.2013.282081; Curtis JR, 2004, EUR RESPIR J, V24, P200, DOI 10.1183/09031936.04.00010104; Dunlop DD, 2003, AM J PUBLIC HEALTH, V93, P1945, DOI 10.2105/AJPH.93.11.1945; Hough CL, 2015, CRIT CARE MED, V43, P2339, DOI 10.1097/CCM.0000000000001205; Hua MS, 2014, AM J RESP CRIT CARE, V189, P428, DOI 10.1164/rccm.201307-1229OC; Kahn JM, 2015, CRIT CARE MED, V43, P282, DOI 10.1097/CCM.0000000000000710; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kelley AS, 2015, NEW ENGL J MED, V373, P747, DOI 10.1056/NEJMra1404684; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Nelson JE, 2005, J CRIT CARE, V20, P79, DOI 10.1016/j.jcrc.2004.11.003; Nelson JE, 2007, ARCH INTERN MED, V167, P2509, DOI 10.1001/archinte.167.22.2509; Nelson JE, 2013, CRIT CARE MED, V41, P2318, DOI 10.1097/CCM.0b013e31828cf12c; Nelson JE, 2010, AM J RESP CRIT CARE, V182, P446, DOI 10.1164/rccm.201002-0210CI; Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46; Rose S. C., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000560; Sihra L, 2011, J PAIN SYMPTOM MANAG, V42, P672, DOI 10.1016/j.jpainsymman.2011.08.002; Sullivan AM, 2016, ANN AM THORAC SOC, V13, P512, DOI 10.1513/AnnalsATS.201508-495OC; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Unroe M, 2010, ANN INTERN MED, V153, P167, DOI 10.7326/0003-4819-153-3-201008030-00007; Wall RJ, 2007, CRIT CARE MED, V35, P271, DOI 10.1097/01.CCM.0000251122.15053.50; Weiss D.S., 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; Weissman DE, 2011, J PALLIAT MED, V14, P17, DOI 10.1089/jpm.2010.0347; Zier LS, 2012, ANN INTERN MED, V156, P360, DOI 10.7326/0003-4819-156-5-201203060-00008; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	192	193	1	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2016	316	1					51	62		10.1001/jama.2016.8474	http://dx.doi.org/10.1001/jama.2016.8474			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DQ2MY	27380343	Green Accepted, Bronze			2023-01-03	WOS:000379037600018
J	Krauss, P; Tziridis, K; Buerbank, S; Schilling, A; Schulze, H				Krauss, Patrick; Tziridis, Konstantin; Buerbank, Stefanie; Schilling, Achim; Schulze, Holger			Therapeutic Value of Ginkgo biloba Extract EGb 761 (R) in an Animal Model (Meriones unguiculatus) for Noise Trauma Induced Hearing Loss and Tinnitus	PLOS ONE			English	Article							PLACEBO-CONTROLLED TRIAL; GAP DETECTION; ACOUSTIC TRAUMA; DOUBLE-BLIND; GUINEA-PIGS; EGB-761; PREVENTION; RESPONSES; STRESS; RATS	Noise induced hearing loss (NIHL) is a common disease in modern societies and may lead to maladaptations within the auditory system that finally result in subjective tinnitus. Available therapies may only alleviate the symptoms rather than restore normal hearing. In a previous study we demonstrated that the prophylactic application of Ginkgo biloba extract EGb 761 (R) significantly reduces NIHL and tinnitus development in our Mongolian gerbil (Meriones unguiculatus) animal model. Here, we tested whether the application of EGb 761 (R) has beneficial effects after the formation of permanent NIHL and tinnitus. To this end we monitored the therapeutic effects of EGb 761 (R) on noise trauma-induced changes in signal processing within the auditory system of our animal model by behavioral (acoustic startle response, ASR) and electrophysiological approaches (auditory brainstem responses, ABR). We found that-in contrast to vehicle-three weeks of daily oral EGb 761 (R) treatment (100 mg/kg body weight) led to a restoration of hearing thresholds back to pre-trauma conditions. In addition, all 9 animals that displayed behavioral signs of subjective tinnitus showed improvement, with 7 of them showing complete relief of tinnitus symptoms during the time of EGb 761 (R) treatment. After discontinuation of EGb 761 (R) treatment, tinnitus related behavior reappeared in all but one of these animals while auditory thresholds remained restored. A detailed analysis of ABR waves revealed that EGb 761 (R) treatment did not simply change auditory processing back to pre-trauma conditions, but led to subtle changes of ABR wave amplitude and latency at different levels of the auditory pathway, with an overall increase of response to low stimulus intensities and a decrease at high intensities. The functional relevance of these changes may be the observed improvement of hearing thresholds while at the same time suppression of responses to high stimulus intensities may point to a global inhibitory mechanism that counteracts tinnitus.	[Krauss, Patrick; Tziridis, Konstantin; Buerbank, Stefanie; Schilling, Achim; Schulze, Holger] Univ Erlangen Nurnberg, Expt Otolaryngol, Waldstr 1, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Schulze, H (corresponding author), Univ Erlangen Nurnberg, Expt Otolaryngol, Waldstr 1, D-91054 Erlangen, Germany.	holger.schulze@uk-erlangen.de		Krauss, Patrick/0000-0002-6611-7733	Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany; Deutsche Forschungsgemeinschaft; Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) within the funding programme Open Access Publishing	Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) within the funding programme Open Access Publishing	This work was supported by the Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. The authors acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) within the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) within the funding programme Open Access Publishing.	Abdel-Kader R, 2007, PHARMACOL RES, V56, P493, DOI 10.1016/j.phrs.2007.09.011; Ahlf S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044519; AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; DeFeudis FV, 2004, DRUG DEVELOP RES, V62, P1, DOI 10.1002/ddr.10351; Drew S, 2001, BRIT MED J, V322, P73, DOI 10.1136/bmj.322.7278.73; Eckert A, 2005, ANN NY ACAD SCI, V1056, P474, DOI 10.1196/annals.1352.023; Eggermont JJ, 2013, HEARING RES, V295, P140, DOI 10.1016/j.heares.2012.01.005; Fehske CJ, 2009, PHARMACOL RES, V60, P68, DOI 10.1016/j.phrs.2009.02.012; Galazyuk A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00088; Guitton Matthieu J., 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/80904; HALFORD JBS, 1991, J PSYCHOSOM RES, V35, P383, DOI 10.1016/0022-3999(91)90033-K; HENRY KR, 1979, J AM AUDITORY SOC, V4, P173; Jezova D, 2002, J PHYSIOL PHARMACOL, V53, P337; JONES DA, 1984, J EPIDEMIOL COMMUN H, V38, P75, DOI 10.1136/jech.38.1.75; Katzenell U, 2001, OTOL NEUROTOL, V22, P321, DOI 10.1097/00129492-200105000-00009; Kopke R, 2005, ACTA OTO-LARYNGOL, V125, P235, DOI 10.1080/00016480410023038; Langguth B, 2009, EXPERT OPIN EMERG DR, V14, P687, DOI 10.1517/14728210903206975; Le Prell CG, 2007, HEARING RES, V226, P22, DOI 10.1016/j.heares.2006.10.006; Lockwood AH, 2002, NEW ENGL J MED, V347, P904, DOI 10.1056/NEJMra013395; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Lynch ED, 2005, DRUG DISCOV TODAY, V10, P1291, DOI 10.1016/S1359-6446(05)03561-0; Massieu L, 2004, BRAIN RES, V1002, P76, DOI 10.1016/j.brainres.2003.12.018; Muller WE, 2003, PHARMACOPSYCHIATRY, V36, pS24; Mwilambwe-Tshilobo L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137749; NEGRI B, 1991, HNO, V39, P192; Oishi N, 2011, EXPERT OPIN EMERG DR, V16, P235, DOI 10.1517/14728214.2011.552427; Pang KCH, 2015, J NEUROTRAUM, V32, P801, DOI 10.1089/neu.2014.3451; Passchier-Vermeer W, 2000, ENVIRON HEALTH PERSP, V108, P123, DOI 10.1289/ehp.00108s1123; Sadlier M, 2008, J LARYNGOL OTOL, V122, P31, DOI 10.1017/S0022215107007438; Schindowski K, 2001, J NEURAL TRANSM, V108, P969, DOI 10.1007/s007020170016; Sendowski I, 2006, HEARING RES, V221, P119, DOI 10.1016/j.heares.2006.08.010; STANGE G, 1975, ARCH OTO-RHINO-LARYN, V209, P203, DOI 10.1007/BF00453774; STANGE G, 1976, ARZNEIMITTEL-FORSCH, V26, P367; Suneja SK, 1998, EXP NEUROL, V151, P273, DOI 10.1006/exnr.1998.6812; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Turner JG, 2008, AM J AUDIOL, V17, pS185, DOI 10.1044/1059-0889(2008/08-0006); Turner JG, 2006, BEHAV NEUROSCI, V120, P188, DOI 10.1037/0735-7044.120.1.188; Tziridis K, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00022; Tziridis K, 2012, JOVE-J VIS EXP, DOI 10.3791/4433; Tziridis K, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/427298; von Boetticher A, 2011, NEUROPSYCH DIS TREAT, V7, P441, DOI 10.2147/NDT.S22793; Walter M., 2012, OPEN J ACOUSTICS, V2, P34, DOI DOI 10.4236/0JA.2012.21004; Weible AP, 2014, CURR BIOL, V24, P1447, DOI 10.1016/j.cub.2014.05.031; Woelk H, 2007, J PSYCHIATR RES, V41, P472, DOI 10.1016/j.jpsychires.2006.05.004; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Yang TH, 2011, J NUTR BIOCHEM, V22, P886, DOI 10.1016/j.jnutbio.2010.08.009; Yoshitake T, 2010, BRIT J PHARMACOL, V159, P659, DOI 10.1111/j.1476-5381.2009.00580.x; Zheng YW, 2012, NEUROPHARMACOLOGY, V62, P940, DOI 10.1016/j.neuropharm.2011.09.027	49	16	19	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2016	11	6							e0157574	10.1371/journal.pone.0157574	http://dx.doi.org/10.1371/journal.pone.0157574			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JQ	27315063	Green Published, Green Submitted, gold			2023-01-03	WOS:000378030000037
J	Yazawa, M; Kido, R; Ohira, S; Hasegawa, T; Hanafusa, N; Iseki, K; Tsubakihara, Y; Shibagaki, Y				Yazawa, Masahiko; Kido, Ryo; Ohira, Seiji; Hasegawa, Takeshi; Hanafusa, Norio; Iseki, Kunitoshi; Tsubakihara, Yoshiharu; Shibagaki, Yugo			Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry	PLOS ONE			English	Article							STARTING DIALYSIS; FRAILTY; INITIATION; OUTCOMES	Background Although dialysis is typically started in an effort to prolong survival, mortality is reportedly high in the first few months. However, it remains unclear whether this is true in Japanese patients who tend to have a better prognosis than other ethnicities, and if health conditions such as functional status (FS) at initiation of dialysis influence prognosis. Methods We investigated the epidemiology of early death and its association with FS using Japanese national registry data in 2007, which included 35,415 patients on incident dialysis and 7,664 with FS data. The main outcome was early death, defined as death within 3 months after initiation of hemodialysis (HD). The main predictor was FS at initiation of HD. Levels of functional disability were categorized as follows: severe (bedridden), moderate (overt difficulties in exerting basic activities of daily living), or mild/none (none or some functional disabilities). Results Early death remained relatively common, especially among elderly patients (overall: 7.1%; those aged >= 80 years: 15.8%). Severely and even only a moderately impaired FS were significantly associated with early death after starting dialysis (adjusted risk ratios: 3.93 and 2.38, respectively). The incidence of early death in those with impaired FS increased with age (36.5% in those with severely impaired FS and aged >= 80 years). Conclusions Early death after starting dialysis was relatively common, especially among the elderly, even in Japanese patients. Further, early death was significantly associated with impaired FS at initiation of HD.	[Yazawa, Masahiko; Shibagaki, Yugo] St Marianna Univ, Div Nephrol & Hypertens, Sch Med, Kawasaki, Kanagawa, Japan; [Kido, Ryo] Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Kyoto, Japan; [Ohira, Seiji] Sapporo Kita Clin, Sapporo, Hokkaido, Japan; [Hasegawa, Takeshi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence, Fukushima, Japan; [Hanafusa, Norio] Tokyo Univ Hosp, Div Total Renal Care Med, Tokyo 113, Japan; [Iseki, Kunitoshi; Tsubakihara, Yoshiharu] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan; [Kido, Ryo] Inagi Municipal Hosp, Tokyo, Japan; [Hasegawa, Takeshi] Showa Univ, Fujigaoka Hosp, Dept Internal Med, Div Nephrol, Yokohama, Kanagawa 227, Japan	Saint Marianna University; Fukushima Medical University; University of Tokyo; Showa University	Yazawa, M (corresponding author), St Marianna Univ, Div Nephrol & Hypertens, Sch Med, Kawasaki, Kanagawa, Japan.	masahikoyazawa@gmail.com		Hasegawa, Takeshi/0000-0003-0420-5583	Committee of Renal Data Registry, Japanese Society for Dialysis Therapy; Grants-in-Aid for Scientific Research [16H05216] Funding Source: KAKEN	Committee of Renal Data Registry, Japanese Society for Dialysis Therapy; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by the Committee of Renal Data Registry, Japanese Society for Dialysis Therapy.	[Anonymous], 2001, CANND ORG REPL REG A, P8; Bao YR, 2012, ARCH INTERN MED, V172, P1071, DOI 10.1001/archinternmed.2012.3020; Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; Cohen LM, 2010, CLIN J AM SOC NEPHRO, V5, P72, DOI 10.2215/CJN.03860609; Couchoud C, 2009, NEPHROL DIAL TRANSPL, V24, P1553, DOI 10.1093/ndt/gfn698; Dogan E, 2005, NEPHROLOGY, V10, P516, DOI 10.1111/j.1440-1797.2005.00433.x; Doi T, 2009, J JPN SOC DIAL THER, V42, P879; European Renal Association-European Dialysis and TransplantAssociation, ERA EDTA REG ANN REP; Hasegawa T, 2009, CLIN J AM SOC NEPHRO, V4, P595, DOI 10.2215/CJN.03540708; Johansen KL, 2007, J AM SOC NEPHROL, V18, P2960, DOI 10.1681/ASN.2007020221; Johansen KL, 2013, SEMIN DIALYSIS, V26, P690, DOI 10.1111/sdi.12126; Kawaguchi Y, 1999, Perit Dial Int, V19 Suppl 3, pS9; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Little R. J. A., 1987, STAT ANAL MISSING DA; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Moss AH, 2008, CLIN J AM SOC NEPHRO, V3, P1379, DOI 10.2215/CJN.00940208; Nakai S, 2010, THER APHER DIAL, V14, P505, DOI 10.1111/j.1744-9987.2010.00893.x; Noordzij M, 2014, KIDNEY INT, V85, P12, DOI 10.1038/ki.2013.316; PAYNE RB, 1973, BMJ-BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; Rothman K, 2008, MODERN EPIDEMIOLOGY, P146; Soucie JM, 1996, J AM SOC NEPHROL, V7, P2169; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; U S Renal Data System. USRDS, 2012, ANN DAT REP ATL CHRO; Wagner M, 2011, AM J KIDNEY DIS, V57, P894, DOI 10.1053/j.ajkd.2010.12.023; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	27	17	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2016	11	6							e0156951	10.1371/journal.pone.0156951	http://dx.doi.org/10.1371/journal.pone.0156951			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TC	27270615	Green Published, gold, Green Submitted			2023-01-03	WOS:000377561000053
J	Ozono, H; Kamijo, Y; Shimizu, K				Ozono, Hiroki; Kamijo, Yoshio; Shimizu, Kazumi			Institutionalize Reciprocity to Overcome the Public Goods Provision Problem	PLOS ONE			English	Article							COLLECTIVE SANCTIONS; RATIONAL COOPERATION; PRISONERS-DILEMMA; PUNISHMENT; HETEROGENEITY; EVOLUTION; GAMES	Cooperation is fundamental to human societies, and one of the important paths for its emergence and maintenance is reciprocity. In prisoner's dilemma (PD) experiments, reciprocal strategies are often effective at attaining and maintaining high cooperation. In many public goods (PG) games or n-person PD experiments, however, reciprocal strategies are not successful at engendering cooperation. In the present paper, we attribute this difficulty to a coordination problem against free riding among reciprocators: Because it is difficult for the reciprocators to coordinate their behaviors against free riders, this may lead to inequality among players, which will demotivate them from cooperating in future rounds. We propose a new mechanism, institutionalized reciprocity (IR), which refers to embedding the reciprocal strategy as an institution (i.e., institutionalizing the reciprocal strategy). We experimentally demonstrate that IR can prevent groups of reciprocators from falling into coordination failure and achieve high cooperation in PG games. In conclusion, we argue that a natural extension of the present study will be to investigate the possibility of IR to serve as a collective punishment system.	[Ozono, Hiroki] Kagoshima Univ, Fac Law Econ & Humanities, Kagoshima 890, Japan; [Kamijo, Yoshio] Kochi Univ Technol, Sch Econ & Management, Kochi, Japan; [Shimizu, Kazumi] Waseda Univ, Sch Polit Sci & Econ, Tokyo, Japan	Kagoshima University; Kochi University Technology; Waseda University	Shimizu, K (corresponding author), Waseda Univ, Sch Polit Sci & Econ, Tokyo, Japan.	skazumi1961@gmail.com		Shimizu, Kazumi/0000-0003-4860-7007; Kamijo, Yoshio/0000-0002-2184-9594	Japanese Ministry of Education, Culture, Sports, Science and Technology [19046002]	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The Grant-in-Aid for Scientific Research on Priority Areas (19046002) provided by the Japanese Ministry of Education, Culture, Sports, Science and Technology, http://www.jsps.go.jp/j-grantsinaid/12_kiban/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r We gratefully acknowledge financial support from the Grant-in-Aid for Scientific Research on Priority Areas (19046002) provided by the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Alexander R.D., 1987, BIOL MORAL SYSTEMS; Anderson L. R., 2008, J SOCIO-ECON, V37, P1010, DOI [DOI 10.1016/J.SOCEC.2006.12.073, DOI 10.1016/j.socec.2006.12.073]; ANDREONI J, 1993, ECON J, V103, P570, DOI 10.2307/2234532; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, J POLICY ANAL MANAG, DOI DOI 10.2307/3323905; Balliet D, 2011, PSYCHOL BULL, V137, P594, DOI 10.1037/a0023489; Cherry TL, 2005, J ECON BEHAV ORGAN, V57, P357, DOI 10.1016/j.jebo.2003.11.010; COOPER R, 1989, RAND J ECON, V20, P568, DOI 10.2307/2555734; Croson R, 2005, ECON LETT, V87, P95, DOI 10.1016/j.econlet.2004.10.007; Croson RTA, 2007, ECON INQ, V45, P199, DOI 10.1111/j.1465-7295.2006.00006.x; Dal Bo P, 2005, AM ECON REV, V95, P1591; Dawes CT, 2007, NATURE, V446, P794, DOI 10.1038/nature05651; DAWES RM, 1980, ANNU REV PSYCHOL, V31, P169, DOI 10.1146/annurev.ps.31.020180.001125; De Herdt T., 2003, REV SOC ECON, V61, P183, DOI [10.1080/0034676032000098219, DOI 10.1080/0034676032000098219, 10.1080/]; de Oliveira ACM, 2015, EXP ECON, V18, P116, DOI 10.1007/s10683-014-9412-1; Denant-Boemont L, 2007, ECON THEOR, V33, P145, DOI 10.1007/s00199-007-0212-0; Devetag G, 2007, EXP ECON, V10, P331, DOI 10.1007/s10683-007-9178-9; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Fischbacher U, 2001, ECON LETT, V71, P397, DOI 10.1016/S0165-1765(01)00394-9; Fischbacher U, 2007, EXP ECON, V10, P171, DOI 10.1007/s10683-006-9159-4; Fowler JH, 2005, NATURE, V433, DOI 10.1038/nature03256; FUDENBERG D, 1986, ECONOMETRICA, V54, P533, DOI 10.2307/1911307; Gachter S., 2006, DISCUSSION PAPERS U; Gachter S, 2008, SCIENCE, V322, P1510, DOI 10.1126/science.1164744; Grujic J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00638; HECKATHORN DD, 1988, AM J SOCIOL, V94, P535, DOI 10.1086/229029; HECKATHORN DD, 1990, AM SOCIOL REV, V55, P366, DOI 10.2307/2095762; Herrmann B, 2008, SCIENCE, V319, P1362, DOI 10.1126/science.1153808; Kamijo Y, 2016, EXP ECON, V19, P202, DOI 10.1007/s10683-015-9433-4; KIM O, 1984, PUBLIC CHOICE, V43, P3, DOI 10.1007/BF00137902; KREPS DM, 1982, J ECON THEORY, V27, P245, DOI 10.1016/0022-0531(82)90029-1; Ledyard J.O., 1995, HDB EXPT EC, DOI DOI 10.3987/CONTENTS-12-85-7; Levinson DJ, 2003, STANFORD LAW REV, V56, P345; Levy DM, 2011, J ECON BEHAV ORGAN, V77, P40, DOI 10.1016/j.jebo.2010.02.018; MILGRAM S, 1963, J ABNORM PSYCHOL, V67, P371, DOI 10.1037/h0040525; Nikiforakis N, 2008, J PUBLIC ECON, V92, P91, DOI 10.1016/j.jpubeco.2007.04.008; Nosenzo D, 2015, EXP ECON, V18, P4, DOI 10.1007/s10683-013-9382-8; Olson Mancur, 1965, LOGIC COLLECTIVE ACT; Rand DG, 2009, SCIENCE, V325, P1272, DOI 10.1126/science.1177418; Rapoport A, 1996, J ECON BEHAV ORGAN, V30, P173, DOI 10.1016/S0167-2681(96)00856-6; Roberts G, 1998, NATURE, V394, P175, DOI 10.1038/28160; Sherratt TN, 2002, J THEOR BIOL, V215, P47, DOI 10.1006/jtbi.2001.2495; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755	43	5	5	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2016	11	6							e0154321	10.1371/journal.pone.0154321	http://dx.doi.org/10.1371/journal.pone.0154321			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DN6KZ	27248493	Green Submitted, Green Published, gold			2023-01-03	WOS:000377184700005
J	Bloomfield, HE; Koeller, E; Greer, N; MacDonald, R; Kane, R; Wilt, TJ				Bloomfield, Hanna E.; Koeller, Eva; Greer, Nancy; MacDonald, Roderick; Kane, Robert; Wilt, Timothy J.			Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							BREAST-CANCER RISK; RANDOMIZED CONTROLLED-TRIAL; NIH-AARP DIET; COGNITIVE DECLINE; POSTMENOPAUSAL WOMEN; PROSTATE-CANCER; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; QUALITY INDEXES; RHEUMATOID-ARTHRITIS	Background: Mediterranean diets may be healthier than typical Western diets. Purpose: To summarize the literature comparing a Mediterranean diet with unrestricted fat intake with other diets regarding their effects on health outcomes in adults. Data Sources: Ovid MEDLINE, CINAHL, and the Cochrane Library from 1990 through April 2016. Study Selection: Controlled trials of 100 or more persons followed for at least 1 year for mortality, cardiovascular, hypertension, diabetes, and adherence outcomes, as well as cohort studies for cancer outcomes. Data Extraction: Data extracted by 1 investigator was verified by another. Two reviewers assessed risk of bias and strength of evidence. Data Synthesis: Two primary prevention trials found no difference in all-cause mortality between diet groups. One large primary prevention trial found that a Mediterranean diet resulted in a lower incidence of major cardiovascular events (hazard ratio [HR], 0.71 [95% CI, 0.56 to 0.90]), breast cancer (HR, 0.43 [CI, 0.21 to 0.88]), and diabetes (HR, 0.70 [CI, 0.54 to 0.92]). Pooled analyses of primary prevention cohort studies showed that compared with the lowest quantile, the highest quantile of adherence to a Mediterranean diet was associated with a reduction in total cancer mortality (risk ratio [RR], 0.86 [CI, 0.82 to 0.91]; 13 studies) and in the incidence of total (RR, 0.96 [CI, 0.95 to 0.97]; 3 studies) and colorectal (RR, 0.91 [CI, 0.84 to 0.98; 9 studies]) cancer. Of 3 secondary prevention studies reporting cardiovascular outcomes, 1 found a lower risk for recurrent myocardial infarction and cardiovascular death with the Mediterranean diet. There was inconsistent, minimal, or no evidence pertaining to any other outcome, including adherence, hypertension, cognitive function, kidney disease, rheumatoid arthritis, and quality of life. Limitations: Few trials; medium risk-of-bias ratings for many studies; low or insufficient strength of evidence for outcomes; heterogeneous diet definitions and components. Conclusion: Limited evidence suggests that a Mediterranean diet with no restriction on fat intake may reduce the incidence of cardiovascular events, breast cancer, and type 2 diabetes mellitus but may not affect all-cause mortality.	Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Bloomfield, Hanna E.] Minneapolis VA Med Ctr, 1 Vet Dr 151, Minneapolis, MN 55417 USA; [Koeller, Eva; Greer, Nancy; MacDonald, Roderick; Wilt, Timothy J.] Minneapolis VA Med Ctr, 1 Vet Dr 111-O, Minneapolis, MN 55417 USA; [Kane, Robert] Univ Minnesota, Div Publ Hlth & Management, D351 Mayo MMC 729,420 Delaware St Southeast, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Bloomfield, HE (corresponding author), Minneapolis VA Med Ctr, 1 Vet Dr 151, Minneapolis, MN 55417 USA.	Hanna.Bloomfield@va.gov		bloomfield, hanna/0000-0002-0756-7064	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative (PROSPERO) [CRD42015020262]	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative (PROSPERO)(US Department of Veterans Affairs)	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. (PROSPERO: CRD42015020262)	Adebamowo CA, 2005, ANN EPIDEMIOL, V15, P789, DOI 10.1016/j.annepidem.2005.01.008; Agurs-Collins T, 2009, AM J CLIN NUTR, V90, P621, DOI 10.3945/ajcn.2009.27666; Anic GM, 2016, EUR J CLIN NUTR, V70, P123, DOI 10.1038/ejcn.2015.122; Ax E, 2014, NUTR CANCER, V66, P77, DOI 10.1080/01635581.2014.851712; Bamia C, 2013, EUR J EPIDEMIOL, V28, P317, DOI 10.1007/s10654-013-9795-x; Bosire C, 2013, AM J EPIDEMIOL, V177, P504, DOI 10.1093/aje/kws261; Buckland G, 2015, INT J CANCER, V137, P598, DOI 10.1002/ijc.29411; Buckland G, 2014, INT J CANCER, V134, P2504, DOI 10.1002/ijc.28573; Buckland G, 2013, INT J CANCER, V132, P2918, DOI 10.1002/ijc.27958; Burr ML, 2003, EUR J CLIN NUTR, V57, P193, DOI 10.1038/sj.ejcn.1601539; Cade JE, 2011, EUR J CLIN NUTR, V65, P920, DOI 10.1038/ejcn.2011.69; Catsburg C, 2015, AM J CLIN NUTR, V101, P817, DOI 10.3945/ajcn.114.097659; Cherbuin N, 2012, AM J GERIAT PSYCHIAT, V20, P635, DOI 10.1097/JGP.0b013e31823032a9; Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Couto E, 2011, BRIT J CANCER, V104, P1493, DOI 10.1038/bjc.2011.106; Couto E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055374; Crous-Bou M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6674; Cuenca-Garcia M, 2014, ANN EPIDEMIOL, V24, P297, DOI 10.1016/j.annepidem.2014.01.007; de Lorgeril M, 1998, ARCH INTERN MED, V158, P1181, DOI 10.1001/archinte.158.11.1181; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; De Lorgeril M, 1996, J AM COLL CARDIOL, P281103; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Desroches S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008722.pub2; Dixon LB, 2004, AM J CLIN NUTR, V80, P1003, DOI 10.1093/ajcn/80.4.1003; Esposito K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008222; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146; Fung TT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115377; Fung TT, 2010, AM J CLIN NUTR, V92, P1429, DOI 10.3945/ajcn.2010.29242; Fung TT, 2006, J NUTR, V136, P466, DOI 10.1093/jn/136.2.466; Galbete C, 2015, J NUTR HEALTH AGING, V19, P305, DOI 10.1007/s12603-015-0441-z; Gardener S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.91; Gardener SL, 2015, MOL PSYCHIATR, V20, P860, DOI 10.1038/mp.2014.79; George SM, 2015, ANN EPIDEMIOL, V25, P788, DOI 10.1016/j.annepidem.2015.05.009; George SM, 2014, AM J EPIDEMIOL, V180, P616, DOI 10.1093/aje/kwu173; Harmon BE, 2015, AM J CLIN NUTR, V101, P587, DOI 10.3945/ajcn.114.090688; Higgins H, 2011, COCHRANE HDB SYSTEMA; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P39, DOI 10.1001/jama.295.1.39; Hu Y, 2015, ARTHRIT CARE RES, V67, P597, DOI 10.1002/acr.22481; Kenfield SA, 2014, EUR UROL, V65, P887, DOI 10.1016/j.eururo.2013.08.009; Kesse-Guyot E, 2013, AM J CLIN NUTR, V97, P369, DOI 10.3945/ajcn.112.047993; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Kim EHJ, 2011, NUTR CANCER, V63, P381, DOI 10.1080/01635581.2011.535963; Kim HJ, 2005, NUTR CANCER, V52, P138, DOI 10.1207/s15327914nc5202_4; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Koyama A, 2015, J GERONTOL A-BIOL, P70354, DOI [10.1093/gerona/g1u097, DOI 10.1093/GER0NA/G1U097]; Kroenke CH, 2005, J CLIN ONCOL, V23, P9295, DOI 10.1200/JCO.2005.02.0198; Kwan ML, 2009, J CLIN ONCOL, V27, P919, DOI 10.1200/JCO.2008.19.4035; Kwok TCY, 2012, EUR J CLIN NUTR, V66, P1135, DOI 10.1038/ejcn.2012.117; Kyro C, 2013, BRIT J NUTR, V109, P920, DOI 10.1017/S0007114512002085; Lagiou P, 2006, BRIT J NUTR, V96, P384, DOI 10.1079/BJN20061824; LeFevre ML, 2014, ANN INTERN MED, V161, P587, DOI 10.7326/M14-1796; Lehert P, 2015, CLIMACTERIC, V18, P678, DOI 10.3109/13697137.2015.1078106; Li WQ, 2014, AM J CLIN NUTR, V99, P559, DOI 10.3945/ajcn.113.073163; Li WQ, 2013, CLIN GASTROENTEROL H, V11, P1130, DOI 10.1016/j.cgh.2013.03.023; Link AR, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/301549; Logan KJ, 2010, J HUM NUTR DIET, V23, P30, DOI 10.1111/j.1365-277X.2009.00989.x; Lopez-Garcia E, 2014, AM J CLIN NUTR, V99, P172, DOI 10.3945/ajcn.113.068106; Maderuelo-Fernandez JA, 2015, PREV MED, V76, pS39, DOI 10.1016/j.ypmed.2014.12.011; Maisonneuve P, 2016, EUR J NUTR, V55, P1069, DOI 10.1007/s00394-015-0920-3; Mannisto S, 2005, CANCER CAUSE CONTROL, V16, P725, DOI 10.1007/s10552-005-1763-7; Martinez-Gonzalez MA, 2015, PROG CARDIOVASC DIS, V58, P50, DOI 10.1016/j.pcad.2015.04.003; Martinez-Lapiscina EH, 2013, J NUTR HEALTH AGING, V17, P544, DOI 10.1007/s12603-013-0027-6; McKellar G, 2007, ANN RHEUM DIS, V66, P1239, DOI 10.1136/ard.2006.065151; Menotti A, 2012, PUBLIC HEALTH NUTR, V15, P1232, DOI 10.1017/S1368980011003235; Meyerhardt JA, 2007, JAMA-J AM MED ASSOC, V298, P754, DOI 10.1001/jama.298.7.754; Michaud DS, 2005, J NATL CANCER I, V97, P518, DOI 10.1093/jnci/dji094; Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1007, DOI 10.1016/j.jalz.2014.11.009; Mozaffarian D, 2015, JAMA-J AM MED ASSOC, V313, P2421, DOI 10.1001/jama.2015.5941; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Mursu J, 2013, AM J CLIN NUTR, V98, P444, DOI 10.3945/ajcn.112.055681; Nissen SE, 2016, ANN INTERN MED, V164, P558, DOI 10.7326/M16-0035; O'Rourke K., 2015, JAMA-J AM MED ASSOC, V314, P1905, DOI 10.1001/jama.2015.14994; Off. Dis. Prev. Health Promot, 2015, DIET GUID AM 2015 20; Olsson E, 2015, J ALZHEIMERS DIS, V43, P109, DOI 10.3233/JAD-140867; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Perez-Tasigchana RF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151596; Psaltopoulou T, 2008, PUBLIC HEALTH NUTR, V11, P1054, DOI 10.1017/S1368980007001607; Reedy J, 2008, AM J EPIDEMIOL, V168, P38, DOI 10.1093/aje/kwn097; Reedy J, 2014, J NUTR, V144, P881, DOI 10.3945/jn.113.189407; Rees K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub2; Roberts RO, 2010, DEMENT GERIATR COGN, V29, P413, DOI 10.1159/000305099; Roth GA, 2015, NEW ENGL J MED, V372, P1333, DOI 10.1056/NEJMoa1406656; Salas-Salvado J, 2014, ANN INTERN MED, V160, P1, DOI 10.7326/M13-1725; Samieri C, 2013, EPIDEMIOLOGY, V24, P490, DOI 10.1097/EDE.0b013e318294a065; Samieri C, 2013, J NUTR, V143, P493, DOI 10.3945/jn.112.169896; Sant M, 2007, INT J CANCER, V121, P911, DOI 10.1002/ijc.22714; Scarmeas N, 2009, ARCH NEUROL-CHICAGO, V66, P216, DOI 10.1001/archneurol.2008.536; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; Schwingshackl L, 2015, CANCER MED-US, V4, P1933, DOI 10.1002/cam4.539; Sieri S, 2004, CANCER EPIDEM BIOMAR, V13, P567; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SINGH RB, 1991, NUTRITION, V7, P210; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Skoldstam L, 2003, ANN RHEUM DIS, V62, P208, DOI 10.1136/ard.62.3.208; Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169; Tangney CC, 2011, AM J CLIN NUTR, V93, P601, DOI 10.3945/ajcn.110.007369; Tangney CC, 2014, NEUROLOGY, V83, P1410, DOI 10.1212/WNL.0000000000000884; Terry P, 2001, CANCER EPIDEM BIOMAR, V10, P1281; Tinker LF, 2008, ARCH INTERN MED, V168, P1500, DOI 10.1001/archinte.168.14.1500; Tognon G, 2012, J NUTR, V142, P1547, DOI 10.3945/jn.112.160499; Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou A, 2015, EUR J NUTR, V54, P1311, DOI 10.1007/s00394-014-0811-z; Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; Tuttle KR, 2008, AM J CARDIOL, V101, P1523, DOI 10.1016/j.amjcard.2008.01.038; Valls-Pedret C, 2015, JAMA INTERN MED, V175, P1094, DOI 10.1001/jamainternmed.2015.1668; van de Rest O, 2015, ADV NUTR, V6, P154, DOI 10.3945/an.114.007617; Velie EM, 2005, AM J CLIN NUTR, V82, P1308, DOI 10.1093/ajcn/82.6.1308; Vormund K, 2015, EUR J NUTR, V54, P139, DOI 10.1007/s00394-014-0695-y; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Vrieling A, 2013, BRIT J CANCER, V108, P188, DOI 10.1038/bjc.2012.521; Wang DD, 2014, JAMA INTERN MED, V174, P1587, DOI 10.1001/jamainternmed.2014.3422; Wengreen H, 2013, AM J CLIN NUTR, V98, P1263, DOI 10.3945/ajcn.112.051276; White C, 2005, BMJ-BRIT MED J, V331, P281, DOI 10.1136/bmj.331.7511.281; Widmer RJ, 2015, AM J MED, V128, P229, DOI 10.1016/j.amjmed.2014.10.014; Xie J, 2014, J OVARIAN RES, V7, DOI 10.1186/s13048-014-0112-4; Yang M, 2015, CANCER PREV RES, V8, P545, DOI 10.1158/1940-6207.CAPR-14-0442; Zazpe I, 2008, J AM DIET ASSOC, V108, P1134, DOI 10.1016/j.jada.2008.04.011	123	98	99	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2016	165	7					491	+		10.7326/M16-0361	http://dx.doi.org/10.7326/M16-0361			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DY0EY	27428849				2023-01-03	WOS:000384771300007
J	Ahmadi, Z; Sundh, J; Bornefalk-Hermansson, A; Ekstrom, M				Ahmadi, Zainab; Sundh, Josefin; Bornefalk-Hermansson, Anna; Ekstrom, Magnus			Long-Term Oxygen Therapy 24 vs 15 h/day and Mortality in Chronic Obstructive Pulmonary Disease	PLOS ONE			English	Article							OXIDATIVE STRESS; SURVIVAL; EXPERIENCE; REGISTER; DYSPNEA; PEOPLE; RELIEF; TRIAL; HOME; AIR	Long-term oxygen therapy (LTOT) >= 15 h/day improves survival in hypoxemic chronic obstructive pulmonary disease ( COPD). LTOT 24 h/day is often recommended but may pose an unnecessary burden with no clear survival benefit compared with LTOT 15 h/day. The aim was to test the hypothesis that LTOT 24 h/day decreases all-cause, respiratory, and cardiovascular mortality compared to LTOT 15 h/day in hypoxemic COPD. This was a prospective, observational, population-based study of COPD patients starting LTOT between October 1, 2005 and June 30, 2009 in Sweden. Overall and cause-specific mortality was analyzed using Cox and Fine-Gray regression, controlling for age, sex, prescribed oxygen dose, PaO2 (air), PaCO2 (air), Forced Expiratory Volume in one second (FEV1), WHO performance status, body mass index, comorbidity, and oral glucocorticoids. A total of 2,249 included patients were included with a median follow-up of 1.1 years (interquartile range, 0.6-2.1). 1,129 (50%) patients died and no patient was lost to follow-up. Higher LTOT duration analyzed as a continuous variable was not associated with any change in mortality rate (hazard ratio [HR] 1.00; (95% confidence interval [CI], 0.98 to 1.02) per 1 h/day increase above 15 h/day. LTOT exactly 24 h/day was prescribed in 539 (24%) patients and LTOT 15-16 h/day in 1,231 (55%) patients. Mortality was similar between the groups for all-cause, respiratory and cardiovascular mortality. In hypoxemic COPD, LTOT 24 h/day was not associated with a survival benefit compared with treatment 15-16 h/day. A design for a registry-based randomized trial (R-RCT) is proposed.	[Ahmadi, Zainab; Ekstrom, Magnus] Lund Univ, Div Resp Med & Allergol, Dept Clin Sci, Lund, Sweden; [Sundh, Josefin] Univ Orebro, Sch Med Sci, Dept Resp Med, Orebro, Sweden; [Bornefalk-Hermansson, Anna] Uppsala Univ, Dept Stat, Uppsala, Sweden	Lund University; Orebro University; Uppsala University	Ahmadi, Z (corresponding author), Lund Univ, Div Resp Med & Allergol, Dept Clin Sci, Lund, Sweden.	zai.ahmd@gmail.com		Bornefalk-Hermansson, Anna/0000-0001-9934-8485	Swedish Society of Medicine; Swedish Respiratory Society; Swedish Heart Lung Foundation; Wera and Emil Cornell Foundation; Scientific Committee of Blekinge County Council; Scientific Committee of the Region of Orebro	Swedish Society of Medicine; Swedish Respiratory Society; Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Wera and Emil Cornell Foundation; Scientific Committee of Blekinge County Council; Scientific Committee of the Region of Orebro	This work was supported by unrestricted grants from The Swedish Society of Medicine, the Swedish Respiratory Society, the Swedish Heart Lung Foundation, and the Wera and Emil Cornell Foundation to ME; and ME and ZA were supported by unrestricted grants from the Scientific Committee of Blekinge County Council. JS was supported by unrestricted grants from the Scientific Committee of the Region of Orebro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; Ahmadi Z, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-30; Alton M, 1985, LAKARTIDNINGEN, V82, P4399; Ameer F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000238.pub2; [Anonymous], 1980, ANN INTERN MED, V93, P391; [Anonymous], 1992, MAN INT STAT CLASS D; ANTHONISEN NR, 1989, AM REV RESPIR DIS, V140, pS95, DOI 10.1164/ajrccm/140.3_Pt_2.S95; Barbaro MPF, 2005, FREE RADICAL RES, V39, P1111, DOI 10.1080/10715760500250257; Carpagnano GE, 2004, THORAX, V59, P1016, DOI 10.1136/thx.2003.020768; Chaouat A, 1999, EUR RESPIR J, V14, P1002, DOI 10.1183/09031936.99.14510029; Cranston JM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001744.pub2; Cranston JM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004769.pub2; Crockett AJ, 2001, INTERN MED J, V31, P448, DOI 10.1046/j.1445-5994.2001.00103.x; Croxton TL, 2006, AM J RESP CRIT CARE, V174, P373, DOI 10.1164/rccm.200507-1161WS; Dellborg M, 1993, Lakartidningen, V90, P3077; Disler RT, 2014, J PAIN SYMPTOM MANAG, V48, P1182, DOI 10.1016/j.jpainsymman.2014.03.009; Ekstrom MP, 2011, AM J RESP CRIT CARE, V183, P1032, DOI 10.1164/rccm.201010-1704OC; Ekstrom MP, 2013, AM J RESP CRIT CARE; Ekstrom MP, 2014, BMJ-BRIT MED J, V348, pg445, DOI DOI 10.1136/BMJ.G445; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; FLENLEY DC, 1981, LANCET, V1, P681; Franklin KA, 2007, RESP MED, V101, P1506, DOI 10.1016/j.rmed.2007.01.009; Frobert O, 2013, NEW ENGL J MED, V369, P1587, DOI 10.1056/NEJMoa1308789; Goldbart J, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-124; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; Gulbas G, 2012, INT J CLIN PRACT, V66, P152, DOI 10.1111/j.1742-1241.2011.02833.x; Hardinge M, 2015, THORAX, V70, P1, DOI 10.1136/thoraxjnl-2015-206865; Holguin Fernando, 2013, Ann Am Thorac Soc, V10 Suppl, pS150, DOI 10.1513/AnnalsATS.201305-116AW; James S, 2015, NAT REV CARDIOL, V12, P312, DOI 10.1038/nrcardio.2015.33; Kampelmacher MJ, 1998, RESP MED, V92, P70, DOI 10.1016/S0954-6111(98)90035-X; Katsenos S, 2011, PULM MED, V2011, DOI 10.1155/2011/325362; Lakemedelsverket (Swedish Medical Products Agency), 2015, LAK KRON OBSTR LUNGS; Lofdahl Kerstin, 2007, Lakartidningen, V104, P1902; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; Ring L, 1997, J ADV NURS, V26, P337, DOI 10.1046/j.1365-2648.1997.1997026337.x; STARK RD, 1972, BRIT MED J, V3, P724, DOI 10.1136/bmj.3.5829.724; Stoller JK, 2010, CHEST, V138, P179, DOI 10.1378/chest.09-2555; STROM K, 1988, EUR RESPIR J, V1, P952; Swedish National Register for Respiratory Failure (Swedevox), 2015, GUID LONG TERM OXYG; Swedish National Register for Respiratory Failure (Swedevox), 2014, ANN REPORT; Uronis HE, 2015, THORAX, V70, P492, DOI 10.1136/thoraxjnl-2014-205720; Utens CMA, 2013, INT J NURS STUD, V50, P1537, DOI 10.1016/j.ijnurstu.2013.03.006; Welfare. SNBoHa, 2008, WELF SNBOHA QUAL CON; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; World Health Organization (WHO), 1978, MAN INT CLASS DIS IN; Zielinski J, 1998, CHEST, V113, P65, DOI 10.1378/chest.113.1.65	46	21	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2016	11	9							e0163293	10.1371/journal.pone.0163293	http://dx.doi.org/10.1371/journal.pone.0163293			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW8GE	27649490	Green Published, gold, Green Submitted			2023-01-03	WOS:000383892100076
J	Maroun, R; Maunoury, F; Benjamin, L; Nachbaur, G; Durand-Zaleski, I				Maroun, Rana; Maunoury, Franck; Benjamin, Laure; Nachbaur, Gaelle; Durand-Zaleski, Isabelle			In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013	PLOS ONE			English	Article							CANCER	Background & Objectives The aim of this study was to assess the economic burden of hospitalisations for metastatic renal cell carcinoma (mRCC), to describe the patterns of prescribing expensive drugs and to explore the impact of geographic and socio-demographic factors on the use of these drugs. Methods We performed a retrospective analysis from the French national hospitals database. Hospital stays for mRCC between 2008 and 2013 were identified by combining the 10th revision of the International Classification of Diseases (ICD-10) codes for renal cell carcinoma (C64) and codes for metastases (C77 to C79). Incident cases were identified out of all hospital stays and followed till December 2013. Descriptive analyses were performed with a focus on hospital stays and patient characteristics. Costs were assessed from the perspective of the French National Health Insurance and were obtained from official diagnosis-related group tariffs for public and private hospitals. Results A total of 15,752 adult patients were hospitalised for mRCC, corresponding to 102,613 hospital stays. Of those patients, 68% were men and the median age at first hospitalisation was 69 years [Min-Max: 18-102]. Over the study period, the hospital mortality rate reached 37%. The annual cost of managing mRCC at hospital varied between 28M(sic) in 2008 and 42M(sic) in 2012 and was mainly driven by inpatient costs. The mean annual per capita cost of hospital management of mRCC varied across the study period from 8,993(sic) (SD: (sic)8,906) in 2008 to 10,216(sic) (SD: (sic)10,527) in 2012. Analysis of the determinants of prescribing expensive drugs at hospital did not show social or territorial differences in the use of these drugs. Conclusion This study is the first to investigate the in-hospital economic burden of mRCC in France. Results showed that in-hospital costs of managing mRCC are mainly driven by expensive drugs and inpatient costs.	[Maroun, Rana; Benjamin, Laure; Nachbaur, Gaelle] GlaxoSmithKline, Marly Le Roi, France; [Maunoury, Franck] Statesia, Le Mans, France; [Durand-Zaleski, Isabelle] AP HP, URC Eco Ile de France, Paris, France; [Maroun, Rana; Durand-Zaleski, Isabelle] INSERM, ECEVE, Paris, France	GlaxoSmithKline; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Maroun, R (corresponding author), GlaxoSmithKline, Marly Le Roi, France.; Maroun, R (corresponding author), INSERM, ECEVE, Paris, France.	rana.r.maroun@gsk.com	; Maroun, Rana/D-5897-2017	Nachbaur, Gaelle/0000-0001-5116-0723; DUPONT-BENJAMIN, Laure/0000-0001-7748-0768; Maroun, Rana/0000-0002-6592-5739	GlaxoSmithKline; Association Nationale de la Recherche et de la Technologie (ANRT)	GlaxoSmithKline(GlaxoSmithKline); Association Nationale de la Recherche et de la Technologie (ANRT)(French National Research Agency (ANR))	This work is a part of a PhD program (CIFRE, Convention Industrielle de Formation par la REcherche) funded by GlaxoSmithKline and the Association Nationale de la Recherche et de la Technologie (ANRT).	A.R. Tu. R, 2016, TUMEURS REIN GEN EPI; Assurance Maladie, 2016, DONN MENS ANN MED RE; Benjamin L, 2015, CURR MED RES OPIN, V31, P323, DOI 10.1185/03007995.2014.986324; Casez P, 2015, MED MALADIES INFECT, V45, P446, DOI 10.1016/j.medmal.2015.10.004; Charles T, 2010, EMC UROLOGIE, V4, P1, DOI [10.1016/S1762-0953(10)52713-4, DOI 10.1016/S1762-0953(10)52713-4]; Geynisman Daniel M, 2015, Clin Genitourin Cancer, V13, pe93, DOI 10.1016/j.clgc.2014.08.013; Hansen RN, 2015, J MANAG CARE SPEC PH, V21, P37, DOI 10.18553/jmcp.2015.21.1.37; InCa, 2014, CANC FRANC; Institut National Du Cancer, 2015, INC NAT CANC; Larkin J, 2013, EXPERT OPIN PHARMACO, V14, P27, DOI 10.1517/14656566.2013.758713; Pal SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063341; Rey G, 2009, BMC PUBLIC HEALTH, V9, P33, DOI DOI 10.1186/1471-2458-9-33; Scherpereel A, 2015, VALUE HEALTH, V18, pA341, DOI 10.1016/j.jval.2015.09.145; Soerensen AV, 2015, EUR UROL, V68, P516, DOI 10.1016/j.eururo.2014.12.017; Windenberger F, 2012, EUR J PUBLIC HEALTH, V22, P347, DOI 10.1093/eurpub/ckr029	15	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2016	11	9							e0162864	10.1371/journal.pone.0162864	http://dx.doi.org/10.1371/journal.pone.0162864			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW8GE	27649305	gold, Green Published, Green Submitted			2023-01-03	WOS:000383892100038
J	White, D; Coombe, D; Rezania, V; Tuszynski, J				White, Diana; Coombe, Dennis; Rezania, Vahid; Tuszynski, Jack			Building a 3D Virtual Liver: Methods for Simulating Blood Flow and Hepatic Clearance on 3D Structures	PLOS ONE			English	Article							CONSTRAINED CONSTRUCTIVE OPTIMIZATION; ARTERIAL TREE MODELS; PACLITAXEL METABOLISM; VASCULAR TREES; NETWORK MODEL; HEMODYNAMICS	In this paper, we develop a spatio-temporal modeling approach to describe blood and drug flow, as well as drug uptake and elimination, on an approximation of the liver. Extending on previously developed computational approaches, we generate an approximation of a liver, which consists of a portal and hepatic vein vasculature structure, embedded in the surrounding liver tissue. The vasculature is generated via constrained constructive optimization, and then converted to a spatial grid of a selected grid size. Estimates for surrounding upscaled lobule tissue properties are then presented appropriate to the same grid size. Simulation of fluid flow and drug metabolism (hepatic clearance) are completed using discretized forms of the relevant convective-diffusive-reactive partial differential equations for these processes. This results in a single stage, uniformly consistent method to simulate equations for blood and drug flow, as well as drug metabolism, on a 3D structure representative of a liver.	[White, Diana] Clarkson Univ, Dept Math, Potsdam, NY USA; [Coombe, Dennis] Comp Modelling Grp Ltd, Calgary, AB, Canada; [Rezania, Vahid] MacEwan Univ, Dept Phys Sci, Edmonton, AB, Canada; [Tuszynski, Jack] Univ Alberta, Dept Phys, Edmonton, AB, Canada; [Tuszynski, Jack] Univ Alberta, Dept Oncol, Edmonton, AB, Canada	Clarkson University; University of Alberta; University of Alberta	Tuszynski, J (corresponding author), Univ Alberta, Dept Phys, Edmonton, AB, Canada.; Tuszynski, J (corresponding author), Univ Alberta, Dept Oncol, Edmonton, AB, Canada.	jackt@ualberta.ca	Tuszynski, Jack/AAA-2073-2020	Tuszynski, Jack/0000-0001-9976-0429	Modelling Group Ltd.	Modelling Group Ltd.	The computer Modelling Group Ltd. only provided financial support in the form of author salary (DC) and access to research material (STARS software package). The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Arias M., 2009, LIVER BIOL PATHOLOGY, V5; ARTS T, 1979, AM J PHYSIOL, V237, pH469, DOI 10.1152/ajpheart.1979.237.4.H469; Bartholomew-Biggs M, 2008, SPRINGER SER OPTIM A, V19, P1, DOI 10.1007/978-0-387-78723-7_1; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; CMG Limited, 2013, STARS US GUID ADV PR; D'Alessandro LA, 2015, PROG BIOPHYS MOL BIO, V117, P78, DOI 10.1016/j.pbiomolbio.2014.11.005; Debbaut C, 2011, IEEE T BIO-MED ENG, V58, P25, DOI 10.1109/TBME.2010.2065229; Dullien F., 1992, POROUS MEDIA FLUID T, Vv2; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; Goulet G., 2009, B APPL MECH, V5, P6; Goulet GC, 2009, ANN BIOMED ENG, V37, P1390, DOI 10.1007/s10439-009-9706-1; Hahn HK, 2005, MATH BIOSCI INTERAC, P55, DOI 10.1007/3-7643-7412-8_5; Hoehme S, 2010, P NATL ACAD SCI USA, V107, P10371, DOI 10.1073/pnas.0909374107; Ierapetritou MG, 2009, CTS-CLIN TRANSL SCI, V2, P228, DOI 10.1111/j.1752-8062.2009.00092.x; Johnson KA, 2011, BIOCHEMISTRY-US, V50, P8264, DOI 10.1021/bi201284u; Johnson TN, 2010, CLIN PHARMACOKINET, V49, P189, DOI 10.2165/11318160-000000000-00000; KAMIYA A, 1972, B MATH BIOPHYS, V34, P431, DOI 10.1007/BF02476705; Karch R, 1999, COMPUT BIOL MED, V29, P19, DOI 10.1016/S0010-4825(98)00045-6; Kretowski M, 2003, COMPUT METH PROG BIO, V70, P129, DOI 10.1016/S0169-2607(01)00200-0; Louman-Gardiner KM, 2011, COMPUT METHOD BIOMEC, V14, P1071, DOI 10.1080/10255842.2010.508037; Monsarrat B, 1998, DRUG METAB DISPOS, V26, P229; Rezania V, 2016, THEOR BIOL MED MODEL, V13, DOI 10.1186/s12976-016-0034-5; Rezania V, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-53; Rezania V, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-52; Risoe C., 1991, BLOOD VOLUME CHANGES, V261, P1763; Schliess F, 2014, HEPATOLOGY, V60, P2040, DOI 10.1002/hep.27136; Schreiner W, 1997, J THEOR BIOL, V187, P147, DOI 10.1006/jtbi.1997.0413; SCHREINER W, 1993, J BIOMED ENG, V15, P148, DOI 10.1016/0141-5425(93)90046-2; SCHREINER W, 1995, J GEN PHYSIOL, V106, P583, DOI 10.1085/jgp.106.4.583; SCHREINER W, 1994, J GEN PHYSIOL, V103, P975, DOI 10.1085/jgp.103.6.975; SCHREINER W, 1993, IEEE T BIO-MED ENG, V40, P482, DOI 10.1109/10.243413; Schreiner W, 2006, MED ENG PHYS, V28, P416, DOI 10.1016/j.medengphy.2005.07.019; Schwen LO, 2016, COMPUT BIOL MED, V73, P108, DOI 10.1016/j.compbiomed.2016.04.004; Schwen LO, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003499; Schwen LO, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/357687; Selle D, 2002, IEEE T MED IMAGING, V21, P1344, DOI 10.1109/TMI.2002.801166; SHOEMAKER CP, 1964, CIRC RES, V15, P216, DOI 10.1161/01.RES.15.3.216; Taniguchi R, 2005, J PHARMACOL SCI, V97, P83, DOI 10.1254/jphs.FP0040603; Vaclavikova R, 2004, DRUG METAB DISPOS, V32, P666, DOI 10.1124/dmd.32.6.666; Van Der Plaats A, 2004, INT J ARTIF ORGANS, V27, P222, DOI 10.1177/039139880402700309; Willmann Stefan, 2005, Expert Opin Drug Metab Toxicol, V1, P159, DOI 10.1517/17425255.1.1.159; ZAMIR M, 1988, J GEN PHYSIOL, V91, P725, DOI 10.1085/jgp.91.5.725; Zamir M, 1999, J THEOR BIOL, V197, P517, DOI 10.1006/jtbi.1998.0892	43	17	17	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2016	11	9							e0162215	10.1371/journal.pone.0162215	http://dx.doi.org/10.1371/journal.pone.0162215			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW8GE	27649537	Green Submitted, Green Published, gold			2023-01-03	WOS:000383892100014
J	Jack, A				Jack, Andrew			BRIEFING PrEP, Truvada, and Gilead	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Jack, Andrew] Financial Times, London, England		Jack, A (corresponding author), Financial Times, London, England.	andrew.jack@ft.com						England NHS, 2016, AUG UPD COMM PROV PR; European Centre for Disease Prevention and Control, 2015, PREEXP PROPH PREV HI; Health Protection Agency, 2011, HIV UK 2011 REP; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; World Health Organization (WHO), 2014, GUID POST PROPH HIV	5	0	0	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 8	2016	354								i4800	10.1136/bmj.i4800	http://dx.doi.org/10.1136/bmj.i4800			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV7FI	27609216				2023-01-03	WOS:000383101300001
J	Burley, SD; Whittingham-Dowd, J; Allen, J; Grosset, JF; Onambele-Pearson, GL				Burley, Simon D.; Whittingham-Dowd, Jayde; Allen, Jeremy; Grosset, Jean-Francois; Onambele-Pearson, Gladys L.			The Differential Hormonal Milieu of Morning versus Evening May Have an Impact on Muscle Hypertrophic Potential	PLOS ONE			English	Article							HEAVY-RESISTANCE EXERCISE; FACTOR BINDING PROTEIN-3; CIRCADIAN-RHYTHMS; SKELETAL-MUSCLE; NUTRITIONAL SUPPLEMENTATION; MUSCULAR PERFORMANCE; BODY-TEMPERATURE; IGF-I; RESPONSES; GROWTH	Substantial gains in muscle strength and hypertrophy are clearly associated with the routine performance of resistance training. What is less evident is the optimal timing of the resistance training stimulus to elicit these significant functional and structural skeletal muscle changes. Therefore, this investigation determined the impact of a single bout of resistance training performed either in the morning or evening upon acute anabolic signalling (insulinlike growth factor-binding protein-3 (IGFBP-3), myogenic index and differentiation) and catabolic processes (cortisol). Twenty-four male participants (age 21.4 +/- 1.9yrs, mass 83.7 +/- 13.7kg) with no sustained resistance training experience were allocated to a resistance exercise group (REP). Sixteen of the 24 participants were randomly selected to perform an additional non-exercising control group (CP) protocol. REP performed two bouts of resistance exercise (80% 1RM) in the morning (AM: 0800 hrs) and evening (PM: 1800 hrs), with the sessions separated by a minimum of 72 hours. Venous blood was collected immediately prior to, and 5 min after, each resistance exercise and control sessions. Serum cortisol and IGFBP-3 levels, myogenic index, myotube width, were determined at each sampling period. All data are reported as mean +/- SEM, statistical significance was set at P <= 0.05. As expected a significant reduction in evening cortisol concentration was observed at pre (AM: 98.4 +/- 10.5, PM: 49.8 +/- 4.4 ng/ml, P<0.001) and post (AM: 98.0 +/- 9.0, PM: 52.7 +/- 6.0 ng/ml, P<0.001) exercise. Interestingly, individual cortisol differences pre vs post exercise indicate a time-of-day effect (AM difference:-2 +/- 2.6%, PM difference: 14.0 +/- 6.7%, P = 0.03). A time-of-day related elevation in serum IGFBP-3 (AM: 3274.9 +/- 345.2, PM: 3605.1 +/- 367.5, p = 0.032) was also evident. Pre exercise myogenic index (AM: 8.0 +/- 0.6%, PM: 16.8 +/- 1.1%) and myotube width (AM: 48.0 +/- 3.0, PM: 71.6 +/- 1.9 mu m) were significantly elevated (P<0.001) in the evening. Post exercise myogenic index was greater AM (11.5 +/- 1.6%) compared with PM (4.6 +/- 0.9%). No difference was observed in myotube width (AM: 48.5 +/- 1.5, PM: 47.8 +/- 1.8 mu m) (P> 0.05). Timing of resistance training regimen in the evening appears to augment some markers of hypertrophic potential, with elevated IGFBP-3, suppressed cortisol and a superior cellular environment. Further investigation, to further elucidate the time course of peak anabolic signalling in morning vs evening training conditions, are timely.	[Burley, Simon D.; Grosset, Jean-Francois; Onambele-Pearson, Gladys L.] Manchester Metropolitan Univ, HEAL Res Ctr, Exercise & Sport Sci, Crewe Green Rd, Crewe CW1 5DU, England; [Whittingham-Dowd, Jayde] Univ Manchester, Fac Life Sci, AV Hill Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England; [Allen, Jeremy] Univ Salford, Sch Hlth Sport & Rehabil Sci, Salford M5 4WT, Greater Manches, England; [Grosset, Jean-Francois] Univ Technol Compiegne, Biomecan & Bioingn, CNRS, UMR 7338, F-60205 Compiegne, France	Manchester Metropolitan University; University of Manchester; University of Salford; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Picardie Universites; Universite de Technologie de Compiegne	Onambele-Pearson, GL (corresponding author), Manchester Metropolitan Univ, HEAL Res Ctr, Exercise & Sport Sci, Crewe Green Rd, Crewe CW1 5DU, England.	g.pearson@mmu.ac.uk	Onambélé-Pearson, Gladys Leopoldine/F-1679-2013; Grosset, Jean-Francois/AFY-2470-2022	Onambélé-Pearson, Gladys Leopoldine/0000-0002-1466-3265; Whittingham-Dowd, Jayde/0000-0002-7939-6081; Grosset, Jean-Francois/0000-0003-4509-0778				Ahtiainen JP, 2003, EUR J APPL PHYSIOL, V89, P555, DOI 10.1007/s00421-003-0833-3; ATKINSON G, 1993, ERGONOMICS, V36, P273, DOI 10.1080/00140139308967882; Bermon S, 1999, ACTA PHYSIOL SCAND, V165, P51; Bird SP, 2004, CHRONOBIOL INT, V21, P131, DOI 10.1081/CBI-120027987; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2003, J PHYSIOL-LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019; Brown SA, 2002, CURR BIOL, V12, P1574, DOI 10.1016/S0960-9822(02)01145-4; Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]; Callard D, 2000, CHRONOBIOL INT, V17, P693, DOI 10.1081/CBI-100101075; Carrier J, 2000, CHRONOBIOL INT, V17, P719, DOI 10.1081/CBI-100102108; DINNEEN S, 1993, J CLIN INVEST, V92, P2283, DOI 10.1172/JCI116832; Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175; Drust B, 2005, CHRONOBIOL INT, V22, P21, DOI 10.1081/CBI-200041039; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Forsling ML, 1998, EXP PHYSIOL, V83, P409, DOI 10.1113/expphysiol.1998.sp004124; Foulstone EJ, 2003, J CELL PHYSIOL, V195, P70, DOI 10.1002/jcp.10227; Gauthier A, 1996, CHRONOBIOL INT, V13, P135, DOI 10.3109/07420529609037077; HACK CE, 1989, BLOOD, V74, P1704; Hawley JA, 2004, EXERC SPORT SCI REV, V32, P4, DOI 10.1097/00003677-200401000-00002; Hayes LD, 2010, CHRONOBIOL INT, V27, P675, DOI 10.3109/07420521003778773; Juul A, 1998, J CLIN ENDOCR METAB, V83, P4408, DOI 10.1210/jc.83.12.4408; Kahn SM, 2002, J ENDOCRINOL, V175, P113, DOI 10.1677/joe.0.1750113; Komi PV, 2000, J BIOMECH, V33, P1197, DOI 10.1016/S0021-9290(00)00064-6; Koziris LP, 1999, J APPL PHYSIOL, V86, P1436, DOI 10.1152/jappl.1999.86.4.1436; KRAEMER RR, 1993, J SPORT MED PHYS FIT, V33, P246; Kraemer WJ, 2004, MED SCI SPORT EXER, V36, P674, DOI 10.1249/01.MSS.0000121945.36635.61; Kraemer WJ, 2003, J STRENGTH COND RES, V17, P455; KRAEMER WJ, 1993, J APPL PHYSIOL, V75, P594, DOI 10.1152/jappl.1993.75.2.594; KRAEMER WJ, 1990, J APPL PHYSIOL, V69, P1442, DOI 10.1152/jappl.1990.69.4.1442; Kraemer WJ, 1998, J APPL PHYSIOL, V85, P1544, DOI 10.1152/jappl.1998.85.4.1544; KRIEGER DT, 1971, J CLIN ENDOCR METAB, V32, P266, DOI 10.1210/jcem-32-2-266; Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359; MELHIM AF, 1993, INT J SPORTS MED, V14, P303, DOI 10.1055/s-2007-1021182; Nindl BC, 2001, J APPL PHYSIOL, V90, P1319, DOI 10.1152/jappl.2001.90.4.1319; Pearson SJ, 2005, CHRONOBIOL INT, V22, P1013, DOI 10.1080/07420520500397900; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Pledge D, 2011, CYTOKINE, V55, P318, DOI 10.1016/j.cyto.2011.05.005; REFINETTI R, 1992, PHYSIOL BEHAV, V51, P613, DOI 10.1016/0031-9384(92)90188-8; Reilly T, 1983, Br J Sports Med, V17, P128; REILLY T, 1990, CHRONOBIOL INT, V7, P59, DOI 10.3109/07420529009056955; Reilly T, 1982, BRIT J SPORTS MED, V16, P115; Reilly T, 2009, EUR J APPL PHYSIOL, V106, P321, DOI 10.1007/s00421-009-1066-x; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; RUDOLF MCJ, 1991, AM J DIS CHILD, V145, P769; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sedliak M, 2008, J SPORT SCI, V26, P1005, DOI 10.1080/02640410801930150; Sedliak M, 2009, J STRENGTH COND RES, V23, P2451, DOI 10.1519/JSC.0b013e3181bb7388; Smilios I, 2003, MED SCI SPORT EXER, V35, P644, DOI 10.1249/01.MSS.0000058366.04460.5F; Souissi N, 2002, J SPORT SCI, V20, P929, DOI 10.1080/026404102320761813; STEPHENSON LA, 1989, EUR J APPL PHYSIOL O, V58, P756, DOI 10.1007/BF00637388; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Uchida MC, 2009, J STRENGTH COND RES, V23, P2003, DOI 10.1519/JSC.0b013e3181b73bf7; West DWD, 2010, INT J BIOCHEM CELL B, V42, P1371, DOI 10.1016/j.biocel.2010.05.012; West DWD, 2013, MED SCI SPORTS EXERC, P2044; Williams AG, 2002, EUR J APPL PHYSIOL, V86, P315, DOI 10.1007/s00421-001-0536-6; WYSE JP, 1994, BRIT J SPORT MED, V28, P167, DOI 10.1136/bjsm.28.3.167; Zafeiridis A, 2003, J APPL PHYSIOL, V94, P591, DOI 10.1152/japplphysiol.00330.2002	58	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2016	11	9							e0161500	10.1371/journal.pone.0161500	http://dx.doi.org/10.1371/journal.pone.0161500			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV3WN	27583459	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000382855600035
J	Chen, GM; Lix, L; Tu, K; Hemmelgarn, BR; Campbell, NRC; McAlister, FA; Quan, H				Chen, Guanmin; Lix, Lisa; Tu, Karen; Hemmelgarn, Brenda R.; Campbell, Norm R. C.; McAlister, Finlay A.; Quan, Hude		Hypertension Outcome Surveillance	Influence of Using Different Databases and 'Look Back' Intervals to Define Comorbidity Profiles for Patients with Newly Diagnosed Hypertension: Implications for Health Services Researchers	PLOS ONE			English	Article							ICD-10 ADMINISTRATIVE DATA; CHRONIC DISEASE SCORE; MEDICARE CLAIMS; RISK; PERFORMANCE; ADJUSTMENT; CHARLSON; ELIXHAUSER; MORTALITY; VALIDITY	Objective To determine the data sources and 'look back' intervals to define comorbidities. Data Sources Hospital discharge abstracts database (DAD), physician claims, population registry and death registry from April 1, 1994 to March 31, 2010 in Alberta, Canada. Study Design Newly-diagnosed hypertension cases from 1997 to 2008 fiscal years were identified and followed up to 12 years. We defined comorbidities using data sources and duration of retrospective observation (6 months, 1 year, 2 years, and 3 years). The C-statistics for logistic regression and concordance index (CI) for Cox model of mortality and cardiovascular disease hospitalization were used to evaluate discrimination performance for each approach of defining comorbidities. Principal Findings The comorbidities prevalence became higher with a longer duration. Using DAD alone underestimated the prevalence by about 75%, compared to using both DAD and physicianclaims. The C-statistic and CI were highest when both DAD and physician claims were used, and model performance improved when observation duration increased from 6 months to one year or longer. Conclusion The comorbidities prevalence is greatly impacted by the data source and duration of retrospective observation. A combination of DAD and physicians claims with at least one year observation duration improves predictions for cardiovascular disease and one-year mortality outcome model performance.	[Chen, Guanmin; Hemmelgarn, Brenda R.; Campbell, Norm R. C.; Quan, Hude] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Chen, Guanmin; Hemmelgarn, Brenda R.; Quan, Hude] Univ Calgary, Inst Publ Hlth, Calgary, AB, Canada; [Lix, Lisa] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Tu, Karen] Univ Toronto, Dept Family & Community Med, ICES, Toronto, ON, Canada; [Hemmelgarn, Brenda R.; Campbell, Norm R. C.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Campbell, Norm R. C.] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada; [McAlister, Finlay A.] Univ Alberta, Div Gen Internal Med, Edmonton, ON, Canada; [Chen, Guanmin] Alberta Hlth Serv, Res Facilitat, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Manitoba; University of Toronto; University of Calgary; University of Calgary; University of Alberta; Alberta Health Services (AHS); University of Calgary	Chen, GM (corresponding author), Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.; Chen, GM (corresponding author), Univ Calgary, Inst Publ Hlth, Calgary, AB, Canada.; Chen, GM (corresponding author), Alberta Hlth Serv, Res Facilitat, Calgary, AB, Canada.	guchen@ucalgary.ca	Chen, Guanmin/AAN-4510-2020; McAlister, Finlay/C-4151-2013	Quan, Hude/0000-0002-7848-7256; McAlister, Finlay/0000-0001-7435-3341; Tu, Karen/0000-0003-0883-4934	Canadian Institutes of Health Research (CIHR) [MOP-125977]; Alberta Innovates - Health Solutions; Canadian Institute for Health Research; Roy and Vi Baay Chair in Kidney Research	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates - Health Solutions; Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Roy and Vi Baay Chair in Kidney Research	This project was funded by Canadian Institutes of Health Research (CIHR, funding reference number: MOP-125977). H.Q. and F.M. salary support is from Alberta Innovates - Health Solutions. F.M. holds the University of Alberta Chair in Cardiac Outcomes Research. K.T. is supported by a Fellowship in Primary Care Research by the Canadian Institute for Health Research. N.C. holds the Heart and Stroke Foundation of Canada CIHR Chair in Hypertension Prevention and Control. B.H. is supported by the Roy and Vi Baay Chair in Kidney Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; H.Q. and F.M. salary support is from Alberta Innovates-Health Solutions, FM holds the University of Alberta Chair in Cardiac Outcomes Research, K.T. is supported from a Fellowship in Primary Care Research by the Canadian Institute for Health Research, N.C. holds the Heart and Stroke Foundation of Canada CIHR Chair in Hypertension Prevention and Control. B.H is supported by the Roy and Vi Baay Chair in Kidney Research.	Austin PC, 2012, ANN EPIDEMIOL, V22, P881, DOI 10.1016/j.annepidem.2012.09.011; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Gonen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965; Howell S, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-96; JOHNSON RE, 1994, J CLIN EPIDEMIOL, V47, P1191, DOI 10.1016/0895-4356(94)90106-6; Klabunde CN, 2006, MED CARE, V44, P921, DOI 10.1097/01.mlr.0000223480.52713.b9; Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1; Leal JR, 2010, CLIN MICROBIOL INFEC, V16, P715, DOI 10.1111/j.1469-0691.2009.02867.x; Lee DS, 2005, MED CARE, V43, P182, DOI 10.1097/00005650-200502000-00012; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Li PX, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-245; Lix LM, 2011, OSTEOPOROSIS INT, V22, P2633, DOI 10.1007/s00198-010-1516-7; Perkins AJ, 2004, J CLIN EPIDEMIOL, V57, P1040, DOI 10.1016/j.jclinepi.2004.03.002; Preen DB, 2006, J CLIN EPIDEMIOL, V59, P940, DOI 10.1016/j.jclinepi.2005.12.013; Quach S, 2010, CAN J CARDIOL, V26, pE306, DOI 10.1016/S0828-282X(10)70438-4; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quan H, 2008, HEALTH SERV RES, V43, P1424, DOI 10.1111/j.1475-6773.2007.00822.x; Quan HD, 2013, CAN J CARDIOL, V29, P592, DOI 10.1016/j.cjca.2012.12.016; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Quan HD, 2009, HYPERTENSION, V54, P1423, DOI 10.1161/HYPERTENSIONAHA.109.139279; Radley DC, 2008, J CLIN EPIDEMIOL, V61, P580, DOI 10.1016/j.jclinepi.2007.08.001; Schneeweiss S, 2004, J GEN INTERN MED, V19, P444, DOI 10.1111/j.1525-1497.2004.30109.x; Sharabiani MTA, 2012, MED CARE, V50, P1109, DOI 10.1097/MLR.0b013e31825f64d0; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Wang PS, 2000, J CLIN EPIDEMIOL, V53, P571, DOI 10.1016/S0895-4356(00)00222-5; Yan Y, 2005, MED CARE, V43, P1073, DOI 10.1097/01.mlr.0000182477.29129.86; Zhang JX, 1999, MED CARE, V37, P1128, DOI 10.1097/00005650-199911000-00005	28	15	15	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2016	11	9							e0162074	10.1371/journal.pone.0162074	http://dx.doi.org/10.1371/journal.pone.0162074			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV3WN	27583532	gold, Green Submitted, Green Published			2023-01-03	WOS:000382855600098
J	Aunger, R; Greenland, K; Ploubidis, G; Schmidt, W; Oxford, J; Curtis, V				Aunger, Robert; Greenland, Katie; Ploubidis, George; Schmidt, Wolf; Oxford, John; Curtis, Valerie			The Determinants of Reported Personal and Household Hygiene Behaviour: A Multi-Country Study	PLOS ONE			English	Article							INFLUENZA TRANSMISSION; RESPIRATORY ILLNESS; VALIDITY; HEALTH; RISK; HOME; CONTAMINATION; INTERVENTION; SANITATION; VARIABLES	A substantial proportion of the total infectious disease burden world-wide is due to person-to-person spread of pathogens within households. A questionnaire-based survey on the determinants of hand-washing with soap and cleaning of household surfaces was conducted in at least 1000 households in each of twelve countries across the world (N = 12,239). A structural equation model of hygiene behaviour and its consequences derived from theory was then estimated on this dataset for both behaviours, using a maximum likelihood procedure. The analysis showed that the frequency of hand washing with soap is significantly related to how automatically it is performed, and whether or not someone is busy, or tired. Surface cleaning was strongly linked to possessing a cleaning routine, the perception that one is living in a dirty environment and that others are doing the behaviour, whether one has a strong sense of contamination, as well as a felt need to keep one's surroundings tidy. Being concerned with good manners is also linked to the performance of both behaviours. This study is the first to identify the role of manners, orderliness and routine on hygiene behaviours globally. Such findings should prove helpful in designing programs to improve domestic hygiene practices.	[Aunger, Robert; Greenland, Katie; Schmidt, Wolf; Curtis, Valerie] London Sch Hyg & Trop Med, Environm Hlth Grp, London, England; [Ploubidis, George] UCL, Inst Educ, London, England; [Oxford, John] Queen Mary Univ London, Sch Med, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; UCL Institute of Education; University of London; Queen Mary University London	Aunger, R (corresponding author), London Sch Hyg & Trop Med, Environm Hlth Grp, London, England.	robert.aunger@lshtm.ac.uk	Ploubidis, George B/G-9531-2011	Ploubidis, George B/0000-0002-8198-5790; Schmidt, Wolf-Peter/0000-0001-7449-4152	Hygiene Council	Hygiene Council	The Hygiene Council approached the LSHTM team to conduct a global study; they paid for some LSHTM staff time, all data collection but played no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.; We would like to thank Oliver Parsons, Lee-Ann Cameron, Ann Walters and Claire Leggott of Tonic Plc for their help in coordinating the study; Kate Norfolk and her staff from Opinion Matters for supervising the data collection, providing details about their methods, and conducting preliminary statistical analyses; and the Hygiene Council for funding the research.	AJZEN I, 1973, J PERS SOC PSYCHOL, V27, P41, DOI 10.1037/h0034440; [Anonymous], 1974, Health Education Monograph, V2, P324; Aunger R, 2014, APPL EVOLUTIONARY AN; Aunger R, 2010, SOC SCI MED, V70, P383, DOI 10.1016/j.socscimed.2009.10.038; Bandura A., 1986, SOCIAL FDNS THOUGHTS; Bloomfield S.F., 2007, AM J INFECT SUPPL 1, V35, P1; Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179; Buss A. R., 1979, PERSONALITY SOCIAL P, V5, P191; Cairncross S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000365; Cogan TA, 2002, J APPL MICROBIOL, V92, P885, DOI 10.1046/j.1365-2672.2002.01598.x; Cole EC, 2012, S AFR J CHILD HEALTH, V6, P109, DOI 10.7196/SAJCH.459; Costa P. T., 1992, PSYCHOL ASSESS, V4, P5, DOI [DOI 10.1037/1040-3590.4.1.5, 10.1037/1040-3590.4.1.5]; Cowling BJ, 2009, ANN INTERN MED, V151, P437, DOI 10.7326/0003-4819-151-7-200910060-00142; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P23; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Curtis V, 2003, SOC SCI MED, V57, P657, DOI 10.1016/S0277-9536(02)00409-4; Curtis V, 2004, P ROY SOC B-BIOL SCI, V271, pS131, DOI 10.1098/rsbl.2003.0144; Curtis V, 2000, TROP MED INT HEALTH, V5, P22, DOI 10.1046/j.1365-3156.2000.00512.x; Curtis V, 2011, LANCET INFECT DIS, V11, P312, DOI 10.1016/S1473-3099(10)70224-3; Curtis V, 2011, PHILOS T R SOC B, V366, P389, DOI 10.1098/rstb.2010.0117; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; Denham S.A., 2003, J FAMILY NURSING, V9, P305, DOI DOI 10.1177/1074840703255447; Dodou D, 2014, COMPUT HUM BEHAV, V36, P487, DOI 10.1016/j.chb.2014.04.005; Douglas M., 1985, RISK ACCEPTABILITY A; Douglas Mary, 1966, PURITY DANGER ANAL C; Duncan LA, 2009, PERS INDIV DIFFER, V47, P541, DOI 10.1016/j.paid.2009.05.001; Ejemot-Nwadiaro RI, 2015, COCHRANE DATABASE SY, P9; EPSTEIN S, 1985, PSYCHOL BULL, V98, P513, DOI 10.1037/0033-2909.98.3.513; Exner M, 2004, J HOSP INFECT, V56, pS70, DOI 10.1016/j.jhin.2003.12.037; Exner M., 2007, GMS KRANKENHAUSHYGIE, V2, P1; Falsey AR, 1999, INFECT CONT HOSP EP, V20, P200, DOI 10.1086/501612; Fishbein M, 1992, FACT INFL BEH BEH CH; Fleeson W, 2008, SOC PERSONAL PSYCHOL, V2, P1667, DOI 10.1111/j.1751-9004.2008.00122.x; Foddy W., 1994, CONSTRUCTING QUESTIO; Grayson ML, 2009, CLIN INFECT DIS, V48, P285, DOI 10.1086/595845; Halder AK, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-545; Horner KL, 1996, PERS INDIV DIFFER, V21, P195, DOI 10.1016/0191-8869(96)00067-0; House T, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-117; Inglis D., 2000, SOCIOLOGICAL HIST EX; Jackson JJ, 2010, J RES PERS, V44, P501, DOI 10.1016/j.jrp.2010.06.005; Jones E. E., 1971, ACTOR OBSERVER DIVER; Judah G, 2012, BRIT J HLTH PSYCHOL; Judah G, 2009, AM J PUBLIC HEALTH, V99, pS405, DOI 10.2105/AJPH.2009.164160; Kaiser FG, 2001, EUR J PSYCHOL ASSESS, V17, P212, DOI 10.1027//1015-5759.17.3.212; Klesges LM, 2004, PREV MED, V38, pS78, DOI 10.1016/j.ypmed.2003.07.003; Kline R. B, 2015, PRINCIPLES PRACTICE, V2nd; Knapp H, 2003, COMPUT HUM BEHAV, V19, P117, DOI 10.1016/S0747-5632(02)00008-0; KNIGHT GP, 1981, DEV PSYCHOL, V17, P430; Lamont Mich?le., 1992, MONEY MORALS MANNERS; Largo TW, 2011, PUBLIC HEALTH REP, V126, P14, DOI 10.1177/00333549111260S104; Larson E, 2001, PUBLIC HEALTH NURS, V18, P116, DOI 10.1046/j.1525-1446.2001.00116.x; Lee A, 2006, J EPIDEMIOL COMMUN H, V60, P530, DOI 10.1136/jech.2005.040121; Lewis M.A., 2002, HLTH BEHAV HLTH ED T, Vthird, P240; Lopez-Quintero C, 2009, AM J PUBLIC HEALTH, V99, P94, DOI 10.2105/AJPH.2007.129759; MacCann C, 2009, LEARN INDIVID DIFFER, V19, P451, DOI 10.1016/j.lindif.2009.03.007; Mattioli MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084939; MISCHEL W, 1995, PSYCHOL REV, V102, P246, DOI 10.1037/0033-295X.102.2.246; Nickmilder M, 2007, PEDIAT ALLERG IMM-UK, V18, P27, DOI 10.1111/j.1399-3038.2006.00487.x; Oxford JS, 2012, ENCY GLOBAL STUDIES, P838; Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879; Rabie T, 2006, TROP MED INT HEALTH, V11, P258, DOI 10.1111/j.1365-3156.2006.01568.x; Rabie T, 2006, TROP MED INT HEALTH, V11, P1; Rose E, 2009, ARCH PEDIAT ADOL MED, V163, P61, DOI 10.1001/archpediatrics.2008.509; Sobsey M. D., 2002, MANAGING WATER HOME; Stange KC, 1998, MED CARE, V36, P851, DOI 10.1097/00005650-199806000-00009; Stauber CE, 2013, INT J ENV RES PUB HE, V10, P1586, DOI 10.3390/ijerph10041586; Sutton S., 2012, SAGE HDB HLTH PSYCHO, P94, DOI DOI 10.4135/9781848608153.N4; Viboud C, 2004, INT CONGR SER, V1263, P291, DOI 10.1016/j.ics.2004.01.013; Vickers R, 1989, PSYCHOSOCIAL RISK FA; Vujcic J, 2014, TROP MED INT HEALTH, V19, P528, DOI 10.1111/tmi.12292; WARNER LG, 1969, AM SOCIOL REV, V34, P153, DOI 10.2307/2092174	71	22	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2016	11	8							e0159551	10.1371/journal.pone.0159551	http://dx.doi.org/10.1371/journal.pone.0159551			35	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT6UQ	27541259	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000381620200002
J	Kaufman, DJ; Baker, R; Milner, LC; Devaney, S; Hudson, KL				Kaufman, David J.; Baker, Rebecca; Milner, Lauren C.; Devaney, Stephanie; Hudson, Kathy L.			A Survey of U.S Adults' Opinions about Conduct of a Nationwide Precision Medicine Initiative (R) Cohort Study of Genes and Environment	PLOS ONE			English	Article							DATABASE; BIOBANK; HEART	Objectives A survey of a population-based sample of U.S adults was conducted to measure their attitudes about, and inform the design of the Precision Medicine Initiative's planned national cohort study. Methods An online survey was conducted by GfK between May and June of 2015. The influence of different consent models on willingness to share data was examined by randomizing participants to one of eight consent scenarios. Results Of 4,777 people invited to take the survey, 2,706 responded and 2,601 (54% response rate) provided valid responses. Most respondents (79%) supported the proposed study, and 54% said they would definitely or probably participate if asked. Support for and willingness to participate in the study varied little among demographic groups; younger respondents, LGBT respondents, and those with more years of education were significantly more likely to take part if asked. The most important study incentive that the survey asked about was learning about one's own health information. Willingness to share data and samples under broad, study-by-study, menu and dynamic consent models was similar when a statement about transparency was included in the consent scenarios. Respondents were generally interested in taking part in several governance functions of the cohort study. Conclusions A large majority of the U.S. adults who responded to the survey supported a large national cohort study. Levels of support for the study and willingness to participate were both consistent across most demographic groups. The opportunity to learn health information about one's self from the study appears to be a strong motivation to participate.	[Kaufman, David J.] NHGRI, Div Genom & Soc, NIH, Rockville, MD 20852 USA; [Baker, Rebecca; Milner, Lauren C.; Devaney, Stephanie; Hudson, Kathy L.] NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA	Kaufman, DJ (corresponding author), NHGRI, Div Genom & Soc, NIH, Rockville, MD 20852 USA.	dave.kaufman@nih.gov			Foundation for the National Institutes of Health	Foundation for the National Institutes of Health	The authors wish to thank the Foundation for the National Institutes of Health, which funded this survey. The authors would also like to thank Vence Bonham, Laura Rodriguez, Alex Lee and the members of the Consent, Education, Regulation and Consultation Working Group of the eMERGE research consortium for their contributions to the survey and manuscript development.; The Foundation for National Institutes of Health directly paid for GfK to field the survey. The authors themselves received no specific funding for the work. FNIH did not participate in data collection, analysis, decisions to publish or preparation of the manuscript. They were involved in discussions about the logistics of study design but did not influence survey content.	BAKER LC, VALIDITY SURVEY HLTH; Bollinger JM, 2014, GENET MED, V16, P932, DOI 10.1038/gim.2014.50; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Genomeweb.com, REG LAUNCH 100K PAT; GfK, 2015, GFK 2015; Gulcher J, 1999, NAT BIOTECHNOL, V17, P620, DOI 10.1038/10796; Hudson K., 2015, PRECISION MED INITIA; Kaufman D, 2009, GENET MED, V11, P329, DOI 10.1097/GIM.0b013e31819994f8; Kaufman D, 2008, GENET MED, V10, P331, DOI 10.1097/GIM.0b013e31818bb3ab; Mathews AW, 2015, WALL STREET J; McQuillan GM, 2003, GENET MED, V5, P35, DOI 10.1097/00125817-200301000-00006; National Human Genome Research Institute, 2005, DES CONS POT US POP; National Institutes of Health, 2015, SUMM RESP REQ INF BU; National Institutes of Health, 2015, MOB PERS TECHN PREC; National Institutes of Health, 2015, ACD PREC MED IN WORK; NIH, 2015, REQ INF NIH PREC MED; North KE, 2003, AM J EPIDEMIOL, V157, P303, DOI 10.1093/aje/kwf208; Oh SS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001918; Palmer LJ, 2007, LANCET, V369, P1980, DOI 10.1016/S0140-6736(07)60924-6; Roden DM, 2008, CLIN PHARMACOL THER, V84, P362, DOI 10.1038/clpt.2008.89; Sanger David, 2015, NEW YORK TIMES; Splansky GL, 2007, AM J EPIDEMIOL, V165, P1328, DOI 10.1093/aje/kwm021; SPSS Inc, 2012, SPSS WIND REL 21 0; The White House, 2015, PREC MED IN PROP PRI	25	63	63	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2016	11	8							e0160461	10.1371/journal.pone.0160461	http://dx.doi.org/10.1371/journal.pone.0160461			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4YN	27532667	gold, Green Published, Green Submitted			2023-01-03	WOS:000381487600031
J	Marshall, J; Booth, T; Devane, N; Galliers, J; Greenwood, H; Hilari, K; Talbot, R; Wilson, S; Woolf, C				Marshall, Jane; Booth, Tracey; Devane, Niamh; Galliers, Julia; Greenwood, Helen; Hilari, Katerina; Talbot, Richard; Wilson, Stephanie; Woolf, Celia			Evaluating the Benefits of Aphasia Intervention Delivered in Virtual Reality: Results of a Quasi-Randomised Study	PLOS ONE			English	Article							COGNITIVE-BEHAVIOR THERAPY; PUBLIC-SPEAKING ANXIETY; QUALITY-OF-LIFE; SENTENCE PRODUCTION; LEXICAL RETRIEVAL; STROKE; PEOPLE; COMMUNICATION; LANGUAGE; EFFICACY	Introduction This study evaluated an intervention for people with aphasia delivered in a novel virtual reality platform called EVA Park. EVA Park contains a number of functional and fantastic locations and allows for interactive communication between multiple users. Twenty people with aphasia had 5 weeks' intervention, during which they received daily language stimulation sessions in EVA Park from a support worker. The study employed a quasi randomised design, which compared a group that received immediate intervention with a waitlist control group. Outcome measures explored the effects of intervention on communication and language skills, communicative confidence and feelings of social isolation. Compliance with the intervention was also explored through attrition and usage data. Results There was excellent compliance with the intervention, with no participants lost to follow up and most (18/20) receiving at least 88% of the intended treatment dose. Intervention brought about significant gains on a measure of functional communication. Gains were achieved by both groups of participants, once intervention was received, and were well maintained. Changes on the measures of communicative confidence and feelings of social isolation were not achieved. Results are discussed with reference to previous aphasia therapy findings.	[Marshall, Jane; Devane, Niamh; Greenwood, Helen; Hilari, Katerina; Talbot, Richard; Woolf, Celia] City Univ London, Div Language & Commun Sci, London, England; [Booth, Tracey; Galliers, Julia; Wilson, Stephanie] City Univ London, Ctr Human Comp Interact Design, London, England	City University London; City University London	Marshall, J (corresponding author), City Univ London, Div Language & Commun Sci, London, England.	J.Marshall@city.ac.uk	Talbot, Richard/GYR-1597-2022; Wilson, Stephanie/AAX-1579-2020	Wilson, Stephanie/0000-0001-6445-654X; Devane, Niamh/0000-0001-8448-1478; Hilari, Katerina/0000-0003-2091-4849	Stroke Association [TSA 2011/10]; Stroke Association [TSA2011/10] Funding Source: researchfish	Stroke Association; Stroke Association	This work was funded by a research grant to JM, SW, and CW from The Stroke Association https://www.stroke.org.uk/ Award Number: TSA 2011/10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali M, 2015, INT J STROKE, V10, P400, DOI 10.1111/ijs.12067; Anderson P, 2003, COGN BEHAV PRACT, V10, P240, DOI 10.1016/S1077-7229(03)80036-6; Anderson PL, 2005, DEPRESS ANXIETY, V22, P156, DOI 10.1002/da.20090; ANTONUCCI TC, 1987, J GERONTOL, V42, P519, DOI 10.1093/geronj/42.5.519; Archibald Lisa M D, 2009, Ther Adv Neurol Disord, V2, P299, DOI 10.1177/1756285609336548; Babbitt E, 2010, TOP STROKE REHABIL, V17, P197; Babbitt EM, 2011, APHASIOLOGY, V25, P727, DOI 10.1080/02687038.2010.537347; Berndt R. S., 2000, QUANTITATIVE PRODUCT; Booth V, 2014, CLIN REHABIL, V28, P419, DOI 10.1177/0269215513509389; Boyle M, 2004, AM J SPEECH-LANG PAT, V13, P236, DOI 10.1044/1058-0360(2004/025); Boyle M., 1995, AM J SPEECH-LANG PAT, V4, P94, DOI [10.1044/1058-0360.0404.94, DOI 10.1044/1058-0360.0404.94]; Bozzacchi C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047783; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Bruce C, 2003, INT J LANG COMM DIS, V38, P131, DOI 10.1080/1368282021000048258; Brundage SB, 2015, AM J SPEECH-LANG PAT, V24, P139, DOI 10.1044/2014_AJSLP-14-0087; Carragher M, 2013, NEUROPSYCHOL REHABIL, V23, P846, DOI 10.1080/09602011.2013.832335; Caute A, 2016, APHASIOLOGY, V30, P245, DOI 10.1080/02687038.2015.1041095; Chapey R., 2008, LANGUAGE INTERVENTIO, Vedition; Cherney LR, 2014, AM J SPEECH-LANG PAT, V23, P343, DOI 10.1044/2014_AJSLP-13-0097; Cherney LR, 2012, SEMIN SPEECH LANG, V33, P243, DOI 10.1055/s-0032-1320044; Cherney LR, 2011, TOP STROKE REHABIL, V18, P352, DOI 10.1310/tsr1804-352; Cherney LR, 2011, J COMMUN DISORD, V44, P493, DOI 10.1016/j.jcomdis.2011.04.002; Cherney LR, 2010, TOP STROKE REHABIL, V17, P423, DOI 10.1310/tsr1706-423; Conroy P, 2009, APHASIOLOGY, V23, P707, DOI 10.1080/02687030802165574; Cruice M, 2010, APHASIOLOGY, V24, P327, DOI 10.1080/02687030802565849; Doesborgh S, 2004, APHASIOLOGY, V18, P213, DOI 10.1080/02687030344000580; Doesborgh SJC, 2004, STROKE, V35, P141, DOI 10.1161/01.STR.0000105460.52928.A6; Estes C, 2011, APHASIOLOGY, V25, P366, DOI 10.1080/02687038.2010.493294; Furnas DW, 2014, APHASIOLOGY, V28, P401, DOI 10.1080/02687038.2013.869304; Fernandes ABGS, 2014, NEUROREHABILITATION, V35, P39, DOI 10.3233/NRE-141105; Greenwood A, 2010, APHASIOLOGY, V24, P991, DOI 10.1080/02687030903168220; Harris SR, 2002, CYBERPSYCHOL BEHAV, V5, P543, DOI 10.1089/109493102321018187; Hawthorne G, 2006, SOC INDIC RES, V77, P521, DOI 10.1007/s11205-005-7746-y; Herbert R., 2013, PROFILE WORD ERRORS; Herbert R, 2008, APHASIOLOGY, V22, P184, DOI 10.1080/02687030701262613; Hilari K, 2003, STROKE, V34, P1944, DOI 10.1161/01.STR.0000081987.46660.ED; Hill AJ, 2009, APHASIOLOGY, V23, P627, DOI 10.1080/02687030801909659; Hinckley JJ, 2001, APHASIOLOGY, V15, P463, DOI 10.1080/02687040042000340; Holland A. L., 1999, COMMUNICATION ACTIVI; Kempler D, 2011, APHASIOLOGY, V25, P1327, DOI 10.1080/02687038.2011.599364; Klinger E, 2005, CYBERPSYCHOL BEHAV, V8, P76, DOI 10.1089/cpb.2005.8.76; Lam JMC, 2010, MED CARE, V48, P380, DOI 10.1097/MLR.0b013e3181ca2647; Laufer Y., 2011, J PHYS THER ED, V25, P59, DOI [10.1097/00001416-201110000-00011, DOI 10.1097/00001416-201110000-00011]; Laver K., 2012, STROKE, V43, pe20, DOI DOI 10.1161/STROKEAHA.111.642439; Lee JB, 2009, APHASIOLOGY, V23, P885, DOI 10.1080/02687030802669534; Lee S, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000269; Linebarger M, 2007, BRAIN LANG, V100, P53, DOI 10.1016/j.bandl.2006.09.001; Lohse KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093318; Marshall J, 2013, APHASIOLOGY, V27, P1128, DOI 10.1080/02687038.2013.786803; Maskey M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100374; McCall D, 2009, APHASIOLOGY, V23, P438, DOI 10.1080/02687030701818000; Moreira MC, 2013, DISABIL REHABIL-ASSI, V8, P357, DOI 10.3109/17483107.2012.749428; Motraghi TE, 2014, J CLIN PSYCHOL, V70, P197, DOI 10.1002/jclp.22051; Nickels L, 2002, REHABILITATION SPOKE; Northcott S, 2011, INT J LANG COMM DIS, V46, P524, DOI 10.1111/j.1460-6984.2011.00079.x; Palmer R, 2013, INT J LANG COMM DIS, V48, P508, DOI 10.1111/1460-6984.12024; Palmer R, 2012, STROKE, V43, P1904, DOI 10.1161/STROKEAHA.112.650671; Proffitt R, 2015, PHYS THER, V95, P441, DOI 10.2522/ptj.20130571; Rochon E, 2005, NEUROPSYCHOL REHABIL, V15, P1, DOI 10.1080/09602010343000327; Rochon E, 2000, BRAIN LANG, V72, P193, DOI 10.1006/brln.1999.2285; Safir MP, 2012, BEHAV MODIF, V36, P235, DOI 10.1177/0145445511429999; Sickert A, 2014, J NEUROL NEUROSUR PS, V85, P51, DOI 10.1136/jnnp-2012-304297; Simmons-Mackie N, 2010, ARCH PHYS MED REHAB, V91, P1814, DOI 10.1016/j.apmr.2010.08.026; Stark J, 2013, INT C VIRT REAL PHIL; Swinburn K., 2004, COMPREHENSIVE APHASI; Theodoros D, 2008, TELEMED J E-HEALTH, V14, P552, DOI 10.1089/tmj.2007.0091; Thompson CK, 2010, APHASIOLOGY, V24, P1242, DOI 10.1080/02687030903474255; Triberti S, 2014, CYBERPSYCH BEH SOC N, V17, P335, DOI 10.1089/cyber.2014.0054; van de Sandt-Koenderman WME, 2011, INT J SPEECH-LANG PA, V13, P21, DOI 10.3109/17549507.2010.502973; van Vuuren S, 2014, LECT NOTES ARTIF INT, V8637, P438, DOI 10.1007/978-3-319-09767-1_55; Wade J, 2003, APHASIOLOGY, V17, P1031, DOI 10.1080/02687030344000373; Wallace SJ, 2014, APHASIOLOGY, V28, P1364, DOI 10.1080/02687038.2014.930262; Wallach HS, 2009, BEHAV MODIF, V33, P314, DOI 10.1177/0145445509331926; Wambaugh JL, 2014, APHASIOLOGY, V28, P1, DOI 10.1080/02687038.2013.845739; Wang M, 2011, NEUROEPIDEMIOLOGY, V36, P2, DOI 10.1159/000320847; Wilson S, 2015, CODESIGN, V11, P21, DOI 10.1080/15710882.2014.997744; Woolf C, 2016, CLIN REHABIL, V30, P359, DOI 10.1177/0269215515582074; Worrall L, 2013, APHASIA RELATED NEUR, P93	78	43	44	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2016	11	8							e0160381	10.1371/journal.pone.0160381	http://dx.doi.org/10.1371/journal.pone.0160381			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT3LI	27518188	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000381382100013
J	Brown, PD; Jaeckle, K; Ballman, KV; Farace, E; Cerhan, JH; Anderson, SK; Carrero, XW; Barker, FG; Deming, R; Burri, SH; Menard, C; Chung, C; Stieber, VW; Pollock, BE; Galanis, E; Buckner, JC; Asher, AL				Brown, Paul D.; Jaeckle, Kurt; Ballman, Karla V.; Farace, Elana; Cerhan, Jane H.; Anderson, S. Keith; Carrero, Xiomara W.; Barker, Fred G., II; Deming, Richard; Burri, Stuart H.; Menard, Cynthia; Chung, Caroline; Stieber, Volker W.; Pollock, Bruce E.; Galanis, Evanthia; Buckner, Jan C.; Asher, Anthony L.			Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PHASE-III TRIAL; NEUROCOGNITIVE FUNCTION; STEREOTACTIC RADIOSURGERY; SURGICAL RESECTION; RADIOTHERAPY; CANCER; TUMORS	IMPORTANCE Whole brain radiotherapy (WBRT) significantly improves tumor control in the brain after stereotactic radiosurgery (SRS), yet because of its association with cognitive decline, its role in the treatment of patients with brain metastases remains controversial. OBJECTIVE To determine whether there is less cognitive deterioration at 3 months after SRS alone vs SRS plus WBRT. DESIGN, SETTING, AND PARTICIPANTS At 34 institutions in North America, patients with 1 to 3 brain metastases were randomized to receive SRS or SRS plus WBRT between February 2002 and December 2013. INTERVENTIONS The WBRT dose schedule was 30 Gy in 12 fractions; the SRS dose was 18 to 22 Gy in the SRS plus WBRT group and 20 to 24 Gy for SRS alone. MAIN OUTCOMES AND MEASURES The primary end pointwas cognitive deterioration (decline >1 SD from baseline on at least 1 cognitive test at 3 months) in participants who completed the baseline and 3-month assessments. Secondary end points included time to intracranial failure, quality of life, functional independence, long-term cognitive status, and overall survival. RESULTS There were 213 randomized participants (SRS alone, n=111; SRS plus WBRT, n=102) with a mean age of 60.6 years (SD, 10.5 years); 103 (48%) were women. There was less cognitive deterioration at 3 months after SRS alone (40/63 patients [63.5%]) than when combined with WBRT (44/48 patients [91.7%]; difference, -28.2%; 90% CI, -41.9% to -14.4%; P<.001). Quality of life was higher at 3 months with SRS alone, including overall quality of life (mean change from baseline, -0.1 vs -12.0 points; mean difference, 11.9; 95% CI, 4.8-19.0 points; P=.001). Time to intracranial failure was significantly shorter for SRS alone compared with SRS plus WBRT (hazard ratio, 3.6; 95% CI, 2.2-5.9; P<.001). There was no significant difference in functional independence at 3 months between the treatment groups (mean change from baseline, -1.5 points for SRS alone vs -4.2 points for SRS plus WBRT; mean difference, 2.7 points; 95% CI, -2.0 to 7.4 points; P=.26). Median overall survival was 10.4 months for SRS alone and 7.4 months for SRS plus WBRT (hazard ratio, 1.02; 95% CI, 0.75-1.38; P=.92). For long-term survivors, the incidence of cognitive deterioration was less after SRS alone at 3 months (5/11 [45.5%] vs 16/17 [94.1%]; difference, -48.7%; 95% CI, -87.6% to -9.7%; P=.007) and at 12 months (6/10 [60%] vs 17/18 [94.4%]; difference, -34.4%; 95% CI, -74.4% to 5.5%; P=.04). CONCLUSIONS AND RELEVANCE Among patients with 1 to 3 brain metastases, the use of SRS alone, compared with SRS combined with WBRT, resulted in less cognitive deterioration at 3 months. In the absence of a difference in overall survival, these findings suggest that for patients with 1 to 3 brainmetastases amenable to radiosurgery, SRS alone may be a preferred strategy.	[Brown, Paul D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Brown, Paul D.; Cerhan, Jane H.; Pollock, Bruce E.; Galanis, Evanthia; Buckner, Jan C.] Mayo Clin, Rochester, MI USA; [Jaeckle, Kurt] Mayo Clin, Jacksonville, FL 32224 USA; [Ballman, Karla V.; Anderson, S. Keith; Carrero, Xiomara W.] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA; [Farace, Elana] Penn State Hershey Med Ctr, Hershey, PA USA; [Barker, Fred G., II] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Deming, Richard] Mercy Med Ctr, Des Moines, IA USA; [Burri, Stuart H.; Asher, Anthony L.] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA; [Menard, Cynthia; Chung, Caroline] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Menard, Cynthia] Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Stieber, Volker W.] Novant Hlth Forsyth Med Ctr, Winston Salem, NC USA; [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Charlotte, NC USA	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Massachusetts General Hospital; Carolinas HealthCare System; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Universite de Montreal	Brown, PD (corresponding author), Mayo Clin, Dept Radiat Oncol, 200 First St SW, Rochester, MN 55905 USA.	brown.paul@mayo.edu	Chung, Caroline/AAM-5504-2021; Buckner, Jan/AAE-6388-2019	Chung, Caroline/0000-0002-9662-1519	NCI [U10CA180821, U10CA180882, CA076001, CA025224, RTOG U10CA21661, NRG U10CA180868]; NATIONAL CANCER INSTITUTE [U10CA180868, U10CA025224, U10CA180867, U10CA021661, U10CA180821, UG1CA189823, U10CA180882, U10CA076001] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This trial was conducted by the NCCTG (Alliance for Clinical Trials in Oncology) in collaboration with other cooperative groups including the Radiation Therapy Oncology Group, and was supported by grants U10CA180821, U10CA180882, CA076001, CA025224, RTOG U10CA21661, and NRG U10CA180868 from the NCI. There were no commercial sponsors of this study. Data confidentiality was governed by National Institutes of Health policy.	Aoyama H, 2007, INT J RADIAT ONCOL, V68, P1388, DOI 10.1016/j.ijrobp.2007.03.048; Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; Begg CB, 2002, JNCI-J NATL CANCER I, V94, P1044; Brown PD, 2013, NEURO-ONCOLOGY, V15, P1429, DOI 10.1093/neuonc/not114; Brown PD, 2006, J NEURO-ONCOL, V76, P283, DOI 10.1007/s11060-005-7020-9; Brown PD, 2003, J CLIN ONCOL, V21, P2519, DOI 10.1200/JCO.2003.04.172; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; Frisk G, 2012, BRIT J CANCER, V106, P1850, DOI 10.1038/bjc.2012.163; Gondi V, 2014, J CLIN ONCOL, V32, P3810, DOI 10.1200/JCO.2014.57.2909; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Kocher M, 2011, J CLIN ONCOL, V29, P134, DOI 10.1200/JCO.2010.30.1655; Li J, 2007, J CLIN ONCOL, V25, P1260, DOI 10.1200/JCO.2006.09.2536; Meyers CA, 2006, J CLIN ONCOL, V24, P1305, DOI 10.1200/JCO.2005.04.6086; Meyers CA, 2004, J CLIN ONCOL, V22, P157, DOI 10.1200/JCO.2004.05.128; Miller FG, 2004, J ROY SOC MED, V97, P576, DOI 10.1258/jrsm.97.12.576; Nabors LB, 2015, J NATL COMPR CANC NE, V13, P1191, DOI 10.6004/jnccn.2015.0148; Onodera S, 2014, J NEURO-ONCOL, V120, P311, DOI 10.1007/s11060-014-1550-y; R Core Team, 2014, LANG ENV STAT COMP; Rapp SR, 2015, J CLIN ONCOL, V33, P1653, DOI 10.1200/JCO.2014.58.4508; Soffietti R, 2013, J CLIN ONCOL, V31, P65, DOI 10.1200/JCO.2011.41.0639; WADE DT, 1992, CURR OPIN NEUROL NEU, V5, P682; WEITZNER MA, 1995, CANCER, V75, P1151, DOI 10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q; Yamamoto M, 2014, LANCET ONCOL, V15, P387, DOI 10.1016/S1470-2045(14)70061-0	25	879	899	4	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	2016	316	4					401	409		10.1001/jama.2016.9839	http://dx.doi.org/10.1001/jama.2016.9839			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DR9MV	27458945	Green Accepted, Bronze			2023-01-03	WOS:000380221700018
J	Wilson, D; Moehlis, J				Wilson, Dan; Moehlis, Jeff			Toward a More Efficient Implementation of Antifibrillation Pacing	PLOS ONE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; CARDIAC TISSUE; VENTRICULAR-TACHYCARDIA; ATRIAL-FIBRILLATION; EXCITABLE MEDIA; SPIRAL WAVES; TRANSTHORACIC DEFIBRILLATION; BIDOMAIN EQUATIONS; MONOPHASIC SHOCKS; HEART	We devise a methodology to determine an optimal pattern of inputs to synchronize firing patterns of cardiac cells which only requires the ability to measure action potential durations in individual cells. In numerical bidomain simulations, the resulting synchronizing inputs are shown to terminate spiral waves with a higher probability than comparable inputs that do not synchronize the cells as strongly. These results suggest that designing stimuli which promote synchronization in cardiac tissue could improve the success rate of defibrillation, and point towards novel strategies for optimizing antifibrillation pacing.	[Wilson, Dan; Moehlis, Jeff] Univ Calif Santa Barbara, Dept Mech Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Wilson, D (corresponding author), Univ Calif Santa Barbara, Dept Mech Engn, Santa Barbara, CA 93106 USA.	dan.d.wilson8@gmail.com			National Science Foundation [NSF-1363243]	National Science Foundation(National Science Foundation (NSF))	This work was supported by National Science Foundation, NSF-1363243 (http://www.nsf.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Support for this work by National Science Foundation Grant NSF-1363243 is gratefully acknowledged.	Ambrosi CM, 2011, HEART RHYTHM, V8, P101, DOI 10.1016/j.hrthm.2010.10.018; [Anonymous], 2008, INTRO PROBABILITY TH; Bell N, 2013, CUSP GENERIC PARALLE; Bellman Richard E., 1962, APPL DYNAMIC PROGRAM, DOI 10.1515/9781400874651; Bilge AK, 2006, PACE, V29, P619, DOI 10.1111/j.1540-8159.2006.00409.x; Bittihn P, 2010, PHILOS T R SOC A, V368, P2221, DOI 10.1098/rsta.2010.0038; Cherry EM, 2008, J THEOR BIOL, V254, P674, DOI 10.1016/j.jtbi.2008.06.030; Cherry EM, 2004, AM J PHYSIOL-HEART C, V286, pH2332, DOI 10.1152/ajpheart.00747.2003; Cysyk J, 2008, BIOPHYS J, V94, P1533, DOI 10.1529/biophysj.107.116244; Dillon SM, 1998, J CARDIOVASC ELECTR, V9, P529, DOI 10.1111/j.1540-8167.1998.tb01847.x; DiMarco JP, 2003, NEW ENGL J MED, V349, P1836, DOI 10.1056/NEJMra035432; Dosdall DJ, 2010, ANNU REV BIOMED ENG, V12, P233, DOI [10.1146/annurev-bioeng-070909-105305, 10.1146/armurev-bioeng-070909-105305]; Duncan OD, 1955, AM J SOCIOL, V60, P493, DOI 10.1086/221609; Efimov IR, 2004, CIRC RES, V95, P21, DOI 10.1161/01.RES.0000130529.18016.35; Epstein AE, 1998, CIRCULATION, V98, P1517, DOI 10.1161/01.CIR.98.15.1517; ERMENTROUT GB, 1991, J MATH BIOL, V29, P195, DOI 10.1007/BF00160535; Faddy SC, 2003, RESUSCITATION, V58, P9, DOI 10.1016/S0300-9572(03)00077-7; Fast VG, 1998, CIRC RES, V82, P375, DOI 10.1161/01.RES.82.3.375; Fenton FH, 2009, CIRCULATION, V120, P467, DOI 10.1161/CIRCULATIONAHA.108.825091; Fishler MG, 2000, IEEE T BIO-MED ENG, V47, P59, DOI 10.1109/10.817620; Gray RA, 2005, P NATL ACAD SCI USA, V102, P4672, DOI 10.1073/pnas.0407860102; Hooks DA, 2002, CIRC RES, V91, P331, DOI 10.1161/01.RES.0000031957.70034.89; HOPPENSTEADT F, 1997, WEAKLY CONNECTED NEU; Ichinose N, 1998, INT J BIFURCAT CHAOS, V8, P2375, DOI 10.1142/S021812749800190X; IDEKER RE, 1995, PACE, V18, P512, DOI 10.1111/j.1540-8159.1995.tb02562.x; Jacq F, 2009, GEN HOSP PSYCHIAT, V31, P266, DOI 10.1016/j.genhosppsych.2009.01.003; Karma A, 1994, CHAOS, V4, P461, DOI 10.1063/1.166024; Keener JP, 1998, CHAOS, V8, P234, DOI 10.1063/1.166300; Kirk DE., 1998, OPTIMAL CONTROL THEO; Kroll MW, 2007, J INTERV CARD ELECTR, V18, P247, DOI 10.1007/s10840-007-9095-z; KROLL MW, 1994, PACE, V17, P1782, DOI 10.1111/j.1540-8159.1994.tb03746.x; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Laughner JI, 2012, AM J PHYSIOL-HEART C, V303, pH753, DOI 10.1152/ajpheart.00404.2012; Li DS, 1999, CIRCULATION, V100, P87, DOI 10.1161/01.CIR.100.1.87; Li WW, 2009, HEART RHYTHM, V6, P1020, DOI 10.1016/j.hrthm.2009.03.015; Luther S, 2011, NATURE, V475, P235, DOI 10.1038/nature10216; PLONSEY R, 1986, MED BIOL ENG COMPUT, V24, P130, DOI 10.1007/BF02443925; PLONSEY R, 1982, BIOPHYS J, V39, P309, DOI 10.1016/S0006-3495(82)84521-9; Rabinovitch A, 1999, CHAOS, V9, P880, DOI 10.1063/1.166460; Ripplinger CM, 2006, AM J PHYSIOL-HEART C, V291, pH184, DOI 10.1152/ajpheart.01300.2005; ROTH BJ, 1994, IEEE T BIO-MED ENG, V41, P232, DOI 10.1109/10.284941; Roth BJ, 1997, IEEE T BIO-MED ENG, V44, P326, DOI 10.1109/10.563303; Rush S, 1978, BIOMEDICAL ENG IEEE, P389, DOI [10.1109/TBME.1978.326270, DOI 10.1109/TBME.1978.326270]; Schneider T, 2000, CIRCULATION, V102, P1780; Spach MS, 2007, CIRC RES, V101, P743, DOI 10.1161/CIRCRESAHA.107.163956; SPACH MS, 1986, CIRC RES, V58, P356, DOI 10.1161/01.RES.58.3.356; Suzuki T, 2010, PACE, V33, P1455, DOI 10.1111/j.1540-8159.2010.02887.x; Sweeney MO, 2004, PACE, V27, P1292, DOI 10.1111/j.1540-8159.2004.00622.x; Swerdlow CD, 1996, CIRCULATION, V94, P2278, DOI 10.1161/01.CIR.94.9.2278; ten Tusscher KHWJ, 2006, AM J PHYSIOL-HEART C, V291, pH1088, DOI 10.1152/ajpheart.00109.2006; Thomas SA, 2006, AM J CRIT CARE, V15, P389; Trayanova N, 1998, J ELECTROCARDIOL, V31, P23, DOI 10.1016/S0022-0736(98)90274-6; Trayanova N, 2001, PHILOS T ROY SOC A, V359, P1327, DOI 10.1098/rsta.2001.0834; Trayanova N., 2009, CARDIAC BIOELECTRIC, P85; Vigmond EJ, 2008, PROG BIOPHYS MOL BIO, V96, P3, DOI 10.1016/j.pbiomolbio.2007.07.012; Walcott GP, 2003, RESUSCITATION, V59, P59, DOI 10.1016/S0300-9572(03)00161-8; Wathen MS, 2004, CIRCULATION, V110, P2591, DOI 10.1161/01.CIR.0000145610.64014.E4; Wilson D, 2015, SIAM REV, V57, P201, DOI 10.1137/140952478; Wilson D, 2014, SIAM J APPL DYN SYST, V13, P944, DOI 10.1137/130942851; Wilson D, 2014, SIAM J APPL DYN SYST, V13, P276, DOI 10.1137/120901702; Winfree AT., 1980, GEOMETRY BIOL TIME; Winter J, 2000, AM J CARDIOL, V86, p71K, DOI 10.1016/S0002-9149(00)01294-7	62	3	3	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158239	10.1371/journal.pone.0158239	http://dx.doi.org/10.1371/journal.pone.0158239			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27391010	Green Published, gold, Green Submitted			2023-01-03	WOS:000380005400039
J	Neves, J; Zhu, J; Sousa-Victor, P; Konjikusic, M; Riley, R; Chew, S; Qi, YY; Jasper, H; Lamba, DA				Neves, Joana; Zhu, Jie; Sousa-Victor, Pedro; Konjikusic, Mia; Riley, Rebeccah; Chew, Shereen; Qi, Yanyan; Jasper, Heinrich; Lamba, Deepak A.			Immune modulation by MANF promotes tissue repair and regenerative success in the retina	SCIENCE			English	Article							NEUROTROPHIC FACTOR; MICROGLIAL ACTIVATION; BLOOD-CELLS; DROSOPHILA; DEGENERATION; MACROPHAGES; MOUSE; SURVIVAL; DNA; DIFFERENTIATION	Regenerative therapies are limited by unfavorable environments in aging and diseased tissues. A promising strategy to improve success is to balance inflammatory and anti-inflammatory signals and enhance endogenous tissue repair mechanisms. Here, we identified a conserved immune modulatory mechanism that governs the interaction between damaged retinal cells and immune cells to promote tissue repair. In damaged retina of flies and mice, platelet-derived growth factor (PDGF)-like signaling induced mesencephalic astrocyte-derived neurotrophic factor (MANF) in innate immune cells. MANF promoted alternative activation of innate immune cells, enhanced neuroprotection and tissue repair, and improved the success of photoreceptor replacement therapies. Thus, immune modulation is required during tissue repair and regeneration. This approach may improve the efficacy of stem-cell-based regenerative therapies.	[Neves, Joana; Zhu, Jie; Sousa-Victor, Pedro; Konjikusic, Mia; Riley, Rebeccah; Chew, Shereen; Qi, Yanyan; Jasper, Heinrich; Lamba, Deepak A.] Buck Inst Res Aging, 8001 Redwood Blvd, Novato, CA 94945 USA	Buck Institute for Research on Aging	Jasper, H; Lamba, DA (corresponding author), Buck Inst Res Aging, 8001 Redwood Blvd, Novato, CA 94945 USA.	hjasper@buckinstitute.org; dlamba@buckinstitute.org	Sousa-Victor, Pedro/AER-5744-2022	Mendes Neves, Joana/0000-0002-1027-3489; Chew, Shereen/0000-0002-7285-6604	NIH [EY018177, EY025779]; Amarantus Biosciences Inc.; Foundation for Retinal Research; Glenn Foundation for Medical Research; NATIONAL EYE INSTITUTE [R01EY025779, R01EY018177] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amarantus Biosciences Inc.; Foundation for Retinal Research; Glenn Foundation for Medical Research; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We acknowledge Amarantus Biosciences Inc. for kindly supplying the hrMANF protein used in these studies. Work in H.J.'s laboratory is supported by NIH grant EY018177, and some of the fly work was supported by Amarantus Biosciences Inc. Work in D.A.L.'s laboratory is supported by NIH grant EY025779 and the Foundation for Retinal Research. J.N. is supported by the Glenn Foundation for Medical Research. The full RNA-seq data set is provided as supplementary materials. J.N., H.J., and D.A.L. are the inventors and the Buck Institute for Research on Aging is the applicant for an international patent application for the use of MANF as an enhancer of cell replacement therapies.	Abrams EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077618; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Aurora AB, 2014, CELL STEM CELL, V15, P15, DOI 10.1016/j.stem.2014.06.009; Babcock DT, 2008, P NATL ACAD SCI USA, V105, P10017, DOI 10.1073/pnas.0709951105; Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110; Belacortu Y, 2011, DEV DYNAM, V240, P2379, DOI 10.1002/dvdy.22753; Cailhier JF, 2005, J IMMUNOL, V174, P2336, DOI 10.4049/jimmunol.174.4.2336; Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x; Chen LJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08133; Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888; Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; DZIENNIS S, 1995, BLOOD, V85, P319; Forbes SJ, 2014, NAT MED, V20, P857, DOI 10.1038/nm.3653; Fox IJ, 2014, SCIENCE, V345, P889, DOI 10.1126/science.1247391; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Gust J, 2011, INVEST OPHTH VIS SCI, V52, P5266, DOI 10.1167/iovs.10-6329; Heino TI, 2001, MECH DEVELOP, V109, P69, DOI 10.1016/S0925-4773(01)00510-X; Henderson MJ, 2013, J BIOL CHEM, V288, P4209, DOI 10.1074/jbc.M112.400648; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Jassim OW, 2003, EMBO J, V22, P5622, DOI 10.1093/emboj/cdg543; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kang MJ, 2009, P NATL ACAD SCI USA, V106, P17043, DOI 10.1073/pnas.0905566106; Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010; Karpac J, 2011, DEV CELL, V20, P841, DOI 10.1016/j.devcel.2011.05.011; KEELER C, 1966, J HERED, V57, P47, DOI 10.1093/oxfordjournals.jhered.a107462; Kelsey EM, 2012, J CELL SCI, V125, P1393, DOI 10.1242/jcs.095323; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015; Lindahl M, 2014, CELL REP, V7, P366, DOI 10.1016/j.celrep.2014.03.023; Lindholm P, 2008, MOL CELL NEUROSCI, V39, P356, DOI 10.1016/j.mcn.2008.07.016; Lindholm P, 2010, DEV NEUROBIOL, V70, P360, DOI 10.1002/dneu.20760; Lindholm P, 2007, NATURE, V448, P73, DOI 10.1038/nature05957; London A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00034; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Luo X, 2007, EMBO J, V26, P380, DOI 10.1038/sj.emboj.7601484; MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161; Markus R, 2005, IMMUNOL LETT, V101, P108, DOI 10.1016/j.imlet.2005.03.021; Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Nadella R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0209-0; Neves J, 2015, DEV CELL, V32, P9, DOI 10.1016/j.devcel.2014.11.028; Palgi M, 2009, P NATL ACAD SCI USA, V106, P2429, DOI 10.1073/pnas.0810996106; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Pastor-Pareja JC, 2008, DIS MODEL MECH, V1, P144, DOI 10.1242/dmm.000950; Pearson RA, 2014, VISUAL NEUROSCI, V31, P333, DOI 10.1017/S0952523814000200; Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014; Petrova PS, 2003, J MOL NEUROSCI, V20, P173, DOI 10.1385/JMN:20:2:173; PITTLER SJ, 1993, P NATL ACAD SCI USA, V90, P9616, DOI 10.1073/pnas.90.20.9616; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Razzell W, 2011, DIS MODEL MECH, V4, P569, DOI 10.1242/dmm.006825; Reynolds J, 2014, EXP EYE RES, V123, P151, DOI 10.1016/j.exer.2013.07.010; Samson ML, 2000, J BIOL CHEM, V275, P31107, DOI 10.1074/jbc.M001346200; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Sinenko SA, 2004, ONCOGENE, V23, P9120, DOI 10.1038/sj.onc.1208156; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Stratoulias V, 2015, CELL MOL LIFE SCI, V72, P1989, DOI 10.1007/s00018-014-1789-7; Tang ZS, 2010, J EXP MED, V207, P867, DOI 10.1084/jem.20091704; Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007; Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358; Voutilainen MH, 2009, J NEUROSCI, V29, P9651, DOI 10.1523/JNEUROSCI.0833-09.2009; Wang LH, 2014, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00113; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520; Won JY, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/391384; Yang S, 2014, NEURON, V81, P349, DOI 10.1016/j.neuron.2013.12.002; Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008; Zeng HY, 2005, INVEST OPHTH VIS SCI, V46, P2992, DOI 10.1167/iovs.05-0118; Zettervall CJ, 2004, P NATL ACAD SCI USA, V101, P14192, DOI 10.1073/pnas.0403789101; Zhang C, 2005, MOL VIS, V11, P887; Zhao H, 2016, MOL NEUROBIOL, V53, P187, DOI 10.1007/s12035-014-9000-6	78	140	146	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2016	353	6294							aaf3646	10.1126/science.aaf3646	http://dx.doi.org/10.1126/science.aaf3646			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP9KX	27365452	Green Accepted			2023-01-03	WOS:000378816200029
J	Dettrick, Z; Gouda, HN; Hodge, A; Jimenez-Soto, E				Dettrick, Zoe; Gouda, Hebe N.; Hodge, Andrew; Jimenez-Soto, Eliana			Measuring Quality of Maternal and Newborn Care in Developing Countries Using Demographic and Health Surveys	PLOS ONE			English	Article							DETERMINANTS; CONTINUITY; SERVICES; IMPACT	Background One of the greatest obstacles facing efforts to address quality of care in low and middle income countries is the absence of relevant and reliable data. This article proposes a methodology for creating a single "Quality Index" (QI) representing quality of maternal and neonatal health care based upon data collected as part of the Demographic and Health Survey (DHS) program. Methods Using the 2012 Indonesian Demographic and Health Survey dataset, indicators of quality of care were identified based on the recommended guidelines outlined in the WHO Integrated Management of Pregnancy and Childbirth. Two sets of indicators were created; one set only including indicators available in the standard DHS questionnaire and the other including all indicators identified in the Indonesian dataset. For each indicator set composite indices were created using Principal Components Analysis and a modified form of Equal Weighting. These indices were tested for internal coherence and robustness, as well as their comparability with each other. Finally a single QI was chosen to explore the variation in index scores across a number of known equity markers in Indonesia including wealth, urban rural status and geographical region. Results The process of creating quality indexes from standard DHS data was proven to be feasible, and initial results from Indonesia indicate particular disparities in the quality of care received by the poor as well as those living in outlying regions. Conclusions The QI represents an important step forward in efforts to understand, measure and improve quality of MNCH care in developing countries.	[Dettrick, Zoe; Gouda, Hebe N.; Hodge, Andrew; Jimenez-Soto, Eliana] Univ Queensland, Sch Publ Hlth, Public Hlth Bldg,Herston Rd, Brisbane, Qld 4006, Australia	University of Queensland	Gouda, HN (corresponding author), Univ Queensland, Sch Publ Hlth, Public Hlth Bldg,Herston Rd, Brisbane, Qld 4006, Australia.	h.gouda@uq.edu.au	Dettrick, Zoe A/I-1479-2017; Dettrick, Zoe/AAP-2862-2021	Dettrick, Zoe A/0000-0003-1091-1820; Dettrick, Zoe/0000-0003-1091-1820; Gouda, Hebe/0000-0002-5709-4509	Australian Postgraduate Award	Australian Postgraduate Award(Australian Government)	This work was funded by an Australian Postgraduate Award scholarship administered through the University of Queensland, Australia.	[Anonymous], 2013, IND DEM HLTH SURV 20; Barber SL, 2008, HEALTH POLICY, V88, P339, DOI 10.1016/j.healthpol.2008.04.003; Basu S, 2012, PLOS MED, V9, P19, DOI DOI 10.1371/J0URNAL.PMED.1001244; Bjorkman M, 2009, Q J ECON, V124, P735, DOI 10.1162/qjec.2009.124.2.735; Bryce J, 2013, PLOS MED, V10; Chaturvedi S, 2014, PLOS ONE, V9; Das J, 2014, ANNU REV ECON, V6, P525, DOI 10.1146/annurev-economics-080213-041350; Das J, 2012, J DEV ECON, V98, P76, DOI 10.1016/j.jdeveco.2011.07.001; Dettrick Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083070; Donabedian A, 1986, QRB Qual Rev Bull, V12, P99; Fan VS, 2005, J GEN INTERN MED, V20, P226, DOI 10.1111/j.1525-1497.2005.40135.x; Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Foa R, 2012, METHODOLOGY SOCIAL D; Graham WJ, 2012, LANCET, V379, pE5, DOI 10.1016/S0140-6736(10)62267-2; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Harimurti P., 2013, NUTS BOLTS JAMKESMAS, P8; Hodge A, 2014, PLOS ONE, V9; Hussein J, 2004, REPROD HEALTH MATTER, V12, P160, DOI 10.1016/S0968-8080(04)24136-2; ICF International, 2014, DHS PROGR QUAL INF P; James CD, 2011, INT J QUAL HEALTH C, V23, P445, DOI 10.1093/intqhc/mzr029; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kozhimannil KB, 2014, J RURAL HLTH; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Lassi ZS, 2010, COCHRANE DB SYST REV, V11, P11; Lassi ZS, 2014, REPROD HLTH, P11; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060762; Marchant T, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0112-1; Mbuagbaw LCE, 2011, MATERN CHILD HLTH J, V15, P1427, DOI 10.1007/s10995-010-0707-3; Ministry of Health and Population (MOHP) [Nepal] New ERA & ICF International Inc, 2012, NEP DEM HLTH SURV 20; Moran AC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001415; NIPORT Mitra and Associates and ICF International, 2013, BANGL DEM HLTH SURV; Paxton A, 2005, INT J GYNECOL OBSTET, V88, P181, DOI 10.1016/j.ijgo.2004.11.026; Philippine Statistics Authority (PSA) [Philippines], 2014, INT I PHIL NAT DEM H; Pileggi-Castro C, 2014, BJOG-INT J OBSTET GY, V121, P110, DOI 10.1111/1471-0528.12637; Raven JH, 2012, MIDWIFERY, V28, pE676, DOI 10.1016/j.midw.2011.09.003; Rutstein SO, 2004, DHS COMP REPORTS NO; Salam RA, 2014, REPROD HLTH, P11; Schroders J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123629; Stanton CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060694; Steiner D, 2008, HLTH MEASUREMENT SCA; Tabachnick BG., 2013, USING MULTIVARIATE S, V6; Titaley CR, 2014, ASIA PAC J CLIN NUTR, V23, P91, DOI 10.6133/apjcn.2014.23.1.18; Uzochukwu B S C, 2004, East Afr Med J, V81, P293; van Duong D, 2004, INT J QUAL HEALTH C, V16, P447, DOI 10.1093/intqhc/mzh073; Victora CG, 2010, HEALTH POLICY PLANN, V25, P253, DOI 10.1093/heapol/czp065; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; World Health Organization, 2015, TRACK UN HLTH COV 1; World Health Organization, 2006, PREGN CHILDB POSTP N	50	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2016	11	6							e0157110	10.1371/journal.pone.0157110	http://dx.doi.org/10.1371/journal.pone.0157110			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DQ0CH	27362354	Green Published, gold, Green Submitted			2023-01-03	WOS:000378865200006
J	Sullenger, BA; Nair, S				Sullenger, Bruce A.; Nair, Smita			From the RNA world to the clinic	SCIENCE			English	Review							DENDRITIC CELL VACCINES; MESSENGER-RNA; HIV-1-INFECTED PATIENTS; TUMOR; IMMUNOTHERAPY; THERAPEUTICS; INTERFERENCE; RECEPTOR; CANCER; ELECTROPORATION	The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.	[Sullenger, Bruce A.] Duke Univ, Med Ctr, Duke Translat Res Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Duke Translat Res Inst, Durham, NC 27710 USA.	bruce.sullenger@duke.edu	Nair, Smita/GYR-2993-2022; Nair Jain, Smita/M-2765-2018	Nair, Smita/0000-0001-5615-7056; Nair Jain, Smita/0000-0002-1542-9913	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065222] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL065222] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010; Amin A, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0055-3; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Benteyn D, 2015, EXPERT REV VACCINES, V14, P161, DOI 10.1586/14760584.2014.957684; Bobbin ML, 2016, ANNU REV PHARMACOL, V56, P103, DOI 10.1146/annurev-pharmtox-010715-103633; Bringmann A, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/623687; Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Ganson NJ, 2016, J ALLERGY CLIN IMMUN, V137, P1610, DOI 10.1016/j.jaci.2015.10.034; Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878; Granstein RD, 2000, J INVEST DERMATOL, V114, P632, DOI 10.1046/j.1523-1747.2000.00929.x; Hanna Mazen, 2014, Curr Heart Fail Rep, V11, P50, DOI 10.1007/s11897-013-0182-4; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Kim YH, 2016, THERANOSTICS, V6, P357, DOI 10.7150/thno.13621; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Lee J, 2008, IMMUNOLOGY, V125, P229, DOI 10.1111/j.1365-2567.2008.02833.x; Lincoff AM, 2016, LANCET, V387, P349, DOI 10.1016/S0140-6736(15)00515-2; McClorey G, 2015, CURR OPIN PHARMACOL, V24, P52, DOI 10.1016/j.coph.2015.07.005; Mehan MR, 2013, ADV EXP MED BIOL, V735, P283, DOI 10.1007/978-1-4614-4118-2_20; Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320; Nair S., 2011, CANC VACCINES RES CL, P217; Nemunaitis J, 2014, ONCOLOGY-BASEL, V87, P21, DOI 10.1159/000360993; Niu YY, 2014, CELL, V156, P836, DOI 10.1016/j.cell.2014.01.027; Ramos AM, 2015, EXPERT OPIN DRUG DIS, V10, P541, DOI 10.1517/17460441.2015.1033394; Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Suhr OB, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0326-6; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8; Van Lint S, 2015, EXPERT REV VACCINES, V14, P235, DOI 10.1586/14760584.2015.957685; Van Nuffel AMT, 2012, CANCER IMMUNOL IMMUN, V61, P1033, DOI 10.1007/s00262-011-1176-2; Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49; Vigneswara V, 2014, BRAIN, V137, P1656, DOI 10.1093/brain/awu037; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Yoon SH, 2009, CANCER GENE THER, V16, P489, DOI 10.1038/cgt.2008.98; Zhao YB, 2010, CANCER RES, V70, P9053, DOI 10.1158/0008-5472.CAN-10-2880	40	169	183	7	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2016	352	6292					1417	1420		10.1126/science.aad8709	http://dx.doi.org/10.1126/science.aad8709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO7PV	27313039	Green Accepted			2023-01-03	WOS:000377975400039
J	Komninou, ER; Remiao, MH; Lucas, CG; Domingues, WB; Basso, AC; Jornada, DS; Deschamps, JC; Beck, RCR; Pohlmann, AR; Bordignon, V; Seixas, FK; Campos, VF; Guterres, SS; Collares, T				Komninou, Eliza Rossi; Remiao, Mariana Harter; Lucas, Caroline Gomes; Domingues, William Borges; Basso, Andrea Cristina; Jornada, Denise Soledade; Deschamps, Joao Carlos; Ruver Beck, Ruy Carlos; Pohlmann, Adriana Raffin; Bordignon, Vilceu; Seixas, Fabiana Kommling; Campos, Vinicius Farias; Guterres, Silvia Staniscuaski; Collares, Tiago			Effects of Two Types of Melatonin-Loaded Nanocapsules with Distinct Supramolecular Structures: Polymeric (NC) and Lipid-Core Nanocapsules (LNC) on Bovine Embryo Culture Model	PLOS ONE			English	Article							IN-VITRO DEVELOPMENT; OXIDATIVE STRESS; GENE-EXPRESSION; NANOPARTICLES; PREIMPLANTATION; IMPLANTATION; MATURATION; DELIVERY; OOCYTE; MOUSE	Melatonin has been used as a supplement in culture medium to improve the efficiency of in vitro produced mammalian embryos. Through its ability to scavenge toxic oxygen derivatives and regulate cellular mRNA levels for antioxidant enzymes, this molecule has been shown to play a protective role against damage by free radicals, to which in vitro cultured embryos are exposed during early development. In vivo and in vitro studies have been performed showing that the use of nanocapsules as active substances carriers increases stability, bioavailability and biodistribution of drugs, such as melatonin, to the cells and tissues, improving their antioxidant properties. These properties can be modulated through the manipulation of formula composition, especially in relation to the supramolecular structures of the nanocapsule core and the surface area that greatly influences drug release mechanisms in biological environments. This study aimed to evaluate the effects of two types of melatonin-loaded nanocapsules with distinct supramolecular structures, polymeric (NC) and lipid-core (LNC) nanocapsules, on in vitro cultured bovine embryos. Embryonic development, apoptosis, reactive oxygen species (ROS) production, and mRNA levels of genes involved in cell apoptosis, ROS and cell pluripotency were evaluated after supplementation of culture medium with non-encapsulated melatonin (Mel), melatonin-loaded polymeric nanocapsules (Mel-NC) and melatonin-loaded lipid-core nanocapsules (Mel-LNC) at 10(-6), 10(-9), and 10(-12) M drug concentrations. The highest hatching rate was observed in embryostreated with 10(-9) M Mel-LNC. When compared to Mel and Mel-NC treatments at the same concentration (10(-9) M), Mel-LNC increased embryo cell number, decreased cell apoptosis and ROS levels, down-regulated mRNA levels of BAX, CASP3, and SHC1 genes, and upregulated mRNA levels of CAT and SOD2 genes. These findings indicate that nanoencapsulation with LNC increases the protective effects of melatonin against oxidative stress and cell apoptosis during in vitro embryo culture in bovine species.	[Komninou, Eliza Rossi; Remiao, Mariana Harter; Lucas, Caroline Gomes; Domingues, William Borges; Deschamps, Joao Carlos; Seixas, Fabiana Kommling; Campos, Vinicius Farias; Collares, Tiago] Univ Fed Pelotas, Biotecnol Ctr Dev Tecnol, Grp Pesquisa Oncol Celular & Mol, PPGB, BR-96010900 Pelotas, RS, Brazil; [Basso, Andrea Cristina] In Vitro Brasil SA, BR-13800970 Mogi Mirim, SP, Brazil; [Jornada, Denise Soledade; Ruver Beck, Ruy Carlos; Guterres, Silvia Staniscuaski] Univ Fed Rio Grande do Sul, Fac Farm, Av Ipiranga 2752, BR-90610000 Porto Alegre, RS, Brazil; [Pohlmann, Adriana Raffin] Univ Fed Rio Grande do Sul, Inst Quim, Dept Quim Organ, BR-91501970 Porto Alegre, RS, Brazil; [Bordignon, Vilceu] McGill Univ, Dept Anim Sci, Ste Anne De Bellevue, PQ H9X 3V9, Canada	Universidade Federal de Pelotas; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; McGill University	Collares, T (corresponding author), Univ Fed Pelotas, Biotecnol Ctr Dev Tecnol, Grp Pesquisa Oncol Celular & Mol, PPGB, BR-96010900 Pelotas, RS, Brazil.; Guterres, SS (corresponding author), Univ Fed Rio Grande do Sul, Fac Farm, Av Ipiranga 2752, BR-90610000 Porto Alegre, RS, Brazil.	silvia.guterres@ufrgs.br; tiago.collares@pq.cnpq.br	Komninou, Eliza Rossi/J-7031-2014; Seixas, Fabiana Kommling/X-2706-2018; Collares, Tiago/K-2779-2019; Beck, Ruy C. R./D-7735-2011; Pohlmann, Adriana Raffin/B-9910-2008; Campos, Vinicius Farias/G-3546-2012; Cristina Basso, Andrea/AHC-5589-2022; Collares, Tiago/S-2117-2016; Guterres, Silvia S/B-6420-2015; Domingues, William Borges/AAM-5818-2021	Komninou, Eliza Rossi/0000-0001-6591-408X; Seixas, Fabiana Kommling/0000-0003-4204-2500; Collares, Tiago/0000-0002-1535-3795; Beck, Ruy C. R./0000-0001-6262-1097; Pohlmann, Adriana Raffin/0000-0001-5222-1807; Campos, Vinicius Farias/0000-0003-2119-293X; Collares, Tiago/0000-0002-1535-3795; Guterres, Silvia S/0000-0002-6085-6826; Domingues, William Borges/0000-0002-4351-2271; Bordignon, Vilceu/0000-0001-7076-7707; , Andrea Cristina Basso/0000-0002-8679-5232; Gomes Lucas, Caroline/0000-0003-3029-7987				Amarnath D, 2007, J REPROD DEVELOP, V53, P1247, DOI 10.1262/jrd.19096; Arias-Alvarez M, 2013, THERIOGENOLOGY, V79, P323, DOI 10.1016/j.theriogenology.2012.09.019; Asgari Z, 2012, CELL J, V14, P203; Barkalina N, 2015, HUM REPROD UPDATE, V21, P627, DOI 10.1093/humupd/dmv027; Barkalina N, 2014, NANOMED-NANOTECHNOL, V10, P921, DOI 10.1016/j.nano.2014.01.001; Barkalina N, 2014, NANOMED-NANOTECHNOL, V10, P859, DOI 10.1016/j.nano.2013.10.011; Campos VF, 2011, THERIOGENOLOGY, V75, P1476, DOI 10.1016/j.theriogenology.2011.01.009; Campos VF, 2011, THERIOGENOLOGY, V76, P1552, DOI 10.1016/j.theriogenology.2011.06.027; Cebrian-Serrano A, 2013, REPROD DOMEST ANIM, V48, P738, DOI 10.1111/rda.12154; Chattoraj A, 2008, COMP BIOCHEM PHYS A, V150, P301, DOI 10.1016/j.cbpa.2008.03.014; Choi J, 2008, MOL REPROD DEV, V75, P1127, DOI 10.1002/mrd.20861; Cruz MHC, 2014, ANIM REPROD SCI, V145, P150, DOI 10.1016/j.anireprosci.2014.01.011; Duarte AA, 2013, EUR PHYS J E, V36, DOI 10.1140/epje/i2013-13098-7; El-Gibaly I, 2003, INT J PHARM, V260, P5, DOI 10.1016/S0378-5173(03)00149-2; El-Raey M, 2011, MOL REPROD DEV, V78, P250, DOI 10.1002/mrd.21295; Feng RL, 2012, INT J NANOMED, V7, P4089, DOI 10.2147/IJN.S33607; Fiel LA, 2011, SOFT MATTER, V7, P7240, DOI 10.1039/c1sm05508a; Fiorentino I, 2015, EXP CELL RES, V330, P240, DOI 10.1016/j.yexcr.2014.09.017; Fischer TW, 2013, J PINEAL RES, V54, P303, DOI 10.1111/jpi.12018; Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835; Gao C, 2012, J PINEAL RES, V52, P305, DOI 10.1111/j.1600-079X.2011.00944.x; Gou ML, 2011, CURR DRUG TARGETS, V12, P1131, DOI 10.2174/138945011795906642; Guerin P, 2001, HUM REPROD UPDATE, V7, P175, DOI 10.1093/humupd/7.2.175; Hoffmeister CRD, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-251; Ishizuka B, 2000, J PINEAL RES, V28, P48, DOI 10.1034/j.1600-079x.2000.280107.x; Jager E, 2009, J BIOMED NANOTECHNOL, V5, P130, DOI 10.1166/jbn.2009.1004; Jornada DS, 2012, SOFT MATTER, V8, P6646, DOI 10.1039/c2sm25754h; Kang JT, 2009, J PINEAL RES, V46, P22, DOI 10.1111/j.1600-079X.2008.00602.x; Karja NWK, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-54; Kumar A, 2015, THERIOGENOLOGY, V83, P1402, DOI 10.1016/j.theriogenology.2014.12.023; Lane M, 2005, REPROD FERT DEVELOP, V17, P371, DOI 10.1071/RD04102; Lord T, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.106450; Lucas CG, 2015, REPROD TOXICOL, V58, P131, DOI 10.1016/j.reprotox.2015.10.004; Manjunatha BM, 2009, REPROD DOMEST ANIM, V44, P12, DOI 10.1111/j.1439-0531.2007.00982.x; Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018; Oliveira CP, 2013, SOFT MATTER, V9, P1141, DOI 10.1039/c2sm26959g; Ourique AF, 2010, J BIOMED NANOTECHNOL, V6, P214, DOI 10.1166/jbn.2010.1120; Papis K, 2007, J PINEAL RES, V43, P321, DOI 10.1111/j.1600-079X.2007.00479.x; Pardeike J, 2009, INT J PHARMACEUT, V366, P170, DOI 10.1016/j.ijpharm.2008.10.003; Pers-Kamczyc E, 2010, THERIOGENOLOGY, V74, P581, DOI 10.1016/j.theriogenology.2010.03.011; Pohlmann AR, 2010, METHODS MOL BIOL, V610, P109, DOI 10.1007/978-1-60327-029-8_7; Pohlmann AR, 2013, EXPERT OPIN DRUG DEL, V10, P623, DOI 10.1517/17425247.2013.769956; Poletto FS, 2015, J NANOSCI NANOTECHNO, V15, P827, DOI 10.1166/jnn.2015.9182; Proietti S, 2014, EXPERT OPIN DRUG MET, V10, P1193, DOI 10.1517/17425255.2014.943183; Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003; Rivara S, 2005, J MED CHEM, V48, P4049, DOI 10.1021/jm048956y; Rodriguez-Alvarez L, 2010, ZYGOTE, V18, P269, DOI 10.1017/S0967199409990323; Rodriguez-Osorio N, 2007, J PINEAL RES, V43, P283, DOI 10.1111/j.1600-079X.2007.00475.x; Sakatani M, 2004, MOL REPROD DEV, V67, P77, DOI 10.1002/mrd.20014; Schaffazick SR, 2007, PHARMAZIE, V62, P354, DOI 10.1691/ph.2007.5.6087; Schaffazick SR, 2006, J BRAZIL CHEM SOC, V17, P562, DOI 10.1590/S0103-50532006000300020; Schaffazick SR, 2005, INT J PHARMACEUT, V289, P209, DOI 10.1016/j.ijpharm.2004.11.003; Schultze E, 2014, EUR J PHARM BIOPHARM, V87, P55, DOI 10.1016/j.ejpb.2014.02.003; Shi JM, 2009, J PINEAL RES, V47, P318, DOI 10.1111/j.1600-079X.2009.00717.x; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4; Takada L, 2012, RES VET SCI, V92, P124, DOI 10.1016/j.rvsc.2010.11.004; Takahashi M, 2012, J REPROD DEVELOP, V58, P1, DOI 10.1262/jrd.11-138N; Tian XZ, 2014, J PINEAL RES, V57, P239, DOI 10.1111/jpi.12163; Venturini CG, 2011, COLLOID SURFACE A, V375, P200, DOI 10.1016/j.colsurfa.2010.12.011; Wang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093641; Wang F, 2013, J PINEAL RES, V55, P267, DOI 10.1111/jpi.12069; Zhang LM, 2013, J PINEAL RES, V54, P24, DOI 10.1111/j.1600-079X.2012.01016.x; Zhao MX, 2011, BIOMATERIALS, V32, P5223, DOI 10.1016/j.biomaterials.2011.03.060; Zhao T, 2014, SCI REP-UK, V4, DOI 10.1038/srep03793	64	21	21	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157561	10.1371/journal.pone.0157561	http://dx.doi.org/10.1371/journal.pone.0157561			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27310006	Green Published, gold, Green Submitted			2023-01-03	WOS:000378029800096
J	Reinhart, JM; Motsinger-Reif, A; Dickey, A; Yale, S; Trepanier, LA				Reinhart, Jennifer M.; Motsinger-Reif, Alison; Dickey, Allison; Yale, Steven; Trepanier, Lauren A.			Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials	PLOS ONE			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; TOXIC EPIDERMAL NECROLYSIS; ADVERSE DRUG-REACTIONS; SULFAMETHOXAZOLE-INDUCED HYPERSENSITIVITY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ENZYME GENE POLYMORPHISMS; STEVENS-JOHNSON-SYNDROME; HIV-INFECTED PATIENTS; INDUCED LIVER-INJURY; TRIMETHOPRIM-SULFAMETHOXAZOLE	Background Hypersensitivity (HS) reactions to sulfonamide antibiotics occur uncommonly, but with potentially severe clinical manifestations. A familial predisposition to sulfonamide HS is suspected, but robust predictive genetic risk factors have yet to be identified. Strongly linked genetic polymorphisms have been used clinically as screening tests for other HS reactions prior to administration of high-risk drugs. Objective The purpose of this study was to evaluate for genetic risk of sulfonamide HS in the immunocompetent population using genome-wide association. Methods Ninety-one patients with symptoms after trimethoprim-sulfamethoxazole (TMP-SMX) attributable to "probable" drug HS based on medical record review and the Naranjo Adverse Drug Reaction Probability Scale, and 184 age-and sex-matched patients who tolerated a therapeutic course of TMP-SMX, were included in a genome-wide association study using both common and rare variant techniques. Additionally, two subgroups of HS patients with a more refined clinical phenotype (fever and rash; or fever, rash and eosinophilia) were evaluated separately. Results For the full dataset, no single nucleotide polymorphisms were suggestive of or reached genome-wide significance in the common variant analysis, nor was any genetic locus significant in the rare variant analysis. A single, possible gene locus association (COL12A1) was identified in the rare variant analysis for patients with both fever and rash, but the sample size was very small in this subgroup (n = 16), and this may be a false positive finding. No other significant associations were found for the subgroups. Conclusions No convincing genetic risk factors for sulfonamide HS were identified in this population. These negative findings may be due to challenges in accurately confirming the phenotype in exanthematous drug eruptions, or to unidentified gene-environment interactions influencing sulfonamide HS.	[Reinhart, Jennifer M.; Trepanier, Lauren A.] Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA; [Motsinger-Reif, Alison; Dickey, Allison] N Carolina State Univ, Dept Stat, Bioinformat Res Ctr, Raleigh, NC 27695 USA; [Yale, Steven] Marshfield Clin Res Fdn, Marshfield, WI USA; [Yale, Steven] North Florida Reg Med Ctr, Gainesville, FL USA	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; North Carolina State University	Trepanier, LA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA.	lauren.trepanier@wisc.edu	Motsinger-Reif, Alison/I-4167-2018	Motsinger-Reif, Alison/0000-0003-1346-2493; Reinhart, Jennifer/0000-0002-3021-5075	NIH [R01 GM100784, T32 OD010423]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Support was provided by NIH R01 GM100784 [http://www.nih.gov] and NIH T32 OD010423. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfirevic A, 2009, PHARMACOGENOMICS, V10, P531, DOI 10.2217/PGS.09.6; [Anonymous], 2008, ZIAG; Ates NA, 2004, ARCH DERMATOL RES, V295, P429, DOI 10.1007/s00403-003-0446-z; Avgeri SG, 2009, INT J ANTIMICROB AG, V33, P394, DOI 10.1016/j.ijantimicag.2008.09.010; Azzopardi D, 2008, CANCER RES, V68, P358, DOI 10.1158/0008-5472.CAN-07-5733; Bousquet PJ, 2008, CURR PHARM DESIGN, V14, P2792, DOI 10.2174/138161208786369731; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Cribb AE, 1996, ADVERSE DRUG REACT T, V15, P9; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Del-Aguila JL, 2014, PHARMACOGENOMICS J, V14, P35, DOI 10.1038/tpj.2013.3; DELOMENIE C, 1994, BRIT J CLIN PHARMACO, V38, P581, DOI 10.1111/j.1365-2125.1994.tb04401.x; Drekonja DM, 2008, PRIMARY CARE, V35, P345, DOI 10.1016/j.pop.2008.01.001; Drekonja DM, 2009, DIAGN MICR INFEC DIS, V63, P201, DOI 10.1016/j.diagmicrobio.2008.10.001; Eliaszewicz M, 2002, J AM ACAD DERMATOL, V47, P40, DOI 10.1067/mjd.2002.120468; Gill HJ, 1999, PHARMACOGENETICS, V9, P43, DOI 10.1097/00008571-199902000-00007; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GRUCHALLA RS, 1991, J ALLERGY CLIN IMMUN, V88, P784, DOI 10.1016/0091-6749(91)90186-R; Gupta D, 2008, JCR-J CLIN RHEUMATOL, V14, P267, DOI 10.1097/RHU.0b013e31817a7e30; HARLE DG, 1988, MOL IMMUNOL, V25, P1347, DOI 10.1016/0161-5890(88)90050-8; HENNESSY S, 1995, J GEN INTERN MED, V10, P380, DOI 10.1007/BF02599836; Hicks D, 2014, HUM MOL GENET, V23, P2353, DOI 10.1093/hmg/ddt637; Hubiche T, 2011, DERMATOLOGY, V222, P140, DOI 10.1159/000324506; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kardaun SH, 2013, BRIT J DERMATOL, V169, P1071, DOI 10.1111/bjd.12501; KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005; Korbila IP, 2009, CAN FAM PHYSICIAN, V55, P60; LANCASTER HO, 1961, AUST J STAT, V3, P20, DOI 10.1111/j.1467-842X.1961.tb00058.x; Laurie CC, 2010, GENET EPIDEMIOL, V34, P591, DOI 10.1002/gepi.20516; Lee S, 2012, BIOSTATISTICS, V13, P762, DOI 10.1093/biostatistics/kxs014; Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009; Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024; Li P, 2015, BRIEF FUNCT GENOMICS, V14, P143, DOI 10.1093/bfgp/elu036; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; McCarty Gale A, 2005, AMIA Annu Symp Proc, P1049; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; Mohanasundaram J, 1998, J Indian Med Assoc, V96, P21; Mooney MA, 2014, TRENDS GENET, V30, P390, DOI 10.1016/j.tig.2014.07.004; Morelli JG, 1999, J PEDIATR-US, V134, P365, DOI 10.1016/S0022-3476(99)70472-5; Morimoto T, 2006, INTERNAL MED, V45, P101, DOI 10.2169/internalmedicine.45.1352; Motsinger-Reif AA, 2013, PHARMACOGENET GENOM, V23, P383, DOI 10.1097/FPC.0b013e32833d7b45; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nelson MR, 2009, PHARMACOGENOMICS J, V9, P23, DOI 10.1038/tpj.2008.4; Neuman MG, 2013, TRANSL RES, V161, P430, DOI 10.1016/j.trsl.2012.12.012; Neuman MG, 2000, CLIN BIOCHEM, V33, P517, DOI 10.1016/S0009-9120(00)00146-6; ORTIZ JE, 1982, ANN PLAS SURG, V9, P249, DOI 10.1097/00000637-198209000-00011; Ozkaya-Bayazit E, 2001, J AM ACAD DERMATOL, V45, P712, DOI 10.1067/mjd.2001.117854; Patel RM, 2008, INDIAN J DERMATOL VE, V74, DOI 10.4103/0378-6323.42883; Pavlos R, 2012, PHARMACOGENOMICS, V13, P1285, DOI [10.2217/PGS.12.108, 10.2217/pgs.12.108]; Pirmohamed M, 2000, PHARMACOGENETICS, V10, P705, DOI 10.1097/00008571-200011000-00005; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Putnam PP, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-369; Quiralte J, 1999, J ALLERGY CLIN IMMUN, V103, P685, DOI 10.1016/S0091-6749(99)70243-5; Rabaud C, 2001, SCAND J INFECT DIS, V33, P759, DOI 10.1080/003655401317074581; Reilly TP, 1998, BIOCHEM PHARMACOL, V55, P803, DOI 10.1016/S0006-2952(97)00547-9; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; Rizzo R, 2010, BREAST CANCER RES TR, V124, P593, DOI 10.1007/s10549-010-1034-5; Rodriguez M, 2004, CLIN INFECT DIS, V38, pE76, DOI 10.1086/383150; Ryan C, 1998, WMJ, V97, P23; Sacco JC, 2012, PHARMACOGENET GENOM, V22, P733, DOI 10.1097/FPC.0b013e328357a735; Saka B, 2010, Med Trop (Mars), V70, P255; Seger RA, 2008, BRIT J HAEMATOL, V140, P255, DOI 10.1111/j.1365-2141.2007.06880.x; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; Takeuchi F, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000433; Thomas M, 2009, SCAND J INFECT DIS, V41, P862, DOI 10.3109/00365540903214256; Walmsley SL, 1998, J ACQ IMMUN DEF SYND, V19, P498, DOI 10.1097/00042560-199812150-00009; Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174; Wang D, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-32; Westphal GA, 2000, INT ARCH OCC ENV HEA, V73, P384, DOI 10.1007/s004200000159; Wolkenstein P, 2005, J INVEST DERMATOL, V125, P1080, DOI 10.1111/j.0022-202X.2005.23939.x; WOLKENSTEIN P, 1995, PHARMACOGENETICS, V5, P255, DOI 10.1097/00008571-199508000-00011; WOLKENSTEIN P, 1995, ARCH DERMATOL, V131, P544, DOI 10.1001/archderm.131.5.544; Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029; Xu J, 2016, BMC GENET, V17, DOI 10.1186/s12863-016-0331-3; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Zielinska E, 1998, EUR J CLIN PHARMACOL, V54, P779, DOI 10.1007/s002280050551	79	12	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2016	11	6							e0156000	10.1371/journal.pone.0156000	http://dx.doi.org/10.1371/journal.pone.0156000			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TC	27272151	Green Published, Green Submitted, gold			2023-01-03	WOS:000377561000005
J	Vermeij, WP; Dolle, MET; Reiling, E; Jaarsma, D; Payan-Gomez, C; Bombardieri, CR; Wu, H; Roks, AJM; Botter, SM; van der Eerden, BC; Youssef, SA; Kuiper, RV; Nagarajah, B; van Oostrom, CT; Brandt, RMC; Barnhoorn, S; Imholz, S; Pennings, JLA; de Bruin, A; Gyenis, A; Pothof, J; Vijg, J; van Steeg, H; Hoeijmakers, JHJ				Vermeij, W. P.; Dolle, M. E. T.; Reiling, E.; Jaarsma, D.; Payan-Gomez, C.; Bombardieri, C. R.; Wu, H.; Roks, A. J. M.; Botter, S. M.; van der Eerden, B. C.; Youssef, S. A.; Kuiper, R. V.; Nagarajah, B.; van Oostrom, C. T.; Brandt, R. M. C.; Barnhoorn, S.; Imholz, S.; Pennings, J. L. A.; de Bruin, A.; Gyenis, A.; Pothof, J.; Vijg, J.; van Steeg, H.; Hoeijmakers, J. H. J.			Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice	NATURE			English	Article							CALORIC RESTRICTION; NUCLEAR ABNORMALITIES; COCKAYNE-SYNDROME; GROWTH; DEGENERATION; COMPONENT; MODELS; CANCER; P53	Mice deficient in the DNA excision-repair gene Ercc1 (Ercc1(Delta/-)) show numerous accelerated ageing features that limit their lifespan to 4-6 months(1-4). They also exhibit a 'survival response', which suppresses growth and enhances cellular maintenance. Such a response resembles the anti-ageing response induced by dietary restriction (also known as caloric restriction)(1,5). Here we report that a dietary restriction of 30% tripled the median and maximal remaining lifespans of these progeroid mice, strongly retarding numerous aspects of accelerated ageing. Mice undergoing dietary restriction retained 50% more neurons and maintained full motor function far beyond the lifespan of mice fed ad libitum. Other DNA-repair-deficient, progeroid Xpg(-/-) (also known as Ercc5(-/-)) mice, a model of Cockayne syndrome(6), responded similarly. The dietary restriction response in Ercc1(Delta/-) mice closely resembled the effects of dietary restriction in wild-type animals. Notably, liver tissue from Ercc1(Delta/-) mice fed ad libitum showed preferential extinction of the expression of long genes, a phenomenon we also observed in several tissues ageing normally. This is consistent with the accumulation of stochastic, transcription-blocking lesions that affect long genes more than short ones. Dietary restriction largely prevented this declining transcriptional output and reduced the number of gamma H2AX DNA damage foci, indicating that dietary restriction preserves genome function by alleviating DNA damage. Our findings establish the Ercc1(Delta/-) mouse as a powerful model organism for health-sustaining interventions, reveal potential for reducing endogenous DNA damage, facilitate a better understanding of the molecular mechanism of dietary restriction and suggest a role for counterintuitive dietary-restriction-like therapy for human progeroid genome instability syndromes and possibly neurodegeneration in general.	[Vermeij, W. P.; Reiling, E.; Payan-Gomez, C.; Bombardieri, C. R.; Botter, S. M.; Brandt, R. M. C.; Barnhoorn, S.; Gyenis, A.; Pothof, J.; Hoeijmakers, J. H. J.] Erasmus Univ, Dept Mol Genet, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Dolle, M. E. T.; Reiling, E.; Nagarajah, B.; van Oostrom, C. T.; Imholz, S.; Pennings, J. L. A.; van Steeg, H.] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, POB 1, NL-3720 BA Bilthoven, Netherlands; [Jaarsma, D.] Erasmus Univ, Med Ctr Rotterdam, Dept Neurosci, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Payan-Gomez, C.] Univ Rosario, Fac Ciencias Nat & Matemat, Carrera 24,63C-69, Bogota, Colombia; [Wu, H.; Roks, A. J. M.] Erasmus Univ, Div Vasc Med & Pharmacol, Dept Internal Med, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Botter, S. M.] Balgrist Univ Hosp, Lab Orthoped Res, Forchstr 340, CH-8008 Zurich, Switzerland; [van der Eerden, B. C.] Erasmus Univ, Dept Internal Med, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Youssef, S. A.; Kuiper, R. V.; de Bruin, A.] Univ Utrecht, Dept Pathobiol, Dutch Mol Pathol Ctr, Fac Vet Med, POB 80125, NL-3508 TC Utrecht, Netherlands; [de Bruin, A.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, POB 30001, NL-9700 RB Groningen, Netherlands; [Vijg, J.] Albert Einstein Coll Med, Dept Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA; [van Steeg, H.] Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, NL-2300 RC Leiden, Netherlands; [Hoeijmakers, J. H. J.] Univ Cologne, CECAD Forschungszentrum, Joseph Stelzmann Str 26, D-50931 Cologne, Germany; [Kuiper, R. V.] Karolinska Inst, Dept Lab Med, SE-17177 Stockholm, Sweden	Erasmus University Rotterdam; Erasmus MC; Netherlands National Institute for Public Health & the Environment; Erasmus University Rotterdam; Erasmus MC; Universidad del Rosario; Erasmus University Rotterdam; Erasmus MC; University of Zurich; Erasmus University Rotterdam; Erasmus MC; Utrecht University; University of Groningen; Yeshiva University; Albert Einstein College of Medicine; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Cologne; Karolinska Institutet	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Dept Mol Genet, Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands.; Dolle, MET (corresponding author), Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, POB 1, NL-3720 BA Bilthoven, Netherlands.	martijn.dolle@rivm.nl; j.hoeijmakers@erasmusmc.nl	Hoeijmakers, Jan/AAX-6972-2021; de Bruin, Alain/AAL-9195-2020; van der Eerden, Bram CJ/I-7496-2012; Payan-Gomez, Cesar/G-8589-2016	van der Eerden, Bram CJ/0000-0003-4403-6497; Roks, Anton J.M./0000-0001-7155-1756; Payan-Gomez, Cesar/0000-0002-0633-1332; Kuiper, Raoul/0000-0001-5645-2389; Pennings, Jeroen L.A./0000-0002-9188-6358; Gyenis, Akos/0000-0002-8104-7681; Brandt, Renata M. C./0000-0003-0514-5623; Dolle, Martijn/0000-0001-6137-6544; Vermeij, Wilbert/0000-0002-9690-1385	National Institute of Health (NIH)/National Institute of Ageing (NIA) [1PO1 AG-17242-02]; National Institute for Public Health and the Environment; Ministry of Health, Welfare and Sport of The Netherlands [S/340005]; European Research Council; European commission [FP7-Health-2008-200880]; DNA Repair [LSHG-CT-2005-512113]; EU ITN Address [GA-316390]; KWO Dutch Cancer Society [5030]; Dutch CAA Foundation; Royal Academy of Arts and Sciences of the Netherlands; European Community [HEALTH-F2-2010-259893]; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER	National Institute of Health (NIH)/National Institute of Ageing (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute for Public Health and the Environment; Ministry of Health, Welfare and Sport of The Netherlands; European Research Council(European Research Council (ERC)European Commission); European commission(European CommissionEuropean Commission Joint Research Centre); DNA Repair; EU ITN Address; KWO Dutch Cancer Society; Dutch CAA Foundation; Royal Academy of Arts and Sciences of the Netherlands; European Community(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank P. de With, J. Rigters, E. Haasdijk, S. Gabriels, E. J. M. Stynenbosch, N. van Vliet, Y. van Loon, J. Baan and the animal caretakers for general assistance with mouse experiments. We thank A. H. J. Danser and J. P. van Leeuwen for support. We acknowledge financial support from the National Institute of Health (NIH)/National Institute of Ageing (NIA) (1PO1 AG-17242-02), the National Institute for Public Health and the Environment and the Ministry of Health, Welfare and Sport of The Netherlands (S/340005), European Research Council Advanced Grant DamAge and Proof of Concept Grant Dementia to J. H. J. H., the European commission FP7 Markage (FP7-Health-2008-200880), DNA Repair (LSHG-CT-2005-512113), EU ITN Address (GA-316390), the KWO Dutch Cancer Society (5030), the Dutch CAA Foundation and the Royal Academy of Arts and Sciences of the Netherlands (academia professorship to J. H. J. H.). The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number HEALTH-F2-2010-259893. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnhoorn S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004686; Bartke A, 2013, PHYSIOL REV, V93, P571, DOI 10.1152/physrev.00006.2012; Barzilai N, 2012, DIABETES, V61, P1315, DOI 10.2337/db11-1300; Bogliolo M, 2013, AM J HUM GENET, V92, P800, DOI 10.1016/j.ajhg.2013.04.002; Borgesius NZ, 2011, J NEUROSCI, V31, P12543, DOI 10.1523/JNEUROSCI.1589-11.2011; Botter SM, 2009, OSTEOARTHR CARTILAGE, V17, P636, DOI 10.1016/j.joca.2008.09.018; Campisi J, 2014, INTERD T GERONT GERI, V39, P45, DOI 10.1159/000358899; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; de Graaf EL, 2013, MOL CELL PROTEOMICS, V12, P1350, DOI 10.1074/mcp.M112.024950; de Waard MC, 2010, ACTA NEUROPATHOL, V120, P461, DOI 10.1007/s00401-010-0715-9; Derks KWJ, 2015, RNA BIOL, V12, P30, DOI 10.1080/15476286.2015.1017202; Dolle MET, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7219; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Durik M, 2012, CIRCULATION, V126, P468, DOI 10.1161/CIRCULATIONAHA.112.104380; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Garinis GA, 2009, NAT CELL BIOL, V11, P604, DOI 10.1038/ncb1866; Gates KS, 2009, CHEM RES TOXICOL, V22, P1747, DOI 10.1021/tx900242k; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Jaarsma D, 2013, MECH AGEING DEV, V134, P180, DOI 10.1016/j.mad.2013.04.003; Jonker MJ, 2013, AGING CELL, V12, P901, DOI 10.1111/acel.12118; Kashiyama K, 2013, AM J HUM GENET, V92, P807, DOI 10.1016/j.ajhg.2013.04.007; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Navarro F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132767; Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456; Partridge L, 2007, NATURE, V450, P165, DOI 10.1038/450165a; Raj DDA, 2014, NEUROBIOL AGING, V35, P2147, DOI 10.1016/j.neurobiolaging.2014.03.025; Ringner M, 2008, NAT BIOTECHNOL, V26, P303, DOI 10.1038/nbt0308-303; Schumacher B, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000161; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Stranahan AM, 2012, J ALZHEIMERS DIS, V30, pS5, DOI 10.3233/JAD-2011-110899; Swenberg JA, 2011, TOXICOL SCI, V120, pS130, DOI 10.1093/toxsci/kfq371; Swindell WR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-585; van der Pluijm I, 2007, PLOS BIOL, V5, P23, DOI 10.1371/journal.pbio.0050002; Vermeij WP, 2016, ANNU REV PHARMACOL, V56, P427, DOI 10.1146/annurev-pharmtox-010814-124316; Waarsing JH, 2004, J BONE MINER RES, V19, P1640, DOI 10.1359/JBMR.040705; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; Wijnhoven SWP, 2005, DNA REPAIR, V4, P1314, DOI 10.1016/j.dnarep.2005.07.002; Wilson BT, 2016, GENET MED, V18, P483, DOI 10.1038/gim.2015.110	46	141	146	4	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2016	537	7620					427	+		10.1038/nature19329	http://dx.doi.org/10.1038/nature19329			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV7EC	27556946	Green Accepted, Green Published			2023-01-03	WOS:000383098000059
J	[Anonymous]				[Anonymous]			Public Decency and Public Health (Reprinted from JAMA, vol 67, pg 815, 1916)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		Armstrong D.B, 1916, J HOME ECON, V8, P422; 1916, JAMA, V67, P815	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2016	316	10					1118	1118		10.1001/jama.2015.17101	http://dx.doi.org/10.1001/jama.2015.17101			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV5TB	27623475				2023-01-03	WOS:000382991100036
J	Edinger, N; Lebendiker, M; Klein, S; Zigler, M; Langut, Y; Levitzki, A				Edinger, Nufar; Lebendiker, Mario; Klein, Shoshana; Zigler, Maya; Langut, Yael; Levitzki, Alexander			Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; CANCER-CELLS; I INTERFERONS; TUMOR-CELLS; KINASE PKR; APOPTOSIS; TLR3	Selective delivery of drugs to tumor cells can increase potency and reduce toxicity. In this study, we describe a novel recombinant chimeric protein, dsRBEC, which can bind polyIC and deliver it selectively into EGFR over-expressing tumor cells. dsRBEC, comprises the dsRNA binding domain (dsRBD) of human PKR (hPKR), which serves as the polyIC binding moiety, fused to human EGF (hEGF), the targeting moiety. dsRBEC shows high affinity towards EGFR and triggers ligand-induced endocytosis of the receptor, thus leading to the selective internalization of polyIC into EGFR over-expressing tumor cells. The targeted delivery of polyIC by dsRBEC induced cellular apoptosis and the secretion of IFN-beta and other pro-inflammatory cytokines. dsRBEC-delivered polyIC is much more potent than naked polyIC and is expected to reduce the toxicity caused by systemic delivery of polyIC.	[Edinger, Nufar; Klein, Shoshana; Zigler, Maya; Langut, Yael; Levitzki, Alexander] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, Jerusalem, Israel; [Lebendiker, Mario] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Prot Purificat Unit, Wolfson Ctr Appl Struct Biol, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, Jerusalem, Israel.	alex.levitzki@mail.huji.ac.il			European Research Council (ERC) [249898]	European Research Council (ERC)(European Research Council (ERC)European Commission)	This work was supported by European Research Council (ERC) Advanced Grant No. 249898 (A.L.) [https://erc.europa.eu/funding-andgrants].	Abourbeh G, 2012, IUBMB LIFE, V64, P324, DOI 10.1002/iub.1002; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bekisz J, 2010, PHARMACEUTICALS, V3, P994, DOI 10.3390/ph3040994; Besch R, 2009, J CLIN INVEST, V119, P2399, DOI 10.1172/JCI37155; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180; CONNOR J, 1985, J CELL BIOL, V101, P582, DOI 10.1083/jcb.101.2.582; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; Galli R, 2010, J IMMUNOL, V184, P6658, DOI 10.4049/jimmunol.0902401; Gambara G, 2015, J CELL MOL MED, V19, P327, DOI 10.1111/jcmm.12379; Garcia-Cattaneo A, 2012, P NATL ACAD SCI USA, V109, P9053, DOI 10.1073/pnas.1115091109; Gatti G, 2013, EUR J IMMUNOL, V43, P1849, DOI 10.1002/eji.201242902; Hertzog PJ, 2012, IMMUNOL CELL BIOL, V90, P471, DOI 10.1038/icb.2012.15; HOMAN ER, 1972, TOXICOL APPL PHARM, V23, P579, DOI 10.1016/0041-008X(72)90098-1; Hutchinson MH, 2006, J CHROMATOGR A, V1128, P125, DOI 10.1016/j.chroma.2006.06.050; Jiang Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-12; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joubran S, 2014, BIOCONJUGATE CHEM, V25, P1644, DOI 10.1021/bc500252a; Kalali BN, 2008, J IMMUNOL, V181, P2694, DOI 10.4049/jimmunol.181.4.2694; Kang J, 2007, ANAL BIOCHEM, V365, P147, DOI 10.1016/j.ab.2007.03.003; KROWN SE, 1985, J BIOL RESP MODIF, V4, P640; Leonard JN, 2008, P NATL ACAD SCI USA, V105, P258, DOI 10.1073/pnas.0710779105; Li M, 2004, PROTEIN EXPRES PURIF, V33, P1, DOI 10.1016/j.pep.2003.08.023; Marenchino M, 2009, PROTEIN EXPRES PURIF, V63, P112, DOI 10.1016/j.pep.2008.09.010; Matsumoto M, 2008, ADV DRUG DELIVER REV, V60, P805, DOI 10.1016/j.addr.2007.11.005; Mellert K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052473; Moiseeva EP, 2007, CARCINOGENESIS, V28, P435, DOI 10.1093/carcin/bgl171; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Orita T, 2013, CURR EYE RES, V38, P53, DOI 10.3109/02713683.2012.721044; Palchetti S, 2015, J BIOL CHEM, V290, P5470, DOI 10.1074/jbc.M114.601625; PELLETIER B, 1988, J BIOCHEM BIOPH METH, V16, P63, DOI 10.1016/0165-022X(88)90104-2; Pohar J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092391; Salaun B, 2007, CLIN CANCER RES, V13, P4565, DOI 10.1158/1078-0432.CCR-07-0274; Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Schaffert D, 2011, PHARM RES-DORDR, V28, P731, DOI 10.1007/s11095-010-0225-4; Shir A, 2011, CLIN CANCER RES, V17, P1033, DOI 10.1158/1078-0432.CCR-10-1140; Singh A, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0222-8; Sun RL, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.178798; Takahashi Hirokazu, 2014, PLoS One, V9, pe82624, DOI 10.1371/journal.pone.0082624; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; Tsai SY, 2015, J IMMUNOL, V195, P4426, DOI 10.4049/jimmunol.1500378; Tsumoto K, 2003, PROTEIN EXPRES PURIF, V28, P1, DOI 10.1016/S1046-5928(02)00641-1; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Vercammen E, 2008, CLIN MICROBIOL REV, V21, P13, DOI 10.1128/CMR.00022-07; Vitale G, 2007, ANN SURG, V246, P259, DOI 10.1097/01.sla.0000261460.07110.f2; Welsh RM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002352; Yamaguchi S, 2013, BIOTECHNOL J, V8, P17, DOI 10.1002/biot.201200025; Yamashita M, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002581; ZABRISKIE DW, 1988, BIOTECHNOL BIOENG, V32, P100, DOI 10.1002/bit.260320114; Zheng XF, 2004, RNA, V10, P1934, DOI 10.1261/rna.7150804; Zigler M, 2016, CANC IMMUNOL R UNPUB	55	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2016	11	9							e0162321	10.1371/journal.pone.0162321	http://dx.doi.org/10.1371/journal.pone.0162321			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9IT	27598772	gold, Green Published, Green Submitted			2023-01-03	WOS:000383254800052
J	Iacobucci, G				Iacobucci, Gareth			Sixty seconds on ... the childhood obesity strategy	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Department of Health, CHILDH OB PLAN ACT; Iacobucci G, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4597; O'Dowd A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4576; Wise J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6026	4	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 26	2016	354								i4684	10.1136/bmj.i4684	http://dx.doi.org/10.1136/bmj.i4684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV3AB	27565682				2023-01-03	WOS:000382792300007
J	Elias, WJ; Lipsman, N; Ondo, WG; Ghanouni, P; Kim, YG; Lee, W; Schwartz, M; Hynynen, K; Lozano, AM; Shah, BB; Huss, D; Dallapiazza, RF; Gwinn, R; Witt, J; Ro, S; Eisenberg, HM; Fishman, PS; Gandhi, D; Halpern, CH; Chuang, R; Pauly, KB; Tierney, TS; Hayes, MT; Cosgrove, GR; Yamaguchi, T; Abe, K; Taira, T; Chang, JW				Elias, W. Jeffrey; Lipsman, Nir; Ondo, William G.; Ghanouni, Pejman; Kim, Young G.; Lee, Wonhee; Schwartz, Michael; Hynynen, Kullervo; Lozano, Andres M.; Shah, Binit B.; Huss, Diane; Dallapiazza, Robert F.; Gwinn, Ryder; Witt, Jennifer; Ro, Susie; Eisenberg, Howard M.; Fishman, Paul S.; Gandhi, Dheeraj; Halpern, Casey H.; Chuang, Rosalind; Pauly, Kim Butts; Tierney, Travis S.; Hayes, Michael T.; Cosgrove, G. Rees; Yamaguchi, Toshio; Abe, Keiichi; Taira, Takaomi; Chang, Jin W.			A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP BRAIN-STIMULATION; QUALITY-OF-LIFE; THALAMIC-STIMULATION; PARKINSONS-DISEASE; MOVEMENT; IRRADIATION; SUPPRESSION; SURGERY; BLIND	BACKGROUND Uncontrolled pilot studies have suggested the efficacy of focused ultrasound thalamotomy with magnetic resonance imaging (MRI) guidance for the treatment of essential tremor. METHODS We enrolled patients with moderate-to-severe essential tremor that had not responded to at least two trials of medical therapy and randomly assigned them in a 3:1 ratio to undergo unilateral focused ultrasound thalamotomy or a sham procedure. The Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire were administered at baseline and at 1, 3, 6, and 12 months. Tremor assessments were videotaped and rated by an independent group of neurologists who were unaware of the treatment assignments. The primary outcome was the between-group difference in the change from baseline to 3 months in hand tremor, rated on a 32-point scale (with higher scores indicating more severe tremor). After 3 months, patients in the sham-procedure group could cross over to active treatment (the openlabel extension cohort). RESULTS Seventy-six patients were included in the analysis. Hand-tremor scores improved more after focused ultrasound thalamotomy (from 18.1 points at baseline to 9.6 at 3 months) than after the sham procedure (from 16.0 to 15.8 points); the between-group difference in the mean change was 8.3 points (95% confidence interval [CI], 5.9 to 10.7; P < 0.001). The improvement in the thalamotomy group was maintained at 12 months (change from baseline, 7.2 points; 95% CI, 6.1 to 8.3). Secondary outcome measures assessing disability and quality of life also improved with active treatment (the blinded thalamotomy cohort) as compared with the sham procedure (P < 0.001 for both comparisons). Adverse events in the thalamotomy group included gait disturbance in 36% of patients and paresthesias or numbness in 38%; these adverse events persisted at 12 months in 9% and 14% of patients, respectively. CONCLUSIONS MRI-guided focused ultrasound thalamotomy reduced hand tremor in patients with essential tremor. Side effects included sensory and gait disturbances. (Funded by InSightec and others; ClinicalTrials.gov number, NCT01827904.)	[Elias, W. Jeffrey; Shah, Binit B.; Huss, Diane; Dallapiazza, Robert F.] Univ Virginia, Hlth Sci Ctr, Box 800212, Charlottesville, VA 22908 USA; [Schwartz, Michael; Hynynen, Kullervo] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Ondo, William G.] Methodist Neurol Inst, Houston, TX USA; [Ghanouni, Pejman; Halpern, Casey H.; Pauly, Kim Butts] Stanford Univ, Sch Med, Stanford, CA USA; [Kim, Young G.; Lee, Wonhee; Chang, Jin W.] Yonsei Univ, Coll Med, Seoul, South Korea; [Gwinn, Ryder; Witt, Jennifer; Ro, Susie; Chuang, Rosalind] Swedish Neurosci Inst, Seattle, WA USA; [Eisenberg, Howard M.; Fishman, Paul S.; Gandhi, Dheeraj] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Tierney, Travis S.] Univ Miami, Sch Med, Nicklaus Childrens Hosp, Miami, FL USA; [Hayes, Michael T.; Cosgrove, G. Rees] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Yamaguchi, Toshio] Shin Yurigaoka Gen Hosp, Kawasaki, Kanagawa, Japan; [Abe, Keiichi; Taira, Takaomi] Tokyo Womens Med Univ, Tokyo, Japan	University of Virginia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; The Methodist Hospital System; The Methodist Hospital - Houston; Stanford University; Yonsei University; Yonsei University Health System; Swedish Medical Center; University System of Maryland; University of Maryland Baltimore; University of Miami; Harvard University; Brigham & Women's Hospital; Tokyo Women's Medical University	Elias, WJ (corresponding author), Univ Virginia, Dept Neurol Surg, Box 800212, Charlottesville, VA 22908 USA.	ksh5m@virginia.edu	Lozano, Andres M/A-5058-2012	Lozano, Andres M./0000-0001-8257-3694; Chang, Jin Woo/0000-0002-2717-0101; Chen, Hong/0000-0003-1904-0857; Taira, Takaomi/0000-0002-9982-4493	InSightec; Focused Ultrasound Foundation; Binational Industrial Research and Development (BIRD) Foundation; GE Healthcare; NeuroPace; Boston Scientific; Daiichi-Sankyo; Eisai; GlaxoSmithKline; Otsuka; Pfizer; Hisamitsu; Dainippon-Sumitomo; Takeda; Kyowa-Hakko; St. Jude Medical	InSightec; Focused Ultrasound Foundation; Binational Industrial Research and Development (BIRD) Foundation; GE Healthcare(General ElectricGE Healthcare); NeuroPace; Boston Scientific(Boston Scientific); Daiichi-Sankyo(Daiichi Sankyo Company Limited); Eisai(Eisai Co Ltd); GlaxoSmithKline(GlaxoSmithKline); Otsuka(Otsuka Pharmaceutical); Pfizer(Pfizer); Hisamitsu; Dainippon-Sumitomo(Dainippon Sumitomo Pharma Co., Ltd.); Takeda(Takeda Pharmaceutical Company Ltd); Kyowa-Hakko; St. Jude Medical(St. Jude Medical)	Supported by InSightec, the Focused Ultrasound Foundation, and the Binational Industrial Research and Development (BIRD) Foundation.; Dr. Elias reports receiving grant support from InSightec and the Focused Ultrasound Foundation; Dr. Lipsman, receiving fees from the Focused Ultrasound Foundation for serving on a steering committee; Dr. Ghanouni and Dr. Butts Pauly, receiving grant support from InSightec and GE Healthcare; Dr. Hynynen, receiving royalties from a patent related to ultrasound therapy (US6770031 B2); Dr. Lozano, receiving grant support from InSightec; Dr. Gwinn, receiving teaching fees from NeuroPace and Boston Scientific; Dr. Cosgrove, receiving consulting fees from InSightec; and Dr. Taira, receiving lecture fees from Daiichi-Sankyo, Eisai, GlaxoSmithKline, Otsuka, Pfizer, Hisamitsu, Dainippon-Sumitomo, Takeda, and Kyowa-Hakko, and grant support from St. Jude Medical. No other potential conflict of interest relevant to this article was reported.	Anderson VC, 2009, NEUROSCI LETT, V462, P166, DOI 10.1016/j.neulet.2009.07.003; [Anonymous], 2015, J THER ULTRASOUND, DOI [DOI 10.1186/2050-5736-3-S1-P26, 10.1186/2050-5736-3-S1-P26]; BENABID AL, 1993, ACTA NEUROCHIR, P39; Chang WS, 2015, J NEUROL NEUROSUR PS, V86, P257, DOI 10.1136/jnnp-2014-307642; Clement GT, 2000, PHYS MED BIOL, V45, P1071, DOI 10.1088/0031-9155/45/4/319; Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303; Deuschl G, 2011, LANCET NEUROL, V10, P148, DOI 10.1016/S1474-4422(10)70322-7; Elias WJ, 2013, J NEUROSURG, V119, P307, DOI 10.3171/2013.5.JNS122327; Elias WJ, 2014, JAMA-J AM MED ASSOC, V311, P948, DOI 10.1001/jama.2014.1397; Elias WJ, 2013, NEW ENGL J MED, V369, P640, DOI 10.1056/NEJMoa1300962; FINDLEY LJ, 1982, BRIT MED J, V285, P608, DOI 10.1136/bmj.285.6342.608; FRY WJ, 1954, J NEUROSURG, V11, P471, DOI 10.3171/jns.1954.11.5.0471; GOLDMAN MS, 1992, STEREOT FUNCT NEUROS, V58, P22, DOI 10.1159/000098966; Ho AL, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1537; Hynynen K, 1997, RADIOLOGY, V204, P247, DOI 10.1148/radiology.204.1.9205255; Koller W, 1997, ANN NEUROL, V42, P292, DOI 10.1002/ana.410420304; Kumar K, 1999, STEREOT FUNCT NEUROS, V72, P47, DOI 10.1159/000029671; Lipsman N, 2013, LANCET NEUROL, V12, P462, DOI 10.1016/S1474-4422(13)70048-6; Lorenz D, 2006, MOVEMENT DISORD, V21, P1114, DOI 10.1002/mds.20884; Louis ED, 2015, PARKINSONISM RELAT D, V21, P729, DOI 10.1016/j.parkreldis.2015.04.019; Louis ED, 2010, MOVEMENT DISORD, V25, P534, DOI 10.1002/mds.22838; McDannold N, 2003, MAGNET RESON MED, V49, P1188, DOI 10.1002/mrm.10453; MEYERS R, 1959, J NEUROSURG, V16, P32, DOI 10.3171/jns.1959.16.1.0032; NELSON E, 1959, J NEUROPATH EXP NEUR, V18, P489, DOI 10.1097/00005072-195910000-00001; Schneier FR, 2001, J CLIN PSYCHIAT, V62, P367, DOI 10.4088/JCP.v62n0511; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Stacy MA, 2007, MOVEMENT DISORD, V22, P833, DOI 10.1002/mds.21412; Tasker RR, 1998, SURG NEUROL, V49, P145, DOI 10.1016/S0090-3019(97)00459-X; Troster AI, 2005, PARKINSONISM RELAT D, V11, P367, DOI 10.1016/j.parkreldis.2005.05.009; WINKLER GF, 1974, NEW ENGL J MED, V290, P984, DOI 10.1056/NEJM197405022901802; Wintermark M, 2014, AM J NEURORADIOL, V35, P891, DOI 10.3174/ajnr.A3808; Witjas T, 2015, NEUROLOGY, V85, P1562, DOI 10.1212/WNL.0000000000002087; Zesiewicz TA, 2005, NEUROLOGY, V64, P2008, DOI 10.1212/01.WNL.0000163769.28552.CD; Zirh A, 1999, J NEUROL NEUROSUR PS, V66, P772, DOI 10.1136/jnnp.66.6.772	34	521	537	5	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2016	375	8					730	739		10.1056/NEJMoa1600159	http://dx.doi.org/10.1056/NEJMoa1600159			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT9ET	27557301	Bronze			2023-01-03	WOS:000381799300011
J	Mishra, T; Arya, RK; Meena, S; Joshi, P; Pal, M; Meena, B; Upreti, DK; Rana, TS; Datta, D				Mishra, Tripti; Arya, Rakesh Kumar; Meena, Sanjeev; Joshi, Pushpa; Pal, Mahesh; Meena, Baleshwar; Upreti, D. K.; Rana, T. S.; Datta, Dipak			Isolation, Characterization and Anticancer Potential of Cytotoxic Triterpenes from Betula utilis Bark	PLOS ONE			English	Article							URSOLIC ACID	Betula utilis, also known as Himalayan silver birch has been used as a traditional medicine for many health ailments like inflammatation, HIV, renal and bladder disorders as well as many cancers from ages. Here, we performed bio-guided fractionation of Betula utilis Bark (BUB), in which it was extracted in methanol and fractionated with hexane, ethyl acetate, chloroform, n-butanol and water. All six fractions were evaluated for their in-vitro anticancer activity in nine different cancer cell lines and ethyl acetate fraction was found to be one of the most potent fractions in terms of inducing cytotoxic activity against various cancer cell lines. By utilizing column chromatography, six triterpenes namely betulin, betulinic acid, lupeol, ursolic acid (UA), oleanolic acid and beta-amyrin have been isolated from the ethyl acetate extract of BUB and structures of these compounds were unraveled by spectroscopic methods. beta-amyrin and UA were isolated for the first time from Betula utilis. Isolated triterpenes were tested for in-vitro cytotoxic activity against six different cancer cell lines where UA was found to be selective for breast cancer cells over non-tumorigenic breast epithelial cells (MCF 10A). Tumor cell selective apoptotic action of UA was mainly attributed due to the activation of extrinsic apoptosis pathway via up regulation of DR4, DR5 and PARP cleavage in MCF-7 cells over non-tumorigenic MCF-10A cells. Moreover, UA mediated intracellular ROS generation and mitochondrial membrane potential disruption also play a key role for its anti cancer effect. UA also inhibits breast cancer migration. Altogether, we discovered novel source of UA having potent tumor cell specific cytotoxic property, indicating its therapeutic potential against breast cancer.	[Mishra, Tripti; Pal, Mahesh] CSIR Natl Bot Res Inst, Phytochem Div, Lucknow 226001, Uttar Pradesh, India; [Arya, Rakesh Kumar; Meena, Sanjeev; Datta, Dipak] CSIR Cent Drug Res Inst CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India; [Joshi, Pushpa] DSB Campus Kumaun Univ, Dept Chem, Naini Tal 263002, India; [Meena, Baleshwar; Upreti, D. K.; Rana, T. S.] CSIR Natl Bot Res Inst, Plant Divers Systemat & Herbarium Div, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Botanical Research Institute (NBRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Kumaun University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Botanical Research Institute (NBRI)	Pal, M (corresponding author), CSIR Natl Bot Res Inst, Phytochem Div, Lucknow 226001, Uttar Pradesh, India.; Datta, D (corresponding author), CSIR Cent Drug Res Inst CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India.	drmpal.nbri@rediffmail.com; dipak.datta@cdri.res.in	Arya, Rakesh/GQQ-7315-2022	MISHRA, Dr. TRIPTI/0000-0002-8918-2749	Council and Scientific and Industrial Research, New Delhi under the project 'Bio-prospection PR' [BSC0106]	Council and Scientific and Industrial Research, New Delhi under the project 'Bio-prospection PR'	The financial support received from the Council and Scientific and Industrial Research, New Delhi under the project 'Bio-prospection PR (BSC0106)'.; The authors are thankful to the Director, CSIR-National Botanical Research Institute, Lucknow, India for facilities and encouragements. The financial support received from the Council of Scientific and Industrial Research, New Delhi under the project 'Bio-prospection PR (BSC0106)' is duly acknowledged. The authors are also thankful to the authorities of the Govind Wildlife Sanctuary (Purola Forest Division) Uttarkashi Uttarakhand, India for providing permission and logistic support during survey of the area.	[Anonymous], [No title captured]; Arya RK, 2015, SCI REP-UK, V5, DOI 10.1038/srep18457; Bisht V. K., 2011, International Journal of Cancer Research (USA), V7, P192, DOI 10.3923/ijcr.2011.192.208; Chauhan N.S., 1999, MED AROMATIC PLANTS; Duan JP, 2015, SCI REP-UK, V5, DOI 10.1038/srep11725; IKUTA A, 1995, PHYTOCHEMISTRY, V38, P1203, DOI 10.1016/0031-9422(94)00445-Y; KHAN MA, 1975, PHYTOCHEMISTRY, V14, P789, DOI 10.1016/0031-9422(75)83036-6; KNIGHT SA, 1974, ORG MAGN RESONANCE, V6, P603, DOI 10.1002/mrc.1270061112; Krishnaswamy N, 1999, CHEM NATURAL PRODUCT; Kumaraswamy M.V., 2008, ADV BIOL RES, V2, P21; Lawless J, 1992, ENCY ESSENTIAL OILS; Mishra T, 2015, NATURAL PRODUCT RES, P1; Pal M, 2015, J ESSENT OIL BEAR PL, V18, P1078, DOI 10.1080/0972060X.2015.1036569; Pal M, 2015, CHEM NAT COMPD+, V51, P326, DOI 10.1007/s10600-015-1271-2; Plante MK, 2013, PROSTATE CANCER P D, V16, P16, DOI 10.1038/pcan.2012.37; Prachayasittikul S, 2010, EXCLI J, V9, P1; Rastogi S, 2015, J ETHNOPHARMACOL, V159, P62, DOI 10.1016/j.jep.2014.11.010; Seebacher W, 2003, MAGN RESON CHEM, V41, P636, DOI 10.1002/mrc.1214; Selvam A. B. D., 2008, Pharmacognosy Reviews, V2, P61; Shanmugam MK, 2013, BIOCHEM PHARMACOL, V85, P1579, DOI 10.1016/j.bcp.2013.03.006; The Ayurvedic Pharmacopeia of India, AYURV PHARM IND 1; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wichtl M, 2004, HERBAL DRUGS PHYTOPH	23	40	45	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2016	11	7							e0159430	10.1371/journal.pone.0159430	http://dx.doi.org/10.1371/journal.pone.0159430			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5ID	27453990	Green Published, gold, Green Submitted			2023-01-03	WOS:000381515200017
J	Villa-Bellosta, R; Gonzalez-Parra, E; Egido, J				Villa-Bellosta, Ricardo; Gonzalez-Parra, Emilio; Egido, Jesus			Alkalosis and Dialytic Clearance of Phosphate Increases Phosphatase Activity: A Hidden Consequence of Hemodialysis	PLOS ONE			English	Article							EXTRACELLULAR PYROPHOSPHATE METABOLISM; VASCULAR SMOOTH-MUSCLE; CHRONIC KIDNEY-DISEASE; ARTERIAL CALCIFICATION; AORTIC CALCIFICATION; MORTALITY RISK; MOUSE MODEL; CALCIUM; MUTATIONS; PRODUCT	Background Extracellular pyrophosphate is a potent endogenous inhibitor of vascular calcification, which is degraded by alkaline phosphatase (ALP) and generated by hydrolysis of ATP via ectonucleotide pyrophosphatase/phosphodiesterase 1 (eNPP1). ALP activity (as routinely measured in clinical practice) represents the maximal activity (in ideal conditions), but not the real activity (in normal or physiological conditions). For the first time, the present study investigated extracellular pyrophosphate metabolism during hemodialysis sessions (including its synthesis via eNPP1 and its degradation via ALP) in physiological conditions. Methods and Findings 45 patients in hemodialysis were studied. Physiological ALP activity represents only 4-6% of clinical activity. ALP activity increased post-hemodialysis by 2% under ideal conditions (87.4 +/- 3.3 IU/L vs. 89.3 +/- 3.6 IU/L) and 48% under physiological conditions (3.5 +/- 0.2 IU/L vs. 5.2 +/- 0.2 IU/L). Pyrophosphate synthesis by ATP hydrolysis remained unaltered posthemodialysis. Post-hemodialysis plasma pH (7.45 +/- 0.02) significantly increased compared with the pre-dialysis pH (7.26 +/- 0.02). The slight variation in pH (similar to 0.2 units) induced a significant increase in ALP activity (9%). Addition of phosphate in post-hemodialysis plasma significantly decreased ALP activity, although this effect was not observed with the addition of urea. Reduction in phosphate levels and increment in pH were significantly associated with an increase in physiological ALP activity post-hemodialysis. A decrease in plasma pyrophosphate levels (3.3 +/- 0.3 mu mol/L vs. 1.9 +/- 0.1 mu mol/L) and pyrophosphate/ATP ratio (1.9 +/- 0.2 vs. 1.4 +/- 0.1) post-hemodialysis was also observed. Conclusion Extraction of uremic toxins, primarily phosphate and hydrogen ions, dramatically increases the ALP activity under physiological conditions. This hitherto unknown consequence of hemodialysis suggests a reinterpretation of the clinical value of this parameter.	[Villa-Bellosta, Ricardo] Fdn Jimenez Diaz FIIS FJD, Fdn Inst Invest Sanitaria, Madrid, Spain; [Villa-Bellosta, Ricardo; Egido, Jesus] Spanish Biomed Res Network Diabet & Associated Me, Madrid, Spain; [Gonzalez-Parra, Emilio; Egido, Jesus] Autonomous Univ Madrid, Div Renal, Fdn Jimenez Diaz, Univ Hosp, Madrid, Spain	Fundacion Jimenez Diaz; Autonomous University of Madrid; Fundacion Jimenez Diaz	Villa-Bellosta, R (corresponding author), Fdn Jimenez Diaz FIIS FJD, Fdn Inst Invest Sanitaria, Madrid, Spain.; Villa-Bellosta, R (corresponding author), Spanish Biomed Res Network Diabet & Associated Me, Madrid, Spain.	ricardo.villa@fjd.es		Villa-Bellosta, Ricardo/0000-0002-1680-552X	Spanish Ministerio de Economia y Competitividad (MINECO); Instituto de Salud Carlos III (ISC-III) ("Sara Borrell") [CD14/00198]; ISC-III and FEDER [PI14/00386]; Foundation SENEFRO (Spanish Nephrology Society); FRIAT (Fundacion Renal Inigo Alvarez de Toledo); FEDER (European fund for Regional Development) [SAF-2014-60699-JIN]	Spanish Ministerio de Economia y Competitividad (MINECO); Instituto de Salud Carlos III (ISC-III) ("Sara Borrell"); ISC-III and FEDER; Foundation SENEFRO (Spanish Nephrology Society); FRIAT (Fundacion Renal Inigo Alvarez de Toledo); FEDER (European fund for Regional Development)(European Commission)	This study was supported by grants given to RV-B. from the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER (European fund for Regional Development) (SAF-2014-60699-JIN); and Instituto de Salud Carlos III (ISC-III) ("Sara Borrell" CD14/00198 postdoctoral contract). JE was supported by grants of ISC-III and FEDER (PI14/00386), Foundation SENEFRO (Spanish Nephrology Society) and FRIAT (Fundacion Renal Inigo Alvarez de Toledo). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albright RA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10006; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Johnson K, 2005, ARTERIOSCL THROM VAS, V25, P686, DOI 10.1161/01.ATV.0000154774.71187.f0; Kraut JA, 2016, AM J KIDNEY DIS, V67, P307, DOI 10.1053/j.ajkd.2015.08.028; Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26; Lomashvili KA, 2005, J AM SOC NEPHROL, V16, P2495, DOI 10.1681/ASN.2004080694; Lomashvili KA, 2014, KIDNEY INT, V85, P1351, DOI 10.1038/ki.2013.521; Malberti F, 2013, DRUGS, V73, P673, DOI 10.1007/s40265-013-0054-y; O'Neill WC, 2007, KIDNEY INT, V72, P792, DOI 10.1038/sj.ki.5002412; O'Neill WC, 2011, KIDNEY INT, V79, P512, DOI 10.1038/ki.2010.461; Riser BL, 2011, NEPHROL DIAL TRANSPL, V26, P3349, DOI 10.1093/ndt/gfr039; Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221; SCHIBLER D, 1968, CLIN SCI, V35, P363; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; SILCOX DC, 1973, J CLIN INVEST, V52, P1863, DOI 10.1172/JCI107369; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI 10.1056/NEJMc1102515; Villa-Bellosta R, 2015, EUR HEART J; Villa-Bellosta R, 2015, CURR CARDIOL REV, V11, P341, DOI 10.2174/1573403X11666150805120505; Villa-Bellosta R, 2013, CIRC J, V77, P2145, DOI 10.1253/circj.CJ-13-0016; Villa-Bellosta R, 2013, CIRCULATION, V127, P2442, DOI 10.1161/CIRCULATIONAHA.112.000571; Villa-Bellosta R, 2011, CIRC J, V75, P2705, DOI 10.1253/circj.CJ-11-0477; Villa-Bellosta R, 2011, AM J PHYSIOL-HEART C, V301, pH61, DOI 10.1152/ajpheart.01020.2010; Villa-Bellosta R, 2011, AM J PHYSIOL-CELL PH, V300, pC210, DOI 10.1152/ajpcell.00229.2010; Wang C, 2012, NAT GENET, V44, P254, DOI 10.1038/ng.1077	26	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2016	11	7							e0159858	10.1371/journal.pone.0159858	http://dx.doi.org/10.1371/journal.pone.0159858			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5ID	27454315	Green Published, gold, Green Submitted			2023-01-03	WOS:000381515200053
J	Martin, JE; Raffel, J; Nicholas, R				Martin, Jessica E.; Raffel, Joel; Nicholas, Richard			Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care	PLOS ONE			English	Article							PALLIATIVE CARE; UNMET NEEDS; PEOPLE; MORTALITY; SERVICE; TRIAL; DEATH; HOME	Introduction In the general ageing population, 40% of deaths occur following a prolonged trajectory of "progressive dwindling," characterised by chronic accumulation of disability and frailty, and associated with increased dependency and reduced reserves. Those who progressively dwindle are poorly catered for by current healthcare systems and would benefit from a coordinated approach to their medical and social care, known as formative care. People with multiple sclerosis (pwMS) may be more likely to progressively dwindle, and may be appropriate targets for formative care pathways. Objectives To determine the proportion of pwMS who follow a progressive dwindling trajectory prior to death. To relate trajectory to place of death, and examine what factors predict the progressively dwindling trajectory. Methods A retrospective observational study of 582 deceased pwMS enrolled in the UK MS Tissue Bank, including death certificates and extensive clinical summaries. Results 73.7% of pwMS had a "progressively dwindling" trajectory of dying. This was predicted by those who reach MS disease milestones earlier. 72.5% of pwMS died an MS-related death, which was predicted by an aggressive disease course from onset. Those who progressively dwindled were equally likely to die in hospital as those with other trajectories to death. Conclusions The progressively dwindling trajectory of dying is very common in pwMS, and can be predicted by earlier disease milestones. Pathways could target pwMS in these years prior to death, to improve care.	[Martin, Jessica E.; Raffel, Joel; Nicholas, Richard] Imperial Coll London, Dept Med, Div Brain Sci, Ctr Neuroinflammat & Neurodegenerat, London, England	Imperial College London	Nicholas, R (corresponding author), Imperial Coll London, Dept Med, Div Brain Sci, Ctr Neuroinflammat & Neurodegenerat, London, England.	r.nicholas@imperial.ac.uk			National Institute for Health Research; Parkinson&quot;s UK [J-1402] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); Parkinson&quot;s UK(Parkinson&apos;s UK)	Dr. Richard Nicholas is supported by the National Institute for Health Research.	[Anonymous], 2008, 9840 DEP HLTH REP; Borreani C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109679; Bowman C, 2014, J ROY SOC MED, V107, P95, DOI 10.1177/0141076813512298; Comptroller and Auditor General, 2019, CHALL US DAT GOV; Degenhardt A, 2009, NAT REV NEUROL, V5, P672, DOI 10.1038/nrneurol.2009.178; Edmonds P, 2010, MULT SCLER J, V16, P627, DOI 10.1177/1352458510364632; Galushko M, 2014, J PALLIAT MED, V17, P274, DOI 10.1089/jpm.2013.0497; Goldacre MJ, 2010, J NEUROL, V257, P706, DOI 10.1007/s00415-009-5392-z; Golla H, 2015, PALLIAT SUPPORT CARE, V13, P1685, DOI 10.1017/S1478951515000607; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Higginson IJ, 2011, POSTGRAD MED J, V87, P769, DOI 10.1136/postgradmedj-2011-130290; Higginson IJ, 2009, J PAIN SYMPTOM MANAG, V38, P816, DOI 10.1016/j.jpainsymman.2009.07.002; Hirst C, 2008, J NEUROL NEUROSUR PS, V79, P1016, DOI 10.1136/jnnp.2007.127332; Jick SS, 2014, J NEUROL, V261, P1508, DOI 10.1007/s00415-014-7370-3; Koffman J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075431; Lynn J, 2003, LIVING WELL END LIFE; Moens K, 2014, J PAIN SYMPTOM MANAG, V48, P660, DOI 10.1016/j.jpainsymman.2013.11.009; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murtagh FEM, 2014, PALLIATIVE MED, V28, P49, DOI 10.1177/0269216313489367; Office for National Statistics, 2013, DEATHS ENGL WAL 2013; Office for National Statistics, SUIC UK 2013; Parliamentary and Health Service Ombudsman, DYING DIGN 2015; Pring A., 2013, CLASSIFICATION PLACE; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; Reynolds R, 2011, ACTA NEUROPATHOL, V122, P155, DOI 10.1007/s00401-011-0840-0; Scalfari A, 2013, NEUROLOGY, V81, P184, DOI 10.1212/WNL.0b013e31829a3388; Shipman C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1720; Sleeman KE, 2013, PALLIATIVE MED, V27, P840, DOI 10.1177/0269216313490436; Solari A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0695-0; Strupp J, 2014, J PALLIAT MED, V17, P1128, DOI 10.1089/jpm.2013.0667	30	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2016	11	7							e0159210	10.1371/journal.pone.0159210	http://dx.doi.org/10.1371/journal.pone.0159210			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS5CG	27441557	Green Submitted, gold, Green Published			2023-01-03	WOS:000380797500044
J	Laursen, L				Laursen, Lucas			PALLIATIVE CARE The other opioid issue	NATURE			English	Editorial Material																			0	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2016	535	7611					S16	S17		10.1038/535S16a	http://dx.doi.org/10.1038/535S16a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR4ZN	27410527	Bronze			2023-01-03	WOS:000379912600011
J	Rosinach, M; Fernandez-Banares, F; Carrasco, A; Ibarra, M; Temino, R; Salas, A; Esteve, M				Rosinach, Merce; Fernandez-Banares, Fernando; Carrasco, Anna; Ibarra, Montserrat; Temino, Rocio; Salas, Antonio; Esteve, Maria			Double-Blind Randomized Clinical Trial: Gluten versus Placebo Rechallenge in Patients with Lymphocytic Enteritis and Suspected Celiac Disease	PLOS ONE			English	Article							INTRAEPITHELIAL LYMPHOCYTOSIS; SENSITIVITY; DUODENOSIS; DISORDERS; DIAGNOSIS; ETIOLOGY; SPECTRUM	Background The role of gluten as a trigger of symptoms in non-coeliac gluten sensitivity has been questioned. Aim To demonstrate that gluten is the trigger of symptoms in a subgroup of patients fulfilling the diagnostic criteria for non-coeliac gluten sensitivity (NCGS), which presented with lymphocytic enteritis, positive celiac genetics and negative celiac serology. Methods Double-blind randomized clinical trial of gluten vs placebo rechallenge. Inclusion criteria: >18 years of age, HLA-DQ2/8+, negative coeliac serology and gluten-dependent lymphocytic enteritis, and GI symptoms, with clinical and histological remission at inclusion. Eighteen patients were randomised: 11 gluten (20 g/day) and 7 placebo. Clinical symptoms, quality of life (GIQLI), and presence of gamma/delta+ cells and transglutaminase deposits were evaluated. Results 91% of patients had clinical relapse during gluten challenge versus 28.5% after placebo (p = 0.01). Clinical scores and GIQLI worsened after gluten but not after placebo (p<0.01). The presence of coeliac tissue markers at baseline biopsy on a gluten-free diet allowed classifying 9 out of the 18 (50%) patients as having probable 'coeliac lite' disease. Conclusion This proof-of-concept study indicates that gluten is the trigger of symptoms in a subgroup of patients fulfilling the diagnostic criteria for NCGS. They were characterized by positive celiac genetics, lymphocytic enteritis, and clinical and histological remission after a gluten-free diet.	[Rosinach, Merce; Fernandez-Banares, Fernando; Carrasco, Anna; Ibarra, Montserrat; Temino, Rocio; Esteve, Maria] Hosp Univ Mutua Terrassa, Dept Gastroenterol, Barcelona, Spain; [Rosinach, Merce; Fernandez-Banares, Fernando; Carrasco, Anna; Salas, Antonio; Esteve, Maria] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain; [Salas, Antonio] Hosp Univ Mutua Terrassa, Dept Pathol, Barcelona, Spain	Hospital Universitario Mutua Terrassa; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Hospital Universitario Mutua Terrassa	Fernandez-Banares, F (corresponding author), Hosp Univ Mutua Terrassa, Dept Gastroenterol, Barcelona, Spain.; Fernandez-Banares, F (corresponding author), Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.	ffbanares@mutuaterrassa.es		Carrasco, Anna/0000-0001-8810-1583; ESTEVE, MARIA/0000-0002-3178-7008; ESTEVE, MARIA/0000-0001-7716-0027; Fernandez-Banares, Fernando/0000-0002-1489-504X	'Fundacion Mutua Madrilena' (Madrid, Spain)	'Fundacion Mutua Madrilena' (Madrid, Spain)	This study was funded by a grant from the 'Fundacion Mutua Madrilena' (Madrid, Spain). This sponsor had no role in the study design, acquisition, analysis or interpretation of the data, or the report writing.	Aziz I, 2010, ALIMENT PHARM THER, V32, P1392, DOI 10.1111/j.1365-2036.2010.04477.x; Aziz I, 2015, J CLIN GASTROENTEROL, V49, P477, DOI 10.1097/MCG.0000000000000184; Biesiekierski JR, 2013, GASTROENTEROLOGY, V145, P320, DOI 10.1053/j.gastro.2013.04.051; Biesiekierski JR, 2011, AM J GASTROENTEROL, V106, P508, DOI 10.1038/ajg.2010.487; Brown I, 2006, ARCH PATHOL LAB MED, V130, P1020; Camarero C, 2000, ACTA PAEDIATR, V89, P285, DOI 10.1080/080352500750028410; Catassi C, 2010, AM J MED, V123, P691, DOI 10.1016/j.amjmed.2010.02.019; Di Sabatino A, 2015, CLIN GASTROENTEROL H, V13, P1604, DOI 10.1016/j.cgh.2015.01.029; Ferch Courtney C, 2012, Gastroenterology, V142, P664, DOI 10.1053/j.gastro.2012.01.020; Fernandez-Banares F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101249; Hayat M, 2002, J CLIN PATHOL, V55, P393, DOI 10.1136/jcp.55.5.393; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Husby S, 2014, J PEDIATR-US, V164, P436, DOI 10.1016/j.jpeds.2013.11.024; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; Kaukinen K, 2000, SCAND J GASTROENTERO, V35, P942, DOI 10.1080/003655200750022995; Koskinen O, 2010, J CLIN GASTROENTEROL, V44, P483, DOI 10.1097/MCG.0b013e3181b64557; Kurppa K, 2009, GASTROENTEROLOGY, V136, P816, DOI 10.1053/j.gastro.2008.11.040; Maglio M, 2011, DIGEST LIVER DIS, V43, P604, DOI 10.1016/j.dld.2011.01.015; Mahadeva S, 2002, J CLIN PATHOL, V55, P424, DOI 10.1136/jcp.55.6.424; Molina-Infante J, 2015, ALIMENT PHARM THER, V41, P807, DOI 10.1111/apt.13155; Polvi A, 1998, HUM IMMUNOL, V59, P169, DOI 10.1016/S0198-8859(98)00008-1; Quintana JM, 2001, REV ESP ENFERM DIG, V93, P700; Rosinach M, 2012, DIGEST LIVER DIS, V44, P643, DOI 10.1016/j.dld.2012.03.006; Rostami K, 2015, WORLD J GASTROENTERO, V21, P2593, DOI 10.3748/wjg.v21.i9.2593; Santolaria S, 2013, GASTROENT HEPAT-BARC, V36, P565, DOI 10.1016/j.gastrohep.2013.06.003; Sapone A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-13; Sapone A, 2010, INT ARCH ALLERGY IMM, V152, P75, DOI 10.1159/000260087; Shahbazkhani B, 2015, NUTRIENTS, V7, P4542, DOI 10.3390/nu7064542; Volta U, 2015, BEST PRACT RES CL GA, V29, P477, DOI 10.1016/j.bpg.2015.04.006; Volta U, 2013, CELL MOL IMMUNOL, V10, P383, DOI 10.1038/cmi.2013.28; Zanini B, 2015, ALIMENT PHARM THER, V42, P968, DOI 10.1111/apt.13372	31	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0157879	10.1371/journal.pone.0157879	http://dx.doi.org/10.1371/journal.pone.0157879			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27392045	Green Submitted, Green Published, gold			2023-01-03	WOS:000380005400024
J	Haukoos, JS; Sasson, C				Haukoos, Jason S.; Sasson, Comilla			Is Prehospital Advanced Life Support Harmful? RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									[Haukoos, Jason S.] Denver Hlth Med Ctr, Denver, CO 80204 USA; [Sasson, Comilla] Univ Colorado, Sch Med, Aurora, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus	Haukoos, JS (corresponding author), Denver Hlth Med Ctr, Denver, CO 80204 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS021749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106057] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Sanghavi P, 2015, ANN INTERN MED, V163, P681, DOI 10.7326/M15-0557; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Stiell IG, 2007, NEW ENGL J MED, V356, P2156, DOI 10.1056/NEJMoa060334; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Tatsioni A, 2007, JAMA-J AM MED ASSOC, V298, P2517, DOI 10.1001/jama.298.21.2517	6	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2016	165	1					71	71		10.7326/L16-5011	http://dx.doi.org/10.7326/L16-5011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ5AD	27380291				2023-01-03	WOS:000379215800021
J	Thorburn, AN; Tseng, HY; Donovan, C; Hansbro, NG; Jarnicki, AG; Foster, PS; Gibson, PG; Hansbro, PM				Thorburn, Alison N.; Tseng, Hsin-Yi; Donovan, Chantal; Hansbro, Nicole G.; Jarnicki, Andrew G.; Foster, Paul S.; Gibson, Peter G.; Hansbro, Philip M.			TLR2, TLR4 AND MyD88 Mediate Allergic Airway Disease (AAD) and Streptococcus pneumoniae-Induced Suppression of AAD	PLOS ONE			English	Article							REGULATORY T-CELLS; OBSTRUCTIVE PULMONARY-DISEASE; TOLL-LIKE RECEPTOR-4; RESPIRATORY-INFECTION; IMMUNE-RESPONSE; COMPONENTS; LIPOPOLYSACCHARIDE; EXPRESSION; AGONISTS; RECOGNITION	Background Exposure to non-pathogenic Streptococcus pneumoniae and vaccination are inversely associated with asthma. Studies in animal models demonstrate that airway administration of S. pneumoniae (live or killed), or its vaccines or components, suppresses the characteristic features of asthma in mouse models of allergic airway disease (AAD). These components could be developed into immunoregulatory therapies. S. pneumoniae components are recognized by Toll-like receptors (TLR) 2 and TLR4, and both induce inflammatory cell responses through the adaptor protein myeloid differentiation primary response gene 88 (MyD88). The involvement of TLR2, TLR4 and MyD88 in the pathogenesis of AAD and asthma is incompletely understood, and has not been studied in S. pneumoniae-mediated suppression of AAD. We investigated the role of TLR2, TLR4 and MyD88 in the development of AAD and S. pneumoniae-mediated suppression of AAD. Methods and Findings OVA-induced AAD and killed S. pneumoniae-mediated suppression of AAD were assessed in wild-type, TLR2(-/-), TLR4(-/-), TLR2/4(-/-) and MyD88(-/-) BALB/c mice. During OVA-induced AAD, TLR2, TLR4 and MyD88 were variously involved in promoting eosinophil accumulation in bronchoalveolar lavage fluid and blood, and T-helper type (Th) 2 cytokine release from mediastinal lymph node T cells and splenocytes. However, all were required for the induction of airways hyperresponsiveness (AHR). In S. pneumoniae-mediated suppression of AAD, TLR2, TLR4 and MyD88 were variously involved in the suppression of eosinophilic and splenocyte Th2 responses but all were required for the reduction in AHR. Conclusions These results highlight important but complex roles for TLR2, TLR4 and MyD88 in promoting the development of OVA-induced AAD, but conversely in the S. pneumoniae-mediated suppression of AAD, with consistent and major contributions in both the induction and suppression of AHR. Thus, TLR signaling is likely required for both the development of asthma and the suppression of asthma by S. pneumoniae, and potentially other immunoregulatory therapies.	[Hansbro, Philip M.] Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; Univ Newcastle, Newcastle, NSW 2300, Australia	Hunter Medical Research Institute; University of Newcastle; University of Newcastle	Hansbro, PM (corresponding author), Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia.	Philip.Hansbro@newcastle.edu.au	Hansbro, Phil/G-7486-2013; Foster, Paul/G-5057-2013; Tseng, Cindy Hsin-Yi/AAB-8958-2022; gibson, peter/G-6194-2014	Hansbro, Phil/0000-0002-4741-3035; Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; , Paul/0000-0002-0827-8299; gibson, peter/0000-0001-5865-489X	Hill family; Asthma Foundation of NSW; Australian Research Council of Australia [DP110101107]; NHMRC [1079187]; Gladys Brawn Memorial Trust; Medical Research Council [MR/K006584/1] Funding Source: researchfish	Hill family; Asthma Foundation of NSW; Australian Research Council of Australia(Australian Research Council); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Gladys Brawn Memorial Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	PMH was funded to perform these studies by The Hill family and the Asthma Foundation of NSW, and Australian Research Council (DP110101107) of Australia. PMH is supported by Research Fellowships from the NHMRC (1079187) and the Gladys Brawn Memorial Trust.	Albiger B, 2007, CELL MICROBIOL, V9, P633, DOI 10.1111/j.1462-5822.2006.00814.x; Aryan Z, 2014, INT ARCH ALLERGY IMM, V164, P46, DOI 10.1159/000362553; Asquith KL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001339; Beckett EL, 2013, J ALLERGY CLIN IMMUN, V131, P752, DOI 10.1016/j.jaci.2012.11.053; Beckett EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039460; Beigelman A, 2014, CURR OPIN ALLERGY CL, V14, P137, DOI 10.1097/ACI.0000000000000036; Bjornvold M, 2009, GENES IMMUN, V10, P181, DOI 10.1038/gene.2008.100; Bortolatto J, 2008, CLIN EXP ALLERGY, V38, P1668, DOI 10.1111/j.1365-2222.2008.03036.x; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Clarke TB, 2011, CELL HOST MICROBE, V9, P404, DOI 10.1016/j.chom.2011.04.012; Conroy H, 2008, ONCOGENE, V27, P168, DOI 10.1038/sj.onc.1210910; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Essilfie AT, 2015, THORAX, V70, P458, DOI 10.1136/thoraxjnl-2014-206067; Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160; Essilfie AT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002244; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; Goodridge HS, 2007, PARASITE IMMUNOL, V29, P127, DOI 10.1111/j.1365-3024.2006.00926.x; Hallstrand TS, 2014, CLIN IMMUNOL, V151, P1, DOI 10.1016/j.clim.2013.12.003; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hansbro PM, 2014, J BIOL CHEM, V289, P18214, DOI 10.1074/jbc.M114.548594; Hansbro PM, 2013, EXPERT OPIN INV DRUG, V22, P49, DOI 10.1517/13543784.2013.732997; Hardy MP, 2004, BIOCHEM J, V380, P83, DOI 10.1042/BJ20040030; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hollingsworth JW, 2006, J IMMUNOL, V176, P5856, DOI 10.4049/jimmunol.176.10.5856; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; Horvat JC, 2010, J IMMUNOL, V184, P4159, DOI 10.4049/jimmunol.0902287; Horvat JC, 2010, J ALLERGY CLIN IMMUN, V125, P617, DOI 10.1016/j.jaci.2009.10.018; Hsu ACY, 2015, AM J RESP CRIT CARE, V191, P1012, DOI 10.1164/rccm.201501-0188OC; Hu XY, 2008, IMMUNOL REV, V226, P41, DOI 10.1111/j.1600-065X.2008.00707.x; Kaiko GE, 2008, J IMMUNOL, V180, P2225, DOI 10.4049/jimmunol.180.4.2225; Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x; Kenny EF, 2009, J IMMUNOL, V183, P3642, DOI 10.4049/jimmunol.0901140; Klein M, 2008, J INFECT DIS, V198, P1028, DOI 10.1086/591626; Koedel U, 2004, BRAIN, V127, P1437, DOI 10.1093/brain/awh171; Krishnaswamy JK, 2012, AM J RESP CELL MOL, V47, P852, DOI 10.1165/rcmb.2011-0414OC; Letiembre M, 2005, INFECT IMMUN, V73, P8397, DOI 10.1128/IAI.73.12.8397-8401.2005; Liu Y, 2001, INFECT IMMUN, V69, P2788, DOI 10.1128/IAI.69.5.2788-2796.2001; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Patel PS, 2015, J IMMUNOL, V194, P5838, DOI 10.4049/jimmunol.1500251; Preston JA, 2011, EUR RESPIR J, V37, P53, DOI 10.1183/09031936.00049510; Preston JA, 2007, VACCINE, V25, P8154, DOI 10.1016/j.vaccine.2007.09.034; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; Regueiro V, 2009, INFECT IMMUN, V77, P714, DOI 10.1128/IAI.00852-08; Schmeck B, 2006, RESP RES, V7, P7149; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Shalaby KH, 2012, J IMMUNOL, V189, P2793, DOI 10.4049/jimmunol.1201194; Starkey MR, 2013, MUCOSAL IMMUNOL, V6, P569, DOI 10.1038/mi.2012.99; Starkey MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042588; Starkey MR, 2013, CURR OPIN PHARMACOL, V13, P337, DOI 10.1016/j.coph.2013.03.005; Starkhammar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104114; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; Tay HL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004549; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Thorburn AN, 2013, J IMMUNOL, V191, P4112, DOI 10.4049/jimmunol.1201232; Thorburn AN, 2012, J IMMUNOL, V188, P4611, DOI 10.4049/jimmunol.1101299; Thorburn AN, 2010, THORAX, V65, P1053, DOI 10.1136/thx.2009.131508; Thorburn AN, 2010, AM J RESP CELL MOL, V43, P511, DOI 10.1165/rcmb.2009-0342TR; Tomlinson G, 2014, J IMMUNOL, V193, P3736, DOI 10.4049/jimmunol.1401413; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhu JK, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/781235	61	25	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0156402	10.1371/journal.pone.0156402	http://dx.doi.org/10.1371/journal.pone.0156402			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27309732	gold, Green Published			2023-01-03	WOS:000378029800003
J	De Stefano, C; Normand, D; Jabre, P; Azoulay, E; Kentish-Barnes, N; Lapostolle, F; Baubet, T; Reuter, PG; Javaud, N; Borron, SW; Vicaut, E; Adnet, F				De Stefano, Carla; Normand, Domitille; Jabre, Patricia; Azoulay, Elie; Kentish-Barnes, Nancy; Lapostolle, Frederic; Baubet, Thierry; Reuter, Paul-Georges; Javaud, Nicolas; Borron, Stephen W.; Vicaut, Eric; Adnet, Frederic			Family Presence during Resuscitation: A Qualitative Analysis from a National Multicenter Randomized Clinical Trial	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; WITNESSED RESUSCITATION; EMERGENCY-DEPARTMENT; RELATIVES; DEATH; CARE; INTERVENTIONS; GUIDELINES; EXPERIENCE; HEALTH	Background The themes of qualitative assessments that characterize the experience of family members offered the choice of observing cardiopulmonary resuscitation (CPR) of a loved one have not been formally identified. Methods and Findings In the context of a multicenter randomized clinical trial offering family members the choice of observing CPR of a patient with sudden cardiac arrest, a qualitative analysis, with a sequential explanatory design, was conducted. The aim of the study was to understand family members' experience during CPR. All participants were interviewed by phone at home three months after cardiac arrest. Saturation was reached after analysis of 30 interviews of a randomly selected sample of 75 family members included in the trial. Four themes were identified: 1-choosing to be actively involved in the resuscitation; 2-communication between the relative and the emergency care team; 3-perception of the reality of the death, promoting acceptance of the loss; 4-experience and reactions of the relatives who did or did not witness the CPR, describing their feelings. Twelve sub-themes further defining these four themes were identified. Transferability of our findings should take into account the country-specific medical system. Conclusions Family presence can help to ameliorate the pain of the death, through the feeling of having helped to support the patient during the passage from life to death and of having participated in this important moment. Our results showed the central role of communication between the family and the emergency care team in facilitating the acceptance of the reality of death.	[De Stefano, Carla; Jabre, Patricia; Lapostolle, Frederic; Reuter, Paul-Georges; Javaud, Nicolas; Adnet, Frederic] Hop Avicenne, AP HP, Urgences, Samu 93, F-93000 Bobigny, France; [Lapostolle, Frederic; Reuter, Paul-Georges; Javaud, Nicolas; Adnet, Frederic] Univ Paris 13, Paris Cite, EA 3509, F-93000 Bobigny, France; [Jabre, Patricia] Univ Paris 05, Ctr Rech Cardiovasc Paris, Inserm U970, Paris, France; [Jabre, Patricia] Hop Necker Enfants Malad, AP HP, Samu Paris, Paris, France; [Azoulay, Elie; Kentish-Barnes, Nancy] Hop St Louis, AP HP, Reanimat Med, Paris, France; [De Stefano, Carla; Normand, Domitille; Baubet, Thierry] Avicenne Hosp, AP HP, Dept Child & Adolescent Psychiat & Gen Psychiat, Paris, France; [De Stefano, Carla; Baubet, Thierry] Univ Paris 13, Paris Cite, Lab UTRPP EA 4403, Inserm 669, F-93000 Bobigny, France; [Borron, Stephen W.] Texas Tech Univ HSC, Dept Emergency Med, El Paso, TX USA; [Vicaut, Eric] Hop Fernand Widal, AP HP, Unite Rech Clin, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; Texas Tech University System; Texas Tech University Health Science Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	De Stefano, C (corresponding author), Hop Avicenne, AP HP, Urgences, Samu 93, F-93000 Bobigny, France.; De Stefano, C (corresponding author), Avicenne Hosp, AP HP, Dept Child & Adolescent Psychiat & Gen Psychiat, Paris, France.; De Stefano, C (corresponding author), Univ Paris 13, Paris Cite, Lab UTRPP EA 4403, Inserm 669, F-93000 Bobigny, France.	carla.destefano85@gmail.com	; Reuter, Paul-Georges/C-1347-2016	Baubet, Thierry/0000-0002-4112-1592; Reuter, Paul-Georges/0000-0001-9022-5876; kentish-barnes, nancy/0000-0003-0024-0429	French Ministry of Health; Research Delegation of the Assistance Publique - Hopitaux de Paris	French Ministry of Health; Research Delegation of the Assistance Publique - Hopitaux de Paris	This study was supported by the Programme Hospitalier de Recherche Clinique 2008 of the French Ministry of Health and by the Research Delegation of the Assistance Publique - Hopitaux de Paris. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Boyd R, 2000, RESUSCITATION, V43, P171, DOI 10.1016/S0300-9572(99)00147-1; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Chapple A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2032; Compton S, 2009, ACAD EMERG MED, V16, P226, DOI 10.1111/j.1553-2712.2008.00336.x; David N, 2008, CONSCIOUS COGN, V17, P523, DOI 10.1016/j.concog.2008.03.004; DOYLE CJ, 1987, ANN EMERG MED, V16, P673, DOI 10.1016/S0196-0644(87)80069-0; DUBIN WR, 1986, ANN EMERG MED, V15, P54, DOI 10.1016/S0196-0644(86)80488-7; Fulbrook Paul, 2007, Eur J Cardiovasc Nurs, V6, P255, DOI 10.1016/j.ejcnurse.2007.07.003; Gallagher S, 2000, TRENDS COGN SCI, V4, P14, DOI 10.1016/S1364-6613(99)01417-5; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; Jabre P, 2014, INTENS CARE MED, V40, P981, DOI 10.1007/s00134-014-3337-1; Jabre P, 2013, NEW ENGL J MED, V368, P1008, DOI 10.1056/NEJMoa1203366; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lewin S, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3496; Lippert FK, 2010, RESUSCITATION, V81, P1445, DOI 10.1016/j.resuscitation.2010.08.013; Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9; Maxton FJC, 2008, J CLIN NURS, V17, P3168, DOI 10.1111/j.1365-2702.2008.02525.x; McClenathan BM, 2002, CHEST, V122, P2204, DOI 10.1378/chest.122.6.2204; Mcmahon-Parkes K, 2009, INT J NURS STUD, V46, P220, DOI 10.1016/j.ijnurstu.2008.08.007; Miller JH, 2009, QUAL HEALTH RES, V19, P1431, DOI 10.1177/1049732309348365; Morrison LJ, 2010, CIRCULATION, V122, pS665, DOI 10.1161/CIRCULATIONAHA.110.970905; Mortelmans LJM, 2010, EUR J EMERG MED, V17, P203, DOI 10.1097/MEJ.0b013e328331477e; O'Connell KJ, 2007, PEDIATRICS, V120, pE565, DOI 10.1542/peds.2006-2914; Osuagwu C C, 1991, J Emerg Nurs, V17, P363; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Rusinova K, 2009, CRIT CARE MED, V37, pS140, DOI [10.1097/CCM.0b013e31819207e7, 10.1097/CCM.0b013e3181b6e145]; Timmermans S, 1998, SOCIOL HEALTH ILL, V20, P144, DOI 10.1111/1467-9566.00095; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tsai E, 2002, NEW ENGL J MED, V346, P1019, DOI 10.1056/NEJM200203283461312; Wray N, 2007, QUAL HEALTH RES, V17, P1392, DOI 10.1177/1049732307308308	30	39	40	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2016	11	6							e0156100	10.1371/journal.pone.0156100	http://dx.doi.org/10.1371/journal.pone.0156100			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DN6XB	27253993	Green Published, Green Submitted, gold			2023-01-03	WOS:000377218700014
J	Sabir, H; Osredkar, D; Maes, E; Wood, T; Thoresen, M				Sabir, Hemmen; Osredkar, Damjan; Maes, Elke; Wood, Thomas; Thoresen, Marianne			Xenon Combined with Therapeutic Hypothermia Is Not Neuroprotective after Severe Hypoxia-Ischemia in Neonatal Rats	PLOS ONE			English	Article							BRAIN-INJURY; HYPOXIA/ISCHEMIA; INHIBITION; ANESTHESIA; ASPHYXIA; RECEPTOR; MODELS; DAMAGE; DEATH	Background Therapeutic hypothermia (TH) is standard treatment following perinatal asphyxia in newborn infants. Experimentally, TH is neuroprotective after moderate hypoxia-ischemia (HI) in seven-day-old (P7) rats. However, TH is not neuroprotective after severe HI. After a moderate HI insult in newborn brain injury models, the anesthetic gas xenon (Xe) doubles TH neuroprotection. The aim of this study was to examine whether combining Xe and TH is neuroprotective as applied in a P7 rat model of severe HI. Design/Methods 120 P7 rat pups underwent a severe HI insult; unilateral carotid artery ligation followed by hypoxia (8% O-2 for 150min at experimental normothermia (NT-37: T-rectal 37 degrees C). Surviving pups were randomised to immediate NT-37 for 5h (n = 36), immediate TH-32: T-rectal 32 degrees C for 5h (n = 25) or immediate TH-32 plus 50% inhaled Xe for 5h (n = 24). Pups were sacrificed after one week of survival. Relative area loss of the ligated hemisphere was measured, and neurons in the subventricular zone of this injured hemisphere were counted, to quantify brain damage. Results Following the HI insult, median (interquartile range, IQR) hemispheric brain area loss was similar in all groups: 63.5% (55.5-75.0) for NT-37 group, 65.0%(57.0-65.0) for TH-32 group, and 66.5% (59.0-72.0) for TH-32+Xe50% group (not significant). Correspondingly, there was no difference in neuronal cell count (NeuN marker) in the subventricular zone across the three treatment groups. Conclusions Immediate therapeutic hypothermia with or without additional 50% inhaled Xe, does not provide neuroprotection one week after severe HI brain injury in the P7 neonatal rat. This model aims to mimic the clinical situation in severely asphyxiated neonates and treatment these newborns remains an ongoing challenge.	[Sabir, Hemmen; Osredkar, Damjan; Maes, Elke; Wood, Thomas; Thoresen, Marianne] Univ Oslo, Inst Basic Med Sci, Dept Physiol, Oslo, Norway; [Sabir, Hemmen] Univ Dusseldorf, Dept Gen Pediat Neonatol & Pediat Cardiol, Dusseldorf, Germany; [Thoresen, Marianne] Univ Bristol, St Michaels Hosp, Sch Clin Sci, Bristol, Avon, England	University of Oslo; Heinrich Heine University Dusseldorf; University of Bristol	Thoresen, M (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Physiol, Oslo, Norway.; Thoresen, M (corresponding author), Univ Bristol, St Michaels Hosp, Sch Clin Sci, Bristol, Avon, England.	marianne.thoresen@medisin.uio.no	Wood, Thomas/GWZ-2481-2022; Osredkar, Damjan/B-6293-2011; Osredkar, Damjan/M-3739-2019; Wood, Tommy/AAC-8252-2019	Wood, Thomas/0000-0001-8962-8571; Osredkar, Damjan/0000-0002-2188-420X; Osredkar, Damjan/0000-0002-2188-420X; Wood, Tommy/0000-0002-1130-2720	Sport Aiding Medical Research for Kids (SPARKS, UK); Norwegian Research Council (NFR); Laerdal Foundation for Acute Medicine; Deutscher Akademischer Austauschdienst (DAAD); Sparks Charity [05BTL01, 14BTL01] Funding Source: researchfish	Sport Aiding Medical Research for Kids (SPARKS, UK); Norwegian Research Council (NFR)(Research Council of Norway); Laerdal Foundation for Acute Medicine; Deutscher Akademischer Austauschdienst (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Sparks Charity	This study was funded by Sport Aiding Medical Research for Kids (SPARKS, UK), Norwegian Research Council (NFR), The Laerdal Foundation for Acute Medicine, and Deutscher Akademischer Austauschdienst (DAAD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azzopardi D, 2016, LANCET NEUROL, V15, P145, DOI 10.1016/S1474-4422(15)00347-6; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Chakkarapani E, 2013, J CEREBR BLOOD F MET, V33, P1752, DOI 10.1038/jcbfm.2013.123; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; David HN, 2008, FASEB J, V22, P1275, DOI 10.1096/fj.07-9420com; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Dingley J, 2014, PEDIATRICS, V133, P809, DOI 10.1542/peds.2013-0787; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Gunn AJ, 1999, PEDIATR RES, V46, P274, DOI 10.1203/00006450-199909000-00005; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Laitio R, 2016, JAMA-J AM MED ASSOC, V315, P1120, DOI 10.1001/jama.2016.1933; Liu X, 2015, PEDIATR RES, V77, P779, DOI 10.1038/pr.2015.49; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Mallard C, 2015, STROKE, V46, P3006, DOI 10.1161/STROKEAHA.115.007776; Neukirchen M, 2012, BRIT J ANAESTH, V109, P887, DOI 10.1093/bja/aes303; Osredkar D, 2014, RESUSCITATION, V85, P567, DOI 10.1016/j.resuscitation.2013.12.006; Palmer GC, 2000, AMINO ACIDS, V19, P151, DOI 10.1007/s007260070043; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Romanko MJ, 2007, J NEUROCHEM, V103, P1121, DOI 10.1111/j.1471-4159.2007.04820.x; Sabir H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109845; Sabir H, 2013, ANESTHESIOLOGY, V119, P345, DOI 10.1097/ALN.0b013e318294934d; Sabir H, 2012, STROKE, V43, P3364, DOI 10.1161/STROKEAHA.112.674481; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Thoresen M, 1996, ARCH DIS CHILD-FETAL, V74, pF3, DOI 10.1136/fn.74.1.F3; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Wood T, 2016, SCI REP-UK, V6, DOI 10.1038/srep23430	30	23	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2016	11	6							e0156759	10.1371/journal.pone.0156759	http://dx.doi.org/10.1371/journal.pone.0156759			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN6XB	27253085	Green Published, gold, Green Submitted			2023-01-03	WOS:000377218700055
J	Xu, MM; Pu, Y; Weichselbaum, RR; Fu, YX				Xu, M. Michelle; Pu, Y.; Weichselbaum, R. R.; Fu, Y-X			Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy	ONCOGENE			English	Review							CYCLIC GMP-AMP; IMMUNOGENIC CELL-DEATH; CYTOSOLIC DNA SENSOR; I INTERFERON; CALRETICULIN EXPOSURE; IMMUNE-SYSTEM; TUMOR MICROENVIRONMENT; ANTI-CD20 ANTIBODY; METASTATIC CANCER; RADIATION	In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8(+) T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.	[Xu, M. Michelle; Weichselbaum, R. R.; Fu, Y-X] Univ Chicago, Dept Pathol & Radiat Oncol, Chicago, IL 60637 USA; [Xu, M. Michelle; Fu, Y-X] Univ Chicago, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA; [Pu, Y.; Fu, Y-X] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol & Immunol, Dallas, TX 75390 USA	University of Chicago; University of Chicago; University of Texas System; University of Texas Southwestern Medical Center Dallas	Weichselbaum, RR; Fu, YX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 6000 Harry Hines Blvd,ND6 200, Dallas, TX 75235 USA.	rrw@radonc.uchicago.edu; yang-xin.fu@utsouthwestern.edu			US National Institutes of Health [CA141975]; Ludwig Foundation; NATIONAL CANCER INSTITUTE [R01CA141975, R01CA134563] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was, in part, supported by US National Institutes of Health Grants CA141975 (to Y-XF), a grant from the Ludwig Foundation (to RRW) and a generous gift from The Foglia Foundation (to Y-XF and RRW).	Abes R, 2010, BLOOD, V116, P926, DOI 10.1182/blood-2009-10-248609; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Ahn J, 2012, P NATL ACAD SCI USA, V109, P19386, DOI 10.1073/pnas.1215006109; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Baselga J, 2001, ANN ONCOL, V12, P35, DOI 10.1023/A:1011163824080; Baselga J, 2001, EUR J CANCER, V37, pS16; Benavides LC, 2009, CLIN CANCER RES, V15, P2895, DOI 10.1158/1078-0432.CCR-08-1126; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Correale P, 2012, INT J CANCER, V130, P1577, DOI 10.1002/ijc.26181; Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806; Deng L, 2015, CLIN CANC RES; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; Dovedi SJ, 2013, BLOOD, V121, P251, DOI 10.1182/blood-2012-05-432393; Formenti SC, 2013, JNCI-J NATL CANCER I, V105, P256, DOI 10.1093/jnci/djs629; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Galluzzi L, 2014, ONCOTARGET, V5, P12472, DOI 10.18632/oncotarget.2998; Gameiro SR, 2014, ONCOTARGET, V5, P403, DOI 10.18632/oncotarget.1719; Gandhi SJ, 2015, CANCER LETT, V368, P185, DOI 10.1016/j.canlet.2015.03.024; Ganss R, 2002, CANCER RES, V62, P1462; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gehrmann M, 2005, CELL DEATH DIFFER, V12, P38, DOI 10.1038/sj.cdd.4401510; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Haynes NM, 2008, CURR OPIN IMMUNOL, V20, P545, DOI 10.1016/j.coi.2008.05.008; Hong WK, 2010, EMIL FREI III CANC M; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kurts C, 2010, NAT REV IMMUNOL, V10, P403, DOI 10.1038/nri2780; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Lim SH, 2011, BLOOD, V118, P2530, DOI 10.1182/blood-2011-01-330357; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345; Liu RR, 2012, CANCER IMMUNOL IMMUN, V61, P855, DOI 10.1007/s00262-011-1146-8; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Minard-Colin V, 2008, BLOOD, V112, P1205, DOI 10.1182/blood-2008-01-135160; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Salama JK, 2012, CANCER-AM CANCER SOC, V118, P2962, DOI 10.1002/cncr.26611; Schaue D, 2012, INT J RADIAT ONCOL, V83, P1306, DOI 10.1016/j.ijrobp.2011.09.049; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Stagg J, 2011, P NATL ACAD SCI USA, V108, P7142, DOI 10.1073/pnas.1016569108; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Suzuki Y, 2012, CANCER RES, V72, P3967, DOI 10.1158/0008-5472.CAN-12-0851; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Westover KD, 2015, LUNG CANCER, V89, P87, DOI 10.1016/j.lungcan.2015.04.009; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu CY, 2014, CLIN CANCER RES, V20, P644, DOI 10.1158/1078-0432.CCR-13-1334; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yang XM, 2013, MOL THER, V21, P91, DOI 10.1038/mt.2012.184; Zelenay S, 2013, TRENDS IMMUNOL, V34, P329, DOI 10.1016/j.it.2013.03.005; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845; Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891	86	10	10	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					585	592		10.1038/onc.2016.231	http://dx.doi.org/10.1038/onc.2016.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27425593	Green Accepted			2023-01-03	WOS:000394167700001
J	Klompas, M; Rhee, C				Klompas, Michael; Rhee, Chanu			The CMS Sepsis Mandate: Right Disease, Wrong Measure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							COMMUNITY-ACQUIRED PNEUMONIA; MEDICARE; TIME		Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Boston, MA USA; Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Klompas, Michael; Rhee, Chanu] Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Klompas, M (corresponding author), Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.	mklompas@partners.org	Rhee, Chanu/AAO-8368-2020; Klompas, Michael/Z-2415-2019					Angus DC, 2015, INTENS CARE MED, V41, P1549, DOI 10.1007/s00134-015-3822-1; Houck PM, 2004, ARCH INTERN MED, V164, P637, DOI 10.1001/archinte.164.6.637; Klouwenberg PMCK, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1035-1; Nicks BA, 2009, ACAD EMERG MED, V16, P184, DOI 10.1111/j.1553-2712.2008.00320.x; Quattromani E, 2011, ACAD EMERG MED, V18, P495, DOI 10.1111/j.1553-2712.2011.01053.x; Rhee C, 2016, INFECT CONT HOSP EP, V37, P163, DOI [10.1017/ice.2015.264, DOI 10.1017/ICE.2015.264]; Rhee C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1266-9; Seymour CW, 2016, CRIT CARE MED, V44, pE122, DOI 10.1097/CCM.0000000000001724; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Welker JA, 2008, ARCH INTERN MED, V168, P351, DOI 10.1001/archinternmed.2007.84	10	35	35	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 4	2016	165	7					517	+		10.7326/M16-0588	http://dx.doi.org/10.7326/M16-0588			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DY0EY	27294338				2023-01-03	WOS:000384771300010
J	Tannock, IF; Hickman, JA				Tannock, Ian F.; Hickman, John A.			Limits to Personalized Cancer Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							METASTATIC BREAST-CANCER; INTRATUMOR HETEROGENEITY; BRANCHED EVOLUTION; PRECISION MEDICINE; TRIAL; ADENOCARCINOMA; MULTICENTER; VEMURAFENIB; INHIBITION; SURVIVAL		[Tannock, Ian F.] Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada; [Tannock, Ian F.] Univ Toronto, Toronto, ON, Canada; [Hickman, John A.] AGON Paris, Paris, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Tannock, IF (corresponding author), Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada.; Tannock, IF (corresponding author), Univ Toronto, Toronto, ON, Canada.							Aisner D, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.11510; Amir E, 2011, J CLIN ONCOL, V29, P2543, DOI 10.1200/JCO.2011.35.2393; Andre F, 2014, LANCET ONCOL, V15, P267, DOI 10.1016/S1470-2045(13)70611-9; Bedard PL, 2016, CLIN CANCER RES, V22, DOI 10.1158/1557-3265.PMSCLINGEN15-PR03; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Bhattacharjee Y, 2012, SCIENCE, V338, P29, DOI 10.1126/science.338.6103.29; Biankin AV, 2015, NATURE, V526, P361, DOI 10.1038/nature15819; Bowen A, 2015, P NATL ACAD SCI USA, V112, P11335, DOI 10.1073/pnas.1504955112; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Carreira S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009448; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Dowsett M, 1995, CLIN CANCER RES, V1, P1511; Fojo T, 2014, JAMA OTOLARYNGOL, V140, P1225, DOI 10.1001/jamaoto.2014.1570; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gray SW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv030; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Johnson GL, 2014, CLIN CANCER RES, V20, P2516, DOI 10.1158/1078-0432.CCR-13-1081; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Lawler M, 2015, ONCOLOGIST, V20, P849, DOI 10.1634/theoncologist.2015-0014; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Liu S, 2016, ONCOTARGET, V7, P11310, DOI 10.18632/oncotarget.7023; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165; Murugaesu N, 2015, CANCER DISCOV, V5, P821, DOI 10.1158/2159-8290.CD-15-0412; National Cancer Institute, CANC MOONSH; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Scannell JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147215; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sohal DPS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv332; Swanton C, 2016, ANN ONCOL, V27, P1443, DOI 10.1093/annonc/mdw192; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886	37	241	261	2	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2016	375	13					1289	1294		10.1056/NEJMsb1607705	http://dx.doi.org/10.1056/NEJMsb1607705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DX3HU	27682039				2023-01-03	WOS:000384265000015
J	Brown, C				Brown, Carolyn			An elusive cancer target	NATURE			English	Editorial Material							RENAL-CELL CARCINOMA; EVEROLIMUS; SUNITINIB; TRIAL											Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016; Haas NB, 2016, LANCET, V387, P2008, DOI 10.1016/S0140-6736(16)00559-6; Motzer RJ, 2015, LANCET ONCOL, V16, P1473, DOI 10.1016/S1470-2045(15)00290-9; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989	4	46	46	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2016	537	7620					S106	S108		10.1038/537S106a	http://dx.doi.org/10.1038/537S106a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV7EC	27626779	hybrid			2023-01-03	WOS:000383098000005
J	Jiang, FZ; Jin, K; Huang, SY; Bao, Q; Shao, ZR; Hu, XQ; Ye, J				Jiang, Fangzhen; Jin, Kai; Huang, Shenyu; Bao, Qi; Shao, Zheren; Hu, Xueqing; Ye, Juan			Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells	PLOS ONE			English	Article							INDUCED APOPTOSIS; CANCER CELLS; IN-VITRO; GROWTH-INHIBITION; DEPHOSPHORYLATION; OSTEOSARCOMA; NANOLIPOSOME; C6-CERAMIDE; DEPENDENCE; PATHWAY	Melanoma is one common skin cancer. In the present study, the potential anti-melanoma activity by a liposomal C6 ceramide was tested in vitro. We showed that the liposomal C6 (ceramide) was cytotoxic and anti-proliferative against a panel of human melanoma cell lines (SK-Mel2, WM-266.4 and A-375 and WM-115). In addition, liposomal C6 induced caspase-dependent apoptotic death in the melanoma cells. Reversely, its cytotoxicity was attenuated by several caspase inhibitors. Intriguingly, liposomal C6 was non-cytotoxic to B10BR mouse melanocytes and primary human melanocytes. Molecularly, liposomal C6 activated protein phosphatase 1 (PP1) to inactivate Akt-mammalian target of rapamycin (mTOR) signaling in melanoma cells. On the other hand, PP1 shRNA knockdown or exogenous expression of constitutively activate Akt1 (CA-Akt1) restored Akt-mTOR activation and significantly attenuated liposomal C6-mediated cytotoxicity and apoptosis in melanoma cells. Our results suggest that liposomal C6 activates PP1 to inhibit melanoma cells.	[Jiang, Fangzhen; Bao, Qi; Shao, Zheren; Hu, Xueqing] Zhejiang Univ, Affiliated Hosp 2, Dept Plast & Reconstruct Surg, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China; [Jin, Kai; Huang, Shenyu; Ye, Juan] Zhejiang Univ, Affiliated Hosp 2, Dept Ophthalmol, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Jin, K (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Ophthalmol, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China.	drkaijinvip@sina.com			Zhejiang Key Laboratory fund of China [2011E10006]; Zhejiang Provincial Public Welfare Technical Program for Applied Research [2015C33180]	Zhejiang Key Laboratory fund of China; Zhejiang Provincial Public Welfare Technical Program for Applied Research	This work was generously supported by grants from Zhejiang Key Laboratory fund of China (2011E10006, to KJ) and Zhejiang Provincial Public Welfare Technical Program for Applied Research (2015C33180, to KJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adiseshaiah PP, 2013, CANCER LETT, V337, P254, DOI 10.1016/j.canlet.2013.04.034; Banerjee Hirendra Nath, 2012, J Cancer Sci Ther, V4, P12; Braeuer RR, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12172; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094; Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026; Dimanche-Boitrel MT, 2011, RECENT PAT ANTI-CANC, V6, P284, DOI 10.2174/157489211796957838; Eggermont AMM, 2014, NAT REV CLIN ONCOL, V11, P181, DOI 10.1038/nrclinonc.2014.36; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; Henry B., 2011, CANC LETT; Hu X, 2015, TUMOUR BIOL; Huo HZ, 2013, MOL CELL BIOCHEM, V378, P171, DOI 10.1007/s11010-013-1608-8; Hutchinson Lisa, 2015, Nat Rev Clin Oncol, V12, P1, DOI 10.1038/nrclinonc.2014.219; Hutchinson L, 2014, NAT REV CLIN ONCOL, V11, P299, DOI [10.1038/nrclinonc.2014.87, 10.1038/nrclinonc.2014.132]; Ilinykh PA, 2014, J BIOL CHEM, V289, P22723, DOI 10.1074/jbc.M114.575050; Ji C, 2010, ONCOGENE, V29, P6557, DOI 10.1038/onc.2010.379; Kester M, 2015, BIOL CHEM, V396, P737, DOI 10.1515/hsz-2015-0129; Kingwell K, 2014, NAT REV DRUG DISCOV, V13, P334, DOI 10.1038/nrd4314; Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398; Mullen T. D., 2011, ANTICANCER AGENTS ME; Mullen TD, 2012, ANTI-CANCER AGENT ME, V12, P340, DOI 10.2174/187152012800228661; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Populo H, 2012, EXPERT OPIN THER TAR, V16, P689, DOI 10.1517/14728222.2012.691472; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Ryland LK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084648; Schadendorf D, 2014, NAT REV CLIN ONCOL, V11, P75, DOI 10.1038/nrclinonc.2013.246; Shen J, 2015, TUMOUR BIOL; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Stover TC, 2005, CLIN CANCER RES, V11, P3465, DOI 10.1158/1078-0432.CCR-04-1770; Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010; Tagaram HRS, 2011, GUT, V60, P695, DOI 10.1136/gut.2010.216671; Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881; Ullal AJ, 2014, CLIN IMMUNOL, V154, P178, DOI 10.1016/j.clim.2014.05.007; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Webster RM, 2014, NAT REV DRUG DISCOV, V13, P491, DOI 10.1038/nrd4326; Wu L, 2015, BIOCHEM BIOPH RES CO, V466, P547, DOI 10.1016/j.bbrc.2015.09.068; Yang L, 2015, EXP CELL RES, V332, P47, DOI 10.1016/j.yexcr.2014.12.017; Yao C, 2012, MOL ONCOL, V6, P392, DOI 10.1016/j.molonc.2012.04.002; Yu T, 2010, CANCER CHEMOTH PHARM, V66, P999, DOI 10.1007/s00280-010-1374-1; Zhai L, 2015, BIOCHEM BIOPH RES CO, V468, P274, DOI 10.1016/j.bbrc.2015.10.113; Zhang P, 2015, SCI REP-UK, V5, DOI 10.1038/srep09275; Zolnik BS, 2008, DRUG METAB DISPOS, V36, P1709, DOI 10.1124/dmd.107.019679	43	15	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2016	11	9							e0159849	10.1371/journal.pone.0159849	http://dx.doi.org/10.1371/journal.pone.0159849			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5SJ	27631768	Green Published, Green Submitted, gold			2023-01-03	WOS:000383706900003
J	Marks, D; Bisset, L; Comans, T; Thomas, M; Ng, SK; O'Leary, S; Conaghan, PG; Scuffham, PA				Marks, Darryn; Bisset, Leanne; Comans, Tracy; Thomas, Michael; Ng, Shu Kay; O'Leary, Shaun; Conaghan, Philip G.; Scuffham, Paul A.			Increasing Capacity for the Treatment of Common Musculoskeletal Problems: A Non-Inferiority RCT and Economic Analysis of Corticosteroid Injection for Shoulder Pain Comparing a Physiotherapist and Orthopaedic Surgeon	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ADVERSE DRUG-REACTIONS; PRIMARY-HEALTH-CARE; ROTATOR CUFF TEARS; SUBACROMIAL IMPINGEMENT; EXERCISE THERAPY; GLOBAL BURDEN; DIAGNOSIS; QUESTIONNAIRE; RELIABILITY	Background Role substitution is a strategy employed to assist health services manage the growing demand for musculoskeletal care. Corticosteroid injection is a common treatment in this population but the efficacy of its prescription and delivery by physiotherapists has not been established against orthopaedic standards. This paper investigates whether corticosteroid injection given by a physiotherapist for shoulder pain is as clinically and cost effective as that from an orthopaedic surgeon. Methods A double blind non-inferiority randomized controlled trial was conducted in an Australian public hospital orthopaedic outpatient service, from January 2013 to June 2014. Adults with a General Practitioner referral to Orthopaedics for shoulder pain received subacromial corticosteroid and local anaesthetic injection prescribed and delivered independently by a physiotherapist or a consultant orthopaedic surgeon. The main outcome measure was total Shoulder Pain and Disability Index (SPADI) score at baseline, six and 12 weeks, applying a non-inferiority margin of 15 points. Secondary outcomes tested for superiority included pain, shoulder movement, perceived improvement, adverse events, satisfaction, quality of life and costs. Results 278 participants were independently assessed by the physiotherapist and the orthopaedic surgeon, with 64 randomised (physiotherapist 33, orthopaedic surgeon 31). There were no significant differences in baseline characteristics between groups. Non-inferiority of injection by the physiotherapist was declared from total SPADI scores at 6 and 12 weeks (upper limit of the 95% one-sided confidence interval 13.34 and 7.17 at 6 and 12 weeks, respectively). There were no statistically significant differences between groups on any outcome measures at 6 or 12 weeks. From the perspective of the health funder, the physiotherapist was less expensive. Conclusions Corticosteroid injection for shoulder pain, provided by a suitably qualified physiotherapist is at least as clinically effective, and less expensive, compared with similar care delivered by an orthopaedic surgeon. Policy makers and service providers should consider implementing this model of care.	[Marks, Darryn; Thomas, Michael] Gold Coast Univ Hosp, Gold Cost Hosp & Hlth Serv, 1 Hosp Blvd, Gold Coast, Qld 4215, Australia; [Marks, Darryn; Bisset, Leanne; Comans, Tracy; Ng, Shu Kay; Scuffham, Paul A.] Griffith Univ, Menzies Hlth Inst Queensland, Parklands Dr, Gold Coast, Qld 4222, Australia; [Comans, Tracy] Metro North Hosp & Hlth Serv, 112 Alfred St, Brisbane, Qld 4006, Australia; [O'Leary, Shaun] Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld 4072, Australia; [O'Leary, Shaun] Royal Brisbane & Womens Hosp, Physiotherapy Dept, Butterfield St, Herston, Qld 4006, Australia; [Conaghan, Philip G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds LS7 4SA, W Yorkshire, England; [Conaghan, Philip G.] Chapel Allerton Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds LS7 4SA, W Yorkshire, England	Gold Coast University Hospital; Griffith University; Menzies Health Institute Queensland; University of Queensland; Royal Brisbane & Women's Hospital; University of Leeds; Chapel Allerton Hospital; Leeds Biomedical Research Centre	Marks, D (corresponding author), Gold Coast Univ Hosp, Gold Cost Hosp & Hlth Serv, 1 Hosp Blvd, Gold Coast, Qld 4215, Australia.; Marks, D (corresponding author), Griffith Univ, Menzies Hlth Inst Queensland, Parklands Dr, Gold Coast, Qld 4222, Australia.	darryn.marks@health.qld.gov.au	Comans, Tracy/D-9308-2018; Scuffham, Paul/B-3066-2014; Scuffham, Paul/AAS-8084-2021; Bisset, Leanne/AAS-8947-2021; Marks, Darryn/AAQ-8598-2021	Comans, Tracy/0000-0003-2840-3496; Scuffham, Paul/0000-0001-5931-642X; Scuffham, Paul/0000-0001-5931-642X; Bisset, Leanne/0000-0001-8807-7093; Marks, Darryn/0000-0002-8884-8596; Ng, Shu Kay/0000-0002-6865-9384; Conaghan, Philip/0000-0002-3478-5665	Queensland Health through the Allied Health Professions Office; Gold Coast Hospital and Health Service	Queensland Health through the Allied Health Professions Office; Gold Coast Hospital and Health Service	We received support from within Queensland Health through the Allied Health Professions Office and the Gold Coast Hospital and Health Service. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angst F, 2011, ARTHRIT CARE RES, V63, pS174, DOI 10.1002/acr.20630; [Anonymous], 2013, MILLIONS PATIENTS BE; Australian Government Department of Health, 2015, MBS ONL MED BEN SCHE, DOI 10.1016/j.jse.2009.04.006; Australian Government Productivity Commission, 2011, 53 AUSTR GOV PROD CO; Brittain E, 2005, STAT MED, V24, P1, DOI 10.1002/sim.1934; Buchbinder R, COCHRANE DB SYST REV, V200, DOI DOI 10.1002/14651858.CD004016; Buchbinder R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061243; Cadogan A, 2012, J REHABIL MED, V44, P877, DOI 10.2340/16501977-1049; Carter T, 2012, PHYSIOTHERAPY, V98, P40, DOI 10.1016/j.physio.2010.12.003; Curtis AJ, 2010, MED J AUSTRALIA, V192, P217, DOI 10.5694/j.1326-5377.2010.tb03482.x; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; Daker-White G, 1999, J EPIDEMIOL COMMUN H, V53, P643, DOI 10.1136/jech.53.10.643; Department of Health, 2006, JOINT DOCTRINE INTER; Department of Health, 2009, ALL HLTH PROF PRESCR; Desmeules F, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-107; Diercks R, 2014, ACTA ORTHOP, V85, P314, DOI 10.3109/17453674.2014.920991; Dorrestijn O, 2011, RHEUMATOLOGY, V50, P389, DOI 10.1093/rheumatology/keq333; Duckett Stephen J, 2005, Aust Health Rev, V29, P201; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Ekeberg OM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3112; Government Queensland, QUEENSL HLTH WAG RAT; Green S, 2003, Cochrane Database Syst Rev, pCD004258; Hambly N, 2007, AM J ROENTGENOL, V189, P1179, DOI 10.2214/AJR.07.2421; Hattam P, 1999, Clin Perform Qual Health Care, V7, P121, DOI 10.1108/14664109910306749; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Health Q, 2014, ATT 3 TOT REM FRAM C; Helliwell PS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3037; Hill JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124557; Hockin J, 1994, PHYSIOTHERAPY, V80, P281, DOI DOI 10.1016/S0031-9406(10)61050-4; James M, 2005, RHEUMATOLOGY, V44, P1447, DOI 10.1093/rheumatology/kei043; Johansson K, 2011, FAM PRACT, V28, P355, DOI 10.1093/fampra/cmq119; Joseph C, 2014, PHYSIOTHERAPY, V100, P277, DOI 10.1016/j.physio.2014.03.007; Jowett S, 2013, RHEUMATOLOGY, V52, P1485, DOI 10.1093/rheumatology/ket149; Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163; Kolber MJ, 2012, INT J SPORTS PHYS TH, V7, P306; Kuijpers T, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-83; Laurant M, 2004, COCHRANE DATABASE SY; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee HJ, 2015, KNEE SURG SPORT TR A, V23, P555, DOI 10.1007/s00167-013-2395-1; Lewis J., 2001, PHYSIOTHERAPY, V87, P458, DOI [DOI 10.1016/S0031-9406(05)60693-1, 10.1016/S0031-9406(05)60693-1]; Lewis JS, 2009, BRIT J SPORT MED, V43, P259, DOI 10.1136/bjsm.2008.052183; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Linsell L, 2006, RHEUMATOLOGY, V45, P215, DOI 10.1093/rheumatology/kei139; Maman E, 2016, AM J SPORT MED, V44, P177, DOI 10.1177/0363546515591266; Marks D, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-503; Mascha EJ, 2011, ANESTH ANALG, V112, P678, DOI 10.1213/ANE.0b013e318206f872; May S, 2010, PHYSIOTHERAPY, V96, P179, DOI 10.1016/j.physio.2009.12.002; Michener LA, 2009, ARCH PHYS MED REHAB, V90, P1898, DOI 10.1016/j.apmr.2009.05.015; Mitchell C, 2005, BMJ-BRIT MED J, V331, P1124, DOI 10.1136/bmj.331.7525.1124; Moosmayer S, 2010, ACTA ORTHOP, V81, P361, DOI 10.3109/17453674.2010.483993; Mullaney Michael J., 2010, Physiotherapy Theory and Practice, V26, P327, DOI 10.3109/09593980903094230; Murphy RJ, 2010, SHOULDER PAIN, V2010; Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; NHS, 2015, REF TREATM RTT WAIT; Norman R, 2013, APPL HEALTH ECON HEA, V11, P287, DOI 10.1007/s40258-013-0035-z; Obradovic M, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-110; OVERMAN SS, 1988, PHYS THER, V68, P199, DOI 10.1093/ptj/68.2.199; Parsons S, 2007, FAM PRACT, V24, P308, DOI 10.1093/fampra/cmm027; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Piaggio G, 2010, JAMA-J AM MED ASSOC, V2012, P2594, DOI DOI 10.1001/JAMA.2012.87802; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Piitulainen K, 2012, DISABIL REHABIL, V34, P2071, DOI 10.3109/09638288.2012.670363; Queensland Government QH, 2015, HOSP PERF; Ramirez J, 2014, MOD RHEUMATOL, V24, P667, DOI 10.3109/14397595.2013.857798; Resteghini P, 2003, J ORTHOP MED, V25, P58; Roach K E, 1991, Arthritis Care Res, V4, P143, DOI 10.1002/art.1790040403; Robb G, 2009, J PRIM HEALTH CARE, V1, P42, DOI 10.1071/HC09042; Roy JS, 2009, ARTHRIT RHEUM-ARTHR, V61, P623, DOI 10.1002/art.24396; Samsson K, 2014, MANUAL THER, V19, P386, DOI 10.1016/j.math.2013.10.004; Scott A, 2013, BRIT J SPORT MED, V47, P536, DOI 10.1136/bjsports-2013-092329; Shiroiwa T, 2010, HEALTH ECON, V19, P422, DOI 10.1002/hec.1481; Smith KL, 2000, J SHOULDER ELB SURG, V9, P395, DOI 10.1067/mse.2000.108962; Stanhope J, 2012, J MULTIDISCIP HEALTH, V5, P37, DOI 10.2147/JMDH.S28891; Tashjian RZ, 2009, J SHOULDER ELB SURG, V18, P927, DOI 10.1016/j.jse.2009.03.021; Taylor William, 2005, N Z Med J, V118, pU1629; The Kings Fund, 2015, MUCH MON DOES NHS NE; Twisk J, 2002, J CLIN EPIDEMIOL, V55, P329, DOI 10.1016/S0895-4356(01)00476-0; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; Virta L, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-17; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Weale A E, 1995, Ann R Coll Surg Engl, V77, P71; Yamamoto A, 2010, J SHOULDER ELB SURG, V19, P116, DOI 10.1016/j.jse.2009.04.006	83	8	8	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2016	11	9							e0162679	10.1371/journal.pone.0162679	http://dx.doi.org/10.1371/journal.pone.0162679			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5SJ	27631987	Green Published, gold			2023-01-03	WOS:000383706900064
J	Galishoff, ML				Galishoff, Mitchel L.			Follow-up to Nonfatal Opioid Overdoses	ANNALS OF INTERNAL MEDICINE			English	Letter									[Galishoff, Mitchel L.] Valley Med & Surg Clin, Valley, AL 36854 USA		Galishoff, ML (corresponding author), Valley Med & Surg Clin, Valley, AL 36854 USA.							Gregg J, 2016, ANN INTERN MED, V164, P62, DOI 10.7326/M15-2687; Larochelle MR, 2016, ANN INTERN MED, V164, P1, DOI 10.7326/M15-0038	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 6	2016	165	5					378	378		10.7326/L16-0111	http://dx.doi.org/10.7326/L16-0111			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV3BC	27595222				2023-01-03	WOS:000382795000013
J	Twardziok, M; Kleinsimon, S; Rolff, J; Jager, S; Eggert, A; Seifert, G; Delebinski, CI				Twardziok, Monika; Kleinsimon, Susann; Rolff, Jana; Jaeger, Sebastian; Eggert, Angelika; Seifert, Georg; Delebinski, Catharina I.			Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma	PLOS ONE			English	Article							ACID INDUCE APOPTOSIS; X-LINKED INHIBITOR; OLEANOLIC ACID; BETULINIC ACID; IN-VIVO; OSTEOSARCOMA CELLS; MISTLETOE EXTRACT; DRUG-COMBINATIONS; NATURAL-PRODUCTS; LUNG-CANCER	Ewing sarcoma is the second most common bone cancer in children and adolescents, with poor prognosis and outcome in similar to 70% of initial diagnoses and 10-15% of relapses. Hydrophobic triterpene acids and hydrophilic lectins and viscotoxins from European mistletoe (Viscum album L.) demonstrate anticancer properties, but have not yet been investigated for Ewing sarcoma. Commercial Viscum album L. extracts are aqueous, excluding the insoluble triterpenes. We recreated a total mistletoe effect by combining an aqueous extract (viscum) and a triterpene extract (TT) solubilized with cyclodextrins. Ewing sarcoma cells were treated with viscum, TT and viscumTT in vitro, ex vivo and in vivo. In vitro and ex vivo treatment of Ewing sarcoma cells with viscum inhibited proliferation and induced apoptosis in a dose-dependent fashion, while viscumTT combination treatment generated a synergistic effect. Apoptosis occurred via intrinsic and extrinsic apoptotic pathways, evidenced by activation of both CASP8 and CASP9. We show that viscumTT treatment shifts the balance of apoptotic regulatory proteins towards apoptosis, mainly via CLSPN, MCL1, BIRC5 and XIAP downregulation. ViscumTT also demonstrated strong antitumor activity in a cell line- and patient-derived mouse model, and may be considered an adjuvant therapy option for pediatric patients with Ewing sarcoma.	[Twardziok, Monika; Kleinsimon, Susann; Eggert, Angelika; Seifert, Georg; Delebinski, Catharina I.] Univ Med Berlin, Charite, Otto Heubner Ctr Pediat & Adolescent Med OHC, Dept Pediat Oncol Hematol, Berlin, Germany; [Twardziok, Monika] Free Univ Berlin, Inst Pharm, Dept Biol, Chem,Pharm, Berlin, Germany; [Rolff, Jana] EPO GmbH, Expt Pharmacol & Oncol, Berlin, Germany; [Jaeger, Sebastian] Birken AG, Niefern Oschelbronn, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Seifert, G (corresponding author), Univ Med Berlin, Charite, Otto Heubner Ctr Pediat & Adolescent Med OHC, Dept Pediat Oncol Hematol, Berlin, Germany.	georg.seifert@charite.de	Eggert, Angelika/AAE-6907-2022	Eggert, Angelika/0000-0003-3476-8184; Delebinski, Catharina/0000-0003-2527-4385	Software AG-Stiftung (Darmstadt, Germany); Federal Ministry for Economic Affairs and Energy on the basis of a decision by the German Bundestag; EPO GmbH; Birken AG	Software AG-Stiftung (Darmstadt, Germany); Federal Ministry for Economic Affairs and Energy on the basis of a decision by the German Bundestag; EPO GmbH; Birken AG	This work was supported by the Software AG-Stiftung (Darmstadt, Germany) and the Federal Ministry for Economic Affairs and Energy on the basis of a decision by the German Bundestag. EPO GmbH and Birken AG provided support in the form of salaries for authors JR and SJ respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Software AG-Stiftung (Darmstadt, Germany) and the Federal Ministry for Economic Affairs and Energy on the basis of a decision by the German Bundestag. EPO GmbH and Birken AG provided support in the form of salaries for authors JR and SJ respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank K. Astrahantseff for comments on and editing of the manuscript.	Akl MR, 2014, EUR J PHARMACOL, V740, P209, DOI 10.1016/j.ejphar.2014.07.011; Amer B, 2013, PHARM BIOL, V51, P981, DOI 10.3109/13880209.2013.773520; Bache M, 2014, INT J MOL SCI, V15, P19777, DOI 10.3390/ijms151119777; Bantel H, 1999, CANCER RES, V59, P2083; Braun JM, 2002, ANTICANCER RES, V22, P4187; Bussing A, 1998, CANCER LETT, V130, P57, DOI 10.1016/S0304-3835(98)00124-4; Chakravarti B, 2012, J ETHNOPHARMACOL, V142, P72, DOI 10.1016/j.jep.2012.04.015; Choi SH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-211; Coumar MS, 2013, CANCER TREAT REV, V39, P802, DOI 10.1016/j.ctrv.2013.02.002; de Almagro M. C., 2012, Experimental Oncology, V34, P200; Decaudin D, 1998, INT J ONCOL, V12, P141; Delebinski CI, 2012, CELL PROLIFERAT, V45, P176, DOI 10.1111/j.1365-2184.2011.00801.x; Delebinski CI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133892; Duan ZF, 2009, CANCER CHEMOTH PHARM, V63, P681, DOI 10.1007/s00280-008-0785-8; Ehrhardt H, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.53; FOUNGBE S, 1991, J ETHNOPHARMACOL, V33, P221, DOI 10.1016/0378-8741(91)90080-W; Frantz M, 2000, ARZNEIMITTEL-FORSCH, V50, P471; FRANZ H, 1981, BIOCHEM J, V195, P481, DOI 10.1042/bj1950481; Fulda S, 1999, KLIN PADIATR, V211, P319, DOI 10.1055/s-2008-1043808; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Greve B, 2012, STRAHLENTHER ONKOL, V188, P1038, DOI 10.1007/s00066-012-0223-z; He XJ, 2012, J AGR FOOD CHEM, V60, P9430, DOI 10.1021/jf3026925; Hingorani P, 2013, PEDIATR BLOOD CANCER, V60, P35, DOI 10.1002/pbc.24290; Hua YQ, 2011, INVEST NEW DRUG, V29, P258, DOI 10.1007/s10637-009-9354-1; Huber R, 2010, EUR J CLIN PHARMACOL, V66, P889, DOI 10.1007/s00228-010-0830-5; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Jager S, 2007, PLANTA MED, V73, P157, DOI 10.1055/s-2007-967106; JAGGY C, 1995, ARZNEIMITTEL-FORSCH, V45-2, P905; Ji HF, 2009, EMBO REP, V10, P194, DOI 10.1038/embor.2009.12; JUNG ML, 1990, CANCER LETT, V51, P103, DOI 10.1016/0304-3835(90)90044-X; Kaatsch P. S. C., 2014, GERMAN CHILDHOOD CAN; Kashkar H, 2010, CLIN CANCER RES, V16, P4496, DOI 10.1158/1078-0432.CCR-10-1664; Kim MS, 2000, GEN PHARMACOL-VASC S, V34, P349, DOI 10.1016/S0306-3623(01)00072-6; Klingbeil MFG, 2013, ONCOL REP, V30, P2316, DOI 10.3892/or.2013.2732; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Leal AS, 2013, ORG BIOMOL CHEM, V11, P1726, DOI 10.1039/c3ob00011g; Liby K, 2009, CANCER PREV RES, V2, P1050, DOI 10.1158/1940-6207.CAPR-09-0085; Lin Patrick P., 2011, Sarcoma, V2011, P276463, DOI 10.1155/2011/276463; Lopez J, 2010, CURR OPIN CELL BIOL, V22, P872, DOI 10.1016/j.ceb.2010.08.025; Lucio KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028596; Mackintosh Carlos, 2013, Recent Pat Biotechnol, V7, P98; Maletzki C, 2013, CANCER IMMUNOL IMMUN, V62, P1283, DOI 10.1007/s00262-013-1455-1; Marvibaigi M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/785479; May WA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080060; Nhiem NX, 2013, J NAT PROD, V76, P495, DOI 10.1021/np300490v; Obexer P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00197; Orhan DD, 2006, Z NATURFORSCH C, V61, P26; Park YK, 2012, ONCOL REP, V28, P2227, DOI 10.3892/or.2012.2026; Paronetto MP, 2013, INT J CELL BIOL, V2013, P12; Petronelli A, 2009, CANCER LETT, V282, P214, DOI 10.1016/j.canlet.2009.03.018; Ryu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-187; Seifert G, 2008, CANCER LETT, V264, P218, DOI 10.1016/j.canlet.2008.01.036; Shyu MH, 2010, J AGR FOOD CHEM, V58, P6110, DOI 10.1021/jf100574j; Society AC, 2014, AM CANC SOC CANC FAC; Soica C, 2014, MOLECULES, V19, P4924, DOI 10.3390/molecules19044924; Stahl M, 2011, PEDIATR BLOOD CANCER, V57, P549, DOI 10.1002/pbc.23040; Struh CM, 2012, PHYTOTHER RES, V26, P1507, DOI 10.1002/ptr.4604; Struh CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062168; Amaral AT, 2014, ADV ANAT PATHOL, V21, P44, DOI 10.1097/PAP.0000000000000003; Timoshenko AV, 2000, BIOSCIENCE REP, V20, P199, DOI 10.1023/A:1005519603863; Ucar EO, 2012, GENET MOL RES, V11, P2801, DOI 10.4238/2012.August.24.5; Van Huyen JPD, 2006, CANCER LETT, V243, P32, DOI 10.1016/j.canlet.2005.11.016; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; von Schoen-Angerer T, 2014, J GASTROINTEST LIVER, V23, P449, DOI 10.15403/jgld.2014.1121.234.acpy; Wei JT, 2013, J APPL TOXICOL, V33, P756, DOI 10.1002/jat.2725; Yan SL, 2010, TOXICOL IN VITRO, V24, P842, DOI 10.1016/j.tiv.2009.12.008; Yang XL, 2012, MOLECULES, V17, P11435, DOI 10.3390/molecules171011435	67	21	25	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2016	11	9							e0159749	10.1371/journal.pone.0159749	http://dx.doi.org/10.1371/journal.pone.0159749			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EJ	27589063	Green Submitted, Green Published, gold			2023-01-03	WOS:000382877800002
J	Sozanski, K; Wisniewska, A; Kalwarczyk, T; Sznajder, A; Holyst, R				Sozanski, Krzysztof; Wisniewska, Agnieszka; Kalwarczyk, Tomasz; Sznajder, Anna; Holyst, Robert			Motion of Molecular Probes and Viscosity Scaling in Polyelectrolyte Solutions at Physiological Ionic Strength	PLOS ONE			English	Article							POLYMER-SOLUTIONS; COMPLEX LIQUIDS; DIFFUSION; MOBILITY; DYNAMICS; MACROMOLECULES; CYTOPLASM; CHAIN; VISCOELASTICITY; NANOPARTICLES	We investigate transport properties of model polyelectrolyte systems at physiological ionic strength (0.154 M). Covering a broad range of flow length scales-from diffusion of molecular probes to macroscopic viscous flow-we establish a single, continuous function describing the scale dependent viscosity of high-salt polyelectrolyte solutions. The data are consistent with the model developed previously for electrically neutral polymers in a good solvent. The presented approach merges the power-law scaling concepts of de Gennes with the idea of exponential length scale dependence of effective viscosity in complex liquids. The result is a simple and applicable description of transport properties of high-salt polyelectrolyte solutions at all length scales, valid for motion of single molecules as well as macroscopic flow of the complex liquid.	[Sozanski, Krzysztof; Wisniewska, Agnieszka; Kalwarczyk, Tomasz; Sznajder, Anna; Holyst, Robert] Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland	Polish Academy of Sciences; Institute of Physical Chemistry of the Polish Academy of Sciences	Holyst, R (corresponding author), Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland.	rholyst@ichf.edu.pl	Kalwarczyk, Tomasz/V-5262-2018; Wiśniewska, Agnieszka/HCI-1785-2022	Kalwarczyk, Tomasz/0000-0003-1136-9789; Wiśniewska, Agnieszka/0000-0001-5317-757X; Holyst, Robert/0000-0002-3211-4286; Sozanski, Krzysztof/0000-0002-4514-3836	National Science Centre [2011/02/A/ST3/00143]	National Science Centre(National Science Centre, Poland)	The authors acknowledge the National Science Centre (https://www.ncn.gov.pl/) for funding the project from the funds granted on the basis of the decision number 2011/02/A/ST3/00143 (Maestro grant).	Amsden B, 2002, POLYMER, V43, P1623, DOI 10.1016/S0032-3861(01)00749-2; Bielejewska A, 2010, ANAL CHEM, V82, P5463, DOI 10.1021/ac1008207; Boris DC, 1998, MACROMOLECULES, V31, P5746, DOI 10.1021/ma971884i; Cai LH, 2011, MACROMOLECULES, V44, P7853, DOI 10.1021/ma201583q; Carrillo JMY, 2010, J PHYS CHEM B, V114, P9391, DOI 10.1021/jp101978k; COHEN J, 1988, J CHEM PHYS, V88, P7111, DOI 10.1063/1.454361; Colby RH, 2010, RHEOL ACTA, V49, P425, DOI 10.1007/s00397-009-0413-5; COLBY RH, 1991, MACROMOLECULES, V24, P3873, DOI 10.1021/ma00013a021; COOPER EC, 1991, POLYMER, V32, P2815, DOI 10.1016/0032-3861(91)90114-X; CUKIER RI, 1984, MACROMOLECULES, V17, P252, DOI 10.1021/ma00132a023; de Gennes PG, 1979, SCALING CONCEPTS IN; de Kort DW, 2015, MACROMOLECULES, V48, P7585, DOI 10.1021/acs.macromol.5b01530; DEGENNES PG, 1976, J PHYS-PARIS, V37, P1461, DOI 10.1051/jphys:0197600370120146100; Dobrynin AV, 2005, PROG POLYM SCI, V30, P1049, DOI 10.1016/j.progpolymsci.2005.07.006; DOBRYNIN AV, 1995, MACROMOLECULES, V28, P1859, DOI 10.1021/ma00110a021; Doi M, 1986, THE THEORY OF POLYME; Dou SC, 2006, J POLYM SCI POL PHYS, V44, P2001, DOI 10.1002/polb.20853; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Gelbart WM, 2000, PHYS TODAY, V53, P38, DOI 10.1063/1.1325230; Heo Y, 2005, J RHEOL, V49, P1117, DOI 10.1122/1.1993595; Holyst R, 2009, PHYS CHEM CHEM PHYS, V11, P9025, DOI 10.1039/b908386c; Izzo D, 2014, SOFT MATTER, V10, P1714, DOI 10.1039/c3sm52630e; Janmey PA, 2014, SOFT MATTER, V10, P1439, DOI 10.1039/c3sm50854d; Jonsson B, 2003, LANGMUIR, V19, P9914, DOI 10.1021/la034850e; Kalwarczyk T, 2014, NANOSCALE, V6, P10340, DOI 10.1039/c4nr00647j; Kalwarczyk T, 2015, ADV COLLOID INTERFAC, V223, P55, DOI 10.1016/j.cis.2015.06.007; Kalwarczyk T, 2011, NANO LETT, V11, P2157, DOI 10.1021/nl2008218; Khorasani FB, 2014, MACROMOLECULES, V47, P5328, DOI 10.1021/ma501248u; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; Konop AJ, 1999, MACROMOLECULES, V32, P2803, DOI 10.1021/ma9818174; Lakowicz JR, 2007, PRINCIPLES OF FLUORE; LANGEVIN D, 1978, POLYMER, V19, P875, DOI 10.1016/0032-3861(78)90191-X; Liu J, 2008, J PHYS CHEM C, V112, P6653, DOI 10.1021/jp800474t; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; Majcher A, 2015, ANAL CHIM ACTA, V855, P51, DOI 10.1016/j.aca.2014.12.008; MANNING GS, 1969, J CHEM PHYS, V51, P924, DOI 10.1063/1.1672157; Miyazaki K, 2004, J CHEM PHYS, V121, P8120, DOI 10.1063/1.1797193; Moulay S, 2006, J APPL POLYM SCI, V100, P954, DOI 10.1002/app.23002; Nishida K, 2002, POLYMER, V43, P1295, DOI 10.1016/S0032-3861(01)00682-6; Nystrom B, 1982, PROG POLYM SCI, V8, P333, DOI [10.1016/0079-6700(82)90003-X, DOI 10.1016/0079-6700(82)90003-X]; ODIJK T, 1979, MACROMOLECULES, V12, P688, DOI 10.1021/ma60070a028; Odijk T, 2000, BIOPHYS J, V79, P2314, DOI 10.1016/S0006-3495(00)76477-0; Pecora R, 2005, MACROMOL SYMP, V229, P18, DOI 10.1002/masy.200551103; PHILLIES GDJ, 1987, MACROMOLECULES, V20, P2280, DOI 10.1021/ma00175a037; PHILLIES GDJ, 1985, J CHEM PHYS, V82, P5242, DOI 10.1063/1.448969; PHILLIES GDJ, 1992, MACROMOLECULES, V25, P4948, DOI 10.1021/ma00045a021; PHILLIES GDJ, 1989, MACROMOLECULES, V22, P4068, DOI 10.1021/ma00200a044; PHILLIES GDJ, 1986, MACROMOLECULES, V19, P2367, DOI 10.1021/ma00163a006; PHILLIES GDJ, 1988, MACROMOLECULES, V21, P214, DOI 10.1021/ma00179a041; PHILLIES GDJ, 1995, MACROMOLECULES, V28, P8198, DOI 10.1021/ma00128a033; RABIN Y, 1988, J POLYM SCI POL LETT, V26, P397, DOI 10.1002/pol.1988.140260904; Rapoport DH, 2007, J PHYS CHEM C, V111, P5726, DOI 10.1021/jp066735t; RUBINSTEIN M, 1994, PHYS REV LETT, V73, P2776, DOI 10.1103/PhysRevLett.73.2776; Rubinstein M, 2012, SOFT MATTER, V8, P9265, DOI 10.1039/c2sm90104h; Saenger W., 1984, PRINCILPES OF NUCLEI; SCHACHMAN HK, 1952, J AM CHEM SOC, V74, P3965, DOI 10.1021/ja01135a533; Sozanski K, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.228301; STONEMASUI J, 1968, J COLLOID INTERF SCI, V28, P187, DOI 10.1016/0021-9797(68)90120-3; Szymanski J, 2006, J PHYS CHEM B, V110, P25593, DOI 10.1021/jp0666784; TAKAHASHI Y, 1985, MACROMOLECULES, V18, P1002, DOI 10.1021/ma00147a033; Teraoka I., 2002, POLYMER SOLUTIONS AN; Tuteja A, 2007, NANO LETT, V7, P1276, DOI 10.1021/nl070192x; Uzum C, 2011, MACROMOLECULES, V44, P7782, DOI 10.1021/ma201466a; UTRACKI LA, 1981, J RHEOL, V25, P329, DOI 10.1122/1.549646; Weiller GF, 2004, PROTEOMICS, V4, P943, DOI 10.1002/pmic.200200648; Wisniewska A, 2014, POLYMER, V55, P4651, DOI 10.1016/j.polymer.2014.07.029; Wyart FB, 2000, EUR PHYS J E, V1, P93, DOI 10.1007/s101890050011; YING QC, 1987, MACROMOLECULES, V20, P362, DOI 10.1021/ma00168a023; Zustiak SP, 2011, BIOPHYS J, V101, P255, DOI 10.1016/j.bpj.2011.05.035	69	6	6	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2016	11	8							e0161409	10.1371/journal.pone.0161409	http://dx.doi.org/10.1371/journal.pone.0161409			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT6ES	27536866	Green Submitted, gold, Green Published			2023-01-03	WOS:000381577000101
J	Mora, S; Ames, JM; Manson, JE				Mora, Samia; Ames, Jeffrey M.; Manson, JoAnn E.			Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease Shared Decision Making in Clinical Practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Mora, Samia; Manson, JoAnn E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA; [Mora, Samia; Manson, JoAnn E.] Harvard Med Sch, Boston, MA USA; [Mora, Samia] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA; [Ames, Jeffrey M.] Software & Mobile Applicat Dev, Boston, MA USA; [Manson, JoAnn E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Manson, JE (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, 900 Commonwealth Ave,Third Floor, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu		Mora, Samia/0000-0001-6283-0980	NCI NIH HHS [CA138962] Funding Source: Medline; NHLBI NIH HHS [HL117861, R01 HL034594, HL034594] Funding Source: Medline; PHS HHS [HHSN268201100001C] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA138962, U01CA138962] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117861, R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amer Diabet Assoc, 2016, DIABETES CARE, V39, pS60, DOI 10.2337/dc16-S011; Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577; De Berardis G, 2012, JAMA-J AM MED ASSOC, V307, P2286, DOI 10.1001/jama.2012.5034; Guirguis-Blake JM, 2016, ANN INTERN MED, V164, P804, DOI 10.7326/M15-2113; Hernandez-Diaz S, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-22; Mainous AG, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000989; Mora S, JAMA INTERN MED, DOI [10.1001/jamainternmed.2016.2648, DOI 10.1001/JAMAINTERNMED.2016]; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Whitlock EP, 2015, AHRQ PUBLICATION, V132; Whitlock EP, 2016, ANN INTERN MED, V164, P826, DOI 10.7326/M15-2112	10	30	35	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2016	316	7					709	710		10.1001/jama.2016.8362	http://dx.doi.org/10.1001/jama.2016.8362			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT5IA	27323335				2023-01-03	WOS:000381514800012
J	Masel, EK; Kitta, A; Huber, P; Rumpold, T; Unseld, M; Schur, S; Porpaczy, E; Watzke, HH				Masel, Eva K.; Kitta, Anna; Huber, Patrick; Rumpold, Tamara; Unseld, Matthias; Schur, Sophie; Porpaczy, Edit; Watzke, Herbert H.			What Makes a Good Palliative Care Physician? A Qualitative Study about the Patient's Expectations and Needs when Being Admitted to a Palliative Care Unit	PLOS ONE			English	Article							OF-LIFE CARE; END; COMMUNICATION; PROGNOSIS; ONCOLOGY; PERSPECTIVES; ISSUES; INFORMATION; DISCUSSIONS; EXPERIENCES	Objective The aims of the study were to examine a) patients' knowledge of palliative care, b) patients' expectations and needs when being admitted to a palliative care unit, and c) patient's concept of a good palliative care physician. Methods The study was based on a qualitative methodology, comprising 32 semistructured interviews with advanced cancer patients admitted to the palliative care unit of the Medical University of Vienna. Interviews were conducted with 20 patients during the first three days after admission to the unit and after one week, recorded digitally, and transcribed verbatim. Data were analyzed using NVivo 10 software, based on thematic analysis enhanced with grounded theory techniques. Results The results revealed four themes: (1) information about palliative care, (2) supportive care needs, (3) being treated in a palliative care unit, and (4) qualities required of palliative care physicians. The data showed that patients lack information about palliative care, that help in social concerns plays a central role in palliative care, and attentiveness as well as symptom management are important to patients. Patients desire a personal patient-physician relationship. The qualities of a good palliative care physician were honesty, the ability to listen, taking time, being experienced in their field, speaking the patient's language, being human, and being gentle. Patients experienced relief when being treated in a palliative care unit, perceived their care as an interdisciplinary activity, and felt that their burdensome symptoms were being attended to with emotional care. Negative perceptions included the overtly intense treatment. Conclusions The results of the present study offer an insight into what patients expect from palliative care teams. Being aware of patient's needs will enable medical teams to improve professional and individualized care.	[Masel, Eva K.; Kitta, Anna; Huber, Patrick; Rumpold, Tamara; Unseld, Matthias; Schur, Sophie; Watzke, Herbert H.] Med Univ Vienna, Div Palliat Care, Dept Internal Med 1, Vienna, Austria; [Porpaczy, Edit] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Masel, EK (corresponding author), Med Univ Vienna, Div Palliat Care, Dept Internal Med 1, Vienna, Austria.	eva.masel@meduniwien.ac.at	Masel, Eva Katharina/AAU-7439-2020; Masel, Eva Katharina/ABH-1594-2020	Masel, Eva Katharina/0000-0001-6415-4488; Kitta, Anna/0000-0001-9102-593X; Unseld, Matthias/0000-0002-1699-9846				Abdul-Razzak A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005653; Aldridge MD, 2015, PALLIATIVE MED, V24; Almack K, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-15; Back AL, 2006, J CLIN ONCOL, V24, P4209, DOI 10.1200/JCO.2006.06.007; Back AL, 2014, J PALLIAT MED, V17, P1019, DOI 10.1089/jpm.2013.0651; Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Beernaert K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137251; Bleidorn J, 2012, DEUT MED WOCHENSCHR, V137, P1343, DOI 10.1055/s-0032-1305045; Bosma H, 2010, PALLIATIVE MED, V24, P510, DOI 10.1177/0269216309351380; Braun V, 2014, INT J QUAL STUD HEAL, V9, DOI 10.3402/qhw.v9.26152; Centeno C, 2015, PALLIATIVE MED, V31; Ciemins EL, 2015, J PALLIAT MED, V18, P282, DOI 10.1089/jpm.2014.0155; Clayton JA, 2005, J PAIN SYMPTOM MANAG, V30, P132, DOI 10.1016/j.jpainsymman.2005.02.014; Dugdale DC, 1999, J GEN INTERN MED, V14, pS34, DOI 10.1046/j.1525-1497.1999.00263.x; Enzinger AC, 2015, J CLIN ONCOL, V33, P3809, DOI 10.1200/JCO.2015.61.9239; Farber Stuart J, 2003, J Palliat Med, V6, P19, DOI 10.1089/10966210360510082; Ferrell B, 2008, J CLIN ONCOL, V26, P3824, DOI 10.1200/JCO.2007.15.7552; Gomes B, 2015, J CLIN ONCOL, V33, P1420, DOI 10.1200/JCO.2014.60.5386; Grande GE, 2000, PALLIATIVE MED, V14, P69, DOI 10.1191/026921600677940614; Gysels M, 2008, BMC MED ETHICS, V9, P1472; Gysels M, 2008, J PAIN SYMPTOM MANAG, V35, P347, DOI 10.1016/j.jpainsymman.2007.05.012; Hoare S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142723; Innes S, 2009, PALLIATIVE MED, V23, P29, DOI 10.1177/0269216308098799; Kapo J, 2007, J PALLIAT MED, V10, P185, DOI 10.1089/jpm.2006.9989; Kogan AC, 2015, J PALLIAT MED, V18, P1019, DOI 10.1089/jpm.2015.0038; Kon AA, 2010, JAMA-J AM MED ASSOC, V304, P903, DOI 10.1001/jama.2010.1208; Mann K, 2015, MED TEACH, V21, P1; Martinsson L, 2016, BMJ SUPPORT PALLIAT, V6, P452, DOI 10.1136/bmjspcare-2014-000688; Masel EK, 2015, SUPPORT CARE CANCER, V23, P2335, DOI 10.1007/s00520-015-2601-4; McAteer R, 2013, AM FAM PHYSICIAN, V88, P807; McIlfatrick S, 2014, PALLIATIVE MED, V28, P273, DOI 10.1177/0269216313502372; Monroe B., 1994, Annals Academy of Medicine Singapore, V23, P252; MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; Murray CD, 2015, PALLIAT SUPPORT CARE, V13, P369, DOI 10.1017/S1478951514000455; Parikh RB, 2013, NEW ENGL J MED, V369, P2347, DOI 10.1056/NEJMsb1305469; Parry R, 2014, BMJ SUPPORT PALLIAT, V4, P331, DOI 10.1136/bmjspcare-2014-000649; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Ranganathan A, 2014, ANN PALLIAT MED, V3, P144, DOI 10.3978/j.issn.2224-5820.2014.07.04; Robinson J, 2015, PALLIATIVE MED, V13; Sampson C, 2014, BMJ SUPPORT PALLIAT, V16; Sandsdalen T, 2015, PALLIATIVE MED, V29, P399, DOI 10.1177/0269216314557882; Sapir R, 2000, SUPPORT CARE CANCER, V8, P458, DOI 10.1007/s005200000163; Seccareccia D, 2015, J PALLIAT MED, V18, P758, DOI 10.1089/jpm.2014.0408; Stephen N, 2013, J PALLIAT MED, V16, P555, DOI 10.1089/jpm.2012.0442; Stiel S, 2010, J PALLIAT MED, V13, P997, DOI 10.1089/jpm.2010.0050; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; van der Plas AGM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133197; Virdun C, 2015, PALLIATIVE MED, V29, P774, DOI 10.1177/0269216315583032; Walczak A, 2013, PATIENT EDUC COUNS, V90, P307, DOI 10.1016/j.pec.2011.08.009; Wheatley VJ, 2007, POSTGRAD MED J, V83, P643, DOI 10.1136/pgmj.2007.058487	50	16	16	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158830	10.1371/journal.pone.0158830	http://dx.doi.org/10.1371/journal.pone.0158830			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3OC	27389693	Green Submitted, gold, Green Published			2023-01-03	WOS:000379811500052
J	Sampaio, J; Machado, D; Gomes, AM; Machado, I; Santos, C; Lima, N; Carvalho, MJ; Cabrita, A; Rodrigues, A; Martins, M				Sampaio, Joana; Machado, Diana; Gomes, Ana Marta; Machado, Idalina; Santos, Cledir; Lima, Nelson; Carvalho, Maria Joao; Cabrita, Antonio; Rodrigues, Anabela; Martins, Margarida			Deciphering the Contribution of Biofilm to the Pathogenesis of Peritoneal Dialysis Infections: Characterization and Microbial Behaviour on Dialysis Fluids	PLOS ONE			English	Article							EXIT-SITE INFECTION; SUBSEQUENT PERITONITIS; CATHETERS; ASSOCIATION; PREVENTION; RATES	Infections are major complications in peritoneal dialysis (PD) with a multifactorial etiology that comprises patient, microbial and dialytic factors. This study aimed at investigating the contribution of microbial biofilms on PD catheters to recalcitrant infections and their interplay with PD related-factors. A prospective observational study was performed on 47 patients attending Centro Hospitalar of Porto and Vila Nova de Gaia/Espinho to whom the catheter was removed due to infectious (n = 16) and non-infectious causes (n = 31). Microbial density on the catheter was assessed by culture methods and the isolated microorganisms identified by matrix-assisted laser desorption/ionization time-of-flight intact cell mass spectrometry. The effect of conventional and three biocompatible PD solutions on 16 Coagulase Negative Staphylococci (CNS) and 10 Pseudomonas aeruginosa strains planktonic growth and biofilm formation was evaluated. Cultures were positive in 87.5% of the catheters removed due infectious and 90.3% removed due to non-infectious causes. However, microbial yields were higher on the cuffs of catheters removed due to infection vs. non-infection. Staphylococci (CNS and Staphylococcus aureus) and P. aeruginosa were the predominant species: 32% and 20% in the infection and 43.3% and 22.7% in the non-infection group, respectively. In general, PD solutions had a detrimental effect on planktonic CNS and P. aeruginosa strains growth. All strains formed biofilms in the presence of PD solutions. The solutions had a more detrimental effect on P. aeruginosa than CNS strains. No major differences were observed between conventional and biocompatible solutions, although in icodextrin solution biofilm biomass was lower than in bicarbonate/lactate solution. Overall, we show that microbial biofilm is universal in PD catheters with the subclinical menace of Staphylococci and P. aeruginosa. Cuffs colonization may significantly contribute to infection. PD solutions differentially impact microbial species. This knowledge is important for the development of infection diagnosis, treatment and preventive strategies.	[Sampaio, Joana; Machado, Diana; Martins, Margarida] Univ Minho, CEB Ctr Biol Engn, LIBRO, Campus Gualtar, Braga, Portugal; [Gomes, Ana Marta] Ctr Hosp Vila Nova de Gaia Espinho, Serv Nefrol, Rua Conceicao Femandes, Vila Nova De Gaia, Portugal; [Machado, Idalina] Univ Porto, Fac Engn, Dept Chem Engn, LEPABE, Rua Campo Alegre 823, P-4100 Porto, Portugal; [Santos, Cledir] BIOREN UFRO Univ La Frontera, CIBAMA, Dept Chem Sci & Nat Resources, Temuco, Chile; [Lima, Nelson] Micoteca Univ Minho, CEB Ctr Biol Engn, Campus Gualtar, Braga, Portugal; [Carvalho, Maria Joao; Cabrita, Antonio; Rodrigues, Anabela] Ctr Hosp Porto, Serv Nefrol, Largo Prof Abel Salazar Porto, Porto, Portugal; [Rodrigues, Anabela] UP, UMIB, ICBAS, Porto, Portugal	Universidade do Minho; Universidade do Porto; Universidade do Porto	Martins, M (corresponding author), Univ Minho, CEB Ctr Biol Engn, LIBRO, Campus Gualtar, Braga, Portugal.; Rodrigues, A (corresponding author), Ctr Hosp Porto, Serv Nefrol, Largo Prof Abel Salazar Porto, Porto, Portugal.; Rodrigues, A (corresponding author), UP, UMIB, ICBAS, Porto, Portugal.	rodrigues.anabela2016@gmail.com; martins.margarida@gmail.com	Santos, Cledir/H-5214-2012; Machado, Idalina/J-2892-2013; Lima, Nelson/D-3651-2009; Santos, Cledir/AAO-8276-2020; Martins, Margarida/F-2313-2010; Soares Rodrigues, Anabela/K-5226-2013	Santos, Cledir/0000-0003-4681-0941; Machado, Idalina/0000-0003-0546-4915; Lima, Nelson/0000-0003-2185-0613; Santos, Cledir/0000-0003-4681-0941; Martins, Margarida/0000-0002-4979-7634; Cabrita, Antonio/0000-0003-3794-9239; Soares Rodrigues, Anabela/0000-0001-8818-2141	Sociedade Portuguesa de Nefrologia research grant; Fundacao para a Ciencia e Tecnologia post doc grant [SFRH/BPD/73663/2010]	Sociedade Portuguesa de Nefrologia research grant; Fundacao para a Ciencia e Tecnologia post doc grant	This work received support from a Sociedade Portuguesa de Nefrologia (http://www.spnefro.pt) research grant to AR and a Fundacao para a Ciencia e Tecnologia (http://www.fct.pt) post doc grant (SFRH/BPD/73663/2010) to MM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baek Joo-Eun, 2004, Korean Journal of Internal Medicine, V19, P104; Barraclough KA, 2009, EXPERT REV ANTI-INFE, V7, P1185, DOI [10.1586/eri.09.100, 10.1586/ERI.09.100]; Bayston R, 1999, PERITON DIALYSIS INT, V19, P550; Broekhuizen CAN, 2008, CRIT CARE MED, V36, P2395, DOI 10.1097/CCM.0b013e3181818268; Burke M, 2011, AM J KIDNEY DIS, V58, P429, DOI 10.1053/j.ajkd.2011.03.022; Cho Y, 2014, T COCHRANE DATABASE, V3; Cho Y, 2014, AM J KIDNEY DIS, V64, P278, DOI 10.1053/j.ajkd.2014.02.025; DASGUPTA MK, 1992, INT BIODETER BIODEGR, V30, P167, DOI 10.1016/0964-8305(92)90061-R; Finkelstein ES, 2002, AM J KIDNEY DIS, V39, P1278, DOI 10.1053/ajkd.2002.33403; Garcia-Lopez E, 2012, NAT REV NEPHROL, V8, P224, DOI 10.1038/nrneph.2012.13; Hall-Stoodley L, 2012, FEMS IMMUNOL MED MIC, V65, P127, DOI 10.1111/j.1574-695X.2012.00968.x; Harrison JJ, 2010, NAT PROTOC, V5, P1236, DOI 10.1038/nprot.2010.71; Hoiby N, 2015, CLIN MICROBIOL INFEC, V21, pS1, DOI 10.1016/j.cmi.2014.10.024; Jones SM, 2011, AM J KIDNEY DIS, V57, P449, DOI 10.1053/j.ajkd.2010.10.053; Lan PG, 2014, CLIN J AM SOC NEPHRO, V9, P1091, DOI 10.2215/CJN.09730913; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Lin CY, 2013, J AM SOC NEPHROL, V24, P2002, DOI 10.1681/ASN.2013040332; Magnussen Eyd Tausen, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-212619; Martins M, 2013, BIOFOULING, V29, P1015, DOI 10.1080/08927014.2013.824566; McGuire AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119238; Mehrotra R, 2013, CLIN J AM SOC NEPHRO, V8, P126, DOI 10.2215/CJN.06910712; Nessim SJ, 2012, PERITON DIALYSIS INT, V32, P316, DOI 10.3747/pdi.2011.00058; Pihl M, 2013, PATHOG DIS, V67, P192, DOI 10.1111/2049-632X.12035; Ramanathan V, 2012, AM J KIDNEY DIS, V60, P976, DOI 10.1053/j.ajkd.2012.06.003; Rocha A, 2012, BLOOD PURIFICAT, V33, P284, DOI 10.1159/000337377; Rodrigues A, 2014, AM J INFECT CONTROL, V42, P1016, DOI 10.1016/j.ajic.2014.05.036; Szeto CC, 2001, KIDNEY INT, V59, P2309, DOI 10.1046/j.1523-1755.2001.00748.x; Szeto CC, 2008, CLIN J AM SOC NEPHRO, V3, P91, DOI 10.2215/CJN.03070707; Szeto CC, 2014, PERITON DIALYSIS INT, V34, P151, DOI 10.3747/pdi.2014.00007; Szeto CC, 2013, CLIN J AM SOC NEPHRO, V8, P1935, DOI 10.2215/CJN.02360213; Szeto CC, 2011, CLIN J AM SOC NEPHRO, V6, P827, DOI 10.2215/CJN.05370610; Szeto CC, 2009, AM J KIDNEY DIS, V54, P702, DOI 10.1053/j.ajkd.2009.04.032; Uppuluri P, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005397; de Luijtgaarden MWM, 2016, NEPHROL DIAL TRANSPL, V31, P120, DOI 10.1093/ndt/gfv295; van Diepen ATN, 2013, PERITON DIALYSIS INT, V33, P604, DOI 10.3747/pdi.2012.00082; van Diepen ATN, 2012, CLIN J AM SOC NEPHRO, V7, P1266, DOI 10.2215/CJN.00980112; van Esch S, 2014, PERITON DIALYSIS INT, V34, P162, DOI 10.3747/pdi.2013.00275; Vargemezis V, 2001, NEPHROL DIAL TRANSPL, V16, P106, DOI 10.1093/ndt/16.suppl_6.106; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	40	11	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157870	10.1371/journal.pone.0157870	http://dx.doi.org/10.1371/journal.pone.0157870			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27336367	Green Published, Green Submitted, gold			2023-01-03	WOS:000378389200059
J	Mercadante, S; Adile, C; Caruselli, A; Ferrera, P; Costanzi, A; Marchetti, P; Casuccio, A				Mercadante, Sebastiano; Adile, Claudio; Caruselli, Amanda; Ferrera, Patrizia; Costanzi, Andrea; Marchetti, Paolo; Casuccio, Alessandra			The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patients' Oncological Pathway	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ASSESSMENT SCALE; OUTCOMES; IMPACT; MODEL; TEAM; LIFE	Aim The aim of this study was to assess how an admission to an acute palliative-supportive care unit (APSCU), may influence the therapeutic trajectory of advanced cancer patients. Methods A consecutive sample of advanced cancer patients admitted to APCU was assessed. The following parameters were collected: patients demographics, including age, gender, primary diagnosis, marital status, and educational level, performance status and reasons for and kind of admission, data about care-givers, recent anticancer treatments, being on/off treatment or uncertain, the previous care setting, who proposed the admission to APSCU. Physical and psychological symptoms were evaluated at admission and at time of discharge. The use of opioids was also recorded. Hospital staying was also recorded. At time of discharge the parameters were recorded and a follow-up was performed one month after discharge. Results 314 consecutive patients admitted to the APSCU were surveyed. Pain was the most frequent reason for admission. Changes of ESAS were highly significant, as well as the use of opioids and breakthrough pain medications (p <0.0005). A significant decrease of the number of "on therapy" patients was reported, and concomitantly a significant number of "off-therapy" patients increased. At one month follow-up, 38.9% patients were at home, 19.7% patients were receiving palliative home care, and 1.6% patients were in hospice. 68.5% of patients were still living. Conclusion Data of this study suggest that the APSCU may have a relevant role for managing the therapeutic trajectory of advanced cancer patients, limiting the risk of futile and aggressive treatment while providing an appropriate care setting.	[Mercadante, Sebastiano; Adile, Claudio; Ferrera, Patrizia] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Palermo, Italy; [Mercadante, Sebastiano; Adile, Claudio; Ferrera, Patrizia] La Maddalena Canc Ctr, Support Palliat Care Unit, Palermo, Italy; [Caruselli, Amanda] SAMO, Home Care Program, Palermo, Italy; [Costanzi, Andrea; Marchetti, Paolo] Univ Rome, Hosp St Andrea, Dept Oncol, Rome, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy	Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Palermo	Mercadante, S (corresponding author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Palermo, Italy.; Mercadante, S (corresponding author), La Maddalena Canc Ctr, Support Palliat Care Unit, Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013; Marchetti, Paolo/J-9890-2018	casuccio, alessandra/0000-0002-5676-9535; Marchetti, Paolo/0000-0002-9064-8761				Albanese TH, 2013, J PALLIAT MED, V16, P289, DOI 10.1089/jpm.2012.0243; Aprile G, 2013, SUPPORT CARE CANCER, V21, P397, DOI 10.1007/s00520-012-1524-6; Braiteh F, 2007, J PALLIAT MED, V10, P948, DOI 10.1089/jpm.2006.0257; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breuer B, 2011, J CLIN ONCOL, V29, P4769, DOI 10.1200/JCO.2011.35.0561; Bruera E, 1991, J Palliat Care, V7, P6; Bruera E, 2010, J CLIN ONCOL, V28, P4013, DOI 10.1200/JCO.2010.29.5618; Cassel JB, 2015, J PAIN SYMPTOM MANAG, V50, P741, DOI 10.1016/j.jpainsymman.2015.06.013; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Cheng Wen-Wu, 2005, J Palliat Med, V8, P1025, DOI 10.1089/jpm.2005.8.1025; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Elsayem A, 2010, SUPPORT CARE CANCER, V18, P67, DOI 10.1007/s00520-009-0631-5; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Gardiner C, 2013, PALLIATIVE MED, V27, P76, DOI 10.1177/0269216312447592; Hui D, 2010, J PALLIAT MED, V13, P49, DOI 10.1089/jpm.2009.0166; Ko W, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-960; Lagman R, 2008, AM J HOSP PALLIAT ME, V25, P24, DOI 10.1177/1049909107307375; Mercadante S, 2008, PALLIATIVE MED, V22, P760, DOI 10.1177/0269216308094338; Mercadante S, 2010, MINERVA ANESTESIOL, V76, P1060; Mercadante S, 2003, SUPPORT CARE CANCER, V11, P114, DOI 10.1007/s00520-002-0403-y; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P935, DOI 10.1007/s00520-012-1608-3; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P702, DOI 10.1016/j.jpainsymman.2011.01.014; Nathaniel JD, 2015, J PAIN SYMPTOM MANAG, V50, P147, DOI 10.1016/j.jpainsymman.2015.02.023; Nipp RD, 2005, BRIT J CANCER, V113, P6; Pantilat SZ, 2010, ARCH INTERN MED, V170, P2038, DOI 10.1001/archinternmed.2010.460; Paris J, 2014, J ONCOL PRACT, V10, P174, DOI 10.1200/JOP.2014.001429; Rigby A, 2008, CANCER-AM CANCER SOC, V113, P3267, DOI 10.1002/cncr.23909; Rocque GB, 2013, J ONCOL PRACT, V9, P51, DOI 10.1200/JOP.2012.000698; Saito AM, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-14; Shin SH, 2014, J PAIN SYMPTOM MANAG, V47, P1028, DOI 10.1016/j.jpainsymman.2013.07.015; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Vasile E, 2014, SUPPORT CARE CANCER, V22, P867, DOI 10.1007/s00520-013-2108-9; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	36	27	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2016	11	6							e0157300	10.1371/journal.pone.0157300	http://dx.doi.org/10.1371/journal.pone.0157300			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WX	27332884	Green Published, gold, Green Submitted			2023-01-03	WOS:000378212800024
J	Sapsirisavat, V; Vongsutilers, V; Thammajaruk, N; Pussadee, K; Riyaten, P; Kerr, S; Avihingsanon, A; Phanuphak, P; Ruxrungtham, K				Sapsirisavat, Vorapot; Vongsutilers, Vorasit; Thammajaruk, Narukjaporn; Pussadee, Kanitta; Riyaten, Prakit; Kerr, Stephen; Avihingsanon, Anchalee; Phanuphak, Praphan; Ruxrungtham, Kiat		PEDA Study Team	Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study	PLOS ONE			English	Article							ANTIMALARIAL-DRUGS; QUALITY; COUNTERFEIT; GUIDELINES; INFECTION; MEDICINES; THERAPY; AFRICA; SAFETY	Objectives Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV), we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam. Methods We sampled Tenofovir 300mg, Efavirenz 600mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia. Results A total of 42 batches of ARV from 15 sources were sampled from January-March 2015. Among those generics, 23, 17, 1, and 1 were Thai-made, Indian-made, Vietnamese-made and Chinese-made, respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription. Conclusion Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity along the HIV treatment and care cascade is available.	[Sapsirisavat, Vorapot; Thammajaruk, Narukjaporn; Pussadee, Kanitta; Riyaten, Prakit; Kerr, Stephen; Avihingsanon, Anchalee; Phanuphak, Praphan; Ruxrungtham, Kiat] Thai Red Cross AIDS Res Ctr, HIV NAT, 104 Ratchadamri Rd, Bangkok 10330, Thailand; [Vongsutilers, Vorasit] Chulalongkorn Univ, Fac Pharmaceut Sci, Rama 4 Rd, Bangkok 10330, Thailand; [Kerr, Stephen] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam Inst Global Hlth & Dev, Trinity Bldg C,Pietersbergweg 17, NL-1105 BM Amsterdam, Netherlands; [Avihingsanon, Anchalee; Phanuphak, Praphan; Ruxrungtham, Kiat] Chulalongkorn Univ, Dept Med, Fac Med, 254 Phyathai Rd, Bangkok, Thailand	Thai Red Cross Society; Chulalongkorn University; University of Amsterdam; Academic Medical Center Amsterdam; Chulalongkorn University	Ruxrungtham, K (corresponding author), Thai Red Cross AIDS Res Ctr, HIV NAT, 104 Ratchadamri Rd, Bangkok 10330, Thailand.; Ruxrungtham, K (corresponding author), Chulalongkorn Univ, Dept Med, Fac Med, 254 Phyathai Rd, Bangkok, Thailand.	rkiatchula@gmail.com	Vongsutilers, Vorasit/E-9317-2018; Kerr, Stephen/J-6126-2012	Vongsutilers, Vorasit/0000-0002-5352-7506; Kerr, Stephen/0000-0002-1919-4525; Ruxrungtham, Kiat/0000-0001-7348-2352	Thailand fiscal Year Research Fund through Chulalongkorn University; National Health Security Office (NHSO), Thailand	Thailand fiscal Year Research Fund through Chulalongkorn University; National Health Security Office (NHSO), Thailand	This study was supported by the Thailand fiscal Year 2014 Research Fund through Chulalongkorn University, and the National Health Security Office (NHSO), Thailand. The funders did not have any role in the study design, collection of data, analysis and interpretation of the results, writing the manuscript and deciding to submit the manuscript. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit the manuscript for publication.	[Anonymous], 2015, PREQ PROGR UN PROGR; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Hajjou M, 2015, AM J TROP MED HYG, V92, P68, DOI 10.4269/ajtmh.14-0535; Jang WY, 2012, INJURY, V43, P237, DOI 10.1016/j.injury.2011.10.020; Kurtz SP, 2015, 3 C ASS SOC SCI HUM; Kurtz SP, 2014, AIDS CARE, V26, P411, DOI 10.1080/09540121.2013.837139; Laurent C, 2007, AIDS, V21, P768, DOI 10.1097/QAD.0b013e328045c4d7; Lon CT, 2006, T ROY SOC TROP MED H, V100, P1019, DOI 10.1016/j.trstmh.2006.01.003; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Manosuthi W, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0053-z; Nagori BP, 2011, CURR MED RES OPIN, V27, P541, DOI 10.1185/03007995.2010.548374; Nayyar GML, 2012, LANCET INFECT DIS, V12, P488, DOI 10.1016/S1473-3099(12)70064-6; New Generic drug, 2007, NEW GEN DRUG; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Newton PN, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000052; Nsimba Stephen E D, 2008, East Afr J Public Health, V5, P205; Ramachandran G, 2004, AIDS, V18, P1482, DOI 10.1097/01.aids.0000131346.76289.27; Ramautarsing RA, 2013, ANTIVIR THER, V18, P249, DOI 10.3851/IMP2324; Surratt HL, 2013, AM J PUBLIC HEALTH, V103, P1026, DOI 10.2105/AJPH.2012.301092; The Joint United Nations Programme on HIV/AIDS, 2014, 2014 GLOB STAT; US Food and Drug Administration (FDA), DRUGS FDA GLOSS TERM; Wang T, 2015, J CLIN PHARM THER, V40, P68, DOI 10.1111/jcpt.12226; World Health Organization, 2014, QAS14590 WHO; World Health Organization, 2006, INT PHARM, Vfourth; World Health Organization, 2015, WHO LIST PREQ MED PR	25	0	0	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2016	11	6							e0157039	10.1371/journal.pone.0157039	http://dx.doi.org/10.1371/journal.pone.0157039			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WR	27322409	Green Published, gold, Green Submitted			2023-01-03	WOS:000378212000008
J	Hanney, WJ; Masaracchio, M; Liu, XL; Kolber, MJ				Hanney, William J.; Masaracchio, Michael; Liu, Xinliang; Kolber, Morey J.			The Influence of Physical Therapy Guideline Adherence on Healthcare Utilization and Costs among Patients with Low Back Pain: A Systematic Review of the Literature	PLOS ONE			English	Review							CLINICAL GUIDELINES; MANAGEMENT; PHYSIOTHERAPISTS; KNOWLEDGE; ATTITUDES; QUALITY; EXPENDITURES; PREVALENCE; DISABILITY; EXERCISE	Background Low back pain (LBP) is common and associated healthcare costs are significant. While clinical practice guidelines have been established in an attempt to reduce costs and healthcare utilization, it is unclear if adherence to physical therapy guidelines for those with LBP is efficacious. Therefore, the purpose of this study was to assess current evidence and evaluate the impact of physical therapy guideline adherence on subsequent healthcare costs and utilization for patients with LBP. Methods An electronic search was conducted in PubMed, CINAHL (EBSCO Host), AMED (Ovid), and PEDro. Studies included in this review were published in peer reviewed journals and the primary mode of treatment was administered by a physical therapist. Also, the definition of adherence was clearly defined based on claims data and at least one measure of cost or utilization reported. Quality assessment was evaluated via a modified Downs and Black checklist. Due to the conceptual heterogeneity in variable measurements, data were qualitatively synthesized and stratified by reported utilization and cost measures. Results A total of 256 results were identified and after omitting duplicates, 4 articles were retained, which were all retrospective in nature. Quality scores ranged between 19 and 21 points out of a possible 26 on the modified Downs and Black checklist. All identified studies used the same definition of guideline adherence, which focused on billing active codes and minimizing use of passive codes. The results demonstrated trends that, with a few exceptions, suggested those patients with LBP that were treated with an adherent guideline program demonstrated decreased healthcare utilization and an overall healthcare savings. Conclusion Preliminary evidence suggests that adherence to established clinical practice guidelines may assist with decreasing healthcare utilization and costs. Additional research based on prospective randomized controlled trials are needed to provide high quality evidence regarding the impact of guideline adherence among patients with LBP.	[Hanney, William J.] Univ Cent Florida, Dept Hlth Profess, Orlando, FL 32816 USA; [Masaracchio, Michael] Long Isl Univ, Dept Phys Therapy, Brooklyn, NY USA; [Liu, Xinliang] Univ Cent Florida, Dept Hlth Management & Informat, Orlando, FL 32816 USA; [Kolber, Morey J.] Nova SE Univ, Dept Phys Therapy, Ft Lauderdale, FL 33314 USA	State University System of Florida; University of Central Florida; Long Island University-Brooklyn Campus; State University System of Florida; University of Central Florida; Nova Southeastern University	Hanney, WJ (corresponding author), Univ Cent Florida, Dept Hlth Profess, Orlando, FL 32816 USA.	William.Hanney@ucf.edu			New York Physical Therapy Association	New York Physical Therapy Association	This study was supported by a research grant from the New York Physical Therapy Association.	[Anonymous], 1987, SPINE, V12, pS1; [Anonymous], 2001, CROSSING QUALITY CHA; Arnau JM, 2006, EUR SPINE J, V15, P543, DOI 10.1007/s00586-005-1027-y; Bekkering G., 2003, PHYSIOTHERAPY, V89, P82, DOI DOI 10.1016/S0031-9406(05)60579-2; Bekkering GE, 2005, QUAL SAF HEALTH CARE, V14, P107, DOI 10.1136/qshc.2003.009357; Burton AK, 1998, BAILLIERE CLIN RHEUM, V12, P17; Cassidy JD, 1998, SPINE, V23, P1860, DOI 10.1097/00007632-199809010-00012; Chenot JF, 2008, EUR J PAIN, V12, P275, DOI 10.1016/j.ejpain.2007.06.004; Childs JD, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0830-3; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cote AM, 2009, J OCCUP REHABIL, V19, P94, DOI 10.1007/s10926-009-9167-2; Delitto A, 2012, J ORTHOP SPORT PHYS, V42, pA1, DOI 10.2519/jospt.2012.42.4.A1; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Fritz JM, 2008, SPINE, V33, P1800, DOI 10.1097/BRS.0b013e31817bd853; Fritz JM, 2007, MED CARE, V45, P973, DOI 10.1097/MLR.0b013e318070c6cd; Fritz JM, 2013, ARCH PHYS MED REHAB, V94, P808, DOI 10.1016/j.apmr.2013.01.008; Fritz JM, 2012, SPINE, V37, P2114, DOI 10.1097/BRS.0b013e31825d32f5; Gellhorn AC, 2012, SPINE, V37, P775, DOI 10.1097/BRS.0b013e3181d79a09; Graves JM, 2014, HEALTH SERV RES, V49, P645, DOI 10.1111/1475-6773.12098; Graves JM, 2012, SPINE, V37, P1617, DOI 10.1097/BRS.0b013e318251887b; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Hanney WJ, 2010, PHYS THER REV, V15, P84, DOI 10.1179/174328810X12719009060308; Hanney WJ, 2010, AM J LIFESTYLE MED, V4, P166, DOI 10.1177/1559827609351134; Harstall C, 2011, J EVAL CLIN PRACT, V17, P693, DOI 10.1111/j.1365-2753.2010.01420.x; Hoenig JM, 2001, AM STAT, V55, P19, DOI 10.1198/000313001300339897; Hoy D, 2012, ARTHRITIS RHEUM-US, V64, P2028, DOI 10.1002/art.34347; Iles R, 2006, PHYSIOTHER RES INT, V11, P93, DOI 10.1002/pri.328; Jette DU, 2003, PHYS THER, V83, P786, DOI 10.1093/ptj/83.9.786; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Ladeira CE, 2015, J MAN MANIP THER, V23, P109, DOI 10.1179/2042618613Y.0000000065; Learman KE, 2014, PHYS THER, V94, P934, DOI 10.2522/ptj.20130567; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Nau E, 2008, STRENGTH COND J, V30, P43, DOI 10.1519/SSC.0b013e31816a6d0f; Ojha HA, 2014, PHYS THER, V94, P14, DOI 10.2522/ptj.20130096; Pabian Patrick, 2008, N Am J Sports Phys Ther, V3, P161; Savigny P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1805; Simmonds MJ, 2012, CLIN J PAIN, V28, P467, DOI 10.1097/AJP.0b013e31825bfe65; Smith M, 2013, J MANIP PHYSIOL THER, V36, P2, DOI 10.1016/j.jmpt.2012.12.001; Staal J.B., 2017, KNGF RICHTLIJN; Staal JB, 2003, OCCUP ENVIRON MED, V60, P618, DOI 10.1136/oem.60.9.618; Stevenson K, 2004, J EVAL CLIN PRACT, V10, P207, DOI 10.1111/j.1365-2753.2003.00479.x; Swinkels ICS, 2005, AUST J PHYSIOTHER, V51, P35, DOI 10.1016/S0004-9514(05)70051-9; van Tulder MW, 2004, SPINE, V29, pE357, DOI 10.1097/01.brs.0000137056.64166.51; Welsh Caitlyn, 2010, N Am J Sports Phys Ther, V5, P85; Williams CM, 2010, ARCH INTERN MED, V170, P271, DOI 10.1001/archinternmed.2009.507	47	49	49	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2016	11	6							e0156799	10.1371/journal.pone.0156799	http://dx.doi.org/10.1371/journal.pone.0156799			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DO1UG	27285608	Green Submitted, Green Published, gold			2023-01-03	WOS:000377564000022
J	van Mansfeld, R; de Vrankrijker, A; Brimicombe, R; Heijerman, H; van Berkhout, FT; Spitoni, C; Grave, S; van der Ent, C; Wolfs, T; Willems, R; Bonten, M				van Mansfeld, Rosa; de Vrankrijker, Angelica; Brimicombe, Roland; Heijerman, Harry; van Berkhout, Ferdinand Teding; Spitoni, Cristian; Grave, Sanne; van der Ent, Cornelis; Wolfs, Tom; Willems, Rob; Bonten, Marc			The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients	PLOS ONE			English	Article							EPIDEMIC STRAIN; TRANSMISSIBLE STRAINS; PARANASAL SINUSES; CROSS-INFECTION; SPREAD; CHILDREN; ADULTS	Introduction Segregation of patients with cystic fibrosis (CF) was implemented to prevent chronic infection with epidemic Pseudomonas aeruginosa strains with presumed detrimental clinical effects, but its effectiveness has not been carefully evaluated. Methods The effect of strict segregation on the incidence of P. aeruginosa infection in CF patients was investigated through longitudinal protocolized follow-up of respiratory tract infection before and after segregation. In two nested cross-sectional studies in 2007 and 2011 the P. aeruginosa population structure was investigated and clinical parameters were determined in patients with and without infection with the Dutch epidemic P. aeruginosa clone (ST406). Results Of 784 included patients 315 and 382 were at risk for acquiring chronic P. aeruginosa infection before and after segregation. Acquisition rates were, respectively, 0.14 and 0.05 per 1,000 days at risk (HR: 0.66, 95% CI [0.2548-1.541]; p = 0.28). An exploratory subgroup analysis indicated lower acquisition after segregation in children < 15 years of age (HR: 0.43, 95% CI[0.21-0.95]; p = 0.04). P. aeruginosa population structure did not change after segregation and ST406 was not associated with lung function decline, death or lung transplantation. Conclusions Strict segregation was not associated with a statistically significant lower acquisition of chronic P. aeruginosa infection and ST406 was not associated with adverse clinical outcome. After segregation there were no new acquisitions of ST406. In an unplanned exploratory analysis chronic acquisition of P. aeruginosa was lower after implementation of segregation in patients under 15 years of age.	[van Mansfeld, Rosa; Grave, Sanne; Willems, Rob; Bonten, Marc] UMCU, Dept Med Microbiol, Utrecht, Netherlands; [de Vrankrijker, Angelica; van der Ent, Cornelis] UMCU, Dept Pediat Pulm Dis, Utrecht, Netherlands; [Brimicombe, Roland] Haga Teaching Hosp, Dept Med Microbiol, The Hague, Netherlands; [Heijerman, Harry] Haga Teaching Hosp, Dept Pulmonol, The Hague, Netherlands; [van Berkhout, Ferdinand Teding] UMCU, Dept Pulmonol, Utrecht, Netherlands; [Spitoni, Cristian] Univ Utrecht, Dept Math, Utrecht, Netherlands; [Wolfs, Tom] UMCU, Dept Pediat Infect Dis, Utrecht, Netherlands; [Bonten, Marc] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Unilever; Utrecht University; Utrecht University Medical Center; Unilever; Utrecht University; Utrecht University Medical Center; Haga Hospital; Haga Hospital; Unilever; Utrecht University; Utrecht University Medical Center; Utrecht University; Unilever; Utrecht University; Utrecht University Medical Center	van Mansfeld, R (corresponding author), UMCU, Dept Med Microbiol, Utrecht, Netherlands.	r.vanmansfeld@vumc.nl	Willems, Rob JL/E-3681-2010	Willems, Rob JL/0000-0002-7370-0812; Van der Ent, Cornelis/0000-0002-2501-4121	Netherlands Organization for Scientific Research (VICI NWO) [918.76.611]	Netherlands Organization for Scientific Research (VICI NWO)(Netherlands Organization for Scientific Research (NWO))	This research was partly funded by the Netherlands Organization for Scientific Research (VICI NWO Grant 918.76.611). http://www.nwo.nl/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aanaes K, 2013, RHINOLOGY, V51, P222, DOI [10.4193/Rhino12.207, 10.4193/Rhin12.207]; Aaron SD, 2010, JAMA-J AM MED ASSOC, V304, P2145, DOI 10.1001/jama.2010.1665; Al-Aloul M, 2004, THORAX, V59, P334, DOI 10.1136/thx.2003.014258; Armstrong D, 2003, J CLIN MICROBIOL, V41, P2266, DOI 10.1128/JCM.41.5.2266-2267.2003; Ashish Abdul, 2013, JRSM Short Rep, V4, P1, DOI 10.1258/shorts.2012.012018; Ashish A, 2012, J CYST FIBROS, V11, P173, DOI 10.1016/j.jcf.2011.11.004; Brimicombe RW, 2008, J CYST FIBROS, V7, P30, DOI 10.1016/j.jcf.2007.04.002; Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0; Curran B, 2004, J CLIN MICROBIOL, V42, P5644, DOI 10.1128/JCM.42.12.5644-5649.2004; Cutting GR, 2015, NAT REV GENET, V16, P45, DOI 10.1038/nrg3849; de Vrankrijker AMM, 2011, CLIN MICROBIOL INFEC, V17, P382, DOI 10.1111/j.1469-0691.2010.03295.x; Dutch Institute for Healthcare Improvement, 2007, CBO GUID DIAGN TREAT; Emond MJ, 2012, NAT GENET, V44, P886, DOI 10.1038/ng.2344; Folkesson A, 2012, NAT REV MICROBIOL, V10, P841, DOI 10.1038/nrmicro2907; Fothergill JL, 2012, EUR RESPIR J, V40, P227, DOI 10.1183/09031936.00204411; Francisco AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-87; Francisco AP, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-152; Frederiksen B, 1999, PEDIATR PULM, V28, P159, DOI 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1; Green DM, 2012, J PEDIATR-US, V161, P290, DOI 10.1016/j.jpeds.2012.01.042; Griffiths AL, 2005, AM J RESP CRIT CARE, V171, P1020, DOI 10.1164/rccm.200409-1194OC; Griffiths AL, 2012, J CYST FIBROS, V11, P49, DOI 10.1016/j.jcf.2011.08.005; Hansen SK, 2012, ISME J, V6, P31, DOI 10.1038/ismej.2011.83; Johansen HK, 2012, J CYST FIBROS, V11, P525, DOI 10.1016/j.jcf.2012.04.011; Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595; Jones AM, 2005, AM J RESP CRIT CARE, V171, P257, DOI 10.1164/rccm.200404-513OC; Jones AM, 2002, THORAX, V57, P924, DOI 10.1136/thorax.57.11.924; Jones AM, 2001, LANCET, V358, P557, DOI 10.1016/S0140-6736(01)05714-2; Koopman M, 2011, RESP MED, V105, P15, DOI 10.1016/j.rmed.2010.07.020; Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8; Liu GH, 1997, BIOMETRICS, V53, P937, DOI 10.2307/2533554; McCallum SJ, 2001, LANCET, V358, P558, DOI 10.1016/S0140-6736(01)05715-4; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Salunkhe P, 2005, J BACTERIOL, V187, P4908, DOI 10.1128/JB.187.14.4908-4920.2005; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Taccetti G, 2012, THORAX, V67, P853, DOI 10.1136/thoraxjnl-2011-200832; Tingpej P, 2010, RESPIROLOGY, V15, P923, DOI 10.1111/j.1440-1843.2010.01792.x; van Mansfeld R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013482; Van Mansfeld R, 2009, J CLIN MICROBIOL, V47, P4096, DOI 10.1128/JCM.01462-09; Wiehlmann L, 2012, INT J MED MICROBIOL, V302, P69, DOI 10.1016/j.ijmm.2011.11.001	39	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0157189	10.1371/journal.pone.0157189	http://dx.doi.org/10.1371/journal.pone.0157189			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TW	27280467	Green Published, gold, Green Submitted			2023-01-03	WOS:000377563000106
J	Al-Mahtab, M; Bazinet, M; Vaillant, A				Al-Mahtab, Mamun; Bazinet, Michel; Vaillant, Andrew			Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg plus Chronic Hepatitis B Infection	PLOS ONE			English	Article							SURFACE-ANTIGEN; VIRUS INFECTION; ANTISENSE OLIGONUCLEOTIDE; ADEFOVIR DIPIVOXIL; NATURAL-HISTORY; IMMUNE GLOBULIN; LAMIVUDINE; ENTECAVIR; ESTABLISHMENT; COMBINATION	Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment, was evaluated in two clinical studies in patients with HBeAg positive chronic HBV infection. The REP 101 study examined REP 2055 monotherapy in 8 patients and the REP 102 study examined REP 2139-Ca, in monotherapy in 12 patients, 9 of which transitioned to short term combined treatment with pegylated interferon alpha 2a or thymosin alpha 1. In both studies NAP monotherapy was accompanied by 2-7 log reductions of serum HBsAg, 3-9 log reductions in serum HBV DNA and the appearance of serum anti-HBsAg antibodies (10-1712 mIU/ml). Eight of the 9 patients transitioning to combined treatment with immunotherapy (pegylated interferon or thymosin alpha 1) in the REP 102 study experienced HBsAg loss and all 9 patients experienced substantial increases in serum anti-HBsAg antibody titers before withdrawal of therapy. For 52 weeks after removal of REP 2055 therapy, rebound of serum viremia (HBV DNA > 1000 copies / ml, HBsAg > 1IU / ml) was not observed in 3 / 8 patients. Suppression of serum virema was further maintained for 290 and 231 weeks in 2 of these patients. After withdrawal of all therapy in the 9 patients that transitioned to combination therapy in the REP 102 study, 8 patients achieved HBV DNA < 116 copies / ml after treatment withdrawal. Viral rebound occurred over a period of 12 to 123 weeks in 7 patients but was still absent in two patients at 135 and 137 weeks of follow-up. Administration tolerability issues observed with REP 2055 were rare with REP 2139-Ca but REP 2139-Ca therapy was accompanied by hair loss, dysphagia and dysgeusia which were considered related to heavy metal exposure endemic at the trial site. These preliminary studies suggest that NAP can elicit important antiviral responses during treatment which may improve the effect of immunotherapy. NAPs may be a potentially useful component of future combination therapies for the treatment of chronic hepatitis B.	[Al-Mahtab, Mamun] Bangabandhu Sheikh Mujib Med Univ, Shahbagh Rd, Dhaka 1000, Bangladesh; [Bazinet, Michel; Vaillant, Andrew] Replicor Inc, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada	Bangabandhu Sheikh Mujib Medical University (BSMMU)	Vaillant, A (corresponding author), Replicor Inc, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	availlant@replicor.com		VAILLANT, Andrew/0000-0002-1433-0700	Replicor Inc.	Replicor Inc.	This work was supported by Replicor Inc. The funder provided support in the form of salaries for authors [AV, MB] and funds required to conduct all clinical activities, but did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Mahtab M, 2015, J CLIN VIROL, V69, P228, DOI 10.1016/j.jcv.2015.06.021; Burda MR, 2001, ANTIVIR RES, V52, P125, DOI 10.1016/S0166-3542(01)00177-2; Cardin RD, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-214; Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285; Cheng JD, 2005, J HEPATOL, V43, P465, DOI 10.1016/j.jhep.2005.02.033; Chi KN, 2005, J NATL CANCER I, V97, P1287, DOI 10.1093/jnci/dji252; Cooreman MP, 2001, J BIOMED SCI, V8, P237, DOI 10.1007/BF02256597; den Brouw MLO, 2009, IMMUNOLOGY, V126, P280, DOI 10.1111/j.1365-2567.2008.02896.x; Franke C, 2007, VIROLOGY, V359, P126, DOI 10.1016/j.virol.2006.09.006; Frenette CT, 2009, AM J GASTROENTEROL, V104, P1948, DOI 10.1038/ajg.2009.204; Fung J, 2011, AM J GASTROENTEROL, V106, P1766, DOI 10.1038/ajg.2011.253; Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087; Hsu CW, 2011, HEPATOLOGY, V54, P101, DOI 10.1002/hep.24363; Islam M. S., 2014, International Food Research Journal, V21, P2121; Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002; Kastelein JJP, 2006, CIRCULATION, V114, P1729, DOI 10.1161/CIRCULATIONAHA.105.606442; Lai CL, 2006, NEW ENGL J MED, V354, P1011, DOI 10.1056/NEJMoa051287; Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513; Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431; Marcellin P, 2008, NEW ENGL J MED, V359, P2442, DOI 10.1056/NEJMoa0802878; Mata JE, 2000, J TOXICOL-CLIN TOXIC, V38, P383, DOI 10.1081/CLT-100100947; Monia BP, 1996, J BIOL CHEM, V271, P14533, DOI 10.1074/jbc.271.24.14533; Moucari R, 2009, HEPATOLOGY, V49, P1151, DOI 10.1002/hep.22744; Noordeen F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140909; Noordeen F, 2013, ANTIMICROB AGENTS CH, V57, P5299, DOI 10.1128/AAC.01005-13; Noordeen F, 2013, ANTIMICROB AGENTS CH, V57, P5291, DOI 10.1128/AAC.01003-13; Protzer-Knolle U, 1998, HEPATOLOGY, V27, P254, DOI 10.1002/hep.510270138; Rakib MA., 2014, INT RES J ENV SCI, V3, P1; Robbins M, 2007, MOL THER, V15, P1663, DOI 10.1038/sj.mt.6300240; Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X; Shi BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044900; Tolcher AW, 2004, CLIN CANCER RES, V10, P5048, DOI 10.1158/1078-0432.CCR-03-0701; Tong S, 2000, B WORLD HEALTH ORGAN, V78, P1068; Vanlandschoot P, 2002, J GEN VIROL, V83, P1281, DOI 10.1099/0022-1317-83-6-1281; Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Wong DKH, 2013, CLIN GASTROENTEROL H, V11, P1004, DOI 10.1016/j.cgh.2013.01.026; Wu J, 2009, HEPATOLOGY, V49, P1132, DOI 10.1002/hep.22751; Xu Y, 2009, MOL IMMUNOL, V46, P2640, DOI 10.1016/j.molimm.2009.04.031; Zoutendijk R, 2011, J INFECT DIS, V204, P415, DOI 10.1093/infdis/jir282	39	118	125	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2016	11	6							e0156667	10.1371/journal.pone.0156667	http://dx.doi.org/10.1371/journal.pone.0156667			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN8ZV	27257978	Green Published, Green Submitted, gold			2023-01-03	WOS:000377369700098
J	Carmello, JC; Alves, F; Basso, FG; Costa, CAD; Bagnato, VS; Mima, EGD; Pavarina, AC				Carmello, Juliana Cabrini; Alves, Fernanda; Basso, Fernanda G.; de Souza Costa, Carlos Alberto; Bagnato, Vanderlei Salvador; de Oliveira Mima, Ewerton Garcia; Pavarina, Ana Claudia			Treatment of Oral Candidiasis Using Photodithazine (R)-Mediated Photodynamic Therapy In Vivo	PLOS ONE			English	Article							LEVEL LASER IRRADIATION; MURINE MODEL; ALBICANS; INACTIVATION; SUSCEPTIBILITY; EPIDEMIOLOGY; FLUCONAZOLE; NYSTATIN; ADHESION; GROWTH	This study evaluated the effectiveness of antimicrobial photodynamic therapy (aPDT) in the treatment of oral candidiasis in a murine model using Photodithazine (R) (PDZ). This model of oral candidiasis was developed to allow the monitoring of the infection and the establishment of the aPDT treatment. Six-week-old female mice were immunosuppressed and inoculated with C. albicans to induce oral candidiasis. PDZ-mediated aPDT and nystatin treatment were carried out for 5 consecutive days with one application per day. The macroscopic evaluation of oral lesions was performed. After each treatment, the tongue was swabbed to recover C. albicans cells. Viable colonies were quantified and the number of CFU/ml determined. The animals were sacrificed 24 hours and 7 days after treatment and the tongues were surgically removed for histological analysis and analysis of inflammatory cytokines expression (IL-1, TNF-alpha and IL-6) by RT-qPCR. Data were analyzed by two-way ANOVA. PDZ-mediated aPDT was as effective as Nystatin (NYS group) in the inactivation of C. albicans, reducing 3 and 3.2 logs(10) respectively, 24 h after treatment (p<0.05). Animals underwent PDZ-mediated aPDT showed complete remission of oral lesions, while animals treated with NYS presented partial remission of oral lesions in both periods assessed. Histological evaluation revealed mild inflammatory infiltrate in the groups treated with aPDT and NYS in both periods assessed. The aPDT induced the TNF-alpha expression when compared with the control (P-L-) (p<0.05), 24 h and 7 days after treatment. In summary, the murine model developed here was able to mimic the infection and PDZ-mediated aPDT was effective to treat mice with oral candidiasis.	[Carmello, Juliana Cabrini; Alves, Fernanda; de Oliveira Mima, Ewerton Garcia; Pavarina, Ana Claudia] UNESP Univ Estadual Paulista, Araraquara Dent Sch, Dept Dent Mat & Prosthodont, Araraquara, SP, Brazil; [Basso, Fernanda G.; de Souza Costa, Carlos Alberto] UNESP Univ Estadual Paulista, Araraquara Dent Sch, Dept Physiol & Pathol, Araraquara, SP, Brazil; [Bagnato, Vanderlei Salvador] Univ Sao Paulo, Phys Inst Sao Carlos, Sao Carlos, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade de Sao Paulo	Pavarina, AC (corresponding author), UNESP Univ Estadual Paulista, Araraquara Dent Sch, Dept Dent Mat & Prosthodont, Araraquara, SP, Brazil.	pavarina@foar.unesp.br	Mima, Ewerton/X-5176-2019; Pavarina, Ana Claudia/J-8640-2013; Mima, Ewerton/F-9496-2014; Bagnato, Vanderlei S/C-3133-2012; Alves, Fernanda/AAJ-3470-2020; Carmello, Juliana Cabrini/J-8305-2016; de Souza Costa, Carlos Alberto/C-6799-2012	Mima, Ewerton/0000-0002-9575-7625; Mima, Ewerton/0000-0002-9575-7625; de Souza Costa, Carlos Alberto/0000-0002-7455-6867; Pavarina, Ana Claudia/0000-0002-9231-1994; INCT de Optica Basica e Aplicada as Ciencias da Vida (CNPq), CePOF (FAPESP)/0000-0002-6403-4037; Bagnato, Vanderlei Salvador/0000-0003-4833-239X; Cabrini Carmello, Juliana/0000-0002-5285-0571	Sao Paulo Research Foundation (FAPESP) [2012/17468-2]; Centro de Pesquisa, Inovacao e Difusao (CEPID) [2013/07276-1]; Fundacao para o Desenvolvimento da UNESP-FUNDUNESP-PROINTER (PROPe/CDC)	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Centro de Pesquisa, Inovacao e Difusao (CEPID); Fundacao para o Desenvolvimento da UNESP-FUNDUNESP-PROINTER (PROPe/CDC)	This work was supported by the Sao Paulo Research Foundation (FAPESP), grants number 2012/17468-2 (http://www.bv.fapesp.br/pt/pesquisa/?sort=-data_inicio&q2=% 28id_pesquisador_exact%3A179294%29+AND+%28%28bolsa_exact%3A%22Bolsas+no+Brasil%22+AND+situacao_exact%3A%22Conclu%C3%ADdos%22%29%29) to JCC, Centro de Pesquisa, Inovacao e Difusao (CEPID), grants number 2013/07276-1 (http://www.bv.fapesp.br/pt/auxilios/58564/cepof-centro-de-pesquisa-em-optica-e-fotonica/ ACP) and Fundacao para o Desenvolvimento da UNESP-FUNDUNESP-PROINTER (PROPe/CDC) to ACP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akpan A, 2002, POSTGRAD MED J, V78, P455, DOI 10.1136/pmj.78.922.455; Blignaut E, 1999, SADJ, V54, P605; Blomgren J, 1998, ACTA ODONTOL SCAND, V56, P202, DOI 10.1080/00016359850142790; Costa ACBP, 2012, OR SURG OR MED OR PA, V114, P67, DOI 10.1016/j.oooo.2012.02.002; Brackett CM, 2011, PHOTOCH PHOTOBIO SCI, V10, P649, DOI 10.1039/c0pp00354a; Brandis A, 2005, PHOTOCHEM PHOTOBIOL, V81, P983, DOI 10.1562/2004-12-01-RA-389R1.1; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Camargo MR, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-98; Carmello JC, 2015, PHOTOCH PHOTOBIO SCI, V14, P1319, DOI 10.1039/c4pp00368c; Quishida CCC, 2015, LASER MED SCI, V30, P685, DOI 10.1007/s10103-013-1397-z; Darwazeh AMG, 1997, J ORAL PATHOL MED, V26, P233, DOI 10.1111/j.1600-0714.1997.tb01229.x; Mima EGD, 2010, ORAL SURG ORAL MED O, V109, P392, DOI 10.1016/j.tripleo.2009.10.006; Demidova TN, 2004, INT J IMMUNOPATH PH, V17, P245, DOI 10.1177/039463200401700304; Donnelly RF, 2008, MICROBIOL RES, V163, P1, DOI 10.1016/j.micres.2007.08.001; Dovigo LN, 2013, BIOFOULING, V29, P1057, DOI 10.1080/08927014.2013.827668; Dovigo LN, 2013, MED MYCOL, V51, P243, DOI 10.3109/13693786.2012.714081; Dovigo LN, 2011, MYCOSES, V54, P123, DOI 10.1111/j.1439-0507.2009.01769.x; Eggimann P, 2003, LANCET INFECT DIS, V3, P685, DOI 10.1016/S1473-3099(03)00801-6; Engelmann M., 2007, J BIOENERG BIOMEMBR, V39, P175, DOI DOI 10.1007/S10863-007-9075-0; Firczuk M, 2011, PHOTOCH PHOTOBIO SCI, V10, P653, DOI 10.1039/c0pp00308e; Gavish L, 2004, LASER SURG MED, V35, P369, DOI 10.1002/lsm.20108; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Gollnick SO, 1997, CANCER RES, V57, P3904; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Jonker MA, 2010, J TRAUMA, V69, P843, DOI 10.1097/TA.0b013e3181c45284; Junqueira JC, 2009, LASER MED SCI, V24, P877, DOI 10.1007/s10103-009-0673-4; KABBUR MB, 1995, COMP HAEMATOL INT, V5, P47, DOI 10.1007/BF00214490; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Kong EF, 2015, INFECT IMMUN, V83, P604, DOI 10.1128/IAI.02843-14; Konopka K, 2007, J DENT RES, V86, P694, DOI 10.1177/154405910708600803; Lambrechts SAG, 2005, ANTIMICROB AGENTS CH, V49, P2026, DOI 10.1128/AAC.49.5.2026-2034.2005; Lushchak, 2001, COMP BIOCH PHYSL C, V153, P175, DOI DOI 10.1016/J.CBPC.2010.10.004; Mima EG, 2012, CLIN MICROBIOL INFEC, V18, pE380, DOI 10.1111/j.1469-0691.2012.03933.x; Monfrecola G, 2004, PHOTOCH PHOTOBIO SCI, V3, P419, DOI 10.1039/b315629j; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Ogawa Y, 2006, J INVEST DERMATOL, V126, P349, DOI 10.1038/sj.jid.5700081; Park H, 2014, VIRULENCE, V5, P625, DOI 10.4161/viru.29699; Pires L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085431; Sanglard D, 2009, FEMS YEAST RES, V9, P1029, DOI 10.1111/j.1567-1364.2009.00578.x; Sardi JCO, 2013, J MED MICROBIOL, V62, P10, DOI 10.1099/jmm.0.045054-0; Seneviratne CJ, 2009, ARCH ORAL BIOL, V54, P1052, DOI 10.1016/j.archoralbio.2009.08.002; Shao Lu-Cheng, 2007, Yaoxue Xuebao, V42, P1129; Soares BM, 2009, J PHOTOCH PHOTOBIO B, V94, P65, DOI 10.1016/j.jphotobiol.2008.07.013; Sorgo AG, 2013, FEMS MICROBIOL LETT, V338, P10, DOI 10.1111/1574-6968.12049; Stadler I, 2000, LASER SURG MED, V27, P255, DOI 10.1002/1096-9101(2000)27:3<255::AID-LSM7>3.0.CO;2-L; Strakhovskaya M. G., 2002, Mikrobiologiya, V71, P345; Strakhovskaya M G, 2002, Dokl Biochem Biophys, V384, P155, DOI 10.1023/A:1016072130789; Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184; Takakura N, 2003, MICROBIOL IMMUNOL, V47, P321, DOI 10.1111/j.1348-0421.2003.tb03403.x; Teichert MC, 2002, ORAL SURG ORAL MED O, V93, P155, DOI 10.1067/moe.2002.120051; Totti Marilda Aparecida Gonçalves, 2004, Braz. oral res., V18, P202, DOI 10.1590/S1806-83242004000300005	52	39	41	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2016	11	6							e0156947	10.1371/journal.pone.0156947	http://dx.doi.org/10.1371/journal.pone.0156947			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN6XB	27253525	gold, Green Published, Green Submitted			2023-01-03	WOS:000377218700067
J	Wong, J; Motulsky, A; Eguale, T; Buckeridge, DL; Abrahamowicz, M; Tamblyn, R				Wong, Jenna; Motulsky, Aude; Eguale, Tewodros; Buckeridge, David L.; Abrahamowicz, Michal; Tamblyn, Robyn			Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006-2015	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Wong, Jenna; Motulsky, Aude; Buckeridge, David L.; Abrahamowicz, Michal; Tamblyn, Robyn] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Eguale, Tewodros] Massachusetts Coll Pharm & Hlth Sci, Sch Pharm, Boston, MA USA	McGill University	Wong, J (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Fac Med, Clin & Hlth Informat Res Grp, 1140 Pine Ave W, Montreal, PQ H3A 1A3, Canada.	jenna.wong@mail.mcgill.ca	Tamblyn, Robyn/L-6010-2016					Bartlett Gillian, 2005, Acta bioeth., V11, P145, DOI 10.4067/S1726-569X2005000200005; CAREY V, 1993, BIOMETRIKA, V80, P517, DOI 10.2307/2337173; Eguale T, 2010, DRUG SAFETY, V33, P559, DOI 10.2165/11534580-000000000-00000; Gardarsdottir H, 2007, J AFFECT DISORDERS, V98, P109, DOI 10.1016/j.jad.2006.07.003; National Center for Health Statistics, HLTH US 2010 SPEC FE; Tamblyn R, 2006, J AM MED INFORM ASSN, V13, P148, DOI 10.1197/jamia.M1887	6	98	100	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2016	315	20					2230	2232		10.1001/jama.2016.3445	http://dx.doi.org/10.1001/jama.2016.3445			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM4US	27218634	Green Published, Bronze			2023-01-03	WOS:000376343000021
J	Schmidt, C				Schmidt, Charles			Controlled attack	NATURE			English	Editorial Material																			0	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2016	537	7620					S109	S110		10.1038/537S109a	http://dx.doi.org/10.1038/537S109a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV7EC	27626780	Bronze			2023-01-03	WOS:000383098000006
J	Larochelle, MR; Liebschutz, JM; Zhang, F; Ross-Degnan, D; Wharam, JF				Larochelle, Marc R.; Liebschutz, Jane M.; Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank			Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter							TIME-VARYING COVARIATE; KAPLAN-MEIER ESTIMATOR; IMPACT		[Larochelle, Marc R.; Liebschutz, Jane M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Larochelle, Marc R.; Liebschutz, Jane M.] Boston Med Ctr, Boston, MA USA; [Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank] Harvard Med Sch, Boston, MA 02115 USA; [Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank] Harvard Pilgrim Hlth Care Inst, Boston, MA USA	Boston University; Boston Medical Center; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Larochelle, MR (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.		Zhang, Fang/HHN-2153-2022	Wharam, James/0000-0003-2053-0757				Beyersmann J, 2006, AM STAT, V60, P295; Snapinn SM, 2005, AM STAT, V59, P301, DOI 10.1198/000313005X70371	2	14	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 6	2016	165	5					376	377		10.7326/L16-0168	http://dx.doi.org/10.7326/L16-0168			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV3BC	27595218				2023-01-03	WOS:000382795000011
J	Wanner, C; Amann, K; Shoji, T				Wanner, Christoph; Amann, Kerstin; Shoji, Tetsuo			The heart and vascular system in dialysis	LANCET			English	Article							CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY-DISEASE; STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; CALCIFICATION PROPENSITY; ENDOTHELIAL DYSFUNCTION; PULMONARY-HYPERTENSION; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; HEMODIALYSIS-PATIENTS	The heart and the vascular tree undergo major structural and functional changes when kidney function declines and renal replacement therapy is required. The many cardiovascular risk factors and adaptive changes the heart undergoes include left ventricular hypertrophy and dilatation with concomitant systolic and diastolic dysfunction. Myocardial fibrosis is the consequence of impaired angio-adaptation, reduced capillary angiogenesis, myocyte-capillary mismatch, and myocardial micro-arteriopathy. The vascular tree can be affected by both atherosclerosis and arteriosclerosis with both lipid rich plaques and abundant media calcification. Development of cardiac and vascular disease is rapid, especially in young patients, and the phenotype resembles all aspects of an accelerated ageing process and latent cardiac failure. The major cause of left ventricular hypertrophy and failure and the most common problem directly affecting myocardial function is fluid overload and, usually, hypertension. In situations of stress, such as intradialytic hypotension and hypoxaemia, the hearts of these patients are more vulnerable to developing cardiac arrest, especially when such episodes occur frequently. As a result, cardiac and vascular mortality are several times higher in dialysis patients than in the general population. Trials investigating one pharmacological intervention (eg, statins) have shown limitations. Pragmatic designs for large trials on cardio-active interventions are mandatory for adequate cardioprotective renal replacement therapy.	[Wanner, Christoph] Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany; [Wanner, Christoph] Univ Hosp Wurzburg, Div Renal, Wurzburg, Germany; [Amann, Kerstin] Univ Erlangen Nurnberg, Dept Nephropathol, Dept Pathol, Erlangen, Germany; [Shoji, Tetsuo] Osaka City Univ, Grad Sch Med, Dept Geriatr & Vasc Med, Osaka, Japan	University of Wurzburg; University of Wurzburg; University of Erlangen Nuremberg; Osaka Metropolitan University	Wanner, C (corresponding author), Med Univ Klin, D-97080 Wurzburg, Germany.	wanner_c@ukw.de			German Research Foundation (Deutsche Forschungsgemeinschaft) [AM 93/12-1]; Bundesministerium fur Bildung und Forschung [BMFBF01 EO1004]	German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; grant AM 93/12-1) and by the Bundesministerium fur Bildung und Forschung (BMFBF01 EO1004). We thank Nathan Levin for his advice.	Agarwal R, 2014, NEPHROL DIAL TRANSPL, V29, P672, DOI 10.1093/ndt/gft515; Amann K, 1998, J AM SOC NEPHROL, V9, P1018; Amann K, 2011, AM J PHYSIOL-RENAL, V300, pF105, DOI 10.1152/ajprenal.00363.2010; Amann K, 2003, KIDNEY INT, V63, P1708, DOI 10.1046/j.1523-1755.2003.00927.x; AMANN K, 1992, KIDNEY INT, V42, P1079, DOI 10.1038/ki.1992.390; Amann K, 2006, J AM SOC NEPHROL, V17, P2112, DOI 10.1681/ASN.2006030204; Arismendi-Morillo G, 2010, ULTRASTRUCT PATHOL, V34, P214, DOI 10.3109/01913121003743690; Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; Berg AH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005218; Buzello M, 2003, J AM SOC NEPHROL, V14, P311, DOI 10.1097/01.ASN.0000045048.71975.FC; Chang AR, 2014, AM J KIDNEY DIS, V64, P567, DOI 10.1053/j.ajkd.2014.04.028; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Cice G, 2003, J AM COLL CARDIOL, V41, P1438, DOI 10.1016/S0735-1097(03)00241-9; Cice G, 2001, J AM COLL CARDIOL, V37, P407, DOI 10.1016/S0735-1097(00)01158-X; Davison SN, 2015, KIDNEY INT, V88, P447, DOI 10.1038/ki.2015.110; de Bie MK, 2009, EUR HEART J, V30, P1559, DOI 10.1093/eurheartj/ehp185; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Di Marco GS, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0487-4; Di Marco GS, 2009, J AM SOC NEPHROL, V20, P2235, DOI 10.1681/ASN.2009010061; Dikow R, 2004, J AM SOC NEPHROL, V15, P1530, DOI 10.1097/01.ASN.0000130154.42061.C6; Drechsler C, 2015, KIDNEY INT, V87, P1201, DOI 10.1038/ki.2014.429; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Flisinski M, 2012, KIDNEY BLOOD PRESS R, V35, P608, DOI 10.1159/000339706; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Grabner A, 2015, CELL METAB, V22, P1020, DOI 10.1016/j.cmet.2015.09.002; Hase H, 2006, KIDNEY INT, V70, P1142, DOI 10.1038/sj.ki.5001726; Hothi DK, 2009, CLIN J AM SOC NEPHRO, V4, P790, DOI 10.2215/CJN.05921108; Hu MC, 2015, J AM SOC NEPHROL, V26, P1290, DOI 10.1681/ASN.2014050465; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826; Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609; Iseki K, 2000, AM J KIDNEY DIS, V36, P820, DOI 10.1053/ajkd.2000.17676; Issa N, 2008, TRANSPLANTATION, V86, P1384, DOI 10.1097/TP.0b013e318188d640; Iwasaki M, 2014, J ATHEROSCLER THROMB, V21, P593; Ix JH, 2003, J AM SOC NEPHROL, V14, P3233, DOI 10.1097/01.ASN.0000095642.25603.7A; Jacobi J, 2006, KIDNEY INT, V69, P2013, DOI 10.1038/sj.ki.5000448; Jacobi J, 2004, CIRCULATION, V110, P2424, DOI 10.1161/01.CIR.0000145142.85645.EA; Jefferies HJ, 2011, CLIN J AM SOC NEPHRO, V6, P1326, DOI 10.2215/CJN.05200610; Joki N, 1997, NEPHROL DIAL TRANSPL, V12, P718, DOI 10.1093/ndt/12.4.718; Keyzer CA, 2016, J AM SOC NEPHROL, V27, P239, DOI 10.1681/ASN.2014070670; Kooman JP, 2017, EXP GERONTOL, V87, P156, DOI 10.1016/j.exger.2016.02.003; Kopecky C, 2015, CLIN J AM SOC NEPHRO, V10, P224, DOI 10.2215/CJN.06560714; Kovesdy CP, 2008, KIDNEY INT, V73, P1355, DOI 10.1038/ki.2008.35; Kuro-o M, 2013, NAT REV NEPHROL, V9, P650, DOI 10.1038/nrneph.2013.111; Levin A, 2014, NEPHROL DIAL TRANSPL, V29, P1037, DOI 10.1093/ndt/gft479; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Levin NW, 2011, CURR OPIN NEPHROL HY, V20, P577, DOI 10.1097/MNH.0b013e32834bbae1; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; Litwin M, 2005, J AM SOC NEPHROL, V16, P1494, DOI 10.1681/ASN.2004110932; London GM, 2016, J AM SOC NEPHROL, V27, P1837, DOI 10.1681/ASN.2015060617; Maggiore Q, 2002, AM J KIDNEY DIS, V40, P280, DOI 10.1053/ajkd.2002.34506; Matsui M, 2014, KIDNEY INT, V85, P393, DOI 10.1038/ki.2013.339; Meyring-Wosten A, 2016, CLIN J AM SOC NEPHRO, V11, P616, DOI 10.2215/CJN.08510815; Nishizawa Y, 2001, AM J KIDNEY DIS, V38, pS4, DOI 10.1053/ajkd.2001.27380; O'Hare AM, 2005, J AM SOC NEPHROL, V16, P514, DOI 10.1681/ASN.2004050409; Obi Y, 2016, AM J KIDNEY DIS, V68, P256, DOI 10.1053/j.ajkd.2016.01.008; Odudu A, 2015, CLIN J AM SOC NEPHRO, V10, P1408, DOI 10.2215/CJN.00200115; Ok E, 2016, LANCET, V388, P285, DOI 10.1016/S0140-6736(16)30389-0; Ortiz A, 2014, LANCET, V383, P1831, DOI 10.1016/S0140-6736(14)60384-6; Pabst S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035310; Paloian NJ, 2014, AM J PHYSIOL-RENAL, V307, pF891, DOI 10.1152/ajprenal.00163.2014; Parfrey PS, 1996, NEPHROL DIAL TRANSPL, V11, P1277; Pinkau T, 2004, J AM SOC NEPHROL, V15, P517, DOI 10.1097/01.ASN.0000107565.17553.71; Raschenberger J, 2015, ATHEROSCLEROSIS, V242, P529, DOI 10.1016/j.atherosclerosis.2015.08.020; Rigatto C, 2009, CLIN J AM SOC NEPHRO, V4, P291, DOI 10.2215/CJN.01840408; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Schwarz U, 2000, NEPHROL DIAL TRANSPL, V15, P218, DOI 10.1093/ndt/15.2.218; Shoji T, 2013, AM J KIDNEY DIS, V62, P568, DOI 10.1053/j.ajkd.2013.02.362; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; Siedlecki AM, 2009, KIDNEY INT, V75, P800, DOI 10.1038/ki.2008.690; Silbernagel G, 2015, J AM COLL CARDIOL, V65, P2291, DOI 10.1016/j.jacc.2015.03.551; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Sise ME, 2013, KIDNEY INT, V84, P682, DOI 10.1038/ki.2013.186; Smith ER, 2014, J AM SOC NEPHROL, V25, P339, DOI 10.1681/ASN.2013060635; Smith GL, 2008, J AM SOC NEPHROL, V19, P141, DOI 10.1681/ASN.2007050554; Soriano S, 2014, AM J PHYSIOL-RENAL, V307, pF1302, DOI 10.1152/ajprenal.00114.2014; Speer T, 2013, NEPHROL DIAL TRANSPL, V28, P2456, DOI 10.1093/ndt/gft080; Stewart J, 2004, AM J PHYSIOL-HEART C, V287, pH2687, DOI 10.1152/ajpheart.00287.2004; Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466; Svensson M, 2006, CLIN J AM SOC NEPHRO, V1, P780, DOI 10.2215/CJN.00630206; Tonelli M, 2013, J AM SOC NEPHROL, V24, P979, DOI 10.1681/ASN.2012080870; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Wetmore JB, 2012, NEPHRON CLIN PRACT, V122, P9, DOI 10.1159/000347143; Wiley LA, 2006, INVEST OPHTH VIS SCI, V47, P439, DOI 10.1167/iovs.05-0656; Zewinger S, 2015, EUR HEART J, V36, P3007, DOI 10.1093/eurheartj/ehv352; Zoccali C, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133729; Zoccali C, 2002, HYPERTENSION, V40, P41, DOI 10.1161/01.HYP.0000022063.50739.60; Zoccali C, 2001, J HYPERTENS, V19, P287, DOI 10.1097/00004872-200102000-00016	89	160	169	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	2016	388	10041					276	284		10.1016/S0140-6736(16)30508-6	http://dx.doi.org/10.1016/S0140-6736(16)30508-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DR2LN	27226133				2023-01-03	WOS:000379736100032
J	Marconi, DG; Resende, BD; Rauber, E; Soares, PD; Fernandes, JM; Mehta, N; Carvalho, AL; Kupelian, PA; Chen, A				Marconi, Daniel Grossi; Resende, Bruno da Costa; Rauber, Erick; Soares, Paula de Cassia; Fernandes Junior, Jose Maria; Mehta, Niraj; Carvalho, Andre Lopes; Kupelian, Patrick A.; Chen, Allen			Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases	PLOS ONE			English	Article							DERMATOLOGICAL TRAINING CENTERS; MOHS MICROGRAPHIC SURGERY; SQUAMOUS-CELL CARCINOMAS; BASAL-CELL; RADIATION-THERAPY; IONIZING-RADIATION; RECURRENCE RATES; RADIOTHERAPY; EXPERIENCE; LESIONS	Introduction To report a single-institutional experience with the use of Superficial X-Ray Therapy (SXRT) for head and neck non-melanoma skin cancer (N-MSC) and to compare outcomes by prescribed fractionation schedules. Materials and Methods The medical records of 597 patients with 1021 lesions (720 BCC, 242 SCC, 59 SCC in situ) treated with kilovoltage radiation from 1979-2013 were retrospectively reviewed. The majority of patients were treated according to 1 of 3 institutional protocols based on the discretion of the radiation oncologist: 1) 22 x 2.5 Gy; 2) 20 x 2.5 Gy; 3) 30 x 2.0 Gy. "T" stage at first presentation was as follows: Tis (59); T1 (765); T2 (175); T3 (6), T4 (9); Tx, (7). All patients were clinical N0 and M0 at presentation. Chi-square test was used to evaluate any potential association between variables. The Kaplan-Meier method was used to analyze survival with the Log Rank test used for comparison. A Cox Regression analysis was performed for multivariate analysis. Results The median follow up was 44 months. No significant difference was observed among the 3 prescribed fractionation schemes (p = 0.78) in terms of RTOG toxicity. There were no failures among SCC in situ, 37 local failures (23 BCC, 14 SCC), 5 regional failures (all SCC) and 2 distant failures (both SCC). For BCC, the 5-year LC was 96% and the 10-year LC was 94%. For SCC the corresponding rates of local control were 92% and 87%, respectively (p = 0.03). The use of > 2.0 Gy daily was significantly associated with improved LC on multivariate analysis (HR: 0.17; CI 95%: 0.05-0.59). Conclusion SXRT for N-MSC of the head and neck is well tolerated, achieves excellent local control, and should continue to be recommended in the management of this disease. Fractionation schedules using > 2.0 Gy daily appear to be associated with improved LC.	[Marconi, Daniel Grossi; Resende, Bruno da Costa; Rauber, Erick; Soares, Paula de Cassia; Fernandes Junior, Jose Maria] Barretos Canc Hosp, Dept Radiat Oncol, Barretos, Brazil; [Mehta, Niraj] South Florida Radiat Oncol, Miami, FL USA; [Carvalho, Andre Lopes] Barretos Canc Hosp, Head & Neck Div, Barretos, Brazil; [Kupelian, Patrick A.; Chen, Allen] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA	Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; University of California System; University of California Los Angeles	Marconi, DG (corresponding author), Barretos Canc Hosp, Dept Radiat Oncol, Barretos, Brazil.	dgmarconi@gmail.com	MARCONI, DANIEL GROSSI/M-9484-2013; Kupelian, Patrick/AAU-6311-2021; Carvalho, Andre Lopes/S-7053-2016	Carvalho, Andre Lopes/0000-0001-7214-6402				ASHBY MA, 1989, CANCER, V63, P1863; Caccialanza M, 2005, INT J DERMATOL, V44, P513, DOI 10.1111/j.1365-4632.2005.02103.x; Caccialanza M, 2003, EUR J DERMATOL, V13, P462; Caccialanza M, 2009, J EUR ACAD DERMATOL, V23, P1044, DOI 10.1111/j.1468-3083.2009.03247.x; Cognetta AB, 2012, J AM ACAD DERMATOL, V67, P1235, DOI 10.1016/j.jaad.2012.06.001; de Launey JW, 1998, J DERMATOL, V37, P71; GOLDSCHMIDT H, 1986, ARCH DERMATOL, V122, P1385, DOI 10.1001/archderm.122.12.1385; GOLDSCHMIDT H, 1994, J AM ACAD DERMATOL, V30, P157, DOI 10.1016/S0190-9622(94)70014-1; Hernandez-Machin B, 2007, INT J DERMATOL, V46, P453, DOI 10.1111/j.1365-4632.2006.03108.x; Huynh NT, 2002, J DERMATOL, V43, P15; Jay L, 2001, INT J RADIAT ONCOL, V51, P748; KINGERY FAJ, 1986, J AM ACAD DERMATOL, V14, P1108, DOI 10.1016/S0190-9622(86)70134-5; Leibovitch I, 2005, J AM ACAD DERMATOL, V53, P253, DOI 10.1016/j.jaad.2005.02.059; Leibovitch I, 2005, J AM ACAD DERMATOL, V52, P997, DOI 10.1016/j.jaad.2004.12.033; Mendenhall WM, 2009, LARYNGOSCOPE, V119, P1994, DOI 10.1002/lary.20608; Panizzon R., 1991, MODERN DERMATOLOGIC; Panizzon R, 1982, P 16 INT C DERM, P482; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; Schalock PC, 2006, J AM ACAD DERMATOL, V55, P912, DOI 10.1016/j.jaad.2005.10.044; Schulte KW, J AM ACAD DERMATOL, V53, P993; Silva JJ, 2000, INT J RADIAT ONCOL, V47, P451, DOI 10.1016/S0360-3016(00)00410-7; STOLL HL, 1964, ARCH DERMATOL, V90, P577, DOI 10.1001/archderm.1964.01600060043007; Thom GA, AUSTRALAS J DERMATOL, V44, P174; Zagrodnik B, 2003, CANCER, V98, P2708, DOI 10.1002/cncr.11798; Zagrodnik B, 2003, CANCER, V98	25	18	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2016	11	7							e0156544	10.1371/journal.pone.0156544	http://dx.doi.org/10.1371/journal.pone.0156544			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0TX	27367229	Green Published, Green Submitted, gold			2023-01-03	WOS:000378914900005
J	King, AC; Hekler, EB; Grieco, LA; Winter, SJ; Sheats, JL; Buman, MP; Banerjee, B; Robinson, TN; Cirimele, J				King, Abby C.; Hekler, Eric B.; Grieco, Lauren A.; Winter, Sandra J.; Sheats, Jylana L.; Buman, Matthew P.; Banerjee, Banny; Robinson, Thomas N.; Cirimele, Jesse			Effects of Three Motivationally Targeted Mobile Device Applications on Initial Physical Activity and Sedentary Behavior Change in Midlife and Older Adults: A Randomized Trial	PLOS ONE			English	Article							HEALTH; INTERVENTIONS; MORTALITY; MEDICINE; DISEASE; TIME	Background While there has been an explosion of mobile device applications (apps) promoting healthful behaviors, including physical activity and sedentary patterns, surprisingly few have been based explicitly on strategies drawn from behavioral theory and evidence. Objective This study provided an initial 8-week evaluation of three different customized physical activity-sedentary behavior apps drawn from conceptually distinct motivational frames in comparison with a commercially available control app. Study Design and Methods Ninety-five underactive adults ages 45 years and older with no prior smartphone experience were randomized to use an analytically framed app, a socially framed app, an affectively framed app, or a diet-tracker control app. Daily physical activity and sedentary behavior were measured using the smartphone's built-in accelerometer and daily self-report measures. Results Mixed-effects models indicated that, over the 8-week period, the social app users showed significantly greater overall increases in weekly accelerometry-derived moderate to vigorous physical activity relative to the other three arms (P values for between-arm differences = .04-.005; Social vs. Control app: d = 1.05, CI = 0.44,1.67; Social vs. Affect app: d = 0.89, CI = 0.27,1.51; Social vs. Analytic app: d = 0.89, CI = 0.27,1.51), while more variable responses were observed among users of the other two motivationally framed apps. Social app users also had significantly lower overall amounts of accelerometry-derived sedentary behavior relative to the other three arms (P values for between-arm differences = .02-.001; Social vs. Control app: d = 1.10, CI = 0.48,1.72; Social vs. Affect app: d = 0.94, CI = 0.32,1.56; Social vs. Analytic app: d = 1.24, CI = 0.59,1.89). Additionally, Social and Affect app users reported lower overall sitting time compared to the other two arms (P values for between-arm differences <.001; Social vs. Control app: d = 1.59, CI = 0.92, 2.25; Social vs. Analytic app: d = 1.89, CI = 1.17, 2.61; Affect vs. Control app: d = 1.19, CI = 0.56, 1.81; Affect vs. Analytic app: d = 1.41, CI = 0.74, 2.07). Conclusion The results provide initial support for the use of a smartphone-delivered social frame in the early induction of both physical activity and sedentary behavior changes. The information obtained also sets the stage for further investigation of subgroups that might particularly benefit from different motivationally framed apps in these two key health promotion areas.	[King, Abby C.] Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA; [King, Abby C.] Stanford Univ, Div Epidemiol, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA; [Hekler, Eric B.; Grieco, Lauren A.; Winter, Sandra J.; Sheats, Jylana L.; Buman, Matthew P.; Robinson, Thomas N.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Sch Med, Stanford, CA 94305 USA; [Banerjee, Banny] Stanford Univ, Sch Earth Energy & Environm Sci, Stanford, CA 94305 USA; [Robinson, Thomas N.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Cirimele, Jesse] Stanford Univ, Dept Comp Sci, Sch Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	King, AC (corresponding author), Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA.; King, AC (corresponding author), Stanford Univ, Div Epidemiol, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA.	king@stanford.edu	King, Abby/AAD-5257-2021; Winter, Sandi/HJA-3055-2022; Buman, Matthew/AAJ-4447-2020	Winter, Sandi/0000-0002-4930-2005; Buman, Matthew/0000-0002-5130-3162; Hekler, Eric B/0000-0002-7434-0775; King, Abby/0000-0002-7949-8811	US Public Health Service grant from the National Heart, Lung, & Blood Institute of the National Institutes of Health (NIH) [RC1 HL099340]; US Public Health Service Grant [1U54EB020405]; US Public Health Service grant from the National Heart, Lung, & Blood Institute [5T32L007034]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [U54EB020405] Funding Source: NIH RePORTER	US Public Health Service grant from the National Heart, Lung, & Blood Institute of the National Institutes of Health (NIH); US Public Health Service Grant(United States Department of Health & Human ServicesUnited States Public Health Service); US Public Health Service grant from the National Heart, Lung, & Blood Institute; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by US Public Health Service grant #RC1 HL099340 from the National Heart, Lung, & Blood Institute of the National Institutes of Health (NIH) awarded to Dr. King; US Public Health Service Grant 1U54EB020405 supporting The National Center for Mobility Data Integration and Insight; and US Public Health Service grant #5T32L007034 from the National Heart, Lung, & Blood Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandura A, 2006, PERSPECT PSYCHOL SCI, V1, P164, DOI 10.1111/j.1745-6916.2006.00011.x; Barradas S, 2013, 34 ANN M SCI SESS SO; Bassett DR, 2010, MED SCI SPORT EXER, V42, P1819, DOI 10.1249/MSS.0b013e3181dc2e54; Bickmore T, 2010, APPL ARTIF INTELL, V24, P648, DOI 10.1080/08839514.2010.492259; Bond DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100821; Bort-Roig J, 2014, SPORTS MED, V44, P671, DOI 10.1007/s40279-014-0142-5; Burke LE, 2015, CIRCULATION, V132, P1157, DOI 10.1161/CIR.0000000000000232; Carlson SA, 2010, AM J PREV MED, V39, P305, DOI 10.1016/j.amepre.2010.06.006; Cialdini R.B., 2006, SOC INFLUENCE, V1, P3, DOI [10.1080/15534510500181459, DOI 10.1080/15534510500181459]; Direito A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-646; Dunton GF, 2009, ANN BEHAV MED, V38, P249, DOI 10.1007/s12160-009-9141-4; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.1093/biomet/58.3.403; Frank LD, 2010, BRIT J SPORT MED, V44, P924, DOI 10.1136/bjsm.2009.058701; Gabriele JM, 2005, ANN BEHAV MED, V29, P210, DOI 10.1207/s15324796abm2903_7; Hekler EB, 2011, CHI 2011, V2011; Hekler EB, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3505; Hekler EB, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-109; Hekler EB, 2012, PSYCHOL HEALTH, V27, P1009, DOI 10.1080/08870446.2011.645213; Katzmarzyk PT, 2009, MED SCI SPORT EXER, V41, P998, DOI 10.1249/MSS.0b013e3181930355; King AC, 2008, ANN BEHAV MED, V35, P251, DOI 10.1007/s12160-008-9032-0; King AC, 2008, AM J PREV MED, V34, P138, DOI 10.1016/j.amepre.2007.09.025; King AC, 2015, AM J PREV MED, V48, P630, DOI 10.1016/j.amepre.2014.10.005; King AC, 2014, ANN BEHAV MED, V47, P71, DOI 10.1007/s12160-013-9530-6; King AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062613; King AC, 2010, AM J PREV MED, V38, P17, DOI 10.1016/j.amepre.2009.08.032; Larsen RN, 2015, CLIN SCI, V129, P117, DOI 10.1042/CS20140790; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; de Rezende LFM, 2016, AM J PREV MED, V51, P253, DOI 10.1016/j.amepre.2016.01.022; Maibach E, 2009, PREV MED, V49, P326, DOI 10.1016/j.ypmed.2009.06.028; Metzler MM, 2003, AM J PUBLIC HEALTH, V93, P803, DOI 10.2105/AJPH.93.5.803; Michie S, 2011, PSYCHOL HEALTH, V26, P1479, DOI 10.1080/08870446.2010.540664; Middelweerd A, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0097-9; Miller W.R., 2008, MANUAL MOTIVATIONAL; Nahum-Shani I, HLTH PSYCHO IN PRESS; Norman GJ, 2007, AM J PREV MED, V33, P336, DOI 10.1016/j.amepre.2007.05.007; Pew Research Center, 2015, SMARTPH US 2015 PEW; Physical Activity Guidelines Advisory Committee, 2008, REP PHYS ACT GUID AD; Pivarnik JM, 2003, MED SCI SPORT EXER, V35, P1004, DOI 10.1249/01.MSS.0000069747.55950.B1; Pulsford RM, 2015, INT J EPIDEMIOL, V44, P1909, DOI 10.1093/ije/dyv191; Raudenbush SW, 2001, PSYCHOL METHODS, V6, P387, DOI 10.1037//1082-989X.6.4.387; Redfern J, 2014, EUR J PREV CARDIOL, V21, P492, DOI 10.1177/2047487312449416; Rosenberger ME, 2016, MED SCI SPORT EXER, V48, P457, DOI 10.1249/MSS.0000000000000778; Spring B, 2013, IEEE PULSE, V4, P34, DOI 10.1109/MPUL.2013.2279620; Spring B, 2012, ARCH INTERN MED, V172, P789, DOI 10.1001/archinternmed.2012.1044; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Umstattd MR, 2008, AM J HEALTH BEHAV, V32, P115; VELICER W, 2011, ANN BEHAV MED S1, V41, pS146; Winter SJ, 2014, NHLBI CARD EP BIOST	49	71	72	7	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2016	11	6							e0156370	10.1371/journal.pone.0156370	http://dx.doi.org/10.1371/journal.pone.0156370			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DQ0AH	27352250	Green Published, Green Submitted, gold			2023-01-03	WOS:000378858900002
J	Khunjan, U; Ekchaweng, K; Panrat, T; Tian, MY; Churngchow, N				Khunjan, Uraiwan; Ekchaweng, Kitiya; Panrat, Tanate; Tian, Miaoying; Churngchow, Nunta			Molecular Cloning of HbPR-1 Gene from Rubber Tree, Expression of HbPR-1 Gene in Nicotiana benthamiana and Its Inhibition of Phytophthora palmivora	PLOS ONE			English	Article							PATHOGENESIS-RELATED PROTEINS; TOBACCO-MOSAIC-VIRUS; DISEASE RESISTANCE; PR-1 PROTEIN; SYSTEM; PLANTS; FAMILY; MODEL; OVEREXPRESSION; SUPPRESSION	This is the first report to present a full-length cDNA (designated HbPR-1) encoding a putative basic HbPR-1 protein from rubber tree (Hevea brasiliensis) treated with salicylic acid. It was characterized and also expressed in Nicotiana benthamiana using Agrobacterium-mediated transient gene expression system in order to investigate the role of HbPR-1 gene in rubber tree against its oomycete pathogen Phytopthora palmivora and to produce recombinant HbPR-1 protein for microbial inhibition test. The HbPR-1 cDNA was 647 bp long and contained an open reading frame of 492 nucleotides encoding 163 amino acid residues with a predicted molecular mass of 17,681 Da and an isoelectric point (pI) of 8.56, demonstrating that HbPR-1 protein belongs to the basic PR-1 type. The predicted 3D structure of HbPR-1 was composed of four alpha-helices, three beta-sheets, seven strands, and one junction loop. Expression and purification of recombinant HbPR-1 protein were successful using Agrobacterium- mediated transient expression and one-step of affinity chromatography. Heterologous expression of HbPR-1 in N. benthamiana reduced necrosis areas which were inoculated with P. palmivora zoospores, indicating that the expressed HbPR-1 protein played an important role in plant resistance to pathogens. The purified recombinant HbPR-1 protein was found to inhibit 64% of P. palmivora zoospore germination on a water agar plate compared with control, suggesting that it was an antimicrobial protein against P. palmivora.	[Khunjan, Uraiwan; Ekchaweng, Kitiya; Churngchow, Nunta] Prince Songkla Univ, Fac Sci, Dept Biochem, Hat Yai, Songkhla, Thailand; [Khunjan, Uraiwan; Ekchaweng, Kitiya; Tian, Miaoying] Univ Hawaii Manoa, Dept Plant & Environm Protect Sci, Manoa, HI USA; [Panrat, Tanate] Prince Songkla Univ, Digital Media Program, Int Coll, Hat Yai, Songkhla, Thailand; [Panrat, Tanate] Prince Songkla Univ, Fac Sci, Ctr Genom & Bioinformat Res, Hat Yai, Songkhla, Thailand	Prince of Songkla University; University of Hawaii System; University of Hawaii Manoa; Prince of Songkla University; Prince of Songkla University	Churngchow, N (corresponding author), Prince Songkla Univ, Fac Sci, Dept Biochem, Hat Yai, Songkhla, Thailand.	nunta.c@psu.ac.th	Panrat, Tanate/J-8841-2013	Panrat, Tanate/0000-0002-8511-9283; Tian, Miaoying/0000-0001-8900-6414	Office of the Higher Education Commission Strategic Scholarships Fellowships Frontier Research Networks (Specific for Southern region); government budget of Prince of Songkla University; Biochemistry Excellence Strengthening Program; Graduate School, Prince of Songkla University; Faculty of Science, Prince of Songkla University 4	Office of the Higher Education Commission Strategic Scholarships Fellowships Frontier Research Networks (Specific for Southern region); government budget of Prince of Songkla University; Biochemistry Excellence Strengthening Program; Graduate School, Prince of Songkla University; Faculty of Science, Prince of Songkla University 4	This work was funded by the Office of the Higher Education Commission Strategic Scholarships Fellowships Frontier Research Networks (Specific for Southern region), the government budget of Prince of Songkla University, a grant from the Biochemistry Excellence Strengthening Program, Faculty of Science, Prince of Songkla University 4, and research funding of the Graduate School, Prince of Songkla University.	Agrawal GK, 2000, BIOCHEM BIOPH RES CO, V278, P290, DOI 10.1006/bbrc.2000.3781; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; BJELLQVIST B, 1994, ELECTROPHORESIS, V15, P529, DOI 10.1002/elps.1150150171; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Breton F, 1997, J PLANT PHYSIOL, V151, P595, DOI 10.1016/S0176-1617(97)80236-2; Buch F, 2014, PHYTOCHEMISTRY, V100, P43, DOI 10.1016/j.phytochem.2014.01.014; CUTT JR, 1989, VIROLOGY, V173, P89, DOI 10.1016/0042-6822(89)90224-9; de Castro E, 2006, NUCLEIC ACIDS RES, V34, pW362, DOI 10.1093/nar/gkl124; Delano W.L, 2002, DELANO SCI; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; Gao S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064189; Garabagi F, 2012, PLANT BIOTECHNOL J, V10, P1118, DOI 10.1111/j.1467-7652.2012.00742.x; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P576; Goodin MM, 2002, PLANT J, V31, P375, DOI 10.1046/j.1365-313X.2002.01360.x; Kapila J, 1997, PLANT SCI, V122, P101, DOI 10.1016/S0168-9452(96)04541-4; Kim YJ, 2000, PHYSIOL PLANTARUM, V108, P51, DOI 10.1034/j.1399-3054.2000.108001051x./; Kitajima S, 1999, J BIOCHEM, V125, P1, DOI 10.1093/oxfordjournals.jbchem.a022244; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Kumar D, 2003, P NATL ACAD SCI USA, V100, P16101, DOI 10.1073/pnas.0307162100; Laitaoja M, 2013, INORG CHEM, V52, P10983, DOI 10.1021/ic401072d; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; Li ZT, 2011, PLANT CELL REP, V30, P1, DOI 10.1007/s00299-010-0934-5; Lindbo JA, 2007, PLANT PHYSIOL, V145, P1232, DOI 10.1104/pp.107.106377; Liu HQ, 2005, BIOINFORMATICS, V21, P671, DOI 10.1093/bioinformatics/bth437; Liu LJ, 2010, PLANT J, V61, P893, DOI 10.1111/j.1365-313X.2009.04109.x; Liu QP, 2006, J GENET, V85, P193, DOI 10.1007/BF02935330; Lu SW, 2013, J PLANT PHYSIOL, V170, P105, DOI 10.1016/j.jplph.2012.08.006; Lu SW, 2011, MOL GENET GENOMICS, V285, P485, DOI 10.1007/s00438-011-0618-z; Ma PD, 2009, APPL BIOCHEM BIOTECH, V158, P243, DOI 10.1007/s12010-008-8332-y; Maheshwari S, 2015, J MOL RECOGNIT, V28, P35, DOI 10.1002/jmr.2410; Marchler-Bauer A, 2015, NUCLEIC ACIDS RES, V43, pD222, DOI 10.1093/nar/gku1221; Mitsuhara I, 2008, MOL GENET GENOMICS, V279, P415, DOI 10.1007/s00438-008-0322-9; Omasits U, 2014, BIOINFORMATICS, V30, P884, DOI 10.1093/bioinformatics/btt607; Park SC, 2010, BIOTECHNOL LETT, V32, P125, DOI 10.1007/s10529-009-0126-y; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Riviere MP, 2008, J EXP BOT, V59, P1225, DOI 10.1093/jxb/ern044; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Rozen S, 2000, Methods Mol Biol, V132, P365; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Santen K, 2005, PHYSIOL MOL PLANT P, V66, P45, DOI 10.1016/j.pmpp.2005.04.006; Sarowar S, 2005, PLANT CELL REP, V24, P216, DOI 10.1007/s00299-005-0928-x; Sels J, 2008, PLANT PHYSIOL BIOCH, V46, P941, DOI 10.1016/j.plaphy.2008.06.011; SHAMLOUL M, 2014, JOVE-J VIS EXP, V86, P1; Shikamoto Y, 2005, J MOL BIOL, V350, P735, DOI 10.1016/j.jmb.2005.05.020; Shin SH, 2014, PLANT PATHOLOGY J, V30, P208, DOI 10.5423/PPJ.NT.11.2013.0112; van Loon LC, 2006, ANNU REV PHYTOPATHOL, V44, P135, DOI 10.1146/annurev.phyto.44.070505.143425; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Wang YL, 2010, J BIOL CHEM, V285, P37872, DOI 10.1074/jbc.M110.146290; Wydro M, 2006, ACTA BIOCHIM POL, V53, P289; Yang HR, 2011, SCI HORTIC-AMSTERDAM, V128, P166, DOI 10.1016/j.scienta.2011.01.015; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhu F, 2012, BIOTECHNOL LETT, V34, P919, DOI 10.1007/s10529-012-0851-5	61	7	7	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157591	10.1371/journal.pone.0157591	http://dx.doi.org/10.1371/journal.pone.0157591			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27337148	Green Submitted, Green Published, gold			2023-01-03	WOS:000378389200023
J	Franco, OH; Chowdhury, R; Troup, J; Voortman, T; Kunutsor, S; Kavousi, M; Oliver-Williams, C; Muka, T				Franco, Oscar H.; Chowdhury, Rajiv; Troup, Jenna; Voortman, Trudy; Kunutsor, Setor; Kavousi, Maryam; Oliver-Williams, Clare; Muka, Taulant			Use of Plant-Based Therapies and Menopausal Symptoms A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CROSSOVER TRIAL; STANDARDIZED SOY EXTRACT; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN; HOT FLUSHES; VASOMOTOR SYMPTOMS; BLACK COHOSH	IMPORTANCE Between 40% and 50% of women in Western countries use complementary therapies to manage menopausal symptoms. OBJECTIVE To determine the association of plant-based therapies with menopausal symptoms, including hot flashes, night sweats, and vaginal dryness. DATA SOURCES The electronic databases Ovid MEDLINE, EMBASE, and Cochrane Central were systematically searched to identify eligible studies published before March 27, 2016. Reference lists of the included studies were searched for further identification of relevant studies. STUDY SELECTION Randomized clinical trials that assessed plant-based therapies and the presence of hot flashes, night sweats, and vaginal dryness. DATA EXTRACTION Data were extracted by 2 independent reviewers using a predesigned data collection form. MAIN OUTCOMES AND MEASURES Hot flashes, night sweats, and vaginal dryness. RESULTS In total, 62 studies were identified, including 6653 individual women. Use of phytoestrogens was associated with a decrease in the number of daily hot flashes (pooled mean difference of changes, -1.31 [95% CI, -2.02 to -0.61]) and vaginal dryness score (pooled mean difference of changes, -0.31 [95% CI, -0.52 to -0.10]) between the treatment groups but not in the number of night sweats (pooled mean difference of changes, -2.14 [95% CI, -5.57 to 1.29]). Individual phytoestrogen interventions such as dietary and supplemental soy isoflavones were associated with improvement in daily hot flashes (pooled mean difference of changes, -0.79 [-1.35 to -0.23]) and vaginal dryness score (pooled mean difference of changes, -0.26 [-0.48 to -0.04]). Several herbal remedies, but not Chinese medicinal herbs, were associated with an overall decrease in the frequency of vasomotor symptoms. There was substantial heterogeneity in quality across the available studies, and 46 (74%) of the included randomized clinical trials demonstrated a high risk of bias within 3 or more areas of study quality. CONCLUSIONS AND RELEVANCE This meta-analysis of clinical trials suggests that composite and specific phytoestrogen supplementations were associated with modest reductions in the frequency of hot flashes and vaginal dryness but no significant reduction in night sweats. However, because of general suboptimal quality and the heterogeneous nature of the current evidence, further rigorous studies are needed to determine the association of plant-based and natural therapies with menopausal health.	[Franco, Oscar H.; Troup, Jenna; Voortman, Trudy; Kavousi, Maryam; Muka, Taulant] Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040,Dr Molewaterpl 50,Off NA29-05, NL-3000 CA Rotterdam, Netherlands; [Chowdhury, Rajiv; Kunutsor, Setor; Oliver-Williams, Clare] Univ Cambridge, Cardiovasc Epidemiol Unit, Dept Publ Hlth & Primary Care, Cambridge, England; [Voortman, Trudy; Muka, Taulant] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Erasmus University Rotterdam; Erasmus MC; University of Cambridge; Harvard University; Harvard T.H. Chan School of Public Health	Muka, T (corresponding author), Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040,Dr Molewaterpl 50,Off NA29-05, NL-3000 CA Rotterdam, Netherlands.	t.muka@erasmusmc.nl	Chowdhury, Rajiv/AHB-1253-2022; Kunutsor, Setor K/H-9807-2019; Kavousi, Maryam/F-1174-2018; Voortman, Trudy/C-2963-2015; Franco, Óscar H/ABE-2305-2020	Kunutsor, Setor K/0000-0002-2625-0273; Kavousi, Maryam/0000-0001-5976-6519; Voortman, Trudy/0000-0003-2830-6813; Franco, Óscar H/0000-0002-4606-4929	Metagenics Inc.; MRC [MR/L003120/1, G0800270] Funding Source: UKRI; British Heart Foundation [RG/08/014/24067, RG/13/13/30194] Funding Source: researchfish; Medical Research Council [G0800270, MR/L003120/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10165] Funding Source: researchfish	Metagenics Inc.; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was sponsored by Metagenics Inc.	Abdali K, 2010, MENOPAUSE, V17, P326, DOI 10.1097/gme.0b013e3181b8e02d; Albertazzi P, 2005, CLIMACTERIC, V8, P371, DOI 10.1080/13697130500345257; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; Amsterdam JD, 2009, J CLIN PSYCHOPHARM, V29, P478, DOI 10.1097/JCP.0b013e3181b2abf2; Aso T, 2012, J WOMENS HEALTH, V21, P92, DOI 10.1089/jwh.2011.2753; Atkinson C, 2004, BREAST CANCER RES, V6, pR170, DOI 10.1186/bcr773; Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Borud EK, 2009, MENOPAUSE, V16, P484, DOI 10.1097/gme.0b013e31818c02ad; Brzezinski A, 1997, MENOPAUSE, V4, P89; Burke GL, 2003, MENOPAUSE, V10, P147, DOI 10.1097/00042192-200310020-00006; Chen MN, 2015, CLIMACTERIC, V18, P260, DOI 10.3109/13697137.2014.966241; Cheng GJ, 2007, MENOPAUSE, V14, P468, DOI 10.1097/GME.0b013e31802cc7d0; Chung DJ, 2007, YONSEI MED J, V48, P289, DOI 10.3349/ymj.2007.48.2.289; Colacurci N, 2004, Minerva Ginecol, V56, P407; Colli MC, 2012, J MED FOOD, V15, P840, DOI 10.1089/jmf.2011.0228; Crisafulli A, 2004, MENOPAUSE, V11, P400, DOI 10.1097/01.GME.0000109314.11228.E5; D'Anna R, 2007, MENOPAUSE, V14, P648, DOI 10.1097/01.gme.0000248708.60698.98; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DiBonaventura MD, 2013, INT J WOMENS HEALTH, V5, P261, DOI 10.2147/IJWH.S39027; Dodin S, 2005, J CLIN ENDOCR METAB, V90, P1390, DOI 10.1210/jc.2004-1148; Duffy R, 2003, PHARMACOL BIOCHEM BE, V75, P721, DOI 10.1016/S0091-3057(03)00116-3; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Evans M, 2011, MATURITAS, V68, P189, DOI 10.1016/j.maturitas.2010.11.012; Farzaneh F, 2013, ARCH GYNECOL OBSTET, V288, P1075, DOI 10.1007/s00404-013-2852-6; Faure ED, 2002, MENOPAUSE, V9, P329, DOI 10.1097/00042192-200209000-00005; Ferrari A, 2009, J OBSTET GYNAECOL RE, V35, P1083, DOI 10.1111/j.1447-0756.2009.01058.x; Frei-Kleiner S, 2005, MATURITAS, V51, P397, DOI 10.1016/j.maturitas.2004.10.003; Fu SF, 2016, MENOPAUSE, V23, P311, DOI 10.1097/GME.0000000000000534; Garcia JT, 2010, MENOPAUSE, V17, P303, DOI 10.1097/gme.0b013e3181bf8e92; Geller SE, 2009, MENOPAUSE, V16, P1156, DOI 10.1097/gme.0b013e3181ace49b; Green R, 2009, WOMENS HEALTH, V5, P127, DOI 10.2217/17455057.5.2.127; Hachul H, 2013, CLIMACTERIC, V16, P36, DOI 10.3109/13697137.2012.698432; Hachul H, 2011, MENOPAUSE, V18, P178, DOI 10.1097/gme.0b013e3181ecf9b9; Haines CJ, 2008, CLIMACTERIC, V11, P244, DOI 10.1080/13697130802073029; Han KK, 2002, OBSTET GYNECOL, V99, P389, DOI 10.1016/S0029-7844(01)01744-6; Hasper I, 2009, MENOPAUSE, V16, P117, DOI [10.1097/GME.0b013e3181806446, 10.1097/gme.0b013e3181806446]; Heger M, 2006, MENOPAUSE, V13, P744, DOI 10.1097/01.gme.0000240632.08182.e4; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Hsu CC, 2011, CLIMACTERIC, V14, P132, DOI 10.3109/13697137.2010.498594; Im EO, 2010, WESTERN J NURS RES, V32, P540, DOI 10.1177/0193945909354343; Jaspers L, 2015, MATURITAS, V81, P93, DOI 10.1016/j.maturitas.2015.02.010; Jeri AR, 2002, FEMALE PATIENT, V27, P35; Jiang K, 2015, CLIMACTERIC, V18, P559, DOI 10.3109/13697137.2015.1042450; Knight D C, 1999, Climacteric, V2, P79, DOI 10.3109/13697139909025570; Komesaroff P A, 2001, Climacteric, V4, P144; Kotsopoulos D, 2000, Climacteric, V3, P161, DOI 10.1080/13697130008500108; Kronenberg F, 2002, ANN INTERN MED, V137, P805, DOI 10.7326/0003-4819-137-10-200211190-00009; Kwee SH, 2007, MATURITAS, V58, P83, DOI 10.1016/j.maturitas.2007.06.005; Lee J, 2010, ARCH PHARM RES, V33, P523, DOI 10.1007/s12272-010-0405-0; Lewis JE, 2006, MENOPAUSE, V13, P631, DOI 10.1097/01.gme.0000191882.59799.67; Lipovac M, 2012, GYNECOL ENDOCRINOL, V28, P203, DOI 10.3109/09513590.2011.593671; Liu ZM, 2014, MENOPAUSE, V21, P653, DOI [10.1097/GME.0000000000000102, 10.1097/gme.0000000000000102]; Lontos S, 2003, MED J AUSTRALIA, V179, P390, DOI 10.5694/j.1326-5377.2003.tb05606.x; MacGregor CA, 2005, EUR J CANCER, V41, P708, DOI 10.1016/j.ejca.2005.01.005; Mohammad-Alizadeh-Charandabi S, 2013, CHIN MED-UK, V8, DOI 10.1186/1749-8546-8-20; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; Nahas EAP, 2007, MATURITAS, V58, P249, DOI 10.1016/j.maturitas.2007.08.012; Nahas EP, 2004, MATURITAS, V48, P372, DOI 10.1016/j.maturitas.2003.09.026; Nedeljkovic M, 2014, MENOPAUSE, V21, P15, DOI [10.1097/GME.0b013e31829374e8, 10.1097/gme.0b013e31829374e8]; Newton KM, 2006, ANN INTERN MED, V145, P869, DOI 10.7326/0003-4819-145-12-200612190-00003; Nikander E, 2003, OBSTET GYNECOL, V101, P1213, DOI 10.1016/S0029-7844(03)00232-1; Penotti M, 2003, FERTIL STERIL, V79, P1112, DOI 10.1016/S0015-0282(03)00158-4; Pockaj BA, 2006, J CLIN ONCOL, V24, P2836, DOI 10.1200/JCO.2005.05.4296; Porzio G, 2002, TUMORI, V88, P128, DOI 10.1177/030089160208800209; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Reed SD, 2013, MATURITAS, V75, P152, DOI 10.1016/j.maturitas.2013.03.003; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rotem C, 2007, GYNECOL ENDOCRINOL, V23, P117, DOI 10.1080/09513590701200900; Scambia G, 2000, MENOPAUSE, V7, P105, DOI 10.1097/00042192-200007020-00006; Shahnazi Mahnaz, 2013, J Caring Sci, V2, P105, DOI 10.5681/jcs.2013.013; Shakeri F, 2015, CLIMACTERIC, V18, P568, DOI 10.3109/13697137.2014.999660; Simbalista RL, 2010, J NUTR, V140, P293, DOI 10.3945/jn.109.113886; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tanmahasamut P, 2015, CLIMACTERIC, V18, P79, DOI 10.3109/13697137.2014.933410; Tice JA, 2003, JAMA-J AM MED ASSOC, V290, P207, DOI 10.1001/jama.290.2.207; Unfer V, 2004, FERTIL STERIL, V82, P145, DOI 10.1016/j.fertnstert.2003.11.041; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; van de Weijer PHM, 2002, MATURITAS, V42, P187, DOI 10.1016/S0378-5122(02)00080-4; van der Sluijs CP, 2009, MENOPAUSE, V16, P336, DOI 10.1097/gme.0b013e3181883dc1; van Die MD, 2009, MENOPAUSE, V16, P156, DOI 10.1097/gme.0b013e31817fa9e0; Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449; Vashisht A, 2001, Climacteric, V4, P250, DOI 10.1080/713605091; Verhoeven MO, 2005, MENOPAUSE, V12, P412, DOI 10.1097/01.gme.0000170603.63022.62; Winther K, 2005, CLIMACTERIC, V8, P162, DOI 10.1080/13697130500117987; Xia Y, 2012, MENOPAUSE, V19, P234, DOI 10.1097/gme.0b013e3182273177; Yang HM, 2007, ACTA OBSTET GYN SCAN, V86, P978, DOI 10.1080/00016340701446108	91	132	137	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2016	315	23					2554	2563		10.1001/jama.2016.8012	http://dx.doi.org/10.1001/jama.2016.8012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP2GQ	27327802	Bronze			2023-01-03	WOS:000378306700019
J	Bonham, VL; Callier, SL; Royal, CD				Bonham, Vence L.; Callier, Shawneequa L.; Royal, Charmaine D.			Will Precision Medicine Move Us beyond Race?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bonham, Vence L.] NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA; [Callier, Shawneequa L.] George Washington Univ, Dept Clin Res & Leadership, Washington, DC USA; [Royal, Charmaine D.] Duke Univ, Dept African & African Amer Studies, Durham, NC 27706 USA; [Royal, Charmaine D.] Duke Univ, Ctr Genom, Race, Ident,Difference, Durham, NC 27706 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); George Washington University; Duke University; Duke University	Bonham, VL (corresponding author), NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA.			Royal, Charmaine/0000-0003-3593-851X; Callier, Shawneequa/0000-0002-1007-333X	Intramural NIH HHS [ZIA HG200324-12] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200324] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427; Precision Medicine Initiative (PMI) Working Group, 2015, PREC MED IN COH PROG; Ramamoorthy A, 2015, CLIN PHARMACOL THER, V97, P263, DOI 10.1002/cpt.61; Temple R, 2007, ANN INTERN MED, V146, P57, DOI 10.7326/0003-4819-146-1-200701020-00010; Wu AHB, 2015, PERS MED, V12, P179, DOI [10.2217/PME.15.4, 10.2217/pme.15.4]	5	68	68	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2016	374	21					2003	2005		10.1056/NEJMp1511294	http://dx.doi.org/10.1056/NEJMp1511294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DM6EN	27223144	Green Accepted			2023-01-03	WOS:000376443500002
J	Cappa, C				Cappa, Chris			ATMOSPHERIC SCIENCE Unexpected player in particle formation	NATURE			English	Editorial Material							SECONDARY ORGANIC AEROSOL; VOLATILITY; NUCLEATION; OXIDATION; PRODUCTS; GROWTH; CARBON	Three studies find that a family of organic compounds affects the formation and initial growth of atmospheric aerosol particles in clean air - with implications for our knowledge of the climate effects of aerosols. SEE LETTERS P.521 & 527	[Cappa, Chris] Univ Calif Davis, Dept Civil & Environm Engn, Davis, CA 95616 USA	University of California System; University of California Davis	Cappa, C (corresponding author), Univ Calif Davis, Dept Civil & Environm Engn, Davis, CA 95616 USA.	cdcappa@ucdavis.edu						Ball SM, 1999, J GEOPHYS RES-ATMOS, V104, P23709, DOI 10.1029/1999JD900411; Bianchi F., 2016, SCIENCE; Carslaw KS, 2013, NATURE, V503, P67, DOI 10.1038/nature12674; D'Andrea SD, 2013, ATMOS CHEM PHYS, V13, P11519, DOI 10.5194/acp-13-11519-2013; Ehn M, 2014, NATURE, V506, P476, DOI 10.1038/nature13032; Farmer DK, 2015, CHEM REV, V115, P4199, DOI 10.1021/cr5006292; Jokinen T, 2015, P NATL ACAD SCI USA, V112, P7123, DOI 10.1073/pnas.1423977112; Kirkby J, 2016, NATURE, V533, P521, DOI 10.1038/nature17953; Kolesar KR, 2015, ATMOS CHEM PHYS, V15, P9327, DOI 10.5194/acp-15-9327-2015; Kroll JH, 2008, ATMOS ENVIRON, V42, P3593, DOI 10.1016/j.atmosenv.2008.01.003; Kroll JH, 2015, J PHYS CHEM A, V119, P10767, DOI 10.1021/acs.jpca.5b06946; Kulmala M, 2013, SCIENCE, V339, P943, DOI 10.1126/science.1227385; Lopez-Hilfiker FD, 2015, ATMOS CHEM PHYS, V15, P7765, DOI 10.5194/acp-15-7765-2015; McConnell JR, 2007, SCIENCE, V317, P1381, DOI 10.1126/science.1144856; Riccobono F, 2014, SCIENCE, V344, P717, DOI 10.1126/science.1243527; Riipinen I, 2012, NAT GEOSCI, V5, P453, DOI 10.1038/ngeo1499; Ruehl CR, 2016, SCIENCE, V351, P1447, DOI 10.1126/science.aad4889; Stocker T.F., 2013, PHYS SCI BAS WORK GR, P1535, DOI 10.1017/CBO9781107415324; Trostl J, 2016, NATURE, V533, P527, DOI 10.1038/nature18271; Zhang RY, 2004, SCIENCE, V304, P1487, DOI 10.1126/science.1095139	20	12	13	4	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2016	533	7604					478	479		10.1038/533478a	http://dx.doi.org/10.1038/533478a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM6EJ	27225118				2023-01-03	WOS:000376443100029
J	Kirkby, J; Duplissy, J; Sengupta, K; Frege, C; Gordon, H; Williamson, C; Heinritzi, M; Simon, M; Yan, C; Almeida, J; Trostl, J; Nieminen, T; Ortega, IK; Wagner, R; Adamov, A; Amorim, A; Bernhammer, AK; Bianchi, F; Breitenlechner, M; Brilke, S; Chen, XM; Craven, J; Dias, A; Ehrhart, S; Flagan, RC; Franchin, A; Fuchs, C; Guida, R; Hakala, J; Hoyle, CR; Jokinen, T; Junninen, H; Kangasluoma, J; Kim, J; Krapf, M; Kurten, A; Laaksonen, A; Lehtipalo, K; Makhmutov, V; Mathot, S; Molteni, U; Onnela, A; Perakyla, O; Piel, F; Petaja, T; Praplan, AP; Pringle, K; Rap, A; Richards, NAD; Riipinen, I; Rissanen, MP; Rondo, L; Sarnela, N; Schobesberger, S; Scott, CE; Seinfeld, JH; Sipila, M; Steiner, G; Stozhkov, Y; Stratmann, F; Tome, A; Virtanen, A; Vogel, AL; Wagner, AC; Wagner, PE; Weingartner, E; Wimmer, D; Winkler, PM; Ye, PL; Zhang, X; Hansel, A; Dommen, J; Donahue, NM; Worsnop, DR; Baltensperger, U; Kulmala, M; Carslaw, KS; Curtius, J				Kirkby, Jasper; Duplissy, Jonathan; Sengupta, Kamalika; Frege, Carla; Gordon, Hamish; Williamson, Christina; Heinritzi, Martin; Simon, Mario; Yan, Chao; Almeida, Joao; Troestl, Jasmin; Nieminen, Tuomo; Ortega, Ismael K.; Wagner, Robert; Adamov, Alexey; Amorim, Antonio; Bernhammer, Anne-Kathrin; Bianchi, Federico; Breitenlechner, Martin; Brilke, Sophia; Chen, Xuemeng; Craven, Jill; Dias, Antonio; Ehrhart, Sebastian; Flagan, Richard C.; Franchin, Alessandro; Fuchs, Claudia; Guida, Roberto; Hakala, Jani; Hoyle, Christopher R.; Jokinen, Tuija; Junninen, Heikki; Kangasluoma, Juha; Kim, Jaeseok; Krapf, Manuel; Kuerten, Andreas; Laaksonen, Ari; Lehtipalo, Katrianne; Makhmutov, Vladimir; Mathot, Serge; Molteni, Ugo; Onnela, Antti; Peraekylae, Otso; Piel, Felix; Petaejae, Tuukka; Praplan, Arnaud P.; Pringle, Kirsty; Rap, Alexandru; Richards, Nigel A. D.; Riipinen, Ilona; Rissanen, Matti P.; Rondo, Linda; Sarnela, Nina; Schobesberger, Siegfried; Scott, Catherine E.; Seinfeld, John H.; Sipilae, Mikko; Steiner, Gerhard; Stozhkov, Yuri; Stratmann, Frank; Tome, Antonio; Virtanen, Annele; Vogel, Alexander L.; Wagner, Andrea C.; Wagner, Paul E.; Weingartner, Ernest; Wimmer, Daniela; Winkler, Paul M.; Ye, Penglin; Zhang, Xuan; Hansel, Armin; Dommen, Josef; Donahue, Neil M.; Worsnop, Douglas R.; Baltensperger, Urs; Kulmala, Markku; Carslaw, Kenneth S.; Curtius, Joachim			Ion-induced nucleation of pure biogenic particles	NATURE			English	Article							ATMOSPHERIC SULFURIC-ACID; AEROSOL FORMATION; MASS-SPECTROMETER; MOLECULAR-WEIGHT; COSMIC-RAYS; SIZE; OZONOLYSIS; PRODUCTS; GROWTH; COAGULATION	Atmospheric aerosols and their effect on clouds are thought to be important for anthropogenic radiative forcing of the climate, yet remain poorly understood(1). Globally, around half of cloud condensation nuclei originate from nucleation of atmospheric vapours(2). It is thought that sulfuric acid is essential to initiate most particle formation in the atmosphere(3,4), and that ions have a relatively minor role(5). Some laboratory studies, however, have reported organic particle formation without the intentional addition of sulfuric acid, although contamination could not be excluded(6,7). Here we present evidence for the formation of aerosol particles from highly oxidized biogenic vapours in the absence of sulfuric acid in a large chamber under atmospheric conditions. The highly oxygenated molecules (HOMs) are produced by ozonolysis of a-pinene. We find that ions from Galactic cosmic rays increase the nucleation rate by one to two orders of magnitude compared with neutral nucleation. Our experimental findings are supported by quantum chemical calculations of the cluster binding energies of representative HOMs. Ion-induced nucleation of pure organic particles constitutes a potentially widespread source of aerosol particles in terrestrial environments with low sulfuric acid pollution.	[Kirkby, Jasper; Williamson, Christina; Heinritzi, Martin; Simon, Mario; Almeida, Joao; Brilke, Sophia; Ehrhart, Sebastian; Franchin, Alessandro; Kuerten, Andreas; Piel, Felix; Rondo, Linda; Wagner, Andrea C.; Wimmer, Daniela; Curtius, Joachim] Goethe Univ Frankfurt, Inst Atmospher & Environm Sci, D-60438 Frankfurt, Germany; [Kirkby, Jasper; Gordon, Hamish; Almeida, Joao; Dias, Antonio; Ehrhart, Sebastian; Franchin, Alessandro; Guida, Roberto; Mathot, Serge; Onnela, Antti; Vogel, Alexander L.] CERN, CH-1211 Geneva, Switzerland; [Duplissy, Jonathan; Yan, Chao; Nieminen, Tuomo; Wagner, Robert; Adamov, Alexey; Chen, Xuemeng; Franchin, Alessandro; Hakala, Jani; Jokinen, Tuija; Junninen, Heikki; Kangasluoma, Juha; Kuerten, Andreas; Lehtipalo, Katrianne; Peraekylae, Otso; Petaejae, Tuukka; Praplan, Arnaud P.; Rap, Alexandru; Rissanen, Matti P.; Sarnela, Nina; Schobesberger, Siegfried; Sipilae, Mikko; Steiner, Gerhard; Vogel, Alexander L.; Wagner, Andrea C.; Wimmer, Daniela; Worsnop, Douglas R.; Kulmala, Markku] Univ Helsinki, Dept Phys, FI-00014 Helsinki, Finland; [Duplissy, Jonathan; Nieminen, Tuomo; Sipilae, Mikko; Kulmala, Markku] Univ Helsinki, Helsinki Inst Phys, FI-00014 Helsinki, Finland; [Sengupta, Kamalika; Pringle, Kirsty; Rap, Alexandru; Richards, Nigel A. D.; Scott, Catherine E.; Carslaw, Kenneth S.] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England; [Frege, Carla; Troestl, Jasmin; Bianchi, Federico; Franchin, Alessandro; Fuchs, Claudia; Hoyle, Christopher R.; Krapf, Manuel; Lehtipalo, Katrianne; Molteni, Ugo; Weingartner, Ernest; Dommen, Josef; Baltensperger, Urs] Paul Scherrer Inst, Lab Atmospher Chem, CH-5232 Villigen, Switzerland; [Heinritzi, Martin; Bernhammer, Anne-Kathrin; Breitenlechner, Martin; Steiner, Gerhard; Hansel, Armin] Univ Innsbruck, Inst Ion & Appl Phys, A-6020 Innsbruck, Austria; [Ortega, Ismael K.] Onera French Aerosp Lab, F-91123 Palaiseau, France; [Amorim, Antonio] Univ Lisbon, SIM, P-1849016 Lisbon, Portugal; [Bernhammer, Anne-Kathrin; Breitenlechner, Martin; Hansel, Armin] Ionicon Analyt GmbH, A-6020 Innsbruck, Austria; [Bianchi, Federico] ETH, Inst Atmospher & Climate Sci, CH-8092 Zurich, Switzerland; [Craven, Jill; Flagan, Richard C.; Seinfeld, John H.; Zhang, Xuan] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; [Hoyle, Christopher R.] WSL Inst Snow & Avalanche Res SLF, CH-7260 Davos, Switzerland; [Kim, Jaeseok; Laaksonen, Ari; Virtanen, Annele; Worsnop, Douglas R.] Univ Eastern Finland, FI-70211 Kuopio, Finland; [Laaksonen, Ari] Finnish Meteorol Inst, FI-00101 Helsinki, Finland; [Makhmutov, Vladimir; Stozhkov, Yuri] Lebedev Phys Inst, Solar & Cosm Ray Res Lab, Moscow 119991, Russia; [Richards, Nigel A. D.] Univ Leeds, Natl Ctr Earth Observat Leeds, Leeds LS2 9JT, W Yorkshire, England; [Riipinen, Ilona] Univ Stockholm, Dept Appl Environm Sci, SE-10961 Stockholm, Sweden; [Steiner, Gerhard; Wagner, Paul E.; Winkler, Paul M.] Univ Vienna, Fac Phys, A-1090 Vienna, Austria; [Stratmann, Frank] Leibniz Inst Tropospher Res, D-04318 Leipzig, Germany; [Tome, Antonio] Univ Beira Interior, P-6201001 Covilha, Portugal; [Ye, Penglin; Donahue, Neil M.] Carnegie Mellon Univ, Ctr Atmospher Particle Studies, Pittsburgh, PA 15213 USA; [Worsnop, Douglas R.] Aerodyne Res Inc, Billerica, MA 01821 USA; [Williamson, Christina] Univ Colorado, CIRES, Boulder, CO 80309 USA; [Kim, Jaeseok] Korea Polar Res Inst, Arct Res Ctr, Inchon 406840, South Korea; [Schobesberger, Siegfried] Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA	Goethe University Frankfurt; European Organization for Nuclear Research (CERN); University of Helsinki; Helsinki Institute of Physics; University of Helsinki; University of Leeds; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Innsbruck; National Office for Aerospace Studies & Research (ONERA); UDICE-French Research Universities; Universite Paris Saclay; Universidade de Lisboa; Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute for Forest, Snow & Landscape Research; University of Eastern Finland; Finnish Meteorological Institute; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute; University of Leeds; Stockholm University; University of Vienna; Leibniz Institut fur Tropospharenforschung (TROPOS); Universidade da Beira Interior; Carnegie Mellon University; Aerodyne Research; University of Colorado System; University of Colorado Boulder; Korea Institute of Ocean Science & Technology (KIOST); Korea Polar Research Institute (KOPRI); University of Washington; University of Washington Seattle	Kirkby, J (corresponding author), Goethe Univ Frankfurt, Inst Atmospher & Environm Sci, D-60438 Frankfurt, Germany.; Kirkby, J (corresponding author), CERN, CH-1211 Geneva, Switzerland.	jasper.kirkby@cern.ch	Franchin, Alessandro/GVR-8219-2022; Donahue, Neil M/A-2329-2008; Kirkby, Jasper/A-4973-2012; Wagner, Andrea Christine/AGH-3531-2022; Amorim, Antonio/C-8460-2013; Schobesberger, Siegfried/L-4454-2014; Praplan, Arnaud P./F-8357-2011; Nieminen, Tuomo/AAB-8686-2020; Petäjä, Tuukka/A-8009-2008; Vogel, Alexander L./A-1772-2017; Nieminen, Tuomo J/D-1618-2011; Jokinen, Tuija/B-3365-2014; Laaksonen, Ari/B-5094-2011; Weingartner, Ernest/B-6793-2009; Scott, Catherine E/K-8758-2013; Bianchi, Federico/G-8428-2012; Chen, Xuemeng/F-6072-2019; Franchin, Alessandro/AAH-3069-2019; Riipinen, Ilona/ABD-5564-2021; Kulmala, Markku T/I-7671-2016; Virtanen, Annele/E-7699-2010; Breitenlechner, Martin/AAA-3402-2021; Rap, Alexandru/G-7532-2016; Sarnela, Nina/AAE-1372-2020; Curtius, Joachim/A-2681-2011; Stozhkov, Yuri/M-7433-2015; Carslaw, Ken S/C-8514-2009; Kangasluoma, Juha/AAY-7941-2021; Sipilä, Mikko/G-3024-2010; Williamson, Christina J/D-1484-2016; kangasluoma, juha/W-7450-2019; Worsnop, Douglas R/D-2817-2009; Simon, Mario/AGI-2749-2022; Adamov, Alexey/V-2477-2018; Steiner, Gerhard/AAD-4219-2020; Yuri, Stozhkov/ABG-7096-2021; Yan, Chao/ABA-5642-2020; Kürten, Andreas/O-3851-2019; Hoyle, Christopher R./B-7786-2008; Tome, Antonio R/A-5681-2013; Makhmutov, Vladimir/N-2086-2015; Hansel, Armin/F-3915-2010; Duplissy, Jonathan/A-1723-2010; Riipinen, Ilona/I-9379-2012; Junninen, Heikki/C-2157-2014; Ortega Colomer, Ismael Kenneth/A-7930-2008	Donahue, Neil M/0000-0003-3054-2364; Kirkby, Jasper/0000-0003-2341-9069; Wagner, Andrea Christine/0000-0003-3159-9434; Amorim, Antonio/0000-0003-0638-2321; Schobesberger, Siegfried/0000-0002-5777-4897; Praplan, Arnaud P./0000-0002-9944-3084; Nieminen, Tuomo/0000-0002-2713-715X; Petäjä, Tuukka/0000-0002-1881-9044; Vogel, Alexander L./0000-0002-1293-6370; Jokinen, Tuija/0000-0002-1280-1396; Laaksonen, Ari/0000-0002-1657-2383; Weingartner, Ernest/0000-0002-2427-4634; Scott, Catherine E/0000-0002-0187-969X; Bianchi, Federico/0000-0003-2996-3604; Chen, Xuemeng/0000-0002-7731-6842; Kulmala, Markku T/0000-0003-3464-7825; Virtanen, Annele/0000-0002-2917-5344; Rap, Alexandru/0000-0002-2319-6769; Curtius, Joachim/0000-0003-3153-4630; Stozhkov, Yuri/0000-0003-1917-0328; Carslaw, Ken S/0000-0002-6800-154X; Kangasluoma, Juha/0000-0002-1639-1187; Sipilä, Mikko/0000-0002-8594-7003; Williamson, Christina J/0000-0002-5188-9378; Worsnop, Douglas R/0000-0002-8928-8017; Steiner, Gerhard/0000-0003-3008-1414; Yan, Chao/0000-0002-5735-9597; Kürten, Andreas/0000-0002-8955-4450; Hoyle, Christopher R./0000-0002-1369-9143; Tome, Antonio R/0000-0001-9144-7120; Makhmutov, Vladimir/0000-0002-2242-1055; Hansel, Armin/0000-0002-1062-2394; Duplissy, Jonathan/0000-0001-8819-0264; Dommen, Josef/0000-0002-0006-0009; Perakyla, Otso/0000-0002-2089-0106; Ehrhart, Sebastian/0000-0002-6517-5341; Gordon, Hamish/0000-0002-1822-3224; Kim, Jaeseok/0000-0002-7920-0288; Junninen, Heikki/0000-0001-7178-9430; Bernhammer, Anne-Kathrin/0000-0002-0614-3649; Winkler, Paul/0000-0001-6861-6029; Lehtipalo, Katrianne/0000-0002-1660-2706; Trostl, Jasmin/0000-0002-2807-0348; Sarnela, Nina/0000-0003-1874-3235; Breitenlechner, Martin/0000-0002-2382-6660; Rissanen, Matti/0000-0003-0463-8098; Simon, Mario/0000-0002-4900-7460; Brilke, Sophia/0000-0003-3133-249X; Wagner, Robert/0000-0001-7365-8020; Molteni, Ugo/0000-0002-1623-1933; Ortega Colomer, Ismael Kenneth/0000-0002-9299-2013	CERN; EC (Marie Curie Initial Training Network MC-ITN CLOUD-TRAIN) [316662]; EC (EU) [656994]; EC (ERC) [616075, 227463]; German Federal Ministry of Education and Research [01LK1222A]; Swiss National Science Foundation [200020_135307, 200021_140663, 206021_144947/1, 20FI20_149002/1]; Academy of Finland (Center of Excellence) [1118615]; Academy of Finland [135054, 133872, 251427, 139656, 139995, 137749, 141217, 141451]; Finnish Funding Agency for Technology and Innovation; Vaisala Foundation; Nessling Foundation; Austrian Science Fund (FWF) [L593]; Portuguese Foundation for Science and Technology [CERN/FP/116387/2010]; Swedish Research Council, Vetenskapsradet [2011-5120]; Presidium of the Russian Academy of Sciences; Russian Foundation for Basic Research [12-02-91522-CERN]; UK Natural Environment Research Council [NE/K015966/1]; Royal Society; US National Science Foundation [AGS1136479, AGS1447056, CHE1012293]; Caltech ESE Grant (Davidow Foundation); Dreyfus Award [EP-11-117]; French National Research Agency (ANR); Nord-Pas de Calais; European Funds for Regional Economic Development (FEDER, Labex-Cappa) [ANR-11-LABX-0005-01]; Directorate For Geosciences [1447056] Funding Source: National Science Foundation; Natural Environment Research Council [NE/K015966/1] Funding Source: researchfish; NERC [NE/K015966/1] Funding Source: UKRI	CERN; EC (Marie Curie Initial Training Network MC-ITN CLOUD-TRAIN); EC (EU)(European CommissionEuropean Commission Joint Research Centre); EC (ERC); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Academy of Finland (Center of Excellence)(Academy of Finland); Academy of Finland(Academy of Finland); Finnish Funding Agency for Technology and Innovation(Finnish Funding Agency for Technology & Innovation (TEKES)); Vaisala Foundation; Nessling Foundation; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Swedish Research Council, Vetenskapsradet(Swedish Research Council); Presidium of the Russian Academy of Sciences(Russian Academy of Sciences); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Royal Society(Royal Society of London); US National Science Foundation(National Science Foundation (NSF)); Caltech ESE Grant (Davidow Foundation); Dreyfus Award; French National Research Agency (ANR)(French National Research Agency (ANR)); Nord-Pas de Calais(Region Hauts-de-France); European Funds for Regional Economic Development (FEDER, Labex-Cappa); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank CERN for supporting CLOUD with important technical and financial resources, and for providing a particle beam from the CERN Proton Synchrotron. We also thank P. Carrie, L.-P. De Menezes, J. Dumollard, F. Josa, I. Krasin, R. Kristic, A. Laassiri, O. S. Maksumov, B. Marichy, H. Martinati, S. V. Mizin, R. Sitals, A. Wasem and M. Wilhelmsson for their contributions to the experiment. We thank the CSC Centre for Scientific Computing in Espoo, Finland for computer time. This research has received funding from the EC Seventh Framework Programme (Marie Curie Initial Training Network MC-ITN CLOUD-TRAIN no. 316662, EU Horizon 2020 Marie Curie grant no. 656994, ERC-Consolidator grant NANODYNAMITE no. 616075 and ERC-Advanced grant ATMNUCLE no. 227463), the German Federal Ministry of Education and Research (project no. 01LK1222A), the Swiss National Science Foundation (project nos 200020_135307, 200021_140663, 206021_144947/1 and 20FI20_149002/1), the Academy of Finland (Center of Excellence project no. 1118615), the Academy of Finland (135054, 133872, 251427, 139656, 139995, 137749, 141217, 141451), the Finnish Funding Agency for Technology and Innovation, the Vaisala Foundation, the Nessling Foundation, the Austrian Science Fund (FWF; project no. L593), the Portuguese Foundation for Science and Technology (project no. CERN/FP/116387/2010), the Swedish Research Council, Vetenskapsradet (grant 2011-5120), the Presidium of the Russian Academy of Sciences and Russian Foundation for Basic Research (grant 12-02-91522-CERN), the UK Natural Environment Research Council (grant NE/K015966/1), the Royal Society (Wolfson Merit Award), the US National Science Foundation (grants AGS1136479, AGS1447056 and CHE1012293), Caltech ESE Grant (Davidow Foundation), Dreyfus Award EP-11-117, the French National Research Agency (ANR), the Nord-Pas de Calais, and the European Funds for Regional Economic Development (FEDER, Labex-Cappa, ANR-11-LABX-0005-01).	Almeida J, 2013, NATURE, V502, P359, DOI 10.1038/nature12663; Asmi E, 2009, ATMOS CHEM PHYS, V9, P141, DOI 10.5194/acp-9-141-2009; Atkinson R, 2006, ATMOS CHEM PHYS, V6, P3625, DOI 10.5194/acp-6-3625-2006; Bianchi F, 2016, SCIENCE, V352, P1109, DOI 10.1126/science.aad5456; Boucher O, 2014, CLIMATE CHANGE 2013: THE PHYSICAL SCIENCE BASIS, P571, DOI 10.1017/cbo9781107415324.016; Chan TW, 2001, J AEROSOL SCI, V32, P321, DOI 10.1016/S0021-8502(00)00081-1; Crounse JD, 2013, J PHYS CHEM LETT, V4, P3513, DOI 10.1021/jz4019207; DITCHFIELD R, 1971, J CHEM PHYS, V54, P724, DOI 10.1063/1.1674902; Ehn M, 2014, NATURE, V506, P476, DOI 10.1038/nature13032; Ehrhart S, 2013, ATMOS CHEM PHYS, V13, P11465, DOI 10.5194/acp-13-11465-2013; EISELE FL, 1993, J GEOPHYS RES-ATMOS, V98, P9001, DOI 10.1029/93JD00031; Ekman AML, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034970; Elm J, 2014, CHEM PHYS LETT, V615, P26, DOI 10.1016/j.cplett.2014.09.060; Enghoff MB, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047036; Frisch M.J., 2013, GAUSSIAN; Fuchs N.A., 1964, MECH AEROSOLS; Gagne S, 2011, ATMOS MEAS TECH, V4, P805, DOI 10.5194/amt-4-805-2011; Gao S, 2004, J PHYS CHEM A, V108, P10147, DOI 10.1021/jp047466e; Graus M, 2010, J AM SOC MASS SPECTR, V21, P1037, DOI 10.1016/j.jasms.2010.02.006; Guenther AB, 2012, GEOSCI MODEL DEV, V5, P1471, DOI 10.5194/gmd-5-1471-2012; Heland J, 2001, ENVIRON SCI TECHNOL, V35, P3207, DOI 10.1021/es000303t; Herschel F. W., 1801, PHILOS T ROYAL SOC L, V91, P318; Hirsikko A, 2011, ATMOS CHEM PHYS, V11, P767, DOI 10.5194/acp-11-767-2011; Iida K, 2009, AEROSOL SCI TECH, V43, P81, DOI 10.1080/02786820802488194; Jokinen T, 2012, ATMOS CHEM PHYS, V12, P4117, DOI 10.5194/acp-12-4117-2012; Junninen H, 2010, ATMOS MEAS TECH, V3, P1039, DOI 10.5194/amt-3-1039-2010; Kangasluoma J, 2014, ATMOS MEAS TECH, V7, P689, DOI 10.5194/amt-7-689-2014; Kathmann SM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.116104; Kerminen VM, 2002, J AEROSOL SCI, V33, P609, DOI 10.1016/S0021-8502(01)00194-X; Kirkby J, 2007, SURV GEOPHYS, V28, P333, DOI 10.1007/s10712-008-9030-6; Kirkby J, 2011, NATURE, V476, P429, DOI 10.1038/nature10343; Kuang C, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009253; Kurten A, 2015, ATMOS CHEM PHYS, V15, P4063, DOI 10.5194/acp-15-4063-2015; Kurten A, 2011, ATMOS MEAS TECH, V4, P437, DOI 10.5194/amt-4-437-2011; Kurten A, 2014, P NATL ACAD SCI USA, V111, P15019, DOI 10.1073/pnas.1404853111; Kurten A, 2012, J PHYS CHEM A, V116, P6375, DOI 10.1021/jp212123n; Kulmala M, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006963; Kulmala M, 2013, SCIENCE, V339, P943, DOI 10.1126/science.1227385; Kulmala M, 2008, ATMOS RES, V90, P132, DOI 10.1016/j.atmosres.2008.01.005; Kurten T, 2015, J PHYS CHEM A, V119, P11366, DOI 10.1021/acs.jpca.5b08948; Laakso L, 2004, ATMOS CHEM PHYS, V4, P2353, DOI 10.5194/acp-4-2353-2004; Lee SH, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009351; Lehtipalo K, 2014, BOREAL ENVIRON RES, V19, P215; Mann GW, 2012, ATMOS CHEM PHYS, V12, P4449, DOI 10.5194/acp-12-4449-2012; Martin ST, 2010, REV GEOPHYS, V48, DOI 10.1029/2008RG000280; Merikanto J, 2009, ATMOS CHEM PHYS, V9, P8601, DOI 10.5194/acp-9-8601-2009; Metzger A, 2010, P NATL ACAD SCI USA, V107, P6646, DOI 10.1073/pnas.0911330107; Mirme S, 2013, ATMOS MEAS TECH, V6, P1061, DOI 10.5194/amt-6-1061-2013; Mirme S, 2010, ATMOS CHEM PHYS, V10, P437, DOI 10.5194/acp-10-437-2010; MOHLER O, 1992, J CHEM PHYS, V97, P8233, DOI 10.1063/1.463394; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Ortega IK, 2012, ATMOS CHEM PHYS, V12, P225, DOI 10.5194/acp-12-225-2012; Ortega IK, 2016, J PHYS CHEM A, V120, P1452, DOI 10.1021/acs.jpca.5b07427; Paasonen P, 2010, ATMOS CHEM PHYS, V10, P11223, DOI 10.5194/acp-10-11223-2010; Riccobono F, 2012, ATMOS CHEM PHYS, V12, P9427, DOI 10.5194/acp-12-9427-2012; Riccobono F, 2014, SCIENCE, V344, P717, DOI 10.1126/science.1243527; Riipinen I, 2011, ATMOS CHEM PHYS, V11, P3865, DOI 10.5194/acp-11-3865-2011; Rissanen MP, 2015, J PHYS CHEM A, V119, P4633, DOI 10.1021/jp510966g; Rissanen MP, 2014, J AM CHEM SOC, V136, P15596, DOI 10.1021/ja507146s; SCEATS MG, 1989, J COLLOID INTERF SCI, V129, P105, DOI 10.1016/0021-9797(89)90419-0; Schobesberger S, 2013, P NATL ACAD SCI USA, V110, P17223, DOI 10.1073/pnas.1306973110; Seinfeld J. H., 2006, ATMOSPHERIC CHEM PHY, P600; Sihto SL, 2006, ATMOS CHEM PHYS, V6, P4079, DOI 10.5194/acp-6-4079-2006; Suni T, 2008, ATMOS CHEM PHYS, V8, P129, DOI 10.5194/acp-8-129-2008; TAIRA M, 1990, ANAL CHEM, V62, P630, DOI 10.1021/ac00205a018; Trostl J, 2016, NATURE, V533, P527, DOI 10.1038/nature18271; Vanhanen J, 2011, AEROSOL SCI TECH, V45, P533, DOI 10.1080/02786826.2010.547889; Wimmer D, 2013, ATMOS MEAS TECH, V6, P1793, DOI 10.5194/amt-6-1793-2013; Zhang K, 2011, ATMOS CHEM PHYS, V11, P7817, DOI 10.5194/acp-11-7817-2011; Zhang RY, 2004, SCIENCE, V304, P1487, DOI 10.1126/science.1095139; ZHANG SH, 1995, AEROSOL SCI TECH, V23, P357, DOI 10.1080/02786829508965320; Zhang X, 2015, P NATL ACAD SCI USA, V112, P14168, DOI 10.1073/pnas.1517742112; Zhao J, 2013, ATMOS CHEM PHYS, V13, P7631, DOI 10.5194/acp-13-7631-2013; Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x	74	327	330	18	420	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2016	533	7604					521	+		10.1038/nature17953	http://dx.doi.org/10.1038/nature17953			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM6EJ	27225125	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000376443100038
J	Wallentin, L; Lindhagen, L; Arnstrom, E; Husted, S; Janzon, M; Johnsen, SP; Kontny, F; Kempf, T; Levin, LA; Lindahl, B; Stridsberg, M; Stahle, E; Venge, P; Wollert, KC; Swahn, E; Lagerqvist, B				Wallentin, Lars; Lindhagen, Lars; Arnstrom, Elisabet; Husted, Steen; Janzon, Magnus; Johnsen, Soren Paaske; Kontny, Frederic; Kempf, Tibor; Levin, Lars-Ake; Lindahl, Bertil; Stridsberg, Mats; Stahle, Elisabeth; Venge, Per; Wollert, Kai C.; Swahn, Eva; Lagerqvist, Bo		FRISC-II Study Grp	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study	LANCET			English	Article							GROWTH-DIFFERENTIATION FACTOR-15; ARTERY-DISEASE; UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; CONSERVATIVE TREATMENT; TROPONIN-T; PROGNOSTIC VALUE; STRATEGY; WOMEN; METAANALYSIS	Background The FRISC-II trial was the first randomised trial to show a reduction in death or myocardial infarction with an early invasive versus a non-invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome. Here we provide a remaining lifetime perspective on the effects on all cardiovascular events during 15 years' follow-up. Methods The FRISC-II prospective, randomised, multicentre trial was done at 58 Scandinavian centres in Sweden, Denmark, and Norway. Between June 17, 1996, and Aug 28, 1998, we randomly assigned (1:1) 2457 patients with non-ST-elevation acute coronary syndrome to an early invasive treatment strategy, aiming for revascularisation within 7 days, or a non-invasive strategy, with invasive procedures at recurrent symptoms or severe exercise-induced ischaemia. Plasma for biomarker analyses was obtained at randomisation. For long-term outcomes, we linked data with national health-care registers. The primary endpoint was a composite of death or myocardial infarction. Outcomes were compared as the average postponement of the next event, including recurrent events, calculated as the area between mean cumulative count-of-events curves. Analyses were done by intention to treat. Findings At a minimum of 15 years' follow-up on Dec 31, 2014, data for survival status and death were available for 2421 (99%) of the initially recruited 2457 patients, and for other events after 2 years for 2182 (89%) patients. During follow-up, the invasive strategy postponed death or next myocardial infarction by a mean of 549 days (95% CI 204-888; p= 0.0020) compared with the non-invasive strategy. This effect was larger in non-smokers (mean gain 809 days, 95% CI 402-1175; p(interaction) = 0.0182), patients with elevated troponin T (778 days, 357-1165; p (interaction) = 0.0241), and patients with high concentrations of growth differentiation factor-15 (1356 days, 507-1650; p (interaction) = 0.0210). The difference was mainly driven by postponement of new myocardial infarction, whereas the early difference in mortality alone was not sustained over time. The invasive strategy led to a mean of 1128 days (95% CI 830-1366) postponement of death or next readmission to hospital for ischaemic heart disease, which was consistent in all subgroups (p< 0.0001). Interpretation During 15 years of follow-up, an early invasive treatment strategy postponed the occurrence of death or next myocardial infarction by an average of 18 months, and the next readmission to hospital for ischaemic heart disease by 37 months, compared with a non-invasive strategy in patients with non-ST-elevation acute coronary syndrome. This remaining lifetime perspective supports that an early invasive treatment strategy should be the preferred option in most patients with non-ST-elevation acute coronary syndrome.	[Wallentin, Lars; Lindahl, Bertil; Lagerqvist, Bo] Uppsala Univ, Dept Med Sci, Cardiol, Uppsala, Sweden; [Wallentin, Lars; Lindhagen, Lars; Arnstrom, Elisabet; Lindahl, Bertil; Lagerqvist, Bo] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Stridsberg, Mats; Venge, Per] Uppsala Univ, Dept Med Sci, Clin Chem, Uppsala, Sweden; [Stahle, Elisabeth] Uppsala Univ, Dept Surg Sci, Thorac Surg, Uppsala, Sweden; [Husted, Steen] Hosp Unit West, Dept Med, Herning Holstebro, Denmark; [Janzon, Magnus; Levin, Lars-Ake; Swahn, Eva] Linkoping Univ, Dept Cardiol, Linkoping, Sweden; [Janzon, Magnus; Levin, Lars-Ake; Swahn, Eva] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Janzon, Magnus; Levin, Lars-Ake] Linkoping Univ, Div Hlth Care Anal, Dept Med & Hlth Sci, Ctr Med Technol Assessment, Linkoping, Sweden; [Johnsen, Soren Paaske] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark; [Kontny, Frederic] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway; [Kontny, Frederic] Drammen Heart Ctr, Drammen, Norway; [Kempf, Tibor; Wollert, Kai C.] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany	Uppsala University; Uppsala University; Uppsala University; Uppsala University; Linkoping University; Linkoping University; Linkoping University; Aarhus University; Stavanger University Hospital; Hannover Medical School	Wallentin, L (corresponding author), Uppsala Clin Res Ctr, Dag Hammarskjolds Vag 14B,MTC Bldg,Sci Pk, S-75237 Uppsala, Sweden.	lars.wallentin@ucr.uu.se	Kempf, Tibor/ABA-3167-2021	Kempf, Tibor/0000-0001-6901-8442	Swedish Heart-Lung Foundation; Swedish Foundation for Strategic Research; Uppsala Clinical Research Center	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Uppsala Clinical Research Center	Swedish Heart-Lung Foundation, Swedish Foundation for Strategic Research, and Uppsala Clinical Research Center.	Alfredsson J, 2014, AM HEART J, V168, P522, DOI 10.1016/j.ahj.2014.06.025; Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.016, 10.1016/j.jacc.2014.09.017]; Bavry AA, 2006, J AM COLL CARDIOL, V48, P1319, DOI 10.1016/j.jacc.2006.06.050; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Clayton TC, 2004, EUR HEART J, V25, P1641, DOI 10.1016/j.ehj.2004.07.032; Damman P, 2014, INT J CARDIOL, V172, P356, DOI 10.1016/j.ijcard.2014.01.025; de Winter RJ, 2005, NEW ENGL J MED, V353, P1095, DOI 10.1056/NEJMoa044259; Diderholm E, 2002, AM HEART J, V143, P760, DOI 10.1067/mhj.2002.121733; Dong HR, 2015, AM J EPIDEMIOL, V181, P532, DOI 10.1093/aje/kwu289; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Fox KAA, 2010, J AM COLL CARDIOL, V55, P2435, DOI 10.1016/j.jacc.2010.03.007; Hagstrom E, 2016, EUR HEART J, V37, P1325, DOI 10.1093/eurheartj/ehv491; Henderson RA, 2015, J AM COLL CARDIOL, V66, P511, DOI 10.1016/j.jacc.2015.05.051; Jernberg T, 2004, EUR J HEART FAIL, V6, P319, DOI 10.1016/j.ejheart.2004.01.007; Jernberg T, 2010, HEART, V96, P1617, DOI 10.1136/hrt.2010.198804; Lagerqvist B, 2002, J AM COLL CARDIOL, V40, P1902, DOI 10.1016/S0735-1097(02)02572-X; Lagerqvist B, 2001, J AM COLL CARDIOL, V38, P41, DOI 10.1016/S0735-1097(01)01308-0; Lagerqvist B, 2006, LANCET, V368, P998, DOI 10.1016/S0140-6736(06)69416-6; Lindahl B, 2001, J AM COLL CARDIOL, V38, P979, DOI 10.1016/S0735-1097(01)01501-7; Manfrini O, 2016, SCI REP-UK, V6, DOI 10.1038/srep27345; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; O'Donoghue M, 2008, JAMA-J AM MED ASSOC, V300, P71, DOI 10.1001/jama.300.1.71; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Tegn N, 2016, LANCET, V387, P1057, DOI 10.1016/S0140-6736(15)01166-6; Venge P, 2002, AM J CARDIOL, V89, P1035, DOI 10.1016/S0002-9149(02)02271-3; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Wallentin L, 2014, CIRCULATION, V129, P293, DOI 10.1161/CIRCULATIONAHA.113.004420; Wollert KC, 2007, CIRCULATION, V116, P1540, DOI 10.1161/CIRCULATIONAHA.107.697714; Wollert KC, 2007, CIRCULATION, V115, P962, DOI 10.1161/CIRCULATIONAHA.106.650846	30	50	54	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 15	2016	388	10054					1903	1911		10.1016/S0140-6736(16)31276-4	http://dx.doi.org/10.1016/S0140-6736(16)31276-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ0AM	27585757				2023-01-03	WOS:000385499000034
J	Tanaka, A; Furubayashi, T; Matsushita, A; Inoue, D; Kimura, S; Katsumi, H; Sakane, T; Yamamoto, A				Tanaka, Akiko; Furubayashi, Tomoyuki; Matsushita, Akifumi; Inoue, Daisuke; Kimura, Shunsuke; Katsumi, Hidemasa; Sakane, Toshiyasu; Yamamoto, Akira			Nasal Absorption of Macromolecules from Powder Formulations and Effects of Sodium Carboxymethyl Cellulose on Their Absorption	PLOS ONE			English	Article							IN-VITRO EVALUATION; DRUG-DELIVERY; INSULIN; MUCOADHESIVE; IMPROVEMENT; SUSPENSION	The nasal absorption of macromolecules from powder formulations and the effect of sodium carboxymethyl cellulose (CMC-Na) as a pharmaceutical excipient on their absorption were studied. Model macromolecules were fluorescein isothiocyanate-labeled dextran (average molecular weight of 4.4kDa, FD4) and insulin. The plasma concentration of FD4 after application of the powder containing 50% starch (control) was higher than that after application of the solution, and the absorption from 50% starch powder was enhanced by the substitution of starch with CMC-Na. The fractional absorption of FD4 after administration of the CMC-Na powder formulation was 30% and 40% higher than that after administration from the solution and the starch powder, respectively. The nasal absorption of insulin from the powder and the effect of CMC-Na were similar with those of FD4. The effective absorption of FD4 and insulin after application of powder with CMC-Na could be due to the increase in the nasal residence of FD4 and insulin. No damage in the nasal mucosa or dysfunction of the mucociliary clearance was observed after application of the drug powder and CMC-Na. The present findings indicate that nasal delivery of powder formulations with the addition of CMC-Na as an excipient is a promising approach for improving the nasal absorption of macromolecules.	[Tanaka, Akiko; Matsushita, Akifumi; Katsumi, Hidemasa; Sakane, Toshiyasu; Yamamoto, Akira] Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina, Kyoto 6078414, Japan; [Furubayashi, Tomoyuki; Inoue, Daisuke] Shujitsu Univ, Sch Pharm, Kita Ku, Nishikawara, Okayama 7038516, Japan; [Kimura, Shunsuke] Doshisha Womens Coll Liberal Arts, Fac Pharmaceut Sci, Kyotanabe, Kyoto 6100395, Japan; [Sakane, Toshiyasu] Kobe Pharmaceut Univ, Dept Pharmaceut Technol, Higashinada Ku, Motoyamakita Machi 4-19-1, Kobe, Hyogo 6588558, Japan	Kyoto Pharmaceutical University; Kobe Pharmaceutical University	Sakane, T (corresponding author), Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina, Kyoto 6078414, Japan.; Sakane, T (corresponding author), Kobe Pharmaceut Univ, Dept Pharmaceut Technol, Higashinada Ku, Motoyamakita Machi 4-19-1, Kobe, Hyogo 6588558, Japan.	sakane@mb.kyoto-phu.ac.jp		Inoue, Daisuke/0000-0003-0219-4331				Dong ZQ, 2011, J PHARM SCI-US, V100, P1866, DOI 10.1002/jps.22428; du Plessis LH, 2010, INT J PHARMACEUT, V385, P181, DOI 10.1016/j.ijpharm.2009.10.031; Fetih G, 2005, J CONTROL RELEASE, V106, P287, DOI 10.1016/j.jconrel.2005.05.017; Harris AS, 1993, J DRUG TARGET, V1, P101, DOI 10.3109/10611869308996066; He L, 2007, J CONTROL RELEASE, V122, P94, DOI 10.1016/j.jconrel.2007.06.017; HIRAI S, 1981, INT J PHARM, V7, P317; HUSSAIN AA, 1979, J PHARM SCI, V68, P1196, DOI 10.1002/jps.2600680942; Inoue D, 2013, BIOL PHARM BULL, V36, P966, DOI 10.1248/bpb.b12-01076; Irifune M, 1999, Auris Nasus Larynx, V26, P49, DOI 10.1016/S0385-8146(98)00062-5; Ishikawa F, 2002, PHARM RES-DORDR, V19, P1097, DOI 10.1023/A:1019881706159; Ishikawa F, 2001, INT J PHARM, V224, P105, DOI 10.1016/S0378-5173(01)00736-0; Krug N, 2005, ALLERGY, V60, P354, DOI 10.1111/j.1398-9995.2005.00703.x; Li M, 2016, MOL PHARMACEUT, V13, P885, DOI 10.1021/acs.molpharmaceut.5b00802; LIU FY, 1993, PHARMACEUT RES, V10, P228, DOI 10.1023/A:1018934810512; Lu HT, 2011, XENOBIOTICA, V41, P567, DOI 10.3109/00498254.2011.563877; Makidon PE, 2010, J AEROSOL MED PULM D, V23, P77, DOI 10.1089/jamp.2009.0766; Marttin E, 1998, ADV DRUG DELIVER REV, V29, P13, DOI 10.1016/S0169-409X(97)00059-8; Merchant HA, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070378; OKUDA M, 1986, Rhinology (Utrecht), V24, P113; Pennington J, 2008, DRUG DEV IND PHARM, V34, P923, DOI [10.1080/03639040802149046, 10.1080/03639040802149046 ]; Rajendran NN, 2011, INT J PHARM SCI RES, V2, P3136; SATIR P, 1990, ANNU REV PHYSIOL, V52, P137, DOI 10.1146/annurev.ph.52.030190.001033; SCHIPPER NGM, 1991, PHARMACEUT RES, V8, P807, DOI 10.1023/A:1015830907632; SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726, DOI 10.1164/ajrccm/137.3.726; Tozaki H, 1997, J PHARM SCI, V86, P1016, DOI 10.1021/js970018g; Ugwoke MI, 2005, ADV DRUG DELIVER REV, V57, P1640, DOI 10.1016/j.addr.2005.07.009; Wang YX, 2014, NANOMEDICINE-UK, V9, P451, DOI [10.2217/NNM.13.102, 10.2217/nnm.13.102]; YAMAMOTO A, 1994, PHARMACEUT RES, V11, P1496, DOI 10.1023/A:1018968611962	28	14	15	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2016	11	9							e0159150	10.1371/journal.pone.0159150	http://dx.doi.org/10.1371/journal.pone.0159150			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9IT	27598527	Green Submitted, gold, Green Published			2023-01-03	WOS:000383254800001
J	Matthews, FE; Bennett, H; Wittenberg, R; Jagger, C; Dening, T; Brayne, C				Matthews, Fiona E.; Bennett, Holly; Wittenberg, Raphael; Jagger, Carol; Dening, Tom; Brayne, Carol		Cognitive Function Ageing Studies	Who Lives Where and Does It Matter? Changes in the Health Profiles of Older People Living in Long Term Care and the Community over Two Decades in a High Income Country	PLOS ONE			English	Article							QUALITY-OF-LIFE; COGNITIVE FUNCTION; RISK-FACTORS; ALZHEIMERS-DISEASE; HOME RESIDENTS; DEMENTIA; PREVALENCE; POPULATION; DEPRESSION; ENGLAND	Background There have been fundamental shifts in the attitude towards, access to and nature of long term care in high income countries. The proportion and profile of the older population living in such settings varies according to social, cultural, and economic characteristics as well as governmental policies. Changes in the profiles of people in different settings are important for policy makers and care providers. Although details will differ, how change occurs across time is important to all, including lower and middle income countries developing policies themselves. Here change is examined across two decades in England. Methods and Findings Using the two Cognitive Function and Ageing Studies (CFAS I: 77% response, CFAS II: 56% response), two population based studies of older people carried out in the same areas conducted two decades apart, the study diagnosis of dementia using the Automated Geriatric Examination for Computer Assisted Taxonomy, health and wellbeing were examined, focusing on long term care. The proportion of individuals with three or more health conditions increased for everyone living in long term care between CFAS I (47.6%, 95% CI: 42.3-53.1) and CFAS II (62.7%, 95% CI: 54.8-70.0) and was consistently higher in those without dementia compared to those with dementia in both studies. Functional impairment measured by activities of daily living increased in assisted living facilities from 48% (95% CI: 44%-52%) to 67% (95% CI: 62%-71%). Conclusions Health profiles of residents in long term care have changed dramatically over time. Dementia prevalence and reporting multiple health conditions have increased. Receiving care in the community puts pressure on unpaid carers and formal services; these results have implications for policies about supporting people at home as well as for service provision within long term care including quality of care, health management, cost, and the development of a skilled, caring, and informed workforce.	[Matthews, Fiona E.] Cambridge Inst Publ Hlth, Cambridge Biomed Campus, Biostat Unit, MRC, Forvie Site,Robinson Way, Cambridge, England; [Matthews, Fiona E.; Jagger, Carol] Newcastle Univ, Inst Hlth & Soc, Edwardson Bldg,Campus Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England; [Bennett, Holly; Brayne, Carol] Univ Cambridge, Sch Clin Med, Cambridge Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England; [Wittenberg, Raphael] London Sch Econ & Polit Sci, Personal Social Serv Res Unit, Houghton St, London, England; [Dening, Tom] Univ Nottingham, Inst Mental Hlth, Triumph Rd, Nottingham, England	MRC Biostatistics Unit; University of Cambridge; Newcastle University - UK; University of Cambridge; University of London; London School Economics & Political Science; University of Nottingham	Brayne, C (corresponding author), Univ Cambridge, Sch Clin Med, Cambridge Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.	cb105@medschl.cam.ac.uk	Matthews, Fiona/O-6932-2015; Brayne, Carol/AAA-4285-2020; Dening, Tom/E-1335-2013; Morris, Josephine D./F-3366-2018	Matthews, Fiona/0000-0002-1728-2388; Brayne, Carol/0000-0001-5307-663X; Dening, Tom/0000-0003-3387-4241; Morris, Josephine D./0000-0001-9404-5602; Jagger, Carol/0000-0002-6377-9926	Medical Research Council [G0601022, G9901400]; MRC [G9901400, MC_U105292687, G0601022] Funding Source: UKRI; Medical Research Council [MC_U105292687] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10084] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	CFAS II has been funded through a grant from the Medical Research Council (grant number G0601022). CFAS I was also funded through the Medical Research Council (grant number G9901400). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anstey KJ, 2007, AM J GERIAT PSYCHIAT, V15, P497, DOI 10.1097/JGP.0b013e31802e21d8; Arfken CL, 2011, PSYCHOTHER PSYCHOSOM, V80, P325, DOI 10.1159/000324795; Bolton M., 2012, CAMPAIGN END LONELIN; Bowman C, 2004, AGE AGEING, V33, P561, DOI 10.1093/ageing/afh177; Caffrey C, 2012, NCHS DATA BRIEF, V91; Campbell Stern M, 1993, BRIT MED J, V306; CFAS, COGN FUNCT AG STUD C; Darton R, 2012, HEALTH SOC CARE COMM, V20, P87, DOI 10.1111/j.1365-2524.2011.01022.x; DCLG, LAYING FDN HOUS STRA; DH/SCLG&CP/SCPI/SR, LIV WELL DEM NAT DEM; England N, NHS 5 YEAR FORW VIEW; Galea S, 2007, ANN EPIDEMIOL, V17, P643, DOI 10.1016/j.annepidem.2007.03.013; Gordon AL, 2014, AGE AGEING, V43, P97, DOI 10.1093/ageing/aft077; Hajek A, 2016, J AM MED DIR ASSOC, V17, P300, DOI 10.1016/j.jamda.2015.10.015; Jagger C, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-21; Kendig H, 2010, AGE AGEING, V39, P342, DOI 10.1093/ageing/afq016; KIYAK HA, 1994, GERONTOLOGIST, V34, P324, DOI 10.1093/geront/34.3.324; Laukkanen P, 2001, AGE AGEING, V30, P489, DOI 10.1093/ageing/30.6.489; Lithgow S, 2012, INT J GERIATR PSYCH, V27, P785, DOI 10.1002/gps.2784; Luppa M, 2008, DEMENT GERIATR COGN, V26, P65, DOI 10.1159/000144027; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Mann AH, 2000, INT J GERIATR PSYCH, V15, P1105, DOI 10.1002/1099-1166(200012)15:12<1105::AID-GPS252>3.0.CO;2-W; Martin-Garcia S, 2013, INT PSYCHOGERIATR, V25, P1077, DOI 10.1017/S1041610213000458; Matthews FE, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-12; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; ONS, 2013, WHAT DOES 2011 CENS; Prince M., 2013, WORLD ALZHEIMER REPO; Rafnsson SB, 2017, AGING MENT HEALTH, V21, P104, DOI 10.1080/13607863.2015.1088510; Ready RE, 2004, INT J GERIATR PSYCH, V19, P256, DOI 10.1002/gps.1075; Schubert CC, 2006, J AM GERIATR SOC, V54, P104, DOI 10.1111/j.1532-5415.2005.00543.x; Spiers NA, 2005, J GERONTOL A-BIOL, V60, P248, DOI 10.1093/gerona/60.2.248; Stewart R, 2014, AGE AGEING, V43, P562, DOI 10.1093/ageing/afu062; van der Lee J, 2015, AGING MENT HEALTH, P1, DOI [10.1080/13607863.2015.1102196, DOI 10.1080/13607863.2015.1102196]; Victor CR, 2005, AGEING SOC, V25, P357, DOI 10.1017/S0144686X04003332	34	28	28	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2016	11	9							e0161705	10.1371/journal.pone.0161705	http://dx.doi.org/10.1371/journal.pone.0161705			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DV4EJ	27589586	Green Published, Green Accepted, gold			2023-01-03	WOS:000382877800015
J	Nemes, A; Fortmann, T; Poeschke, S; Greve, B; Prevedello, D; Santacroce, A; Stummer, W; Senner, V; Ewelt, C				Nemes, Andrei; Fortmann, Thomas; Poeschke, Stephan; Greve, Burkhard; Prevedello, Daniel; Santacroce, Antonio; Stummer, Walter; Senner, Volker; Ewelt, Christian			5-ALA Fluorescence in Native Pituitary Adenoma Cell Lines: Resection Control and Basis for Photodynamic Therapy (PDT)?	PLOS ONE			English	Article							INDUCED PROTOPORPHYRIN-IX; TRANS-SPHENOIDAL MICROSURGERY; FOLLOW-UP; MITOCHONDRIAL; GLIOMA; LIGHT; EXCISION; SURGERY	Objective: Pituitary adenomas (PA), especially invasive ones, are often not completely resectable. Usage of 5-aminolevulinic acid (5-ALA) for fluorescence guided surgery could improve the rate of total resection and, additionally, open the doors for photodynamic therapy (PDT) in case of unresectable or partially resected PAs. The aim of this study was to investigate the uptake of 5-ALA and the effect of 5-ALA based PDT in cell lines. Methods: GH3 and AtT-20 cell lines were incubated with different concentrations of 5-ALA, protoporphyrin IX (PPIX) fluorescence was measured by flow cytometry and fluorescencespectrometry. WST-1 assays were performed to determine the surviving fraction of cells after PDT. PPIX fluorescence intensities and PDT effect of the pituitary adenoma cells were compared to U373MG, a well-known glioblastoma cell line. Results: Both cell lines showed a 5-ALA dependent intracellular PPIX fluorescence. Significant differences after 24hrs of incubation were observed in AtT-20 cells in comparison to GH3. Regardless of the incubation or metabolism time, there was a proliferation inhibiting effect after PDT, with no statistical significance. Conclusion: Since GH3 cells showed a heterogenous uptake of 5-ALA in the flow cytometry profile, but not constantly high concentrations they might have a 5-ALA efflux mechanism, which still needs to be determined. In the case of AtT-20, the cells might need a longer time for the uptake due to their size or slow metabolism. We showed that the different cell lines have different uptake and metabolism mechanisms, which needs to be further investigated. The general uptake of 5-ALA allows the possibility of resection control and PDT for pituitary adenomas. But, the role of PDT for unresectable pituitary adenomas deserves further investigations.	[Nemes, Andrei; Poeschke, Stephan; Senner, Volker] Univ Hosp Muenster, Inst Neuropathol, Munster, Germany; [Fortmann, Thomas; Stummer, Walter; Ewelt, Christian] Univ Hosp Muenster, Dept Neurosurg, Munster, Germany; [Greve, Burkhard] Univ Hosp Muenster, Dept Radiotherapy Radiooncol, Munster, Germany; [Prevedello, Daniel] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Santacroce, Antonio] Univ Hosp Tuebingen, Dept Neurosurg, Tubingen, Germany	University of Munster; University of Munster; University of Munster; University System of Ohio; Ohio State University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Ewelt, C (corresponding author), Univ Hosp Muenster, Dept Neurosurg, Munster, Germany.	christian.ewelt@ukmuenster.de	Stummer, Walter/AAA-3319-2020; Stummer, Walter/AAF-9043-2019					Buchfelder M, 1991, Acta Neurochir Suppl (Wien), V53, P72; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Choi MC, 2013, INT J GYNECOL CANCER, V23, P698, DOI 10.1097/IGC.0b013e31828b5ba2; CIRIC I, 1983, J NEUROSURG, V59, P395, DOI 10.3171/jns.1983.59.3.0395; de Vijlder HC, 2012, ACTA DERM-VENEREOL, V92, P641, DOI 10.2340/00015555-1448; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Eljamel MS, 2009, J NEURO-ONCOL, V92, P417, DOI 10.1007/s11060-009-9820-9; Etminan N, 2011, J NEUROSURG, V115, P281, DOI 10.3171/2011.3.JNS10434; Farrell WE, 2000, FRONT NEUROENDOCRIN, V21, P174, DOI 10.1006/frne.1999.0195; Fernandez-Miranda JC, 2010, ACTA NEUROCHIR, V152, P1281, DOI 10.1007/s00701-009-0487-y; Gopalan R, 2011, NEUROSURGERY, V69, P284, DOI 10.1227/NEU.0b013e31821bc44e; Grebenova D, 2003, J PHOTOCH PHOTOBIO B, V69, P71, DOI 10.1016/S1011-1344(02)00410-4; HARDY J, 1979, HOSP PRACT, V14, P81, DOI 10.1080/21548331.1979.11707562; Higgins TS, 2008, AM J RHINOL, V22, P649, DOI 10.2500/ajr.2008.22.3246; Jain AK, 2007, BRIT J NEUROSURG, V21, P328, DOI 10.1080/02688690701395447; Kawamata T, 2002, NEUROL RES, V24, P259, DOI 10.1179/016164102101199882; Kriska T, 2005, ARCH BIOCHEM BIOPHYS, V433, P435, DOI 10.1016/j.abb.2004.09.025; Li F, 2011, J CELL BIOCHEM, V112, P3035, DOI 10.1002/jcb.23228; Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692; Nadeau V, 2004, PHOTODERMATOL PHOTO, V20, P170, DOI 10.1111/j.1600-0781.2004.00100.x; Onuki J, 2004, ARCH BIOCHEM BIOPHYS, V432, P178, DOI 10.1016/j.abb.2004.09.030; Oruckaptan HH, 2000, SURG NEUROL, V53, P211, DOI 10.1016/S0090-3019(00)00171-3; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67; Robinson DJ, 1998, PHOTOCHEM PHOTOBIOL, V67, P140, DOI 10.1562/0031-8655(1998)067<0140:FPOAIP>2.3.CO;2; Rotenberg B, 2010, LARYNGOSCOPE, V120, P1292, DOI 10.1002/lary.20949; Saeger Wolfgang, 2005, Endocrine, V28, P57, DOI 10.1385/ENDO:28:1:057; Sailer R, 2007, PHOTOCH PHOTOBIO SCI, V6, P145, DOI 10.1039/b611715e; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sharwani A, 2014, Gulf J Oncolog, V1, P79; Sherlock M, 2011, NAT REV ENDOCRINOL, V7, P291, DOI 10.1038/nrendo.2011.42; Stummer W, 2000, J NEUROSURG, V93, P1003, DOI 10.3171/jns.2000.93.6.1003; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Stummer W, 1998, ACTA NEUROCHIR, V140, P995, DOI 10.1007/s007010050206; Stylli SS, 2005, J CLIN NEUROSCI, V12, P389, DOI 10.1016/j.jocn.2005.01.006; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141	36	13	14	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2016	11	9							e0161364	10.1371/journal.pone.0161364	http://dx.doi.org/10.1371/journal.pone.0161364			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV3WN	27583461	gold, Green Published, Green Submitted			2023-01-03	WOS:000382855600025
J	Scholte, M; Neeleman-van der Steen, CWM; van der Wees, PJ; Nijhuis-van der Sanden, MWG; Braspenning, J				Scholte, Marijn; Neeleman-van der Steen, Catherina W. M.; van der Wees, Philip J.; Nijhuis-van der Sanden, Maria W. G.; Braspenning, Joze			The Reasons behind the (Non)Use of Feedback Reports for Quality Improvement in Physical Therapy: A Mixed-Method Study	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; INTRINSIC MOTIVATION; HEALTH-CARE; OF-CARE; IMPACT; CIRCLES	Objectives To explain the use of feedback reports for quality improvements by the reasons to participate in quality measuring projects and to identify barriers and facilitators. Design Mixed methods design. Methods In 2009-2011 a national audit and feedback system for physical therapy (Qualiphy) was initiated in the Netherlands. After each data collection round, an evaluation survey was held amongst its participants. The evaluation survey data was used to explain the use of feedback reports by studying the reasons to participate with Qualiphy with correlation measures and logistic regression. Semi-structured interviews with PTs served to seek confirmation and disentangle barriers and facilitators. Results Analysis of 257 surveys (response rate: 42.8%) showed that therapists with only financial reasons were less likely to use feedback reports (OR = 0.24; 95% CI = 0.11-0.52) compared to therapists with a mixture of reasons. PTs in 2009 and 2010 were more likely to use the feedback reports for quality improvement than PTs in 2011 (OR = 2.41; 95% CI = 1.25-4.64 respectively OR = 3.28; 95% CI = 1.51-7.10). Changing circumstances in 2011, i. e. using EHRs and financial incentives, had a negative effect on the use of feedback reports (OR = 0.40, 95% CI = 0.20-0.78). Interviews with 12 physical therapists showed that feedback reports could serve as a tool to support and structure quality improvement plans. Barriers were distrust and perceived self-reporting bias on indicator scores. Conclusions Implementing financial incentives that are not well-specified and well-targeted can have an adverse effect on using feedback reports to improve quality of care. Distrust is a major barrier to implementing quality systems.	[Scholte, Marijn; van der Wees, Philip J.; Nijhuis-van der Sanden, Maria W. G.; Braspenning, Joze] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Sci Inst Qual Healthcare, Nijmegen, Netherlands; [Neeleman-van der Steen, Catherina W. M.] ROS Caransscoop, Beekbergen, Netherlands; [Scholte, Marijn] Radboud Univ Nijmegen, Dept Social Sci, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Scholte, M (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Sci Inst Qual Healthcare, Nijmegen, Netherlands.; Scholte, M (corresponding author), Radboud Univ Nijmegen, Dept Social Sci, Nijmegen, Netherlands.	m.scholte@maw.ru.nl	van der Wees, Philip Jan/L-4748-2015; der Sanden, Maria WG Nijhuis-van/B-3463-2012; Braspenning, Jozé/AAG-7612-2021; Braspenning, Jozé CC/D-4268-2009	der Sanden, Maria WG Nijhuis-van/0000-0003-2637-6877; Braspenning, Jozé/0000-0003-0800-0630; Braspenning, Jozé CC/0000-0003-0800-0630				Beyer M, 2003, FAM PRACT, V20, P443, DOI 10.1093/fampra/cmg420; Bijlsma-Frankema K, 2005, INT SOCIOL, V20, P259, DOI 10.1177/0268580905055477; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Christianson JB, 2008, MED CARE RES REV, V65, p5S, DOI 10.1177/1077558708324236; Deci E. L, 1985, INTRINSIC MOTIVATION; Dekker HC, 2004, ACCOUNT ORG SOC, V29, P27, DOI 10.1016/S0361-3682(02)00056-9; Friedberg MW, 2011, J GEN INTERN MED, V26, P498, DOI 10.1007/s11606-010-1597-1; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Geissler KH, 2013, MED CARE RES REV, V70, P621, DOI 10.1177/1077558713496319; Giuffrida A, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Gneezy U, 2011, J ECON PERSPECT, V25, P191, DOI 10.1257/jep.25.4.191; Gosden T, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002215; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Grol R, 2011, IMPROVING PATIENT CA; Grol R, 1995, BR J GEN PRACT, V5, P506; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Kaplan HC, 2012, BMJ QUAL SAF, V21, P13, DOI 10.1136/bmjqs-2011-000010; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Kirschner K, 2010, QUAL SAF HEALTH CARE, V19, P248, DOI 10.1136/qshc.2008.031526; Marshall MN, 2004, INT J QUAL HEALTH C, V16, pI57, DOI 10.1093/intqhc/mzh013; Neeleman-van der Steen CWM, 2009, PRESTATIE INDICATORE; Palinkas LA, 2011, ADM POLICY MENT HLTH, V38, P44, DOI 10.1007/s10488-010-0314-z; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Promberger M, 2013, HEALTH PSYCHOL, V32, P950, DOI 10.1037/a0032727; Rasbash J, 2009, USERS GUIDE MLWIN V2, V2, P10; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Schneider A, 2008, J EVAL CLIN PRACT, V14, P185, DOI 10.1111/j.1365-2753.2007.00827.x; Scholte M, 2014, INT J QUAL HEALTH C, V26, P261, DOI 10.1093/intqhc/mzu031; Scott A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008451.pub2; Smith MA, 2012, HEALTH AFFAIR, V31, P570, DOI 10.1377/hlthaff.2011.0853; Wensing M, 2004, J EVAL CLIN PRACT, V10, P457, DOI 10.1111/j.1365-2753.2004.00517.x; Wensing M, 2009, PHARMACOEPIDEM DR S, V18, P763, DOI 10.1002/pds.1778	32	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2016	11	8							e0161056	10.1371/journal.pone.0161056	http://dx.doi.org/10.1371/journal.pone.0161056			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT3LI	27518113	Green Published, Green Submitted, gold			2023-01-03	WOS:000381382100040
J	Chen, J; Li, XZ; Bai, ZJ; Fang, F; Hua, J; Li, Y; Pan, J; Wang, J; Feng, X; Li, YH				Chen, Jiao; Li, Xiaozhong; Bai, Zhenjiang; Fang, Fang; Hua, Jun; Li, Ying; Pan, Jian; Wang, Jian; Feng, Xing; Li, Yanhong			Association of Fluid Accumulation with Clinical Outcomes in Critically Ill Children with Severe Sepsis	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; PEDIATRIC SEVERE SEPSIS; GOAL-DIRECTED THERAPY; VASOACTIVE-INOTROPIC SCORE; SEPTIC SHOCK; INTENSIVE-CARE; CARDIAC-SURGERY; MORTALITY; OVERLOAD; RESUSCITATION	Objective To evaluate whether early and acquired daily fluid overload (FO), as well as fluctuations in fluid accumulation, were associated with adverse outcomes in critically ill children with severe sepsis. Methods This study enrolled 202 children in a pediatric intensive care unit (PICU) with severe sepsis. Early fluid overload was defined as >= 5% fluid accumulation occurring in the first 24 hours of PICU admission. The maximum daily fluid accumulation >= 5% occurring during the next 6 days in patients with at least 48 hours of PICU stay was defined as PICU-acquired daily fluid overload. The fluctuation in fluid accumulation was calculated as the difference between the maximum and the minimum daily fluid accumulation obtained during the first 7 days after admission. Results Of the 202 patients, 61 (30.2%) died during PICU stay. Among all patients, 41 (20.3%) experienced early fluid overload, including 9 with a FO >= 10%. Among patients with at least 48 hours of PICU stay (n = 154), 36 (23.4%) developed PICU-acquired daily fluid overload, including 2 with a FO >= 10%. Both early fluid overload (AOR = 1.20; 95% CI 1.08-1.33; P = 0.001; n = 202) and PICU-acquired daily fluid overload (AOR = 5.47 per log increase; 95% CI 1.15-25.96; P = 0.032; n = 154) were independent risk factors associated with mortality after adjusting for age, illness severity, etc. However, fluctuations in fluid accumulation were not associated with mortality after adjustment. Length of PICU stay increased with greater fluctuations in fluid accumulation in all patients with at least 48 hours of PICU stay (FO <5%, 5%-10% vs. >= 10%: 4 [3-8], 7 [4-11] vs. 10 [6-16] days; P <0.001; n = 154) and in survivors (4 [3-8], 7 [5-11] vs. 10 [5-15] days; P <0.001; n = 121). Early fluid overload achieved an area under-the-receiver-operating-characteristic curve of 0.74 (95% CI 0.65-0.82; P <0.001; n = 202) for predicting mortality in patients with severe sepsis, with a sensitivity of 67.2% and a specificity of 80.1% at the optimal cut-off value of 2.65%. Conclusions Both early and acquired daily fluid overload were independently associated with PICU mortality in children with severe sepsis.	[Chen, Jiao; Bai, Zhenjiang; Hua, Jun; Li, Ying] Soochow Univ, Childrens Hosp, Pediat Intens Care Unit, Suzhou, Jiangsu, Peoples R China; [Chen, Jiao; Li, Xiaozhong; Li, Yanhong] Soochow Univ, Childrens Hosp, Dept Nephrol, Suzhou, Jiangsu, Peoples R China; [Fang, Fang; Pan, Jian; Wang, Jian; Li, Yanhong] Soochow Univ, Childrens Hosp, Pediat Res Inst, Suzhou, Jiangsu, Peoples R China; [Feng, Xing] Soochow Univ, Childrens Hosp, Dept Neonatol, Suzhou, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Li, YH (corresponding author), Soochow Univ, Childrens Hosp, Dept Nephrol, Suzhou, Jiangsu, Peoples R China.; Li, YH (corresponding author), Soochow Univ, Childrens Hosp, Pediat Res Inst, Suzhou, Jiangsu, Peoples R China.	lyh072006@hotmail.com			National Natural Science Foundation of China [81370773]; Natural Science Foundation of Jiangsu Province [BK2012604]; Innovation Projects of Graduate Students in Colleges and Universities of Jiangsu Province; Key Research and Development Program of JiangSu province (Social Development) [BE2016675]; National Natural Science Foundation of China [81370773]; Natural Science Foundation of Jiangsu Province [BK2012604]; Innovation Projects of Graduate Students in Colleges and Universities of Jiangsu Province; Key Research and Development Program of JiangSu province (Social Development) [BE2016675]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Innovation Projects of Graduate Students in Colleges and Universities of Jiangsu Province; Key Research and Development Program of JiangSu province (Social Development); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Innovation Projects of Graduate Students in Colleges and Universities of Jiangsu Province; Key Research and Development Program of JiangSu province (Social Development)	This work was supported by grants from the National Natural Science Foundation of China (81370773), the Natural Science Foundation of Jiangsu Province (BK2012604), the Innovation Projects of Graduate Students in Colleges and Universities of Jiangsu Province, and the Key Research and Development Program of JiangSu province (Social Development, BE2016675). The funders had no role in study design, data collection and, decision to publish, or preparation of the manuscript.	Acheampong A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0970-1; Arikan AA, 2012, PEDIATR CRIT CARE ME, V13, P253, DOI 10.1097/PCC.0b013e31822882a3; Balamuth F, 2014, PEDIATR CRIT CARE ME, V15, P798, DOI 10.1097/PCC.0000000000000225; Basu RK, 2012, PEDIATR NEPHROL, V27, P1067, DOI 10.1007/s00467-011-2024-5; Bellomo R, 2012, CRIT CARE MED, V40, P1753, DOI 10.1097/CCM.0b013e318246b9c6; Bhaskar P, 2015, INTENS CARE MED, V41, P1445, DOI 10.1007/s00134-015-3851-9; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Carcillo JA, 2003, CRIT CARE CLIN, V19, P413, DOI 10.1016/S0749-0704(03)00013-7; Castellanos-Ortega A, 2010, CRIT CARE MED, V38, P1036, DOI 10.1097/CCM.0b013e3181d455b6; Cvetkovic M, 2015, PEDIATR CRIT CARE ME, V16, P410, DOI 10.1097/PCC.0000000000000385; de Galasso L, 2015, PEDIAT NEPHROL; de Oliveira CF, 2010, SHOCK, V34, P44, DOI 10.1097/SHK.0b013e3181e7e6d5; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Foland JA, 2004, CRIT CARE MED, V32, P1771, DOI 10.1097/01.CCM.0000132897.52737.49; Gaies MG, 2014, PEDIATR CRIT CARE ME, V15, P529, DOI 10.1097/PCC.0000000000000153; Gaies MG, 2010, PEDIATR CRIT CARE ME, V11, P234, DOI 10.1097/PCC.0b013e3181b806fc; Gelbart B, 2015, PEDIATR CRIT CARE ME, V16, pE297, DOI 10.1097/PCC.0000000000000507; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Goldstein SL, 2001, PEDIATRICS, V107, P1309, DOI 10.1542/peds.107.6.1309; Gupta RG, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1011-9; Hassinger AB, 2014, PEDIATR CRIT CARE ME, V15, P131, DOI 10.1097/PCC.0000000000000043; Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350; Kelm DJ, 2015, SHOCK, V43, P68, DOI 10.1097/SHK.0000000000000268; Li Y, 2015, EUR J PEDIAT; Lombel RM, 2012, INTENS CARE MED, V38, P663, DOI 10.1007/s00134-012-2503-6; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Malbrain MLNG, 2014, ANAESTH INTENSIVE TH, V46, P361, DOI 10.5603/AIT.2014.0060; Marik PE, 2014, CHEST, V145, P1407, DOI 10.1378/chest.13-2104; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Murphy CV, 2009, CHEST, V136, P102, DOI 10.1378/chest.08-2706; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Pickering JW, 2010, CLIN J AM SOC NEPHRO, V5, P1165, DOI 10.2215/CJN.08531109; Randolph AG, 2014, VIRULENCE, V5, P179, DOI 10.4161/viru.27045; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Ruth A, 2014, PEDIATR CRIT CARE ME, V15, P828, DOI 10.1097/PCC.0000000000000254; Seguin J, 2014, CRIT CARE MED, V42, P2591, DOI 10.1097/CCM.0000000000000517; Selewski DT, 2011, INTENS CARE MED, V37, P1166, DOI 10.1007/s00134-011-2231-3; Sinitsky L, 2015, PEDIATR CRIT CARE ME, V16, P205, DOI 10.1097/PCC.0000000000000318; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Soler YA, 2013, PEDIATR CRIT CARE ME, V14, pE189, DOI 10.1097/PCC.0b013e3182745675; van Paridon BM, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1010-x; Waechter J, 2014, CRIT CARE MED, V42, P2158, DOI 10.1097/CCM.0000000000000520; Wang N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1085-4; Weiss SL, 2015, AM J RESP CRIT CARE, V191, P1147, DOI 10.1164/rccm.201412-2323OC; Weiss SL, 2015, CRIT CARE, V19, DOI [10.1186/s13054-015-1055-x, 10.1186/s13054-014-0623-9]; WERNOVSKY G, 1995, CIRCULATION, V92, P2226, DOI 10.1161/01.CIR.92.8.2226	46	36	37	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2016	11	7							e0160093	10.1371/journal.pone.0160093	http://dx.doi.org/10.1371/journal.pone.0160093			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IL	27467522	gold, Green Published, Green Submitted			2023-01-03	WOS:000381516100108
J	Balzarotti, S; Colombo, B				Balzarotti, Stefania; Colombo, Barbara			Effects of Unilateral Transcranial Direct Current Stimulation of Left Prefrontal Cortex on Processing and Memory of Emotional Visual Stimuli	PLOS ONE			English	Article							MAJOR DEPRESSION; FACIAL EXPRESSIONS; HEMISPHERIC-DIFFERENCES; NEURAL MECHANISMS; DOUBLE-BLIND; BRAIN; TDCS; PERCEPTION; VALENCE; MODULATION	The dorsolateral prefrontal cortex (DLPFC) is generally thought to be involved in affect and emotional processing; however, the specific contribution of each hemisphere continues to be debated. In the present study, we employed unilateral tDCS to test the unique contribution of left DLPFC in the encoding and retrieval of emotional stimuli in healthy subjects. Forty-two right handed undergraduate students received either anodal, cathodal or sham stimulation of left DLPFC while viewing neutral, pleasant, and unpleasant pictures. After completing a filler task, participants were asked to remember as many pictures as possible. Results showed that participants were able to remember a larger amount of emotional (both pleasant and unpleasant) pictures than of neutral ones, regardless of the type of tDCS condition. Participants who received anodal stimulation recalled a significantly higher number of pleasant images than participants in the sham and cathodal conditions, while no differences emerged in the recall of neutral and unpleasant pictures. We conclude that our results provide some support to the role of left prefrontal cortex in the encoding and retrieval of pleasant stimuli.	[Balzarotti, Stefania; Colombo, Barbara] Univ Cattolica Sacro Cuore, Dept Psychol, Largo Gemelli 1, I-20123 Milan, Italy; [Colombo, Barbara] Champlain Coll, Div Educ & Human Studies, 251 South Willard St, Burlington, VT 05402 USA	Catholic University of the Sacred Heart	Colombo, B (corresponding author), Univ Cattolica Sacro Cuore, Dept Psychol, Largo Gemelli 1, I-20123 Milan, Italy.; Colombo, B (corresponding author), Champlain Coll, Div Educ & Human Studies, 251 South Willard St, Burlington, VT 05402 USA.	bcolombo@champlain.edu	Colombo, Barbara/E-9443-2019	Colombo, Barbara/0000-0002-4095-9633; BALZAROTTI, Stefania/0000-0002-9273-8496				Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; AHERN GL, 1985, NEUROPSYCHOLOGIA, V23, P745, DOI 10.1016/0028-3932(85)90081-8; Asthana Manish, 2013, Front Psychiatry, V4, P107, DOI 10.3389/fpsyt.2013.00107; Austin A, 2015, ARXIV151002261; Berlim MT, 2013, J PSYCHIATR RES, V47, P1, DOI 10.1016/j.jpsychires.2012.09.025; Bloise SM, 2007, MEMORY, V15, P192, DOI 10.1080/09658210701204456; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; Boggio PS, 2009, J AFFECT DISORDERS, V101, P91; Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; BRADLEY MM, 1992, J EXP PSYCHOL LEARN, V18, P379, DOI 10.1037/0278-7393.18.2.379; Canli T, 2002, P NATL ACAD SCI USA, V99, P10789, DOI 10.1073/pnas.162356599; Davidson RJ, 2002, ANNU REV PSYCHOL, V53, P545, DOI 10.1146/annurev.psych.53.100901.135148; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; Disner SG, 2011, NAT REV NEUROSCI, V12, P467, DOI 10.1038/nrn3027; Dolcos F, 2004, NEUROIMAGE, V23, P64, DOI 10.1016/j.neuroimage.2004.05.015; Fales CL, 2008, BIOL PSYCHIAT, V63, P377, DOI 10.1016/j.biopsych.2007.06.012; Fregni F, 2006, BIPOLAR DISORD, V8, P203, DOI 10.1111/j.1399-5618.2006.00291.x; Grimm S, 2006, NEUROIMAGE, V30, P325, DOI 10.1016/j.neuroimage.2005.09.006; Grimm S, 2008, BIOL PSYCHIAT, V63, P369, DOI 10.1016/j.biopsych.2007.05.033; Griskevicius V, 2010, EMOTION, V10, P190, DOI 10.1037/a0018421; Hamann S, 2001, TRENDS COGN SCI, V5, P394, DOI 10.1016/S1364-6613(00)01707-1; Hecht D, 2010, NEUROSCI RES, V68, P77, DOI 10.1016/j.neures.2010.06.013; Heller W, 1997, COGNITION EMOTION, V11, P637, DOI 10.1080/026999397379845a; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; Jansari A, 2000, COGNITION EMOTION, V14, P341, DOI 10.1080/026999300378860; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Kensinger EA, 2004, REV NEUROSCIENCE, V15, P241, DOI 10.1515/REVNEURO.2004.15.4.241; Koenigs M, 2009, CLIN NEUROPHYSIOL, V120, P80, DOI 10.1016/j.clinph.2008.10.010; Lane RD, 1997, NEUROPSYCHOLOGIA, V35, P1437, DOI 10.1016/S0028-3932(97)00070-5; Lang PJ, A6 U FLOR; LEY RG, 1979, BRAIN LANG, V7, P127, DOI 10.1016/0093-934X(79)90010-5; Maeoka H, 2012, NEUROSCI LETT, V512, P12, DOI 10.1016/j.neulet.2012.01.037; Mikels JA, 2005, BEHAV RES METHODS, V37, P626, DOI 10.3758/BF03192732; Morgan HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092162; Nitsche M A, 2012, Front Psychiatry, V3, P58, DOI 10.3389/fpsyt.2012.00058; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2003, J PHYSIOL-LONDON, V527, P633; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nitschke JB, 2004, BIOL PSYCHOL, V67, P125, DOI 10.1016/j.biopsycho.2004.03.004; Palm U, 2012, BRAIN STIMUL, V5, P242, DOI 10.1016/j.brs.2011.08.005; Pena-Gomez C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022812; Penolazzi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010623; Priori A, 2003, CLIN NEUROPHYSIOL, V114, P589, DOI 10.1016/S1388-2457(02)00437-6; Quene H, 2008, J MEM LANG, V59, P413, DOI 10.1016/j.jml.2008.02.002; Rodway P, 2003, BRAIN COGNITION, V53, P452, DOI 10.1016/S0278-2626(03)00217-3; Sergerie K, 2005, NEUROIMAGE, V24, P580, DOI 10.1016/j.neuroimage.2004.08.051; Tamietto M, 2006, EXP BRAIN RES, V171, P389, DOI 10.1007/s00221-005-0279-4; Tremblay S, 2014, BRAIN STIMUL, V7, P773, DOI 10.1016/j.brs.2014.10.003; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Wager TD, 2003, NEUROIMAGE, V19, P513; WEDDING D, 1985, INT J NEUROSCI, V27, P277, DOI 10.3109/00207458509149773; Weigand A, 2013, EXP BRAIN RES, V227, P43, DOI 10.1007/s00221-013-3483-7; Yekta M., 2015, PRACTICE CLIN PSYCHO, V3, P185	56	9	9	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2016	11	7							e0159555	10.1371/journal.pone.0159555	http://dx.doi.org/10.1371/journal.pone.0159555			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TG	27433807	gold, Green Published, Green Submitted			2023-01-03	WOS:000380169600071
J	Amari, Y; Morimoto, S; Nakajima, F; Ando, T; Ichihara, A				Amari, Yoshifumi; Morimoto, Satoshi; Nakajima, Fumitaka; Ando, Takashi; Ichihara, Atsuhiro			Serum Soluble (Pro)Renin Receptor Levels in Maintenance Hemodialysis Patients	PLOS ONE			English	Article							PRO RENIN RECEPTOR; RENIN/PRORENIN RECEPTOR; BLOOD-PRESSURE; ANGIOTENSIN; PHYSIOLOGY; EXPRESSION; CLEARANCE; PRORENIN	The (pro)renin receptor [(P)RR] is cleaved by furin to generate soluble (P)RR [s(P)RR], which reflects the status of the tissue renin-angiotensin system. Hemodialysis patients have advanced atherosclerosis. The aim of this study was to investigate the relationships between serum s(P)RR levels and background factors, including indices of atherosclerosis, in hemodialysis patients. Serum s(P)RR levels were measured in hemodialysis patients and clearance of s(P)RR through the membrane of the dialyzer was examined. Furthermore, relationships between serum s(P)RR levels and background factors were assessed. Serum s(P)RR levels were significantly higher in hemodialysis patients (30.4 +/- 6.1 ng/ml, n = 258) than those in subjects with normal renal function (21.4 +/- 6.2 ng/ml, n = 39, P < 0.0001). Clearance of s(P) RR and creatinine were 56.9 +/- 33.5 and 147.6 +/- 9.50 ml/min, respectively. Serum s(P) RR levels were significantly higher in those with ankle-brachial index (ABI) of < 0.9, an indicator of severe atherosclerosis, than those with ABI of >= 0.9 (32.2 +/- 5.9 and 30.1 +/- 6.2 ng/ml, respectively, P < 0.05). An association between low ABI and high serum s(P)RR levels was observed even after correction for age, history of smoking, HbA1c, and LDL-C. Serum s(P)RR levels were significantly higher in hemodialysis patients when compared with subjects with normal renal function, although s(P)RR is dialyzed to some extent, but to a lesser extent than creatinine. High serum s(P)RR levels may be associated with atherosclerosis independent of other risk factors, suggesting that serum s(P)RR could be used as a marker for atherosclerotic conditions in hemodialysis patients.	[Amari, Yoshifumi; Morimoto, Satoshi; Ando, Takashi; Ichihara, Atsuhiro] Tokyo Womens Med Univ, Dept Med Endocrinol & Hypertens 2, Tokyo, Japan; [Amari, Yoshifumi; Nakajima, Fumitaka] Moriguchi Keijinkai Hosp, Dept Nephrol, Osaka, Japan	Tokyo Women's Medical University	Morimoto, S (corresponding author), Tokyo Womens Med Univ, Dept Med Endocrinol & Hypertens 2, Tokyo, Japan.	smorimoto@endm.twmu.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25461258, 16K09657]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (25461258 and 16K09657 to S. M.)	Achard V, 2011, J ENDOCRINOL INVEST, V34, P840, DOI 10.3275/7627; Achard V, 2007, AM J PHYSIOL-REG I, V292, pR274, DOI 10.1152/ajpregu.00439.2005; Amer Diabet Assoc, 2006, DIABETES CARE, V29, pS43; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Burckle CA, 2006, HYPERTENSION, V47, P552, DOI 10.1161/01.HYP.0000199912.47657.04; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Dzau VJ, 2001, AM J CARDIOL, V88, p1L; Engeli S, 2000, HYPERTENSION, V35, P1270, DOI 10.1161/01.HYP.35.6.1270; Fu WC, 2006, NEPHROLOGY, V11, P9, DOI 10.1111/j.1440-1797.2006.00534.x; Hamada K, 2013, CLIN EXPT NEPHROLOGY; Hirose T, 2010, REGUL PEPTIDES, V159, P93, DOI 10.1016/j.regpep.2009.11.006; Hirose T, 2009, PEPTIDES, V30, P2316, DOI 10.1016/j.peptides.2009.09.015; Ichihara A, 2006, HYPERTENSION, V47, P894, DOI 10.1161/01.HYP.0000215838.48170.0b; Ichihara A, 2010, HYPERTENS RES, V33, P177, DOI 10.1038/hr.2009.214; Iseki K, 2011, CLIN EXP NEPHROL; Kaneshiro Y, 2007, J AM SOC NEPHROL, V18, P1789, DOI 10.1681/ASN.2006091062; Kinouchi K, 2010, CIRC RES, V107, P30, DOI 10.1161/CIRCRESAHA.110.224667; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Lindsay RM, 2001, AM J KIDNEY DIS, V38, P565, DOI 10.1053/ajkd.2001.26874; Lowrie EG, 2004, KIDNEY INT, V66, P2077, DOI 10.1111/j.1523-1755.2004.00987.x; Maruyama Nobuhiro, 2013, Front Biosci (Elite Ed), V5, P583; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Morimoto S, 2014, HYPERTENSION RES OFF; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Nguyen G, 2008, CURR OPIN PHARMACOL, V8, P127, DOI 10.1016/j.coph.2007.12.009; Nguyen G, 2014, HYPERTENSION, V63, P297, DOI 10.1161/HYPERTENSIONAHA.113.02217; Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005; Schefe JH, 2006, CIRC RES, V99, P1355, DOI 10.1161/01.RES.0000251700.00994.0d; Siragy HM, 2008, EXP PHYSIOL, V93, P709, DOI 10.1113/expphysiol.2007.040550; Tsuchida K, 2011, CONTRIB NEPHROL, V173, P76, DOI 10.1159/000328957; van Eps CL, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-51; Watanabe N, 2013, J CLIN ENDOCR METAB, V98, P2528, DOI 10.1210/jc.2012-4139; Watanabe N, 2012, HYPERTENSION, V60, P1250, DOI 10.1161/HYPERTENSIONAHA.112.197418; Weir MR, 1999, AM J HYPERTENS, V12, p205S; Yokoyama Hisayo, 2003, J Atheroscler Thromb, V10, P253; Yurugi T, 2012, CLIN EXP NEPHROL, V16, P156, DOI 10.1007/s10157-011-0544-8	36	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2016	11	7							e0158068	10.1371/journal.pone.0158068	http://dx.doi.org/10.1371/journal.pone.0158068			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0TX	27367528	Green Published, Green Submitted, gold			2023-01-03	WOS:000378914900017
J	Botrel, TEA; Clark, O; Pompeo, ACL; Bretas, FFH; Sadi, MV; Ferreira, U; dos Reis, RB				Ayer Botrel, Tobias Engel; Clark, Otovio; Lima Pompeo, Antonio Carlos; Horta Bretas, Francisco Flavio; Sadi, Marcus Vinicius; Ferreira, Ubirajara; dos Reis, Rodolfo Borges			Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							PHASE-II TRIAL; CHEMOHORMONAL THERAPY; CHEMOTHERAPY; ESTRAMUSTINE; RADIOTHERAPY; SURVIVAL; CARE; MITOXANTRONE; PREDNISONE; GUIDELINES	Objective Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT +/- docetaxel) for metastatic hormone-naive prostate cancer (mHNPC). Methods Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI). Results The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p<0.00001), and no heterogeneity (Chi(2) = 0.64; df = 1 [p = 0.42]; I-2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p<0.00001), also with no heterogeneity noted (Chi(2) = 0.48; df = 2 [p = 0.79]; I-2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p<0.0001), with moderate heterogeneity (Chi(2) = 3.84; df = 2 [p = 0.15]; I-2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade >= 3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue. Conclusion The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients.	[Ayer Botrel, Tobias Engel; Clark, Otovio] Evidencias A Kantar Hlth Co, Campinas, SP, Brazil; [Ayer Botrel, Tobias Engel; Clark, Otovio; Lima Pompeo, Antonio Carlos; Horta Bretas, Francisco Flavio; Sadi, Marcus Vinicius; Ferreira, Ubirajara; dos Reis, Rodolfo Borges] Comite Brasileiro Estudos Urooncol CoBEU, Sao Paulo, SP, Brazil		Botrel, TEA (corresponding author), Evidencias A Kantar Hlth Co, Campinas, SP, Brazil.; Botrel, TEA (corresponding author), Comite Brasileiro Estudos Urooncol CoBEU, Sao Paulo, SP, Brazil.	tobias.engel@evidencias.com.br	Pompeo, Antonio Carlos Lima/E-2557-2012; Reis, Rodolfo B/F-5877-2014	Pompeo, Antonio Carlos Lima/0000-0002-7462-3679; Reis, Rodolfo B/0000-0003-0328-1840				Altman Douglas G, 2002, BMC Med Res Methodol, V2, P3, DOI 10.1186/1471-2288-2-3; Amato R, 2013, CANCER CHEMOTH PHARM, V71, P1629, DOI 10.1007/s00280-013-2163-4; [Anonymous], 2011, REV MAN REVMAN COMP; Botrel TEA, 2012, INT BRAZ J UROL, V38, P717, DOI 10.1590/1677-553820133806717; Beltran H, 2011, EUR UROL, V60, P279, DOI 10.1016/j.eururo.2011.04.038; Beri N, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.1534; Castro A A, 1999, Sao Paulo Med J, V117, P138; Clarke M, 2000, COCHRANE LIB; Deeks J, 2006, COCHRANE HDB SYSTEMA; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2001, SYSTEMATIC REV HLTH; Fizazi K, 2015, ANN ONCOL, V26, P1660, DOI 10.1093/annonc/mdv245; Fizazi K, 2015, LANCET ONCOL, V16, P787, DOI 10.1016/S1470-2045(15)00011-X; Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257; Gravis G, 2015, 2015 GENITOURINARY C; Gravis G, 2016, EUR UROL, V70, P256, DOI 10.1016/j.eururo.2015.11.005; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; James ND, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.5001; James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032; Kellokumpu-Lehtinen PL, 2013, LANCET ONCOL, V14, P117, DOI 10.1016/S1470-2045(12)70537-5; Kellokumpu-Lehtinen PLI, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.23; Liaw BC, 2015, AM J HEMATOL-ONCOL, V11, P17; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Loblaw DA, 2007, J CLIN ONCOL, V25, P1596, DOI 10.1200/JCO.2006.10.1949; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Morgan SC, 2008, RADIOTHER ONCOL, V88, P1, DOI 10.1016/j.radonc.2008.04.013; Mottet N, 2012, EUR UROL, V62, P213, DOI 10.1016/j.eururo.2012.03.053; Nakabayashi M, 2013, UROLOGY, V81, P611, DOI 10.1016/j.urology.2012.12.025; Noguchi M, 2004, INT J UROL, V11, P103, DOI 10.1111/j.1442-2042.2004.t01-1-00748.x; Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Rajan Prabhakar, 2015, Urol Oncol, V33, DOI 10.1016/j.urolonc.2015.05.012; Smeeth L, 1999, BMJ-BRIT MED J, V318, P1548, DOI 10.1136/bmj.318.7197.1548; Sweeney C, 2014, J CLIN ONCOL S, V32, P5; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Thalgott M, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-20; Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140-6736(11)61095-7; Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140-6736(08)61815-2; Yang K, 2010, CLIN DRUG INVEST, V30, P229, DOI 10.2165/11532260-000000000-00000	45	21	23	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157660	10.1371/journal.pone.0157660	http://dx.doi.org/10.1371/journal.pone.0157660			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27308831	gold, Green Submitted, Green Published			2023-01-03	WOS:000378029800117
J	Thompson, GN; McArthur, J; Doupe, M				Thompson, Genevieve N.; McArthur, Jennifer; Doupe, Malcolm			Identifying Markers of Dignity-Conserving Care in Long-Term Care: A Modified Delphi Study	PLOS ONE			English	Article							QUALITY INDICATORS; HEALTH-CARE; PALLIATIVE CARE; OLDER-PEOPLE; CAREGIVERS; PERCEPTIONS; RESIDENTS; AUTONOMY; FAMILY; EXPERIENCES	Ensuring that people living in nursing homes (NHs) are afforded with dignity in their daily lives is an essential and humane concern. Promoting dignity-conserving care is fundamentally important. By nature, however, this care is all-encompassing and holistic, and from current knowledge it is challenging to create explicit strategies for measuring dignity-conserving care. In practice the majority of current NH indicators of quality care are derived from information that is routinely collected on NH residents using the RAI-Minimum Data Set (MDS). In this regard, issues that are more tangible to resident dignity such as being treated with respect, compassion, and having opportunities to engage with others are not adequately captured in current NH quality of care indicators. An initial set of markers was created by conducting an integrative literature review of existing markers and indicators of dignity in the NH setting. A modified Delphi process was used to prioritize essential dignity-conserving care markers for use by NH providers, based on factors such as the importance to fostering a culture of dignity, the impact it may have on the residents, and how achievable it is in practice. Through this consensus building technique, we were able to develop a comprehensive set of markers that capture the range and diversity of important dignity-conserving care strategies for use in NHs. The final 10 markers were judged as having high face validity by experts in the field and have explicit implications for enhancing the provision of daily dignified care to NH residents. These markers make an important addition to the traditional quality indicators used in the NH setting and as such, bridge an important gap in addressing the psychosocial and the less easily quantified needs of NH residents.	[Thompson, Genevieve N.] Univ Manitoba, Rady Fac Hlth Sci, Coll Nursing, Winnipeg, MB, Canada; [Thompson, Genevieve N.] CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB, Canada; [McArthur, Jennifer] Univ Alberta, Fac Nursing, Edmonton, AB, Canada; [Doupe, Malcolm] Univ Manitoba, Rady Fac Hlth Sci, Coll Med, Winnipeg, MB, Canada	University of Manitoba; CancerCare Manitoba Foundation; University of Alberta; University of Manitoba	Thompson, GN (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Coll Nursing, Winnipeg, MB, Canada.; Thompson, GN (corresponding author), CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB, Canada.	Genevieve.thompson@umanitoba.ca		Thompson, Genevieve/0000-0003-2558-9926	Government of Manitoba	Government of Manitoba	This project was funded by the Government of Manitoba. There is no funding number allocated for this project as it was done by contract. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderberg P, 2007, J ADV NURS, V59, P635, DOI 10.1111/j.1365-2648.2007.04375.x; Asselin M, 2014, J NURSES PROF DEV, V30, P11, DOI 10.1097/01.NND.0000434028.30432.34; Boisaubin EV, 2007, J MED PHILOS, V32, P447, DOI 10.1080/03605310701626414; Boulkedid R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020476; Campbell SM, 2003, BRIT MED J, V326, P816, DOI 10.1136/bmj.326.7393.816; Campbell SM, 1999, MED CARE, V37, P964, DOI 10.1097/00005650-199909000-00012; Carinci F, 2015, INT J QUAL HEALTH C, V27, P137, DOI 10.1093/intqhc/mzv004; Chochinov Harvey Max, 2005, J Palliat Med, V8 Suppl 1, pS103; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 2004, J CLIN ONCOL, V22, P1336, DOI 10.1200/JCO.2004.12.095; Coventry ML, 2006, J GERONTOL NURS, V32, P42, DOI 10.3928/00989134-20060501-08; Doupe M, 2012, JAMDA, V12, P467; Dwyer LL, 2009, INT J OLDER PEOPLE N, V4, P185, DOI 10.1111/j.1748-3743.2008.00153.x; Enes SPD, 2003, PALLIATIVE MED, V17, P263, DOI 10.1191/0269216303pm699oa; Franklin LL, 2006, NURS ETHICS, V13, P130, DOI 10.1191/0969733006ne851oa; Gallagher A, 2004, NURS ETHICS, V11, P587, DOI 10.1191/0969733004ne744oa; Gallagher A, 2008, BMC NURS, V7, DOI 10.1186/1472-6955-7-11; Haddock J, 1996, J ADV NURS, V24, P924, DOI 10.1111/j.1365-2648.1996.tb02927.x; Hall S, 2009, AGE AGEING, V38, P411, DOI 10.1093/ageing/afp069; Heggestad AKT, 2013, NURS ETHICS, V20, P881, DOI 10.1177/0969733013484484; Jacelon CS, 2004, J ADV NURS, V48, P76, DOI 10.1111/j.1365-2648.2004.03170.x; Jacobson N, 2009, QUAL HEALTH RES, V19, P1536, DOI 10.1177/1049732309349809; Johnstone DE, 2012, CAN J CARDIOL, V28, P599, DOI 10.1016/j.cjca.2012.01.024; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Keeney S, 2001, INT J NURS STUD, V38, P195, DOI 10.1016/S0020-7489(00)00044-4; Lin YP, 2013, NURS ETHICS, V20, P168, DOI 10.1177/0969733012458609; Lobchuk MM, 2007, J PAIN SYMPTOM MANAG, V33, P130, DOI 10.1016/j.jpainsymman.2006.07.015; Lothian K, 2001, BRIT MED J, V322, P668, DOI 10.1136/bmj.322.7287.668; Magee H., 2008, MEASURING DIGNITY CA; McClement SE, 2006, TXB PALLIATIVE MED, P100; McClement Susan E, 2004, Int J Palliat Nurs, V10, P173; Naden D, 2013, NURS ETHICS, V20, P748, DOI 10.1177/0969733012475253; Nekolaichuk Cheryl L, 2004, Palliat Support Care, V2, P243; Oosterveld-Vlug MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073822; Oosterveld-Vlug MG, 2014, J ADV NURS, V70, P97, DOI 10.1111/jan.12171; Periyakoil VS, 2013, J AM GERIATR SOC, V61, P440, DOI 10.1111/jgs.12145; Pleschberger S, AGE AGEING, V36, P197; Proulx Kathryn, 2004, Am J Hosp Palliat Care, V21, P116, DOI 10.1177/104990910402100209; Puchalski CM, 2014, J PALLIAT MED, V17, P105, DOI [10.1089/jpm.2013.9458, 10.1089/jpm.2014.9427]; Pullman D, 2004, J PALLIAT CARE, V20, P171, DOI 10.1177/082585970402000309; Shaw KL, 2014, PALLIATIVE MED, V28, P501, DOI 10.1177/0269216314521852; Zhai X, 2007, J MED PHILOS, V32, P425, DOI 10.1080/03605310701631695	42	6	6	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2016	11	6							e0156816	10.1371/journal.pone.0156816	http://dx.doi.org/10.1371/journal.pone.0156816			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DO5LO	27304853	Green Submitted, Green Published, gold			2023-01-03	WOS:000377824800024
J	Koduvayur, SP; Su, Y; Kay, BK; Lavie, A				Koduvayur, Sujatha P.; Su, Ying; Kay, Brian K.; Lavie, Arnon			Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine	PLOS ONE			English	Article							CANCER-THERAPY; PICOMOLAR AFFINITY; AFFIBODY MOLECULES; TRASTUZUMAB; ANTICANCER; MECHANISM; PROTEINS; 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE; PHARMACOKINETICS; PHOSPHORYLATION	Cytotoxic drugs, such as nucleoside analogs and toxins, commonly suffer from off-target effects. One approach to mitigate this problem is to deliver the cytotoxic drug selectively to the intended site. While for toxins this can be achieved by conjugating the cell-killing moiety to a targeting moiety, it is not an option for nucleoside analogs, which rely on intracellular enzymes to convert them to their active triphosphorylated form. To overcome this limitation, and achieve site-targeted activation of nucleoside analogs, we fused the coding region of a prodrug-activating enzyme, deoxycytidine kinase (dCK), to affinity reagents that bind to the Her2 cell surface protein. We evaluated dCK fusions to an anti-Her2 affibody and Designed Ankyrin Repeat Protein (DARPin) for their ability to kill cancer cells by promoting the activation of the nucleoside analog fludarabine. Cell staining and flow cytometry experiments with three Her2 positive cancer cell lines (BT-474-JB, JIMT-1 and SK-OV-3) indicate dCK fusions binding and cellular internalization. In contrast, these reagents bind only weakly to the Her2 negative cell line, MCF-7. Cell proliferation assays indicate that SK-OV-3 and BT-474-JB cell lines exhibit significantly reduced proliferation rates when treated with targeting-module fused dCK and fludarabine, compared to fludarabine alone. These findings demonstrate that we have succeeded in delivering active dCK into the Her2-positive cells, thereby increasing the activation of fludarabine, which ultimately reduces the dose of nucleoside analog needed for cell killing. This strategy may help establish the therapeutic index required to differentiate between healthy tissues and cancer cells.	[Koduvayur, Sujatha P.; Kay, Brian K.] Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA; [Su, Ying; Lavie, Arnon] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Lavie, Arnon] Jesse Brown VA Med Ctr, Chicago, IL USA; [Koduvayur, Sujatha P.] Stevens Inst Technol, Dept Elect & Comp Engn, Hoboken, NJ 07030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Stevens Institute of Technology	Lavie, A (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA.; Lavie, A (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL USA.	Lavie@uic.edu		Lavie, Arnon/0000-0001-5591-8722	National Institutes of Health [R21 CA155424]; NATIONAL CANCER INSTITUTE [R21CA155424] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant R21 CA155424 from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alley SC, 2008, BIOCONJUGATE CHEM, V19, P759, DOI 10.1021/bc7004329; AVRAMIS VI, 1982, CANCER RES, V42, P2587; BARRUECO JR, 1987, CANCER RES, V47, P700; Bross PF, 2001, CLIN CANCER RES, V7, P1490; Burris HA, 2013, AM SOC CLIN ONCOL ED; Campbell DO, 2012, J BIOL CHEM, V287, P446, DOI 10.1074/jbc.M111.314666; Canonici A, 2013, ONCOTARGET, V4, P1592, DOI 10.18632/oncotarget.1148; Chari RVJ, 2008, ACCOUNTS CHEM RES, V41, P98, DOI 10.1021/ar700108g; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Firer MA, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-70; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Friedman M, 2007, PROTEIN ENG DES SEL, V20, P189, DOI 10.1093/protein/gzm011; Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X; Hansel TT, 2010, NAT REV DRUG DISCOV, V9, P325, DOI 10.1038/nrd3003; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Jordheim LP, 2013, NAT REV DRUG DISCOV, V12, P447, DOI 10.1038/nrd4010; Koduvayur SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087964; Koshkaryev A, 2013, ADV DRUG DELIVER REV, V65, P24, DOI 10.1016/j.addr.2012.08.009; Lambert JM, 2005, CURR OPIN PHARMACOL, V5, P543, DOI 10.1016/j.coph.2005.04.017; Lambert JM, 2013, BRIT J CLIN PHARMACO, V76, P248, DOI 10.1111/bcp.12044; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; Leal M, 2014, ANN NY ACAD SCI, V1321, P41, DOI 10.1111/nyas.12499; Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178; Lofblom J, 2010, FEBS LETT, V584, P2670, DOI 10.1016/j.febslet.2010.04.014; McDonagh CF, 2006, PROTEIN ENG DES SEL, V19, P299, DOI 10.1093/protein/gzl013; Orlova A, 2006, CANCER RES, V66, P4339, DOI 10.1158/0008-5472.CAN-05-3521; PLUNKETT W, 1993, SEMIN ONCOL, V20, P2; Ricci Francesca, 2009, Ther Clin Risk Manag, V5, P187; ROSS SR, 1993, DRUGS, V45, P737, DOI 10.2165/00003495-199345050-00009; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; Singh Y, 2008, CURR MED CHEM, V15, P1802, DOI 10.2174/092986708785132997; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Steiner M, 2011, CLIN CANCER RES, V17, P6406, DOI 10.1158/1078-0432.CCR-11-0483; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Tamaskovic R, 2012, METHOD ENZYMOL, V503, P101, DOI 10.1016/B978-0-12-396962-0.00005-7; Tanner M, 2004, MOL CANCER THER, V3, P1585; Vlashi E, 2009, MOL PHARMACEUT, V6, P1868, DOI 10.1021/mp900158d; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zahnd C, 2007, J MOL BIOL, V369, P1015, DOI 10.1016/j.jmb.2007.03.028; Zahnd C, 2007, NAT METHODS, V4, P269, DOI 10.1038/NMETH1003	42	4	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0157114	10.1371/journal.pone.0157114	http://dx.doi.org/10.1371/journal.pone.0157114			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TW	27280468	Green Published, gold, Green Submitted			2023-01-03	WOS:000377563000086
J	Mitchell, JT; Sweitzer, MM; Tunno, AM; Kollins, SH; McClernon, FJ				Mitchell, John T.; Sweitzer, Maggie M.; Tunno, Angela M.; Kollins, Scott H.; McClernon, F. Joseph			"I Use Weed for My ADHD": A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD	PLOS ONE			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SUBSTANCE USE; HEALTH INFORMATION; INTERNET; WEB; EXPECTANCY; STRATEGIES; CHILDHOOD; POSTINGS; IMPACT	Background Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for problematic cannabis use. However, clinical and anecdotal evidence suggest an increasingly popular perception that cannabis is therapeutic for ADHD, including via online resources. Given that the Internet is increasingly utilized as a source of healthcare information and may influence perceptions, we conducted a qualitative analysis of online forum discussions, also referred to as threads, on the effects of cannabis on ADHD to systematically characterize the content patients and caregivers may encounter about ADHD and cannabis. Methods A total of 268 separate forum threads were identified. Twenty percent (20%) were randomly selected, which yielded 55 separate forum threads (mean number of individual posts per forum thread = 17.53) scored by three raters (Cohen's kappa = 0.74). A final sample of 401 posts in these forum threads received at least one endorsement on predetermined topics following qualitative coding procedures. Results Twenty-five (25%) percent of individual posts indicated that cannabis is therapeutic for ADHD, as opposed to 8% that it is harmful, 5% that it is both therapeutic and harmful, and 2% that it has no effect on ADHD. This pattern was generally consistent when the year of each post was considered. The greater endorsement of therapeutic versus harmful effects of cannabis did not generalize to mood, other (non-ADHD) psychiatric conditions, or overall domains of daily life. Additional themes emerged (e.g., cannabis being considered sanctioned by healthcare providers). Conclusions Despite that there are no clinical recommendations or systematic research supporting the beneficial effects of cannabis use for ADHD, online discussions indicate that cannabis is considered therapeutic for ADHD-this is the first study to identify such a trend. This type of online information could shape ADHD patient and caregiver perceptions, and influence cannabis use and clinical care.	[Mitchell, John T.; Sweitzer, Maggie M.; Tunno, Angela M.; Kollins, Scott H.; McClernon, F. Joseph] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Mitchell, John T.; Sweitzer, Maggie M.; Kollins, Scott H.; McClernon, F. Joseph] Duke Ctr Addict Sci & Technol, Durham, NC USA	Duke University	Mitchell, JT (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.; Mitchell, JT (corresponding author), Duke Ctr Addict Sci & Technol, Durham, NC USA.	john.mitchell@duke.edu	Sweitzer, Maggie/GPK-2525-2022; Kollins, Scott/AAD-6291-2020	Kollins, Scott/0000-0001-6847-6935; Sweitzer, Maggie/0000-0002-5085-3752	National Institute on Drug Abuse [K23 DA032577, K24 DA023464]; NATIONAL INSTITUTE ON DRUG ABUSE [K24DA023464, K23DA032577] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by the National Institute on Drug Abuse (K23 DA032577 to JTM and K24 DA023464 to SHK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allsop DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044864; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2004, MAR MED NEED SCI BAS; Barkley RA, 2007, J SAFETY RES, V38, P113, DOI 10.1016/j.jsr.2006.09.004; Bidwell LC, 2014, DRUG ALCOHOL DEPEN, V135, P88, DOI 10.1016/j.drugalcdep.2013.11.013; Blakely G, 2014, NURS HEALTH SCI, V16, P387, DOI 10.1111/nhs.12122; Blume A, 2009, NEUROPSYCHIATRIE, V23, P42; Boyer Celia, 2004, Stud Health Technol Inform, V100, P159; Boyer EW, 2007, CYBERPSYCHOL BEHAV, V10, P1, DOI 10.1089/cpb.2006.9999; Boyer EW, 2005, PEDIATRICS, V115, P302, DOI 10.1542/peds.2004-1199; Boyer EW, 2001, NEW ENGL J MED, V345, P469, DOI 10.1056/NEJM200108093450619; Burri M, 2006, NICOTINE TOB RES, V8, pS13, DOI 10.1080/14622200601042513; Bylund CL, 2007, PATIENT EDUC COUNS, V66, P346, DOI 10.1016/j.pec.2007.01.009; Crane NA, 2013, NEUROPSYCHOL REV, V23, P117, DOI 10.1007/s11065-012-9222-1; Crean RD, 2011, J ADDICT MED, V5, P1, DOI 10.1097/ADM.0b013e31820c23fa; Daniulaityte R, 2013, DRUG ALCOHOL DEPEN, V130, P241, DOI 10.1016/j.drugalcdep.2012.11.003; De Alwis D, 2014, ADDICT BEHAV, V39, P1278, DOI 10.1016/j.addbeh.2014.04.003; Del Boca FK, 2002, ALCOHOL CLIN EXP RES, V26, P926, DOI 10.1097/00000374-200206000-00024; Falck RS, 2004, DRUG ALCOHOL DEPEN, V74, P45, DOI 10.1016/j.drugalcdep.2003.11.009; Flower A, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-162; Fox S, 2013, HLTH ONLINE 2013, P1; Goldman MS, 2002, ALCOHOL CLIN EXP RES, V26, P737, DOI 10.1097/00000374-200205000-00021; Griffiths P, 2000, SUBST USE MISUSE, V35, P811, DOI 10.3109/10826080009148423; Hadland SE, 2015, J DEV BEHAV PEDIATR, V36, P115, DOI 10.1097/DBP.0000000000000129; Hall W, 2009, LANCET, V374, P1383, DOI 10.1016/S0140-6736(09)61037-0; Hall W, 2009, INT J DRUG POLICY, V20, P458, DOI 10.1016/j.drugpo.2009.02.013; Harty SC, 2015, SUBST USE MISUSE, V50, P1470, DOI 10.3109/10826084.2015.1018545; Hechtman L, FUNCTIONAL ADU UNPUB; Hervey AS, 2004, NEUROPSYCHOLOGY, V18, P485, DOI 10.1037/0894-4105.18.3.485; Johnston L. D., 2022, MONITORING FUTURE NA; Kummervold PE, 2002, NORD J PSYCHIAT, V56, P59, DOI 10.1080/08039480252803945; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lange JE, 2010, DRUG ALCOHOL DEPEN, V108, P138, DOI 10.1016/j.drugalcdep.2009.11.010; Lee SS, 2011, CLIN PSYCHOL REV, V31, P328, DOI 10.1016/j.cpr.2011.01.006; Lipsman A, 2015, US DIGITAL FUTURE FO; Lisdahl KM, 2016, DRUG ALCOHOL DEPEN, V161, P135, DOI 10.1016/j.drugalcdep.2016.01.032; Lisdahl Krista M, 2014, Curr Addict Rep, V1, P144; McMullan M, 2006, PATIENT EDUC COUNS, V63, P24, DOI 10.1016/j.pec.2005.10.006; Miller PG, 2010, ADDICTION, V105, P1557, DOI 10.1111/j.1360-0443.2010.02992.x; Molina BSG, 2013, J AM ACAD CHILD PSY, V52, P250, DOI 10.1016/j.jaac.2012.12.014; Mounteney J, 2010, SUBST USE MISUSE, V45, P266, DOI 10.3109/10826080903368598; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Poole R, 2015, JMIR MENT HEALTH, V2, DOI 10.2196/mental.4123; Rasmussen J, 2016, BRAIN IMAGING BEHAV, V10, P761, DOI 10.1007/s11682-015-9438-9; Saloner B, 2015, PEDIATRICS, V135, P955, DOI 10.1542/peds.2015-0436; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Schifano F, 2006, PROG NEURO-PSYCHOPH, V30, P640, DOI 10.1016/j.pnpbp.2005.11.035; Strohbeck-Kuehner P, 2008, CANNABINOIDS, V3, P1; Tamm L, 2013, DRUG ALCOHOL DEPEN, V133, P607, DOI 10.1016/j.drugalcdep.2013.08.001; Volkow ND, 2016, JAMA PSYCHIAT, V73, P292, DOI 10.1001/jamapsychiatry.2015.3278; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Wald HS, 2007, PATIENT EDUC COUNS, V68, P218, DOI 10.1016/j.pec.2007.05.016; Wartella E, 2015, TEENS HLTH TECHNOLOG; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Zaman T, 2015, J ADDICT MED, V9, P317, DOI 10.1097/ADM.0000000000000138	55	50	50	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0156614	10.1371/journal.pone.0156614	http://dx.doi.org/10.1371/journal.pone.0156614			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27227537	Green Published, gold, Green Submitted			2023-01-03	WOS:000376882500160
J	Liu, ZS; Yan, SY; Wu, JN; He, LY; Li, N; Dong, GR; Fang, JQ; Fu, WB; Fu, LX; Sun, JH; Wang, LP; Wang, S; Yang, J; Zhang, HX; Zhang, JB; Zhao, JP; Zhou, W; Zhou, ZY; Ai, YK; Zhou, KH; Liu, J; Xu, HF; Cai, YY; Liu, BY				Liu, Zhishun; Yan, Shiyan; Wu, Jiani; He, Liyun; Li, Ning; Dong, Guirong; Fang, Jianqiao; Fu, Wenbin; Fu, Lixin; Sun, Jianhua; Wang, Linpeng; Wang, Shun; Yang, Jun; Zhang, Hongxing; Zhang, Jianbin; Zhao, Jiping; Zhou, Wei; Zhou, Zhongyu; Ai, Yanke; Zhou, Kehua; Liu, Jia; Xu, Huanfang; Cai, Yuying; Liu, Baoyan			Acupuncture for Chronic Severe Functional Constipation A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ELECTROACUPUNCTURE; PRUCALOPRIDE; EFFICACY; SAFETY; EPIDEMIOLOGY; LINACLOTIDE; TEGASEROD	Background: Acupuncture has been used for chronic constipation, but evidence for its effectiveness remains scarce. Objective: To determine the efficacy of electroacupuncture (EA) for chronic severe functional constipation (CSFC). Design: Randomized, parallel, sham-controlled trial. (Clinical Trials. gov: NCT01726504) Setting: 15 hospitals in China. Participants: Patients with CSFC and no serious underlying pathologic cause for constipation. Intervention: 28 sessions of EA at traditional acupoints or sham EA (SA) at nonacupoints over 8 weeks. Measurements: The primary outcome was the change from baseline in mean weekly complete spontaneous bowel movements (CSBMs) during weeks 1 to 8. Participants were followed until week 20. Results: 1075 patients (536 and 539 in the EA and SA groups, respectively) were enrolled. The increase from baseline in mean weekly CSBMs during weeks 1 to 8 was 1.76 (95% CI, 1.61 to 1.89) in the EA group and 0.87 (CI, 0.73 to 0.97) in the SA group (between-group difference, 0.90 [CI, 0.74 to 1.10]; P < 0.001). The change from baseline in mean weekly CSBMs during weeks 9 to 20 was 1.96 (CI, 1.78 to 2.11) in the EA group and 0.89 (CI, 0.69 to 0.95) in the SA group (between-group difference, 1.09 [CI, 0.94 to 1.31]; P < 0.001). The proportion of patients having 3 or more mean weekly CSBMs in the EA group was 31.3% and 37.7% over the treatment and follow-up periods, respectively, compared with 12.1% and 14.1% in the SA group (P < 0.001). Acupuncture-related adverse events during treatment were infrequent in both groups, and all were mild or transient. Limitations: Longer-term follow-up was not assessed. Acupuncturists could not be blinded. Conclusion: Eight weeks of EA increases CSBMs and is safe for the treatment of CSFC. Additional study is warranted to evaluate a longer-term treatment and follow-up.	China Acad Chinese Med Sci, Guanganmen Hosp, Inst Basic Res Clin Med, Beijing, Peoples R China; [Wang, Linpeng] Capital Med Univ, Beijing Tradit Chinese Med Hosp, 23 Meishuguan Houjie, Beijing 100010, Peoples R China; [Zhao, Jiping] Beijing Univ Chinese Med, Dongzhimen Hosp, 5 Haiyuncang, Beijing 100700, Peoples R China; Beijing Univ Chinese Med, Huguosi Hosp Chinese Med, 83 Mianhua Hutong, Beijing 100035, Peoples R China; Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China; [Dong, Guirong] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, 110 Ganhe Rd, Shanghai 200437, Peoples R China; [Fang, Jianqiao] Zhejiang Chinese Med Univ, Affiliated Hosp 3, 219 Moganshan Rd, Hangzhou 310005, Zhejiang, Peoples R China; [Fu, Wenbin] Guangdong Prov Hosp Tradit Chinese Med, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China; [Fu, Lixin] Tianjin Univ Tradit Chinese Med, Affiliated Hosp 1, 314,Anshan West Rd, Tianjin 300000, Peoples R China; Nanjing Univ Chinese Med, Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China; [Wang, Shun] Heilongjiang Prov Acad Chinese Med Sci, 33 Xidazhi St, Haerbin 150080, Heilongjiang, Peoples R China; [Yang, Jun] Anhui Univ Chinese Med, Affiliated Hosp 1, 117 Meishan Rd, Hefei 230031, Anhui, Peoples R China; Hubei Prov Hosp Tradit Chinese Med, Wuhan Integrated Tradit Chinese Med & Western Med, Wuhan, Hubei, Peoples R China; [Zhou, Kehua] Daemen Coll, Phys Therapy Wound Care Clin, 4380 Main St, Amherst, NY 14226 USA; [Liu, Baoyan] China Acad Chinese Med Sci, 16 Nanxiaojie Dongzhimennei, Beijing 100700, Peoples R China; [Liu, Zhishun; Wu, Jiani; Xu, Huanfang; Cai, Yuying] China Acad Chinese Med Sci, Guanganmen Hosp, 5 Beixiange St, Beijing 100053, Peoples R China; [Yan, Shiyan; He, Liyun; Ai, Yanke; Liu, Jia] China Acad Chinese Med Sci, Inst Basic Res Clin Med, 16 Nanxiaojie Dongzhimennei, Beijing 100700, Peoples R China; [Li, Ning] Sichuan Univ, West China Hosp, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China; [Sun, Jianhua] Jiangsu Prov Hosp Tradit Chinese Med, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Hongxing] Wuhan Integrated Tradit Chinese Med & Western Med, 215 Zhongshan Ave, Wuhan 430022, Hubei, Peoples R China; [Zhang, Jianbin] Nanjing Univ Chinese Med, 282 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China; [Zhou, Zhongyu] Hubei Prov Hosp Tradit Chinese Med, 4 Huayuanshan St, Wuhan 430061, Hubei, Peoples R China	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Institute of Basic Research In Clinical Medicine, CACMS; Capital Medical University; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Sichuan University; Shanghai University of Traditional Chinese Medicine; Zhejiang Chinese Medical University; Guangzhou University of Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Nanjing University of Chinese Medicine; Anhui University of Chinese Medicine; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; Sichuan University; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Liu, BY (corresponding author), China Acad Chinese Med Sci, 16 Nanxiaojie Dongzhimennei, Beijing 100700, Peoples R China.	13601180524@139.com		Fu, Wen-bin/0000-0002-8928-653X; Dong, guirong/0000-0003-3531-925X; Fang, Jianqiao/0000-0002-5155-8544	Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program	Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program	Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program.	Camilleri M, 2008, NEW ENGL J MED, V358, P2344, DOI 10.1056/NEJMoa0800670; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Gao X, 2015, NEUROGASTROENT MOTIL, V27, P1817, DOI 10.1111/nmo.12694; Gordon M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009118.pub2; Higgins PDR, 2004, AM J GASTROENTEROL, V99, P750, DOI 10.1111/j.1572-0241.2004.04114.x; Johanson JF, 2007, ALIMENT PHARM THER, V25, P599, DOI 10.1111/j.1365-2036.2006.03238.x; Johanson JF, 2004, CLIN GASTROENTEROL H, V2, P796, DOI 10.1016/S1542-3565(04)00356-8; Ke M, 2012, NEUROGASTROENT MOTIL, V24, DOI 10.1111/j.1365-2982.2012.01983.x; Koloski NA, 2013, AM J GASTROENTEROL, V108, P1152, DOI 10.1038/ajg.2013.137; Lembo A, 2003, NEW ENGL J MED, V349, P1360, DOI 10.1056/NEJMra020995; Lembo A, 2010, GASTROENTEROLOGY, V138, pS53, DOI 10.1053/j.gastro.2009.12.050; Lembo AJ, 2011, NEW ENGL J MED, V365, P527, DOI 10.1056/NEJMoa1010863; Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203; Li YQ, 2007, WORLD J GASTROENTERO, V13, P709, DOI 10.3748/wjg.v13.i5.709; Lin SR, 2007, WORLD J GASTROENTERO, V13, P732, DOI 10.3748/wjg.v13.i5.732; Liu ZS, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-176; MACDONALD AJR, 1983, ANN ROY COLL SURG, V65, P44; Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208; Mugie SM, 2011, BEST PRACT RES CL GA, V25, P3, DOI 10.1016/j.bpg.2010.12.010; National Research Council Panel on Handling Missing Data in Clinical Trials Committee on National Statistics Division of Behavioral and Social Sciences and Education, 2010, PREVENTION TREATMENT; Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050; Peng Wei-Na, 2013, Zhongguo Zhen Jiu, V33, P865; Peppas G, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-5; Rome Foundation, 2006, ROM 3 DIAGN CRIT FUN; Scarpignato C, 2012, ALIMENT PHARM THER, V35, P1243, DOI 10.1111/j.1365-2036.2012.05077.x; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Tack J, 2015, NEUROGASTROENT MOTIL, V27, P397, DOI 10.1111/nmo.12505; Tran LC, 2005, J CLIN GASTROENTEROL, V39, P600, DOI 10.1097/01.mcg.0000170769.67320.47; WHO Regional Office for the Western Pacific Region, 2008, WHO STAND AC POINT L; Witt CM, 2011, EUR J PAIN, V15, P193, DOI 10.1016/j.ejpain.2010.06.008; Wu Jia-Ni, 2014, Zhongguo Zhen Jiu, V34, P521; Wu J, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000284; Xiong F, 2014, J HUAZHONG U SCI-MED, V34, P775, DOI 10.1007/s11596-014-1351-8; Yiannakou Y, 2015, AM J GASTROENTEROL, V110, P741, DOI 10.1038/ajg.2015.115; Zhang T, 2013, AM J CHINESE MED, V41, P717, DOI 10.1142/S0192415X13500493; Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652	37	143	175	11	139	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 6	2016	165	11					761	+		10.7326/M15-3118	http://dx.doi.org/10.7326/M15-3118			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EE0KO	27618593				2023-01-03	WOS:000389263900003
J	Hohmann, EL				Hohmann, Elizabeth L.			Are Microbial Politics Local?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CLOSTRIDIUM-DIFFICILE INFECTION; TRANSPLANTATION		[Hohmann, Elizabeth L.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Hohmann, EL (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02115 USA.	ehohmann@partners.org						Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046; Donskey CJ, 2015, INFECT DIS CLIN N AM, V29, P13, DOI 10.1016/j.idc.2014.11.001; Kelly CR, 2016, ANN INTERN MED, V165, P609, DOI 10.7326/M16-0271; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; O'Brien CL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062815; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875	9	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2016	165	9					667	668		10.7326/M16-1784	http://dx.doi.org/10.7326/M16-1784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA8SJ	27548329				2023-01-03	WOS:000386908600010
J	Harter, M; Dirmaier, J; Dwinger, S; Kriston, L; Herbarth, L; Siegmund-Schultze, E; Bermejo, I; Matschinger, H; Heider, D; Konig, HH				Haerter, Martin; Dirmaier, Joerg; Dwinger, Sarah; Kriston, Levente; Herbarth, Lutz; Siegmund-Schultze, Elisabeth; Bermejo, Isaac; Matschinger, Herbert; Heider, Dirk; Koenig, Hans-Helmut			Effectiveness of Telephone-Based Health Coaching for Patients with Chronic Conditions: A Randomised Controlled Trial	PLOS ONE			English	Article							CARE; DISEASE; DISABILITY; SERVICES; PEOPLE; COSTS	Background Chronic diseases, like diabetes mellitus, heart disease and cancer are leading causes of death and disability. These conditions are at least partially preventable or modifiable, e.g. by enhancing patients' self-management. We aimed to examine the effectiveness of telephone-based health coaching (TBHC) in chronically ill patients. Methods and Findings This prospective, pragmatic randomized controlled trial compares an intervention group (IG) of participants in TBHC to a control group (CG) without TBHC. Endpoints were assessed two years after enrolment. Three different groups of insurees with 1) multiple conditions (chronic campaign), 2) heart failure (heart failure campaign), or 3) chronic mental illness conditions (mental health campaign) were targeted. The telephone coaching included evidence-based information and was based on the concepts of motivational interviewing, shared decision-making, and collaborative goal setting. Patients received an average of 12.9 calls. Primary outcome was time from enrolment until hospital readmission within a two-year follow-up period. Secondary outcomes comprised the probability of hospital readmission, number of daily defined medication doses (DDD), frequency and duration of inability to work, and mortality within two years. All outcomes were collected from routine data provided by the statutory health insurance. As informed consent was obtained after randomization, propensity score matching (PSM) was used to minimize selection bias introduced by decliners. For the analysis of hospital readmission and mortality, we calculated Kaplan-Meier curves and estimated hazard ratios (HR). Probability of hospital readmission and probability of death were analysed by calculating odds ratios (OR). Quantity of health service use and inability to work were analysed by linear random effects regression models. PSM resulted in patient samples of 5,309 (IG: 2,713; CG: 2,596) in the chronic campaign, of 660 (IG: 338; CG: 322) in the heart failure campaign, and of 239 (IG: 101; KG: 138) in the mental health campaign. In none of the three campaigns, there were significant differences between IG and CG in time until hospital readmission. In the chronic campaign, the probability of hospital readmission was higher in the IG than in the CG (OR = 1.13; p = 0.045); no significant differences could be found for the other two campaigns. In the heart failure campaign, the IG showed a significantly reduced number of hospital admissions (-0.41; p = 0.012), although the corresponding reduction in the number of hospital days was not significant. In the chronic campaign, the IG showed significantly increased number of DDDs. Most striking, there were significant differences in mortality between IG and CG in the chronic campaign (OR = 0.64; p = 0.005) as well as in the heart failure campaign (OR = 0.44; p = 0.001). Conclusions While TBHC seems to reduce hospitalization only in specific patient groups, it may reduce mortality in patients with chronic somatic conditions. Further research should examine intervention effects in various subgroups of patients, for example for different diagnostic groups within the chronic campaign, or duration of coaching.	[Haerter, Martin; Dirmaier, Joerg; Dwinger, Sarah; Kriston, Levente] Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany; [Herbarth, Lutz; Siegmund-Schultze, Elisabeth] Kaufmann Krankenkasse KKH, Hannover, Germany; [Bermejo, Isaac] Univ Med Ctr Freiburg, Freiburg, Germany; [Matschinger, Herbert; Heider, Dirk; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Harter, M (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany.	m.haerter@uke.de	König, Hans-Helmut/P-1211-2018; Kriston, Levente/D-1713-2013	König, Hans-Helmut/0000-0001-5711-6862; Kriston, Levente/0000-0003-0748-264X; Harter, Martin/0000-0001-7443-9890; Dwinger, Sarah/0000-0003-4868-5662; Matschinger, Herbert/0000-0001-7146-6770; Dirmaier, Joerg/0000-0002-5729-7357	Kaufmannische Krankenkasse Hannover (KKH)	Kaufmannische Krankenkasse Hannover (KKH)	The study is funded by Kaufmannische Krankenkasse Hannover (KKH). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkema GE, 2007, HEALTH SERV RES, V42, P1632, DOI 10.1111/j.1475-6773.2006.00668.x; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; [Anonymous], 2012, GLOBAL EC BURDEN NON; Bauer UE, 2014, LANCET, V384, P45, DOI 10.1016/S0140-6736(14)60648-6; Centers for Medicare & Medicaid Services, CHRONIC CONDITIONS M; Dennis SM, 2013, AUST HEALTH REV, V37, P381, DOI 10.1071/AH13005; DeVol R, 2007, UNHEALTHY AM EC BURD; Dwinger S, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-337; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Harter M, 2013, HEALTH EDUC J, V72, P622, DOI 10.1177/0017896912453990; Hoffmann F, 2007, BUNDESGESUNDHEITSBLA, V50, P1418, DOI 10.1007/s00103-007-0369-5; Hutchison AJ, 2011, J TELEMED TELECARE, V17, P451, DOI 10.1258/jtt.2011.110513; Inglis SC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub3; Jia HM, 2013, VALUE HEALTH, V16, P140, DOI 10.1016/j.jval.2012.08.2208; Jonk Y, 2015, MED CARE, V53, P133, DOI 10.1097/MLR.0000000000000287; Kim SE, 2013, HEALTH SERV RES, V48, P1730, DOI 10.1111/1475-6773.12060; Lin WC, 2012, MED CARE, V50, P91, DOI 10.1097/MLR.0b013e31822dcedf; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Richards T., 2012, BMJ, V344; Ritter PL, 2001, J CLIN EPIDEMIOL, V54, P136, DOI 10.1016/S0895-4356(00)00261-4; Schubert I, 2010, GESUNDHEITSWESEN, V72, P316, DOI 10.1055/s-0030-1249688; Sharabiani MTA, 2012, MED CARE, V50, P1109, DOI 10.1097/MLR.0b013e31825f64d0; Sinnott C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003610; Steventon A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4585; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Veroff D, 2013, HEALTH AFFAIR, V32, P285, DOI 10.1377/hlthaff.2011.0941; Wennberg DE, 2010, NEW ENGL J MED, V363, P1245, DOI 10.1056/NEJMsa0902321; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	31	31	32	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2016	11	9							e0161269	10.1371/journal.pone.0161269	http://dx.doi.org/10.1371/journal.pone.0161269			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5SJ	27632360	Green Published, Green Submitted, gold			2023-01-03	WOS:000383706900017
J	Chatenoud, L				Chatenoud, Lucienne			Precision medicine for autoimmune disease	NATURE BIOTECHNOLOGY			English	Editorial Material							CONGENITAL HEART-BLOCK; MECHANISMS; CELLS	An antigen-specific cell therapy for autoimmune disease avoids compromising immunity as a whole.	[Chatenoud, Lucienne] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Chatenoud, Lucienne] Hop Necker Enfants Malad, CNRS, INSERM, U1151,UMR 8253,INEM, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chatenoud, L (corresponding author), Univ Paris 05, Sorbonne Paris Cite, Paris, France.; Chatenoud, L (corresponding author), Hop Necker Enfants Malad, CNRS, INSERM, U1151,UMR 8253,INEM, Paris, France.	lucienne.chatenoud@inserm.fr						Ambrosi A, 2014, EXP CELL RES, V325, P2, DOI 10.1016/j.yexcr.2014.01.003; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Chatenoud L, 2015, CURR OPIN PHARMACOL, V23, P92, DOI 10.1016/j.coph.2015.05.013; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Gleicher N, 2013, AUTOIMMUN REV, V12, P1039, DOI 10.1016/j.autrev.2013.04.006; Hammers CM, 2015, J INVEST DERMATOL, V135, P742, DOI 10.1038/jid.2014.291; Luo J, 2009, J NEUROSCI, V29, P13898, DOI 10.1523/JNEUROSCI.2833-09.2009; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Phillips William D, 2016, F1000Res, V5, DOI 10.12688/f1000research.8206.1; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Skog A, 2016, ACTA OBSTET GYN SCAN, V95, P98, DOI 10.1111/aogs.12785	11	14	15	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2016	34	9					930	932		10.1038/nbt.3670	http://dx.doi.org/10.1038/nbt.3670			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	DW0RE	27606458				2023-01-03	WOS:000383348500017
J	Liang, FW; Chan, WY; Chen, PJ; Zimmerman, C; Waring, S; Doody, R				Liang, Fu-Wen; Chan, Wenyaw; Chen, Ping-Jen; Zimmerman, Carissa; Waring, Stephen; Doody, Rachelle			Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease	PLOS ONE			English	Article							SURVIVAL; PREDICTORS; MORTALITY; INSTITUTIONALIZATION; PROBABILITIES; DURATION; DEMENTIA; ONSET	Introduction Some Alzheimer's disease (AD) patients die without ever developing cognitively impaired basic activities of daily living (basic ADL), which may reflect slower disease progression or better compensatory mechanisms. Although impaired basic ADL is related to disease severity, it may exert an independent risk for death. This study examined the association between impaired basic ADL and survival of AD patients, and proposed a multistate approach for modeling the time to death for patients who demonstrate different patterns of progression of AD that do or do not include basic ADL impairment. Methods 1029 patients with probable AD at the Baylor College of Medicine Alzheimer's Disease and Memory Disorders Center met the criteria for this study. Two complementary definitions were used to define development of basic ADL impairment using the Physical Self-Maintenance Scale score. A weighted Cox regression model, including a time-dependent covariate (development of basic ADL impairment), and a multistate survival model were applied to examine the effect of basic ADL impairment on survival. Results As expected decreased ability to perform basic ADL at baseline, age at initial visit, years of education, and sex were all associated with significantly higher mortality risk. In those unimpaired at baseline, the development of basic ADL impairment was also associated with a much greater risk of death (hazard ratios 1.77-4.06) over and above the risk conferred by loss of MMSE points. A multi-state Cox model, controlling for those other variables quantified the substantive increase in hazard ratios for death conferred by the development of basic ADL impairment by two definitions and can be applied to calculate the short term risk of mortality in individual patients. Conclusions The current study demonstrates that the presence of basic ADL impairment or the development of such impairments are important predictors of death in AD patients, regardless of severity.	[Liang, Fu-Wen] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Publ Hlth, 1 Univ Rd, Tainan 701, Taiwan; [Chan, Wenyaw] Univ Texas Hlth Sci Ctr Houston, Dept Biostat, 1200 Pressler St,E827, Houston, TX 77030 USA; [Chen, Ping-Jen] Chi Mei Med Ctr, Dept Geriatr & Gerontol, 901 Zhong Hua Rd, Tainan 710, Taiwan; [Zimmerman, Carissa] Rice Univ, Dept Psychol, 6100 Main MS-27, Houston, TX 77005 USA; [Waring, Stephen] Essentia Inst Rural Hlth, 502 East Second St, Duluth, MN 55805 USA; [Doody, Rachelle] Baylor Coll Med, Alzheimers Dis & Memory Disorders Ctr, 7200 Cambridge St,A9-210, Houston, TX 77030 USA	National Cheng Kung University; National Cheng Kung University Hospital; University of Texas System; University of Texas Health Science Center Houston; Chi Mei Hospital; Rice University; Baylor College of Medicine	Chan, WY (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Biostat, 1200 Pressler St,E827, Houston, TX 77030 USA.	wenyaw.chan@uth.tmc.edu	Waring, Stephen/AAR-6870-2021; Chen, Ping-Jen/AAG-8548-2021	Waring, Stephen/0000-0002-9674-0083; Chen, Ping-Jen/0000-0001-7636-0801	Cynthia and George Mitchell Foundation; Cain Foundation in the Baylor Alzheimer's Disease and Memory Disorder Center; Cynthia and George Mitchell Fund	Cynthia and George Mitchell Foundation(General Electric); Cain Foundation in the Baylor Alzheimer's Disease and Memory Disorder Center; Cynthia and George Mitchell Fund	The authors would like to thank the Cynthia and George Mitchell Foundation (http://cgmf.org/p/home.html) and the Cain Foundation (http://www.thecainfoundation.com/bor/site/) in the Baylor Alzheimer's Disease and Memory Disorder Center for providing funds that contributed towards this analysis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the Cynthia and George Mitchell Fund and the Cain Foundation in the Baylor Alzheimer's Disease and Memory Disorder Center for providing funds that contributed towards this analysis.	Aguero-Torres H, 1998, INT J GERIATR PSYCH, V13, P755, DOI 10.1002/(SICI)1099-1166(1998110)13:11<755::AID-GPS862>3.0.CO;2-Y; Aguero-Torres H, 1998, J AM GERIATR SOC, V46, P444, DOI 10.1111/j.1532-5415.1998.tb02464.x; ANDERSEN PK, 1991, SCAND J STAT, V18, P153; BELLONISONZOGNI A, 1989, ARCH GERONTOL GERIAT, V9, P193, DOI 10.1016/0167-4943(89)90039-3; BIANCHETTI A, 1995, DEMENTIA, V6, P108, DOI 10.1159/000106930; Bowen JD, 1996, NEUROLOGY, V47, P433, DOI 10.1212/WNL.47.2.433; Claus JJ, 1998, DEMENT GERIATR COGN, V9, P284, DOI 10.1159/000017073; Doody R, 2005, DEMENT GERIATR COGN, V20, P198, DOI 10.1159/000087300; Doody Rachelle S, 2015, Alzheimers Dement (Amst), V1, P464, DOI 10.1016/j.dadm.2015.08.001; Doody RS, 2010, ALZHEIMERS RES THER, V2, DOI [10.1186/alzrt25, 10.1186/alzrt38]; Doody RS, 2004, DEMENT GERIATR COGN, V17, P1, DOI 10.1159/000074078; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heyman A, 1996, NEUROLOGY, V46, P656, DOI 10.1212/WNL.46.3.656; HIER DB, 1989, ARCH NEUROL-CHICAGO, V46, P1213, DOI 10.1001/archneur.1989.00520470073030; KLEIN JP, 1993, STAT MED, V12, P2315, DOI 10.1002/sim.4780122408; Klein JP, 2003, SURVIVAL ANAL TECHNI, V2nd, DOI DOI 10.1007/B97377; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; Lapane KL, 2001, NEUROLOGY, V56, P650, DOI 10.1212/WNL.56.5.650; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOLSA PK, 1995, ACTA NEUROL SCAND, V91, P159; MOLSA PK, 1986, ACTA NEUROL SCAND, V74, P103; MORITZ DJ, 1993, AM J EPIDEMIOL, V137, P456; Reisberg B, 1996, Int Psychogeriatr, V8, P291, DOI 10.1017/S1041610296002657; Rountree SD, 2009, ALZHEIMERS RES THER, V1, DOI 10.1186/alzrt7; Santerre R, 1996, HELTH EC THEORY INSI; Spiegel R, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt183; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; VANDIJK PTM, 1992, J GERONTOL, V47, pM28; Waring SC, 2005, ALZ DIS ASSOC DIS, V19, P178, DOI 10.1097/01.wad.0000189033.35579.2d; Weuve J., 2012, EPIDEMIOLOGY CAMBRID, V23; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501	32	5	5	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2016	11	8							e0160671	10.1371/journal.pone.0160671	http://dx.doi.org/10.1371/journal.pone.0160671			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4DZ	27571265	gold, Green Published, Green Submitted			2023-01-03	WOS:000382876700005
J	Rohr, JK; Ive, P; Horsburgh, CR; Berhanu, R; Shearer, K; Maskew, M; Long, L; Sanne, I; Bassett, J; Ebrahim, O; Fox, MP				Rohr, Julia K.; Ive, Prudence; Horsburgh, C. Robert; Berhanu, Rebecca; Shearer, Kate; Maskew, Mhairi; Long, Lawrence; Sanne, Ian; Bassett, Jean; Ebrahim, Osman; Fox, Matthew P.			Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa	PLOS ONE			English	Article							DRUG-RESISTANCE MUTATIONS; VIREMIA COPY-YEARS; ANTIRETROVIRAL TREATMENT; VIROLOGICAL FAILURE; INFECTED PATIENTS; 1ST-LINE FAILURE; VIRAL LOAD; THERAPY; MORTALITY; ACCUMULATION	Background South African HIV treatment guidelines call for patients who fail first-line antiretroviral therapy (ART) to be switched to second-line ART, yet logistical issues, clinician decisions and patient preferences make delay in switching to second-line likely. We explore the impact of delaying second-line ART after first-line treatment failure on rates of death and virologic failure. Methods We include patients with documented virologic failure on first-line ART from an observational cohort of 9 South African clinics. We explored predictors of delayed second-line switch and used marginal structural models to analyze rates of death following first-line failure by categorical time to switch to second-line. Cox proportional hazards models were used to examine virologic failure on second-line ART among patients who switched to second- line. Results 5895 patients failed first-line ART, and 63% switched to second-line. Among patients who switched, median time to switch was 3.4 months (IQR: 1.1-8.7 months). Longer time to switch was associated with higher CD4 counts, lower viral loads and more missed visits prior to first-line failure. Worse outcomes were associated with delay in second-line switch among patients with a peak CD4 count on first-line treatment <= 100 cells/mm(3). Among these patients, marginal structural models showed increased risk of death (adjusted HR for switch in 6-12 months vs. 0-1.5 months = 1.47 (95% CI: 0.94-2.29), and Cox models showed increased rates of second-line virologic failure despite the presence of survivor bias (adjusted HR for switch in 3-6 months vs. 0-1.5 months = 2.13 (95% CI: 1.01-4.47)). Conclusions Even small delays in switch to second-line ART were associated with increased death and second-line failure among patients with low CD4 counts on first-line. There is opportunity for healthcare providers to switch patients to second-line more quickly.	[Rohr, Julia K.; Horsburgh, C. Robert; Fox, Matthew P.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA; [Ive, Prudence; Berhanu, Rebecca] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Clin HIV Res Unit,Dept Internal Med, Johannesburg, South Africa; [Horsburgh, C. Robert; Fox, Matthew P.] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02215 USA; [Shearer, Kate; Maskew, Mhairi; Long, Lawrence; Sanne, Ian; Fox, Matthew P.] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Hlth Econ & Epidemiol Res Off,Dept Internal Med, Johannesburg, South Africa; [Sanne, Ian] Right Care, Johannesburg, South Africa; [Bassett, Jean] Witkoppen Hlth & Welf Ctr, Johannesburg, South Africa; [Ebrahim, Osman] Univ Pretoria, Dept Med Microbiol, Pretoria, South Africa	Boston University; University of Witwatersrand; Boston University; University of Witwatersrand; University of Pretoria	Rohr, JK (corresponding author), Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA.	jkrohr@hsph.harvard.edu	Sanne, Ian/ABH-2231-2020; Fox, Matthew/K-2004-2019	MASKEW, MHAIRI/0000-0003-4238-0200; Berhanu, Rebecca/0000-0002-9692-8748; Long, Lawrence/0000-0003-4986-4988; Rohr, Julia Katherine/0000-0002-1180-8764; Horsburgh, C./0000-0001-6838-7895	United States Agency for International Development (USAID) [674-A-12-00029]; National Institutes of Health (NIH) [T32AI102623]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI102623] Funding Source: NIH RePORTER	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	JKR, KS, MM, LL and MPF were funded for this work by United States Agency for International Development (USAID) through the following agreement: 674-A-12-00029. The authors' views expressed in this publication do not necessarily reflect the views of the United States Agency for International Development or the United States Government. Additional support to KS was provided by the National Institutes of Health (NIH) (T32AI102623). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajose O, 2012, AIDS, V26, P929, DOI 10.1097/QAD.0b013e328351f5b2; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Cain LE, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1212; Chirouze C, 2015, JAIDS-J ACQ IMM DEF, V68, P204, DOI 10.1097/QAI.0000000000000416; Ciaffi L, 2015, AIDS, V29, P1473, DOI 10.1097/QAD.0000000000000709; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; El-Khatib Z, 2011, J AIDS CLIN RSCH, V2; El-Khatib Z, 2010, AIDS, V24, P1679, DOI 10.1097/QAD.0b013e32833a097b; Fox MP, 2012, JAIDS; Gsponer T, 2012, AIDS, V26, P57, DOI 10.1097/QAD.0b013e32834e1b5f; Gupta RK, 2014, CLIN INFECT DIS, V58, P1023, DOI 10.1093/cid/cit933; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hoffmann CJ, 2009, CLIN INFECT DIS, V49, P1928, DOI 10.1086/648444; Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e; Howe CJ, 2016, EPIDEMIOLOGY, V27, P91, DOI 10.1097/EDE.0000000000000409; Johnston V, 2012, J ACQ IMMUN DEF SYND, V61, P1, DOI DOI 10.1097/QAI.0B013E318266EE3F; Levison JH, 2011, ANTIVIR THER, V16, P853, DOI 10.3851/IMP1819; Li JZ, 2011, JAMA-J AM MED ASSOC, V305, P1327, DOI 10.1001/jama.2011.375; Lin G, 2012, SAS GLOB FOR 2012 ST; Madec Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082724; Mansana J, 2013, PLOS ONE, V8, DOI DOI 10.1371/J0URNAL.PONE.0072158; Mugavero MJ, 2011, CLIN INFECT DIS, V53, P927, DOI 10.1093/cid/cir526; Murphy RA, 2012, JAIDS-J ACQ IMM DEF, V61, P158, DOI 10.1097/QAI.0b013e3182615ad1; Oyugi J, 2004, J ACQ IMMUN DEF SYND, V36, P5; Petersen ML, 2008, AIDS, V22, P2097, DOI 10.1097/QAD.0b013e32830f97e2; Petersen ML, 2014, AIDS, V28, P2097, DOI 10.1097/QAD.0000000000000349; Ramadhani HO, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu079; Reynolds SJ, 2012, AIDS RES HUM RETROVI; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Scherrer AU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050307; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Sigaloff KCE, 2012, J INFECT DIS, V205, P1739, DOI 10.1093/infdis/jis261; Sigaloff KCE, 2012, AIDS RES HUM RETROV, V28, P171, DOI 10.1089/aid.2011.0136; Sigaloff KCE, 2011, JAIDS-J ACQ IMM DEF, V58, P23, DOI 10.1097/QAI.0b013e318227fc34; Singh K, 2014, VIRUSES-BASEL, V6, P3535, DOI 10.3390/v6093535; South Africa National Department of Health, 2010, CLIN GUID MAN HIV AI; Srasuebkul Preeyaporn, 2007, AIDS Res Ther, V4, P18, DOI 10.1186/1742-6405-4-18; Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745; UNAIDS, S AFR 2013; UNAIDS, 2014, 90 90 90 AMB TREATM; van der Laan Mark J, 2007, Int J Biostat, V3, P3, DOI 10.2202/1557-4679.1022; van Zyl GU, 2011, J MED VIROL, V83, P1764, DOI 10.1002/jmv.22189; Vrijens B, 2005, STAT MED, V24, P2719, DOI 10.1002/sim.2130; Wallis CL, 2014, CLIN INFECT DIS, V59, P706, DOI 10.1093/cid/ciu314; Wallis CL, 2010, JAIDS-J ACQ IMM DEF, V53, P480, DOI 10.1097/QAI.0b013e3181bc478b	45	29	29	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2016	11	8							e0161469	10.1371/journal.pone.0161469	http://dx.doi.org/10.1371/journal.pone.0161469			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TP	27548695	Green Published, gold, Green Submitted			2023-01-03	WOS:000381768400061
J	Hannah-Shmouni, F; Demidowich, A; Stratakis, CA				Hannah-Shmouni, Fady; Demidowich, Andrew; Stratakis, Constantine A.			Cortisol in the Evaluation of Adrenal Insufficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIAGNOSIS		[Hannah-Shmouni, Fady; Demidowich, Andrew; Stratakis, Constantine A.] NICHHD, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stratakis, CA (corresponding author), NICHD, SEGEN, PDEGEN, NIH, 9000 Rockville Pk,Bldg 10,CRC,Room 1-3330,MSC1103, Bethesda, MD 20892 USA.	stratakc@mail.nih.gov	Stratakis, Constantine/AAP-4745-2020; Fady Hannah-Shmouni, FRCPC/AAF-5159-2019	Fady Hannah-Shmouni, FRCPC/0000-0001-6829-6205	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008920] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bornstein SR, 2016, J CLIN ENDOCR METAB, V101, P364, DOI 10.1210/jc.2015-1710; Charmandari E, 2014, LANCET, V383, P2152, DOI 10.1016/S0140-6736(13)61684-0; Dorin RI, 2003, ANN INTERN MED, V139, P194, DOI 10.7326/0003-4819-139-3-200308050-00009; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; Kazlauskaite R, 2008, J CLIN ENDOCR METAB, V93, P4245, DOI 10.1210/jc.2008-0710; Ospina NS, 2016, J CLIN ENDOCR METAB, V101, P427, DOI 10.1210/jc.2015-1700	6	3	3	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2016	316	5					535	536		10.1001/jama.2016.8360	http://dx.doi.org/10.1001/jama.2016.8360			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS9AU	27483068				2023-01-03	WOS:000381075000021
J	Minard, LV; Corkum, A; Sketris, I; Fisher, J; Zhang, Y; Saleh, A				Minard, Laura V.; Corkum, Amber; Sketris, Ingrid; Fisher, Judith; Zhang, Ying; Saleh, Ahmed			Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis	PLOS ONE			English	Article							C-REACTIVE PROTEIN; PRIMARY PREVENTION; JUPITER TRIAL; CARDIOVASCULAR-DISEASE; RISK-ASSESSMENT; ROSUVASTATIN; CHOLESTEROL; THERAPY; PEOPLE; HEALTH	Purpose To examine HMG-CoA reductase inhibitor (statin) drug dispensing patterns to Nova Scotia Seniors' Pharmacare program (NSSPP) beneficiaries over a 14-year period in response to: 1) rosuvastatin market entry in 2003, 2) JUPITER trial publication in 2008, and 3) generic atorvastatin availability in 2010. Methods All NSSPP beneficiaries who redeemed at least one prescription for a statin from April 1, 1999 to March 31, 2013 were included. Aggregated, anonymous monthly prescription counts were extracted by the Nova Scotia Department of Health and Wellness (Nova Scotia, Canada) and changes in dispensing patterns of statins were measured. Data were analyzed using descriptive analyses and interrupted time series methods. Results The percentage of NSSPP beneficiaries dispensed any statin increased from 5.3% in April 1999 to 20.7% in March 2013. In 1999, most NSSPP beneficiaries were dispensed either simvastatin (29.5%) or atorvastatin (28.7%). When rosuvastatin was added to the NSSPP Formulary in August 2003, prescriptions dispensed for simvastatin, lovastatin, pravastatin, and fluvastatin declined significantly (slope change, -0.0027; 95% confidence interval (CI), (-0.0046, -0.0009)). This significant decline continued following the publication of JUPITER (level change, -0.1974; 95% CI, (-0.2991, -0.0957)) and the availability of generic atorvastatin (level change, -0.2436; 95% CI, (-0.3314, -0.1558)). Atorvastatin was not significantly affected by any of the three interventions, although it maintained an overall decreasing trend. Only upon the availability of generic atorvastatin did the upward trend in rosuvastatin use decrease significantly (slope change, -0.0010, 95% CI, (-0.0015, -0.0005)). Conclusions The type and rate of statins dispensed to NSSPP beneficiaries changed from 1999 to 2013 in response to the availability of new agents and publication of the JUPITER trial. The overall proportion of NSSPP beneficiaries dispensed a statin increased approximately 4-fold during the study period. In 2013, rosuvastatin was the most commonly dispensed statin (44.1%) followed by atorvastatin (39.1%).	[Minard, Laura V.; Sketris, Ingrid] Dalhousie Univ, Coll Pharm, Halifax, NS, Canada; [Corkum, Amber; Zhang, Ying] Acadia Univ, Stat Consulting Unit, Wolfville, NS, Canada; [Fisher, Judith] Nova Scotia Dept Hlth & Wellness, Halifax, NS, Canada; [Saleh, Ahmed] Dalhousie Univ, Fac Med, Halifax, NS, Canada	Dalhousie University; Acadia University; Dalhousie University	Minard, LV (corresponding author), Dalhousie Univ, Coll Pharm, Halifax, NS, Canada.	lminard@dal.ca		Sketris, Ingrid/0000-0003-1820-5883; Minard, Laura/0000-0002-1545-3470	Canadian Institutes of Health Research; Drug Evaluation Alliance of Nova Scotia	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Drug Evaluation Alliance of Nova Scotia	Funding for this research was provided by a grant from the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca/e/193.html) to IS and though an unconditional grant from the Drug Evaluation Alliance of Nova Scotia (http://novascotia.ca/dhw/pharmacare/drug-evaluation-alliance-of-novascotia.asp) to LVM. The decision to publish and the content to be published was the decision of the research team. The data used in this report were made available by the Nova Scotia Department of Health and Wellness. Although this research is based on data obtained from the Nova Scotia Department of Health and Wellness, the observations and opinions expressed do not represent those of the Department of Health and Wellness.	Abramson JD, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6123; [Anonymous], NIH PUBLICATION; [Anonymous], 2013, LIP LOW PRIM PREV CA; [Anonymous], 2005, STAT CARD DIS; Barrett B, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0436-9; Brown JD, 2016, RES SOCIAL ADM PHARM; Canadian Institute of Health Information, 2014, DRUG US SEN PUBL DRU; Canadian Institute of Health Information, DRIV PRESCR DRUG SPE; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Carrera M., 2016, AM EC J IN PRESS; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; de Lorgeril M, 2010, ARCH INTERN MED, V170, P1032, DOI 10.1001/archinternmed.2010.184; Dunne SS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0415-3; Fraeyman J, 2013, EXPERT REV PHARM OUT, V13, P141, DOI [10.1586/ERP.12.88, 10.1586/erp.12.88]; Galper BZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138092; Gupta M, 2012, CAN J CARDIOL, V28, P14, DOI 10.1016/j.cjca.2011.09.014; Ioannidis JPA, 2014, JAMA-J AM MED ASSOC, V311, P463, DOI 10.1001/jama.2013.284657; Jackevicius CA, 2001, ARCH INTERN MED, V161, P183, DOI 10.1001/archinte.161.2.183; Jackson G, 2009, INT J CLIN PRACT, V63, P347, DOI 10.1111/j.1742-1241.2009.02013.x; Kappagoda CT, 2009, AM J CARDIOL, V104, P1603, DOI 10.1016/j.amjcard.2009.07.033; Kildemoes HW, 2012, HEALTH POLICY, V108, P216, DOI 10.1016/j.healthpol.2012.08.008; Kones R, 2010, DRUG DES DEV THER, V4, P383, DOI 10.2147/DDDT.S10812; Kwon HY, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1356-z; Launer J, 2015, POSTGRAD MED J, V91, P663, DOI 10.1136/postgradmedj-2015-133766; Lindgren P, 2012, EUR J HEALTH ECON, V13, P445, DOI 10.1007/s10198-011-0315-1; Mamdani MM, 2001, CAN MED ASSOC J, V164, P1695; Manzoli L, 2015, EUR J EPIDEMIOL; Meissner B, 2006, J MANAG CARE PHARM, V12, P331, DOI 10.18553/jmcp.2006.12.4.331; Mintzes B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005699; Murphy AL, 2006, BMC NURS, V5, DOI 10.1186/1472-6955-5-5; Nanchen D, 2011, PREV MED, V52, P159, DOI 10.1016/j.ypmed.2010.11.018; Niederdeppe J, 2013, J GEN INTERN MED, V28, P886, DOI 10.1007/s11606-013-2379-3; Nissen Steven E, 2009, Curr Cardiol Rep, V11, P81; Patel MS, 2014, ANN INTERN MED, V161, pS44, DOI 10.7326/M13-3001; Pichetti S, 2013, APPL HEALTH ECON HEA, V11, P205, DOI 10.1007/s40258-013-0014-4; Polinski JM, 2008, J POPUL THER CLIN PH, V15, pE286; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2007, AM J CARDIOL, V100, P1659, DOI 10.1016/j.amjcard.2007.09.072; Ridker PM, 2010, AM J CARDIOL, V106, P1351, DOI 10.1016/j.amjcard.2010.08.025; Ridker PM, 2009, LANCET, V373, P1175, DOI 10.1016/S0140-6736(09)60447-5; Rikala M, 2013, BASIC CLIN PHARMACOL, V113, P173, DOI 10.1111/bcpt.12075; Schneemann M, 2009, INT J CLIN PRACT, V63, P1118, DOI 10.1111/j.1742-1241.2009.02069.x; Shishehbor MH, 2009, CLEV CLIN J MED, V76, P37, DOI 10.3949/ccjm.75a.08105; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; Sketris IS, 2009, J POPUL THER CLIN PH, V16, pE103; Slejko JF, 2010, CURR MED RES OPIN, V26, P2485, DOI 10.1185/03007995.2010.516994; Spatz ES, 2009, CIRC-CARDIOVASC QUAL, V2, P41, DOI 10.1161/CIRCOUTCOMES.108.832592; Statistics Canada, FOC GEOGR SER 2011 C; Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002; Sullivan HW, 2015, J HEALTH COMMUN, V20, P1391, DOI 10.1080/10810730.2015.1018635; Teng JFT, 2014, PHARMACOTHERAPY, V34, P9, DOI 10.1002/phar.1340; Tziomalos K, 2009, CURR MED RES OPIN, V25, P133, DOI [10.1185/03007990802643557, 10.1185/03007990802643557 ]; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Walley T, 2005, BRIT J CLIN PHARMACO, V60, P543, DOI 10.1111/j.1365-2125.2005.02478.x; Wieringa S, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0229-x; Winkelmayer WC, 2010, WIEN KLIN WOCHENSCHR, V122, P89, DOI 10.1007/s00508-009-1292-6; Yang EY, 2009, J AM COLL CARDIOL, V54, P2388, DOI 10.1016/j.jacc.2009.10.006; Yusuf S, 2009, LANCET, V373, P1152, DOI 10.1016/S0140-6736(09)60357-3; Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402	59	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2016	11	7							e0158608	10.1371/journal.pone.0158608	http://dx.doi.org/10.1371/journal.pone.0158608			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TG	27434392	Green Published, gold, Green Submitted			2023-01-03	WOS:000380169600012
J	Murray, SA				Murray, Scott A.			PERSONAL VIEW Set a low bar for starting palliative care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LUNG-CANCER; END		[Murray, Scott A.] Univ Edinburgh, Ctr Populat Hlth Sci, Primary Palliat Care Res Grp, Usher Inst Populat Hlth Sci & Informat, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Ctr Populat Hlth Sci, Primary Palliat Care Res Grp, Usher Inst Populat Hlth Sci & Informat, Edinburgh EH8 9AG, Midlothian, Scotland.	Scott.Murray@ed.ac.uk		Murray, Scott A/0000-0002-6649-9428				Carduff Emma, 2015, BMC Res Notes, V8, P142, DOI 10.1186/s13104-015-1107-y; Cavers D, 2012, CAN MED ASSOC J, V184, pE373, DOI 10.1503/cmaj.111622; Mackenbach JP, 2012, INT J PUBLIC HEALTH, V57, P915, DOI 10.1007/s00038-012-0381-x; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Murray SA, 2008, BRIT MED J, V336, P958, DOI 10.1136/bmj.39535.491238.94; Murray SA, 2007, J PAIN SYMPTOM MANAG, V34, P393, DOI 10.1016/j.jpainsymman.2006.12.009; Murray SA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2581; Tapsfield J, 2016, BMJ SUPPORT PALLIAT; WHO,, 2020, WHO DEF PALL CAR	9	0	0	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2016	353								i3598	10.1136/bmj.i3598	http://dx.doi.org/10.1136/bmj.i3598			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ2GE	27365045				2023-01-03	WOS:000379019700008
J	Appleby, J				Appleby, John			DATA BRIEFING I'm a healthy patient; get me out of here	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Appleby, John] Kings Fund, London, England		Appleby, J (corresponding author), Kings Fund, London, England.	j.appleby@kingsfund.org.uk						Appleby J, 2016, 19 KINGS FUND; Monitor, 2015, MONITOR Q REPORT PER; NHS England, 2016, BED AV OCC DAT OV; NHS England, 2016, DEL TRANSF CAR; NHS England, 2016, A E ATT EM ADM 2016; NHS Providers, 2015, RIGHT PLAC RIGHT TIM; Triggle N., 2016, BBC NEWS	7	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2016	353								i3585	10.1136/bmj.i3585	http://dx.doi.org/10.1136/bmj.i3585			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ2FV	27356943				2023-01-03	WOS:000379018700003
J	Kunogi, H; Yamaguchi, N; Terao, Y; Sasai, K				Kunogi, Hiroaki; Yamaguchi, Nanae; Terao, Yasuhisa; Sasai, Keisuke			Kidney-Sparing Methods for Extended-Field Intensity-Modulated Radiotherapy (EF-IMRT) in Cervical Carcinoma Treatment	PLOS ONE			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; RADIATION-THERAPY; LYMPH-NODES; CONCURRENT CISPLATIN; CANCER; CHEMOTHERAPY; WOMEN	Coplanar extended-field intensity-modulated radiation therapy (EF-IMRT) targeting the whole-pelvic and para-aortic lymph nodes in patients with advanced cervical cancer results in impaired creatinine clearance. An improvement in renal function cannot be expected unless low-dose (approximately 10 Gy) kidney exposure is reduced. The dosimetric method should be considered during EF-IMRT planning to further reduce low-dose exposure to the kidneys. To assess the usefulness of non-coplanar EF-IMRT with kidney-avoiding beams to spare the kidneys during cervical carcinoma treatment in dosimetric analysis between non-coplanar and coplanar EF-IMRT, we compared the doses of the target organ and organs at risk, including the kidney, in 10 consecutive patients. To estimate the influence of EFRT on renal dysfunction, creatinine clearance values after treatment were also examined in 18 consecutive patients. Of these 18 patients, 10 patients who were included in the dosimetric analysis underwent extended field radiation therapy (EFRT) with concurrent chemotherapy, and eight patients underwent whole-pelvis radiation therapy with concurrent chemotherapy to treat cervical carcinoma between April 2012 and March 2015 at our institution. In the dosimetric analysis, non-coplanar EF-IMRT was effective at reducing low-dose (approximately 10 Gy) exposure to the kidneys, thus maintaining target coverage and sparing other organs at risk, such as the small bowel, rectum, and bladder, compared with coplanar EF-IMRT. Renal function in all 10 patients who underwent EFRT, including coplanar EF-IMRT (with kidney irradiation), was low after treatment, and differed significantly from that of the eight patients who underwent WPRT (no kidney irradiation) 6 months after the first day of treatment (P = 0.005). In conclusion, non-coplanar EF-IMRT should be considered in patients with advanced cervical cancer, particularly in patients with a long life expectancy or with pre-existing renal dysfunction.	[Kunogi, Hiroaki; Yamaguchi, Nanae; Sasai, Keisuke] Juntendo Univ, Dept Radiat Oncol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan; [Terao, Yasuhisa] Juntendo Univ, Dept Gynecol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan	Juntendo University; Juntendo University	Kunogi, H (corresponding author), Juntendo Univ, Dept Radiat Oncol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hkunogi@juntendo.ac.jp	TERAO, YASUHISA/AAH-6307-2019					Beriwal S, 2007, INT J RADIAT ONCOL, V68, P166, DOI 10.1016/j.ijrobp.2006.12.023; Beriwal S, 2006, GYNECOL ONCOL, V102, P195, DOI 10.1016/j.ygyno.2006.01.062; BERMAN ML, 1984, GYNECOL ONCOL, V19, P8, DOI 10.1016/0090-8258(84)90151-3; Dunlop A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120141; Egeler R M, 1999, Semin Urol Oncol, V17, P55; Gay HA, 2012, INT J RADIAT ONCOL, V83, pE353, DOI 10.1016/j.ijrobp.2012.01.023; Gerszten K, 2006, GYNECOL ONCOL, V102, P182, DOI 10.1016/j.ygyno.2005.12.044; Jabbour SK, 2014, PRACT RADIAT ONCOL, V4, P82, DOI 10.1016/j.prro.2013.06.004; Jung J, 2014, ANTICANCER RES, V34, P4361; Marks LB, 2010, INT J RADIAT ONCOL, V76, pS10, DOI 10.1016/j.ijrobp.2009.07.1754; Mundt AJ, 2003, INT J RADIAT ONCOL, V56, P1354, DOI 10.1016/S0360-3016(03)00325-0; Mundt AJ, 2001, GYNECOL ONCOL, V82, P456, DOI 10.1006/gyno.2001.6250; Murakami N, 2014, ANTICANCER RES, V34, P5091; Orlandi E, 2014, RADIOTHER ONCOL, V113, P260, DOI 10.1016/j.radonc.2014.11.024; ROTMAN M, 1995, JAMA-J AM MED ASSOC, V274, P387, DOI 10.1001/jama.274.5.387; Toita T, 2010, JPN J CLIN ONCOL, V40, P456, DOI 10.1093/jjco/hyp191; Varia MA, 1998, INT J RADIAT ONCOL, V42, P1015, DOI 10.1016/S0360-3016(98)00267-3; Varlotto JM, 2006, AM J CLIN ONCOL-CANC, V29, P281, DOI 10.1097/01.coc.0000217828.95729.b5; Wersall PJ, 2005, RADIOTHER ONCOL, V77, P88, DOI 10.1016/j.radonc.2005.03.022; Zhang GY, 2014, J GYNECOL ONCOL, V25, P14, DOI 10.3802/jgo.2014.25.1.14	20	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2016	11	6							e0156623	10.1371/journal.pone.0156623	http://dx.doi.org/10.1371/journal.pone.0156623			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN8ZV	27258030	Green Published, gold, Green Submitted			2023-01-03	WOS:000377369700090
J	Zhao, Y; Tu, P; Zhou, GY; Zhou, ZC; Lin, XX; Yang, HL; Lu, Z; Gao, TW; Tu, YT; Xie, HF; Zheng, QS; Gu, Y; Tao, JN; Zhu, XJ				Zhao, Yi; Tu, Ping; Zhou, Guoyu; Zhou, Zhanchao; Lin, Xiaoxi; Yang, Huilan; Lu, Zhong; Gao, Tianwen; Tu, Yating; Xie, Hongfu; Zheng, Qingshan; Gu, Ying; Tao, Jining; Zhu, Xuejun			Hemoporfin Photodynamic Therapy for Port Wine Stain: A Randomized Controlled Trial	PLOS ONE			English	Article							PULSED-DYE-LASER; PWS BIRTHMARKS; ERYTHEMA; EFFICACY; PDT; CANCER	Background and Objectives Photodynamic therapy (PDT) has shown potentially beneficial results in treating port-wine stain, but its benefit risk profile remains undefined. This study aimed to evaluate the efficacy and safety of PDT conducted with hemoporfin and a 532 nm continuous wave laser to treat port-wine stain clinically. Patients and Methods This randomized clinical trial was conducted in eight hospitals in China. Participants were adolescent and adult patients (age range: 14-65 years old) with port-wine stain. During stage 1 (day 1 to week 8) all patients were randomized at a 3:1 ratio to treatment (532 nm laser irradiation (96-120 J/cm(2)) with hemoporfin (5mg/kg; PDT-hemoporfin, n = 330)) or placebo groups (irradiation with placebo (PDT -placebo, n = 110)); during stage 2 (week 8 to 16) patients in both groups were offered treatment. Clinician-evaluators, who were blind to the study, classified each case on the following four-level scale according to assessment of before and after standardized pictures of the lesion area: no improvement: <20%; some improvement: 20-59%; great improvement: 60-89%; or nearly completely resolved: >= 90%. The primary efficacy endpoint was proportion of patients achieving at least some improvement at week 8. The secondary efficacy endpoints were proportion of patients achieving nearly completely resolved or at least great improvement at week 8, proportion of patients achieving early completely resolved, at least great improvement, or at least some improvement at week 16, and the corresponding satisfaction of the investigators and the patients (designated as 'excellent', 'good', 'moderate', or 'ineffective') at weeks 8 and 16. Results Compared to the PDT-placebo group, the PDT-hemoporfin group showed a significantly higher proportion of patients that achieved at least some improvement (89.7% [n = 295; 95% CI, 85.9%-92.5%] vs. 24.5% [n = 27; 95% CI, 17.4%-33.3%]) at week 8 (P < 0.0001) and higher improvements for all secondary efficacy endpoints. Treatment reactions occurred in 99.5% (n = 731; 95% CI, 98.7%-99.8%) of the PDT-hemoporfin treatments (n = 735). Hyperpigmentation occurred in 22.9 per 100 patient-treatments (n = 168; 95% CI, 20.0-26.0) in the PDT-hemoporfin treated patients. Conclusions Hemoporfin-mediated PDT is an effective and safe treatment option for adolescent and adult patients with port-wine stain.	[Zhao, Yi; Tu, Ping; Zhu, Xuejun] Peking Univ, Dept Dermatol & Venereol, Hosp 1, Beijing 100871, Peoples R China; [Zhou, Guoyu] Shanghai Jiao Tong Univ, Sch Med, Dept Oral Maxillofacial Surg, Peoples Hosp 9, Shanghai 200030, Peoples R China; [Zhou, Zhanchao] Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China; [Zhou, Zhanchao] Peking Union Med Coll, Nanjing, Jiangsu, Peoples R China; [Lin, Xiaoxi] Shanghai Jiao Tong Univ, Sch Med, Dept Plast & Reconstruct Surg, Peoples Hosp 9, Shanghai 200030, Peoples R China; [Yang, Huilan] Guangzhou Mil Command, Gen Hosp, Dept Dermatol, Guangzhou, Guangdong, Peoples R China; [Lu, Zhong] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China; [Gao, Tianwen] Fourth Mil Med Univ, Xijing Hosp, Inst Dermatol Chinese PLA, Xian 710032, Peoples R China; [Tu, Yating] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Dermatol, Wuhan 430074, Peoples R China; [Xie, Hongfu] Cent S Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China; [Zheng, Qingshan] Shanghai Univ Chinese Tradit Med, Ctr Drug Clin Res, Shanghai, Peoples R China; [Gu, Ying] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China; [Tao, Jining] Shanghai Fudan Zhangjiang Biopharmaceut Co Ltd, Shanghai, Peoples R China	Peking University; Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Dermatology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Shanghai Jiao Tong University; Southern Theater Command General Hospital; Fudan University; Air Force Military Medical University; Huazhong University of Science & Technology; Central South University; Shanghai University of Traditional Chinese Medicine; Chinese People's Liberation Army General Hospital	Zhu, XJ (corresponding author), Shanghai Fudan Zhangjiang Biopharmaceut Co Ltd, Shanghai, Peoples R China.	jntao@fd-zj.com; bjzhuxj@gmail.com	Zhao, Yi/M-5881-2018	Zhao, Yi/0000-0002-4531-8632	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.; Chinese PLA General Hospital	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.; Chinese PLA General Hospital	This study was co-sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and the Chinese PLA General Hospital, and was funded by the former. The sponsors had no role in the collection, management, or analysis of the data, or interpretation of the data, preparation of the manuscript, or decision to submit the manuscript for publication. In collaboration with the academic coauthors, both cosponsors were involved in the design of the study. The funder was involved in the conduct of the study and reviewed the manuscript prior to submission, and provided support in the form of salaries for authors [JN Tao], but did not have any additional role in the data collection and analysis, decision to publish, or preparation of the manuscript.	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Currie CLA, 2000, BRIT J DERMATOL, V143, P360, DOI 10.1046/j.1365-2133.2000.03663.x; DIXON JA, 1984, PLAST RECONSTR SURG, V73, P771, DOI 10.1097/00006534-198405000-00009; Faurschou A, 2009, BRIT J DERMATOL, V160, P359, DOI 10.1111/j.1365-2133.2008.08993.x; Gao K, 2013, BRIT J DERMATOL, V168, P1040, DOI 10.1111/bjd.12130; Greve B, 2004, LASER SURG MED, V34, P168, DOI 10.1002/lsm.20003; Gu Y, 2007, ANN DERMATOL VENER, V134, P241, DOI 10.1016/S0151-9638(07)91816-5; Gu Y, 1994, CHINESE J LASER MED, V3, P215; Huang NY, 2011, LASER MED SCI, V26, P665, DOI 10.1007/s10103-011-0890-5; Huikeshoven M, 2007, NEW ENGL J MED, V356, P1235, DOI 10.1056/NEJMoa064329; JACOBS AH, 1976, PEDIATRICS, V58, P218; Jiang L, 1998, CHINESE MED J-PEKING, V111, P136; Jung B, 2005, LASER SURG MED, V37, P186, DOI 10.1002/lsm.20218; Kelly KM, 2005, ARCH FACIAL PLAST S, V7, P287, DOI 10.1001/archfaci.7.5.287; Klapman MH, 2001, J AM ACAD DERMATOL, V44, P300, DOI 10.1067/mjd.2001.111353; Le KVT, 1999, DERMATOL SURG, V25, P127, DOI 10.1046/j.1524-4725.1999.08166.x; MALM M, 1988, ANN PLAS SURG, V20, P512, DOI 10.1097/00000637-198806000-00002; Mayor S, 2003, BRIT MED J, V327, P698, DOI 10.1136/bmj.327.7417.698-b; ORENSTEIN A, 1990, LASER SURG MED, V10, P334, DOI 10.1002/lsm.1900100406; Orten SS, 1996, ARCH OTOLARYNGOL, V122, P1174; Qin ZP, 2007, PHOTODIAGN PHOTODYN, V4, P53, DOI 10.1016/j.pdpdt.2007.01.001; Rasband W, IMAGEJ IMAGE PROCESS; Song K, 2005, BIOCHEM BIOPH RES CO, V337, P127, DOI 10.1016/j.bbrc.2005.09.021; Stangeland KZ, 2012, J EUR ACAD DERMATOL, V26, P849, DOI 10.1111/j.1468-3083.2011.04167.x; Sun PH, 2011, ACTA PHARMACOL SIN, V32, P1549, DOI 10.1038/aps.2011.132; Tomson N, 2006, BRIT J DERMATOL, V154, P676, DOI 10.1111/j.1365-2133.2005.07113.x; Tournas JA, 2009, PHOTODIAGN PHOTODYN, V6, P195, DOI 10.1016/j.pdpdt.2009.10.002; Uppsala Monitoring Center, 2000, WHO ART ADV REACT TE; Wei YQ, 2007, PHOTOCHEM PHOTOBIOL, V83, P1319, DOI 10.1111/j.1751-1097.2007.00160.x; World Health Organisation, UPPS MON CTR SYST ST; Xiao Q, 2011, J DERMATOL, V38, P1146, DOI 10.1111/j.1346-8138.2011.01292.x; Yamamoto T, 2008, SKIN RES TECHNOL, V14, P26, DOI 10.1111/j.1600-0846.2007.00256.x; Yuan KH, 2008, PHOTODIAGN PHOTODYN, V5, P50, DOI 10.1016/j.pdpdt.2007.12.001; Yuan KH, 2012, PHOTODIAGN PHOTODYN, V9, P332, DOI 10.1016/j.pdpdt.2012.03.007; Yuan KH, 2009, PHOTODIAGN PHOTODYN, V6, P189, DOI 10.1016/j.pdpdt.2009.08.001; Yung A, 2005, BRIT J DERMATOL, V153, P601, DOI 10.1111/j.1365-2133.2005.06707.x; Zhang B, 2014, PHOTODIAGN PHOTODYN, V11, P491, DOI 10.1016/j.pdpdt.2014.06.004; Zhao Y, 2013, PHOTODIAGN PHOTODYN, V10, P96, DOI 10.1016/j.pdpdt.2012.10.001; Zhao Y, 2011, PHOTODERMATOL PHOTO, V27, P17, DOI 10.1111/j.1600-0781.2010.00555.x	39	38	39	4	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0156219	10.1371/journal.pone.0156219	http://dx.doi.org/10.1371/journal.pone.0156219			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27227544	Green Submitted, Green Published, gold			2023-01-03	WOS:000376882500085
J	Moosa, MR; Maree, JD; Chirehwa, MT; Benatar, SR				Moosa, Mohammed Rafique; Maree, Jonathan David; Chirehwa, Maxwell T.; Benatar, Solomon R.			Use of the 'Accountability for Reasonableness' Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; HEALTH-CARE; PATIENT SURVIVAL; GRAFT-SURVIVAL; LONG-TERM; TRANSPLANT RECIPIENTS; COST-EFFECTIVENESS; HIV; OUTCOMES	Universal access to renal replacement therapy is beyond the economic capability of most low and middle-income countries due to large patient numbers and the high recurrent cost of treating end stage kidney disease. In countries where limited access is available, no systems exist that allow for optimal use of the scarce dialysis facilities. We previously reported that using national guidelines to select patients for renal replacement therapy resulted in biased allocation. We reengineered selection guidelines using the 'Accountability for Reasonableness' (procedural fairness) framework in collaboration with relevant stakeholders, applying these in a novel way to categorize and prioritize patients in a unique hierarchical fashion. The guidelines were primarily premised on patients being transplantable. We examined whether the revised guidelines enhanced fairness of dialysis resource allocation. This is a descriptive study of 1101 end stage kidney failure patients presenting to a tertiary renal unit in a middle-income country, evaluated for dialysis treatment over a seven-year period. The Assessment Committee used the accountability for reasonableness-based guidelines to allocate patients to one of three assessment groups. Category 1 patients were guaranteed renal replacement therapy, Category 3 patients were palliated, and Category 2 were offered treatment if resources allowed. Only 25.2% of all end stage kidney disease patients assessed were accepted for renal replacement treatment. The majority of patients (48%) were allocated to Category 2. Of 134 Category 1 patients, 98% were accepted for treatment while 438 (99.5%) Category 3 patients were excluded. Compared with those palliated, patients accepted for dialysis treatment were almost 10 years younger, employed, married with children and not diabetic. Compared with our previous selection process our current method of priority setting based on procedural fairness arguably resulted in more equitable allocation of treatment but, more importantly, it is a model that is morally, legally and ethically more defensible.	[Moosa, Mohammed Rafique] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Med, Div Nephrol, Cape Town, South Africa; [Moosa, Mohammed Rafique; Maree, Jonathan David] Tygerberg Acad Hosp, Renal Unit, Cape Town, South Africa; [Chirehwa, Maxwell T.] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Interdisciplinary Hlth Sci, Biostat Unit,Ctr Evidence Based Hlth Care, Cape Town, South Africa; [Benatar, Solomon R.] Univ Cape Town, Ctr Bioeth, Cape Town, South Africa	Stellenbosch University; Stellenbosch University; University of Cape Town	Moosa, MR (corresponding author), Univ Stellenbosch, Fac Med & Hlth Sci, Dept Med, Div Nephrol, Cape Town, South Africa.; Moosa, MR (corresponding author), Tygerberg Acad Hosp, Renal Unit, Cape Town, South Africa.	rmm@sun.ac.za	Chirehwa, Maxwell T/P-5740-2018	Chirehwa, Maxwell T/0000-0002-1685-4882; Moosa, Mohammed/0000-0003-1696-0113				Aalten J, 2006, TRANSPLANT INT, V19, P901, DOI 10.1111/j.1432-2277.2006.00367.x; Alexander S., 1962, LIFE, P102; Bamgboye Ebun L, 2009, Ethn Dis, V19, pS1; Barsoum RS, 2003, KIDNEY INT, V63, P111, DOI 10.1046/j.1523-1755.63.s83.23.x; Bass D, 2005, SAMJ S AFR MED J, V95, P42; Benatar S, 2006, CAMB Q HEALTHC ETHIC, V15, P322; Benatar SR, 2011, AM J PUBLIC HEALTH, V101, P646, DOI 10.2105/AJPH.2009.188458; Benatar SR, 2004, NEW ENGL J MED, V351, P81, DOI 10.1056/NEJMhpr033471; Benatar SR, 2015, REFERENCE MODULE BIO, DOI [10.1097/01.ASN.0000120370.35927.40, DOI 10.1097/01.ASN.0000120370.35927.40]; Byskov Jens, 2009, Health Res Policy Syst, V7, P23, DOI 10.1186/1478-4505-7-23; Callahan D., 1995, SETTING LIMITS MED G; Carson RC, 2009, CLIN J AM SOC NEPHRO, V4, P1611, DOI 10.2215/CJN.00510109; Cosio FG, 2008, AM J TRANSPLANT, V8, P593, DOI 10.1111/j.1600-6143.2007.02101.x; Cosio FG, 2002, KIDNEY INT, V62, P1440, DOI 10.1111/j.1523-1755.2002.kid582.x; Cosio FG, 1999, CLIN TRANSPLANT, V13, P336, DOI 10.1034/j.1399-0012.1999.130410.x; Curran SP, 2014, TRANSPLANTATION, V97, P64, DOI 10.1097/TP.0b013e3182a688a4; Daniels N, 2000, BMJ-BRIT MED J, V321, P1300, DOI 10.1136/bmj.321.7272.1300; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Daniels N., 2002, SETTING LIMITS FAIRL, DOI [10.1093/acprof:oso/9780195149364.001.0001, DOI 10.1093/ACPROF:OSO/9780195149364.001.0001]; Denhaerynck K, 2007, AM J TRANSPLANT, V7, P108, DOI 10.1111/j.1600-6143.2006.01611.x; Dogan E, 2005, NEPHROLOGY, V10, P516, DOI 10.1111/j.1440-1797.2005.00433.x; Eggers PW, 2011, CURR OPIN NEPHROL HY, V20, P241, DOI 10.1097/MNH.0b013e3283454319; Etheredge HR, 2013, CLIN TRANSPLANT, V27, P684, DOI 10.1111/ctr.12200; Fabrizii V, 2004, J AM SOC NEPHROL, V15, P1052, DOI 10.1097/01.ASN.0000120370.35927.40; Faravardeh A, 2013, TRANSPLANTATION, V96, P1089, DOI 10.1097/TP.0b013e3182a688e5; Gane E, 2002, TRANSPLANTATION, V74, P427, DOI 10.1097/00007890-200208270-00001; Garcia-Garcia G, 2005, KIDNEY INT, V68, pS58, DOI 10.1111/j.1523-1755.2005.09710.x; Gibson Jennifer, 2006, J Health Serv Res Policy, V11, P32, DOI 10.1258/135581906775094280; Gore JL, 2006, AM J TRANSPLANT, V6, P357, DOI 10.1111/j.1600-6143.2005.01198.x; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; HARNETT JD, 1987, TRANSPLANTATION, V44, P369, DOI 10.1097/00007890-198709000-00009; Hurst FP, 2011, TRANSPLANTATION, V92, P1101, DOI 10.1097/TP.0b013e3182336095; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Kevany S, 2013, GLOB PUBLIC HEALTH, V8, P570, DOI 10.1080/17441692.2013.790461; Kher V, 2002, KIDNEY INT, V62, P350, DOI 10.1046/j.1523-1755.2002.00426.x; Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37; Maluka S, 2010, SOC SCI MED, V71, P751, DOI 10.1016/j.socscimed.2010.04.035; Marckmann G, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00023; Martin D, 2003, HEALTH CARE ANAL, V11, P59, DOI 10.1023/A:1025338013629; Mayosi BM, 2014, NEW ENGL J MED, V371, P1344, DOI 10.1056/NEJMsr1405012; Moosa MR, 2006, KIDNEY INT, V70, P1107, DOI 10.1038/sj.ki.5001750; Moosa MR, 2016, SAMJ S AFR MED J, V106, P156, DOI [10.7196/SAMJ.2016.v106i2.9928, 10.7196/SAMJ.2016.V106I2.9928]; Moosa M. R., 2014, KIDNEY TRANSPLANTATI, P643; Moosa MR, 2003, SAMJ S AFR MED J, V93, P689; Moosa MR, 2013, GUIDELINE PRIORITY S; Muller E, 2010, NEW ENGL J MED, V362, P2336, DOI 10.1056/NEJMc0900837; Murphy D, 2016, ANN INTERN MED, V165, P473, DOI 10.7326/M16-0273; Naicker S, 2005, KIDNEY DIS DEV WORLD, P137, DOI [10.1201/b14128-8, DOI 10.1201/B14128-8]; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Norheim OF, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0624-4; Norheim OF, 2014, COST EFFECT RESOUR A, V12, DOI 10.1186/1478-7547-12-18; Norman Daniels, 1988, AM MY PARENTS KEEPER; Nugent RA, 2011, NEPHRON CLIN PRACT, V118, pC269, DOI 10.1159/000321382; Persad G, 2009, LANCET, V373, P423, DOI 10.1016/S0140-6736(09)60137-9; Revanur VK, 2001, CLIN TRANSPLANT, V15, P89, DOI 10.1034/j.1399-0012.2001.150202.x; Roland ME, 2008, AM J TRANSPLANT, V8, P355, DOI 10.1111/j.1600-6143.2007.02061.x; Rutecki GW., 2016, ETHIC MED, V27, P99; Sakhuja V, 2003, KIDNEY INT, V63, P115, DOI 10.1046/j.1523-1755.63.s83.24.x; Sakhuja Vinay, 2006, Ethn Dis, V16, pS2; Saudan P, 2001, NEPHROL DIAL TRANSPL, V16, P824, DOI 10.1093/ndt/16.4.824; Scheper-Hughes N, 2003, LANCET, V361, P1645, DOI 10.1016/S0140-6736(03)13305-3; Shaheen FAM, 2005, KIDNEY INT, V68, pS37, DOI 10.1111/j.1523-1755.2005.09807.x; Smart NA, 2011, AM J MED, V124, P1073, DOI 10.1016/j.amjmed.2011.04.026; Stock PG, 2010, NEW ENGL J MED, V363, P2004, DOI 10.1056/NEJMoa1001197; United States Renal Data System, 2015, USRDS ANN DAT REP EP; Vachharajani TJ, 2014, NAT REV NEPHROL, V10, P116, DOI 10.1038/nrneph.2013.256; White SL, 2008, B WORLD HEALTH ORGAN, V86, P229, DOI 10.2471/BLT.07.041715; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820; Yap DYH, 2014, WORLD J GASTROENTERO, V20, P468, DOI 10.3748/wjg.v20.i2.468; Yap DYH, 2010, TRANSPLANTATION, V90, P325, DOI 10.1097/TP.0b013e3181e5b811	70	33	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2016	11	10							e0164201	10.1371/journal.pone.0164201	http://dx.doi.org/10.1371/journal.pone.0164201			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DZ2UK	27701466	Green Published, gold			2023-01-03	WOS:000385696900049
J	Poole, D; Cortegiani, A; Chieregato, A; Russo, E; Pellegrini, C; De Blasio, E; Mengoli, F; Volpi, A; Grossi, S; Gianesello, L; Orzalesi, V; Fossi, F; Chiara, O; Coniglio, C; Gordini, G				Poole, Daniele; Cortegiani, Andrea; Chieregato, Arturo; Russo, Emanuele; Pellegrini, Concetta; De Blasio, Elvio; Mengoli, Francesca; Volpi, Annalisa; Grossi, Silvia; Gianesello, Lara; Orzalesi, Vanni; Fossi, Francesca; Chiara, Osvaldo; Coniglio, Carlo; Gordini, Giovanni		Trauma Update Working Grp	Blood Component Therapy and Coagulopathy in Trauma: A Systematic Review of the Literature from the Trauma Update Group	PLOS ONE			English	Review							FRESH-FROZEN PLASMA; LOGISTIC-REGRESSION; TRANSFUSION; MORTALITY; MODELS; QUALITY; RATIOS; MULTICENTER; STATISTICS; PLATELETS	Background Traumatic coagulopathy is thought to increase mortality and its treatment to reduce preventable deaths. However, there is still uncertainty in this field, and available literature results may have been overestimated. Methods We searched the MEDLINE database using the PubMed platform. We formulated four queries investigating the prognostic weight of traumatic coagulopathy defined according to conventional laboratory testing, and the effectiveness in reducing mortality of three different treatments aimed at contrasting coagulopathy (high fresh frozen plasma/packed red blood cells ratios, fibrinogen, and tranexamic acid administration). Randomized controlled trials were selected along with observational studies that used a multivariable approach to adjust for confounding. Strict criteria were adopted for quality assessment based on a two-step approach. First, we rated quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Then, this rating was downgraded if other three criteria were not met: high reporting quality according to shared standards, absence of internal methodological and statistical issues not detailed by the GRADE system, and absence of external validity issues. Results With few exceptions, the GRADE rating, reporting and methodological quality of observational studies was "very low", with frequent external validity issues. The only two randomized trials retrieved were, instead, of high quality. Only weak evidence was found for a relation between coagulopathy and mortality. Very weak evidence was found supporting the use of fibrinogen administration to reduce mortality in trauma. On the other hand, we found high evidence that the use of 1: 1 vs. 1: 2 high fresh frozen plasma/packed red blood cells ratios failed to obtain a 12% mortality reduction. This does not exclude lower mortality rates, which have not been investigated. The use of tranexamic acid in trauma was supported by "high" quality evidence according to the GRADE classification but was downgraded to "moderate" for external validity issues. Conclusions Tranexamic acid is effective in reducing mortality in trauma. The other transfusion practices we investigated have been inadequately studied in the literature, as well as the independent association between mortality and coagulopathy measured with traditional laboratory testing. Overall, in this field of research literature quality is poor.	[Poole, Daniele] San Martino Hosp, Anesthesia & Intens Care Operat Unit, Belluno, Italy; [Cortegiani, Andrea] Univ Palermo, Sect Anesthesia Analgesia Intens Care & Emergency, Policlin P Giaccone, Dept Biopathol & Med Biotechnol DIBIMED, Palermo, Italy; [Chieregato, Arturo; Fossi, Francesca] ASST Great Metropolitan Niguarda Hosp, Neurointens Care Unit, Milan, Italy; [Russo, Emanuele] Bufalini Hosp, Surg & Severe Trauma Dept, Anaesthesia & Intens Care Unit, Cesena, Italy; [Pellegrini, Concetta; De Blasio, Elvio] AO Rummo, Anesthesia & Intens Care, Benevento, Italy; [Mengoli, Francesca; Coniglio, Carlo; Gordini, Giovanni] Maggiore Hosp, UOC Intens Care & Terr Emergency Dept, Bologna, Italy; [Volpi, Annalisa; Grossi, Silvia] AOU Parma, Anesthesia & Intens Care, Parma, Italy; [Gianesello, Lara] AOU Careggi, Dept Struct Anesthesia & Intens Care Orthoped Sur, Florence, Italy; [Orzalesi, Vanni] AOU Careggi, CTO, Neuroanesthesia & Neurointens Care, Florence, Italy; [Chiara, Osvaldo] ASST Great Metropolitan Niguarda Hosp, Trauma Ctr Dept, Milan, Italy	ULSS 1 Dolomiti; Ospedale di Belluno; University of Palermo; AUSL di Bologna; University of Parma; University Hospital of Parma; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Poole, D (corresponding author), San Martino Hosp, Anesthesia & Intens Care Operat Unit, Belluno, Italy.	daniele.poole@alice.it	Volpi, Annalisa/AHH-5394-2022; Coniglio, Carlo/AAB-7128-2022; Russo, Emanuele/AAP-5645-2020; Gordini, Giovanni/AAB-8170-2022; Cortegiani, Andrea/H-4902-2016; Poole, Daniele/X-7210-2019; chiara, osvaldo/R-6151-2018	Volpi, Annalisa/0000-0001-5337-9155; Coniglio, Carlo/0000-0002-8207-0525; Russo, Emanuele/0000-0002-6531-5527; Gordini, Giovanni/0000-0003-4518-0204; Cortegiani, Andrea/0000-0003-1416-9993; Poole, Daniele/0000-0001-5279-9844; Sanson, Gianfranco/0000-0001-8319-635X; chiara, osvaldo/0000-0003-2409-2109				ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Austin PC, 2004, J CLIN EPIDEMIOL, V57, P1138, DOI 10.1016/j.jclinepi.2004.04.003; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Bagley SC, 2001, J CLIN EPIDEMIOL, V54, P979, DOI 10.1016/S0895-4356(01)00372-9; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Borgman MA, 2011, VOX SANG, V101, P44, DOI 10.1111/j.1423-0410.2011.01466.x; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Cap A, 2014, CURR OPIN CRIT CARE, V20, P638, DOI 10.1097/MCC.0000000000000158; Collins GS, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-103; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hagemo JS, 2014, CRIT CARE, V18, DOI 10.1186/cc13798; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Hunt BJ, 2015, BRIT J HAEMATOL, V170, P788, DOI 10.1111/bjh.13580; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Ioannidis JPA, 2007, CAN MED ASSOC J, V176, P1091, DOI 10.1503/cmaj.060410; Ioannidis JPA, 2016, J CLIN EPIDEMIOL, V73, P82, DOI 10.1016/j.jclinepi.2016.02.012; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Katz MH, 2003, ANN INTERN MED, V138, P644, DOI 10.7326/0003-4819-138-8-200304150-00012; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Mallett S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-20; Mitra B, 2010, INJURY, V41, P35, DOI 10.1016/j.injury.2009.09.029; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Moss M, 2003, CHEST, V123, P923, DOI 10.1378/chest.123.3.923; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Pham HP, 2013, BRIT J ANAESTH, V111, P71, DOI 10.1093/bja/aet376; Poole D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113676; Poole D, 2014, INTENS CARE MED, V40, P1927, DOI 10.1007/s00134-014-3510-6; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; Sambasivan CN, 2011, J TRAUMA, V71, pS329, DOI 10.1097/TA.0b013e318227edd3; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Sun GW, 1996, J CLIN EPIDEMIOL, V49, P907, DOI 10.1016/0895-4356(96)00025-X; Sylvestre MP, 2006, ANN INTERN MED, V145, P361, DOI 10.7326/0003-4819-145-5-200609050-00009; Teixeira PGR, 2009, J TRAUMA, V66, P693, DOI 10.1097/TA.0b013e31817e5c77; Theusinger OM, 2014, CURR OPIN CRIT CARE, V20, P646, DOI 10.1097/MCC.0000000000000152; Wafaisade A, 2011, J TRAUMA, V70, P81, DOI 10.1097/TA.0b013e3182032e0b; World Health Organization, 2015, GLOB STAT REP ROAD S	45	10	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2016	11	10							e0164090	10.1371/journal.pone.0164090	http://dx.doi.org/10.1371/journal.pone.0164090			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0TR	27695109	Green Submitted, Green Published, gold			2023-01-03	WOS:000385553100088
J	Arfe, A; Scotti, L; Varas-Lorenzo, C; Nicotra, F; Zambon, A; Kollhorst, B; Schink, T; Garbe, E; Herings, R; Straatman, H; Schade, R; Villa, M; Lucchi, S; Valkhoff, V; Romio, S; Thiessard, F; Schuemie, M; Pariente, A; Sturkenboom, M; Corrao, G				Arfe, Andrea; Scotti, Lorenza; Varas-Lorenzo, Cristina; Nicotra, Federica; Zambon, Antonella; Kollhorst, Bianca; Schink, Tania; Garbe, Edeltraut; Herings, Ron; Straatman, Huub; Schade, Rene; Villa, Marco; Lucchi, Silvia; Valkhoff, Vera; Romio, Silvana; Thiessard, Frantz; Schuemie, Martijn; Pariente, Antoine; Sturkenboom, Miriam; Corrao, Giovanni		Safety Non-Steroidal Anti-Inflamm	Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDIVIDUAL PARTICIPANT DATA; HEALTH-CARE DATABASES; CYCLO-OXYGENASE-2 INHIBITORS; MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK; COX-2 INHIBITORS; METAANALYSIS; MISCLASSIFICATION; HOSPITALIZATION; EPIDEMIOLOGY	OBJECTIVES To investigate the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. DESIGN Nested case-control study. SETTING Five population based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom). PARTICIPANTS Adult individuals (age >= 18 years) who started NSAID treatment in 2000-10. Overall, 92 163 hospital admissions for heart failure were identified and matched with 8 246 403 controls (matched via risk set sampling according to age, sex, year of cohort entry). MAIN OUTCOME MEASURE Association between risk of hospital admission for heart failure and use of 27 individual NSAIDs, including 23 traditional NSAIDs and four selective COX 2 inhibitors. Associations were assessed by multivariable conditional logistic regression models. The dose-response relation between NSAID use and heart failure risk was also assessed. RESULTS Current use of any NSAID (use in preceding 14 days) was found to be associated with a 19% increase of risk of hospital admission for heart failure (adjusted odds ratio 1.19; 95% confidence interval 1.17 to 1.22), compared with past use of any NSAIDs (use >183 days in the past). Risk of admission for heart failure increased for seven traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, nimesulide, and piroxicam) and two COX 2 inhibitors (etoricoxib and rofecoxib). Odds ratios ranged from 1.16 (95% confidence interval 1.07 to 1.27) for naproxen to 1.83 (1.66 to 2.02) for ketorolac. Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses (>= 2 defined daily dose equivalents), although some confidence intervals were wide. Even medium doses (0.9-1.2 defined daily dose equivalents) of indomethacin and etoricoxib were associated with increased risk. There was no evidence that celecoxib increased the risk of admission for heart failure at commonly used doses. CONCLUSIONS The risk of hospital admission for heart failure associated with current use of NSAIDs appears to vary between individual NSAIDs, and this effect is dose dependent. This risk is associated with the use of a large number of individual NSAIDs reported by this study, which could help to inform both clinicians and health regulators.	[Arfe, Andrea; Scotti, Lorenza; Nicotra, Federica; Zambon, Antonella; Corrao, Giovanni] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Unit Biostat Epidemiol & Publ Hlth, I-20126 Milan, Italy; [Varas-Lorenzo, Cristina] RTI Hlth Solut, Barcelona, Spain; [Kollhorst, Bianca; Schink, Tania; Garbe, Edeltraut] Leibniz Inst Prevent Res & Epidemiol, Bremen, Germany; [Herings, Ron; Straatman, Huub] PHARMO Inst, Utrecht, Netherlands; [Schade, Rene; Valkhoff, Vera; Romio, Silvana; Schuemie, Martijn; Sturkenboom, Miriam] Erasmus Univ, Dept Med Informat, Med Ctr, Rotterdam, Netherlands; [Villa, Marco; Lucchi, Silvia] Local Hlth Author ASL Cremona, Cremona, Italy; [Thiessard, Frantz; Pariente, Antoine] Univ Bordeaux Segalen, Bordeaux, France	University of Milano-Bicocca; Research Triangle Institute; Leibniz Institute for Prevention Research & Epidemiology (BIPS); Erasmus University Rotterdam; Erasmus MC; UDICE-French Research Universities; Universite de Bordeaux	Corrao, G (corresponding author), Univ Milano Bicocca, Dept Stat & Quantitat Methods, Unit Biostat Epidemiol & Publ Hlth, I-20126 Milan, Italy.	giovanni.corrao@unimib.it	Scotti, Lorenza/AAB-9544-2019; Schink, Tania/A-4585-2017; Pariente, Antoine/S-9231-2019; Thiessard, Frantz/T-7304-2019; Herings, Ron/AAE-4096-2021	Scotti, Lorenza/0000-0002-3861-9058; Schink, Tania/0000-0002-0224-1866; Pariente, Antoine/0000-0002-7873-5483; Thiessard, Frantz/0000-0002-9469-3156; Herings, Ron/0000-0002-2561-8734; Sturkenboom, Miriam/0000-0003-1360-2388; Schuemie, Martijn/0000-0002-0817-5361	European Community [223495]	European Community(European Commission)	The research leading to the results of this study received funding from the European Community's seventh Framework Programme (grant agreement no 223495-the SOS Project). The funding source did not play any role in planning and implementing this study, in interpreting its results, and in writing this paper.	Altman DG, 2007, BRIT MED J, V334, P424, DOI 10.1136/bmj.38977.682025.2C; Amer M, 2010, CARDIOL REV, V18, P204, DOI 10.1097/CRD.0b013e3181ce1521; Avillach P, 2013, J AM MED INFORM ASSN, V20, P184, DOI 10.1136/amiajnl-2012-000933; Back M, 2012, EUR HEART J, V33, P1928, DOI 10.1093/eurheartj/ehr421; Bernatsky S, 2005, RHEUMATOLOGY, V44, P677, DOI 10.1093/rheumatology/keh610; Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; Bleumink GS, 2003, DRUGS, V63, P525, DOI 10.2165/00003495-200363060-00001; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Cooper H, 2009, PSYCHOL METHODS, V14, P165, DOI 10.1037/a0015565; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; Corrao G, 2014, EUR J HEART FAIL, V16, P729, DOI 10.1002/ejhf.105; Delaney JAC, 2011, PHARMACOEPIDEM DR S, V20, P83, DOI 10.1002/pds.2065; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duong M, 2014, BRIT J CLIN PHARMACO, V77, P887, DOI 10.1111/bcp.12239; Fabule J, 2014, THER ADV MUSCULOSKEL, V6, P111, DOI 10.1177/1759720X14541668; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Fries JF, 1996, SCAND J RHEUMATOL, P1; Rodriguez LAG, 2008, J AM COLL CARDIOL, V52, P1628, DOI 10.1016/j.jacc.2008.08.041; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HOSMER DW, 2000, WILEY PS TX, P1; Howes Laurence Guy, 2007, Ther Clin Risk Manag, V3, P831; Huerta C, 2006, HEART, V92, P1610, DOI 10.1136/hrt.2005.082388; Jurek AM, 2005, INT J EPIDEMIOL, V34, P680, DOI 10.1093/ije/dyi060; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Kim KY, 2003, CLIN THER, V25, P1593, DOI 10.1016/S0149-2918(03)80158-3; Koffeman AR, 2014, BRIT J GEN PRACT, V64, pE191, DOI 10.3399/bjgp14X677815; Krishnan E, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000282; LUI KJ, 1988, AM J EPIDEMIOL, V127, P1064, DOI 10.1093/oxfordjournals.aje.a114882; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Mangoni AA, 2010, BRIT J CLIN PHARMACO, V69, P689, DOI 10.1111/j.1365-2125.2010.03627.x; McGettigan P, 2008, BRIT J CLIN PHARMACO, V65, P927, DOI 10.1111/j.1365-2125.2008.03121.x; McGettigan P, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001098; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Moride Y, 2005, ARTHRITIS RES THER, V7, pR333, DOI 10.1186/ar1488; Patrono C, 2014, CIRCULATION, V129, P907, DOI 10.1161/CIRCULATIONAHA.113.004480; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Rodriguez LAG, 2003, EPIDEMIOLOGY, V14, P240; ROMANO PS, 1994, MED CARE, V32, P81, DOI 10.1097/00005650-199401000-00006; Saczynski JS, 2012, PHARMACOEPIDEM DR S, V21, P129, DOI 10.1002/pds.2313; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Scott PA, 2008, EUR J HEART FAIL, V10, P1102, DOI 10.1016/j.ejheart.2008.07.013; Sedgwick P, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5310; Smith EUR, 2010, BEST PRACT RES CL RH, V24, P811, DOI 10.1016/j.berh.2010.10.004; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7086; Trifiro G, 2014, J INTERN MED, V275, P551, DOI 10.1111/joim.12159; Valkhoff VE, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-192; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; Yood MU, 2007, PHARMACOEPIDEM DR S, V16, P961, DOI 10.1002/pds.1454	50	137	148	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2016	354								i4857	10.1136/bmj.i4857	http://dx.doi.org/10.1136/bmj.i4857			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ4UK	27682515	hybrid, Green Published			2023-01-03	WOS:000385855700002
J	Wu, HL; Feng, JY; Lv, WT; Huang, QL; Fu, MS; Cai, MX; He, QQ; Shang, J				Wu, Huali; Feng, Junyi; Lv, Wenting; Huang, Qiaoling; Fu, Mengsi; Cai, Minxuan; He, Qiangqiang; Shang, Jing			Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice	PLOS ONE			English	Article							PITUITARY-ADRENAL AXIS; 5-HT1A RECEPTOR; TACROLIMUS OINTMENT; TOPICAL APPLICATION; ATOPIC-DERMATITIS; RETINOIC ACID; SKIN; SYSTEM; BRAIN; HYDROQUINONE	Dermatosis often as a chronic disease requires effective long-term treatment; a comprehensive evaluation of mental health of dermatology drug does not receive enough attention. An interaction between dermatology and psychiatry has been increasingly described. Substantial evidence has accumulated that psychological stress can be associated with pigmentation, endocrine and immune systems in skin to create the optimal responses against pathogens and other physicochemical stressors to maintain or restore internal homeostasis. Additionally, given the common ectodermal origin shared by the brain and skin, we are interested in assessing how disruption of skin systems (pigmentary, endocrine and immune systems) may play a key role in brain functions. Thus, we selected three drugs (hydroquinone, isotretinoin, tacrolimus) with percutaneous excessive delivery to respectively intervene in these systems and then evaluate the potential neurotoxic effects. Firstly, C57BL/6 mice were administrated a dermal dose of hydroquinone cream, isotretinoin gel or tacrolimus ointment (2%, 0.05%, 0.1%, respectively, 5 times of the clinical dose). Behavioral testing was performed and levels of proteins were measured in the hippocampus. It was found that mice treated with isotretinoin or tacrolimus, presented a lower activity in open-field test and obvious depressive-like behavior in tail suspension test. Besides, they damaged cytoarchitecture, reduced the level of 5-HT-5-HT1A/1B system and increased the expression of apoptosis-related proteins in the hippocampus. To enable sensitive monitoring the dose-response characteristics of the consecutive neurobehavioral disorders, mice received gradient concentrations of hydroquinone (2%, 4%, 6%). Subsequently, hydroquinone induced behavioral disorders and hippocampal dysfunction in a dose-dependent response. When doses were high as 6% which was 3 times higher than 2% dose, then 100% of mice exhibited depressive-like behavior. Certainly, 6% hydroquinone exposure elicited the most serious impairment of hippocampal structure and survival. The fact that higher doses of hydroquinone are associated with a greater risk of depression is further indication that hydroquinone is responsible for the development of depression. These above data demonstrated that chronic administration of different dermatology drugs contributed into common mental distress. This surprising discovery of chemical stressors stimulating the hippocampal dysfunction, paves the way for exciting areas of study on the cross-talk between the skin and the brain, as well as is suggesting how to develop effective and safe usage of dermatological drugs in daily practice.	[Wu, Huali; Feng, Junyi; Lv, Wenting; Huang, Qiaoling; Fu, Mengsi; Cai, Minxuan; Shang, Jing] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China; [Wu, Huali; Feng, Junyi; Lv, Wenting; Huang, Qiaoling; Fu, Mengsi; Cai, Minxuan; Shang, Jing] China Pharmaceut Univ, Jiangsu Key Lab TCM Evaluat & Translat Res, Nanjing, Jiangsu, Peoples R China; [He, Qiangqiang] Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Key Lab Tibetan Med Pharmacol & Safety Ev, Xining, Qinghai Provinc, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; Chinese Academy of Sciences	Shang, J (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.; Shang, J (corresponding author), China Pharmaceut Univ, Jiangsu Key Lab TCM Evaluat & Translat Res, Nanjing, Jiangsu, Peoples R China.	shangjing21cn@163.com			National Science and Technology Infrastructure Program of China [2012BAI30B001]; One Hundred Person Project of The Chinese Academy of Sciences, Applied Basic Research Programs of Qinghai Province [Y229461211]; Science and Technology Plan Projects in Qinghai Province [2015-ZJ-733]	National Science and Technology Infrastructure Program of China; One Hundred Person Project of The Chinese Academy of Sciences, Applied Basic Research Programs of Qinghai Province; Science and Technology Plan Projects in Qinghai Province	This study was supported by (1) National Science and Technology Infrastructure Program of China (2012BAI30B001) Prof Jing Shang, (2) One Hundred Person Project of The Chinese Academy of Sciences, Applied Basic Research Programs of Qinghai Province (Y229461211) Prof Jing Shang, and (3) Science and Technology Plan Projects in Qinghai Province (2015-ZJ-733) Prof Jing Shang.	Akhavan A, 2003, AM J CLIN DERMATOL, V4, P473, DOI 10.2165/00128071-200304070-00004; Alenina N, 2015, BEHAV BRAIN RES, V277, P49, DOI 10.1016/j.bbr.2014.07.038; Alikhan FS, 2011, CUTAN OCUL TOXICOL, V30, P175, DOI 10.3109/15569527.2011.560914; ANGEL A, 1972, TOXICOL APPL PHARM, V21, P214, DOI 10.1016/0041-008X(72)90064-6; Arck PC, 2003, AM J PATHOL, V162, P803, DOI 10.1016/S0002-9440(10)63877-1; Borovaya A, 2013, INT J DERMATOL, V52, P1040, DOI 10.1111/ijd.12169; Bremner JD, 2012, J CLIN PSYCHIAT, V73, P37, DOI 10.4088/JCP.10r05993; Claudet I, 2015, PEDIATR EMERG CARE, V31, P44, DOI 10.1097/PEC.0000000000000301; CloezTayarani I, 1997, P NATL ACAD SCI USA, V94, P9899, DOI 10.1073/pnas.94.18.9899; Draelos ZD, 2010, CUTIS, V86, P153; English JC, 2005, FOOD CHEM TOXICOL, V43, P483, DOI 10.1016/j.fct.2004.11.015; Ganceviciene R, 2009, BRIT J DERMATOL, V160, P345, DOI 10.1111/j.1365-2133.2008.08959.x; Harada M, 2000, Ryoikibetsu Shokogun Shirizu, P86; Hategan A, 2015, J NEUROPSYCH CLIN N, V27, pE140, DOI 10.1176/appi.neuropsych.14010011; Hazama Y, 2016, BIOL PHARM BULL, V39, P343, DOI 10.1248/bpb.b15-00727; Hiramoto K, 2011, CLIN EXP DERMATOL, V36, P52, DOI 10.1111/j.1365-2230.2010.03777.x; Jaako-Movits K, 2005, EUR J NEUROSCI, V22, P2871, DOI 10.1111/j.1460-9568.2005.04481.x; Jiang S, 2016, EVID-BASED COMPL ALT, V2047412, P25; Korabel Hanna, 2008, Przegl Lek, V65, P244; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lee WS, 2016, KOREAN J INTERN MED, V31, P779, DOI 10.3904/kjim.2015.066; Liao S, 2012, EXP DERMATOL, V21, P635, DOI 10.1111/j.1600-0625.2012.01531.x; Mielke H, 2011, TOXICOL LETT, V204, P190, DOI 10.1016/j.toxlet.2011.04.032; Mitchell A, 1919, BRIT MED J, V1919, P465, DOI 10.1136/bmj.2.3067.465; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Nordlind K, 2008, EXP DERMATOL, V17, P301, DOI 10.1111/j.1600-0625.2007.00670.x; Palchaudhuri M, 2005, CELL TISSUE RES, V321, P159, DOI 10.1007/s00441-005-1112-x; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; Paterson LM, 2013, MED RES REV, V33, P54, DOI 10.1002/med.20245; Ping FF, 2012, NEUROSCI LETT, V514, P173, DOI 10.1016/j.neulet.2012.02.087; Popova NK, 2013, REV NEUROSCIENCE, V24, P191, DOI 10.1515/revneuro-2012-0082; Schettler T, 2006, INT J ANDROL, V29, P134, DOI 10.1111/j.1365-2605.2005.00567.x; Schuller E, 2004, J ALLERGY CLIN IMMUN, V114, P137, DOI 10.1016/j.jaci.2004.03.021; Seo DH, 2012, APPL MICROBIOL BIOT, V95, P1417, DOI 10.1007/s00253-012-4297-4; Skobowiat C, 2016, EXP DERMATOL, V25, P120, DOI 10.1111/exd.12890; Skobowiat C, 2015, J INVEST DERMATOL, V135, P1638, DOI 10.1038/jid.2014.450; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; Slominski A, 2005, DERMATOLOGY, V211, P199, DOI 10.1159/000087012; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski Andrzej, 2008, Drug Discov Today Dis Mech, V5, P137; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2013, ENDOCR REV, V34, P827, DOI 10.1210/er.2012-1092; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Tobin DJ, 2006, CHEM SOC REV, V35, P52, DOI 10.1039/b505793k; Topping DC, 2007, FOOD CHEM TOXICOL, V45, P70, DOI 10.1016/j.fct.2006.07.019; Undre NA, 2009, BRIT J DERMATOL, V160, P665, DOI 10.1111/j.1365-2133.2008.08974.x; VANE F M, 1988, Skin Pharmacology, V1, P237; Wijdicks EFM, 2001, LIVER TRANSPLANT, V7, P937, DOI 10.1053/jlts.2001.27475; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wu H, 2014, SCI WORLD J, DOI 10.1155/2014/237356; Wu HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089663; Zhou J, 2014, J DERMATOL SCI, V73, P110, DOI 10.1016/j.jdermsci.2013.09.005	52	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2016	11	9							e0162570	10.1371/journal.pone.0162570	http://dx.doi.org/10.1371/journal.pone.0162570			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JB	27606422	Green Published, Green Submitted, gold			2023-01-03	WOS:000383255600066
J	Mekuria, Y; Yilma, D; Mekonnen, Z; Kassa, T; Gedefaw, L				Mekuria, Yewulsew; Yilma, Daniel; Mekonnen, Zeleke; Kassa, Tesfaye; Gedefaw, Lealem			Renal Function Impairment and Associated Factors among HAART Naive and Experienced Adult HIV Positive Individuals in Southwest Ethiopia: A Comparative Cross Sectional Study	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC KIDNEY-DISEASE; INFECTED PATIENTS; PREVALENCE; DYSFUNCTION; GUIDELINES	Background Human immunodeficiency virus (HIV) infection and its treatment cause renal diseases. Renal disease is associated with an increasing cause of morbidity and mortality in HIV positive individuals than in the general population. It has been also associated with adverse outcomes, such as complications of decreased renal functions and progression to renal failure. Objective To determine the prevalence and factors associated with renal function impairment among highly active antiretroviral therapy (HAART) naive and HAART experienced adult HIV positive individuals. Methods A facility based comparative cross-sectional study was conducted in Jimma University Specialized Hospital (JUSH) from June to September 2014. HIV positive individuals who visited JUSH during the study period were included in the study. Sociodemographic and clinical data were collected using a structured questionnaire. Blood specimen was analyzed for renal function tests. Descriptive statistics, Mann-Whitney U test and logistic regression analysis were done using SPSS version 16 software. Results A total of 446 HIV positive individuals, 223 HAART naive and 223 HAART experienced, were recruited. The overall prevalence of renal function impairment was 18.2%[95% 14.6-21.7]. The prevalence of renal impairment in HAART naive and HAART experienced persons was 28.7%[95% CI: 23.1-34.4] and 7.6% [95% CI: 4.6-11.6], respectively. Age >= 50 years (AOR = 3.6; 95% CI 1.4, 9.6), advanced WHO stage (AOR = 2.3; 95% CI 1.1, 4.7), and CD4 count <200 (AOR = 6.9; 95% CI 3.3, 14.2) were independent risk factors among HAART naive participants. Female gender (AOR = 6.6; 95 CI % 1.2, 34), age >= 50 years (AOR = 12.1; 95% CI 1.7, 84) and CD4 count <200 (AOR = 17; 95% CI 5.2, 58) were independent risk factors among HAART experienced participants. Conclusion The prevalence of renal function impairment was higher among HAART naive than HAART experienced HIV positive individuals. Renal function impairment was associated with disease advancement and old age.	[Mekuria, Yewulsew] Jimma Univ Specialized Hosp, Dept Clin Lab Sci, Jimma, Ethiopia; [Yilma, Daniel] Jimma Univ, Coll Hlth Sci, Dept Internal Med, Jimma, Ethiopia; [Mekonnen, Zeleke; Kassa, Tesfaye; Gedefaw, Lealem] Jimma Univ, Coll Hlth Sci, Dept Med Lab Sci & Pathol, Jimma, Ethiopia	Jimma University; Jimma University	Gedefaw, L (corresponding author), Jimma Univ, Coll Hlth Sci, Dept Med Lab Sci & Pathol, Jimma, Ethiopia.	lealem.gedefaw@ju.edu.et	Yilma, Daniel/AAJ-2072-2021; Mekonnen, Zeleke/AAF-3877-2020	Yilma, Daniel/0000-0001-6058-2696; Mekonnen, Zeleke/0000-0003-3418-7291	Jimma University	Jimma University	The study was funded by Jimma University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansari Naheed, KIDNEY INVOLVEMENT H; BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; Bygrave H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017609; Cailhol J, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-40; Cheung CY, 2007, NEPHROL DIAL TRANSPL, V22, P3186, DOI 10.1093/ndt/gfm350; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Crum-Cianflone N, 2010, AIDS PATIENT CARE ST, V24, P353, DOI 10.1089/apc.2009.0326; DAVIES DF, 1950, J CLIN INVEST, V29, P496, DOI 10.1172/JCI102286; Deti EK, 2007, 4 IAS C HIV PATH TRE; FolefackKaze Francois, 2013, Saudi J Kidney Dis Transpl, V24, P1291, DOI 10.4103/1319-2442.121280; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Jeff Dubin, 2002, E MED            FEB; Kahsu G, 2013, J INTERDISCIPL HISTO, V1; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Mpondo BCT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089573; Msango L, 2011, AIDS, V25, P1421, DOI 10.1097/QAD.0b013e328348a4b1; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Mulenga LB, 2008, AIDS, V22, P1821, DOI 10.1097/QAD.0b013e328307a051; National renal foundation, HIV CHRON REN DIS; Owiredu WKBA, 2013, AFR HEALTH SCI, V13, P101, DOI 10.4314/ahs.v13i1.14; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Peters PJ, 2008, KIDNEY INT, V74, P925, DOI 10.1038/ki.2008.305; Petersen PH, 1996, EUR J CLIN CHEM CLIN, V34, P983; Plebani M, 2006, CLIN CHEM LAB MED, V44, P750, DOI 10.1515/CCLM.2006.123; Post FA, 2009, CURR OPIN INFECT DIS, V22, P43, DOI 10.1097/QCO.0b013e328320ffec; Scarpino M, 2013, EUR REV MED PHARMACO, V17, P2660; Schwartz EJ, 2005, J AM SOC NEPHROL, V16, P2412, DOI 10.1681/ASN.2005040340; Struik GM, 2011, INT J STD AIDS, V22, P457, DOI 10.1258/ijsa.2011.010521; Torre D, 2005, HIV MED, V6, P66, DOI 10.1111/j.1468-1293.2005.00268.x; Wools-Kaloustian K, 2007, NEPHROL DIAL TRANSPL, V22, P2208, DOI 10.1093/ndt/gfm223; World Health Organization, 2014, POL BRIEF CONS GUID; Wyatt Christina M, 2012, Top Antivir Med, V20, P106; Yusuf R, 2011, NIGER J PHARM SCI, V10	33	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2016	11	8							e0161180	10.1371/journal.pone.0161180	http://dx.doi.org/10.1371/journal.pone.0161180			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT6ES	27537338	Green Submitted, Green Published, gold			2023-01-03	WOS:000381577000065
J	Assuncao, AR; Bottaro, M; Ferreira, JB; Izquierdo, M; Cadore, EL; Gentil, P				Assuncao, Ari R.; Bottaro, Martim; Ferreira-Junior, Joao B.; Izquierdo, Mikel; Cadore, Eduardo L.; Gentil, Paulo			The Chronic Effects of Low- and High-Intensity Resistance Training on Muscular Fitness in Adolescents	PLOS ONE			English	Article							ENDURANCE DEVELOPMENT; POSITION STATEMENT; STRENGTH GAINS; ADAPTATIONS; EXERCISE; PROTOCOLS; CHILDREN; PERFORMANCE; SIZE; HYPERTROPHY	To compare the effects of high-load, low-repetition maximum (LRM) and low-load, high-repetition maximum (HRM) resistance training regimens on muscular fitness in untrained adolescents. Forty-five untrained adolescents of both sexes (13.7 +/- 0.8 years; 161.3 +/- 7.5 cm, 56.8 +/- 13.4 kg) were randomly assigned into one of three groups: 1) LRM (n = 17): volunteers performed three sets of 4-6-repetition maximum (RM); 2) HRM (n = 16): volunteers performed three sets of 12-15 RM; and 3) control (CON, n = 12). Training was performed two times a week for 9 weeks. After training, there were significant increases in 1 RM chest press (LRM = 14.8% and HRM = 14.2%, p<0.05) and squat (LRM = 26.4% and HRM = 25.7%, p<0.05), with no differences between the LRM and HRM groups (p>0.05). Additionally, muscular endurance increased significantly for the chest press (LRM = 14.5% and HRM = 21.8%, p<0.05) and squat test (LRM = 31.4% and HRM = 32.4%, p<0.05) following resistance training, with no difference between the LRM and HRM groups (p>0.05). These results suggest that both high-load, low-repetition and moderate-load, high-repetition resistance training can be prescribed to improve muscular fitness in untrained adolescents.	[Assuncao, Ari R.; Bottaro, Martim] Univ Brasilia, Coll Phys Educ, Brasilia, DF, Brazil; [Ferreira-Junior, Joao B.] Fed Inst Sudeste Minas Gerais, Campus Rio Pomba, Rio Pomba, MG, Brazil; [Izquierdo, Mikel] Univ Publ Navarra, Dept Hlth Sci, Campus Tudela, Tudela, Navarre, Spain; [Cadore, Eduardo L.] Univ Fed Rio Grande do Sul, Sch Phys Educ, Pa, RS, Brazil; [Gentil, Paulo] Univ Fed Goias, Coll Phys Educ, Goiania, Go, Brazil	Universidade de Brasilia; Instituto Federal do Sudeste de Minas Gerais; Universidad Publica de Navarra; Universidade Federal do Rio Grande do Sul; Universidade Federal de Goias	Ferreira, JB (corresponding author), Fed Inst Sudeste Minas Gerais, Campus Rio Pomba, Rio Pomba, MG, Brazil.	jbfjunior@gmail.com	Bottaro, Martim/X-1433-2019; Izquierdo, Mikel/A-4894-2010; Izquierdo, Mikel/O-8049-2019; Gentil, Paulo/L-7968-2016; Cadore, Eduardo L./T-3016-2017; Bottaro, Martim/H-9593-2014	Bottaro, Martim/0000-0002-4315-3176; Izquierdo, Mikel/0000-0002-1506-4272; Gentil, Paulo/0000-0003-2459-4977; Cadore, Eduardo L./0000-0003-4397-9485; 				ANDERSON T, 1982, RES Q EXERCISE SPORT, V53, P1; Beck TW, 2013, J STRENGTH COND RES, V27, P2323, DOI 10.1519/JSC.0b013e318278eea0; Behm DG, 2008, APPL PHYSIOL NUTR ME, V33, P547, DOI 10.1139/H08-020; Behringer M, 2011, PEDIATR EXERC SCI, V23, P186, DOI 10.1123/pes.23.2.186; Behringer M, 2010, PEDIATRICS, V126, pE1199, DOI 10.1542/peds.2010-0445; BERGER RA, 1962, RES QUART, V33, P334, DOI 10.1080/10671188.1962.10616460; Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6; Carpinelli RN, 2008, J EXERC SCI FIT, V6, P67; Carpinelli RF., 2004, J EXERC PHYSL, V2004, P1; Chen TC, 2014, EUR J APPL PHYSIOL, V114, P1183, DOI 10.1007/s00421-014-2848-3; Chestnut JL, 1999, J STRENGTH COND RES, V13, P353, DOI 10.1519/00124278-199911000-00009; DELORME TL, 1945, J BONE JOINT SURG, V27, P645; Drinkwater EJ, 2005, J STRENGTH COND RES, V19, P382; Faigenbaum AD, 2010, BRIT J SPORT MED, V44, P56, DOI 10.1136/bjsm.2009.068098; Faigenbaum AD, 2005, PEDIATR EXERC SCI, V17, P237, DOI 10.1123/pes.17.3.237; Faigenbaum AD, 2001, J STRENGTH COND RES, V15, P459; Faigenbaum AD, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e5; Faigenbaum AD, 2011, PEDIATR EXERC SCI, V23, P573, DOI 10.1123/pes.23.4.573; Faigenbaum AD, 2009, J STRENGTH COND RES, V23, pS60, DOI 10.1519/JSC.0b013e31819df407; Faigenbaum AD, 2008, PEDIATR EXERC SCI, V20, P457, DOI 10.1123/pes.20.4.457; Fleck SJ, 2011, REV KRONOS, V10, P15; Folland JP, 2002, BRIT J SPORT MED, V36, P370, DOI 10.1136/bjsm.36.5.370; Gentil Paulo, 2013, Asian J Sports Med, V4, P101; Gentil P, 2010, J STRENGTH COND RES, V24, P639, DOI 10.1519/JSC.0b013e3181ad3373; Holm L, 2008, J APPL PHYSIOL, V105, P1454, DOI 10.1152/japplphysiol.90538.2008; Izquierdo M, 2006, J APPL PHYSIOL, V100, P1647, DOI 10.1152/japplphysiol.01400.2005; Izquierdo-Gabarren M, 2010, MED SCI SPORT EXER, V42, P1191, DOI 10.1249/MSS.0b013e3181c67eec; Jungblut S, 2009, MED SPORT, V13, P203; Kraemer WJ, 2004, MED SCI SPORT EXER, V36, P674, DOI 10.1249/01.MSS.0000121945.36635.61; Lloyd RS, 2014, BRIT J SPORT MED, V48, P498, DOI 10.1136/bjsports-2013-092952; Mitchell CJ, 2012, J APPL PHYSIOL, V113, P71, DOI 10.1152/japplphysiol.00307.2012; Ortega FB, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7279; OSHEA P, 1966, RES QUART, V37, P95, DOI 10.1080/10671188.1966.10614741; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; ROONEY KJ, 1994, MED SCI SPORT EXER, V26, P1160; Sampson JA, 2015, SCAND J MED SCI SPOR; Schoenfeld BJ, 2015, J STRENGTH COND RES, V29, P2954, DOI 10.1519/JSC.0000000000000958; Schoenfeld BJ, 2014, J STRENGTH COND RES, V28, P2909, DOI 10.1519/JSC.0000000000000480; Schoenfeld BJ, 2010, J STRENGTH COND RES, V24, P2857, DOI 10.1519/JSC.0b013e3181e840f3; Stone WJ, 1994, J STRENGTH COND RES, V8, P231; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; WITHERS RT, 1970, RES QUART, V41, P110, DOI 10.1080/10671188.1970.10614954	42	22	22	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2016	11	8							e0160650	10.1371/journal.pone.0160650	http://dx.doi.org/10.1371/journal.pone.0160650			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3KR	27509050	Green Published, gold, Green Submitted			2023-01-03	WOS:000381380400043
J	Marvibaigi, M; Amini, N; Supriyanto, E; Majid, FAA; Jaganathan, SK; Jamil, S; Almaki, JH; Nasiri, R				Marvibaigi, Mohsen; Amini, Neda; Supriyanto, Eko; Majid, Fadzilah Adibah Abdul; Jaganathan, Saravana Kumar; Jamil, Shajarahtunnur; Almaki, Javad Hamzehalipour; Nasiri, Rozita			Antioxidant Activity and ROS-Dependent Apoptotic Effect of Scurrula ferruginea (Jack) Danser Methanol Extract in Human Breast Cancer Cell MDA-MB-231	PLOS ONE			English	Article							MISTLETOE VISCUM-ALBUM; TUMOR-GROWTH STIMULATION; IN-VITRO; BIOACTIVE COMPOUNDS; CYTOTOXIC ACTIVITY; DEATH; MITOCHONDRIA; MECHANISMS; ASSAY; METASTASIS	Scurrula ferruginea (Jack) Danser is one of the mistletoe species belonging to Loranthaceae family, which grows on the branches of many deciduous trees in tropical countries. This study evaluated the antioxidant activities of S. ferruginea extracts. The cytotoxic activity of the selected extracts, which showed potent antioxidant activities, and high phenolic and flavonoid contents, were investigated in human breast cancer cell line (MDA-MB-231) and non-cancer human skin fibroblast cells (HSF-1184). The activities and characteristics varied depending on the different parts of S. ferruginea, solvent polarity, and concentrations of extracts. The stem methanol extract showed the highest amount of both phenolic (273.51 +/- 4.84 mg gallic acid/g extract) and flavonoid contents (163.41 +/- 4.62 mg catechin/g extract) and strong DPPH center dot radical scavenging (IC50 = 27.81 mu g/mL) and metal chelation activity (IC50 = 80.20 mu g/mL). The stem aqueous extract showed the highest ABTS(center dot+) scavenging ability. The stem methanol and aqueous extracts exhibited dose-dependent cytotoxic activity against MDA-MB-231 cells with IC50 of 19.27 and 50.35 mu g/mL, respectively. Furthermore, the extracts inhibited the migration and colony formation of MDA-MB-231 cells in a concentration-dependent manner. Morphological observations revealed hallmark properties of apoptosis in treated cells. The methanol extract induced an increase in ROS generation and mitochondrial depolarization in MDA-MB-231 cells, suggesting its potent apoptotic activity. The present study demonstrated that the S. ferruginea methanol extract mediated MDA-MB-231 cell growth inhibition via induction of apoptosis which was confirmed by Western blot analysis. It may be a potential anticancer agent; however, its in vivo anticancer activity needs to be investigated.	[Marvibaigi, Mohsen; Amini, Neda; Supriyanto, Eko; Jaganathan, Saravana Kumar] Univ Teknol Malaysia, Fac Biosci & Med Engn, IJN UTM Cardiovasc Engn Ctr, Skudai, Johor, Malaysia; [Majid, Fadzilah Adibah Abdul; Almaki, Javad Hamzehalipour; Nasiri, Rozita] Univ Teknol Malaysia, Fac Chem Engn, Bioproc Engn Dept, Skudai, Johor, Malaysia; [Jamil, Shajarahtunnur] Univ Teknol Malaysia, UTM Johor Bahru, Fac Sci, Dept Chem, Skudai, Johor, Malaysia; [Majid, Fadzilah Adibah Abdul] Univ Malaysia Terengganu, Inst Marine Biotechnol, Kuala Terengganu, Malaysia	Universiti Teknologi Malaysia; Universiti Teknologi Malaysia; Universiti Teknologi Malaysia; Universiti Malaysia Terengganu	Marvibaigi, M; Supriyanto, E (corresponding author), Univ Teknol Malaysia, Fac Biosci & Med Engn, IJN UTM Cardiovasc Engn Ctr, Skudai, Johor, Malaysia.	mohsen_marvi@yahoo.com; eko.sup1950@gmail.com	Nasiri, Rozita/AAG-9484-2020; abdul majid, fadzilah adibah/AAA-1134-2022; Nasiri, Rozita/ABI-3475-2020; Jamil, Shajarahtunnur/GXG-9807-2022; Jaganathan, Saravana Kumar/N-2385-2017; Supriyanto, Eko/AAZ-1135-2021	Nasiri, Rozita/0000-0002-3897-8034; abdul majid, fadzilah adibah/0000-0001-8122-9605; Nasiri, Rozita/0000-0002-3897-8034; Jaganathan, Saravana Kumar/0000-0002-2785-137X; Amini, Neda/0000-0001-5084-1279; Marvibaigi, Mohsen/0000-0002-0640-2268; SUPRIYANTO, EKO/0000-0002-2142-8351				Abhyankar G, 2010, INNOV FOOD SCI EMERG, V11, P526, DOI 10.1016/j.ifset.2010.02.005; Ameer OZ, 2009, INT J PHARMACOL, V5, P44, DOI 10.3923/ijp.2009.44.50; Anders GT, 2002, FITOTERAPIA, V73, P400; Ashraf MF, 2013, SCI WORLD J, DOI 10.1155/2013/216894; Astley SB, 2003, TRENDS FOOD SCI TECH, V14, P93, DOI 10.1016/S0924-2244(02)00281-9; Barlow B. A., 1991, Flora Malesiana Bulletin, V10, P335; BECKER H, 1986, ONCOLOGY, V43, P2, DOI 10.1159/000226413; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Bussing A, 2006, ARZNEIMITTEL-FORSCH, V56, P508; Bussing A., 2000, MISTLETOE GENUS VISC, P123; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dashora N, 2011, PHARM CROPS, V2, P24, DOI [10.2174/2210290601102010024, DOI 10.2174/2210290601102010024]; DECKER EA, 1990, J AGR FOOD CHEM, V38, P674, DOI 10.1021/jf00093a019; Delanty N, 2000, ARCH NEUROL-CHICAGO, V57, P1265, DOI 10.1001/archneur.57.9.1265; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Ganie SA, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/792574; Gardner PT, 2000, FOOD CHEM, V68, P471, DOI 10.1016/S0308-8146(99)00225-3; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Grieve M., 1994, MODERN HERBAL, P547; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harmsma M, 2006, ARZNEIMITTEL-FORSCH, V56, P474; Heinzerling L, 2006, J CLIN IMMUNOL, V26, P347, DOI 10.1007/s10875-006-9023-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu YL, 2012, J AGR FOOD CHEM, V60, P852, DOI 10.1021/jf2052515; Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4; Isa NM, 2013, J FUNCT FOODS, V5, P87, DOI 10.1016/j.jff.2012.08.008; Johansson S, 2003, CELL MOL LIFE SCI, V60, P165, DOI 10.1007/s000180300011; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Katsarou A, 2012, REC NAT PROD, V6, P394; Kelter G, 2007, ANTICANCER RES, V27, P223; Koizumi T, 1996, TOXICOLOGY, V114, P125, DOI 10.1016/S0300-483X(96)03477-4; Kris-Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002-9343(01)00995-0; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuete V, 2012, PLANTA MED, V78, P193, DOI 10.1055/s-0031-1280319; Kumar J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098696; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lin KL, 2011, CHEM-BIOL INTERACT, V194, P148, DOI 10.1016/j.cbi.2011.10.002; Lohezic-Le Devehat F, 2002, Z NATURFORSCH C, V57, P1092; Maier G, 2002, ANTI-CANCER DRUG, V13, P373, DOI 10.1097/00001813-200204000-00006; Martin EJ, 2004, J PHARMACOL EXP THER, V310, P33, DOI 10.1124/jpet.104.066019; Marvibaigi M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/785479; Massaoka MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038698; Mathew S, 2006, FOOD CHEM TOXICOL, V44, P198, DOI 10.1016/j.fct.2005.06.013; Miliauskas G, 2004, FOOD CHEM, V85, P231, DOI 10.1016/j.foodchem.2003.05.007; Oluwaseun AA, 2008, AFR J BIOTECHNOL, V7, P3138; Onay-Ucar E, 2006, FITOTERAPIA, V77, P556, DOI 10.1016/j.fitote.2006.08.001; Osadebe PO, 2004, J ETHNOPHARMACOL, V95, P133, DOI 10.1016/j.jep.2004.06.029; Perry L, 1978, MED PLANTS E SE ASIA, P2138; Phang CW, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-243; Pieme CA, 2012, TOXICOL ENVIRON CHEM, V94, P987, DOI 10.1080/02772248.2012.674135; Ramaekers FCS, 2007, MEDICINA-BUENOS AIRE, V67, P79; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Sahreen S, 2010, FOOD CHEM, V122, P1205, DOI 10.1016/j.foodchem.2010.03.120; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shim HY, 2007, MOL CELLS, V24, P95; Singh R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079242; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steiner R, 1961, VORTRAG VOM 2 4, p[312, 242]; Stevigny C., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P173, DOI 10.2174/1568011053174864; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Tian LQ, 2012, MOL MED REP, V5, P126, DOI 10.3892/mmr.2011.624; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Velioglu YS, 1998, J AGR FOOD CHEM, V46, P4113, DOI 10.1021/jf9801973; Vicas S., 2008, Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca. Agriculture, V65, P327; Vicas S, 2009, NOT BOT HORTI AGROBO, V37, P112; Vicas SI, 2011, J MED PLANTS RES, V5, P2237; Vicas SI, 2011, NOT BOT HORTI AGROBO, V39, P48; Yoo KM, 2008, FOOD CHEM, V106, P929, DOI 10.1016/j.foodchem.2007.07.006; Zhao YL, 2012, Z NATURFORSCH C, V67, P129, DOI 10.5560/ZNC.2012.67c0129; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	79	31	31	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2016	11	7							e0158942	10.1371/journal.pone.0158942	http://dx.doi.org/10.1371/journal.pone.0158942			36	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ9CP	27410459	Green Submitted, Green Published, gold			2023-01-03	WOS:000379508300044
J	Meara, E; Horwitz, JR; Powell, W; McClelland, L; Zhou, WP; O'Malley, AJ; Morden, NE				Meara, Ellen; Horwitz, Jill R.; Powell, Wilson; McClelland, Lynn; Zhou, Weiping; O'Malley, A. James; Morden, Nancy E.			State Legal Restrictions and Prescription-Opioid Use among Disabled Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESCRIBING PATTERNS; MONITORING PROGRAMS; DRUG OVERDOSE; UNITED-STATES; TRENDS; MORTALITY; LAWS; FLORIDA; DEATHS; IMPACT	BACKGROUND In response to rising rates of opioid abuse and overdose, U.S. states enacted laws to restrict the prescribing and dispensing of controlled substances. The effect of these laws on opioid use is unclear. METHODS We tested associations between prescription-opioid receipt and state controlled-substances laws. Using Medicare administrative data for fee-for-service disabled beneficiaries 21 to 64 years of age who were alive throughout the calendar year (8.7 million person-years from 2006 through 2012) and an original data set of laws (e.g., prescription-drug monitoring programs), we examined the annual prevalence of beneficiaries with four or more opioid prescribers, prescriptions yielding a daily morphine-equivalent dose (MED) of more than 120 mg, and treatment for nonfatal prescription-opioid overdose. We estimated how opioid outcomes varied according to eight types of laws. RESULTS From 2006 through 2012, states added 81 controlled-substance laws. Opioid receipt and potentially hazardous prescription patterns were common. In 2012 alone, 47% of beneficiaries filled opioid prescriptions (25% in one to three calendar quarters and 22% in every calendar quarter); 8% had four or more opioid prescribers; 5% had prescriptions yielding a daily MED of more than 120 mg in any calendar quarter; and 0.3% were treated for a nonfatal prescription-opioid overdose. We observed no significant associations between opioid outcomes and specific types of laws or the number of types enacted. For example, the percentage of beneficiaries with a prescription yielding a daily MED of more than 120 mg did not decline after adoption of a prescription-drug monitoring program (0.27 percentage points; 95% confidence interval, -0.05 to 0.59). CONCLUSIONS Adoption of controlled-substance laws was not associated with reductions in potentially hazardous use of opioids or overdose among disabled Medicare beneficiaries, a population particularly at risk.	[Meara, Ellen; Powell, Wilson; Zhou, Weiping; O'Malley, A. James; Morden, Nancy E.] Dartmouth Inst Hlth Policy & Clin Practice, WTRB Level 5,1 Med Ctr Dr, Lebanon, NH 03756 USA; [Meara, Ellen; Horwitz, Jill R.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Horwitz, Jill R.; McClelland, Lynn] Univ Calif Los Angeles, Sch Law, Los Angeles, CA 90024 USA	Dartmouth College; National Bureau of Economic Research; University of California System; University of California Los Angeles	Meara, E (corresponding author), Dartmouth Inst Hlth Policy & Clin Practice, WTRB Level 5,1 Med Ctr Dr, Lebanon, NH 03756 USA.	ellen.r.meara@dartmouth.edu		Meara, Ellen/0000-0003-0211-1970	National Institute on Aging; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG019783, U01AG046830] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funded by the National Institute on Aging and others.	[Anonymous], 2002, PRESCR DRUGS STAT MO; [Anonymous], 2014, OP PAINK PRESCR YOU; [Anonymous], 2016, PREV PRESCR DRUG OV; [Anonymous], 2014, 2014 NASCSA SURV CON; [Anonymous], 2012, 2006 2011 RXHCC MOD; Arlotta C. J., 2015, FORBES; Bachhuber MA, 2014, JAMA INTERN MED, V174, P1668, DOI 10.1001/jamainternmed.2014.4005; Baehren DF, 2010, ANN EMERG MED, V56, P19, DOI 10.1016/j.annemergmed.2009.12.011; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Betses M, 2013, NEW ENGL J MED, V369, P989, DOI 10.1056/NEJMp1308222; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bonito AJ., 2008, AHRQ PUBLICATION; Braden JB, 2010, ARCH INTERN MED, V170, P1425, DOI 10.1001/archinternmed.2010.273; Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division of Unintentional Injury Prevention, 2012, PRESCR DRUG OV STAT; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Davis C. S., 2015, LEG INT RED OV MORT; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Franklin GM, 2005, AM J IND MED, V48, P91, DOI 10.1002/ajim.20191; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Haffajee RL, 2015, JAMA-J AM MED ASSOC, V313, P891, DOI 10.1001/jama.2014.18514; Jena AB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1393; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Kilby A., 2015, OPIOIDS MASSES WELFA; Larrick AK, 2014, REQUEST COMMENTS ENH; McDonald JH, 2015, HDB BIOL STAT, P254; Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183; National Alliance for Model State Drug Laws, 2014, STAT REQ PRESCR DISP; National Center for Health Statistics; Centers for Disease Control and Prevention; U. S Department of Health and Human Services, 2015, MULT CAUS DEATH 1999; Pacula RL, 2015, J POLICY ANAL MANAG, V34, P7, DOI 10.1002/pam.21804; Panis C, 2000, SSA PROGRAM DATA USE; Paulozzi LJ, 2015, MMWR SURVEILL SUMM, V64, P1, DOI 10.15585/mmwr.ss6409a1; Prescription Drug Monitoring Program Center of Excellence, 2014, PRESCR DRUG MON PROG; Reifler LM, 2012, PAIN MED, V13, P434, DOI 10.1111/j.1526-4637.2012.01327.x; Robst J, 2007, HEALTH CARE FINANC R, V28, P15; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931	39	156	156	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2016	375	1					44	53		10.1056/NEJMsa1514387	http://dx.doi.org/10.1056/NEJMsa1514387			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ1ZP	27332619	Green Accepted, Bronze			2023-01-03	WOS:000379000200004
J	Sarpatwari, A; Kesselheim, AS				Sarpatwari, Ameet; Kesselheim, Aaron S.			Navigating the Dermatological Drug Cost Curve	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								IMPORTANCE Physicians from many specialties as well as primary care prescribe dermatologic medications; as insurance formularies become increasingly restrictive and more patients are covered with high-deductible insurance plans, many patients are forced to pay high retail prices to obtain their medications. OBJECTIVES To determine the changes in the prices of commonly prescribed dermatologic medications since 2009 and to identify trends in price increases for different classes of drugs. DESIGN, SETTING, AND PARTICIPANTS Four national chain pharmacies received surveys requesting price data on commonly prescribed dermatologic drugs in 2009, 2011, 2014, and 2015. The initial survey requested information on 72 brand-name drugs. Subsequent surveys increased to eventually include 120 additional brand-name drugs and their generic alternatives when available. Owing to the frequency of prescription, diseases treated, or unusual price increases, 19 brand-name drugs surveyed in all 4 years were selected for final price trend analysis, which was conducted from August 1 to 15, 2015. MAIN OUTCOMES AND MEASURES Retail prices of topical and systemic drugs for the treatment of various dermatologic conditions. RESULTS Prices of surveyed brand-name drugs increased rapidly between 2009 and 2015. Of the 19 brand-name drugs analyzed, the retail prices of 7 drugs more than quadrupled during the study period. Among these 19 drugs, the mean price increase was 401% during the 6-year survey period, with the majority of the price increases occurring after 2011. Prices of topical antineoplastic drugs had the greatest mean absolute and percentage increase ($10 926.58 [1240%]). Prices of drugs in the antiinfective class had the smallest mean absolute increase ($333.99); prices of psoriasis medications had the smallest mean percentage increase (180%). Prices of acne and rosacea medications increased a mean of 195%, and prices of topical corticosteroids increased a mean of 290% during the study period. Selected generic drugs surveyed in 2011 and 2014 also increased a mean of 279% during the 3-year period. CONCLUSIONS AND RELEVANCE The price of prescription dermatologic drugs rose considerably from 2009 to 2015, with the vast majority of price increases occurring after 2011. Percent increases for multiple, frequently prescribed medications greatly outpaced inflation, national health expenditure growth, and increases in reimbursements for physician services.	Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sarpatwari, A (corresponding author), Brigham & Womens Hosp, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	asarpatwari@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Altman D., WASHINGTON POST; [Anonymous], PRESCR MED COST CONT; DiJulio B, KAISER HLTH TRACKING; Kirchoff SM, SPECIALTY DRUGS BACK; Peters JR, 2009, DERMATOL THER, V22, P229, DOI 10.1111/j.1529-8019.2009.01236.x; Rosenberg ME, 2016, JAMA DERMATOL, V152, P158, DOI 10.1001/jamadermatol.2015.3897; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Silverman E., WALL STREET J; US Food & Drug Administration, OR BOOK APPR DRUG PR	9	0	0	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2016	315	24					2724	2725		10.1001/jama.2016.3851	http://dx.doi.org/10.1001/jama.2016.3851			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP7WG	27367767				2023-01-03	WOS:000378709300023
J	Wenzel, M; Zahn, D; Rowland, Z; Kubiak, T				Wenzel, Mario; Zahn, Daniela; Rowland, Zarah; Kubiak, Thomas			The Benefits of Self-Set Goals: Is Ego Depletion Really a Result of Self-Control Failure?	PLOS ONE			English	Article							POSITIVE AFFECT; MODEL; RESOURCE; TASK	Research on ego depletion aims at explaining self-control failures in daily life. Both resource models and motivational accounts have been proposed for explanation. The aim of the present research was to test the different assumptions in two dual-task experiments where we operationalized ego depletion as a performance deviation from a self-set goal. In two experiments, we found evidence for this deviation contradicting motivational accounts of ego depletion: Participants experiencing ego depletion set themselves a stricter instead of a more lenient goal than controls, in that they chose to eat less cookies or wanted to perform better. Moreover, only participants without an initial self-control task could adhere to their self-set goal, whereas participants in the ego depletion condition in both experiments could not follow through with their more ambitious intentions. Taken together, our findings demonstrate the importance of goals in ego depletion research.	[Wenzel, Mario; Zahn, Daniela; Rowland, Zarah; Kubiak, Thomas] Johannes Gutenberg Univ Mainz, Inst Psychol, D-55122 Mainz, Germany	Johannes Gutenberg University of Mainz	Wenzel, M (corresponding author), Johannes Gutenberg Univ Mainz, Inst Psychol, D-55122 Mainz, Germany.	wenzelma@uni-mainz.de	Kubiak, Thomas/D-4655-2009	Kubiak, Thomas/0000-0003-0095-9265; Zahn, Daniela/0000-0002-0477-1369; Wenzel, Mario/0000-0003-2839-9482	Internal University Research Funding	Internal University Research Funding	The study was funded by the Internal University Research Funding (https://www.uni-mainz.de/forschung/140_ENG_HTML.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiken L. S., 1991, MULTIPLE REGRESSION; Baumeister RF, 2002, SELF IDENTITY, V1, P129, DOI 10.1080/152988602317319302; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bush G, 2003, MOL PSYCHIATR, V8, P60, DOI 10.1038/sj.mp.4001217; Carter EC, 2015, J EXP PSYCHOL GEN, V144, P796, DOI 10.1037/xge0000083; Carter EC, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00823; Carter EC, 2013, BEHAV BRAIN SCI, V36, P683, DOI 10.1017/S0140525X13000952; Converse PD, 2009, J APPL PSYCHOL, V94, P1318, DOI 10.1037/a0014604; Dewitte S, 2009, J CONSUM RES, V36, P394, DOI 10.1086/598615; Eisinga R, 2013, INT J PUBLIC HEALTH, V58, P637, DOI 10.1007/s00038-012-0416-3; Fishbach A, 2010, J EXP SOC PSYCHOL, V46, P29, DOI 10.1016/j.jesp.2009.09.008; Hagger M. S., 2016, PERSPECTIVE IN PRESS; Hagger MS, 2010, PSYCHOL BULL, V136, P495, DOI 10.1037/a0019486; Hofmann W, 2009, PERSPECT PSYCHOL SCI, V4, P162, DOI 10.1111/j.1745-6924.2009.01116.x; Huberts JCD, 2014, PERS SOC PSYCHOL REV, V18, P119, DOI 10.1177/1088868313507533; Inzlicht M, 2012, PERSPECT PSYCHOL SCI, V7, P450, DOI 10.1177/1745691612454134; Job V, 2010, PSYCHOL SCI, V21, P1686, DOI 10.1177/0956797610384745; Kurzban R, 2013, BEHAV BRAIN SCI, V36, P661, DOI 10.1017/S0140525X12003196; Moller AC, 2006, PERS SOC PSYCHOL B, V32, P1024, DOI 10.1177/0146167206288008; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Muraven M, 1998, J PERS SOC PSYCHOL, V74, P774, DOI 10.1037/0022-3514.74.3.774; Schmeichel BJ, 2010, J PERS SOC PSYCHOL, V99, P162, DOI 10.1037/a0019797; Shamosh NA, 2007, COGNITION EMOTION, V21, P1833, DOI 10.1080/02699930701273658; Wenzel M, 2014, COGNITION EMOTION, V28, P747, DOI 10.1080/02699931.2013.851069; Wenzel M, 2013, EUR J SOC PSYCHOL, V43, P175, DOI 10.1002/ejsp.1936	25	4	4	4	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0157009	10.1371/journal.pone.0157009	http://dx.doi.org/10.1371/journal.pone.0157009			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DO1TW	27280531	Green Published, gold, Green Submitted			2023-01-03	WOS:000377563000066
J	Frye, J; Youngner, SJ				Frye, John; Youngner, Stuart J.			A Call for a Patient-Centered Response to Legalized Assisted Dying	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SUICIDE		Case Western Reserve Univ, Dept Bioeth, Cleveland, OH 44106 USA; [Frye, John; Youngner, Stuart J.] Case Western Reserve Univ, Sch Med, Dept Bioeth, 10900 Euclid Ave,TA 200, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Youngner, SJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Bioeth, 10900 Euclid Ave,TA 200, Cleveland, OH 44106 USA.	sxy2@case.edu		Frye, John/0000-0002-7869-7181				[Anonymous], 2015, CAN APPR ASS DYING C; Campbell CS, 2010, HASTINGS CENT REP, V40, P26, DOI 10.1353/hcr.2010.0016; Canadian Medical Association, 2015, PRINC BAS REC CAN AP; Dobscha Steven K, 2004, J Palliat Med, V7, P451, DOI 10.1089/1096621041349374; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Quill TE, 2003, ANN INTERN MED, V138, P208, DOI 10.7326/0003-4819-138-3-200302040-00013	6	6	6	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2016	165	10					733	+		10.7326/M16-1319	http://dx.doi.org/10.7326/M16-1319			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EC2RB	27669333				2023-01-03	WOS:000387970500019
J	Barer, D				Barer, David			In ICH associated with antiplatelet therapy, platelet transfusion increased death or dependence	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Barer, David] Sunderland Royal Hosp, Sunderland, Tyne & Wear, England	Sunderland Royal Hospital	Barer, D (corresponding author), Sunderland Royal Hosp, Sunderland, Tyne & Wear, England.							Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Kumar A, 2015, TRANSFUSION, V55, P1116, DOI 10.1111/trf.12943	2	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2016	165	4					JC19	JC19		10.7326/ACPJC-2016-165-4-019	http://dx.doi.org/10.7326/ACPJC-2016-165-4-019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT1UI	27538180				2023-01-03	WOS:000381267200006
J	Cui, B; Feng, L; Wang, CX; Yang, DS; Yu, ML; Zeng, ZH; Wang, Y; Sun, CJ; Zhao, X; Cui, HX				Cui, Bo; Feng, Lei; Wang, Chunxin; Yang, Dongsheng; Yu, Manli; Zeng, Zhanghua; Wang, Yan; Sun, Changjiao; Zhao, Xiang; Cui, Haixin			Stability and Biological Activity Evaluation of Chlorantraniliprole Solid Nanodispersions Prepared by High Pressure Homogenization	PLOS ONE			English	Article							ORAL DELIVERY; DOSAGE FORMS; NANOSUSPENSIONS; FORMULATION; BIOAVAILABILITY; MICROEMULSION; DRUG; NANOCRYSTALS; NANOPARTICLES; NANOEMULSIONS	Poorly water-soluble compounds are difficult to develop as pesticide products and face great challenges in water-based and environmentally friendly formulation development. In this study, high pressure homogenization combined with lyophilization was adopted to prepare the solid nanodispersions of chlorantraniliprole with poor solubility and high melting point. The mean particle sizes of the solid nanodispersions with different pesticide contents were all less than 75 nm, even when the content was up to 91.5%. For the 2.5% chlorantraniliprole solid nanodispersion with the mean particle size of 29 nm, the suspensibility and wetting time in water were 97.32% and 13 s, respectively. The re-dispersibility and wettability were superior to those of conventional water dispersible granules. The retention on the rice leaf of 18.7 mg/cm(2) was 1.5 and 3 times that of commercial aqueous suspension concentrate and pure water. The bioassay result to diamondback moths indicated that the toxicity of the solid nanodispersion was 3.3 and 2.8 times that of technical and aqueous suspension concentrate, respectively. Moreover, the solid nanodispersion has the advantages of total avoidance of organic solvents, significant reduction of surfactants and feasibility of obtaining high concentration nanoformulations. The solid nanodispersion is an attractive candidate for improving pesticide solubility and efficacy, and its application in crop production will reduce both residues in food and environmental pollution of pesticide.	[Cui, Bo; Feng, Lei; Wang, Chunxin; Yang, Dongsheng; Yu, Manli; Zeng, Zhanghua; Wang, Yan; Sun, Changjiao; Zhao, Xiang; Cui, Haixin] Chinese Acad Agr Sci, Inst Environm & Sustainable Dev Agr, Beijing, Peoples R China	Chinese Academy of Agricultural Sciences; Institute of Environment & Sustainable Development in Agriculture, CAAS	Cui, HX (corresponding author), Chinese Acad Agr Sci, Inst Environm & Sustainable Dev Agr, Beijing, Peoples R China.	cuihaixin@caas.cn			Major National Scientific Research Program of China [2014CB932200]; Basic Scientific Research Foundation of National non-Profit Scientific Institute of China [BSRF201406]	Major National Scientific Research Program of China; Basic Scientific Research Foundation of National non-Profit Scientific Institute of China	This research was supported by Major National Scientific Research Program of China (No. 2014CB932200) and Basic Scientific Research Foundation of National non-Profit Scientific Institute of China (No. BSRF201406). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017; Acosta E, 2009, CURR OPIN COLLOID IN, V14, P3, DOI 10.1016/j.cocis.2008.01.002; Ali HSM, 2011, J CONTROL RELEASE, V149, P175, DOI 10.1016/j.jconrel.2010.10.007; Bernhard MJ, 2005, ENVIRON TOXICOL CHEM, V24, P1738, DOI 10.1897/04-234R.1; Cheong JN, 2008, J FOOD ENG, V89, P204, DOI 10.1016/j.jfoodeng.2008.04.018; Chin CP, 2012, IND ENG CHEM RES, V51, P4710, DOI 10.1021/ie201151p; Cordova D, 2006, PESTIC BIOCHEM PHYS, V84, P196, DOI 10.1016/j.pestbp.2005.07.005; Cowan-Ellsberry C, 2014, CRIT REV ENV SCI TEC, V44, P1893, DOI 10.1080/10739149.2013.803777; Cui B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135953; Dickinson E, 1997, J COLLOID INTERF SCI, V185, P515, DOI 10.1006/jcis.1996.4605; Dixit RP, 2010, J PHARM SCI-US, V99, P4892, DOI 10.1002/jps.22208; Dizaj SM, 2015, RES PHARM SCI, V10, P95; Dong LF, 2013, MOD AGR, V12, P14; Duan Q., 2009, AGROCHEMICALS, P252; Fu Q, 2013, COLLOID SURFACE B, V109, P161, DOI 10.1016/j.colsurfb.2013.01.066; George M, 2013, EUR J PHARM SCI, V48, P142, DOI 10.1016/j.ejps.2012.10.004; Hsieh CW, 2012, J OLEO SCI, V61, P483, DOI 10.5650/jos.61.483; Huang QR, 2010, J FOOD SCI, V75, pR50, DOI 10.1111/j.1750-3841.2009.01457.x; Jafari SM, 2008, FOOD HYDROCOLLOID, V22, P1191, DOI 10.1016/j.foodhyd.2007.09.006; Kakran M, 2012, EUR J PHARM BIOPHARM, V80, P113, DOI 10.1016/j.ejpb.2011.08.006; Kanaujia P, 2015, POWDER TECHNOL, V285, P2, DOI 10.1016/j.powtec.2015.05.012; Karadag A, 2014, J AGR FOOD CHEM, V62, P1852, DOI 10.1021/jf404065p; Kawakami K, 2012, ADV DRUG DELIVER REV, V64, P480, DOI 10.1016/j.addr.2011.10.009; Khalil HPSA, 2014, CARBOHYD POLYM, V99, P649, DOI 10.1016/j.carbpol.2013.08.069; Kipp JE, 2004, INT J PHARMACEUT, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019; Knowles Alan, 2008, Environmentalist, V28, P35, DOI 10.1007/s10669-007-9045-4; Kocbek P, 2006, INT J PHARMACEUT, V312, P179, DOI 10.1016/j.ijpharm.2006.01.008; Lahm GP, 2007, BIOORG MED CHEM LETT, V17, P6274, DOI 10.1016/j.bmcl.2007.09.012; Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X; Levai G, 2015, J SUPERCRIT FLUID, V100, P34, DOI 10.1016/j.supflu.2015.02.019; [李慧 Li Hui], 2012, [应用化学, Chinese Journal of Applied Chemistry], V29, P327; Li P, 2009, J PHARM SCI-US, V98, P1750, DOI 10.1002/jps.21547; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; [刘盼西 Liu Panxi], 2014, [农药学学报, Chinese Journal of Pesticide Science], V16, P206; Malhat F, 2012, B ENVIRON CONTAM TOX, V88, P349, DOI 10.1007/s00128-011-0465-y; McClements DJ, 2010, ADV COLLOID INTERFAC, V159, P213, DOI 10.1016/j.cis.2010.06.010; Mishra PR, 2009, INT J PHARMACEUT, V371, P182, DOI 10.1016/j.ijpharm.2008.12.030; Mitri K, 2011, INT J PHARMACEUT, V420, P141, DOI 10.1016/j.ijpharm.2011.08.026; Moschwitzer J, 2004, EUR J PHARM BIOPHARM, V58, P615, DOI 10.1016/j.ejpb.2004.03.022; Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6; Pan BL, 2009, VET PARASITOL, V164, P353, DOI 10.1016/j.vetpar.2009.05.030; Pluciennik Zofia, 2012, Journal of Fruit and Ornamental Plant Research, V20, P85, DOI 10.2478/v10290-012-0018-4; Pu XH, 2009, INT J PHARMACEUT, V379, P167, DOI 10.1016/j.ijpharm.2009.05.062; Qian L, 2005, ENV OCCUP MED, V22, P167; Roach A, 2008, INNOV FOOD SCI EMERG, V9, P1, DOI 10.1016/j.ifset.2007.03.027; Salazar J, 2011, INT J PHARMACEUT, V420, P395, DOI 10.1016/j.ijpharm.2011.09.003; Santiago LG, 2002, BRAZ J CHEM ENG, V19, P411, DOI 10.1590/S0104-66322002000400009; Shen LN, 2012, EXPLORATION ENG, V39, P78; Silva HD, 2012, FOOD BIOPROCESS TECH, V5, P854, DOI 10.1007/s11947-011-0683-7; Tanpradit N, 2015, THERIOGENOLOGY, V83, P1553, DOI 10.1016/j.theriogenology.2015.01.035; Tubesha Z, 2013, J NANOMATER, V2013, DOI 10.1155/2013/453290; Verma S, 2009, INT J PHARMACEUT, V380, P216, DOI 10.1016/j.ijpharm.2009.07.005; Wakil W, 2012, CHIL J AGR RES, V72, P53, DOI 10.4067/S0718-58392012000100009; Wang YF, 2014, J SCI FOOD AGR, V94, P1000, DOI 10.1002/jsfa.6360; Ye R, 2014, FOOD HYDROCOLLOID, V35, P670, DOI 10.1016/j.foodhyd.2013.08.022; Yuan H., 2000, CHINESE J PESTIC SCI, V2, P66, DOI DOI 10.3321/J.ISSN:1008-7303.2000.04.012; Zeng H, 2008, J DISPER SCI TECHNOL, V29, P358, DOI 10.1080/01932690701716085; Zhang H, 2011, INT J PHARMACEUT, V415, P293, DOI 10.1016/j.ijpharm.2011.05.075; [张鹏 Zhang Peng], 2013, [植物保护, Plant Protection], V39, P89; Zhang XG, 2011, J AGR FOOD CHEM, V59, P1308, DOI 10.1021/jf1034459; [张子勇 Zhang Ziyong], 2015, [农药, Agrochemicals], V54, P91; Zhuang ZX, 2009, CHEM J CHINESE U, V30, P332	62	18	22	3	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2016	11	8							e0160877	10.1371/journal.pone.0160877	http://dx.doi.org/10.1371/journal.pone.0160877			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3IE	27500828	gold, Green Submitted, Green Published			2023-01-03	WOS:000381373500061
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: NHS continuing care is a mess	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Appleby J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1563; Barker K., 2014, NEW SETTLEMENT HLTH; *COMM FUND CAR SUP, 2011, SUMM RESP CALL EV; *DEP HLTH, 2007, FRAM ASS NHS CONT HE; *DEP HLTH, 2012, NAT FRAM NHS FUND CO; HAYWARD C, 2014, BBC NEWS; McNicoll A., 2013, COMMUNITY CARE; *NHS BENCHM, 2015, OLD PEOPL AC CAR SET; *NHS ENGL, 2015, MONTH DEL TRANS CAR; POWELL T, 2014, SOCIAL POLICY NOTE S; Thompson J., 2015, DELAYED TRANSFERS CA; 2015, INDEPENDENT AGE FACT	12	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 5	2016	354								i4214	10.1136/bmj.i4214	http://dx.doi.org/10.1136/bmj.i4214			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS9DD	27495806	Bronze, Green Published			2023-01-03	WOS:000381081800001
J	Jay, JJ; Brouwer, C				Jay, Jeremy J.; Brouwer, Cory			Lollipops in the Clinic: Information Dense Mutation Plots for Precision Medicine	PLOS ONE			English	Article							CANCER	Introduction Concise visualization is critical to present large amounts of information in a minimal space that can be interpreted quickly. Clinical applications in precision medicine present an important use case due to the time dependent nature of the interpretations, although visualization is increasingly necessary across the life sciences. In this paper we describe the Lollipops software for the presentation of panel or exome sequencing results. Source code and binaries are freely available at https://github.com/pbnjay/lollipops. Although other software and web resources exist to produce lollipop diagrams, these packages are less suited to clinical applications. The demands of precision medicine require the ability to easily fit into a workflow and incorporate external information without manual intervention. Results The Lollipops software provides a simple command line interface that only requires an official gene symbol and mutation list making it easily scriptable. External information is integrated using the publicly available Uniprot and Pfam resources. Heuristics are used to select the most informative components and condense them for a concise plot. The output is a flexible Scalable Vector Graphic (SVG) diagram that can be displayed in a web page or graphic illustration tool. Conclusion The Lollipops software creates information-dense, publication-quality mutation plots for automated pipelines and high-throughput workflows in precision medicine. The automatic data integration enables clinical data security, and visualization heuristics concisely present knowledge with minimal user configuration.	[Jay, Jeremy J.; Brouwer, Cory] Bioinformat Serv Div, North Carolina Res Campus, Kannapolis, NC 28081 USA; [Jay, Jeremy J.; Brouwer, Cory] Univ N Carolina, Bioinformat & Genom Dept, Charlotte, NC 28223 USA	University of North Carolina; University of North Carolina Charlotte	Jay, JJ (corresponding author), Bioinformat Serv Div, North Carolina Res Campus, Kannapolis, NC 28081 USA.; Jay, JJ (corresponding author), Univ N Carolina, Bioinformat & Genom Dept, Charlotte, NC 28223 USA.	jeremy.jay@uncc.edu	Jay, Jeremy/AAV-5143-2020	Jay, Jeremy/0000-0002-5761-7533				Aksoy BA, 2014, BIOINFORMATICS, V30, P2051, DOI 10.1093/bioinformatics/btu164; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989; Bauer DT, 2010, J AM MED INFORM ASSN, V17, P416, DOI 10.1136/jamia.2009.000505; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Hawkins Robert C, 2007, Clin Biochem Rev, V28, P179; Ou J, 2016, TRACKVIEWER BIOCONDU; Schroeder MP, 2015, MUTS NEEDLE PLOT MUT; Turner Tychele, 2013, J Clin Bioinforma, V3, P14, DOI 10.1186/2043-9113-3-14	10	72	72	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2016	11	8							e0160519	10.1371/journal.pone.0160519	http://dx.doi.org/10.1371/journal.pone.0160519			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3GL	27490490	gold, Green Published, Green Submitted			2023-01-03	WOS:000381368900064
J	Matos, M; Marefati, A; Gutierrez, G; Wahlgren, M; Rayner, M				Matos, Maria; Marefati, Ali; Gutierrez, Gemma; Wahlgren, Marie; Rayner, Marilyn			Comparative Emulsifying Properties of Octenyl Succinic Anhydride (OSA)-Modified Starch: Granular Form vs Dissolved State	PLOS ONE			English	Article							PICKERING-TYPE EMULSIONS; PARTICLES; FOOD; RETROGRADATION; EMULSIFICATION; RESVERATROL; GELATINIZATION; STABILIZATION; NANOPARTICLES; AMYLOPECTIN	The emulsifying ability of OSA-modified and native starch in the granular form, in the dissolved state and a combination of both was compared. This study aims to understand mixed systems of particles and dissolved starch with respect to what species dominates at droplet interfaces and how stability is affected by addition of one of the species to already formed emulsions. It was possible to create emulsions with OSA-modified starch isolated from Quinoa as sole emulsifier. Similar droplet sizes were obtained with emulsions prepared at 7% (w/w) oil content using OSA-modified starch in the granular form or molecularly dissolved but large differences were observed regarding stability. Pickering emulsions kept their droplet size constant after one month while emulsions formulated with OSA-modified starch dissolved exhibited coalescence. All emulsions stabilized combining OSA-modified starch in granular form and in solution showed larger mean droplet sizes with no significant differences with respect to the order of addition. These emulsions were unstable due to coalescence regarding presence of free oil. Similar results were obtained when emulsions were prepared by combining OSA-modified granules with native starch in solution. The degree of surface coverage of starch granules was much lower in presence of starch in solution which indicates that OSA-starch is more surface active in the dissolved state than in granular form, although it led to unstable systems compared to starch granule stabilized Pickering emulsions, which demonstrated to be extremely stable.	[Matos, Maria; Marefati, Ali; Wahlgren, Marie; Rayner, Marilyn] Lund Univ, Dept Food Technol Engn & Nutr, POB 124, SE-22100 Lund, Sweden; [Matos, Maria; Gutierrez, Gemma] Univ Oviedo, Dept Chem & Environm Engn, Julian Claveria 8, E-33006 Oviedo, Spain	Lund University; University of Oviedo	Rayner, M (corresponding author), Lund Univ, Dept Food Technol Engn & Nutr, POB 124, SE-22100 Lund, Sweden.	marilyn.rayner@food.lth.se	Rayner, Marilyn D/B-2679-2017; MAREFATI, ALI/AAC-1876-2019	Rayner, Marilyn D/0000-0001-6338-7124; MAREFATI, ALI/0000-0002-6288-7052; Gutierrez, Gemma/0000-0003-2700-4944; Wahlgren, Marie/0000-0002-1705-3964; Maria, Matos/0000-0002-6980-0554	Crafoord Foundation [20140816]; Vinnova-the Swedish Innovation Agency [2014-0587]; Department of Food Technology, Engineering, and Nutrition of Lund University	Crafoord Foundation; Vinnova-the Swedish Innovation Agency(Vinnova); Department of Food Technology, Engineering, and Nutrition of Lund University	The study was supported by the Crafoord Foundation through the call Research Grants 2014 (Ref. 20140816) to MM, MW, and MR; Vinnova-the Swedish Innovation Agency through the Planning Grant Fall 2014 Marie Curie Incoming (Ref. 2014-0587) to MM, MW, and MR; and Department of Food Technology, Engineering, and Nutrition of Lund University to MM and MW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aberle T, 1997, STARCH-STARKE, V49, P215, DOI 10.1002/star.19970490602; Aveyard R, 2003, ADV COLLOID INTERFAC, V100, P503, DOI 10.1016/S0001-8686(02)00069-6; Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0; Chevalier Y, 2013, COLLOID SURFACE A, V439, P23, DOI 10.1016/j.colsurfa.2013.02.054; Dickinson E, 2012, TRENDS FOOD SCI TECH, V24, P4, DOI 10.1016/j.tifs.2011.09.006; FEIGIN RI, 1980, J COLLOID INTERF SCI, V75, P525, DOI 10.1016/0021-9797(80)90475-0; Fredriksson H, 1998, CARBOHYD POLYM, V35, P119, DOI 10.1016/S0144-8617(97)00247-6; GUDMUNDSSON M, 1994, THERMOCHIM ACTA, V246, P329, DOI 10.1016/0040-6031(94)80100-2; Huck-Iriarta C, 2001, PROCEDIA FOOD SCI, V1, P116; Kargar M, 2012, J COLLOID INTERF SCI, V366, P209, DOI 10.1016/j.jcis.2011.09.073; KLEIN J, 1984, NATURE, V308, P836, DOI 10.1038/308836a0; Li C, 2012, STARCH-STARKE, V64, P497, DOI 10.1002/star.201100178; Marefati A, 2015, FOOD HYDROCOLLOID, V51, P261, DOI 10.1016/j.foodhyd.2015.04.022; Marefati A, 2013, COLLOID SURFACE A, V436, P512, DOI 10.1016/j.colsurfa.2013.07.015; Marku D, 2012, INT J PHARMACEUT, V428, P1, DOI 10.1016/j.ijpharm.2012.01.031; Matos M, 2015, J FOOD ENG, V166, P212, DOI 10.1016/j.jfoodeng.2015.06.002; Matos M, 2015, FOOD HYDROCOLLOID, V49, P156, DOI 10.1016/j.foodhyd.2015.03.021; Matos M, 2014, COLLOID SURFACE A, V442, P69, DOI 10.1016/j.colsurfa.2013.05.065; Matos M, 2013, COLLOID SURFACE A, V423, P147, DOI 10.1016/j.colsurfa.2013.01.060; Matos M, 2012, TRIBOL T, V55, P685, DOI 10.1080/10402004.2012.694580; Nilsson L, 2007, J AGR FOOD CHEM, V55, P1469, DOI 10.1021/jf062087z; Nilsson L, 2006, LANGMUIR, V22, P8770, DOI 10.1021/la060870f; Ortega-Ojeda FE, 2001, STARCH-STARKE, V53, P520, DOI 10.1002/1521-379X(200110)53:10<520::AID-STAR520>3.0.CO;2-D; Pando D, 2013, J FOOD ENG, V117, P227, DOI 10.1016/j.jfoodeng.2013.02.020; Perez-Rea D, 2015, ANAL BIOANAL CHEM, P8894; Perez-Rea D, 2015, ANAL BIOANAL CHEM, V407, P4315, DOI 10.1007/s00216-015-8611-8; Pickering SU, 1907, J CHEM SOC, V91, P2001, DOI 10.1039/ct9079102001; Ramsden W, 1903, P R SOC LONDON, V72, P156, DOI 10.1098/rspl.1903.0034; Rayner M, 2014, COLLOID SURFACE A, V458, P48, DOI 10.1016/j.colsurfa.2014.03.053; Rayner M, 2012, FARADAY DISCUSS, V158, P139, DOI 10.1039/c2fd20038d; Rayner M, 2012, J SCI FOOD AGR, V92, P1841, DOI 10.1002/jsfa.5610; Stainsby G., 1897, ADV FOOD EMULSIONS F; Timgren A, 2013, FOOD SCI NUTR, V1, P157, DOI 10.1002/fsn3.17; Timgren A, 2011, PROC FOOD SCI, V1, P95, DOI 10.1016/j.profoo.2011.09.016; Vorwerg W, 2002, CARBOHYD POLYM, V47, P181, DOI 10.1016/S0144-8617(01)00164-3; Wahlgren M, 2013, CURR PHARM BIOTECHNO, V14, P1222	36	34	36	5	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2016	11	8							e0160140	10.1371/journal.pone.0160140	http://dx.doi.org/10.1371/journal.pone.0160140			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS9NO	27479315	Green Submitted, Green Published, gold			2023-01-03	WOS:000381110300026
J	Krakauer, EL; Rajagopal, MR				Krakauer, Eric L.; Rajagopal, M. R.			End-of-life care across the world: a global moral failing	LANCET			English	Editorial Material									[Krakauer, Eric L.] Harvard Med Sch, Ctr Palliat Care, Boston, MA 02115 USA; [Krakauer, Eric L.] Massachusetts Gen Hosp, Div Palliat Care, Boston, MA 02114 USA; [Rajagopal, M. R.] WHO Collaborating Ctr Training & Policy Access Pa, Pallium India, Thiruvananthapuram, Kerala, India	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Krakauer, EL (corresponding author), Harvard Med Sch, Ctr Palliat Care, Boston, MA 02115 USA.; Krakauer, EL (corresponding author), Massachusetts Gen Hosp, Div Palliat Care, Boston, MA 02114 USA.	eric_krakauer@hms.harvard.edu						Chalkidou K, 2014, LANCET ONCOL, V15, pE119, DOI 10.1016/S1470-2045(13)70547-3; DesRosiers T, 2014, J PAIN SYMPTOM MANAG, V47, P786, DOI 10.1016/j.jpainsymman.2013.05.021; Economist Intelligence Unit, 2015, 2015 QUAL DEATH IND; Economist Intelligence Unit, 2010, 2010 QUAL DEATH IND; Gomez-Batiste X, 2012, J PAIN SYMPTOM MANAG, V43, P783, DOI 10.1016/j.jpainsymman.2011.05.006; Krakauer EL, 2007, SUBJECTIVITY ETHNOGR; Krakauer EL, 2008, J PAIN SYMPTOM MANAG, V36, P505, DOI 10.1016/j.jpainsymman.2007.11.015; WHO, DEF PALL CAR; World Health Organization, 2014, GLOBAL ATLAS PALLIAT	9	4	4	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	2016	388	10043					444	446						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DS2EK	27507744				2023-01-03	WOS:000380559400007
J	Petersen, RY; Royse, E; Kemp, MW; Miura, Y; Noe, A; Jobe, AH; Hillman, NH				Petersen, Rebecca Y.; Royse, Emily; Kemp, Matthew W.; Miura, Yuichiro; Noe, Andres; Jobe, Alan H.; Hillman, Noah H.			Distending Pressure Did Not Activate Acute Phase or Inflammatory Responses in the Airways and Lungs of Fetal, Preterm Lambs	PLOS ONE			English	Article							SUSTAINED INFLATION; MECHANICAL VENTILATION; 1ST INFLATION; TIDAL VOLUME; INJURY; BIRTH; SURFACTANT; RESUSCITATION; PULMONARY; ENDOTOXIN	Background Mechanical ventilation at birth causes airway injury and lung inflammation in preterm sheep. Continuous positive airway pressure (CPAP) is being increasingly used clinically to transition preterm infants at birth. Objective To test if distending pressures will activate acute phase reactants and inflammatory changes in the airways of fetal, preterm lambs. Methods The head and chest of fetal lambs at 128 +/- 1 day GA were surgically exteriorized. With placental circulation intact, fetal lambs were then randomized to one of five 15 minute interventions: PEEP of 0, 4, 8, 12, or 16 cmH(2)O. Recruitment volumes were recorded. Fetal lambs remained on placental support for 30 min after the intervention. The twins of each 0 cmH(2)O animal served as controls. Fetal lung fluid (FLF), bronchoalveolar lavage fluid (BAL), right mainstem bronchi and peripheral lung tissue were evaluated for inflammation. Results Recruitment volume increased from 0.4 +/- 0.04 mL/kg at 4 cmH(2)O to 2.4 +/- 0.3 mL/kg at 16 cmH(2)O. The lambs were surfactant deficient, and all pressures were below the opening inflection pressure on pressure-volume curve. mRNA expression of early response genes and pro-inflammatory cytokines did not increase in airway tissue or lung tissue at any pressure compared to controls. FLF and BAL also did not have increases in early response proteins. No histologic changes or Egr-1 activation was present at the pressures used. Conclusion Distending pressures as high as 16 cmH(2)O did not recruit lung volume at birth and did not increase markers of injury in the lung or airways in non-breathing preterm fetal sheep.	[Petersen, Rebecca Y.; Royse, Emily; Hillman, Noah H.] St Louis Univ, Div Neonatol, Cardinal Glennon Childrens Hosp, St Louis, MO 63104 USA; [Jobe, Alan H.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; [Kemp, Matthew W.; Miura, Yuichiro; Noe, Andres; Jobe, Alan H.] Univ Western Australia, Sch Women & Infants Hlth, Perth, WA 6009, Australia	Saint Louis University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Western Australia	Hillman, NH (corresponding author), St Louis Univ, Div Neonatol, Cardinal Glennon Childrens Hosp, St Louis, MO 63104 USA.	Hillman@slu.edu	Noé, Andrés/AAU-9612-2020; Miura, Yuichiro/M-3838-2013	Noé, Andrés/0000-0002-6408-7032; Miura, Yuichiro/0000-0002-6693-4119	National Heart, Lung, and Blood Institute [K08-HL097085]; National Institute of Child Health and Human Development [R01-HD072842]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the National Heart, Lung, and Blood Institute, grant K08-HL097085 to NHH and by the National Institute of Child Health and Human Development, grant R01-HD072842 to AHJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjorklund LJ, 1997, PEDIATR RES, V42, P348; CARLTON DP, 1990, J APPL PHYSIOL, V69, P577, DOI 10.1152/jappl.1990.69.2.577; Cheah FC, 2009, AM J PHYSIOL-LUNG C, V296, pL384, DOI 10.1152/ajplung.90547.2008; Chong EM, 2009, PEDIATR RES, V65, P387, DOI 10.1203/PDR.0b013e31819913f5; Cullen AB, 2006, BIOL NEONATE, V90, P17, DOI 10.1159/000091742; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; Fawke J, 2010, AM J RESP CRIT CARE, V182, P237, DOI 10.1164/rccm.200912-1806OC; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Fischer HS, 2013, PEDIATRICS, V132, pE1351, DOI 10.1542/peds.2013-1880; HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; Hillman NH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113473; Hillman NH, 2013, AM J PHYSIOL-LUNG C, V305, pL446, DOI 10.1152/ajplung.00162.2013; Hillman NH, 2012, PEDIATR RES, V72, P593, DOI 10.1038/pr.2012.135; Hillman Noah H, 2012, Clin Perinatol, V39, P769, DOI 10.1016/j.clp.2012.09.009; Hillman NH, 2011, AM J PHYSIOL-LUNG C, V301, pL712, DOI 10.1152/ajplung.00157.2011; Hillman NH, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-124; Hillman NH, 2010, PEDIATR RES, V67, P60, DOI 10.1203/PDR.0b013e3181c1b09e; Hooper SB, 2007, FASEB J, V21, P3329, DOI 10.1096/fj.07-8208com; Jobe AH, 2000, AM J RESP CRIT CARE, V162, P1656, DOI 10.1164/ajrccm.162.5.2003044; Jobe AH, 2008, NEONATOLOGY, V94, P190, DOI 10.1159/000143721; Kallapur SG, 2009, AM J RESP CRIT CARE, V179, P955, DOI 10.1164/rccm.200811-1728OC; Kattwinkel J, 2010, PEDIATRICS, V126, pE1400, DOI 10.1542/peds.2010-2972E; Kramer BW, 2005, AM J RESP CRIT CARE, V171, P73, DOI 10.1164/rccm.200406-745OC; Kramer BW, 2001, AM J RESP CRIT CARE, V164, P982, DOI 10.1164/ajrccm.164.6.2103061; Lista G, 2012, J MATERN-FETAL NEO M, V25, P63, DOI 10.3109/14767058.2012.715008; Lista G, 2011, NEONATOLOGY, V99, P45, DOI 10.1159/000298312; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLean JE, 2016, THORAX, V71, P1012, DOI 10.1136/thoraxjnl-2015-207736; Monkman Shelley, 2003, Paediatr Respir Rev, V4, P15, DOI 10.1016/S1526-0542(02)00312-3; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Mosca F, 2004, J Matern Fetal Neonatal Med, V16 Suppl 2, P17, DOI 10.1080/14767050410001727125; Naik AS, 2001, AM J RESP CRIT CARE, V164, P494, DOI 10.1164/ajrccm.164.3.2010127; Polglase GR, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-43; Polglase GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039535; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Stoll BJ, 2015, JAMA-J AM MED ASSOC, V314, P1039, DOI 10.1001/jama.2015.10244; Tingay DG, 2016, PEDIATR RES, V79, P916, DOI 10.1038/pr.2016.25; Tingay DG, 2016, AM J RESP CELL MOL, V54, P263, DOI 10.1165/rcmb.2015-0127OC; Tingay DG, 2015, AM J PHYSIOL-LUNG C, V309, pL1138, DOI 10.1152/ajplung.00277.2015; Tingay DG, 2015, J APPL PHYSIOL, V118, P890, DOI 10.1152/japplphysiol.00985.2014; Tingay DG, 2014, J APPL PHYSIOL, V116, P251, DOI 10.1152/japplphysiol.01142.2013; VYAS H, 1981, J PEDIATR-US, V99, P787, DOI 10.1016/S0022-3476(81)80412-X	44	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2016	11	7							e0159754	10.1371/journal.pone.0159754	http://dx.doi.org/10.1371/journal.pone.0159754			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IJ	27463520	Green Published, gold, Green Submitted			2023-01-03	WOS:000381515900050
J	Park, EY; Kim, EH; Kim, CY; Kim, MH; Choung, JS; Oh, YS; Moon, HS; Jun, HS				Park, Eun-Young; Kim, Eung-Hwi; Kim, Chul-Young; Kim, Mi-Hwi; Choung, Jin-Seung; Oh, Yoon-Sin; Moon, Hong-Sub; Jun, Hee-Sook			Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119	PLOS ONE			English	Article							PROTEIN-COUPLED RECEPTOR; GLYCEMIC CONTROL; TYPE-2; AGONISTS; FURANOCOUMARINS; PATHOGENESIS; ROOTS	G protein-coupled receptor (GPR) 119 is expressed in pancreatic beta-cells and intestinal L cells, and is involved in glucose-stimulated insulin secretion and glucagon-like peptide-1 (GLP-1) release, respectively. Therefore, the development of GPR119 agonists is a potential treatment for type 2 diabetes. We screened 1500 natural plant extracts for GPR119 agonistic actions and investigated the most promising extract, that from Angelica dahurica (AD), for hypoglycemic actions in vitro and in vivo. Human GPR119 activation was measured in GeneBLAzer T-Rex GPR119-CRE-bla CHO-K1 cells; intracellular cAMP levels and insulin secretion were measured in INS-1 cells; and GLP-1 release was measured in GLUTag cells. Glucose tolerance tests and serum plasma insulin levels were measured in normal C57BL6 mice and diabetic db/db mice. AD extract-treated cells showed significant increases in GPR119 activation, intracellular cAMP levels, GLP-1 levels and glucose-stimulated insulin secretion as compared with controls. In normal mice, a single treatment with AD extract improved glucose tolerance and increased insulin secretion. Treatment with multiple doses of AD extract or n-hexane fraction improved glucose tolerance in diabetic db/db mice. Imperatorin, phellopterin and isoimperatorin were identified in the active fraction of AD extract. Among these, phellopterin activated GPR119 and increased active GLP-1 and insulin secretion in vitro and enhanced glucose tolerance in normal and db/db mice. We suggest that phellopterin might have a therapeutic potential for the treatment of type 2 diabetes.	[Park, Eun-Young; Moon, Hong-Sub] Mokpo Natl Univ, Coll Pharm, Muan Gun 534729, Jeonnam, South Korea; [Kim, Eung-Hwi; Kim, Mi-Hwi; Choung, Jin-Seung; Oh, Yoon-Sin; Jun, Hee-Sook] Gachon Univ, Lee Gil Ya Canc & Diabet Inst, 7-45 Songdo Dong, Inchon 406840, South Korea; [Kim, Chul-Young] Hanyang Univ, Coll Pharm, Ansan 426791, Kyeonggi, South Korea; [Oh, Yoon-Sin; Jun, Hee-Sook] Gil Hosp, Gachon Med Res Inst, Inchon, South Korea; [Jun, Hee-Sook] Gachon Univ, Coll Pharm, 7-45 Songdo Dong, Inchon 406840, South Korea; [Jun, Hee-Sook] Gachon Univ, Gachon Inst Pharmaceut Sci, 7-45 Songdo Dong, Inchon 406840, South Korea	Mokpo National University; Gachon University; Hanyang University; Gachon University; Gachon University; Gachon University	Jun, HS (corresponding author), Gachon Univ, Lee Gil Ya Canc & Diabet Inst, 7-45 Songdo Dong, Inchon 406840, South Korea.; Jun, HS (corresponding author), Gil Hosp, Gachon Med Res Inst, Inchon, South Korea.; Jun, HS (corresponding author), Gachon Univ, Coll Pharm, 7-45 Songdo Dong, Inchon 406840, South Korea.; Jun, HS (corresponding author), Gachon Univ, Gachon Inst Pharmaceut Sci, 7-45 Songdo Dong, Inchon 406840, South Korea.	hsjun@gachon.ac.kr	오, 윤신/AAS-2225-2020	Jun, Hee-Sook/0000-0002-1166-4932; Oh, Yoon Sin/0000-0003-3995-4429	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI12C1564]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI12C1564).	Amer Diabet Assoc, 2009, DIABETES CARE, V32, pS13, DOI 10.2337/dc09-S013; Ban HS, 2003, PLANTA MED, V69, P408, DOI 10.1055/s-2003-39702; Chu ZL, 2008, ENDOCRINOLOGY, V149, P2038, DOI 10.1210/en.2007-0966; Chu ZL, 2007, ENDOCRINOLOGY, V148, P2601, DOI 10.1210/en.2006-1608; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Fyfe MCT, 2008, EXPERT OPIN DRUG DIS, V3, P403, DOI 10.1517/17460441.3.4.403; Jones RM, 2009, EXPERT OPIN THER PAT, V19, P1339, DOI 10.1517/13543770903153878; KIM C M, 1991, Archives of Pharmacal Research (Seoul), V14, P87, DOI 10.1007/BF02857821; Kim YK, 2007, PHYTOTHER RES, V21, P288, DOI 10.1002/ptr.2043; Lechner D, 2004, PHYTOCHEMISTRY, V65, P331, DOI 10.1016/j.phytochem.2003.11.010; Liu DP, 2011, MOLECULES, V16, P6339, DOI 10.3390/molecules16086339; Ohishi T, 2012, EXPERT OPIN INV DRUG, V21, P321, DOI 10.1517/13543784.2012.657797; Overton HA, 2008, BRIT J PHARMACOL, V153, pS76, DOI 10.1038/sj.bjp.0707529; Overton HA, 2006, CELL METAB, V3, P167, DOI 10.1016/j.cmet.2006.02.004; Prokopenko I, 2008, TRENDS GENET, V24, P613, DOI 10.1016/j.tig.2008.09.004; Russell-Jones D, 2012, CLIN ENDOCRINOL, V77, P489, DOI 10.1111/j.1365-2265.2012.04483.x; Seo WD, 2013, J FUNCT FOODS, V5, P1421, DOI 10.1016/j.jff.2013.05.011; Shalaby NMM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/480545; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; TAYLOR SI, 1994, DIABETES, V43, P735, DOI 10.2337/diab.43.6.735; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038; Zhang M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063861	23	20	20	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158796	10.1371/journal.pone.0158796	http://dx.doi.org/10.1371/journal.pone.0158796			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27391814	gold, Green Submitted, Green Published			2023-01-03	WOS:000380005400125
J	Shahabuddin, ASM; Nostlinger, C; Delvaux, T; Sarker, M; Bardaji, A; De Brouwere, V; Broerse, JEW				Shahabuddin, A. S. M.; Nostlinger, Christiana; Delvaux, Therese; Sarker, Malabika; Bardaji, Azucena; De Brouwere, Vincent; Broerse, Jacqueline E. W.			What Influences Adolescent Girls' Decision-Making Regarding Contraceptive Methods Use and Childbearing? A Qualitative Exploratory Study in Rangpur District, Bangladesh	PLOS ONE			English	Article							TEENAGE PREGNANCY; RURAL BANGLADESH; OUTCOMES; MOTHERS; WOMEN; MATTER	Background Bangladesh has the highest rate of adolescent pregnancy in South Asia. Child marriage is one of the leading causes of pregnancies among adolescent girls. Although the country's contraceptive prevalence rate is quite satisfactory, only 52% of married adolescent girls use contraceptive methods. This qualitative study is aimed at exploring the factors that influence adolescent girls' decision-making process in relation to contraceptive methods use and childbearing. Methods and Results We collected qualitative data from study participants living in Rangpur district, Bangladesh. We conducted 35 in-depth interviews with married adolescent girls, 4 key informant interviews, and one focus group discussion with community health workers. Adolescent girls showed very low decision-making autonomy towards contraceptive methods use and childbearing. Decisions were mainly made by either their husbands or mothers-in-law. When husbands were unemployed and financially dependent on their parents, then the mothers-in-law played most important role for contraceptive use and childbearing decisions. Lack of reproductive health knowledge, lack of negotiation and communication ability with husbands and family members, and mistrust towards contraceptive methods also appeared as influential factors against using contraception resulting in early childbearing among married adolescent girls. Conclusions Husbands and mothers-in-law of newly married adolescent girls need to be actively involved in health interventions so that they make more informed decisions regarding contraceptive use to delay pregnancies until 20 years of age. Misunderstanding and distrust regarding contraceptives can be diminished by engaging the wider societal actors in health intervention including neighbours, and other family members.	[Shahabuddin, A. S. M.; Delvaux, Therese; De Brouwere, Vincent] Inst Trop Med, Dept Publ Hlth, Woman & Child Hlth Res Ctr, B-2000 Antwerp, Belgium; [Nostlinger, Christiana] Inst Trop Med, Unit HIV AIDS Policy, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Sarker, Malabika] BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh; [Shahabuddin, A. S. M.; Bardaji, Azucena] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain; [Shahabuddin, A. S. M.; Broerse, Jacqueline E. W.] Vrije Univ Amsterdam, Athena Inst Res Innovat & Commun Hlth & Life Sci, Amsterdam, Netherlands	Institute of Tropical Medicine (ITM); Institute of Tropical Medicine (ITM); Bangladesh Rural Advancement Committee BRAC; BRAC University; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; Vrije Universiteit Amsterdam	Shahabuddin, ASM (corresponding author), Inst Trop Med, Dept Publ Hlth, Woman & Child Hlth Res Ctr, B-2000 Antwerp, Belgium.; Shahabuddin, ASM (corresponding author), Univ Barcelona, Hosp Clin, ISGlobal, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.; Shahabuddin, ASM (corresponding author), Vrije Univ Amsterdam, Athena Inst Res Innovat & Commun Hlth & Life Sci, Amsterdam, Netherlands.	shahab@itg.be	Alonso, Azucena Bardají/V-5978-2018; Bardají, Azucena/AAE-9145-2019	Alonso, Azucena Bardají/0000-0002-5135-0540; Sarker, Malabika/0000-0001-7293-8805	European Commission (EC); Department of Economy, Science and Innovation of Flemish Government, Belgium; European Commission; BRAC head office	European Commission (EC)(European CommissionEuropean Commission Joint Research Centre); Department of Economy, Science and Innovation of Flemish Government, Belgium; European Commission(European CommissionEuropean Commission Joint Research Centre); BRAC head office	This study, part of a PhD research, was funded by the European Commission (EC) and the Department of Economy, Science and Innovation of Flemish Government, Belgium. The first author is particularly grateful to Pr. Vincent De Brouwere as he also added funds for conducting this research.; The authors would like to acknowledge the European Commission and the Department of Economy, Science and Innovation of Flemish Government, Belgium for funding. The first author is particularly grateful to Pr. Vincent De Brouwere as he also added funds for conducting this research. The authors are also grateful to all the BRAC IMNCS project staff working in Rangpur district and BRAC head office for their support to conduct this research smoothly. In addition, authors are thankful to Kristof De Coster (Public Health Department, Institute of Tropical Medicine) for editing the manuscript, all research assistants, translators, Nurul Islam Biplob and Shabnam Mostari (James P Grant School of Public Health, BRAC University) for recruiting and coordinating research assistants.	Adams Melissa K, 2013, Int J Gynaecol Obstet, V123 Suppl 1, pe7, DOI 10.1016/j.ijgo.2013.07.004; Asaduzzaman M., 2009, ASIAN SOC SCI, V5, P147, DOI [10.5539/ass.v5n3p147, DOI 10.5539/ASS.V5N3P147]; Bangladesh Bank, 2015, FOR DIR INV FDI BANG; Blanc AK, 2009, INT PERSPECT SEX R H, V35, P63, DOI 10.1363/ipsrh.35.063.09; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chen XK, 2008, J CLIN EPIDEMIOL, V61, P688, DOI 10.1016/j.jclinepi.2007.08.009; Chen XK, 2007, INT J EPIDEMIOL, V36, P368, DOI 10.1093/ije/dyl284; Chowdhury AMR, 2013, LANCET, V382, P1734, DOI 10.1016/S0140-6736(13)62148-0; Conde-Agudelo A, 2005, AM J OBSTET GYNECOL, V192, P342, DOI 10.1016/j.ajog.2004.10.593; Deb S, 2011, INT Q COMMUNITY HEAL, V31, P401, DOI 10.2190/IQ.31.4.g; Ganchimeg T, 2014, BJOG-INT J OBSTET GY, V121, P40, DOI 10.1111/1471-0528.12630; Gayen Kaberi, 2006, Healthc Q, V9, P110; Gayen K, 2010, SOC SCI MED, V71, P1584, DOI 10.1016/j.socscimed.2010.08.002; Grant MJ, 2008, STUD FAMILY PLANN, V39, P369, DOI 10.1111/j.1728-4465.2008.00181.x; Hameed W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104633; Haque SE, 2012, WOMEN HEALTH ISS, V22, pE171, DOI 10.1016/j.whi.2011.08.004; Hossain MB, 2012, STUD FAMILY PLANN, V27, P98; Kabir H, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-31; Kadir MM, 2003, J BIOSOC SCI, V35, P545, DOI 10.1017/S0021932003005984; Kamal SMM, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1492, DOI 10.1177/1010539513503868; Kamal SMM, 2015, J BIOSOC SCI, V47, P120, DOI 10.1017/S0021932013000746; Kamal SMM, 2012, EUR J CONTRACEP REPR, V17, P144, DOI 10.3109/13625187.2011.646014; Kamal SMM, 2010, ASIA-PAC J PUBLIC HE, V22, P436, DOI 10.1177/1010539510370780; Khan NR, 2014, J DHAKA MED COLL, V23, P7; Lloyd CB, 2008, POPULATION STUDIES, V62, P13; Mukhopadhyay P, 2010, J HEALTH POPUL NUTR, V28, P494; National Institute of Population Research and Training (NIPORT), 2015, BANGL DEM HLTH SURV; Ochako R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1483-1; Rahman M. A., 2014, Journal of Medicine, V15, P9; Santos KA, 2012, CAD SAUDE PUBLICA, V28, P655, DOI 10.1590/S0102-311X2012000400005; Sayem AM, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-16; Schuler SR, 2010, J DEV STUD, V46, P379, DOI 10.1080/00220380903318095; Shahidul Islam M., 2014, ASIAN SOCIAL SCI, V10, P189, DOI [10.5539/ass.v10n2p189, DOI 10.5539/ASS.V10N2P189]; Shattuck D, 2011, AM J PUBLIC HEALTH, V101, P1089, DOI 10.2105/AJPH.2010.300091; United Nations Children's Fund, 2014, PROGR PROSP, DOI [10.1016/j.landurbplan.2012.01.010, DOI 10.1016/J.LANDURBPLAN.2012.01.010]; Williamson Lisa M, 2009, Reprod Health, V6, P3, DOI 10.1186/1742-4755-6-3; Yue K, 2010, PATIENT EDUC COUNS, V81, P402, DOI 10.1016/j.pec.2010.07.018	37	28	28	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157664	10.1371/journal.pone.0157664	http://dx.doi.org/10.1371/journal.pone.0157664			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DP3JL	27336673	Green Published, gold			2023-01-03	WOS:000378389200030
J	Raman, K; Aeschbacher, S; Bossard, M; Hochgruber, T; Zimmermann, AJ; Kaufmann, BA; Pumpol, K; Rickenbacker, P; Pare, G; Conen, D				Raman, Kripa; Aeschbacher, Stefanie; Bossard, Matthias; Hochgruber, Thomas; Zimmermann, Andreas J.; Kaufmann, Beat A.; Pumpol, Katrin; Rickenbacker, Peter; Pare, Guillaume; Conen, David			Whole Blood Gene Expression Differentiates between Atrial Fibrillation and Sinus Rhythm after Cardioversion	PLOS ONE			English	Article							RISK-FACTOR; FOLLOW-UP; PREVALENCE; MANAGEMENT; STROKE; DEATH	Background Treatment to restore sinus rhythm among patients with atrial fibrillation (AF) has limited long-term success rates. Gene expression profiling may provide new insights into AF pathophysiology. Objective To identify biomarkers and improve our understanding of AF pathophysiology by comparing whole blood gene expression before and after electrical cardioversion (ECV). Methods In 46 patients with persistent AF that underwent ECV, whole blood samples were collected 1-2 hours before and 4 to 6 weeks after successful cardioversion. The paired samples were sent for microarray and plasma biomarker comparison. Results Of 13,942 genes tested, expression of SLC25A20 and PDK4 had the strongest associations with AF. Post-cardioversion, SLC25A20 and PDK4 expression decreased by 0.8 (CI 0.7-0.8, p = 2.0x10(-6)) and 0.7 (CI 0.6-0.8, p = 3.0x10(-5)) fold respectively. Median N-terminal proB-type natriuretic peptide (NT-proBNP) concentrations decreased from 127.7 pg/mL to 44.9 pg/mL (p = 2.3x10(-13)) after cardioversion. AF discrimination models combining NT-proBNP and gene expression (NT-proBNP + SLC25A20 area under the curve = 0.88, NT-proBNP + PDK4 AUC = 0.86) had greater discriminative capacity as compared with NT-proBNP alone (AUC = 0.82). Moreover, a model including NT-proBNP, SLC25A20 and PDK4 significantly improved AF discrimination as compared with other models(AUC = 0.87, Net Reclassification Index >0.56, p<5.8x10(-3)). We validated the association between SLC25A20 and PDK4 with AF in an independent sample of 17 patients. Conclusion This study demonstrates that SLC25A20, PDK4, and NT-proBNP have incremental utility as biomarkers discriminating AF from sinus rhythm. Elevated SLC25A20 and PDK4 expression during AF indicates an important role for energy metabolism in AF.	[Raman, Kripa; Bossard, Matthias; Pare, Guillaume] David Braley Cardiac Vasc & Stroke Res Inst, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada; [Raman, Kripa; Pare, Guillaume] David Braley Cardiac Vasc & Stroke Res Inst, Thrombosis & Atherosclerosis Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada; [Raman, Kripa] McMaster Univ, Dept Med Sci, 1280 Main St West, Hamilton, ON L8S 4K1, Canada; [Aeschbacher, Stefanie; Hochgruber, Thomas; Zimmermann, Andreas J.; Conen, David] Univ Basel Hosp, Div Internal Med, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland; [Aeschbacher, Stefanie; Bossard, Matthias; Hochgruber, Thomas; Zimmermann, Andreas J.; Pumpol, Katrin; Conen, David] Univ Basel Hosp, Cardiovasc Res Inst Basel, Spitalstr 2, CH-4031 Basel, Switzerland; [Bossard, Matthias; Kaufmann, Beat A.; Rickenbacker, Peter] Univ Basel Hosp, Div Cardiol, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland; [Bossard, Matthias] Hamilton Hlth Sci, Div Cardiol, Hamilton Gen Hosp, 237 Barton St East, Hamilton, ON L8L 2X2, Canada; [Rickenbacker, Peter] Kantonsspital Bruderholz, Div Cardiol, CH-4101 Bruderholz, Switzerland; [Pare, Guillaume] McMaster Univ, Michael G DeGroote Sch Med, Dept Pathol & Mol Med, 1280 Main St West, Hamilton, ON L8S 4K1, Canada	Population Health Research Institute; McMaster University; McMaster University; University of Basel; University of Basel; University of Basel; McMaster University; Kantonsspital Baselland; McMaster University	Conen, D (corresponding author), Univ Basel Hosp, Div Internal Med, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland.; Conen, D (corresponding author), Univ Basel Hosp, Cardiovasc Res Inst Basel, Spitalstr 2, CH-4031 Basel, Switzerland.	david.conen@usb.ch	Pare, Guillaume/T-9631-2018; Kaufmann, Beat/AAB-7805-2022; Aeschbacher, Stefanie/E-4935-2017	Pare, Guillaume/0000-0002-6795-4760; Kaufmann, Beat/0000-0001-6295-3630	Mach Gaensslen Foundation; Swiss National Science Foundation [PP00P3_133681, PP00P3_159322, 3232B0_141603, 310030_149718]; University of Basel; "Freiwillige Akademische Gesellschaft (FAG)" Basel	Mach Gaensslen Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); University of Basel; "Freiwillige Akademische Gesellschaft (FAG)" Basel	This study was supported by a grant of the Mach Gaensslen Foundation (to David Conen). David Conen and Beat A. Kaufmann have received grants from the Swiss National Science Foundation (PP00P3_133681 and PP00P3_159322 to David Conen, 3232B0_141603 and 310030_149718 to Beat Kaufmann). Matthias Bossard was supported by a grant of the University of Basel and the "Freiwillige Akademische Gesellschaft (FAG)" Basel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abed HS, 2013, JAMA-J AM MED ASSOC, V310, P2050, DOI 10.1001/jama.2013.280521; Barth AS, 2005, CIRC RES, V96, P1022, DOI 10.1161/01.RES.0000165480.82737.33; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Bouwens M, 2007, AM J CLIN NUTR, V86, P1515, DOI 10.1093/ajcn/86.5.1515; Cappato R, 2009, J AM COLL CARDIOL, V53, P1798, DOI 10.1016/j.jacc.2009.02.022; Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119; Conen D, 2011, JAMA-J AM MED ASSOC, V305, P2080, DOI 10.1001/jama.2011.659; Deshmukh A, 2015, CIRC-ARRHYTHMIA ELEC, V8, P32, DOI 10.1161/CIRCEP.114.001632; Dobson MG, 2007, EXPERT REV MOL DIAGN, V7, P359, DOI 10.1586/14737159.7.4.359; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Harrel Jr FE, 2015, HMISC PACKAGE MISCEL; Jeoung Nam Ho, 2010, Korean Diabetes J, V34, P274, DOI 10.4093/kdj.2010.34.5.274; Lin HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096794; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; Ohki R, 2005, INT J CARDIOL, V102, P233, DOI 10.1016/j.ijcard.2004.05.026; PANDE SV, 1975, P NATL ACAD SCI USA, V72, P883, DOI 10.1073/pnas.72.3.883; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Pathak RK, 2015, J AM COLL CARDIOL, V65, P2159, DOI 10.1016/j.jacc.2015.03.002; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Raman K, 2016, STROKE, V47, P652, DOI 10.1161/STROKEAHA.115.011854; RAMSAY RR, 1975, FEBS LETT, V54, P21, DOI 10.1016/0014-5793(75)81059-3; Ritchie ME, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002276; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Schmid R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-349; Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871; Stewart S, 2002, AM J MED, V113, P359, DOI 10.1016/S0002-9343(02)01236-6; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	30	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2016	11	6							e0157550	10.1371/journal.pone.0157550	http://dx.doi.org/10.1371/journal.pone.0157550			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WX	27332823	gold, Green Published, Green Submitted			2023-01-03	WOS:000378212800034
J	Wise, J				Wise, Jacqui			Plant based treatments give modest improvement in menopausal symptoms, review finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Franco OH, 2016, JAMA-J AM MED ASSOC, V315, P2554, DOI 10.1001/jama.2016.8012	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2016	353								i3474	10.1136/bmj.i3474	http://dx.doi.org/10.1136/bmj.i3474			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP8BS	27335343				2023-01-03	WOS:000378723500017
J	Kranz, LM; Diken, M; Haas, H; Kreiter, S; Loquai, C; Reuter, KC; Meng, M; Fritz, D; Vascotto, F; Hefesha, H; Grunwitz, C; Vormehr, M; Husemann, Y; Selmi, A; Kuhn, AN; Buck, J; Derhovanessian, E; Rae, R; Attig, S; Diekmann, J; Jabulowsky, RA; Heesch, S; Hassel, J; Langguth, P; Grabbe, S; Huber, C; Tureci, O; Sahin, U				Kranz, Lena M.; Diken, Mustafa; Haas, Heinrich; Kreiter, Sebastian; Loquai, Carmen; Reuter, Kerstin C.; Meng, Martin; Fritz, Daniel; Vascotto, Fulvia; Hefesha, Hossam; Grunwitz, Christian; Vormehr, Mathias; Huesemann, Yves; Selmi, Abderraouf; Kuhn, Andreas N.; Buck, Janina; Derhovanessian, Evelyna; Rae, Richard; Attig, Sebastian; Diekmann, Jan; Jabulowsky, Robert A.; Heesch, Sandra; Hassel, Jessica; Langguth, Peter; Grabbe, Stephan; Huber, Christoph; Tuereci, Oezlem; Sahin, Ugur			Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy	NATURE			English	Article							CYTOLYTIC T-LYMPHOCYTES; IN-VIVO; IMMUNE-RESPONSES; ANTITUMOR IMMUNITY; ANTIGEN; INTERFERONS; MACROPINOCYTOSIS; VACCINATION; EFFICIENCY; INDUCTION	Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells, are the ideal microenvironment for efficient priming and amplification of T-cell responses(1). However, the systemic delivery of vaccine antigens into dendritic cells (DCs) is hampered by various technical challenges. Here we show that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands. The LPX protects RNA from extracellular ribonucleases and mediates its efficient uptake and expression of the encoded antigen by DC populations and macrophages in various lymphoid compartments. RNA-LPX triggers interferon-alpha (IFN alpha) release by plasmacytoid DCs and macrophages. Consequently, DC maturation in situ and inflammatory immune mechanisms reminiscent of those in the early systemic phase of viral infection are activated(2). We show that RNA-LPX encoding viral or mutant neo-antigens or endogenous self-antigens induce strong effector and memory T-cell responses, and mediate potent IFN alpha-dependent rejection of progressive tumours. A phase I dose-escalation trial testing RNA-LPX that encode shared tumour antigens is ongoing. In the first three melanoma patients treated at a low-dose level, IFN alpha and strong antigen-specific T-cell responses were induced, supporting the identified mode of action and potency. As any polypeptide-based antigen can be encoded as RNA3,4, RNA-LPX represent a universally applicable vaccine class for systemic DC targeting and synchronized induction of both highly potent adaptive as well as type-I-IFN-mediated innate immune mechanisms for cancer immunotherapy.	[Kranz, Lena M.; Diken, Mustafa; Kreiter, Sebastian; Vascotto, Fulvia; Rae, Richard; Attig, Sebastian; Huber, Christoph; Sahin, Ugur] Johannes Gutenberg Univ gGmbH, TRON Translat Oncol, Univ Med Ctr, Freiligrathstr 12, D-55131 Mainz, Germany; [Kranz, Lena M.; Grunwitz, Christian; Vormehr, Mathias; Selmi, Abderraouf; Attig, Sebastian; Sahin, Ugur] Johannes Gutenberg Univ Mainz, Res Ctr Immunotherapy FZI, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany; [Diken, Mustafa; Haas, Heinrich; Kreiter, Sebastian; Reuter, Kerstin C.; Meng, Martin; Fritz, Daniel; Hefesha, Hossam; Grunwitz, Christian; Vormehr, Mathias; Huesemann, Yves; Kuhn, Andreas N.; Buck, Janina; Derhovanessian, Evelyna; Diekmann, Jan; Jabulowsky, Robert A.; Heesch, Sandra; Huber, Christoph; Sahin, Ugur] Biopharmaceut New Technol BioNTech Corp, Goldgrube 12, D-55131 Mainz, Germany; [Loquai, Carmen; Grabbe, Stephan] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany; [Hassel, Jessica] Univ Heidelberg Hosp, Dept Dermatol, Neuenheimer Feld 440, D-69120 Heidelberg, Germany; [Langguth, Peter] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Langenbeckstr 1, D-55131 Mainz, Germany; [Tuereci, Oezlem] Cluster Individualized Immune Intervent, Kupferbergterasse 19, D-55116 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; BioNTech SE; Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz	Sahin, U (corresponding author), Johannes Gutenberg Univ gGmbH, TRON Translat Oncol, Univ Med Ctr, Freiligrathstr 12, D-55131 Mainz, Germany.; Sahin, U (corresponding author), Johannes Gutenberg Univ Mainz, Res Ctr Immunotherapy FZI, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.; Sahin, U (corresponding author), Biopharmaceut New Technol BioNTech Corp, Goldgrube 12, D-55131 Mainz, Germany.	sahin@uni-mainz.de	Grabe, Stephan/AAJ-4578-2021; Sahin, Ugur/L-4818-2017; Vormehr, Mathias/AAJ-7808-2021; Loquai, Carmen/AAW-9241-2020	Grabe, Stephan/0000-0002-6863-8719; Sahin, Ugur/0000-0003-0363-1564; Vormehr, Mathias/0000-0001-7788-3380; Kranz, Lena/0000-0003-1943-3431; Roth, Rene/0000-0002-4333-695X; Vascotto, Fulvia/0000-0002-9839-3484	Rhineland Palatinate government; InnoTop program; CI3 Cutting Edge Cluster Funding of the German Ministry of Technology (BMBF); Collaborative Research Group 1066 of Deutsche Forschungsgemeinschaft (DFG); Graduate School of Immunotherapy 1043 of DFG	Rhineland Palatinate government; InnoTop program; CI3 Cutting Edge Cluster Funding of the German Ministry of Technology (BMBF); Collaborative Research Group 1066 of Deutsche Forschungsgemeinschaft (DFG); Graduate School of Immunotherapy 1043 of DFG	The authors thank M. Holzmann, R. Roth, U. Schmitt, M. Brkic, A. Konig, C. Worm, N. Krimmel, A.-K. Thiel, C. Bender, M. Suchan, A.-L. Popa, P. Bezerra Gomes, S. Herbert, M. Lux, D. Wintergerst, V. Bischoff, R. Krishna, Y. Hajime, J. Gross, A. Spruss, M. Erdeljan, S. Woll, T. Bukur, H. Muramatsu and M. Baiersdorfer for technical support, NIH Tetramer Core Facility for providing gp70 MHC class I tetramer, A. Kong for critical reading, A. Kemmer-Bruck, D. Schwarck, S. Bolte for clinical operations support and K. Kariko for advice. This work was supported by the technology innovation program of the Rhineland Palatinate government, the InnoTop program, the CI3 Cutting Edge Cluster Funding of the German Ministry of Technology (BMBF) and the Collaborative Research Group 1066 of Deutsche Forschungsgemeinschaft (DFG). L.M.K. was funded by the Graduate School of Immunotherapy 1043 of DFG.	Aichele P, 2003, J IMMUNOL, V171, P1148, DOI 10.4049/jimmunol.171.3.1148; Bacher N, 2013, CANCER RES, V73, P5647, DOI 10.1158/0008-5472.CAN-12-3788; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bangham A.D., 1974, METHODS MEMBRANE BIO, VSpringe, P1, DOI [DOI 10.1007/978-1-4615-7422-4_1, 10.1007/978-1-4615- 7422-4_1]; Bar-On L, 2010, METHODS MOL BIOL, V595, P429, DOI 10.1007/978-1-60761-421-0_28; Barichello JM, 2010, METHODS MOL BIOL, V605, P461, DOI 10.1007/978-1-60327-360-2_32; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chuang CM, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-49; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Diken M, 2011, GENE THER, V18, P702, DOI 10.1038/gt.2011.17; Duzgunes N., 2009, METHODS ENZYMOLOGY; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Hess PR, 2006, CANCER IMMUNOL IMMUN, V55, P672, DOI 10.1007/s00262-005-0064-z; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kreiter S, 2008, J IMMUNOL, V180, P309, DOI 10.4049/jimmunol.180.1.309; Kreiter S, 2007, CANCER IMMUNOL IMMUN, V56, P1577, DOI 10.1007/s00262-007-0302-7; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kuhn AN, 2010, GENE THER, V17, P961, DOI 10.1038/gt.2010.52; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; Lin K.-Y., 1996, CANCER RES, P21; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; Mitragotri S, 2014, NAT REV DRUG DISCOV, V13, P655, DOI 10.1038/nrd4363; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Perche F, 2011, NANOMED-NANOTECHNOL, V7, P445, DOI 10.1016/j.nano.2010.12.010; Phua KKL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/680620; Platt CD, 2010, P NATL ACAD SCI USA, V107, P4287, DOI 10.1073/pnas.0910609107; Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202; RACOOSIN EL, 1989, J EXP MED, V170, P1635, DOI 10.1084/jem.170.5.1635; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sarkar K, 2005, IMMUNOLOGY, V116, P513, DOI 10.1111/j.1365-2567.2005.02253.x; Simon P, 2014, CANCER IMMUNOL RES, V2, P1230, DOI 10.1158/2326-6066.CIR-14-0108; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; Zhou WZ, 1999, HUM GENE THER, V10, P2719, DOI 10.1089/10430349950016762; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	52	840	900	53	618	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2016	534	7607					396	+		10.1038/nature18300	http://dx.doi.org/10.1038/nature18300			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5XQ	27281205				2023-01-03	WOS:000377856800038
J	Goldman, O; Gouon-Evans, V				Goldman, Orit; Gouon-Evans, Valerie			Human Pluripotent Stem Cells: Myths and Future Realities for Liver Cell Therapy	CELL STEM CELL			English	Editorial Material							HUMAN FIBROBLASTS; HEPATOCYTES; CULTURE	The severe shortage of organ donors for treating patients with liver disease has prompted in vitro efforts to produce the main functional cells of the liver: hepatocyte-like cells (Hep cells). We consider the key challenges posed by various stem cell technologies and liver pathologies for developing clinically useful Hep cells.	[Goldman, Orit; Gouon-Evans, Valerie] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, Dept Dev & Regenerat Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Gouon-Evans, V (corresponding author), Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, Dept Dev & Regenerat Biol, New York, NY 10029 USA.	valerie.gouon-evans@mssm.edu		Gouon-Evans, Valerie/0000-0001-5424-6573	NIDDK NIH HHS [R01 DK080789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080789] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Du YY, 2014, CELL STEM CELL, V14, P394, DOI 10.1016/j.stem.2014.01.008; Huang PY, 2014, CELL STEM CELL, V14, P370, DOI 10.1016/j.stem.2014.01.003; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Oertel M, 2006, GASTROENTEROLOGY, V130, P507, DOI 10.1053/j.gastro.2005.10.049; Ogawa S, 2013, DEVELOPMENT, V140, P3285, DOI 10.1242/dev.090266; Rezvani M, 2016, CELL STEM CELL, V18, P809, DOI 10.1016/j.stem.2016.05.005; Song GQ, 2016, CELL STEM CELL, V18, P797, DOI 10.1016/j.stem.2016.01.010; Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271; Yusa K, 2011, NATURE, V478, P391, DOI 10.1038/nature10424; Zhu SY, 2014, NATURE, V508, P93, DOI 10.1038/nature13020	10	11	11	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JUN 2	2016	18	6					703	706		10.1016/j.stem.2016.05.019	http://dx.doi.org/10.1016/j.stem.2016.05.019			4	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	DN4WK	27257759	Bronze			2023-01-03	WOS:000377067700008
J	Liggio, J; Li, SM; Hayden, K; Taha, YM; Stroud, C; Darlington, A; Drollette, BD; Gordon, M; Lee, P; Liu, P; Leithead, A; Moussa, SG; Wang, D; O'Brien, J; Mittermeier, RL; Brook, JR; Lu, G; Staebler, RM; Han, YM; Tokarek, TW; Osthoff, HD; Makar, PA; Zhang, JH; Plata, DL; Gentner, DR				Liggio, John; Li, Shao-Meng; Hayden, Katherine; Taha, Youssef M.; Stroud, Craig; Darlington, Andrea; Drollette, Brian D.; Gordon, Mark; Lee, Patrick; Liu, Peter; Leithead, Amy; Moussa, Samar G.; Wang, Danny; O'Brien, Jason; Mittermeier, Richard L.; Brook, Jeffrey R.; Lu, Gang; Staebler, Ralf M.; Han, Yuemei; Tokarek, Travis W.; Osthoff, Hans D.; Makar, Paul A.; Zhang, Junhua; Plata, Desiree L.; Gentner, Drew R.			Oil sands operations as a large source of secondary organic aerosols	NATURE			English	Article							EMISSION RATES; PARTICULATE MATTER; BLACK CARBON; ISOPRENE; ALBERTA; SIMULATION; DEPOSITION; IMPACT	Worldwide heavy oil and bitumen deposits amount to 9 trillion barrels of oil distributed in over 280 basins around the world(1), with Canada home to oil sands deposits of 1.7 trillion barrels(2). The global development of this resource and the increase in oil production from oil sands has caused environmental concerns over the presence of toxic compounds in nearby ecosystems(3,4) and acid deposition(5,6). The contribution of oil sands exploration to secondary organic aerosol formation, an important component of atmospheric particulate matter that affects air quality and climate(7), remains poorly understood. Here we use data from airborne measurements over the Canadian oil sands, laboratory experiments and a box-model study to provide a quantitative assessment of the magnitude of secondary organic aerosol production from oil sands emissions. We find that the evaporation and atmospheric oxidation of low-volatility organic vapours from the mined oil sands material is directly responsible for the majority of the observed secondary organic aerosol mass. The resultant production rates of 45-84 tonnes per day make the oil sands one of the largest sources of anthropogenic secondary organic aerosols in North America. Heavy oil and bitumen account for over ten per cent of global oil production today(8), and this figure continues to grow(9). Our findings suggest that the production of the more viscous crude oils could be a large source of secondary organic aerosols in many production and refining regions worldwide, and that such production should be considered when assessing the environmental impacts of current and planned bitumen and heavy oil extraction projects globally.	[Liggio, John; Li, Shao-Meng; Hayden, Katherine; Stroud, Craig; Darlington, Andrea; Gordon, Mark; Lee, Patrick; Liu, Peter; Leithead, Amy; Moussa, Samar G.; Wang, Danny; O'Brien, Jason; Mittermeier, Richard L.; Brook, Jeffrey R.; Lu, Gang; Staebler, Ralf M.; Han, Yuemei; Makar, Paul A.; Zhang, Junhua] Environm & Climate Change Canada, Air Qual Res Div, Toronto, ON M3H 5T4, Canada; [Taha, Youssef M.; Tokarek, Travis W.; Osthoff, Hans D.] Univ Calgary, Dept Chem, Calgary, AB T2N 1N4, Canada; [Drollette, Brian D.; Plata, Desiree L.; Gentner, Drew R.] Yale Univ, Dept Chem & Environm Engn, New Haven, CT 06520 USA	Environment & Climate Change Canada; University of Calgary; Yale University	Liggio, J; Li, SM (corresponding author), Environm & Climate Change Canada, Air Qual Res Div, Toronto, ON M3H 5T4, Canada.	John.Liggio@canada.ca; Shao-Meng.Li@canada.ca		Darlington, Andrea/0000-0002-7469-5541; Taha, Youssef/0000-0002-6199-3195; Staebler, Ralf/0000-0002-6372-0414; Gordon, Mark/0000-0003-4896-4661; Li, Shao-Meng/0000-0002-7628-6581; O'Brien, Jason/0000-0001-8431-5824; Leithead, Amy/0000-0002-2860-0468; Osthoff, Hans/0000-0001-7155-6493	Clean Air Regulatory Agenda; Joint Oil Sands Monitoring program	Clean Air Regulatory Agenda; Joint Oil Sands Monitoring program	We thank the National Research Council of Canada flight crew of the Convair-580, the technical support staff of the Air Quality Research Division, S. Cober for the management of the study, and the community of Fort McKay for the support of the Oski otin ground site at Fort McKay. The project was supported by the Clean Air Regulatory Agenda and the Joint Oil Sands Monitoring program.	Alberta Energy Regulator, 2013, ALB MIN OIL SANDS PL; BP, 2011, HEAV OIL VS LIGHT OI; Carter WPL, 2010, ATMOS ENVIRON, V44, P5336, DOI 10.1016/j.atmosenv.2010.01.024; Chen YZ, 2015, ATMOS ENVIRON, V105, P109, DOI 10.1016/j.atmosenv.2015.01.042; de Gouw J, 2003, INT J MASS SPECTROM, V223, P365, DOI 10.1016/S1387-3806(02)00926-0; de Gouw JA, 2011, SCIENCE, V331, P1295, DOI 10.1126/science.1200320; de Gouw J, 2007, MASS SPECTROM REV, V26, P223, DOI 10.1002/mas.20119; De Gouw J, 2009, ENVIRON SCI TECHNOL, V43, P7614, DOI 10.1021/es9006004; DeCarlo PF, 2006, ANAL CHEM, V78, P8281, DOI 10.1021/ac061249n; Donahue NM, 2009, ATMOS ENVIRON, V43, P94, DOI 10.1016/j.atmosenv.2008.09.055; Dusseault M., 2002, COLD HEAVY OIL PRODU; Ehn M, 2014, NATURE, V506, P476, DOI 10.1038/nature13032; Emil D.A., 2007, HEAVY OIL NATURAL BI HEAVY OIL NATURAL BI; Freney EJ, 2014, ATMOS CHEM PHYS, V14, P1397, DOI 10.5194/acp-14-1397-2014; Fuzzi S, 2015, ATMOS CHEM PHYS, V15, P8217, DOI 10.5194/acp-15-8217-2015; Garratt J.R., 1994, ATMOSPHERIC BOUNDARY; Gentner DR, 2014, ATMOS CHEM PHYS, V14, P4955, DOI 10.5194/acp-14-4955-2014; Gentner DR, 2012, P NATL ACAD SCI USA, V109, P18318, DOI 10.1073/pnas.1212272109; Gilman JB, 2013, ENVIRON SCI TECHNOL, V47, P1297, DOI 10.1021/es304119a; Gordon M, 2015, ATMOS MEAS TECH, V8, P3745, DOI 10.5194/amt-8-3745-2015; Government of Alberta, 2009, ENV MAN ALB OIL SAND; Grieshop AP, 2009, ATMOS CHEM PHYS, V9, P1263, DOI 10.5194/acp-9-1263-2009; Hakola H, 2006, BIOGEOSCIENCES, V3, P93, DOI 10.5194/bg-3-93-2006; Hayes PL, 2015, ATMOS CHEM PHYS, V15, P5773, DOI 10.5194/acp-15-5773-2015; Helmig D, 2007, ENVIRON SCI TECHNOL, V41, P1545, DOI 10.1021/es0618907; Jathar SH, 2014, P NATL ACAD SCI USA, V111, P10473, DOI 10.1073/pnas.1323740111; Jung KH, 2013, ATMOS ENVIRON, V69, P56, DOI 10.1016/j.atmosenv.2012.12.010; Kelly EN, 2009, P NATL ACAD SCI USA, V106, P22346, DOI 10.1073/pnas.0912050106; Kirk JL, 2014, ENVIRON SCI TECHNOL, V48, P7374, DOI 10.1021/es500986r; Kleinman LI, 2008, ATMOS CHEM PHYS, V8, P1559, DOI 10.5194/acp-8-1559-2008; Kleinman LI, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007786; Li R, 2013, ENVIRON SCI TECHNOL, V47, P12566, DOI 10.1021/es402265y; Liu Y, 2015, ATMOS CHEM PHYS, V15, P13569, DOI 10.5194/acp-15-13569-2015; Miyakawa T, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009493; Moteki N, 2010, AEROSOL SCI TECH, V44, P663, DOI 10.1080/02786826.2010.484450; Murphy BN, 2011, ATMOS CHEM PHYS, V11, P7859, DOI 10.5194/acp-11-7859-2011; Ng NL, 2011, ENVIRON SCI TECHNOL, V45, P910, DOI 10.1021/es102951k; Robinson AL, 2007, SCIENCE, V315, P1259, DOI 10.1126/science.1133061; Robinson NH, 2011, ATMOS CHEM PHYS, V11, P1039, DOI 10.5194/acp-11-1039-2011; Schwarz JP, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007076; Shrivastava MK, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009735; Simpson IJ, 2010, ATMOS CHEM PHYS, V10, P11931, DOI 10.5194/acp-10-11931-2010; Tsimpidi AP, 2010, ATMOS CHEM PHYS, V10, P525, DOI 10.5194/acp-10-525-2010; Vinuesa JF, 2009, BOUND-LAY METEOROL, V133, P1, DOI 10.1007/s10546-009-9416-0; Watmough SA, 2014, SCI TOTAL ENVIRON, V493, P1, DOI 10.1016/j.scitotenv.2014.05.110; Xie Y, 2013, ATMOS CHEM PHYS, V13, P8439, DOI 10.5194/acp-13-8439-2013; Zhang Q, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029979; Zhao J, 2004, ATMOS ENVIRON, V38, P2177, DOI 10.1016/j.atmosenv.2004.01.019; Zhao YL, 2014, ENVIRON SCI TECHNOL, V48, P13743, DOI 10.1021/es5035188	49	103	104	4	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2016	534	7605					91	+		10.1038/nature17646	http://dx.doi.org/10.1038/nature17646			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN3LB	27251281				2023-01-03	WOS:000376962300039
J	Xie, MX; Jiang, Q; Li, L; Zhu, JJ; Zhu, LX; Zhou, D; Zheng, YL; Yang, XD; Zhu, MY; Sun, JN; Xie, WZ; Ye, XJ				Xie, Mixue; Jiang, Qi; Li, Li; Zhu, Jingjing; Zhu, Lixia; Zhou, De; Zheng, Yanlong; Yang, Xiudi; Zhu, Mingyu; Sun, Jianai; Xie, Wanzhuo; Ye, Xiujin			HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; LOW-DOSE CYTARABINE; MESSENGER-RNA EXPRESSION; ELDERLY-PATIENTS; MYELOGENOUS LEUKEMIA; INDUCED APOPTOSIS; GRANULOCYTE; INDUCTION; CHEMOTHERAPY; ACLARUBICIN	Background In China, the combination of homoharringtonine, cytarabine, and G-CSF (HAG) has been extensively applied for treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods We performed a meta-analysis of 2,314 patients (AML, n = 1754; MDS, n = 560) to determine the overall safety and efficacy of this regimen. Results The complete response (CR) rate of AML patients (53%) was significantly higher than that of MDS/transformed-AML patients (45%; P = 0.007). The CR rate of patients with newly diagnosed AML (62%) was significantly higher than in patients with relapsed/refractory AML (50%; P = 0.001). There were no significant difference in CR rates between elderly AML patients (54%) and all AML patients (P = 0.721). When compared with non-HAG regimens for AML/MDS induction therapy, the CR rate of patients treated with HAG was significantly higher than in treated with intensive chemotherapy (P = 0.000). No significant differences in CR rates were observed between patients treated with HAG and those treated with CAG (cytarabine, aclarubicin, G-CSF) regimens (P = 0.073). HAG regimen was well tolerated, with early death (ED) in 2%, grade IV myelosurrpression in 52% and infection in 50%. Reports of ED and rates of myelosuppression were reduced as compared with intensive chemotherapy (P = 0.000 and P = 0.000, respectively). Conclusion The HAG regimen is an effective and safe regimen for the treatment of AML and MDS, and appears to be more effective and better tolerated than intensive chemotherapy. Future randomized controlled trials and further meta-analyses are strongly needed to confirm its efficacy and safety, especially in comparison with intensive chemotherapy.	[Xie, Mixue; Li, Li; Zhu, Jingjing; Zhu, Lixia; Zhou, De; Zheng, Yanlong; Yang, Xiudi; Zhu, Mingyu; Sun, Jianai; Xie, Wanzhuo; Ye, Xiujin] Zhejiang Univ, Senior Dept Haematol, Coll Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Jiang, Qi] Zhejiang Univ, Dept Med Oncol, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Ye, XJ (corresponding author), Zhejiang Univ, Senior Dept Haematol, Coll Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.	wsxmxhh00@163.com						Bai A, 1999, EXP HEMATOL, V27, P259, DOI 10.1016/S0301-472X(98)00041-1; BOEKHORST PAWT, 1993, LEUKEMIA, V7, P1191; Cai Z, 2005, CHINESE MED J-PEKING, V118, P548; Chen C, 2015, LEUKEMIA LYMPHOMA, V56, P141, DOI 10.3109/10428194.2014.910774; CHEN JYZDL, 1990, CANCER RES, V50, P2031; Chen YE, 2008, 2008 IEEE INTERNATIONAL CONFERENCE ON AUTOMATION AND LOGISTICS, VOLS 1-6, P1, DOI 10.1109/ICAL.2008.4636109; Chen YJ, 2007, PROGR MODERN BIOMED, P1520; Chen YJ, 2010, CHIN J GERONTOL, P2913; Deng L, 2014, HEBEI MEDJ, P1328; DILLMAN RO, 1991, BLOOD, V78, P2520; Freireich EJ, 1998, LEUKEMIA, V12, pS54; FRESNO M, 1977, EUR J BIOCHEM, V72, P323, DOI 10.1111/j.1432-1033.1977.tb11256.x; Gu LF, 2011, J CANCER RES CLIN, V137, P997, DOI 10.1007/s00432-010-0947-z; Guan JM, 2010, J CHIN PRACT DIAGN T, P1015; Guo SS, 2010, MEDINNOV CHIN, P80; Guo ZQ, 2013, CHIN J MODERN DRUG, P82; Han QY, 2011, WORLD J INTEGRATED T, P222; Huang K, 2010, CURRENT PHYS, P105; Ji Yu-Ying, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P213; Jia T, 2014, MODERN J INTEGRATED, P1997; Juliusson G, 2009, BLOOD, V113, P4179, DOI 10.1182/blood-2008-07-172007; LEGHA SS, 1984, CANCER TREAT REP, V68, P1085; Li DH, 2007, JMUDANJIANG MED COLL, P52; Li HL, 2012, J GANNAN MED U, P93; Li J, 2010, CHIN JGEN PRACT, P556; Li Q, 2013, J COMPUTER APPL SOFT, P28; Li SY, 2010, ZHEJIANG MED J, V32, P275; Li Y, 2013, JMODERN ONCOL, P1840; Liao AJ, 2007, CHIN J PRACT INTERN, P59; Liu DB, 2006, J FUJIAN MED U, P274; Liu Hong, 2012, Zhonghua Yi Xue Za Zhi, V92, P689; Liu JQ, 2008, SHANDONG MED J, P95; Long BB, 2014, CHIN J PRACTICAL MED, P75; Ma XR, 2009, CHIN J MODERN MED, P22; Mai WY, 2005, CHINESE MED J-PEKING, V118, P487; Naina HVK, 2009, NEW ENGL J MED, V361, P2578, DOI 10.1056/NEJMc0910366; OBRIEN S, 1995, BLOOD, V86, P3322, DOI 10.1182/blood.V86.9.3322.bloodjournal8693322; POWELL R G, 1970, Tetrahedron Letters, V11, P815, DOI 10.1016/S0040-4039(01)97839-6; Rombouts EJC, 2004, BLOOD, V104, P550, DOI 10.1182/blood-2004-02-0566; Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272; Shen Jian-ping, 2012, Zhejiang Da Xue Xue Bao Yi Xue Ban, V41, P485; Shu HE, 2007, CHINJMISDIAGN, P331; Sierra MDLL, 2007, BLOOD, V110, P2276, DOI 10.1182/blood-2007-03-081448; Su J., 2014, CHIN PHARM, P114; Su Ji-Ying, 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V17, P459; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Sun RY, 2010, JMODERN ONCOL, P2055; Sun SF, 2011, J GUIYANG MED COLL; Sun XH, 2010, MED J IND ENTERP, P13; Sun XH, 2009, J CLIN HEMATOL, P382; TAKEMURA Y, 1985, CANCER CHEMOTH PHARM, V14, P206; Tong JS, 2009, CHIN J GERONTOL, P362; Wang JM, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-32; Wang JL, 2011, JLEUKEMIA LYMPHOMA, V20, P151; Wei GQ, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-46; Wei XD, 2006, CHIN JHEMATOL, P64; Wu CH, 2010, J NANCHANG U, P104; Wu LY, 2011, J CANCER RES CLIN, V137, P1563, DOI 10.1007/s00432-011-1020-2; Wu LY, 2009, LEUKEMIA LYMPHOMA, V50, P1461, DOI 10.1080/10428190903096719; Xie WZ, 2006, AM J CHINESE MED, V34, P233, DOI 10.1142/S0192415X06003795; Xie Y, 2010, CHIN MED HERALD, P148; Xu J, 2009, J JIAXING U, P129; YAMADA K, 1995, LEUKEMIA, V9, P10; Yang LH., 2009, CHIN J MODERN MED, P2866; Yang YL, 2009, J BENGBU MED COLL, P307; Ye CM, 2008, J N CHINA COAL MED C, P636; Ye Xiu-jin, 2004, J Zhejiang Univ Sci, V5, P230, DOI 10.1631/jzus.2004.0230; Yi HY., 2009, CHIN J MIS DIAGN, P538; Yuan JH, 2008, MED J COMMUNICAT, P671; Zhan XR, 2009, SHANDONG MED J, P78; Zhang L, 2011, JMODERN ONCOL, P1663; Zhang L, 2009, J CLIN HEMATOL, P502; Zhang P, 2014, CHIN J PHARM EC, P141; Zhang WG, 2008, AM J HEMATOL, V83, P185, DOI 10.1002/ajh.20903; Zhang X.Y., 2014, CHINA SOFT SCI NO, V6, P142; Zhang XH, 2014, J INTER INTENSIVE ME, P170; Zhang YH., 2014, CHIN JCONTROL ENDEMI, P185; Zheng SY, 2011, J MODERN ONCOL, P994; Zhou J, 2011, CHIN J TRAUMA DISABI, P19; Zhou W, 2008, J CLIN HEMATOL, P563	80	11	12	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2016	11	10							e0164238	10.1371/journal.pone.0164238	http://dx.doi.org/10.1371/journal.pone.0164238			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UN	27706258	Green Submitted, Green Published, gold			2023-01-03	WOS:000385697200100
J	Laux, G; Musselmann, B; Kiel, M; Szecsenyi, J; Joos, S				Laux, Gunter; Musselmann, Berthold; Kiel, Marion; Szecsenyi, Joachim; Joos, Stefanie			Differences between Practice Patterns of Conventional and Naturopathic GPs in Germany	PLOS ONE			English	Article							PRIMARY-CARE; ALTERNATIVE MEDICINE; COMPLEMENTARY; PRACTITIONERS	Background Limited evidence exists whether practice patterns of general practitioners (GPs) who have additionally completed training in naturopathy are different from those of conventional GPs. We aimed to assess and compare practice patterns of GPs in conventional and naturopathic GPs. Methods Routine data from 41 GPs (31 with and 11 without additional qualification in NP, respectively) and 180,789 patients, drawn from the CONTinuous morbidity registration Epidemiologic NeTwork (CONTENT)-registry and collected between 2009 and 2014, were used. To assess practice patterns determinants of (non-) phytopharmaceutical prescriptions, referrals and hospitalizations were analyzed using mixed-effects Poisson regression models. As explanatory variables, the qualification of the GP in NM, the age group and sex of the patient, as well as bivariate interactions between these variables were considered. Results GPs additionally qualified in naturopathy exhibited higher rates of phytopharmaceutical prescriptions (p<0.034; independent effect) compared to conventional GPs. This association was not observed with respect to non-phytopharmaceutical prescriptions. However, interaction effects between qualification and age group as well as sex were present with respect to both phytopharmaceutical and non-phytopharmaceutical prescriptions (all p<0.001). No further independent association existed between qualification and either referral rates or hospitalization rates, but again interactions between qualification and age group and sex (only referrals) were statistically significant (all p<0.0001). Conclusion The results show that the rate of phyto-pharmaceutical prescriptions are generally higher when the GP has an additional qualification in naturopathy. Further differences in practice patterns between conventional and naturopathy GPs could be subject to certain age groups and sex. However, the magnitude of these differences seem to be rather small.	[Laux, Gunter; Musselmann, Berthold; Kiel, Marion; Szecsenyi, Joachim; Joos, Stefanie] Univ Heidelberg Hosp, Dept Gen Practice & Hlth Serv Res, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Laux, G (corresponding author), Univ Heidelberg Hosp, Dept Gen Practice & Hlth Serv Res, Heidelberg, Germany.	g.laux@med.uni-heidelberg.de	Laux, Gunter/AAL-9020-2021		"Komitee Forschung Naturmedzin e.V." (KFN) [4/2001]; German Federal Ministry of Research and Education (BMBF) [01GK0301]	"Komitee Forschung Naturmedzin e.V." (KFN); German Federal Ministry of Research and Education (BMBF)(Federal Ministry of Education & Research (BMBF))	Financial support for this study was received from the "Komitee Forschung Naturmedzin e.V." (KFN) (grant number 4/2001, to Prof. Dr. Gunter Laux). The implementation of CONTENT registry was funded by the German Federal Ministry of Research and Education (BMBF) (grant number 01GK0301). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altiner A, 2010, J ANTIMICROB CHEMOTH, V65, P1521, DOI 10.1093/jac/dkq151; Baars Erik W, 2014, BMJ Open, V4, pe005332, DOI 10.1136/bmjopen-2014-005332; Ben-Arye E, 2008, PATIENT EDUC COUNS, V70, P395, DOI 10.1016/j.pec.2007.11.019; De Sutter AI, 2001, FAM PRACT, V18, P209, DOI 10.1093/fampra/18.2.209; Eardley S, 2012, FORSCH KOMPLEMENTMED, V19, P18, DOI 10.1159/000342708; Fischer F, 2014, FORSCH KOMPLEMENTMED, V21, pE1, DOI 10.1159/000360744; Fleming SA, 2010, PRIMARY CARE, V37, P119, DOI 10.1016/j.pop.2009.09.002; Herman PM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001046; Joos S, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/294638; Joos S, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-131; Joos S, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep019; Kooreman P, 2012, EUR J HEALTH ECON, V13, P769, DOI 10.1007/s10198-011-0330-2; Kraft K, 2009, LEHRBUCH NATURHEILVE; Laux Gunter, 2005, Inform Prim Care, V13, P249; Laux G, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-14; National Center for Complementary and Integrative Health (NCCIH), NAT WHAT NAT PRACT D; Stroup WW., 2012, GEN LINEAR MIXED MOD; Studer HP, 2011, FORSCH KOMPLEMENTMED, V18, P315, DOI 10.1159/000334797; Thanner M, 2014, GESUNDHEITSWESEN, V76, P715, DOI 10.1055/s-0033-1364013; WHO Collaborating Centre for Drug Statistics Methodology, AN THER CHEM ATC CLA	20	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2016	11	10							e0163519	10.1371/journal.pone.0163519	http://dx.doi.org/10.1371/journal.pone.0163519			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0TR	27695071	Green Published, Green Submitted, gold			2023-01-03	WOS:000385553100041
J	Elidottir, AS; Halldorsson, TI; Gunnarsdottir, I; Ramel, A				Elidottir, Anita S.; Halldorsson, Thorhallur I.; Gunnarsdottir, Ingibjorg; Ramel, Alfons			Dietary Intake and Cardiovascular Risk Factors in Icelanders Following Voluntarily a Low Carbohydrate Diet	PLOS ONE			English	Article							WEIGHT-LOSS DIETS; LOW-FAT DIET; CORONARY-HEART-DISEASE; OBESE ADULTS; BODY-WEIGHT; OVERWEIGHT; MANAGEMENT; METAANALYSIS; TRIALS; YOUNG	Background/Aim Most studies regarding low-carbohydrate diets (LCDs) have been intervention studies. The aim of the current study was to investigate dietary intake and cardiovascular risk factors among individuals who voluntarily follow a LCD. Methods A cross-sectional study was conducted (N = 54, 20-66yrs) in Reykjavik, Iceland. Participants recorded food intake for three days. Blood samples were analyzed for cardiovascular risk factors. Results Nearly half of the participants were obese and around 60% had been on a LCD for >= 6 months. Fifty percent claimed they had lost weight during the past month. The median intake of carbohydrate, protein and fat were 8%, 22% and 68% E (hereof 25% saturated fatty acids), respectively. The consumption of bread and wholegrain cereals was very low (<5g/day), including the intake of dietary fiber (11g/day). Median fruit intake was 12 g/day. Intake of red meat and meat products was double that of the general population or similar to 900 g/week. Median intake of vitamins and minerals were mostly higher than the estimated average requirements. Cardiovascular risk factors were mostly within normal range. Mean blood lipids were slightly elevated although the high density lipoprotein/total cholesterol ratio was normal. Conclusion Despite poor diet quality and high prevalence of obesity, individuals who voluntarily follow a LCD have cardiovascular risk factors mostly within reference range. These individuals consume very low amounts of carbohydrates and high amounts of fat and saturated fat acids. Intake of red meat and processed meat exceeds recommended intake. Very low intake of whole grain cereals and fruits results in low intake of fiber. Long term health implications need to be examined further in longitudinal studies.	[Elidottir, Anita S.; Halldorsson, Thorhallur I.; Gunnarsdottir, Ingibjorg; Ramel, Alfons] Univ Iceland, Landspitali Natl Univ Hosp Iceland, Unit Nutr Res, Reykjavik, Iceland; [Elidottir, Anita S.; Halldorsson, Thorhallur I.; Gunnarsdottir, Ingibjorg; Ramel, Alfons] Univ Iceland, Fac Food Sci & Nutr, Reykjavik, Iceland; [Halldorsson, Thorhallur I.] Statens Serum Inst, Ctr Fetal Programming, Copenhagen, Denmark	University of Iceland; University of Iceland; Statens Serum Institut	Ramel, A (corresponding author), Univ Iceland, Landspitali Natl Univ Hosp Iceland, Unit Nutr Res, Reykjavik, Iceland.; Ramel, A (corresponding author), Univ Iceland, Fac Food Sci & Nutr, Reykjavik, Iceland.	alfonsra@hi.is		Gunnarsdottir, Ingibjorg/0000-0001-9447-8627				American Heart Association, 2010, LEV CHOL; [Anonymous], NEW ATKINS NEW YOU; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Brinkworth GD, 2009, AM J CLIN NUTR, V90, P23, DOI 10.3945/ajcn.2008.27326; Bueno NB, 2013, BRIT J NUTR, V110, P1178, DOI 10.1017/S0007114513000548; Calton JB, 2010, J INT SOC SPORT NUTR, V7, DOI 10.1186/1550-2783-7-24; Dalen JE, 2014, AM J MED, V127, P364, DOI 10.1016/j.amjmed.2013.12.014; Douketis JD, 2005, INT J OBESITY, V29, P1153, DOI 10.1038/sj.ijo.0802982; Dyson PA, 2007, DIABETIC MED, V24, P1430, DOI 10.1111/j.1464-5491.2007.02290.x; Englyst KN, 2005, BRIT J NUTR, V94, P1, DOI 10.1079/BJN20051457; Forsythe CE, 2010, LIPIDS, V45, P947, DOI 10.1007/s11745-010-3467-3; Frisch S, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-36; Gardner CD, 2010, AM J CLIN NUTR, V92, P304, DOI 10.3945/ajcn.2010.29468; Guldbrand H, 2012, DIABETOLOGIA, V55, P2118, DOI 10.1007/s00125-012-2567-4; Gunnarsdottir I, 2008, INT J OBESITY, V32, P1105, DOI 10.1038/ijo.2008.64; Hession M, 2009, OBES REV, V10, P36, DOI 10.1111/j.1467-789X.2008.00518.x; Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124; Jensen MD, 2014, J AM COLL CARDIOL, V63, P2985, DOI 10.1016/j.jacc.2013.11.004; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; LeCheminant JD, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-36; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Millan J, 2009, VASC HEALTH RISK MAN, V5, P757; Miller Bernard V, 2003, Metab Syndr Relat Disord, V1, P299, DOI 10.1089/1540419031361426; Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252; Naude CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100652; Nordic Nutrition Recommendations, 2014, INT NUTR PHYS ACT; Ramel A, 2009, NUTR RES, V29, P305, DOI 10.1016/j.nutres.2009.05.004; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Santos FL, 2012, OBES REV, V13, P1048, DOI 10.1111/j.1467-789X.2012.01021.x; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Thorgeirsdottir H, 2011, WHAT DO ICELANDERS E; US Department of Health and Human Services & US Department of Agriculture, 2010, DIET GUID AM 2010; Volek JS, 2009, LIPIDS, V44, P297, DOI 10.1007/s11745-008-3274-2; Volek Js, 2004, Nutr Metab (Lond), V1, P13, DOI 10.1186/1743-7075-1-13; World Health Organization, 2008, WAIST CIRCUMFERENCE	39	10	10	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2016	11	8							e0156655	10.1371/journal.pone.0156655	http://dx.doi.org/10.1371/journal.pone.0156655			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU5NN	27560647	Green Published, gold, Green Submitted			2023-01-03	WOS:000382258600002
J	Regenstein, M; Nocella, K; Jewers, MM; Mullan, F				Regenstein, Marsha; Nocella, Kiki; Jewers, Mariellen Malloy; Mullan, Fitzhugh			The Cost of Residency Training in Teaching Health Centers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Regenstein, Marsha; Jewers, Mariellen Malloy; Mullan, Fitzhugh] George Washington Univ, Dept Hlth Policy & Management, Milken Inst, Sch Publ Hlth, Washington, DC USA; [Nocella, Kiki] KCN Consulting, Valencia, CA USA; [Nocella, Kiki] Educ Hlth Ctr Initiat, Seattle, WA USA	George Washington University	Regenstein, M (corresponding author), George Washington Univ, Dept Hlth Policy & Management, Milken Inst, Sch Publ Hlth, Washington, DC USA.							Chen C, 2012, ACAD MED, V87, P1752, DOI 10.1097/ACM.0b013e3182720f4d; Evaluation and initial assessment of HRSA teaching health centers, 2015, OMB CONTR NUMB 0906; Phillips RL, 2013, ACAD MED, V88, P1934, DOI 10.1097/ACM.0000000000000025	3	27	29	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2016	375	7					612	614		10.1056/NEJMp1607866	http://dx.doi.org/10.1056/NEJMp1607866			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DT4VF	27376580				2023-01-03	WOS:000381478600002
J	Chaudhry, HJ; Hengerer, AS; Snyder, GB				Chaudhry, Humayun J.; Hengerer, Arthur S.; Snyder, Gregory B.			Medical Board Expectations for Physicians Recommending Marijuana	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Chaudhry, Humayun J.; Snyder, Gregory B.] Federat State Med Boards, 400 Fuller Wiser Rd,Ste 300, Euless, TX 76039 USA; [Hengerer, Arthur S.] Univ Rochester, Dept Otolaryngol Head & Neck Surg, Rochester, NY USA	University of Rochester	Chaudhry, HJ (corresponding author), Federat State Med Boards, 400 Fuller Wiser Rd,Ste 300, Euless, TX 76039 USA.	hchaudhry@fsmb.org						Chaudhry HJ, 2015, JAMA-J AM MED ASSOC, V313, P1791, DOI 10.1001/jama.2015.4017; Hasin DS, 2015, JAMA PSYCHIAT, V72, P1235, DOI 10.1001/jamapsychiatry.2015.1858; Hill KP, 2015, JAMA-J AM MED ASSOC, V313, P2474, DOI 10.1001/jama.2015.6199	3	16	16	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2016	316	6					577	578		10.1001/jama.2016.7741	http://dx.doi.org/10.1001/jama.2016.7741			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS7TK	27308872				2023-01-03	WOS:000380985600005
J	Lee, JS; Hong, SS; Kim, HG; Lee, HW; Kim, WY; Lee, SK; Son, CG				Lee, Jin-Seok; Hong, Sung-Shin; Kim, Hyeong-Geug; Lee, Hye-Won; Kim, Won-Yong; Lee, Sam-Keun; Son, Chang-Gue			Gongjin-Dan Enhances Hippocampal Memory in a Mouse Model of Scopolamine-Induced Amnesia	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; NEUROTROPHIC FACTOR; NEUROGENESIS; METAANALYSIS; MODULATION; INHIBITORS; DONEPEZIL; RAT	We evaluated the neuropharmacological effects of Gongjin-Dan (GJD) on the memory impairment caused by scopolamine injection. BALB/c mice were orally treated with GJD (100, 200, or 400 mg/kg, daily) or tacrine (THA, 10 mg/kg) for 10 days, and scopolamine (2 mg/kg) was injected intraperitoneally. The radial arm maze and passive avoidance tests were performed to evaluate the animal's learning and memory. Scopolamine increased the task completing time, the number of total errors (reference and working memory error) in the radial arm maze task, and the latency time in the passive avoidance test, which were significantly ameliorated by treatment with GJD. The GJD treatment also attenuated the scopolamine-induced hyperactivation of acetylcholinesterase activity, and suppression of the expression of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and their receptors in the hippocampus. These effects of GJD were supported by both the doublecortin (DCX)-positive staining and Nissl staining, which were used to measure hippocampal neurogenesis and atrophy, respectively. These findings strongly suggest that GJD exerts a potent anti-amnesic effect, and its underlying mechanism might involve the modulation of cholinergic activity.	[Lee, Jin-Seok; Kim, Hyeong-Geug; Kim, Won-Yong; Son, Chang-Gue] Daejeon Univ, Oriental Med Coll, Liver & Immunol Res Ctr, 22-5 Daehung Dong, Daejeon 301724, South Korea; [Hong, Sung-Shin] Daejeon Univ, Korean Med Coll, 22-5 Yongwoon Dong, Daejeon 301724, South Korea; [Lee, Hye-Won] Korea Inst Oriental Med, TKM Based Herbal Drug Res Grp, Daejeon 305811, South Korea; [Lee, Sam-Keun] Daejeon Univ, Dept Appl Chem, 62 Daehak Ro, Daejeon 34520, South Korea	Daejeon University; Daejeon University; Korea Institute of Oriental Medicine (KIOM); Daejeon University	Son, CG (corresponding author), Daejeon Univ, Oriental Med Coll, Liver & Immunol Res Ctr, 22-5 Daehung Dong, Daejeon 301724, South Korea.	ckson@dju.ac.kr	son, chang gue/ABC-2215-2021		National Research Foundation of Korea (NRF); Ministry of Science, ICT and Future Planning [2015003195]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Science, ICT and Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea)	This research was supported by the National Research Foundation of Korea (NRF) and funded by the Ministry of Science, ICT and Future Planning (grant number: 2015003195, URL: www.nrf.re.kr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amieva H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052755; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Birch AM, 2013, NEUROPHARMACOLOGY, V75, P255, DOI 10.1016/j.neuropharm.2013.07.023; Blake MG, 2014, J PHYSIOL-PARIS, V108, P286, DOI 10.1016/j.jphysparis.2014.04.005; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Colovic MB, 2013, CURR NEUROPHARMACOL, V11, P315, DOI 10.2174/1570159X11311030006; Craig LA, 2011, NEUROSCI BIOBEHAV R, V35, P1397, DOI 10.1016/j.neubiorev.2011.03.001; Cutuli D, 2009, J ALZHEIMERS DIS, V17, P161, DOI 10.3233/JAD-2009-1040; Deogracias R, 2004, MOL CELL NEUROSCI, V26, P470, DOI 10.1016/j.mcn.2004.03.007; Doralp S, 2008, NEUROBIOL LEARN MEM, V90, P382, DOI 10.1016/j.nlm.2008.05.013; Erickson KI, 2010, J NEUROSCI, V30, P5368, DOI 10.1523/JNEUROSCI.6251-09.2010; Falsafi SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032082; Garibotto V, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2013.05.020; Goodrich-Hunsaker NJ, 2010, BEHAV NEUROSCI, V124, P405, DOI 10.1037/a0019193; Hagg T, 2009, NEUROSCIENTIST, V15, P20, DOI 10.1177/1073858408324789; Hansen RA, 2008, CLIN INTERV AGING, V3, P211; Hong SS, 2015, J ETHNOPHARMACOL, V168, P268, DOI 10.1016/j.jep.2015.04.001; Imam A., 2016, Bulletin of the Faculty of Pharmacy, Cairo University, V54, P49, DOI 10.1016/j.bfopcu.2015.12.005; Kenney JW, 2008, MOL NEUROBIOL, V38, P101, DOI 10.1007/s12035-008-8037-9; Kida Satoshi, 2012, Exp Neurobiol, V21, P136, DOI 10.5607/en.2012.21.4.136; Mimica N, 2009, PSYCHIAT DANUB, V21, P108; Moon E, 2009, NEUROSCI LETT, V466, P114, DOI 10.1016/j.neulet.2009.09.033; O'Bryant SE, 2009, J ALZHEIMERS DIS, V17, P337, DOI 10.3233/JAD-2009-1051; Prince M, 2015, GLOBAL IMPACT DEMENT; Puzzo D, 2014, BIOCHEM PHARMACOL, V88, P450, DOI 10.1016/j.bcp.2014.01.011; Qizilbash N, 1998, JAMA-J AM MED ASSOC, V280, P1777, DOI 10.1001/jama.280.20.1777; Rafii MS, 2011, NEUROLOGY, V76, P1389, DOI 10.1212/WNL.0b013e318216eb7b; Raina P, 2008, ANN INTERN MED, V148, P379, DOI 10.7326/0003-4819-148-5-200803040-00009; Scheff SW, 2006, NEUROBIOL AGING, V27, P1372, DOI 10.1016/j.neurobiolaging.2005.09.012; Schmitt U, 2009, NEUROSCIENCE, V162, P234, DOI 10.1016/j.neuroscience.2009.04.046; Sunwoo YY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/682720; Tarawneh R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006148; Tota S, 2012, PSYCHOPHARMACOLOGY, V222, P185, DOI 10.1007/s00213-012-2639-7; Tyler WJ, 2002, NEUROSCIENTIST, V8, P524, DOI 10.1177/1073858402238511; UNESCO, 2009, MEM OF THE WORLD; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; WILSON WJ, 1994, ACTA NEUROBIOL EXP, V54, P377	37	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2016	11	8							e0159823	10.1371/journal.pone.0159823	http://dx.doi.org/10.1371/journal.pone.0159823			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS9NS	27483466	Green Submitted, gold, Green Published			2023-01-03	WOS:000381110700015
J	Kayigamba, FR; Franke, MF; Bakker, MI; Rodriguez, CA; Bagiruwigize, E; Wit, FWNM; Rich, ML; van der Loeff, MFS				Kayigamba, Felix R.; Franke, Molly F.; Bakker, Mirjam I.; Rodriguez, Carly A.; Bagiruwigize, Emmanuel; Wit, Ferdinand W. N. M.; Rich, Michael L.; van der Loeff, Maarten F. Schim			Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study	PLOS ONE			English	Article							COMMUNITY-BASED ACCOMPANIMENT; VIRUS-INFECTED PATIENTS; VIROLOGICAL RESPONSES; RURAL RWANDA; SUPPRESSION; ADHERENCE; ADULTS; MORTALITY; OUTCOMES; VIREMIA	Introduction Some antiretroviral therapy naive patients starting combination antiretroviral therapy (cART) experience a limited CD4 count rise despite virological suppression, or vice versa. We assessed the prevalence and determinants of discordant treatment responses in a Rwandan cohort. Methods A discordant immunological cART response was defined as an increase of < 100 CD4 cells/mm3 at 12 months compared to baseline despite virological suppression (viral load [VL] < 40 copies/mL). A discordant virological cART response was defined as detectable VL at 12 months with an increase in CD4 count >= 100 cells/mm(3). The prevalence of, and independent predictors for these two types of discordant responses were analysed in two cohorts nested in a 12-month prospective study of cART-naive HIV patients treated at nine rural health facilities in two regions in Rwanda. Results Among 382 patients with an undetectable VL at 12 months, 112 (29%) had a CD4 rise of < 100 cells/mm(3). Age >= 35 years and longer travel to the clinic were independent determinants of an immunological discordant response, but sex, baseline CD4 count, body mass index and WHO HIV clinical stage were not. Among 326 patients with a CD4 rise of >= 100 cells/mm3, 56 (17%) had a detectable viral load at 12 months. Male sex was associated with a virological discordant treatment response (P = 0.05), but age, baseline CD4 count, BMI, WHO HIV clinical stage, and travel time to the clinic were not. Conclusions Discordant treatment responses were common in cART-naive HIV patients in Rwanda. Small CD4 increases could be misinterpreted as a (virological) treatment failure and lead to unnecessary treatment changes.	[Kayigamba, Felix R.; Bagiruwigize, Emmanuel] CPCD, INTERACT, POB 2181, Kigali, Rwanda; [Franke, Molly F.; Rodriguez, Carly A.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA; [Franke, Molly F.; Rich, Michael L.] Inshuti Mu Buzima, Rwinkwavu, Rwanda; [Bakker, Mirjam I.] KIT Biomed Res, Royal Trop Inst, Amsterdam, Netherlands; [Wit, Ferdinand W. N. M.; van der Loeff, Maarten F. Schim] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands; [Wit, Ferdinand W. N. M.; van der Loeff, Maarten F. Schim] Acad Med Ctr, Ctr Infect & Immun Amsterdam CINIMA, Amsterdam, Netherlands; [Rich, Michael L.] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA; [van der Loeff, Maarten F. Schim] Publ Hlth Serv Amsterdam GGD, Amsterdam, Netherlands	Harvard University; Harvard Medical School; University of Amsterdam; Academic Medical Center Amsterdam; Harvard University; Brigham & Women's Hospital; Public Health Service Amsterdam	Kayigamba, FR (corresponding author), CPCD, INTERACT, POB 2181, Kigali, Rwanda.	fkaigamba@gmail.com	Wit, Ferdinand/AAC-3803-2019; Franke, Molly/AAK-7559-2020	Franke, Molly/0000-0002-4890-5728; Rodriguez, Carly A/0000-0003-0023-2111	Doris Duke Charitable Foundation; Netherlands Organization for Scientific Research/Netherlands Foundation for the Advancement of Tropical Research (NWO/WOTRO); European Union [SANTE/2006/105-316]	Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Netherlands Organization for Scientific Research/Netherlands Foundation for the Advancement of Tropical Research (NWO/WOTRO); European Union(European Commission)	The Doris Duke Charitable Foundation provided financial support of this research. Technical support was provided by the Infectious Disease Network for Treatment and Research in Africa (INTERACT), funded by the Netherlands Organization for Scientific Research/Netherlands Foundation for the Advancement of Tropical Research (NWO/WOTRO) and the European Union (SANTE/2006/105-316). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge and thank the Doris Duke Charitable Foundation for financial support of this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Technical support was provided by the Infectious Disease Network for Treatment and Research in Africa (INTERACT), funded by the Netherlands Organization for Scientific Research/Netherlands Foundation for the Advancement of Tropical Research (NWO/WOTRO) and the European Union (SANTE/2006/105-316). We are grateful to the study staff: Adrienne Socci, Massudi Hakizamungu, Wellars Ndayambaje, Eline Uwitonze, Albertine Mukeshimana, Ernest Nyirinkindi, Jean Damascene Uwamuhoro, Carine Dusenge, Claire Dusabe, and Jean Claude Nyiramana. We also thank Cheryl Amoroso, Benjamin Akimana, Christian Allen, Darius Jazayeri, Ellen Ball, the Rwanda-based PIH-EMR team, and Laboratory Management of the Rwanda National Reference Laboratory. We also thank Frank Cobelens for providing feedback on a draft of this manuscript.	Bartlett JA, 2006, AIDS, V20, P2051, DOI 10.1097/01.aids.0000247578.08449.ff; Coffey S, 2012, SANDES HIV AIDS MED; Dronda F, 2002, CLIN INFECT DIS, V35, P1005, DOI 10.1086/342695; Falster K, 2009, JAIDS-J ACQ IMM DEF, V50, P307, DOI 10.1097/QAI.0b013e3181945ed4; Florence E, 2003, HIV Med, V4, P255, DOI 10.1046/j.1468-1293.2003.00156.x; Franke MF, 2013, CLIN INFECT DIS, V56, P1319, DOI 10.1093/cid/cis1193; Gilson R, 2010, HIV MED, V11, P152, DOI 10.1111/j.1468-1293.2009.00755.x; Gupta N, 2016, AIDS BEHAV, V20, P1009, DOI 10.1007/s10461-015-1185-9; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, GLOB AIDS EP 2013; Julg B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031161; Mannheimer SB, 2006, AIDS CARE, V18, P853, DOI 10.1080/09540120500465160; Mocroft A, 2007, LANCET, V370, P407, DOI 10.1016/S0140-6736(07)60948-9; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Mutevedzi PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021795; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Nsanzimana S, 2012, JAIDS-J ACQ IMM DEF, V59, pE17, DOI 10.1097/QAI.0b013e31823e2278; Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; Podsadecki TJ, 2007, J INFECT DIS, V196, P1773, DOI 10.1086/523704; Prabhakar B, 2011, Indian J Sex Transm Dis AIDS, V32, P94, DOI 10.4103/0253-7184.85412; Saison J, 2014, J INT AIDS SOC, V17, P119, DOI 10.7448/IAS.17.4.19672; Casotti JAS, 2011, REV INST MED TROP SP, V53, P301, DOI 10.1590/S0036-46652011000600001; Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5; TRAC Plus Ministry of Health Rwanda, 2009, GUID PROV COMPR CAR; Tuboi SH, 2007, JAIDS-J ACQ IMM DEF, V45, P52, DOI 10.1097/QAI.0b013e318042e1c3; Tuboi SH, 2010, JAIDS-J ACQ IMM DEF, V53, P70, DOI 10.1097/QAI.0b013e3181c22d19; Wandeler G, 2013, AIDS LONDON ENGLAND, V27, DOI [10.1097/QAD.1090b1013e328362d328887, DOI 10.1097/QAD.1090B1013E328362D328887]; Wandeler G, 2013, AIDS, V27, P2225, DOI 10.1097/QAD.0b013e328362d887; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2013, CONGUID UANT DRU; World Health Organization, 2009, RAP ADV ANT THER HIV; World Health Organization, 2006, ANT THER HIV INF AD; Zoufaly A, 2011, J INFECT DIS, V203, P364, DOI 10.1093/jinfdis/jiq055	34	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2016	11	7							e0159446	10.1371/journal.pone.0159446	http://dx.doi.org/10.1371/journal.pone.0159446			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TL	27438000	Green Published, Green Submitted, gold			2023-01-03	WOS:000380170100047
J	Mogil, JS				Mogil, Jeffrey S.			PERSPECTIVE Equality need not be painful	NATURE			English	Editorial Material							SEX-DIFFERENCES; ANALGESIA; STRESS		[Mogil, Jeffrey S.] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Mogil, Jeffrey S.] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada	McGill University; McGill University	Mogil, JS (corresponding author), McGill Univ, Dept Psychol, Montreal, PQ, Canada.; Mogil, JS (corresponding author), McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada.	jeffrey.mogil@mcgill.ca	Mogil, Jeffrey/AAA-9611-2019	Mogil, Jeffrey/0000-0003-1359-5720				Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Greenspan JD, 2007, PAIN, V132, pS26, DOI 10.1016/j.pain.2007.10.014; Mogil JS, 2012, NAT REV NEUROSCI, V13, P859, DOI 10.1038/nrn3360; Mogil JS, 2005, PAIN, V117, P1, DOI 10.1016/j.pain.2005.06.020; MOGIL JS, 1993, PAIN, V53, P17, DOI 10.1016/0304-3959(93)90050-Y; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]	8	34	36	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2016	535	7611					S7	S7		10.1038/535S7a	http://dx.doi.org/10.1038/535S7a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR4ZN	27410531	Bronze			2023-01-03	WOS:000379912600006
J	Kamal, AH; LeBlanc, TW; Meier, DE				Kamal, Arif H.; LeBlanc, Thomas W.; Meier, Diane E.			Better Palliative Care for All Improving the Lived Experience With Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kamal, Arif H.; LeBlanc, Thomas W.] Duke Univ, Med Ctr, Duke Canc Inst, POB 2715, Durham, NC 27705 USA; [Meier, Diane E.] Ctr Adv Palliat Care, New York, NY USA	Duke University	Kamal, AH (corresponding author), Duke Univ, Med Ctr, Duke Canc Inst, POB 2715, Durham, NC 27705 USA.	arif.kamal@duke.edu	LeBlanc, Thomas W/AAT-3650-2020	LeBlanc, Thomas W/0000-0002-0546-7895				Davis MP, 2015, ANN PALLIAT MED, V4, P99, DOI 10.3978/j.issn.2224-5820.2015.04.04; Gelfman LP, 2013, J PALLIAT MED, V16, P125, DOI 10.1089/jpm.2012.0427; Horwitz RI, 2016, JAMA-J AM MED ASSOC, V315, P1231, DOI 10.1001/jama.2016.2242; Kamal AH, 2015, ANN INTERN MED, V163, P637, DOI 10.7326/M15-0071; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Thomas RA, 2015, J PALLIAT MED, V18, P747, DOI 10.1089/jpm.2015.0035; von Gunten CF, 2002, JAMA-J AM MED ASSOC, V287, P875, DOI 10.1001/jama.287.7.875	7	13	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2016	316	1					29	30		10.1001/jama.2016.6491	http://dx.doi.org/10.1001/jama.2016.6491			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ2MY	27244674				2023-01-03	WOS:000379037600012
J	Dikkers, MF; Westerman, MJ; Rubinstein, SM; van Tulder, MW; Anema, JR				Dikkers, Marije F.; Westerman, Marjan J.; Rubinstein, Sidney M.; van Tulder, Maurits W.; Anema, Johannes R.			Why Neck Pain Patients Are Not Referred to Manual Therapy: A Qualitative Study among Dutch Primary Care Stakeholders	PLOS ONE			English	Article							GENERAL-PRACTITIONER; CONSERVATIVE MANAGEMENT; PHYSICAL-THERAPY; CONTINUED CARE; LOW-BACK; COST; PHYSIOTHERAPY	Background Treatment of neck pain with manual therapy demonstrated to be more effective and cost-effective than general practitioner (GP) care or physiotherapy in a high quality RCT in the Netherlands in 2002. However, referral to manual therapy for neck pain is still relatively low. This study aims to explore the barriers and facilitators affecting the implementation of manual therapy in neck pain management in primary care. Methods An explorative study was conducted comprising semi-structured interviews with GPs (n = 13), physiotherapists (n = 10), manual therapists (n = 7) and their patients with neck pain (n = 27), and three focus groups with additional stakeholders (n = 10-12 per group). A thematic analysis approach was used. Results Different barriers and facilitators for referral were found for patients, GPs and physiotherapists on the individual level, but also in the interaction between stakeholders and their context. Individual perceptions such as knowledge and beliefs about manual therapy for neck pain either impeded or facilitated referral. Fear for complications associated with cervical manipulation was an important barrier for patients as well as GPs. For GPs and physiotherapists it was important whether they perceived it was part of their professional role to refer for manual therapy. Existing relations formed referral behavior, and the trust in a particular practitioner was a recurrent theme among GPs and physiotherapist as well as patients. The contextual factor availability of manual therapy played a role for all stakeholders. Conclusions Barriers and facilitators were found especially in individual perceptions on manual therapy for neck pain (e.g. knowledge and beliefs), the interaction between stakeholders (e.g. collaboration and trust) and the organizational context. Implementation strategies that focus on these different aspects seem to be likely to optimize referral rates and the use of manual therapy in primary care management of neck pain.	[Dikkers, Marije F.; Westerman, Marjan J.; Rubinstein, Sidney M.; van Tulder, Maurits W.] Vrije Univ Amsterdam, Dept Hlth Sci, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands; [Dikkers, Marije F.; Westerman, Marjan J.; Rubinstein, Sidney M.; van Tulder, Maurits W.] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands; [Anema, Johannes R.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands; [Anema, Johannes R.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Rubinstein, SM (corresponding author), Vrije Univ Amsterdam, Dept Hlth Sci, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.; Rubinstein, SM (corresponding author), Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	s.m.rubinstein@vu.nl	van Tulder, Maurits/AAB-9785-2022	van Tulder, Maurits/0000-0002-7589-8471; Rubinstein, Sidney/0000-0002-4819-994X; Westerman, Marjan J./0000-0002-9827-6958	Netherlands Organization for Health Research and Development [171203011]	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development)	This study is supported by a grant from the Netherlands Organization for Health Research and Development (project number 171203011) (www.zonmw.nl). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; [Anonymous], 2004, GEN M CAP TOWN MARCH; Bogduk N, 1999, BEST PRACT RES CL RH, V13, P261, DOI 10.1053/berh.1999.0020; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Bot SDM, 2005, ANN RHEUM DIS, V64, P118, DOI 10.1136/ard.2003.019349; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Fleuren M, 2004, INT J QUAL HEALTH C, V16, P107, DOI 10.1093/intqhc/mzh030; Forsetlund L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003030.pub2; Grol R, 2004, MED J AUSTRALIA, V180, pS57, DOI 10.5694/j.1326-5377.2004.tb05948.x; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Gross A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004249.pub4; Gross AR, 2007, J RHEUMATOL, V34, P1083; Hoving JL, 2006, CLIN J PAIN, V22, P370, DOI 10.1097/01.ajp.0000180185.79382.3f; Hoving JL, 2002, ANN INTERN MED, V136, P713, DOI 10.7326/0003-4819-136-10-200205210-00006; Hurwitz EL, 1996, SPINE, V21, P1746, DOI 10.1097/00007632-199608010-00007; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Korthals-de Bos IBC, 2003, BRIT MED J, V326, P911; Ouwens M, 2012, DE ZACHTE KANTEN VAN; Paulussen, 2010, TSG, V88, P51, DOI [DOI 10.1007/BF03089541, 10.1007/BF03089541]; Perreault K, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-160; Scherer M, 2010, EUR SPINE J, V19, P963, DOI 10.1007/s00586-010-1297-x; Schers H, 2001, Spine (Phila Pa 1976), V26, pE348, DOI 10.1097/00007632-200108010-00013; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; Stirbu-Wagner I, 2012, LANDELIJK INFORM HUI; Tricco AC, 2012, LANCET, V379, P2252, DOI 10.1016/S0140-6736(12)60480-2; Verberne LDM, JAARCIJFERS 2011 TRE; Vos C, 2007, BRIT J GEN PRACT, V57, P23; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wermeling M, 2011, FAM PRACT, V28, P300, DOI 10.1093/fampra/cmq109	29	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157465	10.1371/journal.pone.0157465	http://dx.doi.org/10.1371/journal.pone.0157465			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27311067	Green Published, gold, Green Submitted			2023-01-03	WOS:000378029800077
J	Lenzi, EK; Novatski, A; Farago, PV; Almeida, MA; Zawadzki, SF; Neto, RM				Lenzi, E. K.; Novatski, A.; Farago, P. V.; Almeida, M. A.; Zawadzki, S. F.; Neto, R. Menechini			Diffusion Processes and Drug Release: Capsaicinoids - Loaded Poly (epsilon-caprolactone) Microparticles	PLOS ONE			English	Article							FRACTIONAL DIFFUSION; EQUATION; MODELS	We present a generalmodel based on fractional diffusion equation coupled with a kinetic equation through the boundary condition. It covers several scenarios that may be characterized by usual or anomalous diffusion or present relaxation processes on the surface with non-Debye characteristics. A particular case of this model is used to investigate the experimental data obtained from the drug release of the capsaicinoids-loaded Poly (epsilon-caprolactone) microparticles. These considerations lead us to a good agreement with experimental data and to the conjecture that the burst effect, i.e., an initial large bolus of drug is released before the release rate reaches a stable profile, may be related to an anomalous diffusion manifested by the system.	[Lenzi, E. K.; Novatski, A.; Neto, R. Menechini] Univ Estadual Ponta Grossa, Dept Fis, BR-84030900 Ponta Grossa, Brazil; [Farago, P. V.] Univ Estadual Ponta Grossa, Dept Ciencias Farmaceut, BR-84030900 Ponta Grossa, Brazil; [Almeida, M. A.] Univ Fed Curitiba, Dept Quim, BR-81531980 Curitiba, Parana, Brazil	Universidade Estadual de Ponta Grossa; Universidade Estadual de Ponta Grossa; Universidade Federal do Parana	Lenzi, EK (corresponding author), Univ Estadual Ponta Grossa, Dept Fis, BR-84030900 Ponta Grossa, Brazil.	eklenzi@uepg.br	Lenzi, Ervin Kaminski/N-1767-2019; Novatski, Andressa/D-5366-2013; zawadzki, sonia f/T-1546-2017	Lenzi, Ervin Kaminski/0000-0003-3853-1790; Novatski, Andressa/0000-0002-8327-6285; 	CNPQ [303642/2014-9, 456403/2014-0, 401997/2014-6]; Fundacao Araucaria [613 / 2014, 822/13]	CNPQ(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Araucaria(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FAFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC))	The authors thank CNPQ (grant numbers, 303642/2014-9 (EKL), 456403/2014-0 (PVF), and 401997/2014-6 (RM)) and Fundacao Araucaria (grant numbers, 613 / 2014 (AN) and 822/13 (AN)) for the partial financial support. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida MA, 2014, MAT SCI ENG C-MATER, V40, P345, DOI 10.1016/j.msec.2014.03.049; Barkai E, 2012, PHYS TODAY, V65, P29, DOI 10.1063/PT.3.1677; Benichou O, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.038102; Berg Howard C., 1993, RANDOM WALKS BIOL; Bressloff P. C., 2014, STOCHASTIC PROCESSES; Bressloff PC, 2013, REV MOD PHYS, V85, P135, DOI 10.1103/RevModPhys.85.135; Bueno-Orovio A, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0352; Chechkin AV, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3593198; Chechkin AV, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.040105; Chechkin AV, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046129; Ciuchi F, 2012, J PHYS CHEM C, V116, P8773, DOI 10.1021/jp211097m; Condamin S, 2008, P NATL ACAD SCI USA, V105, P5675, DOI 10.1073/pnas.0712158105; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; Crank J., 1979, MATH DIFFUSION; Guimaraes VG, 2015, SOFT MATTER, V11, P1658, DOI 10.1039/c5sm00151j; Hayman M., 2008, CURR ANAESTH CRIT CA, V19, P338, DOI [10.1016/j.cacc.2008.07.003, DOI 10.1016/J.CACC.2008.07.003]; HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018; Hofling F, 2013, REP PROG PHYS, V76, DOI 10.1088/0034-4885/76/4/046602; Iyiola OS, 2014, AIP ADV, V4, DOI 10.1063/1.4898331; Klafter J., 2012, FRACTIONAL DYNAMICS; KORSMEYER RW, 1981, J MEMBRANE SCI, V9, P211, DOI 10.1016/S0376-7388(00)80265-3; Langlands TAM, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.051102; Mathai AM, 2010, H-FUNCTION: THEORY AND APPLICATIONS, P1, DOI 10.1007/978-1-4419-0916-9; Metzler R, 2014, PHYS CHEM CHEM PHYS, V16, P24128, DOI 10.1039/c4cp03465a; OSHAUGHNESSY B, 1985, PHYS REV LETT, V54, P455, DOI 10.1103/PhysRevLett.54.455; Peng HL, 2010, FOOD CHEM, V121, P23, DOI 10.1016/j.foodchem.2009.11.085; Podlubny I, 1998, FRACTIONAL DIFFERENT, V198, P324; SCHNEIDER WR, 1989, J MATH PHYS, V30, P134, DOI 10.1063/1.528578; Schumer R, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002141; Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0; Siepmann J, 2013, INT J PHARMACEUT, V453, P12, DOI 10.1016/j.ijpharm.2013.04.044; Tateishi AA, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.011147; WANG TT, 1969, J POLYM SCI A2, V7, P2019, DOI 10.1002/pol.1969.160071204; Wyld H. W., 1976, MATH METHODS PHYS; Yin C, 2011, INT J PHARMACEUT, V418, P78, DOI 10.1016/j.ijpharm.2010.12.009; Zola RS, 2007, CHEM PHYS LETT, V438, P144, DOI 10.1016/j.cplett.2007.02.068	36	3	3	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157662	10.1371/journal.pone.0157662	http://dx.doi.org/10.1371/journal.pone.0157662			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27309358	gold, Green Published, Green Submitted			2023-01-03	WOS:000378029800118
J	Huang, ES				Huang, Elbert S.			Management of diabetes mellitus in older people with comorbidities	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTENSIVE GLUCOSE CONTROL; CLINICAL-PRACTICE GUIDELINES; MULTIPLE CHRONIC CONDITIONS; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; FOLLOW-UP; HEALTH OUTCOMES; DECISION AID; ADULTS	Diabetes mellitus is a chronic disease of aging that affects more than 20% of people over 65. In older patients with diabetes, comorbidities are highly prevalent and their presence may alter the relative importance, effectiveness, and safety of treatments for diabetes. Randomized controlled trials have shown that intensive glucose control produces microvascular and cardiovascular benefits but typically after extended treatment periods (five to nine years) and with exposure to short term risks such as mortality (in one trial) and hypoglycemia. Decision analysis, health economics, and observational studies have helped to illustrate the importance of acknowledging life expectancy, hypoglycemia, and treatment burden when setting goals in diabetes. Guidelines recommend that physicians individualize the intensity of glucose control and treatments on the basis of the prognosis (for example, three tiers based on comorbidities and functional impairments) and preferences of individual patients. Very few studies have attempted to formally implement and study these concepts in clinical practice. To better meet the treatment needs of older patients with diabetes and comorbidities, more research is needed to determine the risks and benefits of intensifying, maintaining, or de-intensifying treatments in this population. This research effort should extend to the development and study of decision support tools as well as targeted care management.	[Huang, Elbert S.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago	Huang, ES (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	ehuang@medicine.bsd.uchicago.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081796, K24DK105340, P30DK092949] Funding Source: NIH RePORTER; AHRQ [5R01HS018542-02, 5R01HS018542-03] Funding Source: Federal RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Adams K, 2012, J AM GERIATR SOC, V60, P2333, DOI 10.1111/j.1532-5415.2012.04240.x; Amati F, 2009, DIABETES CARE, V32, P1547, DOI 10.2337/dc09-0267; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Araki A, 2012, GERIATR GERONTOL INT, V12, P7, DOI 10.1111/j.1447-0594.2011.00808.x; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Blaum CS, 2010, MED CARE, V48, P327, DOI 10.1097/MLR.0b013e3181ca4035; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Cegelka A, 2013, J AM GERIATR SOC, V61, P2020, DOI 10.1111/jgs.12514; Centers for Disease Control and Prevention, 2015, RATE PER 100 OF CIVI; Centers for Disease Control and Prevention, 2014, NATIONAL DIABETES ST; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christakis NA, 1999, DEATH FORETOLD PROPH; Cigolle Christine T, 2012, J Gerontol A Biol Sci Med Sci, V67, P1313, DOI 10.1093/gerona/gls095; Clarke PM, 2004, DIABETOLOGIA, V47, P1747, DOI 10.1007/s00125-004-1527-z; Coca SG, 2012, ARCH INTERN MED, V172, P761, DOI 10.1001/archinternmed.2011.2230; Corser W, 2007, DIABETES EDUCATOR, V33, P700, DOI 10.1177/0145721707304086; Denig P, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5651; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Druss BG, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.6.233; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Gandhi GY, 2008, JAMA-J AM MED ASSOC, V299, P2543, DOI 10.1001/jama.299.21.2543; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gerstein HC, 2011, NEW ENGL J MED, V364, P818, DOI 10.1056/NEJMoa1006524; Greenfield S, 2009, ANN INTERN MED, V151, P854, DOI 10.7326/0003-4819-151-12-200912150-00005; Halter JB, 2014, DIABETES, V63, P2578, DOI 10.2337/db14-0020; Hayward RA, 2015, NEW ENGL J MED, V372, P2197, DOI 10.1056/NEJMoa1414266; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Huang ES, 2008, ANN INTERN MED, V149, P11, DOI 10.7326/0003-4819-149-1-200807010-00005; Huang ES, 2013, DIABETES, V62, pA336; Huang ES, 2014, JAMA INTERN MED, V174, P251, DOI 10.1001/jamainternmed.2013.12956; Huang ES, 2009, DIABETES CARE, V32, P2225, DOI 10.2337/dc09-0459; Huang ES, 2006, DIABETES CARE, V29, P259, DOI 10.2337/diacare.29.02.06.dc05-1443; Ickowicz E, 2003, J AM GERIATR SOC, V51, pS265; International Diabetes Federation, 2021, IDF DIABETES ATLAS, VTenth., DOI DOI 10.1214/AOMS/1177699147; Kirkman MS, 2012, DIABETES CARE, V35, P2650, DOI 10.2337/dc12-1801; Laiteerapong N, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110287; Laiteerapong N, 2011, DIABETES CARE, V34, P1749, DOI 10.2337/dc10-2424; Lee PG, 2009, J AM GERIATR SOC, V57, P511, DOI 10.1111/j.1532-5415.2008.02150.x; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; Lipska KJ, 2015, JAMA INTERN MED, V175, P356, DOI 10.1001/jamainternmed.2014.7345; Litwin MS, 2007, CANCER-AM CANCER SOC, V109, P1777, DOI 10.1002/cncr.22615; Miller ME, 2014, DIABETES CARE, V37, P634, DOI 10.2337/dc13-1545; Moreno G, 2013, J AM GERIATR SOC, V61, P2027, DOI 10.1111/jgs.12513; Moritz T, 2009, NEW ENGL J MED, V361, P1024, DOI 10.1056/NEJMc096250; Morley JE, 1998, DIABETIC MED, V15, pS41, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S41::AID-DIA747>3.3.CO;2-5; Mullan RJ, 2009, ARCH INTERN MED, V169, P1560, DOI 10.1001/archinternmed.2009.293; Munshi MN, 2013, DIABETES CARE, V36, P543, DOI 10.2337/dc12-1303; Naik AD, 2011, ARCH INTERN MED, V171, P453, DOI 10.1001/archinternmed.2011.70; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Preis SR, 2009, CIRCULATION, V119, P1728, DOI 10.1161/CIRCULATIONAHA.108.829176; Ray KK, 2009, LANCET, V373, P1765, DOI 10.1016/S0140-6736(09)60697-8; Rutter CM, 2011, MED DECIS MAKING, V31, P10, DOI 10.1177/0272989X10369005; Saunders C, 2013, DIABETIC MED, V30, P300, DOI 10.1111/dme.12047; Schlessinger L, 2002, J BIOMED INFORM, V35, P37, DOI 10.1016/S1532-0464(02)00006-0; Schneider KM, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-82; Seaquist ER, 2013, DIABETES CARE, V36, P1384, DOI 10.2337/dc12-2480; Selvin E, 2006, DIABETES CARE, V29, P2415, DOI 10.2337/dc06-1058; Silveira MJ, 2014, J AM GERIATR SOC, V62, P706, DOI 10.1111/jgs.12736; Sinclair AJ, 2011, DIABETES METAB, V37, pS27, DOI 10.1016/S1262-3636(11)70962-4; Thorpe CT, 2015, DIABETES CARE, V38, P588, DOI 10.2337/dc14-0599; Tierney EF, 2004, DIABETES CARE, V27, P2723, DOI 10.2337/diacare.27.11.2723; Tseng CL, 2014, JAMA INTERN MED, V174, P259, DOI 10.1001/jamainternmed.2013.12963; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; US Department of Veterans Affairs, 2010, VA DOD CLINICAL PRAC; Vijan S, 2014, JAMA INTERN MED, V174, P1227, DOI 10.1001/jamainternmed.2014.2894; Vincent GK, 2010, THE NEXT FOUR DECADE; Weymiller AJ, 2007, ARCH INTERN MED, V167, P1076, DOI 10.1001/archinte.167.10.1076; Wilkinson MJ, 2013, CURR DIABETES REP, V13, P205, DOI 10.1007/s11892-012-0348-6; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Xu Jiaquan, 2010, Natl Vital Stat Rep, V58, P1; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966; Zhou H, 2005, DIABETES CARE, V28, P2856, DOI 10.2337/diacare.28.12.2856; Zoungas S, 2014, NEW ENGL J MED, V371, P1392, DOI 10.1056/NEJMoa1407963	80	35	35	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2016	353								i2200	10.1136/bmj.i2200	http://dx.doi.org/10.1136/bmj.i2200			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP1HF	27307175	Green Published			2023-01-03	WOS:000378240400001
J	Wright, CJ; Zeeman, H; Biezaitis, V				Wright, Courtney J.; Zeeman, Heidi; Biezaitis, Valda			Holistic Practice in Traumatic Brain Injury Rehabilitation: Perspectives of Health Practitioners	PLOS ONE			English	Article							QUALITY-OF-LIFE; COGNITIVE REHABILITATION; CARE PERSPECTIVES; SELF-AWARENESS; DISABILITY; TRANSITION; OUTCOMES; ADULTS; MODEL; PROFESSIONALS	Given that the literature suggests there are various (and often contradictory) interpretations of holistic practice in brain injury rehabilitation and multiple complexities in its implementation (including complex setting, discipline, and client-base factors), this study aimed to examine the experiences of practitioners in their conceptualization and delivery of holistic practice in their respective settings. Nineteen health practitioners purposively sampled from an extensive Brain Injury Network in Queensland, Australia participated in individual interviews. A systematic text analysis process using Leximancer qualitative analysis program was undertaken, followed by manual thematic analysis to develop overarching themes. The findings from this study have identified several items for future inter-professional development that will not only benefit the practitioners working in brain injury rehabilitation settings, but the patients and their families as well.	[Wright, Courtney J.; Zeeman, Heidi] Griffith Univ, Menzies Hlth Inst Queensland, Sch Human Serv & Social Work, Meadowbrook, Qld 4131, Australia; [Wright, Courtney J.; Zeeman, Heidi] Griffith Univ, RECOVER Injury Res Ctr, Meadowbrook, Qld 4131, Australia; [Biezaitis, Valda] Mater Childrens Hosp, ROBIN Team, South Brisbane, Qld, Australia; [Biezaitis, Valda] Mater Res, Improving Treatment Dis, South Brisbane, Qld, Australia	Griffith University; Griffith University; Mater Research	Wright, CJ (corresponding author), Griffith Univ, Menzies Hlth Inst Queensland, Sch Human Serv & Social Work, Meadowbrook, Qld 4131, Australia.; Wright, CJ (corresponding author), Griffith Univ, RECOVER Injury Res Ctr, Meadowbrook, Qld 4131, Australia.	Courtney.wright@griffith.edu.au		Wright, Courtney/0000-0003-4735-4378	Mater Children's Hospital	Mater Children's Hospital	The authors are grateful to the Mater Children's Hospital and the Brain Injury Network team led by Dr. Ron Hazelton, who supported this study throughout. Many thanks in particular, to the participants of the study who gave so generously of their time. Special thanks are also extended to Dr. Valda Biezaitis for her willingness and enthusiasm to engage in research as a practicing clinician.	Allan Chris M, 2006, J Interprof Care, V20, P235, DOI 10.1080/13561820600718139; Australian Institute of Health and Welfare, 2008, AUSTR HLTH 2008; Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Ben-Yishay Y, 2011, HDB HOLISTIC NEUROPS; Ben-Yishay Y., 1990, COGNITIVE REMEDIATIO; Bolderston A, 2012, J MED IMAGING RADIAT, V43, P66, DOI 10.1016/j.jmir.2011.12.002; Brasure M, 2013, ARCH PHYS MED REHAB, V94, P1398, DOI 10.1016/j.apmr.2012.12.019; Breen LJ, 2011, DISABIL REHABIL, V33, P862, DOI 10.3109/09638288.2010.520799; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Cerniauskaite M, 2011, DISABIL REHABIL, V33, P281, DOI 10.3109/09638288.2010.529235; Charleswell C, 2015, J EPIDEMIOL COMMUN H, V69, P290, DOI 10.1136/jech-2014-204239; Chittiboina Prashant, 2013, Pathophysiology, V20, P15, DOI 10.1016/j.pathophys.2012.02.004; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Dalton C, 2012, CLIN REHABIL, V26, P165, DOI 10.1177/0269215511405230; Dion GR, 2014, J VOICE, V28, P88, DOI 10.1016/j.jvoice.2013.08.005; Engel George L, 2012, Psychodyn Psychiatry, V40, P377, DOI 10.1037/h0089260; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Flick U., 2019, INTRO QUALITATIVE RE, V6th; Fossey E, 2002, AUST NZ J PSYCHIAT, V36, P717, DOI 10.1046/j.1440-1614.2002.01100.x; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Gibbins S, 2015, QUAL HEALTH RES, V25, P763, DOI 10.1177/1049732315580105; Goldstein K., 1939, ORG HOLISTIC APPROAC; Guion L.A., 2011, TRIANGULATION ESTABL; Gzil F, 2007, DISABIL REHABIL, V29, P1616, DOI 10.1080/09638280701618620; Haboubi NHJ, 2003, DISABIL REHABIL, V25, P291, DOI 10.1080/0963828021000031188; Hall Pippa, 2005, J Interprof Care, V19 Suppl 1, P188; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Heinemann AW, 2005, REHABIL PSYCHOL, V50, P6, DOI 10.1037/0090-5550.50.1.6; Helps Y. L., 2008, INJURY RES STAT SERI, V45; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hooson JM, 2013, NEUROPSYCHOL REHABIL, V23, P19, DOI 10.1080/09602011.2012.713314; Huber JG, 2010, DISABIL REHABIL, V32, P1955, DOI 10.3109/09638281003797414; Jenesick V, 2000, HDB QUALITATIVE RES; Kelley E, 2014, J HEAD TRAUMA REHAB, V29, P147, DOI 10.1097/HTR.0b013e31826db6b9; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kontos PC, 2012, QUAL HEALTH RES, V22, P1612, DOI 10.1177/1049732312458370; Koskinen S, 2011, DISABIL REHABIL, V33, P2464, DOI 10.3109/09638288.2011.574776; Kuipers P, 2014, J INTERPROF CARE, V28, P246, DOI 10.3109/13561820.2013.821601; Kuipers P, 2009, DISABIL REHABIL, V31, P144, DOI 10.1080/01674820701817938; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Leonardi M, 2009, DISABIL REHABIL, V31, pS83, DOI 10.3109/09638280903317948; Leplege A, 2007, DISABIL REHABIL, V29, P1555, DOI 10.1080/09638280701618661; Lexell J, 2007, J HEAD TRAUMA REHAB, V22, P229, DOI 10.1097/01.HTR.0000281838.00344.03; Lyons AC., 2006, HLTH PSYCHOL CRITICA; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; McEvoy Liz, 2008, Nurse Educ Pract, V8, P412, DOI 10.1016/j.nepr.2008.02.002; McHugh J C, 2007, Ir Med J, V100, P518; McMillan SS, 2013, MED CARE RES REV, V70, P567, DOI 10.1177/1077558713496318; Merriam S. B., 2015, QUALITATIVE RES GUID, V4th; Moos R, 1979, HLTH PSYCHOL HDB; Nicassio PM., 1995, MANAGING CHRONIC ILL; PETRIE HG, 1976, J AESTHET EDUC, V10, P29, DOI 10.2307/3332007; Ponsford J., 2013, TRAUMATIC BRAIN INJU, V2nd ed; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1997, J INT NEUROPSYCH SOC, V3, P497, DOI 10.1017/S1355617797004979; Prigatano GP, 1999, REHABILITATION ADULT; Rahman B, 2013, NEUROPSYCHOL REHABIL, V23, P501, DOI 10.1080/09602011.2013.787938; RAND Corporation, 2012, LAB FORC REENTR ISS; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Rowe H, 1996, J Nurs Manag, V4, P93, DOI 10.1046/j.1365-2834.1996.01946.x; SCHWARTZ MA, 1985, PERSPECT BIOL MED, V28, P331; Silberg T, 2015, BRAIN INJURY, V29, P481, DOI 10.3109/02699052.2014.984758; Smith AE, 2006, BEHAV RES METHODS, V38, P262, DOI 10.3758/BF03192778; Starks H, 2007, QUAL HEALTH RES, V17, P1372, DOI 10.1177/1049732307307031; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; Svestkova O, 2010, DISABIL REHABIL, V32, pS68, DOI 10.3109/09638288.2010.511690; Tate DG, 2003, AM PSYCHOL, V58, P289, DOI 10.1037/0003-066X.58.4.289; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Turner B, 2009, BRAIN INJURY, V23, P51, DOI 10.1080/02699050802635257; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Wilkinson-Meyers L, 2010, SOC SCI MED, V71, P1882, DOI 10.1016/j.socscimed.2010.08.019; Williams J, 2011, DISABIL REHABIL, V33, P423, DOI 10.3109/09638288.2010.498555; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; Wilmot S, 2007, HEALTH CARE ANAL, V15, P59, DOI 10.1007/s10728-006-0032-6; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; World Health Organisation, 2001, ICF INT CLASFUNCT; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408; Young NL, 2009, PHYS OCCUP THER PEDI, V29, P345, DOI 10.3109/01942630903245994; Young NL, 2005, DISABIL REHABIL, V27, P1455, DOI 10.1080/00222930500218946	89	13	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2016	11	6							e0156826	10.1371/journal.pone.0156826	http://dx.doi.org/10.1371/journal.pone.0156826			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DO1SU	27270604	Green Published, Green Submitted, gold			2023-01-03	WOS:000377560200019
J	Karamyan, A; Dunser, MW; Wiebe, DJ; Pilz, G; Wipfler, P; Chroust, V; Novak, HF; Hauer, L; Trinka, E; Sellner, J				Karamyan, Anush; Duenser, Martin W.; Wiebe, Douglas J.; Pilz, Georg; Wipfler, Peter; Chroust, Vaclav; Novak, Helmut F.; Hauer, Larissa; Trinka, Eugen; Sellner, Johann			Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study	PLOS ONE			English	Article							ILL PATIENTS; MORTALITY; MULTICENTER; ADMISSION; COST	Background Over the course of multiple sclerosis (MS) several conditions may arise that require critical care. We aimed to study the reasons for admission and outcome in patients with MS admitted to a neuro-intensive care unit (NICU). Methods We retrospectively searched the electronic charts of a 9-bedded NICU in a tertiary hospital for patients with a diagnosis of multiple sclerosis (MS) from 1993-2015, and matched them to NICU controls without MS based on age and gender. Conditional logistic regression was used to compare admission causes, Charlson's Comorbidity Index, indicators of disease severity, and survival between MS and non-MS patients. Results We identified 61 MS patients and 181 non-MS controls. Respiratory dysfunction was the most frequent reason for NICU admission among MS patients (34.4%), having infectious context as a rule. In a matched analysis, after adjusting for co-morbidities and immunosuppressive medications, patients with MS were more likely to be admitted to the NICU because of respiratory dysfunction (OR = 7.86, 95% CI 3.02-20.42, p<0.001), non-respiratory infections (OR = 3.71, 95% CI 1.29-10.68, p = 0.02), had a higher rate of multiple NICU admissions (OR = 2.53, 95% CI 1.05-6.05, p = 0.04) than non-MS patients. Mortality after NICU admission at a median follow-up time of 1 year was higher in MS than control patients (adjusted OR = 4.21, 95% CI 1.49-11.85, p = 0.04). Conclusion The most common reason for NICU admission in MS patients was respiratory dysfunction due to infection. Compared to non-MS patients, critically ill MS patients had a higher NICU re-admission rate, and a higher mortality.	[Karamyan, Anush; Pilz, Georg; Wipfler, Peter; Chroust, Vaclav; Novak, Helmut F.; Trinka, Eugen; Sellner, Johann] Paracelsus Med Univ, Dept Neurol, Christian Doppler Med Ctr, Salzburg, Austria; [Karamyan, Anush; Pilz, Georg; Wipfler, Peter; Chroust, Vaclav; Novak, Helmut F.; Trinka, Eugen; Sellner, Johann] Ctr Cognit Neurosci, Salzburg, Austria; [Duenser, Martin W.] Univ Hosp Salzburg, Dept Anesthesiol Perioperat & Gen Intens Care Med, Salzburg, Austria; [Duenser, Martin W.] Paracelsus Med Univ, Salzburg, Austria; [Wiebe, Douglas J.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Hauer, Larissa] Paracelsus Med Univ, Dept Psychiat, Christian Doppler Med Ctr, Salzburg, Austria; [Sellner, Johann] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-80290 Munich, Germany	Paracelsus Private Medical University; Paracelsus Private Medical University; University of Pennsylvania; Pennsylvania Medicine; Paracelsus Private Medical University; Technical University of Munich	Sellner, J (corresponding author), Paracelsus Med Univ, Dept Neurol, Christian Doppler Med Ctr, Salzburg, Austria.; Sellner, J (corresponding author), Ctr Cognit Neurosci, Salzburg, Austria.; Sellner, J (corresponding author), Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-80290 Munich, Germany.	j.sellner@salk.at	Selllner, Johann/AAB-1263-2019; Wiebe, Douglas J/Q-1168-2017	Pilz, Georg/0000-0001-8764-2628; Wipfler, Peter/0000-0003-4982-4855; Trinka, Eugen/0000-0002-5950-2692	Merck; Paracelsus Medical University; Bayer; Biogen-Idec; Novartis; Genzyme	Merck(Merck & Company); Paracelsus Medical University; Bayer(Bayer AG); Biogen-Idec(Biogen); Novartis(Novartis); Genzyme(Sanofi-AventisGenzyme Corporation)	This study was in part supported by an unrestricted grant from Merck. JS has received research funding from the Paracelsus Medical University, Bayer, Biogen-Idec, Merck and Novartis, has acted as paid consultant to Novartis and Genzyme, and has received speakers' honoraria from Biogen-Idec, Ever Neuropharma, Genzyme, Novartis and Teva-Ratiopharm. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelman Gabriel, 2013, J Med Econ, V16, P639, DOI 10.3111/13696998.2013.778268; Bernal-Macias S, 2015, LUPUS SCI MED, V2, DOI 10.1136/lupus-2015-000122; Brinkman S, 2013, CRIT CARE MED, V41, P1229, DOI 10.1097/CCM.0b013e31827ca4e1; Broessner G, 2007, CRIT CARE MED, V35, P2025, DOI 10.1097/01.ccm.0000281449.07719.2b; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; Findling O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121856; Finkielman JD, 2004, CRIT CARE MED, V32, P1161, DOI 10.1097/01.CCM.0000126151.56590.99; Goodin DS, 2014, HAND CLINIC, V122, P231, DOI 10.1016/B978-0-444-52001-2.00010-8; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lalmohamed A, 2012, EUR J NEUROL, V19, P1007, DOI 10.1111/j.1468-1331.2012.03668.x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Marrie RA, 2015, NEUROLOGY, V85, P240, DOI 10.1212/WNL.0000000000001718; Marrie RA, 2014, NEUROLOGY, V82, P2112, DOI 10.1212/WNL.0000000000000495; Metnitz PGH, 2003, INTENS CARE MED, V29, P241, DOI 10.1007/s00134-002-1584-z; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Montgomery S, 2013, EUR J NEUROL, V20, P1153, DOI 10.1111/ene.12130; Nardone R, 2015, J SPINAL CORD MED, V13, P1; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Scalfari A, 2013, NEUROLOGY, V81, P184, DOI 10.1212/WNL.0b013e31829a3388; Sellner J, 2011, AUTOIMMUN REV, V10, P495, DOI 10.1016/j.autrev.2011.02.006; Tzelepis GE, 2015, RESP MED, V109, P671, DOI 10.1016/j.rmed.2015.01.018; Vezzani A, 2011, GENDER MED, V8, P32, DOI 10.1016/j.genm.2010.11.011; Williamson EM, 2015, CNS DRUGS, V29, P229, DOI 10.1007/s40263-015-0226-2	23	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2016	11	5							e0155795	10.1371/journal.pone.0155795	http://dx.doi.org/10.1371/journal.pone.0155795			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN5XX	27244560	Green Published, Green Submitted, gold			2023-01-03	WOS:000377146100006
J	King, NB; Strumpf, E; Harper, S				King, Nicholas B.; Strumpf, Erin; Harper, Sam			Has the Increase in Disability Insurance Participation Contributed to Increased Opioid-Related Mortality?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNITED-STATES		[King, Nicholas B.; Strumpf, Erin; Harper, Sam] McGill Univ, Montreal, PQ, Canada; [King, Nicholas B.] McGill Univ, Biomed Eth Unit, 3647 Peel St, Montreal, PQ H3A 1X1, Canada; [Strumpf, Erin] McGill Univ, Dept Econ, Leacock 418,855 Sherbrooke St West, Montreal, PQ H3A 2T7, Canada; [Harper, Sam] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Purvis Hall,1020 Pine Ave West, Montreal, PQ H3A 1A2, Canada	McGill University; McGill University; McGill University; McGill University	King, NB (corresponding author), McGill Univ, Biomed Eth Unit, 3647 Peel St, Montreal, PQ H3A 1X1, Canada.		Harper, Sam/A-3406-2008	Harper, Sam/0000-0002-2767-1053; King, Nicholas/0000-0002-2093-3380				Autor David, 2006, Q J ECON, V118, P157; Chen LH, 2015, MMWR-MORBID MORTAL W, V64, P32; Hansen H, 2014, SOC SCI MED, V103, P76, DOI 10.1016/j.socscimed.2013.06.033; Insurance Supervision Agency, 2015, ANN REP INS MARK REP; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Lakdawalla DN, 2004, HEALTH AFFAIR, V23, P168, DOI 10.1377/hlthaff.23.1.168; Liebman JB, 2015, J ECON PERSPECT, V29, P123, DOI 10.1257/jep.29.2.123; Meara E., 2016, N ENGL J MED; Pacula RL, 2015, 21072 NBER; Wamhoff Steve, 2005, Soc Secur Bull, V66, P21	10	7	7	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2016	165	10					729	+		10.7326/M16-0918	http://dx.doi.org/10.7326/M16-0918			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EC2RB	27571480				2023-01-03	WOS:000387970500017
J	Hadland, SE; Wood, E; Levy, S				Hadland, Scott E.; Wood, Evan; Levy, Sharon			How the paediatric workforce can address the opioid crisis	LANCET			English	Editorial Material							PRIMARY-CARE		[Hadland, Scott E.] Boston Univ, Sch Med, Div Gen Pediat, Dept Pediat, Boston, MA 02118 USA; [Hadland, Scott E.] Boston Childrens Hosp, Div Adolescent Young Adult Med, Dept Med, Boston, MA USA; [Hadland, Scott E.; Levy, Sharon] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Wood, Evan] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Wood, Evan] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Levy, Sharon] Boston Childrens Hosp, Div Dev Med, Boston, MA USA	Boston University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Harvard University; Boston Children's Hospital	Hadland, SE (corresponding author), Boston Univ, Sch Med, Div Gen Pediat, Dept Pediat, Boston, MA 02118 USA.; Hadland, SE (corresponding author), Boston Childrens Hosp, Div Adolescent Young Adult Med, Dept Med, Boston, MA USA.; Hadland, SE (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA USA.	scott.hadland@bmc.org	Hadland, Scott/ABF-8215-2020	Hadland, Scott/0000-0003-3189-6199	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA021913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA037770] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA021913] Funding Source: Medline; NIDA NIH HHS [R03 DA037770, L40 DA042434, K23 DA045085] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		American Academy of Pediatrics Committee on Substance Use and Prevention, 2016, PEDIATRICS, V138; Bateman J, 2014, CHILD ADOL MENT H-UK, V19, P102, DOI 10.1111/camh.12013; Center for Behavioral Health Statistics and Quality, 2015, TREATM EP DAT SET TE; Dunlap B, 2016, JAMA-J AM MED ASSOC, V316, P338, DOI 10.1001/jama.2016.9795; Han B, 2015, RECEIPT SERVICES BEH; Knudsen HK, 2011, J ADDICT MED, V5, P21, DOI 10.1097/ADM.0b013e3181d41ddb; Komaromy M, 2016, SUBST ABUS, V37, P20, DOI 10.1080/08897077.2015.1129388; Lawson E., 2011, GUIDANCE USE SUBSTIT; Richardson LP, 2014, JAMA-J AM MED ASSOC, V312, P809, DOI 10.1001/jama.2014.9259; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; United Nations Office on Drugs and Crime, 2016, WORLD DRUG REP 2016; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4	12	22	22	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 24	2016	388	10051					1260	1261		10.1016/S0140-6736(16)31573-2	http://dx.doi.org/10.1016/S0140-6736(16)31573-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DW5RH	27673455	Green Accepted			2023-01-03	WOS:000383704000011
J	Baghirov, H; Karaman, D; Viitala, T; Duchanoy, A; Lou, YR; Mamaeva, V; Pryazhnikov, E; Khiroug, L; Davies, CD; Sahlgren, C; Rosenholm, JM				Baghirov, Habib; Karaman, Didem; Viitala, Tapani; Duchanoy, Alain; Lou, Yan-Ru; Mamaeva, Veronika; Pryazhnikov, Evgeny; Khiroug, Leonard; Davies, Catharina de Lange; Sahlgren, Cecilia; Rosenholm, Jessica M.			Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier	PLOS ONE			English	Article							BIOMEDICAL APPLICATIONS; IN-VITRO; CELLS; EXOCYTOSIS; NANOCARRIERS; ENDOCYTOSIS; DETERMINES; ABSORPTION; MECHANISM; TRANSPORT	Drug delivery into the brain is impeded by the blood-brain-barrier (BBB) that filters out the vast majority of drugs after systemic administration. In this work, we assessed the transport, uptake and cytotoxicity of promising drug nanocarriers, mesoporous silica nanoparticles (MSNs), in in vitro models of the BBB. RBE4 rat brain endothelial cells and Madin-Darby canine kidney epithelial cells, strain II, were used as BBB models. We studied spherical and rod-shaped MSNs with the following modifications: bare MSNs and MSNs coated with a poly (ethylene glycol)-poly(ethylene imine) (PEG-PEI) block copolymer. In transport studies, MSNs showed low permeability, whereas the results of the cellular uptake studies suggest robust uptake of PEG-PEI-coated MSNs. None of the MSNs showed significant toxic effects in the cell viability studies. While the shape effect was detectable but small, especially in the real-time surface plasmon resonance measurements, coating with PEG-PEI copolymers clearly facilitated the uptake of MSNs. Finally, we evaluated the in vivo detectability of one of the best candidates, i.e. the copolymer-coated rod-shaped MSNs, by two-photon in vivo imaging in the brain vasculature. The particles were clearly detectable after intravenous injection and caused no damage to the BBB. Thus, when properly designed, the uptake of MSNs could potentially be utilized for the delivery of drugs into the brain via transcellular transport.	[Baghirov, Habib; Mamaeva, Veronika; Sahlgren, Cecilia] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Baghirov, Habib; Mamaeva, Veronika; Sahlgren, Cecilia] Abo Akad Univ, Turku, Finland; [Baghirov, Habib; Karaman, Didem; Duchanoy, Alain; Rosenholm, Jessica M.] Abo Akad Univ, Fac Sci & Engn, Phys Chem Lab, Turku, Finland; [Baghirov, Habib; Sahlgren, Cecilia] Abo Akad Univ, Fac Sci & Engn, Cell Biol, Turku, Finland; [Baghirov, Habib; Davies, Catharina de Lange] Norwegian Univ Sci & Technol, Dept Phys, Trondheim, Norway; [Karaman, Didem; Rosenholm, Jessica M.] Abo Akad Univ, Fac Sci & Engn, Pharmaceut Sci Lab, Turku, Finland; [Viitala, Tapani; Lou, Yan-Ru] Univ Helsinki, Div Pharmaceut Biosci, Ctr Drug Res, Helsinki, Finland; [Pryazhnikov, Evgeny; Khiroug, Leonard] Neurotar LtD, Helsinki, Finland; [Sahlgren, Cecilia] Eindhoven Univ Technol, Eindhoven, Netherlands	University of Turku; Abo Akademi University; Abo Akademi University; Abo Akademi University; Norwegian University of Science & Technology (NTNU); Abo Akademi University; University of Helsinki; Eindhoven University of Technology	Sahlgren, C (corresponding author), Univ Turku, Turku Ctr Biotechnol, Turku, Finland.; Sahlgren, C (corresponding author), Abo Akad Univ, Turku, Finland.; Rosenholm, JM (corresponding author), Abo Akad Univ, Fac Sci & Engn, Phys Chem Lab, Turku, Finland.; Sahlgren, C (corresponding author), Abo Akad Univ, Fac Sci & Engn, Cell Biol, Turku, Finland.; Rosenholm, JM (corresponding author), Abo Akad Univ, Fac Sci & Engn, Pharmaceut Sci Lab, Turku, Finland.; Sahlgren, C (corresponding author), Eindhoven Univ Technol, Eindhoven, Netherlands.	csahlgre@btk.fi; jerosenh@abo.fi	Karaman, Didem Sen/AAA-4738-2020; Lou, Yan-Ru/AAX-4008-2020; Viitala, Tapani/N-1434-2014; Lou, Yan-Ru/K-4348-2012; Rosenholm, Jessica Marianne/H-2542-2012	Karaman, Didem Sen/0000-0002-2368-9598; Lou, Yan-Ru/0000-0001-7717-6010; Viitala, Tapani/0000-0001-9074-9450; Lou, Yan-Ru/0000-0001-7717-6010; Rosenholm, Jessica Marianne/0000-0001-6085-1112; Baghirov, Habib/0000-0002-3441-9825; Sahlgren, Cecilia/0000-0003-3350-4937	Academy of Finland [140193, 137101, 260599, 137053, 263861]; Norwegian Research Council [Biotek2021 226159, Nano2021 220005]; Center for Functional Materials; Graduate School of Materials Research; Neurotar LtD	Academy of Finland(Academy of Finland); Norwegian Research Council(Research Council of NorwayEuropean Commission); Center for Functional Materials; Graduate School of Materials Research; Neurotar LtD	Funding for this research work was provided by the Academy of Finland project #140193: "Targeting of cancer cells by design - Nanoparticles as theranostic agents" (JR). Other supporting funding sources the authors acknowledge are Norwegian Research Council projects (Biotek2021 226159 and Nano2021 220005), Academy of Finland projects (#137101, #260599, #137053 and #263861) (CD), Center for Functional Materials (DSK) and Graduate School of Materials Research (AD). Neurotar LtD provided support in the form of salaries for authors EP and LK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Barandeh F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029424; Chabot V, 2009, BIOSENS BIOELECTRON, V24, P1667, DOI 10.1016/j.bios.2008.08.025; Chen Y, 2014, EXPERT OPIN DRUG DEL, V11, P917, DOI 10.1517/17425247.2014.908181; Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y; Desai D, 2014, MESOPOROUS BIOMATERI, V1, P28; Fazlollahi F, 2011, NANOMED-NANOTECHNOL, V7, P588, DOI 10.1016/j.nano.2011.01.008; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Gu J, 2007, SMALL, V3, P1740, DOI 10.1002/smll.200700311; Hanada S, 2014, INT J MOL SCI, V15, P1812, DOI 10.3390/ijms15021812; Harush-Frenkel O, 2008, BIOMACROMOLECULES, V9, P435, DOI 10.1021/bm700535p; He QJ, 2009, SMALL, V5, P2722, DOI 10.1002/smll.200900923; Huang XL, 2010, BIOMATERIALS, V31, P438, DOI 10.1016/j.biomaterials.2009.09.060; Jain KK, 2012, NANOMEDICINE-UK, V7, P1225, DOI 10.2217/nnm.12.86; Jiang XE, 2010, ACS NANO, V4, P6787, DOI 10.1021/nn101277w; Jin H, 2008, NANO LETT, V8, P1577, DOI 10.1021/nl072969s; Kim JS, 2006, TOXICOL SCI, V89, P338, DOI 10.1093/toxsci/kfj027; Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174; Ku ST, 2010, BIOCHEM BIOPH RES CO, V394, P871, DOI 10.1016/j.bbrc.2010.03.006; Kumar R, 2010, ACS NANO, V4, P699, DOI 10.1021/nn901146y; Lee CM, 2014, INT J NANOMED, V9, P243, DOI 10.2147/IJN.S57938; Limnell T., 2011, MESOPOROUS SILICA SI; Liu D, 2014, ACS APPL MATER INTER, V6, P2131, DOI 10.1021/am405219u; Meng H, 2011, ACS NANO, V5, P4434, DOI 10.1021/nn103344k; Panyam J, 2003, PHARM RES-DORDR, V20, P212, DOI 10.1023/A:1022219003551; Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P5, DOI 10.1016/S1359-6446(01)02082-7; Ragnaill MN, 2011, EUR J PHARM BIOPHARM, V77, P360, DOI 10.1016/j.ejpb.2010.12.024; Rosenholm JM, 2011, CURR DRUG TARGETS, V12, P1166; Salvati A, 2011, NANOMED-NANOTECHNOL, V7, P818, DOI 10.1016/j.nano.2011.03.005; Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a; Schulze C, 2011, EURO NANOTOX LETT, V1, P0001; Sen Karaman D, 2014, J COLLOID INTERF SCI, V418, P300, DOI 10.1016/j.jcis.2013.11.080; Sen Karaman D, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-358; Shim KH, 2014, INT J NANOMED, V9, P225, DOI 10.2147/IJN.S58205; Veiseh O, 2005, NANO LETT, V5, P1003, DOI 10.1021/nl0502569; Viitala T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072192; Wang Y, 2015, NANOMED-NANOTECHNOL, V11, P313, DOI 10.1016/j.nano.2014.09.014; Wong HL, 2012, ADV DRUG DELIVER REV, V64, P686, DOI 10.1016/j.addr.2011.10.007; Wu SH, 2011, CHEM COMMUN, V47, P9972, DOI 10.1039/c1cc11760b; Xia TA, 2009, ACS NANO, V3, P3273, DOI 10.1021/nn900918w; Yashunsky V, 2010, BIOPHYS J, V99, P4028, DOI 10.1016/j.bpj.2010.10.017	42	55	55	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2016	11	8							e0160705	10.1371/journal.pone.0160705	http://dx.doi.org/10.1371/journal.pone.0160705			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TP	27547955	Green Published, gold, Green Submitted			2023-01-03	WOS:000381768400018
J	Sharabi, S; Drori, Y; Micheli, M; Friedman, N; Orzitzer, S; Bassal, R; Glatman-Freedman, A; Shohat, T; Mendelson, E; Hindiyeh, M; Mandelboim, M				Sharabi, Sivan; Drori, Yaron; Micheli, Michal; Friedman, Nehemya; Orzitzer, Sara; Bassal, Ravit; Glatman-Freedman, Aharona; Shohat, Tamar; Mendelson, Ella; Hindiyeh, Musa; Mandelboim, Michal			Epidemiological and Virological Characterization of Influenza B Virus Infections	PLOS ONE			English	Article							CHILDREN; LINEAGES; VACCINE; DYNAMICS; SEASON; DIFFERENTIATION; YAMAGATA; VICTORIA; EFFICACY; ISRAEL	While influenza A viruses comprise a heterogeneous group of clinically relevant influenza viruses, influenza B viruses form a more homogeneous cluster, divided mainly into two lineages: Victoria and Yamagata. This divergence has complicated seasonal influenza vaccine design, which traditionally contained two seasonal influenza A virus strains and one influenza B virus strain. We examined the distribution of the two influenza B virus lineages in Israel, between 2011-2014, in hospitalized and in non-hospitalized (community) influenza B virus-infected patients. We showed that influenza B virus infections can lead to hospitalization and demonstrated that during some winter seasons, both influenza B virus lineages circulated simultaneously in Israel. We further show that the influenza B virus Yamagata lineage was dominant, circulating in the county in the last few years of the study period, consistent with the anti-Yamagata influenza B virus antibodies detected in the serum samples of affected individuals residing in Israel in the year 2014. Interestingly, we found that elderly people were particularly vulnerable to Yamagata lineage influenza B virus infections.	[Sharabi, Sivan; Drori, Yaron; Micheli, Michal; Friedman, Nehemya; Orzitzer, Sara; Mendelson, Ella; Hindiyeh, Musa; Mandelboim, Michal] Chaim Sheba Med Ctr, Minist Hlth, Cent Virol Lab, IL-52621 Ramat Gan, Israel; [Sharabi, Sivan; Drori, Yaron; Friedman, Nehemya; Shohat, Tamar; Mendelson, Ella; Hindiyeh, Musa; Mandelboim, Michal] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Tel Aviv, Israel; [Bassal, Ravit; Glatman-Freedman, Aharona; Shohat, Tamar] Israel Minist Hlth, Israel Ctr Dis Control, IL-52621 Tel Hashomer, Israel; [Glatman-Freedman, Aharona] New York Med Coll, Dept Family & Community Med, Valhalla, NY 10595 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; New York Medical College	Mandelboim, M (corresponding author), Chaim Sheba Med Ctr, Minist Hlth, Cent Virol Lab, IL-52621 Ramat Gan, Israel.; Mandelboim, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Tel Aviv, Israel.	michalman@sheba.health.gov.il						Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623; Belshe RB, 2010, VACCINE, V28, P2149, DOI 10.1016/j.vaccine.2009.11.068; Beran J, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-2; Biere B, 2010, J CLIN MICROBIOL, V48, P1425, DOI 10.1128/JCM.02116-09; Chen RB, 2008, J MOL EVOL, V66, P655, DOI 10.1007/s00239-008-9119-z; Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075; Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664; Hindiyeh M, 2005, J CLIN MICROBIOL, V43, P589, DOI 10.1128/JCM.43.2.589-595.2005; KANEGAE Y, 1990, J VIROL, V64, P2860, DOI 10.1128/JVI.64.6.2860-2865.1990; Kim YH, 2009, VIRAL IMMUNOL, V22, P423, DOI 10.1089/vim.2009.0045; Langley JM, 2013, J INFECT DIS, V208, P544, DOI 10.1093/infdis/jit263; Mandelboim M, 2016, ONCOTARGET, V7, P1185, DOI 10.18632/oncotarget.6746; Meningher T, 2014, INFLUENZA OTHER RESP, V8, P422, DOI 10.1111/irv.12249; Nelson MI, 2006, PLOS PATHOG, V2, P1144, DOI 10.1371/journal.ppat.0020125; Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; Osterhaus ADME, 2000, SCIENCE, V288, P1051, DOI 10.1126/science.288.5468.1051; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Skowronski DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038929; Skowronski DM, 2011, PEDIATR INFECT DIS J, V30, P833, DOI 10.1097/INF.0b013e31822db4dc; Socan M, 2014, J CLIN VIROL, V61, P156, DOI 10.1016/j.jcv.2014.06.018; Tan Y, 2013, J VIROL, V87, P12447, DOI 10.1128/JVI.01039-13; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Weil M, 2013, INFLUENZA OTHER RESP, V7, P838, DOI 10.1111/irv.12071; WRIGHT PF, 1980, J INFECT DIS, V141, P430, DOI 10.1093/infdis/141.4.430; WRIGHT PF, 2006, FIELDS VIROLOGY, P1691; Wu CT, 2010, ACTA PAEDIATR, V99, P1701, DOI 10.1111/j.1651-2227.2009.01595.x	28	21	23	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2016	11	8							e0161195	10.1371/journal.pone.0161195	http://dx.doi.org/10.1371/journal.pone.0161195			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4YN	27533045	gold, Green Published, Green Submitted			2023-01-03	WOS:000381487600072
J	Masse-Alarie, H; Cancino, EE; Schneider, C; Hodges, P				Masse-Alarie, Hugo; Cancino, Edith Elgueta; Schneider, Cyril; Hodges, Paul			Paired-Pulse TMS and Fine-Wire Recordings Reveal Short-Interval Intracortical Inhibition and Facilitation of Deep Multifidus Muscle Fascicles	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; SHORT-LATENCY FACILITATION; POSTURAL CONTROL; 2 PHASES; EXCITABILITY; MECHANISMS; CONTRACTION; MODULATION; BRAIN	Objective Paired-pulse transcranial magnetic stimulation (ppTMS) is used to probe inhibitory and excitatory networks within the primary motor cortex (M1). These mechanisms are identified for limb muscles but it is unclear whether they share properties with trunk muscles. The aim was to determine whether it was possible to test the intracortical inhibition and facilitation of the deep multifidus muscle fascicles (DM) and at which inter-stimulus intervals (ISI). Methods In ten pain-free individuals, TMS was applied over M1 and motor evoked potentials ( MEP) were recorded using fine-wire electrodes in DM. MEPs were conditioned with subthreshold stimuli at ISIs of 1 to 12 ms to test short-interval intracortical inhibition (SICI) and at 15 ms for long-interval intracortical facilitation. Short-interval facilitation (SICF) was tested using 1-ms ISI. Results SICI of DM was consistently obtained with ISI of 1-, 3-, 4- and 12-ms. Facilitation of DM MEP was only identified using SICF paradigm. Conclusions A similar pattern of MEP modulation with ISI changes for deep trunk and limb muscles implies that M1 networks share some functional properties. Significance The ppTMS paradigm presents a potential to determine how M1 inhibitory and excitatory mechanisms participate in brain re-organization in back pain that affects control of trunk muscles.	[Masse-Alarie, Hugo; Schneider, Cyril] Univ Laval, CHU Quebec Res Ctr, Neurosci Unit CHUL, Lab Clin Neurosci & neuroStimulat,Dept Rehabil, Quebec City, PQ, Canada; [Cancino, Edith Elgueta; Hodges, Paul] Univ Queensland, NHMRC Ctr Clin Res Excellence Spinal Pain Injury, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia	Laval University; University of Queensland	Hodges, P (corresponding author), Univ Queensland, NHMRC Ctr Clin Res Excellence Spinal Pain Injury, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia.	p.hodges@uq.edu.au	Hodges, Paul W/B-6578-2008	Hodges, Paul W/0000-0002-1206-9107; Schneider, Cyril/0000-0002-2179-0481; Masse-Alarie, Hugo/0000-0003-4472-9656	Fonds de Recherche du Quebec - Sante; Universite Laval; Canadian Institutes for Health Research; National Health and Medical Research Council of Australia [ID1102905]	Fonds de Recherche du Quebec - Sante(Fonds de la Recherche en Sante du Quebec); Universite Laval; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	HMA is supported by the Fonds de Recherche du Quebec - Sante, Universite Laval and the Canadian Institutes for Health Research (studentship & travel grant). PH is supported by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia (ID1102905). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank Richard Preuss for his comments on the first draft. HMA is supported by the Fonds de Recherche du Quebec-Sante, Universite Laval and the Canadian Institutes for Health Research (studentship & travel grant). P.H. is supported by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia (ID1102905). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buccolieri A, 2004, J PHYSIOL-LONDON, V558, P685, DOI 10.1113/jphysiol.2004.064774; Byblow WD, 2006, EXP BRAIN RES, V168, P287, DOI 10.1007/s00221-005-0205-9; Chen R, 1998, J NEUROPHYSIOL, V80, P2870, DOI 10.1152/jn.1998.80.6.2870; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cohen J., 2013, STAT POWER ANAL BEHA; Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641; Di Lazzaro V, 1999, EXP BRAIN RES, V129, P494, DOI 10.1007/s002210050919; Di Lazzaro V, 1998, EXP BRAIN RES, V119, P265; Di Lazzaro V, 2012, BRAIN STIMUL, V5, P512, DOI 10.1016/j.brs.2011.07.008; FERBERT A, 1992, ELECTROEN CLIN NEURO, V85, P382, DOI 10.1016/0168-5597(92)90051-C; Fisher RJ, 2002, EXP BRAIN RES, V143, P240, DOI 10.1007/s00221-001-0988-2; Gagne M, 2008, BRAIN RES, V1195, P77, DOI 10.1016/j.brainres.2007.12.021; Goss DA, 2011, J NEUROSCI METH, V194, P329, DOI 10.1016/j.jneumeth.2010.10.012; Hanajima R, 2002, J PHYSIOL-LONDON, V538, P253, DOI 10.1113/jphysiol.2001.013094; Hanajima R, 1998, J PHYSIOL-LONDON, V509, P607, DOI 10.1111/j.1469-7793.1998.607bn.x; Hanajima R, 2003, EXP BRAIN RES, V151, P427, DOI 10.1007/s00221-003-1455-z; Hanajima R, 1998, NEUROLOGY, V51, P1771, DOI 10.1212/WNL.51.6.1771; Hodges PW, 2013, EUR J PAIN, V17, P1138, DOI 10.1002/j.1532-2149.2013.00286.x; Hodges PW, 1996, SPINE, P21, DOI [10.1007/s00221-012-3008-9, DOI 10.1007/S00221-012-3008-9]; Ilic TV, 2002, J PHYSIOL-LONDON, V545, P153, DOI 10.1113/jphysiol.2002.030122; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; MacDonald D, 2009, PAIN, V142, P183, DOI 10.1016/j.pain.2008.12.002; Masse-Alarie H, 2016, SCAND J PAIN, V12, P74, DOI 10.1016/j.sjpain.2016.03.005; Masse-Alarie H, 2016, EXP BRAIN RES, V234, P1033, DOI 10.1007/s00221-015-4528-x; Masse-Alarie H, 2012, EXP BRAIN RES, V218, P99, DOI 10.1007/s00221-012-3008-9; Nathan PW, 1996, BRAIN, V119, P1809, DOI 10.1093/brain/119.6.1809; Novak K, 2004, CLIN NEUROPHYSIOL, V115, P1931, DOI 10.1016/j.clinph.2004.03.016; Ortu E, 2008, J PHYSIOL-LONDON, V586, P5147, DOI 10.1113/jphysiol.2008.158956; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Reynolds C, 1999, NEUROLOGY, V53, P730, DOI 10.1212/WNL.53.4.730; RIDDING MC, 1995, ANN NEUROL, V37, P181, DOI 10.1002/ana.410370208; Roshan L, 2003, EXP BRAIN RES, V151, P330, DOI 10.1007/s00221-003-1502-9; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Strutton PH, 2005, J SPINAL DISORD TECH, V18, P420, DOI 10.1097/01.bsd.0000169063.84628.fe; Strutton PH, 2004, EXP BRAIN RES, V158, P474, DOI 10.1007/s00221-004-1939-5; Tokimura H, 1996, ELECTROMYOGR MOTOR C, V101, P263, DOI 10.1016/0924-980X(96)95664-7; Tsao H, 2008, BRAIN, V131, P2161, DOI 10.1093/brain/awn154; Tsao H, 2008, J NEUROSCI METH, V171, P132, DOI 10.1016/j.jneumeth.2008.02.005; Tsao H, 2011, SPINE, V36, P1721, DOI 10.1097/BRS.0b013e31821c4267; Tsao H, 2011, CLIN NEUROPHYSIOL, V122, P1580, DOI 10.1016/j.clinph.2011.01.048; Tsao H, 2010, J PAIN, V11, P1120, DOI 10.1016/j.jpain.2010.02.004; Tsao H, 2010, EUR J PAIN, V14, P832, DOI 10.1016/j.ejpain.2010.01.001; Volz LJ, 2015, CEREB CORTEX, V25, P2346, DOI 10.1093/cercor/bhu032; WILKE HJ, 1995, SPINE, V20, P192, DOI 10.1097/00007632-199501150-00011; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 1998, J PHYSIOL-LONDON, V511, P181, DOI 10.1111/j.1469-7793.1998.181bi.x; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028; Ziemann Ulf, 2013, Handb Clin Neurol, V116, P387, DOI 10.1016/B978-0-444-53497-2.00032-2; Zoghi M, 2003, J PHYSIOL-LONDON, V550, P933, DOI 10.1113/jphysiol.2003.042606	49	11	11	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2016	11	8							e0159391	10.1371/journal.pone.0159391	http://dx.doi.org/10.1371/journal.pone.0159391			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3KR	27509086	Green Published, Green Submitted, gold			2023-01-03	WOS:000381380400008
J	Pietribiasi, M; Waniewski, J; Zaluska, A; Zaluska, W; Lindholm, B				Pietribiasi, Mauro; Waniewski, Jacek; Zaluska, Alicja; Zaluska, Wojciech; Lindholm, Bengt			Modelling Transcapillary Transport of Fluid and Proteins in Hemodialysis Patients	PLOS ONE			English	Article							ISOGRAVIMETRIC CAPILLARY-PRESSURE; HUMAN MICROVASCULAR EXCHANGE; ATRIAL-NATRIURETIC-PEPTIDE; FILTRATION COEFFICIENTS; SENSITIVITY-ANALYSIS; SKELETAL-MUSCLE; BLOOD-PRESSURE; PLASMA-VOLUME; ULTRAFILTRATION; HYPOTENSION	Background The kinetics of protein transport to and from the vascular compartment play a major role in the determination of fluid balance and plasma refilling during hemodialysis (HD) sessions. In this study we propose a whole-body mathematical model describing water and protein shifts across the capillary membrane during HD and compare its output to clinical data while evaluating the impact of choosing specific values for selected parameters. Methods The model follows a two-compartment structure (vascular and interstitial space) and is based on balance equations of protein mass and water volume in each compartment. The capillary membrane was described according to the three-pore theory. Two transport parameters, the fractional contribution of large pores (alpha(LP)) and the total hydraulic conductivity (LpS) of the capillary membrane, were estimated from patient data. Changes in the intensity and direction of individual fluid and solute flows through each part of the transport system were analyzed in relation to the choice of different values of small pores radius and fractional conductivity, lymphatic sensitivity to hydraulic pressure, and steady-state interstitial-to-plasma protein concentration ratio. Results The estimated values of LpS and alpha(LP) were respectively 10.0 +/- 8.4 mL/min/mmHg (mean +/- standard deviation) and 0.062 +/- 0.041. The model was able to predict with good accuracy the profiles of plasma volume and serum total protein concentration in most of the patients (average root-mean-square deviation < 2% of the measured value). Conclusions The applied model provides a mechanistic interpretation of fluid transport processes induced by ultrafiltration during HD, using a minimum of tuned parameters and assumptions. The simulated values of individual flows through each kind of pore and lymphatic absorption rate yielded by the model may suggest answers to unsolved questions on the relative impact of these not-measurable quantities on total vascular refilling and fluid balance.	[Pietribiasi, Mauro; Waniewski, Jacek] Inst Biocybernet & Biomed Engn, Warsaw, Poland; [Zaluska, Alicja] Med Univ Lublin, Dept Rehabil & Physiotherapy, Lublin, Poland; [Zaluska, Wojciech] Med Univ Lublin, Dept Nephrol, Lublin, Poland; [Lindholm, Bengt] Karolinska Inst, Baxter Novum & Renal Med, Stockholm, Sweden	Polish Academy of Sciences; Nalecz Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Sciences; Medical University of Lublin; Medical University of Lublin; Karolinska Institutet	Pietribiasi, M (corresponding author), Inst Biocybernet & Biomed Engn, Warsaw, Poland.	mpietribiasi@ibib.waw.pl	; Lindholm, Bengt/P-1334-2017	Pietribiasi, Mauro/0000-0001-8224-783X; Lindholm, Bengt/0000-0003-4269-4293	National Science Centre [N N518 289840];  [UMO-2014/15/N/ST7/05316]	National Science Centre(National Science Centre, Poland); 	This work was supported by grant no. UMO-2014/15/N/ST7/05316 issued by the National Science Center (Poland, http://www.ncn.gov.pl/). M.P. is the beneficiary of the grant. The data were originally collected for the study "Evaluation of disturbances of calcium-phosphate management in patients on dialysis" supported by the National Science Centre, grant no N N518 289840. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akcahuseyin E, 2000, ASAIO J, V46, P81, DOI 10.1097/00002480-200001000-00021; AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Boon D, 2004, NEPHRON CLIN PRACT, V96, P82, DOI 10.1159/000076745; Bos WJW, 2000, AM J KIDNEY DIS, V35, P819, DOI 10.1016/S0272-6386(00)70250-2; BRACE RA, 1977, AM J PHYSIOL, V233, pH136, DOI 10.1152/ajpheart.1977.233.1.H136; BRACE RA, 1976, CIRC RES, V38, P192, DOI 10.1161/01.RES.38.3.192; BRACE RA, 1977, AM J PHYSIOL, V233, pH130, DOI 10.1152/ajpheart.1977.233.1.H130; Campolongo F, 2007, ENVIRON MODELL SOFTW, V22, P1509, DOI 10.1016/j.envsoft.2006.10.004; CHAPPLE C, 1993, COMPUT METH PROG BIO, V41, P33, DOI 10.1016/0169-2607(93)90064-R; Cooper LJ, 2016, B MATH BIOL, V78, P52, DOI 10.1007/s11538-015-0128-y; de los Reyes AA, 2016, J THEOR BIOL, V390, P146, DOI 10.1016/j.jtbi.2015.11.012; Ebah LM, 2013, KIDNEY INT, V84, P980, DOI 10.1038/ki.2013.208; Ellmerer M, 2000, AM J PHYSIOL-ENDOC M, V278, pE352, DOI 10.1152/ajpendo.2000.278.2.E352; GORE RW, 1974, CIRC RES, V34, P581, DOI 10.1161/01.RES.34.4.581; Granger HJ, 1984, DYNAMICS CONTROL TRA, pp189; Guyton A., 2000, KIDNEYS BODY FLUIDS, P264; GUYTON ARTHUR C., 1965, INVEST OPHTHALMOL, V4, P1075; Iimura O, 1996, NEPHRON, V74, P19, DOI 10.1159/000189276; KEDEM O, 1989, BIOCHIM BIOPHYS ACTA, V1000, P411, DOI 10.1016/S0006-3002(89)80036-8; Kellen MR, 2003, AM J PHYSIOL-HEART C, V285, pH1303, DOI 10.1152/ajpheart.00933.2001; Kennedy J., 1995, P ICNN 95 INT C NEUR, V194, P2; Landis E.M., 1963, HDB PHYSL SECTION 2, P961; Lentner C., 1984, GEIGY SCI TABLES PHY; Levick JR, 2010, CARDIOVASC RES, V87, P198, DOI 10.1093/cvr/cvq062; Machek P, 2010, NEPHROL DIAL TRANSPL, V25, P538, DOI 10.1093/ndt/gfp487; MASON EA, 1980, J MEMBRANE SCI, V6, P283, DOI 10.1016/S0376-7388(00)82170-5; Michel CC, 1984, HDB PHYSL, VIV, P375; MORRIS MD, 1991, TECHNOMETRICS, V33, P161, DOI 10.2307/1269043; Palmer BF, 2008, J AM SOC NEPHROL, V19, P8, DOI 10.1681/ASN.2007091006; Pianosi F, 2015, ENVIRON MODELL SOFTW, V70, P80, DOI 10.1016/j.envsoft.2015.04.009; Pietribiasi M, 2015, ASAIO J, V61, P350, DOI 10.1097/MAT.0000000000000206; REDDY NP, 1986, CRIT REV BIOMED ENG, V14, P45; Reed RK, 2010, CARDIOVASC RES, V87, P211, DOI 10.1093/cvr/cvq143; RENKIN EM, 1977, MICROVASC RES, V14, P191, DOI 10.1016/0026-2862(77)90018-8; Ribitsch W, 2012, CLIN NEPHROL, V77, P376, DOI 10.5414/CN107078; Rippe B, 1993, Perit Dial Int, V13 Suppl 2, pS35; RIPPE B, 1994, PHYSIOL REV, V74, P163, DOI 10.1152/physrev.1994.74.1.163; SCHNEDITZ D, 1992, KIDNEY INT, V42, P1425, DOI 10.1038/ki.1992.437; Stachowska-Pietka Joanna, 2007, Adv Perit Dial, V23, P23; Stachowska-Pietka J, 2012, AM J PHYSIOL-RENAL, V302, pF1331, DOI 10.1152/ajprenal.00301.2011; System USRD, USRDS ANN DAT REP 20; Tabei K, 1996, NEPHRON, V74, P266, DOI 10.1159/000189320; THEWS O, 1991, NEPHROL DIAL TRANSPL, V6, P180, DOI 10.1093/ndt/6.3.180; Ursino M, 1997, ARTIF ORGANS, V21, P891; Ursino M, 1997, ARTIF ORGANS, V21, P873; WANIEWSKI J, 1994, J MEMBRANE SCI, V95, P179, DOI 10.1016/0376-7388(94)00110-3; Waniewski J, 2014, ASAIO J, V60, P576, DOI 10.1097/MAT.0000000000000105; WOLF MB, 1989, AM J PHYSIOL, V256, pH282, DOI 10.1152/ajpheart.1989.256.1.H282; WOLF MB, 1994, AM J PHYSIOL, V267, pH383, DOI 10.1152/ajpheart.1994.267.1.H383; WRAIGHT EP, 1974, J PHYSIOL-LONDON, V237, P39, DOI 10.1113/jphysiol.1974.sp010468; XIE SL, 1995, MICROVASC RES, V49, P141, DOI 10.1006/mvre.1995.1012; Yashiro M, 2005, BLOOD PURIFICAT, V23, P431, DOI 10.1159/000088214; Yashiro M, 2002, BLOOD PURIFICAT, V20, P569, DOI 10.1159/000066957; Yashiro M, 2007, THER APHER DIAL, V11, P131, DOI 10.1111/j.1744-9987.2007.00471.x	54	13	13	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2016	11	8							e0159748	10.1371/journal.pone.0159748	http://dx.doi.org/10.1371/journal.pone.0159748			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS9NS	27483369	gold, Green Submitted, Green Published			2023-01-03	WOS:000381110700013
J	Li, J; Chai, HY; Li, Y; Chai, XY; Zhao, Y; Zhao, YF; Tao, T; Xiang, XQ				Li, Jin; Chai, Hongyu; Li, Yang; Chai, Xuyu; Zhao, Yan; Zhao, Yunfan; Tao, Tao; Xiang, Xiaoqiang			A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling	PLOS ONE			English	Article							ACETATE SUCCINATE HPMCAS; DRUG-DELIVERY; IN-VITRO; PELLETS; EXTRUSION/SPHERONIZATION; SIMULATION; GRANULES; SPHERONIZATION; PERMEABILITY; PARAMETERS	Background Amoxicillin is a commonly used antibiotic which has a short half-life in human. The frequent administration of amoxicillin is often required to keep the plasma drug level in an effective range. The short dosing interval of amoxicillin could also cause some side effects and drug resistance, and impair its therapeutic efficacy and patients' compliance. Therefore, a three-pulse release tablet of amoxicillin is desired to generate sustained release in vivo, and thus to avoid the above mentioned disadvantages. Methods The pulsatile release tablet consists of three pulsatile components: one immediate-release granule and two delayed release pellets, all containing amoxicillin. The preparation of a pulsatile release tablet of amoxicillin mainly includes wet granulation craft, extrusion/spheronization craft, pellet coating craft, mixing craft, tablet compression craft and film coating craft. Box-Behnken design, Scanning Electron Microscope and in vitro drug release test were used to help the optimization of formulations. A crossover pharmacokinetic study was performed to compare the pharmacokinetic profile of our in-house pulsatile tablet with that of commercial immediate release tablet. The pharmacokinetic profile of this pulse formulation was simulated by physiologically based pharmacokinetic (PBPK) model with the help of Simcyp (R). Results and Discussion Single factor experiments identify four important factors of the formulation, namely, coating weight of Eudragit L30 D-55 (X-1), coating weight of AQOAT AS-HF (X-2), the extrusion screen aperture (X-3) and compression forces (X-4). The interrelations of the four factors were uncovered by a Box-Behnken design to help to determine the optimal formulation. The immediate-release granule, two delayed release pellets, together with other excipients, namely, Avicel PH 102, colloidal silicon dioxide, polyplasdone and magnesium stearate were mixed, and compressed into tablets, which was subsequently coated with Opadry (R) film to produce pulsatile tablet of amoxicillin. In vitro release study firstly indicated a three-pulse release profile of the tablet. Later the pulse tablet was found to generate the sustained release of amoxicillin in beagle dogs. Furthermore, the Simcyp (R) software was used to simulate the in vivo concentration time curve model of the three-pulse release tablet for amoxicillin in both human and beagle dog. The prediction by PBPK model nicely fitted the observation in human and beagle dog. Conclusions This study has demonstrated the interrelation of factors affecting the pulsatile formulation of amoxicillin using a Box-Behnken design. The three-pulse release tablets of amoxicillin were proven to generate pulsatile release in vitro and sustained release in vivo. This formulation was also found to extend the effective plasma concentration in human compared to the tablet of immediate release based on the simulation data by PBPK modeling. This study provides an example of using PBPK to guide the development of pulsatile dosage forms.	[Li, Jin; Chai, Hongyu; Li, Yang; Chai, Xuyu; Zhao, Yan; Tao, Tao] China State Inst Pharmaceut Ind, Natl Pharmaceut Engn Res Ctr, Shanghai, Peoples R China; [Zhao, Yunfan] Camelot Acad, Durham, NC USA; [Xiang, Xiaoqiang] Fudan Univ, Sch Pharm, Dept Clin Pharm, Shanghai, Peoples R China	Fudan University	Xiang, XQ (corresponding author), Fudan Univ, Sch Pharm, Dept Clin Pharm, Shanghai, Peoples R China.	xiangxq@fudan.edu.cn	Xiang, Xiaoqiang/AAH-2600-2020	Xiang, Xiaoqiang/0000-0002-8683-2603				Abbaspour MR, 2008, EUR J PHARM BIOPHARM, V68, P747, DOI 10.1016/j.ejpb.2007.09.010; Akhter H, 2011, ACTA PHARMACEUT, V61, P313, DOI 10.2478/v10007-011-0026-2; Beloica S, 2015, EUR J PHARM SCI, V75, P151, DOI 10.1016/j.ejps.2015.03.027; Boutell S, 2002, INT J PHARM, V238, P61, DOI 10.1016/S0378-5173(02)00064-9; Box G.E.P., 1960, TECHNOMETRICS, V2, P455, DOI [10.2307/1266454, DOI 10.2307/1266454, 10.1080/00401706.1960.10489912, DOI 10.1080/00401706.1960.10489912]; Bruce LD, 2003, INT J PHARM, V264, P85, DOI 10.1016/S0378-5173(03)00392-2; Eichie FE, 2009, AFR J BIOTECHNOL, V8, P5913; EVANS DF, 1988, GUT, V29, P1035, DOI 10.1136/gut.29.8.1035; Gaikwad A., 2013, J PHARM RES, V6, DOI 10.1016/j.jopr.2013.07.019; Gu Q, 2004, J CHROMATOGR B, V813, P337, DOI 10.1016/j.jchromb.2004.09.031; Hoffman A, 1998, J CONTROL RELEASE, V54, P29, DOI 10.1016/S0168-3659(97)00165-X; Jamei M, 2009, EXPERT OPIN DRUG MET, V5, P211, DOI [10.1517/17425250802691074, 10.1517/17425250802691074 ]; Kambayashi A, 2014, EUR J PHARM BIOPHARM, V87, P236, DOI 10.1016/j.ejpb.2014.01.007; Kanneti R, 2009, CHROMATOGRAPHIA, V70, P407, DOI 10.1365/s10337-009-1171-3; Kesisoglou F, 2015, AAPS J, V17, P1492, DOI 10.1208/s12248-015-9816-7; Lee KN, 2011, J MICROENCAPSUL, V28, P363, DOI 10.3109/02652048.2011.569766; Lennernas H, 2002, EUR J PHARM SCI, V15, P271, DOI 10.1016/S0928-0987(02)00005-2; Mise R, 2015, CHEM PHARM BULL, V63, P1070, DOI 10.1248/cpb.c15-00491; Mu L, 2012, THESIS; Pan Rui-xue, 2014, Yaoxue Xuebao, V49, P1155; Podczeck F, 2008, INT J PHARMACEUT, V361, P33, DOI 10.1016/j.ijpharm.2008.05.008; Qi XL, 2015, J PHARM PHARMACOL, V67, P493, DOI 10.1111/jphp.12339; Ravishankar H, 2006, DRUG DEV IND PHARM, V32, P709, DOI 10.1080/03639040600637556; ROBERTSON S, 2007, AMOXICILLIN CLINPHAR; Ross AC, 2000, J PHARM PHARMACOL, V52, P903, DOI 10.1211/0022357001774787; Rostami-Hodjegan A, 2007, NAT REV DRUG DISCOV, V6, P140, DOI 10.1038/nrd2173; Saigal Nitin, 2009, Recent Pat Drug Deliv Formul, V3, P64; SARISUTA N, 1994, J CONTROL RELEASE, V31, P215, DOI 10.1016/0168-3659(94)90002-7; Sawicki W, 2005, EUR J PHARM BIOPHARM, V60, P153, DOI 10.1016/j.ejpb.2004.11.003; Schellekens RCA, 2008, J CONTROL RELEASE, V132, P91, DOI 10.1016/j.jconrel.2008.08.008; Sousa JJ, 2002, INT J PHARM, V232, P91, DOI 10.1016/S0378-5173(01)00908-5; Tanno F, 2004, DRUG DEV IND PHARM, V30, P9, DOI 10.1081/DDC-120027506; Tanno FK, 2008, J PHARM SCI-US, V97, P2665, DOI 10.1002/jps.21172; Tomer G, 2002, INT J PHARM, V231, P107, DOI 10.1016/S0378-5173(01)00876-6; Tomer G, 2001, INT J PHARM, V217, P237, DOI 10.1016/S0378-5173(01)00611-1; Weitschies W, 2008, EUR J PHARM BIOPHARM, V70, P641, DOI 10.1016/j.ejpb.2008.05.011; Young CR, 2005, INT J PHARMACEUT, V301, P112, DOI 10.1016/j.ijpharm.2005.05.025; Zhang CG, 2012, INT J PHARMACEUT, V430, P141, DOI 10.1016/j.ijpharm.2012.04.013	38	4	5	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2016	11	8							e0160260	10.1371/journal.pone.0160260	http://dx.doi.org/10.1371/journal.pone.0160260			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS9NO	27479702	Green Submitted, Green Published, gold			2023-01-03	WOS:000381110300037
J	Khan, F; Ahmed, F; Pushparaj, PN; Abuzenadah, A; Kumosani, T; Barbour, E; AlQahtani, M; Gauthaman, K				Khan, Fazal; Ahmed, Farid; Pushparaj, Peter Natesan; Abuzenadah, Adel; Kumosani, Taha; Barbour, Elie; AlQahtani, Mohammed; Gauthaman, Kalamegam			Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest	PLOS ONE			English	Article							CYTOCHROME-C; CANCER; QUERCETIN; PROLIFERATION; MYRICETIN; MITOCHONDRIA; ANTIOXIDANT; ACTIVATION; FLAVONOIDS; INDUCTION	Introduction Phoenix dactylifera L (Date palm) is a native plant of the Kingdom of Saudi Arabia (KSA) and other Middle Eastern countries. Ajwa date has been described in the traditional and alternative medicine to provide several health benefits including anticholesteremic, antioxidant, hepatoprotective and anticancer effects, but most remains to be scientifically validated. Herein, we evaluated the anticancer effects of the Methanolic Extract of Ajwa Date (MEAD) on human breast adenocarcinoma (MCF7) cells in vitro. Methods MCF7 cells were treated with various concentrations (5, 10, 15, 20 and 25 mg/ml) of MEAD for 24, 48 and 72 h and changes in cell morphology, cell cycle, apoptosis related protein and gene expression were studied. Results Phase contrast microscopy showed various morphological changes such as cell shrinkage, vacuolation, blebbing and fragmentation. MTT (2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay demonstrated statistically significant dose-dependent inhibitions of MCF7 cell proliferation from 35% to 95%. Annexin V-FITC and TUNEL assays showed positive staining for apoptosis of MCF7 cells treated with MEAD (15 mg and 25 mg for 48 h). Flow cytometric analyses of MCF7 cells with MEAD (15 mg/ml and 20 mg/ml) for 24 h demonstrated cell cycle arrest at 'S' phase; increased p53, Bax protein expression; caspase 3activation and decreased the mitochondrial membrane potential (MMP). Quantitative real time PCR (qRT-PCR) analysis showed up-regulation of p53, Bax, Fas, and FasL and downregulation of Bcl-2. Conclusions MEAD inhibited MCF7 cells in vitro by the inducing cell cycle arrest and apoptosis. Our results indicate the anticancer effects of Ajwa dates, which therefore may be used as an adjunct therapy with conventional chemotherapeutics to achieve a synergistic effect against breast cancer.	[Khan, Fazal; Kumosani, Taha; Barbour, Elie] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia; [Khan, Fazal; Ahmed, Farid; Pushparaj, Peter Natesan; AlQahtani, Mohammed; Gauthaman, Kalamegam] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia; [Khan, Fazal; Abuzenadah, Adel] King Abdulaziz Univ, King Fahd Med Res Ctr, Ctr Innovat Personalized Med, Jeddah, Saudi Arabia; [Kumosani, Taha] King Abdulaziz Univ, King Fahd Med Res Ctr, Biochem Unit, Jeddah, Saudi Arabia; [Barbour, Elie] Amer Univ Beirut, Fac Agr & Food Sci, Dept Agr, Beirut, Lebanon	King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; King Abdulaziz University; American University of Beirut	Gauthaman, K (corresponding author), King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia.	kgauthaman@kau.edu.sa	Kalamegam, Gauthaman/O-6336-2019; Kalamegam, Gauthaman/H-9857-2012; Ahmed, Farid/GWV-5959-2022; Pushparaj, Peter Natesan/H-9871-2012; Ahmed, Farid/AAO-6286-2020; Kumosani, Taha A/E-4362-2013; Al-Qahtani, Mohammed Hussain/AAZ-1729-2020; Ahmed, Farid/I-1192-2012; KHAN, FAZAL/N-9792-2013	Kalamegam, Gauthaman/0000-0002-5208-4598; Pushparaj, Peter Natesan/0000-0001-7574-1880; Ahmed, Farid/0000-0002-7464-7726; Ahmed, Farid/0000-0002-7464-7726; KHAN, FAZAL/0000-0003-1794-8167	King Abdulaziz City for Science and Technology (KACST) [AT-34-237]	King Abdulaziz City for Science and Technology (KACST)	King Abdulaziz City for Science and Technology (KACST) provided the postgraduate grant funding [AT-34-237] to Fazal Khan, with which this study was performed. http://www.kacst.edu.sa/en/Pages/default.aspx.; would like to acknowledge the financial support by King Abdulaziz City for Science and Technology (KACST) through postgraduate grant funding [AT-34-237] as well as the technical and logistics support provided by the Center of Excellence in Genomic Medicine Research and the Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.	Ali A, 2011, FUNCT FOODS HEALTH D, V1, P118; American Cancer Society, 2016, CANC FACTS FIGURES 2; Baliga MS, 2011, FOOD RES INT, V44, P1812, DOI 10.1016/j.foodres.2010.07.004; Bhanot A., 2011, INT J PHYTOMED, V3, P9; Cao P, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/958243; Chien SY, 2009, HUM EXP TOXICOL, V28, P493, DOI 10.1177/0960327109107002; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chou CC, 2010, ARCH PHARM RES, V33, P1181, DOI 10.1007/s12272-010-0808-y; Duo J, 2012, MOL MED REP, V5, P1453, DOI 10.3892/mmr.2012.845; Eid N, 2014, J NUTR SCI, V3, DOI 10.1017/jns.2014.16; El-Azim M. H. M. A., 2015, Journal of Microbial and Biochemical Technology, V7, P47; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ishurd O, 2004, J MED FOOD, V7, P252, DOI 10.1089/1096620041224085; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Kim Jin-Hyung, 2007, Ann N Y Acad Sci, V1095, P598, DOI 10.1196/annals.1397.102_2; Ko CH, 2005, BIOCHEM PHARMACOL, V69, P913, DOI 10.1016/j.bcp.2004.12.005; Lansky EP, 2005, INVEST NEW DRUG, V23, P11, DOI 10.1023/B:DRUG.0000047101.02178.07; Li LY, 2009, J AGR FOOD CHEM, V57, P826, DOI 10.1021/jf803407q; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Nihal M, 2014, ARCH BIOCHEM BIOPHYS, V563, P101, DOI 10.1016/j.abb.2014.04.019; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Phillips PA, 2011, CANCER LETT, V308, P181, DOI 10.1016/j.canlet.2011.05.002; Ragab AR, 2013, J ENV ANAL TOXICOL, V3, P2161; Rodgers EH, 1998, CHEM-BIOL INTERACT, V116, P213, DOI 10.1016/S0009-2797(98)00092-1; Saggu S, 2015, SAUDI MED J, V36, P1176, DOI 10.15537/smj.2015.10.12268; Saleh E. A., 2011, Food and Nutrition Sciences, V2, P1134, DOI 10.4236/fns.2011.210152; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Seeram NP, 2004, J AGR FOOD CHEM, V52, P2512, DOI 10.1021/jf0352778; Seo HS, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150165; Shahraki Samira, 2016, J Tradit Complement Med, V6, P89, DOI 10.1016/j.jtcme.2014.11.018; Sheikh BY, 2014, EUR SCI J, V10; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Syed DN, 2008, CANCER LETT, V265, P167, DOI 10.1016/j.canlet.2008.02.050; Thomasset SC, 2007, INT J CANCER, V120, P451, DOI 10.1002/ijc.22419; Unnati S, 2013, CHIN J NAT MEDICINES, V11, P16, DOI 10.3724/SP.J.1009.2013.00016; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87; Zhang CR, 2013, J AGR FOOD CHEM, V61, P5834, DOI 10.1021/jf401371v	43	40	42	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2016	11	7							e0158963	10.1371/journal.pone.0158963	http://dx.doi.org/10.1371/journal.pone.0158963			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS5CG	27441372	Green Submitted, Green Published, gold			2023-01-03	WOS:000380797500032
J	Huang, CT; Chuang, YC; Tsai, YJ; Ko, WJ; Yu, CJ				Huang, Chun-Ta; Chuang, Yu-Chung; Tsai, Yi-Ju; Ko, Wen-Je; Yu, Chong-Jen			High Mortality in Severe Sepsis and Septic Shock Patients with Do-Not-Resuscitate Orders in East Asia	PLOS ONE			English	Article							INTENSIVE-CARE UNITS; ICU ADMISSION; MULTICENTER; DECISIONS; OUTCOMES; THERAPY; DEATH; MORBIDITY; RISK; END	Background Severe sepsis is a potentially deadly illness and always requires intensive care. Do-not-resuscitate (DNR) orders remain a debated issue in critical care and limited data exist about its impact on care of septic patients, particularly in East Asia. We sought to assess outcome of severe sepsis patients with regard to DNR status in Taiwan. Methods A retrospective cohort study was conducted in intensive care units (ICUs) between 2008 and 2010. All severe sepsis patients were included for analysis. Primary outcome was association between DNR orders and ICU mortality. Volume of interventions was used as proxy indicator to indicate aggressiveness of care. Results Sixty-seven (9.4%) of 712 patients had DNR orders on ICU admission, and these patients were older and had higher disease severity compared with patients without DNR orders. Notably, DNR patients experienced high ICU mortality (90%). Multivariate analysis revealed that the presence of DNR orders was independently associated with ICU mortality (odds ratio: 6.13; 95% confidence interval: 2.66-14.10). In propensity score-matched cohort, ICU mortality rate (91%) in the DNR group was statistically higher than that (62%) in the non-DNR group (p < 0.001). Regarding ICU interventions, arterial and central venous catheterization were more commonly used in DNR patients than in non-DNR patients. Conclusions From the Asian perspective, septic patients placed on DNR orders on ICU admission had exceptionally high mortality. In contrast to Western reports, DNR patients received more ICU interventions, reflecting more aggressive approach to dealing with this patient population. The findings in some ways reflect differences between East and West cultures and suggest that DNR status is an important confounder in ICU studies involving severely septic patients.	[Huang, Chun-Ta; Chuang, Yu-Chung; Yu, Chong-Jen] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Huang, Chun-Ta] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Huang, Chun-Ta] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Tsai, Yi-Ju] Fu Jen Catholic Univ, Coll Med, Grad Inst Biomed & Pharmaceut Sci, New Taipei, Taiwan; [Ko, Wen-Je] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Fu Jen Catholic University; National Taiwan University; National Taiwan University Hospital	Huang, CT (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan.; Huang, CT (corresponding author), Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan.; Huang, CT (corresponding author), Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.	huangct@ntu.edu.tw	; CHUANG, YU-CHUNG/F-4627-2016	HUANG, CHUN-TA/0000-0002-5234-4986; CHUANG, YU-CHUNG/0000-0003-3094-8276; Yu, Chong-Jen/0000-0001-5664-9392	National Taiwan University Hospital [105-N3262]	National Taiwan University Hospital(National Taiwan University)	This study was supported by the National Taiwan University Hospital grant number 105-N3262 (CTH). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1991, JAMA, V265, P1868; Arabi YM, 2013, CRIT CARE, V17, DOI 10.1186/cc12680; Azoulay E, 2009, INTENS CARE MED, V35, P623, DOI 10.1007/s00134-008-1310-6; Beach MC, 2002, J AM GERIATR SOC, V50, P2057, DOI 10.1046/j.1532-5415.2002.50620.x; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; Bradford MA, 2014, CRIT CARE MED, V42, P2042, DOI 10.1097/CCM.0000000000000403; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; Chang DW, 2014, J GEN INTERN MED, V29, P1256, DOI 10.1007/s11606-014-2906-x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dzeng E, 2015, JAMA INTERN MED, V175, P812, DOI 10.1001/jamainternmed.2015.0295; Fuchs L, 2012, INTENS CARE MED, V38, P1654, DOI 10.1007/s00134-012-2629-6; Garnacho-Montero J, 2008, J ANTIMICROB CHEMOTH, V61, P436, DOI 10.1093/jac/dkm460; Garnacho-Montero J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1000-z; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; HOLTZMAN J, 1994, J AM GERIATR SOC, V42, P275, DOI 10.1111/j.1532-5415.1994.tb01751.x; Hoste EAJ, 2003, J AM SOC NEPHROL, V14, P1022, DOI 10.1097/01.ASN.0000059863.48590.E9; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kazaure H, 2011, ARCH SURG-CHICAGO, V146, P922, DOI 10.1001/archsurg.2011.69; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Luo Zhehui, 2010, Med Care Res Rev, V67, P528, DOI 10.1177/1077558710361486; McLean RF, 2000, CRIT CARE MED, V28, P100, DOI 10.1097/00003246-200001000-00016; Mehter Hashim M, 2014, Ann Am Thorac Soc, V11, P1592, DOI 10.1513/AnnalsATS.201406-244BC; Meissner A, 2010, CRIT CARE MED, V38, P1060, DOI 10.1097/CCM.0b013e3181cd1110; Payne JK, 2008, J GERONTOL NURS, V34, P11, DOI 10.3928/00989134-20081001-06; Phua J, 2015, JAMA INTERN MED, V175, P363, DOI 10.1001/jamainternmed.2014.7386; Powell ES, 2013, J EMERG MED, V44, P742, DOI 10.1016/j.jemermed.2012.09.034; Quill CM, 2014, CHEST, V146, P573, DOI 10.1378/chest.13-2529; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Santonocito C, 2013, J CRIT CARE, V28, P14, DOI 10.1016/j.jcrc.2012.07.005; Shepardson LB, 1999, MED CARE, V37, P727, DOI 10.1097/00005650-199908000-00003; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WENGER NS, 1995, ARCH INTERN MED, V155, P2063, DOI 10.1001/archinte.155.19.2063; Yang Y, 2010, J CRIT CARE, V25, P398, DOI 10.1016/j.jcrc.2009.09.001; Zingmond DS, 2005, ARCH INTERN MED, V165, P1705, DOI 10.1001/archinte.165.15.1705	41	48	49	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2016	11	7							e0159501	10.1371/journal.pone.0159501	http://dx.doi.org/10.1371/journal.pone.0159501			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR0DZ	27416064	Green Published, gold, Green Submitted			2023-01-03	WOS:000379579500133
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: End of life care in hospital is everyone's business	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Bowden J, 2013, J ROY COLL PHYS EDIN, V43, P24, DOI 10.4997/JRCPE.2013.105; Curie Marie, 2015, TRIGGERS PALLIATIVE; Leadership Alliance for the Care of Dying People, 2014, ON CHANC GET IT RIGH; National Council for Palliative Care, 2016, STAFF PREP CAR CAP C; National Palliative and End of Life Care Partnership, 2014, AMB PALL END LIF CAR; NHS England, 2016, COMM PERS CTR END LI; Office for National Statistics, 2015, DEATHS REG ENGL WAL; Pollock K, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4855; Royal College of Physicians of London, 2015, CENS CONS PHYS HIGH; Royal College of Physicians of London, 2014, END LIF CAR AUD DYIN	10	0	0	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2016	354								i3888	10.1136/bmj.i3888	http://dx.doi.org/10.1136/bmj.i3888			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS1JA	27417270	Bronze, Green Published			2023-01-03	WOS:000380350500008
J	Barbar, SD; Pauchard, LA; Bruyere, R; Bruillard, C; Hayez, D; Croisier, D; Pugin, J; Charles, PE				Barbar, Saber-Davide; Pauchard, Laure-Anne; Bruyere, Remi; Bruillard, Caroline; Hayez, Davy; Croisier, Delphine; Pugin, Jerome; Charles, Pierre-Emmanuel			Mechanical Ventilation Alters the Development of Staphylococcus aureus Pneumonia in Rabbit	PLOS ONE			English	Article							TIDAL-VOLUME VENTILATION; TOLL-LIKE RECEPTOR-2; LUNG INJURY; NOSOCOMIAL PNEUMONIA; GENE-EXPRESSION; PRESSURE; BACTEREMIA; ACTIVATION; CYTOKINES; IMPACT	Ventilator-associated pneumonia (VAP) is common during mechanical ventilation (MV). Beside obvious deleterious effects on muco-ciliary clearance, MV could adversely shift the host immune response towards a pro-inflammatory pattern through toll-like receptor (TLRs) up-regulation. We tested this hypothesis in a rabbit model of Staphylococcus aureus VAP. Pneumonia was caused by airway challenge with S. aureus, in either spontaneously breathing (SB) or MV rabbits (n = 13 and 17, respectively). Pneumonia assessment regarding pulmonary and systemic bacterial burden, as well as inflammatory response was done 8 and 24 hours after S. aureus challenge. In addition, ex vivo stimulations of whole blood taken from SB or MV rabbits (n = 7 and 5, respectively) with TLR2 agonist or heat-killed S. aureus were performed. Data were expressed as mean +/- standard deviation. After 8 hours of infection, lung injury was more severe in MV animals (1.40 +/- 0.33 versus [vs] 2.40 +/- 0.55, p = 0.007), along with greater bacterial concentrations (6.13 +/- 0.63 vs. 4.96 +/- 1.31 colony forming units/gram, p = 0.002). Interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha serum concentrations reached higher levels in MV animals (p = 0.010). Whole blood obtained from MV animals released larger amounts of cytokines if stimulated with TLR2 agonist or heat-killed S. aureus (e.g., TNF-alpha: 1656 +/- 166 vs. 1005 +/- 89; p = 0.014). Moreover, MV induced TLR2 overexpression in both lung and spleen tissue. MV hastened tissue injury, impaired lung bacterial clearance, and promoted a systemic inflammatory response, maybe through TLR2 overexpression.	[Barbar, Saber-Davide; Pauchard, Laure-Anne; Bruyere, Remi; Bruillard, Caroline; Charles, Pierre-Emmanuel] Univ Bourgogne, INRA, UMR 1347, Lab Ventilat Immunite Poumon,Pole Microbiol Envir, Dijon, France; [Hayez, Davy; Croisier, Delphine] Vivexia SARL, Gemeaux, France; [Pugin, Jerome] Univ Hosp Geneva, Intens Care Lab, CH-1211 Geneva 14, Switzerland; [Pugin, Jerome] Fac Med, Dept Microbiol & Mol Med, CH-1211 Geneva 14, Switzerland	INRAE; Institut Agro; AgroSup Dijon; Universite de Bourgogne; University of Geneva; University of Geneva	Charles, PE (corresponding author), Univ Bourgogne, INRA, UMR 1347, Lab Ventilat Immunite Poumon,Pole Microbiol Envir, Dijon, France.	pierre-emmanuel.charles@chu-dijon.fr		Barbar, Saber Davide/0000-0002-5089-8088; Charles, Pierre-Emmanuel/0000-0002-0201-9544; Croisier, Delphine/0000-0002-8744-5832	Pfizer; "Vivexia" company	Pfizer(Pfizer); "Vivexia" company	PEC received a grant from Pfizer, namely the ASPIRE competitive grant in 2011.DCB and DH received support from the "Vivexia" company in the form of salaries. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Bouadma L, 2004, CRIT CARE MED, V32, P1563, DOI 10.1097/01.CCM.0000129674.25259.D4; Bouadma L, 2010, CRIT CARE MED, V38, P789, DOI 10.1097/CCM.0b013e3181ce21af; Bregeon F, 2005, ANESTHESIOLOGY, V102, P331; Broccard A, PRONE POSITIONING AT; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Charles PE, 2005, CRIT CARE MED, V33, P1029, DOI 10.1097/01.CCM.0000163404.35338.72; Charles PE, 2004, INTENS CARE MED, V30, P2263, DOI 10.1007/s00134-004-2442-y; Charles PE, 2002, CRIT CARE MED, V30, P2278, DOI 10.1097/00003246-200210000-00016; Charles PE, 2011, CRIT CARE, V15, DOI 10.1186/cc10330; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Christaki E, 2014, VIRULENCE, V5, P57, DOI 10.4161/viru.26514; Croisier-Bertin D, 2014, ANTIMICROB AGENTS CH, V58, P1855, DOI 10.1128/AAC.01707-13; Dhanireddy S, 2006, LAB INVEST, V86, P790, DOI 10.1038/labinvest.3700440; Droemann D, 2003, HISTOCHEM CELL BIOL, V119, P103, DOI 10.1007/s00418-003-0497-4; Dunzendorfer S, 2004, CIRC RES, V95, P684, DOI 10.1161/01.RES.0000143900.19798.47; Elson G, 2007, BLOOD, V109, P1574, DOI 10.1182/blood-2006-06-032961; Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082; Hess DR, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.11.014; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; Hilmi D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096416; Kajikawa O, 2005, GENE, V344, P193, DOI 10.1016/j.gene.2004.09.032; Kuipers MT, 2011, CRIT CARE, V15, DOI 10.1186/cc10437; Ladoire S, 2013, ANESTHESIOLOGY; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luna CM, 1999, CHEST, V116, P1075, DOI 10.1378/chest.116.4.1075; Magret M, 2011, CRIT CARE, V15, DOI 10.1186/cc10036; Mourgeon E, 2000, AM J PHYSIOL-LUNG C, V279, pL699, DOI 10.1152/ajplung.2000.279.4.L699; Murphy DB, 2000, AM J RESP CRIT CARE, V162, P27, DOI 10.1164/ajrccm.162.1.9908110; Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; Ricard JD, 2001, AM J RESP CRIT CARE, V163, P1176, DOI 10.1164/ajrccm.163.5.2006053; Rubinstein E, 2008, CLIN INFECT DIS, V46, pS378, DOI 10.1086/533594; Neto AS, 2014, INTENS CARE MED, V40, P950, DOI 10.1007/s00134-014-3318-4; Neto AS, 2014, CURR OPIN CRIT CARE, V20, P25, DOI 10.1097/MCC.0000000000000044; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Summers C, 2014, THORAX, V69, P623, DOI 10.1136/thoraxjnl-2013-204742; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Torres A, 2009, INTENS CARE MED, V35, P9, DOI 10.1007/s00134-008-1336-9; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Valenza F, 2003, CRIT CARE MED, V31, P1993, DOI 10.1097/01.CCM.0000070401.65534.F9; Vaneker M, 2008, ANESTHESIOLOGY, V109, P465, DOI 10.1097/ALN.0b013e318182aef1; Villar J, 2010, INTENS CARE MED, V36, P1049, DOI 10.1007/s00134-010-1799-3; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Wunderink RG, 2012, CLIN INFECT DIS, V54, P621, DOI 10.1093/cid/cir895; Xiang M, 2010, MOL MED, V16, P69, DOI 10.2119/molmed.2009.00097	48	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158799	10.1371/journal.pone.0158799	http://dx.doi.org/10.1371/journal.pone.0158799			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27391952	Green Published, Green Submitted, gold			2023-01-03	WOS:000380005400126
J	McCartney, CR; Marshall, JC				McCartney, Christopher R.; Marshall, John C.			Polycystic Ovary Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMBINED ORAL-CONTRACEPTIVES; IMPAIRED GLUCOSE-TOLERANCE; HORMONE PULSE-GENERATOR; ANDROGEN EXCESS; INSULIN-RESISTANCE; WOMEN; RISK; HIRSUTISM; CRITERIA; PCOS	A 22-year-old woman reports having hirsutism and irregular menses. She describes unpredictable and infrequent menses (five or six per year) since menarche at 11 years of age. Dark, coarse facial hair began to develop at 13 years of age. The symptoms worsened after she gained weight in college. The physical examination includes a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 29, blood pressure of 135/85 mm Hg, and moderate hirsutism without virilization. Laboratory tests reveal a total testosterone level of 65 ng per deciliter (2.3 nmol per liter) (assay reference range, 14 to 53 ng per deciliter [0.5 to 1.8 nmol per liter]), calculated free testosterone level of 15.3 pg per milliliter (53.1 pmol per liter) (assay reference range, 0.6 to 6.8 pg per milliliter [2.1 to 23.6 pmol per liter]), and glycated hemoglobin level of 5.7% (normal value, <= 5.6%). How should this case be evaluated and managed?	[Marshall, John C.] Univ Virginia, Sch Med, Ctr Res Reprod, POB 800391, Charlottesville, VA 22908 USA; [Marshall, John C.] Univ Virginia, Sch Med, Dept Med, Div Endocrinol & Metab, POB 800391, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Marshall, JC (corresponding author), Univ Virginia, Sch Med, Ctr Res Reprod, POB 800391, Charlottesville, VA 22908 USA.; Marshall, JC (corresponding author), Univ Virginia, Sch Med, Dept Med, Div Endocrinol & Metab, POB 800391, Charlottesville, VA 22908 USA.	jcm9h@virginia.edu			AstraZeneca; Euroscreen; Millendo Therapeutics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD028934] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); Euroscreen; Millendo Therapeutics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Dr. Marshall reports receiving fees for serving on an advisory board from AstraZeneca and consulting fees from Euroscreen and Millendo Therapeutics (previously Atterocor). No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2017, Diabetes Care, V40, pS4, DOI 10.2337/dc15-S005; Azziz R, 2006, J CLIN ENDOCR METAB, V91, P4237, DOI 10.1210/jc.2006-0178; Azziz R, 2009, FERTIL STERIL, V91, P456, DOI 10.1016/j.fertnstert.2008.06.035; Beller JP, 2013, AM J OBSTET GYNECOL, V208, P39, DOI 10.1016/j.ajog.2012.01.037; Boomsma CM, 2006, HUM REPROD UPDATE, V12, P673, DOI 10.1093/humupd/dml036; Conway G, 2014, EUR J ENDOCRINOL, V171, pP1, DOI 10.1530/EJE-14-0253; Cosma M, 2008, J CLIN ENDOCR METAB, V93, P1135, DOI 10.1210/jc.2007-2429; Dewailly D, 2014, HUM REPROD UPDATE, V20, P334, DOI 10.1093/humupd/dmt061; Diamanti-Kandarakis E, 2004, J CLIN ENDOCR METAB, V89, P1273, DOI 10.1210/jc.2003-031205; Diamanti-Kandarakis E, 2012, ENDOCR REV, V33, P981, DOI 10.1210/er.2011-1034; Domecq JP, 2013, J CLIN ENDOCR METAB, V98, P4646, DOI 10.1210/jc.2013-2374; Dumesic DA, 2015, ENDOCR REV, V36, P487, DOI 10.1210/er.2015-1018; Dumesic DA, 2013, STEROIDS, V78, P782, DOI 10.1016/j.steroids.2013.04.004; Eagleson CA, 2000, J CLIN ENDOCR METAB, V85, P4047, DOI 10.1210/jc.85.11.4047; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; Ehrmann DA, 1999, DIABETES CARE, V22, P141, DOI 10.2337/diacare.22.1.141; Fauser BCJM, 2012, FERTIL STERIL, V97, P28, DOI 10.1016/j.fertnstert.2011.09.024; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; Goodman NF, 2015, ENDOCR PRACT, V21, P1415, DOI 10.4158/EP15748.DSCPT2; Goodman NF, 2015, ENDOCR PRACT, V21, P1291, DOI 10.4158/EP15748.DSC; Hudecova M, 2009, HUM REPROD, V24, P1176, DOI 10.1093/humrep/den482; Legro RS, 2008, J CLIN ENDOCR METAB, V93, P420, DOI 10.1210/jc.2007-2287; Legro RS, 2007, NEW ENGL J MED, V356, P551, DOI 10.1056/NEJMoa063971; Legro RS, 2014, NEW ENGL J MED, V371, P119, DOI 10.1056/NEJMoa1313517; Legro RS, 2013, J CLIN ENDOCR METAB, V98, P4565, DOI 10.1210/jc.2013-2350; Legro RS, 1999, J CLIN ENDOCR METAB, V84, P165, DOI 10.1210/jc.84.1.165; Lopez LM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006133.pub5; Martin KA, 2008, J CLIN ENDOCR METAB, V93, P1105, DOI 10.1210/jc.2007-2437; McAllister JM, 2014, P NATL ACAD SCI USA, V111, pE1519, DOI 10.1073/pnas.1400574111; Moran LJ, 2009, FERTIL STERIL, V92, P1966, DOI 10.1016/j.fertnstert.2008.09.018; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Pastor CL, 1998, J CLIN ENDOCR METAB, V83, P582, DOI 10.1210/jc.83.2.582; Perales-Puchalt A, 2013, STEROIDS, V78, P767, DOI 10.1016/j.steroids.2013.05.005; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Solorzano CMB, 2012, STEROIDS, V77, P332, DOI 10.1016/j.steroids.2011.12.007; Swiglo BA, 2008, J CLIN ENDOCR METAB, V93, P1153, DOI 10.1210/jc.2007-2430; Tang T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003053.pub5; Tasali E, 2008, SLEEP MED CLIN, V3, P37, DOI 10.1016/j.jsmc.2007.11.001; Teede HJ, 2011, MED J AUSTRALIA, V195, pS69, DOI 10.5694/mja11.10915; Veltman-Verhulst SM, 2012, HUM REPROD UPDATE, V18, P638, DOI 10.1093/humupd/dms029; Vinogradova Y, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2135; White T, 2005, AM J OBSTET GYNECOL, V192, P2055, DOI 10.1016/j.ajog.2005.02.067; Wild RA, 2011, FERTIL STERIL, V95, P1073, DOI 10.1016/j.fertnstert.2010.12.027; Wild RA, 2010, J CLIN ENDOCR METAB, V95, P2038, DOI 10.1210/jc.2009-2724; Witchel SF, 2015, HORM RES PAEDIAT; Workowski Kimberly A, 2010, MMWR Recomm Rep, V59, P1; Zawadski J., 1992, POLYCYSTIC OVARY SYN, P377	47	227	246	8	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2016	375	1					54	64		10.1056/NEJMcp1514916	http://dx.doi.org/10.1056/NEJMcp1514916			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ1ZP	27406348	Green Accepted			2023-01-03	WOS:000379000200005
J	Jayanti, A; Foden, P; Wearden, A; Mitra, S				Jayanti, Anuradha; Foden, Philip; Wearden, Alison; Mitra, Sandip			Illness Beliefs in End Stage Renal Disease and Associations with Self-Care Modality Choice	PLOS ONE			English	Article							SHORT DAILY HEMODIALYSIS; CHRONIC KIDNEY-DISEASE; DIALYSIS PATIENTS; COMMON-SENSE; IN-CENTER; PERCEPTIONS; HOME; REPRESENTATIONS; SYMPTOMS; SURVIVAL	Background Interest in self-care haemodialysis (HD) has increased because it improves patients'clinical and quality-of-life outcomes. Patients who undertake self-management for haemodialysis may hold illness beliefs differently to those choosing institutional care at the time of making the modality choice or moulded by their illness and dialysis treatment experience. Illness perceptions amongst predialysis patients and in those undertaking fully-assisted and self-care haemodialysis are being investigated in a combined cross-sectional and longitudinal study. Study Design The study data are derived from the BASIC-HHD study, a multicentre observational study on factors influencing home haemodialysis uptake. 535 patients were enrolled into three groups: Predialysis CKD-5 group, prevalent 'in-centre' HD and self-care HD groups (93% at home). We explore illness perceptions in the cross-sectional analyses of the three study groups, using the revised Illness Perception Questionnaire (IPQ-R). Predialysis patients' illness beliefs were reassessed prospectively, typically between 4 and 12 months after dialysis commencement. Results Illness belief subscales are significantly different between in-centre and self-care HD groups. In a step-wise hierarchical regression analysis, after adjustment for age, education, marital status, diabetes, dialysis vintage, depression, anxiety scores, and IPQ-R subscales, personal control (p = 0.01) and illness coherence (p = 0.04) are significantly higher in the self-care HD group. In the predialysis group, no significant associations were found between illness representations and modality choices. In prospectively observed predialysis group, scores for personal control, treatment control, timeline cyclical and emotional representations reduced significantly after commencing dialysis and increased significantly for illness coherence. Conclusions Illness beliefs differ between hospital and self-care haemodialysis patients. Patient's affect and neurocognitive ability may have an important role in determining illness beliefs. The impact of modality upon illness representations may also be significant and remains to be explored.	[Jayanti, Anuradha; Mitra, Sandip] Cent Manchester Hosp NHS Trust, Dept Nephrol, Manchester, Lancs, England; [Foden, Philip] Univ Manchester, Dept Biostat, Manchester, Lancs, England; [Wearden, Alison] Univ Manchester, Sch Psychol Sci, Manchester, Lancs, England	University of Manchester; University of Manchester	Jayanti, A (corresponding author), Cent Manchester Hosp NHS Trust, Dept Nephrol, Manchester, Lancs, England.	anu_5577@yahoo.co.in			Baxter Clinical Evidence Council; NIHR-CLAHRC for Greater Manchester, UK; Manchester Academic Health Science Centre (MAHSC), NIHR; Baxter	Baxter Clinical Evidence Council; NIHR-CLAHRC for Greater Manchester, UK; Manchester Academic Health Science Centre (MAHSC), NIHR; Baxter	The research is funded by Baxter Clinical Evidence Council and NIHR-CLAHRC for Greater Manchester, UK. This funding has been secured through open competition. The study was initiated and designed by the investigators. Baxter Clinical Evidence Council partly funded this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge the contributions of all research team members who have played a crucial role in data acquisition. We also acknowledge the support of Manchester Academic Health Science Centre (MAHSC), NIHR and the funding support from Baxter for the BASIC-HHD study. We thank principal investigators from all participating centres for their contribution to facilitating the study locally.	Byrne M, 2005, J PSYCHOSOM RES, V58, P403, DOI 10.1016/j.jpsychores.2004.11.010; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Chilcot J, 2012, SEMIN DIALYSIS, V25, P59, DOI 10.1111/j.1525-139X.2011.00987.x; Chilcot J, 2011, J HEALTH PSYCHOL, V16, P1127, DOI 10.1177/1359105311401672; Chilcot J, 2011, AM J NEPHROL, V33, P358, DOI 10.1159/000326752; Chilcot J, 2010, J PSYCHOSOM RES, V68, P203, DOI 10.1016/j.jpsychores.2009.08.010; Clark S, 2014, SEMIN DIALYSIS, V27, P42, DOI 10.1111/sdi.12159; Finkelstein FO, 2012, KIDNEY INT, V82, P561, DOI 10.1038/ki.2012.168; Fischer M, 2010, BRIT J HEALTH PSYCH, V15, P887, DOI 10.1348/135910710X492693; Griva K, 2010, J PSYCHOSOM RES, V69, P363, DOI 10.1016/j.jpsychores.2010.04.008; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Hall PA, 2006, HEALTH PSYCHOL, V25, P778, DOI 10.1037/0278-6133.25.6.778; Halm EA, 2006, CHEST, V129, P573, DOI 10.1378/chest.129.3.573; Jaber BL, 2011, CLIN J AM SOC NEPHRO, V6, P1049, DOI 10.2215/CJN.10451110; Jansen DL, 2013, BRIT J HEALTH PSYCH, V18, P244, DOI 10.1111/bjhp.12002; Jayanti A, 2014, HEMODIAL INT, V18, P767, DOI 10.1111/hdi.12176; Jayanti A, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-197; Komenda P, 2012, KIDNEY INT, V81, P307, DOI 10.1038/ki.2011.338; LEVENTHAL H, 1992, COGNITIVE THER RES, V16, P143, DOI 10.1007/BF01173486; Malmstrom RK, 2008, NEPHROL DIAL TRANSPL, V23, P1990, DOI 10.1093/ndt/gfm910; McFarlane PA, 2003, KIDNEY INT, V64, P1004, DOI 10.1046/j.1523-1755.2003.00157.x; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nesrallah GE, 2012, J AM SOC NEPHROL, V23, P696, DOI 10.1681/ASN.2011070676; Parfeni M, 2013, NEPHROL DIAL TRANSPL, V28, P2407, DOI 10.1093/ndt/gft194; Petrie KJ, 2006, CLIN MED, V6, P536, DOI 10.7861/clinmedicine.6-6-536; Rao A, 2015, NEPHRON, V129, P31, DOI 10.1159/000370272; Rocco MV, 2015, AM J KIDNEY DIS, V66, P459, DOI 10.1053/j.ajkd.2015.02.331; Searle A, 2007, J PSYCHOSOM RES, V63, P175, DOI 10.1016/j.jpsychores.2007.02.006; Suri RS, 2013, J AM SOC NEPHROL, V24, P498, DOI 10.1681/ASN.2012060595; Tasmoc A, 2013, ARCH MED SCI, V9, P831, DOI 10.5114/aoms.2013.38678; Tennankore KK, 2012, NAT REV NEPHROL, V8, P515, DOI 10.1038/nrneph.2012.145; Timmers L, 2008, PSYCHOL HEALTH, V23, P679, DOI 10.1080/14768320701246535; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085	33	13	13	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2016	11	7							e0154299	10.1371/journal.pone.0154299	http://dx.doi.org/10.1371/journal.pone.0154299			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0TX	27368055	Green Submitted, Green Published, gold			2023-01-03	WOS:000378914900002
J	Mayor, S				Mayor, Susan			Asthma patients in England with easier access to primary care have fewer hospital admissions	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Fleetcroft R, 2016, BRIT J GEN PRACT, V66, pE640, DOI 10.3399/bjgp16X686089	1	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 23	2016	353								i3508	10.1136/bmj.i3508	http://dx.doi.org/10.1136/bmj.i3508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP8BX	27338873				2023-01-03	WOS:000378724000008
J	ElNaggar, AC; Hays, JL; Chen, JL				ElNaggar, Adam C.; Hays, John L.; Chen, James L.			Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series	PLOS ONE			English	Article							SOFT-TISSUE SARCOMA; HIGH-GRADE OSTEOSARCOMA; MULTICENTER PHASE-II; SORAFENIB; ANTHRACYCLINE; CHEMOTHERAPY; COMBINATION; DOXORUBICIN; PAZOPANIB; CRITERIA	Background Patients with metastatic sarcoma who progress on vascular endothelial growth factor receptor inhibitors (VEGFRi) have limited treatment options. Upregulation of the mTOR pathway has been demonstrated to be a means of resistance to targeted VEGFRi in metastatic sarcoma. Patients and methods Retrospective cohort study to evaluate the clinical benefit at four months of combining mTOR inhibition (mTORi) via everolimus with VEGFRi in patients who have derived benefit from single-agent VEGFRi but have progressed. Patients with recurrent, metastatic soft tissue or bone sarcomas who progressed after deriving clinical benefit to VEGFRi beyond 12 weeks were continued on VEGFRi with the addition of everolimus (5 mg daily). Progression free survival was measured from start of VEGFRi to disease progression on single agent VEGFRi as well as from the addition of everolimus therapy to disease progression or drug discontinuation due to toxicity. Clinical benefit was defined as stable disease or partial response at 4 months. Results Nine patients were evaluated. Two patients did not tolerate therapy due to GI toxicity and one elected to discontinue therapy. Of the remaining six patients, the clinical benefit rate at four months was 50%. Progression free survival (PFS) for these patients was 3.1 months ranging from 0.5 to 7.2 months with one patient remaining on combination therapy. Conclusion In this heavily pre-treated, advanced sarcoma population, the addition of mTOR inhibition to VEGFRi based therapy resulted in a clinical benefit for a subset of patients. Prospective studies will be needed to verify these results.	[ElNaggar, Adam C.; Hays, John L.] Ohio State Univ, Dept Obstet & Gynecol, Div Gynecol Oncol, Columbus, OH 43210 USA; [Hays, John L.; Chen, James L.] Ohio State Univ, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA; [Chen, James L.] Ohio State Univ, Div Bioinformat, Dept Biomed Informat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chen, JL (corresponding author), Ohio State Univ, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA.; Chen, JL (corresponding author), Ohio State Univ, Div Bioinformat, Dept Biomed Informat, Columbus, OH 43210 USA.	James.Chen@osumc.edu	ElNaggar, Adam/V-6999-2019	ElNaggar, Adam/0000-0003-3409-583X				Bramwell VH, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003293; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; George S, 2009, J CLIN ONCOL, V27, P3154, DOI 10.1200/JCO.2008.20.9890; Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151; Grignani G, 2015, LANCET ONCOL, V16, P98, DOI 10.1016/S1470-2045(14)71136-2; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Judson I, 2014, LANCET ONCOL, V15, P415, DOI 10.1016/S1470-2045(14)70063-4; Katz D, 2013, J CLIN ONCOL, V31; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Mir O, 2015, JOURNAL OF CLINICAL; Motzer R, 2015, JOURNAL OF CLINICAL; Pignochino Y, 2013, CLIN CANCER RES, V19, P2117, DOI 10.1158/1078-0432.CCR-12-2293; Richter S, 2010, 2010 ASCO ANNUAL MEE; Rodrigues HV, 2015, INVEST NEW DRUG, V33, P700, DOI 10.1007/s10637-015-0238-2; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; Van Glabbeke M, 1999, J CLIN ONCOL, V17, P150, DOI 10.1200/JCO.1999.17.1.150; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wang XR, 2009, EXPERT OPIN THER TAR, V13, P1193, DOI 10.1517/14728220903225008; Yang SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026343; Yoo C, 2013, INVEST NEW DRUG, V31, P1602, DOI 10.1007/s10637-013-0028-7	23	3	3	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2016	11	6							e0156985	10.1371/journal.pone.0156985	http://dx.doi.org/10.1371/journal.pone.0156985			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KF	27295141	Green Published, Green Submitted, gold			2023-01-03	WOS:000377821300016
J	Contreras, JL				Contreras, Jorge L.			The president says patients should own their genetic data. He's wrong	NATURE BIOTECHNOLOGY			English	Letter									[Contreras, Jorge L.] Univ Utah, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah	Contreras, JL (corresponding author), Univ Utah, Salt Lake City, UT USA.	jorge.contreras@law.utah.edu		Contreras, Jorge/0000-0002-7899-3060				Department of Homeland Security, 2015, FED REGISTER, V80, P53942; Hirschfeld D, 2016, NY TIMES, pA15; Skloot R., 2010, IMMORTAL LIFE HENRIE	3	2	2	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2016	34	6					585	586		10.1038/nbt.3608	http://dx.doi.org/10.1038/nbt.3608			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	DO5TT	27281407				2023-01-03	WOS:000377846400013
J	Frazee, C; Chochinov, HM				Frazee, Catherine; Chochinov, Harvey Max			The Annals of Medical Assistance in Dying	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Frazee, Catherine] Ryerson Univ, 350 Victoria St, Toronto, ON M5B 2K3, Canada; [Chochinov, Harvey Max] Univ Manitoba, 3017-675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada	Toronto Metropolitan University; University of Manitoba	Frazee, C (corresponding author), Ryerson Univ, 350 Victoria St, Toronto, ON M5B 2K3, Canada.			Chochinov, Harvey/0000-0003-2656-4704				Canadian Medical Association, 2015, PRINC BAS REC CAN AP; Government of Canada, 2016, INF MED ASS DYING	2	3	3	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2016	165	10					731	+		10.7326/M16-1685	http://dx.doi.org/10.7326/M16-1685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EC2RB	27668405				2023-01-03	WOS:000387970500018
J	Hoppstadter, J; Hachenthal, N; Valbuena-Perez, JV; Lampe, S; Astanina, K; Kunze, MM; Bruscoli, S; Riccardi, C; Schmid, T; Diesel, B; Kiemer, AK				Hoppstaedter, Jessica; Hachenthal, Nina; Valbuena-Perez, Jenny Vanessa; Lampe, Sebastian; Astanina, Ksenia; Kunze, Michael M.; Bruscoli, Stefano; Riccardi, Carlo; Schmid, Tobias; Diesel, Britta; Kiemer, Alexandra K.			Induction of Glucocorticoid-induced Leucine Zipper (GILZ) Contributes to Anti-inflammatory Effects of the Natural Product Curcumin in Macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN HUR; INFLAMMATORY-BOWEL-DISEASE; FACTOR-KAPPA-B; MESSENGER-RNA; NITRIC-OXIDE; TRANSLATIONAL CONTROL; TRANSGENIC MICE; HUMAN ALVEOLAR; CELL-DEATH; RECEPTOR 4	GILZ (glucocorticoid-induced leucine zipper) is inducible by glucocorticoids and plays a key role in their mode of action. GILZ attenuates inflammation mainly by inhibition of NF-kappa B and mitogen-activated protein kinase activation but does not seem to be involved in the severe side effects observed after glucocorticoid treatment. Therefore, GILZ might be a promising target for new therapeutic approaches. The present work focuses on the natural product curcumin, which has previously been reported to inhibit NF-kappa B. GILZ was inducible by curcumin in macrophage cell lines, primary human monocyte-derived macrophages, and murine bone marrow-derived macrophages. The up-regulation of GILZ was neither associated with glucocorticoid receptor activation nor with transcriptional induction or mRNA or protein stabilization but was a result of enhanced translation. Because the GILZ 3'-UTR contains AU-rich elements (AREs), we analyzed the role of the mRNA-binding protein HuR, which has been shown to promote the translation of ARE-containing mRNAs. Our results suggest that curcumin treatment induces HuR expression. An RNA immunoprecipitation assay confirmed that HuR can bind GILZ mRNA. In accordance, HuR overexpression led to increased GILZ protein levels but had no effect on GILZ mRNA expression. Our data employing siRNA in LPS-activated RAW264.7 macrophages show that curcumin facilitates its anti-inflammatory action by induction of GILZ in macrophages. Experiments with LPS-activated bone marrow-derived macrophages from wild-type and GILZ knock-out mice demonstrated that curcumin inhibits the activity of inflammatory regulators, such as NF-kappa B or ERK, and subsequent TNF-kappa production via GILZ. In summary, our data indicate that HuR-dependent GILZ induction contributes to the anti-inflammatory properties of curcumin.	[Hoppstaedter, Jessica; Hachenthal, Nina; Valbuena-Perez, Jenny Vanessa; Astanina, Ksenia; Diesel, Britta; Kiemer, Alexandra K.] Univ Saarland, Dept Pharm, Pharmaceut Biol, D-66041 Saarbrucken, Germany; [Lampe, Sebastian; Kunze, Michael M.; Schmid, Tobias] Goethe Univ Frankfurt, Fac Med, Inst Biochem 1, D-60590 Frankfurt, Germany; [Bruscoli, Stefano; Riccardi, Carlo] Univ Perugia, Pharmacol Sect, Dept Med, I-06132 Perugia, Italy	Saarland University; Goethe University Frankfurt; University of Perugia	Kiemer, AK (corresponding author), Univ Saarland, Pharmaceut Biol, POB 15 11 50, D-66041 Saarbrucken, Germany.	pharm.bio.kiemer@mx.uni-saarland.de	Hoppstädter, Jessica/AAM-2548-2020; Kiemer, Alexandra K./I-9300-2012; Riccardi, Carlo/N-4610-2014	Kiemer, Alexandra K./0000-0002-7224-9900; Riccardi, Carlo/0000-0001-9257-3997; Hoppstadter, Jessica/0000-0001-8758-1554; Valbuena Perez, J. Vanessa/0000-0001-7734-6251; Schmid, Tobias/0000-0002-1952-5259	Deutsche Forschungsgemeinschaft, Bonn, Germany [KI702]	Deutsche Forschungsgemeinschaft, Bonn, Germany(German Research Foundation (DFG))	This work was supported, in part, by Deutsche Forschungsgemeinschaft, Bonn, Germany (Grant KI702). The authors declare that they have no conflicts of interest with the contents of this article.	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Aggarwal B. B., 2013, British Journal of Pharmacology, V169, P1672, DOI 10.1111/bph.12131; Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; Astanina K, 2015, SCI REP-UK, V5, DOI 10.1038/srep11453; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Brumatti LV, 2014, MOLECULES, V19, P21127, DOI 10.3390/molecules191221127; Bruscoli S, 2015, BLOOD, V126, P1790, DOI 10.1182/blood-2015-03-631580; Carroll R. E., 2011, CANCER PREV RES, DOI [10.1158/1940-6207, DOI 10.1158/1940-6207]; Chakravarti N., 2010, CANCER PREV RES, DOI [10.1158/1940-6207, DOI 10.1158/1940-6207]; Chen FY, 2014, J CARDIOVASC PHARM, V63, P544, DOI 10.1097/FJC.0000000000000079; Cheng AL, 2001, ANTICANCER RES, V21, P2895; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; de Oliveira LF, 2016, LANGMUIR, V32, P3217, DOI 10.1021/acs.langmuir.6b00214; Delfino DV, 2006, INT IMMUNOPHARMACOL, V6, P1126, DOI 10.1016/j.intimp.2006.02.001; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Di Marco B, 2007, NUCLEIC ACIDS RES, V35, P517, DOI 10.1093/nar/gkl1080; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fejer G, 2015, IMMUNOBIOLOGY, V220, P169, DOI 10.1016/j.imbio.2014.11.005; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gao SS, 2015, J MOL CELL CARDIOL, V85, P131, DOI 10.1016/j.yjmcc.2015.04.025; Gupta SC, 2013, BIOFACTORS, V39, P2, DOI 10.1002/biof.1079; Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8; Hahn RT, 2014, ATHEROSCLEROSIS, V234, P391, DOI 10.1016/j.atherosclerosis.2014.03.028; Hamdi H, 2007, HEPATOLOGY, V46, P1986, DOI 10.1002/hep.21880; Holt PR, 2005, DIGEST DIS SCI, V50, P2191, DOI 10.1007/s10620-005-3032-8; Hoppstadter J, 2015, ONCOTARGET, V6, P38446, DOI 10.18632/oncotarget.6197; Hoppstadter J, 2015, J IMMUNOL, V194, P6057, DOI 10.4049/jimmunol.1403207; Hoppstadter J, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00055; Hoppstadter J, 2012, EUR J IMMUNOL, V42, P1282, DOI 10.1002/eji.201142081; Hoppstadter J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-124; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; Kiemer AK, 2002, IMMUNOL CELL BIOL, V80, P550, DOI 10.1046/j.1440-1711.2002.01124.x; Kiemer AK, 2001, IMMUNOL CELL BIOL, V79, P11, DOI 10.1046/j.1440-1711.2001.00969.x; Kiemer AK, 2009, J INNATE IMMUN, V1, P29, DOI 10.1159/000142731; Kim GY, 2005, J IMMUNOL, V174, P8116, DOI 10.4049/jimmunol.174.12.8116; Kunze MM, 2016, BBA-GENE REGUL MECH, V1859, P848, DOI 10.1016/j.bbagrm.2016.05.005; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2009, MOL CELL BIOL, V29, P2622, DOI 10.1128/MCB.01495-08; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Parodi FE, 2006, ANN VASC SURG, V20, P360, DOI 10.1007/s10016-006-9054-7; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Simone LE, 2013, CURR OPIN GENET DEV, V23, P35, DOI 10.1016/j.gde.2012.12.006; Soetikno V., 2011, NUTR METAB LOND; Vago JP, 2015, J IMMUNOL, V194, P4940, DOI 10.4049/jimmunol.1401722; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Yoon JH, 2014, NUCLEIC ACIDS RES, V42, P1196, DOI 10.1093/nar/gkt903; Young NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111559; Yu TX, 2013, MOL BIOL CELL, V24, P85, DOI 10.1091/mbc.E12-07-0531; Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200; Zhou HY, 2011, CURR DRUG TARGETS, V12, P332, DOI 10.2174/138945011794815356; Zhou YY, 2015, CELL PHYSIOL BIOCHEM, V36, P631, DOI 10.1159/000430126; Zhou Y, 2016, J BIOL CHEM, V291, P291, DOI 10.1074/jbc.M115.693853; Ziaei A, 2015, J ETHNOPHARMACOL, V160, P94, DOI 10.1016/j.jep.2014.10.041	61	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2016	291	44					22949	22960		10.1074/jbc.M116.733253	http://dx.doi.org/10.1074/jbc.M116.733253			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EB2XB	27629417	Green Published, hybrid			2023-01-03	WOS:000387224800008
J	Seino, H; Arai, Y; Nagao, N; Ozawa, N; Hamada, K				Seino, Haruyoshi; Arai, Yukari; Nagao, Norio; Ozawa, Noriyasu; Hamada, Kazuhiko			Efficient Percutaneous Delivery of the Antimelanogenic Agent Glabridin Using Cationic Amphiphilic Chitosan Micelles	PLOS ONE			English	Article							TYROSINASE ACTIVITY; DRUG-DELIVERY; HAIR CYCLE; HUMAN-SKIN; IN-VITRO; MELANOGENESIS; DERIVATIVES; CELLS; PIGMENTATION; PENETRATION	Partially myristoylated chitosan pyrrolidone carboxylate (PMCP) is a cationic amphiphilic chitosan derivative. Glabridin (Glab) from licorice root extracts is a hydrophobic antimelanogenic agent. Here we assessed the effects of cationic Glab-containing polymeric micelles derived from PMCP (Glab/PMCP-PM) on the ability of Glab to penetrate the skin and inhibit melanogenesis using a human skin model. The amount of Glab absorbed 24 h after the application of Glab/PMCP-PM was approximately four times higher than that of conventional oil-in-water micelles (control) prepared using Tween 60. Further, the release of IL-1 alpha, a mediator of inflammation, was not detected. Treatment with Glab/PMCP-PM significantly increased the inhibition of melanogenesis compared with control. The inhibition of melanogenesis depends upon the enhanced ability of Glab to penetrate the skin, particularly the epidermis. Moreover, the inhibition of melanogenesis and the cationic potential of the Glab/PMCP-PM levels were increased by the cationic phospholipid copolymer. Therefore, Glab/PMCP-PM shows potential as an effective transdermal delivery system for treating skin hyperpigmentation.	[Seino, Haruyoshi; Arai, Yukari; Ozawa, Noriyasu; Hamada, Kazuhiko] Pias Corp, Cent Res Lab, Nishi Ku, 1-3-1 Murotani, Kobe, Hyogo, Japan; [Nagao, Norio] Prefectural Univ Hiroshima, Fac Life & Environm Sci, 562 Nanatsuka, Shobara, Japan		Seino, H (corresponding author), Pias Corp, Cent Res Lab, Nishi Ku, 1-3-1 Murotani, Kobe, Hyogo, Japan.; Nagao, N (corresponding author), Prefectural Univ Hiroshima, Fac Life & Environm Sci, 562 Nanatsuka, Shobara, Japan.	hseino@pias.co.jp; nagao@pu-hiroshima.ac.jp		Seino, Haruyoshi/0000-0001-9293-5409	 [Pias Corporation]		The funder (Pias Corporation) provided support in the form of salaries for authors Haruyoshi Seino, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Norio Nagao conducted joint research to instruct about this study. The specific roles of these authors are articulated in the 'author contributions' section.	Acosta N, 2003, MACROMOL BIOSCI, V3, P546, DOI 10.1002/mabi.200300009; Bajaj G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030899; Brozyna AA, 2013, HUM PATHOL, V44, P2071, DOI 10.1016/j.humpath.2013.02.022; BURNETTE RR, 1987, J PHARM SCI, V76, P765, DOI 10.1002/jps.2600761003; CABANES J, 1994, J PHARM PHARMACOL, V46, P982, DOI 10.1111/j.2042-7158.1994.tb03253.x; Chen R. H., 2000, INT J COSMETIC SCI, V22, P349, DOI [DOI 10.1111/J.1467-2494.2000.00036.X, 10.1111/j.1467-2494.2000.00036.x]; Fujimori H, 2010, BIOSCI BIOTECH BIOCH, V74, P918, DOI 10.1271/bbb.90700; Goh MJ, 2012, PHYTOTHER RES, V26, P1107, DOI 10.1002/ptr.3682; HIRANO S, 1989, BIOMATERIALS, V10, P574, DOI 10.1016/0142-9612(89)90066-5; HIRANO S, 1987, CARBOHYD RES, V165, P120, DOI 10.1016/0008-6215(87)80085-X; Hsieh CY, 2005, BIOMATERIALS, V26, P5617, DOI 10.1016/j.biomaterials.2005.02.012; Hsieh MJ, 2014, BRIT J PHARMACOL, V171, P3037, DOI 10.1111/bph.12626; Jiang GB, 2006, MOL PHARMACEUT, V3, P152, DOI 10.1021/mp050010c; Jin YH, 1999, ARCH PHARM RES, V22, P232, DOI 10.1007/BF02976355; Joly-Tonetti N, 2016, EXP DERMATOL, V25, P501, DOI 10.1111/exd.13016; Kameyama K, 1996, J AM ACAD DERMATOL, V34, P29, DOI 10.1016/S0190-9622(96)90830-0; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Michalczyk D, 2009, ACTA BIOCHIM POL, V56, P343; Michalczyk-Wetula D, 2013, ACTA BIOCHIM POL, V60, P313; Miwa A, 1998, PHARMACEUT RES, V15, P1844, DOI 10.1023/A:1011901921995; Nakajima M, 1998, PIGM CELL RES, V11, P12, DOI 10.1111/j.1600-0749.1998.tb00705.x; Nerya O, 2003, J AGR FOOD CHEM, V51, P1201, DOI 10.1021/jf020935u; Ni-Komatsu L, 2008, MOL PHARMACOL, V74, P1576, DOI 10.1124/mol.108.050633; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; Nokhodchi A, 2003, INT J PHARM, V250, P359, DOI 10.1016/S0378-5173(02)00554-9; Nonaka K, 2001, J OLEO SCI, V50, P773, DOI [DOI 10.5650/JOS.50.773, 10.5650/jos.50.773]; Perez-Bernal A, 2000, Am J Clin Dermatol, V1, P261; SEINO H, 1991, AGR BIOL CHEM TOKYO, V55, P2421, DOI 10.1271/bbb1961.55.2421; Seino H, 2002, J JPN COSMETIC SCI S, V26, P71; Silva SS, 2013, ACTA BIOMATER, V9, P6790, DOI 10.1016/j.actbio.2013.02.027; SLOMINSKI A, 1990, J THEOR BIOL, V143, P123, DOI 10.1016/S0022-5193(05)80292-9; Slominski A, 1998, ANTICANCER RES, V18, P3709; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Som I, 2012, J PHARM BIOALLIED SC, V4, P2, DOI 10.4103/0975-7406.92724; Welss T, 2004, TOXICOL IN VITRO, V18, P231, DOI 10.1016/j.tiv.2003.09.009; Wolnicka-Glubisz A, 2015, ARCH DERMATOL RES, V307, P89, DOI 10.1007/s00403-014-1523-1; Yokota T, 1998, PIGM CELL RES, V11, P355, DOI 10.1111/j.1600-0749.1998.tb00494.x; YOSHIOKA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1901, DOI 10.1271/bbb.59.1901; Zhang C, 2007, COLLOID SURFACE B, V55, P192, DOI 10.1016/j.colsurfb.2006.11.031; Zhao K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053314	41	10	10	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2016	11	10							e0164061	10.1371/journal.pone.0164061	http://dx.doi.org/10.1371/journal.pone.0164061			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0TR	27695112	Green Published, gold, Green Submitted			2023-01-03	WOS:000385553100083
J	Chi, A; Wen, SJ; Monga, M; Almubarak, M; He, XQ; Rojanasakul, Y; Tse, W; Remick, SC				Chi, Alexander; Wen, Sijin; Monga, Manish; Almubarak, Mohammed; He, Xiaoqing; Rojanasakul, Yon; Tse, William; Remick, Scot C.			Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer	PLOS ONE			English	Article							TUMOR-CONTROL; RADIATION; CONCURRENT; EXPERIENCE; TOXICITY; TRIAL	Background Image-guided (IG) intensity-modulated radiotherapy (IMRT) enables maximal tumor margin reduction for the sparing of organs at risk (OARs) when used to treat locally advanced non-small cell lung cancer (NSCLC) with definitive chemo-radiation. It also allows for the incorporation of stereotactic ablative radiotherapy (SABR) into the treatment regimen. Here, we describe our initial experience in combining definitive upfront SABR to the primary lesion with chemo-radiation delivered with conventionally fractionated IG-IMRT to the remaining regional disease; along with clinical outcome following chemo-radiation with conventionally fractionated IG-IMRT alone in the treatment of locally advanced NSCLC. Methods The clinical outcome of 29 patients with locally advanced NSCLC who underwent conventionally fractionated IG-IMRT, or definitive upfront SABR followed by IG-IMRT combined with chemotherapy (induction, concurrent, or both) was retrospectively reviewed. Results After a median follow up of 23.7 months, the median overall survival (OS) and progression-free survival (PFS) were 19.8 and 11.3 months, respectively. The 2 year local, regional, and distant control was 60%, 62%, and 38%, respectively. No local failure was observed in 3 patients following SABR + IG-IMRT while 6/26 patients failed locally following IG-IMRT alone. SABR + IG-IMRT was well tolerated. No >= grade 3 radiation-related toxicity was observed. Conclusion Definitive upfront SABR followed by IG-IMRT in selected patients with locally advanced NSCLC warrants further investigation in future clinical trials, while chemo-radiation with IG-IMRT alone was well tolerated.	[Chi, Alexander] West Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; [Wen, Sijin] West Virginia Univ, Sch Publ Hlth, Dept Biostat, Morgantown, WV 26506 USA; [Monga, Manish] Bristol Meyers Squibb, Oncol, Princeton, NJ USA; [Almubarak, Mohammed; Remick, Scot C.] West Virginia Univ, Mary Babb Randolph Canc Ctr, Div Hematol & Oncol, Morgantown, WV 26506 USA; [He, Xiaoqing; Rojanasakul, Yon] West Virginia Univ, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; [Tse, William] Univ Louisville, James Graham Brown Canc Ctr, Dept Hematol, Louisville, KY 40292 USA	West Virginia University; West Virginia University; West Virginia University; West Virginia University; University of Louisville	Chi, A (corresponding author), West Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.	achiaz2010@gmail.com		Wen, Sijin/0000-0002-6955-2917	NIGMS NIH HHS [U54 GM104942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Ball D, 2013, J THORAC ONCOL, V8, P315, DOI 10.1097/JTO.0b013e31827dc74d; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Bral S, 2010, INT J RADIAT ONCOL, V77, P1352, DOI 10.1016/j.ijrobp.2009.06.075; Cannon DM, 2013, J CLIN ONCOL, V31, P4343, DOI 10.1200/JCO.2013.51.5353; Chi A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00151; Chi A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00156; Chi A, 2010, RADIOTHER ONCOL, V94, P1, DOI 10.1016/j.radonc.2009.12.008; Curran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325; Donato V, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00286; Fowler JF, 2004, INT J RADIAT ONCOL, V60, P1241, DOI 10.1016/j.ijrobp.2004.07.691; Guckenberger M, 2012, STRAHLENTHER ONKOL, V188, P894, DOI 10.1007/s00066-012-0161-9; Ihle NT, 2012, JNCI-J NATL CANCER I, V104, P228, DOI 10.1093/jnci/djr523; Jiang ZQ, 2012, INT J RADIAT ONCOL, V83, P332, DOI 10.1016/j.ijrobp.2011.06.1963; Kong FM, 2005, INT J RADIAT ONCOL, V63, P324, DOI 10.1016/j.ijrobp.2005.02.010; Liao ZXX, 2010, INT J RADIAT ONCOL, V76, P775, DOI 10.1016/j.ijrobp.2009.02.032; Meng DQ, 2013, LUNG CANCER, V81, P1, DOI 10.1016/j.lungcan.2013.03.019; Onishi H, 2007, J THORAC ONCOL, V2, pS94, DOI 10.1097/JTO.0b013e318074de34; Soliman M, 2013, RADIOTHER ONCOL, V106, P299, DOI 10.1016/j.radonc.2012.12.008; Sura S, 2008, RADIOTHER ONCOL, V87, P17, DOI 10.1016/j.radonc.2008.02.005; Toulany M, 2007, MOL CANCER RES, V5, P863, DOI 10.1158/1541-7786.MCR-06-0297; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454	22	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0162453	10.1371/journal.pone.0162453	http://dx.doi.org/10.1371/journal.pone.0162453			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JE	27611833	Green Published, Green Submitted, gold			2023-01-03	WOS:000383255900102
J	da Silva, EC; Roriz, AKC; Eickemberg, M; Mello, AL; Cortes, EBQ; Feitosa, CA; Medeiros, JMB; Ramos, LB				da Silva, Emanuelle Cruz; Carneiro Roriz, Anna Karla; Eickemberg, Michaela; Mello, Adriana Lima; Quadros Cortes, Elvira Barbosa; Feitosa, Caroline Alves; Barreto Medeiros, Jairza Maria; Ramos, Lilian Barbosa			Factors Associated with Anemia in the Institutionalized Elderly	PLOS ONE			English	Article							PREVALENCE; HEALTH	As a common problem in long-term care facilities (LTCFs), anemia affects 25-63% of the elderly. The aim of the present study was to describe the prevalence and characteristics of anemia and its associated factors in the institutionalized elderly. The cross-sectional study was carried out with three hundred thirteen individuals aged >= 60 years, of both genders, living in long-term care facilities for the elderly in Salvador, Bahia, Brazil. Poisson regression (PR) with robust variance estimates was used to assess the factors related to anemia. The prevalence of anemia was 38%. Mild anemia was predominant in both genders (male: 26.8%; female: 21.1%), as normocytic and normochromic anemia, with no anisocytosis (69.75%). Anemia was associated with thinness (PR: 1.68; 95% CI: 1.04-2.72) and with moderate (PR: 1.98; 95% CI: 1.07-3.63) and total (PR: 2.61; 95% CI: 1.34-5.07) dependence in the final model. Severe dependence exhibited borderline significance (PR: 1.94; 95% CI: 1.00-3.77). The prevalence of anemia was high in the institutionalized elderly in both genders, with characteristics suggesting chronic diseases as the causal factor, and the frequency of occurrence was higher in thinness elderly with moderate to total dependence.	[da Silva, Emanuelle Cruz; Barreto Medeiros, Jairza Maria; Ramos, Lilian Barbosa] Univ Fed Bahia UFBA, Univ Fed Bahia, Food Nutr & Hlth Grad Program, Salvador, BA, Brazil; [da Silva, Emanuelle Cruz; Carneiro Roriz, Anna Karla; Eickemberg, Michaela; Mello, Adriana Lima; Ramos, Lilian Barbosa] Univ Fed Bahia, Aging Related Res & Intervent Ctr, Salvador, BA, Brazil; [Carneiro Roriz, Anna Karla; Mello, Adriana Lima; Barreto Medeiros, Jairza Maria; Ramos, Lilian Barbosa] Univ Fed Bahia, Sch Nutr, Dept Nutr Sci, Salvador, BA, Brazil; [Eickemberg, Michaela; Feitosa, Caroline Alves] Univ Fed Bahia, Collect Hlth Inst, Collect Hlth Grad Program, Salvador, BA, Brazil; [Eickemberg, Michaela; Feitosa, Caroline Alves] Bahian Sch Med & Publ Hlth, Salvador, BA, Brazil; [Quadros Cortes, Elvira Barbosa] Univ Fed Bahia, Fac Med, Dept Med, Salvador, BA, Brazil	Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia	da Silva, EC (corresponding author), Univ Fed Bahia UFBA, Univ Fed Bahia, Food Nutr & Hlth Grad Program, Salvador, BA, Brazil.; da Silva, EC (corresponding author), Univ Fed Bahia, Aging Related Res & Intervent Ctr, Salvador, BA, Brazil.	emanuelle_cruz@hotmail.com	BARRETOMEDEIROS, JAIRZA MARIA/AAF-6159-2021; Wachholz, Patrick/G-5142-2010	Wachholz, Patrick/0000-0002-4474-009X; C. RORIZ, ANNA KARLA/0000-0002-1768-5646	Bahia State Research Foundation - FAPESB [PET 0007/2013]	Bahia State Research Foundation - FAPESB	The present study was funded by Bahia State Research Foundation - FAPESB (grant PET 0007/2013 to LBR; URL: http://www.fapesb.ba.gov.br/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Academy of Family Physicians American Dietetic Association, 2002, PHYS GUID NUTR CHRON; Andres E, 2013, GERIATR GERONTOL INT, V13, P519, DOI 10.1111/ggi.12017; Andres E, 2008, EUR J INTERN MED, V19, P488, DOI 10.1016/j.ejim.2008.01.016; [Anonymous], 2002, DIABETES CARE S1, V26, pS5; Nakashima ATA, 2012, NUTRITION, V28, P640, DOI 10.1016/j.nut.2011.09.016; Astor BC, 2002, ARCH INTERN MED, V162, P1401, DOI 10.1001/archinte.162.12.1401; Azeredo Z, 2003, REV FACUL MED LISBOA, V8, P199; Balducci L, 2006, CRIT REV ONCOL HEMAT, V58, P156, DOI 10.1016/j.critrevonc.2005.09.003; Bosco RD, 2013, CAD SAUDE PUBLICA, V29, P1322, DOI 10.1590/S0102-311X2013000700007; Cereda E, 2011, J AM MED DIR ASSOC, V12, P174, DOI 10.1016/j.jamda.2010.11.013; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Corona LP, 2014, REV SAUDE PUBL, V48, P723, DOI 10.1590/S0034-8910.2014048005039; Du Bois D, 1989, NUTRITION, V5, P863; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Janssen I, 2000, J APPL PHYSIOL, V89, P465, DOI 10.1152/jappl.2000.89.2.465; Janssen I, 2004, AM J EPIDEMIOL, V159, P413, DOI 10.1093/aje/kwh058; Jelliffe D B, 1966, Monogr Ser World Health Organ, V53, P3; Kyle UG, 2004, CLIN NUTR, V23, P1430, DOI 10.1016/j.clnu.2004.09.012; Macedo VF, 2011, REV BRAS GERIATR GER, V5, P214; MAHONEY F I, 1965, Md State Med J, V14, P61; Morley JE, 2012, J AM MED DIR ASSOC, V13, P191, DOI 10.1016/j.jamda.2011.12.057; Onem Y, 2010, ARCH GERONTOL GERIAT, V50, P56, DOI 10.1016/j.archger.2009.01.010; Organization. WH, 2011, HAEM CONC DIAGN AN A; Sgnaolin Vanessa, 2013, Rev. Bras. Hematol. Hemoter., V35, P115, DOI 10.5581/1516-8484.20130032; Stauffer ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084943; Tettamanti M, 2010, HAEMATOL-HEMATOL J, V95, P1849, DOI 10.3324/haematol.2010.023101; Tseng CK, 2012, ARCH GERONTOL GERIAT, V55, P77, DOI 10.1016/j.archger.2011.06.019; World Health Organization, 1995, WHO TECHN REP SER	29	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2016	11	9							e0162240	10.1371/journal.pone.0162240	http://dx.doi.org/10.1371/journal.pone.0162240			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JB	27607057	Green Published, gold			2023-01-03	WOS:000383255600032
J	McEvoy, RD; Antic, NA; Heeley, E; Luo, YM; Ou, Q; Zhang, XL; Mediano, O; Chen, R; Drager, LF; Liu, ZH; Chen, GF; Du, BL; McArdle, N; Mukherjee, S; Tripathi, M; Billot, L; Li, Q; Lorenzi-Filho, G; Barbe, F; Redline, S; Wang, JG; Arima, H; Neal, B; White, DP; Grunstein, RR; Zhong, NS; Anderson, CS				McEvoy, R. Doug; Antic, Nick A.; Heeley, Emma; Luo, Yuanming; Ou, Qiong; Zhang, Xilong; Mediano, Olga; Chen, Rui; Drager, Luciano F.; Liu, Zhihong; Chen, Guofang; Du, Baoliang; McArdle, Nigel; Mukherjee, Sutapa; Tripathi, Manjari; Billot, Laurent; Li, Qiang; Lorenzi-Filho, Geraldo; Barbe, Ferran; Redline, Susan; Wang, Jiguang; Arima, Hisatomi; Neal, Bruce; White, David P.; Grunstein, Ron R.; Zhong, Nanshan; Anderson, Craig S.		SAVE Investigators Coordinators	CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE; HEART HEALTH; END-POINTS; ASSOCIATION; HYPERTENSION; METAANALYSIS; STROKE; RISK	BACKGROUND Obstructive sleep apnea is associated with an increased risk of cardiovascular events; whether treatment with continuous positive airway pressure ( CPAP) prevents major cardiovascular events is uncertain. METHODS After a 1-week run-in period during which the participants used sham CPAP, we randomly assigned 2717 eligible adults between 45 and 75 years of age who had moderate-to-severe obstructive sleep apnea and coronary or cerebrovascular disease to receive CPAP treatment plus usual care ( CPAP group) or usual care alone ( usual-care group). The primary composite end point was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for unstable angina, heart failure, or transient ischemic attack. Secondary end points included other cardiovascular outcomes, health-related quality of life, snoring symptoms, daytime sleepiness, and mood. RESULTS Most of the participants were men who had moderate-to-severe obstructive sleep apnea and minimal sleepiness. In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea-hypopnea index ( the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up. After a mean follow-up of 3.7 years, a primary end-point event had occurred in 229 participants in the CPAP group ( 17.0%) and in 207 participants in the usual-care group ( 15.4%) ( hazard ratio with CPAP, 1.10; 95% confidence interval, 0.91 to 1.32; P = 0.34). No significant effect on any individual or other composite cardiovascular end point was observed. CPAP significantly reduced snoring and daytime sleepiness and improved health-related quality of life and mood. CONCLUSIONS Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease. (Funded by the National Health and Medical Research Council of Australia and others; SAVE ClinicalTrials.gov number, NCT00738179; Australian New Zealand Clinical Trials Registry number, ACTRN12608000409370.)	[McEvoy, R. Doug; Antic, Nick A.] Flinders Univ S Australia, Adelaide Inst Sleep Hlth, Adelaide, SA, Australia; [McEvoy, R. Doug; Antic, Nick A.; Heeley, Emma; Neal, Bruce; Anderson, Craig S.] Flinders Univ S Australia, Sch Med, Fac Med Nursing & Hlth Sci, Adelaide, SA, Australia; [McEvoy, R. Doug; Antic, Nick A.; Mukherjee, Sutapa] Southern Adelaide Local Hlth Network, Sleep Hlth Serv, Resp & Sleep Serv, Adelaide, SA, Australia; [Heeley, Emma; Billot, Laurent; Li, Qiang; Arima, Hisatomi; Neal, Bruce; Anderson, Craig S.] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia; [Heeley, Emma; Billot, Laurent; Li, Qiang; Arima, Hisatomi; Neal, Bruce; Anderson, Craig S.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Grunstein, Ron R.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Grunstein, Ron R.] Royal Prince Alfred Hosp, Sydney Hlth Partners, Dept Resp & Sleep Med, Sydney, NSW, Australia; [Anderson, Craig S.] Royal Prince Alfred Hosp, Dept Neurol, Sydney, NSW, Australia; [McArdle, Nigel; Mukherjee, Sutapa] Sir Charles Gairdner Hosp, Western Australian Sleep Disorders Res Inst, Perth, WA, Australia; [Luo, Yuanming; Zhong, Nanshan] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Ou, Qiong] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China; [Ou, Qiong] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China; [Zhang, Xilong] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Chen, Rui] Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China; [Liu, Zhihong] Peking Univ, Dept Cardiol, Fuwai Hosp, Hlth Sci Ctr, Beijing, Peoples R China; [Anderson, Craig S.] Peking Univ, George Inst Global Hlth China, Hlth Sci Ctr, Beijing, Peoples R China; [Chen, Guofang] Xuzhou Cent Hosp, Dept Neurol, Xuzhou, Peoples R China; [Du, Baoliang] Hejian Municipal Peoples Hosp, Hejian, Peoples R China; [Wang, Jiguang] Shanghai Jiao Tong Univ, Shanghai Inst Hypertens, Ruijin Hosp, Shanghai, Peoples R China; [Mediano, Olga] Univ Hosp Guadalajara, Guadalajara, Spain; [Barbe, Ferran] Inst Recerca Biomed Lleida, Resp Dept, Lleida, Spain; [Barbe, Ferran] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain; [Drager, Luciano F.; Lorenzi-Filho, Geraldo] Inst Coracao Incor, Sao Paulo, Brazil; [Drager, Luciano F.; Lorenzi-Filho, Geraldo] Univ Hosp, Sao Paulo, Brazil; [Drager, Luciano F.] Univ Sao Paulo, Hypertens Unit, Div Renal, Sch Med, Sao Paulo, Brazil; [Tripathi, Manjari] All India Inst Med Sci, Dept Neurol, Delhi, India; [Redline, Susan; White, David P.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA USA; [Redline, Susan; White, David P.] Harvard Med Sch, Boston, MA USA	Flinders University South Australia; Flinders University South Australia; George Institute for Global Health; University of Sydney; University of Sydney; University of Sydney; Woolcock Institute of Medical Research; University of Sydney; University of Sydney; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Nanjing Medical University; Soochow University - China; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking University; Peking University; Shanghai Jiao Tong University; Institut de Recerca Biomedica - IRB Lleida; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Universidade de Sao Paulo; Universidade de Sao Paulo; All India Institute of Medical Sciences (AIIMS) New Delhi; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	McEvoy, RD (corresponding author), Flinders Univ S Australia, Adelaide Inst Sleep Hlth, Adelaide, SA, Australia.; McEvoy, RD (corresponding author), Rep Gen Hosp, Resp & Sleep Serv, Southern Adelaide Local Hlth Network, Adelaide, SA 5041, Australia.; Luo, YM (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	doug.mcevoy@flinders.edu.au; yuanmingluo9431@yahoo.co.uk	Palmer, Lyle John/K-3196-2014; McEvoy, Doug/ABB-8052-2020; Mukherjee, Sutapa/U-7262-2017; Barbé, Ferran/A-5988-2010; Marks, Guy B./F-5058-2013; Mediano, Olga/AAZ-2784-2021; Drager, Luciano F/A-1535-2014; Wang, Ji Guang/AAP-4045-2021; Lorenzi-Filho, Geraldo GLF/E-1062-2012; Billot, Laurent/Y-1241-2019; Demchuk, Andrew M/E-1103-2012	Palmer, Lyle John/0000-0002-1628-3055; Mukherjee, Sutapa/0000-0001-5021-1648; Barbé, Ferran/0000-0002-2340-8928; Marks, Guy B./0000-0002-8976-8053; Mediano, Olga/0000-0001-7824-1523; Wang, Ji Guang/0000-0001-8511-1524; Lorenzi-Filho, Geraldo GLF/0000-0002-7011-7373; Billot, Laurent/0000-0002-4975-9793; Demchuk, Andrew M/0000-0002-4930-7789; Carcel, Cheryl/0000-0001-8942-953X; Anderson, Craig/0000-0002-7248-4863; Senior, Hugh/0000-0002-7081-2499; Epton, Michael/0000-0003-4644-366X; VIGIL GIMENEZ, LAURA/0000-0002-0837-9524; Neal, Bruce/0000-0002-0490-7465; Freed, Ruth/0000-0003-4170-1746; Liu, Zhihong/0000-0001-8639-6306; Li, Qiang/0000-0002-4384-8226; Heeley, Emma/0000-0001-9190-2832; Pinar, Maria/0000-0003-1613-839X; Egea, Carlos/0000-0002-7618-7444; McKenna, Amanda/0000-0002-5481-6094; Masdeu Margalef, Maria Jose/0000-0003-0437-2074	National Health and Medical Research Council of Australia; Grants-in-Aid for Scientific Research [15H04773] Funding Source: KAKEN	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Funded by the National Health and Medical Research Council of Australia and others; SAVE ClinicalTrials.gov number, NCT00738179; Australian New Zealand Clinical Trials Registry number, ACTRN12608000409370.	Antic NA, 2015, SLEEP, V38, P1247, DOI 10.5665/sleep.4902; Arzt M, 2005, AM J RESP CRIT CARE, V172, P1447, DOI 10.1164/rccm.200505-702OC; Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Cadby G, 2015, CHEST, V148, P945, DOI 10.1378/chest.15-0229; Campos-Rodriguez F, 2012, ANN INTERN MED, V156, P115, DOI 10.7326/0003-4819-156-2-201201170-00006; Chai-Coetzer CL, 2011, THORAX, V66, P213, DOI 10.1136/thx.2010.152801; Craig SE, 2012, THORAX, V67, P1090, DOI 10.1136/thoraxjnl-2012-202178; Gaisl T, 2015, EUR RESPIR J, V46, P532, DOI 10.1183/09031936.00029315; Gantner D, 2010, RESPIROLOGY, V15, P952, DOI 10.1111/j.1440-1843.2010.01797.x; Gottlieb DJ, 2014, NEW ENGL J MED, V370, P2276, DOI 10.1056/NEJMoa1306766; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Heeley E, 2016, INT J STROKE, V11, P148, DOI 10.1177/1747493015607504; Hohl M, 2014, CURR CARDIOL REV, V10, P362, DOI 10.2174/1573403X1004140707125137; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; Iftikhar IH, 2015, J CLIN SLEEP MED, V11, P475, DOI 10.5664/jcsm.4610; Iftikhar IH, 2014, J HYPERTENS, V32, P2341, DOI 10.1097/HJH.0000000000000372; Johnson KG, 2010, J CLIN SLEEP MED, V6, P131; Lavie L, 2015, SLEEP MED REV, V20, P27, DOI 10.1016/j.smrv.2014.07.003; Lee CH, 2016, CIRCULATION, V133, P2008, DOI 10.1161/CIRCULATIONAHA.115.019392; Loke YK, 2012, CIRC-CARDIOVASC QUAL, V5, P720, DOI 10.1161/CIRCOUTCOMES.111.964783; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marin JM, 2012, JAMA-J AM MED ASSOC, V307, P2169, DOI 10.1001/jama.2012.3418; Montesi SB, 2012, J CLIN SLEEP MED, V8, P587, DOI 10.5664/jcsm.2170; Parra O, 2011, EUR RESPIR J, V37, P1128, DOI 10.1183/09031936.00034410; Peker Y, 2016, AM J RESP CRIT CARE; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Phillips CL, 2012, THORAX, V67, P639, DOI 10.1136/thoraxjnl-2011-200874; Pressman GS, 2015, AM J CARDIOL, V115, P1563, DOI 10.1016/j.amjcard.2015.02.061; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Schwarz EI, 2015, RESPIROLOGY, V20, P889, DOI 10.1111/resp.12573; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Worsnop CJ, 1998, AM J RESP CRIT CARE, V157, P111, DOI 10.1164/ajrccm.157.1.9609063	33	1055	1103	11	228	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 8	2016	375	10					919	931		10.1056/NEJMoa1606599	http://dx.doi.org/10.1056/NEJMoa1606599			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU9IG	27571048	Green Published, Bronze			2023-01-03	WOS:000382529500005
J	Savage, N				Savage, Neil			THE MYTH OF ANONYMITY	NATURE			English	Editorial Material																			0	6	8	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	2016	537	7619					S70	S72		10.1038/537S70a	http://dx.doi.org/10.1038/537S70a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DU9LQ	27602747	Bronze			2023-01-03	WOS:000382539100008
J	Wang, A; Huen, SC; Luan, HH; Yu, S; Zhang, CL; Gallezot, JD; Booth, CJ; Medzhitov, R				Wang, Andrew; Huen, Sarah C.; Luan, Harding H.; Yu, Shuang; Zhang, Cuiling; Gallezot, Jean-Dominique; Booth, Carmen J.; Medzhitov, Ruslan			Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral Inflammation	CELL			English	Article							OXIDATIVE STRESS; PPAR-ALPHA; RESISTANCE; MICE; PROTECTION; INFECTION; SEPSIS; SUPPRESSION; APOPTOSIS; TOXICITY	Acute infections are associated with a set of stereotypic behavioral responses, including anorexia, lethargy, and social withdrawal. Although these so-called sickness behaviors are the most common and familiar symptoms of infections, their roles in host defense are largely unknown. Here, we investigated the role of anorexia in models of bacterial and viral infections. We found that anorexia was protective while nutritional supplementation was detrimental in bacterial sepsis. Furthermore, glucose was necessary and sufficient for these effects. In contrast, nutritional supplementation protected against mortality from influenza infection and viral sepsis, whereas blocking glucose utilization was lethal. In both bacterial and viral models, these effects were largely independent of pathogen load and magnitude of inflammation. Instead, we identify opposing metabolic requirements tied to cellular stress adaptations critical for tolerance of differential inflammatory states.	[Wang, Andrew; Huen, Sarah C.; Luan, Harding H.; Yu, Shuang; Zhang, Cuiling; Medzhitov, Ruslan] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Wang, Andrew] Yale Univ, Sch Med, Dept Med Rheumatol, New Haven, CT 06520 USA; [Huen, Sarah C.] Yale Univ, Sch Med, Dept Med Nephrol, New Haven, CT 06520 USA; [Gallezot, Jean-Dominique] Yale Univ, Sch Med, Dept Radiol & Biomed Imaging, Yale PET Ctr, New Haven, CT 06520 USA; [Booth, Carmen J.] Yale Univ, Sch Med, Sect Comparat Med, New Haven, CT 06520 USA; [Medzhitov, Ruslan] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Howard Hughes Medical Institute	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.; Medzhitov, R (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	ruslan.medzhitov@yale.edu		Wang, Andrew/0000-0002-6951-8081; Huen, Sarah/0000-0001-6420-2400	HHMI; Else Kroner Fresenius Foundation; Blavatnik Family Foundation; NIH [AI046688, AI089771, CA157461, T32 AR07107-39, P30-DK079310]; American Heart Association [13FTF17070000]; Gruber Science Fellowship; NATIONAL CANCER INSTITUTE [R01CA157461, P30CA016359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089771, T32AI007019, R37AI046688, R01AI046688, K08AI128745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, P30DK079310] Funding Source: NIH RePORTER	HHMI(Howard Hughes Medical Institute); Else Kroner Fresenius Foundation; Blavatnik Family Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Gruber Science Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the R.M. lab for helpful discussions, Marya Shanabrough and Tamas Horvath for help with processing of brain specimens, and David Mangelsdorf and Steven Kliewer for making available the Fgf21<SUP>-/-</SUP> mice. This study was supported by the HHMI, Else Kroner Fresenius Foundation, The Blavatnik Family Foundation, and grants from the NIH (AI046688, AI089771, and CA157461). A.W. was supported by NIH grant T32 AR07107-39. S.C.H. was supported by American Heart Association grant 13FTF17070000. H.H.L. was supported by the Gruber Science Fellowship. Plasma creatinine was processed through the Yale George M. O'Brien Kidney Center, NIH grant P30-DK079310. Preparation of histology sections were performed by the Yale Research Pathology and Histology Core.	Adamo SA, 2005, ARCH INSECT BIOCHEM, V60, P185, DOI 10.1002/arch.20068; Agwunobi AO, 2000, J CLIN ENDOCR METAB, V85, P3770, DOI 10.1210/jc.85.10.3770; Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI [10.1056/NEJMra1208623, 10.1056/NEJMc1312359]; Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Archer KA, 2006, INFECT IMMUN, V74, P3325, DOI 10.1128/IAI.02049-05; Auerbuch V, 2004, J EXP MED, V200, P527, DOI 10.1084/jem.20040976; Ayres JS, 2012, ANNU REV IMMUNOL, V30, P271, DOI 10.1146/annurev-immunol-020711-075030; Ayres JS, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000150; Boison D, 2013, EPILEPSY CURR, V13, P219, DOI 10.5698/1535-7597-13.5.219; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Budd A, 2007, ANTIMICROB AGENTS CH, V51, P2965, DOI 10.1128/AAC.00219-07; Burke JD, 2014, J VIROL, V88, P3485, DOI 10.1128/JVI.02649-13; Camara-Lemarroy CR, 2015, EXP THER MED, V9, P1018, DOI 10.3892/etm.2015.2190; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; Esposito V, 2013, AM J PHYSIOL-RENAL, V304, pF440, DOI 10.1152/ajprenal.00487.2011; Feingold KR, 2012, ENDOCRINOLOGY, V153, P2689, DOI 10.1210/en.2011-1496; Figueiredo N, 2013, IMMUNITY, V39, P874, DOI 10.1016/j.immuni.2013.08.039; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Greseth MD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004021; HART BL, 1988, NEUROSCI BIOBEHAV R, V12, P123, DOI 10.1016/S0149-7634(88)80004-6; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Jamieson AM, 2013, SCIENCE, V340, P1230, DOI 10.1126/science.1233632; Janssens S, 2014, NAT IMMUNOL, V15, P910, DOI 10.1038/ni.2991; KLUGER MJ, 1975, SCIENCE, V188, P166, DOI 10.1126/science.1114347; Kolls JK, 2006, J CLIN INVEST, V116, P860, DOI 10.1172/JCI28111; Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893; Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118; Levy RG, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001903.pub2, 10.1002/14651858.CD001903.pub3]; Li MV, 2010, BIOCHEM BIOPH RES CO, V395, P395, DOI 10.1016/j.bbrc.2010.04.028; Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434; Liu JZ, 2012, CELL HOST MICROBE, V11, P227, DOI 10.1016/j.chom.2012.01.017; Liu LL, 2016, P NATL ACAD SCI USA, V113, P1564, DOI 10.1073/pnas.1518000113; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Ma Y, 2005, NEUROSCIENCE, V135, P1203, DOI 10.1016/j.neuroscience.2005.07.014; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Miller ES, 1998, PHYSIOL BEHAV, V65, P535, DOI 10.1016/S0031-9384(98)00199-1; MILLER NE, 1964, B BRIT PSYCHOL SOC, V17, P1; MURRAY MJ, 1979, AM J CLIN NUTR, V32, P593, DOI 10.1093/ajcn/32.3.593; Nairz M, 2015, CELL HOST MICROBE, V18, P254, DOI 10.1016/j.chom.2015.06.017; Pecchi E, 2009, PHYSIOL BEHAV, V97, P279, DOI 10.1016/j.physbeh.2009.02.040; Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106; Raberg L, 2007, SCIENCE, V318, P812, DOI 10.1126/science.1148526; Sayyah M, 2003, NEUROSCIENCE, V122, P1073, DOI 10.1016/j.neuroscience.2003.08.043; Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432; Seron-Arbeloa Carlos, 2013, J Clin Med Res, V5, P1, DOI 10.4021/jocmr1210w; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Singer BH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149136; SMORODINTSEV AA, 1978, VOP VIRUSOL+, P201; Soares MP, 2014, TRENDS IMMUNOL, V35, P483, DOI 10.1016/j.it.2014.08.001; Song Y, 2014, CELL MOL NEUROBIOL, V34, P839, DOI 10.1007/s10571-014-0060-y; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Terbach N, 2009, BIOCHEM SOC T, V37, P1126, DOI 10.1042/BST0371126; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WING EJ, 1980, INFECT IMMUN, V28, P771; Yang LC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5436; Yoo SH, 2013, BIOCHEM BIOPH RES CO, V436, P366, DOI 10.1016/j.bbrc.2013.05.073	60	286	294	5	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	2016	166	6					1512	+		10.1016/j.cell.2016.07.026	http://dx.doi.org/10.1016/j.cell.2016.07.026			26	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EA1GG	27610573	Green Accepted, Bronze			2023-01-03	WOS:000386339900022
J	Mayor, S				Mayor, Susan			Some breast cancer patients with low genetic risk may not need chemotherapy, trial shows	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Hudis CA, 2016, NEW ENGL J MED, V375, P790, DOI 10.1056/NEJMe1607947	2	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 25	2016	354								i4635	10.1136/bmj.i4635	http://dx.doi.org/10.1136/bmj.i4635			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV3AA	27561820				2023-01-03	WOS:000382792200005
J	Lin, FR; Hazzard, WR; Blazer, DG				Lin, Frank R.; Hazzard, William R.; Blazer, Dan G.			Priorities for Improving Hearing Health Care for Adults A Report From the National Academies of Sciences, Engineering, and Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Lin, Frank R.] Johns Hopkins Univ, Dept Otolaryngol, Baltimore, MD USA; [Lin, Frank R.] Johns Hopkins Univ, Dept Geriatr Med, Baltimore, MD USA; [Lin, Frank R.] Johns Hopkins Univ, Dept Mental Hlth, Baltimore, MD USA; [Lin, Frank R.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; [Hazzard, William R.] Wake Forest Univ, Bowman Gray Sch Med, Dept Gerontol & Geriatr Med, Sticht Ctr Aging, Winston Salem, NC USA; [Blazer, Dan G.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Wake Forest University; Wake Forest Baptist Medical Center; Duke University	Lin, FR (corresponding author), Johns Hopkins Ctr Aging & Hlth, 2024 E Monument St,Ste 2-700, Baltimore, MD 21205 USA.	flin1@jhmi.edu						Blazer D.G., 2016, HEARING HLTH CARE AD, DOI [10.17226/23446, DOI 10.17226/23446]; Cassel C, 2016, JAMA-J AM MED ASSOC, V315, P553, DOI 10.1001/jama.2016.0044; Lustig TA, 2014, HEAR LOSS HLTH AG WO; President's Council of Advisors on Science and Technology, 2015, AG AM HEAR LOSS IMP	4	24	25	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2016	316	8					819	820		10.1001/jama.2016.7916	http://dx.doi.org/10.1001/jama.2016.7916			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT8JL	27254725				2023-01-03	WOS:000381736200009
J	Upshur, R				Upshur, Ross			Unresolved issues in Canada's law on physician-assisted dying	LANCET			English	Editorial Material									[Upshur, Ross] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Family & Community Med, Toronto, ON M5T 3M7, Canada; [Upshur, Ross] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Clin Publ Hlth, Toronto, ON M5T 3M7, Canada; [Upshur, Ross] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Upshur, R (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Family & Community Med, Toronto, ON M5T 3M7, Canada.; Upshur, R (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Div Clin Publ Hlth, Toronto, ON M5T 3M7, Canada.; Upshur, R (corresponding author), Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.	ross.upshur@utoronto.ca						[Anonymous], 2016, GLOBE MAIL; Canadian Medical Association, 2015, CMA UPD ASS DYING PO; Government of Canada Department of Justice, 2015, CONS PHYS ASS DYING; Kirkey S., 2015, NATL POST; Parliament of Canada, 2016, MED ASS DYING PAT CT; Provincial Territorial Expert Advisory Group on Physician Assisted Dying, 2015, FIN REP NOV 30 PROV; Schuklenk U, 2011, BIOETHICS, V25, P1, DOI 10.1111/j.1467-8519.2011.01939.x; Stone L, 2016, GLOBE MAIL; Truth and Reconciliation Commission of Canada, 2015, HON TRUTH REC FUT SU	9	10	10	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	2016	388	10044					545	547		10.1016/S0140-6736(16)31255-7	http://dx.doi.org/10.1016/S0140-6736(16)31255-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DS4NA	27511772				2023-01-03	WOS:000380756600010
J	Curti, A; Schwarz, A; Trachsler, J; Tomonaga, Y; Ambuhl, PM				Curti, Adriano; Schwarz, Albin; Trachsler, Johannes; Tomonaga, Yuki; Ambuehl, Patrice M.			Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy	PLOS ONE			English	Article							DIAGNOSED MULTIPLE-MYELOMA; ACUTE-RENAL-FAILURE; FREE LIGHT-CHAINS; PLASMA-EXCHANGE; HEMODIALYSIS; CHEMOTHERAPY; IMPAIRMENT; SURVIVAL; KIDNEY; IMPACT	Background High Cut-Off (HCO) dialysis membranes efficiently reduce serum free light chain (FLC) concentrations and may improve renal recovery and survival from multiple myeloma (MM) associated renal failure with cast nephropathy. However, clinical trials comparing dialysis with HCO versus conventional filters are lacking. The aim of this study was to assess clinical outcomes and economic impact of HCO dialyzers compared to conventional hemodialysis membranes in cast nephropathy. Methods Multicenter retrospective analysis of 19 patients treated for renal failure from FLC associated cast nephropathy with standard induction chemotherapy (bortezomib/dexamethasone). We compared hemodialysis treatment with High Cut-Off (n = 12) versus conventional dialyzers (n = 7). Primary endpoint was survival; secondary endpoints were renal recovery, renal function and treatment costs. Results At 12 months, patient survival was 25% in the HCO group versus 0% in controls (p = NS). A tendency towards faster renal recovery (p = 0.066) and better renal function at 3, 6 and 12 months (p = 0.109) after diagnosis of MM was noted in the HCO group. Complete renal response rate was achieved in 10.5 and 0% of HCO and control patients, respectively, partial renal response in 15.8 and 5.3%, and minor renal response in 26.3 and 15.8%, respectively. Both patient survival and renal recovery were significantly correlated with the extent of free light chain (FLC) reduction in serum. Median treatment costs were CHF 230'000 and 223'000 (p = NS) in the HCO and control group, respectively. Conclusions Hemodialysis treatment with HCO membranes for cast nephropathy tended towards better survival as well as faster and better recovery of renal function versus conventional dialyzers. Moreover, total medical costs were comparable between groups. In the absence of results from randomized prospective trials on this topic, the use of HCO dialyzers in patients with renal failure from cast nephropathy may be recommended. Prospective randomized trials are required.	[Curti, Adriano; Schwarz, Albin; Trachsler, Johannes; Ambuehl, Patrice M.] Stadtspital Waid Zurich, Div Renal, Zurich, Switzerland; [Tomonaga, Yuki] Univ Zurich, Epidemiol Biostat & Prevent Inst, Med Econ, Zurich, Switzerland	University of Zurich	Ambuhl, PM (corresponding author), Stadtspital Waid Zurich, Div Renal, Zurich, Switzerland.	patrice.ambuehl@waid.zuerich.ch						Basnayake K, 2011, KIDNEY INT, V79, P1289, DOI 10.1038/ki.2011.94; Blade J, 1998, ARCH INTERN MED, V158, P1889, DOI 10.1001/archinte.158.17.1889; Clark WF, 2005, ANN INTERN MED, V143, P777, DOI 10.7326/0003-4819-143-11-200512060-00005; Decourt A, 2016, CLIN J AM SOC NEPHRO, V11, P431, DOI 10.2215/CJN.06290615; Dimopoulos MA, 2014, ANN ONCOL, V25, P195, DOI 10.1093/annonc/mdt483; Dimopoulos MA, 2010, J CLIN ONCOL, V28, P4976, DOI 10.1200/JCO.2010.30.8791; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Ecotiere L, 2016, NEPHROL DIAL TRANSPL, V31, P64, DOI 10.1093/ndt/gfv283; Gonsalves WI, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.20; Heher EC, 2013, CLIN J AM SOC NEPHRO, V8, P2007, DOI 10.2215/CJN.12231212; Hutchison CA, 2007, J AM SOC NEPHROL, V18, P886, DOI 10.1681/ASN.2006080821; Hutchison CA, 2012, NEPHROL DIAL TRANSPL, V27, P3823, DOI 10.1093/ndt/gfr773; Hutchison CA, 2009, CLIN J AM SOC NEPHRO, V4, P745, DOI 10.2215/CJN.04590908; Hutchison CA, 2008, ARTIF ORGANS, V32, P910, DOI 10.1111/j.1525-1594.2008.00653.x; JOHNSON WJ, 1990, ARCH INTERN MED, V150, P863, DOI 10.1001/archinte.150.4.863; Knudsen LM, 2000, EUR J HAEMATOL, V65, P175, DOI 10.1034/j.1600-0609.2000.90221.x; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Ludwig H, 2014, ONCOLOGIST, V19, P829, DOI 10.1634/theoncologist.2014-0042; Peters NO, 2011, HEMODIAL INT, V15, P538, DOI 10.1111/j.1542-4758.2011.00587.x; Scheid C, 2014, HAEMATOLOGICA, V99, P148, DOI 10.3324/haematol.2013.087585; Statistik Bf, 2005, BRUTT DAT IND; Zannetti BA, 2015, AM J HEMATOL, V90, P647, DOI 10.1002/ajh.24035; ZUCCHELLI P, 1988, KIDNEY INT, V33, P1175, DOI 10.1038/ki.1988.127	24	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2016	11	7							e0159942	10.1371/journal.pone.0159942	http://dx.doi.org/10.1371/journal.pone.0159942			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IL	27467401	Green Published, Green Submitted, gold			2023-01-03	WOS:000381516100077
J	Schiff, GD; Seoane-Vazquez, E; Wright, A				Schiff, Gordon D.; Seoane-Vazquez, Enrique; Wright, Adam			Incorporating Indications into Medication Ordering - Time to Enter the Age of Reason	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Schiff, Gordon D.; Wright, Adam] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA; [Schiff, Gordon D.; Wright, Adam] Harvard Med Sch, Boston, MA 02115 USA; [Seoane-Vazquez, Enrique] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Schiff, GD (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA.; Schiff, GD (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							[Anonymous], 1833, BOSTON MED SURG J, V9, P98; Brigham Project Team on AHRQ En- hancing Medication Safety CPOE Safety and Quality by Indications Based Prescribing, 2015, WEB SER AHRQ; Kuntz JL, 2014, PATIENT EDUC COUNS, V97, P310, DOI 10.1016/j.pec.2014.08.021; Persell SD, 2004, AM J HEALTH-SYST PH, V61, P2523, DOI 10.1093/ajhp/61.23.2523; Zargarzadeh AH, 2011, INT J CLIN PHARM-NET, V33, P252, DOI 10.1007/s11096-011-9488-z	5	41	42	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2016	375	4					306	309		10.1056/NEJMp1603964	http://dx.doi.org/10.1056/NEJMp1603964			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DS0UV	27464201	Green Published			2023-01-03	WOS:000380313200004
J	Foley, KR; Taffe, J; Bourke, J; Einfeld, SL; Tonge, BJ; Trollor, J; Leonard, H				Foley, Kitty-Rose; Taffe, John; Bourke, Jenny; Einfeld, Stewart L.; Tonge, Bruce J.; Trollor, Julian; Leonard, Helen			Young People with Intellectual Disability Transitioning to Adulthood: Do Behaviour Trajectories Differ in Those with and without Down Syndrome?	PLOS ONE			English	Article							MENTAL ILL-HEALTH; PSYCHIATRIC-DISORDERS; MALADAPTIVE BEHAVIOR; EMOTIONAL-PROBLEMS; CHILDREN; PSYCHOPATHOLOGY; ADOLESCENTS; DEPRESSION; DEMENTIA; ASSOCIATION	Background Young people with intellectual disability exhibit substantial and persistent problem behaviours compared with their non-disabled peers. The aim of this study was to compare changes in emotional and behavioural problems for young people with intellectual disability with and without Down syndrome as they transition into adulthood in two different Australian cohorts. Methods Emotional and behavioural problems were measured over three time points using the Developmental Behaviour Checklist (DBC) for those with Down syndrome (n = 323 at wave one) and compared to those with intellectual disability of another cause (n = 466 at wave one). Outcome scores were modelled using random effects regression as linear functions of age, Down syndrome status, ability to speak and gender. Results DBC scores of those with Down syndrome were lower than those of people without Down syndrome indicating fewer behavioural problems on all scales except communication disturbance. For both groups disruptive, communication disturbance, anxiety and self-absorbed DBC subscales all declined on average over time. There were two important differences between changes in behaviours for these two cohorts. Depressive symptoms did not significantly decline for those with Down syndrome compared to those without Down syndrome. The trajectory of the social relating behaviours subscale differed between these two cohorts, where those with Down syndrome remained relatively steady and, for those with intellectual disability from another cause, the behaviours increased over time. Conclusions These results have implications for needed supports and opportunities for engagement in society to buffer against these emotional and behavioural challenges.	[Foley, Kitty-Rose; Trollor, Julian] UNSW Australia, Sch Psychiat, Dept Dev Disabil, Neuropsychiat, Sydney, NSW, Australia; [Taffe, John; Tonge, Bruce J.] Monash Univ, Sch Psychol Psychiat & Psychol Med, Ctr Dev Psychiat & Psychol, Melbourne, Vic, Australia; [Bourke, Jenny; Leonard, Helen] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Einfeld, Stewart L.] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia; [Einfeld, Stewart L.] Univ Sydney, Brain & Mind Res Inst, Sydney, NSW, Australia	University of New South Wales Sydney; Monash University; Telethon Kids Institute; University of Western Australia; University of Sydney; University of Sydney	Bourke, J (corresponding author), Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia.	Jenny.Bourke@telethonkids.org	Tonge, Bruce J/T-8036-2018; Foley, Kitty-Rose/C-8800-2018; Leonard, Helen/A-1010-2013	Tonge, Bruce J/0000-0002-4236-9688; Foley, Kitty-Rose/0000-0002-1956-4995; Leonard, Helen/0000-0001-6405-5834	Australian Research Council [LP0989847]	Australian Research Council(Australian Research Council)	The study was funded by the Australian Research Council (Linkage Grant #LP0989847). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen D, 2008, J INTELLECT DISABILI, V12, P267, DOI 10.1177/1744629508100494; Baumer N, 2014, CURR OPIN PEDIATR, V26, P428, DOI 10.1097/MOP.0000000000000122; Berkovits LD, 2014, J INTELL DISABIL RES, V58, P765, DOI 10.1111/jir.12088; Blacher J, 2006, J INTELL DISABIL RES, V50, P184, DOI 10.1111/j.1365-2788.2005.00768.x; Blacher J, 2003, CURR OPIN PSYCHIATR, V16, P495, DOI 10.1097/00001504-200309000-00001; Bourke J, 2008, J PEDIATR-US, V153, P320, DOI 10.1016/j.jpeds.2008.02.047; Bower C, 2012, REPORT W AUSTR REGIS; BURT DB, 1995, AM J MENT RETARD, V100, P262; Clarke AR, 2003, J INTELL DISABIL RES, V47, P210, DOI 10.1046/j.1365-2788.2003.00470.x; COLLACOTT RA, 1992, BRIT J PSYCHIAT, V161, P671, DOI 10.1192/bjp.161.5.671; COOPER SA, 1994, BRIT J PSYCHIAT, V165, P399, DOI 10.1192/bjp.165.3.399; Coppus A, 2006, J INTELL DISABIL RES, V50, P768, DOI 10.1111/j.1365-2788.2006.00842.x; de la Torre R, 2012, PROG BRAIN RES, V197, P1, DOI 10.1016/B978-0-444-54299-1.00001-7; Douma JCH, 2006, J AM ACAD CHILD PSY, V45, P1224, DOI 10.1097/01.chi.0000233158.21925.95; Dyke P., 2007, SYNDROME NEEDS OPINI; Dykens EM, 2007, MENT RETARD DEV D R, V13, P272, DOI 10.1002/mrdd.20159; Dykens EM, 2015, J NEURODEV DISORD, V7, DOI 10.1186/s11689-015-9101-1; Dykens EM, 1997, AM J MENT RETARD, V102, P228, DOI 10.1352/0895-8017(1997)102<0228:MBICWP>2.0.CO;2; Dykens EM, 2002, J INTELL DISABIL RES, V46, P484, DOI 10.1046/j.1365-2788.2002.00431.x; EINFELD SL, 1995, J AUTISM DEV DISORD, V25, P81, DOI 10.1007/BF02178498; Einfeld SL, 1996, J INTELL DISABIL RES, V40, P99, DOI 10.1111/j.1365-2788.1996.tb00611.x; Einfeld SL, 2001, AM J MENT RETARD, V106, P73, DOI 10.1352/0895-8017(2001)106<0073:LCOBAE>2.0.CO;2; Einfeld SL, 2006, JAMA-J AM MED ASSOC, V296, P1981, DOI 10.1001/jama.296.16.1981; Einfeld SL, 2006, INT REV RES MENT RET, V33, P247, DOI 10.1016/S0074-7750(06)33010-8; Esbensen AJ, 2008, AM J MENT RETARD, V113, P263, DOI 10.1352/0895-8017(2008)113[263:SACIHF]2.0.CO;2; Fitzgerald P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070401; Foley KR, 2013, CHILD CARE HLTH DEV, V39, P789, DOI 10.1111/cch.12019; Foley K-R, 2014, SOCIAL PSYCHIAT PSYC; Foley KR, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0266-z; Fonseca LM, 2014, NEUROPSYCH DIS TREAT, V10, P2209, DOI 10.2147/NDT.S68831; Glass TA, 2006, J AGING HEALTH, V18, P604, DOI 10.1177/0898264306291017; Glidden LM, 2014, AJIDD-AM J INTELLECT, V119, P389, DOI 10.1352/1944-7558-119.5.389; Gray KM, 2011, RES DEV DISABIL, V32, P1194, DOI 10.1016/j.ridd.2010.12.044; Griffith GM, 2010, J AUTISM DEV DISORD, V40, P610, DOI 10.1007/s10803-009-0906-1; Guralnick MJ, 2007, CHILD DEV, V78, P459, DOI 10.1111/j.1467-8624.2007.01009.x; Haynes A, 2013, RES DEV DISABIL, V34, P847, DOI 10.1016/j.ridd.2012.11.008; Hughes EK, 2010, J CLIN PSYCHOL, V66, P978, DOI 10.1002/jclp.20695; KHAN S, 2002, MENTAL HLTH ASPECTS, V5, P46; Leonard H, 2005, SOCIAL SCI MED, V60; Leonard H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017875; Makary AT, 2014, RES DEV DISABIL, V35, P1868, DOI 10.1016/j.ridd.2014.04.010; Mantry D, 2008, J INTELL DISABIL RES, V52, P141, DOI 10.1111/j.1365-2788.2007.00985.x; McGillivray JA, 2007, RES DEV DISABIL, V28, P59, DOI 10.1016/j.ridd.2005.11.001; Mohr C, 2005, J INTELL DISABIL RES, V49, P469, DOI 10.1111/j.1365-2788.2005.00701.x; Mohr C, 2011, DEV BEHAV CHECKLIST; MYERS BA, 1991, J NERV MENT DIS, V179, P609, DOI 10.1097/00005053-199110000-00004; Partington M, 2000, AM J MED GENET, V92, P57, DOI 10.1002/(SICI)1096-8628(20000501)92:1<57::AID-AJMG10>3.0.CO;2-0; Patti P. J., 2006, INT J DISABIL HUM DE, V5, DOI [DOI 10.155/UDHD.2006.5.4.357, 10.1515/IJDHD.2006.5.4.357]; Pruijssers AC, 2014, J INTELLECTUAL DISAB, V58; Taffe J, 2008, INT J METHODS PSYCHI, V17; Thomas K, 2010, INT REV RES MENTAL R; Thomas K, 2011, J PEDIATR-US, V158, P194, DOI 10.1016/j.jpeds.2010.08.045; Tonge BJ, 2003, INT REV RES MENT RET, V26, P61, DOI 10.1016/S0074-7750(03)01002-4; Walker JC, 2011, RES DEV DISABIL, V32, P1432, DOI 10.1016/j.ridd.2011.02.010; Wark S, 2014, J INTELLECT DISABILI, V18, P305, DOI 10.1177/1744629514552152	55	12	12	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0157667	10.1371/journal.pone.0157667	http://dx.doi.org/10.1371/journal.pone.0157667			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR6IK	27391326	Green Published, Green Submitted, gold			2023-01-03	WOS:000380005400017
J	Zakharchenko, M; Los, F; Brodska, H; Balik, M				Zakharchenko, Mychajlo; Los, Ferdinand; Brodska, Helena; Balik, Martin			The Effects of High Level Magnesium Dialysis/Substitution Fluid on Magnesium Homeostasis under Regional Citrate Anticoagulation in Critically Ill	PLOS ONE			English	Article							CONTINUOUS VENOVENOUS HEMODIAFILTRATION; RENAL-REPLACEMENT THERAPY; ACID-BASE; SERUM MAGNESIUM; HEPARIN; HEMODIALYSIS; RISK; HEMOFILTRATION; HYPOMAGNESEMIA; METABOLISM	Background The requirements for magnesium (Mg) supplementation increase under regional citrate anticoagulation (RCA) because citrate acts by chelation of bivalent cations within the blood circuit. The level of magnesium in commercially available fluids for continuous renal replacement therapy (CRRT) may not be sufficient to prevent hypomagnesemia. Methods Patients (n = 45) on CRRT (2,000 ml/h, blood flow (Qb) 100 ml/min) with RCA modality (4% trisodium citrate) using calcium free fluid with 0.75 mmol/l of Mg with additional magnesium substitution were observed after switch to the calcium-free fluid with magnesium concentration of 1.50 mmol/l (n = 42) and no extra magnesium replenishment. All patients had renal indications for CRRT, were treated with the same devices, filters and the same postfilter ionized calcium endpoint (< 0.4 mmol/l) of prefilter citrate dosage. Under the high level Mg fluid the Qb, dosages of citrate and CRRT were consequently escalated in 9h steps to test various settings. Results Median balance of Mg was -0.91 (-1.18 to -0.53) mmol/h with Mg 0.75 mmol/l and 0.2 (0.06-0.35) mmol/h when fluid with Mg 1.50 mmol/l was used. It was close to zero (0.02 (-0.12-0.18) mmol/h) with higher blood flow and dosage of citrate, increased again to 0.15 (-0.11-0.25) mmol/h with 3,000 ml/h of high magnesium containing fluid (p< 0.001). The arterial levels of Mg were mildly increased after the change for high level magnesium containing fluid (p< 0.01). Conclusions Compared to ordinary dialysis fluid the mildly hypermagnesemic fluid provided even balances and adequate levels within ordinary configurations of CRRT with RCA and without a need for extra magnesium replenishment.	[Zakharchenko, Mychajlo; Balik, Martin] Charles Univ Prague, Fac Med 1, Dept Anesthesiol & Intens Care, Prague, Czech Republic; [Zakharchenko, Mychajlo; Los, Ferdinand; Brodska, Helena; Balik, Martin] Gen Univ Hosp Prague, Prague, Czech Republic; [Los, Ferdinand; Brodska, Helena] Charles Univ Prague, Fac Med 1, Dept Clin Biochem, Prague, Czech Republic	Charles University Prague; General University Hospital Prague; Charles University Prague	Balik, M (corresponding author), Charles Univ Prague, Fac Med 1, Dept Anesthesiol & Intens Care, Prague, Czech Republic.; Balik, M (corresponding author), Gen Univ Hosp Prague, Prague, Czech Republic.	martin.balik@vfn.cz	Lahoda Brodska, Helena/I-6694-2017	Lahoda Brodska, Helena/0000-0001-7962-8287	ESICM Stoutenbeek Award	ESICM Stoutenbeek Award	The study (ClinicalTrials.gov Identifier: NCT01361581) was supported in part from ESICM Stoutenbeek Award 2012.	Alves SC, 2013, NEPHROL DIAL TRANSPL, V28, P910, DOI 10.1093/ndt/gfs268; Balik M, 2005, BLOOD PURIFICAT, V23, P325, DOI 10.1159/000087770; Balik M, 2014, BLOOD PURIFICAT, V38, P263, DOI 10.1159/000369956; Balik M, 2013, J CRIT CARE, V28, P87, DOI 10.1016/j.jcrc.2012.06.003; Balik M, 2012, BLOOD PURIFICAT, V33, P80, DOI 10.1159/000334641; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bollmann MD, 2004, INTENS CARE MED, V30, P1103, DOI 10.1007/s00134-004-2251-3; Brain M, 2012, CRIT CARE RESUSC, V14, P274; Brain M, 2011, CRIT CARE RESUSC, V13, P72; Cole L, 2003, INTENS CARE MED, V29, P1113, DOI 10.1007/s00134-003-1812-1; Dorval M, 2003, INTENS CARE MED, V29, P1186, DOI 10.1007/s00134-003-1801-4; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Escuela MP, 2005, INTENS CARE MED, V31, P151, DOI 10.1007/s00134-004-2508-x; Fairley J, 2015, J CRIT CARE, V30, P1349, DOI 10.1016/j.jcrc.2015.07.029; Hebert P, 1997, CRIT CARE MED, V25, P749, DOI 10.1097/00003246-199705000-00007; Hetzel GR, 2011, NEPHROL DIAL TRANSPL, V26, P232, DOI 10.1093/ndt/gfq575; Huijgen HJ, 2000, AM J CLIN PATHOL, V114, P688, DOI 10.1309/JR9Y-PPTX-AJTC-QDRD; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; Matias PJ, 2014, BLOOD PURIFICAT, V38, P244, DOI 10.1159/000366124; Morgera S, 2005, NEPHRON CLIN PRACT, V101, pC211, DOI 10.1159/000088177; Morgera S, 2004, NEPHRON CLIN PRACT, V97, pC131, DOI 10.1159/000079171; Morgera S, 2009, CRIT CARE MED, V37, P2018, DOI 10.1097/CCM.0b013e3181a00a92; Oudemans-van Straaten HM, 2009, CRIT CARE MED, V37, P545, DOI 10.1097/CCM.0b013e3181953c5e; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Relton S, 1992, ASAIO J, V38, pM691, DOI 10.1097/00002480-199207000-00127; Seabra VF BE, 2008, AM J KIDNEY DIS, V52; Soliman HM, 2003, CRIT CARE MED, V31, P1082, DOI 10.1097/01.CCM.0000060867.17556.A0; Tong Garrison M, 2005, J Intensive Care Med, V20, P3, DOI 10.1177/0885066604271539; Uchino S, 2003, INTENS CARE MED, V29, P575, DOI 10.1007/s00134-003-1672-8; Wu MY, 2012, AM J KIDNEY DIS, V59, P810, DOI 10.1053/j.ajkd.2011.11.030; Zakharchenko M, 2016, BLOOD PURIFICAT, V41, P41, DOI 10.1159/000440972; Zhang ZH, 2012, INTENS CARE MED, V38, P20, DOI 10.1007/s00134-011-2438-3	32	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158179	10.1371/journal.pone.0158179	http://dx.doi.org/10.1371/journal.pone.0158179			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27391902	Green Published, Green Submitted, gold			2023-01-03	WOS:000380005400035
J	Guang-Han, O; Leang-Chung, C; Vellasamy, KM; Mariappan, V; Li-Yen, C; Vadivelu, J				Guang-Han, Ong; Leang-Chung, Choh; Vellasamy, Kumutha Malar; Mariappan, Vanitha; Li-Yen, Chang; Vadivelu, Jamuna			Experimental Phage Therapy for Burkholderia pseudomallei Infection	PLOS ONE			English	Article							MYCOBACTERIUM-AVIUM; IN-VIVO; BACTERIOPHAGE; MELIOIDOSIS; RESISTANCE; SUSCEPTIBILITY; EFFICACY; MODEL; MICE	Burkholderia pseudomallei is an intracellular Gram-negative bacterial pathogen intrinsically resistant to a variety of antibiotics. Phages have been developed for use as an alternative treatment therapy, particularly for bacterial infections that do not respond to conventional antibiotics. In this study, we investigated the use of phages to treat cells infected with B. pseudomallei. Phage C34 isolated from seawater was purified and characterised on the basis of its host range and morphology using transmission electron microscopy (TEM). Phage C34 was able to lyse 39.5% of B. pseudomallei clinical strains. Due to the presence of contractile tail, phage C34 is classified as a member of the family Myoviridae, a tailed double-stranded DNA virus. When 2 x 10(5) A549 cells were exposed to 2 x 10(7) PFU of phage C34, 24 hours prior to infection with 2 x 10(6) CFU of B. pseudomallei, it was found that the survivability of the cells increased to 41.6 +/- 6.8% as compared to 22.8 +/- 6.0% in untreated control. Additionally, application of phage successfully rescued 33.3% of mice infected with B. pseudomallei and significantly reduced the bacterial load in the spleen of the phage-treated mice. These findings indicate that phage can be a potential antimicrobial agent for B. pseudomallei infections.	[Guang-Han, Ong; Leang-Chung, Choh; Vellasamy, Kumutha Malar; Mariappan, Vanitha; Li-Yen, Chang; Vadivelu, Jamuna] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Li-Yen, Chang] Univ Malaya, TIDREC, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya	Vadivelu, J (corresponding author), Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.	jamuna@ummc.edu.my	CHANG, LI-YEN/B-8353-2010; VADIVELU, JAMUNARANI S/B-8696-2010; Mariappan, Vanitha/I-4769-2013; Vellasamy, Kumutha Malar/A-6592-2017; Mariappan, Vanitha/ABD-4066-2020; Vellasamy, Kumutha Malar/CAF-0007-2022	VADIVELU, JAMUNARANI S/0000-0001-7322-3676; Mariappan, Vanitha/0000-0002-2351-1597; Vellasamy, Kumutha Malar/0000-0001-7661-3928; Mariappan, Vanitha/0000-0002-2351-1597; Vellasamy, Kumutha Malar/0000-0001-7661-3928; Ong, Guang Han/0000-0003-3286-3823; Chang, Li-Yen/0000-0001-6850-2435	Ministry of Education (MOE), Malaysia under the High Impact Research (HIR)-MOE [UM.C/625/1/HIR/MoE/CHAN/02 H-50001-A000013, UM.C/625/1/HIR/MoE/CHAN/13/5 (H-50001-00-A000033)]; Postgraduate Research Fund under University of Malaya [PV066/2011A]; University of Malaya Research Grant (UMRG) [RP013C-13HTM]; University of Malaya Postgraduate Research Fund [PV066/2011A]	Ministry of Education (MOE), Malaysia under the High Impact Research (HIR)-MOE; Postgraduate Research Fund under University of Malaya; University of Malaya Research Grant (UMRG); University of Malaya Postgraduate Research Fund(Universiti Malaya)	Research in the authors' laboratory was supported by Ministry of Education (MOE), Malaysia under the High Impact Research (HIR)-MOE, project UM.C/625/1/HIR/MoE/CHAN/13/5 (H-50001-00-A000033), University of Malaya Research Grant (UMRG) (RP013C-13HTM) and University of Malaya Postgraduate Research Fund (PV066/2011A). Funding was awarded to JV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Research in the authors' laboratory was supported by Ministry of Education (MOE), Malaysia under the High Impact Research (HIR)-MOE, project UM.C/625/1/HIR/MoE/CHAN/02 H-50001-A000013 and the Postgraduate Research Fund (PV066/2011A) under University of Malaya.	Ackermann Hans-W., 2009, V501, P127, DOI 10.1007/978-1-60327-164-6_13; Alegado RA, 2011, CELL MICROBIOL, V13, P1618, DOI 10.1111/j.1462-5822.2011.01645.x; Brockhurst MA, 2007, INFECT GENET EVOL, V7, P547, DOI 10.1016/j.meegid.2007.01.005; Broxmeyer L, 2002, J INFECT DIS, V186, P1155, DOI 10.1086/343812; Brussow H, 2005, MICROBIOL-SGM, V151, P2133, DOI 10.1099/mic.0.27849-0; Bruynoghe R, 1921, C R SOC BIOL, V85, P1; Capparelli R, 2007, ANTIMICROB AGENTS CH, V51, P2765, DOI 10.1128/AAC.01513-06; Capra ML, 2004, LETT APPL MICROBIOL, V38, P499, DOI 10.1111/j.1472-765X.2004.01525.x; Carmody LA, 2010, J INFECT DIS, V201, P264, DOI 10.1086/649227; Chan BK, 2013, FUTURE MICROBIOL, V8, P769, DOI [10.2217/fmb.13.47, 10.2217/FMB.13.47]; CHAOWAGUL W, 1993, J INFECT DIS, V168, P1181, DOI 10.1093/infdis/168.5.1181; Cheng AC, 2005, CLIN MICROBIOL REV, V18, P383, DOI 10.1128/CMR.18.2.383-416.2005; Choh LC, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00005; Conejero L, 2011, AM J PATHOL, V179, P270, DOI 10.1016/j.ajpath.2011.03.031; d'Herelle F., 1917, ACAD SCI PARIS, V165, P3; DANCE DAB, 1989, J ANTIMICROB CHEMOTH, V24, P295, DOI 10.1093/jac/24.3.295; Danelishvili L, 2006, MICROB DRUG RESIST, V12, P1, DOI 10.1089/mdr.2006.12.1; dHerelle F., 1926, BACTERIOPHAGE SON CO; Dubos RJ, 1943, J EXP MED, V78, P161, DOI 10.1084/jem.78.3.161; Filippov AA, 2012, ADV EXP MED BIOL, V954, P337, DOI 10.1007/978-1-4614-3561-7_41; Gatedee J, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-366; Hall AR, 2012, APPL ENVIRON MICROB, V78, P5646, DOI 10.1128/AEM.00757-12; Hanlon GW, 2007, INT J ANTIMICROB AG, V30, P118, DOI 10.1016/j.ijantimicag.2007.04.006; Hyman Paul, 2009, V501, P175, DOI 10.1007/978-1-60327-164-6_18; Jenney AWJ, 2001, INT J ANTIMICROB AG, V17, P109, DOI 10.1016/S0924-8579(00)00334-4; Kvitko BH, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-289; Labrie SJ, 2010, NAT REV MICROBIOL, V8, P317, DOI 10.1038/nrmicro2315; Limmathurotsakul D, 2006, CLIN INFECT DIS, V43, P979, DOI 10.1086/507632; Lipsitz Rebecca, 2012, Emerg Infect Dis, V18, pe2, DOI 10.3201/eid1812.120638; Markoishvili K, 2002, INT J DERMATOL, V41, P453, DOI 10.1046/j.1365-4362.2002.01451.x; Merril CR, 1996, P NATL ACAD SCI USA, V93, P3188, DOI 10.1073/pnas.93.8.3188; Nasner-Posso KM, 2015, INT J INFECT DIS, V35, P103, DOI 10.1016/j.ijid.2015.05.009; Nobrega FL, 2015, TRENDS MICROBIOL, V23, P185, DOI 10.1016/j.tim.2015.01.006; O'Flynn G, 2004, APPL ENVIRON MICROB, V70, P3417, DOI 10.1128/AEM.70.6.3417-3424.2004; OHSHIMA Y, 1988, MED MICROBIOL IMMUN, V177, P229; Puthucheary S D, 2009, Med J Malaysia, V64, P266; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Sariya L, 2006, SCI ASIA, V32, P9; Scanlan PD, 2011, MOL ECOL, V20, P981, DOI 10.1111/j.1365-294X.2010.04903.x; Semler DD, 2014, ANTIMICROB AGENTS CH, V58, P4005, DOI 10.1128/AAC.02388-13; SMITH HW, 1982, J GEN MICROBIOL, V128, P307; SMITH HW, 1987, J GEN MICROBIOL, V133, P1111; SOOKPRANEE M, 1992, ANTIMICROB AGENTS CH, V36, P158, DOI 10.1128/AAC.36.1.158; Sulakvelidze A, 2001, ANTIMICROB AGENTS CH, V45, P649, DOI 10.1128/AAC.45.3.649-659.2001; Suppiah J, 2010, FEMS MICROBIOL LETT, V306, P9, DOI 10.1111/j.1574-6968.2010.01923.x; Takemura-Uchiyama I, 2014, MICROBES INFECT, V16, P512, DOI 10.1016/j.micinf.2014.02.011; Van Twest Rohan, 2009, V501, P15, DOI 10.1007/978-1-60327-164-6_2; Wiersinga WJ, 2012, NEW ENGL J MED, V367, P1035, DOI 10.1056/NEJMra1204699; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yordpratum U, 2011, FEMS MICROBIOL LETT, V314, P81, DOI 10.1111/j.1574-6968.2010.02150.x	51	24	25	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158213	10.1371/journal.pone.0158213	http://dx.doi.org/10.1371/journal.pone.0158213			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3OC	27387381	Green Published, gold, Green Submitted			2023-01-03	WOS:000379811500016
J	Xue, MF; Gong, SL; Dai, JP; Chen, G; Hu, JY				Xue, MingFeng; Gong, SuiLiang; Dai, JiaPing; Chen, Gang; Hu, JunYu			The Treatment of Fibrosis of Joint Synovium and Frozen Shoulder by Smad4 Gene Silencing in Rats	PLOS ONE			English	Article							TGF-BETA; DIFFERENTIATION; CELLS	Soft tissue fibrosis at the joint induced by inflammation is the pathological basis of frozen shoulder. In the present study, we utilized a lentiviral approach to silence the Smad4 gene in an in vitro fibrosis model of fibroblasts and an in vivo frozen shoulder model. We observed the change in the fibrosis process and the biological indicators of frozen shoulder. The in vitro fibrosis models (Rat myoblasts L6, Rat synovial cell RSC-364 and Rat chondrocytes RCs) were established using TGF-beta 1 induction, and the effect of Smad4 gene silencing on fibrosis was analyzed. The method of Kanno A was employed to establish a rat model of frozen shoulder, and Smad4 in the relevant part was knocked down with the lentiviral approach. We then examined the abduction and rotation angles and the length of synovial intima and measured the inflammatory factors in effusion and the fibrotic markers of tissues. We found that Smad4 knockdown suppressed the proliferation and expression of fibrotic markers in L6, RSC-364 and RCs cells induced by TGF-beta 1. MMP activity measurements showed that Smad4 knockdown significantly reversed the decrease in MMP activity in these three cell lines that were induced by TGF-beta 1. Furthermore, using lentivirus in the rat frozen shoulder model, we found that Smad4 silencing attenuated the inflammatory response and fibrosis. It significantly inhibited the increase of the Vimentin, a-SMA, collagen I and III, Lama1 and Timp1 proteins in synovial tissue as well as the inflammatory factors of TNF-alpha, IL-1 alpha/beta, IL-6 and IL-10 in effusion. MMP acidity assays revealed that Smad4 silencing inhibited MMP activity in the synovial, cartilage and ligament tissues in the model animals. The assessment of the phosphorylated Smad2/3 in the nuclei isolated from the synovial tissues showed that Smad4 silencing significantly inhibited the phosphorylation and subsequent nuclear translocation of Smad2/3 proteins. Moreover, Smad4-shRNA lentivirus inhibited the decrease in both the abduction and rotation angles caused by immobilization as well as the decrease in the length of the synovial intima. Based on shoulder movement data, Smad4 knockdown can increase the rotation limitation caused by immobilization. In summary, Smad4 silencing can suppress chronic inflammation and fibrosis in joint tissues by inhibiting the TGF-beta/Smad pathway and can play a positive role in the prevention and treatment of joint stiffness.	[Xue, MingFeng; Gong, SuiLiang; Dai, JiaPing; Chen, Gang; Hu, JunYu] Jiaxing Second Hosp, Dept Orthopaed Surg, Jia Xing 31400, Peoples R China		Gong, SL (corresponding author), Jiaxing Second Hosp, Dept Orthopaed Surg, Jia Xing 31400, Peoples R China.	suiliangg55@163.com			Jia Xing Science & Technology Bureau [2012AY1071-7]	Jia Xing Science & Technology Bureau	This study was supported by Fund of Jia Xing Science & Technology Bureau (2012AY1071-7).	Asghari MH, 2015, RES PHARM SCI, V10, P429; [陈疾忤 Chen Jiwu], 2004, [中国临床解剖学杂志, Chinese Journal of Clinical Anatomy], V22, P55; Foster W, 2003, J ORTHOP RES, V21, P798, DOI 10.1016/S0736-0266(03)00059-7; Goto Y, 2004, CELL TISSUE RES, V315, P209, DOI 10.1007/s00441-003-0824-z; Hand GCR, 2007, J BONE JOINT SURG BR, V89B, P928, DOI 10.1302/0301-620X.89B7.19097; Hao JM, 1999, J MOL CELL CARDIOL, V31, P667, DOI 10.1006/jmcc.1998.0902; Kanno A, 2010, J SHOULDER ELB SURG, V19, P700, DOI 10.1016/j.jse.2010.02.004; Kopp J, 2005, J BIOL CHEM, V280, P21570, DOI 10.1074/jbc.m502071200; [李宏云 LI Hong-yun], 2009, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University. Medical Science], V29, P1363; Li YC, 2016, AM J PHYSIOL-GASTR L, V310, pG262, DOI 10.1152/ajpgi.00257.2015; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Omari A, 2001, J SHOULDER ELB SURG, V10, P353, DOI 10.1067/mse.2001.115986; Pennison M, 2007, CURR OPIN ONCOL, V19, P579, DOI 10.1097/CCO.0b013e3282f0ad0e; Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059; Schnaper HW, 2003, AM J PHYSIOL-RENAL, V284, pF243, DOI 10.1152/ajprenal.00300.2002	15	22	25	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2016	11	6							e0158093	10.1371/journal.pone.0158093	http://dx.doi.org/10.1371/journal.pone.0158093			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AH	27351864	Green Published, Green Submitted, gold			2023-01-03	WOS:000378858900031
J	Sekercioglu, N; Thabane, L; Martinez, JPD; Nesrallah, G; Longo, CJ; Busse, JW; Akhtar-Danesh, N; Agarwal, A; Al-Khalifah, R; Iorio, A; Guyatt, GH				Sekercioglu, Nigar; Thabane, Lehana; Martinez, Juan Pablo Diaz; Nesrallah, Gihad; Longo, Christopher J.; Busse, Jason W.; Akhtar-Danesh, Noori; Agarwal, Arnav; Al-Khalifah, Reem; Iorio, Alfonso; Guyatt, Gordon H.			Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis	PLOS ONE			English	Review							CORONARY-ARTERY CALCIFICATION; LANTHANUM CARBONATE; HEMODIALYSIS-PATIENTS; VASCULAR CALCIFICATION; FERRIC CITRATE; DOUBLE-BLIND; SEVELAMER HYDROCHLORIDE; AORTIC CALCIFICATION; CALCIUM-CARBONATE; SERUM PHOSPHORUS	Background Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been linked to poor health outcomes, including diminished quality and length of life. This condition is characterized by high phosphate levels and requires phosphate-lowering agents-phosphate binders. The objective of this systematic review is to compare the effects of available phosphate binders on patient-important outcomes in patients with CKD-MBD. Methods Data sources included MEDLINE and EMBASE Trials from 1996 to February 2016. We also searched the Cochrane Register of Controlled Trials up to April 2016. Teams of two reviewers, independently and in duplicate, screened titles and abstracts and potentially eligible full text reports to determine eligibility, and subsequently abstracted data and assessed risk of bias in eligible randomized controlled trials (RCTs). Eligible trials enrolled patients with CKD-MBD, randomized them to receive calcium (delivered as calcium acetate, calcium citrate or calcium carbonate), non-calcium-based phosphate binders (NCBPB) (sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate, sucroferric oxyhydroxide and ferric citrate), phosphorus restricted diet, placebo or no treatment, and reported effects on all-cause mortality, cardiovascular mortality or hospitalization at >= 4 weeks follow-up. We performed network meta-analyses (NMA) for all cause-mortality for individual agents (seven-node analysis) and conventional meta-analysis of calcium vs. NCBPBs for all-cause mortality, cardiovascular mortality and hospitalization. In the NMAs, we calculated the effect estimates for direct, indirect and network meta-analysis estimates; for both NMA and conventional meta-analysis, we pooled treatment effects as risk ratios (RR) and calculated 95% confidence intervals (CIs) using random effect models. We used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to rate the quality of evidence for each paired comparison. Results Our search yielded 1190 citations, of which 71 RCTs were retrieved for full review and 15 proved eligible. With 13 eligible studies from a prior review, we included 28 studies with 8335 participants; 25 trials provided data for our quantitative synthesis. Results suggest higher mortality with calcium than either sevelamer (NMA RR, 1.89 [95% CI, 1.02 to 3.50], moderate quality evidence) or NCBPBs (conventional meta-analysis RR, 1.76 [95% CI, 1.21 to 2.56, moderate quality evidence). Conventional meta-analysis suggested no difference in cardiovascular mortality between calcium and NCBPBs (RR, 2.54 [95% CI, 0.67 to 9.62 low quality evidence). Our results suggest higher hospitalization, although non-significant, with calcium than NCBPBs (RR, 1.293 [95% CI, 0.94 to 1.74, moderate quality evidence). Discussion/Conclusions Use of calcium results in higher mortality than either sevelamer in particular and NCBPBs in general (moderate quality evidence). Our results raise questions about whether administration of calcium as an intervention for CKD-MBD remains ethical. Further research is needed to explore the effects of different types of phosphate binders, including novel agents such as iron, on quality and quantity of life.	[Sekercioglu, Nigar; Thabane, Lehana; Martinez, Juan Pablo Diaz; Busse, Jason W.; Akhtar-Danesh, Noori; Iorio, Alfonso; Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Thabane, Lehana] McMaster Univ, Dept Pediat & Anesthesia, Hamilton, ON, Canada; [Thabane, Lehana] St Josephs Healthcare, Ctr Evaluat Med, Hamilton, ON, Canada; [Thabane, Lehana] St Josephs Healthcare, Father Sean OSullivan Res Ctr, Biostat Unit, Hamilton, ON, Canada; [Thabane, Lehana] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Nesrallah, Gihad] Humber River Hosp, Toronto, ON, Canada; [Nesrallah, Gihad] Univ Toronto, Dept Med, Toronto, ON, Canada; [Longo, Christopher J.] DeGroote Sch Business, 4350 South Serv Rd, Burlington, ON, Canada; [Busse, Jason W.] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada; [Busse, Jason W.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; [Agarwal, Arnav] Univ Toronto, Fac Med, Toronto, ON, Canada; [Al-Khalifah, Reem] King Saud Univ, Div Pediat Endocrinol, Riyadh, Saudi Arabia; [Iorio, Alfonso; Guyatt, Gordon H.] McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; Population Health Research Institute; University of Toronto; McMaster University; McMaster University; University of Toronto; King Saud University; McMaster University	Sekercioglu, N (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.	nigars2003@yahoo.com	Khalifah, Reem/H-6486-2019; Busse, Jason/CAH-3696-2022; Nesrallah, Gihad/AAY-7534-2020; SEKERCIOGLU, Nigar/AFR-0250-2022; Agarwal, Arnav/J-1553-2014; Iorio, Alfonso/B-9478-2013	Khalifah, Reem/0000-0002-5304-3528; Busse, Jason/0000-0002-0178-8712; SEKERCIOGLU, Nigar/0000-0001-6461-8801; Agarwal, Arnav/0000-0002-0931-7851; Iorio, Alfonso/0000-0002-3331-8766				[Anonymous], 2013, USRDS 2013 ANN DAT R; [Anonymous], 2015, AM J KIDNEY DIS OFFI, V20, P00633; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Barreto DV, 2008, NEPHRON CLIN PRACT, V110, pC273, DOI 10.1159/000170783; Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Block GA, 2015, AM J KIDNEY DIS, V65, P728, DOI 10.1053/j.ajkd.2014.10.014; Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223; Bolland MJ, 2013, THER ADV DRUG SAF, V4, P199, DOI 10.1177/2042098613499790; Cernaro V, 2016, INT J NEPHROL RENOV, V9, P11, DOI 10.2147/IJNRD.S78040; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chaimani A, 2012, RES SYNTH METHODS, V3, P161, DOI 10.1002/jrsm.57; Chan CT, 2009, NEPHROL DIAL TRANSPL, V24, P3867, DOI 10.1093/ndt/gfp495; Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523-1755.2002.00434.x; Cheung AK, 2000, KIDNEY INT, V58, P353, DOI 10.1046/j.1523-1755.2000.00173.x; Cosmai L, 2015, J NEPHROL, V28, P647, DOI 10.1007/s40620-015-0226-9; Cozzolino M, 2014, CURR DRUG METAB, V15, P953; Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710; de Francisco ALM, 2010, NEPHROL DIAL TRANSPL, V25, P3707, DOI 10.1093/ndt/gfq292; Di Iorio B, 2013, AM J KIDNEY DIS, V62, P771, DOI 10.1053/j.ajkd.2013.03.023; Di Iorio B, 2012, CLIN J AM SOC NEPHRO, V7, P487, DOI 10.2215/CJN.03820411; Floege J, 2014, KIDNEY INT, V86, P638, DOI 10.1038/ki.2014.58; Granata A, 2016, EUR J INTERN MED, V30, P1, DOI 10.1016/j.ejim.2016.02.019; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; IBELS LS, 1979, AM J MED, V66, P790, DOI 10.1016/0002-9343(79)91118-5; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Jono S, 1997, ARTERIOSCL THROM VAS, V17, P1135, DOI 10.1161/01.ATV.17.6.1135; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Kakuta T, 2011, AM J KIDNEY DIS, V57, P422, DOI 10.1053/j.ajkd.2010.10.055; Kooienga L, 2007, SEMIN DIALYSIS, V20, P342, DOI 10.1111/j.1525-139X.2007.00304.x; Lee CT, 2015, J NEPHROL, V28, P105, DOI 10.1007/s40620-014-0108-6; Lee WH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002917; Lee YK, 2013, CLIN NEPHROL, V79, P136, DOI 10.5414/CN107362; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Lewis JB, 2015, J AM SOC NEPHROL, V26, P493, DOI 10.1681/ASN.2014020212; Locatelli F, 2014, EXPERT OPIN DRUG SAF, V13, P551, DOI 10.1517/14740338.2014.907791; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; Moe SM, 2006, EUR J CLIN INVEST, V36, P51, DOI 10.1111/j.1365-2362.2006.01665.x; NG KP, 2015, J RENIN-ANGIO-ALDO S, V16, P599, DOI DOI 10.1177/1470320315575849; O'Seaghdha CM, 2011, NEPHROL DIAL TRANSPL, V26, P2885, DOI 10.1093/ndt/gfq808; Ohtake T, 2013, J CARDIOVASC PHARM T, V18, P439, DOI 10.1177/1074248413486355; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Qunibi W, 2008, AM J KIDNEY DIS, V51, P952, DOI 10.1053/j.ajkd.2008.02.298; Rebic D, 2015, REN FAIL, V19, P1; Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518; Sadek T, 2003, NEPHROL DIAL TRANSPL, V18, P582, DOI 10.1093/ndt/18.3.582; Sanchez-Perales C, 2015, NEFROLOGIA, V35, P157, DOI 10.1016/j.nefro.2015.05.017; Schwarz S, 2006, CLIN J AM SOC NEPHRO, V1, P825, DOI 10.2215/CJN.02101205; Shroff RC, 2008, CIRCULATION, V118, P1748, DOI 10.1161/CIRCULATIONAHA.108.783738; Spasovski G, 2015, EXPERT OPIN PHARMACO, V16, P2589, DOI 10.1517/14656566.2015.1092521; Suki WN, 2008, J RENAL NUTR, V18, P91, DOI 10.1053/j.jrn.2007.10.019; Tagawa M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114678; Takahara Y, 2014, CLIN NEPHROL, V82, P181, DOI 10.5414/CN108269; Takei T, 2008, NEPHRON CLIN PRACT, V108, pC278, DOI 10.1159/000127361; Toussaint Nigel, 2006, Hemodial Int, V10, P280, DOI 10.1111/j.1542-4758.2006.00109.x; Toussaint ND, 2011, NEPHROLOGY, V16, P290, DOI 10.1111/j.1440-1797.2010.01412.x; Urena-Torres P, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-71; Voormolen N, 2007, NEPHROL DIAL TRANSPL, V22, P2909, DOI 10.1093/ndt/gfm286; Wada K, 2014, THER APHER DIAL, V18, P353, DOI 10.1111/1744-9987.12153; Wilkieson Trevor J, 2015, Can J Kidney Health Dis, V2, P29, DOI 10.1186/s40697-015-0065-6; Wilson R, 2009, CURR MED RES OPIN, V25, P3021, DOI 10.1185/03007990903399398; Wu HC, 2015, RENAL FAILURE, V37, P343, DOI 10.3109/0886022X.2015.1087862; Wuthrich RP, 2013, CLIN J AM SOC NEPHRO, V8, P280, DOI 10.2215/CJN.08230811; Xu J, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-29; Yang H, 2004, KIDNEY INT, V66, P2293, DOI 10.1111/j.1523-1755.2004.66015.x; Yokoyama K, 2014, NEPHROL DIAL TRANSPL, V29, P1053, DOI 10.1093/ndt/gft483; Yokoyama K, 2014, CLIN J AM SOC NEPHRO, V9, P543, DOI 10.2215/CJN.05170513; Zhai CJ, 2015, INT UROL NEPHROL, V47, P527, DOI 10.1007/s11255-014-0876-x; 2012, KIDNEY INT S, V2013, P1	74	48	51	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2016	11	6							e0156891	10.1371/journal.pone.0156891	http://dx.doi.org/10.1371/journal.pone.0156891			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TJ	27276077	Green Published, gold, Green Submitted			2023-01-03	WOS:000377561700045
J	Lim, SY; Lu, N; Oza, A; Fisher, M; Rai, SK; Menendez, ME; Choi, HK				Lim, Sian Yik; Lu, Na; Oza, Amar; Fisher, Mark; Rai, Sharan K.; Menendez, Mariano E.; Choi, Hyon K.			Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HEALTH		[Lim, Sian Yik; Lu, Na; Oza, Amar; Fisher, Mark; Choi, Hyon K.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA; [Rai, Sharan K.] Arthrit Res Canada, Vancouver, BC, Canada; [Menendez, Mariano E.] Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Arthritis Research Canada; Harvard University; Massachusetts General Hospital	Choi, HK (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA.	hchoi@partners.org			NIAMS NIH HHS [T32 AR007258, R01AR065944, R01 AR065944] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007258, R01AR065944] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agency for Healthcare Research and Quality, OV NAT NAT INP SAMPL; Neogi T, 2011, NEW ENGL J MED, V364, P443, DOI 10.1056/NEJMcp1001124; Patel NJ, 2014, CIRCULATION, V129, P2371, DOI 10.1161/CIRCULATIONAHA.114.008201; Rournie CL, 2008, PHARMACOEPIDEM DR S, V17, P20, DOI 10.1002/pds.1518; Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573; Zhu YY, 2011, ARTHRITIS RHEUM-US, V63, P3136, DOI 10.1002/art.30520	6	66	67	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2016	315	21					2345	2347		10.1001/jama.2016.3517	http://dx.doi.org/10.1001/jama.2016.3517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN6KO	27272587	Bronze, Green Accepted			2023-01-03	WOS:000377183100025
J	Roy, PM; Rachas, A; Meyer, G; Le Gal, G; Durieux, P; El Kouri, D; Honnart, D; Schmidt, J; Legall, C; Hausfater, P; Chretien, JM; Mottier, D				Roy, Pierre-Marie; Rachas, Antoine; Meyer, Guy; Le Gal, Gregoire; Durieux, Pierre; El Kouri, Dominique; Honnart, Didier; Schmidt, Jeannot; Legall, Catherine; Hausfater, Pierre; Chretien, Jean-Marie; Mottier, Dominique		PREVENU Study Grp	Multifaceted Intervention to Prevent Venous Thromboembolism in Patients Hospitalized for Acute Medical Illness: A Multicenter Cluster-Randomized Trial	PLOS ONE			English	Article							PULMONARY-EMBOLISM; CLINICAL-PRACTICE; PROPHYLAXIS; GUIDELINES; THROMBOPROPHYLAXIS; CARE; THROMBOSIS; INPATIENTS; ADMISSION; INCREASE	Background Misuse of thromboprophylaxis may increase preventable complications for hospitalized medical patients. Objectives To assess the net clinical benefit of a multifaceted intervention in emergency wards (educational lectures, posters, pocket cards, computerized clinical decision support systems and, where feasible, electronic reminders) for the prevention of venous thromboembolism. Patients/Methods Prospective cluster-randomized trial in 27 hospitals. After a pre-intervention period, centers were randomized as either intervention (n = 13) or control (n = 14). All patients over 40 years old, admitted to the emergency room, and hospitalized in a medical ward were included, totaling 1,402 (712 intervention and 690 control) and 15,351 (8,359 intervention and 6,992 control) in the pre-intervention and intervention periods, respectively. Results Symptomatic venous thromboembolism or major bleeding (primary outcome) occurred at 3 months in 3.1% and 3.2% of patients in the intervention and control groups, respectively (adjusted odds ratio: 1.02 [95% confidence interval: 0.78-1.34]). The rates of thromboembolism (1.9% vs. 1.9%), major bleedings (1.2% vs. 1.3%), and mortality (11.3% vs. 11.1%) did not differ between the groups. Between the pre-intervention and intervention periods, the proportion of patients who received prophylactic anticoagulant treatment more steeply increased in the intervention group (from 35.0% to 48.2%: + 13.2%) than the control (40.7% to 44.1%: + 3.4%), while the rate of adequate thromboprophylaxis remained stable in both groups (52.4% to 50.9%: -1.5%; 49.1% to 48.8%: -0.3%). Conclusions Our intervention neither improved adequate prophylaxis nor reduced the rates of clinical events. New strategies are required to improve thromboembolism prevention for hospitalized medical patients.	[Roy, Pierre-Marie] Univ Angers, CHU Angers, Ctr Vasc & Coagulat, Dept Med Urgence,Inst MITOVASC,EA3860, Angers, France; [Rachas, Antoine] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Unite Epidemiol & Rech Clin, INSERM,Ctr Invest Epidemiol 4, Paris, France; [Meyer, Guy] Univ Paris 05, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris,INSERM,U970,CIC 1418, Serv Pneumol & Soins Intensifs,Sorbonne Paris Cit, Paris, France; [Le Gal, Gregoire] Univ Bretagne Occidentale, CHU Cavale Blanche, Dept Med Interne & Pneumol, GETBO,CIC INSERM 1412,EA3878, Brest, France; [Durieux, Pierre] Univ Paris 05, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris,Dept Sante Publ & Infor, Sorbonne Paris Cite,Ctr Rech Cordeliers,INSERM,UM, Paris, France; [El Kouri, Dominique] CHU Hotel Dieu, Serv Urgences Med Polyvalente, Nantes, France; [Honnart, Didier] Hop Bocage, CHU Dijon, Dept Med Urgence, Dijon, France; [Schmidt, Jeannot] Univ Clermont Ferrand, CHU Gabriel Montpied, Serv Accueil Urgences, Clermont Ferrand, France; [Legall, Catherine] CH Argenteuil Victor Dupouy, Serv Urgences, Argenteuil, France; [Hausfater, Pierre] Univ Paris 06, CHU La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Urgences, Paris, France; [Chretien, Jean-Marie] CHU Angers, Cellule Gest Donnees & Evaluat, Delegat Rech Clin & Innovat, Angers, France; [Mottier, Dominique] Univ Bretagne Occidentale, CHU Cavale Blanche, CIC INSERM 1412, GETBO,Dept Med Interne & Pneumol,EA3878, Brest, France; [Rachas, Antoine] Hop Bicetre, Assistance Publ Hop Paris, Sante Publ Epidemiol, Le Kremlin Bicetre, France; [Le Gal, Gregoire] Ottawa Hosp Res Inst, Div Haematol, Thrombosis Program, Dept Med, Ottawa, ON, Canada; [Le Gal, Gregoire] Univ Ottawa, Ottawa, ON, Canada	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU Brest; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Universite Paris Cite; Nantes Universite; CHU de Nantes; CHU Dijon Bourgogne; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Brest; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Roy, PM (corresponding author), Univ Angers, CHU Angers, Ctr Vasc & Coagulat, Dept Med Urgence,Inst MITOVASC,EA3860, Angers, France.	PMRoy@chu-angers.fr	Roy, Pierre-Marie/AAA-7737-2022		French Ministry of Health (PHRC) [21-09]; French investigation network on VTE (INNOVTE)	French Ministry of Health (PHRC); French investigation network on VTE (INNOVTE)	The study was supported by two grants from the French Ministry of Health (PHRC 2008 and 2011: 21-09) and received further financial aid from Bayer HealthCare SAS, France and Sanofi SAS, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study was supported by the French investigation network on VTE (INNOVTE). We would like to thank all the members of the PREVENU study group and the research assistants, secretaries, physicians, and residents of the emergency departments for their invaluable collaboration. We also wish to thank Babak Khoshnood for his statistical support and Guillaume de Charette for his technical support.	AFSSAPS, 2009, PREV TRAIT MAL THROM; Alikhan R, 2004, J CLIN PATHOL, V57, P1254, DOI 10.1136/jcp.2003.013581; ANDERSON FA, 1994, ARCH INTERN MED, V154, P669, DOI 10.1001/archinte.154.6.669; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Dentali F, 2007, ANN INTERN MED, V146, P278, DOI 10.7326/0003-4819-146-4-200702200-00007; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Donner A, 1998, J R STAT SOC C-APPL, V47, P95, DOI 10.1111/1467-9876.00100; Fontaine A, 2006, J INTERN MED, V260, P369, DOI 10.1111/j.1365-2796.2006.01699.x; Garcia DA, 2009, BLOOD COAGUL FIBRIN, V20, P541, DOI 10.1097/MBC.0b013e32832d6cfc; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Grimshaw J, 2006, J GEN INTERN MED, V21, pS14, DOI 10.1111/j.1525-1497.2006.00357.x; Guyatt GH, 2012, CHEST, V141, p53S, DOI 10.1378/chest.11-2288; Kahn SR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008201.pub2; Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296; Kerry SM, 1998, BRIT MED J, V316, P549, DOI 10.1136/bmj.316.7130.549; Khanna R, 2012, J GEN INTERN MED, V27, P318, DOI 10.1007/s11606-011-1871-x; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Labarere J, 2007, INT J QUAL HEALTH C, V19, P301, DOI 10.1093/intqhc/mzm034; Maynard G, 2013, J HOSP MED, V8, P582, DOI 10.1002/jhm.2071; Murray DM, 2004, AM J PUBLIC HEALTH, V94, P423, DOI 10.2105/AJPH.94.3.423; Nendaz MR, 2010, J THROMB HAEMOST, V8, P1230, DOI 10.1111/j.1538-7836.2010.03817.x; Oger E, 2002, THROMB HAEMOSTASIS, V88, P592; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; Piazza G, 2009, CIRCULATION, V119, P2196, DOI 10.1161/CIRCULATIONAHA.108.841197; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Tapson VF, 2007, CHEST, V132, P936, DOI 10.1378/chest.06-2993; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310	28	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0154832	10.1371/journal.pone.0154832	http://dx.doi.org/10.1371/journal.pone.0154832			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27227406	Green Submitted, Green Published, gold			2023-01-03	WOS:000376882500008
J	Sinsky, C; Colligan, L; Li, L; Prgomet, M; Reynolds, S; Goeders, L; Westbrook, J; Tutty, M; Blike, G				Sinsky, Christine; Colligan, Lacey; Li, Ling; Prgomet, Mirela; Reynolds, Sam; Goeders, Lindsey; Westbrook, Johanna; Tutty, Michael; Blike, George			Allocation of Physician Time in Ambulatory Practice: A Time and Motion Study in 4 Specialties	ANNALS OF INTERNAL MEDICINE			English	Article							ELECTRONIC MEDICAL-RECORDS; PRIMARY-CARE PRACTICES; WORK-LIFE BALANCE; EXAMINATION ROOM; HEALTH RECORDS; OFFICE VISITS; PATIENT-CARE; SATISFACTION; DOCTORS; BURNOUT	Background: Little is known about how physician time is allocated in ambulatory care. Objective: To describe how physician time is spent in ambulatory practice. Design: Quantitative direct observational time and motion study (during office hours) and self-reported diary (after hours). Setting: U.S. ambulatory care in 4 specialties in 4 states (Illinois, New Hampshire, Virginia, and Washington). Participants: 57 U. S. physicians in family medicine, internal medicine, cardiology, and orthopedics who were observed for 430 hours, 21 of whom also completed after-hours diaries. Measurements: Proportions of time spent on 4 activities (direct clinical face time, electronic health record [EHR] and desk work, administrative tasks, and other tasks) and self-reported afterhours work. Results: During the office day, physicians spent 27.0% of their total time on direct clinical face time with patients and 49.2% of their time on EHR and desk work. While in the examination room with patients, physicians spent 52.9% of the time on direct clinical face time and 37.0% on EHR and desk work. The 21 physicians who completed after-hours diaries reported 1 to 2 hours of after-hours work each night, devoted mostly to EHR tasks. Limitations: Data were gathered in self-selected, high-performing practices and may not be generalizable to other settings. The descriptive study design did not support formal statistical comparisons by physician and practice characteristics. Conclusion: For every hour physicians provide direct clinical face time to patients, nearly 2 additional hours is spent on EHR and desk work within the clinic day. Outside office hours, physicians spend another 1 to 2 hours of personal time each night doing additional computer and other clerical work.	[Sinsky, Christine; Goeders, Lindsey; Tutty, Michael] Amer Med Assoc, 330 North Wabash Ave,Suite 39300, Chicago, IL 60611 USA; [Colligan, Lacey] Sharp End Advisory LLC, POB 222, Hanover, NH 03755 USA; [Li, Ling; Prgomet, Mirela; Westbrook, Johanna] Macquarie Univ, Ctr Hlth Syst & Safety Res, Australian Inst Hlth Innovat, Fac Med & Hlth Sci, Level 6,75 Talavera Rd, Sydney, NSW 2109, Australia; [Reynolds, Sam] Amer Med Assoc, 4622 North Damen Ave, Chicago, IL 60625 USA; [Blike, George] Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr,Bldg 50, Lebanon, NH 03756 USA	American Medical Association; Macquarie University; American Medical Association; Dartmouth College	Li, L (corresponding author), Macquarie Univ, Ctr Hlth Syst & Safety Res, Australian Inst Hlth Innovat, Fac Med & Hlth Sci, Level 6,75 Talavera Rd, Sydney, NSW 2109, Australia.	Ling.Li@mq.edu.au	Prgomet, Mirela/AAJ-7735-2020; Colligan, Lacey/AAC-7076-2020; Westbrook, Johanna I/J-9045-2018	Prgomet, Mirela/0000-0001-5629-3680; Westbrook, Johanna I/0000-0003-1083-8192; Li, Ling/0000-0002-1642-142X	American Medical Association	American Medical Association	American Medical Association.	[Anonymous], AHRQ PUBLICATION; Arabadzhiyska PN, 2013, INTERN MED J, V43, P1321, DOI 10.1111/imj.12223; Arndt B, 2015, N AM PRIM CAR RES GR; Arya R, 2010, ACAD EMERG MED, V17, P490, DOI 10.1111/j.1553-2712.2010.00718.x; Babbott S, 2014, J AM MED INFORM ASSN, V21, pE100, DOI 10.1136/amiajnl-2013-001875; Ballermann MA, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-32; Bank AJ, 2013, CLINICOECONOMIC OUTC, V5, P399, DOI 10.2147/CEOR.S49010; Baron RJ, 2010, NEW ENGL J MED, V362, P1632, DOI 10.1056/NEJMon0910793; Black AD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000387; Casalino LP, 2016, HEALTH AFFAIR, V35, P401, DOI 10.1377/hlthaff.2015.1258; Chen MA, 2011, J GEN INTERN MED, V26, P58, DOI 10.1007/s11606-010-1494-7; Colligan L, 2015, INT J MED INFORM, V84, P469, DOI 10.1016/j.ijmedinf.2015.03.003; Devine EB, 2010, HEALTH SERV RES, V45, P152, DOI 10.1111/j.1475-6773.2009.01063.x; Doerr E, 2010, J GEN INTERN MED, V25, P1289, DOI 10.1007/s11606-010-1470-2; Farber J, 2007, ANN INTERN MED, V147, P693, DOI 10.7326/0003-4819-147-10-200711200-00005; Fiks AG, 2011, J AM MED INFORM ASSN, V18, P38, DOI 10.1136/jamia.2010.004135; Friedberg M.W., 2013, FACTORS AFFECTING PH; Ghorob A, 2012, J AM BOARD FAM MED, V25, P143, DOI 10.3122/jabfm.2012.02.120007; Gilchrist V, 2005, ANN FAM MED, V3, P494, DOI 10.1370/afm.391; Gottschalk A, 2005, ANN FAM MED, V3, P488, DOI 10.1370/afm.404; Grumbach K, 2004, JAMA-J AM MED ASSOC, V291, P1246, DOI 10.1001/jama.291.10.1246; Himmelstein DU, 2010, AM J MED, V123, P40, DOI 10.1016/j.amjmed.2009.09.004; Holman GT, 2016, J AM MED INFORM ASSN, V23, P29, DOI 10.1093/jamia/ocv107; Hopkins Kevin, 2014, Fam Pract Manag, V21, P23; Howard KA., 2012, ADAPTING EHR SCRIBE; Jamoom Eric, 2013, NCHS Data Brief, P1; Koshy S, 2010, J UROLOGY, V184, P258, DOI 10.1016/j.juro.2010.03.040; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Li L, 2015, CRIT CARE RESUSC, V17, P159; McDonald CJ, 2014, JAMA INTERN MED, V174, P1860, DOI 10.1001/jamainternmed.2014.4506; McDonald CJ, 2012, ARCH INTERN MED, V172, P285, DOI 10.1001/archinternmed.2011.1678; McGinn T, 2004, CAN MED ASSOC J, V171, P1369, DOI 10.1503/cmaj.1031981; Misra-Hebert AD, 2015, AM J MED, V128, P1025, DOI 10.1016/j.amjmed.2015.03.035; Montague E, 2014, INT J MED INFORM, V83, P225, DOI 10.1016/j.ijmedinf.2013.11.003; Murphy DR, 2012, AM J MED, V125, P209, DOI 10.1016/j.amjmed.2011.07.029; Ratanawongsa N, 2016, JAMA INTERN MED, V176, P125, DOI 10.1001/jamainternmed.2015.6186; Ratwani RM, 2015, J AM MED INFORM ASSN, V22, P1179, DOI 10.1093/jamia/ocv050; Reuben DB, 2014, JAMA INTERN MED, V174, P1190, DOI 10.1001/jamainternmed.2014.1315; Romano MJ, 2011, ARCH INTERN MED, V171, P897, DOI 10.1001/archinternmed.2010.527; Shanafelt TD, 2016, MAYO CLIN PROC, V91, P836, DOI 10.1016/j.mayocp.2016.05.007; Shanafelt TD, 2015, MAYO CLIN PROC, V90, P1600, DOI 10.1016/j.mayocp.2015.08.023; Shanafelt TD, 2012, ARCH INTERN MED, V172, P1377, DOI 10.1001/archinternmed.2012.3199; Sinsky CA, 2013, ANN FAM MED, V11, P272, DOI 10.1370/afm.1531; Sinsky CA, 2010, HEALTH AFFAIR, V29, P966, DOI 10.1377/hlthaff.2010.0356; Walter SR, 2014, BMJ QUAL SAF, V23, P231, DOI 10.1136/bmjqs-2013-002097; Westbrook JI., 2014, WORK OBSERVATION MET; Westbrook JI, 2008, MED J AUSTRALIA, V188, P506, DOI 10.5694/j.1326-5377.2008.tb01762.x; Westbrook JI, 2013, J AM MED INFORM ASSN, V20, P1150, DOI 10.1136/amiajnl-2012-001414; Westbrook JI, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-319; Westbrook JI, 2010, QUAL SAF HEALTH CARE, V19, P284, DOI 10.1136/qshc.2009.039255; Westbrook Johanna I, 2009, Int J Med Inform, V78 Suppl 1, pS25, DOI 10.1016/j.ijmedinf.2008.09.003; Willard-Grace R, 2014, J AM BOARD FAM MED, V27, P229, DOI 10.3122/jabfm.2014.02.130215	52	621	623	3	73	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 6	2016	165	11					753	+		10.7326/M16-0961	http://dx.doi.org/10.7326/M16-0961			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EE0KO	27595430				2023-01-03	WOS:000389263900002
J	Dore, GJ; Altice, F; Litwin, AH; Dalgard, O; Gane, EJ; Shibolet, O; Luetkemeyer, A; Nahass, R; Peng, CY; Conway, B; Grebely, J; Howe, AYM; Gendrano, IN; Chen, E; Huang, HC; Dutko, FJ; Nickle, DC; Nguyen, Y; Wahl, J; Barr, E; Robertson, MN; Platt, HL				Dore, Gregory J.; Altice, Frederick; Litwin, Alain H.; Dalgard, Olav; Gane, Edward J.; Shibolet, Oren; Luetkemeyer, Anne; Nahass, Ronald; Peng, Cheng-Yuan; Conway, Brian; Grebely, Jason; Howe, Anita Y. M.; Gendrano, Isaias N.; Chen, Erluo; Huang, Hsueh-Cheng; Dutko, Frank J.; Nickle, David C.; Bach-Yen Nguyen; Wahl, Janice; Barr, Eliav; Robertson, Michael N.; Platt, Heather L.		C-EDGE CO-STAR Study Grp	Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							HCV NS5A INHIBITOR; GENOTYPE 1; MK-5172; MK-8742; RIBAVIRIN; PEOPLE; EFFICACY; SAFETY; EPIDEMIOLOGY; COINFECTION	Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID). Objective: To evaluate elbasvir-grazoprevir in treating HCV infection in PWID. Design: Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688) Setting: Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan, the United Kingdom, and the United States. Patients: 301 treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection who were at least 80% adherent to visits for opioid agonist therapy (OAT). Intervention: The immediate-treatment group (ITG) received elbasvir-grazoprevir for 12 weeks; the deferred-treatment group (DTG) received placebo for 12 weeks, no treatment for 4 weeks, then open-label elbasvir-grazoprevir for 12 weeks. Measurements: The primary outcome was sustained virologic response at 12 weeks (SVR12), evaluated separately in the ITG and DTG. Other outcomes included SVR24, viral recurrence or reinfection, and adverse events. Results: The SVR12 was 91.5% (95% CI, 86.8% to 95.0%) in the ITG and 89.5% (95% CI, 81.5% to 94.8%) in the active phase of the DTG. Drug use at baseline and during treatment did not affect SVR12 or adherence to HCV therapy. Among 18 patients with posttreatment viral recurrence through 24-week follow-up, 6 had probable reinfection. If the probable reinfections were assumed to be responses, SVR12 was 94.0% (CI, 89.8% to 96.9%) in the ITG. One patient in the ITG (1 of 201) and 1 in the placebo-phase DTG (1 of 100) discontinued treatment because of an adverse event. Limitation: These findings may not be generalizable to PWID who are not receiving OAT, nor do they apply to persons with genotype 3 infection, a common strain in PWID. Conclusion: Patients with HCV infection who were receiving OAT and treated with elbasvir-grazoprevir had high rates of SVR12, regardless of ongoing drug use. These results support the removal of drug use as a barrier to interferon-free HCV treatment for patients receiving OAT.	UNSW Australia, Kirby Inst, Sydney, NSW, Australia; [Altice, Frederick] Yale Sch Med, 135 Coll St,Suite 323, New Haven, CT 06510 USA; Montefiore Med Ctr, 111 East 210th St, Bronx, NY 10467 USA; Akershus Univ Hosp, Lorenskog, Norway; Auckland Clin Studies, Auckland, New Zealand; Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; Univ Calif San Francisco, San Francisco, CA USA; ID Care, Hillsborough, NJ USA; China Med Univ, Taichung, Taiwan; Vancouver Infect Dis Ctr, Vancouver, BC, Canada; Merck & Co Inc, Kenilworth, NJ USA; [Dore, Gregory J.; Grebely, Jason] UNSW, UNSW Australia, Kirby Inst, Wallace Wurth Bldg, Sydney, NSW 2052, Australia; [Litwin, Alain H.] Montefiore Med Ctr, 1510 Waters Pl, Bronx, NY 10461 USA; [Dalgard, Olav] Akershus Univ Hosp, Infeksjonsmedisinsk Poliklin, Sykehusveien 25, N-1478 Lorenskog, Norway; [Gane, Edward J.] Auckland Clin Studies, Medacs House,3 Ferncroft St,Ground Floor, Auckland 1150, New Zealand; [Shibolet, Oren] Tel Aviv Sourasky Med Ctr, Gastrointestinal & Liver Dis, 6 Waitzmann St, IL-64239 Tel Aviv, Israel; [Luetkemeyer, Anne] Univ Calif San Francisco, 995 Potrero Ave,Box 0874,Bldg 80,Fourth Floor, San Francisco, CA 94110 USA; [Nahass, Ronald] ID Care, 105 Raider Blvd,Suite 101, Hillsborough, NJ 08844 USA; [Peng, Cheng-Yuan] China Med Univ, Sch Med, 2 Yuh Der Rd, Taichung 40447, Taiwan; [Conway, Brian] Vancouver Infect Dis Ctr, 201-1200 Burrard St, Vancouver, BC V6Z 2C7, Canada; [Howe, Anita Y. M.] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada; [Gendrano, Isaias N.] Merck & Co Inc, 126 East Lincoln Ave,POB 2000,RY34-A474, Rahway, NJ 07065 USA; [Chen, Erluo] Merck & Co Inc, 126 East Lincoln Ave,POB 2000,RY34-A316, Rahway, NJ 07065 USA; [Huang, Hsueh-Cheng] Merck & Co Inc, 2000 Galloping Hill Rd,POB 539,K-15-4-D402, Kenilworth, NJ 07033 USA; [Dutko, Frank J.] Merck & Co Inc, 351 North Sumneytown Pike,UG3C-06, N Wales, PA 19454 USA; [Nickle, David C.] Merck Sharp & Dohme Corp, 33 Ave Louis Pasteur, Boston, MA 02115 USA; [Bach-Yen Nguyen] Merck & Co Inc, 351 North Sumneytown Pike,UG4C-06, N Wales, PA 19454 USA; [Wahl, Janice] Merck & Co Merck & Co Inc, 126 East Lincoln Ave,POB 2000,RY34-A484, Rahway, NJ 07065 USA; [Barr, Eliav] Merck & Co Inc, 351 North Sumneytown Pike,UG3C-96, N Wales, PA 19454 USA; [Robertson, Michael N.] Merck & Co Inc, 351 North Sumneytown Pike,UG3C-56, N Wales, PA 19454 USA; [Platt, Heather L.] Merck & Co Inc, 351 North Sumneytown Pike, N Wales, PA 19454 USA	University of New South Wales Sydney; Kirby Institute; Yale University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Oslo; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; University of California System; University of California San Francisco; China Medical University Taiwan; Merck & Company; University of New South Wales Sydney; Kirby Institute; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Oslo; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; University of California System; University of California San Francisco; China Medical University Taiwan; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company	Dore, GJ (corresponding author), UNSW, UNSW Australia, Kirby Inst, Wallace Wurth Bldg, Sydney, NSW 2052, Australia.	gdore@kirby.unsw.edu.au	Dore, Gregory John/ABD-5665-2021; Nickle, David/ABF-2727-2020; Streinu-Cercel, Adrian/M-5835-2017	Dore, Gregory John/0000-0002-4741-2622; Streinu-Cercel, Adrian/0000-0001-6382-5067; Ustianowski, Andrew/0000-0002-6134-7855; Altice, Frederick/0000-0002-7860-693X	Merck Co.	Merck Co.(Merck & Company)	Merck & Co.	American Association for the Study of Liver Diseases Infectious Diseases Society of America International Antiviral Society-USA, 2015, REC TEST MAN TREAT H; Aspinall EJ, 2013, CLIN INFECT DIS, V57, pS80, DOI 10.1093/cid/cit306; Barua S, 2015, ANN INTERN MED, V163, P215, DOI 10.7326/M15-0406; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Coburn CA, 2013, CHEMMEDCHEM, V8, P1930, DOI 10.1002/cmdc.201300343; Fraser IP, 2013, 8 INT WORKSH CLIN PH; Grebely J, 2015, INT J DRUG POLICY, V26, P1028, DOI 10.1016/j.drugpo.2015.07.005; Grebely J, 2013, CLIN INFECT DIS, V57, pS29, DOI 10.1093/cid/cit264; Hajarizadeh B, 2013, NAT REV GASTRO HEPAT, V10, P553, DOI 10.1038/nrgastro.2013.107; Lahser F, 2012, HEPATOLOGY, V56, p236A; Lalezari J, 2015, J HEPATOL, V63, P364, DOI 10.1016/j.jhep.2015.03.029; Lawitz E, 2015, LANCET, V385, P1075, DOI 10.1016/S0140-6736(14)61795-5; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Marshall WL, 2015, HEPATOLOGY, V62, p573A; Marshall WL, 2013, GLOBAL ANTIVIRAL S2, V9, P61; Martin B, 2014, J HEPATOL, V61, P538, DOI 10.1016/j.jhep.2014.05.043; Martin NK, 2012, HEPATOLOGY, V55, P49, DOI 10.1002/hep.24656; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; Pawlotsky JM, 2015, J HEPATOL, V63, P199, DOI 10.1016/j.jhep.2015.03.025; Rockstroh JK, 2015, LANCET HIV, V2, pE319, DOI 10.1016/S2352-3018(15)00114-9; Serti E, 2015, GASTROENTEROLOGY, V149, P190, DOI 10.1053/j.gastro.2015.03.004; Sulkowski M, 2015, LANCET, V385, P1087, DOI 10.1016/S0140-6736(14)61793-1; Sulkowski MS, 2014, JAMA-J AM MED ASSOC, V312, P353, DOI 10.1001/jama.2014.7734; Summa V, 2012, ANTIMICROB AGENTS CH, V56, P4161, DOI 10.1128/AAC.00324-12; U.S. Food and Drug Administration, 2016, PRESCR INF ZEP ELB G; Zeuzem S, 2015, ANN INTERN MED, V163, P1, DOI 10.7326/M15-0785	27	260	262	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2016	165	9					625	+		10.7326/M16-0816	http://dx.doi.org/10.7326/M16-0816			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA8SJ	27537841				2023-01-03	WOS:000386908600005
J	Elands, RJJ; Simons, CCJM; van Dongen, M; Schouten, LJ; Verhage, BAJ; van den Brandt, PA; Weijenberg, MP				Elands, Rachel J. J.; Simons, Colinda C. J. M.; van Dongen, Martien; Schouten, Leo J.; Verhage, Bas A. J.; van den Brandt, Piet A.; Weijenberg, Matty P.			A Systematic Literature Review and Meta-Regression Analysis on Early-Life Energy Restriction and Cancer Risk in Humans	PLOS ONE			English	Review							WORLD-WAR-II; INTERMITTENT CALORIE RESTRICTION; INDUCED MAMMARY TUMORIGENESIS; CPG ISLAND METHYLATION; BREAST-CANCER; COLORECTAL-CANCER; TESTICULAR CANCER; PHYSICAL-ACTIVITY; DIETARY RESTRICTION; EUROPEAN COUNTRIES	Background In animal models, long-term moderate energy restriction (ER) is reported to decelerate carcinogenesis, whereas the effect of severe ER is inconsistent. The impact of early-life ER on cancer risk has never been reviewed systematically and quantitatively based on observational studies in humans. Objective We conducted a systematic review of observational studies and a meta-(regression) analysis on cohort studies to clarify the association between early-life ER and organ site-specific cancer risk. Methods PubMed and EMBASE (1982 - August 2015) were searched for observational studies. Summary relative risks (RRs) were estimated using a random effects model when available >= 3 studies. Results Twenty-four studies were included. Eleven publications, emanating from seven prospective cohort studies and some reporting on multiple cancer endpoints, met the inclusion criteria for quantitative analysis. Women exposed to early-life ER (ranging from 220-1660 kcal/day) had a higher breast cancer risk than those not exposed (RRRE all ages = 1.28, 95% CI: 1.05-1.56; RRRE for 10-20 years of age = 1.21, 95% CI: 1.09-1.34). Men exposed to early-life ER (ranging from 220-800kcal/day) had a higher prostate cancer risk than those not exposed (RRRE = 1.16, 95% CI: 1.03-1.30). Summary relative risks were not computed for colorectal cancer, because of heterogeneity, and for stomach-, pancreas-, ovarian-, and respiratory cancer because there were <3 available studies. Longer duration of exposure to ER, after adjustment for severity, was positively associated with overall cancer risk in women (p = 0.02). Ecological studies suggest that less severe ER is generally associated with a reduced risk of cancer. Conclusions Early-life transient severe ER seems to be associated with increased cancer risk in the breast (particularly ER exposure at adolescent age) and prostate. The duration, rather than severity of exposure to ER, seems to positively influence relative risk estimates. This result should be interpreted with caution due to the limited number of studies and difficulty in disentangling duration, severity, and geographical setting of exposure.	[Elands, Rachel J. J.; Simons, Colinda C. J. M.; van Dongen, Martien; Schouten, Leo J.; Verhage, Bas A. J.; van den Brandt, Piet A.; Weijenberg, Matty P.] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Epidemiol, Maastricht, Netherlands	Maastricht University	Elands, RJJ (corresponding author), Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Epidemiol, Maastricht, Netherlands.	rachel.elands@maastrichtuniversity.nl	Schouten, Leo J/AAB-2275-2019	Schouten, Leo J/0000-0003-3361-7560; van den Brandt, Piet/0000-0001-8781-8099	Wereld Kanker Onderzoek Fonds Nederland (WCRF-NL), as part of the World Cancer Research Fund International grant program [2012/618, 2013/973]	Wereld Kanker Onderzoek Fonds Nederland (WCRF-NL), as part of the World Cancer Research Fund International grant program	This work was supported by Wereld Kanker Onderzoek Fonds Nederland (WCRF-NL), as part of the World Cancer Research Fund International grant program (grant numbers 2012/618 and 2013/973 to MPW).	Angell-Andersen E, 2004, ANN HUM BIOL, V31, P342, DOI 10.1080/03014460410001685304; Anisimov VN, 2013, CRIT REV ONCOL HEMAT, V87, P201, DOI 10.1016/j.critrevonc.2013.01.005; Becker N, 2001, J CANCER RES CLIN, V127, P293, DOI 10.1007/s004320000222; Bennett MK, 1949, J POLIT ECON, V57, P185, DOI 10.1086/256805; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Borsoi L, 2011, CANCER EPIDEMIOL, V35, P120, DOI 10.1016/j.canep.2010.06.018; Bown MJ, 2010, EUR J VASC ENDOVASC, V40, P669, DOI 10.1016/j.ejvs.2010.07.011; BRUNDTLAND GH, 1980, ANN HUM BIOL, V7, P307, DOI 10.1080/03014468000004381; Burger G, 1948, MALNUTRITION STARV 1; BurgerG SH, 1948, MALNUTRITION STARV 2; Chauvenet M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-282; CHENEY KE, 1983, J GERONTOL, V38, P420, DOI 10.1093/geronj/38.4.420; Cleary MP, 2007, EXP BIOL MED, V232, P70; Cleary Margot P, 2011, J Carcinog, V10, P21, DOI 10.4103/1477-3163.85181; Da Li Q, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-315; De Assis S, 2006, ANN NY ACAD SCI, V1089, P14, DOI 10.1196/annals.1386.039; Dirx MJM, 2001, AM J EPIDEMIOL, V154, P530, DOI 10.1093/aje/154.6.530; Dirx MJM, 2003, CANCER-AM CANCER SOC, V97, P46, DOI 10.1002/cncr.11052; Dirx MJM, 2003, INT J CANCER, V106, P766, DOI 10.1002/ijc.11277; Dirx MJM, 1999, CANCER CAUSE CONTROL, V10, P189, DOI 10.1023/A:1008821524297; Dogan S, 2010, ONCOL LETT, V1, P167, DOI 10.3892/ol_00000031; Dols M vAA, 1946, VOEDING, P193; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elias SG, 2004, J NATL CANCER I, V96, P539, DOI 10.1093/jnci/djh087; Elias SG, 2004, INT J CANCER, V108, P628, DOI 10.1002/ijc.11584; Elias SG, 2007, CANCER CAUSE CONTROL, V18, P1, DOI 10.1007/s10552-006-0080-0; ENGELMAN RW, 1994, CANCER RES, V54, P5724; Fair Alecia Malin, 2009, V472, P57, DOI 10.1007/978-1-60327-492-0_3; Fentiman IS, 2007, INT J CLIN PRACT, V61, P937, DOI 10.1111/j.1742-1241.2007.01288.x; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; HANSEN OG, 1947, P NUTR SOC, V5, P263; Heinen MM, 2011, AM J CLIN NUTR, V94, P1314, DOI 10.3945/ajcn.110.007542; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hilakivi-Clarke L, 2007, CURR CANCER DRUG TAR, V7, P465; Hughes LAE, 2011, AM J EPIDEMIOL, V174, P1127, DOI 10.1093/aje/kwr247; Hughes LAE, 2010, INT J EPIDEMIOL, V39, P1333, DOI 10.1093/ije/dyq062; Hughes LAE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007951; Hursting SD, 2010, CARCINOGENESIS, V31, P83, DOI 10.1093/carcin/bgp280; Jacobsen R, 2006, INT J ANDROL, V29, P199, DOI 10.1111/j.1365-2605.2005.00605.x; Keinan-Boker L, 2009, JNCI-J NATL CANCER I, V101, P1489, DOI 10.1093/jnci/djp327; Kim HC, 2005, J GASTROEN HEPATOL, V20, P1920, DOI 10.1111/j.1440-1746.2005.03943.x; Kim HC, 2005, J CANCER RES CLIN, V131, P733, DOI 10.1007/s00432-005-0017-0; Klebanov Simon, 2007, V35, P176; KLURFELD DM, 1989, J NUTR, V119, P286, DOI 10.1093/jn/119.2.286; KLURFELD DM, 1989, INT J CANCER, V43, P922, DOI 10.1002/ijc.2910430532; Koupil I, 2009, INT J CANCER, V124, P1416, DOI 10.1002/ijc.24093; KRITCHEVSKY D, 1989, NUTR CANCER, V12, P259, DOI 10.1080/01635588909514025; KRITCHEVSKY D, 1987, AM J CLIN NUTR, V45, P236, DOI 10.1093/ajcn/45.1.236; KUMAR SP, 1990, CANCER RES, V50, P5761; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Lv MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115147; Mahabir S, 2013, J ADOLESCENT HEALTH, V52, pS30, DOI 10.1016/j.jadohealth.2012.08.008; Martin B, 2008, AGEING RES REV, V7, P209, DOI 10.1016/j.arr.2008.01.002; McCarty CA, 1997, MED HYPOTHESE; Mizuno NK, 2013, CANCER PREV RES, V6, P540, DOI 10.1158/1940-6207.CAPR-13-0033; Moher David, 2009, Open Med, V3, pe123; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Moller H, 2001, HUM REPROD, V16, P1007, DOI 10.1093/humrep/16.5.1007; NOLEN GA, 1972, J NUTR, V102, P1477; Okasha M, 2002, BEST PRACT RES CL EN, V16, P225, DOI 10.1053/beem.2002.0204; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Papadopoulos FC, 2009, EUR J CANCER PREV, V18, P207, DOI 10.1097/CEJ.0b013e32831bc558; Richiardi L, 2004, CANCER EPIDEM BIOMAR, V13, P2157; Roberts SB, 2013, ADV NUTR, V4, P563, DOI 10.3945/an.113.004317; Robsahm TE, 2002, BRIT J CANCER, V86, P362, DOI 10.1038/sj.bjc.6600084; ROEBUCK BD, 1993, CANCER RES, V53, P46; Ronckers CM, 2005, BREAST CANCER RES, V7, P21, DOI 10.1186/bcr970; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Schouten LJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027960; Sell C, 2003, HORM METAB RES, V35, P705, DOI 10.1055/s-2004-814156; Simons CCJM, 2014, CANCER EPIDEM BIOMAR, V23, P1852, DOI 10.1158/1055-9965.EPI-13-1285; Soeters MR, 2012, AM J PHYSIOL-ENDOC M, V303, pE1397, DOI 10.1152/ajpendo.00397.2012; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Strom A, 1948, EXAMINATION DIET NOR; Svensson E, 2005, CANCER CAUSE CONTROL, V16, P215, DOI 10.1007/s10552-004-3073-x; Svensson E, 2002, EUR J CANCER PREV, V11, P489, DOI 10.1097/00008469-200210000-00012; SYLVESTER PW, 1982, CANCER RES, V42, P4943; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thorn M, 1998, CANCER CAUSE CONTROL, V9, P145, DOI 10.1023/A:1008826109697; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; van Noord PAH, 2004, J NUTR, V134, p3399S, DOI 10.1093/jn/134.12.3399S; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Vin-Raviv N, 2012, INT J CLIN PRACT, V66, P948, DOI 10.1111/j.1742-1241.2012.02966.x; Vin-Raviv N, 2014, INT PSYCHOGERIATR, V26, P499, DOI 10.1017/S1041610213002081; WALFORD RL, 1992, P NATL ACAD SCI USA, V89, P11533, DOI 10.1073/pnas.89.23.11533; Walford RL, 1999, TOXICOL SCI, V52, P61, DOI 10.1093/toxsci/52.suppl_1.61; Walford RL, 2002, J GERONTOL A-BIOL, V57, pB211, DOI 10.1093/gerona/57.6.B211; Wanderas EH, 1995, EUR J CANCER, V31A, P2044, DOI 10.1016/0959-8049(95)00321-5; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Weijenberg Matty P, 2013, Curr Nutr Rep, V2, P19; Wells G., 2009, VIS COMMUN Q	95	10	10	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2016	11	9							e0158003	10.1371/journal.pone.0158003	http://dx.doi.org/10.1371/journal.pone.0158003			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW8GC	27643873	Green Submitted, Green Published, gold			2023-01-03	WOS:000383891900001
J	Aitken, E; Jackson, A; Kearns, R; Steven, M; Kinsella, J; Clancy, M; Macfarlane, A				Aitken, Emma; Jackson, Andrew; Kearns, Rachel; Steven, Mark; Kinsella, John; Clancy, Marc; Macfarlane, Alan			Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial	LANCET			English	Article							BRACHIAL-PLEXUS BLOCK; VASCULAR ACCESS; FUNCTIONAL PATENCY; EARLY FAILURE; HEMODIALYSIS; RISK; STENOSIS; GRAFT; LONG	Background Arteriovenous fistulae are the optimum form of vascular access in end-stage renal failure. However, they have a high early failure rate. Regional compared with local anaesthesia results in greater vasodilatation and increases short-term blood flow. This study investigated whether regional compared with local anaesthesia improved medium-term arteriovenous fistula patency. Methods This observer-blinded, randomised controlled trial was done at three university hospitals in Glasgow, UK. Adults undergoing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1: 1; in blocks of eight) using a computer-generated allocation system to receive either local anaesthesia (0.5% L-bupivacaine and 1% lidocaine injected subcutaneously) or regional (brachial plexus block [BPB]) anaesthesia (0.5% L-bupivacaine and 1.5% lidocaine with epinephrine). Patients were excluded if they were coagulopathic, had no suitable vessels, or had a previous failed ipsilateral fistula. The primary endpoint was arteriovenous fistula patency at 3 months. We analysed the data on an intention-to-treat basis. This study was registered with ClinicalTrials.gov (NCT01706354) and is complete. Findings Between Feb 6, 2013, and Dec 4, 2015, 163 patients were assessed for eligibility and 126 patients were randomly assigned to local anaesthesia (n=63) or BPB (n=63). All patients completed follow-up on an intention-to-treat basis. Primary patency at 3 months was higher in the BPB group than the local anaesthesia group (53 [84%] of 63 patients vs 39 [62%] of 63; odds ratio [OR] 3.3 [95% CI 1.4-7.6], p=0.005) and was greater in radiocephalic fistulae (20 [77%] of 26 patients vs 12 [48%] of 25; OR 3.6 [1.4-3.6], p=0.03). There were no significant adverse events related to the procedure. Interpretation Compared with local anaesthesia, BPB significantly improved 3 month primary patency rates for arteriovenous fistulae.	[Aitken, Emma; Jackson, Andrew; Clancy, Marc] Queen Elizabeth Univ Hosp, Dept Renal Surg, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland; [Kearns, Rachel; Kinsella, John; Macfarlane, Alan] Glasgow Royal Infirm, Dept Anaesthesia, Glasgow, Lanark, Scotland; [Steven, Mark] Golden Jubilee Natl Hosp, Dept Anaesthesia, Clydebank, Scotland; [Kearns, Rachel; Kinsella, John; Macfarlane, Alan] Univ Glasgow, Dept Anaesthesia Crit Care & Pain Med, Glasgow, Lanark, Scotland	Queen Elizabeth University Hospital (QEUH); University of Glasgow; Golden Jubilee Hospital; University of Glasgow	Aitken, E (corresponding author), Queen Elizabeth Univ Hosp, Dept Renal Surg, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	emmaaitken@nhs.net	Aitken, Emma/AAV-8554-2021; Aitken, Emma/AAW-4473-2020	Aitken, Emma/0000-0001-8939-7478; Macfarlane, Alan/0000-0003-3858-6468; Kearns, Rachel/0000-0001-6156-6858; Clancy, Marc/0000-0002-1709-9743	Regional Anaesthesia UK; Darlinda's Charity for Renal Research	Regional Anaesthesia UK; Darlinda's Charity for Renal Research	Regional Anaesthesia UK, Darlinda's Charity for Renal Research.; We thank the patients, surgeons, and nursing staff at the Western Infirmary, Stobhill Hospital Glasgow and Queen Elizabeth University Hospital, Glasgow. We are also grateful to the Trial Steering Committee and statistician. EA's salary was funded by Darlinda's Charity for Renal Research. AM received funding from Regional Anaesthesia UK.	Agarwal AK, 2007, SEMIN DIALYSIS, V20, P53, DOI 10.1111/j.1525-139X.2007.00242.x; Aitken EL, 2014, J VASC ACCESS, V15, P481, DOI 10.5301/jva.5000238; Bakken AM, 2007, J VASC SURG, V45, P776, DOI 10.1016/j.jvs.2006.12.046; Bray BD, 2012, QJM-INT J MED, V105, P1097, DOI 10.1093/qjmed/hcs143; Chazapis M, 2014, BMJ QUAL IMPROV REPO, V3; Dember LM, 2008, JAMA-J AM MED ASSOC, V299, P2164, DOI 10.1001/jama.299.18.2164; FERNSTROM A, 1988, ACTA CHIR SCAND, V154, P257; Glover GW, 2007, ANAESTHESIA, V62, P425, DOI 10.1111/j.1365-2044.2006.04943_2.x; Golledge J, 1999, BRIT J SURG, V86, P211, DOI 10.1046/j.1365-2168.1999.01007.x; Hofstra L, 1995, J AM SOC NEPHROL, V6, P1625; Howell SJ, 1998, BRIT J ANAESTH, V80, P14, DOI 10.1093/bja/80.1.14; Konner K, 2003, J AM SOC NEPHROL, V14, P1669, DOI 10.1097/01.ASN.0000069219.88168.39; Laskowski IA, 2007, ANN VASC SURG, V21, P730, DOI 10.1016/j.avsg.2007.07.001; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lin Peter H, 2005, Vasc Endovascular Surg, V39, P135, DOI 10.1177/153857440503900202; Lo Monte AI, 2011, J VASC ACCESS, V12, P331, DOI 10.5301/JVA.2011.8560; Lok CE, 2007, CLIN J AM SOC NEPHRO, V2, P1043, DOI 10.2215/CJN.01080307; Lok CE, 2006, J AM SOC NEPHROL, V17, P3204, DOI 10.1681/ASN.2006030190; Macfarlane AJR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-263; Masengu A, 2016, CLIN KIDNEY J, V9, P142, DOI 10.1093/ckj/sfv131; Meena S, 2015, SOUTH AFR J ANAESTH, V21, P12, DOI 10.1080/22201181.2015.1075764; MOUQUET C, 1989, ANESTHESIOLOGY, V70, P909, DOI 10.1097/00000542-198906000-00005; National Kidney Care Audit, 2011, NAT KIDN CAR AUD VAS; Nguyen TH, 2007, J VASC ACCESS, V8, P275, DOI 10.1177/112972980700800410; Perlas A, 2009, REGION ANESTH PAIN M, V34, P171, DOI 10.1097/AAP.0b013e31819a3f81; Reynolds TS, 2011, J VASC ACCESS, V12, P336, DOI 10.5301/JVA.2011.8827; Riella MC, 2013, NAT REV NEPHROL, V9, P348, DOI 10.1038/nrneph.2013.76; Rodriguez J, 2004, REGION ANESTH PAIN M, V29, P534, DOI 10.1016/j.rapm.2004.07.223; Rodriguez JA, 2000, NEPHROL DIAL TRANSPL, V15, P402, DOI 10.1093/ndt/15.3.402; Sahin L, 2011, J VASC SURG, V54, P749, DOI 10.1016/j.jvs.2010.12.045; Sandhu NS, 2006, J ULTRAS MED, V25, P1555, DOI 10.7863/jum.2006.25.12.1555; Schenk WG, 2010, AM SURGEON, V76, P938; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Shemesh D, 2006, ULTRASOUND MED BIOL, V32, P817, DOI 10.1016/j.ultrasmedbio.2006.02.1420; Shemesh D, 2003, CARDIOVASC SURG, V11, P35, DOI 10.1016/S0967-2109(02)00148-5; Sites BD, 2010, REGION ANESTH PAIN M, V35, pS74, DOI 10.1097/AAP.0b013e3181d34ff5; Soares LG, 2007, REGION ANESTH PAIN M, V32, P94, DOI 10.1016/j.rapm.2006.10.007; Thomson PC, 2007, QJM-INT J MED, V100, P415, DOI 10.1093/qjmed/hcm040; Tozzi M, 2014, J VASC ACCESS, V15, P385, DOI 10.5301/jva.5000276; Vascular Access Work Group, 2006, AM J KIDNEY DIS, V48, pS248, DOI 10.1053/j.ajkd.2006.04.040; Wilmink T, 2016, EUR J VASC ENDOVASC, V51, P134, DOI 10.1016/j.ejvs.2015.10.005; Wong V, 1996, EUR J VASC ENDOVASC, V12, P207, DOI 10.1016/S1078-5884(96)80108-0; Zaliunate R, 2011, DOES REGIONAL COMP L, P584	43	66	68	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 10	2016	388	10049					1067	1074		10.1016/S0140-6736(16)30948-5	http://dx.doi.org/10.1016/S0140-6736(16)30948-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV0OD	27492881				2023-01-03	WOS:000382616900028
J	Amador, A; Huitron-Resendiz, S; Roberts, AJ; Kamenecka, TM; Solt, LA; Burris, TP				Amador, Ariadna; Huitron-Resendiz, Salvador; Roberts, Amanda J.; Kamenecka, Theodore M.; Solt, Laura A.; Burris, Thomas P.			Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation	PLOS ONE			English	Article							EYE-MOVEMENT SLEEP; CIRCADIAN CLOCK; CAFFEINE DEPENDENCE; METABOLIC SYNDROME; WAKE PATTERNS; MODAFINIL; DOPAMINE; ALPHA; AMPHETAMINE; DURATION	The circadian clock maintains appropriate timing for a wide range of behaviors and physiological processes. Circadian behaviors such as sleep and wakefulness are intrinsically dependent on the precise oscillation of the endogenous molecular machinery that regulates the circadian clock. The identical core clock machinery regulates myriad endocrine and metabolic functions providing a link between sleep and metabolic health. The REV-ERBs (REV-ERB alpha and REV-ERB beta) are nuclear receptors that are key regulators of the molecular clock and have been successfully targeted using small molecule ligands. Recent studies in mice suggest that REV-ERB-specific synthetic agonists modulate metabolic activity as well as alter sleep architecture, inducing wakefulness during the light period. Therefore, these small molecules represent unique tools to extensively study REV-ERB regulation of sleep and wakefulness. In these studies, our aim was to further investigate the therapeutic potential of targeting the REV-ERBs for regulation of sleep by characterizing efficacy, and optimal dosing time of the REV-ERB agonist SR9009 using electroencephalographic (EEG) recordings. Applying different experimental paradigms in mice, our studies establish that SR9009 does not lose efficacy when administered more than once a day, nor does tolerance develop when administered once a day over a three-day dosing regimen. Moreover, through use of a time response paradigm, we determined that although there is an optimal time for administration of SR9009 in terms of maximal efficacy, there is a 12-hour window in which SR9009 elicited a response. Our studies indicate that the REV-ERBs are potential therapeutic targets for treating sleep problems as those encountered as a consequence of shift work or jet lag.	[Amador, Ariadna; Kamenecka, Theodore M.; Solt, Laura A.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL 34583 USA; [Huitron-Resendiz, Salvador; Roberts, Amanda J.] Scripps Res Inst, Dept Mol & Cellular Neurosci, La Jolla, CA 92037 USA; [Burris, Thomas P.] St Louis Univ, Sch Med, Dept Physiol & Pharmacol, St Louis, MO 63104 USA	Scripps Research Institute; Scripps Research Institute; Saint Louis University	Burris, TP (corresponding author), St Louis Univ, Sch Med, Dept Physiol & Pharmacol, St Louis, MO 63104 USA.	burristp@slu.edu	Burris, Thomas/B-3886-2016	Burris, Thomas/0000-0003-2922-4449	National Institute of Mental Health [MH093429]	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was funded by a grant from the National Institute of Mental Health (MH093429) to TPB. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandin C, 2015, INT J OBESITY, V39, P828, DOI 10.1038/ijo.2014.182; Banerjee S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6759; Baraldo M, 2008, EXPERT OPIN DRUG MET, V4, P175, DOI 10.1517/17425255.4.2.175; Bernstein GA, 2002, DRUG ALCOHOL DEPEN, V66, P1, DOI 10.1016/S0376-8716(01)00181-8; Bourgin P, 2000, J NEUROSCI, V20, P7760; Brown SA, 2012, DEV CELL, V22, P477, DOI 10.1016/j.devcel.2012.02.007; Cao JJ, 2011, ACS MED CHEM LETT, V2, P48, DOI 10.1021/ml1002025; Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007; Chang ST, 2010, CHINESE J PHYSIOL, V53, P318, DOI 10.4077/CJP.2010.AMK067; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; Chun SK, 2014, ACS CHEM BIOL, V9, P703, DOI 10.1021/cb400752k; Chung S, 2014, CELL, V157, P858, DOI 10.1016/j.cell.2014.03.039; Crumbley C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017290; Crumbley C, 2010, J BIOL CHEM, V285, P35386, DOI 10.1074/jbc.M110.129288; Danaceau JP, 2007, EUR J PHARMACOL, V559, P46, DOI 10.1016/j.ejphar.2006.11.045; Edgar DM, 1997, J PHARMACOL EXP THER, V283, P757; Fang B, 2014, CELL, V159, P1140, DOI 10.1016/j.cell.2014.10.022; Franken P, 2006, P NATL ACAD SCI USA, V103, P7118, DOI 10.1073/pnas.0602006103; Garaulet M, 2010, INT J OBESITY, V34, P1667, DOI 10.1038/ijo.2010.118; Gilbert R M, 1984, Prog Clin Biol Res, V158, P185; Golombek DA, 2010, PHYSIOL REV, V90, P1063, DOI 10.1152/physrev.00009.2009; HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331; Hart CL, 2008, NEUROPSYCHOPHARMACOL, V33, P761, DOI 10.1038/sj.npp.1301472; Hedlund PB, 2005, BIOL PSYCHIAT, V58, P831, DOI 10.1016/j.biopsych.2005.05.012; Huitron-Resendiz S, 2004, SLEEP, V27, P857, DOI 10.1093/sleep/27.5.857; Huitron-Resendiz S, 2005, J NEUROSCI, V25, P5465, DOI 10.1523/JNEUROSCI.4501-04.2005; Jones HA, 2005, EXP CLIN PSYCHOPHARM, V13, P259, DOI 10.1037/1064-1297.13.3.259; JUERGENS S, 1991, J SUBST ABUSE TREAT, V8, P43, DOI 10.1016/0740-5472(91)90026-7; Kennaway DJ, 2007, AM J PHYSIOL-REG I, V293, pR1528, DOI 10.1152/ajpregu.00018.2007; Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001; Kopp C, 2002, EUR J NEUROSCI, V16, P1099, DOI 10.1046/j.1460-9568.2002.02156.x; KROBOTH PD, 1983, DRUG INTEL CLIN PHAR, V17, P495, DOI 10.1177/106002808301700701; Kronholm E, 2011, J SLEEP RES, V20, P288, DOI 10.1111/j.1365-2869.2010.00899.x; Laposky A, 2005, SLEEP, V28, P395, DOI 10.1093/sleep/28.4.395; LEMMER B, 1987, CHRONOBIOL INT, V4, P319, DOI 10.3109/07420528709083522; Lemmer B, 2007, PHYSIOL BEHAV, V90, P285, DOI 10.1016/j.physbeh.2006.09.006; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; Loland CJ, 2012, BIOL PSYCHIAT, V72, P405, DOI 10.1016/j.biopsych.2012.03.022; LUCAS EA, 1980, PSYCHOPHARMACOLOGY, V68, P179, DOI 10.1007/BF00432138; Macdermct H G, 1925, Can Med Assoc J, V15, P658; Malcolm R, 2006, AM J DRUG ALCOHOL AB, V32, P577, DOI 10.1080/00952990600920425; Mang GM, 2016, SLEEP, V39, P589, DOI 10.5665/sleep.5534; MIGNOT E, 1994, SLEEP, V17, P436, DOI 10.1093/sleep/17.5.436; Milagro FI, 2012, CHRONOBIOL INT, V29, P1180, DOI 10.3109/07420528.2012.719967; Moller-Levet CS, 2013, P NATL ACAD SCI USA, V110, pE1132, DOI 10.1073/pnas.1217154110; MROSOVSKY N, 1994, CHRONOBIOL INT, V11, P232, DOI 10.3109/07420529409067792; Nguyen TL, 2011, SYNAPSE, V65, P733, DOI 10.1002/syn.20892; Nielsen LS, 2011, OBES REV, V12, P78, DOI 10.1111/j.1467-789X.2010.00724.x; Nishino S, 1998, Sleep Res Online, V1, P49; Novak M, 1997, DRUG SAFETY, V16, P133, DOI 10.2165/00002018-199716020-00005; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; REINBERG A, 1986, INT J CLIN PHARM RES, V6, P33; RITSCHEL WA, 1994, METHOD FIND EXP CLIN, V16, P57; Roehrs T, 2002, PSYCHOPHARMACOLOGY, V161, P137, DOI 10.1007/s00213-002-1041-2; Rothman RB, 2001, SYNAPSE, V39, P32, DOI 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3; Ruiz-Lozano T, 2016, CLIN NUTR, V35, P1308, DOI 10.1016/j.clnu.2016.02.007; Rush CR, 2002, BEHAV PHARMACOL, V13, P105, DOI 10.1097/00008877-200203000-00002; SEIDEL WF, 1985, PSYCHOPHARMACOLOGY, V87, P194, DOI 10.1007/BF00431806; Shiromani PJ, 2004, AM J PHYSIOL-REG I, V287, pR47, DOI 10.1152/ajpregu.00138.2004; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; TOURET M, 1995, NEUROSCI LETT, V189, P43, DOI 10.1016/0304-3940(95)11448-6; TREDGER JM, 1977, XENOBIOTICA, V7, P481; TUREK FW, 1986, CLIN NEUROPHARMACOL, V9, P83; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Uguen M, 2013, BRIT J PHARMACOL, V169, P632, DOI 10.1111/bph.12149; Wisorl JP, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-20; Zhang EE, 2010, NAT REV MOL CELL BIO, V11, P764, DOI 10.1038/nrm2995; Zolkowska D, 2009, J PHARMACOL EXP THER, V329, P738, DOI 10.1124/jpet.108.146142	68	9	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2016	11	9							e0162452	10.1371/journal.pone.0162452	http://dx.doi.org/10.1371/journal.pone.0162452			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9IX	27603791	Green Published, Green Submitted, gold			2023-01-03	WOS:000383255200066
J	Hirsch, FR; Suda, K; Wiens, J; Bunn, PA				Hirsch, Fred R.; Suda, Kenichi; Wiens, Jacinta; Bunn, Paul A., Jr.			New and emerging targeted treatments in advanced non-small-cell lung cancer	LANCET			English	Article							CISPLATIN PLUS GEMCITABINE; MULTICENTER PHASE-II; ADULT PATIENTS PTS; OPEN-LABEL; GROWTH-FACTOR; 1ST-LINE TREATMENT; EGFR MUTATIONS; ACQUIRED-RESISTANCE; CLINICAL ACTIVITY; SINGLE-ARM	Targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers and clinicians have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials.	[Hirsch, Fred R.; Suda, Kenichi; Bunn, Paul A., Jr.] Univ Colorado, Ctr Canc, Dept Med, Div Med Oncol, Aurora, CO USA; [Hirsch, Fred R.; Suda, Kenichi; Bunn, Paul A., Jr.] Univ Colorado, Ctr Canc, Dept Pathol, Aurora, CO USA; [Hirsch, Fred R.; Wiens, Jacinta] Int Assoc Study Lung Canc, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Hirsch, FR (corresponding author), Univ Colorado, Dept Med, Anschutz Med Campus,Res 1 South L18-8119, Aurora, CO 80045 USA.	fred.hirsch@ucdenver.edu		Suda, Kenichi/0000-0002-0842-8832	University of Colorado from Genentech; BMS; Lilly; Amgen; Bayer; Claris; AstraZeneca; Merck; Novartis; Pfizer; Genentech/Roche; Celgene; Daiichi	University of Colorado from Genentech; BMS(Bristol-Myers Squibb); Lilly(Eli Lilly); Amgen(Amgen); Bayer(Bayer AG); Claris; AstraZeneca(AstraZeneca); Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer); Genentech/Roche(Roche HoldingGenentech); Celgene(Bristol-Myers SquibbCelgene Corporation); Daiichi(Daiichi Sankyo Company Limited)	FRH has participated in scientific advisory boards for Genentech/Roche, BMS, Merck, AstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, Novartis, Ventana, and HTG. FRH is a co-investigator of a University of Colorado-owned patent. FRH's laboratory has received research funding through the University of Colorado from Genentech, BMS, Lilly, Amgen, Bayer, and Claris. PAB has received consulting fees from AstraZeneca, BMS, Merck, Novartis, Pfizer, Lilly, Genentech/Roche, Celgene, and Daiichi. JW and KS declare no competing interests.	Antonia S, 2016, LANCET ONCOL, V17, P299, DOI 10.1016/S1470-2045(15)00544-6; Awad MM, 2016, J CLIN ONCOL, V34, P879, DOI 10.1200/JCO.2015.64.2777; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brose MS, 2002, CANCER RES, V62, P6997; Calles A, 2015, J THORAC ONCOL, V10, P1726, DOI 10.1097/JTO.0000000000000687; Camidge DR, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8001; Cascone T, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9069; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; De Greve J, 2012, LUNG CANCER, V76, P123, DOI 10.1016/j.lungcan.2012.01.008; Dhanasekaran SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6893; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Drilon A.R., 2016, J CLIN ONCOL S, V34, DOI DOI 10.1200/JC0.2016.34.15_SUPPL.108; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2015, CLIN CANCER RES, V21, P3913, DOI 10.1158/1078-0432.CCR-14-2789; Farago AF, 2015, J THORAC ONCOL, V10, P1670, DOI 10.1097/01.JTO.0000473485.38553.f0; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Felip E, 2015, J CLIN ONCOL, V33; Fernandez-Cuesta L, 2014, CANCER DISCOV, V4, P415, DOI 10.1158/2159-8290.CD-13-0633; Gandhi L, 2014, J CLIN ONCOL, V32, P68, DOI 10.1200/JCO.2012.47.2787; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Gautschi O, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9014; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gettinger SN, 2015, J CLIN ONCOL, V33, P2004, DOI 10.1200/JCO.2014.58.3708; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; Hellmann MD, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3001; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2013, J THORAC ONCOL, V8, P373, DOI 10.1097/JTO.0b013e31827ed0ff; Horn L, 2014, J CLIN ONCOL, V32, p5s; Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Jia Y, 2016, CANCER RES, V76, P1591, DOI 10.1158/0008-5472.CAN-15-2581; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kang D, 2016, INT J PRECIS ENG MAN, V17, P5, DOI 10.1007/s12541-016-0001-4; Kim HS, 2013, LUNG CANCER, V80, P249, DOI 10.1016/j.lungcan.2013.02.015; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Kim MY, 2015, LUNG CANCER, V88, P24, DOI 10.1016/j.lungcan.2015.01.016; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kris MG, 2015, ANN ONCOL, V26, P1421, DOI 10.1093/annonc/mdv186; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Langer CJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9057; Lee SH, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9013; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Litvak AM, 2014, J THORAC ONCOL, V9, P1669, DOI 10.1097/JTO.0000000000000344; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma WJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0277-y; Maemondo M, 2010, N ENGL J MED; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Matikas A, 2016, CLIN LUNG CANCER, V17, P474, DOI 10.1016/j.cllc.2016.05.006; Mazieres J, 2015, J CLIN ONCOL, V33, P992, DOI 10.1200/JCO.2014.58.3302; Mazieres J, 2013, J CLIN ONCOL, V31, P1997, DOI 10.1200/JCO.2012.45.6095; Mitsudomi T, 2013, NAT REV CLIN ONCOL, V10, P235, DOI 10.1038/nrclinonc.2013.22; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok T, 2015, J CLIN ONCOL, V33; Nakaoku T, 2014, CLIN CANCER RES, V20, P3087, DOI 10.1158/1078-0432.CCR-14-0107; Naoki K, 2002, CANCER RES, V62, P7001; Nokihara H, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9008; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Ou SHI, 2016, J CLIN ONCOL, V34, P661, DOI 10.1200/JCO.2015.63.9443; Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paik PK, 2015, J CLIN ONCOL, V33; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Park K, 2016, LANCET ONCOL, V17, P577, DOI 10.1016/S1470-2045(16)30033-X; Park K, 2015, J CLIN ONCOL, V33; Paz-Ares L, 2016, ANN ONCOL, V27, P1573, DOI 10.1093/annonc/mdw214; Paz-Ares L, 2016, J THORAC ONCOL, V11, pS153, DOI 10.1016/S1556-0864(16)30326-4; Paz-Ares L, 2015, LANCET ONCOL, V16, P328, DOI 10.1016/S1470-2045(15)70046-X; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Pennell NA, 2015, SEMIN ONCOL, V42, pS3, DOI 10.1053/j.seminoncol.2015.09.016; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Planchard D, 2016, LANCET ONCOL, V17, P894; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Ramalingam S, 2016, J THORAC ONCOL, V11, pS152, DOI 10.1016/S1556-0864(16)30324-0; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; Redig AJ, 2015, J CLIN ONCOL, V33, P975, DOI 10.1200/JCO.2014.59.8433; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rizvi NA, 2015, J CLIN ONCOL, V33; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Rosell R, 2016, J THORAC ONCOL, V11, pS114, DOI 10.1016/S1556-0864(16)30245-3; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Sacher AG, 2016, JAMA ONCOL, V2, P1014, DOI 10.1001/jamaoncol.2016.0173; Sacher AG, 2016, JAMA ONCOL, DOI [10.1001/jamaoncol.2016.0639, DOI 10.1001/JAMAONCOL.2016]; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Sequist LV, 2015, NEW ENGL J MED, V373, P578, DOI 10.1056/NEJMc1506831; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Seto T, 2006, LUNG CANCER-J IASLC, V53, P91, DOI 10.1016/j.lungcan.2006.02.009; Seto T, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9012; Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X; Seto T, 2013, LANCET ONCOL, V14, P590, DOI 10.1016/S1470-2045(13)70142-6; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shaw AT, 2016, LANCET ONCOL, V17, P234, DOI 10.1016/S1470-2045(15)00488-X; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2015, J CLIN ONCOL, V33; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Solomon BJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9009; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Soria JC, 2015, LANCET ONCOL, V16, P990, DOI 10.1016/S1470-2045(15)00121-7; Subbiah V, 2016, P NATL ACAD SCI USA, V113, pE1419, DOI 10.1073/pnas.1522052113; Suda K, 2015, SCI REP-UK, V5, DOI 10.1038/srep14447; Suda K, 2015, ARCH TOXICOL, V89, P1227, DOI 10.1007/s00204-015-1524-7; Suda K, 2012, CANCER METAST REV, V31, P807, DOI 10.1007/s10555-012-9391-7; Suda K, 2011, J THORAC ONCOL, V6, P1152, DOI 10.1097/JTO.0b013e318216ee52; Suda K, 2010, CANCER METAST REV, V29, P49, DOI 10.1007/s10555-010-9209-4; Takano T, 2008, J CLIN ONCOL, V26, P5589, DOI 10.1200/JCO.2008.16.7254; Takeuchi K, 2016, ANN ONCOL, V27, P185, DOI 10.1093/annonc/mdv501; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tan DSW, 2016, J THORAC ONCOL, V11, P946, DOI 10.1016/j.jtho.2016.05.008; Tao Z, 2016, CLIN CANCER RES, V22, P122, DOI 10.1158/1078-0432.CCR-15-0589; Thatcher N, 2015, LANCET ONCOL, V16, P763, DOI 10.1016/S1470-2045(15)00021-2; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Togashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031323; Tomizawa K, 2011, LUNG CANCER, V74, P139, DOI 10.1016/j.lungcan.2011.01.014; Tsao AS, 2016, J THORAC ONCOL, V11, P613, DOI 10.1016/j.jtho.2016.03.012; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Van der Steen N, 2016, J THORAC ONCOL, V11, P1423, DOI 10.1016/j.jtho.2016.05.005; Wang R, 2012, J CLIN ONCOL, V30, P4352, DOI 10.1200/JCO.2012.44.1477; Wang SH, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0268-z; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Wu YL, 2013, LANCET ONCOL, V14, P777, DOI 10.1016/S1470-2045(13)70254-7; Yang JCH, 2015, LANCET ONCOL, V16, P830, DOI 10.1016/S1470-2045(15)00026-1; Yang JCH, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9002; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yu HA, 2013, J THORAC ONCOL, V8, P346, DOI 10.1097/JTO.0b013e31827e1f83; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zhu VW, 2016, LUNG CANCER, V97, P48, DOI 10.1016/j.lungcan.2016.04.013; Zou HLY, 2015, P NATL ACAD SCI USA, V112, P3493, DOI 10.1073/pnas.1420785112	158	310	320	11	151	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	2016	388	10048					1012	1024		10.1016/S0140-6736(16)31473-8	http://dx.doi.org/10.1016/S0140-6736(16)31473-8			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU9GL	27598681				2023-01-03	WOS:000382524400031
J	Williams, AR; Bisaga, A				Williams, Arthur R.; Bisaga, Adam			From AIDS to Opioids - How to Combat an Epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES		[Williams, Arthur R.; Bisaga, Adam] Columbia Univ, Dept Psychiat, Div Subst Abuse, New York State Psychiat Inst, New York, NY 10027 USA	Columbia University; New York State Psychiatry Institute	Williams, AR (corresponding author), Columbia Univ, Dept Psychiat, Div Subst Abuse, New York State Psychiat Inst, New York, NY 10027 USA.		BISAGA, Adam/R-4898-2019; Williams, Arthur Robin/H-8511-2019	Williams, Arthur Robin/0000-0002-7380-6203; Bisaga, Adam/0000-0003-4243-6462	NATIONAL INSTITUTE ON DRUG ABUSE [K24DA029647] Funding Source: NIH RePORTER; NIDA NIH HHS [K24 DA029647, T32 DA007294] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bentzley BS, 2015, J SUBST ABUSE TREAT, V52, P48, DOI 10.1016/j.jsat.2014.12.011; Buck JA, 2011, HEALTH AFFAIR, V30, P1402, DOI 10.1377/hlthaff.2011.0480; Nosyk B, 2013, HEALTH AFFAIR, V32, P1462, DOI 10.1377/hlthaff.2012.0846; Sigmon SC, 2015, JAMA PSYCHIAT, V72, P395, DOI 10.1001/jamapsychiatry.2014.2421; Wen HF, 2013, JAMA PSYCHIAT, V70, P1355, DOI 10.1001/jamapsychiatry.2013.2169	5	54	54	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2016	375	9					813	815		10.1056/NEJMp1604223	http://dx.doi.org/10.1056/NEJMp1604223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU9HA	27579632	Green Accepted, Bronze			2023-01-03	WOS:000382526000003
J	Ichikura, K; Okumura, Y; Takeuchi, T				Ichikura, Kanako; Okumura, Yasuyuki; Takeuchi, Takashi			Associations of Adverse Clinical Course and Ingested Substances among Patients with Deliberate Drug Poisoning: A Cohort Study from an Intensive Care Unit in Japan	PLOS ONE			English	Article							ASPIRATION PNEUMONITIS; RISK-FACTORS; OVERDOSE; HOSPITALS; ADMISSION; OUTCOMES; IMPACT; OSLO	Objectives Some patients with deliberate drug poisoning subsequently have an adverse clinical course. The present study aimed to examine whether the type of drugs ingested and psychiatric diagnoses were related to an adverse clinical course. Methods We conducted a cohort study of patients with deliberate drug poisoning admitted to the intensive care unit of a university hospital located in Tokyo, Japan, between September 2006 and June 2013. Intensive care unit (ICU) stay of >= 4 days was used as a primary outcome measure, while the incidence of aspiration pneumonitis was used as a secondary outcome measure. Ingested substances and psychiatric diagnoses were used as explanatory variables. Results Of the 676 patients with deliberate drug poisoning, 88% had a history of psychiatric treatment and 82% had ingested psychotropic drugs. Chlorpromazine-promethazine-phenobarbital combination drug (Vegetamin (R)) ranked fifth among the most frequently ingested substances in cases of deliberate drug poisoning and had the highest incidence of prolonged ICU stay (20%) and aspiration pneumonitis (29%). The top three major classes consisted of benzodiazepines (79%), new-generation antidepressants (25%), and barbiturates/non-barbiturates (23%). Barbiturate overdose was independently associated with increased odds of both prolonged ICU stay (8% vs. 17%; odds ratio [OR], 2.97; 95% confidence interval [CI], 1.60-5.55) and aspiration pneumonitis (8% vs. 24%; OR, 3.83; 95% CI, 2.18-6.79) relative to those associated with overdose of only other sedative-hypnotics (i.e., benzodiazepines). Conclusion These results suggest that judicious prescribing of barbiturates by psychiatrists could reduce the risk of an adverse clinical course when a patient attempts an overdose.	[Ichikura, Kanako] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Sect Liaison Psychiat & Palliat Med, Tokyo, Japan; [Ichikura, Kanako; Okumura, Yasuyuki] Assoc Hlth Econ Res & Social Insurance & Welf, Inst Hlth Econ & Policy, Res Dept, Tokyo, Japan; [Takeuchi, Takashi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Sect Psychiat & Behav Sci, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Okumura, Y (corresponding author), Assoc Hlth Econ Res & Social Insurance & Welf, Inst Hlth Econ & Policy, Res Dept, Tokyo, Japan.	yokumura@blue.zero.jp		Okumura, Yasuyuki/0000-0001-5851-8919	 [26870914]; Grants-in-Aid for Scientific Research [26870914] Funding Source: KAKEN	; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Funding for this study was provided by a Grant-in-Aid for Young Scientists (B) (No. 26870914) by the Japan Society for the Promotion of Science. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando S, 2009, CLIN PSYCHIATR, V51, P749; Ando S, 2014, PSYCHIAT CLIN NEUROS, V68, P721, DOI 10.1111/pcn.12198; BOUKNIGHT RR, 1986, J FAM PRACTICE, V23, P223; Christ A, 2006, INTENS CARE MED, V32, P1423, DOI 10.1007/s00134-006-0277-4; Dobson AJ, 2008, AN INTRODUCTION TO G; Eddleston M, 2002, LANCET, V360, P1163, DOI 10.1016/S0140-6736(02)11204-9; Eyer F, 2009, HUM EXP TOXICOL, V28, P511, DOI 10.1177/0960327109106970; Foundation for Promotion of Cancer Research, 2014, CANC STAT JAP 2014; Hendrix L, 2013, EMERG MED J, V30, DOI 10.1136/emermed-2011-201033; Heyerdahl F, 2009, BRIT J PSYCHIAT, V194, P73, DOI 10.1192/bjp.bp.107.048322; Hirata K, 1998, JPN J HOSP PHARM, V24, P340, DOI DOI 10.5649/JJPHCS1975.24.340; Hovda KE, 2008, CLIN TOXICOL, V46, P35, DOI 10.1080/15563650601185969; Isbister GK, 2004, CRIT CARE MED, V32, P88, DOI 10.1097/01.CCM.0000104207.42729.E4; Kamijo Y, 2007, PSYCHIATRY, V10, P297; Liisanantti J, 2003, RESUSCITATION, V56, P49, DOI 10.1016/S0300-9572(02)00284-8; Mactier R, 2014, AM J KIDNEY DIS, V64, P347, DOI 10.1053/j.ajkd.2014.04.031; Maignan M, 2014, BASIC CLIN PHARMACOL, V114, P281, DOI 10.1111/bcpt.12132; Manini AF, 2015, ACAD EMERG MED, V22, P499, DOI 10.1111/acem.12658; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Mowry JB, 2013, CLIN TOXICOL, V51, P949, DOI 10.3109/15563650.2013.863906; Novack V, 2006, EUR J INTERN MED, V17, P485, DOI 10.1016/j.ejim.2006.02.029; Okumura Y, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001857; Okumura Y, 2012, GEN HOSP PSYCHIAT, V34, P681, DOI 10.1016/j.genhosppsych.2012.07.009; Prescott K, 2009, BRIT J CLIN PHARMACO, V68, P260, DOI 10.1111/j.1365-2125.2009.03458.x; Schwake L, 2009, INTENS CARE MED, V35, P266, DOI 10.1007/s00134-008-1250-1; Shimizu S., 2015, JPN J CLIN PHARM, V18, P1173; Tournier M, 2009, PHARMACOPSYCHIATRY, V42, P51, DOI 10.1055/s-0028-1100426; Varnik A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-61; Wada K, 2009, JAPANESE J GEN HOSP, V21, P258; Wilkinson S, 2002, J PUBLIC HEALTH MED, V24, P179, DOI 10.1093/pubmed/24.3.179; Xiang YX, 2012, AM J EMERG MED, V30, P293, DOI 10.1016/j.ajem.2010.11.031; Zyoud SH, 2010, HUM PSYCHOPHARM CLIN, V25, P500, DOI 10.1002/hup.1140	32	11	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2016	11	8							e0161996	10.1371/journal.pone.0161996	http://dx.doi.org/10.1371/journal.pone.0161996			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU5NN	27560966	gold, Green Submitted, Green Published			2023-01-03	WOS:000382258600125
J	Sun, H; Lou, XY; Wu, XY; Wang, H; Qu, Q; Tan, SL; Ruan, JS; Qu, J; Chen, H				Sun, Hong; Lou, Xiao-Ya; Wu, Xiao-Ying; Wang, Huan; Qu, Qiang; Tan, Shen-Lan; Ruan, Jun-Shan; Qu, Jian; Chen, Hui			Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells	PLOS ONE			English	Article							MEDIATED INDUCTION; DRUG INTERACTIONS; HUMAN HEPATOCYTES; CLOPIDOGREL; RECEPTOR; CYP3A4; IDENTIFICATION; POLYMORPHISMS; OMEPRAZOLE; PROMOTER	Background Cytochrome P450 2C19 (CYP2C19) is an important drug-metabolizing enzyme (DME), which is responsible for the biotransformation of several kinds of drugs such as proton pump inhibitors, platelet aggregation inhibitors and antidepressants. Previous studies showed that Buchang NaoXinTong capsules (NXT) increased the CYP2C19 metabolic activity in vitro and enhanced the antiplatelet effect of clopidogrel in vivo. However, the underlying molecular mechanism remained unclear. In the present study, we examined whether Pregnane X receptor (PXR) plays a role in NXT-mediated regulation of CYP2C19 expression. Methods We applied luciferase assays, real-time quantitative PCR (qPCR), Western blotting and cell-based analysis of metabolic activity experiments to investigate the NXT regulatory effects on the CYP2C19 promoter activity, the mRNA/protein expression and the metabolic activity. Results Our results demonstrated that NXT significantly increased the CYP2C19 promoter activity when co-transfected with PXR in HepG2 cells. Mutations in PXR responsive element abolished the NXT inductive effects on the CYP2C19 promoter transcription. Additionally, NXT incubation (150 and 250 mu g/mL) also markedly up-regulated endogenous CYP2C19 mRNA and protein levels in PXR-transfected HepG2 cells. Correspondingly, NXT leaded to a significant enhancement of the CYP2C19 catalytic activity in PXR-transfected HepG2 cells. Conclusion In summary, this is the first study to suggest that NXT could induce CYP2C19 expression via PXR activation.	[Sun, Hong; Ruan, Jun-Shan] Fujian Med Univ, Fujian Prov Hosp, Prov Clin Coll, Dept Pharm, Fuzhou, Fujan, Peoples R China; [Lou, Xiao-Ya] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China; [Lou, Xiao-Ya] Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China; [Wu, Xiao-Ying; Wang, Huan; Chen, Hui] Fujian Med Univ, Prov Clin Coll, Hypertens Lab, Fujian Prov Cardiovasc Dis Inst,Fujian Prov Hosp, Fuzhou, Fujian, Peoples R China; [Qu, Qiang] Cent S Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China; [Tan, Shen-Lan; Qu, Jian] Cent S Univ, Xiangya Hosp 2, Inst Clin Pharm, Dept Pharm, Changsha, Hunan, Peoples R China	Fujian Medical University; Fujian Provincial Hospital; Central South University; Central South University; Fujian Medical University; Fujian Provincial Hospital; Central South University; Central South University	Chen, H (corresponding author), Fujian Med Univ, Prov Clin Coll, Hypertens Lab, Fujian Prov Cardiovasc Dis Inst,Fujian Prov Hosp, Fuzhou, Fujian, Peoples R China.; Qu, J (corresponding author), Cent S Univ, Xiangya Hosp 2, Inst Clin Pharm, Dept Pharm, Changsha, Hunan, Peoples R China.	qujian@csu.edu.cn; chenhuiwyd@sina.com			National Natural Science Foundation of China [81373838, 81403021]; Health and Family Planning Commission of Fujian Province Medical Innovation project [2014-CX-5]; National Scientific foundation of China [81503166]; Youth Foundation of Xiangtan Hospital in Central South University [2014Q08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Health and Family Planning Commission of Fujian Province Medical Innovation project; National Scientific foundation of China(National Natural Science Foundation of China (NSFC)); Youth Foundation of Xiangtan Hospital in Central South University	The National Natural Science Foundation of China (No. 81373838 and No. 81403021) and Health and Family Planning Commission of Fujian Province Medical Innovation project (No. 2014-CX-5); the National Scientific foundation of China (No. 81503166) and the Youth Foundation of Xiangtan Hospital in Central South University (2014Q08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Chen C, 2009, STROKE, V40, P859, DOI 10.1161/STROKEAHA.108.531616; Chen H., 2011, EVID-BASED COMPL ALT, V2011; Chen H, 2014, CHIN J INTEGR MED, V20, P894, DOI 10.1007/s11655-014-2023-z; Chen H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/430262; Chen YP, 2003, MOL PHARMACOL, V64, P316, DOI 10.1124/mol.64.2.316; Collet JP, 2009, LANCET, V373, P309, DOI 10.1016/S0140-6736(08)61845-0; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; Guo L, 2011, DRUG METAB DISPOS, V39, P528, DOI 10.1124/dmd.110.035873; Haiyu X., 2015, MOL BIOSYST, V12, P233, DOI DOI 10.1039/C5MB00460H; Hart SN, 2010, DRUG METAB DISPOS, V38, P988, DOI 10.1124/dmd.109.031831; Hasegawa M, 2012, DRUG METAB DISPOS, V40, P474, DOI 10.1124/dmd.111.042754; Huang L, 2011, DRUG METAB PHARMACOK, V26, P331, DOI 10.2133/dmpk.DMPK-10-RG-115; Li HS, 2010, MOL PHARMACOL, V78, P704, DOI 10.1124/mol.110.065185; Lin R, 2015, J CLIN PHARM THER, V40, P308, DOI 10.1111/jcpt.12254; Liu XL, 2010, CHINESE MED J-PEKING, V123, P3178, DOI 10.3760/cma.j.issn.0366-6999.2010.22.002; Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Rana R, 2010, DRUG METAB DISPOS, V38, P591, DOI 10.1124/dmd.109.030387; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Sibbing D, 2009, THROMB HAEMOSTASIS, V101, P714, DOI 10.1160/TH08-12-0808; Wang LS, 2004, CLIN PHARMACOL THER, V75, P191, DOI 10.1016/j.clpt.2003.09.014; Wang SS, 2015, J PHARMACEUT BIOMED, V111, P104, DOI 10.1016/j.jpba.2015.01.020; Yin OQP, 2004, PHARMACOGENETICS, V14, P841, DOI 10.1097/00008571-200412000-00007; Yu CN, 2011, J ETHNOPHARMACOL, V136, P137, DOI 10.1016/j.jep.2011.04.022; Yu CN, 2009, CHEM-BIOL INTERACT, V177, P58, DOI 10.1016/j.cbi.2008.08.013; Zhang FB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/802784	28	9	15	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2016	11	7							e0160285	10.1371/journal.pone.0160285	http://dx.doi.org/10.1371/journal.pone.0160285			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IL	27467078	gold, Green Published, Green Submitted			2023-01-03	WOS:000381516100144
J	Halbert, CH; McDonald, J; Vadaparampil, S; Rice, L; Jefferson, M				Halbert, Chanita Hughes; McDonald, Jasmine; Vadaparampil, Susan; Rice, LaShanta; Jefferson, Melanie			Conducting Precision Medicine Research with African Americans	PLOS ONE			English	Article							RESEARCH PARTICIPATION; DIETARY INTERVENTIONS; PHYSICAL-ACTIVITY; GENETIC RESEARCH; PROSTATE-CANCER; INCREASED RISK; RECRUITMENT; RETENTION; INTENTIONS; TRIAL	Importance Precision medicine is an approach to detecting, treating, and managing disease that is based on individual variation in genetic, environmental, and lifestyle factors. Precision medicine is expected to reduce health disparities, but this will be possible only if studies have adequate representation of racial minorities. Objective It is critical to anticipate the rates at which individuals from diverse populations are likely to participate in precision medicine studies as research initiatives are being developed. We evaluated the likelihood of participating in a clinical study for precision medicine. Design, Setting, Participants Observational study conducted between October 2010 and February 2011 in a national sample of African Americans. Main Outcome Measure Intentions to participate in a government sponsored study that involves providing a biospecimen and generates data that could be shared with other researchers to conduct future studies. Results One third of respondents would participate in a clinical study for precision medicine. Only gender had a significant independent association with participation intentions. Men had a 1.86 (95% CI = 1.11, 3.12, p = 0.02) increased likelihood of participating in a precision medicine study compared to women in the model that included overall barriers and facilitators. In the model with specific participation barriers, distrust was associated with a reduced likelihood of participating in the research described in the vignette (OR = 0.57, 95% CI = 0.34, 0.96, p = 0.04). Conclusion and Relevance African Americans may have low enrollment in PMI research. As PMI research is implemented, extensive efforts will be needed to ensure adequate representation. Additional research is needed to identify optimal ways of ethically describing precision medicine studies to ensure sufficient recruitment of racial minorities.	[Halbert, Chanita Hughes; Rice, LaShanta] Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA; [Halbert, Chanita Hughes; Rice, LaShanta] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Halbert, Chanita Hughes; Rice, LaShanta] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA; [McDonald, Jasmine; Jefferson, Melanie] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA; [Vadaparampil, Susan] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Columbia University; H Lee Moffitt Cancer Center & Research Institute	Halbert, CH (corresponding author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.; Halbert, CH (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.; Halbert, CH (corresponding author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA.	hughesha@musc.edu	McDonald, Jasmine/L-4249-2019	McDonald, Jasmine/0000-0002-8270-8074	National Human Genome Research Institute [R01HG004346]; American Cancer Society [RSG-11-268-01-CPPB]; National Cancer Institute [UG1CA189848]; National Center for Advancing Translational Science [UL1TR001450]	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Advancing Translational Science	This research was supported by National Human Genome Research Institute grant #R01HG004346, grant #RSG-11-268-01-CPPB from the American Cancer Society, grant #UG1CA189848 from the National Cancer Institute, and grant #UL1TR001450 from the National Center for Advancing Translational Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahaghotu C, 2004, PROSTATE CANCER P D, V7, P165, DOI 10.1038/sj.pcan.4500719; Bussey-Jones J, 2010, GENET MED, V12, P116, DOI 10.1097/GIM.0b013e3181cd6689; Bussey-Jones J, 2009, J GEN INTERN MED, V24, P299, DOI 10.1007/s11606-008-0883-7; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458; Ford JG, 2008, CANCER, V112, P228, DOI 10.1002/cncr.23157; Fuqua SR, 2005, ETHNIC DIS, V15, pS18; George S, 2014, AM J PUBLIC HEALTH, V104, pE16, DOI 10.2105/AJPH.2013.301706; Haga SB, 2010, GENET MED, V12, P81, DOI 10.1097/GIM.0b013e3181ca2bbf; Halbert CH, 2008, AM J MED GENET A, V146A, P166, DOI 10.1002/ajmg.a.32067; Halbert CH, 2006, GENET MED, V8, P576, DOI 10.1097/01.gim.0000237719.37908.54; Halbert CH, 2014, CANCER EPIDEM BIOMAR, V23, P1306, DOI 10.1158/1055-9965.EPI-13-1064; Henderson G, 2008, GENET MED, V10, P193, DOI 10.1097/GIM.0b013e318164e4f5; Kennedy BM, 2011, HEALTH EDUC RES, V26, P923, DOI 10.1093/her/cyr061; Kessler L, 2005, GENET MED, V7, P230, DOI 10.1097/01.GIM.0000159901.98315.FE; McDonald JA, 2014, PUBLIC HEALTH GENOM, V17, P173, DOI 10.1159/000360472; McDonald JA, 2012, J NATL MED ASSOC, V104, P324, DOI 10.1016/S0027-9684(15)30172-3; McDonald JA, 2012, GENET TEST MOL BIOMA, V16, P252, DOI 10.1089/gtmb.2011.0119; McQuillan Geraldine M, 2011, IRB, V33, P9; McQuillan GM, 2003, GENET MED, V5, P35, DOI 10.1097/00125817-200301000-00006; National Institutes of Health, THE PRECISION MEDICI; National Institutes of Health, PRECISION MEDICINE I; Newton RL, 2014, OBES REV, V15, P93, DOI 10.1111/obr.12209; Parra-Medina D, 2004, J AM DIET ASSOC, V104, P70, DOI 10.1016/j.jada.2003.10.014; Pew Research Institute, ASSESSING THE REPRES; Powell IJ, 2001, J NATL MED ASSOC, V93, P120; Smith TW, 2003, ALTRUISM IN CONTEMPO; Wyatt SB, 2003, ETHNIC DIS, V13, P438; Yancey AK, 2006, ANNU REV PUBL HEALTH, V27, P1, DOI 10.1146/annurev.publhealth.27.021405.102113	30	31	31	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2016	11	7							e0154850	10.1371/journal.pone.0154850	http://dx.doi.org/10.1371/journal.pone.0154850			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DS5CG	27441706	Green Submitted, Green Published, gold			2023-01-03	WOS:000380797500003
J	Voorn, EL; Koopman, FS; Brehm, MA; Beelen, A; de Haan, A; Gerrits, KHL; Nollet, F				Voorn, Eric L.; Koopman, Fieke S.; Brehm, Merel A.; Beelen, Anita; de Haan, Arnold; Gerrits, Karin H. L.; Nollet, Frans			Aerobic Exercise Training in Post-Polio Syndrome: Process Evaluation of a Randomized Controlled Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; CARDIORESPIRATORY RESPONSES; FATIGUE; FITNESS; POLIOMYELITIS; INDIVIDUALS; PERFORMANCE; THRESHOLD; THERAPY; LOAD	Objective To explore reasons for the lack of efficacy of a high intensity aerobic exercise program in post-polio syndrome (PPS) on cardiorespiratory fitness by evaluating adherence to the training program and effects on muscle function. Design A process evaluation using data from an RCT. Patients Forty-four severely fatigued individuals with PPS were randomized to exercise therapy (n = 22) or usual care (n = 22). Methods Participants in the exercise group were instructed to exercise 3 times weekly for 4 months on a bicycle ergometer (60-70% heart rate reserve). Results The attendance rate was high (median 89%). None of the participants trained within the target heart rate range during >75% of the designated time. Instead, participants exercised at lower intensities, though still around the anaerobic threshold (AT) most of the time. Muscle function did not improve in the exercise group. Conclusion Our results suggest that severely fatigued individuals with PPS cannot adhere to a high intensity aerobic exercise program on a cycle ergometer. Despite exercise intensities around the AT, lower extremity muscle function nor cardiorespiratory fitness improved. Improving the aerobic capacity in PPS is difficult through exercise primarily focusing on the lower extremities, and may require a more individualized approach, including the use of other large muscle groups instead.	[Voorn, Eric L.; Koopman, Fieke S.; Brehm, Merel A.; Beelen, Anita; Nollet, Frans] Univ Amsterdam, Acad Med Ctr, Dept Rehabil, Amsterdam, Netherlands; [Voorn, Eric L.; de Haan, Arnold; Gerrits, Karin H. L.] Vrije Univ Amsterdam, Fac Behav & Movement Sci, MOVE Res Inst Amsterdam, Dept Human Movement Sci, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Voorn, EL (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Rehabil, Amsterdam, Netherlands.; Voorn, EL (corresponding author), Vrije Univ Amsterdam, Fac Behav & Movement Sci, MOVE Res Inst Amsterdam, Dept Human Movement Sci, Amsterdam, Netherlands.	e.l.voorn@amc.uva.nl	Brehm, Merel-Anne/K-8638-2017; Brehm, Merel-Anne/AAK-7419-2020	Brehm, Merel-Anne/0000-0002-3425-4661; Brehm, Merel-Anne/0000-0002-3425-4661; Voorn, Eric/0000-0003-0807-2124; Koopman, Fieke Sophia/0000-0001-5260-0727	Prinses Beatrix SpierFonds (PBF; The Dutch Public Fund for Neuromuscular Disorders); ZonMw (the Netherlands Organisation for Health Research and Development) [ZonMw 89000003]	Prinses Beatrix SpierFonds (PBF; The Dutch Public Fund for Neuromuscular Disorders); ZonMw (the Netherlands Organisation for Health Research and Development)(Netherlands Organization for Health Research and Development)	This work was funded by Prinses Beatrix SpierFonds (PBF; The Dutch Public Fund for Neuromuscular Disorders), ZonMw (the Netherlands Organisation for Health Research and Development, ID: ZonMw 89000003) /het Revalidatiefonds/Revalidatie Nederland/de Nederlandse Vereniging van Revalidatieartsen (the Netherlands Society of Physical and Rehabilitation Medicine).	Akubat I, 2012, J SPORT SCI, V30, P1473, DOI 10.1080/02640414.2012.712711; Bickerstaffe A, 2014, CLIN NEUROPHYSIOL, V125, P1255, DOI 10.1016/j.clinph.2013.11.003; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BORG K, 1991, J NEUROL NEUROSUR PS, V54, P236, DOI 10.1136/jnnp.54.3.236; Borresen J, 2009, SPORTS MED, V39, P779, DOI 10.2165/11317780-000000000-00000; Cup EH, 2007, ARCH PHYS MED REHAB, V88, P1452, DOI 10.1016/j.apmr.2007.07.024; Durstine JL, 2009, ACSMS EXERCISE MANAG; Ernstoff B, 1996, ARCH PHYS MED REHAB, V77, P843, DOI 10.1016/S0003-9993(96)90268-3; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; GRIMBY G, 1989, SCAND J REHABIL MED, V21, P19; JONES DR, 1989, JAMA-J AM MED ASSOC, V261, P3255, DOI 10.1001/jama.261.22.3255; Kenney WL, 2012, PHYSL SPORT EXERCISE; Klein MG, 2008, ARCH PHYS MED REHAB, V89, P297, DOI 10.1016/j.apmr.2007.08.156; Koopman FS, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-8; Koopman FS, 2015, NEUROREHABILITATION; KRIZ JL, 1992, ARCH PHYS MED REHAB, V73, P49; Londeree BR, 1997, MED SCI SPORT EXER, V29, P837, DOI 10.1097/00005768-199706000-00016; Manzi V, 2009, MED SCI SPORT EXER, V41, P2090, DOI 10.1249/MSS.0b013e3181a6a959; March of Dimes, 2000, INT C POSTP SYNDR ID; Medical Research Council, 1976, 45 MED RES COUNC, V45; Mostert S, 2002, MULT SCLER J, V8, P161, DOI 10.1191/1352458502ms779oa; Nollet F, 1999, ARCH PHYS MED REHAB, V80, P136, DOI 10.1016/S0003-9993(99)90110-7; Oncu J, 2009, CLIN REHABIL, V23, P155, DOI 10.1177/0269215508098893; Rekand T, 2004, ACTA NEUROL SCAND, V109, P120, DOI 10.1034/j.1600-0404.2003.00186.x; SULLIVAN M, 1985, AM HEART J, V109, P458, DOI 10.1016/0002-8703(85)90548-4; Tan SJ, 2010, PEDIATR EXERC SCI, V22, P477, DOI 10.1123/pes.22.3.477; Tersteeg IM, 2011, ARCH PHYS MED REHAB, V92, P899, DOI 10.1016/j.apmr.2011.01.005; Vercoulen J., 1999, GEDRAGSTHERAPIE, V32, P131; Voorn EL, 2014, ARCH PHYS MED REHABI; Voorn EL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101660; Voorn EL, 2013, NEUROMUSCULAR DISORD, V23, P892, DOI 10.1016/j.nmd.2013.06.372; Wasserman K, 2005, EUR RESP MON, P146, DOI DOI 10.1249/01.MSS.0000172593.20181.14; Willen C, 2001, ARCH PHYS MED REHAB, V82, P66, DOI 10.1053/apmr.2001.9626	33	9	9	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2016	11	7							e0159280	10.1371/journal.pone.0159280	http://dx.doi.org/10.1371/journal.pone.0159280			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR1JR	27419388	Green Submitted, Green Published, gold			2023-01-03	WOS:000379662300010
J	Crow, JM				Crow, James Mitchell			BIOMEDICINE Move over, morphine	NATURE			English	Editorial Material																		Fleet J, 2015, BJOG-INT J OBSTET GY, V122, P983, DOI 10.1111/1471-0528.13249; Zadina JE, 2016, NEUROPHARMACOLOGY, V105, P215, DOI 10.1016/j.neuropharm.2015.12.024; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	3	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2016	535	7611					S4	S6		10.1038/535S4a	http://dx.doi.org/10.1038/535S4a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR4ZN	27410530				2023-01-03	WOS:000379912600004
J	Kakehashi, A; Ishii, N; Fujioka, M; Doi, K; Gi, M; Wanibuchi, H				Kakehashi, Anna; Ishii, Naomi; Fujioka, Masaki; Doi, Kenichiro; Gi, Min; Wanibuchi, Hideki			Ethanol-Extracted Brazilian Propolis Exerts Protective Effects on Tumorigenesis in Wistar Hannover Rats	PLOS ONE			English	Article							ACID PHENETHYL ESTER; PROSTATE-CANCER CELLS; ABERRANT CRYPT FOCI; CAFFEIC ACID; RED PROPOLIS; BREAST-CANCER; ARTEPILLIN-C; IN-VIVO; GROWTH; CARCINOGENESIS	The present study was conducted over a course of 104 weeks to estimate the carcinogenicity of ethanol-extracted Brazilian green propolis (EEP). Groups of 50 male and 50 female Wistar Hannover rats, 6-week-old at commencement were exposed to EEP at doses of 0, 0.5 or 2.5% in the diet. Survival rates of 0.5% and 2.5% EEP-treated male and female rats, respectively, were significantly higher than those of respective control groups. Overall histopathological evaluation of neoplasms in rat tissues after 2 years showed no significant increase of tumors or preneoplastic lesions in any organ of animals administered EEP. Significantly lower incidences of pituitary tumors in 0.5% EEP male and 2.5% EEP female groups, malignant lymphoma/ leukemia in both 2.5% EEP-treated males and females and total thyroid tumors in 0.5% EEP male group were found. Administration of EEP caused significant decreases of lymphoid hyperplasia of the thymus and lymph nodes in 2.5% EEP-treated rats, tubular cell hyperplasia of kidneys in all EEP groups, and cortical hyperplasia of adrenals in EEP-treated females. In the blood, significant reduction of neutrophils in all EEP-treated males and band neutrophils in 2.5% EEP-treated females was found indicating lower levels of inflammation. Total cholesterol and triglicerides levels were significantly lower in the blood of 2.5% EEP-treated female rats. In conclusion, under the conditions of the 2-year feeding experiment, EEP was not carcinogenic, did not induce significant histopathological changes in any organ, and further exerted anti-inflammatory and antitumorigenic effects resulting in increase of survival of Wistar Hannover rats.	[Kakehashi, Anna; Ishii, Naomi; Fujioka, Masaki; Doi, Kenichiro; Gi, Min; Wanibuchi, Hideki] Osaka City Univ, Grad Sch Med, Dept Mol Pathol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan	Osaka Metropolitan University	Wanibuchi, H (corresponding author), Osaka City Univ, Grad Sch Med, Dept Mol Pathol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	wani@med.osaka-cu.ac.jp	Fujioka, Masaki/C-7817-2019; Kakehashi, Anna/ABF-2986-2020	Fujioka, Masaki/0000-0003-0048-2874; Kakehashi, Anna/0000-0003-1149-1450	Ministry of Health, Labor and Welfare of Japan	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This research was supported by a grant from the Ministry of Health, Labor and Welfare of Japan (grant title: Research on genotoxicity and carcinogenicity of food additives and health foods). No number existed.	Ahn MR, 2007, CANCER LETT, V252, P235, DOI 10.1016/j.canlet.2006.12.039; Alizadeh AM, 2015, ARCH IRAN MED, V18, P18, DOI 0151801/AIM.006; Almeida E. C. de, 2002, J. Venom. Anim. Toxins, V8, P191, DOI 10.1590/S0104-79302002000200002; Basini G, 2012, INVEST NEW DRUG, V30, P186, DOI 10.1007/s10637-010-9550-z; Baykara M, 2015, DIAGN INTERV RADIOL, V21, P317, DOI 10.5152/dir.2015.14075; Borrelli F, 2002, FITOTERAPIA, V73, pS38, DOI 10.1016/S0367-326X(02)00189-2; Bufalo MC, 2015, J PHARM PHARMACOL, V67, P740, DOI 10.1111/jphp.12364; Campos JF, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/296186; Cavendish RL, 2015, J ETHNOPHARMACOL, V173, P127, DOI 10.1016/j.jep.2015.07.022; CHIAO C, 1995, CANCER RES, V55, P3576; Chirumbolo S, 2015, J CLIN BIOCHEM NUTR, V56, P163, DOI 10.3164/jcbn.14-110; Conti BJ, 2015, J PHARM PHARMACOL, V67, P1431, DOI 10.1111/jphp.12431; da Silva RO, 2015, J ETHNOPHARMACOL, V170, P66, DOI 10.1016/j.jep.2015.05.009; Fu JY, 2004, BIOMED ENVIRON SCI, V17, P469; GHISALBERTI EL, 1979, BEE WORLD, V60, P59, DOI 10.1080/0005772X.1979.11097738; Jung BI, 2010, PHYTOTHER RES, V24, P295, DOI 10.1002/ptr.2966; Khalil Mahmoud Lotfy, 2006, Asian Pac J Cancer Prev, V7, P22; Kimoto N, 1999, CANCER LETT, V147, P221, DOI 10.1016/S0304-3835(99)00305-5; Kimoto T, 1996, Gan To Kagaku Ryoho, V23, P1855; Kimoto T, 2001, VIRCHOWS ARCH, V438, P259, DOI 10.1007/s004280000350; Kubina R, 2015, ADV CLIN EXP MED, V24, P203, DOI 10.17219/acem/31792; Li HZ, 2007, INT J ONCOL, V31, P601; Li X, 2011, TOXICOL IN VITRO, V25, P630, DOI 10.1016/j.tiv.2010.12.013; Lopez BG, 2015, J APPL MICROBIOL, DOI 10.11110m.12874; Luo JQ, 2001, ANTICANCER RES, V21, P1665; Mani F, 2006, J ETHNOPHARMACOL, V105, P95, DOI 10.1016/j.jep.2005.10.011; Mishima S, 2005, BIOL PHARM BULL, V28, P1025, DOI 10.1248/bpb.28.1025; Missima F, 2010, PHYTOTHER RES, V24, P1501, DOI 10.1002/ptr.3142; Moreno MIN, 2005, J AGR FOOD CHEM, V53, P8957, DOI 10.1021/jf0513359; Nouhi A., 2008, ARAK MED U J, V11, P102; OECD, 2009, TEST 451 CARC STUD; OECD, 2009, GOOD LAB PRACT; Okamoto Y, 2015, J TOXICOL SCI, V40, P235, DOI 10.2131/jts.40.235; Orsolic N, 2005, BIOMED PHARMACOTHER, V59, P561, DOI 10.1016/j.biopha.2005.03.013; Padmavathi R, 2006, COMP BIOCHEM PHYS C, V143, P349, DOI 10.1016/j.cbpc.2006.03.009; Patel Seema, 2016, Journal of Dietary Supplements, V13, P245, DOI 10.3109/19390211.2015.1008614; Ribeiro DR, 2015, BASIC CLIN PHARMACOL, V117, P85, DOI 10.1111/bcpt.12374; Schmidt JO, 1992, OTHER PRODUCTS HIVE, P927; Selamoglu ZS, 2015, ADV CLIN EXP MED, V24, P227, DOI 10.17219/acem/40461; Senedese JM, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen049; Shimizu K, 2004, ARCH BIOCHEM BIOPHYS, V424, P181, DOI 10.1016/j.abb.2004.02.021; Szliszka E, 2009, MOLECULES, V14, P738, DOI [10.3390/molecules14020738, 10.3390/molecules]; Szliszka E, 2011, INT J ONCOL, V38, P941, DOI 10.3892/ijo.2011.930; Valente MJ, 2011, FOOD CHEM TOXICOL, V49, P86, DOI 10.1016/j.fct.2010.10.001; Wagh VD, 2013, ADV PHARMACOL SCI, V2013, DOI 10.1155/2013/308249; Xie XL, 2015, FOOD CHEM TOXICOL, V83, P193, DOI 10.1016/j.fct.2015.06.007; Yasui Y, 2008, ONCOL REP, V20, P493, DOI 10.3892/or_00000033; Zhang JL, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/307594; Zhao JQ, 2009, INDIAN J EXP BIOL, V47, P264	49	13	14	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158654	10.1371/journal.pone.0158654	http://dx.doi.org/10.1371/journal.pone.0158654			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27391589	gold, Green Published, Green Submitted			2023-01-03	WOS:000380005400097
J	Liu, R; Huang, Q; Shan, JJ; Duan, JA; Zhu, ZH; Liu, P; Bian, Y; Shang, EX; Qian, DW				Liu, Rui; Huang, Qiong; Shan, Jinjun; Duan, Jin-ao; Zhu, Zhenhua; Liu, Pei; Bian, Yong; Shang, Er-xin; Qian, Dawei			Metabolomics of the Antipyretic Effects of Bubali Cornu (Water Buffalo Horn) in Rats	PLOS ONE			English	Article							PATTERN-RECOGNITION APPROACH; MASS-SPECTROMETRY; ANIMAL HORNS; INDUCED INFLAMMATION; BIOCHEMICAL-CHANGES; FEBRILE RESPONSE; RHINOCEROS HORN; BAKERS-YEAST; FEVER; LYSOPHOSPHATIDYLCHOLINE	Bubali Cornu (water buffalo horn, WBH) has been used for thousands of years in traditional Chinese medicine (TCM) as an effective treatment for heat. In the present study, we have carried out a metabolomics profiling study on plasma and urine samples to explore potential biomarkers and determine how WBH exerts its antipyretic effects in yeast-induced pyrexia at a metabolomic level. Ultra-high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS), together with multivariate statistical analysis, was used to detect and identify potential biomarkers associated with pyrexia and with WBH treatment. In total, sixteen endogenous metabolites were identified in plasma samples and twenty-one metabolites were detected in urine samples. The biomarkers identified in this study, using metabolic pathway analysis (MetPA), are involved in glycerophospholipid, arachidonic acid, amino acid, sphingolipid, and purine metabolism, all of which are disturbed in rats with pyrexia. As a result, WBH affect arachidonic acid metabolism and oxidative stress in yeast-induced pyrexia rats chiefly. The present study determines the important substances underlying the antipyretic efficacy of WBH at a metabolic level. It might pave the way for further investigations into the mechanisms of action of other animal horn-derived traditional Chinese medicines (TCMs).	[Liu, Rui; Duan, Jin-ao; Zhu, Zhenhua; Liu, Pei; Bian, Yong; Shang, Er-xin; Qian, Dawei] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Nanjing, Jiangsu, Peoples R China; [Liu, Rui; Duan, Jin-ao; Zhu, Zhenhua; Liu, Pei; Bian, Yong; Shang, Er-xin; Qian, Dawei] Nanjing Univ Chinese Med, Natl & Local Collaborat Engn Ctr Chinese Med Reso, Nanjing, Jiangsu, Peoples R China; [Liu, Rui] Nanjing Univ Chinese Med, Jiangsu Key Lab Res & Dev Marine Bioresource Phar, Nanjing, Jiangsu, Peoples R China; [Liu, Rui; Duan, Jin-ao; Zhu, Zhenhua; Liu, Pei; Shang, Er-xin; Qian, Dawei] Nanjing Univ Chinese Med, Jiangsu Key Lab High Technol Res TCM Formulae, Nanjing, Jiangsu, Peoples R China; [Huang, Qiong] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Shan, Jinjun] Nanjing Univ Chinese Med, Inst Pediat, Jiangsu Key Lab Pediat Resp Dis, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing Medical University; Nanjing University of Chinese Medicine	Liu, R; Duan, JA (corresponding author), Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Nanjing, Jiangsu, Peoples R China.; Liu, R; Duan, JA (corresponding author), Nanjing Univ Chinese Med, Natl & Local Collaborat Engn Ctr Chinese Med Reso, Nanjing, Jiangsu, Peoples R China.; Liu, R (corresponding author), Nanjing Univ Chinese Med, Jiangsu Key Lab Res & Dev Marine Bioresource Phar, Nanjing, Jiangsu, Peoples R China.; Liu, R; Duan, JA (corresponding author), Nanjing Univ Chinese Med, Jiangsu Key Lab High Technol Res TCM Formulae, Nanjing, Jiangsu, Peoples R China.	cpulr@126.com; dja@njutcm.edu.cn			Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Technology Research Funds of State Administration of Traditional Chinese Medicine [201407002]; National Science Foundation of China [81202861, 81274017]; Doctoral Fund of Ministry of Education of China [20113237120011]; Flagship Major Development of Jiangsu Higher Education Institutions; Qin Lan Project	Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Technology Research Funds of State Administration of Traditional Chinese Medicine; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Flagship Major Development of Jiangsu Higher Education Institutions; Qin Lan Project	This study was funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Technology Research Funds of State Administration of Traditional Chinese Medicine (201407002), National Science Foundation of China (81202861 and 81274017), Doctoral Fund of Ministry of Education of China (20113237120011), and the Flagship Major Development of Jiangsu Higher Education Institutions, and Qin Lan Project.	Adham KG, 2012, NEUROENDOCRINOL LETT, V33, P713; Bayle MS, 2000, ACTA PAEDIATR, V89, P367, DOI 10.1080/080352500750028573; Brkic L, 2012, ATHEROSCLEROSIS, V224, P348, DOI 10.1016/j.atherosclerosis.2012.07.038; BUT PP, 1990, J ETHNOPHARMACOL, V30, P157; BUT PPH, 1991, J ETHNOPHARMACOL, V33, P45; Feleder C, 2007, AM J PHYSIOL-REG I, V293, pR1135, DOI 10.1152/ajpregu.00067.2007; Fraunberger P, 2002, CLIN CHEM LAB MED, V40, P304, DOI 10.1515/CCLM.2002.048; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gao XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100017; Gao XY, 2013, CHEM-BIOL INTERACT, V204, P39, DOI 10.1016/j.cbi.2013.04.001; Guan NZ, 2015, METABOLOMICS, V11, P1106, DOI 10.1007/s11306-014-0766-3; Kaneko K, 2011, J INVEST DERMATOL, V131, P1262, DOI 10.1038/jid.2011.37; Kondeti V, 2016, J ALLERGY CLIN IMMUN, V137, P289, DOI 10.1016/j.jaci.2015.06.030; Liu R, 2015, J LIQ CHROMATOGR R T, V38, P1185, DOI 10.1080/10826076.2015.1025142; Liu R, 2012, J LIQ CHROMATOGR R T, V35, P205, DOI 10.1080/10826076.2011.597070; Liu R, 2011, J SEP SCI, V34, P354, DOI 10.1002/jssc.201000617; Liu R, 2010, PEPTIDES, V31, P786, DOI 10.1016/j.peptides.2010.02.016; Liu R, 2010, AM J CHINESE MED, V38, P293, DOI 10.1142/S0192415X10007853; Liu SM, 2011, AM J CHINESE MED, V39, P95, DOI 10.1142/S0192415X11008671; Luo JY, 2013, SCI REP-UK, V3, DOI [10.1038/srep02243, 10.1038/srep03108]; Luo JY, 2011, J ETHNOPHARMACOL, V136, P210, DOI 10.1016/j.jep.2011.04.053; Hung ND, 2012, INFLAMM RES, V61, P473, DOI 10.1007/s00011-012-0434-x; Ferreira APO, 2012, INFLAMM RES, V61, P103, DOI 10.1007/s00011-011-0392-8; Panasenko OM, 2003, FREE RADICAL BIO MED, V34, P553, DOI 10.1016/S0891-5849(02)01358-8; Romanovsky AA, 2005, FRONT BIOSCI-LANDMRK, V10, P2193, DOI 10.2741/1690; Schober C, 2009, BIOORG CHEM, V37, P202, DOI 10.1016/j.bioorg.2009.09.002; Strobel G, 2002, LIFE SCI, V71, P55, DOI 10.1016/S0024-3205(02)01620-X; Su SL, 2013, J PROTEOME RES, V12, P852, DOI 10.1021/pr300935x; [王斐 Wang Fei], 2005, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V21, P163; [王斐 WANG Fei], 2007, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V23, P36; Wang PC, 2015, AM J CHINESE MED, V43, P1281, DOI 10.1142/S0192415X15500731; Wang XJ, 2012, J PROTEOME RES, V11, P1284, DOI 10.1021/pr200963e; Zhang FS, 2013, J PHARMACEUT BIOMED, V81-82, P168, DOI 10.1016/j.jpba.2013.04.005	33	12	18	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2016	11	7							e0158478	10.1371/journal.pone.0158478	http://dx.doi.org/10.1371/journal.pone.0158478			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3NH	27384078	Green Published, gold, Green Submitted			2023-01-03	WOS:000379809400052
J	Manchado, E; Weissmueller, S; Morris, JP; Chen, CC; Wullenkord, R; Lujambio, A; de Stanchina, E; Poirier, JT; Gainor, JF; Corcoran, RB; Engelman, JA; Rudin, CM; Rosen, N; Lowe, SW				Manchado, Eusebio; Weissmueller, Susann; Morris, John P.; Chen, Chi-Chao; Wullenkord, Ramona; Lujambio, Amaia; de Stanchina, Elisa; Poirier, John T.; Gainor, Justin F.; Corcoran, Ryan B.; Engelman, Jeffrey A.; Rudin, Charles M.; Rosen, Neal; Lowe, Scott W.			A combinatorial strategy for treating KRAS-mutant lung cancer	NATURE			English	Article							MEK INHIBITION; MEDIATED REACTIVATION; SELECTIVE INHIBITOR; FEEDBACK ACTIVATION; ACQUIRED-RESISTANCE; COLON-CANCER; RAS; POTENT; BRAF; DISCOVERY	Therapeutic targeting of KRAS-mutant lung adenocarcinoma represents a major goal of clinical oncology. KRAS itself has proved difficult to inhibit, and the effectiveness of agents that target key KRAS effectors has been thwarted by activation of compensatory or parallel pathways that limit their efficacy as single agents. Here we take a systematic approach towards identifying combination targets for trametinib, a MEK inhibitor approved by the US Food and Drug Administration, which acts downstream of KRAS to suppress signalling through the mitogen-activated protein kinase (MAPK) cascade. Informed by a short-hairpin RNA screen, we show that trametinib provokes a compensatory response involving the fibroblast growth factor receptor 1 (FGFR1) that leads to signalling rebound and adaptive drug resistance. As a consequence, genetic or pharmacological inhibition of FGFR1 in combination with trametinib enhances tumour cell death in vitro and in vivo. This compensatory response shows distinct specificities: it is dominated by FGFR1 in KRAS-mutant lung and pancreatic cancer cells, but is not activated or involves other mechanisms in KRAS wild-type lung and KRAS-mutant colon cancer cells. Importantly, KRAS-mutant lung cancer cells and patients' tumours treated with trametinib show an increase in FRS2 phosphorylation, a biomarker of FGFR activation; this increase is abolished by FGFR1 inhibition and correlates with sensitivity to trametinib and FGFR inhibitor combinations. These results demonstrate that FGFR1 can mediate adaptive resistance to trametinib and validate a combinatorial approach for treating KRAS-mutant lung cancer.	[Manchado, Eusebio; Weissmueller, Susann; Morris, John P.; Chen, Chi-Chao; Wullenkord, Ramona; Lujambio, Amaia; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10065 USA; [Weissmueller, Susann] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; [Chen, Chi-Chao] Cornell Univ, Weill Cornell Grad Sch Med Sci, New York, NY 10065 USA; [Lujambio, Amaia] Icahn Sch Med Mt Sinai, Dept Oncol Sci, Liver Canc Program, Tisch Canc Inst, New York, NY 10029 USA; [de Stanchina, Elisa; Poirier, John T.; Rudin, Charles M.; Rosen, Neal] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10065 USA; [Poirier, John T.; Rudin, Charles M.; Rosen, Neal] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Gainor, Justin F.; Corcoran, Ryan B.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Dept Med, Ctr Canc, Boston, MA 02114 USA; [Gainor, Justin F.; Corcoran, Ryan B.; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Lowe, Scott W.] Howard Hughes Med Inst, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Lowe, SW (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10065 USA.; Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10065 USA.; Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.; Lowe, SW (corresponding author), Howard Hughes Med Inst, New York, NY 10065 USA.	rosenn@mskcc.org; lowes@mskcc.org	Rosen, Neal/ABF-2677-2020; Gainor, Justin/T-5411-2019; Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Lujambio, Amaia/0000-0002-2798-1481; Poirier, John/0000-0001-9795-5644	National Cancer Institute; Center of Experimental Therapeutics; Stand Up To Cancer grant from the American Association for Cancer Research; Cancer Center Support grant; Jane Coffin Childs Memorial Fund for Medical Research; National Institutes of Health/National Cancer Institute [K99/R00]; Watson School of Biological Sciences; Bayer Foundation; EMBO Long-Term fellowship; Geoffrey Beene Cancer Research Center; NATIONAL CANCER INSTITUTE [P01CA129243, P30CA008748, P50CA127003, R01CA169351] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center of Experimental Therapeutics; Stand Up To Cancer grant from the American Association for Cancer Research; Cancer Center Support grant; Jane Coffin Childs Memorial Fund for Medical Research; National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Watson School of Biological Sciences(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Bayer Foundation(Bayer AG); EMBO Long-Term fellowship(European Molecular Biology Organization (EMBO)); Geoffrey Beene Cancer Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. Sanchez-Cespedes, R. Somwar, and H. Varmus for sharing cell lines; S. Tian, J. Ahn, M. Taylor, A. Shroff, and J. Plevy for technical assistance; C. J. Sherr, L. E. Dow, P Lito, T Kastenhuber, and J. Leibold for advice on experimental design and/or for editing the manuscript: and other members of the Lowe laboratory for advice and discussions. This work was supported by a program project grant from the National Cancer Institute (S.W.L.. N.R.). a grant from the Center of Experimental Therapeutics (S.W.L., N.R.), a Stand Up To Cancer grant from the American Association for Cancer Research (N.R., J.A.E., C.R.), and a Cancer Center Support grant to MSKCC. E.M. was supported by The Jane Coffin Childs Memorial Fund for Medical Research and a K99/R00 grant from the National Institutes of Health/National Cancer Institute. S.W. was supported by the Annette Kade Fellowship from the Watson School of Biological Sciences. R.W. was supported by a Carl-Duisberg Fellowship from the Bayer Foundation. A.L. was supported by an EMBO Long-Term fellowship. E.d.S. received support through the Geoffrey Beene Cancer Research Center. S.W.L. is the Geoffrey Beene Chair of Cancer Biology and a Howard Hughes Medical Institute investigator.	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Fellmann C, 2011, MOL CELL, V41, P733, DOI 10.1016/j.molcel.2011.02.008; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Gozgit JM, 2012, MOL CANCER THER, V11, P690, DOI 10.1158/1535-7163.MCT-11-0450; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Huch M, 2013, EMBO J, V32, P2708, DOI 10.1038/emboj.2013.204; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li F, 2015, CANCER DISCOV, V5, P438, DOI 10.1158/2159-8290.CD-14-0763; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Poirier JT, 2015, ONCOGENE, V34, P5869, DOI 10.1038/onc.2015.38; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Taylor James, 2007, Curr Protoc Bioinformatics, VChapter 10, DOI 10.1002/0471250953.bi1005s19; Traer E, 2014, BLOOD, V123, P1516, DOI 10.1182/blood-2013-07-518381; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	36	267	272	0	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2016	534	7609					647	+		10.1038/nature18600	http://dx.doi.org/10.1038/nature18600			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP7JV	27338794	Green Submitted, Green Accepted			2023-01-03	WOS:000378676000028
J	Torjesen, I				Torjesen, Ingrid			Doctors give patients potentially harmful procedures at end of life, global review finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Cardona-Morrell M, 2016, INT J QUAL HEALTH C, V28, P456, DOI 10.1093/intqhc/mzw060	1	0	0	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2016	353								i3613	10.1136/bmj.i3613	http://dx.doi.org/10.1136/bmj.i3613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DQ2FV	27357962				2023-01-03	WOS:000379018700007
J	Hamidou, Z; Chibaudel, B; Hebbar, M; de Larauze, MH; Andre, T; Louvet, C; Brusquant, D; Garcia-Larnicol, ML; de Gramont, A; Bonnetain, F				Hamidou, Zeinab; Chibaudel, Benoist; Hebbar, Mohamed; de Larauze, Marine Hug; Andre, Thierry; Louvet, Christophe; Brusquant, David; Garcia-Larnicol, Marie-Line; de Gramont, Aimery; Bonnetain, Franck			Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial	PLOS ONE			English	Article							CLINICAL-TRIALS; 5-FLUOROURACIL; CHEMOTHERAPY; OUTCOMES	Purpose We previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7) and irinotecan (FOLFIRI; irinotecan plus 5-fluorouracil/leucovorin) is not superior to FOLFOX4 in patients at advanced stage of colorectal cancer with liver metastases. Here we aimed to determine whether time to health-related quality of life (HRQoL) score definitive deterioration (TUDD) differs by study arm. Methods HRQoL was evaluated using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 at baseline and every 4 cycles until the end of the study or death. Functional scale, symptom scale, global health status, and financial difficulties were analyzed. The TUDD was defined as the time interval between randomization and the first decrease in HRQoL score >= 5-point with no further improvement in HRQoL score >= 5 points or any further HRQoL data. TUDD was estimated using the Kaplan-Meier method and the long-rank test. Cox regression analyses were used to identify HRQoL items influencing TUDD. Sensitivity analyses were done using a multiple imputation method and different definitions of TUDD. Results Of the 284 patients, 171 (60.2%) completed HRQoL questionnaires. Cox multivariate analysis showed no statistically significant difference in TUDD for most of the QLQ-C30 scales between treatments. Patients with dyspnea and those without symptoms at baseline had a significantly longer TUDD when there was a delay > 12 months between diagnosis of the primary tumor and metastases (HR 0.48 [0.26-0.89]) and when there was diarrhea (HR 0.59 [0.36-0.96]), respectively. Conclusion This study shows that TUDD does not differ significantly according to type of treatment. The TUDD method produces meaningful longitudinal HRQoL results that may facilitate effective clinical decision making in patients with mCRC.	[Hamidou, Zeinab; Bonnetain, Franck] Natl Clin Res Platform Qual Life Oncol, Marseille, France; [Hamidou, Zeinab] Coll Med, Publ Hlth Lab, Marseille, France; [Chibaudel, Benoist; Andre, Thierry; Garcia-Larnicol, Marie-Line] St Antoine Hosp, Dept Med Oncol, Paris, France; [Hebbar, Mohamed; de Gramont, Aimery] Ctr Hosp Reg Univ, Claude Huriez Hosp, Med Oncol Serv, Lille, France; [de Larauze, Marine Hug; Brusquant, David] Grp Cooperateur Multidisciplinaire Oncol GERCOR, Paris, France; [Louvet, Christophe] Inst Mutualiste Montsouris, Dept Med Oncol, Paris, France; [Bonnetain, Franck] Univ Hosp Besancon, Methodol & Qual Life Unit Oncol EA3181, Besancon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; CHU Besancon	Hamidou, Z (corresponding author), Natl Clin Res Platform Qual Life Oncol, Marseille, France.; Hamidou, Z (corresponding author), Coll Med, Publ Hlth Lab, Marseille, France.	zeinab.hamidou@univ-amu.fr	André, Thierry P/N-8830-2017	André, Thierry P/0000-0002-5103-7095; Chibaudel, Benoist/0000-0003-1279-2044	Group Cooperateur Multidisciplinaire en Oncologie (GERCOR) (France); Ligue nationale contre le cancer; National clinical research Platform for Quality of life in Oncology; Sanofi-Aventis	Group Cooperateur Multidisciplinaire en Oncologie (GERCOR) (France); Ligue nationale contre le cancer(Ligue nationale contre le cancer); National clinical research Platform for Quality of life in Oncology; Sanofi-Aventis(Sanofi-Aventis)	This work was funded by the Group Cooperateur Multidisciplinaire en Oncologie (GERCOR) (France) and the Ligue nationale contre le cancer. This work was also supported by the National clinical research Platform for Quality of life in Oncology labelled by the National Cancer Ligue and the French National Cancer, Institute, and by Sanofi-Aventis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Anota A, 2015, QUAL LIFE RES, V24, P5, DOI 10.1007/s11136-013-0583-6; BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; Bezjak A, 2006, J CLIN ONCOL, V24, P3831, DOI 10.1200/JCO.2006.05.8073; Bonnetain F, 2016, J CLIN ONCOL; Bonnetain F, 2010, EUR J CANCER, V46, P2753, DOI 10.1016/j.ejca.2010.07.023; Carsin AE, 2008, BRIT J CANCER, V99, P266, DOI 10.1038/sj.bjc.6604467; Curley SA, 2005, SEMIN ONCOL, V32, pS109, DOI 10.1053/j.seminoncol.2005.06.011; Donaldson GW, 2005, J CLIN ONCOL, V23, P7380, DOI 10.1200/JCO.2005.07.022; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; Gray NM, 2011, BRIT J CANCER, V104, P1697, DOI 10.1038/bjc.2011.155; Hamidou Z, 2011, ONCOLOGIST, V16, P1458, DOI 10.1634/theoncologist.2011-0085; Hebbar M, 2015, ANN ONCOL, V26, P340, DOI 10.1093/annonc/mdu539; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kabbinavar FF, 2008, ONCOLOGIST, V13, P1021, DOI 10.1634/theoncologist.2008-0003; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVI F, 1992, CANCER, V69, P893, DOI 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Misiakos EP, 2011, WORLD J GASTROENTERO, V17, P4067, DOI 10.3748/wjg.v17.i36.4067; Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9; Osoba D, 1999, INT J CANCER, P132; Ramsey SD, 2002, AM J GASTROENTEROL, V97, P1228, DOI 10.1111/j.1572-0241.2002.05694.x; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; StataCorp, 2009, STAT STAT SOFTW REL; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Wei AC, 2006, ANN SURG ONCOL, V13, P668, DOI 10.1245/ASO.2006.05.039	27	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157067	10.1371/journal.pone.0157067	http://dx.doi.org/10.1371/journal.pone.0157067			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27310205	Green Published, gold, Green Submitted			2023-01-03	WOS:000378029800032
J	Comblain, F; Dubuc, JE; Lambert, C; Sanchez, C; Lesponne, I; Serisier, S; Henrotin, Y				Comblain, Fanny; Dubuc, Jean-Emile; Lambert, Cecile; Sanchez, Christelle; Lesponne, Isabelle; Serisier, Samuel; Henrotin, Yves			Identification of Targets of a New Nutritional Mixture for Osteoarthritis Management Composed by Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract	PLOS ONE			English	Article							CHONDROCYTE HYPERTROPHY; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; CELLS; MICE; INTERLEUKIN-1-BETA; ANGIOGENESIS; EXPRESSION; MMP-13; GENES	Objective We have previously demonstrated that a mixture of curcuminoids extract, hydrolyzed collagen and green tea extract (COT) inhibited inflammatory and catabolic mediator's synthesis by osteoarthritic human chondrocytes. The objective of this study was to identify new targets of COT using genomic and proteomic approaches. Design Cartilage specimens were obtained from 12 patients with knee osteoarthritis. Primary human chondrocytes were cultured in monolayer until confluence and then incubated for 24 or 48 hours in the absence or in the presence of human interleukin(IL)-1 beta (10(-11)M) and with or without COT, each compound at the concentration of 4 mu g/ml. Microarray gene expression profiling between control, COT, IL-1 beta and COT IL-1 beta conditions was performed. Immunoassays were used to confirm the effect of COT at the protein level. Results More than 4000 genes were differentially expressed between conditions. The key regulated pathways were related to inflammation, cartilage metabolism and angiogenesis. The IL-1 beta stimulated chemokine ligand 6, matrix metalloproteinase-beta, bone morphogenetic protein-2 and stanniocalcin1 gene expressions and protein productions were down-regulated by COT. COT significantly decreased stanniocalcin1 production in basal condition. Serpin E1 gene expression and protein production were down-regulated by IL-1 beta. COT reversed the inhibitory effect of IL-1 beta. Serpin E1 gene expression was up-regulated by COT in control condition. Conclusion The COT mixture has beneficial effect on osteoarthritis physiopathology by regulating the synthesis of key catabolic, inflammatory and angiogenesis factors. These findings give a scientific rationale for the use of these natural ingredients in the management of osteoarthritis.	[Comblain, Fanny; Lambert, Cecile; Sanchez, Christelle; Henrotin, Yves] Univ Liege, Arthropole Liege, Bone & Cartilage Res Unit, CHU Sart Tilman, Liege, Belgium; [Dubuc, Jean-Emile] Clin Univ St Luc, Dept Orthoped, B-1200 Brussels, Belgium; [Lesponne, Isabelle; Serisier, Samuel] Royal Canin Res Ctr, Aimargues, France; [Henrotin, Yves] Princess Paola Hosp, Phys Therapy & Rehabil Dept, Vivalia, Marche En Famen, Belgium	University of Liege; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Henrotin, Y (corresponding author), Univ Liege, Arthropole Liege, Bone & Cartilage Res Unit, CHU Sart Tilman, Liege, Belgium.; Henrotin, Y (corresponding author), Princess Paola Hosp, Phys Therapy & Rehabil Dept, Vivalia, Marche En Famen, Belgium.	yhenrotin@ulg.ac.be	Serisier, Samuel/AAI-4608-2020	Serisier, Samuel/0000-0002-5702-1350; Henrotin, Yves/0000-0003-1073-449X; sanchez, christelle/0000-0002-1005-8172	Royal Canin SAS	Royal Canin SAS	The research leading to these results was supported by a grant of Royal Canin SAS. Royal Canin SAS gave final approval of the version to be published. FC received her PhD fellow from Royal Canin SAS. IL and SS are employed by Royal Canin SAS. The funder revised the manuscript critically for important intellectual content. The funder gave final approval of the version to be published.	Carter GT, 2014, PHYS MED REH CLIN N, V25, P457, DOI 10.1016/j.pmr.2014.01.007; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Comblain F, 2015, J VET PHARM THER; Comblain F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121654; Davidson ENB, 2015, ANN RHEUM DIS, V74, P1257, DOI 10.1136/annrheumdis-2013-204528; De Ceuninck F, 2004, BIOCHEM BIOPH RES CO, V323, P960, DOI 10.1016/j.bbrc.2004.08.184; EFSA, 2005, EUROPEAN FOOD SAFETY, V174, P1; Hashimoto S, 2013, J BONE JOINT SURG AM, V95A, P1457, DOI 10.2106/JBJS.L.00497; He LF, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-39; Henrotin Y, 2011, OSTEOARTHR CARTILAGE, V19, P1, DOI 10.1016/j.joca.2010.10.017; Henrotin Y, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-56; Henrotin Y, 2014, MATURITAS, V78, P184, DOI 10.1016/j.maturitas.2014.04.015; Henrotin Y, 2014, THER ADV MUSCULOSKEL, V6, P20, DOI 10.1177/1759720X13514669; Henrotin Y, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0361-z; Hochberg MC, 2012, OSTEOARTHR CARTILAGE, V20, P1465, DOI 10.1016/j.joca.2012.07.022; Ko FC, 2016, J ORTHOP RES; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lambert C, 2013, ARTHRITIS RHEUM; Law AYS, 2013, MOL CELL ENDOCRINOL, V374, P73, DOI 10.1016/j.mce.2013.04.024; Leblanc KT, 2015, J CELL PHYSIOL, V230, P440, DOI 10.1002/jcp.24727; Li NG, 2011, CURR MED CHEM, V18, P977, DOI 10.2174/092986711794940905; Little CB, 2009, ARTHRITIS RHEUM-US, V60, P3723, DOI 10.1002/art.25002; Liu Y, 2015, MED SCI MONITOR, V21, P363, DOI 10.12659/MSM.892160; Madej W, 2014, OSTEOARTHR CARTILAGE, V22, P1018, DOI 10.1016/j.joca.2014.04.024; Marques-Rocha JL, 2015, FASEB J, V29, P3595, DOI 10.1096/fj.14-260323; Mathy-Hartert M, 2008, OSTEOARTHR CARTILAGE, V16, P756, DOI 10.1016/j.joca.2007.10.009; Mathy-Hartert M, 2009, INFLAMM RES, V58, P899, DOI 10.1007/s00011-009-0063-1; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Mobasheri A, 2012, INT J MOL SCI, V13, P4202, DOI 10.3390/ijms13044202; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; Ohara H, 2010, BIOSCI BIOTECH BIOCH, V74, P2096, DOI 10.1271/bbb.100193; Pecchi E, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4443; Pesesse L, 2014, OSTEOARTHR CARTILAGE, V22, P547, DOI 10.1016/j.joca.2014.01.010; Pesesse L, 2013, OSTEOARTHR CARTILAGE, V21, P1913, DOI 10.1016/j.joca.2013.08.018; Ramos YFM, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0528-x; Reynard LN, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.4; Sandell LJ, 2008, OSTEOARTHR CARTILAGE, V16, P1560, DOI 10.1016/j.joca.2008.04.027; Scaife S, 2004, RHEUMATOLOGY, V43, P1346, DOI 10.1093/rheumatology/keh347; Schadow S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053955; Sherwood J, 2014, ANN RHEUM DIS; Walrand S, 2008, J AGR FOOD CHEM, V56, P7790, DOI 10.1021/jf800691f; Wu JB, 2015, ARTERIOSCL THROM VAS, V35, P111, DOI 10.1161/ATVBAHA.114.304554; Wuyts A, 2003, LAB INVEST, V83, P23, DOI 10.1097/01.LAB.0000048719.53282.00; Xu J, 2014, IN VITRO CELL DEV BI; Yeung BHY, 2012, MOL CELL ENDOCRINOL, V349, P272, DOI 10.1016/j.mce.2011.11.007	46	16	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2016	11	6							e0156902	10.1371/journal.pone.0156902	http://dx.doi.org/10.1371/journal.pone.0156902			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TJ	27275599	gold, Green Submitted, Green Published			2023-01-03	WOS:000377561700047
J	Sun, LS; Li, GH; Miller, TLK; Salorio, C; Byrne, MW; Bellinger, DC; Ing, C; Park, R; Radcliffe, J; Hays, SR; DiMaggio, CJ; Cooper, TJ; Rauh, V; Maxwell, LG; Youn, A; McGowan, FX				Sun, Lena S.; Li, Guohua; Miller, Tonya L. K.; Salorio, Cynthia; Byrne, Mary W.; Bellinger, David C.; Ing, Caleb; Park, Raymond; Radcliffe, Jerilynn; Hays, Stephen R.; DiMaggio, Charles J.; Cooper, Timothy J.; Rauh, Virginia; Maxwell, Lynne G.; Youn, Ahrim; McGowan, Francis X.			Association Between a Single General Anesthesia Exposure Before Age 36 Months and Neurocognitive Outcomes in Later Childhood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACADEMIC-PERFORMANCE; CHILDREN; BRAIN; SURGERY; INFANCY; RISK; NEURODEVELOPMENT; NEUROTOXICITY; EPIDEMIOLOGY; DISORDERS	IMPORTANCE Exposure of young animals to commonly used anesthetics causes neurotoxicity including impaired neurocognitive function and abnormal behavior. The potential neurocognitive and behavioral effects of anesthesia exposure in young children are thus important to understand. OBJECTIVE To examine if a single anesthesia exposure in otherwise healthy young children was associated with impaired neurocognitive development and abnormal behavior in later childhood. DESIGN, SETTING, AND PARTICIPANTS Sibling-matched cohort study conducted between May 2009 and April 2015 at 4 university-based US pediatric tertiary care hospitals. The study cohort included sibling pairs within 36 months in age and currently 8 to 15 years old. The exposed siblings were healthy at surgery/anesthesia. Neurocognitive and behavior outcomes were prospectively assessed with retrospectively documented anesthesia exposure data. EXPOSURES A single exposure to general anesthesia during inguinal hernia surgery in the exposed sibling and no anesthesia exposure in the unexposed sibling, before age 36 months. MAIN OUTCOMES AND MEASURES The primary outcome was global cognitive function (IQ). Secondary outcomes included domain-specific neurocognitive functions and behavior. A detailed neuropsychological battery assessed IQ and domain-specific neurocognitive functions. Parents completed validated, standardized reports of behavior. RESULTS Among the 105 sibling pairs, the exposed siblings (mean age, 17.3 months at surgery/anesthesia; 9.5% female) and the unexposed siblings (44% female) had IQ testing at mean ages of 10.6 and 10.9 years, respectively. All exposed children received inhaled anesthetic agents, and anesthesia duration ranged from 20 to 240 minutes, with a median duration of 80 minutes. Mean IQ scores between exposed siblings (scores: full scale = 111; performance = 108; verbal = 111) and unexposed siblings (scores: full scale = 111; performance = 107; verbal = 111) were not statistically significantly different. Differences in mean IQ scores between sibling pairs were: full scale = -0.2 (95% CI, -2.6 to 2.9); performance = 0.5 (95% CI, -2.7 to 3.7); and verbal = -0.5 (95% CI, -3.2 to 2.2). No statistically significant differences in mean scores were found between sibling pairs in memory/learning, motor/processing speed, visuospatial function, attention, executive function, language, or behavior. CONCLUSIONS AND RELEVANCE Among healthy children with a single anesthesia exposure before age 36 months, compared with healthy siblings with no anesthesia exposure, there were no statistically significant differences in IQ scores in later childhood. Further study of repeated exposure, prolonged exposure, and vulnerable subgroups is needed.	[Sun, Lena S.; Ing, Caleb] Columbia Univ, Med Ctr, Morgan Stanley Childrens Hosp New York Presbyteri, 622 W 168th St,CH 4-440 N, New York, NY 10032 USA; [Li, Guohua; Rauh, Virginia; Youn, Ahrim] Columbia Univ, Mailman Sch Publ Hlth, 622 W 168th St,CH 4-440 N, New York, NY 10032 USA; [Li, Guohua; Byrne, Mary W.] Columbia Univ, Coll Phys & Surg, 622 W 168th St,CH 4-440 N, New York, NY 10032 USA; [Miller, Tonya L. K.; Bellinger, David C.; Park, Raymond] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA; [Salorio, Cynthia] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA; [Byrne, Mary W.] Columbia Univ, Sch Nursing, 622 W 168th St,CH 4-440 N, New York, NY 10032 USA; [Radcliffe, Jerilynn; Maxwell, Lynne G.; McGowan, Francis X.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA; [Hays, Stephen R.; Cooper, Timothy J.] Vanderbilt Univ, Med Ctr, Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN USA; [DiMaggio, Charles J.] NYU, Sch Med, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Columbia University; Columbia University; Harvard University; Boston Children's Hospital; Harvard Medical School; Johns Hopkins University; Kennedy Krieger Institute; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Vanderbilt University; New York University	Sun, LS (corresponding author), Columbia Univ, Med Ctr, 622 W 168th St,CH 4-440 N, New York, NY 10032 USA.	lss4@cumc.columbia.edu	zhou, hua/A-6862-2017	DiMaggio, Charles/0000-0003-2356-6659; Hays, Stephen/0000-0003-2166-8811	US Food and Drug Administration [HHSF223200810036C]; SmartTots grant; Columbia University; Vanderbilt University; Boston Children's Hospital; Children's Hospital of Philadelphia; National Center for Advancing Translational Sciences, NIH [UL1 TR000040];  [R34 HD060741]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255, R01HD084566] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R34HD060741] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000040] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL [R49CE002096] Funding Source: NIH RePORTER	US Food and Drug Administration; SmartTots grant; Columbia University; Vanderbilt University; Boston Children's Hospital; Children's Hospital of Philadelphia; National Center for Advancing Translational Sciences, NIH; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The study was supported by grant R34 HD060741 (to Dr Sun), US Food and Drug Administration contract HHSF223200810036C (to Dr Sun), a SmartTots grant (to Dr Sun), and intramural departmental funding from Columbia University (to Dr Sun), Vanderbilt University (to Dr Hays), Boston Children's Hospital (to Drs Miller and McGowan), and Children's Hospital of Philadelphia (to Drs Maxwell and McGowan). This study was also supported by the National Center for Advancing Translational Sciences, NIH, through grant UL1 TR000040.	Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; Backeljauw B, 2015, PEDIATRICS, V136, pE1, DOI 10.1542/peds.2014-3526; Bartels M, 2009, TWIN RES HUM GENET, V12, P246, DOI 10.1375/twin.12.3.246; Bellinger DC, 2012, ENVIRON HEALTH PERSP, V120, P501, DOI 10.1289/ehp.1104170; Bellinger DC, 2011, CIRCULATION, V124, P1361, DOI 10.1161/CIRCULATIONAHA.111.026963; BELLINGER DC, 1995, NEW ENGL J MED, V332, P549, DOI 10.1056/NEJM199503023320901; Block RI, 2012, ANESTHESIOLOGY, V117, P494, DOI 10.1097/ALN.0b013e3182644684; Bong CL, 2013, ANESTH ANALG, V117, P1419, DOI 10.1213/ANE.0b013e318299a7c2; Brooks BL, 2010, CHILD NEUROPSYCHOL, V16, P80, DOI 10.1080/09297040903146966; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Davidson AJ, 2016, LANCET, V387, P239, DOI 10.1016/S0140-6736(15)00608-X; DeFrances Carol J, 2007, Vital Health Stat 13, P1; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Hackman DA, 2010, NAT REV NEUROSCI, V11, P651, DOI 10.1038/nrn2897; Hansen TG, 2011, ANESTHESIOLOGY, V114, P1076, DOI 10.1097/ALN.0b013e31820e77a0; Harrison PL, 2003, TECHNICAL REPORT ADA; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Psaty BM, 2015, JAMA-J AM MED ASSOC, V313, P1515, DOI 10.1001/jama.2015.1149; Rabbitts JA, 2010, ANESTH ANALG, V111, P1011, DOI 10.1213/ANE.0b013e3181ee8479; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Ronfani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127052; Satomoto M, 2009, ANESTHESIOLOGY, V110, P628, DOI 10.1097/ALN.0b013e3181974fa2; SmartTots, 2015, CONS STAT US AN SED; Stratmann G, 2014, NEUROPSYCHOPHARMACOL, V39, P2275, DOI 10.1038/npp.2014.134; Sun LS, 2012, J NEUROSURG ANESTH, V24, P382, DOI 10.1097/ANA.0b013e31826a0371; Susser E, 2010, AM J EPIDEMIOL, V172, P537, DOI 10.1093/aje/kwq196; The R Foundation, R PROJECT STAT COMPU; Tzong KYS, 2012, J NEUROSURG ANESTH, V24, P391, DOI 10.1097/ANA.0b013e31826a0345; Wechsler D., 1999, WECHSLER ABBREVIATED; WEISS B, 1988, TRENDS PHARMACOL SCI, V9, P59, DOI 10.1016/0165-6147(88)90118-6; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d	37	454	475	6	76	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2016	315	21					2312	2320		10.1001/jama.2016.6967	http://dx.doi.org/10.1001/jama.2016.6967			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN6KO	27272582	Green Accepted, Bronze			2023-01-03	WOS:000377183100020
J	Fiore, LD; Lavori, PW				Fiore, Louis D.; Lavori, Philip W.			Integrating Randomized Comparative Effectiveness Research with Patient Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CLINICAL-TRIAL; INFORMED-CONSENT; POINT; ATTITUDES		[Fiore, Louis D.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Dept Vet Affairs, VA Cooperat Studies Program, Boston, MA USA; [Lavori, Philip W.] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Stanford University	Lavori, PW (corresponding author), Stanford Univ, Dept Hlth Res & Policy, HRP Redwood Bldg,259 Campus Dr, Stanford, CA 94305 USA.	lavori@stanford.edu						[Anonymous], 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18430; [Anonymous], 2015, ID REC PART HLTH RES; Cho MK, 2015, ANN INTERN MED, V162, P690, DOI 10.7326/M15-0166; D'Avolio L, 2012, J AM MED INFORM ASSN, V19, pE170, DOI 10.1136/amiajnl-2011-000623; Faden R, 2013, MED CARE, V51, pS53, DOI 10.1097/MLR.0b013e31829b1e4b; Fiore LD, 2011, CLIN TRIALS, V8, P183, DOI [10.1177/1740774510395635, 10.1177/1740774511398368]; Geogio M, 2006, J CLIN EPIDEMIOL, V59, P497, DOI 10.1016/j.jclinepi.2005.11.007; Noto MJ, 2015, JAMA-J AM MED ASSOC, V313, P369, DOI 10.1001/jama.2014.18400; Weir CR, 2014, CLIN TRIALS, V11, P292, DOI 10.1177/1740774514523848; Winhusen T, 2014, CONTEMP CLIN TRIALS, V39, P158, DOI 10.1016/j.cct.2014.08.009	10	74	74	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2016	374	22					2152	2158		10.1056/NEJMra1510057	http://dx.doi.org/10.1056/NEJMra1510057			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB2RP	27248620	Bronze			2023-01-03	WOS:000387209900008
J	Pan, L; Ren, LL; Chen, F; Feng, YQ; Luo, YQ				Pan, Long; Ren, Lili; Chen, Fang; Feng, Yuqian; Luo, Youqing			Antifeedant Activity of Ginkgo biloba Secondary Metabolites against Hyphantria cunea Larvae: Mechanisms and Applications	PLOS ONE			English	Article							SUSCEPTIBILITY; EXTRACTS; ENZYMES	Ginkgo biloba is a typical relic plant that rarely suffers from pest hazards. This study analyzed the pattern of G. biloba pest hazards in Beijing; tested the antifeedant activity of G. biloba extracts, including ginkgo flavonoids, ginkgolide, and bilobalide, against Hyphantria cunea larvae; determined the activities of glutathione transferase (GSTs), acetylcholinesterase (AChE), carboxylesterase (CarE) and mixed-functional oxidase (MFO), in larvae after feeding on these G. biloba secondary metabolites; and screened for effective botanical anti-feedants in the field. In this study, no indicators of insect infestation were found for any of the examined leaves of G. biloba; all tested secondary metabolites showed significant antifeedant activity and affected the activity of the four larval detoxifying enzymes. Ginkgolide had the highest antifeedant activity and the most significant effect on the detoxifying enzymes (P< 0.05). Spraying leaves with G. biloba extracts or ginkgolide both significantly repelled H. cunea larvae in the field (P< 0.05), although the former is more economical and practical. This study investigated the antifeedant activity of G. biloba secondary metabolites against H. cunea larvae, and the results provide new insights into the mechanism of G. biloba pest resistance. This study also developed new applications of G. biloba secondary metabolites for effective pest control.	[Pan, Long; Ren, Lili; Chen, Fang; Feng, Yuqian; Luo, Youqing] Beijing Forestry Univ, Minist Educ, Key Lab Silviculture & Conservat, Beijing 100083, Peoples R China	Beijing Forestry University	Luo, YQ (corresponding author), Beijing Forestry Univ, Minist Educ, Key Lab Silviculture & Conservat, Beijing 100083, Peoples R China.	Youqingluo@126.com			Special Project for Scientific Research of Forestry Commonweal Industry of National Forestry Bureau [201404401]	Special Project for Scientific Research of Forestry Commonweal Industry of National Forestry Bureau	This study was supported by Special Project for Scientific Research of Forestry Commonweal Industry of National Forestry Bureau (201404401).	Akhtar Y, 2004, J APPL ENTOMOL, V128, P32, DOI 10.1046/j.1439-0418.2003.00806.x; Batala E., 2009, International Journal of Sustainable Development and Planning, V4, P344, DOI 10.2495/SDP-V4-N4-345-356; [戴宇婷 Dai Yuting], 2012, [植物保护, Plant Protection], V38, P79; Dong Jun-Feng, 2002, Acta Entomologica Sinica, V45, P296; Fuentes-Contreras E, 2007, J ECON ENTOMOL, V100, P551, DOI 10.1603/0022-0493(2007)100[551:EOARAA]2.0.CO;2; Hu Xiao, 2011, Journal of Beijing Forestry University, V33, P151; Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146; Jimenez AA, 2013, REV COLOMB ENTOMOL, V39, P113; Kamila D, 2013, PLOS ONE, V8; Leng Ping-sheng, 2001, Journal of Plant Resources and Environment, V10, P15; Li J, 2009, J CHROMATOGR A, V1216, P8759, DOI 10.1016/j.chroma.2009.03.002; Li Ling, 2011, Shengtaixue Zazhi, V30, P53; Li Shui-Qing, 2005, Chinese Bulletin of Entomology, V42, P491; Liang HL, 2008, ACTA AGR JIANGXI, V20, P49; Mohanta TK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032822; Morimoto M, 2003, J AGR FOOD CHEM, V51, P389, DOI 10.1021/jf025627a; Namountougou M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048412; Pan Ya-Fei, 2006, Chinese Bulletin of Entomology, V43, P496; Peng Lu, 2010, Acta Entomologica Sinica, V53, P572; Prisila M, 2015, PLOS ONE, V10; Pszczolkowski MA, 2011, J AGR FOOD CHEM, V59, P10879, DOI 10.1021/jf202386c; Rong J., 2003, ENTOMOL KNOWLEDG, V40, P13; Silva AX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036366; So SS, 2012, ENTOMOL RES, V42, P158, DOI 10.1111/j.1748-5967.2012.00449.x; Tang RB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0049256, 10.1371/journal.pone.0045597]; van Beek TA, 2009, J CHROMATOGR A, V1216, P2002, DOI 10.1016/j.chroma.2009.01.013; Van Leeuwen T, 2005, PEST MANAG SCI, V61, P499, DOI 10.1002/ps.1001; Wang Chen-Zhu, 2007, Chinese Bulletin of Entomology, V44, P311; [王瑞龙 Wang Ruilong], 2012, [生态学报, Acta Ecologica Sinica], V32, P5191; Wei Hui, 2004, Yingyong Shengtai Xuebao, V15, P473; Xu D, 2009, J PEST SCI, V82, P195, DOI 10.1007/s10340-008-0239-4; Yang Zhong-Qi, 2007, Chinese Bulletin of Entomology, V44, P465; Yin Fei, 2013, Chinese Journal of Applied Entomology, V50, P1335, DOI 10.7679/j.issn.2095-1353.2013.183; Yuezhi Liao, 2012, Scientia Silvae Sinicae, V48, P99; Zhang YA, 2008, CN, Patent No. [CN 101228853 A, 101228853]; Zhang YL., 2008, HEBEI J FOREST ORCHA, V23, P70; Zhu L, 2000, CHINESE J ECOL, V19, P36	37	44	45	2	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2016	11	5							e0155682	10.1371/journal.pone.0155682	http://dx.doi.org/10.1371/journal.pone.0155682			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2FT	27214257	Green Published, Green Submitted, gold			2023-01-03	WOS:000376880200021
J	Dimopoulos, MA; Oriol, A; Nahi, H; San-Miguel, J; Bahlis, NJ; Usmani, SZ; Rabin, N; Orlowski, RZ; Komarnicki, M; Suzuki, K; Plesner, T; Yoon, SS; Ben Yehuda, D; Richardson, PG; Goldschmidt, H; Reece, D; Lisby, S; Khokhar, NZ; O'Rourke, L; Chiu, C; Qin, X; Guckert, M; Ahmadi, T; Moreau, P				Dimopoulos, M. A.; Oriol, A.; Nahi, H.; San-Miguel, J.; Bahlis, N. J.; Usmani, S. Z.; Rabin, N.; Orlowski, R. Z.; Komarnicki, M.; Suzuki, K.; Plesner, T.; Yoon, S. -S.; Ben Yehuda, D.; Richardson, P. G.; Goldschmidt, H.; Reece, D.; Lisby, S.; Khokhar, N. Z.; O'Rourke, L.; Chiu, C.; Qin, X.; Guckert, M.; Ahmadi, T.; Moreau, P.		POLLUX Investigators	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY DARATUMUMAB; OPEN-LABEL; INTERFERENCE; MONOTHERAPY; ELOTUZUMAB; SURVIVAL; CRITERIA; CD38	BACKGROUND Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS At a median follow-up of 13.5 months in a protocol-specified interim analysis, 169 events of disease progression or death were observed (in 53 of 286 patients [18.5%] in the daratumumab group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.37; 95% confidence interval [CI], 0.27 to 0.52; P<0.001 by stratified log-rank test). The Kaplan-Meier rate of progression-free survival at 12 months was 83.2% (95% CI, 78.3 to 87.2) in the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control group. A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%, P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%, P<0.001). In the daratumumab group, 22.4% of the patients had results below the threshold for minimal residual disease (1 tumor cell per 105 white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.	[Dimopoulos, M. A.] Univ Athens, Athens, Greece; [Oriol, A.] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Inst Catala Oncol, Barcelona, Spain; [San-Miguel, J.] Univ Navarra Clin, Inst Invest Sanitaria Navarra, Ctr Invest Med Aplicada, Pamplona, Spain; [Nahi, H.] Karolinska Inst, Stockholm, Sweden; [Nahi, H.] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden; [Bahlis, N. J.] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada; [Reece, D.] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada; [Usmani, S. Z.] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA; [Rabin, N.] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England; [Orlowski, R. Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; [Komarnicki, M.] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland; [Suzuki, K.] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan; [Plesner, T.] Vejle Hosp, Vejle, Denmark; [Plesner, T.] Univ Southern Denmark, Vejle, Denmark; [Lisby, S.] Genmab, Copenhagen, Denmark; [Yoon, S. -S.] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Ben Yehuda, D.] Hadassah Hebrew Univ Med Ctr, Dept Hematol, Jerusalem, Israel; [Richardson, P. G.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA; [Goldschmidt, H.] Univ Heidelberg Hosp, Heidelberg, Germany; [Goldschmidt, H.] German Canc Res Ctr, Heidelberg, Germany; [Khokhar, N. Z.; O'Rourke, L.; Chiu, C.; Qin, X.; Guckert, M.; Ahmadi, T.] Janssen Res & Dev, Spring House, PA USA; [Moreau, P.] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France	National & Kapodistrian University of Athens; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; Institut de Recerca Contra la Leucemia Josep Carreras (IJC); University of Navarra; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Tom Baker Cancer Clinic; University of Calgary; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Carolinas HealthCare System; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Texas System; UTMD Anderson Cancer Center; Poznan University of Medical Sciences; Japanese Red Cross Medical Center; University of Tokyo; University of Southern Denmark; Lillebaelt Hospital; University of Southern Denmark; Genmab; Seoul National University (SNU); Hebrew University of Jerusalem; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Johnson & Johnson; Janssen Pharmaceuticals; Nantes Universite; CHU de Nantes	Dimopoulos, MA (corresponding author), Univ Athens, Sch Med, Alexandra Hosp, 80 Vas Sofias, Athens 11528, Greece.	mdimop@med.uoa.gr	Goldschmidt, Hartmut/AAL-8069-2021; Hernandez-Rivas, Jose-Angel/ADF-6441-2022; Yoon, Sung-Soo/J-2773-2012; Dimopoulos, Meletios Athanasios/AAD-4130-2019; San-Miguel, Jesús F./V-8977-2018; Blimark, Cecilie Hveding/AAZ-6423-2021; , Van Eygen Koen/AAF-7668-2020; Usmani, Saad Z/HCI-4676-2022; Oriol, Albert/K-9923-2017; Usmani, Saad Z/H-2705-2012; nahi, hareth/AAA-3445-2020; Kim, Kihyun/D-5175-2013	Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; San-Miguel, Jesús F./0000-0002-9183-4857; Blimark, Cecilie Hveding/0000-0003-3297-6019; , Van Eygen Koen/0000-0001-8285-906X; Usmani, Saad Z/0000-0002-5484-8731; Oriol, Albert/0000-0001-6804-2221; Chiu, Christopher W./0000-0001-9744-991X; Orlowski, Robert/0000-0002-5723-4129; Dimopoulos, Meletios/0000-0001-8990-3254; Salomo, Morten/0000-0002-1660-1607; moreau, philippe/0000-0003-1780-8746; Cook, Gordon/0000-0003-1717-0412; Salwender, Hans/0000-0001-7803-0814; nahi, hareth/0000-0003-4711-5094; Ramasamy, Karthik/0000-0003-3385-3707; Kim, Kihyun/0000-0002-5878-8895	Janssen Research and Development; Janssen; Celgene; Amgen; Novartis; Millennium; Onyx; Bristol-Myers Squibb; Merck Sharp and Dohme; Skyline; Sanofi; Array BioPharma; Takeda Pharmaceutical; Pharmacyclics; Janssen-Cilag; BioTheryX; Forma Therapeutics; Incyte; Rigel Pharmaceuticals; Spectrum Pharmaceuticals; Chugai; Otsuka Pharmaceutical; Merck; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Janssen Research and Development; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Celgene(Bristol-Myers SquibbCelgene Corporation); Amgen(Amgen); Novartis(Novartis); Millennium(Takeda Pharmaceutical Company Ltd); Onyx; Bristol-Myers Squibb(Bristol-Myers Squibb); Merck Sharp and Dohme(Merck & Company); Skyline; Sanofi; Array BioPharma(Pfizer); Takeda Pharmaceutical(Takeda Pharmaceutical Company Ltd); Pharmacyclics; Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); BioTheryX; Forma Therapeutics; Incyte; Rigel Pharmaceuticals; Spectrum Pharmaceuticals; Chugai; Otsuka Pharmaceutical(Otsuka Pharmaceutical); Merck(Merck & Company); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Janssen Research and Development.; Dr. Dimopoulos reports receiving fees for serving on advisory boards from Janssen, Celgene, Amgen, and Novartis and grant support from Janssen; Dr. Oriol, receiving fees for serving on advisory boards from Celgene, Janssen, and Amgen; Dr. San-Miguel, receiving fees for serving on advisory boards from Celgene, Novartis, Janssen, Millennium, Onyx, Bristol-Myers Squibb, Merck Sharp and Dohme, and Amgen; Dr. Bahlis, receiving fees for serving on advisory boards, lecture fees, and grant support from Celgene, Janssen, and Amgen; Dr. Usmani, receiving fees for serving on advisory boards and committees from Celgene, Skyline, Sanofi, Janssen, Array BioPharma, and Bristol-Myers Squibb, consulting fees from Amgen (formerly Onyx) and Takeda Pharmaceutical (formerly Millennium), lecture fees from Celgene, Amgen, and Takeda Pharmaceutical, and grant support from Celgene, Amgen, Takeda Pharmaceutical, Sanofi, Janssen, Array BioPharma, Pharmacyclics, and Bristol-Myers Squibb; Dr. Rabin, receiving fees for serving on advisory boards from Bristol-Myers Squibb, Takeda Pharmaceutical, Novartis, and Amgen, lecture fees from Janssen-Cilag and Celgene, and travel support from Janssen-Cilag and Takeda Pharmaceutical; Dr. Orlowski, receiving fees for serving on advisory boards from BioTheryX, Forma Therapeutics, Bristol-Myers Squibb, Incyte, Rigel Pharmaceuticals, Amgen, and Takeda Pharmaceutical and grant support from Bristol-Myers Squibb, Amgen, Takeda Pharmaceutical, and Spectrum Pharmaceuticals; Dr. Plesner, receiving grants from Janssen and honoraria from Janssen and Genmab during the conduct of the trial; Dr. Richardson, receiving fees for serving on advisory boards from Celgene and Janssen; Dr. Goldschmidt, receiving fees for serving on advisory boards from Celgene, Janssen, Novartis, Bristol-Myers Squibb, Onyx, Amgen, and Takeda Pharmaceutical and research support to his institution from Celgene, Janssen, Novartis, Chugai, Bristol-Myers Squibb, and Millennium; Dr. Reece, receiving consulting fees from Janssen, Celgene, Takeda Pharmaceutical, Bristol-Myers Squibb, and Amgen, honoraria from Janssen, Celgene, Takeda Pharmaceutical, Bristol-Myers Squibb, Novartis, and Amgen, and research support from Janssen, Celgene, Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol-Myers Squibb, Merck, Novartis, and Amgen; Dr. Lisby, being an employee of Genmab; Dr. Khokhar, Ms. O'Rourke, Dr. Chiu, Mr. Qin, Ms. Guckert, and Dr. Ahmadi, being employees of Janssen; Ms. O'Rourke and Ms. Guckert, holding stock in Johnson & Johnson; and Dr. Moreau, receiving fees for serving on advisory boards and participating in symposia from Celgene, Novartis, Takeda Pharmaceutical, Amgen, and Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.	Chapuy CI, 2015, TRANSFUSION, V55, P1545, DOI 10.1111/trf.13069; Chari A, 2015, BLOOD, V126; de Weers M, 2011, J IMMUNOL, V186, P1840, DOI 10.4049/jimmunol.1003032; DeMets D L, 1995, Cancer Treat Res, V75, P1; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Durie BGM, 2015, LEUKEMIA, V29, P2416, DOI 10.1038/leu.2015.290; European Medicines Agency, 2016, EPAR SUMM PUBL DARZ; Krejcik J, 2016, BLOOD; Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Lammerts van Bueren J, 2014, 56 ANN M EXP AM SOC; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Laubach JP, 2015, CLIN CANCER RES, V21, P2660, DOI 10.1158/1078-0432.CCR-14-3190; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lonial S, 2014, LEUKEMIA, V28, P258, DOI 10.1038/leu.2013.220; Lonial S, 2016, LANCET, V387, P1551, DOI 10.1016/S0140-6736(15)01120-4; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; los MA, 2015, NEW ENGL J MED, V372, P142; Martinez-Lopez J, 2014, BLOOD, V123, P3073, DOI 10.1182/blood-2014-01-550020; McCudden C, 2016, CLIN CHEM LAB MED, V54, P1095, DOI 10.1515/cclm-2015-1031; McKeage K, 2016, DRUGS, V76, P275, DOI 10.1007/s40265-015-0536-1; Moreau P, 2016, NEW ENGL J MED, V374, P1621, DOI 10.1056/NEJMoa1516282; Moreau P, 2015, AM SOC CLIN ONCOL ED, V35, pe504, DOI DOI 10.14694/EDB00K_; Overdijk MB, 2016, J IMMUNOL, V197, P807, DOI 10.4049/jimmunol.1501351; Overdijk MB, 2015, MABS-AUSTIN, V7, P311, DOI 10.1080/19420862.2015.1007813; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Plesner T, 2016, BLOOD; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Richardson Paul G, 2007, J Natl Compr Canc Netw, V5, P149; Zonder JA, 2012, BLOOD, V120, P552, DOI 10.1182/blood-2011-06-360552	32	962	999	4	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2016	375	14					1319	1331		10.1056/NEJMoa1607751	http://dx.doi.org/10.1056/NEJMoa1607751			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DY3EZ	27705267	Green Published			2023-01-03	WOS:000384974900005
J	Kaspersen, KA; Dinh, KM; Erikstrup, LT; Burgdorf, KS; Pedersen, OB; Sorensen, E; Petersen, MS; Hjalgrim, H; Rostgaard, K; Nielsen, KR; Ullum, H; Erikstrup, C				Kaspersen, Kathrine Agergard; Dinh, Khoa Manh; Erikstrup, Lise Tornvig; Burgdorf, Kristoffer Solvsten; Pedersen, Ole Birger; Sorensen, Erik; Petersen, Mikkel Steen; Hjalgrim, Henrik; Rostgaard, Klaus; Nielsen, Kaspar Rene; Ullum, Henrik; Erikstrup, Christian			Low-Grade Inflammation Is Associated with Susceptibility to Infection in Healthy Men: Results from the Danish Blood Donor Study (DBDS)	PLOS ONE			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; INCREASED RISK; WOMEN; LIFE; DISTRIBUTIONS; PREDICTORS; QUALITY; MARKERS; OBESITY	Introduction The aim of this study was to examine whether low-grade inflammation (LGI) is associated with a subsequently increased risk of infection. Methods We included 15,754 healthy participants from the Danish Blood Donor Study, who completed a questionnaire on health-related items. LGI was defined as a C-reactive protein level between 3 and 10 mg/L. Infections were identified by ICD-10 codes in the Danish National Patient Register and ATC-codes in the Danish Prescription Register. Multivariable Cox proportional hazard analysis was used as the statistical model. Results During 53,302 person-years of observation, 571 participants were hospitalized for infection. Similarly, during 26,125 person-years of observation, 7,276 participants filled a prescription of antimicrobials. LGI was associated with increased risk of hospital-based treatment for infection only among men (hazard ratio = 1.60, 95% confidence interval (CI): 1.10-2.34) and specifically infections were abscesses and infections of the skin and subcutaneous tissue. Similarly, LGI was associated with the overall use of antimicrobials among men, and particularly with phenoxymethylpenicillin and broad-spectrum antimicrobials for treatment of urinary tract infections. The difference between men and women was not statistically significant. Conclusions In a large cohort of healthy individuals, LGI was associated with an increased risk of infection among healthy male blood donors.	[Kaspersen, Kathrine Agergard; Dinh, Khoa Manh; Petersen, Mikkel Steen; Erikstrup, Christian] Aarhus Univ Hosp, Dept Clin Immunol, Aarhus, Denmark; [Pedersen, Ole Birger] Naestved Hosp, Dept Clin Immunol, Naestved, Denmark; [Hjalgrim, Henrik; Rostgaard, Klaus] Statens Serum Inst, Dept Epidemiol Res, Copenhagen S, Denmark; [Erikstrup, Lise Tornvig] Aarhus Univ Hosp, Dept Clin Microbiol, Aarhus, Denmark; [Burgdorf, Kristoffer Solvsten; Sorensen, Erik; Ullum, Henrik] Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen S, Denmark; [Nielsen, Kaspar Rene] Aalborg Univ Hosp, Dept Clin Immunol, Aalborg, Denmark	Aarhus University; Naestved Hospital; Statens Serum Institut; Aarhus University; Rigshospitalet; University of Copenhagen; Aalborg University; Aalborg University Hospital	Kaspersen, KA (corresponding author), Aarhus Univ Hosp, Dept Clin Immunol, Aarhus, Denmark.	kathrinekaspersen@gmail.com	Pedersen, Ole Birger/W-8679-2019; Hjalgrim, Henrik/AAG-4973-2021	Pedersen, Ole Birger/0000-0003-2312-5976; Burgdorf, Kristoffer/0000-0001-5814-6844; Ullum, Henrik/0000-0001-7306-9058; Dinh, Khoa Manh/0000-0003-1881-5673; Kaspersen, Kathrine Agergard/0000-0002-7973-3623; Erikstrup, Christian/0000-0001-6551-6647; Rostgaard, Klaus/0000-0001-6220-9414	Lundbeckfonden; The Danish Council for Independent Research; Danish Administrative Regions; Bloddonorernes Forskningsfond; Fonden til Laegevidenskabens Fremme	Lundbeckfonden(Lundbeckfonden); The Danish Council for Independent Research; Danish Administrative Regions; Bloddonorernes Forskningsfond; Fonden til Laegevidenskabens Fremme	This study is funded by Lundbeckfonden, The Danish Council for Independent Research, The Danish Administrative Regions, Bloddonorernes Forskningsfond, and Fonden til Laegevidenskabens Fremme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831; Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206; Baik I, 2000, ARCH INTERN MED, V160, P3082, DOI 10.1001/archinte.160.20.3082; Cao Y, 2012, TUMOR BIOL, V33, P1039, DOI 10.1007/s13277-012-0337-z; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; de Ferranti S, 2002, CLIN CHIM ACTA, V317, P1, DOI 10.1016/S0009-8981(01)00797-5; Dinh KM, 2015, ATHEROSCLEROSIS, V242, P222, DOI 10.1016/j.atherosclerosis.2015.07.031; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Haffner SM, 2006, AM J CARDIOL, V97, p3A, DOI 10.1016/j.amjcard.2005.11.010; Hage FG, 2007, J AM COLL CARDIOL, V50, P1115, DOI 10.1016/j.jacc.2007.06.012; Imhof A, 2003, CLIN CHEM, V49, P669, DOI 10.1373/49.4.669; Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477; Kaspersen KA, 2015, EPIDEMIOLOGY, V26, P580, DOI 10.1097/EDE.0000000000000301; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kornum JB, 2010, EUR RESPIR J, V36, P1330, DOI 10.1183/09031936.00184209; Kotze SR, 2016, VOX SANG, V111, P144, DOI 10.1111/vox.12396; Kotze SR, 2015, TRANSFUSION, V55, P1303, DOI 10.1111/trf.13011; Kuikka LK, 2009, J AM MED DIR ASSOC, V10, P348, DOI 10.1016/j.jamda.2009.02.007; Laaksonen DE, 2004, DIABETOLOGIA, V47, P1403, DOI 10.1007/s00125-004-1472-x; Legouffe E, 1998, LEUKEMIA LYMPHOMA, V31, P351, DOI 10.3109/10428199809059228; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Mraz M, 2014, J ENDOCRINOL, V222, pR113, DOI 10.1530/JOE-14-0283; Muller LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587; Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P2423, DOI 10.1002/art.20431; Ording AG, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005082; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pfitzner T, 2008, ORTHOPADE, V37, P1116, DOI 10.1007/s00132-008-1342-1; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Rifai N, 2003, CLIN CHEM, V49, P666, DOI 10.1373/49.4.666; Rigas AS, 2015, TRANSFUSION, V55, P1752, DOI 10.1111/trf.13085; Rigas AS, 2014, TRANSFUSION, V54, P789, DOI 10.1111/trf.12518; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Sesso HD, 2003, JAMA-J AM MED ASSOC, V290, P2945, DOI 10.1001/jama.290.22.2945; Sorensen CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088196; Sun SY, 2012, ANNU REV NUTR, V32, P261, DOI 10.1146/annurev-nutr-071811-150623; Tsilidis KK, 2008, INT J CANCER, V123, P1133, DOI 10.1002/ijc.23606; Villegas R, 2012, NUTR METAB CARDIOVAS, V22, P223, DOI 10.1016/j.numecd.2010.07.007; World Health Organization, INT CLASS DIS; Zacho J, 2016, CLIN CHEM, V62, P335, DOI 10.1373/clinchem.2015.249680	40	21	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2016	11	10							e0164220	10.1371/journal.pone.0164220	http://dx.doi.org/10.1371/journal.pone.0164220			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UK	27701463	Green Published, gold, Green Submitted			2023-01-03	WOS:000385696900051
J	Yan, I; Bendavid, E; Korenromp, EL				Yan, Isabel; Bendavid, Eran; Korenromp, Eline L.			Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis	PLOS ONE			English	Article							ISONIAZID PREVENTIVE THERAPY; RIO-DE-JANEIRO; SOUTH-AFRICA; COTRIMOXAZOLE PROPHYLAXIS; POSITIVE ADULTS; HIV; SURVIVAL; TARGETS; DEATHS; TRENDS	Introduction Antiretroviral therapy (ART) reduces mortality in patients with active tuberculosis (TB), but the population-level relationship between ART coverage and TB mortality is untested. We estimated the reduction in population-level TB mortality that can be attributed to increasing ART coverage across 41 high HIV-TB burden countries. Methods We compiled TB mortality trends between 1996 and 2011 from two sources: (1) national program-reported TB death notifications, adjusted for annual TB case detection rates, and (2) WHO TB mortality estimates. National coverage with ART, as proportion of HIV-infected people in need, was obtained from UNAIDS. We applied panel linear regressions controlling for HIV prevalence (5-year lagged), coverage of TB interventions (estimated by WHO and UNAIDS), gross domestic product per capita, health spending from domestic sources, urbanization, and country fixed effects. Results Models suggest that that increasing ART coverage was followed by reduced TB mortality, across multiple specifications. For death notifications at 2 to 5 years following a given ART scale-up, a 1% increase in ART coverage predicted 0.95% faster mortality rate decline (p = 0.002); resulting in 27% fewer TB deaths in 2011 alone than would have occurred without ART. Based on WHO death estimates, a 1% increase in ART predicted a 1.0% reduced TB death rate (p<0.001), and 31% fewer deaths in 2011. TB mortality was higher at higher HIV prevalence (p<0.001), but not related to coverage of isoniazid preventive therapy, cotrimoxazole preventive therapy, or other covariates. Conclusion This econometric analysis supports a substantial impact of ART on population-level TB mortality realized already within the first decade of ART scale-up, that is apparent despite variable-quality mortality data.	[Yan, Isabel] City Univ Hong Kong, Dept Econ & Finance, Kowloon, Hong Kong, Peoples R China; [Bendavid, Eran] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA; [Bendavid, Eran] Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA; [Bendavid, Eran] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; [Korenromp, Eline L.] Univ Med Ctr, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Korenromp, Eline L.] Avenir Hlth, Geneva, Switzerland	City University of Hong Kong; Stanford University; Stanford University; Stanford University; Erasmus University Rotterdam; Erasmus MC	Korenromp, EL (corresponding author), Univ Med Ctr, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.; Korenromp, EL (corresponding author), Avenir Hlth, Geneva, Switzerland.	ekorenromp@AvenirHealth.org			National Institute for Drug Abuse [DA015612]; Doris Duke Charitable Foundation; National Natural Science Foundation [71403061]; Global Research Unit (GRU) at the City University of Hong Kong; NATIONAL INSTITUTE ON AGING [P30AG017253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015612, R37DA015612] Funding Source: NIH RePORTER	National Institute for Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Global Research Unit (GRU) at the City University of Hong Kong; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	EB was supported by the National Institute for Drug Abuse (DA015612) and by the Doris Duke Charitable Foundation. IY acknowledges support by the National Natural Science Foundation (project no. 71403061) and by the Global Research Unit (GRU) at the City University of Hong Kong. The funders of the study had no role in study design, data collection and analysis, data interpretation, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, GLOBAL TUBERCULOSIS; [Anonymous], 2011, INDICATOR AND MEASUR; Au-Yeung Christopher, 2011, Clin Epidemiol, V3, P21, DOI 10.2147/CLEP.S15574; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Bendavid E, 2012, JAMA-J AM MED ASSOC, V307, P2060, DOI 10.1001/jama.2012.2001; Bendavid E, 2009, ANN INTERN MED, V150, P688, DOI 10.7326/0003-4819-150-10-200905190-00117; Blok L, 2014, INT HEALTH, V6, P181, DOI 10.1093/inthealth/ihu055; Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413; Charalambous S, 2010, AIDS, V24, pS5, DOI 10.1097/01.aids.0000391010.02774.6f; Cohen T, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000296; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Creswell J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094465; Dieleman JL, 2013, JOURNAL OF DEVELOPME, P1; Dowdy DW, 2014, JAIDS-J ACQ IMM DEF, V66, P552, DOI 10.1097/QAI.0000000000000219; Duber HC, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-21; Durovni B, 2013, LANCET INFECT DIS, V13, P852, DOI 10.1016/S1473-3099(13)70187-7; Fazito E, 2012, SEX TRANSM INFECT, V88, pI86, DOI 10.1136/sextrans-2012-050632; Floyd S, 2012, TROP MED INT HEALTH, V17, pe84, DOI 10.1111/j.1365-3156.2012.03032.x; Floyd S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013499; Glaziou P, 2011, B WORLD HEALTH ORGAN, V89, P573, DOI [10.2471/BLT.11.087510, DOI 10.2471/BLT.11.O87510]; Glaziou P, 2016, EPRINT ARXIV 2016 16; Glaziou P, 2011, B WORLD HEALTH ORGAN, V89, P573, DOI 10.2471/BLT.11.087510; Harries AD, 2015, LANCET INFECT DIS, V15, P1492, DOI 10.1016/S1473-3099(15)00242-X; Kabali C, 2011, INT J TUBERC LUNG D, V15, P1515, DOI 10.5588/ijtld.10.0788; Kasamba I, 2012, TROP MED INT HEALTH, V17, pe66, DOI 10.1111/j.1365-3156.2012.02841.x; Korenromp EL, 2009, INT J TUBERC LUNG D, V13, P283; Korenromp EL, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-18; Korenromp EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038816; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Maher D, 2005, INT J TUBERC LUNG D, V9, P123; Manosuthi W, 2006, JAIDS-J ACQ IMM DEF, V43, P42, DOI 10.1097/01.qai.0000230521.86964.86; Nunn AJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a257; Organisation for Economic Co-operation and Development, 2014, DEVELOPMENT ASSISTAN; Pretorius C, 2014, AIDS, V28, pS25, DOI 10.1097/QAD.0000000000000085; Samandari T, 2011, LANCET, V377, P1588, DOI 10.1016/S0140-6736(11)60204-3; Stoneburner R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100431; Suthar AB, 2015, LANCET HIV, V2, pE137, DOI 10.1016/S2352-3018(15)00005-3; The Global Fund to Fight AIDS Tuberculosis and Malaria, 2011, THE GLOBAL FUND RESU; UNAIDS, 2014, FAST TRACK ENDING TH; UNAIDS, 2013, REPORT ON THE GLOBAL; Uyei J, 2011, LANCET INFECT DIS, V11, P855, DOI 10.1016/S1473-3099(11)70145-1; van der Werf MJ, 2007, B WORLD HEALTH ORGAN, V85, P370, DOI 10.2471/BLT.06.039941; Vapattanawong P, 2011, B WORLD HEALTH ORGAN, V89, P806, DOI 10.2471/BLT.10.083931; Watera C, 2006, JAIDS-J ACQ IMM DEF, V42, P373, DOI 10.1097/01.qai.0000221679.14445.1b; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2013, CONSOLIDATED GUIDELI; Williams BG, 2010, P NATL ACAD SCI USA, V107, P19485, DOI [10.1073.pnas.1005660107, DOI 10.1073/PANS.1005660107]; Williams BG, 2011, TUBERCULOSIS AMONG P; World Health Organization, 2013, CARTOGRAPHER GLOBAL, P104; World Health Organization, 2011, STOP TB PARTNERSHIP; Yan I, 2014, TUBERCULOSIS AND MAL; Yassin MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063174	52	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2016	11	8							e0160481	10.1371/journal.pone.0160481	http://dx.doi.org/10.1371/journal.pone.0160481			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT6ES	27536864	Green Published, Green Submitted, gold			2023-01-03	WOS:000381577000021
J	Aljohi, A; Matou-Nasri, S; Ahmed, N				Aljohi, Ali; Matou-Nasri, Sabine; Ahmed, Nessar			Antiglycation and Antioxidant Properties of Momordica charantia	PLOS ONE			English	Article							GLYCATION; EXTRACTS; PRODUCTS; PULP	The accumulation of advanced glycation endproducts (AGEs) and oxidative stress underlie the pathogenesis of diabetic complications. In many developing countries, diabetes treatment is unaffordable, and plants such as bitter gourd (or bitter melon; Momordica charantia) are used as traditional remedies because they exhibit hypoglycaemic properties. This study compared the antiglycation and antioxidant properties of aqueous extracts of M. charantia pulp (MCP), flesh (MCF) and charantin in vitro. Lysozyme was mixed with methylglyoxal and 0-15 mg/ml of M. charantia extracts in a pH 7.4 buffer and incubated at 37 degrees C for 3 days. Crosslinked AGEs were assessed using gel electrophoresis, and the carboxymethyllysine (CML) content was analyzed by enzyme-linked immunosorbent assays. The antioxidant activities of the extracts were evaluated using assays to assess DPPH (1,1-diphenyl-2picryl- hydrazyl) and hydroxyl radical scavenging activities, metal-chelating activity and reducing power of the extracts. The phenolic, flavonol and flavonoid content of the extracts were also determined. All extracts inhibited the formation of crosslinked AGEs and CML in a dose-dependent manner, with MCF being the most potent. The antioxidant activity of MCF was higher than that of MCP, but MCP showed the highest metal-chelating activity. MCF had the highest phenolic and flavonoid contents, whereas MCP had the highest flavonol content. M. charantia has hypoglycaemic effects, but this study shows that M. charantia extracts are also capable of preventing AGE formation in vitro. This activity may be due to the antioxidant properties, particularly the total phenolic content of the extracts. Thus, the use of M. charantia deserves more attention, as it may not only reduce hyperglycaemia but also protect against the build-up of tissue AGEs and reduce oxidative stress in patients with diabetes.	[Aljohi, Ali; Ahmed, Nessar] Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester, Lancs, England; [Matou-Nasri, Sabine] King Saud Bin Abdulaziz Univ Hlth Sci, Med Genom Res Dept, Minist Natl Guard Hlth Affairs, King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia	Manchester Metropolitan University; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); Ministry of National Guard - Health Affairs	Ahmed, N (corresponding author), Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester, Lancs, England.	N.Ahmed@mmu.ac.uk						Muhammad SA, 2007, EUR J PHARMACOL, V561, P32, DOI 10.1016/j.ejphar.2007.01.041; Ahmed I, 2001, DIABETES RES CLIN PR, V51, P155, DOI 10.1016/S0168-8227(00)00224-2; Ahmed N, 2005, DIABETES RES CLIN PR, V67, P3, DOI 10.1016/j.diabres.2004.09.004; Baby Joseph, 2013, Asian Pacific Journal of Tropical Disease, V3, P93, DOI 10.1016/S2222-1808(13)60052-3; Boo HO, 2012, IND CROP PROD, V40, P129, DOI 10.1016/j.indcrop.2012.02.042; Bucala R, 2014, J CLIN INVEST, V124, P1887, DOI 10.1172/JCI75224; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Elosta A, 2012, CURR DIABETES REV, V8, P92, DOI 10.2174/157339912799424528; Fernandes Nafisa P C, 2007, BMC Complement Altern Med, V7, P29, DOI 10.1186/1472-6882-7-29; Fujiwara Y, 2011, FREE RADICAL BIO MED, V50, P883, DOI 10.1016/j.freeradbiomed.2010.12.033; Ghous T, 2015, PAK J PHARM SCI, V28, P1217; Gogi MD, 2010, CROP PROT, V29, P884, DOI 10.1016/j.cropro.2010.03.014; Hsieh CL, 2005, J ETHNOPHARMACOL, V102, P357, DOI 10.1016/j.jep.2005.06.044; Kamata Katsuo, 2009, J Smooth Muscle Res, V45, P125; Keter LK, 2012, J ETHNOPHARMACOL, V139, P74, DOI 10.1016/j.jep.2011.10.014; Kislinger T, 2004, CURR MED CHEM, V11, P2185, DOI 10.2174/0929867043364649; Kubola J, 2008, FOOD CHEM, V110, P881, DOI 10.1016/j.foodchem.2008.02.076; Kuong Y, 2009, J MED PLANTS RES, V3, P894; Loizzo MR, 2012, J FOOD COMPOS ANAL, V25, P179, DOI 10.1016/j.jfca.2011.09.002; Mashilipa C, 2011, J MED FOOD, V14, P1647, DOI 10.1089/jmf.2011.0054; Miliauskas G, 2004, FOOD CHEM, V85, P231, DOI 10.1016/j.foodchem.2003.05.007; Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; Samak G, 2009, FOOD CHEM, V115, P631, DOI 10.1016/j.foodchem.2008.12.078; Sell DR, 2012, GERONTOLOGY, V58, P227, DOI 10.1159/000334668; Shan B, 2012, FOOD BIOPROD PROCESS, V90, P579, DOI 10.1016/j.fbp.2011.09.004; Singh Jaipaul, 2011, Open Med Chem J, V5, P70, DOI 10.2174/1874104501105010070; Srikanth V, 2011, NEUROBIOL AGING, V32, P763, DOI 10.1016/j.neurobiolaging.2009.04.016; Styskal J, 2012, FREE RADICAL BIO MED, V52, P46, DOI 10.1016/j.freeradbiomed.2011.10.441; Tang SY, 2004, FREE RADICAL BIO MED, V36, P1575, DOI 10.1016/j.freeradbiomed.2004.03.017; Trakoon-osot W., 2013, Journal of Pharmacy Research, V6, P859, DOI 10.1016/j.jopr.2013.08.007; Tsai SY, 2006, FOOD CHEM, V98, P670, DOI 10.1016/j.foodchem.2005.07.003; Tsuji-Naito K, 2009, FOOD CHEM, V116, P854, DOI 10.1016/j.foodchem.2009.03.042; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Virdi J, 2003, J ETHNOPHARMACOL, V88, P107, DOI 10.1016/S0378-8741(03)00184-3; Waheed Akbar, 2006, Pak J Pharm Sci, V19, P322	36	31	35	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2016	11	8							e0159985	10.1371/journal.pone.0159985	http://dx.doi.org/10.1371/journal.pone.0159985			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3KY	27513747	gold, Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000381381100022
J	Liyanage, T; Ninomiya, T; Wang, A; Neal, B; Jun, M; Wong, MG; Jardine, M; Hillis, GS; Perkovic, V				Liyanage, Thaminda; Ninomiya, Toshiharu; Wang, Amanda; Neal, Bruce; Jun, Min; Wong, Muh Geot; Jardine, Meg; Hillis, Graham S.; Perkovic, Vlado			Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							DISEASE; RISK; ADHERENCE; PREVENTION; HEALTH; MEN	Background A Mediterranean dietary pattern is widely recommended for the prevention of chronic disease. We sought to define the most likely effects of the Mediterranean diet on vascular disease and mortality. Methods We searched MEDLINE, EMBASE and the Cochrane Central Register without language restriction for randomized controlled trials comparing Mediterranean to control diets. Data on study design, patient characteristics, interventions, follow-up duration, outcomes and adverse events were sought. Individual study relative risks (RR) were pooled to create summary estimates. Results Six studies with a total of 10950 participants were included. Effects on major vascular events (n = 477), death (n = 693) and vascular deaths (n = 315) were reported for 3, 5 and 4 studies respectively. For one large study (n = 1000) there were serious concerns about the integrity of the data. When data for all studies were combined there was evidence of protection against major vascular events (RR 0.63, 95% confidence interval 0.53-0.75), coronary events (0.65, 0.50-0.85), stroke (0.65, 0.48-0.88) and heart failure (0.30, 0.17-0.56) but not for all-cause mortality (1.00, 0.86-1.15) or cardiovascular mortality (0.90, 0.72-1.11). After the study of concern was excluded the benefit for vascular events (0.69, 0.55-0.86) and stroke (0.66, 0.48-0.92) persisted but apparently positive findings for coronary events (0.73, 0.51-1.05) and heart failure (0.25, 0.05-1.17) disappeared. Conclusion The Mediterranean diet may protect against vascular disease. However, both the quantity and quality of the available evidence is limited and highly variable. Results must be interpreted with caution.	[Liyanage, Thaminda; Ninomiya, Toshiharu; Wang, Amanda; Neal, Bruce; Jun, Min; Wong, Muh Geot; Jardine, Meg; Hillis, Graham S.; Perkovic, Vlado] Univ Sydney, Sydney Med Sch, George Inst Global Hlth, POB M201,Missenden Rd, Sydney, NSW 2050, Australia; [Liyanage, Thaminda; Wong, Muh Geot] Armadale Kelmscott Mem Hosp, South Metropolitan Hlth Serv, Armadale, WA 6112, Australia; [Jun, Min] Univ Calgary, Dept Med, Div Nephrol, Calgary, AB, Canada; [Jardine, Meg] Concord Repatriat Gen Hosp, Hosp Rd, Sydney, NSW 2139, Australia	George Institute for Global Health; University of Sydney; University of Calgary; Concord Repatriation General Hospital	Ninomiya, T (corresponding author), Univ Sydney, Sydney Med Sch, George Inst Global Hlth, POB M201,Missenden Rd, Sydney, NSW 2050, Australia.	tninomiya@georgeinstitute.org.au	Jardine, Meg/AAS-1864-2020; Jardine, Meg/AFR-1699-2022; Perkovic, Vlado/AAY-1933-2021	Jardine, Meg/0000-0002-0160-2375; Jardine, Meg/0000-0002-0160-2375; Jun, Min/0000-0003-1460-7535; Wang, Ying/0000-0001-9753-6888; Wang, Ying/0000-0002-0367-6677; Neal, Bruce/0000-0002-0490-7465	Australian Postgraduate Award; National Health and Medical Research Council of Australia (NHMRC); Canadian Institutes of Health Research; Alberta Innovates Health Solutions; NHMRC; Australian Research Council; National Heart Foundation; National Health and Medical Research Council (NHMRC) of Australia	Australian Postgraduate Award(Australian Government); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Innovates Health Solutions; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); National Heart Foundation(National Heart Foundation of Australia); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Thaminda Liyanage was supported by an Australian Postgraduate Award and Vlado Perkovic was supported by a National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship. Min Jun was supported by postdoctoral fellowships from the Canadian Institutes of Health Research and Alberta Innovates Health Solutions, and an NHMRC early career fellowship. Bruce Neal was supported by an Australian Research Council Future Fellowship and a NHMRC senior research fellowship. Meg Jardine was supported by a Career Development Fellowship from the NHMRC and the National Heart Foundation. This study was supported by the National Health and Medical Research Council (NHMRC) of Australia Program Grant. However, the funding body had no role in study design, data collection and analysis, interpretation or manuscript preparation.	Buckland G, 2008, OBES REV, V9, P582, DOI 10.1111/j.1467-789X.2008.00503.x; Buckland G, 2009, AM J EPIDEMIOL, V170, P1518, DOI 10.1093/aje/kwp282; Burr ML, 2003, EUR J CLIN NUTR, V57, P193, DOI 10.1038/sj.ejcn.1601539; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Eckel RH, 2014, J AM COLL CARDIOL, V63, P2960, DOI 10.1016/j.jacc.2013.11.003; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Germano G, 2012, EUR HEART J, V33, P137; Grosso G, 2014, CRIT REV FOOD SCI, V54, P593, DOI 10.1080/10408398.2011.596955; Higgins J., 2011, COCHRANE HDB SYST RE; Horton R, 2005, LANCET, V366, P354, DOI 10.1016/S0140-6736(05)67006-7; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Martinez-Gonzalez MA, 2008, BMJ-BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE; Myung SK, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f10; Ng GWB, 2011, SEX HEALTH, V8, P43, DOI 10.1071/SH09065; Nordmann AJ, 2011, AM J MED, V124, P841, DOI 10.1016/j.amjmed.2011.04.024; Paraskevi Detopoulou, 2013, HELLENIC J NUTR DIET, V4, P27; Polonsky WH, 2000, DIABETES SPECTRUM, V13, P36; Psaltopoulou T, 2004, AM J CLIN NUTR, V80, P1012, DOI 10.1093/ajcn/80.4.1012; Psaltopoulou T, 2013, ANN NEUROL, V74, P580, DOI 10.1002/ana.23944; Reddy KS, 1998, CIRCULATION, V97, P596; Rees K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub2; Rumawas ME, 2009, AM J CLIN NUTR, V90, P1608, DOI 10.3945/ajcn.2009.27908; Schwingshackl L, 2014, NUTR METAB CARDIOVAS, V24, P929, DOI 10.1016/j.numecd.2014.03.003; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Toobert DJ, 2003, DIABETES CARE, V26, P2288, DOI 10.2337/diacare.26.8.2288; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; WHO, 2011, CARDIOVASCULAR DIS; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S	33	98	101	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2016	11	8							e0159252	10.1371/journal.pone.0159252	http://dx.doi.org/10.1371/journal.pone.0159252			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3KR	27509006	Green Published, Green Submitted, gold			2023-01-03	WOS:000381380400006
J	Tap, WD; Jones, RL; Van Tine, BA; Chmielowski, B; Elias, AD; Adkins, D; Agulnik, M; Cooney, MM; Livingston, MB; Pennock, G; Hameed, MR; Shah, GD; Qin, A; Shahir, A; Cronier, DM; Ilaria, R; Conti, O; Cosaert, J; Schwartz, GK				Tap, William D.; Jones, Robin L.; Van Tine, Brian A.; Chmielowski, Bartosz; Elias, Anthony D.; Adkins, Douglas; Agulnik, Mark; Cooney, Matthew M.; Livingston, Michael B.; Pennock, Gregory; Hameed, Meera R.; Shah, Gaurav D.; Qin, Amy; Shahir, Ashwin; Cronier, Damien M.; Ilaria, Robert, Jr.; Conti, Ilaria; Cosaert, Jan; Schwartz, Gary K.			Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial	LANCET			English	Article							INTENSIFIED DOXORUBICIN; EUROPEAN-ORGANIZATION; 1ST-LINE TREATMENT; DOSE DOXORUBICIN; PLUS IFOSFAMIDE; GROWTH-FACTOR; III TRIAL; PDGF; STANDARD	Background Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 months, but few, if any, novel treatments or chemotherapy combinations have been able to improve these poor outcomes. Olaratumab is a human antiplatelet-derived growth factor receptor a monoclonal antibody that has antitumour activity in human sarcoma xenografts. We aimed to assess the efficacy of olaratumab plus doxorubicin in patients with advanced or metastatic soft-tissue sarcoma. Methods We did an open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA. For both the phase 1b and phase 2 parts of the study, eligible patients were aged 18 years or older and had a histologically confirmed diagnosis of locally advanced or metastatic soft-tissue sarcoma not previously treated with an anthracycline, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and available tumour tissue to determine PDGFR alpha expression by immunohistochemistry. In the phase 2 part of the study, patients were randomly assigned in a 1:1 ratio to receive either olaratumab (15 mg/kg) intravenously on day 1 and day 8 plus doxorubicin (75 mg/m(2)) or doxorubicin alone (75 mg/m(2)) on day 1 of each 21-day cycle for up to eight cycles. Randomisation was dynamic and used the minimisation randomisation technique. The phase 1b primary endpoint was safety and the phase 2 primary endpoint was progression-free survival using a two-sided a level of 0.2 and statistical power of 0.8. This study was registered with ClinicalTrials.gov, number NCT01185964. Findings 15 patients were enrolled and treated with olaratumab plus doxorubicin in the phase 1b study, and 133 patients were randomised (66 to olaratumab plus doxorubicin; 67 to doxorubicin alone) in the phase 2 trial, 129 (97%) of whom received at least one dose of study treatment (64 received olaratumab plus doxorubicin, 65 received doxorubicin). Median progression-free survival in phase 2 was 6.6 months (95% CI 4.1-8.3) with olaratumab plus doxorubicin and 4.1 months (2.8-5.4) with doxorubicin (stratified hazard ratio [HR] 0.67; 0.44-1.02, p = 0.0615). Median overall survival was 26.5 months (20.9-31.7) with olaratumab plus doxorubicin and 14.7 months (9.2-17.1) with doxorubicin (stratified HR 0.46, 0.30-0.71, p = 0.0003). The objective response rate was 18.2% (9.8-29.6) with olaratumab plus doxorubicin and 11.9% (5.3-22.2) with doxorubicin (p = 0.3421). Steady state olaratumab serum concentrations were reached during cycle 3 with mean maximum and trough concentrations ranging from 419 mu g/mL (geometric coefficient of variation in percentage [CV%] 26.2) to 487 mu g/mL (CV% 33.0) and from 123 mu g/mL (CV% 31.2) to 156 mu g/mL (CV% 38.0), respectively. Adverse events that were more frequent with olaratumab plus doxorubicin versus doxorubicin alone included neutropenia (37 [58%] vs 23 [35%]), mucositis (34 [53%] vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [18%]), and diarrhoea (22 [34%] vs 15 [23%]). Febrile neutropenia of grade 3 or higher was similar in both groups (olaratumab plus doxorubicin: eight [13%] of 64 patients vs doxorubicin: nine [14%] of 65 patients). Interpretation This study of olaratumab with doxorubicin in patients with advanced soft-tissue sarcoma met its predefined primary endpoint for progression-free survival and achieved a highly significant improvement of 11.8 months in median overall survival, suggesting a potential shift in the treatment of soft-tissue sarcoma.	[Tap, William D.; Hameed, Meera R.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Tap, William D.] Weill Cornell Med Coll, New York, NY USA; [Jones, Robin L.] Univ Washington, Seattle, WA 98195 USA; [Jones, Robin L.] Royal Marsden Hosp, London, England; [Van Tine, Brian A.; Adkins, Douglas] Washington Univ, St Louis, MO USA; [Chmielowski, Bartosz] Univ Calif Los Angeles, Med Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Elias, Anthony D.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Agulnik, Mark] Northwestern Univ, Chicago, IL 60611 USA; [Cooney, Matthew M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Div Hematol & Oncol, Cleveland, OH USA; [Livingston, Michael B.] Charlotte Mecklenburg Hosp Author, Carolinas Healthcare Syst, Charlotte, NC USA; [Pennock, Gregory] Baptist MD Anderson Canc Ctr, Jacksonville, FL USA; [Shah, Gaurav D.] Novartis Pharmaceut, E Hanover, NJ USA; [Qin, Amy; Cosaert, Jan] Eli Lilly & Co, Bridgewater, NJ USA; [Shahir, Ashwin; Cronier, Damien M.] Eli Lilly & Co, Windlesham, Surrey, England; [Ilaria, Robert, Jr.; Conti, Ilaria] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; [Schwartz, Gary K.] Columbia Univ, Sch Med, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University; University of Washington; University of Washington Seattle; Royal Marsden NHS Foundation Trust; Washington University (WUSTL); UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Northwestern University; Case Western Reserve University; Case Western Reserve University Hospital; Carolinas HealthCare System; University of Texas System; UTMD Anderson Cancer Center; Novartis; Eli Lilly; Eli Lilly; Eli Lilly; Columbia University	Tap, WD (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.	tapw@mskcc.org; tapw@mskcc.org	Jones, Robin L/AAO-3738-2020; van+Tine, Brain/AAI-1919-2019	Jones, Robin L/0000-0003-4173-3844; 	Eli Lilly and Company; NATIONAL CANCER INSTITUTE [P50CA140146, P30CA008748] Funding Source: NIH RePORTER	Eli Lilly and Company(Eli Lilly); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Eli Lilly and Company.	Bramwell V H, 2000, Sarcoma, V4, P103, DOI 10.1080/13577140020008066; Bui-Nguyen B, 2012, ANN ONCOL, V23, P777, DOI 10.1093/annonc/mdr282; Chawla SP, 2015, JAMA ONCOL, V9, P1; Chen CY, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.131250; D'Angelo S. P., 2014, Sarcoma, V2014, P391967, DOI 10.1155/2014/391967; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fayette J, 2009, INVEST NEW DRUG, V27, P482, DOI 10.1007/s10637-008-9217-1; Judson I, 2014, LANCET ONCOL, V15, P415, DOI 10.1016/S1470-2045(14)70063-4; Le Cesne A, 2000, J CLIN ONCOL, V18, P2676, DOI 10.1200/JCO.2000.18.14.2676; Loizos N, 2005, MOL CANCER THER, V4, P369; Lorigan P, 2007, J CLIN ONCOL, V25, P3144, DOI 10.1200/JCO.2006.09.7717; Movva S, 2015, ONCOTARGET, V6, P12234, DOI 10.18632/oncotarget.3498; Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood-2007-07-103697; O'Sullivan Brian, 2003, Surg Oncol Clin N Am, V12, P333, DOI 10.1016/S1055-3207(03)00011-5; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Paulsson J, 2014, FUTURE ONCOL, V10, P1695, DOI [10.2217/fon.14.83, 10.2217/FON.14.83]; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Riedel RF, 2012, CANCER-AM CANCER SOC, V118, P1474, DOI 10.1002/cncr.26415; Ryan CW, 2013, EUR J CANCER, V49, pS876; Sharma S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-385; Singer S, 2000, Lancet Oncol, V1, P75, DOI 10.1016/S1470-2045(00)00016-4; Tonra J, 2005, AACR NCI EORTC MOL T, pA67	22	401	421	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	2016	388	10043					488	497		10.1016/S0140-6736(16)30587-6	http://dx.doi.org/10.1016/S0140-6736(16)30587-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS2EK	27291997	Green Accepted			2023-01-03	WOS:000380559400028
J	Vieira, WF; Kenzo-Kagawa, B; Cogo, JC; Baranauskas, V; da Cruz-Hofling, MA				Vieira, Willians Fernando; Kenzo-Kagawa, Bruno; Cogo, Jose Carlos; Baranauskas, Vitor; da Cruz-Hofling, Maria Alice			Low-Level Laser Therapy (904 nm) Counteracts Motor Deficit of Mice Hind Limb following Skeletal Muscle Injury Caused by Snakebite-Mimicking Intramuscular Venom Injection	PLOS ONE			English	Article							RAT SCIATIC-NERVE; CELL-PROLIFERATION; BOTHROPS-JARARACA; CATWALK METHOD; GAIT ANALYSIS; SAO-PAULO; IRRADIATION; PAIN; REGENERATION; LOCOMOTION	Myotoxins present in Bothrops venom disrupt the sarcolemma of muscle fibers leading to the release of sarcoplasmic proteins and loss of muscle homeostasis. Myonecrosis and tissue anoxia induced by vascularization impairment can lead to amputation or motor functional deficit. The objective of this study was to investigate the dynamic behavior of motor function in mice subjected to injection of Bothrops jararacussu venom (Bjssu) and exposed to low-level laser therapy (LLLT). Male Swiss mice received Bjssu injection (830 mu g/kg) into the medial portion of the right gastrocnemius muscle. Three hours later the injected region was irradiated with diode semiconductor Gallium Arsenide (GaAs-904 nm, 4 J/cm(2)) laser following by irradiation at 24, 48 and 72 hours. Saline injection (0.9% NaCl) was used as control. Gait analysis was performed 24 hours before Bjssu injection and at every period post-Bjssu using CatWalk method. Data from spatiotemporal parameters Stand, Maximum Intensity, Swing, Swing Speed, Stride Length and Step Cycle were considered. The period of 3 hours post venom-induced injury was considered critical for all parameters evaluated in the right hindlimb. Differences (p<0.05) were concentrated in venom and venom + placebo laser groups during the 3 hours post-injury period, in which the values of stand of most animals were null. After this period, the gait characteristics were re-established for all parameters. The venom + laser group kept the values at 3 hours post-Bjssu equal to that at 24 hours before Bjssu injection indicating that the GaAs laser therapy improved spatially and temporally gait parameters at the critical injury period caused by Bjssu. This is the first study to analyze with cutting edge technology the gait functional deficits caused by snake envenoming and gait gains produced by GaAs laser irradiation. In this sense, the study fills a gap on the field of motor function after laser treatment following snake envenoming.	[Vieira, Willians Fernando; Baranauskas, Vitor] Univ Estadual Campinas, UNICAMP, Fac Elect Engn & Computat, Dept Semicond Instruments & Photon DSIF, Campinas, SP, Brazil; [Cogo, Jose Carlos] Univ Vale Paraiba UNIVAP, Inst Res & Dev IP&D, Sao Jose Dos Campos, SP, Brazil; [Vieira, Willians Fernando; Kenzo-Kagawa, Bruno; da Cruz-Hofling, Maria Alice] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Biochem & Tissue Biol DBBT, Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade do Vale do Paraiba; Universidade de Sao Paulo; Universidade Estadual de Campinas	da Cruz-Hofling, MA (corresponding author), Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Biochem & Tissue Biol DBBT, Campinas, SP, Brazil.	hofling@unicamp.br	Vieira, Willians F/A-8235-2018	Vieira, Willians F/0000-0003-3022-7997	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/53625-1]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [488792/2011, 486142/2012-4]; CNPq [305099/2011-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) at the Departamento de Semicondutores, Instrumentos e Fotonica (FEEC-UNICAMP); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) at Departamento de Bioquimica e Biologia Tecidual (IB-UNICAMP)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) at the Departamento de Semicondutores, Instrumentos e Fotonica (FEEC-UNICAMP)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) at Departamento de Bioquimica e Biologia Tecidual (IB-UNICAMP)	This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (Proc. 05/53625-1) (http://www.fapesp.br/) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, grants #488792/2011 and #486142/2012-4) (http://www.cnpq.br/). MACH is a IA research fellow from CNPq (grant #305099/2011-6); WFV was a Master Sci. student granted with a scholarship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (http://www.capes.gov.br/) at the Departamento de Semicondutores, Instrumentos e Fotonica (FEEC-UNICAMP) and Departamento de Bioquimica e Biologia Tecidual (IB-UNICAMP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves AN, 2014, AM J PHYS MED REHAB, V93, P1073, DOI 10.1097/PHM.0000000000000158; Amaral AC, 2001, LASER MED SCI, V16, P44, DOI 10.1007/PL00011336; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Barbosa AM, 2008, TOXICON, V51, P1236, DOI 10.1016/j.toxicon.2008.02.007; Ben-Dov N, 1999, BBA-MOL CELL RES, V1448, P372, DOI 10.1016/S0167-4889(98)00147-5; Bervar M, 2000, J NEUROSCI METH, V102, P109, DOI 10.1016/S0165-0270(00)00281-8; Borato E, 2008, REV BRAS MED ESPORTE, V14, P446, DOI 10.1590/S1517-86922008000500009; Bozkurt A, 2011, BEHAV BRAIN RES, V219, P55, DOI 10.1016/j.bbr.2010.12.018; Bozkurt A, 2008, J NEUROSCI METH, V170, P117, DOI 10.1016/j.jneumeth.2008.01.006; Brazilian Health Ministry, 1999, MAN DIAGN TREATM ENV, P131; CARDOSO JLC, 1993, Q J MED, V86, P315; Andraus RAC, 2010, ACTA ORTOP BRAS, V18, P152, DOI 10.1590/S1413-78522010000300007; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; CRISCO JJ, 1994, AM J SPORT MED, V22, P702, DOI 10.1177/036354659402200521; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009; Doin-Silva R, 2009, PHOTOCHEM PHOTOBIOL, V85, P63, DOI 10.1111/j.1751-1097.2008.00397.x; Dourado DM, 2003, LASER SURG MED, V33, P352, DOI 10.1002/lsm.10237; Dourado DM, 2011, PHOTOCHEM PHOTOBIOL, V87, P418, DOI 10.1111/j.1751-1097.2010.00878.x; Ferreira-Gomes J, 2008, J PAIN, V9, P945, DOI 10.1016/j.jpain.2008.05.012; Filipe VM, 2006, J NEUROSCI METH, V153, P55, DOI 10.1016/j.jneumeth.2005.10.006; Gabriel AF, 2007, J NEUROSCI METH, V163, P9, DOI 10.1016/j.jneumeth.2007.02.003; Gabriel AF, 2009, BEHAV BRAIN RES, V198, P477, DOI 10.1016/j.bbr.2008.12.018; Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-4; GRILLNER S, 1975, PHYSIOL REV, V55, P247, DOI 10.1104/pp.55.2.247; GUTIERREZ J M, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P211; Gutierrez Jose Maria, 1995, P645; Gutierrez JM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002162; Hui Wen Fan, 1995, P667; Iwata A, 2010, MUSCLE NERVE, V41, P694, DOI 10.1002/mus.21567; Milani R, 1997, QJM-MON J ASSOC PHYS, V90, P323, DOI 10.1093/qjmed/90.5.323; Moller KA, 2008, J NEUROSCI METH, V174, P1, DOI 10.1016/j.jneumeth.2008.06.017; Picolo G, 2002, BRAZ J MED BIOL RES, V35, P1221, DOI 10.1590/S0100-879X2002001000016; Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728-200503000-00016; PUBLICOVER SJ, 1978, J NEUROPATH EXP NEUR, V37, P544, DOI 10.1097/00005072-197809000-00009; Pugliese Livia Souza, 2003, Pesqui Odontol Bras, V17, P307; Queiroz LD, 2002, TOXICON, V40, P1483, DOI 10.1016/S0041-0101(02)00166-6; QUEIROZ LS, 1984, TOXICON, V22, P339, DOI 10.1016/0041-0101(84)90077-1; SANTOS PM, 1995, J NEUROSCI METH, V61, P79, DOI 10.1016/0165-0270(95)00026-Q; Shefer G, 2002, J CELL SCI, V115, P1461; Shefer G, 2003, BBA-MOL CELL RES, V1593, P131, DOI 10.1016/S0167-4889(02)00350-6; Smith KC, 2005, PHOTOMED LASER SURG, V23, P78, DOI 10.1089/pho.2005.23.78; Song H, 2004, AM J SPORT MED, V32, P1263, DOI 10.1177/0363546503262199; TONUSSI CR, 1992, PAIN, V48, P421, DOI 10.1016/0304-3959(92)90095-S; Varejao ASP, 2003, EXP NEUROL, V183, P695, DOI 10.1016/S0014-4886(03)00208-5; Varejao ASP, 2002, MUSCLE NERVE, V26, P630, DOI 10.1002/mus.10242; Vladimirov YA, 2004, BIOCHEMISTRY-MOSCOW+, V69, P81, DOI 10.1023/B:BIRY.0000016356.93968.7e; WALKER JL, 1994, J NEUROSCI METH, V52, P47, DOI 10.1016/0165-0270(94)90054-X; WALT. World Association for Laser Therapy, 1994, DOS REC; WROGEMANN K, 1976, LANCET, V1, P672; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x	52	13	13	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2016	11	7							e0158980	10.1371/journal.pone.0158980	http://dx.doi.org/10.1371/journal.pone.0158980			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6IK	27392016	Green Submitted, Green Published, gold			2023-01-03	WOS:000380005400179
J	Vinogradova, Y; Coupland, C; Brindle, P; Hippisley-Cox, J				Vinogradova, Yana; Coupland, Carol; Brindle, Peter; Hippisley-Cox, Julia			Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DANISH POPULATION; HEART-DISEASE; LOW-RISK; ADHERENCE; THERAPY; NONADHERENCE; INEQUALITIES; CHOLESTEROL; PREDICTORS; PREVENTION	OBJECTIVES To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. DESIGN Prospective open cohort study. SETTING 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. PARTICIPANTS Incident statin users aged 25-84 years identified between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. MAIN OUTCOME MEASURES Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who discontinued (defined as any subsequent prescription between discontinuation and study end). RESULTS Of 431 023 patients prescribed statins as primary prevention with a median follow-up time of 137 weeks, 47% (n = 204 622) discontinued treatment and 72% (n = 147 305) of those who discontinued restarted. Of 139 314 patients prescribed statins as secondary prevention with median follow-up time of 182 weeks, 41% (n = 57 791) discontinued treatment and 75% (43 211) of those who discontinued restarted. Younger patients (aged = 50 years), older patients (>= 75 years), women, and patients with chronic liver disease were more likely to discontinue statins and less likely to restart. However, patients in ethnic minority groups, current smokers, and patients with type 1 diabetes were more likely to discontinue treatment but then were more likely to restart, whereas patients with hypertension and type 2 diabetes were less likely to discontinue treatment and more likely to restart if they did discontinue. These results were mainly consistent in the primary prevention and secondary prevention groups. CONCLUSIONS Although a large proportion of statin users discontinue, many of them restart. For many patient groups previously considered as "stoppers," the problem of statin treatment " stopping" could be part of the wider issue of poor adherence. Identification of patient groups associated with completely stopping or stop-starting behaviour has positive implications for patients and doctors as well as suggesting areas for future research.	[Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia] Univ Nottingham, Div Primary Care, Univ Pk, Nottingham NG2 7RD, England; [Brindle, Peter] Bristol Clin Commissioning Grp, Avon Primary Care Res Collaborat, Bristol, Avon, England; [Brindle, Peter] Univ Bristol, Bristol, Avon, England	University of Nottingham; University of Bristol	Vinogradova, Y (corresponding author), Univ Nottingham, Div Primary Care, Univ Pk, Nottingham NG2 7RD, England.	Yana.Vinogradova@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306; Vinogradova, Yana/0000-0002-3030-5257	ClinRisk	ClinRisk	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any additional organisation for the submitted work; JH-C is a professor of clinical epidemiology at the University of Nottingham and unpaid director of QResearch, a not-for-profit organisation that is a joint partnership between the University of Nottingham and EMIS (Egton Medical Information System; commercial IT supplier for 60% of general practices in the UK); JH-C is also a paid director of ClinRisk, which produces open and closed source software to ensure the reliable and updatable implementation of clinical risk algorithms (including QRISK2) within clinical computer systems to help improve patient care; no other relationships or activities that could appear to have influenced the submitted work.	Abramson JD, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6123; Brookhart MA, 2007, ARCH INTERN MED, V167, P847, DOI 10.1001/archinte.167.8.847; Caspard H, 2005, CLIN THER, V27, P1639, DOI 10.1016/j.clinthera.2005.10.005; Casula M, 2012, PATIENT PREFER ADHER, V6, P805, DOI 10.2147/PPA.S29092; Daskalopoulou SS, 2008, EUR HEART J, V29, P2083, DOI 10.1093/eurheartj/ehn346; Ferrajolo C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112037; Granger BB, 2013, EUR J CARDIOVASC NUR, V12, P276, DOI 10.1177/1474515112447734; Halava H, 2014, CAN MED ASSOC J, V186, pE449, DOI 10.1503/cmaj.131807; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832; Hippisley-Cox J, 2007, HEART, V93, P1256, DOI 10.1136/hrt.2006.110171; Hippisley-Cox Julia, 2010, BMJ, V340, pc2197, DOI 10.1136/bmj.c2197; Ingebrigtsen TS, 2015, THORAX, V70, P33, DOI 10.1136/thoraxjnl-2014-205795; Jensen MT, 2016, DIABETES RES CLIN PR, V111, P51, DOI 10.1016/j.diabres.2015.10.022; Jones PH, 2003, AM J CARDIOL, V92, P152, DOI 10.1016/S0002-9149(03)00530-7; Larsen J, 2002, BRIT J CLIN PHARMACO, V53, P375, DOI 10.1046/j.1365-2125.2002.01563.x; Lemstra M, 2012, CAN J CARDIOL, V28, P574, DOI 10.1016/j.cjca.2012.05.007; Malhotra A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6340; Mancini GBJ, 2013, CAN J CARDIOL, V29, P1553, DOI 10.1016/j.cjca.2013.09.023; Mann DM, 2010, ANN PHARMACOTHER, V44, P1410, DOI 10.1345/aph.1P150; Mauskop Alexander, 2011, Curr Cardiol Rep, V13, P553, DOI 10.1007/s11886-011-0221-2; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; National Institute for Health and Care Excellence, 2014, LIP MOD CARD RISK AS; National Institute for Health and Care Excellence, 2008, LIP MOD CARD RISK AS; Nielsen SF, 2016, EUR HEART J, V37, P908, DOI 10.1093/eurheartj/ehv641; Pastori D, 2015, DIGEST LIVER DIS, V47, P4, DOI 10.1016/j.dld.2014.07.170; Prasad V, 2014, ANN INTERN MED, V160, P867, DOI 10.7326/M13-2974; Rosenbaum D, 2013, NUTR METAB CARDIOVAS, V23, P871, DOI 10.1016/j.numecd.2012.04.012; Royal Pharmaceutical Society of Great Britain British Medical Association, 2013, BRIT NAT FORM 66; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6; Schedlbauer A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004371.pub3; Smeeth L, 2003, QJM-INT J MED, V96, P337, DOI 10.1093/qjmed/hcg064; Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Svensson E, 2015, CLIN EPIDEMIOL, V7, P213, DOI 10.2147/CLEP.S78145; Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5; Trusler D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4350; Vinogradova Y, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008701; Warren JR, 2013, PHARMACOEPIDEM DR S, V22, P1298, DOI 10.1002/pds.3526; Young RP, 2009, EUR RESPIR REV, V18, P222, DOI 10.1183/09059180.00005309; Zhang HB, 2013, ANN INTERN MED, V158, P526, DOI 10.7326/0003-4819-158-7-201304020-00004	41	77	77	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	2016	353								i3305	10.1136/bmj.i3305	http://dx.doi.org/10.1136/bmj.i3305			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ2FP	27353261	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000379018000003
J	Adami, F; Figueiredo, FWD; Paiva, LD; de Sa, TH; Santos, EFD; Martins, BL; Valenti, VE; de Abreu, LC				Adami, Fernando; dos Santos Figueiredo, Francisco Winter; Paiva, Laercio da Silva; de Sa, Thiago Herick; de Sousa Santos, Edige Felipe; Martins, Bruno Luis; Valenti, Vitor Engracia; de Abreu, Luiz Carlos			Mortality and Incidence of Hospital Admissions for Stroke among Brazilians Aged 15 to 49 Years between 2008 and 2012	PLOS ONE			English	Article							CASE-FATALITY RATES; DECLINE; SYSTEM; HEALTH	Introduction The objective was to analyze rates of stroke-related mortality and incidence of hospital admissions in Brazilians aged 15 to 49 years according to region and age group between 2008 and 2012. Methods Secondary analysis was performed in 2014 using data from the Hospital and Mortality Information Systems and the Brazilian Institute of Geography and Statistics. Stroke was defined by ICD, 10th revision (I60-I64). Crude and standardized mortality (WHO reference) and incidence of hospital admissions per 100,000 inhabitants, stratified by region and age group, were estimated. Absolute and relative frequencies; and linear regression were also used. The software used was Stata 11.0. Results There were 35,005 deaths and 131,344 hospital admissions for stroke in Brazilians aged 15-49 years old between 2008 and 2012. Mortality decreased from 7.54 (95% CI 7.53; 7.54) in 2008 to 6.32 (95% CI 6.31; 6.32) in 2012 (beta = -0.27, p = 0.013, r(2) = 0.90). During the same time, incidence of hospital admissions stabilized: 24.67 (95% CI 24.66; 24.67) in 2008 and 25.11 (95% CI 25.10; 25.11) in 2012 (beta = 0.09, p = 0.692, r(2) = 0.05). There was a reduction in mortality in all Brazilian regions and in the age group between 30 and 49 years. Incidence of hospitalizations decreased in the South, but no significant decrease was observed in any age group. Conclusion We observed a decrease in stroke-related mortality, particularly in individuals over 30 years old, and stability of the incidence of hospitalizations; and also regional variation in stroke-related hospital admission incidence and mortality among Brazilian young adults.	[Adami, Fernando; dos Santos Figueiredo, Francisco Winter; Paiva, Laercio da Silva; de Sousa Santos, Edige Felipe; Martins, Bruno Luis; de Abreu, Luiz Carlos] Fac Med ABC, Lab Epidemiol & Anal Dados, Dept Saude Coletividade, Santo Andre, SP, Brazil; [Adami, Fernando; dos Santos Figueiredo, Francisco Winter; Paiva, Laercio da Silva; de Sousa Santos, Edige Felipe; de Abreu, Luiz Carlos] Fac Med ABC, Lab Delineamento Estudos & Escrita Cient, Dept Saude Coletividade, Santo Andre, SP, Brazil; [de Sousa Santos, Edige Felipe] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, BR-01255 Sao Paulo, SP, Brazil; [de Sa, Thiago Herick] Univ Sao Paulo, Fac Saude Publ, Dept Nutr, Sao Paulo, SP, Brazil; [de Sousa Santos, Edige Felipe] Fac Leao Sampaio, Unidade Saude, Juazeiro De Norte, Ceara, Brazil; [Valenti, Vitor Engracia] Univ Estadual Paulista, Fac Filosofia & Ciencias, Dept Fonoaudiol, Marilia, SP, Brazil	Faculdade de Medicina do ABC; Faculdade de Medicina do ABC; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Estadual Paulista	Adami, F (corresponding author), Fac Med ABC, Lab Epidemiol & Anal Dados, Dept Saude Coletividade, Santo Andre, SP, Brazil.; Adami, F (corresponding author), Fac Med ABC, Lab Delineamento Estudos & Escrita Cient, Dept Saude Coletividade, Santo Andre, SP, Brazil.	fernando.adami@fmabc.br	de Abreu, Luiz Carlos/AAL-8219-2021; Valenti, Vitor E/C-1968-2012; Paiva, Laércio S/B-3190-2015; Valenti, Vitor Engracia/Q-6355-2019; de Abreu, Luiz Carlos/B-7873-2012; Figueiredo, Winter/A-7152-2015; Adami, Fernando/D-3855-2012; Sa, Thiago Herick de/N-1952-2015	de Abreu, Luiz Carlos/0000-0002-7618-2109; Valenti, Vitor E/0000-0001-7477-3805; Paiva, Laércio S/0000-0003-3646-2621; de Abreu, Luiz Carlos/0000-0002-7618-2109; Figueiredo, Winter/0000-0002-9377-6443; Adami, Fernando/0000-0003-1918-3364; Sa, Thiago Herick de/0000-0002-9348-4483	Foundation for Research of the State of Sao Paulo - FAPESP [2013/08943-1]	Foundation for Research of the State of Sao Paulo - FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by the Foundation for Research of the State of Sao Paulo - FAPESP (reference number No: 2013/08943-1). The funders had the role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre C, 2006, STROKE, V37, P2784, DOI 10.1161/01.STR.0000244768.46566.73; Bensenor IM, 2015, ARQ NEURO-PSIQUIAT, V73, P746, DOI 10.1590/0004-282X20150115; Cabral NL, 2009, J NEUROL NEUROSUR PS, V80, P749, DOI 10.1136/jnnp.2008.164475; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Figueiroa BD, 2013, CAD SAUDE PUBLICA, V29, P475, DOI 10.1590/S0102-311X2013000300006; Garritano CR, 2012, ARQ BRAS CARDIOL, V98, P519, DOI 10.1590/S0066-782X2012005000041; George Mary G, 2011, Ann Neurol, V70, P713, DOI 10.1002/ana.22539; IPEA, ATL DES HUM BRAS; Kleinbaum D.G., 2008, APPL REGRESSION ANAL; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Lackland DT, 2014, STROKE, V45, P315, DOI 10.1161/01.str.0000437068.30550.cf; Lotufo Paulo Andrade, 2005, Sao Paulo Med. J., V123, P3; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Minelli C, 2007, STROKE, V38, P2906, DOI 10.1161/STROKEAHA.107.484139; Ministerio da Saude do Brasil, 2013, COORD GER INF MORT S, P0; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Putaala J, 2012, STROKE, V43, P2624, DOI 10.1161/STROKEAHA.112.662866; Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; Smajlovic D, 2015, VASC HEALTH RISK MAN, V11, P157, DOI 10.2147/VHRM.S53203; Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X; World Health Organization, 2007, INT CLASS DIS	21	17	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2016	11	6							e0152739	10.1371/journal.pone.0152739	http://dx.doi.org/10.1371/journal.pone.0152739			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WX	27332892	Green Published, Green Submitted, gold			2023-01-03	WOS:000378212800002
J	de Vries, J; Figdor, C				de Vries, Jolanda; Figdor, Carl			IMMUNOTHERAPY Cancer vaccine triggers antiviral-type defences	NATURE			English	Editorial Material							HUMAN DENDRITIC CELLS; IN-VIVO; ANTIGEN; RESPONSES; DEC-205		[de Vries, Jolanda; Figdor, Carl] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, Dept Tumor Immunol, NL-6525 GA Nijmegen, Netherlands	Radboud University Nijmegen	de Vries, J (corresponding author), Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, Dept Tumor Immunol, NL-6525 GA Nijmegen, Netherlands.	jolanda.devries@radboudumc.nl; carl.figdor@radboudumc.nl	de Vries, I. Jolanda M./F-5563-2010	de Vries, I. Jolanda M./0000-0002-8653-4040				Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kuhn AN, 2010, GENE THER, V17, P961, DOI 10.1038/gt.2010.52; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583	10	18	18	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2016	534	7607					329	331						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5XQ	27281206				2023-01-03	WOS:000377856800022
J	Zhao, J; Xia, YF; Kaminski, J; Hao, ZL; Mott, F; Campbell, J; Sadek, R; Kong, FM				Zhao, Jing; Xia, Yingfeng; Kaminski, Joseph; Hao, Zhonglin; Mott, Frank; Campbell, Jeff; Sadek, Ramses; Kong, Feng-Ming (Spring)			Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies	PLOS ONE			English	Article							PHASE-III TRIAL; HYPERFRACTIONATED RADIATION-THERAPY; LOW-DOSE CARBOPLATIN; STAGE-III; THORACIC RADIOTHERAPY; INDUCTION CHEMOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; ELDERLY-PATIENTS; CLINICAL-TRIAL; RISK-FACTORS	Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT), and determine whether high radiation dose and newer chemotherapy regimens were associated with the risk of TRD. Data from randomized clinical trials for locally advanced/unresectable NSCLC patients were analyzed. Eligible studies had to have at least one arm with CCRT. The primary endpoint was TRD. Pooled odds ratios (ORs) for TRDs were calculated. In this study, a total of fifty-three trials (8940 patients) were eligible. The pooled TRD rate (accounting for heterogeneity) was 1.44% for all patients. In 20 trials in which comparison of TRDs between CCRT and non-CCRT was possible, the OR (95% CI) of TRDs was 1.08 (0.70-1.66) (P = 0.71). Patients treated with third-generation chemotherapy and concurrent radiotherapy had an increase of TRDs compared to those with other regimens in CCRT (2.70% vs. 1.37%, OR = 1.50, 95% CI: 1.09-2.07, P = 0.008). No significant difference was found in TRDs between high (>= 66 Gy) and low (< 66 Gy) radiation dose during CCRT (P = 0.605). Neither consolidation (P = 0.476) nor induction chemotherapy (P = 0.175) had significant effects with increased TRDs in this study. We concluded that CCRT is not significantly associated with the risk of TRD compared to non-CCRT. The third-generation chemotherapy regimens may be a risk factor with higher TRDs in CCRT, while high dose radiation is not significantly associated with more TRDs. This observation deserves further study.	[Zhao, Jing; Kaminski, Joseph; Campbell, Jeff; Kong, Feng-Ming (Spring)] Georgia Regents Univ, Med Coll Georgia, GRU Canc Ctr, Dept Radiat Oncol, Augusta, GA USA; [Zhao, Jing] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan 430074, Peoples R China; [Xia, Yingfeng] Three Gorges Univ, Peoples Hosp, Hosp Yichang 1, Yichang, Peoples R China; [Hao, Zhonglin; Mott, Frank] Georgia Regents Univ, Med Coll Georgia, GRU Canc Ctr, Dept Internal Med, Augusta, GA USA; [Sadek, Ramses] Georgia Regents Univ, Med Coll Georgia, GRU Canc Ctr, Dept Biostat & Epidemiol, Augusta, GA USA; [Kong, Feng-Ming (Spring)] Indiana Univ Sch Med, Dept Radiat Oncol, Simon Canc Ctr, Indianapolis, IN 46202 USA	University System of Georgia; Augusta University; Huazhong University of Science & Technology; China Three Gorges University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Indiana University System; Indiana University Bloomington	Kong, FM (corresponding author), Georgia Regents Univ, Med Coll Georgia, GRU Canc Ctr, Dept Radiat Oncol, Augusta, GA USA.; Kong, FM (corresponding author), Indiana Univ Sch Med, Dept Radiat Oncol, Simon Canc Ctr, Indianapolis, IN 46202 USA.	fkong@gru.edu	Kaminski, Joseph/AAB-6493-2020; Kong, Feng-Ming/Y-2825-2019	Kong, Feng-Ming/0000-0003-2652-098X; Kaminski, Joseph/0000-0002-7518-4962	National Institute of Health R01 grant [CA142840]; NATIONAL CANCER INSTITUTE [R01CA142840] Funding Source: NIH RePORTER	National Institute of Health R01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institute of Health R01 grant CA142840 to Dr. Feng-Ming (Spring) Kong. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, NCCN CLIN PRACTICE G; Atagi S, 2005, JPN J CLIN ONCOL, V35, P195, DOI 10.1093/jjco/hyi060; Atagi S, 2012, LANCET ONCOL, V13, P671, DOI 10.1016/S1470-2045(12)70139-0; Ball D, 1999, RADIOTHER ONCOL, V52, P129, DOI 10.1016/S0167-8140(99)00093-6; Belani CP, 2005, J CLIN ONCOL, V23, P5883, DOI 10.1200/JCO.2005.55.405; Belderbos J, 2007, EUR J CANCER, V43, P114, DOI 10.1016/j.ejca.2006.09.005; Bradley J, 2005, SEMIN ONCOL, V32, pS111, DOI 10.1053/j.seminoncol.2005.03.020; Bradley J, 2011, 53 ANN M AM SOC RAD; Cakir S, 2004, LUNG CANCER-J IASLC, V43, P309, DOI 10.1016/j.lungcan.2003.09.009; Clamon G, 1999, J CLIN ONCOL, V17, P4, DOI 10.1200/JCO.1999.17.1.4; CLAMON G, 1994, CANCER INVEST, V12, P273, DOI 10.3109/07357909409023025; Crvenkova S, 2009, CONTRIBUTIONS MACEDO, V30, P197; Curran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325; Dasgupta Anirban, 2006, J Cancer Res Ther, V2, P47; Fournel P, 2005, J CLIN ONCOL, V23, P5910, DOI 10.1200/JCO.2005.03.070; Fujiwara Y, 2011, ANN ONCOL, V22, P376, DOI 10.1093/annonc/mdq360; Goksel T, 2005, RESPIROLOGY, V10, P456, DOI 10.1111/j.1440-1843.2005.00739.x; Gouda Yousry S, 2006, J Egypt Natl Canc Inst, V18, P73; Groen HJM, 2004, ANN ONCOL, V15, P427, DOI 10.1093/annonc/mdh100; Hanna N, 2008, J CLIN ONCOL, V26, P5755, DOI 10.1200/JCO.2008.17.7840; Hara S, 2001, CALCIFIED TISSUE INT, V68, P23, DOI 10.1007/BF02684999; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Horstmann E, 2005, NEW ENGL J MED, V352, P895, DOI 10.1056/NEJMsa042220; Huber RM, 2006, J CLIN ONCOL, V24, P4397, DOI 10.1200/JCO.2005.05.4163; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; JEREMIC B, 1995, J CLIN ONCOL, V13, P452, DOI 10.1200/JCO.1995.13.2.452; Jeremic B, 1996, J CLIN ONCOL, V14, P1065, DOI 10.1200/JCO.1996.14.4.1065; Kong FM, 2014, J THORAC DIS, V6, P336, DOI 10.3978/j.issn.2072-1439.2014.01.23; Kong FM, 2005, INT J RADIAT ONCOL, V63, P324, DOI 10.1016/j.ijrobp.2005.02.010; Kong FM, SEMIN RAD O IN PRESS; Kubota K, 2000, ANN ONCOL, V11, P445, DOI 10.1023/A:1008328207137; Machtay M, 2012, INT J RADIAT ONCOL, V82, P425, DOI 10.1016/j.ijrobp.2010.09.004; Masters GA, 1998, J CLIN ONCOL, V16, P2157, DOI 10.1200/JCO.1998.16.6.2157; Minami-Shimmyo Y, 2012, J THORAC ONCOL, V7, P177, DOI 10.1097/JTO.0b013e31823c4c07; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mornex F, 2013, LUNG CANCER, V80, P68, DOI 10.1016/j.lungcan.2012.12.007; O'Rourke N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002140.pub3; Ohe Y, 2001, EUR J CANCER, V37, P54, DOI 10.1016/S0959-8049(00)00350-6; Sarihan S, 2004, J INT MED RES, V32, P375, DOI 10.1177/147323000403200405; Scagliotti GV, 2006, BRIT J CANCER, V94, P1375, DOI 10.1038/sj.bjc.6603115; Schild SE, 2002, INT J RADIAT ONCOL, V54, P729, DOI 10.1016/S0360-3016(02)03018-3; Song CH, 2010, INT J RADIAT ONCOL, V78, P651, DOI 10.1016/j.ijrobp.2009.08.068; Takeda K, 2011, JPN J CLIN ONCOL, V41, P25, DOI 10.1093/jjco/hyq163; Vokes EE, 2007, J CLIN ONCOL, V25, P1698, DOI 10.1200/JCO.2006.07.3569; Vokes EE, 2009, CLIN LUNG CANCER, V10, P193, DOI 10.3816/CLC.2009.n.027; Zatloukal P, 2004, LUNG CANCER-J IASLC, V46, P87, DOI 10.1016/j.lungcan.2004.03.004	46	8	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2016	11	6							e0157455	10.1371/journal.pone.0157455	http://dx.doi.org/10.1371/journal.pone.0157455			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KO	27300551	Green Published, Green Submitted, gold			2023-01-03	WOS:000377822200052
J	Koshkelashvili, N; Lai, JYK				Koshkelashvili, Nikoloz; Lai, Julie Y. K.			Hyperkalemia after Missed Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Koshkelashvili, Nikoloz; Lai, Julie Y. K.] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA	Yeshiva University	Koshkelashvili, N (corresponding author), Albert Einstein Med Ctr, Philadelphia, PA 19141 USA.	nika.koshkelashvili@gmail.com							0	6	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2016	374	23					2268	2268		10.1056/NEJMicm1512236	http://dx.doi.org/10.1056/NEJMicm1512236			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO6VB	27276564				2023-01-03	WOS:000377920500010
J	Casper, C; Hascoet, JM; Ertl, T; Gadzinowski, JS; Carnielli, V; Rigo, J; Lapillonne, A; Couce, ML; Vagero, M; Palmgren, I; Timdahl, K; Hernell, O				Casper, Charlotte; Hascoet, Jean-Michel; Ertl, Tibor; Gadzinowski, Janusz S.; Carnielli, Virgilio; Rigo, Jacques; Lapillonne, Alexandre; Couce, Maria L.; Vagero, Marten; Palmgren, Ingrid; Timdahl, Kristina; Hernell, Olle			Recombinant Bile Salt-Stimulated Lipase in Preterm Infant Feeding: A Randomized Phase 3 Study	PLOS ONE			English	Article							HUMAN-MILK; INTRAUTERINE GROWTH; PANCREATIC LIPASE; DOCOSAHEXAENOIC ACID; CONTROLLED-TRIAL; LIPID DIGESTION; ABSORPTION; BORN; PASTEURIZATION; RESTRICTION	Introduction Feeding strategies are critical for healthy growth in preterm infants. Bile salt-stimulated lipase (BSSL), present in human milk, is important for fat digestion and absorption but is inactivated during pasteurization and absent in formula. This study evaluated if recombinant human BSSL (rhBSSL) improves growth in preterm infants when added to formula or pasteurized breast milk. Patients and Methods LAIF (Lipase Added to Infant Feeding) was a randomized, double-blind, placebo-controlled phase 3 study in infants born before 32 weeks of gestation. The primary efficacy variable was growth velocity (g/kg/day) during 4 weeks intervention. Follow-up visits were at 3 and 12 months. The study was performed at 54 centers in 10 European countries. Results In total 415 patients were randomized (rhBSSL n = 207, placebo n = 208), 410 patients were analyzed (rhBSSL n = 206, placebo n = 204) and 365 patients were followed until 12 months. Overall, there was no significantly improved growth velocity during rhBSSL treatment compared to placebo (16.77 vs. 16.56 g/kg/day, estimated difference 0.21 g/kg/day, 95% CI [-0.40; 0.83]), nor were secondary endpoints met. However, in a predefined subgroup, small for gestational age infants, there was a significant effect on growth in favor of rhBSSL during treatment. The incidence of adverse events was higher in the rhBSSL group during treatment. Conclusions Although this study did not meet its primary endpoint, except in a subgroup of infants small for gestational age, and there was an imbalance in short-term safety, these data provide insights in nutrition, growth and development in preterm infants.	[Casper, Charlotte] Univ Toulouse 3, Neonatol Unit, F-31062 Toulouse, France; [Hascoet, Jean-Michel] Univ Lorraine, Dept Neonatol, Nancy, France; [Ertl, Tibor] Univ Pecs, Sch Med, Dept Neonatol, Pecs, Hungary; [Gadzinowski, Janusz S.] Poznan Univ Med Sci, Chair & Dept Neonatol, Poznan, Poland; [Carnielli, Virgilio] Polytech Univ Marche, Ancona, Italy; [Carnielli, Virgilio] Salesis Children Hosp, Ancona, Italy; [Rigo, Jacques] Univ Liege, Dept Neonatol, Liege, Belgium; [Lapillonne, Alexandre] Paris Descartes Univ, EA 7328, Necker Enfants Malades Hosp, Paris, France; [Couce, Maria L.] Univ Clin Hosp, Dept Neonatol, Santiago De Compostela, Spain; [Vagero, Marten; Palmgren, Ingrid; Timdahl, Kristina] Swedish Orphan Biovitrum Sobi, Stockholm, Sweden; [Hernell, Olle] Umea Univ, Pediat, Dept Clin Sci, Umea, Sweden	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Lorraine; University of Pecs; Poznan University of Medical Sciences; Marche Polytechnic University; University of Liege; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Complexo Hospitalario Universitario de Santiago de Compostela; Umea University	Timdahl, K (corresponding author), Swedish Orphan Biovitrum Sobi, Stockholm, Sweden.	kristina.timdahl@sobi.com	Couce, Maria Luz/R-8981-2019	Tscherning, Charlotte/0000-0001-7111-8979; Couce, Maria Luz/0000-0003-4861-9905; Gadzinowski, Janusz/0000-0001-8397-6989	Swedish Orphan Biovitrum AB (publ)	Swedish Orphan Biovitrum AB (publ)	This study was fully funded by Swedish Orphan Biovitrum AB (publ). The sponsor designed the study in agreement with external medical experts and was responsible for analyzing the study results. The sponsor decided to publish the data, and the article was prepared in collaboration with the study investigators.	Andersson EL, 2011, J LIPID RES, V52, P1949, DOI 10.1194/jlr.M015685; Andersson Y, 2007, ACTA PAEDIATR, V96, P1445, DOI 10.1111/j.1651-2227.2007.00450.x; Barone G, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-28; Bayley N., 2006, J PSYCHOEDUC ASSESS, V25, P180, DOI [10.1177/0734282906297199, DOI 10.1177/0734282906297199]; BJORKSTEN B, 1980, BMJ-BRIT MED J, V281, P765, DOI 10.1136/bmj.281.6243.765; Casper C, 2014, J PEDIATR GASTR NUTR, V59, P61, DOI 10.1097/MPG.0000000000000365; CHEN Q, 1994, BBA-LIPID LIPID MET, V1210, P239, DOI 10.1016/0005-2760(94)90127-9; Clark RH, 2003, PEDIATRICS, V111, P986, DOI 10.1542/peds.111.5.986; Ehrenkranz RA, 2006, PEDIATRICS, V117, P1253, DOI 10.1542/peds.2005-1368; Eidelman AI, 2012, BREASTFEED MED, V7, P323, DOI 10.1089/bfm.2012.0067; Funkquist EL, 2007, ACTA PAEDIATR, V96, P596, DOI 10.1111/j.1651-2227.2007.00222.x; Hascoet JMS, 2015, E PAS; Henderson TR, 1998, J PEDIATR-US, V132, P876, DOI 10.1016/S0022-3476(98)70323-3; HERNELL O, 1975, EUR J CLIN INVEST, V5, P267, DOI 10.1111/j.1365-2362.1975.tb02294.x; Lapillonne A, 2013, J PEDIATR-US, V162, pS90, DOI 10.1016/j.jpeds.2012.11.058; Li X, 2007, PEDIATR RES, V62, P537, DOI 10.1203/PDR.0b013e3181559e75; Lindquist S, 2010, CURR OPIN CLIN NUTR, V13, P314, DOI 10.1097/MCO.0b013e328337bbf0; Llanos A, 2005, PEDIATR RES, V58, P735, DOI 10.1203/01.PDR.0000180542.68526.A2; Makrides M, 2009, JAMA-J AM MED ASSOC, V301, P175, DOI 10.1001/jama.2008.945; McLeod G, 2013, J PAEDIATR CHILD H, V49, pE332, DOI 10.1111/jpc.12013; Miller J, 2012, AM J CLIN NUTR, V95, P648, DOI 10.3945/ajcn.111.026351; Olsen IE, 2010, PEDIATRICS, V125, pE214, DOI 10.1542/peds.2009-0913; Pilling EL, 2008, BEST PRACT RES CL EN, V22, P447, DOI 10.1016/j.beem.2008.03.002; Sharma R, 2013, CLIN PERINATOL, V40, P27, DOI 10.1016/j.clp.2012.12.012; SHIRAI K, 1982, J BIOL CHEM, V257, P1253; Uauy R, 2000, PEDIATR RES, V47, P127, DOI 10.1203/00006450-200001000-00022; Yang YQ, 2000, PEDIATR RES, V47, P184, DOI 10.1203/00006450-200002000-00006	27	23	23	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2016	11	5							e0156071	10.1371/journal.pone.0156071	http://dx.doi.org/10.1371/journal.pone.0156071			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN5XX	27244221	Green Published, gold, Green Submitted			2023-01-03	WOS:000377146100014
J	Ludwig, DS				Ludwig, David S.			Lowering the Bar on the Low-Fat Diet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BODY-WEIGHT		[Ludwig, David S.] Boston Childrens Hosp, New Balance Fdn Obes Prevent Ctr, Boston, MA USA; [Ludwig, David S.] Harvard Med Sch, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Ludwig, DS (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu		Ludwig, David/0000-0003-3307-8544	NIDDK NIH HHS [K24 DK082730] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK082730] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blundell JE, 1997, J AM DIET ASSOC, V97, pS63, DOI 10.1016/S0002-8223(97)00733-5; Freedhoff Y, 2016, LANCET, V388, P849, DOI 10.1016/S0140-6736(16)31338-1; HILL JO, 1995, AM J CLIN NUTR, V62, p264S, DOI 10.1093/ajcn/62.1.264S; Kearns CE, 2016, JAMA INTERN MED, V176, P1680, DOI 10.1001/jamainternmed.2016.5394; Ludwig DS, 2014, JAMA-J AM MED ASSOC, V311, P2167, DOI 10.1001/jama.2014.4133; Mansoor N, 2016, BRIT J NUTR, V115, P466, DOI 10.1017/S0007114515004699; Mozaffarian D, 2015, JAMA-J AM MED ASSOC, V313, P2421, DOI 10.1001/jama.2015.5941; Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296; Stubbs RJ, 2001, J NUTR, V131, p2775S, DOI 10.1093/jn/131.10.2775S; Wang DD, 2016, JAMA INTERN MED, V176, P1134, DOI 10.1001/jamainternmed.2016.2417	10	27	29	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2016	316	20					2087	2088		10.1001/jama.2016.15473	http://dx.doi.org/10.1001/jama.2016.15473			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ED1XD	27681384				2023-01-03	WOS:000388637300013
J	DeWeerdt, S				DeWeerdt, Sarah			Through the barrier	NATURE			English	Editorial Material																			0	3	3	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 22	2016	537	7621					S154	S157		10.1038/537S154a	http://dx.doi.org/10.1038/537S154a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DW3MO	27652783				2023-01-03	WOS:000383545900006
J	Leppert, J; Patel, C				Leppert, John; Patel, Chirag			Beyond the genome	NATURE			English	Editorial Material							CANCER		[Leppert, John] Stanford Univ, Stanford, CA 94305 USA; [Patel, Chirag] Harvard Univ, Boston, MA 02115 USA	Stanford University; Harvard University	Leppert, J (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	jleppert@stanford.edu		Leppert, John/0000-0001-9980-3863	NHGRI NIH HHS [U54 HG007963] Funding Source: Medline; NIEHS NIH HHS [R00 ES023504, R21 ES025052] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG007963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES025052, R00ES023504] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85	4	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	2016	537	7620					S105	S105		10.1038/537S105a	http://dx.doi.org/10.1038/537S105a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV7EC	27626778	Green Accepted			2023-01-03	WOS:000383098000004
J	Hasegawa, K; Saiura, A; Takayama, T; Miyagawa, S; Yamamoto, J; Ijichi, M; Teruya, M; Yoshimi, F; Kawasaki, S; Koyama, H; Oba, M; Takahashi, M; Mizunuma, N; Matsuyama, Y; Watanabe, T; Makuuchi, M; Kokudo, N				Hasegawa, Kiyoshi; Saiura, Akio; Takayama, Tadatoshi; Miyagawa, Shinichi; Yamamoto, Junji; Ijichi, Masayoshi; Teruya, Masanori; Yoshimi, Fuyo; Kawasaki, Seiji; Koyama, Hiroto; Oba, Masaru; Takahashi, Michiro; Mizunuma, Nobuyuki; Matsuyama, Yutaka; Watanabe, Toshiaki; Makuuchi, Masatoshi; Kokudo, Norihiro			Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial	PLOS ONE			English	Article							III COLON-CANCER; INTRAVENOUS FLUOROURACIL; PHASE-III; STAGE-II; HEPATIC RESECTION; PLUS LEUCOVORIN; FOLINIC ACID; NSABP C-07; CHEMOTHERAPY; SURGERY	Background The high recurrence rate after surgery for colorectal cancer liver metastasis (CLM) remains a crucial problem. The aim of this trial was to evaluate the efficacy of adjuvant therapy with uracil-tegafur and leucovorin (UFT/LV). Methods In the multicenter, open-label, phase III trial, patients undergoing curative resection of CLM were randomly assigned in a 1:1 ratio to either the UFT/LV group or surgery alone group. The UFT/LV group orally received 5 cycles of adjuvant UFT/LV (UFT 300mg/m(2) and LV 75mg/day for 28 days followed by a 7-day rest per cycle). The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included overall survival (OS). Results Between February 2004 and December 2010, 180 patients (90 in each group) were enrolled into the study. Of these, 3 patients (2 in the UFT/LV group and 1 in the surgery alone group) were excluded from the efficacy analysis. Median follow-up was 4.76 (range, 0.15-9.84) years. The RFS rate at 3 years was higher in the UFT/LV group (38.6%, n = 88) than in the surgery alone group (32.3%, n = 89). The median RFS in the UFT/LV and surgery alone groups were 1.45 years and 0.70 years, respectively. UFT/LV significantly prolonged the RFS compared with surgery alone with the hazard ratio of 0.56 (95% confidence interval, 0.38-0.83; P = 0.003). The hazard ratio for death of the UFT/LV group against the surgery alone group was not significant (0.80; 95% confidence interval, 0.48-1.35; P = 0.409). Conclusion Adjuvant therapy with UFT/LV effectively prolongs RFS after hepatic resection for CLM and can be recommended as an alternative choice.	[Hasegawa, Kiyoshi; Oba, Masaru; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan; [Saiura, Akio; Takahashi, Michiro] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastrointestinal Surg, Tokyo, Japan; [Takayama, Tadatoshi] Nihon Univ, Sch Med, Dept Digest Surg, Tokyo, Japan; [Miyagawa, Shinichi] Shinshu Univ, Sch Med, Dept Surg 1, Matsumoto, Nagano, Japan; [Yamamoto, Junji] Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama, Japan; [Ijichi, Masayoshi] JCHO Tokyo Yamate Med Ctr, Dept Surg, Tokyo, Japan; [Teruya, Masanori] Showa Gen Hosp, Dept Surg, Tokyo, Japan; [Yoshimi, Fuyo] Ibaraki Prefectural Cent Hosp & Canc Ctr, Dept Surg, Ibaraki, Japan; [Kawasaki, Seiji] Juntendo Univ, Sch Med, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan; [Koyama, Hiroto] JCHO Tokyo Takanawa Hosp, Dept Surg, Tokyo, Japan; [Mizunuma, Nobuyuki] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan; [Matsuyama, Yutaka] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo, Japan; [Watanabe, Toshiaki] Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Tokyo, Japan; [Makuuchi, Masatoshi] Japanese Red Cross Med Ctr, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan	University of Tokyo; Japanese Foundation for Cancer Research; Nihon University; Shinshu University; National Defense Medical College - Japan; Juntendo University; Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo; Japanese Red Cross Medical Center; University of Tokyo	Kokudo, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan.	KOKUDO-2SU@h.u-tokyo.ac.jp	Saiura, Akio/AAH-5008-2020	Saiura, Akio/0000-0001-5600-2847	Ministry of Education, Culture, Sports, Science and Technology of Japan; Japanese Foundation for Multidisciplinary Treatment of Cancer; Public Trust Haraguchi Memorial Cancer Research Fund; Japanese Clinical Oncology Fund	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Foundation for Multidisciplinary Treatment of Cancer(Japanese Foundation for Multidisciplinary Treatment of Cancer); Public Trust Haraguchi Memorial Cancer Research Fund; Japanese Clinical Oncology Fund	This trial was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to NK); Japanese Foundation for Multidisciplinary Treatment of Cancer (to KH); Public Trust Haraguchi Memorial Cancer Research Fund (to KH); and Japanese Clinical Oncology Fund (to KH). These sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Araujo R, 2013, ANN SURG ONCOL, V20, P4312, DOI 10.1245/s10434-013-3162-8; Arnold D, 2011, CURR COLORECT CANC R, V7, P180, DOI 10.1007/s11888-011-0096-z; Beppu T, 2012, J HEPATO-BIL-PAN SCI, V19, P72, DOI 10.1007/s00534-011-0460-z; Borner MM, 2002, EUR J CANCER, V38, P349, DOI 10.1016/S0959-8049(01)00371-9; Choti MA, 2008, CURR COLORECT CANC R, V4, P160, DOI 10.1007/s11888-008-0026-x; Douillard JY, 2002, J CLIN ONCOL, V20, P3605, DOI 10.1200/JCO.2002.04.123; Fong YM, 2013, LANCET ONCOL, V14, P1148, DOI 10.1016/S1470-2045(13)70478-9; Kokudo N, 2007, J CLIN ONCOL, V25, P1299, DOI 10.1200/JCO.2006.09.9069; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; Lembersky BC, 2006, J CLIN ONCOL, V24, P2059, DOI 10.1200/JCO.2005.04.7498; Lorenz M, 1998, ANN SURG, V228, P756, DOI 10.1097/00000658-199812000-00006; Mitry E, 2008, J CLIN ONCOL, V26, P4906, DOI 10.1200/JCO.2008.17.3781; Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9; Nordlinger B, 2013, LANCET ONCOL, V14, P1208, DOI 10.1016/S1470-2045(13)70447-9; Oba M, 2014, ANN SURG ONCOL, V21, P1817, DOI 10.1245/s10434-014-3504-1; Portier G, 2006, J CLIN ONCOL, V24, P4976, DOI 10.1200/JCO.2006.06.8353; Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6; Rudroff C, 1999, LANGENBECK ARCH SURG, V384, P243, DOI 10.1007/s004230050199; Saiura A, 2014, DRUG DISCOV THER, V8, P48, DOI 10.5582/ddt.8.48; Schulze T, 2009, CANCER IMMUNOL IMMUN, V58, P61, DOI 10.1007/s00262-008-0526-1; Shimada Y, 2014, EUR J CANCER, V50, P2231, DOI 10.1016/j.ejca.2014.05.025; Ychou M, 2009, ANN ONCOL, V20, P1964, DOI 10.1093/annonc/mdp236; Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539	26	62	63	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2016	11	9							e0162400	10.1371/journal.pone.0162400	http://dx.doi.org/10.1371/journal.pone.0162400			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EJ	27588959	Green Published, gold, Green Submitted			2023-01-03	WOS:000382877800055
J	Mann, J; Morenga, LT; McLean, R; Swinburn, B; Mhurchu, CN; Jackson, R; Kennedy, J; Beaglehole, R				Mann, Jim; Morenga, Lisa Te; McLean, Rachael; Swinburn, Boyd; Mhurchu, Cliona Ni; Jackson, Rod; Kennedy, Jonathan; Beaglehole, Robert			Dietary guidelines on trial: the charges are not evidence based	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; FATTY-ACIDS; LIFE-STYLE; METAANALYSIS; PREVENTION; MANAGEMENT; OBESITY; RISK		[Mann, Jim; Morenga, Lisa Te; McLean, Rachael] Univ Otago, Dept Human Nutr, Dunedin, New Zealand; [Mann, Jim] Univ Otago, Dept Med, Dunedin, New Zealand; [McLean, Rachael] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; [Mann, Jim; Morenga, Lisa Te] Univ Otago, Riddet Inst, Dunedin, New Zealand; [Mhurchu, Cliona Ni] Univ Auckland, Natl Inst Hlth Innovat, Auckland, New Zealand; [Swinburn, Boyd; Jackson, Rod] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand; [Swinburn, Boyd] Deakin Univ, Ctr Populat Hlth Res, Melbourne, Vic, Australia; [Kennedy, Jonathan] Univ Otago, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; [Beaglehole, Robert] Univ Auckland, Auckland, New Zealand; [Mann, Jim; Morenga, Lisa Te; Mhurchu, Cliona Ni; Jackson, Rod] Univ Otago, Dept Med, Healthier Lives Natl Sci Challenge, Dunedin, New Zealand	University of Otago; University of Otago; University of Otago; University of Otago; University of Auckland; University of Auckland; Deakin University; University of Otago; University of Auckland; University of Otago	Mann, J (corresponding author), Univ Otago, Dept Human Nutr, Dunedin, New Zealand.; Mann, J (corresponding author), Univ Otago, Dept Med, Dunedin, New Zealand.; Mann, J (corresponding author), Univ Otago, Riddet Inst, Dunedin, New Zealand.; Mann, J (corresponding author), Univ Otago, Dept Med, Healthier Lives Natl Sci Challenge, Dunedin, New Zealand.	jim.mann@otago.ac.nz	McLean, Rachael/AAF-7596-2019; Te Morenga, Lisa/C-4459-2011	McLean, Rachael/0000-0002-0005-328X; Te Morenga, Lisa/0000-0003-3526-0091; Jackson, Rod/0000-0001-5914-6934; Ni Mhurchu, Cliona/0000-0002-1144-9167				Bloomfield HE, 2016, ANN INTERN MED, V165, P491, DOI 10.7326/M16-0361; Cleland V, 2013, OBESITY, V21, pE448, DOI 10.1002/oby.20172; de Souza RJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3978; Dietary Guidelines Advisory Committee to the US Department of Health and Human Services and the US Department of Agriculture, 2015, SCI REP 2015 DIET D; Guasch-Ferre M, 2015, AM J CLIN NUTR, V102, P1563, DOI 10.3945/ajcn.115.116046; Hession M, 2009, OBES REV, V10, P36, DOI 10.1111/j.1467-789X.2008.00518.x; Hooper L, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011583.pub2, 10.1002/14651858.CD011737]; Hooper L, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7666; Laatikainen T, 2005, AM J EPIDEMIOL, V162, P764, DOI 10.1093/aje/kwi274; Ley SH, 2014, LANCET, V383, P1999, DOI 10.1016/S0140-6736(14)60613-9; Mann J, 2014, LANCET, V384, P1479, DOI 10.1016/S0140-6736(14)61413-6; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Michas G, 2014, ATHEROSCLEROSIS, V234, P320, DOI 10.1016/j.atherosclerosis.2014.03.013; Mortality Trends, 2014, TRENDS NAT MORT RAT; Nordic Council of Ministers, 2013, NORD NUTR REC 2012 1; O'Flaherty M, 2013, HEART, V99, P159, DOI 10.1136/heartjnl-2012-302300; Tobias DK, 2015, LANCET DIABETES ENDO, V3, P968, DOI 10.1016/S2213-8587(15)00367-8; WHO, 2015, SUG INT AD CHILDR; [WHO Expert Consultation Joint Food and Agriculture Organization of the United Nations], 2008, WHO EXP CONS FATS FA; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P	20	5	5	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2016	388	10047					851	853		10.1016/S0140-6736(16)31278-8	http://dx.doi.org/10.1016/S0140-6736(16)31278-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU0RI	27597453				2023-01-03	WOS:000381911800009
J	Arias, P; Corral-Bergantinos, Y; Robles-Garcia, V; Madrid, A; Oliviero, A; Cudeiro, J				Arias, Pablo; Corral-Bergantinos, Yoanna; Robles-Garcia, Veronica; Madrid, Antonio; Oliviero, Antonio; Cudeiro, Javier			Bilateral tDCS on Primary Motor Cortex: Effects on Fast Arm Reaching Tasks	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; SPINAL NETWORK EXCITABILITY; HEALTHY-SUBJECTS; BRAIN-STIMULATION; CORTICAL STIMULATION; VOLUNTARY MOVEMENT; CHRONIC STROKE; HUMANS; INHIBITION	Background The effects produced by transcranial direct current stimulation (tDCS) applied to the motor system have been widely studied in the past, chiefly focused on primary motor cortex (M1) excitability. However, the effects on functional tasks are less well documented. Objective This study aims to evaluate the effect of tDCS-M1 on goal-oriented actions (i.e., arm-reaching movements; ARM), in a reaction-time protocol. Methods 13 healthy subjects executed dominant ARM as fast as possible to one of two targets in front of them while surface EMG was recorded. Participants performed three different sessions. In each session they first executed ARM (Pre), then received tDCS, and finally executed Post, similar to Pre. Subjects received three different types of tDCS, one per session: In one session the anode was on right-M1 (AR), and the cathode on the left-M1 (CL), thus termed AR-CL; AL-CR reversed the montage; and Sham session was applied likewise. Real stimulation was 1mA-10min while subjects at rest. Three different variables and their coefficients of variation (CV) were analyzed: Premotor times (PMT), reaction-times (RT) and movement-times (MT). Results triceps-PMT were significantly increased at Post-Sham, suggesting fatigue. Results obtained with real tDCS were not different depending on the montage used, in both cases PMT were significantly reduced in all recorded muscles. RT and MT did not change for real or sham stimulation. RT-CV and PMT-CV were reduced after all stimulation protocols. Conclusion tDCS reduces premotor time and fatigability during the execution of fast motor tasks. Possible underlying mechanisms are discussed.	[Arias, Pablo; Corral-Bergantinos, Yoanna; Robles-Garcia, Veronica; Madrid, Antonio; Cudeiro, Javier] Univ A Coruna, INEF Galicia, Dept Med, Neurosci & Motor Control Grp NEUROcom, La Coruna, Spain; [Arias, Pablo; Corral-Bergantinos, Yoanna; Robles-Garcia, Veronica; Madrid, Antonio; Cudeiro, Javier] Univ A Coruna, Biomed Res Inst A Coruna INIBIC, Dept Med, Neurosci & Motor Control Grp NEUROcom, La Coruna, Spain; [Oliviero, Antonio] SESCAM, Hosp Nacl Paraplej, FENNSI Grp, Toledo, Spain; [Cudeiro, Javier] Ctr Estimulac Cerebral Galicia, La Coruna, Spain	Universidade da Coruna; Universidade da Coruna; Instituto de Investigacion Biomedica de A Coruna (INIBIC); Hospital Nacional de Paraplejicos	Arias, P (corresponding author), Univ A Coruna, INEF Galicia, Dept Med, Neurosci & Motor Control Grp NEUROcom, La Coruna, Spain.	pabloarias.neurocom@udc.es	Oliviero, Antonio/ABH-4485-2020; Arias, Pablo/C-7926-2015; Madrid, Antonio/AAS-5777-2020; Arias, Pablo/AAP-9721-2021	Oliviero, Antonio/0000-0001-7723-0478; Madrid, Antonio/0000-0001-8564-6502; Arias, Pablo/0000-0002-9029-5310	Xunta de Galicia, Ayudas Grupos Consolidados (Conselleria de Educacion), Spain; FPU-MECD Spain [AP2010-2774, AP2010-2775]	Xunta de Galicia, Ayudas Grupos Consolidados (Conselleria de Educacion), Spain(Xunta de Galicia); FPU-MECD Spain	This work was supported by Xunta de Galicia, Ayudas Grupos Consolidados (Conselleria de Educacion, 2014), Spain. VRG and YCB are granted by FPU-MECD AP2010-2774 and AP2010-2775 Spain.	Andrews RK, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-51; Battaglia-Mayer A, 2003, CEREB CORTEX, V13, P1009, DOI 10.1093/cercor/13.10.1009; Brass M, 2001, ACTA PSYCHOL, V106, P3, DOI 10.1016/S0001-6918(00)00024-X; Cantello R, 2011, CLIN NEUROPHYSIOL, V122, P1622, DOI 10.1016/j.clinph.2011.01.008; Cengiz B, 2013, EXP BRAIN RES, V225, P321, DOI 10.1007/s00221-012-3369-0; Cisek P, 2010, ANNU REV NEUROSCI, V33, P269, DOI 10.1146/annurev.neuro.051508.135409; COLEBATCH JG, 1989, BRAIN, V112, P749, DOI 10.1093/brain/112.3.749; d'Avella A, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00042; Dean C, 1999, GAIT POSTURE, V10, P135, DOI 10.1016/S0966-6362(99)00026-0; Derakhshan I, 2003, NEUROL RES, V25, P538, DOI 10.1179/016164103101201797; DONDERS FC, 1969, ACTA PSYCHOL, V30, P412, DOI 10.1016/0001-6918(69)90065-1; EICHENBERGER A, 1984, J PHYSIOL-LONDON, V347, P545, DOI 10.1113/jphysiol.1984.sp015082; Faber LG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048073; FERBERT A, 1992, J PHYSIOL-LONDON, V453, P525, DOI 10.1113/jphysiol.1992.sp019243; FLANDERS M, 1991, J NEUROSCI, V11, P2680; Flanders M, 1996, EXP BRAIN RES, V110, P67; FRANK JS, 1986, ELECTROEN CLIN NEURO, V63, P361, DOI 10.1016/0013-4694(86)90021-0; FU QG, 1993, J NEUROPHYSIOL, V70, P2097, DOI 10.1152/jn.1993.70.5.2097; Galletti C, 2003, EXP BRAIN RES, V153, P158, DOI 10.1007/s00221-003-1589-z; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; GEORGOPOULOS AP, 1995, TRENDS NEUROSCI, V18, P506, DOI 10.1016/0166-2236(95)92775-L; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Glover S, 2012, EUR J NEUROSCI, V35, P909, DOI 10.1111/j.1460-9568.2012.08018.x; Gorsler A, 2003, CLIN NEUROPHYSIOL, V114, P1800, DOI 10.1016/S1388-2457(03)00157-3; Goto K, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3658757; GOTTSDANKER R, 1985, J EXP PSYCHOL HUMAN, V11, P765, DOI 10.1037/0096-1523.11.6.765; Hanakawa T, 2011, NEUROSCI RES, V70, P144, DOI 10.1016/j.neures.2011.02.010; Hodges PW, 1996, ELECTROMYOGR MOTOR C, V101, P511, DOI 10.1016/S0921-884X(96)95190-5; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Kalaska JF, 1997, CURR OPIN NEUROBIOL, V7, P849, DOI 10.1016/S0959-4388(97)80146-8; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; Katsuki F, 2014, EUR J NEUROSCI; Kidgell DJ, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-64; Kobayashi M, 2003, NEUROIMAGE, V20, P2259, DOI 10.1016/S1053-8119(03)00220-9; Lindenberg R, 2010, NEUROLOGY, V75, P2176, DOI 10.1212/WNL.0b013e318202013a; Lomond KV, 2010, EXP BRAIN RES, V206, P271, DOI 10.1007/s00221-010-2405-1; Marquez J, 2015, RESTOR NEUROL NEUROS, V33, P509, DOI 10.3233/RNN-140490; Mattia M, 2012, Front Neuroeng, V5, P12, DOI 10.3389/fneng.2012.00012; Mattia M, 2013, J NEUROSCI, V33, P11155, DOI 10.1523/JNEUROSCI.4664-12.2013; MELLAH S, 1990, EXP BRAIN RES, V82, P178; Mirabella G, 2012, CEREB CORTEX, V22, P1124, DOI 10.1093/cercor/bhr187; Mirabella G, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00206; Mirabella G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062793; Mirabella G, 2008, COGN NEUROPSYCHOL, V25, P996, DOI 10.1080/02643290802003216; Mordillo-Mateos L, 2012, BRAIN STIMUL, V5, P214, DOI 10.1016/j.brs.2011.05.001; Nelson JT, 2014, NEUROIMAGE, V85, P909, DOI 10.1016/j.neuroimage.2012.11.061; NETZ J, 1995, EXP BRAIN RES, V104, P527; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Reynolds C, 1999, NEUROLOGY, V53, P730, DOI 10.1212/WNL.53.4.730; RIEDO R, 1988, J PHYSIOL-LONDON, V397, P371, DOI 10.1113/jphysiol.1988.sp017006; Roche N, 2011, J PHYSIOL-LONDON, V589, P2813, DOI 10.1113/jphysiol.2011.205161; Roche N, 2009, J PHYSIOL-LONDON, V587, P5653, DOI 10.1113/jphysiol.2009.177550; Saiote C, 2014, RESTOR NEUROL NEUROS, V32, P423, DOI 10.3233/RNN-130372; Schieppati M, 1996, J PHYSIOL-LONDON, V491, P551, DOI 10.1113/jphysiol.1996.sp021239; Schlaug G, 2008, ARCH NEUROL-CHICAGO, V65, P1571, DOI 10.1001/archneur.65.12.1571; Stagg CJ, 2009, EUR J NEUROSCI, V30, P1412, DOI 10.1111/j.1460-9568.2009.06937.x; Strigaro G, 2015, J PHYSIOL-LONDON, V593, P2365, DOI 10.1113/JP270135; Tanaka M, 2014, BRAIN RES, V1561, P60, DOI 10.1016/j.brainres.2014.03.009; TANJI J, 1976, J NEUROPHYSIOL, V39, P1062, DOI 10.1152/jn.1976.39.5.1062; Vicario CM, 2013, NEUROSCIENCE, V245, P121, DOI 10.1016/j.neuroscience.2013.04.041; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Waters-Metenier S, 2014, J NEUROSCI, V34, P1037, DOI 10.1523/JNEUROSCI.2282-13.2014; Zhang J, 1997, J NEUROSCI, V17, P2227; Ziemann U, 1999, J PHYSIOL-LONDON, V518, P895, DOI 10.1111/j.1469-7793.1999.0895p.x	72	9	10	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2016	11	8							e0160063	10.1371/journal.pone.0160063	http://dx.doi.org/10.1371/journal.pone.0160063			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT3GL	27490752	Green Submitted, Green Published, gold			2023-01-03	WOS:000381368900030
J	Cao, HJ; Mu, YJ; Li, X; Wang, YY; Chen, S; Liu, JP				Cao, Huijuan; Mu, Yujie; Li, Xun; Wang, Yuyi; Chen, Shiuan; Liu, Jian-ping			A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer	PLOS ONE			English	Review							MULTICENTER; GUIDELINES	Background Prostate cancer is the most common malignant tumor associated with male reproductive system. Objective The existing eligible randomized controlled trials (RCTs) were critically appraised for the safety and effectiveness of CHM for prostate cancer. Methods A literature search was conducted by using PubMed, CENTRAL, CNKI, CBM, VIP and Wanfang databases until August 2015. RCTs of CHM or CHM plus conventional medicine for prostate cancer patients were included. The primary outcomes appraised were survival time, time to progression and quality of life. The risk of bias assessment according to the Cochrane Handbook was used to evaluate the methodological quality of the included trials. Revman 5.3 software was used for data analyses. Risk ratio and mean difference (MD) with a 95% confidence interval (CI) were used as effect measures. Meta-analysis was to be used if sufficient trials without obvious clinical or statistical heterogeneity were available. Results A total of 17 RCTs involving 1224 participants were analyzed. One trial was about CHM comparing to no treatment. The remaining 16 trials used CHMs as adjunctive treatment for endocrine therapy. Due to the poor quality of methodologies of most trials, only limited evidence showed that a combination of CHM and endocrine therapy might be more effective in restraining the development of the disease (MD 10.37 months, 95% CI 9.10 to 11.63 months), increasing patients' survival time (7-15 months) or improving patients' performance status, when compared to endocrine therapy alone (Karnofsky performance scale average changed 15 scores between groups). No severe adverse event was reported related to CHM. Conclusion Due to the insufficient quality of trials that were analyzed, it is not appropriate to recommend any kind of CHMs in treating prostate cancer at the present time. Well-designed trials with high methodological quality are needed to validate the effect of CHMs for patients with prostate cancer.	[Cao, Huijuan; Li, Xun; Liu, Jian-ping] Beijing Univ Chinese Med, Beijing, Peoples R China; [Mu, Yujie] Beijing Aerosp Gen Hosp, Beijing, Peoples R China; [Wang, Yuyi] Chongqing Tradit Chinese Hosp, Chongqing, Peoples R China; [Chen, Shiuan] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA USA	Beijing University of Chinese Medicine; City of Hope; Beckman Research Institute of City of Hope	Liu, JP (corresponding author), Beijing Univ Chinese Med, Beijing, Peoples R China.	Liujp@bucm.edu.cn		Liu, Jianping/0000-0002-0320-061X; Li, Xun/0000-0002-3513-5904	State Administration of Traditional Chinese Medicine [201207012]; Beijing Municipal Organization Department talents project [2015000020124G083]; Beijing University of Chinese Medicine [2015-JYB-JSMS037]	State Administration of Traditional Chinese Medicine; Beijing Municipal Organization Department talents project; Beijing University of Chinese Medicine	Jian-Ping Liu is supported by the Research Capacity Establishment Grant (No. 201207012) from the State Administration of Traditional Chinese Medicine. Hui-Juan Cao is supported by the Beijing Municipal Organization Department talents project (Grant No. 2015000020124G083) and the Research Capacity Establishment Grant (No. 2015-JYB-JSMS037) from the Beijing University of Chinese Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Jian-Ping Liu is supported by the Research Capacity Establishment Grant ( No. 201207012) from the State Administration of Traditional Chinese Medicine. Huijuan Cao is supported by the Beijing Municipal Organization Department talents project(Grant No. 2015000020124G083) and the Research Capacity Establishment Grant (No. 2015-JYB-JSMS037) from the Beijing University of Chinese Medicine.	BRENDLER C B, 1988, Keio Journal of Medicine, V37, P10; Chen YY, 2007, SCI TECHNOLOGY INFOR, P194; Chen ZF., 2013, JILIN J MED, V34, P4450; Dong SM., 2007, CHIN J CLIN MED RES, V13, P533; Gu ZM, 2007, J GUANGDONG COLL PHA, P92; Guns E S, 2002, Can J Urol, V9, P1684; Guo W. H., 2010, THESIS; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Higgins J., 2009, COCHRANE HDB SYSTEMA; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hu F.F., 2006, THESIS; Huang GJ, 2010, JIANGSU J TRADITIONA, P18; Huang GQ, 2014, MED FORUM, V18, P1; Jia Ying-Jie, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P448; Klempner SJ, 2012, ONCOLOGIST, V17, P830, DOI 10.1634/theoncologist.2012-0094; Liu H., 2012, CHIN J INF TRADIT CH, V19, P61; Liu SJ, 2012, INFORM TRADITIONAL C, P50; Lu J. X., 2012, THESIS; Oh WK, 2004, J CLIN ONCOL, V22, P3705, DOI 10.1200/JCO.2004.10.195; Pang R, 2013, J SURG INTEGRATIVE T, V19, P374; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng Y, 2010, CHINESE J ANDROLOGY, P53; Peng Y, 2010, CHINESE J ANDROLOGY, P44; Peyromaure M, 2005, J UROLOGY, V174, P1794, DOI 10.1097/01.ju.0000176817.46279.93; Schmitt B, 1999, COCHRANE DB SYST REV, DOI 001510.001002/14651858; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Tang JW, 2014, FORUM TRADITIONAL CH, V29, P15; Twardowski P, 2015, CANCER-AM CANCER SOC, V121, P2942, DOI 10.1002/cncr.29421; Wang Q, 2011, SHIYONG YIYAO ZAZHI, V51, P69; Wang Q., 2009, THESIS; [王宇翎 Wang Yuling], 2005, [中国药理学通报, Chinese Pharmacological Bulletin], V21, P444; Woolam GL, 2000, CA-CANCER J CLIN, V50, P6, DOI 10.3322/canjclin.50.1.6; Yang L, 2015, CHINESE J CANCER RES, V27, P13, DOI 10.3978/j.issn.1000-9604.2015.01.07; Zhang P, 2014, JIANGSU J TRADITIONA, V46, P39; Zheng W., 2014, THESIS; Zhou H, 2013, J SICHUAN TRADITIONA, V31, P95	36	13	14	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2016	11	8							e0160253	10.1371/journal.pone.0160253	http://dx.doi.org/10.1371/journal.pone.0160253			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3GL	27490098	gold, Green Published, Green Submitted			2023-01-03	WOS:000381368900042
J	Din, MO; Danino, T; Prindle, A; Skalak, M; Selimkhanov, J; Allen, K; Julio, E; Atolia, E; Tsimring, LS; Bhatia, SN; Hasty, J				Din, M. Omar; Danino, Tal; Prindle, Arthur; Skalak, Matt; Selimkhanov, Jangir; Allen, Kaitlin; Julio, Ellixis; Atolia, Eta; Tsimring, Lev S.; Bhatia, Sangeeta N.; Hasty, Jeff			Synchronized cycles of bacterial lysis for in vivo delivery	NATURE			English	Article							CANCER; SALMONELLA	The widespread view of bacteria as strictly pathogenic has given way to an appreciation of the prevalence of some beneficial microbes within the human body(1-3). It is perhaps inevitable that some bacteria would evolve to preferentially grow in environments that harbour disease and thus provide a natural platform for the development of engineered therapies(4-6). Such therapies could benefit from bacteria that are programmed to limit bacterial growth while continually producing and releasing cytotoxic agents in situ(7-10). Here we engineer a clinically relevant bacterium to lyse synchronously at a threshold population density and to release genetically encoded cargo. Following quorum lysis, a small number of surviving bacteria reseed the growing population, thus leading to pulsatile delivery cycles. We used microfluidic devices to characterize the engineered lysis strain and we demonstrate its potential as a drug delivery platform via co-culture with human cancer cells in vitro. As a proof of principle, we tracked the bacterial population dynamics in ectopic syngeneic colorectal tumours in mice via a luminescent reporter. The lysis strain exhibits pulsatile population dynamics in vivo, with mean bacterial luminescence that remained two orders of magnitude lower than an unmodified strain. Finally, guided by previous findings that certain bacteria can enhance the efficacy of standard therapies(11), we orally administered the lysis strain alone or in combination with a clinical chemotherapeutic to a syngeneic mouse transplantation model of hepatic colorectal metastases. We found that the combination of both circuit-engineered bacteria and chemotherapy leads to a notable reduction of tumour activity along with a marked survival benefit over either therapy alone. Our approach establishes a methodology for leveraging the tools of synthetic biology to exploit the natural propensity for certain bacteria to colonize disease sites.	[Din, M. Omar; Prindle, Arthur; Selimkhanov, Jangir; Julio, Ellixis; Hasty, Jeff] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Danino, Tal; Skalak, Matt; Allen, Kaitlin; Atolia, Eta; Bhatia, Sangeeta N.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Tsimring, Lev S.; Hasty, Jeff] Univ Calif San Diego, BioCircuits Inst, La Jolla, CA 92093 USA; [Bhatia, Sangeeta N.] Broad Inst Harvard & MIT, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] Brigham & Womens Hosp, Dept Med, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Marble Ctr Canc Nanomed, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Ludwig Ctr Mol Oncol, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Hasty, Jeff] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; [Danino, Tal] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	University of California System; University of California San Diego; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of California System; University of California San Diego; Columbia University	Hasty, J (corresponding author), Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.; Hasty, J (corresponding author), Univ Calif San Diego, BioCircuits Inst, La Jolla, CA 92093 USA.; Hasty, J (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA.	jhasty@eng.ucsd.edu	Din, Omar/AAK-8962-2020	Tsimring, Lev/0000-0003-0709-3548; Allen, Kaitlin/0000-0001-8036-1110; Atolia, Eta/0000-0001-7366-464X	National Institute of General Medical Sciences of the National Institutes of Health [R01GM069811]; San Diego Center for Systems Biology [P50 GM085764]; Koch Institute Support Grant from the National Cancer Institute (Swanson Biotechnology Center) [P30-CA14051]; Core Center Grant from the National Institute of Environmental Health Sciences [P30-ES002109]; Ludwig Center for Molecular Oncology at MIT; Amar G. Bose Research Grant; Misrock Postdoctoral fellowship; NIH Pathway to Independence Award NIH [K99 CA197649-01]; Department of Defense National Defense Science and Engineering Graduate Fellowship; Helen Hay Whitney Foundation; Burroughs Wellcome Fund; NATIONAL CANCER INSTITUTE [R00CA197649, DP1CA174420, K99CA197649, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069811, P50GM085764] Funding Source: NIH RePORTER	National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); San Diego Center for Systems Biology; Koch Institute Support Grant from the National Cancer Institute (Swanson Biotechnology Center); Core Center Grant from the National Institute of Environmental Health Sciences; Ludwig Center for Molecular Oncology at MIT; Amar G. Bose Research Grant; Misrock Postdoctoral fellowship; NIH Pathway to Independence Award NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense National Defense Science and Engineering Graduate Fellowship(United States Department of Defense); Helen Hay Whitney Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The UCSD team was supported by the National Institute of General Medical Sciences of the National Institutes of Health (R01GM069811) and the San Diego Center for Systems Biology (P50 GM085764). The MIT team was supported by a Koch Institute Support Grant (P30-CA14051) from the National Cancer Institute (Swanson Biotechnology Center), a Core Center Grant (P30-ES002109) from the National Institute of Environmental Health Sciences, the Ludwig Center for Molecular Oncology at MIT and an Amar G. Bose Research Grant. T.D. was supported by the Misrock Postdoctoral fellowship and the NIH Pathway to Independence Award NIH (K99 CA197649-01). A.P. was supported by the Department of Defense National Defense Science and Engineering Graduate Fellowship and holds a Simons Foundation Fellowship of the Helen Hay Whitney Foundation and a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. S.N.B. is an HHMI Investigator. We would like to thank R. Johnson for help with constructing microfluidic devices, H. Fleming for help with editing the manuscript, and H. Ding of The Barbara K. Ostrom (1978) Bioinformatics and Computing Facility in the Swanson Biotechnology Center for help with the statistical tests carried out in this study. We would also like to thank L. You for providing the lysis gene used in this study.	Baban Chwanrow K, 2010, Bioeng Bugs, V1, P385, DOI 10.4161/bbug.1.6.13146; Chen RW, 2013, CANCER RES, V73, P1352, DOI 10.1158/0008-5472.CAN-12-1979; Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Danino T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3519; Danino T, 2013, JOVE-J VIS EXP, DOI 10.3791/50540; Danino T, 2012, ACS SYNTH BIOL, V1, P465, DOI 10.1021/sb3000639; Danino T, 2010, NATURE, V463, P326, DOI 10.1038/nature08753; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Derman AI, 2009, MOL MICROBIOL, V73, P534, DOI 10.1111/j.1365-2958.2009.06771.x; Fischbach MA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005568; Forbes NS, 2010, NAT REV CANCER, V10, P784, DOI 10.1038/nrc2934; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; GERDES K, 1988, BIO-TECHNOL, V6, P1402, DOI 10.1038/nbt1288-1402; Hoption Cann SA, 2003, MED J, V79, P672; Leone V, 2015, CELL HOST MICROBE, V17, P681, DOI 10.1016/j.chom.2015.03.006; Loeffler M, 2009, CANCER IMMUNOL IMMUN, V58, P769, DOI 10.1007/s00262-008-0555-9; Marguet P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011909; Pawelek JM, 1997, CANCER RES, V57, P4537; Prindle A, 2012, ACS SYNTH BIOL, V1, P458, DOI 10.1021/sb300060e; Prindle A, 2012, NATURE, V481, P39, DOI 10.1038/nature10722; Ruder WC, 2011, SCIENCE, V333, P1248, DOI 10.1126/science.1206843; Ryan RM, 2009, GENE THER, V16, P329, DOI 10.1038/gt.2008.188; Thaiss CA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005113; Weber W, 2012, NAT REV GENET, V13, P21, DOI 10.1038/nrg3094; WOOD T K, 1990, Biotechnology Techniques, V4, P39, DOI 10.1007/BF00156608; Xuan CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083744; YOUNG KD, 1982, J VIROL, V44, P993, DOI 10.1128/JVI.44.3.993-1002.1982	29	322	341	34	446	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	2016	536	7614					81	+		10.1038/nature18930	http://dx.doi.org/10.1038/nature18930			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS7YM	27437587	Green Submitted, Green Accepted			2023-01-03	WOS:000380999200034
J	Hung, YC; Cheng, YC; Muo, CH; Chiu, HE; Liu, CT; Hu, WL				Hung, Yu-Chiang; Cheng, Yu-Chen; Muo, Chih-Hsin; Chiu, Hsienhsueh Elley; Liu, Chun-Ting; Hu, Wen-Long			Adjuvant Chinese Herbal Products for Preventing Ischemic Stroke in Patients with Atrial Fibrillation	PLOS ONE			English	Article							SALVIA-MILTIORRHIZA; RISK-FACTORS; WARFARIN; DANSHEN; ANTIOXIDANT; THERAPEUTICS; MEDICINE; ESTROGEN; TAIWAN; CELLS	Objective Chinese herbal products (CHPs) are widely used for atrial fibrillation (AF) in Taiwan. We investigated the effect of adjuvant CHPs in preventing ischemic stroke in patients with AF. Methods Taiwanese patients in the Health Insurance Database newly diagnosed with AF during 2000-2011 were enrolled. Medication treatment with/without CHPs was administered within 7 days after the AF diagnosis. The clinical endpoint was an ischemic stroke. The Chi-square test, Fisher's exact test, and Student t test were used to examine differences between the traditional Chinese medicine (TCM) and non-TCM cohorts. Cox proportional hazard regression was used to assess the risk for ischemic stroke between two cohorts. Results Three hundred and eleven patients underwent TCM treatment and 1715 patients did not. Compared to non-TCM users, TCM users had a lower incidence of stroke (12.59% vs. 1.93%, respectively) and lower risk of stroke [CHA(2)DS(2)-VASc score = 0-2 (hazard ratio = 0.20; 95% confidence interval = 0.06-0.65)]. Compared to non-TCM users, the stroke risk was significantly lower in TCM users with AF who were female or younger than 65 years, but not in males, people more than 65 years old, or people with comorbidities. Compared to TCM users, non-TCM users who received conventional treatment had a higher ischemic stroke risk. The risk for AF-related hospitalization was significantly lower in TCM users (0.64%) than in non-TCM users (38.1%). Conclusions Users of TCM with AF have a lower risk of new-onset ischemic stroke. Therefore, adjuvant CHP therapy may have a protective effect and may be used in AF patients to prevent ischemic stroke.	[Hung, Yu-Chiang; Cheng, Yu-Chen; Liu, Chun-Ting; Hu, Wen-Long] Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, Kaohsiung, Taiwan; [Hung, Yu-Chiang; Cheng, Yu-Chen; Liu, Chun-Ting; Hu, Wen-Long] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Hung, Yu-Chiang; Chiu, Hsienhsueh Elley] I Shou Univ, Sch Chinese Med Post Baccalaureate, Kaohsiung, Taiwan; [Muo, Chih-Hsin] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan; [Hu, Wen-Long] Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan; [Hu, Wen-Long] Fooyin Univ, Coll Nursing, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; I Shou University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Kaohsiung Medical University; Fooyin University	Hung, YC; Hu, WL (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, Kaohsiung, Taiwan.; Hung, YC; Hu, WL (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Hung, YC (corresponding author), I Shou Univ, Sch Chinese Med Post Baccalaureate, Kaohsiung, Taiwan.; Hu, WL (corresponding author), Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan.; Hu, WL (corresponding author), Fooyin Univ, Coll Nursing, Kaohsiung, Taiwan.	hungyuchiang@gmail.com; oolonghu@gmail.com	Hu, Wen-Long/N-1660-2014; Liu, Chun-Ting/GWM-4693-2022; Hung, yu-chiang/ABE-7636-2020	Hu, Wen-Long/0000-0001-9549-6202; 	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW) [105TDU-B-212-133019]; China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project [BM10501010037]; NRPB Stroke Clinical Trial Consortium [MOST 104-2325-B039-005]; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project; NRPB Stroke Clinical Trial Consortium; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan	The use of National Health Insurance Research Database (NHIRD) was supported by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All of the authors' contributions were independent from the study sponsors.	Ageno W, 2012, CHEST, V141, pE44S, DOI 10.1378/chest.11-2292; [Anonymous], 2010, CHINESE PHARMACOPOEI, V1, P236; [Anonymous], 2008, TAIWAN J CLIN CHINES, V14, P308; Bonaccini L, 2015, PLANTA MED, V81, P1003, DOI 10.1055/s-0035-1546196; Cai Y, 2004, J AGR FOOD CHEM, V52, P7884, DOI 10.1021/jf0489116; Chan TYK, 2001, ANN PHARMACOTHER, V35, P501, DOI 10.1345/aph.19029; Chao TF, 2012, STROKE, V43, P2551, DOI 10.1161/STROKEAHA.112.667865; Chen Fen-yan, 2015, Zhongguo Zhong Yao Za Zhi, V40, P1649; Chen LC, 2010, INT J GYNECOL OBSTET, V109, P63, DOI 10.1016/j.ijgo.2009.10.014; Chen LY, 2001, CHINESE TRADITIONAL, V32, P134; Chen Q., 1998, PHARM CLIN BASIS REN, P382; Chen WG, 2010, J TRADIT CHIN MED, V30, P47, DOI 10.1016/S0254-6272(10)60012-X; Cheng EY, 2016, AM J CARDIOL, V117, P1021, DOI 10.1016/j.amjcard.2015.12.040; Cheng TO, 2007, INT J CARDIOL, V121, P9, DOI 10.1016/j.ijcard.2007.01.004; Cheng TO, 2006, INT J CARDIOL, V113, P437, DOI 10.1016/j.ijcard.2005.10.026; Chiang TL, 1997, HEALTH POLICY, V39, P225, DOI 10.1016/S0168-8510(96)00877-9; Chien KL, 2010, INT J CARDIOL, V139, P173, DOI 10.1016/j.ijcard.2008.10.045; Chinese Materia Medical Compiling Committee of the National Administration Bureau of Traditional Chinese Medicine, 1998, RAD SALV MILT, P1654; Chiu HE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086351; Chu FY, 2010, CHIN J INTEGR MED, V16, P399, DOI 10.1007/s11655-010-9999-9; Chua YT, 2015, SINGAP MED J, V56, P11, DOI 10.11622/smedj.2015004; Chung JWY, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/819871; Covel CL, 2014, THROMB HAEMOSTASIS, V111, P385, DOI 10.1160/TH13-04-0347; Ge BK, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/957362; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Hung YC, 2010, BBA-PROTEINS PROTEOM, V1804, P1310, DOI 10.1016/j.bbapap.2010.02.001; Hung YC, 2009, J ETHNOPHARMACOL, V124, P463, DOI 10.1016/j.jep.2009.05.020; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Lee JJ, 2011, J ETHNOPHARMACOL, V134, P824, DOI 10.1016/j.jep.2011.01.033; Lee S, 2010, AUTON NEUROSCI-BASIC, V155, P5, DOI 10.1016/j.autneu.2010.02.003; Li J, 2009, J LIAONING U TCM, V11, P83, DOI [10.13194/ j. jlunivtcm. 2009.06.84. lij. 037, DOI 10.13194/J.JLUNIVTCM.2009.06.84.LIJ.037]; Li JL, 2000, RES TRADITIONAL CHIN, V16, P57; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Liu P, 2010, PHYTOMEDICINE, V17, P794, DOI 10.1016/j.phymed.2010.01.004; Liu R, 2013, BRAIN RES, V1514, P83, DOI 10.1016/j.brainres.2013.01.023; Liu S. J., 2015, J PRACTICAL TRADITIO, V29, P7; Liu W, 2015, COMPLEMENT THER MED, V23, P100, DOI 10.1016/j.ctim.2014.12.008; Lomuscio A, 2011, J CARDIOVASC ELECTR, V22, P241, DOI 10.1111/j.1540-8167.2010.01878.x; Lu Li, 2015, Zhong Yao Cai, V38, P781; Marchlinski F, 2012, HARRISONS PRINCIPLES; Michaud GF, 2015, HARRISONS PRINCIPLES; Nagajyothi PC, 2015, J PHOTOCH PHOTOBIO B, V146, P10, DOI 10.1016/j.jphotobiol.2015.02.008; Nutescu EA, 2006, EXPERT OPIN DRUG SAF, V5, P433, DOI 10.1517/14740338.5.3.433; Pellman J, 2015, COMPR PHYSIOL, V5, P649, DOI 10.1002/cphy.c140047; Qin RA, 2014, J ETHNOPHARMACOL, V156, P190, DOI 10.1016/j.jep.2014.08.023; Qin RA, 2012, J TRADIT CHIN MED, V32, P63, DOI 10.1016/S0254-6272(12)60033-8; Qiu Zhong-xia, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P787; Shia CS, 2011, J ETHNOPHARMACOL, V137, P1388, DOI 10.1016/j.jep.2011.08.003; Sim Y, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0922-y; Smith W, 2012, HARRISONS PRINCIPLES; Sohrabji F, 2013, NEUROCHEM INT, V63, P291, DOI 10.1016/j.neuint.2013.06.013; Sze FKH, 2005, ACTA NEUROL SCAND, V111, P118, DOI 10.1111/j.1600-0404.2004.00369.x; Tang Jian-yang, 2012, Xiamen Daxue Xuebao (Ziran Kexue Ban), V51, P789; Tian HL, 2015, INT J GENOMICS, V2015, DOI 10.1155/2015/782635; Tsai CF, 2015, INT J STROKE, V10, P485, DOI 10.1111/ijs.12508; Tsai DS, 2014, J ETHNOPHARMACOL, V155, P1534, DOI 10.1016/j.jep.2014.07.047; Tsai HH, 2013, EUR J CLIN PHARMACOL, V69, P629, DOI 10.1007/s00228-012-1359-6; Wang B, 2013, J PRACT TRADIT CHIN, V29, P168; Wu Bing, 2007, Asian Journal of Ecotoxicology, V2, P18; Wu B, 2007, STROKE, V38, P1973, DOI 10.1161/STROKEAHA.106.473165; Wu CC, 2011, EXP DIABETES RES, DOI 10.1155/2011/514738; Xiao Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/936459; Xu Hong-Ke, 2007, Zhongguo Zhen Jiu, V27, P96; Xu KD, 2015, SCI REP-UK, V5, DOI 10.1038/srep08823; You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304; Zhang DY, 2013, CARBOHYD POLYM, V95, P114, DOI 10.1016/j.carbpol.2013.03.015; Zhou W, 2014, J ETHNOPHARMACOL, V151, P66, DOI 10.1016/j.jep.2013.11.007; Zhou X., 2015, CHINESE MED MODERN D, V12, P50	69	10	10	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2016	11	7							e0159333	10.1371/journal.pone.0159333	http://dx.doi.org/10.1371/journal.pone.0159333			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TD	27428543	Green Published, gold, Green Submitted			2023-01-03	WOS:000380169300052
J	Chen, HY; Chiu, YL; Hsu, SP; Pai, MF; Yang, JY; Peng, YS				Chen, Hung Yuan; Chiu, Yen Ling; Hsu, Shih Ping; Pai, Mei Fen; Yang, Ju Yeh; Peng, Yu Sen			Relationship between Fetuin A, Vascular Calcification and Fracture Risk in Dialysis Patients	PLOS ONE			English	Article							BONE-MINERAL DENSITY; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; SERUM FETUIN; MAINTENANCE HEMODIALYSIS; CARDIOVASCULAR-DISEASE; RANCHO BERNARDO; ASSOCIATION; MORTALITY; HIP	Background Fractures are a common morbidity that lead to worse outcomes in dialysis patients. Fetuin A inhibits vascular calcification (VC), potentially promotes bone mineralization and its level positively correlates with bone mineral density in the general population. On the other hand, the presence of VC is associated with low bone volume in dialysis patients. Whether the fetuin A level and VC can predict the occurrence of fractures in dialysis patients remains unknown. Methods We performed this prospective, observational cohort study including 685 dialysis patients (629 hemodialysis and 56 peritoneal dialysis) from a single center in Taiwan for a median follow-up period of 3.4 years. The baseline fetuin A level and status of presence of aortic arch calcification (VC) and incidence of major fractures (hip, pelvis, humerus, proximal forearm, lower leg or vertebrae) were assessed using adjusted Cox proportional hazards models, recursive partitioning analysis and competing risk models. Results Overall, 177 of the patients had major fractures. The incidence rate of major fractures was 3.29 per 100 person-years. In adjusted analyses, the patients with higher baseline fetuin A levels had a lower incidence of fractures (adjusted hazard ratio (HR), 0.3; 95% CI, 0.18-0.5, fetuin A tertile 3 vs. tertile 1 and HR, 0.52; 95% CI, 0.34-0.78, tertile 2 vs. tertile 1). The presence of aortic arch calcification (VC) independently predicted the occurrence of fractures (adjusted HR, 1.95; 95% CI, 1.34-2.84) as well. When accounting for death as an event in competing risk models, the patients with higher baseline fetuin A levels remained to have a lower incidence of fractures (SHR, 0.31; 95% CI, 0.17-0.56, fetuin A tertile 3 vs. tertile 1 and 0.51; 95% CI, 0.32-0.81, tertile 2 vs. tertile 1). Interpretations Lower baseline fetuin A levels and the presence of VC were independently linked to higher risk of incident fractures in prevalent dialysis patients.	[Chen, Hung Yuan; Chiu, Yen Ling; Hsu, Shih Ping; Pai, Mei Fen; Yang, Ju Yeh; Peng, Yu Sen] Far Eastern Mem Hosp, Dept Internal Med, Div Nephrol, New Taipei, Taiwan; [Chen, Hung Yuan; Chiu, Yen Ling; Hsu, Shih Ping; Pai, Mei Fen; Yang, Ju Yeh; Peng, Yu Sen] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Div Nephrol,Dept Internal Med, Taipei, Taiwan	Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital	Peng, YS (corresponding author), Far Eastern Mem Hosp, Dept Internal Med, Div Nephrol, New Taipei, Taiwan.; Peng, YS (corresponding author), Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Div Nephrol,Dept Internal Med, Taipei, Taiwan.	taan70@yahoo.com.tw	peng, yu/GXW-2071-2022; Chiu, Yen-Ling/AAV-3431-2021	Chiu, Yen-Ling/0000-0003-4504-5571; Yang, Ju-Yeh/0000-0003-3034-021X	Far Eastern Memorial Hospital (FEMH), Taiwan [FEMH-95-C-025, FEMH-2011-C-006, FEMH-2012-D-032, FEMH-2014-D-021, FEMH-2015-D-034]	Far Eastern Memorial Hospital (FEMH), Taiwan	This study was supported by grants from Far Eastern Memorial Hospital (FEMH) (FEMH-95-C-025, FEMH-2011-C-006, FEMH-2012-D-032, FEMH-2014-D-021, FEMH-2015-D-034), Taiwan.	Adragao T, 2009, CLIN J AM SOC NEPHRO, V4, P450, DOI 10.2215/CJN.01870408; Ball AM, 2002, JAMA-J AM MED ASSOC, V288, P3014, DOI 10.1001/jama.288.23.3014; Beaubrun AC, 2013, J AM SOC NEPHROL, V24, P1461, DOI 10.1681/ASN.2012090916; Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532-5415.2003.51110.x; Carballido-Gamio J, 2013, BONE, V57, P290, DOI 10.1016/j.bone.2013.08.017; Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P2264, DOI 10.2215/CJN.09711010; Chen HY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000619; Chen HY, 2010, AM J KIDNEY DIS, V56, P720, DOI 10.1053/j.ajkd.2010.06.015; Chen HY, 2009, EUR J ENDOCRINOL, V160, P777, DOI 10.1530/EJE-08-0813; Chiu YL, 2008, NEPHROL DIAL TRANSPL, V23, P3685, DOI 10.1093/ndt/gfn303; Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024; Drueke TB, 2011, CLIN J AM SOC NEPHRO, V6, P700, DOI 10.2215/CJN.01370211; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fink HA, 2015, J BONE MINER RES, V30, P1394, DOI 10.1002/jbmr.2475; GORDON L, 1985, CANCER TREAT REP, V69, P1065; Hermans MMH, 2007, KIDNEY INT, V72, P202, DOI 10.1038/sj.ki.5002178; Ix JH, 2006, CIRCULATION, V113, P1760, DOI 10.1161/CIRCULATIONAHA.105.588723; Ix JH, 2011, J AM COLL CARDIOL, V58, P2372, DOI 10.1016/j.jacc.2011.08.035; Ix JH, 2009, J BONE MINER RES, V24, P514, DOI [10.1359/jbmr.081017, 10.1359/JBMR.081017]; Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754; Jahnen-Dechent W, 2008, J MOL MED, V86, P379, DOI 10.1007/s00109-007-0294-y; Jahnen-Dechent W, 2011, CIRC RES, V108, P1494, DOI 10.1161/CIRCRESAHA.110.234260; Jamal SA, 2006, J BONE MINER RES, V21, P543, DOI 10.1359/JBMR.060105; Jamal SA, 2007, J BONE MINER RES, V22, P503, DOI 10.1359/JBMR.070112; Jamal SA, 2007, AM J KIDNEY DIS, V49, P674, DOI 10.1053/j.ajkd.2007.02.264; Kapustin AN, 2015, CIRC RES, V116, P1312, DOI 10.1161/CIRCRESAHA.116.305012; Ketteler M, 2003, LANCET, V361, P827, DOI 10.1016/S0140-6736(03)12710-9; Laughlin GA, 2012, J AM COLL CARDIOL, V59, P1688, DOI 10.1016/j.jacc.2012.01.038; London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48; McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224; Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523-1755.2005.00333.x; Modder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217; Ott SM, 2013, NAT REV NEPHROL, V9, P681, DOI 10.1038/nrneph.2013.182; Price PA, 2004, J BIOL CHEM, V279, P19169, DOI 10.1074/jbc.M307880200; Rabier B, 2010, BONE, V46, P176, DOI 10.1016/j.bone.2009.06.032; Roman-Garcia P, 2010, BONE, V46, P121, DOI 10.1016/j.bone.2009.09.006; Rossier A, 2012, NEPHROL DIAL TRANSPL, V27, P352, DOI 10.1093/ndt/gfr326; Rudang R, 2013, J BONE MINER RES, V28, P2305, DOI 10.1002/jbmr.1974; Schafer C, 2003, J CLIN INVEST, V112, P357, DOI 10.1172/JCI200317202; Scialla JJ, 2014, CLIN J AM SOC NEPHRO, V9, P745, DOI 10.2215/CJN.05450513; Seto J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047338; Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279; Tomiyama C, 2010, J BONE MINER RES, V25, P499, DOI 10.1359/jbmr.090735; Toroian D, 2008, CALCIFIED TISSUE INT, V82, P116, DOI 10.1007/s00223-007-9085-2; Toussaint ND, 2009, CLIN J AM SOC NEPHRO, V4, P221, DOI 10.2215/CJN.02550508; van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546; Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P1676, DOI 10.1093/ndt/gfh891; Yamada K, 2008, AM J CLIN NUTR, V87, P106, DOI 10.1093/ajcn/87.1.106	48	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2016	11	7							e0158789	10.1371/journal.pone.0158789	http://dx.doi.org/10.1371/journal.pone.0158789			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ9CN	27398932	Green Published, gold, Green Submitted			2023-01-03	WOS:000379508100008
J	Okumura, N; Kakutani, K; Inoue, R; Matsumoto, D; Shimada, T; Nakahara, M; Kiyanagi, Y; Itoh, T; Koizumi, N				Okumura, Naoki; Kakutani, Kazuya; Inoue, Ryota; Matsumoto, Daiki; Shimada, Tomoki; Nakahara, Makiko; Kiyanagi, Yumiko; Itoh, Takehiro; Koizumi, Noriko			Generation and Feasibility Assessment of a New Vehicle for Cell-Based Therapy for Treating Corneal Endothelial Dysfunction	PLOS ONE			English	Article							INTRAOCULAR IRRIGATING SOLUTIONS; PROLIFERATIVE CAPACITY; ROCK INHIBITOR; IN-VITRO; TRANSPLANTATION; KERATOPLASTY; MEMBRANE; CULTURE; EXPANSION; SURVIVAL	The corneal endothelium maintains corneal transparency by its pump and barrier functions; consequently, its decompensation due to any pathological reason causes severe vision loss due to corneal haziness. Corneal transplantation is the only therapeutic choice for treating corneal endothelial dysfunction, but associated problems, such as a shortages of donor corneas, the difficulty of the surgical procedure, and graft failure, still need to be resolved. Regenerative medicine is attractive to researchers as a means of providing innovative therapies for corneal endothelial dysfunction, as it now does for other diseases. We previously demonstrated the successful regeneration of corneal endothelium in animal models by injecting cultured corneal endothelial cells (CECs) in combination with a Rho kinase (ROCK) inhibitor. The purpose of the present study was to optimize the vehicle for clinical use in cell-based therapy. Our screening of cell culture media revealed that RELAR medium promoted CEC adhesion. We then modified RELAR medium by removing hormones, growth factors, and potentially toxic materials to generate a cell therapy vehicle (CTV) composed of amino acid, salts, glucose, and vitamins. Injection of CECs in CTV enabled efficient engraftment and regeneration of the corneal endothelium in the rabbit corneal endothelial dysfunction model, with restoration of a transparent cornea. The CECs retained > 85% viability after a 24 hour preservation as a cell suspension in CTV at 4 degrees C and maintained their potency to regenerate the corneal endothelium in vivo. The vehicle developed here is clinically applicable for cell-based therapy aimed at treating the corneal endothelium. Our strategy involves the generation of vehicle from a culture medium appropriate for a given cell type by removing materials that are not favorable for clinical use.	[Okumura, Naoki; Kakutani, Kazuya; Inoue, Ryota; Matsumoto, Daiki; Shimada, Tomoki; Nakahara, Makiko; Koizumi, Noriko] Doshisha Univ, Fac Life & Med Sci, Dept Biomed Engn, Kyotanabe, Japan; [Kiyanagi, Yumiko; Itoh, Takehiro] Cell Sci & Technol Inst Inc, Sendai, Miyagi, Japan	Doshisha University	Koizumi, N (corresponding author), Doshisha Univ, Fac Life & Med Sci, Dept Biomed Engn, Kyotanabe, Japan.	nkoizumi@mail.doshisha.ac.jp			Ministry of Education, Culture, Sports, Science and Technology	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Program for the Strategic Research Foundation at Private Universities from Ministry of Education, Culture, Sports, Science and Technology http://www.mext.go.jp/a_menu/koutou/shinkou/07021403/002/002/1218299.htm.	ARAIE M, 1990, ARCH OPHTHALMOL-CHIC, V108, P882, DOI 10.1001/archopht.1990.01070080126049; ARAIE M, 1988, INVEST OPHTH VIS SCI, V29, P1884; Bourne WM, 1997, INVEST OPHTH VIS SCI, V38, P779; Broggi A, 2015, MOL IMMUNOL, V63, P127, DOI 10.1016/j.molimm.2014.06.037; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; ENGELMANN K, 1989, IN VITRO CELL DEV B, V25, P1065; ENGELMANN K, 1995, CORNEA, V14, P62; Eye Bank Association of America, 2013, EYE BANKING STATISTI; GLASSER DB, 1985, AM J OPHTHALMOL, V99, P321, DOI 10.1016/0002-9394(85)90363-0; Ishino Y, 2004, INVEST OPHTH VIS SCI, V45, P800, DOI 10.1167/iovs.03-0016; Joyce NC, 2012, EXP EYE RES, V95, P16, DOI 10.1016/j.exer.2011.08.014; Joyce NC, 2005, EXP EYE RES, V81, P629, DOI 10.1016/j.exer.2005.06.012; Joyce NC, 2003, PROG RETIN EYE RES, V22, P359, DOI 10.1016/S1350-9462(02)00065-4; Kang R, 2014, MOL MED, V20, P466, DOI 10.2119/molmed.2014.00117; Koizumi N, 2007, INVEST OPHTH VIS SCI, V48, P4519, DOI 10.1167/iovs.07-0567; Kruse FE, 2014, CURR OPIN OPHTHALMOL, V25, P325, DOI 10.1097/ICU.0000000000000072; LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010; Li W, 2007, INVEST OPHTH VIS SCI, V48, P614, DOI 10.1167/iovs.06-1126; Mimura T, 2004, INVEST OPHTH VIS SCI, V45, P2992, DOI 10.1167/iovs.03-1174; Nakahara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069009; Okumura N, 2015, INVEST OPHTH VIS SCI, V56, P2933, DOI 10.1167/iovs.14-15163; Okumura N, 2014, CORNEA, V33, pS37, DOI 10.1097/ICO.0000000000000229; Okumura N, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058000, 10.1371/journal.pone.0075961]; Okumura N, 2012, AM J PATHOL, V181, P268, DOI 10.1016/j.ajpath.2012.03.033; Okumura N, 2009, INVEST OPHTH VIS SCI, V50, P3680, DOI 10.1167/iovs.08-2634; Patel SV, 2012, EXP EYE RES, V95, P40, DOI 10.1016/j.exer.2011.05.013; Peh GSL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028310; Peh GSL, 2011, TRANSPLANTATION, V91, P811, DOI 10.1097/TP.0b013e3182111f01; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Price MO, 2013, CURR OPIN OPHTHALMOL, V24, P329, DOI 10.1097/ICU.0b013e32836229ab; Rosin DL, 2011, J AM SOC NEPHROL, V22, P416, DOI 10.1681/ASN.2010040430; Schaefer L, 2014, J BIOL CHEM, V289, P35237, DOI 10.1074/jbc.R114.619304; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shima N, 2011, INVEST OPHTH VIS SCI, V52, P8711, DOI 10.1167/iovs.11-7592; Sumide T, 2006, FASEB J, V20, P392, DOI 10.1096/fj.04-3035fje; Tan DTH, 2012, LANCET, V379, P1749, DOI 10.1016/S0140-6736(12)60437-1; Turner N.A., 2015, J MOL CELL CARDIOL; Veldman PB, 2014, CURR OPIN OPHTHALMOL, V25, P306, DOI 10.1097/ICU.0000000000000073; YAMANE I, 1981, EXP CELL RES, V134, P470, DOI 10.1016/0014-4827(81)90448-1; Zhu C, 2004, INVEST OPHTH VIS SCI, V45, P1743, DOI 10.1167/iovs.03-0814	40	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2016	11	6							e0158427	10.1371/journal.pone.0158427	http://dx.doi.org/10.1371/journal.pone.0158427			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AM	27355373	Green Published, Green Submitted, gold			2023-01-03	WOS:000378859400064
J	Goli, S; Moradhvaj; Rammohan, A; Shruti; Pradhan, J				Goli, Srinivas; Moradhvaj; Rammohan, Anu; Shruti; Pradhan, Jalandhar			High Spending on Maternity Care in India: What Are the Factors Explaining It?	PLOS ONE			English	Article							JANANI SURAKSHA YOJANA; OF-POCKET EXPENDITURE; INSTITUTIONAL DELIVERY; CASH TRANSFER; HEALTH; PROGRAM; BIRTHS; COSTS	Background and Objectives High maternity-related health care spending is often cited as an important barrier in utilizing quality health care during pregnancy and childbirth. This study has two objectives: (i) to measure the levels of expenditure on total maternity care in disaggregated components such as ANCs, PNCs, and Natal care expenditure; (ii) to quantify the extent of catastrophic maternity expenditure (CME) incurred by households and identify the factors responsible for it. Methods and Findings Data from the 71st round of the National Sample Survey (2014) was used to estimate maternity expenditure and its predictors. CME was measured as a share of consumption expenditure by different cut-offs. The two-part model was used to identify the factors associated with maternity spending and CME. The findings show that household spending on maternity care (US$149 in constant price) is much higher than previous estimates (US$50 in constant price). A significant proportion of households in India (51%) are incurring CME. Along with economic and educational status, type of health care and place of residence emerged as significant factors in explaining CME. Conclusion Findings from this study assume importance in the context of an emerging demand for higher maternity entitlements and government spending on public health care in India. To reduce CME, India needs to improve the availability and accessibility of better-quality public health services and increase maternity entitlements in line with maternity expenditure identified in this study.	[Goli, Srinivas; Moradhvaj] JNU, CSRD, SSS, New Delhi, India; [Rammohan, Anu] Univ Western Australia, Discipline Econ, Crawley, WA, Australia; [Shruti] BHU, Discipline Econ, Fac Social Sci, Varanasi, Uttar Pradesh, India; [Pradhan, Jalandhar] Natl Inst Technol, Dept Humanities & Social Sci, Rourkela, Orissa, India	University of Western Australia; Banaras Hindu University (BHU); National Institute of Technology (NIT System); National Institute of Technology Rourkela	Goli, S (corresponding author), JNU, CSRD, SSS, New Delhi, India.	sirispeaks2u@gmail.com	Pradhan, Jalandhar/N-1820-2017; Pradhan, Jalandhar/HIK-1917-2022; Goli, Srinivas/J-7238-2012	Pradhan, Jalandhar/0000-0001-5998-0363; Goli, Srinivas/0000-0002-8481-484X; Rammohan, Anu/0000-0002-9062-4508; , Moradhvaj/0000-0002-8798-385X				[Anonymous], 2012, JOURNAL OF HEALTH EC, V43, P154; Balarajan Y, 2011, LANCET, V377, P505, DOI 10.1016/S0140-6736(10)61894-6; Berki S E, 1986, Health Aff (Millwood), V5, P138, DOI 10.1377/hlthaff.5.4.138; Bonu S., 2007, ERD WORKING PAPER SE, V102; Bonu S, 2009, HEALTH POLICY PLANN, V24, P445, DOI 10.1093/heapol/czp032; Canadian Institute for Health Information (CIHI), 2006, GIV BIRTH CAN; Coffey D, 2014, SOC SCI MED, V114, P89, DOI 10.1016/j.socscimed.2014.05.035; Deaton A., 2010, Economic and Political Weekly, V45, P78; Dhar RSG, 2009, J HEALTH POPUL NUTR, V27, P368; Dongre AA, 2010, EFFECT MONETARY INCE; Dreze J., 2013, UNCERTAIN GLORY INDI, DOI 10.2307/j.ctt32bcbm; Forum for Medical Ethics Society, 2015, ECON POLIT WEEKLY, V40, P22; Garg S, 2012, NATL MED J INDIA, V25, P111; Griffiths P, 2001, J BIOSOC SCI, V33, P339, DOI 10.1017/S002193200100339X; Horton R, 2011, LANCET, V377, P181, DOI 10.1016/S0140-6736(10)62179-4; Hussain Z, 2011, ECON POLIT WEEKLY, V46, P46; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Kesterton AJ, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-30; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Ministry of Finance, 2015, EC SURV IND; Ministry of Health and Family Welfare (MoHFW), 2014, ANN REP 2013 14; Ministry of Health and Family Welfare (MoHFW), 2009, ANN REP PEOPL HLTH; Modugu HR, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1048; Mohanty SK, 2013, MATERN CHILD HLTH J, V17, P1441, DOI 10.1007/s10995-012-1151-3; Mohanty SK, 2013, HEALTH POLICY PLANN, V28, P247, DOI 10.1093/heapol/czs057; MOSPI, 2015, MILL DEV GOALS IND C; Murray CJ, 2000, GLOBAL PROGRAMME EVI, V24; Nalin T, 2011, PAYING PRICE I DELIV; National Sample Survey Organization (NSSO), 2015, 71 NSSO MIN STAT PRO; NSSO, 2004, HLTH CAR COND AG NSS; Office of the Registrar General India, 2013, SPEC B MAT MORT IND; Patnaik U., 2010, ECON POLIT WEEKLY, V45, P74; Patra S, 2016, HEALTH CARE WOMEN IN, V37, P531, DOI 10.1080/07399332.2014.946509; Paul VK, 2011, LANCET, V377, P332, DOI 10.1016/S0140-6736(10)61492-4; Perkins M, 2009, HEALTH POLICY PLANN, V24, P289, DOI 10.1093/heapol/czp013; Roy K, 2007, HEALTH POLICY, V80, P297, DOI 10.1016/j.healthpol.2006.03.012; Sakthivel Selvaraj, 2009, Economic and Political Weekly, V44, P55; Sambo Mohd Nasiq, 2013, Niger Med J, V54, P87, DOI 10.4103/0300-1652.110034; Scott K, 2010, AIDS CARE, V22, P1606, DOI 10.1080/09540121.2010.507751; Sharma DC, 2015, LANCET, V385, P2031, DOI 10.1016/S0140-6736(15)60977-1; Shobha Malini, 2008, Health and Population - Perspectives and Issues, V31, P126; Shukla M, 2015, INDAN J COMMUNITY HE, V27, P241; Skordis-Worrall J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-150; Subramanian SV, 2004, EPIDEMIOL REV, V26, P78, DOI 10.1093/epirev/mxh003; Subramanian SV., 2008, BROWN J WORLD AFF, V14, P127; Subramanyam MA, 2011, INDIAN J MED RES, V133, P461; Sundararaman T, 2015, EC POLITICAL WEEKLY, V50; UNICEF WHO & World Bank Group., 2021, LEVELS TRENDS CHILD; United Nations, 2015, SUST DEV GOAL 3 SDGS; Wagstaff A, 2003, HEALTH ECON, V12, P921, DOI 10.1002/hec.776; WHO, 2010, WOR HEALT REP, P1; WHO UNICEF UNFPA, 2014, WORLD TRENDS MAT MOR; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1; WYSZEWIANSKI L, 1986, HEALTH SERV RES, V21, P617; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	55	26	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2016	11	6							e0156437	10.1371/journal.pone.0156437	http://dx.doi.org/10.1371/journal.pone.0156437			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DP3KZ	27341520	Green Published, gold, Green Submitted			2023-01-03	WOS:000378393600002
J	Coleman, CI; Tangirala, M; Evers, T				Coleman, Craig I.; Tangirala, Muralikrishna; Evers, Thomas			Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States	PLOS ONE			English	Article							MEDICATION PERSISTENCE; THERAPY; SCORE	A retrospective cohort analysis of the US MarketScan claims databases was performed to compare persistence and discontinuation rates between the vitamin K antagonist warfarin and the non-vitamin K antagonist oral anticoagulants rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation. The analysis included adult patients with non-valvular atrial fibrillation newly initiated on rivaroxaban, dabigatran, or warfarin between November 1, 2011 and December 31, 2013, with a baseline CHA2DS2-VASc score >= 2, two or more non-valvular atrial fibrillation diagnosis codes (427.31), and >= 6 months' continuous medical and pharmacy benefit enrollment before oral anticoagulant initiation. Propensity score matching was performed to match patients receiving rivaroxaban with those receiving dabigatran (1: 1) and warfarin (1: 1). Patients were followed until the first event of inpatient death, end of continuous enrollment, or end of study period. Medication persistence was defined as absence of a refill gap of > 60 days. Discontinuation was defined as no additional refill for > 90 days and through to end of follow-up. Hazard ratios (HRs) of oral anticoagulant persistence and discontinuation were estimated using Cox proportional hazard models. In total, 3,2634 patients were included (n = 10878/oral anticoagulant group). Rivaroxaban was associated with better persistence than both dabigatran (HR 0.64, 95% confidence interval [CI] 0.62-0.67) and warfarin (HR 0.62, 95% CI 0.59-0.64) and lower discontinuation than dabigatran (HR 0.61, 95% CI 0.58-0.64) and warfarin (HR 0.65, 95% CI 0.62-0.68). Real world analysis of oral anticoagulant use may reveal whether the relatively high persistence/ low discontinuation demonstrated for rivaroxaban translates into lower rates of stroke.	[Coleman, Craig I.] Univ Connecticut, Sch Pharm, Storrs, CT USA; [Tangirala, Muralikrishna] Bayer HealthCare Pharmaceut, Whippany, NJ USA; [Evers, Thomas] Bayer Pharma AG, Wuppertal, Germany	University of Connecticut; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Coleman, CI (corresponding author), Univ Connecticut, Sch Pharm, Storrs, CT USA.	craig.coleman@hhchealth.org		Coleman, Craig/0000-0003-4868-7158	Bayer HealthCare Pharmaceuticals; Janssen Scientific Affairs, LLC	Bayer HealthCare Pharmaceuticals(Bayer AGBayer Healthcare Pharmaceuticals); Janssen Scientific Affairs, LLC	Funding for this study was provided by Bayer HealthCare Pharmaceuticals who provided support in the form of salaries for author MT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the "author contributions" section. Bayer Pharma AG provided support in the form of salaries for author TE, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the "author contributions" section. This study was also funded by Janssen Scientific Affairs, LLC. who had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Bayer HealthCare, 2011, FDA APPR BAYERS XAR; Beyer-Westendorf J, 2016, EUROPACE, V18, P1150, DOI 10.1093/europace/euv421; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coleman CI, 2013, J INVEST MED, V61, P878, DOI [10.231/JIM.0b013e31828df1bf, 10.2310/JIM.0b013e31828df1bf]; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Danielson E., 2015, HLTH RES DATA REAL W; Douxfils J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000515; Gomes T, 2012, ARCH INTERN MED, V172, P1687, DOI 10.1001/archinternmed.2012.4485; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; January CT, 2014, J AM COLL CARDIOL, V64, P2304, DOI 10.1016/j.jacc.2014.04.004; Laliberte F, 2014, CURR MED RES OPIN, V30, P1317, DOI 10.1185/03007995.2014.907140; Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024; Nelson WW, 2015, CURR MED RES OPIN, V31, P1831, DOI 10.1185/03007995.2015.1074064; Nelson WW, 2014, CURR MED RES OPIN, V30, P2461, DOI 10.1185/03007995.2014.933577; Patel AA, 2013, CLIN THER, V35, P1794, DOI 10.1016/j.clinthera.2013.09.010; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Zalesak M, 2013, CIRC-CARDIOVASC QUAL, V6, P567, DOI 10.1161/CIRCOUTCOMES.113.000192	19	30	30	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2016	11	6							e0157769	10.1371/journal.pone.0157769	http://dx.doi.org/10.1371/journal.pone.0157769			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WU	27327275	Green Published, Green Submitted, gold			2023-01-03	WOS:000378212400041
J	Watts, G				Watts, Geoff			Elizabeth Stanfield Bell Wilson	LANCET			English	Biographical-Item																		WILSON EO, PUBLICATION LIST	1	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2016	387	10036					2376	2376		10.1016/S0140-6736(16)30744-9	http://dx.doi.org/10.1016/S0140-6736(16)30744-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO1ST	27312299	Bronze			2023-01-03	WOS:000377560100019
J	Wilke, S; Groenveld, D; Grittner, U; List, J; Floel, A				Wilke, Skadi; Groenveld, Dennis; Grittner, Ulrike; List, Jonathan; Floeel, Agnes			cSPider - Evaluation of a Free and Open-Source Automated Tool to Analyze Corticomotor Silent Period	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; MILD COGNITIVE IMPAIRMENT; HUMAN MOTOR CORTEX; CORTICAL EXCITABILITY; INTRACORTICAL INHIBITION; SPORTS CONCUSSION; BRAIN-STIMULATION; IFCN COMMITTEE; MUSCLE; INDIVIDUALS	Background The corticomotor silent period (CSP), as assessed noninvasively by transcranial magnetic stimulation (TMS) in the primary motor cortex, has been found to reflect intracortical inhibitory mechanisms. Analysis of CSP is mostly conducted manually. However, this approach is time-consuming, and comparison of results from different laboratories may be compromised by inter-rater variability in analysis. No open source program for automated analysis is currently available. Methods/Results Here, we describe cross-validation with the manual analysis of an in-house written automated tool to assess CSP (cSPider). Results from automated routine were compared with results of the manual evaluation. We found high inter-method reliability between automated and manual analysis (p<0.001), and significantly reduced time for CSP analysis (median = 10.3 sec for automated analysis of 10 CSPs vs. median = 270 sec for manual analysis of 10 CSPs). cSPider can be downloaded free of charge. Conclusion cSPider allows automated analysis of CSP in a reliable and time-efficient manner. Use of this open-source tool may help to improve comparison of data from different laboratories.	[Wilke, Skadi; Groenveld, Dennis; List, Jonathan; Floeel, Agnes] Charite, Dept Neurol, D-13353 Berlin, Germany; [Groenveld, Dennis] Univ Twente, Dept Biomed Engn, POB 217, NL-7500 AE Enschede, Netherlands; [Grittner, Ulrike; Floeel, Agnes] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany; [Floeel, Agnes] Charite, NeuroCure Cluster Excellence, D-13353 Berlin, Germany; [Grittner, Ulrike] Charite, Dept Biostat & Clin Epidemiol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Twente; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wilke, S; Floel, A (corresponding author), Charite, Dept Neurol, D-13353 Berlin, Germany.; Floel, A (corresponding author), Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany.; Floel, A (corresponding author), Charite, NeuroCure Cluster Excellence, D-13353 Berlin, Germany.	skadi.wilke@charite.de; agnes.floeel@charite.de	Grittner, Ulrike/I-2026-2019; Floel, Agnes/A-9426-2017	Grittner, Ulrike/0000-0003-2595-0224; Wilke, Skadi/0000-0002-1424-516X	Deutsche Forschungsgemeinschaft [Fl- 365 379-8/1, 379-10/1, 379-11/1, DFG-Exc-257]; Bundesministerium fur Bildung und Forschung [FKZ0315673A, 01EO0801, 01GY1144]; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Charite Universitatsmedizin Berlin; Berlin Institute of Health	This work was supported by grants from the Deutsche Forschungsgemeinschaft (AF: Fl- 365 379-8/1; 379-10/1; 379-11/1; DFG-Exc-257, http://www.dfg.de/), and Bundesministerium fur Bildung und Forschung (AF: FKZ0315673A; 01EO0801; 01GY1144, https://www.bmbf.de/). JL is a participant in the Charite Clinical Scientist Program funded by the Charite Universitatsmedizin Berlin and the Berlin Institute of Health (http://www.charite.de/charite/, https://www.bihealth.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; [Anonymous], 2014, NATURE, V514, P536, DOI 10.1038/514536a; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; CANTELLO R, 1992, NEUROLOGY, V42, P1951; Cantello R, 2002, J CLIN NEUROPHYSIOL, V19, P272, DOI 10.1097/00004691-200208000-00003; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Damron LA, 2008, J NEUROSCI METH, V173, P121, DOI 10.1016/j.jneumeth.2008.06.001; Daskalakis ZJ, 2003, CLIN NEUROPHYSIOL, V114, P938, DOI 10.1016/S1388-2457(03)00038-5; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Durkovic J, 2008, MANAG INFORATION SYS, V3; Easterbrook SM, 2014, NAT GEOSCI, V7, P779, DOI 10.1038/ngeo2283; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hautzinger M., 2006, BECK DEPRESSIONS INV; Ho KH, 1998, EXP BRAIN RES, V122, P433, DOI 10.1007/s002210050531; Huang YD, 2013, BRIEF BIOINFORM, V14, P391, DOI 10.1093/bib/bbs078; Inghilleri M, 1996, EXP BRAIN RES, V109, P467; Julkunen P, 2013, J NEUROSCI METH, V217, P75, DOI 10.1016/j.jneumeth.2013.04.019; Kallioniemi E, 2014, CLIN NEUROPHYSIOL, V125, P2247, DOI 10.1016/j.clinph.2014.03.012; King NKK, 2006, J NEUROSCI METH, V150, P96, DOI 10.1016/j.jneumeth.2005.06.007; List J, 2014, BRAIN STIMUL, V7, P381, DOI 10.1016/j.brs.2014.02.006; Macdonell RAL, 2001, NEUROLOGY, V57, P706, DOI 10.1212/WNL.57.4.706; McClintock SM, 2011, BIOL PSYCHIAT, V70, P19, DOI 10.1016/j.biopsych.2011.02.031; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Menzler K, 2014, EPILEPSIA, V55, P362, DOI 10.1111/epi.12515; Nilsson J, 1997, J CLIN NEUROPHYSIOL, V14, P136, DOI 10.1097/00004691-199703000-00006; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Poston B, 2012, EUR J NEUROSCI, V36, P2964, DOI 10.1111/j.1460-9568.2012.08212.x; Rabago CA, 2009, CLIN NEUROPHYSIOL, V120, P1577, DOI 10.1016/j.clinph.2009.04.020; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Tataroglu C, 2004, SEIZURE-EUR J EPILEP, V13, P481, DOI 10.1016/j.seizure.2003.11.003; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2013, NEUROREPORT, V24, P46, DOI 10.1097/WNR.0b013e32835c36b8; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; van Kuijk AAA, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-1; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x; ZIEMANN U, 1993, NEUROSCI LETT, V156, P167, DOI 10.1016/0304-3940(93)90464-V	48	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2016	11	6							e0156066	10.1371/journal.pone.0156066	http://dx.doi.org/10.1371/journal.pone.0156066			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN6KZ	27249017	gold, Green Published, Green Submitted			2023-01-03	WOS:000377184700028
J	Wise, J				Wise, Jacqui			GPs achieve dramatic cut in antibiotic prescriptions	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		O'Neill J., 2016, Tackling drug-resistant infections globally: final report and recommendations; Owen J, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2863	2	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2016	353								i3002	10.1136/bmj.i3002	http://dx.doi.org/10.1136/bmj.i3002			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN3CL	27229522				2023-01-03	WOS:000376939900009
J	Withington, P				Withington, Phil			The art of medicine Utopia, health, and happiness	LANCET			English	Editorial Material									[Withington, Phil] Univ Sheffield, Dept Hist, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Withington, P (corresponding author), Univ Sheffield, Dept Hist, Sheffield S10 2TN, S Yorkshire, England.	p.withington@sheffield.ac.uk			ESRC [ES/K00493X/1] Funding Source: UKRI; Economic and Social Research Council [ES/K00493X/1] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		[Anonymous], 2011, HAPPINESS LESSONS NE; Davies W., 2015, HAPPINESS IND GOVT B; Dolan P., 2014, HAPPINESS DESIGN FIN; Withington Phil., 2017, SUFFERING HAPPINESS	4	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2016	387	10033					2084	2085		10.1016/S0140-6736(16)30532-3	http://dx.doi.org/10.1016/S0140-6736(16)30532-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DM6HC	27308674	Green Accepted			2023-01-03	WOS:000376450800018
J	Apicella, M; Migliore, C; Capeloa, T; Menegon, S; Cargnelutti, M; Degiuli, M; Sapino, A; Sottile, A; Sarotto, I; Casorzo, L; Cassoni, P; De Simone, M; Comoglio, PM; Marsoni, S; Corso, S; Giordano, S				Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Degiuli, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; Cassoni, P.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.			Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; GENE AMPLIFICATION; LUNG-CANCER; ACTIVATION; MUTATIONS; ADENOCARCINOMA; SENSITIVITY; INHIBITORS; GEFITINIB; GROWTH	Amplification of the MET oncogene occurs in 2-4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level ( 26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.	[Apicella, M.; Migliore, C.; Corso, S.; Giordano, S.] Univ Torino, Dept Oncol, Candiolo, Italy; [Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy; [Capeloa, T.] Univ Torino, Dept Clin & Biol Sci, Orbassano, Italy; [Degiuli, M.] Osped Molinette, Dept Surg, Turin, Italy; [Sapino, A.; Cassoni, P.] Univ Torino, Dept Med Sci, Turin, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Corso, S; Giordano, S (corresponding author), Univ Torino, IRCCS, FPO, Candiolo Canc Inst,Dept Oncol, Str Prov 142, I-10060 Turin, Italy.	simona.corso@unito.it; silvia.giordano@unito.it	Sapino, Anna/AGY-9901-2022; Giordano, Silvia/J-9858-2018; Sapino, Anna/J-4113-2018; Casorzo, Laura/AAB-7684-2020; Cassoni, Paola/I-8544-2018; sarotto, ivana/AAB-7797-2020	Sapino, Anna/0000-0003-3542-9571; Giordano, Silvia/0000-0003-1854-1086; Sapino, Anna/0000-0003-3542-9571; Casorzo, Laura/0000-0002-2509-7369; CORSO, Simona/0000-0002-5069-1503; Menegon, Silvia/0000-0002-5078-2464; Migliore, Cristina/0000-0003-3722-2814; Marsoni, Silvia/0000-0002-5361-7122; sottile, antonino/0000-0003-4252-3240; Comoglio, Paolo/0000-0002-7056-5328	Italian Association for Cancer Research (AIRC) [15464]; Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	We thank all our colleagues for helpful scientific discussion; Drs Martinoglio, Porporato and Buscarino for technical support with RT-PCR and sequencing; Dr Perra for tumor microdissection; Dr Giove for support with immunohistochemistry; animal facility employees; Dr Natale for critical manuscript reading. SG and SC are EuroPDX Consortium members. This work was funded by the Italian Association for Cancer Research (AIRC); IG grant 15464 to SG and Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute 2013.	Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2102er11; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Crew KD, 2004, SEMIN ONCOL, V31, P450, DOI 10.1053/j.seminoncol.2004.04.021; Cunningham D, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.16; Doi T., 2015, J CLIN ONCOL S3, V33; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Lee J, 2015, ONCOTARGET, V6, P28211, DOI 10.18632/oncotarget.4721; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Puri Neelu, 2008, J Carcinog, V7, P9; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Shah AM, 2015, J CLIN ONCOL, V33; Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Wild CP, 2003, NAT REV CANCER, V3, P676, DOI 10.1038/nrc1166	33	22	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1200	1210		10.1038/onc.2016.283	http://dx.doi.org/10.1038/onc.2016.283			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524418				2023-01-03	WOS:000395861300004
J	Kim, JE; Go, J; Koh, EK; Song, SH; Sung, JE; Lee, HA; Lee, YH; Hong, JT; Hwang, DY				Kim, Ji Eun; Go, Jun; Koh, Eun Kyoung; Song, Sung Hwa; Sung, Ji Eun; Lee, Hyun Ah; Lee, Young Hee; Hong, Jin Tae; Hwang, Dae Youn			Gallotannin-Enriched Extract Isolated from Galla Rhois May Be a Functional Candidate with Laxative Effects for Treatment of Loperamide-Induced Constipation of SD Rats	PLOS ONE			English	Article							TANNINS; POMEGRANATE; INHIBITION; GROWTH; LEAVES; CELLS	Several natural products containing tannins are used as traditional medicines for treatment of constipation; however, their pharmacological mechanism is not well understood. The laxative effects of gallotannin-enriched extract isolated from Galla Rhois (GEGR) were investigated using a constipation model induced by loperamide (Lop) injection. After analysis for antioxidant activity of GEGR, alterations in the excretion parameters, histological structure, mucin secretion, and related protein levels were measured in the transverse colon of Sprague Dawley (SD) rats with Lop-induced constipation following treatment with 250, 500 and 1,000 mg/ml of GEGR. The number and weight of feces increased significantly by 48-79% and 128-159%, respectively, in the Lop+GEGR treated group relative to the Lop+vehicle treated group, while food intake and water consumption were maintained at a constant level. The thickness of mucosa, muscle and flat luminal surface, as well as the number of goblet cells and crypt of lieberkuhnwere enhanced in the Lop+GEGR treated group. Moreover, mucin secretion increased significantly in a dose dependent manner in the Lop+GEGR treated group. Furthermore, the downstream signaling pathway of the muscarinic acetylcholine receptors (mAChR) M2 and M3 was recovered by GEGR treatment, although the expression level varied. The levels of Ga expression and inositol triphosphate (IP3) concentration were also recovered in the Lop+GEGR treated group relative to the Lop+vehicle treated group. The results of the present study provide strong evidence that tannins distributed in various medicinal plants are important candidates for improving chronic constipation induced by Lop treatment in animal models.	[Kim, Ji Eun; Go, Jun; Koh, Eun Kyoung; Song, Sung Hwa; Sung, Ji Eun; Lee, Hyun Ah; Hwang, Dae Youn] Pusan Natl Univ, Dept Biomat Sci, Coll Nat Resources & Life Sci, Life & Ind Convergence Res Inst, Miryang, South Korea; [Lee, Young Hee] Pusan Natl Univ, Dept Organ Mat Sci & Engn, Busan, South Korea; [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Chungju, South Korea	Pusan National University; Pusan National University; Chungbuk National University	Hwang, DY (corresponding author), Pusan Natl Univ, Dept Biomat Sci, Coll Nat Resources & Life Sci, Life & Ind Convergence Res Inst, Miryang, South Korea.	dyhwang@pusan.ac.kr	Lee, Young Hee/A-5424-2013		Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2014R1A1A2058360]; Korea Institute of Planning Evaluation for Technology of Food, Agriculture, Forestry and Fisheries [114034-03-1-HD030]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education; Korea Institute of Planning Evaluation for Technology of Food, Agriculture, Forestry and Fisheries	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2058360).; We thank Jin Hyang Hwang and the animal technicians for directing the Animal Facility and Care at the Laboratory Animal Resources Center. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2058360) and the Korea Institute of Planning Evaluation for Technology of Food, Agriculture, Forestry and Fisheries (grant no. 114034-03-1-HD030).	Abbas S, 2012, PHYTOTHER RES, V26, P704, DOI 10.1002/ptr.3634; AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; Ahn YJ, 1998, J APPL MICROBIOL, V84, P439, DOI 10.1046/j.1365-2672.1998.00363.x; [Anonymous], 1969, FOOD COSMET TOXICOL, V7, P364; Ata N, 1996, ONCOL RES, V8, P503; Barbehenn RV, 2011, PHYTOCHEMISTRY, V72, P1551, DOI 10.1016/j.phytochem.2011.01.040; Burleigh DE, 1998, EUR J PHARMACOL, V152, P39; CELIK AF, 1995, ALIMENT PHARM THER, V9, P63; Cha ChunNam, 2013, Journal of Veterinary Clinics, V30, P353; Chae HS, 2010, AM J CHINESE MED, V38, P973, DOI 10.1142/S0192415X10008391; Clinton C, 2009, NAT MED J, V1, P13; De Lillo AR, 2000, AM J GASTROENTEROL, V95, P901, DOI 10.1016/S0002-9270(00)00718-8; Go Jun, 2015, Lab Anim Res, V31, P101, DOI 10.5625/lar.2015.31.3.101; Guarize L, 2012, NAT PROD RES, V26, P331, DOI 10.1080/14786411003754264; Hs S Oz, 2005, J NUTR BIOCH, V16, P297; Karlsson NG, 1997, J BIOL CHEM, V272, P27025, DOI 10.1074/jbc.272.43.27025; 차준남, 2013, [Journal of Food Hygiene and Safety, 한국식품위생안전성학회지], V28, P95, DOI 10.13103/JFHS.2013.28.2.095; Khalif IL, 2005, DIGEST LIVER DIS, V37, P838, DOI 10.1016/j.dld.2005.06.008; Khan N, 2007, CANCER RES, V67, P3475, DOI 10.1158/0008-5472.CAN-06-3941; Kim JE, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-333; Kim SH, 2005, INT IMMUNOPHARMACOL, V5, P1820, DOI 10.1016/j.intimp.2005.06.007; Kumari M, 2012, RES J RECENT SCI, V1, P70; Lee HY, 2012, FOOD CHEM TOXICOL, V50, P895, DOI 10.1016/j.fct.2011.12.001; Lee JJ, 2012, AVIAN PATHOL, V41, P403, DOI 10.1080/03079457.2012.702888; Lee S. M., 1997, J APPL ENTOMOL, V36, P83; Lee TY, 2006, J PHARM PHARMACOL, V58, P659, DOI 10.1211/jpp.58.5.0011; Lee YH, 2015, TEXT RES J, V85, P1045, DOI 10.1177/0040517514559580; Lee YH, 2009, MATERIALS, V2, P10, DOI 10.3390/ma2010010; Meite S, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-7; Najeeb-ur-Rehman, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-16; Oh H, 2003, PHYTOTHER RES, V17, P417, DOI 10.1002/ptr.1148; Philippe D, 2003, J CLIN INVEST, V111, P1329, DOI 10.1172/JCI200316750; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Shimotoyodome A, 2000, COMP BIOCHEM PHYS A, V126, P203, DOI 10.1016/S1095-6433(00)00194-X; Voderholzer WA, 1997, AM J GASTROENTEROL, V92, P95; Walia R, 2009, CURR OPIN PEDIATR, V21, P661, DOI 10.1097/MOP.0b013e32832ff241; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005; Wintola OA, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-95; Zoppi G, 1998, ACTA PAEDIATR, V87, P836, DOI 10.1080/080352598750013590	39	21	21	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2016	11	9							e0161144	10.1371/journal.pone.0161144	http://dx.doi.org/10.1371/journal.pone.0161144			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5AC	27618438	Green Published, gold, Green Submitted			2023-01-03	WOS:000383653100006
J	Gulland, A				Gulland, Anne			Drug deaths hit record high in England and Wales, figures show	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Office for National Statistics, 2016, DEATHS REL DRUG POIS; Public Health England, 2016, UND PREV DRUG REL DE; Wise J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4754	3	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2016	354								i4921	10.1136/bmj.i4921	http://dx.doi.org/10.1136/bmj.i4921			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV7FM	27613757				2023-01-03	WOS:000383101800012
J	Mukumbang, FC; van Belle, S; Marchal, B; van Wyk, B				Mukumbang, Ferdinand C.; van Belle, Sara; Marchal, Bruno; van Wyk, Brian			Towards Developing an Initial Programme Theory: Programme Designers and Managers Assumptions on the Antiretroviral Treatment Adherence Club Programme in Primary Health Care Facilities in the Metropolitan Area of Western Cape Province, South Africa	PLOS ONE			English	Article							HIV; MECHANISMS; RETENTION; TANZANIA; BARRIERS	Background The antiretroviral adherence club intervention was rolled out in primary health care facilities in theWestern Cape province of South Africa to relieve clinic congestion, and improve retention in care, and treatment adherence in the face of growing patient loads. We adopted the realist evaluation approach to evaluate what aspects of antiretroviral club intervention works, for what sections of the patient population, and under which community and health systems contexts, to inform guidelines for scaling up of the intervention. In this article, we report on a step towards the development of a programme theory-the assumptions of programme designers and health service managers with regard to how and why the adherence club intervention is expected to achieve its goals and perceptions on how it has done so (or not). Methods We adopted an exploratory qualitative research design. We conducted a document review of 12 documents on the design and implementation of the adherence club intervention, and key informant interviews with 12 purposively selected programme designers and managers. Thematic content analysis was used to identify themes attributed to the programme actors, context, mechanisms, and outcomes. Using the context-mechanism-outcome configurational tool, we provided an explanatory focus of how the adherence club intervention is roll-out and works guided by the realist perspective. Results We classified the assumptions of the adherence club designers and managers into the roll-out, implementation, and utilisation of the adherence club programme, constructed around the providers, management/operational staff, and patients, respectively. Two rival theories were identified at the patient-perspective level. We used these perspectives to develop an initial programme theory of the adherence club intervention, which will be tested in a later phase. Conclusion The perspectives of the programme designers and managers provided an important step towards developing an initial programme theory, which will guide our realist evaluation of the adherence club programme in South Africa.	[Mukumbang, Ferdinand C.; Marchal, Bruno; van Wyk, Brian] Univ Western Cape, Sch Publ Hlth, Bellville, Western Cape Pr, South Africa; [Mukumbang, Ferdinand C.; van Belle, Sara; Marchal, Bruno] Inst Trop Med, Dept Publ Hlth, Antwerp, Belgium; [van Belle, Sara] Univ Antwerp, Inst Dev & Management, Antwerp, Belgium	University of the Western Cape; Institute of Tropical Medicine (ITM); University of Antwerp	Mukumbang, FC (corresponding author), Univ Western Cape, Sch Publ Hlth, Bellville, Western Cape Pr, South Africa.; Mukumbang, FC (corresponding author), Inst Trop Med, Dept Publ Hlth, Antwerp, Belgium.	mukumbang@gmail.com	Mukumbang, Ferdinand C/J-4215-2019; Van Belle, Sara/HHN-6814-2022; Mukumbang, Ferdinand/GQB-3347-2022	Mukumbang, Ferdinand C/0000-0003-1441-2172; 	Medical Research Council of South Africa; African Doctoral Dissertation Research Fellowship (ADDRF) award by the Africa Population and Health Research Center (APHRC); International Development Research Centre (IDRC)	Medical Research Council of South Africa(South African Medical Research Council); African Doctoral Dissertation Research Fellowship (ADDRF) award by the Africa Population and Health Research Center (APHRC); International Development Research Centre (IDRC)	The PhD from which this study emanated was funded by the Medical Research Council of South Africa in terms of the National Health Scholars Programme from funds provided for this purpose by the National Department of Health, http://www.mrc.ac.za/. This research was partially funded by an African Doctoral Dissertation Research Fellowship (ADDRF) award offered by the Africa Population and Health Research Center (APHRC) in partnership with the International Development Research Centre (IDRC), http://aphrc.org/.	Adefolalu AO., 2013, DISEASES-BASEL, V1, P18, DOI [10.3390/diseases1010018, DOI 10.3390/DISEASES1010018, 0.3390/diseases1010018]; Astbury B, 2010, AM J EVAL, V31, P363, DOI 10.1177/1098214010371972; Bateman C, 2013, SAMJ S AFR MED J, V103, P71, DOI [10.7196/samj.6666, 10.7196/SAMJ.6666]; Bemelmans M, 2014, TROP MED INT HEALTH, V19, P968, DOI 10.1111/tmi.12332; Berman P., 1978, STUDY MACRO MICROIMP; Bezabhe WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097353; Birckmayer JD, 2000, THEORY BASED EVALUAT; Blamey A, 2007, EVALUATION-US, V13, P439, DOI [10.1177/1356389007082129, DOI 10.1177/1356389007082129]; Bowen GA, 2009, QUAL RES J, V9, P27, DOI 10.3316/QRJ0902027; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Campion EW, 2015, NEW ENGL J MED, V372, P301, DOI 10.1056/NEJMp1414213; Creswell J.W., 2003, RES DESIGN, Vsecond; Decroo T, 2013, INT HEALTH, V5, P169, DOI 10.1093/inthealth/iht016; Ford N, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001060; Gerbic P., 2005, Internet and Higher Education, V8, P45, DOI 10.1016/j.iheduc.2004.12.003; Grimsrud A, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19984; Kagee A, 2011, GLOB PUBLIC HEALTH, V6, P83, DOI 10.1080/17441691003796387; Kheswa J., 2014, MEDITERR J SOC SCI, V5, P450, DOI [10. 5901/mjss.2014.95914p450, DOI 10.5901/MJSS.2014.95914P450]; Leeuw FL, 2003, AM J EVAL, V24, P5, DOI 10.1177/109821400302400102; Linsley P, 2015, NURSE RES, V22, P28, DOI 10.7748/nr.22.3.28.e1306; Luque-Fernandez MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056088; Manzano A, 2016, EVALUATION-US, V22, P342, DOI 10.1177/1356389016638615; Marsland R, 2012, MED ANTHROPOL Q, V26, P470, DOI 10.1111/maq.12002; Miles M.B., 1994, QUALITATIVE DATA ANA; Mukumbang FC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009977; O'Reilly M, 2013, QUAL RES, V13, P190, DOI 10.1177/1468794112446106; Pawson R, 2003, ESRC UK CTR EVIDENCE, V18, P1; Pawson R., 2006, EVIDENCE BASED POLIC, DOI DOI 10.4135/9781849209120; Pawson R., 2009, EVIDENCE BASED PUBLI, P43, DOI [DOI 10.1093/ACPROF:OSO/9780199563623.003.04, DOI 10.1093/ACPROF:0S0/9780199563623.001.0001]; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; Pawson R, 2012, EVALUATION-US, V18, P176, DOI 10.1177/1356389012440912; Pedersen LH, 2008, EVALUATION, V14, P271, DOI [10.1177/1356389008090856, DOI 10.1177/1356389008090856]; Porter S, 2007, J ADV NURS, V60, P79, DOI 10.1111/j.1365-2648.2007.04360.x; Rasschaert F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091544; Roura M, 2009, AIDS PATIENT CARE ST, V23, P203, DOI 10.1089/apc.2008.0129; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Shenton A. K., 2004, ED INFORM, V22, P63, DOI DOI 10.3233/EFI-2004-22201; Thaler R., 2008, NUDGE; Tilley N., 1997, REALIST EVALUATION; Tilley N., 2004, REALIST EVALUATION; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Treatment Action Campaign, 2015, 12 TREATM ACT CAMP, P57; Tufford L, 2012, QUAL SOC WORK, V11, P80, DOI 10.1177/1473325010368316; Uebel KE, 2013, JAIDS-J ACQ IMM DEF, V63, pE94, DOI 10.1097/QAI.0b013e318291cd08; UNAIDS, 2016, NUMB PEOPL LIV HIV; Vandendyck M, 2015, AIDS RES TREAT OPEN, V2, P44, DOI [10.17140/HARTOJ-2-107, DOI 10.17140/HARTOJ-2-107]; Wand T, 2011, NURS HEALTH SCI, V13, P199, DOI 10.1111/j.1442-2018.2011.00601.x; Westhorp, 2014, REALIST IMPACT EVALU; Wilkinson LS, 2013, S AFR J HIV MED, V14, P48, DOI [10.7196/SAJHIVMED.924, 10.7196/sajhivmed.924]; Wong G., 2013, REALIST SYNTHESIS RA	50	23	24	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2016	11	8							e0161790	10.1371/journal.pone.0161790	http://dx.doi.org/10.1371/journal.pone.0161790			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DU5NN	27560352	Green Published, Green Submitted, gold			2023-01-03	WOS:000382258600099
J	Fattahi, F; Brandsma, CA; Lodewijk, M; Reinders-Luinge, M; Postma, DS; Timens, W; Hylkema, MN; Ten Hacken, NHT				Fattahi, Fatemeh; Brandsma, Corry-Anke; Lodewijk, Monique; Reinders-Luinge, Marjan; Postma, Dirkje S.; Timens, Wim; Hylkema, Machteld N.; Ten Hacken, Nick H. T.			Atopy and Inhaled Corticosteroid Use Associate with Fewer IL-17(+) Cells in Asthmatic Airways	PLOS ONE			English	Article							T(H)17 CELLS; TH17 CELLS; INFLAMMATION; NEUTROPHILIA; EXPRESSION; INTERLEUKIN-17; DISTINCT; MODERATE; LINEAGE; SPUTUM	Background Interleukin (IL)-17 plays a critical role in numerous immune and inflammatory responses and was recently suggested to contribute to the pathogenesis of nonatopic (non-eosinophil/neutrophil-dominant) asthma. We aimed to compare expression of IL-17 in bronchial airways between atopic and nonatopic asthmatics, with/without inhaled corticosteroid (ICS) use and to identify its major cellular source. Methods Bronchial biopsies from 114 patients with mild-to-moderate asthma were investigated: 33 nonatopic, 63 non-corticosteroid users, 90 nonsmokers. IL-17 expression was correlated with atopy and inflammatory cell counts (EPX, NP57, CD3, CD4, CD8, CD20, CD68), taking ICS use and smoking into account. Multiple linear regression analyses were used to determine the independent factors as well as the most relevant inflammatory cells contributing to IL-17 expression. Double immunostainings were performed to confirm the major cellular source of IL-17. Results In non-ICS users, nonatopic asthmatics had more IL-17(+) cells in the airway wall than atopic asthmatics. In both atopic and nonatopic asthmatics, ICS use was associated with lower numbers of IL-17(+) cells, independent of smoking. The number of IL-17(+) cells was associated with the number of neutrophils (B: 0.26, 95% CI: 0.17-0.35) and eosinophils (B: 0.18, 95% CI: 0.07-0.29). The majority of IL-17(+) cells were neutrophils, as confirmed by double immunostaining. Conclusions We show for the first time that atopy and ICS use are associated with lower numbers of IL-17(+) cells in asthmatic airways. Importantly, IL-17(+) cells were mostly neutrophils which conflicts with the paradigm that lymphocytes (Th17) are the main source of IL-17.	[Fattahi, Fatemeh; Postma, Dirkje S.; Ten Hacken, Nick H. T.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Fattahi, Fatemeh; Brandsma, Corry-Anke; Lodewijk, Monique; Reinders-Luinge, Marjan; Timens, Wim; Hylkema, Machteld N.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Fattahi, Fatemeh; Brandsma, Corry-Anke; Lodewijk, Monique; Reinders-Luinge, Marjan; Postma, Dirkje S.; Timens, Wim; Hylkema, Machteld N.; Ten Hacken, Nick H. T.] Univ Groningen, Univ Med Ctr Groningen, Res Inst Asthma & COPD GRIAC, Groningen, Netherlands; [Fattahi, Fatemeh] Univ Tehran Med Sci, Immunol Asthma & Allergy Res Inst, Tehran, Iran	University of Groningen; University of Groningen; University of Groningen; Immunology Asthma & Allergy Research Institute - Iran; Tehran University of Medical Sciences	Ten Hacken, NHT (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands.; Ten Hacken, NHT (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Res Inst Asthma & COPD GRIAC, Groningen, Netherlands.	n.h.t.ten.hacken@umcg.nl	Timens, Wim/K-5570-2013	Timens, Wim/0000-0002-4146-6363				Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Bajoriuniene I, 2012, LUNG, V190, P487, DOI 10.1007/s00408-012-9411-y; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Broekema M, 2009, AM J RESP CRIT CARE, V180, P1170, DOI 10.1164/rccm.200906-0828OC; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chesne J, 2015, J ALLERGY CLIN IMMUN, V135, P1643, DOI 10.1016/j.jaci.2014.12.1872; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Di Stefano A, 2009, CLIN EXP IMMUNOL, V157, P316, DOI 10.1111/j.1365-2249.2009.03965.x; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Eustace A, 2011, CHEST, V139, P1089, DOI 10.1378/chest.10-0779; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Handoyo S, 2009, CURR ALLERGY ASTHM R, V9, P439, DOI 10.1007/s11882-009-0065-7; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Iwakura Y, 2008, IMMUNOL REV, V226, P57, DOI 10.1111/j.1600-065X.2008.00699.x; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Katayama M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062231; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Ramirez-Velazquez C, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-23; Sorbello V, 2015, ALLERGY, V70, P236, DOI 10.1111/all.12547; Sun YC, 2005, CHINESE MED J-PEKING, V118, P953; Tan HL, 2011, AM J RESP CRIT CARE, V184, P252, DOI 10.1164/rccm.201102-0236OC; Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zijlstra GJ, 2012, EUR RESPIR J, V39, P439, DOI 10.1183/09031936.00017911	36	8	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2016	11	8							e0161433	10.1371/journal.pone.0161433	http://dx.doi.org/10.1371/journal.pone.0161433			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TR	27552197	Green Submitted, Green Published, gold			2023-01-03	WOS:000381768800040
J	Mitchell, SL; Mor, V; Gozalo, PL; Servadio, JL; Teno, JM				Mitchell, Susan L.; Mor, Vincent; Gozalo, Pedro L.; Servadio, Joseph L.; Teno, Joan M.			Tube Feeding in US Nursing Home Residents With Advanced Dementia, 2000-2014	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Mitchell, Susan L.] Harvard Med Sch, Hebrew SeniorLife Inst Aging Res, Boston, MA USA; [Mor, Vincent; Gozalo, Pedro L.; Servadio, Joseph L.] Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; [Teno, Joan M.] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA	Harvard University; Harvard Medical School; Hebrew SeniorLife; Brown University; University of Washington; University of Washington Seattle	Mitchell, SL (corresponding author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.	smitchell@hsl.harvard.edu		Servadio, Joseph/0000-0002-9988-5712	NATIONAL INSTITUTE ON AGING [K24AG033640, P01AG027296] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG027296, K24AG033640, K24 AG033640, P01AG02729] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cegelka A, 2014, J AM GERIATR SOC, V62, P1590, DOI 10.1111/jgs.12924; Mitchell SL, 2003, JAMA-J AM MED ASSOC, V290, P73, DOI 10.1001/jama.290.1.73; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Sampson EL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007209.pub2; Teno JM, 2012, J AM GERIATR SOC, V60, P1918, DOI 10.1111/j.1532-5415.2012.04148.x; Thomas KS, 2014, J AGING HEALTH, V26, P250, DOI 10.1177/0898264313513611	6	75	76	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2016	316	7					769	770		10.1001/jama.2016.9374	http://dx.doi.org/10.1001/jama.2016.9374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT5IA	27533163	Bronze, Green Accepted			2023-01-03	WOS:000381514800024
J	Winters, C; Kwakkel, G; Nijland, R; van Wegen, E				Winters, Caroline; Kwakkel, Gert; Nijland, Rinske; van Wegen, Erwin		EXPLICIT-Stroke Consortium	When Does Return of Voluntary Finger Extension Occur Post-Stroke? A Prospective Cohort Study	PLOS ONE			English	Article							MOTOR EVOKED-POTENTIALS; UPPER-LIMB RECOVERY; PREDICTING RECOVERY; UPPER EXTREMITY; STROKE; IMPACT; TIME; LOCATION; SUBTYPES; NEGLECT	Objectives Patients without voluntary finger extension early post-stroke are suggested to have a poor prognosis for regaining upper limb capacity at 6 months. Despite this poor prognosis, a number of patients do regain upper limb capacity. We aimed to determine the time window for return of voluntary finger extension during motor recovery and identify clinical characteristics of patients who, despite an initially poor prognosis, show upper limb capacity at 6 months post-stroke. Methods Survival analysis was used to assess the time window for return of voluntary finger extension (Fugl-Meyer Assessment hand sub item finger extension >= 1). A cut-off of >= 10 points on the Action Research Arm Test was used to define return of some upper limb capacity (i.e. ability to pick up a small object). Probabilities for regaining upper limb capacity at 6 months post-stroke were determined with multivariable logistic regression analysis using patient characteristics. Results 45 of the 100 patients without voluntary finger extension at 8 +/- 4 days post-stroke achieved an Action Research Arm Test score of >= 10 points at 6 months. The median time for regaining voluntary finger extension for these recoverers was 4 weeks (lower and upper percentile respectively 2 and 8 weeks). The median time to return of VFE was not reached for the whole group (N = 100). Patients who had moderate to good lower limb function (Motricity Index leg >= 35 points), no visuospatial neglect (single-letter cancellation test asymmetry between the contralesional and ipsilesional sides of <2 omissions) and sufficient somatosensory function (Erasmus MC modified Nottingham Sensory Assessment >= 33 points) had a 0.94 probability of regaining upper limb capacity at 6 months post-stroke. Conclusions We recommend weekly monitoring of voluntary finger extension within the first 4 weeks post-stroke and preferably up to 8 weeks. Patients with paresis mainly restricted to the upper limb, no visuospatial neglect and sufficient somatosensory function are likely to show at least some return of upper limb capacity at 6 months post-stroke.	[Winters, Caroline; Kwakkel, Gert; van Wegen, Erwin] Vrije Univ Amsterdam, Med Ctr, MOVE Res Inst, Dept Rehabil Med, Amsterdam, Netherlands; [Winters, Caroline; Kwakkel, Gert; van Wegen, Erwin] Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Amsterdam, Netherlands; [Kwakkel, Gert; Nijland, Rinske] Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands; [Kwakkel, Gert] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Evanston, IL 60208 USA	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Northwestern University	Kwakkel, G (corresponding author), Vrije Univ Amsterdam, Med Ctr, MOVE Res Inst, Dept Rehabil Med, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Evanston, IL 60208 USA.	g.kwakkel@vumc.nl		Kwakkel, Gert/0000-0002-4041-4043; van Wegen, Erwin/0000-0002-7920-9995	EXPLICIT-stroke grant from the Dutch Organization for Health Research and Development (ZonMw) [89000001]; European Research Council under the European Union [291339-4D-EEG]	EXPLICIT-stroke grant from the Dutch Organization for Health Research and Development (ZonMw); European Research Council under the European Union(European Research Council (ERC))	The research leading to these results has received funding from the EXPLICIT-stroke grant from the Dutch Organization for Health Research and Development (ZonMw grant No. 89000001), supported by the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement no. 291339-4D-EEG. The funding organizations had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.	Baker SN, 2011, J PHYSIOL-LONDON, V589, P5603, DOI 10.1113/jphysiol.2011.215160; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Buxbaum LJ, 2004, NEUROLOGY, V62, P749, DOI 10.1212/01.WNL.0000113730.73031.F4; Cheng B, 2014, STROKE, V45, P1695, DOI 10.1161/STROKEAHA.114.005152; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Corbetta M, 2005, NAT NEUROSCI, V8, P1603, DOI 10.1038/nn1574; Coupar F, 2012, CLIN REHABIL, V26, P291, DOI 10.1177/0269215511420305; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Farne A, 2004, J NEUROL NEUROSUR PS, V75, P1401, DOI 10.1136/jnnp.2002.003095; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Hendricks HT, 2003, CEREBROVASC DIS, V16, P265, DOI 10.1159/000071126; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katz N, 1999, ARCH PHYS MED REHAB, V80, P379, DOI 10.1016/S0003-9993(99)90273-3; Kumar P, 2016, J STROKE, V18, P50, DOI 10.5853/jos.2015.01186; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Kwakkel G, 2016, NEUROREHABIL NEURAL; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Kwakkel G, 2015, LANCET NEUROL, V14, P224, DOI 10.1016/S1474-4422(14)70160-7; Kwakkel G, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-49; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Nijboer TCW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100584; Nijboer TCW, 2013, CORTEX, V49, P2021, DOI 10.1016/j.cortex.2012.11.006; Nijland RHM, 2010, STROKE, V41, P745, DOI 10.1161/STROKEAHA.109.572065; PALMER E, 1992, J PHYSIOL-LONDON, V448, P397, DOI 10.1113/jphysiol.1992.sp019048; Plummer P, 2003, PHYS THER, V83, P732, DOI 10.1093/ptj/83.8.732; Riddle CN, 2009, J NEUROSCI, V29, P4993, DOI 10.1523/JNEUROSCI.3720-08.2009; Schiemanck SK, 2006, STROKE, V37, P1050, DOI 10.1161/01.STR.0000206462.09410.6f; Smania N, 2007, STROKE, V38, P1088, DOI 10.1161/01.STR.0000258077.88064.a3; Stinear C, 2010, LANCET NEUROL, V9, P1228, DOI 10.1016/S1474-4422(10)70247-7; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; Stolk-Hornsveld F, 2006, CLIN REHABIL, V20, P160, DOI 10.1191/0269215506cr932oa; van der Lee JH, 2001, J REHABIL MED, V33, P110; van Kordelaar J, 2014, ARCH PHYS MED REHAB, V95, P338, DOI 10.1016/j.apmr.2013.10.006; van Kuijk AA, 2009, NEUROREHAB NEURAL RE, V23, P45, DOI 10.1177/1545968308317578; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Winters C, 2015, NEUROREHAB NEURAL RE, V29, P614, DOI 10.1177/1545968314562115; Wolf S, 2015, PHYSIOTHERAPY, V101, pe22; World Health Organization (WHO), 2001, INTERNATIONAL CLASSI; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	43	26	26	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2016	11	8							e0160528	10.1371/journal.pone.0160528	http://dx.doi.org/10.1371/journal.pone.0160528			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT3GR	27494257	Green Submitted, Green Published, gold			2023-01-03	WOS:000381369500052
J	Cameron, EG; Goldberg, JL				Cameron, Evan G.; Goldberg, Jeffrey L.			Promoting CNS repair	SCIENCE			English	Editorial Material							ASTROCYTES; CELLS; INJURY		[Cameron, Evan G.; Goldberg, Jeffrey L.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94303 USA	Stanford University	Cameron, EG (corresponding author), Stanford Univ, Dept Ophthalmol, Stanford, CA 94303 USA.	ecamer1@stanford.edu		Goldberg, Jeffrey/0000-0002-1390-7360	NATIONAL EYE INSTITUTE [F32EY025915, R01EY026766] Funding Source: NIH RePORTER; NEI NIH HHS [EY025915, EY026766, F32 EY025915] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Gourine AV, 2010, SCIENCE, V329, P571, DOI 10.1126/science.1190721; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Lutz AB, 2014, DEV CELL, V28, P7, DOI 10.1016/j.devcel.2013.12.002; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Zuchero JB, 2015, DEVELOPMENT, V142, P3805, DOI 10.1242/dev.129304	15	2	3	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2016	353	6294					30	31		10.1126/science.aag3327	http://dx.doi.org/10.1126/science.aag3327			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP9KX	27365439				2023-01-03	WOS:000378816200022
J	Kang, YN; Li, H; Wu, J; Xu, XT; Sun, X; Zhao, XD; Xu, NJ				Kang, Yani; Li, Hua; Wu, Jun; Xu, Xiaoting; Sun, Xue; Zhao, Xiaodong; Xu, Nianjun			Transcriptome Profiling Reveals the Antitumor Mechanism of Polysaccharide from Marine Algae Gracilariopsis lemaneiformis	PLOS ONE			English	Article							RED ALGA; CANCER; APOPTOSIS; PRODUCTS; THERAPY	Seaweed is one of the important biomass producers and possesses active metabolites with potential therapeutic effects against tumors. The red alga Gracilariopsis lemaneiformis (Gp. lemaneiformis) possesses antitumor activity, and the polysaccharide of Gp. lemaneiformis (PGL) has been demonstrated to be an ingredient with marked anticancer activity. However, the anticancer mechanism of PGL remains to be elucidated. In this study, we analyzed the inhibitory effect of PGL on the cell growth of 3 human cancer cell lines and found that PGL inhibited cell proliferation, reduced cell viability, and altered cell morphology in a time- and concentration-dependent manner. Our transcriptome analysis indicates that PGL can regulate the expression of 758 genes, which are involved in apoptosis, the cell cycle, nuclear division, and cell death. Furthermore, we demonstrated that PGL induced apoptosis and cell cycle arrest and modulated the expression of related genes in the A549 cell line. Our work provides a framework to understand the effects of PGL on cancer cells, and can serve as a resource for delineating the antitumor mechanisms of Gp. lemaneiformis.	[Kang, Yani; Xu, Xiaoting; Sun, Xue; Xu, Nianjun] Ningbo Univ, Key Lab Marine Biotechnol Zhejiang Prov, Sch Marine Sci, Ningbo, Zhejiang, Peoples R China; [Kang, Yani; Li, Hua; Wu, Jun; Zhao, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Sch Biomed Engn, BioID Ctr, Shanghai, Peoples R China	Ningbo University; Shanghai Jiao Tong University	Xu, NJ (corresponding author), Ningbo Univ, Key Lab Marine Biotechnol Zhejiang Prov, Sch Marine Sci, Ningbo, Zhejiang, Peoples R China.	xunianjun@nbu.edu.cn	Kang, Yani/AAQ-1503-2020	Kang, Yani/0000-0002-6753-386X; LI, HUA/0000-0003-2153-2500	SMC-Morningstar Excellent Young Scholars Program of Shanghai Jiao Tong University [15X100090011]; National Natural Science Foundation of China [91229123, 41376151, 31072229, 31501054]	SMC-Morningstar Excellent Young Scholars Program of Shanghai Jiao Tong University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Support was provided by SMC-Morningstar Excellent Young Scholars Program of Shanghai Jiao Tong University (15X100090011) and National Natural Science Foundation of China (91229123, 41376151, 31072229 and 31501054).	Arakaki N, 2015, PHYTOTAXA, V208, P175, DOI 10.11646/phytotaxa.208.2.7; [陈美珍 CHEN Meizhen], 2008, [中国海洋药物, Chinese Journal of Marine Drugs], V27, P46; Cui L, 2013, J THORAC DIS, V5, P698, DOI 10.3978/j.issn.2072-1439.2013.10.10; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Raposo MFD, 2015, MAR DRUGS, V13, P2967, DOI 10.3390/md13052967; Fan YL, 2012, ADV MATER RES-SWITZ, V468-471, P1941, DOI 10.4028/www.scientific.net/AMR.468-471.1941; Han Z, 2015, PHYS CHEM CHEM PHYS, V17, P21576, DOI 10.1039/c5cp02139a; Harada H, 1997, BIOL PHARM BULL, V20, P541, DOI 10.1248/bpb.20.541; Hornburger MC, 2014, FASEB J, V28, P1938, DOI 10.1096/fj.13-235754; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Indovina P, 2015, ONCOTARGET, V6, P17873, DOI 10.18632/oncotarget.4286; Kang Y, 2015, J FISHERIES CHINA, V39; Khanavi M, 2010, BIOL RES, V43, P31, DOI [10.4067/S0716-97602010000100005, /S0716-97602010000100005]; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Landstrom FJ, 2015, ACTA OTO-LARYNGOL, V135, P1070, DOI 10.3109/00016489.2015.1049663; Li YH, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0537-8; Liao XB, 2015, FOOD FUNCT, V6, P2542, DOI [10.1039/c4fo01185f, 10.1039/C4FO01185F]; [卢佳芳 LU Jia-Fang], 2009, [海洋与湖沼, Oceanologia et Limnologia Sinica], V40, P484; Nickles D, 2012, MOL CELL BIOL, V32, P3372, DOI 10.1128/MCB.06739-11; Rodrigues D, 2015, MAR DRUGS, V13, P713, DOI 10.3390/md13020713; Ropellato J, 2015, CARBOHYD POLYM, V117, P476, DOI 10.1016/j.carbpol.2014.09.089; Sun Y, 2015, J BIOCH MOL TOXICOLO; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Wang XM, 2014, INT J BIOL MACROMOL, V69, P542, DOI 10.1016/j.ijbiomac.2014.06.017; Williams GH, 2012, J PATHOL, V226, P352, DOI 10.1002/path.3022; Xiao X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089534; Xiong ZQ, 2013, MAR DRUGS, V11, P700, DOI 10.3390/md11030700; Yusup A, 2011, EVIDENCE BASED COMPL, V2012; Zong AZ, 2012, CARBOHYD POLYM, V90, P1395, DOI 10.1016/j.carbpol.2012.07.026	31	18	20	2	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2016	11	6							e0158279	10.1371/journal.pone.0158279	http://dx.doi.org/10.1371/journal.pone.0158279			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AM	27355352	Green Published, Green Submitted, gold			2023-01-03	WOS:000378859400043
J	Kawanishi, Y; Saijo, Y; Yoshioka, E; Nakagi, Y; Yoshida, T; Miyamoto, T; Sengoku, K; Ito, Y; Miyashita, C; Araki, A; Kishi, R				Kawanishi, Yasuyuki; Saijo, Yasuaki; Yoshioka, Eiji; Nakagi, Yoshihiko; Yoshida, Takahiko; Miyamoto, Toshinobu; Sengoku, Kazuo; Ito, Yoshiya; Miyashita, Chihiro; Araki, Atsuko; Kishi, Reiko			The Association between Prenatal Yoga and the Administration of Ritodrine Hydrochloride during Pregnancy: An Adjunct Study of the Japan Environment and Children's Study	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRETERM BIRTH; OBSTETRICAL PRACTICE; GYNECOLOGY JSOG; LABOR; PREVENTION; GUIDELINES; EFFICACY; THERAPY; EDITION	Introduction While the beneficial effects of prenatal yoga have been reported in recent years, little is known about its effectiveness in pregnant Japanese women. Despite several adverse effects, ritodrine hydrochloride is frequently prescribed to suppress preterm labor in Japan, and its usage may therefore indicate cases of preterm labor. This study aimed to clarify the association between prenatal yoga and ritodrine hydrochloride use during pregnancy. Methods An observational study was conducted as an adjunct study by the Hokkaido unit of the Japan Environment and Children's Study. Information on prenatal yoga practice was collected using a self-questionnaire between March 21, 2012, and July 7, 2015, targeting women who had recently delivered. Ritodrine hydrochloride use was identified from medical records. A total of 2,692 women were analyzed using logistic regression models that adjusted for possible confounders. Results There were 567 (21.1%) women who practiced prenatal yoga, which was associated with a lower risk of ritodrine hydrochloride use (adjusted odds ratio [OR] 0.77; 95% CI 0.61-0.98). This was especially evident in women with a total practice duration that exceeded 900 minutes throughout their pregnancy (adjusted OR 0.54; 95% CI 0.38-0.76). A sensitivity analysis that excluded patients with threatened abortion during the study period produced similar results. Conclusions Prenatal yoga was associated with a lower risk of ritodrine hydrochloride use, particularly in women with more than 900 minutes of practice time over the course of their pregnancy. Prenatal yoga may be a beneficial option for pregnant women in the selection of alternative therapies.	[Kawanishi, Yasuyuki; Saijo, Yasuaki; Yoshioka, Eiji; Nakagi, Yoshihiko; Yoshida, Takahiko] Asahikawa Med Univ, Dept Hlth Sci, Asahikawa, Hokkaido, Japan; [Miyamoto, Toshinobu; Sengoku, Kazuo] Asahikawa Med Univ, Dept Obstet & Gynecol, Asahikawa, Hokkaido, Japan; [Ito, Yoshiya] Japanese Red Cross Hokkaido Coll Nursing, Fac Nursing, Kitami, Hokkaido, Japan; [Miyashita, Chihiro; Araki, Atsuko; Kishi, Reiko] Hokkaido Univ, Ctr Environm & Hlth Sci, Sapporo, Hokkaido, Japan	Asahikawa Medical College; Asahikawa Medical College; Hokkaido University	Kawanishi, Y (corresponding author), Asahikawa Med Univ, Dept Hlth Sci, Asahikawa, Hokkaido, Japan.	y-kawani@asahikawa-med.ac.jp	Yoshioka, Eiji/AAY-5495-2020; Ikeda-Araki, Atsuko/A-4105-2012; Saijo, Yasuaki/J-3796-2019	Ikeda-Araki, Atsuko/0000-0002-3065-262X; Saijo, Yasuaki/0000-0002-6211-8202; Yoshioka, Eiji/0000-0003-3316-1057	Ministry of the Environment, Japan; Asahikawa Medical University	Ministry of the Environment, Japan(Ministry of the Environment, Japan); Asahikawa Medical University	This study was partly supported by a grant for the Japan Environment & Children's Study from the Ministry of the Environment, Japan. The adjunct study on prenatal yoga was supported by a grant for Innovative Research in Life Science from Asahikawa Medical University.	Beck S, 2010, B WORLD HEALTH ORGAN, V88, P31, DOI 10.2471/BLT.08.062554; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Christiaens I, 2008, J REPROD IMMUNOL, V79, P50, DOI 10.1016/j.jri.2008.04.002; Chuntharapat Songporn, 2008, Complement Ther Clin Pract, V14, P105, DOI 10.1016/j.ctcp.2007.12.007; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Cunningham FG, 2010, WILLIAMS OBSTET, Vxv; Environment. Mot, JAP ENV CHILDR STUD; Field T, 2012, J BODYW MOV THER, V16, P204, DOI 10.1016/j.jbmt.2011.08.002; GIBBS RS, 1993, AM J OBSTET GYNECOL, V169, P460, DOI 10.1016/0002-9378(93)90341-F; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Gyetvai K, 1999, OBSTET GYNECOL, V94, P869, DOI 10.1016/S0029-7844(99)00329-4; Kawagoe Y, 2011, J PREGNANCY, V2011, DOI 10.1155/2011/965060; Kawamoto T, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-25; Kawanishi Y, 2015, EFFECTS PRENATAL YOG, V62, P221, DOI DOI 10.11236/JPH.62.5_; Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860; Lamont RF, 2000, BRIT J OBSTET GYNAEC, V107, P439, DOI 10.1111/j.1471-0528.2000.tb13259.x; Lawn JE, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S1; Martins RF, 2014, J ALTERN COMPLEM MED, V20, P24, DOI 10.1089/acm.2012.0715; Michikawa T, 2015, J EPIDEMIOL, V25, P452, DOI 10.2188/jea.JE20140186; Minakami H, 2014, J OBSTET GYNAECOL RE, V40, P1469, DOI 10.1111/jog.12419; Minakami H, 2011, J OBSTET GYNAECOL RE, V37, P1174, DOI 10.1111/j.1447-0756.2011.01653.x; Murase N., 2003, J HLTH WELFARE STAT, V49, P1; Nakajima Y, 2011, J OBSTET GYNAECOL RE, V37, P629, DOI 10.1111/j.1447-0756.2010.01403.x; Narendran S, 2005, J ALTERN COMPLEM MED, V11, P237, DOI 10.1089/acm.2005.11.237; National Center for Complementary and Integrative Health (NCCIH), YOG FOR HLTH 2013; Neilson JP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004352.pub3; Rakhshani A, 2012, PREV MED, V55, P333, DOI 10.1016/j.ypmed.2012.07.020; Robinson JN, 2015, RISK FACTORS PRETERM; Satyapriya M, 2013, COMPLEMENT THER CLIN, V19, P230, DOI 10.1016/j.ctcp.2013.06.003; Satyapriya M, 2009, INT J GYNECOL OBSTET, V104, P218, DOI 10.1016/j.ijgo.2008.11.013; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Slattery MM, 2002, LANCET, V360, P1489, DOI 10.1016/S0140-6736(02)11476-0; Steel A, 2014, MIDWIFERY, V30, P1157, DOI 10.1016/j.midw.2014.03.015; Steinborn A, 1999, CYTOKINE, V11, P66, DOI 10.1006/cyto.1998.0399; Steinborn A, 1998, OBSTET GYNECOL, V91, P329, DOI 10.1016/S0029-7844(97)00680-7; Sun YC, 2010, MIDWIFERY, V26, pE31, DOI 10.1016/j.midw.2009.01.005; TUCKER JM, 1991, OBSTET GYNECOL, V77, P343; Vesalainen RK, 1999, BRIT J OBSTET GYNAEC, V106, P238, DOI 10.1111/j.1471-0528.1999.tb08237.x; Yasuda R, 2012, J OBSTET GYNAECOL RE, V38, P574, DOI 10.1111/j.1447-0756.2011.01756.x	39	2	2	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2016	11	6							e0158155	10.1371/journal.pone.0158155	http://dx.doi.org/10.1371/journal.pone.0158155			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP9FD	27348869	Green Published, Green Submitted, gold			2023-01-03	WOS:000378801200039
J	Knutson, S; Raja, E; Bomgarden, R; Nlend, M; Chen, AS; Kalyanasundaram, R; Desai, S				Knutson, Steve; Raja, Erum; Bomgarden, Ryan; Nlend, Marie; Chen, Aoshuang; Kalyanasundaram, Ramaswamy; Desai, Surbhi			Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer	PLOS ONE			English	Article							CARCINOEMBRYONIC ANTIGEN CEA; PROTEIN-COUPLED RECEPTOR; SITE-SPECIFIC CONJUGATION; POTENT ANTITUMOR-ACTIVITY; CONTENT SCREENING ASSAY; CELLS IN-VITRO; MONOCLONAL-ANTIBODY; BIOLOGICAL EVALUATION; PACLITAXEL CONJUGATE; RADIOLABELED ANTIBODIES	Antibodies are widely available and cost-effective research tools in life science, and anti-body conjugates are now extensively used for targeted therapy, immunohistochemical staining, or in vivo diagnostic imaging of cancer. Significant advances in site-specific anti-body labeling technologies have enabled the production of highly characterized and homogenous conjugates for biomedical purposes, and some recent studies have utilized site-specific labeling to synthesize bifunctional antibody conjugates with both imaging and drug delivery properties. While these advances are important for the clinical safety and efficacy of such biologics, these techniques can also be difficult, expensive, and time-consuming. Furthermore, antibody-drug conjugates (ADCs) used for tumor treatment generally remain distinct from conjugates used for diagnosis. Thus, there exists a need to develop simple dual-labeling methods for efficient therapeutic and diagnostic evaluation of antibody conjugates in pre-clinical model systems. Here, we present a rapid and simple method utilizing commercially available reagents for synthesizing a dual-labeled fluorescent ADC. Further, we demonstrate the fluorescent ADC's utility for simultaneous targeted therapy and molecular imaging of cancer both in vitro and in vivo. Employing non-site-specific, amine-reactive chemistry, our novel biopharmaceutical theranostic is a monoclonal antibody specific for a carcinoembryonic antigen (CEA) biomarker conjugated to both paclitaxel and a near-infrared (NIR), polyethylene glycol modified ( PEGylated) fluorophore (DyLight (TM) 680-4xPEG). Using in vitro systems, we demonstrate that this fluorescent ADC selectively binds a CEA-positive pancreatic cancer cell line (BxPC-3) in immunofluorescent staining and flow cytometry, exhibits efficient internalization kinetics, and is cytotoxic. Model studies using a xenograft of BxPC-3 cells in athymic mice also show the fluorescent ADC's efficacy in detecting tumors in vivo and inhibiting tumor growth more effectively than equimolar amounts of unconjugated drug. Overall, our results demonstrate that non-selective, amine-targeting chemistry is an effective dual-labeling method for synthesizing and evaluating a bifunctional fluorescent antibody-drug conjugate, allowing concurrent detection, monitoring and treatment of cancer.	[Knutson, Steve; Raja, Erum; Bomgarden, Ryan; Nlend, Marie; Desai, Surbhi] Thermo Fisher Sci, Dept Res & Dev, Rockford, IL USA; [Knutson, Steve; Chen, Aoshuang; Kalyanasundaram, Ramaswamy] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA	Thermo Fisher Scientific; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford	Knutson, S; Desai, S (corresponding author), Thermo Fisher Sci, Dept Res & Dev, Rockford, IL USA.; Knutson, S (corresponding author), Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA.	steve.knutson@thermofisher.com; surbhi.desai@thermofisher.com			Thermo Fisher Scientific (Rockford, IL); "Project Research Award" courtesy of the Master's in Medical Biotechnology Program at the University of Illinois College of Medicine in Rockford, IL; Thermo Fisher Scientific	Thermo Fisher Scientific (Rockford, IL); "Project Research Award" courtesy of the Master's in Medical Biotechnology Program at the University of Illinois College of Medicine in Rockford, IL; Thermo Fisher Scientific	Funding is provided by a combination of private resources from Thermo Fisher Scientific (Rockford, IL) and a "Project Research Award" courtesy of the Master's in Medical Biotechnology Program at the University of Illinois College of Medicine in Rockford, IL. No grants are associated with the funding of this project. One or more of the authors have a direct affiliation to the commercial funder (Thermo Fisher Scientific) of this research study. The commercial affiliation and funding from this organization provided support in the form of research materials and salaries for authors (SK, ER, RB, MN, and SD), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	ABE M, 1984, BREAST CANCER RES TR, V4, P269, DOI 10.1007/BF01806038; Agarwal P, 2015, BIOCONJUGATE CHEM, V26, P176, DOI 10.1021/bc5004982; Axup JY, 2012, P NATL ACAD SCI USA, V109, P16101, DOI 10.1073/pnas.1211023109; Behrens CR, 2014, MABS-AUSTIN, V6, P46, DOI 10.4161/mabs.26632; Boeggeman E, 2009, BIOCONJUGATE CHEM, V20, P1228, DOI 10.1021/bc900103p; Boutureira O, 2015, CHEM REV, V115, P2174, DOI 10.1021/cr500399p; Bradley MO, 2001, J CONTROL RELEASE, V74, P233, DOI 10.1016/S0168-3659(01)00321-2; BUCHEGGER F, 1983, J EXP MED, V158, P413, DOI 10.1084/jem.158.2.413; Cao HST, 2012, HEPATO-GASTROENTEROL, V59, P1994, DOI 10.5754/hge11836; Carter PJ, 2008, CANCER J, V14, P154, DOI 10.1097/PPO.0b013e318172d704; Casi G, 2012, J CONTROL RELEASE, V161, P422, DOI 10.1016/j.jconrel.2012.01.026; Chalker JM, 2009, CHEM-ASIAN J, V4, P630, DOI 10.1002/asia.200800427; Chen XY, 2005, J MED CHEM, V48, P1098, DOI 10.1021/jm049165z; Conway BR, 1999, J BIOMOL SCREEN, V4, P75, DOI 10.1177/108705719900400207; Correale P, 2003, INT J CANCER, V104, P437, DOI 10.1002/ijc.10969; DiJoseph JF, 2004, BLOOD, V103, P1807, DOI 10.1182/blood-2003-07-2466; Dimitrov Dimiter S., 2009, V525, P1, DOI 10.1007/978-1-59745-554-1_1; Dykstra M, 1992, BIOL ELECT MICROSCOP, P309; Feng Y, 2014, BIOMEDICINES, V2, P1, DOI 10.3390/biomedicines2010001; Flygare JA, 2013, CHEM BIOL DRUG DES, V81, P113, DOI 10.1111/cbdd.12085; Ford CHJ, 1996, CYTOMETRY, V23, P228; Francisco JA, 2003, BLOOD, V102, P1458, DOI 10.1182/blood-2003-01-0039; Fukunaga S, 2006, LIFE SCI, V80, P17, DOI 10.1016/j.lfs.2006.08.022; Ghosh RN, 2005, J BIOMOL SCREEN, V10, P476, DOI 10.1177/1087057105274896; Ghosh RN, 2004, ASSAY DRUG DEV TECHN, V2, P473, DOI 10.1089/adt.2004.2.473; GOLDENBERG DM, 1995, TUMOR BIOL, V16, P62, DOI 10.1159/000217930; Goldenberg M, 1982, Patent No. [4,348,376, 4348376]; Gradishar WJ, 2006, EXPERT OPIN PHARMACO, V7, P1041, DOI 10.1517/14656566.7.8.1041; Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755; Guillemard V, 2001, CANCER RES, V61, P694; Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; He D, 2005, INT J BIOCHEM CELL B, V37, P192, DOI 10.1016/j.biocel.2004.06.015; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P1; Hiroshima Y, 2014, J LAPAROENDOSC ADV S, V24, P241, DOI 10.1089/lap.2013.0418; Hofer T, 2009, BIOCHEMISTRY-US, V48, P12047, DOI 10.1021/bi901744t; HOFFER PB, 1973, INVEST RADIOL, V8, P288, DOI 10.1097/00004424-197307000-00072; Hong EE, 2015, MOL PHARMACEUT, V12, P1703, DOI 10.1021/acs.molpharmaceut.5b00175; Hu CMJ, 2010, MOL PHARMACEUT, V7, P914, DOI 10.1021/mp900316a; Ikeda H, 2009, CLIN CANCER RES, V15, P4028, DOI 10.1158/1078-0432.CCR-08-2867; Ito S, 2001, ENDOSCOPY, V33, P849, DOI 10.1055/s-2001-17328; Jain N, 2015, PHARM RES-DORDR, V32, P3526, DOI 10.1007/s11095-015-1657-7; Jeger S, 2010, ANGEW CHEM INT EDIT, V49, P9995, DOI 10.1002/anie.201004243; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; Junutula JR, 2010, CLIN CANCER RES, V16, P4769, DOI 10.1158/1078-0432.CCR-10-0987; Katz J, 2011, CLIN CANCER RES, V17, P6428, DOI 10.1158/1078-0432.CCR-11-0488; Kaushal S, 2008, J GASTROINTEST SURG, V12, P1938, DOI 10.1007/s11605-008-0581-0; Kovtun YV, 2007, CANCER LETT, V255, P232, DOI 10.1016/j.canlet.2007.04.010; Lee SU, 2013, BIOL PHARM BULL, V36, P1754; Li C, 1998, CANCER RES, V58, P2404; Li C, 1996, ANTI-CANCER DRUG, V7, P642, DOI 10.1097/00001813-199608000-00004; Liu JKH, 2014, ANN MED SURG, V3, P113, DOI 10.1016/j.amsu.2014.09.001; Luo Y, 1999, BIOCONJUGATE CHEM, V10, P755, DOI 10.1021/bc9900338; Lyon RP, 2012, METHOD ENZYMOL, V502, P123, DOI 10.1016/B978-0-12-416039-2.00006-9; Ma DS, 2006, CLIN CANCER RES, V12, P2591, DOI 10.1158/1078-0432.CCR-05-2107; Maawy AA, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.101504; Maawy AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097965; Maawy AA, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.126016; MACH JP, 1980, NEW ENGL J MED, V303, P5, DOI 10.1056/NEJM198007033030102; Maruani A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7645; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; McDonagh CF, 2006, PROTEIN ENG DES SEL, V19, P299, DOI 10.1093/protein/gzl013; Metildi CA, 2014, J AM COLL SURGEONS, V219, P132, DOI 10.1016/j.jamcollsurg.2014.02.021; Metildi CA, 2014, J SURG ONCOL, V109, P451, DOI 10.1002/jso.23507; Metildi CA, 2014, ANN SURG ONCOL, V21, P1405, DOI 10.1245/s10434-014-3495-y; Moreau K, 2015, METHODS, V75, P19, DOI 10.1016/j.ymeth.2014.11.005; Mullard A, 2013, NAT REV DRUG DISCOV, V12, DOI 10.1038/nrd4034; Naumovski L, 2010, CURR OPIN MOL THER, V12, P248; Nunes JPM, 2015, CHEM COMMUN, V51, P10624, DOI 10.1039/c5cc03557k; Panowski S, 2014, MABS-AUSTIN, V6, P34, DOI 10.4161/mabs.27022; PEDLEY RB, 1993, BRIT J CANCER, V68, P69, DOI 10.1038/bjc.1993.288; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Polakis P, 2005, CURR OPIN PHARMACOL, V5, P382, DOI 10.1016/j.coph.2005.04.008; PRIMUS FJ, 1977, CANCER RES, V37, P1544; Quiles S, 2010, J MED CHEM, V53, P586, DOI 10.1021/jm900899g; Rabuka D, 2012, NAT PROTOC, V7, P1052, DOI 10.1038/nprot.2012.045; Rao JH, 2007, CURR OPIN BIOTECH, V18, P17, DOI 10.1016/j.copbio.2007.01.003; RESNICOFF M, 1987, P NATL ACAD SCI USA, V84, P7295, DOI 10.1073/pnas.84.20.7295; Ross SL, 2012, CELL METAB, V15, P905, DOI 10.1016/j.cmet.2012.03.017; Rowland G, 1986, CANC IMMUNOL IMMUNOT, V21; Ryppa C, 2009, INT J PHARMACEUT, V368, P89, DOI 10.1016/j.ijpharm.2008.09.055; Safavy A, 2004, BIOCONJUGATE CHEM, V15, P1264, DOI 10.1021/bc049868v; Safavy A, 2003, BIOCONJUGATE CHEM, V14, P302, DOI 10.1021/bc020033z; Sapra P, 2005, CLIN CANCER RES, V11, P5257, DOI 10.1158/1078-0432.CCR-05-0204; Sarkar S, 2009, AUTOPHAGY, V5, P307, DOI 10.4161/auto.5.3.7664; Sassoon I, 2013, METHODS MOL BIOL, V1045, P1, DOI 10.1007/978-1-62703-541-5_1; Sato T, 1988, J BIOACT COMPAT POLY, V3, P195; Schiff PB, PROMOTION MICROTUBUL; Schlag BD, 2004, J PHARMACOL EXP THER, V310, P865, DOI 10.1124/jpet.104.067306; Schmidt MM, 2008, CANCER IMMUNOL IMMUN, V57, P1879, DOI 10.1007/s00262-008-0518-1; Schumacher FF, 2014, ORG BIOMOL CHEM, V12, P7261, DOI 10.1039/c4ob01550a; Senba T, 1998, ANTICANCER RES, V18, P17; Sharkey R, 1992, J IMMUNOTHER, V11, P144; Shen BQ, 2012, NAT BIOTECHNOL, V30, P184, DOI 10.1038/nbt.2108; SHIH LB, 1994, CANCER IMMUNOL IMMUN, V38, P92, DOI 10.1007/BF01526203; STARLING JJ, 1988, CANCER RES, V48, P6211; Strop P, 2013, CHEM BIOL, V20, P161, DOI 10.1016/j.chembiol.2013.01.010; TSALTAS G, 1992, ANTICANCER RES, V12, P2133; Wang J, 2007, ACTA PHARMACOL SIN, V28, P1698, DOI 10.1111/j.1745-7254.2007.00640.x; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Whelan J, 2002, DRUG DISCOV TODAY, V7, P90, DOI 10.1016/S1359-6446(01)02149-3; Whiteman KR, 2014, MABS-AUSTIN, V6, P556, DOI 10.4161/mabs.27756; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Wu AM, 2008, CANCER J, V14, P191, DOI 10.1097/PPO.0b013e31817b07ae; Yu SF, 2015, CLIN CANCER RES, V21, P3298, DOI 10.1158/1078-0432.CCR-14-2035	107	28	30	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157762	10.1371/journal.pone.0157762	http://dx.doi.org/10.1371/journal.pone.0157762			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27336622	Green Submitted, Green Published, gold			2023-01-03	WOS:000378389200040
J	Shirasu, T; Koyama, H; Miura, Y; Hoshina, K; Kataoka, K; Watanabe, T				Shirasu, Takuro; Koyama, Hiroyuki; Miura, Yutaka; Hoshina, Katsuyuki; Kataoka, Kazunori; Watanabe, Toshiaki			Nanoparticles Effectively Target Rapamycin Delivery to Sites of Experimental Aortic Aneurysm in Rats	PLOS ONE			English	Article							POLYMERIC MICELLES; ANTITUMOR-ACTIVITY; IV COLLAGENASE; DOUBLE-BLIND; BLOOD; MODEL; LOCALIZATION; DEGENERATION; GELATINASE; INHIBITION	Several drugs targeting the pathogenesis of aortic aneurysm have shown efficacy in model systems but not in clinical trials, potentially owing to the lack of targeted drug delivery. Here, we designed a novel drug delivery system using nanoparticles to target the disrupted aortic aneurysm micro-structure. We generated poly(ethylene glycol)-shelled nanoparticles incorporating rapamycin that exhibited uniform diameter and long-term stability. When injected intravenously into a rat model in which abdominal aortic aneurysm (AAA) had been induced by infusing elastase, labeled rapamycin nanoparticles specifically accumulated in the AAA. Microscopic analysis revealed that rapamycin nanoparticles were mainly distributed in the media and adventitia where the wall structures were damaged. Co-localization of rapamycin nanoparticles with macrophages was also noted. Rapamycin nanoparticles injected during the process of AAA formation evinced significant suppression of AAA formation and mural inflammation at 7 days after elastase infusion, as compared with rapamycin treatment alone. Correspondingly, the activities of matrix metalloproteinases and the expression of inflammatory cytokines were significantly suppressed by rapamycin nanoparticle treatment. Our findings suggest that the nanoparticle-based delivery system achieves specific delivery of rapamycin to the rat AAA and might contribute to establishing a drug therapy approach targeting aortic aneurysm.	[Shirasu, Takuro; Koyama, Hiroyuki; Hoshina, Katsuyuki; Watanabe, Toshiaki] Univ Tokyo, Grad Sch Med, Dept Surg, Div Vasc Surg, Tokyo, Japan; [Koyama, Hiroyuki] Tokyo Univ Hosp, Translat Res Ctr, Tokyo 113, Japan; [Koyama, Hiroyuki] Saitama Med Univ, Saitama Med Ctr, Dept Vasc Surg, Saitama, Japan; [Miura, Yutaka; Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Mat Engn, Tokyo, Japan; [Miura, Yutaka; Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo, Japan; [Miura, Yutaka; Kataoka, Kazunori] Univ Tokyo, Ctr Dis Biol & Integrat Med, Grad Sch Med, Tokyo, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; University of Tokyo; University of Tokyo; University of Tokyo	Koyama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Surg, Div Vasc Surg, Tokyo, Japan.; Koyama, H (corresponding author), Tokyo Univ Hosp, Translat Res Ctr, Tokyo 113, Japan.; Koyama, H (corresponding author), Saitama Med Univ, Saitama Med Ctr, Dept Vasc Surg, Saitama, Japan.	hkoyama-tky@umin.ac.jp	Miura, Yutaka/Q-8383-2018; Kataoka, Kazunori/K-7108-2012; Miura, Yutaka/AAT-5859-2020	Miura, Yutaka/0000-0002-0506-7138; Kataoka, Kazunori/0000-0002-8591-413X; Miura, Yutaka/0000-0002-0506-7138	Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) from the Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology of Japan [23591859]	Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) from the Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program, no specific number) from the Japan Society for the Promotion of Science (JSPS) and Grants-in-Aid for Scientific Research (No. 23591859 to K.H.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973; ANIDJAR S, 1992, J VASC SURG, V16, P139, DOI 10.1016/0741-5214(92)90101-D; [Anonymous], 2011, CIRCULATION, V124, P2020, DOI [10.1161/CIR.0b013e31822e80c3, DOI 10.1161/CIR.0B013E31822E80C3]; Baxter BT, 2008, CIRCULATION, V117, P1883, DOI 10.1161/CIRCULATIONAHA.107.735274; Brewster DC, 2003, J VASC SURG, V37, P1106, DOI 10.1067/mva.2003.363; Cabral H, 2005, J CONTROL RELEASE, V101, P223, DOI 10.1016/j.jconrel.2004.08.022; Cabral H, 2011, NAT NANOTECHNOL, V6, P815, DOI [10.1038/nnano.2011.166, 10.1038/NNANO.2011.166]; Cabral H, 2007, J CONTROL RELEASE, V121, P146, DOI 10.1016/j.jconrel.2007.05.024; CAMPA JS, 1987, ATHEROSCLEROSIS, V65, P13, DOI 10.1016/0021-9150(87)90003-7; Choke E, 2006, ANN NY ACAD SCI, V1085, P315, DOI 10.1196/annals.1383.007; Crowe A, 1999, DRUG METAB DISPOS, V27, P627; Daugherty A, 2004, ARTERIOSCL THROM VAS, V24, P429, DOI 10.1161/01.ATV.0000118013.72016.ea; Davis V, 1998, ARTERIOSCL THROM VAS, V18, P1625, DOI 10.1161/01.ATV.18.10.1625; Dobrin P B, 1994, Cardiovasc Surg, V2, P484; Forrest ML, 2006, J CONTROL RELEASE, V110, P370, DOI 10.1016/j.jconrel.2005.10.008; Golledge J, 2010, CARDIOVASC DRUG THER, V24, P373, DOI 10.1007/s10557-010-6262-8; Habashi JP, 2011, SCIENCE, V332, P361, DOI 10.1126/science.1192152; Harada M, 2011, CANCER SCI, V102, P192, DOI 10.1111/j.1349-7006.2010.01745.x; Hartford CM, 2007, CLIN PHARMACOL THER, V82, P381, DOI 10.1038/sj.clpt.6100317; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; HOLMES DR, 1995, J VASC SURG, V21, P761, DOI 10.1016/S0741-5214(05)80007-2; Karlsson L, 2009, J VASC SURG, V50, P23, DOI 10.1016/j.jvs.2008.12.048; KEEN RR, 1994, J VASC SURG, V20, P774, DOI 10.1016/S0741-5214(94)70165-2; Kurosawa K, 2013, CIRC J, V77, P2860, DOI 10.1253/circj.CJ-13-1252; Laupacis A, 2002, J VASC SURG, V35, P72, DOI 10.1067/mva.2002.121308; Lawrence DM, 2004, J VASC SURG, V40, P334, DOI 10.1016/j.jvs.2004.05.020; Lindholt JS, 1999, INT ANGIOL, V18, P52; LopezCandales A, 1997, AM J PATHOL, V150, P993; MCMILLAN WD, 1995, J VASC SURG, V22, P295, DOI 10.1016/S0741-5214(95)70144-3; MCMILLAN WD, 1995, ARTERIOSCL THROM VAS, V15, P1139, DOI 10.1161/01.ATV.15.8.1139; Miura Y, 2013, ACS NANO, V7, P8583, DOI 10.1021/nn402662d; Mosorin M, 2001, J VASC SURG, V34, P606, DOI 10.1067/mva.2001.117891; Napoli KL, 1997, CLIN BIOCHEM, V30, P135, DOI 10.1016/S0009-9120(96)00157-9; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; Nishiyama N, 2003, CANCER RES, V63, P8977; Nooteboom A, 2002, CRIT CARE MED, V30, P2063, DOI 10.1097/00003246-200209000-00019; NUGENT LJ, 1984, J PHARMACOKINET BIOP, V12, P451, DOI 10.1007/BF01062668; Petrinec D, 1996, J VASC SURG, V23, P336, DOI 10.1016/S0741-5214(96)70279-3; Reeps C, 2009, PATHOBIOLOGY, V76, P243, DOI 10.1159/000228900; Samson R, 2012, SEMIN VASC SURG, V25, P25, DOI 10.1053/j.semvascsurg.2012.03.004; Shiraya S, 2009, ATHEROSCLEROSIS, V202, P34, DOI 10.1016/j.atherosclerosis.2008.03.020; Singh K, 2001, AM J EPIDEMIOL, V154, P236, DOI 10.1093/aje/154.3.236; Steinmetz EF, 2005, ANN SURG, V241, P92, DOI 10.1097/01.sla.0000150258.36236.e0; Thompson RW, 2006, ANN NY ACAD SCI, V1085, P59, DOI 10.1196/annals.1383.029; Thompson Robert W, 2002, Curr Probl Surg, V39, P110, DOI 10.1067/msg.2002.121421; THOMPSON RW, 1995, J CLIN INVEST, V96, P318, DOI 10.1172/JCI118037; Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546; Tolg C, 2012, AM J PATHOL, V181, P1250, DOI 10.1016/j.ajpath.2012.06.036; Uchino H, 2005, BRIT J CANCER, V93, P678, DOI 10.1038/sj.bjc.6602772; Wassef M, 2001, J VASC SURG, V34, P730, DOI 10.1067/mva.2001.116966; Woo HN, 2012, INT J NANOMED, V7, P2197, DOI 10.2147/IJN.S29480; Yanez JA, 2008, CANCER CHEMOTH PHARM, V61, P133, DOI 10.1007/s00280-007-0458-z	52	29	29	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157813	10.1371/journal.pone.0157813	http://dx.doi.org/10.1371/journal.pone.0157813			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27336852	Green Published, gold, Green Submitted			2023-01-03	WOS:000378389200054
J	Ipema, KJR; Struijk, S; van der Velden, A; Westerhuis, R; van der Schans, CP; Gaillard, CAJM; Krijnen, WP; Franssen, CFM				Ipema, Karin J. R.; Struijk, Simone; van der Velden, Annet; Westerhuis, Ralf; van der Schans, Cees P.; Gaillard, Carlo A. J. M.; Krijnen, Wim P.; Franssen, Casper F. M.			Nutritional Status in Nocturnal Hemodialysis Patients - A Systematic Review with Meta-Analysis	PLOS ONE			English	Review							QUALITY-OF-LIFE; IN-CENTER CONVERSION; STAGE RENAL-DISEASE; BODY-MASS INDEX; HOME HEMODIALYSIS; FREQUENT HEMODIALYSIS; CONVENTIONAL HEMODIALYSIS; PHYSICAL FUNCTION; PROTEIN-INTAKE; 3 TIMES	Background Hemodialysis patients experience an elevated risk of malnutrition associated with increased morbidity and mortality. Nocturnal hemodialysis (NHD) results in more effective removal of waste products and fluids. Therefore, diet and fluid restrictions are less restricted in NHD patients. However, it is ambiguous whether transition from conventional hemodialysis (CHD) to NHD leads to improved intake and nutritional status. We studied the effect of NHD on protein intake, laboratory indices of nutritional status, and body composition. Study design Systematic review with meta-analysis. Population NHD patients. Search strategy Systematic literature search from databases, Medline, Cinahl, EMBASE and The Cochrane Library, to identify studies reporting on nutritional status post-transition from CHD to NHD. Intervention Transition from CHD to NHD. Outcomes Albumin, normalized protein catabolic rate (nPCR), dry body weight (DBW), body mass index (BMI), phase angle, protein intake, and energy intake. Results Systematic literature search revealed 13 studies comprising 282 patients that made the transition from CHD to NHD. Meta-analysis included nine studies in 229 patients. In control group controlled studies (n = 4), serum albumin increased significantly from baseline to 4-6 months in NHD patients compared with patients that remained on CHD (mean difference 1.3 g/l, 95% CI 0.02; 2.58, p = 0.05). In baseline controlled studies, from baseline to 4-6 months of NHD treatment, significant increases were ascertained in serum albumin (mean difference (MD) 1.63 g/l, 95% CI 0.73-2.53, p<0.001); nPCR (MD 0.16 g/kg/day; 95% CI 0.04-0.29, p = 0.01); protein intake (MD 18.9 g, 95% CI 9.7-28.2, p<0.001); and energy intake (MD 183.2 kcal, 95% CI 16.8-349.7, p = 0.03). Homogeneity was rejected only for nPCR (baseline versus 4-6 months). DBW, BMI, and phase angle did not significantly change. Similar results were obtained for comparison between baseline and 8-12 months of NHD treatment. Limitations Most studies had moderate sample sizes; some had incomplete dietary records and relatively brief follow-up period. Studies markedly differed with regard to study design. Conclusions NHD is associated with significantly higher protein and energy intake as well as increases in serum albumin and nPCR. However, the data on body composition are inconclusive.	[Ipema, Karin J. R.; Westerhuis, Ralf] Dialysis Ctr Groningen, Groningen, Netherlands; [Ipema, Karin J. R.; Struijk, Simone; van der Velden, Annet; van der Schans, Cees P.; Krijnen, Wim P.] Hanze Univ Groningen, Univ Appl Sci, Res Grp Hlth Ageing Allied Hlth Care & Nursing, Groningen, Netherlands; [Westerhuis, Ralf; Gaillard, Carlo A. J. M.; Franssen, Casper F. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands; [van der Schans, Cees P.] Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil Med, Ctr Rehabil, Groningen, Netherlands	University of Groningen; University of Groningen	Ipema, KJR (corresponding author), Dialysis Ctr Groningen, Groningen, Netherlands.; Ipema, KJR (corresponding author), Hanze Univ Groningen, Univ Appl Sci, Res Grp Hlth Ageing Allied Hlth Care & Nursing, Groningen, Netherlands.	k.ipema@dcg.nl	Gaillard, Carlo/AAC-6729-2022	Gaillard, Carlo/0000-0002-8964-0236; van der Schans, Cees P/0000-0003-4728-4082				Abbott KC, 2004, KIDNEY INT, V65, P597, DOI 10.1111/j.1523-1755.2004.00385.x; Alloatti S, 2002, BLOOD PURIFICAT, V20, P525, DOI 10.1159/000066955; Beberashvilil I, 2014, EUR J CLIN NUTR, V68, P683, DOI 10.1038/ejcn.2014.67; Borenstein M, 2009, INTRO META ANAL, DOI [10.1007/978-3-319-14908-0_2, DOI 10.1002/9780470743386]; Bossola M, 2005, J RENAL NUTR, V15, P244, DOI 10.1053/j.jrn.2005.01.004; Burrowes JD, 2005, NEPHROL DIAL TRANSPL, V20, P2765, DOI 10.1093/ndt/gfi132; Chan CT, 2007, NEPHROL DIAL TRANSPL, V22, P3285, DOI 10.1093/ndt/gfm368; Charra B, 1996, NEPHROL DIAL TRANSPL, V11, P16; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; Charra Bernard, 2007, Hemodial Int, V11, P21, DOI 10.1111/j.1542-4758.2007.00148.x; Clajus C, 2012, NEPHROL DIAL TRANSPL, V27, P220; Cravedi P, 2009, INT J ARTIF ORGANS, V32, P12, DOI 10.1177/039139880903200102; David S, 2009, NEPHROL DIAL TRANSPL, V24, P2232, DOI 10.1093/ndt/gfp029; de Araujo I, 2006, J RENAL NUTR, V16, P27, DOI 10.1053/j.jrn.2005.10.003; Demirci C, 2013, AM J NEPHROL, V37, P559, DOI 10.1159/000351182; Foley RN, 1996, J AM SOC NEPHROL, V7, P728; Fouque D, 2007, NEPHROL DIAL TRANSPL, V22, P45, DOI 10.1093/ndt/gfm020; Fourie E, 2010, CARDIOVAS J AFRI, V21, pS10; Gubensek J, 2013, THER APHER DIAL, V17, P412, DOI 10.1111/1744-9987.12088; Hall YN, 2012, CLIN J AM SOC NEPHRO, V7, P782, DOI 10.2215/CJN.10601011; Herselman M, 2000, J Ren Nutr, V10, P7, DOI 10.1016/S1051-2276(00)90017-7; Ikizler TA, 2002, AM J PHYSIOL-ENDOC M, V282, pE107, DOI 10.1152/ajpendo.2002.282.1.E107; Ikizler TA, 1999, KIDNEY INT, V55, P1945, DOI 10.1046/j.1523-1755.1999.00410.x; Ipema KJR, 2012, J RENAL NUTR, V22, P365, DOI 10.1053/j.jrn.2011.08.010; Johansen KL, 2003, AM J CLIN NUTR, V77, P842, DOI 10.1093/ajcn/77.4.842; Johansen KL, 2003, KIDNEY INT, V63, P291, DOI 10.1046/j.1523-1755.2003.00704.x; Kaysen GA, 2012, KIDNEY INT, V82, P90, DOI 10.1038/ki.2012.75; Kooistra MP, 1998, NEPHROL DIAL TRANSPL, V13, P2853, DOI 10.1093/ndt/13.11.2853; Lacson E, 2001, AM J KIDNEY DIS, V38, P225, DOI 10.1053/ajkd.2001.26079; Lacson E, 2012, J AM SOC NEPHROL, V23, P687, DOI 10.1681/ASN.2011070674; Lacson E, 2010, CLIN J AM SOC NEPHRO, V5, P220, DOI 10.2215/CJN.06070809; Leavey SF, 2001, NEPHROL DIAL TRANSPL, V16, P2386, DOI 10.1093/ndt/16.12.2386; Lindholm B, 1998, NEPHROL DIAL TRANSPL, V13, P66, DOI 10.1093/ndt/13.suppl_6.66; Lindsay RM, 2004, SEMIN DIALYSIS, V17, P85, DOI 10.1111/j.0894-0959.2004.17202.x; Maduell F, 2012, NEPHROL DIAL TRANSPL, V27, P1619, DOI 10.1093/ndt/gfr491; Mahadevan K, 2006, NEPHROLOGY, V11, P413, DOI 10.1111/j.1440-1797.2006.00670.x; Martins AR, 2013, NEPHROL DIAL TRANSPL, V28, P205; McFarlane PA, 2011, CURR OPIN NEPHROL HY, V20, P182, DOI 10.1097/MNH.0b013e3283437046; McPhatter Lesley L, 2012, Nephrol News Issues, V26, P29; McPhatter LL, 1999, ADV RENAL REPLACE TH, V6, P358, DOI 10.1016/S1073-4449(99)70048-8; Moran J, 2012, HEMODIAL INT, V16, P164; Noori N, 2011, AM J KIDNEY DIS, V57, P130, DOI 10.1053/j.ajkd.2010.10.003; O'Sullivan DA, 1998, MAYO CLIN PROC, V73, P1035, DOI 10.4065/73.11.1035; Ouwendyk M, 1996, J CANNT, V6, P26; Pierratos A, 1998, J AM SOC NEPHROL, V9, P859; Pierratos A, 2001, ASAIO J, V47, P446, DOI 10.1097/00002480-200109000-00006; Qureshi AR, 2002, J AM SOC NEPHROL, V13, pS28; Raj DSC, 2004, AM J PHYSIOL-ENDOC M, V286, pE136, DOI 10.1152/ajpendo.00352.2003; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Schorr M, 2011, J RENAL NUTR, V21, P271, DOI 10.1053/j.jrn.2010.04.004; Sikkes ME, 2009, J RENAL NUTR, V19, P494, DOI 10.1053/j.jrn.2009.05.006; Spanner E, 2003, AM J KIDNEY DIS, V42, pS30, DOI 10.1016/S0272-6386(03)00535-3; Stosovic M, 2011, NEPHROL DIAL TRANSPL, V26, P1367, DOI 10.1093/ndt/gfq497; Suri R, 2003, AM J KIDNEY DIS, V42, pS42, DOI 10.1016/S0272-6386(03)00537-7; Veeneman JM, 2003, AM J PHYSIOL-ENDOC M, V284, pE954, DOI 10.1152/ajpendo.00264.2002; Von Gersdorff G, 2010, NDT PLUS, V3; Walsh M, 2005, KIDNEY INT, V67, P1500, DOI 10.1111/j.1523-1755.2005.00228.x; Wells GA, NEWCASTLE OTTAWA SCA	58	7	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2016	11	6							e0157621	10.1371/journal.pone.0157621	http://dx.doi.org/10.1371/journal.pone.0157621			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WR	27322616	gold, Green Published, Green Submitted			2023-01-03	WOS:000378212000032
J	Fan, B; Guan, J; Wang, XM; Cong, YL				Fan, Bing; Guan, Jie; Wang, Xiumei; Cong, Yulong			Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model	PLOS ONE			English	Article							GALLERIA-MELLONELLA MODEL; IN-VIVO EFFICACY; FIELD GEL-ELECTROPHORESIS; TRACT-INFECTION; VITRO SYNERGY; MOUSE MODEL; CARBAPENEM; THERAPY; PNEUMONIA; METAANALYSIS	Few effective therapeutic options are available for treating severe infections caused by extensively drug-resistant Acinetobacter baumannii (XDR-AB). Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tige-cycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains. Colistin, tigecycline, rifampin, and sulbactam monotherapy significantly decreased bacterial counts in murine thigh infections compared with those observed in control mice receiving no treatment. Colistin was the most effective agent tested, displaying bactericidal activity against 91.7% of strains at 48 h post-treatment. With strains showing a relatively low minimum inhibitory concentration (MIC) for meropenem (MIC <= 32 mg/L), combination therapy with colistin plus meropenem caused synergistic inhibition at both 24 h and 48 h post-treatment. However, when the meropenem MIC was >= 64 mg/L, meropenem did not significantly alter the efficacy of colistin. The addition of rifampin and fusidic acid significantly improved the efficacy of colistin, showing a synergistic effect in 100% and 58.3% of strains after 24 h of treatment, respectively, while the addition of tigecycline, fosfomycin, or sulbactam did not show obvious synergistic activity. No clear differences in activities were observed between colistin-rifampin and colistin-fusidic acid combination therapy with most strains. Overall, our in vivo study showed that administering colistin in combination with rifampin or fusidic acid is more efficacious in treating XDR-AB infections than other combinations. The colistin-meropenem combination may be another appropriate option if the MIC is <= 32 mg/L. Further clinical studies are urgently needed to confirm the relevance of these findings.	[Fan, Bing; Cong, Yulong] Chinese Peoples Liberat Army Gen Hosp, Clin Lab South Bldg, Beijing 100853, Peoples R China; [Fan, Bing] Gen Hosp Chinese Peoples Armed Police Forces, Clin Lab Clin Dist 2, Beijing 100039, Peoples R China; [Guan, Jie] Peking Univ, Hosp 1, Dept Clin Lab, Beijing 100034, Peoples R China; [Wang, Xiumei] Gen Hosp Chinese Peoples Armed Police Forces, Dept Clin Lab, Beijing 100039, Peoples R China	Chinese People's Liberation Army General Hospital; Peking University	Cong, YL (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Clin Lab South Bldg, Beijing 100853, Peoples R China.	congyulongpla301@163.com						Barthold SW, 2010, ANTIMICROB AGENTS CH, V54, P643, DOI 10.1128/AAC.00788-09; BELLAHSENE A, 1980, INFECT IMMUN, V29, P873; Biswas S, 2012, EXPERT REV ANTI-INFE, V10, P917, DOI [10.1586/ERI.12.78, 10.1586/eri.12.78]; Cheng A, 2015, CRIT CARE MED, V43, P1194, DOI 10.1097/CCM.0000000000000933; Chuang YC, 2011, CLIN INFECT DIS, V52, P352, DOI 10.1093/cid/ciq154; Clinical and Laboratory Standards Institute, 2014, CLSI DOCUMENT M100 S; Clinical and Laboratory Standards Institute, 2012, CLSI DOCUMENT M07 A9; Dinc G, 2013, CHEMOTHERAPY, V59, P325, DOI 10.1159/000356755; Durante-Mangoni E, 2013, CLIN INFECT DIS, V57, P349, DOI 10.1093/cid/cit253; Galani I, 2014, INT J ANTIMICROB AG, V43, P370, DOI 10.1016/j.ijantimicag.2013.12.010; Gordon NC, 2010, ANTIMICROB AGENTS CH, V54, P5316, DOI 10.1128/AAC.00922-10; GOUBY A, 1992, J CLIN MICROBIOL, V30, P1588, DOI 10.1128/JCM.30.6.1588-1591.1992; Hornsey M, 2011, ANTIMICROB AGENTS CH, V55, P3534, DOI 10.1128/AAC.00230-11; Hornsey M, 2013, INT J ANTIMICROB AG, V41, P285, DOI 10.1016/j.ijantimicag.2012.11.013; Lee HJ, 2013, ANTIMICROB AGENTS CH, V57, P3738, DOI 10.1128/AAC.00703-13; Lefort A, 2014, INT J ANTIMICROB AG, V43, P366, DOI 10.1016/j.ijantimicag.2013.12.001; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Maragakis LL, 2008, CLIN INFECT DIS, V46, P1254, DOI 10.1086/529198; Michail G, 2013, ANTIMICROB AGENTS CH, V57, P6028, DOI 10.1128/AAC.00891-13; Montero A, 2002, ANTIMICROB AGENTS CH, V46, P1946, DOI 10.1128/AAC.46.6.1946-1952.2002; Morinaga Y, 2008, J ANTIMICROB CHEMOTH, V62, P1326, DOI 10.1093/jac/dkn411; Ni WT, 2015, INT J ANTIMICROB AG, V45, P8, DOI 10.1016/j.ijantimicag.2014.10.002; Pachon-Ibanez ME, 2010, ANTIMICROB AGENTS CH, V54, P1165, DOI 10.1128/AAC.00367-09; Paul M, 2014, J ANTIMICROB CHEMOTH, V69, P2305, DOI 10.1093/jac/dku168; Perez F, 2007, ANTIMICROB AGENTS CH, V51, P3471, DOI 10.1128/AAC.01464-06; Phee LM, 2015, ANTIMICROB AGENTS CH, V59, P4544, DOI 10.1128/AAC.00753-15; Pogue JM, 2013, EXPERT REV ANTI-INFE, V11, P881, DOI 10.1586/14787210.2013.827881; Song JY, 2007, J ANTIMICROB CHEMOTH, V60, P317, DOI 10.1093/jac/dkm136; Song JY, 2009, INT J ANTIMICROB AG, V33, P33, DOI 10.1016/j.ijantimicag.2008.07.008; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Vila J, 2012, EXPERT OPIN PHARMACO, V13, P2319, DOI 10.1517/14656566.2012.729820; Wareham DW, 2011, J ANTIMICROB CHEMOTH, V66, P1047, DOI 10.1093/jac/dkr069; Yang HF, 2015, INT J ANTIMICROB AG, V45, P188, DOI 10.1016/j.ijantimicag.2014.10.012; Yilmaz EM, 2012, INT J ANTIMICROB AG, V40, P332, DOI 10.1016/j.ijantimicag.2012.06.003; Zusman O, 2013, ANTIMICROB AGENTS CH, V57, P5104, DOI 10.1128/AAC.01230-13	36	47	51	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2016	11	6							e0157757	10.1371/journal.pone.0157757	http://dx.doi.org/10.1371/journal.pone.0157757			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JQ	27315107	Green Published, Green Submitted, gold			2023-01-03	WOS:000378030000051
J	Shi, YQ; Dong, YW; Huang, WH; Zhu, DC; Mao, H; Su, PZ				Shi, Yanqiang; Dong, Yiwei; Huang, Wenhui; Zhu, Decong; Mao, Hua; Su, Peizhu			Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							INFLAMMATORY-BOWEL-DISEASE; RANDOMIZED CLINICAL-TRIAL; MANAGEMENT; REMISSION; CHILDREN; FECES; ENEMA	Background Fecal microbiota transplantation (FMT) has been recognized as a novel treatment for ulcerative colitis (UC). However, its efficacy and safety remain unclear. Objective We conducted this systematic review to assess the efficacy and safety of FMT in UC. Data Sources PubMed, EMBASE, Cochrane Central, Web of Science Core Collection, and three other Chinese databases were searched for reports of FMT in UC with clear outcomes. Data Extraction and Synthesis We estimated pooled rates [with 95% confidence interval (CI)] of clinical remission among 15 cohort studies and clinical response among 16 cohort studies. Results Twenty five studies (2 randomized controlled trials, 15 cohort studies, and 8 case studies) with 234 UC patients were included. Overall, 41.58% (84/202) patients achieved clinical remission (CR) and 65.28% (126/193) achieved clinical response. Among the cohort studies, the pooled estimate of patients who achieved CR and clinical response were 40.5% (95% CI 24.7%-58.7%), and 66.1% (95% CI 43.7%-83.0%). Most adverse events were slight and self-resolving. The analyses of gut microbiota in 7 studies showed that FMT could increase microbiota diversity and richness, similarity, and certain change of bacterial composition. Conclusion FMT provides a promising effect for UC with few adverse events. Successful FMT may be associated with an increase in microbiota diversity and richness, similarity, and certain change of bacterial composition.	[Shi, Yanqiang; Dong, Yiwei; Huang, Wenhui; Zhu, Decong] Southern Med Univ, Clin Med Sch 2, Guangzhou 510280, Guangdong, Peoples R China; [Mao, Hua; Su, Peizhu] Southern Med Univ, Zhujiang Hosp, Dept Gastroenterol, Guangzhou 510280, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Su, PZ (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Gastroenterol, Guangzhou 510280, Guangdong, Peoples R China.	supeizhu1986@163.com		Shi, Yanqiang/0000-0003-0814-6322				Anderson JL, 2012, ALIMENT PHARM THER, V36, P503, DOI 10.1111/j.1365-2036.2012.05220.x; Angelberger S, 2013, AM J GASTROENTEROL, V108, P1620, DOI 10.1038/ajg.2013.257; Bartosch S, 2004, APPL ENVIRON MICROB, V70, P3575, DOI 10.1128/AEM.70.6.3575-3581.2004; BENNET JD, 1989, LANCET, V1, P164; Berg D, 2015, EXPERT REV GASTROENT, V9, P781, DOI 10.1586/17474124.2015.1013031; Borody T, 2012, AM J GASTROENTEROL, V107, pS665, DOI 10.14309/00000434-201210001-01644; Borody T, 2011, AM J GASTROENTEROL, V106, pS352; BORODY TJ, 1989, MED J AUSTRALIA, V150, P604, DOI 10.5694/j.1326-5377.1989.tb136704.x; Borody TJ, 2003, J CLIN GASTROENTEROL, V37, P42, DOI 10.1097/00004836-200307000-00012; Bringiotti Roberto, 2014, World J Gastrointest Pathophysiol, V5, P550, DOI 10.4291/wjgp.v5.i4.550; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Cammarota G, 2015, PHARMACOL THERAPEUT, V149, P191, DOI 10.1016/j.pharmthera.2014.12.006; Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046; Colman RJ, 2014, J CROHNS COLITIS, V8, P1569, DOI 10.1016/j.crohns.2014.08.006; Cui BT, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0646-2; Damman CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133925; Damman CJ, 2012, AM J GASTROENTEROL, V107, P1452, DOI 10.1038/ajg.2012.93; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; Dekkers OM, 2012, ANN INTERN MED, V156, P37, DOI 10.7326/0003-4819-156-1-201201030-00006; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EISEMAN B, 1958, SURGERY, V44, P854; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hohmann EL, 2014, NEW ENGL J MED, V371, P668, DOI 10.1056/NEJMcpc1400842; Hold GL, 2014, WORLD J GASTROENTERO, V20, P1192, DOI 10.3748/wjg.v20.i5.1192; Karolewska-Bochenek K, 2015, J CROHNS COLITIS, V9, pS294; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kellermayer R, 2015, AM J GASTROENTEROL, V110, P604, DOI 10.1038/ajg.2015.19; Kelly CR, 2015, GASTROENTEROLOGY, V149, P223, DOI 10.1053/j.gastro.2015.05.008; Kump PK, 2013, INFLAMM BOWEL DIS, V19, P2155, DOI 10.1097/MIB.0b013e31829ea325; Kunde S, 2013, J PEDIATR GASTR NUTR, V56, P597, DOI 10.1097/MPG.0b013e318292fa0d; Landy J, 2013, GASTROENTEROLOGY, V144, pS897; Liu Chang-qin WW, 2013, CHINESE J DIGESTION; Macfarlane S, 2004, ADV APPL MICROBIOL, V54, P261, DOI 10.1016/S0065-2164(04)54010-8; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Negroni A, 2012, INFLAMM BOWEL DIS, V18, P913, DOI 10.1002/ibd.21899; Ni XD, 2015, CPEN CHINESE, V22, P29; Oliva S, 2012, ALIMENT PHARM THER, V35, P327, DOI 10.1111/j.1365-2036.2011.04939.x; Petritsch W., 2013, OP187 PRELIMINARY CL; RAO SSC, 1988, GUT, V29, P342, DOI 10.1136/gut.29.3.342; Ren Rongrong, 2015, Zhonghua Nei Ke Za Zhi, V54, P411; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Scaldaferri F, 2015, GASTROENTEROLOGY, V148, pS870; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Sood A, 2009, CLIN GASTROENTEROL H, V7, P1202, DOI 10.1016/j.cgh.2009.07.016; Stange EF, 2008, J CROHNS COLITIS, V2, P1, DOI 10.1016/j.crohns.2007.11.001; Suskind DL, 2015, J PEDIATR GASTR NUTR, V60, P27, DOI 10.1097/MPG.0000000000000544; Tursi A, 2010, AM J GASTROENTEROL, V105, P2218, DOI 10.1038/ajg.2010.218; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vandenplas Y, 2015, J PEDIATR GASTR NUTR, V61, pE12, DOI 10.1097/MPG.0000000000000281; Wallace BC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-80; Wei Y, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/517597; Wells GA, NEWCASTLE OTTAWA SCA; WK-y Wang Mei, 2014, CHINESE J DIGESTIVE; Zhang FM, 2012, AM J GASTROENTEROL, V107, P1755, DOI 10.1038/ajg.2012.251	57	50	54	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2016	11	6							e0157259	10.1371/journal.pone.0157259	http://dx.doi.org/10.1371/journal.pone.0157259			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KF	27295210	Green Published, gold, Green Submitted			2023-01-03	WOS:000377821300029
J	Hoebel, J; Rattay, P; Prutz, F; Rommel, A; Lampert, T				Hoebel, Jens; Rattay, Petra; Pruetz, Franziska; Rommel, Alexander; Lampert, Thomas			Socioeconomic Status and Use of Outpatient Medical Care: The Case of Germany	PLOS ONE			English	Article							INCOME-RELATED INEQUALITIES; SELF-REPORTED UTILIZATION; HEALTH-CARE; SERVICES UTILIZATION; PARTICIPATION; ADULTS; INTERVIEW; PATIENT; ACCESS; ASSOCIATION	Background Socially disadvantaged people have an increased need for medical care due to a higher burden of health problems and chronic diseases. In Germany, outpatient care is chiefly provided by office-based general practitioners and specialists in private practice. People are free to choose the physician they prefer. In this study, national data were used to examine differences in the use of outpatient medical care by socioeconomic status (SES). Methods The analyses were based on data from 6,754 participants in the Robert Koch Institute's German Health Interview and Examination Survey for Adults (DEGS1) aged between 18 and 69 years. The number of outpatient physician visits during the past twelve months was assessed for several medical specializations. SES was determined based on education, occupation, and income. Associations between SES and physician visits were analysed using logistic regression and zero-truncated negative binomial regression for count data. Results After adjusting for sociodemographic factors and health indicators, outpatients with low SES had more contacts with general practitioners than outpatients with high SES (men: incidence rate ratio [IRR] = 1.25; 95% confidence interval [CI] = 1.08-1.46; women: IRR = 1.20; 95% CI = 1.07-1.34). The use of specialists was lower in people with low SES than in those with high SES when sociodemographic factors and health indicators were adjusted for (men: odds ratio [OR] = 0.68; 95% CI = 0.51-0.91; women: OR = 0.56; 95% CI = 0.41-0.77). This applied particularly to specialists in internal medicine, dermatology, and gynaecology. The associations remained after additional adjustment for the type of health insurance and the regional density of office-based physicians. Conclusion The findings suggest that socially disadvantaged people are seen by general practitioners more often than the socially better-off, who are more likely to visit a medical specialist. These differences may be due to differences in patient preferences, physician factors, physician-patient interaction, and potential barriers to accessing specialist care.	[Hoebel, Jens; Rattay, Petra; Lampert, Thomas] Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Unit Social Determinants Hlth, Berlin, Germany; [Pruetz, Franziska; Rommel, Alexander] Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Unit Hlth Reporting, Berlin, Germany	Robert Koch Institute; Robert Koch Institute	Hoebel, J (corresponding author), Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Unit Social Determinants Hlth, Berlin, Germany.	j.hoebel@rki.de			ministry finances the RKI	ministry finances the RKI	The German Health Interview and Examination Survey for Adults (DEGS) is part of the Federal Health Monitoring (FHM) in Germany. The FHM is administered by the Robert Koch Institute (RKI) on behalf of the German Federal Ministry of Health. The ministry finances the RKI and gives substantial funds for the FHM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors are employees of the RKI. No one of the authors received specific funding for this work.	Baumeister SE, 2004, GESUNDHEITSWESEN, V66, P175, DOI 10.1055/s-2004-813028; Bergmann E, 2005, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V48, P1365, DOI 10.1007/s00103-005-1167-6; Bhandari A, 2006, MED CARE RES REV, V63, P217, DOI 10.1177/1077558705285298; Bormann C., 2014, HLTH CARE UTILIZATIO, P29, DOI [10.1007/978-1-4614-9191-0_3, DOI 10.1007/978-1-4614-9191-0_3]; Boyle Sean, 2011, Health Syst Transit, V13, P1; Brauns H., 2003, ADV CROSS NATL COMP, P221, DOI DOI 10.1007/978-1-4419-9186-7_11; Bremer P, 2014, HEALTH ECON REV, V4, DOI 10.1186/s13561-014-0036-0; Bremer P, 2013, PRAVENT GESUNDHEIT, V8, P15, DOI 10.1007/s11553-012-0368-8; Busse R, 2014, HEALT SYST TRANSIT, V16, P1; Cox B, 2009, INT J PUBLIC HEALTH, V54, P55, DOI 10.1007/s00038-009-7104-y; Cylus J, 2015, HEALTH POLICY, V119, P1133, DOI 10.1016/j.healthpol.2015.07.004; Devaux M, 2015, EUR J HEALTH ECON, V16, P21, DOI 10.1007/s10198-013-0546-4; Droomers M, 2004, EUR J PUBLIC HEALTH, V14, P311, DOI 10.1093/eurpub/14.3.311; Ernst J, 2014, GESUNDHEITSWESEN, V76, P187, DOI 10.1055/s-0033-1361150; European Commission, 2013, HLTH IN EU FIN REP C; GANZEBOOM HBG, 1992, SOC SCI RES, V21, P1, DOI 10.1016/0049-089X(92)90017-B; Garcia-Armesto Sandra, 2010, Health Syst Transit, V12, P1; Geyer S, 2015, ARCH GYNECOL OBSTET, V291, P623, DOI 10.1007/s00404-014-3421-3; Gruber S, 2010, J PUBLIC HEALTH-HEID, V18, P351, DOI 10.1007/s10389-010-0321-2; Hoebel J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-913; Hoebel J, 2013, DTSCH ARZTEBL INT, V110, P679, DOI 10.3238/arztebl.2013.0679; Hoffmann F, 2012, GESUNDHEITSWESEN, V74, P291, DOI 10.1055/s-0031-1275711; JanSSen Christian, 2012, Psychosoc Med, V9, pDoc07, DOI 10.3205/psm000085; Jordan S, 2015, BUNDESGESUNDHEITSBLA, V58, P942, DOI 10.1007/s00103-015-2200-z; Kamtsiuris P, 2013, BUNDESGESUNDHEITSBLA, V56, P620, DOI 10.1007/s00103-012-1650-9; Kassenarztliche Bundesvereinigung, 2011, BUND 2011; Klein J., 2014, HLTH CARE UTILIZATIO, P117; Lampert T, 2013, BUNDESGESUNDHEITSBLA, V56, P631, DOI 10.1007/s00103-012-1663-4; Lostao L, 2007, J EPIDEMIOL COMMUN H, V61, P416, DOI 10.1136/jech.2006.047126; Lungen M, 2009, AUSMASS GRUNDE UNGLE; Lungen M, 2008, INT J EQUITY HEALTH, V7, DOI 10.1186/1475-9276-7-1; Mackenbach, 2006, HLTH INEQUALITIES EU; Mackenbach JP, 2008, NEW ENGL J MED, V358, P2468, DOI 10.1056/NEJMsa0707519; Marmot MG., 2006, SOCIAL DETERMINANTS; Mielck A, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-52; O'Malley MS, 2001, AM J PUBLIC HEALTH, V91, P49; Peersman W, 2014, EUR J PUBLIC HEALTH, V24, P91, DOI 10.1093/eurpub/ckt079; Rattay P, 2013, BUNDESGESUNDHEITSBLA, V56, P832, DOI 10.1007/s00103-013-1665-x; Reibling N, 2010, GESUNDHEITSWESEN, V72, P447, DOI 10.1055/s-0029-1234101; Ruckert IM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-232; Sass AC, 2015, BUNDESGESUNDHEITSBLA, V58, P533, DOI 10.1007/s00103-015-2146-1; Schafer Willemijn, 2010, Health Syst Transit, V12, pv; Scheidt-Nave C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-730; Seidel D, 2009, J CANCER RES CLIN, V135, P533, DOI 10.1007/s00432-008-0485-0; Sorensen TH, 2009, HEALTH POLICY, V92, P180, DOI 10.1016/j.healthpol.2009.03.011; Starker A, 2013, BUNDESGESUNDHEITSBLA, V56, P858, DOI 10.1007/s00103-012-1655-4; Stirbu I, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-288; Swart Enno, 2012, Psychosoc Med, V9, pDoc10, DOI 10.3205/psm000088; Terraneo M, 2015, SOC SCI MED, V126, P154, DOI 10.1016/j.socscimed.2014.12.028; Thode N, 2005, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V48, P296, DOI 10.1007/s00103-004-1004-3; van Doorslaer E, 2004, HEALTH ECON, V13, P629, DOI 10.1002/hec.919; von dem Knesebeck O, 2009, GESUNDHEITSWESEN, V71, P59, DOI 10.1055/s-0028-1119371; Willems S, 2005, PATIENT EDUC COUNS, V56, P139, DOI 10.1016/j.pec.2004.02.011; Zok K, 2005, WIDOMONITOR, V2, P1	54	27	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2016	11	5							e0155982	10.1371/journal.pone.0155982	http://dx.doi.org/10.1371/journal.pone.0155982			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DN2GV	27232878	Green Published, Green Submitted, gold			2023-01-03	WOS:000376883000010
J	Leung, NHZ; Chen, A; Yadav, P; Gallien, J				Leung, Ngai-Hang Z.; Chen, Ana; Yadav, Prashant; Gallien, Jeremie			The Impact of Inventory Management on Stock-Outs of Essential Drugs in Sub-Saharan Africa: Secondary Analysis of a Field Experiment in Zambia	PLOS ONE			English	Article								Objective To characterize the impact of widespread inventory management policies on stock-outs of essential drugs in Zambia's health clinics and develop related recommendations. Methods Daily clinic storeroom stock levels of artemether-lumefantrine (AL) products in 2009-2010 were captured in 145 facilities through photography and manual transcription of paper forms, then used to determine historical stock-out levels and estimate demand patterns. Delivery lead-times and estimates of monthly facility accessibility were obtained through worker surveys. A simulation model was constructed and validated for predictive accuracy against historical stock-outs, then used to evaluate various changes potentially affecting product availability. Findings While almost no stock-outs of AL products were observed during Q4 2009 consistent with primary analysis, up to 30% of surveyed facilities stocked out of some AL product during Q1 2010 despite ample inventory being simultaneously available at the national warehouse. Simulation experiments closely reproduced these results and linked them to the use of average past monthly issues and failure to capture lead-time variability in current inventory control policies. Several inventory policy enhancements currently recommended by USAID vertical bar DELIVER were found to have limited impact on product availability. Conclusions Inventory control policies widely recommended and used for distributing medicines in sub-Saharan Africa directly account for a substantial fraction of stock-outs observed in common situations involving demand seasonality and facility access interruptions. Developing central capabilities in peripheral demand forecasting and inventory control is critical. More rigorous independent peer-reviewed research on pharmaceutical supply chain management in low-income countries is needed.	[Leung, Ngai-Hang Z.] Carnegie Mellon Univ, Tepper Sch Business, Pittsburgh, PA 15213 USA; [Chen, Ana] Analyt Operat Engn, Boston, MA USA; [Yadav, Prashant] Univ Michigan, Ross Sch Business, William Davidson Inst, Ann Arbor, MI 48109 USA; [Yadav, Prashant] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Gallien, Jeremie] London Business Sch, Regents Pk, London NW1 4SA, England; [Leung, Ngai-Hang Z.] City Univ Hong Kong, Coll Business, Dept Management Sci, Hong Kong, Hong Kong, Peoples R China	Carnegie Mellon University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of London; London Business School; City University of Hong Kong	Gallien, J (corresponding author), London Business Sch, Regents Pk, London NW1 4SA, England.	jgallien@london.edu	Gallien, Jérémie/L-6428-2013	Gallien, Jérémie/0000-0001-6292-5031; Yadav, Prashant/0000-0001-7836-6641	London Business School; Massachusetts Institute of Technology; World Bank	London Business School; Massachusetts Institute of Technology; World Bank(The World Bank India)	This work was supported by London Business School (JG), Massachusetts Institute of Technology (NHL) and The World Bank. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold K., 2005, JAVA PROGRAMMING LAN; Barrington J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-298; Bossert TJ, 2007, HEALTH POLICY PLANN, V22, P73, DOI 10.1093/heapol/czl041; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Fundafunda B, 2014, COMMUNICATION; Hopp W. J., 2004, Manufacturing & Service Operations Management, V6, P133, DOI 10.1287/msom.1030.0028; Kangwana BB, 2009, AM J TROP MED HYG, V80, P737, DOI 10.4269/ajtmh.2009.80.737; Law A.M., 2000, SIMULATION MODELING, Vthird; Luk R, 2013, LESSONS LEARNED ICTS; Makridakis S., 1998, FORECASTING METHODS, Vthird; Matowe L, 2008, HUM RESOUR HEALTH, V6, DOI 10.1186/1478-4491-6-30; Pasquet A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013414; Picazo OF, 2009, WORLD BANK COUNTRY, P1, DOI 10.1596/978-0-8213-7804-5; Quick JD, 1997, DC2018020003 DEP EN; Ross DF., 2010, INTRO SUPPLY CHAIN M; Snyder LV., 2011, FUNDAMENTALS SUPPLY; USAID &VERBAR; DELIVER PROJECT Task Order 1, 2011, 1 USAID DELIVER PROJ; USAID &VERBAR; DELIVER PROJECT Task Order 3, 2011, 3 USAID DELIVER PROJ; Vledder M, 2015, 1269 ROSS SCH BUS; Waako PJ, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-21; Watson N, 2014, 17 USAID DELIVER PRO; Yadav P., 2007, ANAL PUBLIC PRIVATE	22	31	31	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2016	11	5							e0156026	10.1371/journal.pone.0156026	http://dx.doi.org/10.1371/journal.pone.0156026			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GQ	27227412	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000376882500053
J	Yeh, JS; Kushner, RF; Schiff, GD				Yeh, James S.; Kushner, Robert F.; Schiff, Gordon D.			Obesity and Management of Weight Loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONTROLLED-RELEASE; CONTROLLED-TRIAL; OVERWEIGHT		[Yeh, James S.; Kushner, Robert F.; Schiff, Gordon D.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Yeh, JS (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.			Yeh, James/0000-0003-3549-6096				Apovian CM, 2015, J CLIN ENDOCR METAB, V100, P342, DOI 10.1210/jc.2014-3415; Curfman GD, 2010, NEW ENGL J MED, V363, P972, DOI 10.1056/NEJMe1007993; Gadde KM, 2011, LANCET, V377, P1341, DOI 10.1016/S0140-6736(11)60205-5; Garvey WT, 2012, AM J CLIN NUTR, V95, P297, DOI 10.3945/ajcn.111.024927; Greenway FL, 2010, LANCET, V376, P595, DOI 10.1016/S0140-6736(10)60888-4; Padwal RS, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004094.pub2, DOI 10.1002/14651858.CD004094.PUB2]; Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892; Rasmussen N, 2008, AM J PUBLIC HEALTH, V98, P974, DOI 10.2105/AJPH.2007.110593; Schiff GD, 2011, ARCH INTERN MED, V171, P1433, DOI 10.1001/archinternmed.2011.256; Smith SR, 2010, NEW ENGL J MED, V363, P245, DOI 10.1056/NEJMoa0909809; Swinburn B, 2015, LANCET, V385, P2534, DOI 10.1016/S0140-6736(14)61747-5	11	5	6	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	2016	375	12					1187	1189		10.1056/NEJMclde1515935	http://dx.doi.org/10.1056/NEJMclde1515935			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DW3JE	27653571				2023-01-03	WOS:000383537100015
J	Palumbo, A; Chanan-Khan, A; Weisel, K; Nooka, AK; Masszi, T; Beksac, M; Spicka, I; Hungria, V; Munder, M; Mateos, MV; Mark, TM; Qi, M; Schecter, J; Amin, H; Qin, X; Deraedt, W; Ahmadi, T; Spencer, A; Sonneveld, P				Palumbo, Antonio; Chanan-Khan, Asher; Weisel, Katja; Nooka, Ajay K.; Masszi, Tamas; Beksac, Meral; Spicka, Ivan; Hungria, Vania; Munder, Markus; Mateos, Maria V.; Mark, Tomer M.; Qi, Ming; Schecter, Jordan; Amin, Himal; Qin, Xiang; Deraedt, William; Ahmadi, Tahamtan; Spencer, Andrew; Sonneveld, Pieter		CASTOR Investigators	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY DARATUMUMAB; MONOTHERAPY; PHASE-2; TRIAL; CD38	BACKGROUND Daratumumab, a human IgG kappa monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma. METHODS In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group). The primary end point was progression-free survival. RESULTS A prespecified interim analysis showed that the rate of progression-free survival was significantly higher in the daratumumab group than in the control group; the 12-month rate of progression-free survival was 60.7% in the daratumumab group versus 26.9% in the control group. After a median follow-up period of 7.4 months, the median progression-free survival was not reached in the daratumumab group and was 7.2 months in the control group (hazard ratio for progression or death with daratumumab vs. control, 0.39; 95% confidence interval, 0.28 to 0.53; P < 0.001). The rate of overall response was higher in the daratumumab group than in the control group (82.9% vs. 63.2%, P < 0.001), as were the rates of very good partial response or better (59.2% vs. 29.1%, P < 0.001) and complete response or better (19.2% vs. 9.0%, P = 0.001). Three of the most common grade 3 or 4 adverse events reported in the daratumumab group and the control group were thrombocytopenia (45.3% and 32.9%, respectively), anemia (14.4% and 16.0%, respectively), and neutropenia (12.8% and 4.2%, respectively). Infusion-related reactions that were associated with daratumumab treatment were reported in 45.3% of the patients in the daratumumab group; these reactions were mostly grade 1 or 2 (grade 3 in 8.6% of the patients), and in 98.2% of these patients, they occurred during the first infusion. CONCLUSIONS Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than bortezomib and dexamethasone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia than bortezomib and dexamethasone alone. (Funded by Janssen Research and Development; ClinicalTrials.gov number, NCT02136134.)	[Palumbo, Antonio] Univ Turin, Dept Hematol, Via Genova 3, I-10126 Turin, Italy; [Chanan-Khan, Asher] Mayo Clin Florida, Div Hematol & Med Oncol, Jacksonville, FL USA; [Weisel, Katja] Univ Tubingen, Univ Klinikum Tuebingen, Abt Innere Med 2, Tubingen, Germany; [Munder, Markus] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany; [Nooka, Ajay K.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Masszi, Tamas] Semmelweis Univ, St Laszlo Hosp, Dept Hematol & Stem Cell Transplantat, Budapest, Hungary; [Beksac, Meral] Ankara Univ, Dept Hematol, Ankara, Turkey; [Spicka, Ivan] Charles Univ Prague, Dept Med 1, Dept Clin Hematol, Prague, Czech Republic; [Hungria, Vania] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil; [Mateos, Maria V.] Univ Hosp Salamanca, Inst Invest Biomed Salamanca, Salamanca, Spain; [Mark, Tomer M.] Weill Cornell Med Coll, New York, NY USA; [Qi, Ming; Qin, Xiang; Ahmadi, Tahamtan] Janssen Res & Dev, Spring House, PA USA; [Schecter, Jordan; Amin, Himal] Janssen Res & Dev, Raritan, NJ USA; [Deraedt, William] Janssen Res & Dev, Beerse, Belgium; [Spencer, Andrew] Monash Univ, Alfred Hlth, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic, Australia; [Sonneveld, Pieter] Dept Hematol, Erasmus MC, Rotterdam, Netherlands	University of Turin; Mayo Clinic; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Johannes Gutenberg University of Mainz; Emory University; Semmelweis University; Szent Laszlo Hospital; Ankara University; Charles University Prague; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Cornell University; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Monash University; Erasmus University Rotterdam; Erasmus MC	Palumbo, A (corresponding author), Univ Turin, Dept Hematol, Via Genova 3, I-10126 Turin, Italy.	appalumbo@yahoo.com	Croockewit, A.J./L-4255-2015; Hacıhanefioğlu, Abdullah/G-1501-2018; Hernandez-Rivas, Jose-Angel/ADF-6441-2022; Munder, Markus/K-6737-2013; Corradini, Paolo/N-7584-2017; martinez, joaquin/AAN-6939-2020; Hajek, Roman/I-6639-2017	Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; Corradini, Paolo/0000-0002-9186-1353; martinez, joaquin/0000-0001-7908-0063; Hajek, Roman/0000-0001-6955-6267; Grosicki, Sebastian/0000-0003-2644-1050; Spicka, Ivan/0000-0002-5451-5283; de la Rubia, Javier/0000-0002-8354-768X; lipe, brea/0000-0002-7596-2015; Masszi, Tamas/0000-0003-2322-9863; Mun, Yeung-Chul/0000-0002-1882-3983; CAVO, MICHELE/0000-0003-4514-3227; Warzocha, Krzysztof/0000-0002-2396-3905	Janssen Research and Development	Janssen Research and Development	Supported by Janssen Research and Development.	Anderson KC, 2016, J NATL COMPR CANC NE, V14, P389, DOI 10.6004/jnccn.2016.0046; Chari A, 2015, AM SOC HEM 56 ANN M; de Weers M, 2011, J IMMUNOL, V186, P1840, DOI 10.4049/jimmunol.1003032; DeMets D L, 1995, Cancer Treat Res, V75, P1; Dimopoulos MA, 2016, LANCET ONCOL, V17, P27, DOI 10.1016/S1470-2045(15)00464-7; Dimopoulos MA, 2015, NAT REV CLIN ONCOL, V12, P42, DOI 10.1038/nrclinonc.2014.200; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Durie BGM, 2015, LEUKEMIA, V29, P2416, DOI 10.1038/leu.2015.290; Endell J, 2011, 2011 AM SOC CLIN ONC; Jakubowiak A, 2016, BLOOD, V127, P2833, DOI 10.1182/blood-2016-01-694604; Jansen JHM, 2012, AM SOC HEM 54 ANN M; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Lammerts van Bueren JJ, 2014, AM SOC HEM 56 ANN M; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lin P, 2004, AM J CLIN PATHOL, V121, P482, DOI 10.1039/74R4TB90BUWH27JX; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lonial S, 2016, LANCET, V387, P1551, DOI 10.1016/S0140-6736(15)01120-4; Lonial S, 2011, CLIN CANCER RES, V17, P1264, DOI 10.1158/1078-0432.CCR-10-1805; Mateos MV, 2015, 20 C EUR HEM ASS VIE; McCudden C, 2016, CLIN CHEM LAB MED, V54, P1095, DOI 10.1515/cclm-2015-1031; McKeage K, 2016, DRUGS, V76, P275, DOI 10.1007/s40265-015-0536-1; Overdijk MB, 2015, MABS-AUSTIN, V7, P311, DOI 10.1080/19420862.2015.1007813; Plesner T., 2015, AM SOC HEM 57 ANN M; Rajkumar SV, 2016, MAYO CLIN PROC, V91, P101, DOI 10.1016/j.mayocp.2015.11.007; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1; San-Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470-2045(14)70440-1; Santonocito AM, 2004, LEUKEMIA RES, V28, P469, DOI 10.1016/j.leukres.2003.09.015; Usmani SZ, 2016, BLOOD, V128, P37, DOI 10.1182/blood-2016-03-705210; van der Veer MS, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.42; Yannakou CK, 2014, BLOOD, V124	32	967	1000	3	73	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2016	375	8					754	766		10.1056/NEJMoa1606038	http://dx.doi.org/10.1056/NEJMoa1606038			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT9ET	27557302	Bronze, Green Published			2023-01-03	WOS:000381799300013
J	Torjesen, I				Torjesen, Ingrid			Nursery policies on conjunctivitis may encourage GPs to prescribe antibiotics	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Finnikin S, 2016, BRIT J GEN PRACT, V66, pE674, DOI 10.3399/bjgp16X686125	1	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2016	354								i3754	10.1136/bmj.i3754	http://dx.doi.org/10.1136/bmj.i3754			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DR0EP	27382983				2023-01-03	WOS:000379581100022
J	Gaio, V; Nunes, B; Pechirra, P; Conde, P; Guiomar, R; Dias, CM; Barreto, M				Gaio, Vania; Nunes, Baltazar; Pechirra, Pedro; Conde, Patricia; Guiomar, Raquel; Dias, Carlos Matias; Barreto, Marta			Hospitalization Risk Due to Respiratory Illness Associated with Genetic Variation at IFITM3 in Patients with Influenza A(H1N1)pdm09 Infection: A Case-Control Study	PLOS ONE			English	Article							VIRUS; SUSCEPTIBILITY	Background Recent studies suggest an association between the Interferon Inducible Transmembrane 3 (IFITM3) rs12252 variant and the course of influenza infection. However, it is not clear whether the reported association relates to influenza infection severity. The aim of this study was to estimate the hospitalization risk associated with this variant in Influenza Like Illness (ILI) patients during the H1N1 pandemic influenza. Methods A case-control genetic association study was performed, using nasopharyngeal/oropharyngeal swabs collected during the H1N1 pandemic influenza. Laboratory diagnosis of influenza infection was performed by RT-PCR, the IFITM3 rs12252 was genotyped by RFLP and tested for association with hospitalization. Conditional logistic regression was performed to calculate the confounder-adjusted odds ratio of hospitalization associated with IFITM3 rs12252. Results We selected 312 ILI cases and 624 matched non-hospitalized controls. Within ILI Influenza A(H1N1)pdm09 positive patients, no statistical significant association was found between the variant and the hospitalization risk (Adjusted OR: 0.73 (95% CI: 0.33-1.50)). Regarding ILI Influenza A(H1N1) pdm09 negative patients, CT/CC genotype carriers had a higher risk of being hospitalized than patients with TT genotype (Adjusted OR: 2.54 (95% CI: 1.54-4.19)). Conclusions The IFITM3 rs12252 variant was associated with respiratory infection hospitalization but not specifically in patients infected with Influenza A(H1N1) pdm09.	[Gaio, Vania; Nunes, Baltazar; Dias, Carlos Matias; Barreto, Marta] Inst Nacl Saude Doutor Ricardo Jorge, Dept Epidemiol, P-1649016 Lisbon, Portugal; [Pechirra, Pedro; Conde, Patricia; Guiomar, Raquel] Inst Nacl Saude Doutor Ricardo Jorge, Dept Doencas Infeciosas, P-1649016 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge; Instituto Nacional de Saude Dr. Ricardo Jorge	Barreto, M (corresponding author), Inst Nacl Saude Doutor Ricardo Jorge, Dept Epidemiol, P-1649016 Lisbon, Portugal.	marta.barreto@insa.min-saude.pt	Nunes, Baltazar/V-8903-2019; Dias, Carlos/I-6335-2012; Barreto, Marta/F-5591-2012	Nunes, Baltazar/0000-0001-6230-7209; Dias, Carlos/0000-0002-0206-5874; Gaio, Vania/0000-0001-7626-4991; Conde, Patricia/0000-0002-9346-305X; Guiomar, Raquel/0000-0002-4563-6315; Pechirra, Pedro/0000-0001-6352-1100; Barreto, Marta/0000-0001-6464-548X	National Health Institute Doutor Ricardo Jorge; National Institute of Health Doctor Ricardo Jorge (INSA)	National Health Institute Doutor Ricardo Jorge; National Institute of Health Doctor Ricardo Jorge (INSA)	This study was funded by the National Health Institute Doutor Ricardo Jorge. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge all the Colleagues from Infectious Disease Department from National Institute of Health Doctor Ricardo Jorge (INSA) that supported influenza A(H1N1)pdm09 diagnosis during 2009 Pandemia and 2009/2010 influenza season, to address the excess samples sent to National Influenza Reference Laboratory at INSA.	[Anonymous], 2012, EURO SURVEILL, P17; Arcanjo AC, 2014, ACTA BIOCHIM POL, V61, P403; Bautista E., 2010, CLIN ASPECTS PANDEMI; Boon ACM, 2009, J VIROL, V83, P10417, DOI 10.1128/JVI.00514-09; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; European Centre for Disease Prevention and Control (ECDC), 2009, OV SURV INFL 2009 20; Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921; Froes Filipe, 2014, Rev. Port. Sau. Pub., V32, P55; Graffelman J, 2012, HARDYWEINBERG GRAPHI; Hill AVS, 2006, ANNU REV GENET, V40, P469, DOI 10.1146/annurev.genet.40.110405.090546; Konig R, 2010, NATURE, V463, P813, DOI 10.1038/nature08699; Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792; Mills TC, 2014, J INFECT DIS, V209, P1028, DOI 10.1093/infdis/jit468; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Srivastava B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004857; World Health Organization, 2010, PAND H1N1 2009; Yang X, 2015, INTERFERON INDUCIBLE; Zhang YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2433	20	12	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2016	11	6							e0158181	10.1371/journal.pone.0158181	http://dx.doi.org/10.1371/journal.pone.0158181			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AH	27351739	gold, Green Submitted, Green Published			2023-01-03	WOS:000378858900041
J	Tseng, CL; Hung, YJ; Chen, ZY; Fang, HW; Chen, KH				Tseng, Ching-Li; Hung, Ya-Jung; Chen, Zhi-Yu; Fang, Hsu-Wei; Chen, Ko-Hua			Synergistic Effect of Artificial Tears Containing Epigallocatechin Gallate and Hyaluronic Acid for the Treatment of Rabbits with Dry Eye Syndrome	PLOS ONE			English	Article							CORNEAL EPITHELIAL-CELLS; OCULAR DRUG-DELIVERY; BENZALKONIUM CHLORIDE; SODIUM HYALURONATE; ANIMAL-MODELS; IN-VITRO; SURFACE; DISEASE; SYMPTOMS; EFFICACY	Dry eye syndrome (DES) is a common eye disease. Artificial tears (AT) are used to treat DES, but they are not effective. In this study, we assessed the anti-inflammatory effect of AT containing epigallocatechin gallate (EGCG) and hyaluronic acid (HA) on DES. Human corneal epithelial cells (HCECs) were used in the WST-8 assay to determine the safe dose of EGCG. Lipopolysaccharide-stimulated HCECs showing inflammation were treated with EGCG/HA. The expression of IL-1 beta, IL-6, IL-8, and TNF-alpha was assessed by real-time PCR and AT physical properties such as the viscosity, osmolarity, and pH were examined. AT containing EGCG and HA were topically administered in a rabbit DES model established by treatment with 0.1% benzalkonium chloride (BAC). Tear secretion was assessed and fluorescein, H&E, and TUNEL staining were performed. Inflammatory cytokine levels in the corneas were also examined. The non-toxic optimal concentration of EGCG used for the treatment of HCECs in vitro was 10 mu g/mL. The expression of several inflammatory genes, including IL-1 beta, IL-6, IL-8, and TNF-alpha, was significantly inhibited in inflamed HCECs treated with 10 mu g/mL EGCG and 0.1% (w/v) HA (E10/HA) compared to that in inflamed HCECs treated with either EGCG or HA alone. AT containing E10/HA mimic human tears, with similar osmolarity and viscosity and a neutral pH. Fluorescence examination of the ocular surface of mouse eyes showed that HA increased drug retention on the ocular surface. Topical treatment of DES rabbits with AT plus E10/HA increased tear secretion, reduced corneal epithelial damage, and maintained the epithelial layers and stromal structure. Moreover, the corneas of the E10/HA-treated rabbits showed fewer apoptotic cells, lower inflammation, and decreased IL-6, IL-8, and TNF-alpha levels. In conclusion, we showed that AT plus E10/HA had anti-inflammatory and mucoadhesive properties when used as topical eye drops and were effective for treating DES in rabbits.	[Tseng, Ching-Li; Chen, Zhi-Yu] Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, 250 Wu Hsing St, Taipei 110, Taiwan; [Hung, Ya-Jung; Fang, Hsu-Wei] Natl Taipei Univ Technol, Dept Chem Engn & Biotechnol, 1 Sect 3,Chung Hsiao E Rd, Taipei 106, Taiwan; [Fang, Hsu-Wei] Natl Hlth Res Inst, Inst Biomed Engn & Nanomed Res, 35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan; [Chen, Ko-Hua] Taipei Vet Gen Hosp, Dept Ophthalmol, 201 Sec 2,Shipai Rd, Taipei 112, Taiwan; [Chen, Ko-Hua] Taipei Med Univ, Coll Med, Sch Med, Dept Ophthalmol, 250 Wu Hsing St, Taipei 110, Taiwan	Taipei Medical University; National Taipei University of Technology; National Health Research Institutes - Taiwan; Taipei Veterans General Hospital; Taipei Medical University	Tseng, CL (corresponding author), Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, 250 Wu Hsing St, Taipei 110, Taiwan.	chingli@tmu.edu.tw		Tseng, Ching-Li/0000-0001-9446-4030	Ministry of Science and Technology (MOST), Taiwan [MOST 102-2221-E-038 -007]; National Health Research Institute (NHRI), Taiwan [NHRI-EX103-10334EI]; Innovation grant of Southern Taiwan Science Park [CZ-01-01-01-105]	Ministry of Science and Technology (MOST), Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institute (NHRI), Taiwan(National Health Research Institutes - Taiwan); Innovation grant of Southern Taiwan Science Park	This work was supported by grants from Ministry of Science and Technology (MOST), Taiwan under grant number at MOST 102-2221-E-038 -007; and an integrated research grant in health and medical sciences from National Health Research Institute (NHRI), Taiwan at grant number of NHRI-EX103-10334EI awarded to CL Tseng. An Innovation grant of Southern Taiwan Science Park at grant number of CZ-01-01-01-105 was awarded to HW Fang.	ABELSON MB, 1981, ARCH OPHTHALMOL-CHIC, V99, P301; Barabino S, 2005, INVEST OPHTH VIS SCI, V46, P2766, DOI 10.1167/iovs.04-1326; Barabino S, 2004, INVEST OPHTH VIS SCI, V45, P1641, DOI 10.1167/iovs.03-1055; Baudouin C, 2008, OPHTHALMOLOGY, V115, P109, DOI 10.1016/j.ophtha.2007.01.036; Benelli U, 2010, CONTACT LENS ANTERIO, V33, P61, DOI 10.1016/j.clae.2010.01.003; Brignole F, 2005, GRAEF ARCH CLIN EXP, V243, P531, DOI 10.1007/s00417-004-1040-6; BURSTEIN NL, 1980, INVEST OPHTH VIS SCI, V19, P308; Cavet ME, 2011, MOL VIS, V17, P533; de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077; Doughty MJ, 2009, OPHTHAL PHYSL OPT, V29, P573, DOI 10.1111/j.1475-1313.2009.00683.x; Erdinest N, 2012, INVEST OPHTH VIS SCI, V53, P4396, DOI 10.1167/iovs.12-9724; Fukuda M, 1998, ASIA PACIFIC J OPHTH, V10, P20; Gillespie K, 2008, LIFE SCI, V83, P581, DOI 10.1016/j.lfs.2008.08.011; Hargittai I, 2008, STRUCT CHEM, V19, P697, DOI 10.1007/s11224-008-9370-3; Hessen Michelle, 2014, J Ophthalmic Vis Res, V9, P240; JEAN MD, 2000, CURR EYE RES, V20, P85; Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r; Khan N, 2007, LIFE SCI, V81, P519, DOI 10.1016/j.lfs.2007.06.011; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; Kwon YS, 2011, INVEST OPHTH VIS SCI, V52, P3765; Larrosa M, 2008, FREE RADICAL RES, V42, P903, DOI 10.1080/10715760802510077; LEE H, 2010, ARVO ANN M MAY 2 6 F; Lemp MA, 2007, OCUL SURF, V5, P75; Li C, 2012, ANN SURG ONCOL, V7, P7, DOI DOI 10.1504/IJHPCN.2012.046371; Li N, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-50; Lin ZR, 2011, MOL VIS, V17, P257; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; McDonald CC, 2002, EYE, V16, P601, DOI 10.1038/sj.eye.6700169; Mitsui Y, 2008, J ORTHOP RES, V26, P1032, DOI 10.1002/jor.20558; Nagarwal RC, 2009, J CONTROL RELEASE, V136, P2, DOI 10.1016/j.jconrel.2008.12.018; Pisella PJ, 2002, BRIT J OPHTHALMOL, V86, P418, DOI 10.1136/bjo.86.4.418; Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955; Smith J, 2004, PHARM RES-DORDR, V21, P43, DOI 10.1023/B:PHAM.0000012150.60180.e3; Tiffany JM, 2003, EYE, V17, P923, DOI 10.1038/sj.eye.6700566; Tseng CL, 2015, TRANSFUS APHER SCI, V53, P95, DOI 10.1016/j.transci.2015.05.016; Uematsu M, 2007, OPHTHAL RES, V39, P308, DOI 10.1159/000109986; Wilson G, 1995, J Am Optom Assoc, V66, P435; Wilson SE, 2007, OPHTHALMOLOGY, V114, P76, DOI 10.1016/j.ophtha.2006.05.077; WILSON WS, 1975, BRIT J OPHTHALMOL, V59, P667, DOI 10.1136/bjo.59.11.667; Xiong C, 2008, INVEST OPHTH VIS SCI, V49, P1850, DOI 10.1167/iovs.07-0720; Yeh S, 2003, INVEST OPHTH VIS SCI, V44, P124, DOI 10.1167/iovs.02-0581; Yoon KC, 2007, INVEST OPHTH VIS SCI, V48, P2561, DOI 10.1167/iovs.07-0002; Zhang Z, 2014, INVEST OPHTH VIS SCI, V13, P2963; Zheng XD, 2013, CORNEA, V32, P1260, DOI 10.1097/ICO.0b013e31829cfd44	44	29	29	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2016	11	6							e0157982	10.1371/journal.pone.0157982	http://dx.doi.org/10.1371/journal.pone.0157982			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP3JL	27336157	Green Submitted, gold, Green Published			2023-01-03	WOS:000378389200079
J	Dong, XZ; Sun, XR; Sun, L; Maxim, PG; Xing, L; Huang, Y; Li, WW; Wan, HL; Zhao, XG; Xing, LG; Yu, JM				Dong, Xinzhe; Sun, Xiaorong; Sun, Lu; Maxim, Peter G.; Xing, Lei; Huang, Yong; Li, Wenwu; Wan, Honglin; Zhao, Xianguang; Xing, Ligang; Yu, Jinming			Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; TEXTURE ANALYSIS; F-18-FDG PET/CT; FDG-PET; RESPONSE EVALUATION; SURVIVAL; FEATURES; RADIOTHERAPY; PREDICTION	Introduction To observe the early change of metabolic tumor heterogeneity during chemoradiotherapy and to determine its prognostic value for patients with locally advanced non-small cell lung cancer (NSCLC). Methods From January 2007 to March 2010, 58 patients with NSCLC were included who were received 18F-fluorodeoxyglucose (F-18-FDG) PET/CT before and following 40 Gy radiotherapy with the concurrent cisplatin-based chemotherapy (CCRT). Primary tumor FDG uptake heterogeneity was determined using global and local scale textural features extracted from standardized uptake value (SUV) histogram analysis (coefficient of variation [COV], skewness, kurtosis, area under the curve of the cumulative SUV histogram [AUC-CSH]) and normalized gray-level co-occurrence matrix (contrast, dissimilarity, entropy, homogeneity). SUVmax and metabolic tumor volume (MTV) were also evaluated. Correlations were analyzed between parameters on baseline or during treatments with tumor response, progression-free survival (PFS), and overall survival (OS). Results Compared with non-responders, responders showed significantly greater pre-treatment COV, contrast and MTV (AUC = 0.781, 0.804, 0.686, respectively). Receiver-operating-characteristic curve analysis showed that early change of tumor textural analysis serves as a response predictor with higher sensitivity (73.2%similar to 92.1%) and specificity (80.0%similar to 83.6%) than baseline parameters. Change in AUC-CSH and dissimilarity during CCRT could also predict response with optimal cut-off values (33.0% and 28.7%, respectively). The patients with greater changes in contrast and AUC-CSH had significantly higher 5-year OS (P = 0.008, P = 0.034) and PFS (P = 0.007, P = 0.039). In multivariate analysis, only change in contrast was found as the independent prognostic factor of PFS (HR 0.476, P = 0.021) and OS (HR 0.519, P = 0.015). Conclusions The metabolic tumor heterogeneity change during CCRT characterized by global and local scale textural features may be valuable for predicting treatment response and survival for patients with locally advanced NSCLC.	[Dong, Xinzhe; Zhao, Xianguang; Xing, Ligang; Yu, Jinming] Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan, Shandong, Peoples R China; [Dong, Xinzhe; Zhao, Xianguang; Xing, Ligang; Yu, Jinming] Shandong Canc Hosp & Inst, Key Lab Radiat Oncol Shandong Prov, Jinan, Shandong, Peoples R China; [Sun, Xiaorong; Huang, Yong; Li, Wenwu] Shandong Canc Hosp & Inst, Dept Radiol, Jinan, Shandong, Peoples R China; [Sun, Lu] Jinan Univ, Jinan, Shandong, Peoples R China; [Maxim, Peter G.; Xing, Lei] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; [Maxim, Peter G.; Xing, Lei] Stanford Univ, Sch Med, Inst Canc, Stanford, CA 94305 USA; [Wan, Honglin] Shandong Normal Univ, Coll Phys & Elect Sci, Jinan, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Stanford University; Stanford University; Shandong Normal University	Zhao, XG; Xing, LG (corresponding author), Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan, Shandong, Peoples R China.; Zhao, XG; Xing, LG (corresponding author), Shandong Canc Hosp & Inst, Key Lab Radiat Oncol Shandong Prov, Jinan, Shandong, Peoples R China.	stanfordbonnie@outlook.com; xinglg@medmail.com.cn		Xing, Lei/0000-0003-2536-5359	National Health and Family Planning Commission Institutes of the People's Republic of China [201402011]; National Natural Science Foundation of China [81272502, L1322016]; Shandong Natural Science Foundation [ZR2014YL033, ZR2009CL023]; Educational fund from the China Scholarship Council [201406220074]	National Health and Family Planning Commission Institutes of the People's Republic of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Natural Science Foundation(Natural Science Foundation of Shandong Province); Educational fund from the China Scholarship Council	This work was supported in part by the grant from National Health and Family Planning Commission Institutes of the People's Republic of China (201402011 [http://www.nhfpc.gov.cn] to Ligang Xing), National Natural Science Foundation of China (81272502 and L1322016 [http://www.nsfc.gov.cn] to Ligang Xing), Shandong Natural Science Foundation (ZR2014YL033 and ZR2009CL023 [http://www.sdnsf.gov.cn/portal/] to Ligang Xing) and the Educational fund from the China Scholarship Council (201406220074 [http://www.csc.edu.cn] to XD).	Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Ben-Haim S, 2009, J NUCL MED, V50, P88, DOI 10.2967/jnumed.108.054205; Berghmans T, 2008, J THORAC ONCOL, V3, P6, DOI 10.1097/JTO.0b013e31815e6d6b; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Bundschuh RA, 2014, J NUCL MED, V55, P891, DOI 10.2967/jnumed.113.127340; Bussink J, 2011, NAT REV CLIN ONCOL, V8, P233, DOI 10.1038/nrclinonc.2010.218; Chicklore S, 2013, EUR J NUCL MED MOL I, V40, P133, DOI 10.1007/s00259-012-2247-0; Cook GJR, 2015, RADIOLOGY, V276, P883, DOI 10.1148/radiol.2015141309; Cook GJR, 2013, J NUCL MED, V54, P19, DOI 10.2967/jnumed.112.107375; Coudert B, 2014, LANCET ONCOL, V15, P1493, DOI 10.1016/S1470-2045(14)70475-9; Davnall F, 2012, INSIGHTS IMAGING, V3, P573, DOI 10.1007/s13244-012-0196-6; Desseroit MC, 2016, EUR J NUCL MED MOL I, V43, P1477, DOI 10.1007/s00259-016-3325-5; Dong XZ, 2015, J MED IMAG RADIAT ON, V59, P338, DOI 10.1111/1754-9485.12289; Dong XZ, 2013, NUCL MED COMMUN, V34, P40, DOI 10.1097/MNM.0b013e32835ae50c; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; El Naqa I, 2009, PATTERN RECOGN, V42, P1162, DOI 10.1016/j.patcog.2008.08.011; Fried DV, 2016, RADIOLOGY, V278, P214, DOI 10.1148/radiol.2015142920; Fried DV, 2014, INT J RADIAT ONCOL, V90, P834, DOI 10.1016/j.ijrobp.2014.07.020; Ganeshan B, 2013, RADIOLOGY, V266, P326, DOI 10.1148/radiol.12112428; Hatt M, 2015, J NUCL MED, V56, P38, DOI 10.2967/jnumed.114.144055; Henriksson E, 2007, ANTICANCER RES, V27, P2155; Hoang JK, 2008, J CLIN ONCOL, V26, P1459, DOI 10.1200/JCO.2007.14.3628; Huang W, 2014, J NUCL MED, V55, P1584, DOI 10.2967/jnumed.114.142919; Kang SR, 2014, NUCL MED MOLEC IMAG, V48, P16, DOI 10.1007/s13139-013-0231-7; Kunkel M, 2003, CANCER, V97, P1015, DOI 10.1002/cncr.11159; Lovinfosse P, 2016, EUR J NUCL MED MOL I, V43, P1453, DOI 10.1007/s00259-016-3314-8; Machtay M, 2013, J CLIN ONCOL, V31, P3823, DOI 10.1200/JCO.2012.47.5947; Miller TR, 2003, J NUCL MED, V44, P192; Ohri N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv004; Orlhac F, 2014, J NUCL MED, V55, P414, DOI 10.2967/jnumed.113.129858; Pyka T, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0407-7; Soussan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094017; Swinnen LJ, 2015, BRIT J HAEMATOL, V170, P56, DOI 10.1111/bjh.13389; Tixier F, 2014, J NUCL MED, V55, P1235, DOI 10.2967/jnumed.113.133389; Tixier F, 2012, J NUCL MED, V53, P693, DOI 10.2967/jnumed.111.099127; Tixier F, 2011, J NUCL MED, V52, P369, DOI 10.2967/jnumed.110.082404; Usmanij EA, 2013, J NUCL MED, V54, P1528, DOI 10.2967/jnumed.112.116921; Vaidya M, 2012, RADIOTHER ONCOL, V102, P239, DOI 10.1016/j.radonc.2011.10.014; Yang F, 2013, EUR J NUCL MED MOL I, V40, P716, DOI 10.1007/s00259-012-2332-4; Yu JM, 2009, INT J RADIAT ONCOL, V75, P1468, DOI 10.1016/j.ijrobp.2009.01.019	40	47	50	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2016	11	6							e0157836	10.1371/journal.pone.0157836	http://dx.doi.org/10.1371/journal.pone.0157836			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP0WR	27322376	Green Published, gold, Green Submitted			2023-01-03	WOS:000378212000047
J	Hwang, SD; Kim, SH; Kim, YO; Jin, DC; Song, HC; Choi, EJ; Kim, YL; Kim, YS; Kang, SW; Kim, NH; Yang, CW; Kim, YK				Hwang, Seun Deuk; Kim, Su-Hyun; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Kim, Yong-Lim; Kim, Yon-Su; Kang, Shin-Wook; Kim, Nam-Ho; Yang, Chul Woo; Kim, Yong Kyun			Serum Alkaline Phosphatase Levels Predict Infection-Related Mortality and Hospitalization in Peritoneal Dialysis Patients	PLOS ONE			English	Article							HEMODIALYSIS-PATIENTS; CALCIFICATION; INFLAMMATION	Background Serum alkaline phosphatase (ALP) levels have been reported to be associated with all-cause and cardiovascular mortality in peritoneal dialysis (PD) patients. However, it is unclear whether serum ALP levels predict infection-related clinical outcomes in PD patients. The aim of this study was to determine the relationships between serum ALP levels, infection-related mortality and hospitalization in PD patients. Methods PD patients from the Clinical Research Center registry for end-stage renal disease, a multicenter prospective observational cohort study in Korea, were included in the present study. Patients were categorized into three groups by serum ALP tertiles as follows: Tertile 1, ALP <78 U/L; Tertile 2, ALP = 78-155 U/L; Tertile 3, ALP >155 U/L. Tertile 1 was used as the reference category. The primary outcomes were infection-related mortality and hospitalization. Results A total of 1,455 PD patients were included. The median follow-up period was 32 months. The most common cause of infection-related mortality and hospitalization was PD-related peritonitis. Multivariate Cox regression analyses showed that patients in the highest tertiles of serum ALP levels were at higher risk of infection-related mortality (HR 2.29, 95% CI, 1.42-5.21, P = 0.008) after adjustment for clinical variables. Higher tertiles of serum ALP levels were associated with higher risk of infection-related hospitalization (Tertile 2: HR 1.56, 95% CI, 1.18-2.19, P = 0.009, tertile 3: HR 1.34, 95% CI, 1.03-2.62, P = 0.031). Conclusions Our data showed that elevated serum ALP levels were independently associated with a higher risk of infection-related mortality and hospitalization in PD patients.	[Hwang, Seun Deuk; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Yang, Chul Woo; Kim, Yong Kyun] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Su-Hyun] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul 156756, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; [Kim, Yon-Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120749, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Dept Internal Med, Gwangju, South Korea; [Kim, Yong Kyun] Catholic Univ Korea, Cell Death Dis Res Ctr, Seoul, South Korea	Catholic University of Korea; Chung Ang University; Chung Ang University Hospital; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Chonnam National University; Catholic University of Korea	Kim, YK (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea.; Kim, YK (corresponding author), Catholic Univ Korea, Cell Death Dis Res Ctr, Seoul, South Korea.	drkimyk@catholic.ac.kr			Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azechi T, 2013, J ATHEROSCLER THROMB, V20, P538, DOI 10.5551/jat.15826; Blayney MJ, 2008, KIDNEY INT, V74, P655, DOI 10.1038/ki.2008.248; Campbell EL, 2010, P NATL ACAD SCI USA, V107, P14298, DOI 10.1073/pnas.0914730107; Chuang SH, 2015, SINGAPORE MED J; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; Horowitz MC, 2005, IMMUNOL REV, V208, P141, DOI 10.1111/j.0105-2896.2005.00328.x; Huang JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071636; Inoshita H, 2008, CLIN NEPHROL, V69, P58; Johnson DW, 2009, CLIN J AM SOC NEPHRO, V4, P1620, DOI 10.2215/CJN.01750309; Kerner A, 2005, ARTERIOSCL THROM VAS, V25, P193, DOI 10.1161/01.ATV.0000148324.63685.6a; Kim H, 2014, KIDNEY INT, V86, P991, DOI 10.1038/ki.2014.163; Lammers WJ, 2014, GASTROENTEROLOGY, V147, P1338, DOI 10.1053/j.gastro.2014.08.029; Liu XH, 2014, CLIN J AM SOC NEPHRO, V9, P771, DOI 10.2215/CJN.08280813; Pelletier S, 2012, KIDNEY INT, V82, P581, DOI 10.1038/ki.2012.166; Peters E, 2014, AM J KIDNEY DIS, V63, P1038, DOI 10.1053/j.ajkd.2013.11.027; Regidor DL, 2008, J AM SOC NEPHROL, V19, P2193, DOI 10.1681/ASN.2008010014; Rhee CM, 2014, PERITON DIALYSIS INT, V34, P732, DOI 10.3747/pdi.2013.00110; TIETZ NW, 1983, CLIN CHEM, V29, P751; Vanholder R, 2002, BLOOD PURIFICAT, V20, P477, DOI 10.1159/000063556; Ye HJ, 2015, CLIN CHEM LAB MED, V53, pE110, DOI 10.1515/cclm-2014-0770	21	16	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157361	10.1371/journal.pone.0157361	http://dx.doi.org/10.1371/journal.pone.0157361			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27310428	Green Published, gold, Green Submitted			2023-01-03	WOS:000378029800060
J	Rodriguez-Linan, GM; Nahmad-Molinari, Y; Perez-Angel, G				Rodriguez-Linan, Gustavo M.; Nahmad-Molinari, Yuri; Perez-Angel, Gabriel			Clustering-Induced Attraction in Granular Mixtures of Rods and Spheres	PLOS ONE			English	Article							HARD-SPHERES; FORCES; GASES	Depletion-induced aggregation of rods enhanced by clustering is observed to produce a novel model of attractive pairs of rods separated by a line of spheres in a quasi-2D, vertically-shaken, granular gas of rods and spheres. We show that the stability of these peculiar granular aggregates increases as a function of shaking intensity. Velocity distributions of spheres inside and outside of a pair of rods trapping a line of spheres show a clear suppression of the momentum acquired by the trapped spheres. The condensed phase formed between the rods is caused by a clustering instability of the trapped spheres, enhanced by a vertical guidance produced by the confining rods. The liberated area corresponding to direct excluded-volume pairs and indirect depletion-aggregated pairs is measured as a function of time. The stability of rod pairs mediated by spheres reveals an attraction comparable in strength to the one purely induced by depletion forces.	[Rodriguez-Linan, Gustavo M.; Nahmad-Molinari, Yuri] Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi, Mexico; [Perez-Angel, Gabriel] Ctr Invest & Estudios Avanzados, Dept Fis Aplicada, Yucatan, Mexico; [Rodriguez-Linan, Gustavo M.; Nahmad-Molinari, Yuri] Ave Alvaro Obregon 64, San Luis Potosi 78000, Mexico; [Perez-Angel, Gabriel] AP 73 Cordemex, Merida 97310, Yucatan, Mexico	Universidad Autonoma de San Luis Potosi	Nahmad-Molinari, Y (corresponding author), Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi, Mexico.; Nahmad-Molinari, Y (corresponding author), Ave Alvaro Obregon 64, San Luis Potosi 78000, Mexico.	yuri@ifisica.uaslp.mx	Nahmad-Molinari, Yuri/J-4848-2012; Perez-Angel, Gabriel/AAT-1398-2021; Rodríguez-Liñán, Gustavo M./I-6196-2016	Nahmad-Molinari, Yuri/0000-0002-3477-2282; Rodríguez-Liñán, Gustavo M./0000-0001-9460-6748	Consejo Nacional de Ciencia y Tecnologia [221961, 358584]	Consejo Nacional de Ciencia y Tecnologia(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported by Consejo Nacional de Ciencia y Tecnologia (www.conacyt.mx) grant no. 221961 (YNM, GPA, GMRL) and doctoral scholarship 358584 (GMRL).	Adams M, 1998, NATURE, V393, P349, DOI 10.1038/30700; Bordallo-Favela RA, 2009, EUR PHYS J E, V28, P395, DOI 10.1140/epje/i2008-10432-2; Bose M, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021305; Duran J, 1998, PHYS REV LETT, V80, P3547, DOI 10.1103/PhysRevLett.80.3547; Fisher IZ, 1964, INT MONOGRAPHS ADV M; Fujiwara A, 2006, SCIENCE, V312, P1330, DOI 10.1126/science.1125841; Galanis J, 2010, SOFT MATTER, V6, P1026, DOI 10.1039/b918034f; GOLDHIRSCH I, 1993, PHYS REV LETT, V70, P1619, DOI 10.1103/PhysRevLett.70.1619; HOOVER WG, 1968, J CHEM PHYS, V49, P3609, DOI 10.1063/1.1670641; ISRAELACHVILI JN, 1983, NATURE, V306, P249, DOI 10.1038/306249a0; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; Lekkerkerker H. N., 2011, LECT NOTES PHYS, V833; Melby P, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.051307; Nahmad-Molinari Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.264302; Ni R, 2015, PHYS REV LETT, V114, DOI 10.1103/PhysRevLett.114.018302; Olafsen JS, 1998, PHYS REV LETT, V81, P4369, DOI 10.1103/PhysRevLett.81.4369; OOSAWA F, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740346; Prigogine I., 1947, THESIS U LIBRE BRUXE; Sanders DA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.208002; SHIDA K, 1989, PHYSICA A, V162, P145, DOI 10.1016/0378-4371(89)90562-1; Spahn F, 1998, NATO ADV SCI I E-APP, V350, P401; WU X, 1993, PHYS REV LETT, V71, P1363, DOI 10.1103/PhysRevLett.71.1363	22	5	5	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2016	11	5							e0156153	10.1371/journal.pone.0156153	http://dx.doi.org/10.1371/journal.pone.0156153			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2FY	27218804	gold, Green Submitted, Green Published			2023-01-03	WOS:000376880700046
J	Elf, S; Lin, R; Xia, S; Pan, Y; Shan, C; Wu, S; Lonial, S; Gaddh, M; Arellano, ML; Khoury, HJ; Khuri, FR; Lee, BH; Boggon, TJ; Fan, J; Chen, J				Elf, S.; Lin, R.; Xia, S.; Pan, Y.; Shan, C.; Wu, S.; Lonial, S.; Gaddh, M.; Arellano, M. L.; Khoury, H. J.; Khuri, F. R.; Lee, B. H.; Boggon, T. J.; Fan, J.; Chen, J.			Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin	ONCOGENE			English	Article							PROTEIN-KINASE; CANCER CELLS; DEFICIENCY; AMPK; ATTACHMENT; FAMILY	The oxidative pentose phosphate pathway (PPP) is crucial for cancer cell metabolism and tumor growth. We recently reported that targeting a key oxidative PPP enzyme, 6-phosphogluconate dehydrogenase (6PGD), using our novel small-molecule 6PGD inhibitors Physcion and its derivative 53, shows anticancer effects. Notably, humans with genetic deficiency of either 6PGD or another oxidative PPP enzyme, glucose-6-phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various antimalarial drugs. Inspired by these clinical observations, we examined the anticancer potential of combined treatment with 6PGD inhibitors and antimalarial drugs. We found that stable knockdown of 6PGD sensitizes leukemia cells to antimalarial agent dihydroartemisinin (DHA). Combined treatment with DHA and Physcion activates AMP-activated protein kinase, leading to synergistic inhibition of human leukemia cell viability. Moreover, our combined therapy synergistically attenuates tumor growth in xenograft nude mice injected with human K562 leukemia cells and cell viability of primary leukemia cells from human patients, but shows minimal toxicity to normal hematopoietic cells in mice as well as red blood cells and mononucleocytes from healthy human donors. Our findings reveal the potential for combined therapy using optimized doses of Physcion and DHA as a novel antileukemia treatment without inducing hemolysis.	[Elf, S.; Lin, R.; Xia, S.; Pan, Y.; Shan, C.; Lonial, S.; Gaddh, M.; Arellano, M. L.; Khoury, H. J.; Khuri, F. R.; Fan, J.; Chen, J.] Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE C3002, Atlanta, GA 30322 USA; [Wu, S.] Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA; [Lee, B. H.] Novartis Inst BioMed Res, Cambridge, MA USA; [Boggon, T. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Emory University; Emory University; Novartis; Yale University	Chen, J (corresponding author), Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE C3002, Atlanta, GA 30322 USA.	jchen@emory.edu	Xia, Siyuan/AAM-9606-2020; Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Xia, Siyuan/0000-0001-6756-3519	NIH [CA140515, CA183594, CA174786]; Pharmacological Sciences Training Grant [T32 GM008602]; DoD [W81XWH-12-1-0217]; NATIONAL CANCER INSTITUTE [R01CA174786, R01CA140515, R01CA183594, R01CA120272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008602] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmacological Sciences Training Grant; DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Hematology Division Tissue Bank, Winship Cancer Institute of Emory for providing primary tissue samples from leukemia patients. This work was supported in part by NIH grants CA140515, CA183594, CA174786 (to JC), the Pharmacological Sciences Training Grant T32 GM008602 (to SE), DoD grant W81XWH-12-1-0217 (to JC). SE is an NIH pre-doctoral fellow and an ARCS Foundation Scholar. JC is WCI 5K Scholar, Georgia Cancer Coalition Distinguished Scholar, American Cancer Society Basic Research Scholar and Scholar of the Leukemia and Lymphoma Society.	BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; Caprari P, 2001, ANN HEMATOL, V80, P41, DOI 10.1007/s002770000233; Chakrabarti KR, 2015, ONCOTARGET, V6, P36292, DOI 10.18632/oncotarget.5345; Choudhury Yashmin, 2014, Oncoscience, V1, P446; Corrons JLV, 1996, AM J HEMATOL, V53, P221; Di JM, 2010, MOL BIOL REP, V37, P1849, DOI 10.1007/s11033-009-9620-5; Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; HA J, 1994, J BIOL CHEM, V269, P22162; Hadad S, 2008, 2008 ASCO BREAST CAN; Hadad SM, 2014, CLIN TRANSL ONCOL, V16, P746, DOI 10.1007/s12094-013-1144-8; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Spears LD, 2010, FASEB J S, V24, pIb674; Wang SJ, 2011, CANCER CHEMOTH PHARM, V68, P1421, DOI 10.1007/s00280-011-1643-7	15	42	43	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					254	262		10.1038/onc.2016.196	http://dx.doi.org/10.1038/onc.2016.196			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270429	Green Accepted			2023-01-03	WOS:000393938100010
J	Dinakar, C; O'Connor, GT				Dinakar, Chitra; O'Connor, George T.			The Health Effects of Electronic Cigarettes	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NICOTINE-DELIVERY; HIDDEN FORMALDEHYDE; RESPIRATORY HEALTH; SMOKING REDUCTION; RISK-ASSESSMENT; VAPOR EXTRACT; TOBACCO USE; FOLLOW-UP; LIQUIDS; EXPOSURE		[Dinakar, Chitra] Childrens Mercy Kansas City, Div Allergy Asthma & Immunol, Kansas City, MO USA; [Dinakar, Chitra] Univ Missouri, Kansas City, MO 64110 USA; [O'Connor, George T.] Boston Univ, Sch Med, Div Pulm Allergy Sleep & Crit Care Med, 715 Albany St,Rm R304, Boston, MA 02118 USA	Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Boston University	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Div Pulm Allergy Sleep & Crit Care Med, 715 Albany St,Rm R304, Boston, MA 02118 USA.	goconnor@bu.edu			Teva; Boehringer Ingelheim; GlaxoSmithKline; Merck; MEDA; AstraZeneca; Janssen Pharmaceuticals	Teva(Teva Pharmaceutical Industries); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); MEDA; AstraZeneca(AstraZeneca); Janssen Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	Dr. Dinakar reports receiving speaking fees from Teva, Boehringer Ingelheim, GlaxoSmithKline, and Merck and consulting fees from Teva and MEDA; and Dr. O'Connor, receiving consulting fees from AstraZeneca and research grant support from Janssen Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.	Adkison SE, 2013, AM J PREV MED, V44, P207, DOI 10.1016/j.amepre.2012.10.018; Adriaens K, 2014, INT J ENV RES PUB HE, V11, P11220, DOI 10.3390/ijerph111111220; [Anonymous], 2014, HLTH CONSMOK 50 YE; [Anonymous], 2014, BMJ-BRIT MED J, V349; Bahl V, 2012, REPROD TOXICOL, V34, P529, DOI 10.1016/j.reprotox.2012.08.001; Barrington-Trimis JL, 2014, JAMA-J AM MED ASSOC, V312, P2493, DOI 10.1001/jama.2014.14830; Benowitz NL, 2008, CLIN PHARMACOL THER, V83, P531, DOI 10.1038/clpt.2008.3; Brown J, 2014, ADDICTION, V109, P1531, DOI 10.1111/add.12623; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Bunnell RE, 2015, NICOTINE TOB RES, V17, P228, DOI 10.1093/ntr/ntu166; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Cervellati F, 2014, TOXICOL IN VITRO, V28, P999, DOI 10.1016/j.tiv.2014.04.012; Chen BC, 2015, CLIN TOXICOL, V53, P914, DOI 10.3109/15563650.2015.1090579; Cooper S, 2014, LANCET RESP MED, V2, P728, DOI 10.1016/S2213-2600(14)70157-2; Cummins S. E., 2014, Tobacco Control, V23, piii48, DOI 10.1136/tobaccocontrol-2013-051511; Dwyer JB, 2009, PHARMACOL THERAPEUT, V122, P125, DOI 10.1016/j.pharmthera.2009.02.003; England LJ, 2015, AM J PREV MED, V49, P286, DOI 10.1016/j.amepre.2015.01.015; Etzel RA, 2015, PEDIATRICS, V136, P1008, DOI 10.1542/peds.2015-3108; Fairchild AL, 2015, SCIENCE, V347, P375, DOI 10.1126/science.1260761; Farsalinos K, 2016, INTERN EMERG MED, V11, P85, DOI 10.1007/s11739-015-1361-y; Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P5215, DOI 10.3390/ijerph120505215; Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P3439, DOI 10.3390/ijerph120403439; Farsalinos KE, 2015, NICOTINE TOB RES, V17, P168, DOI 10.1093/ntr/ntu176; Farsalinos KE, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-78; Farsalinos KE, 2014, THER ADV DRUG SAF, V5, P67, DOI 10.1177/2042098614524430; Farsalinos KE, 2013, INT J ENV RES PUB HE, V10, P5146, DOI 10.3390/ijerph10105146; Flouris AD, 2013, INHAL TOXICOL, V25, P91, DOI 10.3109/08958378.2012.758197; Flouris AD, 2012, FOOD CHEM TOXICOL, V50, P3600, DOI 10.1016/j.fct.2012.07.025; Geiss O, 2015, INT J HYG ENVIR HEAL, V218, P169, DOI 10.1016/j.ijheh.2014.10.001; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Grana RA, 2014, JAMA INTERN MED, V174, P812, DOI 10.1001/jamainternmed.2014.187; Green SH, 2016, NEW ENGL J MED, V374, P1301, DOI 10.1056/NEJMp1601154; Hajek P, 2015, NICOTINE TOB RES, V17, P175, DOI 10.1093/ntr/ntu153; Herzog B, 2013, E CIGS REVOLUTIONIZI; Husari A, 2016, NICOTINE TOB RES, V18, P613, DOI 10.1093/ntr/ntv169; Hutzler C, 2014, ARCH TOXICOL, V88, P1295, DOI 10.1007/s00204-014-1294-7; Hwang JH, 2016, J MOL MED, V94, P667, DOI 10.1007/s00109-016-1378-3; Jensen RP, 2015, NEW ENGL J MED, V372, P392, DOI 10.1056/NEJMc1413069; Kalkhoran S, 2016, LANCET RESP MED, V4, P116, DOI 10.1016/S2213-2600(15)00521-4; Kandel ER, 2014, NEW ENGL J MED, V371, P932, DOI 10.1056/NEJMsa1405092; Kim JW, 2015, PEDIATR EMERG CARE, V31, P517, DOI 10.1097/PEC.0000000000000486; Kosmider L, 2014, NICOTINE TOB RES, V16, P1319, DOI 10.1093/ntr/ntu078; Lee PN, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-36; Lerner CA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116732; Lerner CA, 2015, ENVIRON POLLUT, V198, P100, DOI 10.1016/j.envpol.2014.12.033; Leventhal AM, 2015, JAMA-J AM MED ASSOC, V314, P700, DOI 10.1001/jama.2015.8950; Lim HB, 2014, TOX RESEARCH, V30, P13, DOI 10.5487/TR.2014.30.1.013; Lisko JG, 2015, NICOTINE TOB RES, V17, P1270, DOI 10.1093/ntr/ntu279; McGrath-Morrow SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118344; McMillen RC, 2015, NICOTINE TOB RES, V17, P1195, DOI 10.1093/ntr/ntu213; McRobbie H, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010216.pub2; Misra M, 2014, INT J ENV RES PUB HE, V11, P11325, DOI 10.3390/ijerph111111325; Moore D, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1024; Neilson L, 2015, TOXICOL IN VITRO, V29, P1952, DOI 10.1016/j.tiv.2015.05.018; Nitzkin JL, 2015, NEW ENGL J MED, V372, P1575, DOI 10.1056/NEJMc1502242; Oh JA, 2015, J CHROMATOGR SCI, V53, P841, DOI 10.1093/chromsci/bmu146; Ordonez JE, 2015, NICOTINE TOB RES, V17, P209, DOI 10.1093/ntr/ntu223; Paek HJ, 2014, J HEALTH COMMUN, V19, P545, DOI 10.1080/10810730.2013.821560; Palpant NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126259; Polosa R, 2016, DISCOV MED, V21, P99; Popova L, 2013, AM J PUBLIC HEALTH, V103, P923, DOI 10.2105/AJPH.2012.301070; RAHMAN MA, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0122544; Renne R., 1992, INHAL TOXICOL, V4, P95, DOI [10.3109/08958379209145307, DOI 10.3109/08958379209145307]; Roger JM, 2016, J ORAL MAXIL SURG, V74, P1181, DOI 10.1016/j.joms.2015.12.017; Romagna G, 2013, INHAL TOXICOL, V25, P354, DOI 10.3109/08958378.2013.793439; Rubenstein DA, 2015, MOL IMMUNOL, V67, P652, DOI 10.1016/j.molimm.2015.05.020; Scheffler S, 2015, INT J ENV RES PUB HE, V12, P3915, DOI 10.3390/ijerph120403915; Schweitzer KS, 2015, AM J PHYSIOL-LUNG C, V309, pL175, DOI 10.1152/ajplung.00411.2014; Singh T, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-4155; Singh T, 2016, MMWR-MORBID MORTAL W, V65, P361, DOI 10.15585/mmwr.mm6514a1; Sussan TE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116861; Sutfin EL, 2013, DRUG ALCOHOL DEPEN, V131, P214, DOI 10.1016/j.drugalcdep.2013.05.001; Szoltysek-Boldys Izabela, 2014, Przegl Lek, V71, P572; Tierney PA, 2016, TOB CONTROL, V25, pE10, DOI 10.1136/tobaccocontrol-2014-052175; Tseng TY, 2016, NICOTINE TOB RES, V18, P1937, DOI 10.1093/ntr/ntw017; Vakkalanka JP, 2014, CLIN TOXICOL, V52, P542, DOI 10.3109/15563650.2014.913176; Vardavas CI, 2012, CHEST, V141, P1400, DOI 10.1378/chest.11-2443; Varlet V, 2015, INT J ENV RES PUB HE, V12, P4796, DOI 10.3390/ijerph120504796; Varughese S, 2005, AM J IND MED, V47, P411, DOI 10.1002/ajim.20151; Wahba Phil, 2014, FORTUNE; Willershausen I, 2014, HEAD FACE MED, V10, DOI 10.1186/1746-160X-10-39; Williams M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057987; Wills TA, 2015, PEDIATRICS, V135, pE43, DOI 10.1542/peds.2014-0760; Wu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108342; Yan XS, 2015, REGUL TOXICOL PHARM, V71, P24, DOI 10.1016/j.yrtph.2014.11.004; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670	86	167	170	0	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2016	375	14					1372	1381		10.1056/NEJMra1502466	http://dx.doi.org/10.1056/NEJMra1502466			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DY3EZ	27705269				2023-01-03	WOS:000384974900010
J	Pereira, SM; Teixeira, CM; Carvalho, AS; Hernandez-Marrero, P				Pereira, Sandra Martins; Teixeira, Carla Margarida; Carvalho, Ana Sofia; Hernandez-Marrero, Pablo		InPalln	Compared to Palliative Care, Working in Intensive Care More than Doubles the Chances of Burnout: Results from a Nationwide Comparative Study	PLOS ONE			English	Article							MEDICAL ERRORS; OF-LIFE; MASLACH BURNOUT; SELF-CARE; PHYSICIANS; END; PROFESSIONALS; UNITS; ICU; MULTICENTER	Introduction Professionals working in intensive and palliative care units, hence caring for patients at the end-of-life, are at risk of developing burnout. Workplace conditions are determinant factors to develop this syndrome among professionals providing end-of-life care. Objectives To identify and compare burnout levels between professionals working in intensive and palliative care units; and to assess which workplace experiences are associated with burnout. Methods A nationwide, multicentre quantitative comparative survey study was conducted in Portugal using the following instruments: Maslach Burnout Inventory-Human Services Survey, Questionnaire of workplace experiences and ethical decisions, and Questionnaire of socio-demographic and professional characteristics. A total of 355 professionals from 10 intensive care and 9 palliative care units participated in the survey. A series of univariate and multivariate logistic regression analyses were performed; odds ratio sidelong with 95% confidence intervals were calculated. Results 27% of the professionals exhibited burnout. This was more frequent in intensive care units (OR = 2.525, 95% CI: 1.025-6.221, p =.006). Univariate regression analyses showed that higher burnout levels were significantly associated with conflicts, decisions to withhold/withdraw treatment, and implementing palliative sedation. When controlling for socio-demographic and educational characteristics, and setting (intensive care units versus palliative care units), higher burnout levels were significantly and positively associated with experiencing conflicts in the workplace. Having post-graduate education in intensive/palliative care was significantly but inversely associated to higher burnout levels. Conclusions Compared to palliative care, working in intensive care units more than doubled the likelihood of exhibiting burnout. Experiencing conflicts (e.g., with patients and/or families, intra and/or inter-teams) was the most significant determinant of burnout and having post-graduate education in intensive/palliative care protected professionals from developing this syndrome. This highlights the need for promoting empowering workplace conditions, such as team empowerment and conflict management. Moreover, findings suggest the need for implementing quality improvement strategies and organizational redesign strategies aimed at integrating the philosophy, principles and practices of palliative care in intensive care units.	[Pereira, Sandra Martins; Teixeira, Carla Margarida; Carvalho, Ana Sofia; Hernandez-Marrero, Pablo] Univ Catolica Portuguesa, Inst Bioet, Porto, Portugal; [Teixeira, Carla Margarida] Ctr Hosp Porto, Hosp Santo Antonio, Porto, Portugal; [Teixeira, Carla Margarida] Univ Porto, Inst Ciencias Biomed Dr Abel Salazar, Porto, Portugal	Universidade Catolica Portuguesa; Universidade do Porto	Hernandez-Marrero, P (corresponding author), Univ Catolica Portuguesa, Inst Bioet, Porto, Portugal.	pmarrero@porto.ucp.pt	Hernández-Marrero, Pablo/N-3873-2015; Pereira, Sandra Martins/N-3890-2015; Carvalho, Ana Sofia/ABK-1396-2022	Hernández-Marrero, Pablo/0000-0002-8893-3491; Pereira, Sandra Martins/0000-0003-4113-8957; Carvalho, Ana Sofia/0000-0003-1132-8880; Teixeira, Carla Margarida/0000-0002-9581-0756	Fundacao Grunenthal and Fundacao Merck, Sharp and Dohme	Fundacao Grunenthal and Fundacao Merck, Sharp and Dohme	This study was partially supported by Fundacao Grunenthal and Fundacao Merck, Sharp and Dohme (2007/2011), which provided financial support during the period of data collection.	Ahola K, 2005, J AFFECT DISORDERS, V88, P55, DOI 10.1016/j.jad.2005.06.004; Ali NA, 2011, AM J RESP CRIT CARE, V184, P803, DOI 10.1164/rccm.201103-0555OC; Azoulay E, 2009, AM J RESP CRIT CARE, V180, P853, DOI 10.1164/rccm.200810-1614OC; Back AL, 2016, J PAIN SYMPTOM MANAG, V52, P284, DOI 10.1016/j.jpainsymman.2016.02.002; Bakker AB, 2005, J ADV NURS, V51, P276, DOI 10.1111/j.1365-2648.2005.03494.x; Bianchi R, 2014, INT J STRESS MANAGE, V21, P307, DOI 10.1037/a0037906; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Brenninkmeijer V, 2003, OCCUP ENVIRON MED, V60, P16; Chen KY, 2013, INT J MED SCI, V10, P1471, DOI 10.7150/ijms.6743; Chlan LL, 2013, CRIT CARE ALERT, V21, P65; Dewa CS, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-254; Dreano-Hartz S, 2016, PALLIAT SUPPORT CARE, V14, P402, DOI 10.1017/S1478951515000991; Dunwoodie DA, 2007, INTERN MED J, V37, P693, DOI 10.1111/j.1445-5994.2007.01384.x; Embriaco N, 2007, CURR OPIN CRIT CARE, V13, P482, DOI 10.1097/MCC.0b013e3282efd28a; Embriaco N, 2007, AM J RESP CRIT CARE, V175, P686, DOI 10.1164/rccm.200608-1184OC; Embriaco N, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-34; Fahrenkopf AM, 2008, BRIT MED J, V336, P488, DOI 10.1136/bmj.39469.763218.BE; Fassier T, 2010, CURR OPIN CRIT CARE, V16, P654, DOI 10.1097/MCC.0b013e32834044f0; Garrouste-Orgeas M, 2015, INTENS CARE MED, V41, P273, DOI 10.1007/s00134-014-3601-4; Garrouste-Orgeas M, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-2; Hall LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159015; Hartog CS, 2015, INTENS CARE MED, V41, P331, DOI 10.1007/s00134-014-3517-z; Hayashino Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035585; Hernandez-Marrero P, 2006, THESIS; Hernandez-Marrero P, 2016, AM J HOSP PALLIAT ME, V33, P723, DOI 10.1177/1049909115583486; Hill RC, 2016, PALLIATIVE MED, V30, P825, DOI 10.1177/0269216316637237; Hinson TD, 2011, J NURS ADMIN, V41, P103, DOI 10.1097/NNA.0b013e31820c7242; Howell MD, 2012, SEMIN RESP CRIT CARE, V33, P401, DOI 10.1055/s-0032-1322410; Jackson VA, 2008, J PALLIAT MED, V11, P893, DOI 10.1089/jpm.2007.2480; Jones CB, 2008, J NURS ADMIN, V38, P11, DOI 10.1097/01.NNA.0000295636.03216.6f; Kamel G, 2015, AM J HOSP PALLIAT ME, V32, P758, DOI 10.1177/1049909114536979; Kearney MK, 2009, JAMA-J AM MED ASSOC, V301, P1155, DOI 10.1001/jama.2009.352; Koh MYH, 2015, PALLIATIVE MED, V29, P633, DOI 10.1177/0269216315575850; Lederer W, 2008, ANAESTH INTENS CARE, V36, P208, DOI 10.1177/0310057X0803600211; Lepnurm R, 2009, CAN J PSYCHIAT, V54, P170, DOI 10.1177/070674370905400305; Li XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115799; Linzer M, 2014, J GEN INTERN MED, V29, P18, DOI 10.1007/s11606-013-2597-8; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C., 1997, EVALUATING STRESS BO, P191; Maslach C., 1981, MASLACH BURNOUT INVE; Maslach C., 2009, OXFORD HDB ORG WELL, P86, DOI [10.1093/oxfordhb/9780199211913.001.0001, DOI 10.1093/OXFORDHB/9780199211913.003.0005, 10.1093/oxfordhb/9780199211913.003.0005]; Maslach C, 1997, TRUTH BURNOUT ORG CA; Maslach C, 2016, WORLD PSYCHIATRY, V15, P103, DOI 10.1002/wps.20311; Meth ND, 2009, INTENS CARE MED, V35, P2068, DOI 10.1007/s00134-009-1639-5; Morgan L, 2011, DIMENS CRIT CARE NUR, V30, P133, DOI 10.1097/DCC.0b013e31820d2114; Moss M, 2016, CHEST, V150, P17, DOI 10.1016/j.chest.2016.02.649; Moss M, 2016, AM J RESP CRIT CARE, V194, P106, DOI 10.1164/rccm.201604-0708ST; Moss M, 2016, AM J CRIT CARE, V25, P368, DOI 10.4037/ajcc2016133; Muller M, 2010, Z PALLIATMEDIZIN, V11, P227, DOI 10.1055/s-0030-1248520; O'Mahony S, 2016, PALLIATIVE MED, V30, P189, DOI 10.1177/0269216315596459; Olthuis G, 2005, THEOR MED BIOETH, V26, P307, DOI 10.1007/s11017-005-4487-5; Pereira SM, 2012, INT J PALLIAT NURS, V18, P373, DOI 10.12968/ijpn.2012.18.8.373; Pereira SM, 2016, J PALLIAT MED, V19, P1130, DOI 10.1089/jpm.2016.0255; Pereira SM, 2011, NURS ETHICS, V18, P317, DOI 10.1177/0969733011398092; Pereira SM, 2011, THESIS; Perez GK, 2015, J PALLIAT MED, V18, P332, DOI 10.1089/jpm.2014.0221; Poghosyan L, 2010, RES NURS HEALTH, V33, P288, DOI 10.1002/nur.20383; Poncet MC, 2007, AM J RESP CRIT CARE, V175, P698, DOI 10.1164/rccm.200606-806OC; Prins JT, 2009, PSYCHOL HEALTH MED, V14, P654, DOI 10.1080/13548500903311554; Quenot JP, 2012, INTENS CARE MED, V38, P55, DOI 10.1007/s00134-011-2413-z; Reader TW, 2008, INTENS CARE MED, V34, P4, DOI 10.1007/s00134-007-0908-4; Reilly Jo Marie, 2004, J Palliat Med, V7, P55, DOI 10.1089/109662104322737250; Roelofs J, 2005, STRESS HEALTH, V21, P17, DOI 10.1002/smi.1032; Romani M, 2014, LIBYAN J MED, V9, DOI 10.3402/ljm.v9.23556; Sanso N, 2015, J PAIN SYMPTOM MANAG, V50, P200, DOI 10.1016/j.jpainsymman.2015.02.013; Savel RH, 2013, AM J CRIT CARE, V22, P277, DOI 10.4037/ajcc2013857; Schaufeli W.B., 1996, MASLACH BURNOUT INVE, V3rd; Shanafelt TD, 2010, ANN SURG, V251, P995, DOI 10.1097/SLA.0b013e3181bfdab3; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Soderfeldt M, 1996, SCAND J PSYCHOL, V37, P437, DOI 10.1111/j.1467-9450.1996.tb00675.x; Squires Allison, 2014, Burn Res, V1, P59; St Ledger U, 2013, J ADV NURS, V69, P1869, DOI 10.1111/jan.12053; Swetz KM, 2009, J PALLIAT MED, V12, P773, DOI 10.1089/jpm.2009.0050; Teixeira C, 2014, J MED ETHICS, V40, P97, DOI 10.1136/medethics-2012-100619; Teixeira C, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-38; Trankle SA, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-41; van Mol MMC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136955; Verdon M, 2008, INTENS CARE MED, V34, P152, DOI 10.1007/s00134-007-0907-5; Vieira S., 2007, THESIS; Waldman JD, 2004, HEALTH CARE MANAGE R, V29, P2, DOI 10.1097/00004010-200401000-00002; West CP, 2006, JAMA-J AM MED ASSOC, V296, P1071, DOI 10.1001/jama.296.9.1071; Wurm W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149913	82	40	40	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0162340	10.1371/journal.pone.0162340	http://dx.doi.org/10.1371/journal.pone.0162340			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DV9JE	27612293	Green Submitted, Green Published, gold			2023-01-03	WOS:000383255900080
J	Powers, BW; Rinefort, S; Jain, SH				Powers, Brian W.; Rinefort, Scott; Jain, Sachin H.			Nonemergency Medical Transportation Delivering Care in the Era of Lyft and Uber	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE		[Powers, Brian W.] Harvard Med Sch, Boston, MA USA; [Powers, Brian W.] Harvard Sch Business, Boston, MA USA; [Powers, Brian W.; Rinefort, Scott; Jain, Sachin H.] Anthem Inc, CareMore Hlth Syst, 12900 Pk Plaza Dr,Ste 150, Cerritos, CA 90703 USA; [Jain, Sachin H.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA	Harvard University; Harvard Medical School; Harvard University; Stanford University	Jain, SH (corresponding author), Anthem Inc, CareMore Hlth Syst, 12900 Pk Plaza Dr,Ste 150, Cerritos, CA 90703 USA.	sachin.jain@caremore.com						Chan KE, 2014, J AM SOC NEPHROL, V25, P2642, DOI 10.1681/ASN.2013111160; Detsky AS, 2016, NEW ENGL J MED, V374, P806, DOI 10.1056/NEJMp1512206; Government Accountability Office, 2016, NON MED TRANSP UPD M; Swanson BL, STATE 2016 MEDICARE; Syed ST, 2013, J COMMUN HEALTH, V38, P976, DOI 10.1007/s10900-013-9681-1; Transit Cooperative Research Program, 2005, COST BEN AN PROV NON	6	63	64	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2016	316	9					921	922		10.1001/jama.2016.9970	http://dx.doi.org/10.1001/jama.2016.9970			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU8JV	27599325				2023-01-03	WOS:000382460200010
J	Shakib, S; Dundon, BK; Maddison, J; Thomas, J; Stanners, M; Caughey, GE; Clark, RA				Shakib, Sepehr; Dundon, Benjamin K.; Maddison, John; Thomas, Josephine; Stanners, Melinda; Caughey, Gillian E.; Clark, Robyn A.			Effect of a Multidisciplinary Outpatient Model of Care on Health Outcomes in Older Patients with Multimorbidity: A Retrospective Case Control Study	PLOS ONE			English	Article							HEART-FAILURE PATIENTS; CHRONIC DISEASES; RISK; THERAPY; METAANALYSIS; TRANSITIONS; MANAGEMENT; PROGRAMS; ADULTS; DEATH	Objective To evaluate a holistic multidisciplinary outpatient model of care on hospital readmission, length of stay and mortality in older patients with multimorbidity following discharge from hospital. Design and Participants A pilot case-control study between March 2006 and June 2009 of patients referred on discharge to a multidisciplinary, integrated outpatient model of care that includes outpatient follow-up, timely GP communication and dial-in service compared with .1 ratio with cases for age, gender, index admission diagnosis and length of stay. Main outcome measures Non-elective readmission rates, total readmission length of stay and overall survival. Results A total of 252 cases and 1008 control patients were included in the study. Despite the patients referred to the multidisciplinary model of care had slightly more comorbid conditions, significantly higher total length of hospital stay in the previous 12 months and increased prevalence of diabetes and heart failure by comparison to those who received they had significantly improved survival (adjusted hazard ratio 0.70 95% CI 0.51-0.96, p = 0.029) and no excess in the number of hospitalisations observed. Conclusion Following discharge from hospital, holistic multidisciplinary outpatient management is associated with improved survival in older patients with multimorbidity. The findings of this study warrant further examination in randomised and cost-effectiveness trials.	[Shakib, Sepehr; Maddison, John; Stanners, Melinda; Caughey, Gillian E.] Royal Adelaide Hosp, Dept Clin Pharmacol, North Terrace, Adelaide, SA 5000, Australia; [Shakib, Sepehr] Univ Adelaide, Sch Med, Discipline Pharmacol, North Terrace, Adelaide, SA 5000, Australia; [Dundon, Benjamin K.] Monash Hlth, Monash Cardiovasc Res Ctr, Clayton, Vic, Australia; [Thomas, Josephine] Univ Adelaide, Sch Med, Clin Educ, Adelaide, SA 5000, Australia; [Caughey, Gillian E.] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [Clark, Robyn A.] Flinders Univ South Australia, Dept Nursing Acute Care & Cardiovasc Res, Adelaide, SA 5001, Australia	Royal Adelaide Hospital; University of Adelaide; Monash University; University of Adelaide; University of South Australia; Flinders University South Australia	Shakib, S (corresponding author), Royal Adelaide Hosp, Dept Clin Pharmacol, North Terrace, Adelaide, SA 5000, Australia.; Shakib, S (corresponding author), Univ Adelaide, Sch Med, Discipline Pharmacol, North Terrace, Adelaide, SA 5000, Australia.	Sepehr.shakib@sa.gov.au	Stanners, Melinda/AAC-9235-2020; Clark, Robyn A/D-1604-2009	Stanners, Melinda/0000-0002-9480-9438; Clark, Robyn A/0000-0002-5063-2618; Caughey, Gillian/0000-0003-1192-4121; Thomas, Josephine/0000-0001-8124-5920	South Australian Health National Institute of Clinical Studies Fellowship	South Australian Health National Institute of Clinical Studies Fellowship	This study was supported by a South Australian Health National Institute of Clinical Studies Fellowship to Dr. Sepehr Shakib. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; Boult C, 2011, ARCH INTERN MED, V171, P460, DOI 10.1001/archinternmed.2010.540; Boult C, 2009, J AM GERIATR SOC, V57, P2328, DOI 10.1111/j.1532-5415.2009.02571.x; Caughey GE, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-221; Clarke DM, 2009, MED J AUSTRALIA, V190, pS54; Coleman EA, 2004, HEALTH SERV RES, V39, P1449, DOI 10.1111/j.1475-6773.2004.00298.x; Effing T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub2; Ellis SE, 2004, PATIENT EDUC COUNS, V52, P97, DOI 10.1016/S0738-3991(03)00016-8; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Gilbert A., 2013, AGEING WELL AGEING P; Gitlin LN, 2006, J AM GERIATR SOC, V54, P950, DOI 10.1111/j.1532-5415.2006.00733.x; Ho TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093129; Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2; Institute of Medicine, 2015, MEASURING IMPACT INT; Kwan JL, 2013, ANN INTERN MED, V158, P397, DOI 10.7326/0003-4819-158-5-201303051-00006; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Lawlor DA, 2003, BRIT MED J, V327, P712, DOI 10.1136/bmj.327.7417.712; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; McAlister FA, 2009, ANN INTERN MED, V150, P784, DOI 10.7326/0003-4819-150-11-200906020-00006; Mosher HJ, 2015, JAMA INTERN MED, V175, P1298, DOI 10.1001/jamainternmed.2015.2430; Ouwens M, 2005, INT J QUAL HEALTH C, V17, P141, DOI 10.1093/intqhc/mzi016; Pannick S, 2015, JAMA INTERN MED, V175, P1288, DOI 10.1001/jamainternmed.2015.2421; Peytremann-Bridevaux I, 2008, AM J MED, V121, P433, DOI 10.1016/j.amjmed.2008.02.009; Renders CM, 2000, COCHRANE DATABASE SY; Reuben DB, 2012, NEW ENGL J MED, V366, P777, DOI 10.1056/NEJMp1113631; Seiler WO, 2001, NUTRITION, V17, P496, DOI 10.1016/S0899-9007(01)00558-5; Smith SM, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5205; Sommers LS, 2000, ARCH INTERN MED, V160, P1825, DOI 10.1001/archinte.160.12.1825; Wang SM, 2015, EUR J INTERN MED, V94, pe1437; Wilt TJ, 2004, ARCH INTERN MED, V164, P1427, DOI 10.1001/archinte.164.13.1427	30	13	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2016	11	8							e0161382	10.1371/journal.pone.0161382	http://dx.doi.org/10.1371/journal.pone.0161382			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT6ES	27537395	Green Published, gold, Green Accepted			2023-01-03	WOS:000381577000096
J	Boronat-Garcia, A; Palomero-Rivero, M; Guerra-Crespo, M; Millan-Aldaco, D; Drucker-Colin, R				Boronat-Garcia, Alejandra; Palomero-Rivero, Marcela; Guerra-Crespo, Magdalena; Millan-Aldaco, Diana; Drucker-Colin, Rene			Intrastriatal Grafting of Chromospheres: Survival and Functional Effects in the 6-OHDA Rat Model of Parkinson's Disease	PLOS ONE			English	Article							ADRENAL CHROMAFFIN CELLS; EMBRYONIC STEM-CELLS; NERVE GROWTH-FACTOR; DOPAMINE NEURONS; PROGENITOR CELLS; DIFFERENTIATION; MEDULLA; NGF; GENERATION; THERAPIES	Cell replacement therapy in Parkinson's disease (PD) aims at re-establishing dopamine neurotransmission in the striatum by grafting dopamine-releasing cells. Chromaffin cell (CC) grafts produce some transitory improvements of functional motor deficits in PD animal models, and have the advantage of allowing autologous transplantation. However, CC grafts have exhibited low survival, poor functional effects and dopamine release compared to other cell types. Recently, chromaffin progenitor-like cells were isolated from bovine and human adult adrenal medulla. Under low-attachment conditions, these cells aggregate and grow as spheres, named chromospheres. Here, we found that bovine-derived chromosphere- cell cultures exhibit a greater fraction of cells with a dopaminergic phenotype and higher dopamine release than CC. Chromospheres grafted in a rat model of PD survived in 57% of the total grafted animals. Behavioral tests showed that surviving chromosphere cells induce a reduction in motor alterations for at least 3 months after grafting. Finally, we found that compared with CC, chromosphere grafts survive more and produce more robust and consistent motor improvements. However, further experiments would be necessary to determine whether the functional benefits induced by chromosphere grafts can be improved, and also to elucidate the mechanisms underlying the functional effects of the grafts.	[Boronat-Garcia, Alejandra; Palomero-Rivero, Marcela; Guerra-Crespo, Magdalena; Millan-Aldaco, Diana; Drucker-Colin, Rene] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Circuito Exterior S-N,Ciudad Univ, Ciudad Mexico, Mexico	Universidad Nacional Autonoma de Mexico	Drucker-Colin, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Circuito Exterior S-N,Ciudad Univ, Ciudad Mexico, Mexico.	drucker@unam.mx			Direccion General Asuntos del Personal Academico-Programa de Apoyo a Proyectos de Investigacion e Inovacion Tecnologica (DGAPA-PAPIIT) [IN204612]; Consejo Nacional de Ciencia y Tecnologia (CONACyT) [179927]; Secretaria de Ciencia, Tecnologia e Innovacion (SECITI) [ICyTDF/170/2012-SECITI/014/2013]; CONACyT-Mexico	Direccion General Asuntos del Personal Academico-Programa de Apoyo a Proyectos de Investigacion e Inovacion Tecnologica (DGAPA-PAPIIT); Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Secretaria de Ciencia, Tecnologia e Innovacion (SECITI); CONACyT-Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported by the following grants: Direccion General Asuntos del Personal Academico-Programa de Apoyo a Proyectos de Investigacion e Inovacion Tecnologica (DGAPA-PAPIIT) [IN204612], Consejo Nacional de Ciencia y Tecnologia (CONACyT) [179927] and Secretaria de Ciencia, Tecnologia e Innovacion (SECITI) [ICyTDF/170/2012-SECITI/014/2013]. The funding source had not any involvement in the study design, in the collection, analysis and intepretation of data, in the writing or in any decision made for publication.; ABG received a PhD fellowship from CONACyT-Mexico. This work is part of the fulfillment of requirements for ABG's PhD degree in Biomedical Science from the Universidad Nacional Autonoma de Mexico. We thank the Posgrado en Ciencias Biomedicas and the Universidad Nacional Autonoma de Mexico.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Barker RA, 2015, NAT REV NEUROL, V11, P492, DOI 10.1038/nrneurol.2015.123; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; BING G, 1990, NEUROSCIENCE, V34, P687, DOI 10.1016/0306-4522(90)90175-4; BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; Bjorklund A, 2013, MOVEMENT DISORD, V28, P110, DOI 10.1002/mds.25343; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; BOUVIER MM, 1995, J NEUROSCI, V15, P7141; Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9; Cho MS, 2008, P NATL ACAD SCI USA, V105, P3392, DOI 10.1073/pnas.0712359105; Chung KF, 2009, STEM CELLS, V27, P2602, DOI 10.1002/stem.180; Correia AS, 2008, FRONT NEUROSCI-SWITZ, V2, P26, DOI 10.3389/neuro.01.011.2008; CREESE I, 1977, SCIENCE, V197, P596, DOI 10.1126/science.877576; CUNNINGHAM LA, 1991, BRAIN RES, V561, P192, DOI 10.1016/0006-8993(91)91595-R; Date I, 1997, EXP NEUROL, V147, P10, DOI 10.1006/exnr.1997.6579; DRUCKERCOLIN R, 1991, J NEUROSCI METH, V39, P153, DOI 10.1016/0165-0270(91)90081-A; DRUCKERCOLIN R, 1994, MOL CELL NEUROSCI, V5, P485, DOI 10.1006/mcne.1994.1060; Dunnett SB, 1989, EXP BRAIN RES, V78, P343; Ehrhart-Bornstein M, 2010, CELL MOL NEUROBIOL, V30, P1417, DOI 10.1007/s10571-010-9571-3; Ehrhart-Bornstein M, 2008, ANN NY ACAD SCI, V1148, P112, DOI 10.1196/annals.1410.053; Fernandez Espejo Emilio, 2001, Journal of Neuroscience, V21, P9888; Fernandez-Espejo E, 2005, BRAIN RES REV, V49, P343, DOI 10.1016/j.brainresrev.2005.01.004; FIANDACA MS, 1988, EXP NEUROL, V102, P76, DOI 10.1016/0014-4886(88)90080-5; FREED WJ, 1981, NATURE, V292, P351, DOI 10.1038/292351a0; Galan-Rodriguez B, 2008, NEUROBIOL DIS, V29, P529, DOI 10.1016/j.nbd.2007.11.009; Garcia-Montes J, 2012, HEALTH, V4, P1153; Garcia-Montes JR, 2012, CNS NEUROL DISORD-DR, V11, P897, DOI 10.2174/1871527311201070897; Grealish S, 2014, CELL STEM CELL, V15, P653, DOI 10.1016/j.stem.2014.09.017; Grealish S, 2010, BRAIN, V133, P482, DOI 10.1093/brain/awp328; Huber K, 2009, AUTON NEUROSCI-BASIC, V151, P10, DOI 10.1016/j.autneu.2009.07.020; Jensen MB, 2012, J STEM CELL RES S10, P003; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; Kim DS, 2000, J NEUROSCI, V20, P4405, DOI 10.1523/JNEUROSCI.20-12-04405.2000; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648; Lanau F, 1997, J NEUROCHEM, V68, P804; Lindvall Olle, 2004, NeuroRx, V1, P382; Lindvall O, 2013, MOVEMENT DISORD, V28, P268, DOI 10.1002/mds.25378; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; MORIHISA JM, 1984, EXP NEUROL, V84, P643, DOI 10.1016/0014-4886(84)90211-5; NIIJIMA K, 1995, J NEUROSCI, V15, P1180; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Olanow CW, 2004, MOVEMENT DISORD, V19, P997, DOI 10.1002/mds.20243; PERLOW MJ, 1979, SCIENCE, V204, P643, DOI 10.1126/science.571147; Rath A, 2013, CELL TRANSPLANT, V22, P1281, DOI 10.3727/096368912X654984; Root DH, 2015, J NEUROSCI, V35, P3460, DOI 10.1523/JNEUROSCI.4525-13.2015; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Santana MM, 2012, STEM CELL TRANSL MED, V1, P783, DOI 10.5966/sctm.2012-0022; Saxena S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064454; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STROMBERG I, 1985, EXP BRAIN RES, V60, P335; Voutilainen MH, 2009, J NEUROSCI, V29, P9651, DOI 10.1523/JNEUROSCI.0833-09.2009; Vukicevic V, 2015, MOL CELL ENDOCRINOL, V408, P178, DOI 10.1016/j.mce.2014.12.020; Vukicevic V, 2012, CELL TRANSPLANT, V21, P2471, DOI 10.3727/096368912X638874; Vukicevic V, 2012, J MOL NEUROSCI, V48, P420, DOI 10.1007/s12031-012-9746-0	55	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2016	11	8							e0160854	10.1371/journal.pone.0160854	http://dx.doi.org/10.1371/journal.pone.0160854			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4SL	27525967	Green Submitted, Green Published, gold			2023-01-03	WOS:000381471100024
J	Zhou, Y; Zhu, JJ; Gu, ZJ; Yin, XG				Zhou, Yuan; Zhu, Jinjie; Gu, Zejuan; Yin, Xiangguang			Efficacy of Exercise Interventions in Patients with Acute Leukemia: A Meta-Analysis	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; PROGRESSIVE EXERCISE; CANCER SURVIVORS; CHILDREN; FATIGUE; CHEMOTHERAPY; NUTRITION; PROGRAM	Background Decreased physical performance and impaired physiological and psychological fitness have been reported in patients with acute leukemia (AL). We performed a meta-analysis to assess the efficacy of exercise in patients with AL. Methods In this meta-analysis, the electronic databases MEDLINE, Embase, Cochrane, Web of Science, SPORTDiscus, CINAHL and PEDro were searched through November 2015. Three authors participated in the study selection, data extraction and quality assessment. The instrument used for quality assessment was derived from the Cochrane Handbook for Systematic Reviews of Interventions. Analyses were performed according to the recommendations of The Cochrane Collaboration using Review Manager 5.3. Results Nine trials (8 randomized controlled trials and 1 quasi-experimental design trial) with 314 AL participants were included in this meta-analysis. The pooled standardized mean differences between the exercise and control groups were 0.45 (95% confidence interval (CI): 0.09 to 0.80, P value = 0.01, P for heterogeneity = 0.23, I-2 = 28%) for cardiorespiratory fitness and 0.67 ( 95% CI: 0.28 to 1.06, P value = 0.0007, P for heterogeneity = 0.14, I-2 = 43%) for muscle strength. Based on the data for fatigue, anxiety, and depression, there were no significant differences in these parameters between the exercise and control groups. Conclusions Exercise has beneficial effects on cardiorespiratory fitness, muscle strength and functional mobility; however, no significant improvements in fatigue, anxiety, depression or quality of life were observed. Further large-scale randomized trials are needed to assess the safety, feasibility and efficacy of exercise programs for AL patients.	[Zhou, Yuan] Nanjing Med Univ, Hosp 1, Nanjing, Jiangsu, Peoples R China; [Zhu, Jinjie] Nanjing Univ Aeronaut & Astronaut, Coll Aerosp Engn, Nanjing, Jiangsu, Peoples R China; [Gu, Zejuan] Nanjing Med Univ, Hosp 1, Dept Nursing, Nanjing, Jiangsu, Peoples R China; [Yin, Xiangguang] Nanjing Med Univ, Coll Nursing, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University of Aeronautics & Astronautics; Nanjing Medical University; Nanjing Medical University	Gu, ZJ (corresponding author), Nanjing Med Univ, Hosp 1, Dept Nursing, Nanjing, Jiangsu, Peoples R China.	jassicagu@163.com	Zhu, Jinjie/AAI-6265-2020	Zhu, Jinjie/0000-0001-7647-3806	Jiangsu Province, "333 Project" Scientific Research Project [28]	Jiangsu Province, "333 Project" Scientific Research Project	This work was supported by Jiangsu Province, "333 Project" Scientific Research Project [2014] No. 28, http://www.jsrcgz.gov.cn/333gc/gcindex.aspx.	Alibhai SMH, 2015, LEUKEMIA RES, V39, P1178, DOI 10.1016/j.leukres.2015.08.012; Alibhai SMH, 2014, SUPPORT CARE CANCER, V22, P881, DOI 10.1007/s00520-013-2044-8; Aznar S, 2006, APPL PHYSIOL NUTR ME, V31, P407, DOI 10.1139/H06-014; Bergenthal N, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009075.pub2; Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122; Chang PH, 2008, J PAIN SYMPTOM MANAG, V35, P524, DOI 10.1016/j.jpainsymman.2007.06.013; Courneya KS, 2013, JNCI-J NATL CANCER I, V105, P1821, DOI 10.1093/jnci/djt297; Hacker ED, 2006, ONCOL NURS FORUM, V33, P614, DOI 10.1188/06.ONF.614-624; De Macedo TMF, 2010, REV PAUL PEDIATR, V28, P352, DOI DOI 10.1590/S0103-05822010000400011; De Souza AM, 2007, PEDIATR BLOOD CANCER, V49, P56, DOI 10.1002/pbc.21122; Dieli-Conwright CM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-238; Dimeo FC, 2001, CANCER, V92, P1689, DOI 10.1002/1097-0142(20010915)92:6+<1689::AID-CNCR1498>3.0.CO;2-H; Doyle C, 2006, CA-CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323; Hartman A, 2009, PEDIATR BLOOD CANCER, V53, P64, DOI 10.1002/pbc.21942; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Jochem C, 2014, CANCER EPIDEM BIOMAR, V23, P833, DOI 10.1158/1055-9965.EPI-13-0699; Krull KR, 2011, EUR J CANCER, V47, P1380, DOI 10.1016/j.ejca.2011.03.001; Liu RDKS, 2009, CANCER TREAT REV, V35, P185, DOI 10.1016/j.ctrv.2008.09.008; Marchese VG, 2004, PEDIATR BLOOD CANCER, V42, P127, DOI 10.1002/pbc.10481; McCullough DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju036; Mock V, 1998, AAOHN J, V46, P425; Moyer-Mileur LJ, 2009, J PEDIAT HEMATOL ONC, V31, P259, DOI 10.1097/MPH.0b013e3181978fd4; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Sallan Stephen E, 2006, Hematology Am Soc Hematol Educ Program, P128; San Juan AF, 2008, INT J SPORTS MED, V29, P439, DOI 10.1055/s-2007-965571; Schule K, 1983, Rehabilitation (Stuttg), V22, P36; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith-Turchyn J, 2015, SUPPORT CARE CANCER, V23, P2435, DOI 10.1007/s00520-015-2752-3; Tanir MK, 2013, REHABIL NURS, V38, P48, DOI 10.1002/rnj.58; Winningham M, 1992, BIOTHERAPY CANC, P16; Wolin KY, 2010, LEUKEMIA, V24, P1113, DOI 10.1038/leu.2010.54; Yeh CH, 2011, CANCER NURS, V34, P3, DOI 10.1097/NCC.0b013e3181e4553c	32	24	25	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2016	11	7							e0159966	10.1371/journal.pone.0159966	http://dx.doi.org/10.1371/journal.pone.0159966			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IJ	27463234	Green Published, Green Submitted, gold			2023-01-03	WOS:000381515900058
J	Holzinger, D; Danilovic, I; Seemann, R; Kornek, G; Engelmann, J; Pillerstorff, R; Holawe, S; Psyrri, A; Erovic, BM; Farwell, G; Perisanidis, C				Holzinger, Daniel; Danilovic, Ivan; Seemann, Rudolf; Kornek, Gabriela; Engelmann, Johannes; Pillerstorff, Robert; Holawe, Simone; Psyrri, Amanda; Erovic, Boban M.; Farwell, Gregory; Perisanidis, Christos			Prognostic Impact of Pretreatment Plasma Fibrinogen in Patients with Locally Advanced Oral and Oropharyngeal Cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; FIBRIN(OGEN); SURGERY; BINDING	Background We aimed to determine the prognostic significance of pretreatment plasma fibrinigen in patients with oral and oropharyngeal squamous cell carcinoma (OOSCC). Methods A cohort of 183 patients with locally advanced OOSCC receiving preoperative chemoradiotherapy was retrospectively examined. Using ROC curve analysis, a pretreatment plasma fibrinogen cutoff value of 447mg/dL was determined. The primary endpoints were overall survival and recurrence-free survival. A secondary endpoint was to determine whether pretreatment plasma fibrinogen could predict treatment response to neoadjuvant chemoradiotherapy. Cox regression models and Kaplan-Meier curves were used for survival analyses. Results Seventy-one patients had an elevated pretreatment plasma fibrinogen (fibrinogen >447mg/dL). Patients with high fibrinogen showed significantly higher pathologic stages after neoadjuvant treatment than those with low fibrinogen (p = 0.037). In univariate analysis, elevated fibrinogen was associated with poor overall survival (p = 0.005) and recurrence-free survival (p = 0.008) Multivariate analysis revealed that elevated fibrinogen remained an independent risk factor for death (hazard ratio 1.78, 95% CI 1.09-2.90, p = 0.021) and relapse (hazard ratio 1.78, 95% CI 1.11-2.86, p = 0.016). Conclusion Elevated pretreatment plasma fibrinogen is associated with lack of response to neoadjuvant chemoradiotherapy and reduced OS and RFS in patients with OOSCC. Thus, plasma fibrinogen may emerge as a novel prognostic indicator and a potential therapeutic target in OOSCC.	[Holzinger, Daniel; Danilovic, Ivan; Seemann, Rudolf; Engelmann, Johannes; Pillerstorff, Robert; Holawe, Simone; Perisanidis, Christos] Med Univ Vienna, Dept Craniomaxillofacial & Oral Surg, Vienna, Austria; [Kornek, Gabriela] Med Univ Vienna, Dept Med 1, Vienna, Austria; [Psyrri, Amanda] Attikon Univ Hosp, Dept Internal Med 2, Div Oncol, Athens, Greece; [Erovic, Boban M.] Med Univ Vienna, Dept Otolaryngol Head & Neck Surg, Vienna, Austria; [Farwell, Gregory] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Sacramento, CA 95817 USA	Medical University of Vienna; Medical University of Vienna; University Hospital Attikon; Medical University of Vienna; University of California System; University of California Davis	Perisanidis, C (corresponding author), Med Univ Vienna, Dept Craniomaxillofacial & Oral Surg, Vienna, Austria.	christos.perisanidis@meduniwien.ac.at	Erovic, Boban/S-7824-2018	Erovic, Boban/0000-0002-7404-2583; Holzinger, Daniel/0000-0002-2924-0193; Seemann, Rudolf/0000-0003-4234-4090				CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Driemel O, 2009, STRAHLENTHER ONKOL, V185, P296, DOI 10.1007/s00066-009-1914-y; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Freier K, 2008, ORAL ONCOL, V44, P116, DOI 10.1016/j.oraloncology.2007.01.006; Jagielska B, 2011, NEOPLASMA, V58, P129, DOI 10.4149/neo_2011_02_129; Jensen T, 2007, THROMB HAEMOSTASIS, V97, P822, DOI 10.1160/TH07-01-0039; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martino MM, 2013, P NATL ACAD SCI USA, V110, P4563, DOI 10.1073/pnas.1221602110; Palumbo JS, 2010, THROMB RES, V125, pS39, DOI 10.1016/S0049-3848(10)70011-6; Peng P, 2014, INT J ORAL MAX SURG, V43, P393, DOI 10.1016/j.ijom.2013.09.011; Perisanidis C, 2015, CANCER TREAT REV, V41, P960, DOI 10.1016/j.ctrv.2015.10.002; Perisanidis C, 2013, OR SURG OR MED OR PA, V115, P293, DOI 10.1016/j.oooo.2012.03.033; Russmueller G, 2015, ORAL ONCOL, V51, P247, DOI 10.1016/j.oraloncology.2014.11.010; Sahni A, 2008, J THROMB HAEMOST, V6, P176; Sahni A, 2006, BLOOD, V107, P126, DOI 10.1182/blood-2005-06-2460; Shu YJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-566; Staton CA, 2003, EXPERT OPIN BIOL TH, V3, P1105, DOI 10.1517/eobt.3.7.1105.21272; Steinbrecher KA, 2010, CANCER RES, V70, P2634, DOI 10.1158/0008-5472.CAN-09-3465; Tang LQ, 2014, BRIT J CANCER, V111, P1102, DOI 10.1038/bjc.2014.393; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Zheng S, 2009, CANCER SCI, V100, P859, DOI 10.1111/j.1349-7006.2009.01115.x	23	13	13	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2016	11	6							e0158697	10.1371/journal.pone.0158697	http://dx.doi.org/10.1371/journal.pone.0158697			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0CH	27362659	Green Published, Green Submitted, gold			2023-01-03	WOS:000378865200109
J	Gall, C; Schmidt, S; Schittkowski, MP; Antal, A; Ambrus, GG; Paulus, W; Dannhauer, M; Michalik, R; Mante, A; Bola, M; Lux, A; Kropf, S; Brandt, SA; Sabel, BA				Gall, Carolin; Schmidt, Sein; Schittkowski, Michael P.; Antal, Andrea; Ambrus, Geza Gergely; Paulus, Walter; Dannhauer, Moritz; Michalik, Romualda; Mante, Alf; Bola, Michal; Lux, Anke; Kropf, Siegfried; Brandt, Stephan A.; Sabel, Bernhard A.			Alternating Current Stimulation for Vision Restoration after Optic Nerve Damage: A Randomized Clinical Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; BRAIN-STIMULATION; ELECTRICAL-STIMULATION; IMPROVES VISION; FIELDS; EEG	Background Vision loss after optic neuropathy is considered irreversible. Here, repetitive transorbital alternating current stimulation (rtACS) was applied in partially blind patients with the goal of activating their residual vision. Methods We conducted a multicenter, prospective, randomized, double-blind, sham-controlled trial in an ambulatory setting with daily application of rtACS (n = 45) or sham-stimulation (n = 37) for 50 min for a duration of 10 week days. A volunteer sample of patients with optic nerve damage (mean age 59.1 yrs) was recruited. The primary outcome measure for efficacy was super-threshold visual fields with 48 hrs after the last treatment day and at 2-months follow-up. Secondary outcome measures were near-threshold visual fields, reaction time, visual acuity, and resting-state EEGs to assess changes in brain physiology. Results The rtACS-treated group had a mean improvement in visual field of 24.0% which was significantly greater than after sham-stimulation (2.5%). This improvement persisted for at least 2 months in terms of both within-and between-group comparisons. Secondary analyses revealed improvements of near-threshold visual fields in the central 5 degrees and increased thresholds in static perimetry after rtACS and improved reaction times, but visual acuity did not change compared to shams. Visual field improvement induced by rtACS was associated with EEG power-spectra and coherence alterations in visual cortical networks which are interpreted as signs of neuromodulation. Current flow simulation indicates current in the frontal cortex, eye, and optic nerve and in the subcortical but not in the cortical regions. Conclusion rtACS treatment is a safe and effective means to partially restore vision after optic nerve damage probably by modulating brain plasticity. This class 1 evidence suggests that visual fields can be improved in a clinically meaningful way.	[Gall, Carolin; Michalik, Romualda; Bola, Michal; Sabel, Bernhard A.] Univ Magdeburg, Fac Med, Inst Med Psychol, Magdeburg, Germany; [Schmidt, Sein; Mante, Alf; Brandt, Stephan A.] Charite, Dept Neurol, Berlin, Germany; [Schittkowski, Michael P.] Univ Gottingen, Dept Ophthalmol, Univ Med Ctr, Gottingen, Germany; [Antal, Andrea; Ambrus, Geza Gergely; Paulus, Walter] Univ Gottingen, Dept Clin Neurophysiol, Univ Med Ctr, Gottingen, Germany; [Dannhauer, Moritz] Univ Utah, Ctr Integrat Biomed Comp, Salt Lake City, UT USA; [Dannhauer, Moritz] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA; [Lux, Anke; Kropf, Siegfried] Univ Magdeburg, Inst Biometry & Med Informat, Magdeburg, Germany	Otto von Guericke University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen; University of Gottingen; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Otto von Guericke University	Gall, C (corresponding author), Univ Magdeburg, Fac Med, Inst Med Psychol, Magdeburg, Germany.	imp@med.ovgu.de	Schmidt, Sein/AFR-1244-2022; Schittkowski, Michael P./J-8747-2019; Ambrus, Géza Gergely/G-2716-2014; Schmidt, Sein/AAT-2308-2021; Paulus, Walter/A-3544-2009	Ambrus, Géza Gergely/0000-0002-8400-8178; Paulus, Walter/0000-0001-5549-8377; Bola, Michal/0000-0002-4609-8029	German Federal Education and Research Ministry, grant ERA-net Neuron (BMBF) [01EW1210]; University of Magdeburg (LOM-grant); German Research Foundation [BR 1691/8-1]; National Institute of General Medical Sciences of the National Institutes of Health (USA) [P41 GM103545-17]; EBS (Germany); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103545] Funding Source: NIH RePORTER	German Federal Education and Research Ministry, grant ERA-net Neuron (BMBF)(Federal Ministry of Education & Research (BMBF)); University of Magdeburg (LOM-grant); German Research Foundation(German Research Foundation (DFG)); National Institute of General Medical Sciences of the National Institutes of Health (USA); EBS (Germany); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was funded in part, by the German Federal Education and Research Ministry, grant ERA-net Neuron (BMBF 01EW1210) to BAS and CG, by the University of Magdeburg (LOM-grant to MB), by the German Research Foundation, Grant number BR 1691/8-1 to SS, and by the National Institute of General Medical Sciences of the National Institutes of Health (USA) under grant number P41 GM103545-17 to MD, and by EBS (Germany). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; Antal A, 2011, RESTOR NEUROL NEUROS, V29, P365, DOI 10.3233/RNN-2011-0609; Bola Michal, 2014, Neurology, V83, P542, DOI 10.1212/WNL.0000000000000672; Bola M, 2015, CORTEX, V67, P134, DOI 10.1016/j.cortex.2015.03.020; Bola M, 2015, NEUROIMAGE, V114, P398, DOI 10.1016/j.neuroimage.2015.03.057; Chrysikou EG, 2011, RESTOR NEUROL NEUROS, V29, P375, DOI 10.3233/RNN-2011-0610; Connell N, 2014, NEUROLOGY, V83, P484, DOI 10.1212/WNL.0000000000000664; Dannhauer M, 2011, HUM BRAIN MAPP, V32, P1383, DOI 10.1002/hbm.21114; Eichelbaum S, 2014, NEUROIMAGE, V101, P513, DOI 10.1016/j.neuroimage.2014.04.085; Foik AT, 2015, INVEST OPHTH VIS SCI, V56, P1711, DOI 10.1167/iovs.14-15617; Gall C, 2015, CONTEMP CLIN TRIALS, V43, P231, DOI 10.1016/j.cct.2015.06.005; Gall C, 2013, NEUROPSYCHOLOGIA, V51, P2271, DOI 10.1016/j.neuropsychologia.2013.06.028; Gall C, 2011, BRAIN STIMUL, V4, P175, DOI 10.1016/j.brs.2011.07.003; Gall C, 2009, INVEST OPHTH VIS SCI, V50, P2765, DOI 10.1167/iovs.08-2519; Ghaffarieh A, 2012, INT REV NEUROBIOL, V105, P1, DOI 10.1016/B978-0-12-398309-1.00002-0; Greenwald BD, 2012, BRAIN INJURY, V26, P1338, DOI 10.3109/02699052.2012.706356; Haueisen J, 2002, NEUROIMAGE, V15, P159, DOI 10.1006/nimg.2001.0962; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; Laczo B, 2012, BRAIN STIMUL, V5, P484, DOI 10.1016/j.brs.2011.08.008; Lindenblatt G, 2001, PHYS MED BIOL, V46, P3051, DOI 10.1088/0031-9155/46/11/319; Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496; Merlet I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057330; Nair DG, 2011, RESTOR NEUROL NEUROS, V29, P411, DOI 10.3233/RNN-2011-0612; Pereda E, 2005, PROG NEUROBIOL, V77, P1, DOI 10.1016/j.pneurobio.2005.10.003; Plow EB, 2012, NEUROREHAB NEURAL RE, V26, P616, DOI 10.1177/1545968311431963; Poggel DA, 2004, NEUROLOGY, V63, P2069, DOI 10.1212/01.WNL.0000145773.26378.E5; Raz N, 2012, ANN NEUROL, V71, P531, DOI 10.1002/ana.22692; Reato D, 2010, J NEUROSCI, V30, P15067, DOI 10.1523/JNEUROSCI.2059-10.2010; Sabel BA, 2014, JAMA OPHTHALMOL, V132, P381, DOI 10.1001/jamaophthalmol.2013.7963; Sabel BA, 2011, RESTOR NEUROL NEUROS, V29, P493, DOI 10.3233/RNN-2011-0624; Sabel BA, 2011, PROG BRAIN RES, V192, P199, DOI 10.1016/B978-0-444-53355-5.00013-0; Sahraie A, 2013, INVEST OPHTH VIS SCI, V54, P3579, DOI 10.1167/iovs.12-11231; Schatz A, 2011, INVEST OPHTH VIS SCI, V52, P4485, DOI 10.1167/iovs.10-6932; Schmidt S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00325; Schmidt S, 2013, BRAIN STIMUL, V6, P87, DOI 10.1016/j.brs.2012.03.008; Schmidt SL, 2014, BRAIN STIMUL, V7, P878, DOI 10.1016/j.brs.2014.07.033; Song SB, 2011, RESTOR NEUROL NEUROS, V29, P427, DOI 10.3233/RNN-2011-0614; Vosskuhl J, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00257; Zaehle T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013766	39	71	74	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2016	11	6							e0156134	10.1371/journal.pone.0156134	http://dx.doi.org/10.1371/journal.pone.0156134			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AM	27355577	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000378859400006
J	Wallach, J; Kang, H; Colestock, T; Morris, H; Bortolotto, ZA; Collingridge, GL; Lodge, D; Halberstadt, AL; Brandt, SD; Adejare, A				Wallach, Jason; Kang, Heather; Colestock, Tristan; Morris, Hamilton; Bortolotto, Zuner A.; Collingridge, Graham L.; Lodge, David; Halberstadt, Adam L.; Brandt, Simon D.; Adejare, Adeboye			Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues	PLOS ONE			English	Article							METHYL-D-ASPARTATE; PREPULSE INHIBITION; ACOUSTIC STARTLE; CHANNEL COMPLEX; SIGMA-RECEPTORS; PHENCYCLIDINE; MK-801; ANTAGONISTS; KETAMINE; MODULATE	1,2-Diarylethylamines including lanicemine, lefetamine, and remacemide have clinical relevance in a range of therapeutic areas including pain management, epilepsy, neurodegenerative disease and depression. More recently 1,2-diarylethylamines have been sold as 'legal highs' in a number of different forms including powders and tablets. These compounds are sold to circumvent governmental legislation regulating psychoactive drugs. Examples include the opioid MT-45 and the dissociative agents diphenidine (DPH) and 2-methoxydiphenidine (2-MXP). A number of fatal and non-fatal overdoses have been linked to abuse of these compounds. As with many 'legal highs', little is known about their pharmacology. To obtain a better understanding, the effects of DPH, 2-MXP and its 3-and 4-MeO-isomers, and 2-Cl-diphenidine (2-Cl-DPH) were investigated using binding studies at 46 central nervous system receptors including the N-methyl-D-aspartate receptor (NMDAR), serotonin, dopamine, norepinephrine, histamine, and sigma receptors as well as the reuptake transporters for serotonin, dopamine and norepinephrine. Reuptake inhibition potencies were measured at serotonin, norepinephrine and dopamine transporters. NMDAR antagonism was established in vitro using NMDAR-induced field excitatory postsynaptic potential (fEPSP) experiments. Finally, DPH and 2-MXP were investigated using tests of pre-pulse inhibition of startle (PPI) in rats to determine whether they reduce sensorimotor gating, an effect observed with known dissociative drugs such as phencyclidine (PCP) and ketamine. The results suggest that these 1,2-diarylethylamines are relatively selective NMDAR antagonists with weak off-target inhibitory effects on dopamine and norepinephrine reuptake. DPH and 2-MXP significantly inhibited PPI. DPH showed greater potency than 2-MXP, acting with a median effective dose (ED50) of 9.5 mg/kg, which is less potent than values reported for other commonly abused dissociative drugs such as PCP and ketamine.	[Wallach, Jason; Colestock, Tristan; Morris, Hamilton; Adejare, Adeboye] Univ Sci, Pharmaceut Sci, Philadelphia Coll Pharm, Philadelphia, PA USA; [Kang, Heather] Univ Bristol, Ctr Synapt Plast, Sch Clin Sci, Bristol, Avon, England; [Bortolotto, Zuner A.; Collingridge, Graham L.; Lodge, David] Univ Bristol, Sch Physiol Pharmacol & Neurosci, Ctr Synapt Plast, Bristol, Avon, England; [Collingridge, Graham L.] Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Collingridge, Graham L.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Halberstadt, Adam L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Brandt, Simon D.] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Byrom St, Liverpool L3 5UX, Merseyside, England	University of Bristol; University of Bristol; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California San Diego; Liverpool John Moores University	Wallach, J (corresponding author), Univ Sci, Pharmaceut Sci, Philadelphia Coll Pharm, Philadelphia, PA USA.	jwallach@mail.usciences.edu	collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Wallach, Jason/AAK-3776-2020; Halberstadt, Adam L/J-9328-2015	Collingridge, Graham L/0000-0002-9572-5359; Brandt, Simon D./0000-0001-8632-5372; Wallach, Jason/0000-0002-2467-5761	USA NIH NIMH Psychoactive Drug Screening Program; NIMH [MH100644]; NIDA [DA002925]; MRC [MR/K023098/1] Funding Source: UKRI; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH100644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002925] Funding Source: NIH RePORTER; Medical Research Council [MR/K023098/1] Funding Source: researchfish	USA NIH NIMH Psychoactive Drug Screening Program; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors gratefully acknowledge support of the USA NIH NIMH Psychoactive Drug Screening Program for the screening of the compounds in receptors and the monoamine transporter assays. Dr. Halberstadt was supported by NIMH (MH100644) and NIDA (DA002925).	Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; ANIS NA, 1983, BRIT J PHARMACOL, V79, P565, DOI 10.1111/j.1476-5381.1983.tb11031.x; [Anonymous], 2012, ACMD REP METH; Berger ML, 2009, BIOORGAN MED CHEM, V17, P3456, DOI 10.1016/j.bmc.2009.03.025; Besnard J, 2012, NATURE, V492, P215, DOI 10.1038/nature11691; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Ceolin L, 2012, NEUROCHEM INT, V61, P517, DOI 10.1016/j.neuint.2012.02.035; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEMONTIS MG, 1985, PHARMACOL RES COMMUN, V17, P471, DOI 10.1016/0031-6989(85)90082-7; Elliott SP, 2015, J ANAL TOXICOL, V39, P287, DOI 10.1093/jat/bkv006; Fray MJ, 2006, BIOORG MED CHEM LETT, V16, P4345, DOI 10.1016/j.bmcl.2006.05.051; Fray MJ, 2010, BIOORG MED CHEM LETT, V20, P3788, DOI 10.1016/j.bmcl.2010.04.052; Geyer M A, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0807s03; Gray NM, 1989, Patent, Patent No. [EP346791A1, 346791]; Guitart X, 2004, PSYCHOPHARMACOLOGY, V174, P301, DOI 10.1007/s00213-004-1920-9; Halberstadt AL, 2016, PSYCHOPHARM IN PRESS; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2015, CLIN TOXICO IN PRESS; JANIRI L, 1994, DRUG ALCOHOL DEPEN, V36, P139, DOI 10.1016/0376-8716(94)90096-5; Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014; Lodge D, 2015, BRIT J PHARMACOL, V172, P4254, DOI 10.1111/bph.13222; MANSBACH RS, 1991, PSYCHOPHARMACOLOGY, V105, P162, DOI 10.1007/BF02244303; MANSBACH RS, 1989, NEUROPSYCHOPHARMACOL, V2, P299, DOI 10.1016/0893-133X(89)90035-3; McLaughlin G, 2016, DRUG TEST ANAL, V8, P99, DOI 10.1002/dta.1800; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Morris H, 2014, DRUG TEST ANAL, V6, P614, DOI 10.1002/dta.1620; NATSUKA K, 1987, J MED CHEM, V30, P1779, DOI 10.1021/jm00393a017; NOZAKI M, 1983, LIFE SCI, V33, P431, DOI 10.1016/0024-3205(83)90534-9; Palmer GC, 1997, EXCITATORY AMINO ACI, P109; Pochwat B, 2014, EXPERT OPIN INV DRUG, V23, P1181, DOI 10.1517/13543784.2014.918951; Reynolds I J, 2001, Curr Protoc Pharmacol, VChapter 1, DOI 10.1002/0471141755.ph0120s11; Reynolds LJ, 1999, METH MOL B, V128, P93; Roth B, 2013, PSYCHOACTIVE DRUG SC; Roth BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059334; Sanacora G, 2014, MOL PSYCHIATR, V19, P978, DOI 10.1038/mp.2013.130; TRICKLEBANK MD, 1989, EUR J PHARMACOL, V167, P127, DOI 10.1016/0014-2999(89)90754-1; Uchiyama N, 2014, FORENSIC TOXICOL, V32, P9, DOI 10.1007/s11419-013-0194-5; Vilner BJ, 2000, J PHARMACOL EXP THER, V292, P900; Volianskis A, 2013, J PHYSIOL-LONDON, V591, P955, DOI 10.1113/jphysiol.2012.247296; Vollenweider FX, 2001, BRAIN RES BULL, V56, P495, DOI 10.1016/S0361-9230(01)00646-3; Wallach J. V., 2014, THESIS; Wallach J, 2015, DRUG TEST ANAL, V7, P358, DOI 10.1002/dta.1689; Wiley JL, 2003, PSYCHOPHARMACOLOGY, V165, P378, DOI 10.1007/s00213-002-1297-6; Wink CSD, 2016, DRUG TEST ANAL, V8, P1005, DOI 10.1002/dta.1946; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WOODRUFF GN, 1987, NEUROPHARMACOLOGY, V26, P903, DOI 10.1016/0028-3908(87)90068-2; YAMAMOTO H, 1995, J NEUROSCI, V15, P731	49	48	48	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2016	11	6							e0157021	10.1371/journal.pone.0157021	http://dx.doi.org/10.1371/journal.pone.0157021			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JQ	27314670	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000378030000008
J	Golding, A; Guay, JA; Herrera-Rincon, C; Levin, M; Kaplan, DL				Golding, Anne; Guay, Justin A.; Herrera-Rincon, Celia; Levin, Michael; Kaplan, David L.			A Tunable Silk Hydrogel Device for Studying Limb Regeneration in Adult Xenopus Laevis	PLOS ONE			English	Article							DRUG-DELIVERY; FIBROIN; ENVIRONMENT; CARTILAGE; PATHWAYS; RELEASE; POLYMER	In certain amphibian models limb regeneration can be promoted or inhibited by the local wound bed environment. This research introduces a device that can be utilized as an experimental tool to characterize the conditions that promotes limb regeneration in the adult frog ( Xenopus laevis) model. In particular, this device was designed to manipulate the local wound environment via a hydrogel insert. Initial characterization of the hydrogel insert revealed that this interaction had a significant influence on mechanical forces to the animal, due to the contraction of the hydrogel. The material and mechanical properties of the hydrogel insert were a factor in the device design in relation to the comfort of the animal and the ability to effectively manipulate the amputation site. The tunable features of the hydrogel were important in determining the pro-regenerative effects in limb regeneration, which was measured by cartilage spike formation and quantified by micro-computed tomography. The hydrogel insert was a factor in the observed morphological outcomes following amputation. Future work will focus on characterizing and optimizing the device's observed capability to manipulate biological pathways that are essential for limb regeneration. However, the present work provides a framework for the role of a hydrogel in the device and a path forward for more systematic studies.	[Golding, Anne] Tufts Univ, Dept Chem & Biol Engn, Medford, MA 02155 USA; [Guay, Justin A.; Herrera-Rincon, Celia; Levin, Michael] Tufts Univ, Dept Biol, Ctr Regenerat & Dev Biol, Medford, MA USA; [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Tufts University; Tufts University; Tufts University	Kaplan, DL (corresponding author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.	david.kaplan@tufts.edu	Levin, Michael/A-5918-2011; Herrera-Rincon, Celia/M-3100-2019	Levin, Michael/0000-0001-7292-8084; Herrera-Rincon, Celia/0000-0003-0748-8718	NIH [R01 AR005593, R01 AR061988]; W. M. Keck Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); W. M. Keck Foundation(W.M. Keck Foundation)	NIH (R01 AR005593, R01 AR061988) funding for DK and ML and W. M. Keck Foundation to ML and DK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agha R, 2011, J SURG RES, V171, P700, DOI 10.1016/j.jss.2011.07.007; Ahadian S, 2015, BIOCONJUGATE CHEM, V26, P1984, DOI 10.1021/acs.bioconjchem.5b00360; Alzahrani MM, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00214; Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200; Bielefeld KA, 2013, CELL MOL LIFE SCI, V70, P2059, DOI 10.1007/s00018-012-1152-9; Boudrant J, 2010, PROCESS BIOCH, V45, P1757; Carlson BM, 2007, PRINCIPLES REGENERAT; Caroline W., 2009, DEV DYNAM, V238, P1226; Carter DR, 2001, J BIOMECHANICS; Chao Edmund Y S, 2003, Eur Cell Mater, V6, P72; Chin MS, 2010, TISSUE ENG PART C-ME, V16, P397, DOI [10.1089/ten.tec.2009.0185, 10.1089/ten.TEC.2009.0185]; Clement-Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102; Coughlan DC, 2004, J CONTROL RELEASE, V98, P97, DOI 10.1016/j.jconrel.2004.04.014; Dawson Lindsay A, 2016, REGENERATION, DOI [10.1002/reg2.51, DOI 10.1002/REG2.51]; DENT JN, 1962, J MORPHOL, V110, P61, DOI 10.1002/jmor.1051100105; Endo T, 2004, DEV BIOL, V270, P135, DOI 10.1016/j.ydbio.2004.02.016; Ferguson MWJ, 2004, PHILOS T R SOC B, V359, P839, DOI 10.1098/rstb.2004.1475; Fernando WA, 2011, DEV BIOL, V350, P301, DOI 10.1016/j.ydbio.2010.11.035; Haremaki T, 2015, DEV BIOL, V408, P305, DOI 10.1016/j.ydbio.2015.07.013; Hechavarria D, 2010, MED ENG PHYS, V32, P1065, DOI 10.1016/j.medengphy.2010.07.010; Hofmann S, 2006, J CONTROL RELEASE, V111, P219, DOI 10.1016/j.jconrel.2005.12.009; Hudson EP, 2005, CURR OPIN BIOTECH, V16, P637, DOI 10.1016/j.copbio.2005.10.004; Imoto T, 1997, CELL MOL LIFE SCI, V53, P215, DOI 10.1007/PL00000593; Kareska S, 2010, FACTORS AFFECTING HY, V7; KIM SW, 1992, PHARMACEUT RES, V9, P283, DOI 10.1023/A:1015887213431; Kramarenko EY, 2006, POLYM SCI SER C+, V48, P1, DOI 10.1134/S1811238206010012; Laftah WA, 2011, POLYM-PLAST TECHNOL, V50, P1475, DOI 10.1080/03602559.2011.593082; Lancerotto L, 2014, ADV WOUND CARE, V3, P626, DOI 10.1089/wound.2013.0491; Leppik LP, 2015, SCI REP-UK, V5, DOI 10.1038/srep18353; Lin GF, 2013, DEV CELL, V24, P41, DOI 10.1016/j.devcel.2012.11.017; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Monaghan JR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-1; MULLERGERBL M, 1987, J ANAT, V154, P103; Numata K, 2010, ADV DRUG DELIVER REV, V62, P1497, DOI 10.1016/j.addr.2010.03.009; Olczyk P, 2014, ROLE EXTRACELLULAR M, V2014, P12; Partlow BP, 2014, ADV FUNCT MATER, V24, P4615, DOI 10.1002/adfm.201400526; Pufe T, 2004, AM J PATHOL, V164, P185, DOI 10.1016/S0002-9440(10)63109-4; Qiu Y, 2012, ADV DRUG DELIVER REV, V64, P49, DOI 10.1016/j.addr.2012.09.024; Rao N, 2014, BMC DEV BIOL, V14, DOI 10.1186/1471-213X-14-32; Ratner BD, 2004, CHEM ENG; Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379; Sambasivarao SV, 2013, CURR OPIN STRUC BIOL, V18, P1199, DOI DOI 10.1016/J.MICINF.2011.07.011.INNATE; Santosh N, 2011, DEV DYNAM, V240, P1127, DOI 10.1002/dvdy.22503; Satoh A, 2005, DEV DYNAM, V233, P1444, DOI 10.1002/dvdy.20484; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; SKINNER HCW, 1975, YALE J BIOL MED, V48, P377; Stocum DL, 2011, DEV DYNAM, V240, P943, DOI 10.1002/dvdy.22553; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Timasheff SN, 1996, PROTEIN STAB FOLD TH, V379, P253; Tsonis PA, 2000, DEV BIOL, V221, P273, DOI 10.1006/dbio.2000.9667; Vernon AE, 2003, DEVELOPMENT, V130, P71, DOI 10.1242/dev.00180; Wenk E, 2011, J CONTROL RELEASE, V150, P128, DOI 10.1016/j.jconrel.2010.11.007; Wiegand C, 2013, WOUND REPAIR REGEN, V21, P793, DOI 10.1111/wrr.12111; Witte MB, 1997, SURG CLIN N AM, V77, P509, DOI 10.1016/S0039-6109(05)70566-1; Wu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054764; Yuehuei HA., 2003, HDB HISTOLOGY METHOD	56	11	11	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2016	11	6							e0155618	10.1371/journal.pone.0155618	http://dx.doi.org/10.1371/journal.pone.0155618			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN8ZV	27257960	Green Published, gold, Green Submitted			2023-01-03	WOS:000377369700018
J	Lee, YM; Kim, SA; Lee, IK; Kim, JG; Park, KG; Jeong, JY; Jeon, JH; Shin, JY; Lee, DH				Lee, Yu-Mi; Kim, Se-A; Lee, In-Kyu; Kim, Jung-Guk; Park, Keun-Gyu; Jeong, Ji-Yun; Jeon, Jae-Han; Shin, Ji-Yeon; Lee, Duk-Hee			Effect of a Brown Rice Based Vegan Diet and Conventional Diabetic Diet on Glycemic Control of Patients with Type 2 Diabetes: A 12-Week Randomized Clinical Trial	PLOS ONE			English	Article							PERSISTENT ORGANIC POLLUTANTS; CARDIOVASCULAR RISK; INSULIN-RESISTANCE; BODY-WEIGHT; LOW-FAT; METAANALYSIS; MANAGEMENT; VEGETARIAN; FIBER; INTERVENTIONS	Objective Several intervention studies have suggested that vegetarian or vegan diets have clinical benefits, particularly in terms of glycemic control, in patients with type 2 diabetes (T2D); however, no randomized controlled trial has been conducted in Asians who more commonly depend on plant-based foods, as compared to Western populations. Here, we aimed to compare the effect of a vegan diet and conventional diabetic diet on glycemic control among Korean individuals. Materials and Methods Participants diagnosed with T2D were randomly assigned to follow either a vegan diet (excluding animal-based food including fish; n = 46) or a conventional diet recommended by the Korean Diabetes Association 2011 (n = 47) for 12 weeks. HbA1c levels were measured at weeks 0, 4, and 12, and the primary study endpoint was the change in HbA1c levels over 12 weeks. Results The mean HbA1c levels at weeks 0, 4, and 12 were 7.7%, 7.2%, and 7.1% in the vegan group, and 7.4%, 7.2%, and 7.2% in the conventional group, respectively. Although both groups showed significant reductions in HbA1C levels, the reductions were larger in the vegan group than in the conventional group (-0.5% vs. -0.2%; p-for-interaction = 0.017). When only considering participants with high compliance, the difference in HbA1c level reduction between the groups was found to be larger (-0.9% vs. -0.3%). The beneficial effect of vegan diets was noted even after adjusting for changes in total energy intake or waist circumference over the 12 weeks. Conclusion Both diets led to reductions in HbA1c levels; however, glycemic control was better with the vegan diet than with the conventional diet. Thus, the dietary guidelines for patients with T2D should include a vegan diet for the better management and treatment. However, further studies are needed to evaluate the long-term effects of a vegan diet, and to identify potential explanations of the underlying mechanisms.	[Lee, Yu-Mi; Lee, Duk-Hee] Kyungpook Natl Univ, Sch Med, Dept Preventat Med, Daegu, South Korea; [Kim, Se-A; Lee, Duk-Hee] Kyungpook Natl Univ, Dept Biomed Sci, Daegu, South Korea; [Kim, Se-A; Lee, Duk-Hee] Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program BK21, Daegu, South Korea; [Lee, In-Kyu; Kim, Jung-Guk; Park, Keun-Gyu; Jeong, Ji-Yun; Jeon, Jae-Han] Kyungpook Natl Univ, Sch Med, Dept Endocrinol, Daegu, South Korea; [Shin, Ji-Yeon] Eulji Univ, Sch Med, Dept Prevent Med, Daejeon, South Korea; [Jeong, Ji-Yun] Soonchunhyang Univ, Gumi Hosp, Dept Internal Med, Gumi, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Kyungpook National University; Eulji University; Soonchunhyang University	Lee, DH (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Preventat Med, Daegu, South Korea.; Lee, DH (corresponding author), Kyungpook Natl Univ, Dept Biomed Sci, Daegu, South Korea.; Lee, DH (corresponding author), Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program BK21, Daegu, South Korea.	lee_dh@knu.ac.kr	Lee, In-Kyu/AAR-6374-2021		Korea Health Industry Development Institute - Ministry of Health Welfare [A111716-12020000100]; Korean Health Technology R&D Project - Ministry of Health and Welfare, Republic of Korea [HI13C0715, HI11C1300]	Korea Health Industry Development Institute - Ministry of Health Welfare; Korean Health Technology R&D Project - Ministry of Health and Welfare, Republic of Korea	This research was supported by the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare (A111716-12020000100), as well as the Korean Health Technology R&D Project, funded by the Ministry of Health and Welfare, Republic of Korea (HI13C0715 and HI11C1300).	Ajala O, 2013, AM J CLIN NUTR, V97, P505, DOI 10.3945/ajcn.112.042457; Amer Diabet Associat, 2008, DIABETES CARE, V31, pS61, DOI 10.2337/dc08-S061; Artinian NT, 2010, CIRCULATION, V122, P406, DOI 10.1161/CIR.0b013e3181e8edf1; Barnard ND, 2005, AM J MED, V118, P991, DOI 10.1016/j.amjmed.2005.03.039; Barnard ND, 2006, DIABETES CARE, V29, P1777, DOI 10.2337/dc06-0606; Barnard ND, 2009, NUTR REV, V67, P255, DOI 10.1111/j.1753-4887.2009.00198.x; Barnard ND, 2009, AM J CLIN NUTR, V89, pS1588, DOI 10.3945/ajcn.2009.26736H; Cao YM, 2009, J CLIN LIPIDOL, V3, P19, DOI 10.1016/j.jacl.2008.12.008; Chandalia M, 2000, NEW ENGL J MED, V342, P1392, DOI 10.1056/NEJM200005113421903; Committee of Clinical Practice Guidelines KDA, 2011, 2011 CLIN PRACT GUID; Craig WJ, 2009, AM J CLIN NUTR, V89, pS1627, DOI 10.3945/ajcn.2009.26736N; De Vadder F, 2014, CELL, V156, P84, DOI 10.1016/j.cell.2013.12.016; Evert AB, 2013, DIABETES CARE, V36, P3821, DOI 10.2337/dc13-2042; Goff LM, 2005, EUR J CLIN NUTR, V59, P291, DOI 10.1038/sj.ejcn.1602076; Kahleova H, 2011, DIABETIC MED, V28, P549, DOI 10.1111/j.1464-5491.2010.03209.x; Kelly BC, 2007, SCIENCE, V317, P236, DOI 10.1126/science.1138275; Le LT, 2014, NUTRIENTS, V6, P2131, DOI 10.3390/nu6062131; Lee DH, 2008, DIABETES, V57, P3108, DOI 10.2337/db08-0668; Lee DH, 2014, ENDOCR REV, V35, P557, DOI 10.1210/er.2013-1084; Lee DH, 2012, ENVIRON INT, V47, P115, DOI 10.1016/j.envint.2012.06.009; Lind L, 2012, J INTERN MED, V271, P537, DOI 10.1111/j.1365-2796.2012.02536.x; Livesey G, 2009, AM J CLIN NUTR, V89, P114, DOI 10.3945/ajcn.2008.26842; Mishra S, 2013, EUR J CLIN NUTR, V67, P718, DOI 10.1038/ejcn.2013.92; STORY JA, 1978, AM J CLIN NUTR, V31, pS199, DOI 10.1093/ajcn/31.10.S199; Wang FL, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002408; WHO, 2003, WHO TECHN REP SER; Yokoyama Y, 2014, CARDIOVASC DIAGN THE, V4, P373, DOI 10.3978/j.issn.2223-3652.2014.10.04; Yokoyama Y, 2014, JAMA INTERN MED, V174, P577, DOI 10.1001/jamainternmed.2013.14547	28	59	59	3	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2016	11	6							e0155918	10.1371/journal.pone.0155918	http://dx.doi.org/10.1371/journal.pone.0155918			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN6XB	27253526	Green Submitted, Green Published, gold			2023-01-03	WOS:000377218700011
J	Briasoulis, A; Afonso, L				Briasoulis, Alexandros; Afonso, Luis			Do NOACs ENSURE safe cardioversion in atrial fibrillation?	LANCET			English	Editorial Material							ORAL ANTICOAGULANTS; EFFICACY; WARFARIN; OUTCOMES; RISK		[Briasoulis, Alexandros] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA; [Afonso, Luis] Wayne State Univ, Div Cardiol, Detroit, MI USA	Mayo Clinic; Wayne State University	Briasoulis, A (corresponding author), Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA.	alexbriasoulis@gmail.com	Briasoulis, Alexandros/AAD-3965-2019	Briasoulis, Alexandros/0000-0002-5740-9670				Berger M, 1998, AM J CARDIOL, V82, P1545, DOI 10.1016/S0002-9149(98)00704-8; Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367; Coleman CM, 2015, PACE, V38, P731, DOI 10.1111/pace.12618; Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062; FLEGEL KM, 1987, LANCET, V1, P526; Goette A, 2016, LANCET; Hansen ML, 2015, EUROPACE, V17, P18, DOI 10.1093/europace/euu189; January CT, 2014, CIRCULATION, V130, pE199, DOI [10.1161/CIR.0000000000000041, 10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.021, 10.1016/j.jacc.2014.03.022]; Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901; Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546; Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0	12	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2016	388	10055					1958	1960		10.1016/S0140-6736(16)31410-6	http://dx.doi.org/10.1016/S0140-6736(16)31410-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ6EQ	27590222				2023-01-03	WOS:000385954800005
J	Hou, WC; Zhang, W; Chen, GD; Luo, YP				Hou, Wencheng; Zhang, Wei; Chen, Guode; Luo, Yanping			Optimization of Extraction Conditions for Maximal Phenolic, Flavonoid and Antioxidant Activity from Melaleuca bracteata Leaves Using the Response Surface Methodology	PLOS ONE			English	Article							CHEMICAL-COMPOSITION; OCIMUM-GRATISSIMUM; ESSENTIAL OILS; L.; COMMON; CAPACITY; STRESS; FRUIT; SKIN	Melaleuca bracteata is a yellow-leaved tree belonging to the Melaleuca genus. Species from this genus are known to be good sources of natural antioxidants, for example, the "tea tree oil" derived from M. alternifolia is used in food processing to extend the shelf life of products. In order to determine whether M. bracteata contains novel natural antioxidants, the components of M. bracteata ethanol extracts were analyzed by gas chromatography-mass spectrometry. Total phenolic and flavonoid contents were extracted and the antioxidant activities of the extracts evaluated. Single-factor experiments, central composite rotatable design (CCRD) and response surface methodology (RSM) were used to optimize the extraction conditions for total phenolic content (TPC) and total flavonoid content (TFC). Ferric reducing power (FRP) and 1,1-Diphenyl-2-picrylhydrazyl radical (DPPH.) scavenging capacity were used as the evaluation indices of antioxidant activity. The results showed that the main components of M. bracteata ethanol extracts are methyl eugenol (86.86%) and trans-cinnamic acid methyl ester (6.41%). The single-factor experiments revealed that the ethanol concentration is the key factor determining the TPC, TFC, FRP and DPPH.scavenging capacity. RSM results indicated that the optimal condition of all four evaluation indices was achieved by extracting for 3.65 days at 53.26 degrees C in 34.81% ethanol. Under these conditions, the TPC, TFC, FRP and DPPH.scavenging capacity reached values of 88.6 +/- 1.3 mg GAE/g DW, 19.4 +/- 0.2 mg RE/g DW, 2.37 +/- 0.01 mMFe(2+)/g DW and 86.0 +/- 0.3%, respectively, which were higher than those of the positive control, methyl eugenol (FRP 0.97 +/- 0.02 mM, DPPH.scavenging capacity 58.6 +/- 0.7%) at comparable concentrations. Therefore, the extracts of M. bracteata leaves have higher antioxidant activity, which did not only attributed to the methyl eugenol. Further research could lead to the development of a potent new natural antioxidant.	[Hou, Wencheng; Luo, Yanping] Hainan Univ, Key Lab Protect & Dev Utilizat Trop Crop Germplas, Minist Educ, Haikou 570228, Hainan, Peoples R China; [Hou, Wencheng; Luo, Yanping] Hainan Univ, Coll Environm & Plant Protect, Haikou 570228, Hainan, Peoples R China; [Zhang, Wei; Chen, Guode] Hainan Prov Forestry Sci Inst, Tongshen Branch Off, Wuzhishan 572200, Hainan, Peoples R China	Hainan University; Hainan University	Luo, YP (corresponding author), Hainan Univ, Key Lab Protect & Dev Utilizat Trop Crop Germplas, Minist Educ, Haikou 570228, Hainan, Peoples R China.; Luo, YP (corresponding author), Hainan Univ, Coll Environm & Plant Protect, Haikou 570228, Hainan, Peoples R China.	yanpluo@126.com			National Natural Science Foundation of China [21162007, 21402059]; Opening Project of Shanghai Key Laboratory of Chemical Biology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Opening Project of Shanghai Key Laboratory of Chemical Biology	We are grateful for financial support from the National Natural Science Foundation of China (No. 21162007, 21402059) and the Opening Project of Shanghai Key Laboratory of Chemical Biology (2015).	Ai XingMei, 2014, Journal of West China Forestry Science, V43, P29; Asoodeh A, 2012, J PEPT SCI, V18, P10, DOI 10.1002/psc.1409; Bouaziz M, 2009, FOOD CHEM TOXICOL, V47, P2755, DOI 10.1016/j.fct.2009.08.005; Budhiraja SS, 1999, J MANIP PHYSIOL THER, V22, P447, DOI 10.1016/S0161-4754(99)70033-3; Chamani J, 2006, J COLLOID INTERF SCI, V293, P52, DOI 10.1016/j.jcis.2005.06.015; Chang CC, 2002, J FOOD DRUG ANAL, V10, P178; COSGROVE D. J., 1948, BULL IMPERIAL INST [GR BRIT], V46, P46; Du B., 2014, BIOACTIVE CARBOHYDRA, V3, P11, DOI [10.1016/j.bcdf.2013.12.001, DOI 10.1016/J.BCDF.2013.12.001]; Garcia-Salas P, 2010, MOLECULES, V15, P8813, DOI 10.3390/molecules15128813; Gliwa J, 2011, J AGR FOOD CHEM, V59, P11473, DOI 10.1021/jf2023353; Gulluce M, 2007, FOOD CHEM, V103, P1449, DOI 10.1016/j.foodchem.2006.10.061; Halake K, 2016, J IND ENG CHEM, V35, P1, DOI 10.1016/j.jiec.2016.01.003; Han QX, 2003, PLANT PROTECTION, V30, P60; Hefnawy H. T. M., 2013, Asian Pacific Journal of Tropical Disease, V3, P277; Holetzi FB, 2003, ACTA PROTOZOOL, V42, P269; Hou Shuting, 2014, ACTA BOTANICA BOREALI-OCCIDENTALIA SINICA, V34, P2491, DOI 10.7606/j.issn.1000-4025.2014.12.2491; Ibrahim MM, 2015, SAUDI J BIOL SCI, V22, P168, DOI 10.1016/j.sjbs.2014.11.019; Juergens UR, 2003, RESP MED, V97, P250, DOI 10.1053/rmed.2003.1432; Kim SG, 2009, COLLOID SURFACE A, V348, P289, DOI 10.1016/j.colsurfa.2009.07.043; Kim SC, 2016, J IND ENG CHEM, V38, P93, DOI 10.1016/j.jiec.2016.04.010; Kumarappan CT, 2012, SAUDI J BIOL SCI, V19, DOI 10.1016/j.sjbs.2012.04.004; Kuppusamy S, 2016, PROCESS SAF ENVIRON, V100, P173, DOI 10.1016/j.psep.2016.01.009; Kuppusamy S, 2016, IND CROP PROD, V83, P630, DOI 10.1016/j.indcrop.2015.12.060; Lee LS, 2016, J CEREAL SCI, V68, P181, DOI 10.1016/j.jcs.2015.07.005; Lemos JD, 2005, MEM I OSWALDO CRUZ, V100, P55, DOI 10.1590/S0074-02762005000100011; [林晓红 Lin Xiaohong], 2015, [热带作物学报, Chinese Journal of Tropical Crops], V36, P991; Liu GL, 2010, J ANHUI AGR SCI, V38, P12062; Martins N, 2016, TRENDS FOOD SCI TECH, V48, P1, DOI 10.1016/j.tifs.2015.11.008; Mokrani A, 2016, SEP PURIF TECHNOL, V162, P68, DOI 10.1016/j.seppur.2016.01.043; Naczk M, 2006, J PHARMACEUT BIOMED, V41, P1523, DOI 10.1016/j.jpba.2006.04.002; Padalia RC, 2015, IND CROP PROD, V63, P264, DOI 10.1016/j.indcrop.2014.09.039; Qian ZJ, 2008, BIORESOURCE TECHNOL, V99, P1690, DOI 10.1016/j.biortech.2007.04.005; Qu FX, 2011, NO HORTICULTURE, V8, P152; Saurav K, 2012, SAUDI J BIOL SCI, V19, P81, DOI 10.1016/j.sjbs.2011.07.003; Shim JY, 2010, TOXICOL APPL PHARM, V242, P318, DOI 10.1016/j.taap.2009.11.005; Silva CJ, 2010, QUIM NOVA, V33, P104, DOI 10.1590/S0100-40422010000100019; Silva EM, 2007, SEP PURIF TECHNOL, V55, P381, DOI 10.1016/j.seppur.2007.01.008; Singh M, 2014, EUR J MED CHEM, V84, P206, DOI 10.1016/j.ejmech.2014.07.013; Sokmen M, 2004, J AGR FOOD CHEM, V52, P3309, DOI 10.1021/jf049859g; Tang JC, 2016, APPL ENERG, V169, P696, DOI 10.1016/j.apenergy.2016.02.042; Tao Yan-Yan, 2004, Zhong Xi Yi Jie He Xue Bao, V2, P145, DOI 10.3736/jcim20040223; Tchabo W, 2015, IND CROP PROD, V63, P214, DOI 10.1016/j.indcrop.2014.09.053; Wang LF, 2016, FOOD CHEM, V196, P509, DOI 10.1016/j.foodchem.2015.09.083; Wojtunik-Kulesza KA, 2016, BIOMED PHARMACOTHER, V78, P39, DOI 10.1016/j.biopha.2015.12.024; [吴丽君 Wu Lijun], 2010, [福建林学院学报, Journal of Fujian College of Forestry], V30, P314; Xu GH, 2007, J AGR FOOD CHEM, V55, P330, DOI 10.1021/jf062517l; Yang LiQiong, 2014, Guizhou Agricultural Sciences, V42, P150; [叶征美 Ye Zhengmei], 2014, [热带作物学报, Chinese Journal of Tropical Crops], V35, P992; Yoshimura M, 2008, PHYTOCHEMISTRY, V69, P3062, DOI 10.1016/j.phytochem.2008.04.004; ZHONG CY, 2009, FLAVOUR FRAGRANCE CO, V6, P8	50	27	28	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2016	11	9							e0162139	10.1371/journal.pone.0162139	http://dx.doi.org/10.1371/journal.pone.0162139			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9JE	27611576	Green Published, gold, Green Submitted			2023-01-03	WOS:000383255900047
J	McCarthy, M				McCarthy, Michael			US drug industry group launches campaign to defend pricing	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; McCarthy M, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1944; McCarthy M, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5989	3	0	0	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2016	354								i4902	10.1136/bmj.i4902	http://dx.doi.org/10.1136/bmj.i4902			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV7FM	27612867				2023-01-03	WOS:000383101800006
J	Hodson, R				Hodson, Richard			PRECISION MEDICINE	NATURE			English	Editorial Material																			0	112	114	5	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	2016	537	7619					S49	S49		10.1038/537S49a	http://dx.doi.org/10.1038/537S49a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU9LQ	27602738	Bronze			2023-01-03	WOS:000382539100057
J	Korshoj, M; Lidegaard, M; Krustrup, P; Jorgensen, MB; Sogaard, K; Holtermann, A				Korshoj, Mette; Lidegaard, Mark; Krustrup, Peter; Jorgensen, Marie Birk; Sogaard, Karen; Holtermann, Andreas			Long Term Effects on Risk Factors for Cardiovascular Disease after 12-Months of Aerobic Exercise Intervention - A Worksite RCT among Cleaners	PLOS ONE			English	Article							ALL-CAUSE MORTALITY; ISCHEMIC-HEART-DISEASE; C-REACTIVE PROTEIN; OCCUPATIONAL PHYSICAL-ACTIVITY; FEMALE HOSPITAL CLEANERS; CARDIORESPIRATORY FITNESS; ENERGY-EXPENDITURE; LEISURE-TIME; BLOOD-PRESSURE; OXYGEN-UPTAKE	Objectives Occupational groups exposed to high occupational physical activity have an increased risk for cardiovascular disease (CVD). This may be explained by the high relative aerobic workload. Enhanced cardiorespiratory fitness reduces the relative aerobic workload. Thus, the aim was to evaluate the 12-months effects of worksite aerobic exercise on risk factors for CVD among cleaners. Methods One hundred and sixteen cleaners aged 18-65 years were randomized to a group performing aerobic exercise and a reference group receiving lectures. Outcomes were collected at baseline and after 12-months. A repeated measures 2x2 multi-adjusted mixed-model design was applied to compare the between-group differences using intention-to-treat analysis. Results Between-group differences (p 0.05) were found favouring the aerobic exercise group: cardiorespiratory fitness 2.15 (SE 1.03) mlO(2)/min/kg, aerobic workload -2.15 (SE 1.06)% HRR, resting HR-5.31 (SE 1.61) beats/min, high sensitive C-reactive protein -0.65 (SE 0.24) mu g/ml. The blood pressure was unaltered. Stratified analyses on relative aerobic workload at baseline revealed that those with relative aerobic workloads >= 30% of HRR seems to impose a notable adverse effect on resting and ambulatory blood pressure. Conclusion This long-term worksite aerobic exercise intervention among cleaners led to several beneficial effects, but also potential adverse effects among those with high relative aerobic workloads.	[Korshoj, Mette; Lidegaard, Mark; Jorgensen, Marie Birk; Holtermann, Andreas] Natl Res Ctr Working Environm, Lerso Parkalle 105, DK-2100 Copenhagen O, Denmark; [Korshoj, Mette; Krustrup, Peter] Univ Copenhagen, Copenhagen Ctr Team Sport & Hlth, Dept Nutr Exercise & Sports, Norre Alle 51, DK-2200 Copenhagen N, Denmark; [Krustrup, Peter] Univ Exeter, Coll Life & Environm Sci, Sport & Hlth Sci, St. Lukes Campus, Exeter, Devon, England; [Sogaard, Karen; Holtermann, Andreas] Univ Southern Denmark, Inst Sports Sci & Clin Biomech, DK-5230 Odense M, Denmark	National Research Centre for the Working Environment; University of Copenhagen; University of Exeter; University of Southern Denmark	Korshoj, M (corresponding author), Natl Res Ctr Working Environm, Lerso Parkalle 105, DK-2100 Copenhagen O, Denmark.	mkl@nrcwe.dk	Søgaard, Karen/B-7933-2008; Krustrup, Peter/D-2659-2019	Søgaard, Karen/0000-0003-3968-6364; Krustrup, Peter/0000-0002-1461-9838; Jorgensen, Marie Birk/0000-0002-1479-2622	Danish Working Environment Research Fund [20100019624/5]	Danish Working Environment Research Fund	The study is externally funded by The Danish Working Environment Research Fund (journal number 20100019624/5).	Aadahl M, 2013, EUR J PREV CARDIOL, V20, P1088, DOI 10.1177/2047487312462825; Aladin AI, 2014, AM J CARDIOL, V114, P1701, DOI 10.1016/j.amjcard.2014.08.042; Altman DG., 2009, OPEN MED-WARSAW, V3, P51; Aspenes ST, 2011, MED SCI SPORT EXER, V43, P1465, DOI 10.1249/MSS.0b013e31820ca81c; Assah FK, 2011, INT J EPIDEMIOL, V40, P112, DOI 10.1093/ije/dyq098; Barreira T, 2009, INT J EXER SCI, V2, P60; Bartholomew LK, 1998, HEALTH EDUC BEHAV, V25, P545, DOI 10.1177/109019819802500502; Baumgart, 1998, Blood Press Monit, V3, P303; Bjorner JB, 2007, CURR MED RES OPIN, V23, P731, DOI 10.1185/030079907X178757; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Bonjer F., 1971, ENCY OCCUPATIONAL HL; Brage S, 2005, EUR J CLIN NUTR, V59, P561, DOI 10.1038/sj.ejcn.1602118; Brage S, 2004, J APPL PHYSIOL, V96, P343, DOI 10.1152/japplphysiol.00703.2003; Canoy D, 2008, CURR OPIN CARDIOL, V23, P591, DOI 10.1097/HCO.0b013e328313133a; CHRISTENSEN SL, 1993, FRESEN J ANAL CHEM, V345, P343, DOI 10.1007/BF00322627; Clays E, 2007, J OCCUP ENVIRON MED, V49, P360, DOI 10.1097/JOM.0b013e31803b94e2; Clays E, 2014, AM J EPIDEMIOL, V179, P559, DOI 10.1093/aje/kwt294; Clays E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1002; Conn VS, 2009, AM J PREV MED, V37, P330, DOI 10.1016/j.amepre.2009.06.008; Cooney MT, 2010, AM HEART J, V159, P612, DOI 10.1016/j.ahj.2009.12.029; DAVIES CTM, 1971, INT Z ANGEW PHYSIOL, V29, P299; de Koning L, 2007, EUR HEART J, V28, P850, DOI 10.1093/eurheartj/ehm026; Detry MA, 2014, JAMA-J AM MED ASSOC, V312, P85, DOI 10.1001/jama.2014.7523; Garde AH, 2000, CLIN CHEM, V46, P551; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Groeneveld IF, 2010, SCAND J WORK ENV HEA, V36, P202, DOI 10.5271/sjweh.2891; Han TS, 2006, BMJ-BRIT MED J, V333, P695, DOI 10.1136/bmj.333.7570.695; Hansen AM, 2007, INT J HYG ENVIR HEAL, V210, P471, DOI 10.1016/j.ijheh.2007.01.012; HARMA MI, 1988, ERGONOMICS, V31, P39, DOI 10.1080/00140138808966647; Holtermann A, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000556; Holtermann A, 2010, SCAND J WORK ENV HEA, V36, P357, DOI 10.5271/sjweh.2913; Holtermann A, 2009, SCAND J WORK ENV HEA, V35, P466, DOI 10.5271/sjweh.1357; Ilmarinen J, 1997, SCAND J WORK ENV HEA, V23, P49; Ingebrigtsen J, 2013, J ERGONOMICS, V3; JORGENSEN K, 1985, ERGONOMICS, V28, P365, DOI 10.1080/00140138508963145; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Karlqvist L, 2003, EUR J APPL PHYSIOL, V89, P536, DOI 10.1007/s00421-003-0832-4; KARVONEN MJ, 1957, ANN MED EXP BIOL FEN, V35, P307; Kasapis C, 2005, J AM COLL CARDIOL, V45, P1563, DOI 10.1016/j.jacc.2004.12.077; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Korshoj M, 2015, DOES AEROBIC E UNPUB; Korshoj M, 2015, INT ARCH OCCUP ENV H; Korshoj M, 2015, SCAND J WORK ENV HEA, V41, P140, DOI 10.5271/sjweh.3475; Korshoj M, 2013, ERGONOMICS, V56, P935, DOI 10.1080/00140139.2013.782427; Korshoj M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-645; Krause N, 2010, SCAND J WORK ENV HEA, P1; Krause N, 2007, SCAND J WORK ENV HEA, V33, P405, DOI 10.5271/sjweh.1171; Krause N, 2015, SCAND J WORK ENV HEA, V41, P124, DOI 10.5271/sjweh.3476; Kristiansen J., 2011, BIOMEDICAL ENG ONLIN, P10; Kruger D., 1997, RISK ASSESSMENT PREV; Li J, 2013, CURR OPIN CARDIOL, V28, P575, DOI 10.1097/HCO.0b013e328364289c; Loprinzi P, 2013, SCAND J MED SCI SPOR, V23, P164, DOI 10.1111/j.1600-0838.2011.01356.x; Louhevaara V, 1999, OCCUPATIONAL ERGONOM, P261; Nauman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045021; O'Brien E, 2001, BMJ-BRIT MED J, V322, P531, DOI 10.1136/bmj.322.7285.531; Okita K, 2004, ARTERIOSCL THROM VAS, V24, P1868, DOI 10.1161/01.ATV.0000140199.14930.32; Plaisance EP, 2006, SPORTS MED, V36, P443, DOI 10.2165/00007256-200636050-00006; Pohjonen T, 2001, PREV MED, V32, P465, DOI 10.1006/pmed.2001.0837; Proper KI, 2003, CLIN J SPORT MED, V13, P106, DOI 10.1097/00042752-200303000-00008; SALTIN B, 1968, CIRCULATION, V38, P1104, DOI 10.1161/01.CIR.38.6.1104; Shimaoka M, 1998, EUR J APPL PHYSIOL O, V77, P10; Sjogren B, 2003, INT J OCCUP ENV HEAL, V9, P134; Skotte J, 2014, J PHYS ACT HEALTH, V11, P76, DOI 10.1123/jpah.2011-0347; Sogaard K, 1996, EUR J APPL PHYSIOL, V73, P73, DOI 10.1007/BF00262812; Sogaard K, 2006, ANTIPODE, V38, P579, DOI 10.1111/j.0066-4812.2006.00596.x; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8; Twisk J, 2013, J CLIN EPIDEMIOL, V66, P1022, DOI 10.1016/j.jclinepi.2013.03.017; Unge J, 2007, INT ARCH OCC ENV HEA, V81, P209, DOI 10.1007/s00420-007-0208-x; WESTGARD JO, 1981, CLIN CHEM, V27, P493; White IR, 2012, CLIN TRIALS, V9, P396, DOI 10.1177/1740774512450098; Wu HC, 2002, ERGONOMICS, V45, P280, DOI 10.1080/00140130210123499; Zoller B, 2012, THROMB RES, V129, P577, DOI 10.1016/j.thromres.2011.07.050	73	11	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2016	11	8							e0158547	10.1371/journal.pone.0158547	http://dx.doi.org/10.1371/journal.pone.0158547			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT3KY	27513932	gold, Green Published, Green Submitted			2023-01-03	WOS:000381381100007
J	Rugo, HS; Olopade, OI; DeMichele, A; Yau, C; van 't Veer, LJ; Buxton, MB; Hogarth, M; Hylton, NM; Paoloni, M; Perlmutter, J; Symmans, WF; Yee, D; Chien, AJ; Wallace, AM; Kaplan, HG; Boughey, JC; Haddad, TC; Albain, KS; Liu, MC; Isaacs, C; Khan, QJ; Lang, JE; Viscusi, RK; Pusztai, L; Moulder, SL; Chui, SY; Kemmer, KA; Elias, AD; Edmiston, KK; Euhus, DM; Haley, BB; Nanda, R; Northfelt, DW; Tripathy, D; Wood, WC; Ewing, C; Schwab, R; Lyandres, J; Davis, SE; Hirst, GL; Sanil, A; Berry, DA; Esserman, LJ				Rugo, H. S.; Olopade, O. I.; DeMichele, A.; Yau, C.; van 't Veer, L. J.; Buxton, M. B.; Hogarth, M.; Hylton, N. M.; Paoloni, M.; Perlmutter, J.; Symmans, W. F.; Yee, D.; Chien, A. J.; Wallace, A. M.; Kaplan, H. G.; Boughey, J. C.; Haddad, T. C.; Albain, K. S.; Liu, M. C.; Isaacs, C.; Khan, Q. J.; Lang, J. E.; Viscusi, R. K.; Pusztai, L.; Moulder, S. L.; Chui, S. Y.; Kemmer, K. A.; Elias, A. D.; Edmiston, K. K.; Euhus, D. M.; Haley, B. B.; Nanda, R.; Northfelt, D. W.; Tripathy, D.; Wood, W. C.; Ewing, C.; Schwab, R.; Lyandres, J.; Davis, S. E.; Hirst, G. L.; Sanil, A.; Berry, D. A.; Esserman, L. J.		I-SPY 2 Investigators	Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; TRIALS; MODEL	BACKGROUND The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer. The goal is to match experimental regimens with responding cancer subtypes. We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin. METHODS In this ongoing trial, women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter; cancers are categorized into eight biomarker subtypes on the basis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone receptors, and a 70-gene assay. Patients undergo adaptive randomization within each biomarker subtype to receive regimens that have better performance than the standard therapy. Regimens are evaluated within 10 biomarker signatures (i.e., prospectively defined combinations of biomarker subtypes). Veliparib-carboplatin plus standard therapy was considered for HER2-negative tumors and was therefore evaluated in 3 signatures. The primary end point is pathological complete response. Tumor volume changes measured by magnetic resonance imaging during treatment are used to predict whether a patient will have a pathological complete response. Regimens move on from phase 2 if and when they have a high Bayesian predictive probability of success in a subsequent phase 3 neoadjuvant trial within the biomarker signature in which they performed well. RESULTS With regard to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success in a phase 3 trial. A total of 72 patients were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned to receive control therapy; at the completion of chemotherapy, the estimated rates of pathological complete response in the triple-negative population were 51% (95% Bayesian probability interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the control group. The toxicity of veliparib-carboplatin was greater than that of the control. CONCLUSIONS The process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer.	[Rugo, H. S.; Yau, C.; van 't Veer, L. J.; Buxton, M. B.; Hylton, N. M.; Chien, A. J.; Ewing, C.; Lyandres, J.; Davis, S. E.; Hirst, G. L.; Esserman, L. J.] Univ Calif San Francisco, San Francisco, CA 94115 USA; [Paoloni, M.] QuantumLeap Healthcare Collaborat, San Francisco, CA USA; [Yau, C.] Buck Inst Res & Aging, Novato, CA USA; [Hogarth, M.] Univ Calif Davis, Davis, CA 95616 USA; [Wallace, A. M.; Schwab, R.] Univ Calif San Diego, San Diego, CA 92103 USA; [Tripathy, D.] Univ So Calif, Los Angeles, CA USA; [Olopade, O. I.; Nanda, R.] Univ Chicago, Chicago, IL 60637 USA; [Albain, K. S.] Loyola Univ, Chicago, IL 60611 USA; [DeMichele, A.] Univ Penn, Philadelphia, PA 19104 USA; [Perlmutter, J.] Gemini Grp, Ann Arbor, MI USA; [Symmans, W. F.; Pusztai, L.; Moulder, S. L.; Berry, D. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Euhus, D. M.; Haley, B. B.] UT Southwestern Med Ctr, Dallas, TX USA; [Sanil, A.; Berry, D. A.] Berry Consultants, Austin, TX USA; [Yee, D.] Univ Minnesota, Minneapolis, MN USA; [Boughey, J. C.; Haddad, T. C.] Mayo Clin, Rochester, MN USA; [Kaplan, H. G.] Swedish Med Ctr, Seattle, WA USA; [Liu, M. C.; Isaacs, C.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA; [Khan, Q. J.] Univ Kansas, Lawrence, KS 66045 USA; [Lang, J. E.; Viscusi, R. K.] Univ Arizona, Tucson, AZ USA; [Northfelt, D. W.] Mayo Clin, Scottsdale, AZ USA; [Chui, S. Y.; Kemmer, K. A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Elias, A. D.] Univ Denver, Denver, CO USA; [Edmiston, K. K.] Inova Fairfax Hosp, Falls Church, VA USA; [Wood, W. C.] Emory Univ, Atlanta, GA 30322 USA	University of California System; University of California San Francisco; Buck Institute for Research on Aging; University of California System; University of California Davis; University of California System; University of California San Diego; University of Southern California; University of Chicago; Loyola University Chicago; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Swedish Medical Center; University of Kansas; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; Oregon Health & Science University; University of Denver; Inova Fairfax Hospital; Emory University	Esserman, LJ (corresponding author), Univ Calif San Francisco, UCSF Carol Franc Buck Breast Care Ctr, 1600 Div St,Box 1710, San Francisco, CA 94115 USA.	laura.esserman@ucsf.edu	Pusztai, Lajos/AAB-2901-2019; kaplan, henry/ABI-4845-2020; Lang, Julie Eileen/J-9764-2019; Hylton, Nola/AAF-7861-2019	Lang, Julie Eileen/0000-0002-7534-6124; Lynce, Filipa/0000-0001-6615-7076; McDonald, Elizabeth/0000-0002-7209-4216; Hirst, Gillian/0000-0002-4502-0035; Hui, Jane Yuet Ching/0000-0002-2628-0720; Yee, Douglas/0000-0002-3387-4009; Diamond, Jennifer/0000-0002-0703-2772	QuantumLeap Healthcare Collaborative; NATIONAL CANCER INSTITUTE [P30CA023100, P30CA016672] Funding Source: NIH RePORTER	QuantumLeap Healthcare Collaborative; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.	Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68; Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927; Berry DA, 2015, MOL ONCOL, V9, P951, DOI 10.1016/j.molonc.2015.02.011; Berry DA, 2012, NAT REV CLIN ONCOL, V9, P199, DOI 10.1038/nrclinonc.2011.165; Cortazar P, 2019, LANCET, V393, P986; Cortazar P, 2015, ANN SURG ONCOL, V22, P1441, DOI 10.1245/s10434-015-4404-8; DeMichele A, 2015, CLIN CANCER RES, V21, P2911, DOI 10.1158/1078-0432.CCR-14-1760; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Glas AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-278; Gradishar WJ, 2015, J NATL COMPR CANC NE, V13, P1475, DOI 10.6004/jnccn.2015.0176; Park JW, 2016, NEW ENGL J MED, V375, P11, DOI 10.1056/NEJMoa1513750; Prowell TM, 2012, NEW ENGL J MED, V366, P2438, DOI 10.1056/NEJMp1205737; Roepman P, 2009, CLIN CANCER RES, V15, P7003, DOI 10.1158/1078-0432.CCR-09-0449; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Viale G, 2014, ANN ONCOL, V25, P816, DOI 10.1093/annonc/mdu026; von Minckwitz G, 2014, LANCET ONCOL, V15, P747, DOI 10.1016/S1470-2045(14)70160-3; Wolff D, 2014, CANC RES S, V73; Yee D, 2012, J CLIN ONCOL, V30, P4584, DOI 10.1200/JCO.2012.44.1022	20	362	377	4	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2016	375	1					23	34		10.1056/NEJMoa1513749	http://dx.doi.org/10.1056/NEJMoa1513749			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ1ZP	27406347	Green Accepted, Bronze			2023-01-03	WOS:000379000200002
J	Banga, R; Procopio, FA; Noto, A; Pollakis, G; Cavassini, M; Ohmiti, K; Corpataux, JM; de Leval, L; Pantaleo, G; Perreau, M				Banga, Riddhima; Procopio, Francesco Andrea; Noto, Alessandra; Pollakis, Georgios; Cavassini, Matthias; Ohmiti, Khalid; Corpataux, Jean-Marc; de Leval, Laurence; Pantaleo, Giuseppe; Perreau, Matthieu			PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals	NATURE MEDICINE			English	Article							CXC CHEMOKINE RECEPTOR-5; LATENT RESERVOIR; STEM-CELL; REPLICATION	The mechanisms responsible for the persistence of HIV-1 after many years of suppressive antiretroviral therapy (ART) have been only partially elucidated. Most of the studies investigating HIV-1 persistence have been performed with blood, although it is well known that germinal centers (GCs) within lymph nodes (LNs) serve as primary sites for HIV-1 replication. We sought to identify the memory CD4 T cell populations in blood and LNs that are responsible for the production of replication-competent and infectious HIV-1, as well as for active and persistent virus transcription in ART-treated (for 1.5-14.0 years), aviremic (<50 HIV RNA copies/ml) HIV-infected individuals. We demonstrate that LN CD4 T cells that express programmed cell death 1 (PDCD1; also known as PD-1), which are composed of about 65% T follicular helper cells as defined by the expression of the cell surface receptors CXCR5 and PD-1, are the major source of replication-competent HIV-1 and of infectious virus, as compared to any other (CXCR5-PD-1- and CXCR5(+)PD-1(-)) blood or LN memory CD4 T cell populations. LN PD-1(+) cells accounted for 46% and 96% of the total pools of memory CD4 T cells containing inducible replication-competent or infectious virus, respectively. Notably, higher levels of cell-associated HIV-1 RNA were present in LN PD-1(+) cells after long-term (up to 12 years) ART than in other memory CD4 T cell subpopulations. These results indicate that LN PD-1(+) cells are the major CD4 T cell compartment in the blood and LNs for the production of replication-competent and infectious HIV-1, and for active and persistent virus transcription in long-term-ART-treated aviremic individuals. Thus, these cells may represent a major obstacle to finding a functional cure for HIV-1 infection.	[Banga, Riddhima; Procopio, Francesco Andrea; Noto, Alessandra; Ohmiti, Khalid; Pantaleo, Giuseppe; Perreau, Matthieu] Univ Lausanne, Univ Lausanne Hosp, Serv Immunol & Allergy, Lausanne, Switzerland; [Pollakis, Georgios] Univ Liverpool, Inst Infect & Global Hlth IGH, Dept Clin Infect Microbiol & Immunol CIMI, Liverpool, Merseyside, England; [Cavassini, Matthias] Univ Lausanne, Univ Lausanne Hosp, Infect Dis Serv, Lausanne, Switzerland; [Corpataux, Jean-Marc] Univ Lausanne, Univ Lausanne Hosp, Serv Vasc Surg, Lausanne, Switzerland; [de Leval, Laurence] Univ Lausanne, Univ Lausanne Hosp, Inst Pathol, Lausanne, Switzerland; [Pantaleo, Giuseppe] Univ Lausanne, Univ Lausanne Hosp, Swiss Vaccine Res Inst, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Liverpool; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Pantaleo, G; Perreau, M (corresponding author), Univ Lausanne, Univ Lausanne Hosp, Serv Immunol & Allergy, Lausanne, Switzerland.; Pantaleo, G (corresponding author), Univ Lausanne, Univ Lausanne Hosp, Swiss Vaccine Res Inst, Lausanne, Switzerland.	giuseppe.pantaleo@chuv.ch; matthieu.perreau@chuv.ch	Perreau, Matthieu/D-6309-2017; Georgios, Pollakis/Y-2341-2019; Pantaleo, Giuseppe/K-6163-2016; de Leval, Laurence/M-4889-2017; Procopio, Francesco/ABD-8065-2021; cavassini, matthias/F-8987-2017	de Leval, Laurence/0000-0003-3994-516X; Pollakis, Georgios/0000-0002-9659-5461; cavassini, matthias/0000-0003-0933-7833	Bristol-Myers Squibb	Bristol-Myers Squibb(Bristol-Myers Squibb)	We are grateful to N. Grandchamp, P. Pochon, X. Bron, M: Graff, A. Cretignier, R. Mamin, F. Bellanger, L. Leuenberger and C. Andre for technical assistance, and to D. Alves and the study manager N. Rettby. This work was funded by an educational grant from Bristol-Myers Squibb (M.P.).	Altman DG, 1991, PRACTICAL STAT MED R; Banga R, 2016, J VIROL, V90, P1858, DOI 10.1128/JVI.02359-15; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Bullen CK, 2014, NAT MED, V20, P425, DOI 10.1038/nm.3489; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Casazza J.P.I., 2015, C RETR OPP INF SEATT, V49; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111; Fukazawa Y, 2015, NAT MED, V21, P132, DOI 10.1038/nm.3781; Ganusov VV, 2007, TRENDS IMMUNOL, V28, P514, DOI 10.1016/j.it.2007.08.009; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Lorenzo-Redondo R, 2016, NATURE, V530, P51, DOI 10.1038/nature16933; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Procopio FA, 2015, EBIOMEDICINE, V2, P874, DOI 10.1016/j.ebiom.2015.06.019; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sobolewski M.C.A., 2013, C RETR OPP INF ATL I, V174LB; Vandergeeten C, 2014, J VIROL, V88, P12385, DOI 10.1128/JVI.00609-14; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	25	300	309	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2016	22	7					754	761		10.1038/nm.4113	http://dx.doi.org/10.1038/nm.4113			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DQ7DK	27239760				2023-01-03	WOS:000379366900014
J	Young, KH; Baird, JR; Savage, T; Cottam, B; Friedman, D; Bambina, S; Messenheimer, DJ; Fox, B; Newell, P; Bahjat, KS; Gough, MJ; Crittenden, MR				Young, Kristina H.; Baird, Jason R.; Savage, Talicia; Cottam, Benjamin; Friedman, David; Bambina, Shelly; Messenheimer, David J.; Fox, Bernard; Newell, Pippa; Bahjat, Keith S.; Gough, Michael J.; Crittenden, Marka R.			Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy	PLOS ONE			English	Article							ANTITUMOR IMMUNITY; LOCAL RADIATION; BREAST-CANCER; MOUSE MODEL; RADIOTHERAPY; OX40; INFILTRATION; EXPRESSION; METASTASES; ANTIBODIES	The anecdotal reports of promising results seen with immunotherapy and radiation in advanced malignancies have prompted several trials combining immunotherapy and radiation. However, the ideal timing of immunotherapy with radiation has not been clarified. Tumor bearing mice were treated with 20Gy radiation delivered only to the tumor combined with either anti-CTLA4 antibody or anti-OX40 agonist antibody. Immunotherapy was delivered at a single timepoint around radiation. Surprisingly, the optimal timing of these therapies varied. Anti-CTLA4 was most effective when given prior to radiation therapy, in part due to regulatory T cell depletion. Administration of anti-OX40 agonist antibody was optimal when delivered one day following radiation during the post-radiation window of increased antigen presentation. Combination treatment of anti-CTLA4, radiation, and anti-OX40 using the ideal timing in a transplanted spontaneous mammary tumor model demonstrated tumor cures. These data demonstrate that the combination of immunotherapy and radiation results in improved therapeutic efficacy, and that the ideal timing of administration with radiation is dependent on the mechanism of action of the immunotherapy utilized.	[Young, Kristina H.; Baird, Jason R.; Savage, Talicia; Cottam, Benjamin; Friedman, David; Bambina, Shelly; Messenheimer, David J.; Fox, Bernard; Bahjat, Keith S.; Gough, Michael J.; Crittenden, Marka R.] Providence Portland Med Ctr, Robert W Franz Canc Ctr, Earle A Chiles Res Inst, 4805 NE Glisan St, Portland, OR 97213 USA; [Young, Kristina H.; Newell, Pippa; Crittenden, Marka R.] Oregon Clin, Portland, OR 97213 USA; [Newell, Pippa] Providence Portland Med Ctr, Providence Hepatobiliary & Pancreat Canc Program, 4805 NE Glisan St, Portland, OR 97213 USA	Providence Portland Medical Center; Providence Portland Medical Center	Young, KH (corresponding author), Providence Portland Med Ctr, Robert W Franz Canc Ctr, Earle A Chiles Res Inst, 4805 NE Glisan St, Portland, OR 97213 USA.; Young, KH (corresponding author), Oregon Clin, Portland, OR 97213 USA.	kristina.young@providence.org	Gough, Michael/AAY-3419-2020	Gough, Michael/0000-0002-5575-0074; Friedman, David/0000-0002-1295-1562; Young, Kristina/0000-0002-3363-0063	RSNA Research and Education Foundation; NIH [HHSN272201300006C]; RSNA RE Foundation; NATIONAL CANCER INSTITUTE [R01CA182311] Funding Source: NIH RePORTER	RSNA Research and Education Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RSNA RE Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	KHY received an RSNA Research and Education Foundation Research Resident Grant.; We acknowledge the NIH Tetramer Core Facility (contract HHSN272201300006C) for provision of MHC tetramers. This study was funded, in part, by an RSNA R&E Foundation Research Resident Grant to KHY.	Barker CA, 2013, CANCER IMMUNOL RES, V1, P92, DOI 10.1158/2326-6066.CIR-13-0082; Belcaid Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101764; Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762; BRATTAIN MG, 1980, CANCER RES, V40, P2142; Crittenden MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069527; Crittenden MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039295; Curti BD, 2013, CANCER RES, V73, P7189, DOI 10.1158/0008-5472.CAN-12-4174; Demaria S, 2005, CLIN CANCER RES, V11, P728; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265; Evans DE, 2001, J IMMUNOL, V167, P6804, DOI 10.4049/jimmunol.167.12.6804; Filatenkov A, 2015, CLIN CANCER RES, V21, P3727, DOI 10.1158/1078-0432.CCR-14-2824; Gough MJ, 2008, CANCER RES, V68, P5206, DOI 10.1158/0008-5472.CAN-07-6484; Gough MJ, 2012, IMMUNOTHERAPY-UK, V4, P125, DOI [10.2217/IMT.11.157, 10.2217/imt.11.157]; Gough MJ, 2010, J IMMUNOTHER, V33, P798, DOI 10.1097/CJI.0b013e3181ee7095; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hiniker SM, 2012, TRANSL ONCOL, V5, P404, DOI 10.1593/tlo.12280; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang RR, 2011, CLIN CANCER RES, V17, P4101, DOI 10.1158/1078-0432.CCR-11-0407; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Pilones KA, 2009, CLIN CANCER RES, V15, P597, DOI 10.1158/1078-0432.CCR-08-1277; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Redmond WL, 2014, CANCER IMMUNOL RES, V2, P142, DOI 10.1158/2326-6066.CIR-13-0031-T; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Seung SK, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003649; Sharabi AB, 2015, CANCER IMMUNOL RES, V3, P345, DOI 10.1158/2326-6066.CIR-14-0196; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Stein WD, 2011, CLIN CANCER RES, V17, P907, DOI 10.1158/1078-0432.CCR-10-1762; Thibault I, 2014, J NEUROSURG-SPINE, V21, P711, DOI 10.3171/2014.7.SPINE13895; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Videtic GMM, 2014, INT J RADIAT ONCOL, V90, P203, DOI 10.1016/j.ijrobp.2014.05.017; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Yokouchi H, 2008, CANCER SCI, V99, P361, DOI 10.1111/j.1349-7006.2007.00664.x; Young KH, 2014, CANCER IMMUNOL RES, V2, P1011, DOI 10.1158/2326-6066.CIR-13-0207; Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	39	177	183	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0157164	10.1371/journal.pone.0157164	http://dx.doi.org/10.1371/journal.pone.0157164			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TW	27281029	Green Submitted, gold, Green Published			2023-01-03	WOS:000377563000100
J	FitzGerald, JM; Bleecker, ER; Nair, P; Korn, S; Ohta, K; Lommatzsch, M; Ferguson, GT; Busse, WW; Barker, P; Sproule, S; Gilmartin, G; Werkstrom, V; Aurivillius, M; Goldman, M				FitzGerald, J. Mark; Bleecker, Eugene R.; Nair, Parameswaran; Korn, Stephanie; Ohta, Ken; Lommatzsch, Marek; Ferguson, Gary T.; Busse, William W.; Barker, Peter; Sproule, Stephanie; Gilmartin, Geoffrey; Werkstrom, Viktoria; Aurivillius, Magnus; Goldman, Mitchell		CALIMA Study Investigators	Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial	LANCET			English	Article							CELL-MEDIATED CYTOTOXICITY; PERSISTENT ASTHMA; MEPOLIZUMAB; SAFETY; QUESTIONNAIRE; PREVALENCE; MEDI-563; EFFICACY; ADULTS; DREAM	Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor a monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts. Methods In this randomised, double-blind, parallel-group, placebo-controlled, phase 3 study (CALIMA) undertaken at 303 sites in 11 countries, we enrolled patients aged 12-75 years with severe asthma uncontrolled by medium dosage to high-dosage inhaled corticosteroids plus long-acting 132-agonists (ICS plus LABA) and a history of two or more exacerbations in the previous year. Patients were randomly assigned (1:1:1) to receive 56 weeks of benralizumab 30 mg every 4 weeks (Q4W), benralizumab 30 mg every 8 weeks (Q8W; first three doses 4 weeks apart), or placebo (all subcutaneous injection). Patients were stratified (2:1) by baseline blood eosinophil counts 300 cells per pL or greater and less than 300 cells per pL, respectively. Patients and study centre staff were masked to treatment allocation. The primary endpoint was annual exacerbation rate ratio versus placebo for patients receiving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per pL or greater (intention-to-treat analysis). Key secondary endpoints were pre-bronchodilator forced expiratory volume in 1 s (FEV1) and total asthma symptom score. This study is registered with ClinicalTrials.gov, number NCT01914757. Findings Between Aug 21, 2013, and March 16, 2015, 2505 patients were enrolled, of whom 1306 patients were randomised; 425 patients were randomly assigned to and received benralizumab 30 mg Q4W, 441 to benralizumab 30 mg Q8W, and 440 to placebo. 728 patients were included in the primary analysis population. Benralizumab resulted in significantly lower annual exacerbation rates with the Q4W regimen (rate 0.60 [95% CI 0.48-0.74], rate ratio 0.64 [95% CI 0.49-0.85], p=0.0018, n=241) and Q8W regimen (rate 0.66 [95% CI 0.54-0.82], rate ratio 0.72 [95% CI 0.54-0.95], p=0.0188, n=239) compared with placebo (rate 0.93 [95% CI 0.77-1.12], n=248). Benralizumab also significantly improved pre-bronchodilator FEV, (Q4W and Q8W) and total asthma symptom score (Q8W only) in these patients. The most common adverse events were nasopharyngitis (90 [21%] in the Q4W group, 79 [18%] in the Q8W group, and 92 [21%] in the placebo group) and worsening asthma (61 [14%] in the Q4W group, 47 [11%] in the Q8W group, and 68 [15%] in the group). Interpretation Benralizumab significantly reduced annual exacerbation rates and was generally well tolerated for patients with severe, uncontrolled asthma with blood eosinophils 300 cells per pL or greater. Our data further refine the patient population likely to receive the greatest benefit from benralizumab treatment.	[FitzGerald, J. Mark] Vancouver Gen Hosp, UBC Inst Heart & Lung Hlth, Lung Ctr, Vancouver, BC, Canada; [Bleecker, Eugene R.] Wake Forest Sch Medcine Winston, Winston Salem, NC USA; [Nair, Parameswaran] McMaster Univ, Hamilton, ON, Canada; [Nair, Parameswaran] St Josephs Healthcare, Hamilton, ON, Canada; [Korn, Stephanie] Univ Med Mainz, Mainz, Germany; [Ohta, Ken] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan; [Lommatzsch, Marek] Univ Klinikum Rostock, Rostock, Germany; [Ferguson, Gary T.] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Barker, Peter; Sproule, Stephanie; Goldman, Mitchell] AstraZeneca, Gaithersburg, MD USA; [Gilmartin, Geoffrey] AstraZeneca, Cambridge, MA USA; [Werkstrom, Viktoria; Aurivillius, Magnus] AstraZeneca, Molndal, Sweden	University of British Columbia; McMaster University; Johannes Gutenberg University of Mainz; University of Rostock; University of Wisconsin System; University of Wisconsin Madison; AstraZeneca; AstraZeneca; AstraZeneca	FitzGerald, JM (corresponding author), Vancouver Gen Hosp, Gordon & Leslie Diamond Hlth Care Ctr, Lung Ctr, Vancouver, BC V5Z 1M9, Canada.	mark.fitzgerald@vch.ca			AstraZeneca; Kyowa Hakko Kirin	AstraZeneca(AstraZeneca); Kyowa Hakko Kirin(Kyowa Kirin Ltd)	AstraZeneca and Kyowa Hakko Kirin.	Bleecker ER, 2016, LANCET; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Ghazi A, 2012, EXPERT OPIN BIOL TH, V12, P113, DOI 10.1517/14712598.2012.642359; GlaxoSmithKline LLC, 2015, NUC MEP; Global Initiative For Asthma, 2016, GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper Elizabeth F, 2005, Health Qual Life Outcomes, V3, P58, DOI 10.1186/1477-7525-3-58; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Parameswaran K, 2006, CAN RESPIR J, V13, P129; Pavord ID, 2010, THORAX, V65, P370, DOI 10.1136/thx.2009.122697; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peters SP, 2006, RESP MED, V100, P1139, DOI 10.1016/j.rmed.2006.03.031; Rudulier CD, 2016, ALLERGY, V71, P283, DOI 10.1111/all.12816; Talini D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-005748; Tan LD, 2016, J ASTHMA ALLERGY, V9, P71, DOI 10.2147/JAA.S78049; Teva Respiratory LLC, 2016, CINQ RESL; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Wang B, 2014, AM J RESP CRIT CARE, V189; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5	30	752	779	3	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 29	2016	388	10056					2128	2141		10.1016/s0140-6736(16)31322-8	http://dx.doi.org/10.1016/s0140-6736(16)31322-8			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA1DJ	27609406				2023-01-03	WOS:000386332400034
J	Stacey, AF; Gill, TK; Price, K; Warmington, R; Taylor, AW				Stacey, Anne F.; Gill, Tiffany K.; Price, Kay; Warmington, Rosemary; Taylor, Anne W.			Unpaid Informal Caregivers in South Australia: Population Characteristics, Prevalence and Age-Period-Cohort Effects 1994-2014	PLOS ONE			English	Article							CARE; HEALTH	Background The ongoing need for an availability of informal carers is taking on greater relevance as the global burden of disease transitions from acute fatal diseases to long termmorbidity. Growing evidence suggests that extra burden on family carers may further impact on their health and ability to provide care. Importantas it is to monitor the prevalence of those conditions which influence the burden of disease, it is also important to monitor the prevalence and health profiles of those who provide the informal care. The aim of this study was to demonstrate the prevalence and demographics of adult carers aged 15 and over in the state of South Australia over 20 years between 1994 and 2014. Methods Data from nine representative, cross-sectional population surveys, conducted in South Australia, Australia were used, (total N = 26,788 and n = 1,504 carers). The adjusted prevalence estimate of carers and their demographic characteristics were determined. So as to examine whether there were any generational effects on the prevalence of carers, an Age-Period Cohort (APC) analysis was undertaken. Results The prevalence estimates of carers increased during the two decades from 3.7% in 1994 to 6.7% by 2014. Large increases in the proportion of retired carers, those aged 70 years and over, those carers employed, and those with higher educational qualifications were observed. There were also larger proportions of respondents with a country of birth other than Australia, UK, Ireland and European counties. The APC analysis illustrated an increasing prevalence rate over each decade for carers aged 20-80 years, especially for those over the age of 60 years. Conclusions The results illustrate changing carer characteristics and carer prevalence estimates in South Australia as new generations of carers take on the caring role. There is a need to include questions regarding informal carers within ongoing mainstream population surveys, particularly at state levels, so as to plan for their future health care and home support.	[Stacey, Anne F.; Gill, Tiffany K.; Taylor, Anne W.] Univ Adelaide, Discipline Med, Populat Res & Outcome Studies, Adelaide, SA, Australia; [Price, Kay] Univ South Australia, Sch Nursing & Midwifery, Adelaide, SA, Australia; [Warmington, Rosemary] Carers SA, Adelaide, SA, Australia	University of Adelaide; Flinders University South Australia; University of South Australia	Stacey, AF (corresponding author), Univ Adelaide, Discipline Med, Populat Res & Outcome Studies, Adelaide, SA, Australia.	anne.stacey@adelaide.edu.au	Gill, Tiffany/F-9042-2010; Taylor, Anne w/F-5708-2010	Gill, Tiffany/0000-0002-2822-2436; Taylor, Anne w/0000-0002-4422-7974	Carers SA	Carers SA	Funding was received from Carers SA. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIHW, 2000, DIS AG AUSTR POP PAT; Anderson LA, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.130090; [Anonymous], 2015, EC VAL INF CAR AUSTR; Australian Bureau of Statistics, 2018, DISABILITY AGEING CA; Australian Bureau of Statistics, 2011, SOCIO EC INDEXES ARE; Australian Bureau of Statistics (ABS), 2012, DIS AG CAR AUSTR SUM; Australian Bureau of Statistics (ABS), 2015, AUSTR DEM STAT COUNT; Australian Institute of Health and Welfare, 2018, CDK16 AUSTR I HLTH W; Australian Institute of Health and Welfare, 2015, AUSTR BURD DIS STUD, V1; Australian Institute of Health and Welfare (AIHW), 2015, AUSTR WELF 2015 BRIE; Australian Institute of Health and Welfare (AIHW). Australia's Health, 2014, LEAD TYP ILL HLTH; Berglund E, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0309-2; Bloch B. S, 1998, INT TECHNICAL C ENHA; Borowski A, 1997, AGEING SOCIAL POLICY, P37; Brehaut JC, 2009, AM J PUBLIC HEALTH, V99, P1254, DOI 10.2105/AJPH.2007.129817; Bruhn JG, 2014, CLIN SOCIOL RES PRAC, P1, DOI 10.1007/978-94-017-8857-1; Bryant L, 2013, AGEING SOC, V33, P1401, DOI 10.1017/S0144686X12000657; Carers V, 2015, RISING VALUE CARERS; Colombo F, 2011, OECD HLTH POLICY STU, DOI [10.1787/9789264097759-en+-, DOI 10.1757/9789264097759-44+-]; Day C, 2015, J YOUTH STUD, V18, P855, DOI 10.1080/13676261.2014.1001826; Farfan-Portet MI, 2010, EUR J PUBLIC HEALTH, V20, P52, DOI 10.1093/eurpub/ckp045; Grady PA, 2014, NURS OUTLOOK, V62, P362, DOI 10.1016/j.outlook.2014.05.007; Hastrup LH, 2011, SCAND J PUBLIC HEALT, V39, P598, DOI 10.1177/1403494811414247; Hirst M, 2005, SOC SCI MED, V61, P697, DOI 10.1016/j.socscimed.2005.01.001; Hirst M, 2002, J EPIDEMIOL COMMUN H, V56, P579, DOI 10.1136/jech.56.8.579; Hosseinpoor AR, 2013, AGE AGEING, V42, P330, DOI 10.1093/ageing/afs196; Hsu HC, 2001, GERONTOLOGIST, V41, P742, DOI 10.1093/geront/41.6.742; Hugo G., 2014, DEMOGRAPHIC FACTS AG; Hugo G, 2009, OLDER CARERS CARERS, P233; Jenkins A., 2003, FUTURE SUPPLY INFORM; Jowsey T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-374; Kaambwa B, 2015, SOC SCI MED, V140, P81, DOI 10.1016/j.socscimed.2015.06.034; Knight BG, 2010, J GERONTOL B-PSYCHOL, V65, P5, DOI 10.1093/geronb/gbp096; Levine C, 2005, AM J PUBLIC HEALTH, V95, P2071, DOI 10.2105/AJPH.2005.067702; Lin SF, 2012, AM J PUBLIC HEALTH, V102, P2157, DOI 10.2105/AJPH.2011.300602; Lutomski JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081673; Park HJ, 2015, J AGING SOC POLICY, V27, P280, DOI 10.1080/08959420.2015.1024536; Prince M, 2007, AM J PUBLIC HEALTH, V97, P224; Public Policy Institute, 2015, RES REPORT; Reinhard S., 2012, HOME ALONE FAMILY CA; Reither EN, 2009, SOC SCI MED, V69, P1439, DOI 10.1016/j.socscimed.2009.08.040; Rutherford MJ, 2010, STATA J, V10, P606, DOI 10.1177/1536867X1101000405; SA Health Health Omnibus Survey, 2002, METH BRIEF REP S AUS; Schofield D, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-561; Sinha M, 2012, SPOTLIGHT CANADIANS; Talley RC, 2007, AM J PUBLIC HEALTH, V97, P393, DOI 10.2105/AJPH.2004.059337; Taylor AW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125233; Trivedi R, 2014, CHRONIC ILLN, V10, P167, DOI 10.1177/1742395313506947; Turcotte M, FAMILY CAREGIVING WH; Twigg Julia, 1996, CARERS PERCEIVED POL; van den Berg B, 2014, J HEALTH ECON, V35, P123, DOI 10.1016/j.jhealeco.2014.01.008; Viana MC, 2013, REV BRAS PSIQUIATR, V35, P115, DOI 10.1590/1516-4446-2012-0919; Yeandle S, 2007, 2 CES CAR UK	53	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2016	11	9							e0161994	10.1371/journal.pone.0161994	http://dx.doi.org/10.1371/journal.pone.0161994			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DW8GE	27649074	gold, Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000383892100010
J	Luo, XT; Zhang, JF; Castelberg, R; Wu, T; Yu, PM; He, CQ; Wang, P				Luo, Xiaotian; Zhang, Jifeng; Castelberg, Rachel; Wu, Tao; Yu, Pengming; He, Chengqi; Wang, Pu			The Effects of Traditional Chinese Exercise in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis	PLOS ONE			English	Article							KNEE EXTENSOR STRENGTH; TAI-CHI EXERCISE; REHABILITATION PROGRAM; HEART-FAILURE; COPD; QIGONG; QUALITY; HEALTH; COMPLEMENTARY; INDIVIDUALS	Background Chronic obstructive pulmonary disease (COPD) is a major public health problem worldwide. However, several studies that have assessed the role of traditional Chinese exercise in the management of this disease include broad variations in sample sizes and results. Therefore, this meta-analysis was conducted to assess the effects of traditional Chinese exercise on patients with COPD. Methods Two investigators independently identified and extracted data from selected articles. A computerized search of electronic databases through August 2015 was conducted. Mean differences (MDs) and 95% confidence intervals (CIs) were calculated to analyze the combined data. The methodological quality was evaluated using the Cochrane risk-of-bias tool. Heterogeneity was assessed with the I-2 test. Results Ten randomized, controlled trials (RCTs) involving 622 patients met the inclusion criteria. There were significant improvements in the 6-minute walking distance test (6 MWD;MWD = 12.10 m; 95% CI, 7.56-16.65 m; p<0.001); forced expiratory volume in one second (FEV1% predicted; WMD = 9.02; 95% CI, 6.80-11.23; p<0.00001); forced expiratory volume in 1 second/forced vital capacity (FEV(1)/FVC) ratio (Tiffenau Index; WMD = 6.67; 95% CI, 5.09-8.24; p<0.00001); and quality of life, as evaluated by the Chronic Respiratory Disease Questionnaire (CRDQ; WMD = 0.85 score; 95% CI, 0.52-1.18; p<0.00001). Conclusions Traditional Chinese exercise could provide an effective alternative method for managing COPD. Larger and higher-quality trials are required.	[Luo, Xiaotian; Wu, Tao; Yu, Pengming; He, Chengqi; Wang, Pu] Sichuan Univ, West China Hosp, Dept Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China; [Luo, Xiaotian; He, Chengqi; Wang, Pu] Dept Key Lab Rehabil Med Sichuan, Chengdu, Sichuan, Peoples R China; [Zhang, Jifeng] Datong Second Peoples Hosp, Dept Gen Surg Med, Datong, Shanxi, Peoples R China; [Castelberg, Rachel] Univ North Texas Hlth Sci Ctr, Dept Phys Therapy, 3500 Camp Bowie Blvd, Ft Worth, TX USA	Sichuan University; University of North Texas System; University of North Texas Health Science Center	He, CQ; Wang, P (corresponding author), Sichuan Univ, West China Hosp, Dept Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.; He, CQ; Wang, P (corresponding author), Dept Key Lab Rehabil Med Sichuan, Chengdu, Sichuan, Peoples R China.	hxkfhcq@163.com; wangpu0816@qq.com			National Natural Science Foundation of China [81401858, 0040205401634]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study is supported by the National Natural Science Foundation of China (grant no. 81401858); author Pu Wang designed the study. This study is also supported by the National Natural Science Foundation of China (grant no. 0040205401634); author Chengqi He made the decision to publish.	Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104; Chan AWK, 2013, COMPLEMENT THER MED, V21, P585, DOI 10.1016/j.ctim.2013.09.008; Chan AWK, 2013, SCI WORLD J, DOI 10.1155/2013/425082; Chan AWK, 2011, COMPLEMENT THER MED, V19, P3, DOI 10.1016/j.ctim.2010.12.007; Chapman KR, 2006, EUR RESPIR J, V27, P188, DOI 10.1183/09031936.06.00024505; Chen YW, 2016, BRIT J SPORT MED, V50, P397, DOI 10.1136/bjsports-2014-094388; Christou EA, 2003, J GERONTOL A-BIOL, V58, P763; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ding M, 2014, J ALTERN COMPLEM MED, V20, P79, DOI 10.1089/acm.2013.0087; Ding M, 2012, AM J PHYS MED REHAB, V91, P1091, DOI 10.1097/PHM.0b013e31826edd21; Green RH, 2001, THORAX, V56, P143, DOI 10.1136/thorax.56.2.143; Guell R, 2000, CHEST, V117, P976, DOI 10.1378/chest.117.4.976; Guo JB, 2016, CLIN REHABIL, V30, P750, DOI 10.1177/0269215515604903; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Lacasse Y, 2007, Eura Medicophys, V43, P475; Lan C, 1998, MED SCI SPORT EXER, V30, P345, DOI 10.1097/00005768-199803000-00003; Lan C, 2000, ARCH PHYS MED REHAB, V81, P604, DOI 10.1053/mr.2000.3849; Langhorst J, 2012, SCHMERZ, V26, P311, DOI 10.1007/s00482-012-1178-9; Leung RWM, 2013, EUR RESPIR J, V41, P1051, DOI 10.1183/09031936.00036912; Li JX, 2009, J BIOMECH, V42, P967, DOI 10.1016/j.jbiomech.2009.03.001; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liu XD, 2012, HONG KONG J OCCUP TH, V22, P38, DOI 10.1016/j.hkjot.2012.06.002; Mishra SI, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008465.pub2; Ng BHP, 2014, J CARDIOPULM REHABIL, V34, P367, DOI 10.1097/HCR.0000000000000062; Ng BHP, 2011, J ALTERN COMPLEM MED, V17, P243, DOI 10.1089/acm.2010.0215; Ng L, 2014, EUR J INTEGR MED, V6, P248, DOI 10.1016/j.eujim.2014.01.007; Niu RC, 2014, HEART LUNG CIRC, V23, P347, DOI 10.1016/j.hlc.2013.10.057; Puhan MA, 2011, EUR RESPIR J, V37, P784, DOI 10.1183/09031936.00063810; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Sharma M, 2013, J EVID-BASED INTEGR, V18, P209, DOI 10.1177/2156587213478174; Spruit MA, 2013, EUR RESPIR J, V41, P1005, DOI 10.1183/09031936.00128512; Spruit MA, 2012, J AM MED DIR ASSOC, V13, P291, DOI 10.1016/j.jamda.2011.06.009; The Chinese Medical Association Respiratory Neurology Chronic Obstructive Pulmonary Disease Committee, 2013, CHIN J TUBERE RESPIR, V36, P255; Tsang WWN, 2005, MED SCI SPORT EXER, V37, P280, DOI 10.1249/01.MSS.0000152735.06282.58; Wu G, 2004, J ELECTROMYOGR KINES, V14, P343, DOI 10.1016/j.jelekin.2003.09.002; Wu G, 2002, ARCH PHYS MED REHAB, V83, P1364, DOI 10.1053/apmr.2002.34596; Wu WB, 2014, INT J CHRONIC OBSTR, V9, P1253, DOI 10.2147/COPD.S70862; Xu D, 2004, BRIT J SPORT MED, V38, P50, DOI 10.1136/bjsm.2002.003335; Xu DQ, 2005, AGE AGEING, V34, P439, DOI 10.1093/ageing/afi114; Yan Jun-Hong, 2013, PLoS One, V8, pe61806, DOI 10.1371/journal.pone.0061806; Yeh GY, 2010, RESP CARE, V55, P1475; Yeh GY, 2004, AM J MED, V117, P541, DOI 10.1016/j.amjmed.2004.04.016; 杜舒婷, 2013, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V28, P374	45	23	25	1	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2016	11	9							e0161564	10.1371/journal.pone.0161564	http://dx.doi.org/10.1371/journal.pone.0161564			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EJ	27589054	Green Published, gold, Green Submitted			2023-01-03	WOS:000382877800011
J	Mayor, S				Mayor, Susan			Donor faecal transplantation is highly curative in recurrent C difficile infection, trial finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Kelly CR, 2016, ANN INTERN MED, V165, P609, DOI 10.7326/M16-0271	1	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	2016	354								i4638	10.1136/bmj.i4638	http://dx.doi.org/10.1136/bmj.i4638			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV2ZZ	27558248				2023-01-03	WOS:000382792100001
J	Rasmussen, JJ; Selmer, C; Ostergren, PB; Pedersen, KB; Schou, M; Gustafsson, F; Faber, J; Juul, A; Kistorp, C				Rasmussen, Jon Jarlov; Selmer, Christian; Ostergren, Peter Busch; Pedersen, Karen Boje; Schou, Morten; Gustafsson, Finn; Faber, Jens; Juul, Anders; Kistorp, Caroline			Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study	PLOS ONE			English	Article							SERUM INHIBIN-B; HORMONE-BINDING GLOBULIN; YOUNG MEN; SEMEN PARAMETERS; SENSITIVITY TEST; REFERENCE RANGES; BLOOD; REVERSIBILITY; CONSEQUENCES; BODYBUILDERS	Aims Abuse of anabolic androgenic steroids (AAS) is highly prevalent among male recreational athletes. The objective of this study was to investigate the impact of AAS abuse on reproductive hormone levels and symptoms suggestive of hypogonadism in current and former AAS abusers. Methods This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95% CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. All participants were aged 18-50 years and were involved in recreational strength training. Reproductive hormones (FSH, LH, testosterone, inhibin B and anti-Mullerian hormone (AMH)) were measured using morning blood samples. Symptoms of hypogonadism (depressive symptoms, fatigue, decreased libido and erectile dysfunction) were recorded systematically. Results Former AAS abusers exhibited significantly lower median (25th - 75th percentiles) total and free testosterone levels than control participants (total testosterone: 14.4 (11.9-17.7) nmol/l vs. 18.8 (16.6-22.0) nmol/l) (P < 0.01). Overall, 27.2%(13.3; 45.5) of former AAS abusers exhibited plasma total testosterone levels below the lower reference limit (12.1 nmol/l) whereas no control participants exhibited testosterone below this limit (P < 0.01). Gonadotropins were significantly suppressed, and inhibin B and AMH were significantly decreased in current AAS abusers compared with former AAS abusers and control participants (P < 0.01). The group of former AAS abusers had higher proportions of participants with depressive symptoms ((24.2%) (11.1; 42.2)), erectile dysfunction ((27.3%) (13.3; 45.6)) and decreased libido ((40.1%) (23.2; 57.0)) than the other two groups (trend analyses: P < 0.05). Conclusions Former AAS abusers exhibited significantly lower plasma testosterone levels and higher frequencies of symptoms suggestive of hypogonadism than healthy control participants years after AAS cessation. Current AAS abusers exhibited severely decreased AMH and inhibin B indicative of impaired spermatogenesis.	[Rasmussen, Jon Jarlov; Selmer, Christian; Faber, Jens; Kistorp, Caroline] Copenhagen Univ Hosp, Dept Internal Med, Herlev, Denmark; [Ostergren, Peter Busch] Copenhagen Univ Hosp, Dept Urol, Herlev, Denmark; [Pedersen, Karen Boje] Copenhagen Univ Hosp, Dept Internal Med, Slagelse, Denmark; [Schou, Morten] Copenhagen Univ Hosp, Dept Cardiol, Herlev, Denmark; [Schou, Morten] Copenhagen Univ Hosp, Dept Cardiol, Gentofte, Denmark; [Gustafsson, Finn] Rigshosp, Dept Cardiol, Ctr Heart, Copenhagen, Denmark; [Juul, Anders] Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-1168 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Rasmussen, JJ (corresponding author), Copenhagen Univ Hosp, Dept Internal Med, Herlev, Denmark.	jon.ras@dadlnet.dk	Rasmussen, Jon/H-6357-2019; Selmer, Christian/H-3314-2019; Østergren, Peter/AAR-2794-2020; Juul, Anders/F-5864-2013	Rasmussen, Jon/0000-0003-2898-1771; Selmer, Christian/0000-0002-0534-3163; Juul, Anders/0000-0002-0534-4350; Gustafsson, Finn/0000-0003-2144-341X; Ostergren, Peter Busch/0000-0003-4762-039X; Kistorp, Caroline/0000-0002-3019-6775	AntiDoping Denmark; Research Foundation of Herlev Hospital; Danish Heart Foundation [15-R99-A5797-22952]; University of Copenhagen	AntiDoping Denmark; Research Foundation of Herlev Hospital; Danish Heart Foundation; University of Copenhagen	Funded by AntiDoping Denmark (no specific grant number, URL: http://www.antidoping.dk/), Research Foundation of Herlev Hospital (no specific grant number, URL: https://www.herlevhospital.dk/), Danish Heart Foundation (grant number: 15-R99-A5797-22952, URL: https://www.hjerteforeningen.dk/), and Faculty Scholarship from University of Copenhagen to JJR (no specific grant number, URL: http://sund.ku.dk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aksglaede L, 2010, J CLIN ENDOCR METAB, V95, P5357, DOI 10.1210/jc.2010-1207; Allison PD, 2012, HANDLING MISSING DAT, DOI [10.1016/j.drugalcdep.2010.01.011, DOI 10.1016/J.DRUGALCDEP.2010.01.011]; Barbotin AL, 2015, EUR J ENDOCRINOL, V172, P669, DOI 10.1530/EJE-14-0932; Barthel A, 2010, CLIN J SPORT MED, V20, P117, DOI 10.1097/JSM.0b013e3181d235ae; BARTSCH W, 1980, MATURITAS, V2, P109, DOI 10.1016/0378-5122(80)90044-4; Beck AT, 1996, MANUAL FOR THE BECK; Bhasin S, 2011, J CLIN ENDOCR METAB, V96, P2430, DOI 10.1210/jc.2010-3012; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P1001, DOI 10.1016/S0895-4356(98)00092-4; Boregowda K, 2011, FERTIL STERIL, V96, pE7, DOI 10.1016/j.fertnstert.2011.04.029; Coward RM, 2013, J UROLOGY, V190, P2200, DOI 10.1016/j.juro.2013.06.010; Gazvani MR, 1997, HUM REPROD, V12, P1706, DOI 10.1093/humrep/12.8.1706; Hart RJ, 2015, HUM REPROD, V30, P2713, DOI 10.1093/humrep/dev244; Hengevoss J, 2015, J STEROID BIOCHEM, V150, P86, DOI 10.1016/j.jsbmb.2015.03.003; JAROW JP, 1990, AM J SPORT MED, V18, P429, DOI 10.1177/036354659001800417; Jorgensen N, 2010, FERTIL STERIL, V94, P2128, DOI 10.1016/j.fertnstert.2009.12.051; Kanayama G, 2015, ADDICTION, V110, P823, DOI 10.1111/add.12850; Kanayama G, 2010, DRUG ALCOHOL DEPEN, V109, P6, DOI 10.1016/j.drugalcdep.2010.01.011; Kelsey TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109346; KNUTH UA, 1989, FERTIL STERIL, V52, P1041; Krause A, 2004, EXP CLIN ENDOCR DIAB, V112, P236, DOI 10.1055/s-2004-817969; Lloyd F H, 1996, BMJ, V313, P100; Nieschlag E, 2015, EUR J ENDOCRINOL, V173, pR47, DOI 10.1530/EJE-15-0080; Parkinson AB, 2006, MED SCI SPORT EXER, V38, P644, DOI 10.1249/01.mss.0000210194.56834.5d; Pope HG, 2014, ENDOCR REV, V35, P341, DOI 10.1210/er.2013-1058; Pope HG, 2000, ARCH GEN PSYCHIAT, V57, P133, DOI 10.1001/archpsyc.57.2.133; Rahnema CD, 2014, FERTIL STERIL, V101, P1271, DOI 10.1016/j.fertnstert.2014.02.002; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Sagoe D, 2014, ANN EPIDEMIOL, V24, P383, DOI 10.1016/j.annepidem.2014.01.009; Sakamoto H, 2007, UROLOGY, V69, P152, DOI 10.1016/j.urology.2006.09.012; Schmidt PJ, 2004, ARCH GEN PSYCHIAT, V61, P997, DOI 10.1001/archpsyc.61.10.997; Sikaris K, 2005, J CLIN ENDOCR METAB, V90, P5928, DOI 10.1210/jc.2005-0962; SINNECKER G, 1989, J CLIN ENDOCR METAB, V68, P1195, DOI 10.1210/jcem-68-6-1195; Tan RS, 2009, MED HYPOTHESES, V72, P723, DOI 10.1016/j.mehy.2008.12.042; Torres-Calleja J, 2000, FERTIL STERIL, V74, P1055, DOI 10.1016/S0015-0282(00)01557-0; TUREK PJ, 1995, J UROLOGY, V153, P1628, DOI 10.1016/S0022-5347(01)67482-2; Urhausen A, 2003, J STEROID BIOCHEM, V84, P369, DOI 10.1016/S0960-0760(03)00105-5; van Breda E, 2003, INT J SPORTS MED, V24, P195, DOI 10.1055/s-2003-39089; Wikberg Carl, 2015, Prim Care Companion CNS Disord, V17, DOI 10.4088/PCC.14m01758	38	73	74	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2016	11	8							e0161208	10.1371/journal.pone.0161208	http://dx.doi.org/10.1371/journal.pone.0161208			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4YN	27532478	Green Published, Green Submitted, gold			2023-01-03	WOS:000381487600075
J	Sheldon, T				Sheldon, Tony			ANTIMICROBIAL RESISTANCE Saving antibiotics for when they are really needed: the Dutch example	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							REDUCTION					tonysheldon5@cs.com						[Anonymous], 2016, TACKL DRUG RES INF G; European Ctr Dis Prevention Contro, 2015, EFSA J, V13, DOI [10.2903/j.efsa.2015.4006, 10.2903/j.efsa.20Y15.4204]; Grave K, 2010, J ANTIMICROB CHEMOTH, V65, P2037, DOI 10.1093/jac/dkq247; Mevius D, 2014, J VERBRAUCH LEBENSM, V9, P177, DOI 10.1007/s00003-014-0874-z; Sheldon T., 2010, BMJ-BRIT MED J, V341, pc5677, DOI [10.1136/bmj.c5677, DOI 10.1136/BMJ.C5677]; Speksnijder DC, 2015, ZOONOSES PUBLIC HLTH, V62, P79, DOI 10.1111/zph.12167; VANBUCHEM FL, 1981, LANCET, V2, P883; ZonMw, 2015, ANT RES PROGR	8	4	4	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	2016	354								i4192	10.1136/bmj.i4192	http://dx.doi.org/10.1136/bmj.i4192			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS9CS	27488916				2023-01-03	WOS:000381080600002
J	Nunes, PC; Aquino, JD; Rockenbach, II; Stamford, TLM				Nunes, Polyana Campos; Aquino, Jailane de Souza; Rockenbach, Ismael Ivan; Montenegro Stamford, Tania Lucia			Physico-Chemical Characterization, Bioactive Compounds and Antioxidant Activity of Malay Apple [Syzygium malaccense (L.) Merr. & LM Perry]	PLOS ONE			English	Article							IN-VITRO ANTIOXIDANT; ACUTE LUNG INJURY; PHENOLIC-COMPOUNDS; CYANIDIN-3-O-GLUCOSIDE; CYANIDIN-3-GLUCOSIDE; ANTHOCYANINS; INFLAMMATION; POMEGRANATE	The purpose of this study was to evaluate the physico-chemical characteristics, bioactive compounds and antioxidant activity of Malay apple fruit (Syzygium malaccense) grown in Brazil with regard to the geographical origin and its peel fractions and edible portion analyzed independently. Fruit diameter, weight, yield, and centesimal composition, ascorbic acid, reductive sugars, total soluble solids, pH and fiber content were determined. Total phenolics (1293 mg gallic acid equivalent/100 g) and total anthocyanins (1045 mg/100 g) contents were higher in the peel, with the major anthocyanin identified using HPLC-DAD-MS/MS as cyanidin 3-glucoside. Higher values for DPPH antiradical scavenging activity (47.52 mu Mol trolox equivalent antioxidant capacity/g) and Ferric Reducing Antioxidant Potential (FRAP, 0.19 mM ferreous sulfate/g) were also observed in the peel fraction. All extracts tested showed the ability to inhibit oxidation in the beta-carotene/linoleic acid system. This study highlights the potential of Malay apple fruit as a good source of antioxidant compounds with potential benefits to human health.	[Nunes, Polyana Campos; Montenegro Stamford, Tania Lucia] Fed Univ Pernambuco UFPE, Ctr Hlth Sci, Dept Nutr, Recife, PE, Brazil; [Aquino, Jailane de Souza] Fed Univ Paraiba UFPB, Ctr Hlth Sci, Dept Nutr, Joao Pessoa, Paraiba, Brazil; [Rockenbach, Ismael Ivan] Fed Univ Paraiba UFPB, Ctr Technol & Reg Dev, Dept Food Technol, Joao Pessoa, Paraiba, Brazil	Universidade Federal de Pernambuco; Universidade Federal da Paraiba; Universidade Federal da Paraiba	Rockenbach, II (corresponding author), Fed Univ Paraiba UFPB, Ctr Technol & Reg Dev, Dept Food Technol, Joao Pessoa, Paraiba, Brazil.	ismael.rockenbach@gmail.com	Rockenbach, Ismael I/P-2188-2014	Rockenbach, Ismael I/0000-0001-8513-5411; Stamford, Tania Lucia Montenegro/0000-0001-5816-9413; de Souza Aquino, Jailane/0000-0002-7221-9867	National Council for Scientific and Technological Development-Brazil	National Council for Scientific and Technological Development-Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by a research fellowship from National Council for Scientific and Technological Development-Brazil (http://cnpq.br) awarded to PCN. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AOAC, 2002, OFF METH AN, V16; Arumugam B, 2014, LWT-FOOD SCI TECHNOL, V59, P707, DOI 10.1016/j.lwt.2014.06.041; Azevedo JCS, 2010, THESIS; Balasundram N, 2006, FOOD CHEM, V99, P191, DOI 10.1016/j.foodchem.2005.07.042; Banerjee A, 2005, FOOD CHEM, V90, P727, DOI 10.1016/j.foodchem.2004.04.033; Benherlal PS, 2007, J SCI FOOD AGR, V87, P2560, DOI 10.1002/jsfa.2957; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Clerici MTPS, 2011, FOOD RES INT, V44, P1658, DOI 10.1016/j.foodres.2011.04.020; Corley J, 2015, BRIT J NUTR, V114, P1088, DOI 10.1017/S000711451500210X; Costa Raquel Silva, 2006, Rev. Bras. Frutic., V28, P117, DOI 10.1590/S0100-29452006000100032; Doshi P, 2006, INT J FOOD SCI TECH, V41, P1, DOI 10.1111/j.1365-2621.2006.01214.x; Faria AF, 2011, FOOD CHEM, V126, P1571, DOI 10.1016/j.foodchem.2010.12.007; Fu YH, 2014, BIOCHEM PHARMACOL, V90, P126, DOI 10.1016/j.bcp.2014.05.004; Ikram EHK, 2009, J FOOD COMPOS ANAL, V22, P388, DOI 10.1016/j.jfca.2009.04.001; [Institute of Medicine IOM], 2001, DIET REF INT VIT C V; Institute of Medicine, 2001, DIET REF INT EN CARB; Judprasong K, 2013, FOOD CHEM, V140, P507, DOI 10.1016/j.foodchem.2013.01.057; Khoshnam F, 2007, SCI HORTIC-AMSTERDAM, V114, P21, DOI 10.1016/j.scienta.2007.05.008; Lee J, 2005, J AOAC INT, V88, P1269; Longo L, 2007, INNOV FOOD SCI EMERG, V8, P329, DOI 10.1016/j.ifset.2007.03.023; Loypimai P, 2016, J FOOD SCI TECH MYS, V53, P461, DOI 10.1007/s13197-015-2002-1; MARCO GJ, 1968, J AM OIL CHEM SOC, V45, P594, DOI 10.1007/BF02668958; Morton JF, 1987, FRUITS WARM CLIMATES, P378; Oliveira FIP, 2011, FOOD BIOPROCESS TECH, V4, P610, DOI 10.1007/s11947-010-0351-3; Pratheeshkumar P, 2014, TOXICOL APPL PHARM, V280, P127, DOI 10.1016/j.taap.2014.06.028; Rabeque CS, 2011, ANC SCI LIFE, V30, P110; Rabeta MS, 2013, MALAY APPLE WATER AP, V20, P673; Radunic M, 2015, FOOD CHEM, V177, P53, DOI 10.1016/j.foodchem.2014.12.102; Reynertson KA, 2008, FOOD CHEM, V109, P883, DOI 10.1016/j.foodchem.2008.01.021; Rockenbach II, 2011, FOOD CHEM, V127, P174, DOI 10.1016/j.foodchem.2010.12.137; Rodrigues E, 2011, CIENCIA TECNOL ALIME, V31, P911, DOI 10.1590/S0101-20612011000400027; Satpathy G, 2011, FOOD RES INT, V44, P2076, DOI 10.1016/j.foodres.2011.01.040; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Song J, 2013, FOOD CHEM TOXICOL, V58, P306, DOI 10.1016/j.fct.2013.05.003; Tang L, 2016, FOOD CHEM, V196, P550, DOI 10.1016/j.foodchem.2015.09.089; Tsuda T, 1998, LIPIDS, V33, P583, DOI 10.1007/s11745-998-0243-5; [U. S. Department of Agriculture Agricultural Research Service USDA], 2014, FOOD GROUP 09 FRUITS; Xu YJ, 2014, HEART FAIL REV, V19, P113, DOI 10.1007/s10741-013-9379-6; Yan XR, 2015, J SURG RES, V199, P592, DOI 10.1016/j.jss.2015.06.013; Zanatta CF, 2007, FOOD CHEM, V101, P1526, DOI 10.1016/j.foodchem.2006.04.004	41	16	16	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2016	11	6							e0158134	10.1371/journal.pone.0158134	http://dx.doi.org/10.1371/journal.pone.0158134			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AH	27352306	gold, Green Published, Green Submitted			2023-01-03	WOS:000378858900036
J	Stranak, Z; Saliba, E; Kosma, P; Posfay-Barbe, K; Yunis, K; Farstad, T; Unnebrink, K; van Wyk, J; Wegzyn, C; Notario, G; Kalus, S; Campbell, FJ				Stranak, Zbynek; Saliba, Elie; Kosma, Paraskevi; Posfay-Barbe, Klara; Yunis, Khalid; Farstad, Teresa; Unnebrink, Kristina; van Wyk, Jean; Wegzyn, Colleen; Notario, Gerard; Kalus, Stefanie; Campbell, Fiona J.			Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI)	PLOS ONE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; RISK-FACTORS; PREMATURE-INFANTS; PRETERM INFANTS; INFECTION; CHILDREN; BRONCHIOLITIS; PALIVIZUMAB; PROPHYLAXIS; PREVENTION	Background Preterm infants are at high risk of developing respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI). This observational epidemiologic study evaluated RSV disease burden and risk factors for RSV-associated LRTI hospitalization in preterm infants 33 weeks+0 days to 35 weeks+6 days gestational age not receiving RSV prophylaxis. Methods Preterm infants <= 6 months of age during RSV season (1 October 2013-30 April 2014) were followed at 72 sites across 23 countries from September 2013-July 2014 (study period). RSV testing was performed according to local clinical practice. Factors related to RSV-associated hospitalization for LRTI were identified using multivariable logistic regression with backward selection. Results Of the 2390 evaluable infants, 204 and 127 were hospitalized for LRTI during the study period and RSV season, respectively. Among these subjects, 64/204 and 46/127, respectively, were hospitalized for confirmed RSV LRTI. Study period and RSV season normalized RSV hospitalization rates (per 100 infant years) were 4.1 and 6.1, respectively. Factors associated with an increased risk of RSV-related LRTI hospitalization in multivariable analyses were smoking of family members (P < 0.0001), non-hemodynamically significant congenital heart disease diagnosis (P = 0.0077), maternal age of <= 25 years at delivery (P = 0.0009), low maternal educational level (P = 0.0426), household presence of children aged 4 to 5 years (P = 0.0038), age on 1 October <= 3 months (P = 0.0422), and presence of paternal atopy (P < 0.0001). Conclusions During the 2013-2014 RSV season across 23 countries, for preterm infants 33-35 weeks gestation <= 6 months old on 1 October not receiving RSV prophylaxis, confirmed RSV LRTI hospitalization incidence was 4.1 per 100 infant years during the study period and 6.1 per 100 infant years during the RSV season. This study enhances the findings of single-country studies of common risk factors for severe RSV infection in preterm infants and suggests that combinations of 4-6 risk factors may be used to accurately predict risk of RSV hospitalization. These findings may be useful in the identification of infants most at risk of severe RSV infection.	[Stranak, Zbynek] Charles Univ Prague, Fac Med 3, Inst Care Mother & Child, Prague, Czech Republic; [Saliba, Elie] Univ Tours, Inserm U930, Tours, France; [Saliba, Elie] Univ Hosp Clocheville, Dept Neonatol, Tours, France; [Kosma, Paraskevi] Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden; [Posfay-Barbe, Klara] Geneva Sch Med, Dept Pediat, Geneva, Switzerland; [Posfay-Barbe, Klara] Univ Hosp Geneva, Geneva, Switzerland; [Yunis, Khalid] Amer Univ Beirut, Dept Pediat & Adolescent Med, Beirut, Lebanon; [Farstad, Teresa] Akershus Univ Hosp, Dept Pediat, Lorenskog, Norway; [Unnebrink, Kristina] AbbVie Deutschland GmbH & Co KG, Data & Stat Sci, Ludwigshafen, Germany; [van Wyk, Jean; Notario, Gerard] AbbVie Inc, Virol, N Chicago, IL USA; [Wegzyn, Colleen] AbbVie Inc, Neonatol, N Chicago, IL USA; [Kalus, Stefanie] GKM Gesell Therapieforsch MbH, Biostat, Munich, Germany; [Campbell, Fiona J.] AbbVie Ltd, Neonatol & HIV, Dublin, Ireland	Charles University Prague; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours; Karolinska Institutet; University of Geneva; University of Geneva; American University of Beirut; University of Oslo; AbbVie; AbbVie; AbbVie; AbbVie	Stranak, Z (corresponding author), Charles Univ Prague, Fac Med 3, Inst Care Mother & Child, Prague, Czech Republic.	z.stranak@seznam.cz	Posfay-Barbe, Klara M/E-9131-2013; Posfay-Barbe, Klara M./AAV-2515-2021	Posfay-Barbe, Klara M/0000-0001-9464-5704; Posfay-Barbe, Klara M./0000-0001-9464-5704; Stranak, Zbynek/0000-0001-7095-3198; Yunis, Khalid/0000-0002-6384-2745	AbbVie Inc.; AbbVie	AbbVie Inc.(AbbVie); AbbVie(AbbVie)	Financial support for the epidemiologic study was provided by AbbVie Inc. The funder played a direct role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript through the participation of the coauthors. Medical writing support was provided by John E. Fincke, PhD, and Lisa M. Havran, PhD, at Complete Publication Solutions, LLC; this support was funded by AbbVie.	ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Ambrose CS, 2014, PEDIATR INFECT DIS J, V33, P576, DOI 10.1097/INF.0000000000000219; American Academy of Pediatrics (AAP) Committee on Fetus and Newborn and American College of Obstetricians and Gynecologists ACOG Committee on Obstetric Practice, 2012, STAND TERM REP REPR, P497; Blanken MO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059161; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Carbonell-Estrany X, 2008, EUR J CLIN MICROBIOL, V27, P891, DOI 10.1007/s10096-008-0520-8; Cilla G, 2006, EPIDEMIOL INFECT, V134, P506, DOI 10.1017/S0950268805005571; Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2; Feltes TF, 2011, PEDIATR RES, V70, P186, DOI 10.1203/PDR.0b013e318220a553; Fenton TR, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-59; Figueras Aloy J, 2010, AN PEDIAT BARC, V73; Figueras-Aloy J, 2008, PEDIATR INFECT DIS J, V27, P788, DOI 10.1097/INF.0b013e3181710990; Garcia CG, 2010, PEDIATRICS, V126, pE1453, DOI 10.1542/peds.2010-0507; German Society for Paediatric Infectious Diseases (DGPI) German Society of Pediatric Cardiology (DGPK) Society of Pediatric Pneumology (GPP) Society of Neonatology and Pediatric Intensive Care Medicine (GNPI) Professional Association of Child and Adolescent Physicians (BVKJ), 2012, GUID PREV SER ILLN R; Gijtenbeek RGP, 2015, EUR J PEDIATR, V174, P435, DOI 10.1007/s00431-014-2415-2; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Holman RC, 2003, PEDIATR INFECT DIS J, V22, P483, DOI 10.1097/00006454-200306000-00001; Law BJ, 2004, PEDIATR INFECT DIS J, V23, P806, DOI 10.1097/01.inf.0000137568.71589.bd; Liese JG, 2003, EUR J PEDIATR, V162, P230, DOI 10.1007/s00431-002-1105-7; MEERT K, 1990, CRIT CARE MED, V18, P1357, DOI 10.1097/00003246-199012000-00009; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Pickerling LK., 2012, RED BOOK 2012 REPORT, V29th ed, P609; Resch B, 2002, INFECTION, V30, P193, DOI 10.1007/s15010-002-2122-1; Resch B, 2008, MONATSSCHR KINDERH, V156, P381, DOI DOI 10.1007/S00112-008-1722-Y; Robinson JL, 2011, PAED CHILD HEALT-CAN, V16, P487, DOI 10.1093/pch/16.8.487; Samson L, 2009, PAED CHILD HEALT-CAN, V14, P521, DOI 10.1093/pch/14.8.521; Simoes EAF, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-78; Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144; Steyerberg EW., 2009, CLIN PREDICTION MODE, DOI [10.1007/978-0-387-77244-8, DOI 10.1007/978-0-387-77244-8]; Weisman LE, 2003, PEDIATR INFECT DIS J, V22, pS33, DOI 10.1097/00006454-200302001-00005; WHO, 2010, ICD10, V10; Zhang XB, 2014, WORLD J PEDIATR, V10, P360, DOI 10.1007/s12519-014-0513-x	33	29	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2016	11	6							e0157446	10.1371/journal.pone.0157446	http://dx.doi.org/10.1371/journal.pone.0157446			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO8JO	27310438	Green Submitted, gold, Green Published			2023-01-03	WOS:000378029800073
J	Todorovic, A				Todorovic, Ana			WHAT YOUR PATIENT IS THINKING Palliative care is not just for those who are dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												rsnow@bmj.com	Todorovic, Ana/ABG-2264-2020						0	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2016	353								i2846	10.1136/bmj.i2846	http://dx.doi.org/10.1136/bmj.i2846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP1HF	27306758	Bronze, Green Published			2023-01-03	WOS:000378240400003
J	Kelly, CR; Khoruts, A; Staley, C; Sadowsky, MJ; Abd, M; Alani, M; Bakow, B; Curran, P; McKenney, J; Tisch, A; Reinert, SE; Machan, JT; Brandt, LJ				Kelly, Colleen R.; Khoruts, Alexander; Staley, Christopher; Sadowsky, Michael J.; Abd, Mortadha; Alani, Mustafa; Bakow, Brianna; Curran, Patrizia; McKenney, Joyce; Tisch, Allison; Reinert, Steven E.; Machan, Jason T.; Brandt, Lawrence J.			Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIAL; IRRITABLE-BOWEL-SYNDROME; DISEASE; EPIDEMIOLOGY; VANCOMYCIN; PREVENTION; GUIDELINES; RESOLUTION; DIAGNOSIS; DIARRHEA	Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials. Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI. Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494) Setting: Two academic medical centers. Patients: 46 patients who had 3 or more recurrences of CDI and received a full course of vancomycin for their most recent acute episode. Intervention: Fecal microbiota transplantation with donor stool (heterologous) or patient's own stool (autologous) administered by colonoscopy. Measurements: The primary end point was resolution of diarrhea without the need for further anti-CDI therapy during the 8-week follow-up. Safety data were compared between treatment groups via review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT. Fecal microbiota analyses were performed on patients' stool before and after FMT and also on donors' stool. Results: In the intention-to-treat analysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042). Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [ P = 0.033]). All 9 patients who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT. There were no SAEs related to FMT. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors. Limitation: The study included only patients who had 3 or more recurrences and excluded those who were immunocompromised and aged 75 years or older. Conclusion: Donor stool administered via colonoscopy seemed safe and was more efficacious than autologous FMT in preventing further CDI episodes.	Brown Univ, Miriam Hosp, Warren Alpert Med Sch, Providence, RI 02912 USA; Lifespan Hosp Syst, Providence, RI USA; Univ Minnesota, Minneapolis, MN USA; Albert Einstein Coll Med, Montefiore Med Ctr, Bronx, NY 10467 USA; Univ Rhode Isl, Kingston, RI 02881 USA; [Kelly, Colleen R.; Curran, Patrizia; McKenney, Joyce] Miriam Hosp, Womens Med Collaborat, 146 West River St,Suite 11C, Providence, RI 02904 USA; [Khoruts, Alexander] Univ Minnesota, Dept Med, Div Gastroenterol Hepatol & Nutr, 420 Delaware St SE,MMC 36, Minneapolis, MN 55455 USA; [Staley, Christopher; Sadowsky, Michael J.] Inst Biotechnol, 1479 Gortner Ave,Suite 140, St Paul, MN 55108 USA; [Abd, Mortadha; Brandt, Lawrence J.] Albert Einstein Coll Med, 625 Ullmann Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA; [Alani, Mustafa] Albert Einstein Coll Med, Montefiore Med Ctr, Div Gastroenterol, Dept Med, 111 East 210th St, Bronx, NY 10467 USA; [Bakow, Brianna] Brown Univ, Warren Alpert Med Sch, Box G-A1, Providence, RI 02912 USA; [Tisch, Allison] Optum Care Plus, 475 Kilvert St,Suite 310, Warwick, RI 02886 USA; [Reinert, Steven E.] Lifespan Informat Serv, Coro Bldg,167 Point St, Providence, RI 02903 USA; [Machan, Jason T.] Rhode Isl Hosp, Lifespan Biostat Core, 593 Eddy St,Grads Dorm 206A, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Lifespan Health Rhode Island; University of Minnesota System; University of Minnesota Twin Cities; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Rhode Island; Lifespan Health Rhode Island; Miriam Hospital; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Brown University; Optum; Lifespan Health Rhode Island; Rhode Island Hospital	Kelly, CR (corresponding author), Miriam Hosp, Womens Med Collaborat, 146 West River St,Suite 11C, Providence, RI 02904 USA.	colleen_r_kelly@brown.edu	Abd, Mortadha/AAX-4717-2020; Machan, Jason/D-3897-2013; Khoruts, Alexander/ABF-5119-2020; Staley, Christopher/K-1142-2019; Sadowsky, Michael/J-2507-2016	Machan, Jason/0000-0003-2048-4914; Khoruts, Alexander/0000-0002-3205-3188; Staley, Christopher/0000-0002-2309-0083; Sadowsky, Michael/0000-0001-8779-2781	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [1R21DK0939839]; National Institutes of Health [R21AI114722-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI114722] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Drs. Kelly and Brandt received funding from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (1R21DK0939839). Drs. Khoruts and Sadowsky received grant support from the National Institutes of Health (R21AI114722-01).	Acar EF, 2013, BIOMETRICS, V69, P427, DOI 10.1111/biom.12006; Agrawal M, 2016, J CLIN GASTROENTEROL, V50, P403, DOI 10.1097/MCG.0000000000000410; Baxter M, 2015, CLIN INFECT DIS, V61, P140, DOI 10.1093/cid/civ247; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Gerding DN, 2015, JAMA-J AM MED ASSOC, V313, P1719, DOI 10.1001/jama.2015.3725; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Guo B, 2012, ALIMENT PHARM THER, V35, P865, DOI 10.1111/j.1365-2036.2012.05033.x; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Jackson M., 2015, J CLIN GASTROENTEROL; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kelly CR, 2014, AM J GASTROENTEROL, V109, P1065, DOI 10.1038/ajg.2014.133; Koo HL, 2014, INFECT CONT HOSP EP, V35, P667, DOI 10.1086/676433; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; McFarland LV, 1999, INFECT CONT HOSP EP, V20, P43, DOI 10.1086/501553; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; Piche T, 2007, CAN J GASTROENTEROL, V21, P727, DOI 10.1155/2007/262478; Pimentel M, 2011, NEW ENGL J MED, V364, P22, DOI 10.1056/NEJMoa1004409; Polage CR, 2015, JAMA INTERN MED, V175, P1792, DOI 10.1001/jamainternmed.2015.4114; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Shankar V, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-13; Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4; Surawicz CM, 2000, CLIN INFECT DIS, V31, P1012, DOI 10.1086/318130; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Wilcox MH, 2010, J CLIN MICROBIOL, V48, P4347, DOI 10.1128/JCM.02028-10; Zipursky JS, 2012, CLIN INFECT DIS, V55, P1652, DOI 10.1093/cid/cis809	29	365	380	2	67	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2016	165	9					609	+		10.7326/M16-0271	http://dx.doi.org/10.7326/M16-0271			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA8SJ	27547925	Green Accepted			2023-01-03	WOS:000386908600003
J	Iwashyna, TJ; Hodgson, CL				Iwashyna, Theodore J.; Hodgson, Carol L.			Early mobilisation in ICU is far more than just exercise	LANCET			English	Editorial Material									[Iwashyna, Theodore J.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Iwashyna, Theodore J.] VA Ann Arbor Hlth Syst, Ctr Clin Management Res, Ann Arbor, MI 48105 USA; [Iwashyna, Theodore J.; Hodgson, Carol L.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Hodgson, Carol L.] Alfred Hosp, Dept Physiotherapy, Melbourne, Vic, Australia	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; Monash University; Florey Institute of Neuroscience & Mental Health	Iwashyna, TJ (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.; Iwashyna, TJ (corresponding author), VA Ann Arbor Hlth Syst, Ctr Clin Management Res, Ann Arbor, MI 48105 USA.; Iwashyna, TJ (corresponding author), Monash Univ, Australian & New Zealand Intens Care Res Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.	tiwashyn@umich.edu		Hodgson, Carol/0000-0001-9002-2075				Hodgson CL, 2016, CRIT CARE MED, V44, P1145, DOI 10.1097/CCM.0000000000001643; Hodgson CL, 2016, AM J RESP CRIT CARE, V193, P1071, DOI 10.1164/rccm.201512-2497ED; Morris PE, 2016, JAMA-J AM MED ASSOC, V315, P2694, DOI 10.1001/jama.2016.7201; Needham Dale M, 2013, BMJ, V346, pf1532, DOI 10.1136/bmj.f1532; Schaller SJ, 2016, LANCET, V388, P1377, DOI 10.1016/S0140-6736(16)31637-3; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; The AVERTTrial Collaboration group, 2015, LANCET, V298, P46	7	8	11	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2016	388	10052					1351	1352		10.1016/S0140-6736(16)31745-7	http://dx.doi.org/10.1016/S0140-6736(16)31745-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DX5FD	27707476				2023-01-03	WOS:000384404300006
J	Fregin, T; Bickmeyer, U				Fregin, Torsten; Bickmeyer, Ulf			Electrophysiological Investigation of Different Methods of Anesthesia in Lobster and Crayfish	PLOS ONE			English	Article							CARBON-DIOXIDE; CRUSTACEANS; BEHAVIOR; TEMPERATURE; NEURONS; CRABS; MODULATION; ANIMALS; CIRCUIT; PAIN	Objectives In search for methods of anesthesia of crustaceans, an implanted electrode into lobster and crayfish CNS enabled us to monitor signal propagation in the nerve system of animals undergoing different protocols. Results Cooling (tap water 0 degrees C, sea water -1,8 degrees C) and anesthesia with MgCl2 (10%) were both discarded as anesthetic procedures because responses to external stimuli were still detectable under treatment. Contrarily, bubbling the aquarium water with CO2 can be considered a "partially successful" anesthesia, because signal propagation is inhibited but before that the animals show discomfort. The procedure of "electro-stunning" induces epileptic-form seizures in the crustacean CNS (lobster, crayfish), which overlay but do not mitigate the response to external stimuli. After several minutes the activity declines before the nervous system starts to recover. A feasible way to sacrifice lobsters is to slowly raise the water temperature (1 degrees C min(-1)), as all electrical activities in the CNS cease at temperatures above similar to 30 degrees C, whereas below this temperature the animals do not show signs of stress or escape behavior (e.g. tail flips) in the warming water. Conclusion CO2 is efficient to anaesthetize lobster and crayfish but due to low pH in water is stressful to the animals previous to anesthesia. Electrical stunning induces epileptiform seizures but paralyses the animals and leads to a reversible decline of nerve system activity after seizure. Electric stunning or slowly warming just before preparation may meet ethical expectations regarding anaesthesia and to sacrifice crustaceans.	[Fregin, Torsten; Bickmeyer, Ulf] Helmholtz Zentrum Polar & Meeresforsch, Alfred Wegener Inst, Handelshafen 12, D-27570 Bremerhaven, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Bickmeyer, U (corresponding author), Helmholtz Zentrum Polar & Meeresforsch, Alfred Wegener Inst, Handelshafen 12, D-27570 Bremerhaven, Germany.	Ulf.Bickmeyer@awi.de		Bickmeyer, Ulf/0000-0002-5351-2902	German Federal Ministry of Food and Agriculture (BMEL) through the Federal Office for Agriculture and Food (BLE) [2812HS009]	German Federal Ministry of Food and Agriculture (BMEL) through the Federal Office for Agriculture and Food (BLE)	German Federal Ministry of Food and Agriculture (BMEL) through the Federal Office for Agriculture and Food (BLE), grant number 2812HS009.	Aaser CS, 1949, NORDISK VET MEDISIN, V1, P221; BAKER JR, 1955, J MAR BIOL ASSOC UK, V34, P15, DOI 10.1017/S0025315400008572; BAKER JR, 1962, SCIENCE, V135, P587, DOI 10.1126/science.135.3503.587-a; Barr S, 2008, ANIM BEHAV, V75, P745, DOI 10.1016/j.anbehav.2007.07.004; BENARDE MA, 1962, SCIENCE, V135, P587, DOI 10.1126/science.135.3503.587; Bickmeyer U, 2012, MAR DRUGS, V10, P223, DOI 10.3390/md10010223; Bierbower SM, 2010, J EXP ZOOL PART A, V313A, P484, DOI 10.1002/jez.620; Bierbower SM, 2013, J EXP ZOOL PART A, V319A, P340, DOI 10.1002/jez.1798; Chung Y.S., 2012, OPEN J MOL INTEGR PH, V2, P75, DOI DOI 10.4236/OJMIP.2012.23011; Cruz-Bermudez ND, 2007, J EXP BIOL, V210, P2873, DOI 10.1242/jeb.002949; Edwards DH, 1999, TRENDS NEUROSCI, V22, P153, DOI 10.1016/S0166-2236(98)01340-X; Elwood RW, 2012, ANIM WELFARE, V21, P23, DOI 10.7120/096272812X13353700593365; Fish F. R., 1943, Transactions of the American Fisheries Society, V1942, P25; FORWARD RB, 1990, BIOL BULL-US, V178, P195, DOI 10.2307/1541819; GREGORY NG, 1988, BRIT VET J, V144, P573, DOI 10.1016/0007-1935(88)90027-9; GREGORY NG, 1987, BRIT VET J, V143, P175, DOI 10.1016/0007-1935(87)90009-1; Gruhn M, 2002, J NEUROSCI METH, V118, P33, DOI 10.1016/S0165-0270(02)00127-9; GUNTER G, 1962, SCIENCE, V135, P588, DOI 10.1126/science.135.3503.588; GUNTER G, 1961, SCIENCE, V133, P327, DOI 10.1126/science.133.3449.327; Hamilton JL, 2007, J EXP BIOL, V210, P1025, DOI 10.1242/jeb.02717; HOBBS H H JR, 1981, Smithsonian Contributions to Zoology, P1; Hoenderken R, 1978, ELEKT BEDWELMING SLA, VXI; KERKUT G. A., 1958, BEHAVIOR, V13, P259, DOI 10.1163/156853957X00047; KERKUT GA, 1956, NATURE, V178, P426, DOI 10.1038/178426a0; KRAVITZ EA, 1988, SCIENCE, V241, P1775, DOI 10.1126/science.2902685; Lagerspetz KYH, 2006, BIOL REV, V81, P237, DOI 10.1017/S1464793105006998; Liu YC, 2010, J NEUROPHYSIOL, V104, P675, DOI 10.1152/jn.00391.2010; Makowska IJ, 2009, APPL ANIM BEHAV SCI, V121, P230, DOI 10.1016/j.applanim.2009.10.001; Marder E, 2011, P NATL ACAD SCI USA, V108, P15542, DOI 10.1073/pnas.1010674108; MESSENGER JB, 1985, COMP BIOCHEM PHYS C, V82, P203, DOI 10.1016/0742-8413(85)90230-0; Pantin C. F. A., 1962, NOTES MICROSCOPICAL; Payette AL, 2003, COMP BIOCHEM PHYS A, V136, P539, DOI 10.1016/S1095-6433(03)00203-4; POST G, 1979, PROG FISH CULT, V41, P142, DOI 10.1577/1548-8659(1979)41[142:CAAFAO]2.0.CO;2; Reimers U., 2008, THESIS; Roth B, 2010, ANIM WELFARE, V19, P287; RUNHAM N. W., 1965, MALCOLOGIA, V2, P231; Smaldon G., 1979, SYNOPSIS METHODS NAR; Sneddon LU, 2015, J EXP BIOL, V218, P967, DOI 10.1242/jeb.088823; Southward A.J., 1963, CATALOGUE MAIN MARIN; Steneck RS, 2013, CAN J FISH AQUAT SCI, V70, P1612, DOI 10.1139/cjfas-2013-0094; Tang LS, 2012, J NEUROSCI, V32, P10075, DOI 10.1523/JNEUROSCI.1443-12.2012; Tang LS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000469; Tani M, 1998, COMP BIOCHEM PHYS A, V119, P845, DOI 10.1016/S1095-6433(98)01025-3; Wiese KE., 2002, CRUSTACEAN NERVOUS S, Vxxi; Wiese KE, 2002, CRUSTACEAN EXPT SYST, Vxiv	45	18	19	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2016	11	9							e0162894	10.1371/journal.pone.0162894	http://dx.doi.org/10.1371/journal.pone.0162894			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW8GC	27642755	Green Published, gold, Green Submitted			2023-01-03	WOS:000383891900023
J	Maury, S; Chevret, S; Thomas, X; Heim, D; Leguay, T; Huguet, F; Chevallier, P; Hunault, M; Boissel, N; Escoffre-Barbe, M; Hess, U; Vey, N; Pignon, JM; Braun, T; Marolleau, JP; Cahn, JY; Chalandon, Y; Lheritier, V; Beldjord, K; Bene, MC; Ifrah, N; Dombret, H				Maury, Sebastien; Chevret, Sylvie; Thomas, Xavier; Heim, Dominik; Leguay, Thibaut; Huguet, Francoise; Chevallier, Patrice; Hunault, Mathilde; Boissel, Nicolas; Escoffre-Barbe, Martine; Hess, Urs; Vey, Norbert; Pignon, Jean-Michel; Braun, Thorsten; Marolleau, Jean-Pierre; Cahn, Jean-Yves; Chalandon, Yves; Lheritier, Veronique; Beldjord, Kheira; Bene, Marie C.; Ifrah, Norbert; Dombret, Herve			Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGNOSTIC-SIGNIFICANCE; MONOCLONAL-ANTIBODIES; CD20 EXPRESSION; CHEMOIMMUNOTHERAPY; IMMUNOTHERAPY; ASPARAGINASE; CHEMOTHERAPY; MULTICENTER	BACKGROUND Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial. METHODS We randomly assigned adults (18 to 59 years of age) with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to receive chemotherapy with or without rituximab, with event-free survival as the primary end point. Rituximab was given during all treatment phases, for a total of 16 to 18 infusions. RESULTS From May 2006 through April 2014, a total of 209 patients were enrolled: 105 in the rituximab group and 104 in the control group. After a median follow-up of 30 months, event-free survival was longer in the rituximab group than in the control group (hazard ratio, 0.66; 95% confidence interval [CI], 0.45 to 0.98; P = 0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) and 52% (95% CI, 43 to 63), respectively. Treatment with rituximab remained associated with longer event-free survival in a multivariate analysis. The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group. CONCLUSIONS Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL. (Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678.)	[Maury, Sebastien] Univ Paris Est, Hop Henri Mondor, AP HP, Inst Mondor Rech Biomed,Dept Hematol,Equipe 21, Creteil, France; [Chevret, Sylvie] Univ Paris Diderot, Hop St Louis, AP HP, Serv Biostat,Inst Univ Hematol, Paris, France; [Boissel, Nicolas; Beldjord, Kheira; Dombret, Herve] Univ Paris Diderot, Hop St Louis, AP HP, Dept Hematol,Inst Univ Hematol, Paris, France; [Thomas, Xavier] Hop Lyon Sud, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France; [Lheritier, Veronique] Hop Lyon Sud, Hosp Civils Lyon, Grp Res Adult Acute Lymphoblast Leukemia Coordina, Pierre Benite, France; [Leguay, Thibaut] CHU Haut Leveque, Dept Hematol, Pessac, France; [Huguet, Francoise] Inst Univ Canc, Dept Hematol, Toulouse, France; [Chevallier, Patrice] CHU Nantes, Hotel Dieu, Dept Clin Hematol, Nantes, France; [Bene, Marie C.] CHU Nantes, Serv Hematol Biol, Nantes, France; [Hunault, Mathilde; Ifrah, Norbert] CHU Angers, Dept Hematol, Angers, France; [Escoffre-Barbe, Martine] CHU, Dept Hematol, Rennes, France; [Vey, Norbert] Inst J Paoli I Calmettes, Dept Hematol, Marseille, France; [Pignon, Jean-Michel] Ctr Hosp Dunkerque, Dept Hematol, Dunkerque, France; [Braun, Thorsten] Univ Paris Nord, Hop Avicenne, AP HP, Dept Hematol, Bobigny, France; [Marolleau, Jean-Pierre] Univ Picardie Jules Verne, CHU, Dept Hematol, Amiens, France; [Cahn, Jean-Yves] CHU Grenoble, Dept Hematol, Grenoble, France; [Heim, Dominik] Univ Spital, Klin Hamatol, Basel, Switzerland; [Heim, Dominik; Hess, Urs; Chalandon, Yves] Swiss Grp Clin Canc Res, Bern, Switzerland; [Hess, Urs] Kantonsspital St Gallen, Klin Onkol Hamatol, St Gallen, Switzerland; [Chalandon, Yves] Univ Hosp, Dept Med Specialties, Div Hematol, Geneva, Switzerland; [Chalandon, Yves] Univ Geneva, Geneva, Switzerland	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; CHU Lyon; CHU Bordeaux; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Rennes; UNICANCER; Institut Paoli-Calmette (IPC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Swiss Group for Clinical Cancer Research (SAKK); Kantonsspital St. Gallen; University of Geneva; University of Geneva	Dombret, H (corresponding author), Univ Paris Diderot, Hop St Louis, EA 3518, Inst Univ Hematol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	herve.dombret@sls.aphp.fr	Braun, Thorsten/GRJ-8918-2022; Boissel, Nicolas/P-2190-2018; Chalandon, Yves/AAF-5125-2019; maury, sebastien/Q-6573-2018; Vey, Norbert/AGE-3573-2022	maury, sebastien/0000-0002-1170-8683; Vey, Norbert/0000-0001-7027-040X; IFRAH, Norbert/0000-0003-3063-850X; Chalandon, Yves/0000-0001-9341-8104; hunault, mathilde/0000-0001-7777-5216; chevret, sylvie/0000-0001-6449-4730	Regional Clinical Research Office, Paris	Regional Clinical Research Office, Paris	Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678.	Avramis VI, 2002, BLOOD, V99, P1986, DOI 10.1182/blood.V99.6.1986; Beldjord K, 2014, BLOOD, V123, P3739, DOI 10.1182/blood-2014-01-547695; Bene MC, 2011, LEUKEMIA, V25, P567, DOI 10.1038/leu.2010.312; Chevallier P, 2015, HAEMATOLOGICA, V100, pE128, DOI 10.3324/haematol.2014.120220; COX C, 1988, STAT MED, V7, P435, DOI 10.1002/sim.4780070309; DeAngelo DJ, 2015, HEMATOL-AM SOC HEMAT, P400, DOI 10.1182/asheducation-2015.1.400; Dhedin N, 2015, BLOOD, V125, P2486, DOI 10.1182/blood-2014-09-599894; Dombret H, 2014, CURR HEMATOL MALIG R, V9, P158, DOI 10.1007/s11899-014-0210-9; Dworzak MN, 2008, BLOOD, V112, P3982, DOI 10.1182/blood-2008-06-164129; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fry TJ, 2013, HEMATOL-AM SOC HEMAT, P348, DOI 10.1182/asheducation-2013.1.348; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Gokbuget N, 2004, ANN HEMATOL, V83, P201, DOI 10.1007/s00277-003-0752-8; Gokbuget Nicola, 2006, Hematology Am Soc Hematol Educ Program, P133; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Hoelzer D, 2012, BLOOD REV, V26, P25, DOI 10.1016/j.blre.2011.08.001; Huguet F, 2009, J CLIN ONCOL, V27, P911, DOI 10.1200/JCO.2008.18.6916; Kantarjian H, 2013, CANCER-AM CANCER SOC, V119, P2728, DOI 10.1002/cncr.28136; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Maury S, 2010, HAEMATOL-HEMATOL J, V95, P324, DOI 10.3324/haematol.2009.010306; Moorman AV, 2007, BLOOD, V109, P3189, DOI 10.1182/blood-2006-10-051912; Oriol A, 2008, CANCER-AM CANCER SOC, V113, P117, DOI 10.1002/cncr.23522; Ribrag V, 2016, LANCET, V387, P2402, DOI 10.1016/S0140-6736(15)01317-3; Thomas DA, 2010, J CLIN ONCOL, V28, P3880, DOI 10.1200/JCO.2009.26.9456; Thomas DA, 2009, BLOOD, V113, P6330, DOI 10.1182/blood-2008-04-151860; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; Woo MH, 2000, J CLIN ONCOL, V18, P1525, DOI 10.1200/JCO.2000.18.7.1525	29	183	189	2	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	2016	375	11					1044	1053		10.1056/NEJMoa1605085	http://dx.doi.org/10.1056/NEJMoa1605085			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV6ZG	27626518	Green Published, Bronze			2023-01-03	WOS:000383085000007
J	de Freitas-Blanco, VS; Franz-Montan, M; Groppo, FC; de Carvalho, JE; Figueira, GM; Serpe, L; Sousa, IMO; Damasio, VAG; Yamane, LT; de Paula, E; Rodrigues, RAF				de Freitas-Blanco, Veronica Santana; Franz-Montan, Michelle; Groppo, Francisco Carlos; de Carvalho, Joao Ernesto; Figueira, Glyn Mara; Serpe, Luciano; Oliveira Sousa, Ilza Maria; Guilherme Damasio, Viviane Aparecida; Yamane, Lais Thiemi; de Paula, Eneida; Ferreira Rodrigues, Rodney Alexandre			Development and Evaluation of a Novel Mucoadhesive Film Containing Acmella oleracea Extract for Oral Mucosa Topical Anesthesia	PLOS ONE			English	Article							IN-VITRO ASSAYS; SPILANTHES-ACMELLA; DENTAL ANXIETY; HELIOPSIS-LONGIPES; ANALGESIC ACTIVITY; SYSTEMIC TOXICITY; DELIVERY-SYSTEMS; SKIN PENETRATION; VIVO; PERMEATION	Purpose To develop an anesthetic mucoadhesive film containing Acmella oleracea (jambu) extract for topical use on oral mucosa. Methods Ethanolic extracts from aerial parts of jambu were prepared by maceration. Pigment removal was obtained by adsorption with activated carbon. Three mucoadhesive films were developed using a film casting method: 10 or 20% of crude jambu extract (10% JB and 20% JB), and 10% of crude jambu extract treated with activated carbon (10% JBC). The mucoadhesive films were characterized regarding their uniformity, thickness, pH, and spilanthol content, and their stability was evaluated during 120 days. Gas chromatography was used to quantify the amount of spilanthol. In vitro tests determined the permeation of spilanthol across pig esophageal epithelium mucosa in Franz diffusion cells. Topical anesthetic efficacy was assessed in vivo using a tail flick test in mice. Results The three mucoadhesive films showed physical stability and visual appearances suitable for use on oral mucosa. The permeation study revealed that the spilanthol from 10% JBC presented higher flux and permeability coefficient values, compared to 10% or 20% JB (p < 0.001). Moreover, 10% JBC showed better topical anesthetic efficacy than the other films (p < 0.01). Conclusion Mucoadhesive film containing crude extract of jambu treated with activated carbon is a potential alternative for oral, topical use, encouraging future clinical studies.	[de Freitas-Blanco, Veronica Santana; Franz-Montan, Michelle; Groppo, Francisco Carlos; de Carvalho, Joao Ernesto; Serpe, Luciano; Ferreira Rodrigues, Rodney Alexandre] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, Brazil; [de Freitas-Blanco, Veronica Santana; de Carvalho, Joao Ernesto; Figueira, Glyn Mara; Oliveira Sousa, Ilza Maria; Yamane, Lais Thiemi; Ferreira Rodrigues, Rodney Alexandre] Univ Estadual Campinas, Chem Biol & Agr Res Ctr CPQBA, Paulinia, Brazil; [de Carvalho, Joao Ernesto] Univ Estadual Campinas, Fac Pharmaceut Sci, Campinas, SP, Brazil; [Guilherme Damasio, Viviane Aparecida; de Paula, Eneida] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas	Rodrigues, RAF (corresponding author), Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, Brazil.; Rodrigues, RAF (corresponding author), Univ Estadual Campinas, Chem Biol & Agr Res Ctr CPQBA, Paulinia, Brazil.	rodney@cpqba.unicamp.br	de Paula, Eneida/C-3031-2013; Franz-Montan, Michelle/AAN-1071-2021; de Olivei Sousa, Ilza Maria/AAK-7866-2020; groppo, francisco carlos/HIK-2053-2022; Franz-Montan, Michelle/E-2865-2010; Figueira, Glyn/C-9605-2017; Franz-Montan, Michelle/V-3301-2019	de Paula, Eneida/0000-0003-4504-5723; Franz-Montan, Michelle/0000-0003-0760-1389; groppo, francisco carlos/0000-0002-8513-773X; Figueira, Glyn/0000-0002-0159-9735; Franz-Montan, Michelle/0000-0003-0760-1389; Rodrigues, Rodney A. F./0000-0001-5631-0970	Brazilian National Council for Scientific and Technological Development (CNPq) [133666/2012-3]	Brazilian National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Brazilian National Council for Scientific and Technological Development (CNPq, #133666/2012-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu Al-Melh M, 2007, ORAL SURG ORAL MED O, V103, pE16, DOI 10.1016/j.tripleo.2006.11.033; Aksungur P, 2004, J CONTROL RELEASE, V98, P269, DOI 10.1016/j.jconrel.2004.05.002; Al-Melh Manal Abu, 2008, J Clin Dent, V19, P43; [Anonymous], 2003, GUIDE VALIDATION ANA; [Anonymous], 2007, FDA PUBLIC HEALTH AD; [Anonymous], 2008, PLANTAS MED BRASIL N; [Anonymous], 2010, PRODUCT MONOGRAPH EM; Anvisa, 2010, BRAZILIAN PHARMACOPO, P56; Armfield JM, 2013, COMMUNITY DENT ORAL, V41, P279, DOI 10.1111/cdoe.12005; Arrau S, 2011, J ETHNOPHARMACOL, V133, P164, DOI 10.1016/j.jep.2010.09.016; Bae SS, 2010, PHYTOCHEM ANALYSIS, V21, P438, DOI 10.1002/pca.1215; Bansal R., 2005, ACTIVATED CARBON ADS, P1, DOI DOI 10.1201/9781420028812; Barman S., 2009, PHARM ONLINE, V1, P1027; Baruah R. N., 1993, Journal of Essential Oil Research, V5, P693; Bolognesi C, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.3995; Boonen J, 2010, J PHARMACEUT BIOMED, V53, P243, DOI 10.1016/j.jpba.2010.02.010; Briggs M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001177.pub3; Chakraborty A., 2004, Indian Journal of Pharmacology, V36, P148; Chakraborty A, 2010, INDIAN J PHARMACOL, V42, P277, DOI 10.4103/0253-7613.70106; Cilia-Lopez VG, 2010, PHARM BIOL, V48, P195, DOI 10.3109/13880200903078495; CORNWELL PA, 1994, J PHARM PHARMACOL, V46, P261, DOI 10.1111/j.2042-7158.1994.tb03791.x; de Araujo DR, 2010, PHARM RES-DORDR, V27, P1677, DOI 10.1007/s11095-010-0151-5; Del Consuelo ID, 2005, J PHARM SCI-US, V94, P2777, DOI 10.1002/jps.20409; del Consuelo ID, 2005, PHARM RES-DORDR, V22, P1525, DOI 10.1007/s11095-005-6020-y; Di Stasi LC, 2002, PLANTAS MEDICINAIS A, P472; Dias AMA, 2012, J SUPERCRIT FLUID, V61, P62, DOI 10.1016/j.supflu.2011.09.020; Diaz-del-Consuelo I, 2005, ARCH ORAL BIOL, V50, P981, DOI 10.1016/j.archoralbio.2005.04.008; Donaldson D, 1995, Anesth Prog, V42, P7; Eitner S, 2006, J ORAL REHABIL, V33, P588, DOI 10.1111/j.1365-2842.2005.01589.x; Fang C, 2008, EUR J PHARM BIOPHARM, V68, P735, DOI 10.1016/j.ejpb.2007.02.007; Fosquiera E, 2012, EFFECTIVENESS ACMELL; Franz TJ, 2009, SKIN PHARMACOL PHYS, V22, P276, DOI 10.1159/000235828; Franz-Montan M, 2015, J LIPOSOME RES, V25, P11, DOI 10.3109/08982104.2014.911315; Franz-Montan M, 2013, J LIPOSOME RES, V23, P54, DOI 10.3109/08982104.2012.742536; Godin B, 2007, ADV DRUG DELIVER REV, V59, P1152, DOI 10.1016/j.addr.2007.07.004; Gordon D, 2013, J ANXIETY DISORD, V27, P365, DOI 10.1016/j.janxdis.2013.04.002; GRANT GJ, 1993, J PHARMACOL TOXICOL, V29, P223, DOI 10.1016/1056-8719(93)90029-E; Hmud R, 2009, DENT ANXIETY CAUSES; HOLST A, 1985, SWED DENT J, V9, P185; Hutchins H S Jr, 1997, Anesth Prog, V44, P87; Jirovetz L, 2005, J ESSENT OIL RES, V17, P429, DOI 10.1080/10412905.2005.9698952; Kolesnikov Y, 2008, EUR J PHARMACOL, V579, P126, DOI 10.1016/j.ejphar.2007.10.014; Kulkarni U, 2010, J PHARM SCI-US, V99, P1265, DOI 10.1002/jps.21907; Kulkarni UD, 2011, AAPS PHARMSCITECH, V12, P579, DOI 10.1208/s12249-011-9624-z; Lehman PA, 2011, SKIN PHARMACOL PHYS, V24, P224, DOI 10.1159/000324884; Lemos T. L. G., 1991, Journal of Essential Oil Research, V3, P369; Ley Jakob P., 2006, V43, P21; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Malamed SF, 2013, MANUAL ANESTESIA LOC, V3; Marra DE, 2006, ARCH DERMATOL, V142, P1024, DOI 10.1001/archderm.142.8.1024; McGrath C, 2004, COMMUNITY DENT ORAL, V32, P67, DOI 10.1111/j.1600-0528.2004.00119.x; McMillan AS, 2000, BRIT J ORAL MAX SURG, V38, P58, DOI 10.1054/bjom.1999.0143; Meechan J G, 2005, Anesth Prog, V52, P91, DOI 10.2344/0003-3006(2005)52[91:FITDOI]2.0.CO;2; Meechan JG, 1996, BRIT DENT J, V181, P333, DOI 10.1038/sj.bdj.4809252; Miyazawa T, 2006, Agent for enhancing flavor of food/beverage products such as fish paste, milk beverages and snacks, contains plant extract or plant essential oil containing spilanthol, or spilanthol patent, Patent No. [JP2006296356-A 02, 2006296356]; Miyazawa T, 2006, Agent for enhancing flavor of food/beverage products such as fish paste, milk beverages and snacks, contains plant extract or plant essential oil containing spilanthol, or spilanthol patent, P17, Patent No. [JP2006296356-A 02, JP4530906-B2, JP2006296356-A, 4530906]; Miyazawa T, 2006, Agent for enhancing flavor of food/beverage products such as fish paste, milk beverages and snacks, contains plant extract or plant essential oil containing spilanthol, or spilanthol patent, P17, Patent No. [JP4530906-B2, 4530906]; Mohammed D, 2014, PHARM RES-DORDR, V31, P394, DOI 10.1007/s11095-013-1169-2; Morales JO, 2011, EUR J PHARM BIOPHARM, V77, P187, DOI 10.1016/j.ejpb.2010.11.023; Morris GA, 2010, BIOTECHNOL GENET ENG, V27, P257, DOI 10.1080/02648725.2010.10648153; Naik AD, 2012, J CHROMATOGR A, V1260, P61, DOI 10.1016/j.chroma.2012.08.043; Nokhodchi A, 2007, INT J PHARMACEUT, V335, P97, DOI 10.1016/j.ijpharm.2006.10.041; OECD, 2004, 428 ORG EC COOP DEV, DOI DOI 10.1787/9789264071087-EN; Nomura ECO, 2013, J ETHNOPHARMACOL, V150, P583, DOI 10.1016/j.jep.2013.09.007; Ogle Orrett E, 2012, Dent Clin North Am, V56, P133, DOI 10.1016/j.cden.2011.08.003; Ozsoy HD, 2010, J FOOD ENG, V101, P106, DOI 10.1016/j.jfoodeng.2010.06.018; Parirokh M, 2012, J ENDODONT, V38, P1553, DOI 10.1016/j.joen.2012.08.011; Prachayasittikul S, 2009, MOLECULES, V14, P850, DOI 10.3390/molecules14020850; Prachayasittikul V, 2013, EXCLI J, V12, P291; Ramsewak RS, 1999, PHYTOCHEMISTRY, V51, P729, DOI 10.1016/S0031-9422(99)00101-6; Rios MY, 2007, J ETHNOPHARMACOL, V110, P364, DOI 10.1016/j.jep.2006.09.041; Rodrigues R, 2014, INVENTORSPROCESSO PU; Rodrigues RAF, 2006, QUIM NOVA, V29, P368, DOI 10.1590/S0100-40422006000200030; Rodriguez-Reinoso F, 2001, ENCY MAT SCI TECHNOL, P22; Scheepers JC, 2011, AFR J BIOTECHNOL, V10, P16976, DOI 10.5897/AJB11.1999; Schuller AA, 2003, COMMUNITY DENT ORAL, V31, P116, DOI 10.1034/j.1600-0528.2003.00026.x; Sharma V, 2011, PHYTOMEDICINE, V18, P1161, DOI 10.1016/j.phymed.2011.06.001; Shin SC, 2004, INT J PHARMACEUT, V287, P73, DOI 10.1016/j.ijpharm.2004.08.012; States FaEMotU, 2000, SAFETY ASSESSMENT JA; Svensson P, 1992, Anesth Prog, V39, P79; Tran AN, 2014, J DRUGS DERMATOL, V13, P1118; van Wijk AJ, 2009, J DENT, V37, P700, DOI 10.1016/j.jdent.2009.05.023; Woolfson AD, 1998, INT J PHARM, V169, P83, DOI 10.1016/S0378-5173(98)00109-4; Wu LC, 2008, J AGR FOOD CHEM, V56, P2341, DOI 10.1021/jf073057e; Yadav R., 2011, INT J PHARM PHARM SC, V3, P245; Yang Z, 2013, INT J PHARMACEUT, V447, P231, DOI 10.1016/j.ijpharm.2013.02.048; Yu HY, 2002, J PHARM PHARMACOL, V54, P1221, DOI 10.1211/002235702320402062; Zhao W, 2011, INTRO NATURAL PRODUC, P5	88	21	21	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2016	11	9							e0162850	10.1371/journal.pone.0162850	http://dx.doi.org/10.1371/journal.pone.0162850			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5JO	27626796	gold, Green Published, Green Submitted			2023-01-03	WOS:000383680600057
J	Kocher, KE; Ayanian, JZ				Kocher, Keith E.; Ayanian, John Z.			Flipping the Script - A Patient-Centered Approach to Fixing Acute Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kocher, Keith E.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Ayanian, John Z.] Univ Michigan, Div Gen Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Kocher, Keith E.] Univ Michigan, Sch Med, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA; [Kocher, Keith E.; Ayanian, John Z.] Univ Michigan, Inst Health Policy & Innovat, Ann Arbor, MI 48109 USA; [Ayanian, John Z.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA; [Ayanian, John Z.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kocher, KE (corresponding author), Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA.; Kocher, KE (corresponding author), Univ Michigan, Sch Med, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA.; Kocher, KE (corresponding author), Univ Michigan, Inst Health Policy & Innovat, Ann Arbor, MI 48109 USA.			Kocher, Keith/0000-0001-7256-8859	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS024160] Funding Source: NIH RePORTER; AHRQ HHS [K08 HS024160] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Giesen P, 2011, ANN INTERN MED, V155, P108, DOI 10.7326/0003-4819-155-2-201107190-00006; Kaplan G., 2015, TRANSFORMING HLTH CA; Pines JM, 2016, ANN EMERG MED; Pitts SR, 2010, HEALTH AFFAIR, V29, P1620, DOI 10.1377/hlthaff.2009.1026; Selevan J, 2015, POPUL HEALTH MANAG, V18, P233, DOI 10.1089/pop.2014.0157	5	10	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 8	2016	375	10					915	917		10.1056/NEJMp1601899	http://dx.doi.org/10.1056/NEJMp1601899			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU9IG	27602664				2023-01-03	WOS:000382529500004
J	Ilic, I; Jankovic, S; Ilic, M				Ilic, Irena; Jankovic, Slobodan; Ilic, Milena			Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis	PLOS ONE			English	Article							III COLON-CANCER; 1ST-LINE TREATMENT; PHASE-II; FLUOROURACIL; LEUCOVORIN; METAANALYSIS; CAPECITABINE; COMBINATION; EFFICACY; THERAPY	Background Colorectal cancer is one of the leading causes of cancer deaths in both sexes in the world. Improvement of existing therapy modalities and implementing new ones in order to improve survival of patients with colorectal cancer represents a great challenge for medicine. The aim of this paper was to assess the impact that adding bevacizumab to chemotherapy has on survival in patients with metastatic colorectal cancer, compared to the use of chemotherapy alone. Methods Hazard ratios (HRs) with their 95% confidence intervals (CI) were determined from the studies and pooled. Two-sided p values were reported and considered to indicate statistical significance if less than 0.05. Results A total of 12 studies that meet the inclusion criteria were identified in the literature search, 3 phase II studies and 9 phase III studies. Based on the random effects meta-analysis, a statistically significant improvement was identified for both overall survival (HR = 0.84; 95% CI: 0.74-0.94; p = 0.003) and progression free survival (HR = 0.64; 95% CI: 0.55-0.73; p < 0.00001) in patients with metastatic colorectal cancer when bevacizumab was added to chemotherapy, compared to chemotherapy treatment alone. Conclusion The findings of this meta analysis confirm the benefit of adding bevacizumab to chemotherapy in terms of survival and progression free survival, but the magnitude of this effect is not consistent throughout the included studies. This suggests the need for further research of interaction of bevacizumab with chemotherapeutic agents as well as recognition of patients' characteristics important for the treatment selection criteria.	[Ilic, Irena] Univ Kragujevac, Fac Med Sci, Kragujevac, Serbia; [Jankovic, Slobodan] Univ Kragujevac, Fac Med Sci, Dept Pharmacol, Kragujevac, Serbia; [Ilic, Milena] Univ Kragujevac, Fac Med Sci, Dept Epidemiol, Kragujevac, Serbia	University of Kragujevac; University of Kragujevac; University of Kragujevac	Ilic, I (corresponding author), Univ Kragujevac, Fac Med Sci, Kragujevac, Serbia.	ajrini10@gmail.com	Ilic, Irena/T-8121-2019; Ilic, Milena/W-1498-2019; Jankovic, Slobodan/Q-4607-2016	Ilic, Irena/0000-0001-5347-3264; Jankovic, Slobodan/0000-0002-1519-8828; Ilic, Milena/0000-0003-3229-4990				Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711; Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Amit L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051780; [Anonymous], 2014, REV MAN REVMAN COMP; Chen YX, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/594930; Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Guan Zhong-Zhen, 2011, Chin J Cancer, V30, P682, DOI 10.5732/cjc.011.10188; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hung A, 2013, ONCOLOGIST, V18, P54, DOI 10.1634/theoncologist.2012-0050; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Labianca R, 2010, ANN ONCOL, V21, pv70, DOI 10.1093/annonc/mdq168; Lan YT, 2012, INT J COLORECTAL DIS, V27, P657, DOI 10.1007/s00384-011-1366-6; Lee YA, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054889, 10.1371/journal.pone.0063255]; Lv C, 2013, CANCER BIOTHER RADIO, V28, P501, DOI 10.1089/cbr.2012.1458; Macedo LT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-89; Moehler M, 2009, WORLD J GASTROENTERO, V15, P449, DOI 10.3748/wjg.15.449; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Institutes of Health, 2015, QUAL ASS CONTR INT S; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Passardi A, 2015, ANN ONCOL, V26, P1201, DOI 10.1093/annonc/mdv130; Rucker G, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-79; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Spitalnic Stuart, 2005, HOSP PHYS, V44, P43; Stathopoulos GP, 2010, ONCOLOGY-BASEL, V78, P376, DOI 10.1159/000320520; Su Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035629; Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723; Thornton AD, 2006, BRIT J SURG, V93, P1456, DOI 10.1002/bjs.5624; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2004, DOI 10.1200/JCO.2010.29.5436; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Welch S, 2010, ANN ONCOL, V21, P1152, DOI 10.1093/annonc/mdp533; Zhang GL, 2015, INT J CLIN EXP MED, V8, P1434	42	28	29	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2016	11	8							e0161912	10.1371/journal.pone.0161912	http://dx.doi.org/10.1371/journal.pone.0161912			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EG	27579775	gold, Green Published, Green Submitted			2023-01-03	WOS:000382877400046
J	Stein, AC; Gaetano, JN; Jacobs, J; Kunnavakkam, R; Bissonnette, M; Pekow, J				Stein, Adam C.; Gaetano, John Nick; Jacobs, Jeffrey; Kunnavakkam, Rangesh; Bissonnette, Marc; Pekow, Joel			Northern Latitude but Not Season Is Associated with Increased Rates of Hospitalizations Related to Inflammatory Bowel Disease: Results of a Multi-Year Analysis of a National Cohort	PLOS ONE			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; UNITED-STATES; RISK; EXACERBATIONS; EXPOSURE; ADMISSIONS; SYMPTOMS; FLARES	Background and Aims There is growing evidence that the incidence and severity of inflammatory bowel disease (IBD) may be geographically and seasonally related. Why these associations are observed remains unclear. We assessed the impact of geographic location, season, and exposure to ultraviolet light on disease severity by measuring national hospital IBD-related discharge rates. Methods Utilizing the Nationwide Inpatient Sample (NIS), we identified all patients with IBD-related discharges from 2001-2007. Patients were included if they were discharged from states above the 40th parallel (north) or at or below the 35th parallel (south); and their discharge fell within the winter (January, February, and March) or summer (July, August, and September). Groups of patients were assessed comparing north to south within each season, and summer to winter within each region. UV index was recorded from the National Weather Service data and compared to monthly discharge rates. Results There was a consistent pattern of increased IBD-related hospitalization rates in northern states compared to southern states for both ulcerative colitis and Crohn's disease. Differences in IBD-related hospitalization rates by season, however, were not uniform across the years studied. UV index was significantly inversely associated although not proportional to discharge rates for both Crohn's disease and ulcerative colitis. Conclusions In the US, there is a significant increased rate of IBD-related hospitalizations in the northern compared to southern states, which not fully explained by differences in UV exposure.	[Stein, Adam C.; Gaetano, John Nick; Jacobs, Jeffrey; Bissonnette, Marc; Pekow, Joel] Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Kunnavakkam, Rangesh] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Pekow, J (corresponding author), Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, 5841 S Maryland Ave, Chicago, IL 60637 USA.	jpekow@medicine.bsd.uchicago.edu		Jacobs, Jeffrey/0000-0001-9066-5900; Pekow, Joel/0000-0002-4790-8994	National Institutes of Health [K08 DK09015, P30DK42086]; NATIONAL CANCER INSTITUTE [R01CA164124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK090152] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Institutes of Health (K08 DK09015 (JP), P30DK42086). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ananthakrishnan AN, 2008, AM J GASTROENTEROL, V103, P2789, DOI 10.1111/j.1572-0241.2008.02054.x; Ananthakrishnan AN, 2012, GASTROENTEROLOGY, V142, P482, DOI 10.1053/j.gastro.2011.11.040; Aratari A, 2006, DIGEST LIVER DIS, V38, P319, DOI 10.1016/j.dld.2005.10.002; Ardizzone S, 2009, INT J IMMUNOPATH PH, V22, P63, DOI 10.1177/039463200902200108; Auslander JN, 2005, AM J GASTROENTEROL, V100, P2233, DOI 10.1111/j.1572-0241.2005.50127.x; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; DON BAC, 1984, LANCET, V2, P1156; Dopico XC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8000; Duarte-Garcia A, 2012, J RHEUMATOL, V39, P1392, DOI 10.3899/jrheum.111196; Economou M, 2008, INFLAMM BOWEL DIS, V14, P709, DOI 10.1002/ibd.20352; Govani SM, 2015, J CROHNS COLITIS, V9, P77, DOI 10.1093/ecco-jcc/jju002; Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223-012-9619-0; Hazratjee N, 2013, AM J GASTROENTEROL, V108, P1024, DOI 10.1038/ajg.2012.343; Jantchou P, 2014, INFLAMM BOWEL DIS, V20, P75, DOI 10.1097/01.MIB.0000436275.12131.4f; Karamanolis DG, 1997, HEPATO-GASTROENTEROL, V44, P1334; Kasahara AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065785; Khalili H, 2012, GUT, V61, P1686, DOI 10.1136/gutjnl-2011-301574; Lee JH, 2015, DIGEST DIS SCI, V60, P3373, DOI 10.1007/s10620-015-3863-x; Lewis JD, 2004, GASTROENTEROLOGY, V126, P665, DOI 10.1053/j.gastro.2003.12.003; Limketkai BN, 2014, ALIMENT PHARM THER, V40, P508, DOI 10.1111/apt.12845; Lofgren E, 2007, J VIROL, V81, P5429, DOI 10.1128/JVI.01680-06; Nerich V, 2011, ALIMENT PHARM THER, V33, P940, DOI 10.1111/j.1365-2036.2011.04601.x; Nerich V, 2010, INFLAMM BOWEL DIS, V16, P813, DOI 10.1002/ibd.21122; Ng SC, 2013, GUT, V62, P630, DOI 10.1136/gutjnl-2012-303661; Sample HNI, 2013, HEALTHC COST UT PROJ; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; SONNENBERG A, 1991, GASTROENTEROLOGY, V100, P143, DOI 10.1016/0016-5085(91)90594-B; SONNENBERG A, 1994, AM J GASTROENTEROL, V89, P847; SONNENBERG A, 1991, GASTROENTEROLOGY, V101, P122, DOI 10.1016/0016-5085(91)90468-Z; TYSK C, 1993, SCAND J GASTROENTERO, V28, P95, DOI 10.3109/00365529309096052; Ulitsky A, 2011, JPEN-PARENTER ENTER, V35, P308, DOI 10.1177/0148607110381267; Zeng L, 1996, SCAND J GASTROENTERO, V31, P79, DOI 10.3109/00365529609031631	32	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2016	11	8							e0161523	10.1371/journal.pone.0161523	http://dx.doi.org/10.1371/journal.pone.0161523			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EG	27579718	Green Submitted, gold, Green Published			2023-01-03	WOS:000382877400027
J	Coffin, PO; Behar, E; Rowe, C; Santos, GM; Coffa, D; Bald, M; Vittinghoff, E				Coffin, Phillip O.; Behar, Emily; Rowe, Christopher; Santos, Glenn-Milo; Coffa, Diana; Bald, Matthew; Vittinghoff, Eric			Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; HEROIN USERS; OVERDOSE PREVENTION	Background: Unintentional overdose involving opioid analgesics is a leading cause of injury-related death in the United States. Objective: To evaluate the feasibility and effect of implementing naloxone prescription to patients prescribed opioids for chronic pain. Design: 2-year nonrandomized intervention study. Setting: 6 safety-net primary care clinics in San Francisco, California. Participants: 1985 adults receiving long-term opioid therapy for pain. Intervention: Providers and clinic staff were trained and supported in naloxone prescribing. Measurements: Outcomes were proportion of patients prescribed naloxone, opioid-related emergency department (ED) visits, and prescribed opioid dose based on chart review. Results: 38.2% of 1985 patients receiving long-term opioids were prescribed naloxone. Patients prescribed higher doses of opioids and with an opioid-related ED visit in the past 12 months were independently more likely to be prescribed naloxone. Patients who received a naloxone prescription had 47% fewer opioid-related ED visits per month in the 6 months after receipt of the prescription (incidence rate ratio [IRR], 0.53 [95% CI, 0.34 to 0.83]; P = 0.005) and 63% fewer visits after 1 year (IRR, 0.37 [CI, 0.22 to 0.64]; P < 0.001) compared with patients who did not receive naloxone. There was no net change over time in opioid dose among those who received naloxone and those who did not (IRR, 1.03 [CI, 0.91 to 1.27]; P = 0.61). Limitation: Results are observational and may not be generalizable beyond safety-net settings. Conclusion: Naloxone can be coprescribed to primary care patients prescribed opioids for pain. When advised to offer naloxone to all patients receiving opioids, providers may prioritize those with established risk factors. Providing naloxone in primary care settings may have ancillary benefits, such as reducing opioid-related adverse events.	[Coffin, Phillip O.; Behar, Emily; Rowe, Christopher; Santos, Glenn-Milo] San Francisco Dept Publ Hlth, 25 Van Ness Ave,Suite 500, San Francisco, CA 94102 USA; [Vittinghoff, Eric] Univ Calif San Francisco, 550 16th St, San Francisco, CA 94158 USA; [Coffa, Diana] Univ Calif San Francisco, Sch Med, 1001 Potrero Ave,SFGH 80, San Francisco, CA 94110 USA; [Bald, Matthew] Kaiser Permanente San Francisco, 2425 Geary Blvd,M160, San Francisco, CA 94115 USA	San Francisco Department of Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Coffin, PO (corresponding author), San Francisco Dept Publ Hlth, 25 Van Ness Ave,Suite 500, San Francisco, CA 94102 USA.	phillip.coffin@ucsf.edu	Coffin, Phillip O/G-3286-2012	Coffin, Phillip O/0000-0002-3891-6570; Santos, Glenn-Milo/0000-0003-1009-5317	National Institutes of Health; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA036776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	National Institutes of Health.	Albert S, 2011, PAIN MED, V12, pS77, DOI 10.1111/j.1526-4637.2011.01128.x; [Anonymous], 2016, MED LETT DRUGS THER, V58, P1; Bartoszek M, 2012, OPERATION OPIOIDSAFE; Coffin PO, 2013, ANN INTERN MED, V158, P1, DOI 10.7326/0003-4819-158-1-201301010-00003; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Giglio Rebecca E, 2015, Inj Epidemiol, V2, P10; Greenland S, 2003, EPIDEMIOLOGY, V14, P300, DOI 10.1097/00001648-200305000-00009; Hirsch A, 2014, PAIN MED, V15, P1187, DOI 10.1111/pme.12391; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Khalid L, 2015, PAIN MED, V16, P480, DOI 10.1111/pme.12602; Maxwell S, 2006, J ADDICT DIS, V25, P89, DOI 10.1300/J069v25n03_11; National Services Scotland, 2014, NAT NAL PROGR SCOTL; Paone D, 2010, ILLICIT DRUG USE NY, P1; Rudd RA, 2014, MMWR-MORBID MORTAL W, V63, P849; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Substance Abuse and Mental Health Services Administration: Office of Applied Studies, 2009, DRUG AB WARN NETW EM, P178; Svendsen K, 2011, PALLIATIVE MED, V25, P725, DOI 10.1177/0269216311398300; Visconti AJ, 2015, J URBAN HEALTH, V92, P758, DOI 10.1007/s11524-015-9967-y; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Walley A.Y., 2012, BYSTANDER OVERDOSE E; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631	22	117	118	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2016	165	4					245	+		10.7326/M15-2771	http://dx.doi.org/10.7326/M15-2771			24	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT1UI	27366987	Green Accepted			2023-01-03	WOS:000381267200013
J	Sachse, D; Solevag, AL; Berg, JP; Nakstad, B				Sachse, Daniel; Solevag, Anne Lee; Berg, Jens Petter; Nakstad, Britt			The Role of Plasma and Urine Metabolomics in Identifying New Biomarkers in Severe Newborn Asphyxia: A Study of Asphyxiated Newborn Pigs following Cardiopulmonary Resuscitation	PLOS ONE			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CARDIAC-ARREST; PERINATAL ASPHYXIA; ASPHYCTIC NEWBORN; MODEL; COMPRESSIONS; REGRESSION; TRANSPORT; HYPOXIA; PACKAGE	Background Optimizing resuscitation is important to prevent morbidity and mortality from perinatal asphyxia. The metabolism of cells and tissues is severely disturbed during asphyxia and resuscitation, and metabolomic analyses provide a snapshot of many small molecular weight metabolites in body fluids or tissues. In this study metabolomics profiles were studied in newborn pigs that were asphyxiated and resuscitated using different protocols to identify biomarkers for subject characterization, intervention effects and possibly prognosis. Methods A total of 125 newborn Noroc pigs were anesthetized, mechanically ventilated and inflicted progressive asphyxia until asystole. Pigs were randomized to resuscitation with a FiO(2) 0.21 or 1.0, different duration of ventilation before initiation of chest compressions (CC), and different CC to ventilation ratios. Plasma and urine samples were obtained at baseline, and 2 h and 4 h after return of spontaneous circulation (ROSC, heart rate > = 100 bpm). Metabolomics profiles of the samples were analyzed by nuclear magnetic resonance spectroscopy. Results Plasma and urine showed severe metabolic alterations consistent with hypoxia and acidosis 2 h and 4 h after ROSC. Baseline plasma hypoxanthine and lipoprotein concentrations were inversely correlated to the duration of hypoxia sustained before asystole occurred, but there was no evidence for a differential metabolic response to the different resuscitation protocols or in terms of survival. Conclusions Metabolic profiles of asphyxiated newborn pigs showed severe metabolic alterations. Consistent with previously published reports, we found no evidence of differences between established and alternative resuscitation protocols. Lactate and pyruvate may have a prognostic value, but have to be independently confirmed.	[Sachse, Daniel; Berg, Jens Petter] Univ Oslo, Inst Clin Med, Dept Med Biochem, Oslo, Norway; [Sachse, Daniel] Univ Oslo, Dept Chem, Oslo, Norway; [Solevag, Anne Lee; Nakstad, Britt] Akershus Univ Hosp, Dept Paediat & Adolescent Med, N-1478 Oslo, Norway; [Berg, Jens Petter] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway; [Nakstad, Britt] Univ Oslo, Campus Akershus Univ Hosp, Inst Clin Med, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo	Nakstad, B (corresponding author), Akershus Univ Hosp, Dept Paediat & Adolescent Med, N-1478 Oslo, Norway.; Nakstad, B (corresponding author), Univ Oslo, Campus Akershus Univ Hosp, Inst Clin Med, Oslo, Norway.	britt.nakstad@medisin.uio.no	Solevåg, Anne Lee/AAH-9734-2021; Berg, Jens P/G-1455-2012	Solevåg, Anne Lee/0000-0002-8009-7169; Berg, Jens P/0000-0003-0157-5888				[Anonymous], 2010, R LANG ENV STAT COMP; Atzori L, 2010, J MATERN-FETAL NEO M, V23, P134, DOI 10.3109/14767058.2010.517033; Barkauskas DA, 2009, FTICRMS PROGR ANAL F; Barkauskas DA, 2010, ANAL CHIM ACTA, V657, P191, DOI 10.1016/j.aca.2009.10.043; BELL JD, 1988, CHEM BRIT, V24, P1021; Chalkias A, 2014, RESUSCITATION, V85, P595, DOI 10.1016/j.resuscitation.2014.01.025; Cloarec O, 2005, ANAL CHEM, V77, P517, DOI 10.1021/ac048803i; Dannevig I, 2013, PEDIATR RES, V73, P163, DOI 10.1038/pr.2012.167; Dannevig Ingrid, 2012, Open Respir Med J, V6, P89, DOI 10.2174/1874306401206010089; Dannevig I, 2011, NEONATOLOGY, V99, P153, DOI 10.1159/000302718; Fanos V, 2014, BIOMED RES INT; Fanos V, 2014, J MATERN-FETAL NEO M, V27, P39, DOI 10.3109/14767058.2014.955966; Fanos V, 2014, CLIN BIOCHEM, V47, P708, DOI 10.1016/j.clinbiochem.2014.05.020; Fanos V, 2014, EARLY HUM DEV, V90, pS78, DOI 10.1016/S0378-3782(14)70024-6; Feingold KR, 2011, J LIPID RES, V52, P1, DOI 10.1194/jlr.E012138; Hering-Smith KS, 2000, AM J PHYSIOL-RENAL, V278, pF492, DOI 10.1152/ajprenal.2000.278.3.F492; HOHMANN B, 1974, KIDNEY INT, V5, P261, DOI 10.1038/ki.1974.35; IWAMOTO HS, 1985, AM J PHYSIOL, V249, pF836, DOI 10.1152/ajprenal.1985.249.6.F836; Jun JC, 2013, AM J PHYSIOL-ENDOC M, V304, pE424, DOI 10.1152/ajpendo.00515.2012; KRIAT M, 1992, NMR BIOMED, V5, P179, DOI 10.1002/nbm.1940050404; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Longini M, 2015, CLIN CHIM ACTA, V444, P250, DOI 10.1016/j.cca.2015.02.004; Mevik BH, 2007, J STAT SOFTW, V18, P1, DOI 10.18637/jss.v018.i02; Ponnusamy V, 2016, PEDIATR RES, V79, P799, DOI 10.1038/pr.2015.276; Reinke SN, 2013, J PROTEOME RES, V12, P4230, DOI 10.1021/pr400617m; Sachse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052399; Savman K, 2013, TRANSL STROKE RES, V4, P228, DOI 10.1007/s12975-012-0216-3; Skappak C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065035; Solberg R, 2010, PLOS ONE, V5; Solevag AL, 2011, ARCH DIS CHILD-FETAL, V96, pF417, DOI 10.1136/adc.2010.200386; Solevag AL, 2010, RESUSCITATION, V81, P1571, DOI 10.1016/j.resuscitation.2010.06.007; Solevag AL, 2010, NEONATOLOGY, V98, P64, DOI 10.1159/000275560; Stacklies W, 2007, BIOINFORMATICS, V23, P1164, DOI 10.1093/bioinformatics/btm069; Walsh BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050520; Westerhuis JA, 2008, METABOLOMICS, V4, P81, DOI 10.1007/s11306-007-0099-6; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1	36	23	23	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2016	11	8							e0161123	10.1371/journal.pone.0161123	http://dx.doi.org/10.1371/journal.pone.0161123			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4UN	27529347	Green Published, gold, Green Submitted			2023-01-03	WOS:000381476700048
J	Wang, SA; Xu, MQ; Wang, WQ; Cao, XC; Piao, MY; Khan, S; Yan, F; Cao, HL; Wang, BM				Wang, Sinan; Xu, Mengque; Wang, Weiqiang; Cao, Xiaocang; Piao, Meiyu; Khan, Samiullah; Yan, Fang; Cao, Hailong; Wang, Bangmao			Systematic Review: Adverse Events of Fecal Microbiota Transplantation	PLOS ONE			English	Review							CLOSTRIDIUM-DIFFICILE INFECTION; INFLAMMATORY-BOWEL-DISEASE; TERM-FOLLOW-UP; ULCERATIVE-COLITIS; CROHNS-DISEASE; EFFECTIVE THERAPY; NASOGASTRIC TUBE; GUT MICROBIOTA; RECURRENT; OUTCOMES	Background Fecal microbiota transplantation (FMT) is a microbiota-based therapy that shows therapeutic potential in recurrent or refractory Clostridium difficile infections and other intestinal or extra-intestinal disorders. Nonetheless, adverse events (AEs) remain a major challenge in the application of FMT. Aim To review the AEs of FMT and to address the concerns of safety during the procedure. Methods Publications were retrieved in the databases of Medline, Embase and Cochrane Library. AEs were classified according to their causality with FMT or their severity. Results A total of 7562 original articles about FMT were identified in this study, 50 of them fulfilled the inclusion criteria. Totally 78 kinds of AEs were revealed enrolled in these 50 selected publications. The total incidence rate of AEs was 28.5%. Among the 42 publications, 5 kinds were definitely and 38 kinds were probably related to FMT. The commonest FMT-attributable AE was abdominal discomfort, which was reported in 19 publications. For upper gastrointestinal routes of FMT, 43.6%(89/204) patients were compromised by FMT-attributable AE, while the incidence dropped to 17.7% (76/430) for lower gastrointestinal routes. In contrast, the incidences of serious adverse events (SAEs) were 2.0% (4/196) and 6.1% (40/659) for upper and lower gastrointestinal routes, respectively. A total of 44 kinds of SAEs occurred in 9.2% patients, including death (3.5%, 38/1089), infection (2.5%, 27/1089), relapse of inflammatory bowel diseases (0.6%, 7/1089) and Clostridium difficile infection (0.9%, 10/1089). Conclusion Consequently, both AEs and SAEs are not rare and should be carefully monitored throughout FMT. However, high quality randomized controlled trials are still needed for the more definite incidence of AEs of FMT.	[Wang, Sinan; Xu, Mengque; Wang, Weiqiang; Cao, Xiaocang; Piao, Meiyu; Khan, Samiullah; Yan, Fang; Cao, Hailong; Wang, Bangmao] Tianjin Med Univ, Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China; [Yan, Fang; Cao, Hailong] Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Med Ctr, Nashville, TN 37232 USA	Tianjin Medical University; Vanderbilt University	Cao, HL; Wang, BM (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China.; Cao, HL (corresponding author), Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Med Ctr, Nashville, TN 37232 USA.	cao_hailong@163.com; tjmughgi@hotmail.com		cao, xiaocang/0000-0001-8376-3481	National Natural Science Foundation of China [81570478, 81300272, 81470796]; Tianjin Research Program of Application Foundation and Advanced Technology of China [13JCQNJC10600, 15JCZDJC36600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Research Program of Application Foundation and Advanced Technology of China	This study is supported by the grants (81570478 to B.W., 81300272 to H.C. and 81470796 to F.Y.) from the National Natural Science Foundation of China, and the grants (13JCQNJC10600 to H.C. and 15JCZDJC36600 to F.Y.) from Tianjin Research Program of Application Foundation and Advanced Technology of China.	Aas J, 2003, CLIN INFECT DIS, V36, P580, DOI 10.1086/367657; Anderson JL, 2012, ALIMENT PHARM THER, V36, P503, DOI 10.1111/j.1365-2036.2012.05220.x; Angelberger S, 2013, AM J GASTROENTEROL, V108, P1620, DOI 10.1038/ajg.2013.257; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bakken JS, 2011, CLIN GASTROENTEROL H, V9, P1044, DOI 10.1016/j.cgh.2011.08.014; Borody T, 2012, AM J GASTROENTEROL, V107, pS591, DOI 10.14309/00000434-201210001-01481; Borody T, 2011, AM J GASTROENTEROL, V106, pS352; Borody T, 2011, AM J GASTROENTEROL, V106, pS352; BORODY TJ, 1989, MED J AUSTRALIA, V150, P604, DOI 10.5694/j.1326-5377.1989.tb136704.x; Borody TJ, 2004, J CLIN GASTROENTEROL, V38, P475, DOI 10.1097/01.mcg.0000128988.13808.dc; Borody TJ, 2003, J GASTROEN HEPATOL, V18, pB8; Brandt L, 2013, AM J GASTROENTEROL, V108, pS556, DOI 10.14309/00000434-201310001-01840; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Cui BT, 2015, J GASTROEN HEPATOL, V30, P51, DOI 10.1111/jgh.12727; De Leon LM, 2013, CLIN GASTROENTEROL H, V11, P1036, DOI 10.1016/j.cgh.2013.04.045; Dutta SK, 2014, CLIN GASTROENTEROL H, V12, P1572, DOI 10.1016/j.cgh.2013.12.032; EISEMAN B, 1958, SURGERY, V44, P854; Fischer M, 2014, AM J GASTROENTEROL, V109, pS487, DOI 10.14309/00000434-201410002-01643; Fischer M, 2014, AM J GASTROENTEROL, V109, pS195, DOI 10.14309/00000434-201410002-00674; Frank DN, 2011, INFLAMM BOWEL DIS, V17, P179, DOI 10.1002/ibd.21339; Friedman-Moraco RJ, 2014, AM J TRANSPLANT, V14, P477, DOI 10.1111/ajt.12577; Garborg K, 2010, SCAND J INFECT DIS, V42, P857, DOI 10.3109/00365548.2010.499541; Greenberg A, 2013, AM J GASTROENTEROL, V108, pS540, DOI 10.14309/00000434-201310001-01791; Guo B, 2012, ALIMENT PHARM THER, V35, P865, DOI 10.1111/j.1365-2036.2012.05033.x; Gustafsson A, 1998, SCAND J GASTROENTERO, V33, P721; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Hedin CR, 2012, GUT, V61, P311, DOI 10.1136/gut.2011.238568; Hohmann EL, 2014, NEW ENGL J MED, V371, P668, DOI 10.1056/NEJMcpc1400842; Hooper LV, 2010, NAT REV IMMUNOL, V10, P159, DOI 10.1038/nri2710; Hornig M, 2013, CURR OPIN RHEUMATOL, V25, P488, DOI 10.1097/BOR.0b013e32836208de; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ianiro G, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000097; Joossens M, 2011, GUT, V60, P631, DOI 10.1136/gut.2010.223263; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500; Kelly CR, 2014, AM J GASTROENTEROL, V109, P1065, DOI 10.1038/ajg.2014.133; Kelly CR, 2014, CLIN GASTROENTEROL H, V12, P283, DOI 10.1016/j.cgh.2013.09.060; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Kronman MP, 2015, J PEDIATR GASTR NUTR, V60, P23, DOI 10.1097/MPG.0000000000000545; Kubinak JL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9642; Kump PK, 2013, INFLAMM BOWEL DIS, V19, P2155, DOI 10.1097/MIB.0b013e31829ea325; Kunde S, 2013, J PEDIATR GASTR NUTR, V56, P597, DOI 10.1097/MPG.0b013e318292fa0d; Landy J, 2011, ALIMENT PHARM THER, V34, P409, DOI 10.1111/j.1365-2036.2011.04737.x; Lee CH, 2014, EUR J CLIN MICROBIOL, V33, P1425, DOI 10.1007/s10096-014-2088-9; Lepage P, 2011, GASTROENTEROLOGY, V141, P227, DOI 10.1053/j.gastro.2011.04.011; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Luckey D, 2013, INDIAN J MED RES, V138, P732; Macconnachie AA, 2009, QJM-INT J MED, V102, P781, DOI 10.1093/qjmed/hcp118; Mandalia A, 2014, GASTROENTEROLOGY, V146, pS252; Mandalia A, 2014, AM J GASTROENTEROL, V109, P1956, DOI 10.1038/ajg.2014.350; Mattila E, 2012, GASTROENTEROLOGY, V142, P490, DOI 10.1053/j.gastro.2011.11.037; Mellow M, 2010, AM J GASTROENTEROL, V105, pS135, DOI 10.14309/00000434-201010001-00367; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Mondot S, 2011, INFLAMM BOWEL DIS, V17, P185, DOI 10.1002/ibd.21436; Obi O, 2014, AM J GASTROENTEROL, V109, pS629, DOI 10.14309/00000434-201410002-02172; Pepin J, 2005, CLIN INFECT DIS, V40, P1591, DOI 10.1086/430315; Pierog A, 2014, PEDIATR INFECT DIS J, V33, P1198, DOI 10.1097/INF.0000000000000419; Pinn DM, 2014, AM J GASTROENTEROL, V109, P1831, DOI [10.1038/ajg.2014.295, 10.1038/ajg.2014.395]; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Ray A, 2014, OCHSNER J, V14, P538; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Russell GH, 2014, J PEDIATR GASTR NUTR, V58, P588, DOI 10.1097/MPG.0000000000000283; Russell SL, 2012, CURR OPIN GASTROEN, V28, P563, DOI 10.1097/MOG.0b013e3283573017; Satokari R, 2015, ALIMENT PHARM THER, V41, P46, DOI 10.1111/apt.13009; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; SCHWAN A, 1983, LANCET, V2, P845; Schwartz M, 2013, AM J GASTROENTEROL, V108, P1367, DOI 10.1038/ajg.2013.164; Sha S, 2014, ALIMENT PHARM THER, V39, P1003, DOI 10.1111/apt.12699; Silverman MS, 2010, CLIN GASTROENTEROL H, V8, P471, DOI 10.1016/j.cgh.2010.01.007; Sun W, 2014, AM J GASTROENTEROL, V109, pS420, DOI 10.14309/00000434-201410002-01421; Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4; Suskind DL, 2015, INFLAMM BOWEL DIS, V21, P556, DOI 10.1097/MIB.0000000000000307; Suskind DL, 2015, J PEDIATR GASTR NUTR, V60, P27, DOI 10.1097/MPG.0000000000000544; Tilg H, 2011, J CLIN INVEST, V121, P2126, DOI 10.1172/JCI58109; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Trubiano JA, 2013, EUR J GASTROEN HEPAT, V25, P255, DOI 10.1097/MEG.0b013e32835b2da9; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vandenplas Y, 2015, J PEDIATR GASTR NUTR, V61, pE12, DOI 10.1097/MPG.0000000000000281; Vermeire S, 2012, GASTROENTEROLOGY, V142, pS360; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wang M, 2013, J GASTROEN HEPATOL, V28, P590; Wilson D, 2014, AM J GASTROENTEROL, V109, pS207, DOI 10.14309/00000434-201410002-00714; Xu MQ, 2015, WORLD J GASTROENTERO, V21, P102, DOI 10.3748/wjg.v21.i1.102; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875; Zhang FM, 2013, WORLD J GASTROENTERO, V19, P7213, DOI 10.3748/wjg.v19.i41.7213; ZHANG FM, 2012, AM J GASTROENTEROL, V107, P1755, DOI DOI 10.1038/AJG.2012.251]	92	226	244	3	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2016	11	8							e0161174	10.1371/journal.pone.0161174	http://dx.doi.org/10.1371/journal.pone.0161174			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4UN	27529553	Green Published, Green Submitted, gold			2023-01-03	WOS:000381476700051
J	Kim, S; Feinberg, B; Kant, R; Chui, B; Goldman, K; Park, J; Moses, W; Blaha, C; Iqbal, Z; Chow, C; Wright, N; Fissell, WH; Zydney, A; Roy, S				Kim, Steven; Feinberg, Benjamin; Kant, Rishi; Chui, Benjamin; Goldman, Ken; Park, Jaehyun; Moses, Willieford; Blaha, Charles; Iqbal, Zohora; Chow, Clarence; Wright, Nathan; Fissell, William H.; Zydney, Andrew; Roy, Shuvo			Diffusive Silicon Nanopore Membranes for Hemodialysis Applications	PLOS ONE			English	Article							WEARABLE ARTIFICIAL-KIDNEY; QUALITY-OF-LIFE; HEMOFILTRATION MEMBRANES; PREDICT MORTALITY; DIALYSIS PATIENTS; TRANSPORT; ULTRAFILTRATION; PERFORMANCE; DISEASE; SYSTEMS	Hemodialysis using hollow-fiber membranes provides life-sustaining treatment for nearly 2 million patients worldwide with end stage renal disease (ESRD). However, patients on hemodialysis have worse long-term outcomes compared to kidney transplant or other chronic illnesses. Additionally, the underlying membrane technology of polymer hollow-fiber membranes has not fundamentally changed in over four decades. Therefore, we have proposed a fundamentally different approach using microelectromechanical systems (MEMS) fabrication techniques to create thin-flat sheets of silicon-based membranes for implantable or portable hemodialysis applications. The silicon nanopore membranes (SNM) have biomimetic slit-pore geometry and uniform pores size distribution that allow for exceptional permeability and selectivity. A quantitative diffusion model identified structural limits to diffusive solute transport and motivated a new microfabrication technique to create SNM with enhanced diffusive transport. We performed in vitro testing and extracorporeal testing in pigs on prototype membranes with an effective surface area of 2.52 cm(2) and 2.02 cm(2), respectively. The diffusive clearance was a two-fold improvement in with the new microfabrication technique and was consistent with our mathematical model. These results establish the feasibility of using SNM for hemodialysis applications with additional scale-up.	[Kim, Steven] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA; [Feinberg, Benjamin; Kant, Rishi; Park, Jaehyun; Blaha, Charles; Iqbal, Zohora; Chow, Clarence; Wright, Nathan; Roy, Shuvo] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Chui, Benjamin] Ben Chui Consulting, Sunnyvale, CA USA; [Goldman, Ken] H Cubed, Olmsted Falls, OH USA; [Moses, Willieford] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Blaha, Charles; Wright, Nathan; Fissell, William H.; Roy, Shuvo] Silicon Kidney LLC, San Francisco, CA 94122 USA; [Fissell, William H.] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Nashville, TN USA; [Zydney, Andrew] Penn State Univ, Dept Chem Engn, State Coll, PA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Roy, S (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.; Roy, S (corresponding author), Silicon Kidney LLC, San Francisco, CA 94122 USA.	Shuvo.roy@ucsf.edu		Fissell, William/0000-0002-3960-3998	American Society of Nephrology Ben J. Lipps Research Fellowship; National Institute of Diabetes, and Digestive, and Kidney Diseases of the National Institutes of Health [F32 DK103468]; National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [R01 EB014315, U01EB021214]; Wildwood Foundation; John and Marcia Goldman Foundation; H-Cubed; Ben Chui Consulting; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [U01EB021214, R01EB014315] Funding Source: NIH RePORTER	American Society of Nephrology Ben J. Lipps Research Fellowship; National Institute of Diabetes, and Digestive, and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Wildwood Foundation; John and Marcia Goldman Foundation; H-Cubed; Ben Chui Consulting; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by the American Society of Nephrology Ben J. Lipps Research Fellowship, National Institute of Diabetes, and Digestive, and Kidney Diseases of the National Institutes of Health under the Award Number F32 DK103468, National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Numbers R01 EB014315 and U01EB021214, Wildwood Foundation and the John and Marcia Goldman Foundation. The funders, H-Cubed and Ben Chui Consulting, provided support in the form of salaries for authors BC and KG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], 2011, FRESENIUS OPTIFLUX D; Buoncristiani U, 1998, NEPHROL DIAL TRANSPL, V13, P148, DOI 10.1093/ndt/13.suppl_6.148; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Cheung AK, 2006, J AM SOC NEPHROL, V17, P546, DOI 10.1681/ASN.2005020132; Conlisk AT, 2009, ANN BIOMED ENG, V37, P722, DOI 10.1007/s10439-009-9642-0; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Daugirdas JT, 2012, KIDNEY INT, V82, P147, DOI 10.1038/ki.2012.130; Daugirdas JT., 2007, HDB DIALYSIS; Dechadilok P, 2006, IND ENG CHEM RES, V45, P6953, DOI 10.1021/ie051387n; Del Vecchio L, 2011, SEMIN DIALYSIS, V24, P56, DOI 10.1111/j.1525-139X.2010.00819.x; Finkelstein FO, 2012, KIDNEY INT, V82, P561, DOI 10.1038/ki.2012.168; Fissell WH, 2006, ASAIO J, V52, P221, DOI 10.1097/01.mat.0000205228.30516.9c; Fissell WH, 2009, J MEMBRANE SCI, V326, P58, DOI 10.1016/j.memsci.2008.09.039; Gura V, 2009, CLIN J AM SOC NEPHRO, V4, P1441, DOI 10.2215/CJN.02790409; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; Johnson DG, 2013, ADV CHRONIC KIDNEY D, V20, P508, DOI 10.1053/j.ackd.2013.08.001; Kanani DM, 2010, J MEMBRANE SCI, V349, P405, DOI 10.1016/j.memsci.2009.12.003; Kaysen GA, 2001, J AM SOC NEPHROL, V12, P1549, DOI 10.1681/ASN.V1271549; Kim S, 2013, ADV CHRONIC KIDNEY D, V20, P516, DOI 10.1053/j.ackd.2013.08.006; Kimmel PL, 2000, KIDNEY INT, V57, P2093, DOI 10.1046/j.1523-1755.2000.00059.x; Langsdorf LJ, 1994, TRANSPORT PROPERTIES; Lee DBN, 2008, CLIN EXP NEPHROL, V12, P171, DOI 10.1007/s10157-008-0050-9; LI L, 2010, J BIOMATER SCI POLYM; Muthusubramaniam L, 2011, ANN BIOMED ENG, V39, P1296, DOI 10.1007/s10439-011-0256-y; OPONG WS, 1991, AICHE J, V37, P1497, DOI 10.1002/aic.690371007; Papra A, 2001, LANGMUIR, V17, P1457, DOI 10.1021/la000609d; Popat KC, 2004, BIOSENS BIOELECTRON, V19, P1037, DOI 10.1016/j.bios.2003.10.007; PORTER MC, 1972, IND ENG CHEM PROD RD, V11, P234, DOI 10.1021/i360043a002; Randoux C, 2001, KIDNEY INT, V60, P1571, DOI 10.1046/j.1523-1755.2001.00970.x; Ronco C, 2001, BLOOD PURIFICAT, V19, P347, DOI 10.1159/000046964; Saran R, 2006, KIDNEY INT, V69, P1222, DOI 10.1038/sj.ki.5000186; Smith RA, 2011, MEAS SCI TECHNOL, V22, DOI 10.1088/0957-0233/22/4/045802; Twardowski ZJ, 2008, HEMODIAL INT, V12, P173, DOI 10.1111/j.1542-4758.2008.00253.x; Tzamaloukas AH, 1998, KIDNEY INT, V53, P1405, DOI 10.1046/j.1523-1755.1998.00896.x; United States Renal Data System, 2015, 2015 USRDS ANN DAT R; US Department of Health and Human Services, 2013, OPTN DAT ORG PROC TR; Zhu JM, 2006, BIOMACROMOLECULES, V7, P1036, DOI 10.1021/bm050611p	37	17	17	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2016	11	7							e0159526	10.1371/journal.pone.0159526	http://dx.doi.org/10.1371/journal.pone.0159526			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR8TL	27438878	Green Published, gold			2023-01-03	WOS:000380170100053
J	Feudtner, C				Feudtner, Chris			A Hand to Hold	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Feudtner, Chris] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia	Feudtner, C (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	feudtner@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434					0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2016	316	2					147	148		10.1001/jama.2016.2972	http://dx.doi.org/10.1001/jama.2016.2972			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ9CW	27404180				2023-01-03	WOS:000379509000008
J	Gori, S; Inno, A; Rossi, V; Turazza, M; Fiorio, E; Fabi, A; Bisagni, G; Foglietta, J; Santini, D; Pavese, I; Pellegrino, A; Zambelli, A; Vici, P; Leonardi, V; Barni, S; Saracchini, S; Bogina, G; Marchetti, F; Duranti, S; Lunardi, G; Montemurro, F				Gori, Stefania; Inno, Alessandro; Rossi, Valentina; Turazza, Monica; Fiorio, Elena; Fabi, Alessandra; Bisagni, Giancarlo; Foglietta, Jennifer; Santini, Daniele; Pavese, Ida; Pellegrino, Arianna; Zambelli, Alberto; Vici, Patrizia; Leonardi, Vita; Barni, Sandro; Saracchini, Silvana; Bogina, Giuseppe; Marchetti, Fabiana; Duranti, Simona; Lunardi, Gianluigi; Montemurro, Filippo			Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study	PLOS ONE			English	Article							PLUS CAPECITABINE; SURVIVAL; WOMEN; COMBINATION; PERTUZUMAB; DOCETAXEL; THERAPY; BENEFIT	Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p<0.001). Multivariate analysis revealed the benefit of lapatinib-based therapy in terms of PFS and OS was significantly associated with time-to-progression (TTP) on prior first-line trastuzumab-based therapy. In particular, each additional month on first-line trastuzumab based therapy was associated with a reduction in hazard of progression and death after the initiation of lapatinib-based therapy of 2% and 4%, respectively. Conclusions A longer TTP to first line trastuzumab seems to predict a prolonged PFS and OS with subsequent lapatinib and capecitabine.	[Gori, Stefania; Inno, Alessandro; Turazza, Monica; Marchetti, Fabiana; Duranti, Simona; Lunardi, Gianluigi] Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy; [Rossi, Valentina] Osped Civile Saluzzo, Med Oncol, Saluzzo, Italy; [Fiorio, Elena] AO Univ Integrata Verona, Med Oncol, Verona, Italy; [Fabi, Alessandra] INT Regina Elena, Med Oncol A, Rome, Italy; [Bisagni, Giancarlo] IRCCS AO S Maria Nuova, Med Oncol, Reggio Emilia, Italy; [Foglietta, Jennifer] Osped S Maria Misericordia, Med Oncol, Perugia, Italy; [Santini, Daniele] Univ Campus Biomed, Med Oncol, Rome, Italy; [Pavese, Ida; Pellegrino, Arianna] San Pietro Fatebenefratelli Hosp, Med Oncol, Rome, Italy; [Zambelli, Alberto] IRCCS Fdn S Maugeri, Med Oncol, Pavia, Italy; [Vici, Patrizia] INT Regina Elena, Med Oncol B, Rome, Italy; [Leonardi, Vita] ARNAS Civ, Med Oncol, Palermo, Italy; [Barni, Sandro] AO Treviglio Bergamo, Med Oncol, Bergamo, Italy; [Saracchini, Silvana] S Maria Angeli Hosp, Med Oncol, Pordenone, Italy; [Bogina, Giuseppe] Sacro Cuore Don Calabria Hosp, Pathol, Verona, Italy; [Montemurro, Filippo] Candiolo Canc Inst IRCCS, Invest Clin Oncol INCO, Fdn Piemonte Oncol, Candiolo, Italy	IRCCS Sacro Cuore Don Calabria; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Hospital Santa Maria della Misericordia; University Campus Bio-Medico - Rome Italy; Istituti Clinici Scientifici Maugeri IRCCS; A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli; IRCCS Sacro Cuore Don Calabria; IRCCS Fondazione del Piemonte per l'Oncologia	Gori, S (corresponding author), Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy.	stefania.gori@sacrocuore.it	Bisagni, Giancarlo/AAC-2735-2020; GORI, Stefania/N-8827-2016; Inno, Alessandro/AAA-8268-2022; Fabi, Alessandra/AAC-1021-2019; Fiorio, Elena/AAC-5849-2022; Duranti, Simona/ABD-2502-2020; Saracchini, Silvana/ABD-9637-2020; GORI, Stefania/AAB-4802-2022; Montemurro, Filippo/AAC-1957-2019; Duranti, Simona/ABD-7914-2021; Zambelli, Alberto/HGB-1572-2022	Bisagni, Giancarlo/0000-0003-1042-3771; GORI, Stefania/0000-0001-6320-405X; Inno, Alessandro/0000-0001-6331-6908; Fiorio, Elena/0000-0002-1354-4600; Duranti, Simona/0000-0002-1924-238X; Saracchini, Silvana/0000-0002-7626-872X; GORI, Stefania/0000-0001-6320-405X; Zambelli, Alberto/0000-0002-1374-1831; Vici, Patrizia/0000-0001-7528-9783; Fabi, Alessandra/0000-0002-0758-8033; Montemurro, Filippo/0000-0003-4231-2291	Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute	F. Montemurro is supported by Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute 2012 - http://www.fprconlus.it/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson M, 2011, J CLIN ONCOL, V29, P264, DOI 10.1200/JCO.2010.30.8213; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Cameron D, 2008, BREAST CANCER RES TR, V112, P533, DOI 10.1007/s10549-007-9885-0; Cameron D, 2010, ONCOLOGIST, V15, P924, DOI 10.1634/theoncologist.2009-0181; Fabi A, 2013, EXPERT OPIN PHARMACO, V14, P699, DOI 10.1517/14656566.2013.779672; FALKSON G, 1990, CANCER, V66, P1621, DOI 10.1002/1097-0142(19901001)66:7<1621::AID-CNCR2820660729>3.0.CO;2-G; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Giordano SH, 2014, J CLIN ONCOL, V32, P2078, DOI 10.1200/JCO.2013.54.0948; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; Kim H, 2013, RADIAT ONCOL J, V31, P222, DOI 10.3857/roj.2013.31.4.222; Majewski IJ, 2015, J CLIN ONCOL, V33, P1334, DOI 10.1200/JCO.2014.55.2158; Slamon D. J., 2011, NEW ENGL J MED, V344, P783; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Thery JC, 2014, EUR J CANCER, V50, P892, DOI 10.1016/j.ejca.2014.01.003; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124	20	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2016	11	5							e0156221	10.1371/journal.pone.0156221	http://dx.doi.org/10.1371/journal.pone.0156221			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GI	27224517	Green Published, Green Submitted, gold			2023-01-03	WOS:000376881700074
J	Ma, XL; Wang, XS; Huang, JW; Chen, YT; Zhang, J; Zhang, BL; Shi, CL; Liu, L				Ma, Xuelei; Wang, Xiaoshan; Huang, Jingwen; Chen, Yingtai; Zhang, Jing; Zhang, Binglan; Shi, Changle; Liu, Lei			Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis	PLOS ONE			English	Article							CELL LUNG-CANCER; PHASE-II TRIAL; CONTROLLED SUPERIORITY TRIAL; PLUS ADJUVANT CHEMOTHERAPY; TAXANE-BASED CHEMOTHERAPY; QUALITY-OF-LIFE; CONSERVING SURGERY; OPEN-LABEL; PREOPERATIVE CHEMOTHERAPY; 1ST-LINE TREATMENT	Background Neoadjuvant therapy is administered to breast cancer patients as an induction process before surgery or radiotherapy to reduce tumor size. Human epidermal growth factor receptor-2 (HER-2) negative breast cancer lacks effective standard target therapy. Bevacizumab has a controversial role in the treatment of breast cancer and we conduct a meta-analysis to evaluate the value of adding bevacizumab in neoadjuvant regimen. Methods Potentially eligible studies were retrieved using PubMed, EMBASE and Medline. Clinical characteristics of patients and statistical data with pathological complete response (pCR) data were collected. Then a meta-analysis model was established to investigate the correlation between administration of bevacizumab in neoadjuvant therapy and pCR rates in HER2 negative breast cancer. Results Seven eligible studies and 5408 patients were yielded. The pCR rates for "breast" or "breast plus lymph node" were similar. In subgroup analysis, we emphasized on patients with triple-negative breast cancer (TNBC). In the criterion of "lesions in breast" the pooled ORs was 1.55 [1.29, 1.86], P<0.00001 and regarding to the evaluation criterion of "lesions in breast and lymph nodes", the pooled ORs was 1.48 [1.23, 1.78], P<0.0001, in favor of bevacizumab administration. Conclusion According to our pooled results, we finally find that bevacizumab addition as a neoadjuvant chemotherapy component, for induction use with limited cycle to improve the pCR rates and patients may avoid long-term adverse event and long-term invalid survival improvement. Especially in subgroup analysis, pCR rates could be improved significantly and physicians could consider bevacizumab with caution. As patients could avoid the adverse event caused by long-term using of bevacizumab, long-term quality of life improvement may be achieved, especially in TNBC.	[Ma, Xuelei; Zhang, Binglan] Sichuan, West China Hosp, West China Med Sch, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Ma, Xuelei; Zhang, Binglan] Sichuan, West China Hosp, West China Med Sch, Ctr Canc, Chengdu, Sichuan, Peoples R China; [Wang, Xiaoshan] Sichuan Prov Peoples Hosp, Dept Clin Oncol, Chengdu, Sichuan, Peoples R China; [Huang, Jingwen; Zhang, Jing; Shi, Changle; Liu, Lei] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Sichuan, Peoples R China; [Chen, Yingtai] Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Dept Abdominal Surg, Beijing, Peoples R China	Sichuan Provincial People's Hospital; Sichuan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Liu, L (corresponding author), Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Sichuan, Peoples R China.	liuleihx@gmail.com			National Natural Science Foundation of China, Beijing, China [81101991]; Research Award Fund for New Young Teachers in Higher Education Institutions, China [20120181120024]	National Natural Science Foundation of China, Beijing, China(National Natural Science Foundation of China (NSFC)); Research Award Fund for New Young Teachers in Higher Education Institutions, China	This study was supported by the National Natural Science Foundation of China, Beijing, China (Grant No. 81101991) and Research Award Fund for New Young Teachers in Higher Education Institutions, China (Grant No. 20120181120024). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the article.	Bahri S, 2009, ANN SURG ONCOL, V16, P1619, DOI 10.1245/s10434-009-0441-5; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Boughey JC, 2014, ANN SURG, V260, P608, DOI 10.1097/SLA.0000000000000924; Brodowicz T, 2014, BRIT J CANCER, V111, P2051, DOI 10.1038/bjc.2014.504; Buzdar AU, 2007, CLIN CANCER RES, V13, P228, DOI 10.1158/1078-0432.CCR-06-1345; Cao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145442; Chen JH, 2008, CANCER-AM CANCER SOC, V112, P17, DOI 10.1002/cncr.23130; Chen XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108405; Clavarezza M, 2013, BREAST, V22, P470, DOI 10.1016/j.breast.2013.03.012; Cobleigh MA, 2003, SEMIN ONCOL, V30, P117, DOI 10.1053/j.seminoncol.2003.08.013; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Cortes J, 2012, EUR J CANCER, V48, P475, DOI 10.1016/j.ejca.2011.11.021; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Gerber B, 2013, ANN ONCOL, V24, P2978, DOI 10.1093/annonc/mdt361; Gerber B, 2014, ANN SURG ONCOL, V21, P2517, DOI 10.1245/s10434-014-3606-9; Gianni L, 2014, LANCET ONCOL, V15, P640, DOI 10.1016/S1470-2045(14)70080-4; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Greenberg S, 2010, CANCER J, V16, P33, DOI 10.1097/PPO.0b013e3181d38514; Greil R, 2009, EJSO-EUR J SURG ONC, V35, P1048, DOI 10.1016/j.ejso.2009.01.014; Guarneri V, 2015, ANN SURG ONCOL, V22, P2881, DOI 10.1245/s10434-015-4371-0; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hurvitz SA, 2013, J CLIN ONCOL, V31, P1157, DOI 10.1200/JCO.2012.44.9694; Killelea BK, 2015, J AM COLL SURGEONS, V220, P1063, DOI 10.1016/j.jamcollsurg.2015.02.011; Kim HR, 2013, ANN ONCOL, V24, P1485, DOI 10.1093/annonc/mds658; Luangdilok S, 2014, J BREAST CANCER, V17, P376, DOI 10.4048/jbc.2014.17.4.376; Maass N, 2013, J CANCER RES CLIN, V139, P2047, DOI 10.1007/s00432-013-1518-x; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Makhoul I, 2016, AM J CLIN ONCOL-CANC, V39, P248, DOI 10.1097/COC.0000000000000046; Makhoul I, 2015, AM J CLIN ONCOL-CANC, V38, P74, DOI 10.1097/COC.0b013e31828940c3; Martin M, 2011, LANCET ONCOL, V12, P369, DOI 10.1016/S1470-2045(11)70037-7; Montagna E, 2012, CLIN BREAST CANCER, V12, P207, DOI 10.1016/j.clbc.2012.03.008; Mrozek E, 2014, CLIN BREAST CANCER, V14, P228, DOI 10.1016/j.clbc.2014.02.005; Nalwoga H, 2011, BREAST CANCER RES TR, V130, P1063, DOI 10.1007/s10549-011-1740-7; Oizumi S, 2012, ONCOLOGIST, V17, P863, DOI 10.1634/theoncologist.2011-0426; Perez EA, 2014, J CLIN ONCOL, V32, P3744, DOI 10.1200/JCO.2014.55.5730; Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868; Rastogi P, 2011, CLIN BREAST CANCER, V11, P228, DOI 10.1016/j.clbc.2011.04.001; Rose S, 2011, CANCER DISCOV, V1, DOI 10.1158/2159-8290.CD-ND112311OL-08; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rouzier R, 2004, CANCER, V101, P918, DOI 10.1002/cncr.20491; Sanchez-Rovira P, 2013, CLIN TRANSL ONCOL, V15, P810, DOI 10.1007/s12094-013-1006-4; Schneider BP, 2013, CLIN CANCER RES, V19, P1281, DOI 10.1158/1078-0432.CCR-12-3029; Sharma SP, 2012, J NATL CANCER I, V104, P800, DOI 10.1093/jnci/djs265; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Thongprasert S, 2011, J THORAC ONCOL, V6, P1872, DOI 10.1097/JTO.0b013e31822adaf7; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Truong PT, 2007, INT J RADIAT ONCOL, V68, P59, DOI 10.1016/j.ijrobp.2006.12.017; Vergine M, 2013, G CHIR, V34, P254, DOI 10.11138/gchir/2013.34.9.254; von Minckwitz G, 2014, ANN ONCOL, V25, P2363, DOI 10.1093/annonc/mdu455; von Minckwitz G, 2014, ANN ONCOL, V25, P81, DOI 10.1093/annonc/mdt410; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065; von Minckwitz G, 2010, J CLIN ONCOL, V28, P2015, DOI 10.1200/JCO.2009.23.8303; Williamson PR, 2002, STAT MED, V21, P3337, DOI 10.1002/sim.1303	54	11	13	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2016	11	8							e0160148	10.1371/journal.pone.0160148	http://dx.doi.org/10.1371/journal.pone.0160148			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV4EG	27579484	Green Submitted, Green Published, gold			2023-01-03	WOS:000382877400002
J	Kantarjian, HM; DeAngelo, DJ; Stelljes, M; Martinelli, G; Liedtke, M; Stock, W; Gokbuget, N; O'Brien, S; Wang, KM; Wang, T; Paccagnella, ML; Sleight, B; Vandendries, E; Advani, AS				Kantarjian, Hagop M.; DeAngelo, Daniel J.; Stelljes, Matthias; Martinelli, Giovanni; Liedtke, Michaela; Stock, Wendy; Gokbuget, Nicola; O'Brien, Susan; Wang, Kongming; Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S.			Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM-FOLLOW-UP; INTENSIVE CONSOLIDATION; MONOCLONAL-ANTIBODY; INDUCTION THERAPY; ADULTS; CHEMOTHERAPY; ANTIGEN; TRIAL; IMMUNOCONJUGATE; BLINATUMOMAB	BACKGROUND The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard therapy. METHODS In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group). The primary end points were complete remission (including complete remission with incomplete hematologic recovery) and overall survival. RESULTS Of the 326 patients who underwent randomization, the first 218 (109 in each group) were included in the primary intention-to-treat analysis of complete remission. The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the standard-therapy group (80.7% [95% confidence interval {CI}, 72.1 to 87.7] vs. 29.4% [95% CI, 21.0 to 38.8], P < 0.001). Among the patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, P < 0.001); the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 months [95% CI, 3.9 to 5.4] vs. 3.1 months [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 0.96]; P = 0.03). In the survival analysis, which included all 326 patients, progression-free survival was significantly longer in the inotuzumab ozogamicin group (median, 5.0 months [95% CI, 3.7 to 5.6] vs. 1.8 months [95% CI, 1.5 to 2.2]; hazard ratio, 0.45 [97.5% CI, 0.34 to 0.61]; P < 0.001); the median overall survival was 7.7 months (95% CI, 6.0 to 9.2) versus 6.7 months (95% CI, 4.9 to 8.3), and the hazard ratio was 0.77 (97.5% CI, 0.58 to 1.03) (P = 0.04). In the safety population, the most frequent grade 3 or higher nonhematologic adverse events with inotuzumab ozogamicin were liver-related. Veno-occlusive liver disease of any grade occurred in 15 patients (11%) who received inotuzumab ozogamicin and in 1 patient (1%) who received standard therapy. CONCLUSIONS The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease. Both progression-free and overall survival were longer with inotuzumab ozogamicin. Veno-occlusive liver disease was a major adverse event associated with inotuzumab ozogamicin. (Funded by Pfizer; INO-VATE ALL ClinicalTrials.gov number, NCT01564784.)	[Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA; [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Vandendries, Erik] Pfizer, Cambridge, MA USA; [Stelljes, Matthias] Univ Klinikum Munster, Munster, Germany; [Gokbuget, Nicola] Goethe Univ Frankfurt, Frankfurt, Germany; [Martinelli, Giovanni] Univ Bologna, DIMES Dept Expt Diagnost & Specialty Med, Inst Seragnoli, Bologna, Italy; [Liedtke, Michaela] Stanford Canc Inst, Stanford, CA USA; [O'Brien, Susan] Univ Calif Irvine, Med Ctr, Orange, CA 92668 USA; [Stock, Wendy] Univ Chicago, Chicago, IL 60637 USA; [Wang, Kongming] Pfizer, Pearl River, NY USA; [Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara] Pfizer, Groton, CT USA; [Advani, Anjali S.] Cleveland Clin, Cleveland, OH 44106 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Pfizer; University of Munster; Goethe University Frankfurt; University of Bologna; Stanford Cancer Institute; University of California System; University of California Irvine; University of Chicago; Pfizer; Pfizer; Cleveland Clinic Foundation	Kantarjian, HM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA.	hkantarjian@mdanderson.org	Martinelli, Giovanni/AAK-9211-2020	Martinelli, Giovanni/0000-0002-1025-4210	Pfizer; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Pfizer(Pfizer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Pfizer.	Advani A, 2010, J CLIN ONCOL, V28, P2085, DOI 10.1200/JCO.2009.25.1900; Annino L, 2002, BLOOD, V99, P863, DOI 10.1182/blood.V99.3.863; Bouchard H, 2014, BIOORG MED CHEM LETT, V24, P5357, DOI 10.1016/j.bmcl.2014.10.021; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Daver N, 2013, CURR HEMATOL MALIG R, V8, P123, DOI 10.1007/s11899-013-0160-7; DiJoseph JF, 2004, BLOOD, V103, P1807, DOI 10.1182/blood-2003-07-2466; Fielding AK, 2007, BLOOD, V109, P944, DOI 10.1182/blood-2006-05-018192; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Gokbuget N, 2000, HEMATOL ONCOL CLIN N, V14, P1307, DOI 10.1016/S0889-8588(05)70188-X; Goldstone AH, 2008, BLOOD, V111, P1827, DOI 10.1182/blood-2007-10-116582; Hanna R, 1996, CANCER RES, V56, P3062; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; HINMAN LM, 1993, CANCER RES, V53, P3336; Jabbour E, 2015, BLOOD, V125, P4010, DOI 10.1182/blood-2014-08-596403; Jain Nitin, 2014, Front Biosci (Elite Ed), V6, P40; Kantarjian H, 2004, CANCER-AM CANCER SOC, V101, P2788, DOI 10.1002/cncr.20668; Kantarjian H, 2013, CANCER-AM CANCER SOC, V119, P2728, DOI 10.1002/cncr.28136; LARSON RA, 1995, BLOOD, V85, P2025, DOI 10.1182/blood.V85.8.2025.bloodjournal8582025; Le Jeune C, 2015, EUR J HAEMATOL, V94, P99, DOI 10.1111/ejh.12408; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; O'Brien S, 2008, CANCER-AM CANCER SOC, V113, P3186, DOI 10.1002/cncr.23919; Piccaluga PP, 2011, LEUKEMIA LYMPHOMA, V52, P325, DOI 10.3109/10428194.2010.529206; Rowe JM, 2005, BLOOD, V106, P3760, DOI 10.1182/blood-2005-04-1623; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; Shah NN, 2015, PEDIATR BLOOD CANCER, V62, P964, DOI 10.1002/pbc.25410; Shor B, 2015, MOL IMMUNOL, V67, P107, DOI 10.1016/j.molimm.2014.09.014; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Takeuchi J, 2002, LEUKEMIA, V16, P1259, DOI 10.1038/sj.leu.2402526; Tavernier E, 2007, LEUKEMIA, V21, P1907, DOI 10.1038/sj.leu.2404824; Thomas DA, 1999, CANCER-AM CANCER SOC, V86, P1216, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O; Thomas X, 2004, J CLIN ONCOL, V22, P4075, DOI 10.1200/JCO.2004.10.050; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Topp MS, 2014, J CLIN ONCOL, V32, P4134, DOI 10.1200/JCO.2014.56.3247; VAICKUS L, 1991, CRIT REV ONCOL HEMAT, V11, P267, DOI 10.1016/1040-8428(91)90029-C; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; Zhao LH, 2016, BIOMETRICS, V72, P215, DOI 10.1111/biom.12384	38	724	740	7	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2016	375	8					740	753		10.1056/NEJMoa1509277	http://dx.doi.org/10.1056/NEJMoa1509277			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT9ET	27292104	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000381799300012
J	Huang, DX; Lin, C; Wen, XJ; Gu, SY; Zhao, P				Huang, Daoxiang; Lin, Chao; Wen, Xuejun; Gu, Shuying; Zhao, Peng			A Potential Nanofiber Membrane Device for Filling Surgical Residual Cavity to Prevent Glioma Recurrence and Improve Local Neural Tissue Reconstruction	PLOS ONE			English	Article							NERVE GROWTH-FACTOR; VASCULOGENIC MIMICRY; CANCER RECURRENCE; GLIOBLASTOMA; TEMOZOLOMIDE; CELLS; CHEMOTHERAPY; COMBINATION	This study aims to develop a novel device with nanofiber membrane capable of sustained release of temozolomide (TMZ) and neuron growth factor (NGF). An improved bio-availability of TMZ and NGF in surroundings proximal to the device was expected to be attained for a prolonged period of time. The device was developed by integrating TMZ-doped polycaprolactone (PCL) nanofiber (TP) membrane and NGF-coated PCL (NGFP) membrane using sodium alginate hydrogel. TP was prepared by direct electrospinning of TMZ/ PCL. NGFP membrane was developed by layer-by-layer assembling technology. The incorporation of TMZ-doped nanofiber and NGFP nanofiber in the device was confirmed by scanning electron microscopy. The number of NGF layer in NGF-coated PCL membrane could be readily measured with energy spectrum analysis. The in vitro release study showed that TP-NGFP-TP membrane could efficiently liberate TMZ to inhibit the growth of C6 glioma cells, and sufficient NGF to induce the differentiation of PC12 neuron cells over four weeks. Such TP-NGFP-TP membrane device can be employed as a tampon to fill up surgical residual cavity and afford residual glioma removal, structural support, hemostasis, and local neural tissue reconstruction in the surgical treatment of glioma. The study opens a horizon to develop multifunctional biomaterial device for maximized glioma treatment efficacy.	[Huang, Daoxiang; Lin, Chao; Wen, Xuejun; Zhao, Peng] Tongji Univ, Sch Med, Shanghai East Hosp, Inst Biomed Engn & Nanosci,Inst Translat Nanomed, Shanghai, Peoples R China; [Gu, Shuying] Tongji Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Civil Engn Mat, Shanghai, Peoples R China; [Huang, Daoxiang; Gu, Shuying] Tongji Univ, Sch Mat Sci & Engn, Inst Nano & Biopolymer Mat, Shanghai, Peoples R China	Tongji University; Tongji University; Tongji University	Zhao, P (corresponding author), Tongji Univ, Sch Med, Shanghai East Hosp, Inst Biomed Engn & Nanosci,Inst Translat Nanomed, Shanghai, Peoples R China.; Gu, SY (corresponding author), Tongji Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Civil Engn Mat, Shanghai, Peoples R China.; Gu, SY (corresponding author), Tongji Univ, Sch Mat Sci & Engn, Inst Nano & Biopolymer Mat, Shanghai, Peoples R China.	gushuying@tongji.edu.cn; zp@tongji.edu.cn	Zhao, Peng/HDO-7507-2022		Ministry of Science and Technology of the People's Republic of China [2014CB964600, 2012CB966300]; National Natural Science Funds of China [81271369]; Fundamental Research Funds for the Central Universities	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); National Natural Science Funds of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the Ministry of Science and Technology of the People's Republic of China (2014CB964600 to Dr. Peng Zhao); Ministry of Science and Technology of the People's Republic of China (2012CB966300 to Dr. Xuejun Wen); National Natural Science Funds of China (81271369 to Dr. Xuejun Wen); and Fundamental Research Funds for the Central Universities (Dr. Peng Zhao).	Aloe L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-239; Falsini B, 2016, BRAIN, V139, P404, DOI 10.1093/brain/awv366; Feng XY, 2015, ACS APPL MATER INTER, V7, P27885, DOI 10.1021/acsami.5b09934; Gonzalez-Astorga B, 2013, EUR J CANCER, V49, pS794; Goodenberger ML, 2012, CANCER GENET-NY, V205, P613, DOI 10.1016/j.cancergen.2012.10.009; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Ju RJ, 2016, INT J NANOMED, V11, P1131, DOI 10.2147/IJN.S94467; Kaplan JA, 2016, BIOMATERIALS, V76, P273, DOI 10.1016/j.biomaterials.2015.10.060; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu S, 2015, NANOMED-NANOTECHNOL, V11, P1047, DOI 10.1016/j.nano.2015.03.001; Liu YP, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0558-x; Middleton MR, 2002, INT J CANCER, V100, P615, DOI 10.1002/ijc.10532; Mustafa AM, 2016, FOOD CHEM, V192, P782, DOI 10.1016/j.foodchem.2015.07.079; Naito E, 2015, IN VITRO CELL DEV-AN, V51, P1012, DOI 10.1007/s11626-015-9935-6; Narin S, 2013, FEBS J, V280, P418; Ni SL, 2014, ANN BIOMED ENG, V42, P214, DOI 10.1007/s10439-013-0903-6; Okonogi N, 2015, ANTICANCER RES, V35, P1229; Paw I, 2015, CANCER LETT, V362, P1, DOI 10.1016/j.canlet.2015.03.015; Reardon DA, 2006, ONCOLOGIST, V11, P152, DOI 10.1634/theoncologist.11-2-152; Zhu TH, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.41982; Zong S, 2015, EUR J PHARM BIOPHARM, V93, P127, DOI 10.1016/j.ejpb.2015.03.029	22	13	14	1	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2016	11	8							e0161435	10.1371/journal.pone.0161435	http://dx.doi.org/10.1371/journal.pone.0161435			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TP	27548322	Green Submitted, Green Published, gold			2023-01-03	WOS:000381768400057
J	Guthrie, B; Kavanagh, K; Robertson, C; Barnett, K; Treweek, S; Petrie, D; Ritchie, L; Bennie, M				Guthrie, Bruce; Kavanagh, Kimberley; Robertson, Chris; Barnett, Karen; Treweek, Shaun; Petrie, Dennis; Ritchie, Lewis; Bennie, Marion			Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; HOSPITAL ADMISSIONS; POPULATION; PHYSICIANS; CRITERIA	OBJECTIVE To evaluate the effectiveness of feedback on safety of prescribing compared with moderately enhanced usual care. Design Three arm, highly pragmatic cluster randomised trial. Setting and participants 262/278 (94%) primary care practices in three Scottish health boards. Interventions Practices were randomised to: "usual care," consisting of emailed educational material with support for searching to identify patients (88 practices at baseline, 86 analysed); usual care plus feedback on practice's high risk prescribing sent quarterly on five occasions (87 practices, 86 analysed); or usual care plus the same feedback incorporating a behavioural change component (87 practices, 86 analysed). Main outcome measures The primary outcome was a patient level composite of six prescribing measures relating to high risk use of antipsychotics, non-steroidal anti-inflammatories, and antiplatelets. Secondary outcomes were the six individual measures. The primary analysis compared high risk prescribing in the two feedback arms against usual care at 15 months. Secondary analyses examined immediate change and change in trend of high risk prescribing associated with implementation of the intervention within each arm. Results In the primary analysis, high risk prescribing as measured by the primary outcome fell from 6.0% (3332/55 896) to 5.1% (2845/55 872) in the usual care arm, compared with 5.9% (3341/56 194) to 4.6% (2587/56 478) in the feedback only arm (odds ratio 0.88 (95% confidence interval 0.80 to 0.96) compared with usual care; P=0.007) and 6.2% (3634/58 569) to 4.6% (2686/58 582) in the feedback plus behavioural change component arm (0.86 (0.78 to 0.95); P=0.002). In the pre-specified secondary analysis of change in trend within each arm, the usual care educational intervention had no effect on the existing declining trend in high risk prescribing. Both types of feedback were associated with significantly more rapid decline in high risk prescribing after the intervention compared with before. Conclusions Feedback of prescribing safety data was effective at reducing high risk prescribing. The intervention would be feasible to implement at scale in contexts where electronic health records are in general use.	[Guthrie, Bruce] Univ Dundee, Populat Hlth Sci Div, Dundee DD2 4BF, Scotland; [Kavanagh, Kimberley; Robertson, Chris] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland; [Barnett, Karen] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Treweek, Shaun] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland; [Petrie, Dennis] Univ Melbourne, Ctr Hlth Policy, Melbourne, Vic, Australia; [Ritchie, Lewis] Univ Aberdeen, Dept Acad Primary Care, Aberdeen, Scotland; [Bennie, Marion] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland; [Bennie, Marion] NHS Natl Serv Scotland, Informat Serv Div, Edinburgh, Midlothian, Scotland	University of Dundee; University of Strathclyde; University of Edinburgh; University of Aberdeen; University of Melbourne; University of Aberdeen; University of Strathclyde; NHS National Services Scotland	Guthrie, B (corresponding author), Univ Dundee, Populat Hlth Sci Div, Dundee DD2 4BF, Scotland.	b.guthrie@dundee.ac.uk	Petrie, Dennis/L-7689-2018; Treweek, Shaun/AAE-8006-2019; Petrie, Dennis/AAK-5153-2020; Guthrie, Bruce/HHM-9696-2022	Petrie, Dennis/0000-0002-3882-2531; Treweek, Shaun/0000-0002-7239-7241; Petrie, Dennis/0000-0002-3882-2531; Kavanagh, Kimberley/0000-0002-2679-5409	Scottish Government Chief Scientist Office [CZH/3/17]; Chief Scientist Office of the Scottish Government Health Directorates; MRC [MR/K007017/1] Funding Source: UKRI; Medical Research Council [MC_PC_13040, MR/K007017/1] Funding Source: researchfish; Chief Scientist Office [HSRU2, CZH/3/17] Funding Source: researchfish	Scottish Government Chief Scientist Office; Chief Scientist Office of the Scottish Government Health Directorates; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chief Scientist Office	The study was funded by Scottish Government Chief Scientist Office project grant CZH/3/17. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. ST works at the Health Services Research Unit, University of Aberdeen, which is funded by the Chief Scientist Office of the Scottish Government Health Directorates.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Avery AJ, 2012, LANCET, V379, P1310, DOI 10.1016/S0140-6736(11)61817-5; Avery AJ, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X588501; Ballard C, 2008, PLOS MED, V5, P587, DOI 10.1371/journal.pmed.0050076; Ballard C, 2009, LANCET NEUROL, V8, P151, DOI 10.1016/S1474-4422(08)70295-3; Banerjee S., 2009, USE ANTIPSYCHOTIC ME, DOI DOI 10.1111/J.1532-5415.2012.03923.X; Barnett KN, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0133-9; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; Curtis JR, 2005, AM J MANAG CARE, V11, P537; de Groot DA, 2014, AGE AGEING, V43, P773, DOI 10.1093/ageing/afu075; Donnar A, 2000, DESIGN ANAL CLUSTER; Dreischulte T, 2016, NEW ENGL J MED, V374, P1053, DOI 10.1056/NEJMsa1508955; Dreischulte T, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-24; Dreischulte Tobias, 2012, BMC Clin Pharmacol, V12, P5, DOI 10.1186/1472-6904-12-5; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Grudniewicz A, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0347-5; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Guthrie B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068976; Guthrie B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-002359; Guthrie Bruce, 2011, BMJ, V342, pd3514, DOI 10.1136/bmj.d3514; Hallsworth M, 2016, LANCET, V387, P1743, DOI 10.1016/S0140-6736(16)00215-4; Holland R, 2008, BRIT J CLIN PHARMACO, V65, P303, DOI 10.1111/j.1365-2125.2007.03071.x; HOLM M, 1990, Scandinavian Journal of Primary Health Care, V8, P113, DOI 10.3109/02813439008994941; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Hui Chen L, 2014, DRUG POISONING DEATH, P1999; Ivers N, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Judge J, 2006, J AM MED INFORM ASSN, V13, P385, DOI 10.1197/jamia.M1945; O'Mahony D, 2010, EUR GERIATR MED, V1, P45, DOI 10.1016/j.eurger.2010.01.007; Peterson JF, 2007, STUD HEALTH TECHNOL, V129, P1037; Pimlott NJG, 2003, CAN MED ASSOC J, V168, P835; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Rotondi M., 2011, CRTSIZE SAMPLE SIZE; Royal S, 2006, QUAL SAF HEALTH CARE, V15, P23, DOI 10.1136/qshc.2004.012153; Ruscitto A, 2015, EUR J PAIN, V19, P59, DOI 10.1002/ejp.520; Schwarzer R., 1992, SELF EFFICACY THOUGH, P217, DOI 10.4324/9781315800820; Shojania Kaveh G, 2009, Cochrane Database Syst Rev, pCD001096, DOI 10.1002/14651858.CD001096.pub2; Spencer R, 2014, BRIT J GEN PRACT, V64, pE181, DOI 10.3399/bjgp14X677806; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x	40	23	23	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2016	354								i4079	10.1136/bmj.i4079	http://dx.doi.org/10.1136/bmj.i4079			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT9HB	27540041	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000381806600001
J	Grimberg-Peters, D; Buren, C; Windolf, J; Wahlers, T; Paunel-Gorgulu, A				Grimberg-Peters, Deborah; Bueren, Carina; Windolf, Joachim; Wahlers, Thorsten; Paunel-Goerguelue, Adnana			Hyperbaric Oxygen Reduces Production of Reactive Oxygen Species in Neutrophils from Polytraumatized Patients Yielding in the Inhibition of p38 MAP Kinase and Downstream Pathways	PLOS ONE			English	Article							EXTRACELLULAR TRAPS; ACTIVATION; APOPTOSIS; CELLS; MCL-1; REPERFUSION; RECRUITMENT; RESISTANCE; EXPRESSION; NETOSIS	Trauma represents the leading cause of death among young people in western countries. Among the beneficial role of neutrophils in host defence, excessive priming and activation of neutrophils after major trauma lead to an overwhelming inflammatory response and secondary host tissue injury due to the release of toxic metabolites and enzymes. Hyperbaric oxygen (HBO) therapy has been proposed to possess antiinflammatory effects and might represent an appropriate therapeutic option to lower inflammation in a broad range of patients. Here, we studied the effects of HBO on the activity of neutrophils isolated from severely injured patients (days 1-2 after trauma), in fact on the production of reactive oxygen species (ROS) and release of neutrophil extracellular traps (NETs). We found exposure to HBO therapy to significantly diminish phorbol-12-myristate-13-acetate (PMA)-induced ROS production in neutrophils isolated from patients and healthy volunteers. At the same time, marked decrease in NETs release was found in control cells and a less pronounced reduction in patient neutrophils. Impaired ability to produce ROS following exposure to HBO was demonstrated to be linked to a strong downregulation of the activity of p38 MAPK. Only slight suppression of ERK activity could be found. In addition, HBO did not influence neutrophil chemotaxis or apoptosis, respectively. Collectively, this study shows for the first time that HBO therapy suppresses ROS production in inflammatory human neutrophils, and thus might impair ROS-dependent pathways, e.g. kinases activation and NETs release. Thus, HBO might represent a feasible therapy for patients suffering from systemic inflammation, including those with multiple trauma.	[Grimberg-Peters, Deborah; Bueren, Carina; Windolf, Joachim] Univ Hosp Dusseldorf, Dept Trauma & Hand Surg, Moorenstr 5, D-40225 Dusseldorf, Germany; [Wahlers, Thorsten; Paunel-Goerguelue, Adnana] Univ Cologne, Ctr Heart, Dept Cardiothorac Surg, Kerpener Str 62, D-50937 Cologne, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf	Paunel-Gorgulu, A (corresponding author), Univ Cologne, Ctr Heart, Dept Cardiothorac Surg, Kerpener Str 62, D-50937 Cologne, Germany.	adnana.paunel-goerguelue@uk-koeln.de						Almzaiel AJ, 2015, BIOCHEM CELL BIOL, V93, P405, DOI 10.1139/bcb-2014-0157; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Blanc A, 2003, INT J MOL MED, V11, P229; BOTHA AJ, 1995, SURGERY, V118, P358, DOI 10.1016/S0039-6060(05)80345-9; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; Chen MF, 1998, LIVER, V18, P110; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Conde de la Rosa L, 2006, J HEPATOL, V44, P918, DOI 10.1016/j.jhep.2005.07.034; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Dzhagalov I, 2007, BLOOD, V109, P1620, DOI 10.1182/blood-2006-03-013771; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Ganguly BJ, 2002, APOPTOSIS, V7, P499, DOI 10.1023/A:1020686908831; Gray RD, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-12; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006; Hakkim A, 2011, NAT CHEM BIOL, V7, P75, DOI 10.1038/NCHEMBIO.496; Hattori H, 2010, P NATL ACAD SCI USA, V107, P3546, DOI 10.1073/pnas.0914351107; Hornstein T, 2016, J LEUKOCYTE BIOL, V99, P163, DOI 10.1189/jlb.3A1114-537RR; Jones MR, 2005, J IMMUNOL, V175, P7530, DOI 10.4049/jimmunol.175.11.7530; Kalns J, 2002, IMMUNOL LETT, V83, P125, DOI 10.1016/S0165-2478(02)00068-8; Kannan S, 2002, MED HYPOTHESES, V59, P266, DOI 10.1016/S0306-9877(02)00214-1; Kendall AC, 2013, WOUND REPAIR REGEN, V21, P860, DOI 10.1111/wrr.12108; Keshari RS, 2013, J CELL BIOCHEM, V114, P532, DOI 10.1002/jcb.24391; Leach RM, 1998, BRIT MED J, V317, P1140; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Li ZS, 2010, FEBS LETT, V584, P2291, DOI 10.1016/j.febslet.2010.03.040; Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5; Lustenberger T, 2016, IMMUNOBIOLOGY, V221, P427, DOI 10.1016/j.imbio.2015.11.011; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Margraf S, 2008, SHOCK, V30, P352, DOI 10.1097/SHK.0b013e31816a6bb1; Masuoka HC, 2009, J BIOL CHEM, V284, P30039, DOI 10.1074/jbc.M109.039545; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Meng W, 2012, CRIT CARE, V16, DOI 10.1186/cc11442; Meng W, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/149560; Milot E, 2011, THESCIENTIFICWORLDJO, V11, P1948, DOI 10.1100/2011/131539; Min KJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.35; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Oehmcke S, 2009, J INNATE IMMUN, V1, P225, DOI 10.1159/000203700; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pashevin DO, 2015, PATHOBIOLOGY, V82, P290, DOI 10.1159/000440982; Paunel-Gorgulu A, 2009, J IMMUNOL, V183, P6198, DOI 10.4049/jimmunol.0901264; Peng HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100814; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Rajalingam K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003102; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366; SIMMS HH, 1991, J SURG RES, V50, P362, DOI 10.1016/0022-4804(91)90204-Y; Singer M, 2004, J IMMUNOL, V173, P4197, DOI 10.4049/jimmunol.173.6.4197; STERLING DL, 1993, CIRCULATION, V88, P1931, DOI 10.1161/01.CIR.88.4.1931; THOM SR, 1990, TOXICOL APPL PHARM, V105, P340, DOI 10.1016/0041-008X(90)90195-Z; Thom SR, 2008, J BIOL CHEM, V283, P10822, DOI 10.1074/jbc.M709200200; Tjarnstrom J, 1999, EUR SURG RES, V31, P147, DOI 10.1159/000008633; Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Wolters PJ, 2009, J IMMUNOL, V182, P8056, DOI 10.4049/jimmunol.0801323; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53	58	12	14	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2016	11	8							e0161343	10.1371/journal.pone.0161343	http://dx.doi.org/10.1371/journal.pone.0161343			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT4UN	27529549	Green Published, gold, Green Submitted			2023-01-03	WOS:000381476700069
J	Singhal, A; Tien, YY; Hsia, RY				Singhal, Astha; Tien, Yu-Yu; Hsia, Renee Y.			Racial-Ethnic Disparities in Opioid Prescriptions at Emergency Department Visits for Conditions Commonly Associated with Prescription Drug Abuse	PLOS ONE			English	Article							SEEKING BEHAVIOR; CHRONIC PAIN; CARE; TRENDS; US; BURDEN	Prescription drug abuse is a growing problem nationally. In an effort to curb this problem, emergency physicians might rely on subjective cues such as race-ethnicity, often unknowingly, when prescribing opioids for pain-related complaints, especially for conditions that are often associated with drug-seeking behavior. Previous studies that examined racial-ethnic disparities in opioid dispensing at emergency departments (EDs) did not differentiate between prescriptions at discharge and drug administration in the ED. We examined racialethnic disparities in opioid prescription at ED visits for pain-related complaints often associated with drug-seeking behavior and contrasted them with conditions objectively associated with pain. We hypothesized a priori that racial-ethnic disparities will be present among opioid prescriptions for conditions associated with non-medical use, but not for objective pain-related conditions. Using data from the National Hospital Ambulatory Medical Care Survey for 5 years (2007-2011), the odds of opioid prescription during ED visits made by non-elderly adults aged 18-65 for 'non-definitive' conditions (toothache, back pain and abdominal pain) or 'definitive' conditions (long-bone fracture and kidney stones) were modeled. Opioid prescription at discharge and opioid administration at the ED were the primary outcomes. We found significant racial-ethnic disparities, with non-Hispanic Blacks being less likely (adjusted odds ratio ranging from 0.56-0.67, p-value < 0.05) to receive opioid prescription at discharge during ED visits for back pain and abdominal pain, but not for toothache, fractures and kidney stones, compared to non-Hispanic whites after adjusting for other covariates. Differential prescription of opioids by race-ethnicity could lead to widening of existing disparities in health, and may have implications for disproportionate burden of opioid abuse among whites. The findings have important implications for medical provider education to include sensitization exercises towards their inherent biases, to enable them to consciously avoid these biases from defining their practice behavior.	[Singhal, Astha] Boston Univ, Sch Dent Med, Hlth Policy & Hlth Serv Res, Boston, MA 02215 USA; [Tien, Yu-Yu] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA; [Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Hsia, Renee Y.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA	Boston University; University of Iowa; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hsia, RY (corresponding author), Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.; Hsia, RY (corresponding author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.	renee.hsia@ucsf.edu		Singhal, Astha/0000-0001-9191-6978				[Anonymous], 2014, ED Manag, V26, P5; Barry CL, 2016, ADDICTION, V111, P85, DOI 10.1111/add.13077; Bijur P, 2008, AM J EMERG MED, V26, P270, DOI 10.1016/j.ajem.2007.05.010; Billings J, 2013, HEALTH AFFAIR, V32, P2099, DOI 10.1377/hlthaff.2012.1276; Boccuzzi J, 2015, J AM DENT ASSOC, V146, P655, DOI 10.1016/j.adaj.2015.07.008; Burgess DJ, 2011, J GEN INTERN MED, V26, P828, DOI 10.1007/s11606-011-1748-z; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Centers for Disease Control and Prevention, 1999, VIT SIGNS OV PRESCR; CENTERS FOR DISEASE CONTROL AND PREVENTION, 2013, MMWR-MORBID MORTAL W; Cepeda MS, 2014, CLIN J PAIN, V30, P1051, DOI 10.1097/AJP.0000000000000067; Compton WM, 2015, PREV MED, V80, P5, DOI 10.1016/j.ypmed.2015.04.003; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Gilson AM, 2009, PAIN MED, V10, pS89, DOI 10.1111/j.1526-4637.2009.00668.x; Grover CA, 2012, WEST J EMERG MED, V13, P416, DOI 10.5811/westjem.2012.4.11600; Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859; Hansen J., 2011, REPORT TO THE SUBCOM; Hawkins SC, 2008, J EMERG MED, V34, P125, DOI 10.1016/j.jemermed.2007.07.001; Hupp JR, 2014, AM J EMERG MED, V32, P480, DOI 10.1016/j.ajem.2014.01.056; International Pain Summit Of The International Association For The Study Of Pain, 2011, J Pain Palliat Care Pharmacother, V25, P29, DOI 10.3109/15360288.2010.547560; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Kea B, 2014, ACAD EMERG MED, V21, P946, DOI 10.1111/acem.12425; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; LaCalle E, 2010, ANN EMERG MED, V56, P42, DOI 10.1016/j.annemergmed.2010.01.032; Lee HH, 2012, AM J PUBLIC HEALTH, V102, pe77, DOI DOI 10.2105/AJPH.2012; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Lewis CW, 2015, J AM DENT ASSOC, V146, P295, DOI 10.1016/j.adaj.2015.01.013; Mazer-Amirshahi M, 2014, ACAD EMERG MED, V21, P236, DOI 10.1111/acem.12328; McCaig LF, 2012, ANN EMERG MED, V60, P716, DOI 10.1016/j.annemergmed.2012.07.010; McCracken LM, 2012, J PAIN, V13, P32, DOI 10.1016/j.jpain.2011.09.007; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; Moskowitz D, 2011, J GEN INTERN MED, V26, P846, DOI 10.1007/s11606-011-1672-2; National Center for Health Statistics, 2011, AMB CAR DRUG DAT SYS; Nelson LS, 2015, JAMA-J AM MED ASSOC, V314, P1453, DOI 10.1001/jama.2015.12397; Okunseri C, 2014, J PUBLIC HEALTH DENT, V74, P283, DOI 10.1111/jphd.12055; Ondler C, 2014, AM J EMERG MED, V32, P1215, DOI 10.1016/j.ajem.2014.07.013; Pew Childrens Dental Campaign, 2012, PEW CHILDR DENT CAMP; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Shah AA, 2015, MED CARE, V53, P1000, DOI 10.1097/MLR.0000000000000444; Speiser AM, 2015, J AM DENT ASSOC, V146, P655, DOI 10.1016/j.adaj.2015.07.009; Sullivan MD, 2013, PAIN, V154, pS94, DOI 10.1016/j.pain.2013.09.009; Tamayo-Sarver JH, 2003, AM J PUBLIC HEALTH, V93, P2067, DOI 10.2105/AJPH.93.12.2067; Todd KH, 2000, ANN EMERG MED, V35, P11, DOI 10.1016/S0196-0644(00)70099-0; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Wall T, 2012, J PUBLIC HEALTH DENT, V72, P216, DOI 10.1111/j.1752-7325.2012.00339.x; Weiner SG, 2015, J EMERG MED, V48, P424, DOI 10.1016/j.jemermed.2014.11.008; Weiner SG, 2013, ANN EMERG MED, V62, P281, DOI 10.1016/j.annemergmed.2013.05.025	47	157	157	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2016	11	8							e0159224	10.1371/journal.pone.0159224	http://dx.doi.org/10.1371/journal.pone.0159224			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DT3IE	27501459	gold, Green Published			2023-01-03	WOS:000381373500004
J	Gordon, AC; Mason, AJ; Thirunavukkarasu, N; Perkins, GD; Cecconi, M; Cepkova, M; Pogson, DG; Aya, HD; Anjum, A; Frazier, GJ; Santhakumaran, S; Ashby, D; Brett, SJ				Gordon, Anthony C.; Mason, Alexina J.; Thirunavukkarasu, Neeraja; Perkins, Gavin D.; Cecconi, Maurizio; Cepkova, Magda; Pogson, David G.; Aya, Hollmann D.; Anjum, Aisha; Frazier, Gregory J.; Santhakumaran, Shalini; Ashby, Deborah; Brett, Stephen J.		VANISH Investigators	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock The VANISH Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFUSION; CORTICOSTEROIDS; THERAPY; INJURY; SEPSIS	IMPORTANCE Norepinephrine is currently recommended as the first-line vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative. OBJECTIVE To compare the effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS A factorial (2x2), double-blind, randomized clinical trial conducted in 18 general adult intensive care units in the United Kingdom between February 2013 and May 2015, enrolling adult patients who had septic shock requiring vasopressors despite fluid resuscitation within a maximum of 6 hours after the onset of shock. INTERVENTIONS Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 104), norepinephrine and hydrocortisone (n = 101), or norepinephrine and placebo (n = 103). MAIN OUTCOMES AND MEASURES The primary outcomewas kidney failure-free days during the 28-day period after randomization, measured as (1) the proportion of patients who never developed kidney failure and (2) median number of days alive and free of kidney failure for patients who did not survive, who experienced kidney failure, or both. Rates of renal replacement therapy, mortality, and serious adverse events were secondary outcomes. RESULTS A total of 409 patients (median age, 66 years; men, 58.2%) were included in the study, with a median time to study drug administration of 3.5 hours after diagnosis of shock. The number of survivors who never developed kidney failure was 94 of 165 patients (57.0%) in the vasopressin group and 93 of 157 patients (59.2%) in the norepinephrine group (difference, -2.3%[95% CI, -13.0% to 8.5%]). The median number of kidney failure-free days for patients who did not survive, who experienced kidney failure, or both was 9 days (interquartile range [IQR], 1 to -24) in the vasopressin group and 13 days (IQR, 1 to -25) in the norepinephrine group (difference, -4 days [95% CI, -11 to 5]). There was less use of renal replacement therapy in the vasopressin group than in the norepinephrine group (25.4% for vasopressin vs 35.3% for norepinephrine; difference, -9.9% [95% CI, -19.3% to -0.6%]). There was no significant difference in mortality rates between groups. In total, 22 of 205 patients (10.7%) had a serious adverse event in the vasopressin group vs 17 of 204 patients (8.3%) in the norepinephrine group (difference, 2.5%[95% CI, -3.3% to 8.2%]). CONCLUSIONS AND RELEVANCE Among adults with septic shock, the early use of vasopressin compared with norepinephrine did not improve the number of kidney failure-free days. Although these findings do not support the use of vasopressin to replace norepinephrine as initial treatment in this situation, the confidence interval included a potential clinically important benefit for vasopressin, and larger trials may be warranted to assess this further.	[Gordon, Anthony C.] Imperial Coll London, Sect Anaesthet Pain Med & Intens Care Med, Dept Surg & Canc, London W6 8RF, England; [Mason, Alexina J.] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England; [Thirunavukkarasu, Neeraja; Anjum, Aisha; Frazier, Gregory J.; Santhakumaran, Shalini; Ashby, Deborah] Imperial Coll London, Sch Publ Hlth, Imperial Clin Trials Unit, London W6 8RF, England; [Perkins, Gavin D.] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry, W Midlands, England; [Cecconi, Maurizio; Aya, Hollmann D.] St Georges Univ Hosp Natl Hlth Serv Fdn Trust, Anaesthesia & Intens Care Med, London, England; [Cepkova, Magda] Whittington Hlth Natl Hlth Serv, Intens Care Unit, London, England; [Pogson, David G.] Portsmouth Hosp Natl Hlth Serv Trust, Acad Dept Crit Care, Portsmouth, Hants, England; [Brett, Stephen J.] Imperial Coll Healthcare Natl Hlth Serv Trust, Ctr Perioperat & Crit Care Res, London, England	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; University of Warwick; Portsmouth Hospitals NHS Trust; Imperial College London	Gordon, AC (corresponding author), Imperial Coll London, Charing Cross Hosp, ICU 11N, Fulham Palace Rd, London W6 8RF, England.	anthony.gordon@imperial.ac.uk	Cecconi, Maurizio/HDN-8785-2022; Mellinghoff, Johannes/V-4844-2019; Gordon, Anthony/A-3472-2012; Prowle, John/D-5014-2009; Perkins, Gavin/E-7613-2010; Hoste, Eric/A-6353-2008; Cecconi, Maurizio/A-6241-2012; Shankar-Hari, Manu/I-6948-2012; Ostermann, Marlies/B-8777-2015	Cecconi, Maurizio/0000-0002-4376-6538; Mellinghoff, Johannes/0000-0002-5455-8953; Gordon, Anthony/0000-0002-0419-547X; Prowle, John/0000-0002-5002-2721; Hoste, Eric/0000-0001-9301-8055; Cecconi, Maurizio/0000-0002-4376-6538; Shankar-Hari, Manu/0000-0002-5338-2538; Harris, Clair/0000-0002-1575-8768; Ostermann, Marlies/0000-0001-9500-9080; Perkins, Gavin/0000-0003-3027-7548; Mason, Alexina/0000-0001-7319-4545; Warwick, Jane/0000-0002-7320-6603; McAuley, Daniel/0000-0002-3283-1947; Di Tomasso, Nora/0000-0001-5706-8928	UK National Institute for Health Research (NIHR) under its Research for Patient Benefit program [PB-PG-0610-22350]; NIHR Clinician Scientist Award; NIHR Comprehensive Biomedical Research Centre based at Imperial College Healthcare National Health System (NHS) Trust and Imperial College London; UK Intensive Care Foundation; National Institute for Health Research [NIHR/CS/009/007, PB-PG-0610-22350, NF-SI-0514-10139] Funding Source: researchfish	UK National Institute for Health Research (NIHR) under its Research for Patient Benefit program; NIHR Clinician Scientist Award; NIHR Comprehensive Biomedical Research Centre based at Imperial College Healthcare National Health System (NHS) Trust and Imperial College London; UK Intensive Care Foundation; National Institute for Health Research(National Institute for Health Research (NIHR))	This article presents independent research funded by grant PB-PG-0610-22350 from the UK National Institute for Health Research (NIHR) under its Research for Patient Benefit program and an NIHR Clinician Scientist Award (Dr Gordon). It was supported by the NIHR Comprehensive Biomedical Research Centre based at Imperial College Healthcare National Health System (NHS) Trust and Imperial College London, and also by the UK Intensive Care Foundation.	Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; Bauer SR, 2008, J CRIT CARE, V23, P500, DOI 10.1016/j.jcrc.2008.04.002; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Ertmer C, 2007, SHOCK, V27, P281, DOI 10.1097/01.shk.0000235140.97903.90; Gordon AC, 2014, CRIT CARE MED, V42, P1325, DOI 10.1097/CCM.0000000000000212; Gordon AC, 2010, INTENS CARE MED, V36, P83, DOI 10.1007/s00134-009-1687-x; Harvey SE, 2006, INTENS CARE MED, V32, P2020, DOI 10.1007/s00134-006-0358-4; Landry DW, 1997, CIRCULATION, V95, P1122; Lauzier F, 2006, INTENS CARE MED, V32, P1782, DOI 10.1007/s00134-006-0378-0; LENZ K, 1991, GASTROENTEROLOGY, V101, P1060, DOI 10.1016/0016-5085(91)90734-3; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; O'Callaghan DJP, 2015, INTENS CARE MED, V41, P2177, DOI 10.1007/s00134-015-3849-3; Patel BM, 2002, ANESTHESIOLOGY, V96, P576, DOI 10.1097/00000542-200203000-00011; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Russell JA, 2009, CRIT CARE MED, V37, P811, DOI 10.1097/CCM.0b013e3181961ace; Seymour CW, 2015, JAMA-J AM MED ASSOC, V314, P708, DOI 10.1001/jama.2015.7885; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Torgersen C, 2011, INTENS CARE MED, V37, P1432, DOI 10.1007/s00134-011-2312-3; Torgersen C, 2010, INTENS CARE MED, V36, P57, DOI 10.1007/s00134-009-1630-1; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	22	301	323	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2016	316	5					509	518		10.1001/jama.2016.10485	http://dx.doi.org/10.1001/jama.2016.10485			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS9AU	27483065	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000381075000017
J	Banerjee, M; Wiebel, JL; Guo, C; Gay, B; Haymart, MR				Banerjee, Mousumi; Wiebel, Jaime L.; Guo, Cui; Gay, Brittany; Haymart, Megan R.			Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTTREATMENT SURVEILLANCE; INCREASING INCIDENCE; THERAPY; TRENDS; MANAGEMENT; EFFICACY; BURDEN; LIVER; RISK	OBJECTIVE To determine whether the use of imaging tests after primary treatment of differentiated thyroid cancer is associated with more treatment for recurrence and fewer deaths from the disease. DESIGN Population based retrospective cohort study. SETTING Surveillance Epidemiology and End Results-Medicare database in the United States. PARTICIPANTS 28 220 patients diagnosed with differentiated thyroid cancer between 1998 and 2011. The study cohort was followed up to 2013, with a median follow-up of 69 months. MAIN OUTCOME MEASURES Treatment for recurrence of differentiated thyroid cancer (additional neck surgery, additional radioactive iodine treatment, or radiotherapy), and deaths due to differentiated thyroid cancer. We conducted propensity score analyses to assess the relation between imaging (neck ultrasound, radioiodine scanning, or positron emission tomography (PET) scanning) and treatment for recurrence (logistic model) and death (Cox proportional hazards model). RESULTS From 1998 until 2011, we saw an increase in incident cancer (rate ratio 1.05, 95% confidence interval 1.05 to 1.06), imaging (1.13, 1.12 to 1.13), and treatment for recurrence (1.01, 1.01 to 1.02); the change in death rate was not significant. In multivariable analysis, use of neck ultrasounds increased the likelihood of additional surgery (odds ratio 2.30, 95% confidence interval 2.05 to 2.58) and additional radioactive iodine treatment (1.45, 1.26 to 1.69). Radioiodine scans were associated with additional surgery (odds ratio 3.39, 95% confidence interval 3.06 to 3.76), additional radioactive iodine treatment (17.83, 14.49 to 22.16), and radiotherapy (1.89, 1.71 to 2.10). Use of PET scans was associated with additional surgery (odds ratio 2.31, 95% confidence interval 2.09 to 2.55), additional radioactive iodine treatment (2.13, 1.89 to 2.40), and radiotherapy (4.98, 4.52 to 5.49). Use of neck ultrasounds or PET scans did not significantly affect disease specific survival (hazard ratio 1.14, 95% confidence interval 0.98 to 1.27, and 0.91, 0.77 to 1.07, respectively). However, radioiodine scans were associated with an improved disease specific survival (hazard ratio 0.70, 95% confidence interval 0.60 to 0.82). CONCLUSIONS The marked rise in use of imaging tests after primary treatment of differentiated thyroid cancer has been associated with an increased treatment for recurrence. However, with the exception of radioiodine scans in presumed iodine avid disease, this association has shown no clear improvement in disease specific survival. These findings emphasize the importance of curbing unnecessary imaging and tailoring imaging after primary treatment to patient risk.	[Banerjee, Mousumi; Guo, Cui] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Banerjee, Mousumi; Haymart, Megan R.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Wiebel, Jaime L.] Endocrine Associates Dallas, Dallas, TX USA; [Gay, Brittany; Haymart, Megan R.] Univ Michigan, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA; [Haymart, Megan R.] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Haymart, MR (corresponding author), Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.; Haymart, MR (corresponding author), Univ Michigan, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.; Haymart, MR (corresponding author), Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA.	meganhay@med.umich.edu		Haymart, Megan/0000-0002-1083-1575	National Institutes of Health [1K07CA154595-02]; National Cancer Institute [5 P30 CA 046592]; Punya Foundation for Thyroid Cancer Research; NATIONAL CANCER INSTITUTE [P30CA046592, T32CA083654] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Punya Foundation for Thyroid Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MRH is supported by National Institutes of Health grant 1K07CA154595-02. MB is partly supported by grant 5 P30 CA 046592 from the National Cancer Institute. Support was provided by the Punya Foundation for Thyroid Cancer Research. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.	Aschebrook-Kilfoy B, 2013, CANCER EPIDEM BIOMAR, V22, P1252, DOI 10.1158/1055-9965.EPI-13-0242; Banerjee M, 2014, J CLIN ENDOCR METAB, V99, P3737, DOI 10.1210/jc.2014-2197; Boltz MM, 2013, SURGERY, V154, P1363, DOI 10.1016/j.surg.2013.06.042; Bresner L, 2015, J CLIN ENDOCR METAB, V100, P977, DOI 10.1210/jc.2014-3169; Butt DA, 2014, NEUROEPIDEMIOLOGY, V43, P28, DOI 10.1159/000365590; Cooper DS, 2010, THYROID, V20, P942, DOI 10.1089/thy.2009.0110.cxn2; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; Fritz A, 2000, INT CLASSIFICATION D; Griffeth Landis K, 2005, Proc (Bayl Univ Med Cent), V18, P321; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hollenbeak CS, 2013, EUR J ENDOCRINOL, V168, P549, DOI 10.1530/EJE-12-0848; Huang BS, 2009, RADIOLOGY, V251, P166, DOI 10.1148/radiol.2511081300; Hyder O, 2013, J GASTROINTEST SURG, V17, P1774, DOI 10.1007/s11605-013-2302-6; Hyder O, 2013, SURGERY, V154, P256, DOI 10.1016/j.surg.2013.04.021; Lang BHH, 2013, WORLD J SURG, V37, P2853, DOI 10.1007/s00268-013-2202-7; Misra S, 2013, J SURG ONCOL, V108, P47, DOI 10.1002/jso.23345; Morris LGT, 2013, THYROID, V23, P886, DOI 10.1089/thy.2013.0045; Nixon IJ, 2014, SURGERY, V156, P137, DOI 10.1016/j.surg.2014.03.027; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Roh JL, 2009, AM J SURG, V197, P459, DOI [10.1016/j.amjsurg.2008.04.017, 10.1016/j.amjsurg.2008.06.040]; Sawka AM, 2009, THYROID, V19, P451, DOI 10.1089/thy.2008.0392; Schreinemakers JMJ, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-192; Singh SM, 2017, MED CARE, V55, pE44, DOI 10.1097/MLR.0000000000000274; Smallridge RC, 2014, THYROID, V24, P1501, DOI 10.1089/thy.2014.0043; Song HJ, 2015, EUR J ENDOCRINOL, V173, P399, DOI 10.1530/EJE-15-0296; Sprague BL, 2008, CANCER CAUSE CONTROL, V19, P585, DOI 10.1007/s10552-008-9122-0; Terezakis SA, 2009, INT J RADIAT ONCOL, V73, P795, DOI 10.1016/j.ijrobp.2008.05.012; Tufano RP, 2015, THYROID, V25, P15, DOI 10.1089/thy.2014.0098; Tuttle RM, 2010, THYROID, V20, P1341, DOI 10.1089/thy.2010.0178; Van Nostrand D, 2011, ORAL DIS, V17, P154, DOI 10.1111/j.1601-0825.2010.01726.x; Wang WP, 2000, J CLIN ENDOCR METAB, V85, P1107, DOI 10.1210/jc.85.3.1107; Warren JL, 2002, MED CARE, V40, P55; Wiebel JL, 2015, THYROID, V25, P1026, DOI 10.1089/thy.2015.0062; Wiebel JL, 2015, CANCER-AM CANCER SOC, V121, P1387, DOI 10.1002/cncr.29210; Witkowski ER, 2012, J GASTROINTEST SURG, V16, P121, DOI 10.1007/s11605-011-1699-z	38	16	16	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2016	354								i3839	10.1136/bmj.i3839	http://dx.doi.org/10.1136/bmj.i3839			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DS0WA	27443325	hybrid, Green Published			2023-01-03	WOS:000380316300005
J	Endendijk, JJ; Groeneveld, MG; Bakermans-Kranenburg, MJ; Mesman, J				Endendijk, Joyce J.; Groeneveld, Marleen G.; Bakermans-Kranenburg, Marian J.; Mesman, Judi			Gender-Differentiated Parenting Revisited: Meta-Analysis Reveals Very Few Differences in Parental Control of Boys and Girls	PLOS ONE			English	Article							MOTHER-CHILD INTERACTION; SEX-DIFFERENCES; MATERNAL CONTROL; PSYCHOLOGICAL CONTROL; CORPORAL PUNISHMENT; BEHAVIOR PROBLEMS; PUBLICATION BIAS; SELF-REGULATION; TRANSACTIONAL-ANALYSIS; CONFIDENCE-INTERVALS	Although various theories describe mechanisms leading to differential parenting of boys and girls, there is no consensus about the extent to which parents do treat their sons and daughters differently. The last meta-analyses on the subject were conducted more than fifteen years ago, and changes in gender-specific child rearing in the past decade are quite plausible. In the current set of meta-analyses, based on 126 observational studies (15,034 families), we examined mothers' and fathers' differential use of autonomy-supportive and controlling strategies with boys and girls, and the role of moderators related to the decade in which the study was conducted, the observational context, and sample characteristics. Databases of Web of Science, ERIC, PsychInfo, Online Contents, Picarta, and Proquest were searched for studies examining differences in observed parental control of boys and girls between the ages of 0 and 18 years. Few differences were found in parents' use of control with boys and girls. Parents were slightly more controlling with boys than with girls, but the effect size was negligible (d = 0.08). The effect was larger, but still small, in normative groups and in samples with younger children. No overall effect for gender-differentiated autonomy-supportive strategies was found (d = 0.03). A significant effect of time emerged: studies published in the 1970s and 1980s reported more autonomy-supportive strategies with boys than toward girls, but from 1990 onwards parents showed somewhat more autonomy-supportive strategies with girls than toward boys. Taking into account parents' gender stereotypes might uncover subgroups of families where gender-differentiated control is salient, but based on our systematic review of the currently available large data base we conclude that in general the differences between parenting of boys versus girls are minimal.	[Endendijk, Joyce J.; Groeneveld, Marleen G.; Bakermans-Kranenburg, Marian J.; Mesman, Judi] Leiden Univ, Ctr Child & Family Studies, Leiden, Netherlands; [Endendijk, Joyce J.] Univ Utrecht, Child & Adolescent Studies, Utrecht, Netherlands	Leiden University; Leiden University - Excl LUMC; Utrecht University	Mesman, J (corresponding author), Leiden Univ, Ctr Child & Family Studies, Leiden, Netherlands.	mesmanj@fsw.leidenuniv.nl	Endendijk, Joyce/AAB-2184-2021; Bakermans-Kranenburg, Marian/AAF-7746-2020	Bakermans-Kranenburg, Marian/0000-0001-7763-0711	European Research Council [240885]; Netherlands Organization for Scientific Research [453-09-003]	European Research Council(European Research Council (ERC)European Commission); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	This research was supported by a European Research Council (https://erc.europa.eu/) Starting Grant awarded to JM (project # 240885). MJBK was supported by the Netherlands Organization for Scientific Research (http://www.nwo.nl/en; VICI Grant 453-09-003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahl RE, 2013, INFANT BEHAV DEV, V36, P199, DOI 10.1016/j.infbeh.2013.01.005; Ainsworth M.D.S, 2015, PATTERNS ATTACHMENT; Alink LRA, 2006, CHILD DEV, V77, P954, DOI 10.1111/j.1467-8624.2006.00912.x; Andersson G, 2006, DEMOGRAPHY, V43, P255, DOI 10.1353/dem.2006.0010; [Anonymous], 2013, GLOBAL GENDER GAP RE; Archer J, 2004, REV GEN PSYCHOL, V8, P291, DOI 10.1037/1089-2680.8.4.291; Arnold F., 1984, J COMP FAM STUD, V15, P299, DOI DOI 10.3138/JCFS.15.2.299; Baillargeon RH, 2007, DEV PSYCHOL, V43, P13, DOI 10.1037/0012-1649.43.1.13; Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; Barber BK, 1996, CHILD DEV, V67, P3296, DOI 10.2307/1131780; BARBER BK, 1994, CHILD DEV, V65, P1120, DOI 10.2307/1131309; Barber BK., 2002, INTRUSIVE PARENTING, P262, DOI [10.1037/10422-000, DOI 10.1037/10422-009]; BARKLEY RA, 1989, J CHILD PSYCHOL PSYC, V30, P379, DOI 10.1111/j.1469-7610.1989.tb00253.x; Barnett D, 1998, CHILD DEV, V69, P1657, DOI 10.1111/j.1467-8624.1998.tb06183.x; Basow S. A., 1999, APPEARANCE NEW LOOK, P25, DOI [10.1037/10325-001, DOI 10.1037/10325-001]; BAUMRIND D, 1971, DEV PSYCHOL, V4, P1, DOI 10.1037/h0030372; BEFERA MS, 1985, J CHILD PSYCHOL PSYC, V26, P439, DOI 10.1111/j.1469-7610.1985.tb01945.x; Belden AC, 2007, ATTACH HUM DEV, V9, P239, DOI 10.1080/14616730701455395; BELLINGER DC, 1982, SEX ROLES, V8, P1123, DOI 10.1007/BF00290968; BEM SL, 1981, PSYCHOL REV, V88, P354, DOI 10.1037/0033-295X.88.4.354; BEM SL, 1983, SIGNS, V8, P598, DOI 10.1086/493998; Bender HL, 2007, DEV PSYCHOPATHOL, V19, P227, DOI 10.1017/S0954579407070125; Bernstein VJ, 2005, J APPL DEV PSYCHOL, V26, P241, DOI 10.1016/j.appdev.2005.02.002; BEZIRGANIAN S, 1992, J AM ACAD CHILD PSY, V31, P790, DOI 10.1097/00004583-199209000-00004; BLACKWELDER DE, 1986, J PERS SOC PSYCHOL, V50, P80; Block JH, 1979, PSYCHOL WOMEN FUTURE, P29; Boeldt DL, 2012, INFANT CHILD DEV, V21, P85, DOI 10.1002/icd.764; Borenstein M., 2009, INTRO META ANAL; Bowlby J., 1969, ATTACHMENT LOSS, V1; BraungartRieker U, 1997, J APPL DEV PSYCHOL, V18, P411; BRIGHT MC, 1984, J GENET PSYCHOL, V144, P219, DOI 10.1080/00221325.1984.9923428; BRODY GH, 1985, BEHAV RES THER, V23, P291, DOI 10.1016/0005-7967(85)90007-5; BRODY GH, 1992, CHILD DEV, V63, P82, DOI 10.2307/1130903; BRODY GH, 1986, DEV PSYCHOL, V22, P291, DOI 10.1037/0012-1649.22.3.291; BRONSTEIN P, 1984, DEV PSYCHOL, V20, P995, DOI 10.1037/0012-1649.20.6.995; Bronstein P, 2007, SEX ROLES, V56, P661, DOI 10.1007/s11199-007-9182-8; Buckholtz JW, 2008, MOL PSYCHIATR, V13, P313, DOI 10.1038/sj.mp.4002020; Bumpus MF, 2001, DEV PSYCHOL, V37, P163, DOI 10.1037/0012-1649.37.2.163; Cabrera NJ, 2000, CHILD DEV, V71, P127, DOI 10.1111/1467-8624.00126; CALDERA YM, 1989, CHILD DEV, V60, P70, DOI 10.2307/1131072; Calkins SD, 1998, SOC DEV, V7, P350, DOI 10.1111/1467-9507.00072; Campbell JJ., 1999, THESIS; CAMPBELL SB, 1986, J ABNORM CHILD PSYCH, V14, P425, DOI 10.1007/BF00915436; Celano M, 2008, FAM PROCESS, V47, P7, DOI 10.1111/j.1545-5300.2008.00236.x; Chaplin TM, 2005, EMOTION, V5, P80, DOI 10.1037/1528-3542.5.1.80; Chen XY, 2001, PARENT-SCI PRACT, V1, P159, DOI 10.1207/S15327922PAR0103_01; Chen XY, 2000, INT J BEHAV DEV, V24, P119, DOI 10.1080/016502500383557; CHERRY L, 1976, DEV PSYCHOL, V12, P278, DOI 10.1037/0012-1649.12.4.278; Christopoulou C, 1988, THESIS; Ciarrocchi JW., 1983, THESIS; Cipriano EA, 2010, J APPL DEV PSYCHOL, V31, P221, DOI 10.1016/j.appdev.2010.02.004; Cohen J., 1988, STAT POWER ANAL BEHA, P18, DOI [10.4324/9780203771587, DOI 10.1016/B978-0-12-179060-8.50006-2]; COPELAND AP, 1984, J DIVORCE, V8, P17; Coulson SL., 2001, THESIS; CROCKENBERG S, 1990, DEV PSYCHOL, V26, P961, DOI 10.1037/0012-1649.26.6.961; CULP RE, 1983, SEX ROLES, V9, P475, DOI 10.1007/BF00289787; Cyr M, 2014, CHILD PSYCHIAT HUM D, V45, P555, DOI 10.1007/s10578-013-0424-4; Das Eiden R, 2001, ALCOHOL CLIN EXP RES, V25, P1621, DOI 10.1097/00000374-200111000-00010; Deater-Deckard K, 2000, CHILD DEV, V71, P468, DOI 10.1111/1467-8624.00158; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; DECI EL, 1994, J PERS, V62, P119, DOI 10.1111/j.1467-6494.1994.tb00797.x; DEKOVIC M, 1992, J MARRIAGE FAM, V54, P675, DOI 10.2307/353253; Dennis T, 2006, DEV PSYCHOL, V42, P84, DOI 10.1037/0012-1649.42.1.84; DeWolff MS, 1997, CHILD DEV, V68, P571, DOI 10.2307/1132107; Dodson TA, 2006, CAREER DEV Q, V54, P283, DOI 10.1002/j.2161-0045.2006.tb00194.x; Donovan WL, 2000, DEV PSYCHOL, V36, P402, DOI 10.1037/0012-1649.36.3.402; DUMAS JE, 1995, J ABNORM PSYCHOL, V104, P104, DOI 10.1037/0021-843X.104.1.104; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Eddy JM, 2001, AGGRESSIVE BEHAV, V27, P14, DOI 10.1002/1098-2337(20010101/31)27:1<14::AID-AB2>3.0.CO;2-2; Eley TC, 2010, J CHILD PSYCHOL PSYC, V51, P772, DOI 10.1111/j.1469-7610.2010.02227.x; Else-Quest NM, 2006, PSYCHOL BULL, V132, P33, DOI 10.1037/0033-2909.132.1.33; EMBER CR, 1994, J CONFLICT RESOLUT, V38, P620, DOI 10.1177/0022002794038004002; Emmons Y. D., 2001, THESIS; Endendijk JJ, 2016, CHILD DEV; Endendijk JJ, 2014, PARENT-SCI PRACT, V14, P141, DOI 10.1080/15295192.2014.972753; Ex CTGM, 1998, SEX ROLES, V38, P171; FAGOT BI, 1993, CHILD DEV, V64, P258, DOI 10.2307/1131450; Fagot BI, 1996, J SOC PERS RELAT, V13, P295, DOI 10.1177/0265407596132008; FAGOT BI, 1985, SEX ROLES, V12, P471, DOI 10.1007/BF00288169; FAGOT BI, 1985, SEX ROLES, V12, P341, DOI 10.1007/BF00287600; FALENDER CA, 1975, DEV PSYCHOL, V11, P830, DOI 10.1037/0012-1649.11.6.830; Feldman R, 2003, DEV PSYCHOL, V39, P680, DOI 10.1037/0012-1649.39.4.680; FELDMAN SS, 1986, MERRILL PALMER QUART, V32, P365; Fisher P. A., 1993, J FAMILY PSYCHOL, V7, P250, DOI DOI 10.1037/0893-3200.7.2.250; Flynn CP, 1999, J MARRIAGE FAM, V61, P971, DOI 10.2307/354017; Frampton K. L., 2012, THESIS; FRANKEL MT, 1983, DEV PSYCHOL, V19, P694; Frodi A., 1985, INFANT MENT HEALTH J, V6, P60, DOI DOI 10.1002/1097-0355(198522)6:2<60::AID-; Fuligni AJ, 1998, DEV PSYCHOL, V34, P782, DOI 10.1037/0012-1649.34.4.782; Gaertner BM, 2008, INFANT CHILD DEV, V17, P339, DOI 10.1002/ICD.580; Gardner F, 2000, Clin Child Fam Psychol Rev, V3, P185, DOI 10.1023/A:1009503409699; Gershoff ET, 2002, PSYCHOL BULL, V128, P539, DOI 10.1037//0033-2909.128.4.539; Gjerde PF, J RES ADOLESC, V1, P63; GOLDSTEIN H, 1995, J ROY STAT SOC A STA, V158, P175, DOI 10.2307/2983411; GOLINKOFF RM, 1979, CHILD DEV, V50, P28, DOI 10.2307/1129037; GORDON BN, 1983, CHILD PSYCHIAT HUM D, V13, P153, DOI 10.1007/BF00705856; Grolnick WS, 2013, PSYCHOL PARENTAL CON; Gross D, 2009, PREV SCI, V10, P54, DOI 10.1007/s11121-008-0116-7; Gunnoe ML, 1999, J EARLY ADOLESCENCE, V19, P199, DOI 10.1177/0272431699019002004; Gustafsson HC, 2012, J FAM PSYCHOL, V26, P115, DOI 10.1037/a0026283; Hank K., 2000, DEMOGR RES, V2, DOI [https://doi.org/10.4054/DemRes.2000.2.1, DOI 10.4054/DEMRES.2000.2.1]; Harris RJ, 1998, SEX ROLES, V38, P239, DOI 10.1023/A:1018785100469; Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203; Henderson S. A., 2007, THESIS; HESS RD, 1984, CHILD DEV, V55, P2017, DOI 10.1111/j.1467-8624.1984.tb03899.x; Higgins KN, 2008, THESIS; Holt EC., 2007, THESIS; Huang CY, 2014, J CROSS CULT PSYCHOL, V45, P507, DOI 10.1177/0022022113513652; Huerta Maria., 2013, OECD SOCIAL EMPLOYME, V140, DOI [10.1787/5k4dlw9w6czq-en, DOI 10.1787/5K4DLW9W6CZQ-EN]; Hughes C, 1999, SOC DEV, V8, P143, DOI 10.1111/1467-9507.00088; HYDE JS, 1984, DEV PSYCHOL, V20, P722, DOI 10.1037/0012-1649.20.4.722; Infa Lloyd CA., 2010, THESIS; Inglehart Ronald, 2003, RISING TIDE GENDER E; Inoff-Germain G., 1988, J EARLY ADOLESCENCE, V8, P17, DOI [10.1177/0272431688081002, DOI 10.1177/0272431688081002]; Jaffee SR, 2004, DEV PSYCHOL, V40, P1047, DOI 10.1037/0012-1649.40.6.1047; Janssens JMAM, 1997, INT J BEHAV DEV, V20, P509, DOI 10.1080/016502597385252; Joosen KJ, 2012, ATTACH HUM DEV, V14, P101, DOI 10.1080/14616734.2012.661217; Julious SA, 2004, PHARM STAT, V3, P217, DOI 10.1002/pst.126; JURICH AP, 1976, PSYCHOL REP, V38, P883, DOI 10.2466/pr0.1976.38.3.883; KAGAN J, 1963, CHILD DEV, V34, P899, DOI 10.1111/j.1467-8624.1963.tb05162.x; Kalpidou MD, 1998, J GENET PSYCHOL, V159, P103, DOI 10.1080/00221329809596138; Kapungu CT, 2006, J YOUTH ADOLESCENCE, V35, P787, DOI 10.1007/s10964-006-9102-1; Karreman A, 2006, INFANT CHILD DEV, V15, P561, DOI 10.1002/icd.478; Kauffman CM, 1985, THESIS; Kawabata Y, 2011, DEV REV, V31, P240, DOI 10.1016/j.dr.2011.08.001; Keenan K, 1997, PSYCHOL BULL, V121, P95, DOI 10.1037/0033-2909.121.1.95; Kenney-Benson GA, 2005, J PERS, V73, P23, DOI 10.1111/j.1467-6494.2004.00303.x; KERIG PK, 1993, DEV PSYCHOL, V29, P931, DOI 10.1037/0012-1649.29.6.931; Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851; Kochanska G, 2001, CHILD DEV, V72, P1091, DOI 10.1111/1467-8624.00336; KOCHANSKA G, 1995, CHILD DEV, V66, P597, DOI 10.2307/1131937; Kochanska G, 2003, DEV PSYCHOL, V39, P949, DOI 10.1037/0012-1649.39.6.949; Kochanska G, 2009, CHILD DEV, V80, P1288, DOI 10.1111/j.1467-8624.2009.01332.x; Kok R, 2013, DEV PSYCHOBIOL, V55, P451, DOI 10.1002/dev.21049; KUCZYNSKI L, 1984, DEV PSYCHOL, V20, P1061, DOI 10.1037/0012-1649.20.6.1061; Kuczynski L., 1994, PARENTING CHILDRENS, P78; LAFRENIERE PJ, 1992, DEV PSYCHOPATHOL, V4, P385, DOI 10.1017/S0954579400000857; Lamb M.E., 2010, ROLE FATHER CHILD DE, P1, DOI DOI 10.1007/978-1-4613-9820-2_7; LAOSA LM, 1978, CHILD DEV, V49, P1129, DOI 10.1111/j.1467-8624.1978.tb04081.x; Larsson H, 2008, J ABNORM CHILD PSYCH, V36, P633, DOI 10.1007/s10802-007-9151-2; Leaper C, 1998, DEV PSYCHOL, V34, P3, DOI 10.1037/0012-1649.34.1.3; Lee IC, 2011, PSYCHOL BULL, V137, P1029, DOI 10.1037/a0025410; Lengua LJ, 2007, J APPL DEV PSYCHOL, V28, P40, DOI 10.1016/j.appdev.2006.10.001; Lengua LJ, 2014, SOC DEV, V23, P631, DOI 10.1111/sode.12071; Li JJ, 2013, J CLIN CHILD ADOLESC, V42, P174, DOI 10.1080/15374416.2012.736355; Lindsey EW, 2005, INFANT BEHAV DEV, V28, P165, DOI 10.1016/j.infbeh.2005.02.004; Linver MR, 2002, DEV PSYCHOL, V38, P719, DOI 10.1037//0012-1649.38.5.719; Liu MW, 2010, SCAND J PSYCHOL, V51, P109, DOI 10.1111/j.1467-9450.2009.00795.x; LOEB RC, 1980, MERRILL PALMER QUART, V26, P205; Loeber R, 2013, BRAIN RES FDN S SERI, V1, P137, DOI [10.1007/978-1-4614-7557-6_6, DOI 10.1007/978-1-4614-7557-6_6]; Longeway KP., 1983, THESIS; Lundberg S, 2005, OXFORD REV ECON POL, V21, P340, DOI 10.1093/oxrep/gri020; LYTTON H, 1991, PSYCHOL BULL, V109, P267, DOI 10.1037/0033-2909.109.2.267; Maccoby E.E., 1974, PSYCHOL SEX DIFFEREN; MACCOBY EE, 1984, DEV PSYCHOL, V20, P459, DOI 10.1037/0012-1649.20.3.459; Mandara J, 2012, FAM RELAT, V61, P129, DOI 10.1111/j.1741-3729.2011.00688.x; MARGOLIN G, 1975, DEV PSYCHOL, V11, P537, DOI 10.1037/h0076682; MARTINEZ EA, 1988, FAM RELAT, V37, P275, DOI 10.2307/584562; McFadyenKetchum SA, 1996, CHILD DEV, V67, P2417, DOI 10.1111/j.1467-8624.1996.tb01865.x; McHale SM, 2003, SOC DEV, V12, P125, DOI 10.1111/1467-9507.00225; MCLAUGHLIN B, 1983, DEV PSYCHOL, V19, P667; MCLAUGHLIN B, 1980, CHILD DEV, V51, P580; Mills RSL, 1998, CAN J BEHAV SCI, V30, P132, DOI 10.1037/h0085803; MINTON C, 1971, CHILD DEV, V42, P1873, DOI 10.1111/j.1467-8624.1971.tb03777.x; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Morrell J, 2003, J CHILD PSYCHOL PSYC, V44, P489, DOI 10.1111/1469-7610.t01-1-00139; Morsbach SK, 2006, CLIN CHILD FAM PSYCH, V9, P1, DOI 10.1007/s10567-006-0001-5; MULLIS RL, 1985, PERCEPT MOTOR SKILL, V60, P567, DOI 10.2466/pms.1985.60.2.567; Mulvaney MK, 2007, J FAM PSYCHOL, V21, P389, DOI 10.1037/0893-3200.21.3.389; Nelson D. A., 2002, INTRUSIVE PARENTING, P161, DOI DOI 10.1037/10422-006; Nelson DA, 2013, J APPL DEV PSYCHOL, V34, P1, DOI 10.1016/j.appdev.2012.07.003; Neppl TK, 2009, DEV PSYCHOL, V45, P1241, DOI 10.1037/a0014850; OBRIEN M, 1987, J CHILD LANG, V14, P269, DOI 10.1017/S0305000900012927; OLDERSHAW L, 1986, CHILD DEV, V57, P722; Huber MO, 2012, REV LAT AM PSICOL, V44, P75; Patterson J., 2017, DEEP LEARNING PRACTI; Payton ME, 2003, J INSECT SCI, V3, DOI 10.1093/jis/3.1.34; Pettit GS, 2001, CHILD DEV, V72, P583, DOI 10.1111/1467-8624.00298; Pierce CA, 2008, ORGAN RES METHODS, V11, P188, DOI 10.1177/1094428106296641; POMERLEAU A, 1990, SEX ROLES, V22, P359, DOI 10.1007/BF00288339; POWER TG, 1985, CHILD DEV, V56, P1514; Roberts WL., 1983, FAMILY INTERATIONS C; ROBINSON EA, 1981, J CONSULT CLIN PSYCH, V49, P245, DOI 10.1037/0022-006X.49.2.245; Rodriguez MMD, 2009, FAM PROCESS, V48, P195, DOI 10.1111/j.1545-5300.2009.01277.x; ROTHBAUM F, 1994, PSYCHOL BULL, V116, P55, DOI 10.1037/0033-2909.116.1.55; Russell A, 1996, INT J BEHAV DEV, V19, P291, DOI 10.1080/016502596385794; Scaramella LV, 2008, SOC DEV, V17, P578, DOI 10.1111/j.1467-9507.2007.00439.x; SCHAEFER ES, 1965, CHILD DEV, V36, P413, DOI 10.1111/j.1467-8624.1965.tb05305.x; SERBIN LA, 1990, SEX ROLES, V23, P613, DOI 10.1007/BF00289251; Shaw DS, 1998, J ABNORM CHILD PSYCH, V26, P95, DOI 10.1023/A:1022665704584; Silverman IW, 1995, J APPL DEV PSYCHOL, V16, P569, DOI 10.1016/0193-3973(95)90005-5; Smith CL, 2004, DEV PSYCHOL, V40, P29, DOI 10.1037/0012-1649.40.1.29; Smith CL, 2010, PARENT-SCI PRACT, V10, P1, DOI 10.1080/15295190903014588; Smith JR, 1997, ARCH PEDIAT ADOL MED, V151, P777, DOI 10.1001/archpedi.1997.02170450027004; SMITH PK, 1977, CHILD DEV, V48, P1250, DOI 10.1111/j.1467-8624.1977.tb03929.x; Soenens B, 2007, DEV PSYCHOL, V43, P633, DOI 10.1037/0012-1649.43.3.633; Soenens B, 2010, DEV REV, V30, P74, DOI 10.1016/j.dr.2009.11.001; Stormshak EA, 2000, J CLIN CHILD PSYCHOL, V29, P17, DOI 10.1207/S15374424jccp2901_3; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; SWIM JK, 1995, J PERS SOC PSYCHOL, V68, P199, DOI 10.1037/0022-3514.68.2.199; Tabachnick B. G., 2001, USING MULTIVARIATE A, V4th; Tam VCW, 2004, MARRIAGE FAM REV, V35, P45, DOI [10.1300/J002v35n03_04, DOI 10.1300/J002V35N03_04]; Tamis-LeMonda CS, 2009, J APPL DEV PSYCHOL, V30, P321, DOI 10.1016/j.appdev.2008.12.018; The Fatherhood Institute, 2010, FATH REP 2010 11 FAI; Thomson RM, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-247; Trautmann-Villalba P, 2006, PRAX KINDERPSYCHOL K, V55, P169; Tulananda O, 2001, J FAM PSYCHOL, V15, P676, DOI 10.1037//0893-3200.15.4.676; U.S. Department of Labor Bureau of Labor Statistics, 2012, 1038 US DEP LAB BUR; van Ijzendoorn MH, 2005, PSYCHOL BULL, V131, P301, DOI 10.1037/0033-2909.131.2.301; Van Zeijl J, 2007, J FAM PSYCHOL, V21, P626, DOI 10.1037/0893-3200.21.4.626; Van Zeijl J, 2006, J CONSULT CLIN PSYCH, V74, P994, DOI 10.1037/0022-006X.74.6.994; Webster-Stratton C, 1999, J CHILD PSYCHOL PSYC, V40, P917, DOI 10.1017/S0021963099004199; Whipple EE, 1997, CHILD ABUSE NEGLECT, V21, P431, DOI 10.1016/S0145-2134(97)00004-5; Williamson N.E., 1976, SONS DAUGHTERS CROSS; Wilson EC., 1980, THESIS; Wood W, 2002, PSYCHOL BULL, V128, P699, DOI 10.1037//0033-2909.128.5.699; Wood W, 2012, ADV EXP SOC PSYCHOL, V46, P55, DOI 10.1016/B978-0-12-394281-4.00002-7; Yagmur S, 2014, ATTACH HUM DEV, V16, P371, DOI 10.1080/14616734.2014.912489; Yaman A, 2010, J CHILD FAM STUD, V19, P617, DOI 10.1007/s10826-009-9346-y; Zahn-Waxler C, 2008, ANNU REV CLIN PSYCHO, V4, P275, DOI 10.1146/annurev.clinpsy.3.022806.091358; Zevalkink J, 2001, INT J BEHAV DEV, V25, P167, DOI 10.1080/01650250042000113	222	127	128	5	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2016	11	7							e0159193	10.1371/journal.pone.0159193	http://dx.doi.org/10.1371/journal.pone.0159193			33	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DR0DZ	27416099	Green Published, gold, Green Submitted			2023-01-03	WOS:000379579500096
J	Ivanov, IV; Mackeben, M; Vollmer, A; Martus, P; Nguyen, NX; Trauzettel-Klosinski, S				Ivanov, Iliya V.; Mackeben, Manfred; Vollmer, Annika; Martus, Peter; Nguyen, Nhung X.; Trauzettel-Klosinski, Susanne			Eye Movement Training and Suggested Gaze Strategies in Tunnel Vision - A Randomized and Controlled Pilot Study	PLOS ONE			English	Article							VISUAL-ATTENTION; HOMONYMOUS HEMIANOPIA; RETINITIS-PIGMENTOSA; WALKING; SPEED; ORIENTATION; MECHANISMS; ONSETS; ADULTS	Purpose Degenerative retinal diseases, especially retinitis pigmentosa (RP), lead to severe peripheral visual field loss (tunnel vision), which impairs mobility. The lack of peripheral information leads to fewer horizontal eye movements and, thus, diminished scanning in RP patients in a natural environment walking task. This randomized controlled study aimed to improve mobility and the dynamic visual field by applying a compensatory Exploratory Saccadic Training (EST). Methods Oculomotor responses during walking and avoiding obstacles in a controlled environment were studied before and after saccade or reading training in 25 RP patients. Eye movements were recorded using a mobile infrared eye tracker (Tobii glasses) that measured a range of spatial and temporal variables. Patients were randomly assigned to two training conditions: Saccade (experimental) and reading (control) training. All subjects who first performed reading training underwent experimental training later (waiting list control group). To assess the effect of training on subjects, we measured performance in the training task and the following outcome variables related to daily life: Response Time (RT) during exploratory saccade training, Percent Preferred Walking Speed (PPWS), the number of collisions with obstacles, eye position variability, fixation duration, and the total number of fixations including the ones in the subjects' blind area of the visual field. Results In the saccade training group, RTs on average decreased, while the PPWS significantly increased. The improvement persisted, as tested 6 weeks after the end of the training. On average, the eye movement range of RP patients before and after training was similar to that of healthy observers. In both, the experimental and reading training groups, we found many fixations outside the subjects' seeing visual field before and after training. The average fixation duration was significantly shorter after the training, but only in the experimental training condition. Conclusions We conclude that the exploratory saccade training was beneficial for RP patients and resulted in shorter fixation durations after the training. We also found a significant improvement in relative walking speed during navigation in a real-world like controlled environment.	[Ivanov, Iliya V.; Vollmer, Annika; Trauzettel-Klosinski, Susanne] Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Vis Rehabil Res Unit, Tubingen, Germany; [Ivanov, Iliya V.] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, ZEISS Vis Sci Lab, Tubingen, Germany; [Mackeben, Manfred] Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA; [Vollmer, Annika; Nguyen, Nhung X.] Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Low Vis Clin, Tubingen, Germany; [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; The Smith-Kettlewell Eye Research Institute; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Ivanov, IV (corresponding author), Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Vis Rehabil Res Unit, Tubingen, Germany.; Ivanov, IV (corresponding author), Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, ZEISS Vis Sci Lab, Tubingen, Germany.	iliya.ivanov@uni-tuebingen.de			Kniese Foundation; Funke Foundation; Stiftung Auge; Pro Retina; AKF-Programm, University Eye Hospital, University of Tuebingen [296-0-0]; Deutsche Forschungsgemeinschaft; Open Access Publishing Fund of University of Tubingen	Kniese Foundation; Funke Foundation; Stiftung Auge; Pro Retina; AKF-Programm, University Eye Hospital, University of Tuebingen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Open Access Publishing Fund of University of Tubingen	This work was supported by the Kniese Foundation; Funke Foundation; Stiftung Auge; and Pro Retina to ST-K. AKF-Programm, University Eye Hospital, University of Tuebingen, Grant Nr. 296-0-0 to IVI. We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tubingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank our anonymous reviewers for their helpful suggestions and criticism. This study was supported by: Kniese Foundation; Funke Foundation; Stiftung Auge; Pro Retina. AKF-Programm, University Eye Hospital, University of Tuebingen, Grant Nr. 296-0-0 to IVI.	Black A, 1996, CLIN EXP OPTOM, V80, P1, DOI DOI 10.1111/J.1444-0938.1997.TB04841.X; Carrasco M, 2011, VISION RES, V51, P1484, DOI 10.1016/j.visres.2011.04.012; CLARKCARTER DD, 1986, ERGONOMICS, V29, P779, DOI 10.1080/00140138608968314; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Curtis CE, 2008, J NEUROPHYSIOL, V99, P133, DOI 10.1152/jn.00899.2007; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Engbert R, 2003, VISION RES, V43, P1035, DOI 10.1016/S0042-6989(03)00084-1; Genensky SM, 1979, CPS100HEW; HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794; Kastner S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/annurev.neuro.23.1.315; KROSE BJA, 1989, VISION RES, V29, P1607, DOI 10.1016/0042-6989(89)90142-9; Kuyk T, 2010, J VISUAL IMPAIR BLIN, V104, P215, DOI 10.1177/0145482X1010400405; LOWE J, 1992, OPTOMETRY VISION SCI, V69, P182, DOI 10.1097/00006324-199203000-00003; Luo G, 2008, J VISION, V8, DOI 10.1167/8.14.25; Mackeben M, 1998, VISION RES, V29, P1631; Mannan SK, 2010, J NEUROL, V257, P1812, DOI 10.1007/s00415-010-5615-3; Nguyen NX, 2011, ACTA OPHTHALMOL, V89, pE82, DOI 10.1111/j.1755-3768.2010.02081.x; Nguyen NX, 2012, OPHTHALMOLOGE, V109, P30; Pambakian ALM, 2000, J NEUROL NEUROSUR PS, V69, P751, DOI 10.1136/jnnp.69.6.751; Pambakian ALM, 2004, J NEUROL NEUROSUR PS, V75, P1443, DOI 10.1136/jnnp.2003.025957; Peli E, 2006, INV OPHTHALMOL VIS S, V47; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Roth T, 2009, NEUROLOGY, V72, P324, DOI 10.1212/01.wnl.0000341276.65721.f2; RUBIN GS, 1992, VISION RES, V32, P895, DOI 10.1016/0042-6989(92)90032-E; RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5; Schreij D, 2008, PERCEPT PSYCHOPHYS, V70, P208, DOI 10.3758/PP.70.2.208; Soong GP, 2001, OPTOMETRY VISION SCI, V78, P657, DOI 10.1097/00006324-200109000-00011; Stuart S, 2014, IEEE ENG MED BIO, P5739, DOI 10.1109/EMBC.2014.6944931; THEEUWES J, 1991, PERCEPT PSYCHOPHYS, V49, P83, DOI 10.3758/BF03211619; Turano KA, 2005, VISION RES, V45, P3117, DOI 10.1016/j.visres.2005.06.017; Turano KA, 1998, OPTOMETRY VISION SCI, V75, P879, DOI 10.1097/00006324-199812000-00010; Wiecek E, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00472	32	28	29	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2016	11	6							e0157825	10.1371/journal.pone.0157825	http://dx.doi.org/10.1371/journal.pone.0157825			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ0AH	27351629	Green Published, Green Submitted, gold			2023-01-03	WOS:000378858900018
J	Zhang, T; Cui, BT; Li, P; He, Z; Long, CY; Wei, L; Peng, ZY; Ji, GZ; Zhang, FM				Zhang, Ting; Cui, Bota; Li, Pan; He, Zhi; Long, Chuyan; Wei, Lu; Peng, Zhaoyuan; Ji, Guozhong; Zhang, Faming			Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; CHRONIC INTESTINAL INFLAMMATION; RANDOMIZED CONTROLLED-TRIAL; INNATE LYMPHOID-CELLS; T-CELLS; CROHNS-DISEASE; TH17 CELLS; IN-VIVO; RECEPTOR	Objective There were no reports on predicting long-term efficacy of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). This study aimed to detect short-term changes of cytokines and C-reactive protein (CRP) in patients with UC undergoing FMT, and to evaluate the predictive value of CRP and cytokines for the long-term efficacy of FMT. Methods Nineteen patients with moderate to severe UC (Mayo score >= 6) were treated with single fresh FMT through mid-gut. Serum samples were collected before and three days post-FMT. Clinical responses were evaluated by a minimum follow-up of three months. Patients with clinical improvement and remission at the assessment point of three-month were included as response group, while patients without clinical improvement or remission were included as non-response group. Serum concentrations of cytokines (IL-1 beta, IL-2, IL-4, IL-6, IL-10, IL-11, IL-17A, IFN-gamma, TNF, TNFR-1, TNFR-2, MCP-1, G-CSF, GM-CSF) and CRP were assayed to predict the clinical response of FMT. Results In total, 10.5% (2/19) of patients achieved clinical remission and 47.4% (9/19) achieved clinical improvement (Response group, including clinical remission and clinical improvement), 42.1% (8/19) failed to benefit from FMT (Non-response group). In both Response group and Non-response group, the level of CRP at three days after FMT didn't show significant decrease compared with that before FMT (p>0.05). However, in Response group, CRP level at three months after FMT decreased significantly than that before FMT (p<0.05). Compared with healthy controls (n = 9), patients with UC showed a higher baseline level of serum IL-6, TNFR-2 and G-CSF, and a lower level of IL-2 and IL-4 (p<0.05). In both Response group and Non-response group, none of the eleven detectable cytokines showed a significant difference between the value at three days after FMT and that before FMT (p>0.05). Conclusions Patients with moderate to severe UC presented a complex disorder of cytokines. However, the efficacy of FMT for UC might not be predicted by the short-term surveillance of cytokines and CRP.	[Zhang, Ting; Cui, Bota; Li, Pan; He, Zhi; Long, Chuyan; Wei, Lu; Peng, Zhaoyuan; Ji, Guozhong; Zhang, Faming] Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, Nanjing, Jiangsu, Peoples R China; [Zhang, Ting; Cui, Bota; Li, Pan; He, Zhi; Long, Chuyan; Wei, Lu; Peng, Zhaoyuan; Ji, Guozhong; Zhang, Faming] Nanjing Med Univ, Key Lab Holist Integrat Enterol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Ji, GZ; Zhang, FM (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, Nanjing, Jiangsu, Peoples R China.; Ji, GZ; Zhang, FM (corresponding author), Nanjing Med Univ, Key Lab Holist Integrat Enterol, Nanjing, Jiangsu, Peoples R China.	jgz@njmu.edu.cn; fzhang@njmu.edu.cn		Long, Chuyan/0000-0002-8800-3825	Intestine Initiative Foundation; Clinical Science and Technology Foundation of Jiangsu Province [BL2014097]; National Gastroenterology Research Project [2015BAI13B07]	Intestine Initiative Foundation; Clinical Science and Technology Foundation of Jiangsu Province; National Gastroenterology Research Project	This study was supported by publicly donated funds, the Intestine Initiative Foundation, Clinical Science and Technology Foundation of Jiangsu Province (BL2014097) and the National Gastroenterology Research Project (2015BAI13B07).	Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood-2011-04-325225; Angelberger S, 2013, AM J GASTROENTEROL, V108, P1620, DOI 10.1038/ajg.2013.257; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Atreya R, 2011, GASTROENTEROLOGY, V141, P2026, DOI 10.1053/j.gastro.2011.08.032; Babickova J, 2015, WORLD J GASTROENTERO, V21, P11321, DOI 10.3748/wjg.v21.i40.11321; Backhed F, 2012, CELL HOST MICROBE, V12, P611, DOI 10.1016/j.chom.2012.10.012; BENNET JD, 1989, LANCET, V1, P164; BORODY TJ, 1989, MED J AUSTRALIA, V150, P604, DOI 10.5694/j.1326-5377.1989.tb136704.x; BREESE E, 1993, IMMUNOLOGY, V78, P127; Caballero S, 2015, ANNU REV IMMUNOL, V33, P227, DOI 10.1146/annurev-immunol-032713-120238; Chang S, 2015, WORLD J GASTROENTERO, V21, P11246, DOI 10.3748/wjg.v21.i40.11246; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; Cui BT, 2016, GASTROENTEROLOGY, V150, P285, DOI 10.1053/j.gastro.2015.05.065; Cui BT, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0646-2; Cui BT, 2015, J GASTROEN HEPATOL, V30, P51, DOI 10.1111/jgh.12727; D'Haens G, 2007, GASTROENTEROLOGY, V132, P763, DOI 10.1053/j.gastro.2006.12.038; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; Feuerstein JD, 2014, MAYO CLIN PROC, V89, P1553, DOI 10.1016/j.mayocp.2014.07.002; Ford AC, 2011, AM J GASTROENTEROL, V106, P644, DOI 10.1038/ajg.2011.73; Francescone R, 2015, INFLAMM BOWEL DIS, V21, P409, DOI 10.1097/MIB.0000000000000236; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Gordon H, 2014, J CROHNS COLITIS, V8, P256, DOI 10.1016/j.crohns.2013.10.007; Holtmann MH, 2002, EUR J IMMUNOL, V32, P3142, DOI 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4; Jiang WY, 2014, INFLAMM RES, V63, P943, DOI 10.1007/s00011-014-0768-7; Kai Y, 2005, GASTROENTEROLOGY, V128, P922, DOI 10.1053/j.gastro.2005.01.013; Kao DN, 2014, J CLIN GASTROENTEROL, V48, P625, DOI 10.1097/MCG.0000000000000131; Kleiner G, 2015, EXP THER MED, V9, P2047, DOI 10.3892/etm.2015.2370; Kump PK, 2013, INFLAMM BOWEL DIS, V19, P2155, DOI 10.1097/MIB.0b013e31829ea325; Kunde S, 2013, J PEDIATR GASTR NUTR, V56, P597, DOI 10.1097/MPG.0b013e318292fa0d; Liu L, 2008, INT IMMUNOPHARMACOL, V8, P1481, DOI 10.1016/j.intimp.2008.04.013; Liu ZG, 2005, CELL RES, V15, P24, DOI 10.1038/sj.cr.7290259; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Perrier C, 2013, INFLAMM BOWEL DIS, V19, P246, DOI 10.1002/ibd.23023; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Sakuraba A, 2009, GASTROENTEROLOGY, V137, P1736, DOI 10.1053/j.gastro.2009.07.049; Sands BE, 2015, GASTROENTEROLOGY, V149, P1275, DOI 10.1053/j.gastro.2015.07.003; Schuijt TJ, 2013, TRENDS MICROBIOL, V21, P221, DOI 10.1016/j.tim.2013.02.001; Sha S, 2014, ALIMENT PHARM THER, V39, P1003, DOI 10.1111/apt.12699; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Wallace KL, 2014, WORLD J GASTROENTERO, V20, P6, DOI 10.3748/wjg.v20.i1.6; Xanthoulea S, 2004, J EXP MED, V200, P367, DOI 10.1084/jem.20040435; Zhang FM, 2012, AM J GASTROENTEROL, V107, P1755, DOI 10.1038/ajg.2012.251	44	21	24	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2016	11	6							e0158227	10.1371/journal.pone.0158227	http://dx.doi.org/10.1371/journal.pone.0158227			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP9FD	27347881	Green Published, gold, Green Submitted			2023-01-03	WOS:000378801200052
J	Isla, RAT; Ameh, OI; Mapiye, D; Swanepoel, CR; Bello, AK; Ratsela, AR; Okpechi, IG				Isla, Ramon A. Tamayo; Ameh, Oluwatoyin I.; Mapiye, Darlington; Swanepoel, Charles R.; Bello, Aminu K.; Ratsela, Andrew R.; Okpechi, Ikechi G.			Baseline Predictors of Mortality among Predominantly Rural-Dwelling End-Stage Renal Disease Patients on Chronic Dialysis Therapies in Limpopo, South Africa	PLOS ONE			English	Article							AMBULATORY PERITONEAL-DIALYSIS; HEMODIALYSIS-PATIENTS; SURVIVAL; MODALITY; IMPACT; RISK	Background Dialysis therapy for end-stage renal disease (ESRD) continues to be the readily available renal replacement option in developing countries. While the impact of rural/remote dwelling on mortality among dialysis patients in developed countries is known, it remains to be defined in sub-Saharan Africa. Methods A single-center database of end-stage renal disease patients on chronic dialysis therapies treated between 2007 and 2014 at the Polokwane Kidney and Dialysis Centre (PKDC) of the Pietersburg Provincial Hospital, Limpopo South Africa, was retrospectively reviewed. All-cause, cardiovascular, and infection-related mortalities were assessed and associated baseline predictors determined. Results Of the 340 patients reviewed, 52.1% were male, 92.9% were black Africans, 1.8% were positive for the human immunodeficiency virus (HIV), and 87.5% were rural dwellers. The average distance travelled to the dialysis centre was 112.3 +/- 73.4 Km while 67.6% of patients lived in formal housing. Estimated glomerular filtration rate (eGFR) at dialysis initiation was 7.1 +/- 3.7 mls/min while hemodialysis (HD) was the predominant modality offered (57.1%). Ninety-two (92) deaths were recorded over the duration of follow-up with the majority (34.8%) of deaths arising from infection-related causes. Continuous ambulatory peritoneal dialysis(CAPD) was a significant predictor of all-cause mortality (HR: 1.62, CI: 1.07-2.46) and infection-related mortality (HR: 2.27, CI: 1.13-4.60). On multivariable cox regression, CAPD remained a significant predictor of all-cause mortality (HR: 2.00, CI: 1.29-3.10) while the risk of death among CAPD patients was also significantly modified by diabetes mellitus(DM) status (HR: 4.99, CI: 2.13-11.71). Conclusion CAPD among predominantly rural dwelling patients in the Limpopo province of South Africa is associated with an increased risk of death from all-causes and infection-related causes.	[Isla, Ramon A. Tamayo; Ratsela, Andrew R.] Pietersburg Prov Hosp, Polokwane Kidney & Dialysis Ctr, Polokwane, South Africa; [Isla, Ramon A. Tamayo; Ratsela, Andrew R.] Univ Limpopo, Polokwane, South Africa; [Ameh, Oluwatoyin I.; Swanepoel, Charles R.; Okpechi, Ikechi G.] Univ Cape Town, Div Nephrol & Hypertens, ZA-7925 Cape Town, South Africa; [Mapiye, Darlington] Univ Western Cape, South African Natl Bioinformat Inst, South Africa Bioinformat Unit, MRC, Cape Town, South Africa; [Bello, Aminu K.] Univ Alberta, Dept Med, Div Nephrol, Edmonton, AB, Canada	University of Limpopo; University of Cape Town; University of the Western Cape; University of Alberta	Ameh, OI (corresponding author), Univ Cape Town, Div Nephrol & Hypertens, ZA-7925 Cape Town, South Africa.	amethystpj2@yahoo.co.uk	Bello, Aminu K/D-2213-2013	Bello, Aminu K/0000-0002-6905-5937				Barsoum RS, 2002, ARTIF ORGANS, V26, P737, DOI 10.1046/j.1525-1594.2002.07061.x; Cheung AK, 2004, KIDNEY INT, V65, P2380, DOI 10.1111/j.1523-1755.2004.00657.x; Collins AJ, 2013, AM J KIDNEY DIS, V61, pE1, DOI 10.1053/j.ajkd.2012.11.031; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; GAMBA G, 1993, NEPHRON, V65, P23, DOI 10.1159/000187435; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Isla RAT, 2014, PERITON DIALYSIS INT, V34, P518, DOI 10.3747/pdi.2013.00334; Johnson DW, 2009, AM J KIDNEY DIS, V53, P290, DOI 10.1053/j.ajkd.2008.06.032; MAILLOUX LU, 1991, AM J KIDNEY DIS, V18, P326, DOI 10.1016/S0272-6386(12)80091-6; Obiagwu PN, 2015, TROP MED INT HEALTH, V20, P2, DOI 10.1111/tmi.12409; Okpechi IG, 2012, J NEPHROL, V25, P551, DOI 10.5301/jn.5000032; Okpechi IG, 2012, PERITON DIALYSIS INT, V32, P254, DOI 10.3747/pdi.2011.00100; Pei YPC, 2000, KIDNEY INT, V58, P1293, DOI 10.1046/j.1523-1755.2000.00285.x; Piraino B, 2010, BLOOD PURIFICAT, V29, P145, DOI 10.1159/000245641; Rizvi S Adibul Hasan, 2003, Kidney Int Suppl, pS96; Robson NZMH, 2010, ASIA-PAC J PUBLIC HE, V22, P271, DOI 10.1177/1010539509357446; Schroijen MA, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-69; Stack AG, 2003, KIDNEY INT, V64, P1071, DOI 10.1046/j.1523-1755.2003.00165.x; Swanepoel CR, 2013, NAT REV NEPHROL, V9, P610, DOI 10.1038/nrneph.2013.168; Thompson S, 2012, KIDNEY INT, V82, P352, DOI 10.1038/ki.2012.167; Verduijn M, 2011, NEPHROL DIAL TRANSPL, V26, P56, DOI 10.1093/ndt/gfq661; Vonesh EF, 2004, KIDNEY INT, V66, P2389, DOI 10.1111/j.1523-1755.2004.66028.x; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Yu XQ, 2015, AM J KIDNEY DIS, V65, P147, DOI 10.1053/j.ajkd.2014.08.023; ZENT R, 1994, PERITON DIALYSIS INT, V14, P48	26	15	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2016	11	6							e0156642	10.1371/journal.pone.0156642	http://dx.doi.org/10.1371/journal.pone.0156642			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO5KO	27300372	Green Published, gold, Green Submitted			2023-01-03	WOS:000377822200011
J	Dalmasso, M; Strain, R; Neve, H; Franz, CMAP; Cousin, FJ; Ross, RP; Hill, C				Dalmasso, Marion; Strain, Ronan; Neve, Horst; Franz, Charles M. A. P.; Cousin, Fabien J.; Ross, R. Paul; Hill, Colin			Three New Escherichia coli Phages from the Human Gut Show Promising Potential for Phage Therapy	PLOS ONE			English	Article							COMPLETE GENOME SEQUENCE; SHIGELLA-SONNEI; BACTERIOPHAGE; COCKTAIL; GENERATION; VOLUNTEERS; BIOCONTROL; O157-H7; BLAST	With the emergence of multi-drug resistant bacteria the use of bacteriophages (phages) is gaining renewed interest as promising anti-microbial agents. The aim of this study was to isolate and characterize phages from human fecal samples. Three new coliphages, phi APCEc01, phi APCEc02 and phi APCEc03, were isolated. Their phenotypic and genomic characteristics, and lytic activity against biofilm, and in combination with ciprofloxacin, were investigated. All three phages reduced the growth of E. coli strain DPC6051 at multiplicity of infection (MOI) between 10(-3) and 10(5). A cocktail of all three phages completely inhibited the growth of E. coli. The phage cocktail also reduced biofilm formation and prevented the emergence of phage-resistant mutants which occurred with single phage. When combined with ciprofloxacin, phage alone or in cocktail inhibited the growth of E. coli and prevented the emergence of resistant mutants. These three new phages are promising biocontrol agents for E. coli infections.	[Dalmasso, Marion; Strain, Ronan; Cousin, Fabien J.; Hill, Colin] Natl Univ Ireland Univ Coll Cork, Sch Microbiol, Cork, Ireland; [Dalmasso, Marion; Strain, Ronan; Cousin, Fabien J.; Ross, R. Paul; Hill, Colin] Natl Univ Ireland Univ Coll Cork, APC Microbiome Inst, Cork, Ireland; [Neve, Horst; Franz, Charles M. A. P.] Max Rubner Inst, Dept Microbiol & Biotechnol, Kiel, Germany; [Ross, R. Paul] TEAGASC, Ctr Biotechnol, Moorepk Food Res Ctr, Fermoy, Cork, Ireland; [Dalmasso, Marion] Normandie Univ, UNICAEN, ABTE EA4651, F-14032 Caen, France	University College Cork; University College Cork; Teagasc; Universite de Caen Normandie	Hill, C (corresponding author), Natl Univ Ireland Univ Coll Cork, Sch Microbiol, Cork, Ireland.; Hill, C (corresponding author), Natl Univ Ireland Univ Coll Cork, APC Microbiome Inst, Cork, Ireland.	c.hill@ucc.ie	Ross, Paul/A-7584-2015; Hill, Colin/A-5611-2012	Ross, Paul/0000-0003-4876-8839; Hill, Colin/0000-0002-8527-1445; Dalmasso, Marion/0000-0003-1875-2748; Strain, Ronan/0000-0003-2465-4626; Cousin, Fabien/0000-0001-6874-387X	Science Foundation Ireland [SFI/12/RC/2273]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	The authors received financial support from Science Foundation Ireland (http://www.sfi.ie/) under Grant Number SFI/12/RC/2273. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedon Stephen T, 2011, Bacteriophage, V1, P46, DOI 10.4161/bact.1.1.13980; Alikhan NF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-402; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansari S, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0059-2; Baron F, 2006, LAIT, V86, P251, DOI 10.1051/lait:2006005; Brussow H, 2012, VIROLOGY, V434, P138, DOI 10.1016/j.virol.2012.09.015; Brussow H, 2005, MICROBIOL-SGM, V151, P2133, DOI 10.1099/mic.0.27849-0; Bruttin A, 2005, ANTIMICROB AGENTS CH, V49, P2874, DOI 10.1128/AAC.49.7.2874-2878.2005; Casey E, 2015, APPL ENVIRON MICROB, V81, P1319, DOI 10.1128/AEM.03413-14; Cha SB, 2012, J VET MED SCI, V74, P1037, DOI 10.1292/jvms.11-0556; Chang HW, 2011, J MICROBIOL, V49, P927, DOI 10.1007/s12275-011-1577-0; Chaudhuri RR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008801; Claesson MJ, 2012, NATURE, V488, P178, DOI 10.1038/nature11319; Comeau AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000799; Coulter LB, 2014, VIRUSES-BASEL, V6, P3778, DOI 10.3390/v6103778; Crossman LC, 2010, J BACTERIOL, V192, P5822, DOI 10.1128/JB.00710-10; Cusack S, 2013, GERONTOLOGY, V59, P114, DOI 10.1159/000343158; Dalmasso M, 2014, TRENDS MICROBIOL, V22, P399, DOI 10.1016/j.tim.2014.02.010; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Denou E, 2009, VIROLOGY, V388, P21, DOI 10.1016/j.virol.2009.03.009; Dufour N, 2015, CRIT CARE MED, V43, pE190, DOI 10.1097/CCM.0000000000000968; Endersen L, 2014, ANNU REV FOOD SCI T, V5, P327, DOI 10.1146/annurev-food-030713-092415; Field D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119684; Hatfull GF, 2011, CURR OPIN VIROL, V1, P298, DOI 10.1016/j.coviro.2011.06.009; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Hejnova J, 2005, MICROBIOL-SGM, V151, P385, DOI 10.1099/mic.0.27469-0; Holt KE, 2012, NAT GENET, V44, P1056, DOI 10.1038/ng.2369; Hoyles L, 2014, RES MICROBIOL, V165, P803, DOI 10.1016/j.resmic.2014.10.006; Hu J, 2015, CLIN MICROBIOL INFEC, V21, P729, DOI 10.1016/j.cmi.2015.01.015; Iguchi A, 2009, J BACTERIOL, V191, P347, DOI 10.1128/JB.01238-08; Jeffery IB, 2016, ISME J, V10, P170, DOI 10.1038/ismej.2015.88; Kamal F, 2015, APPL ENVIRON MICROB, V81, P1132, DOI 10.1128/AEM.02850-14; Kim M, 2011, APPL ENVIRON MICROB, V77, P2042, DOI 10.1128/AEM.02504-10; Kropinski AM, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-76; Laslett D, 2004, NUCLEIC ACIDS RES, V32, P11, DOI 10.1093/nar/gkh152; Lu TK, 2011, CURR OPIN MICROBIOL, V14, P524, DOI 10.1016/j.mib.2011.07.028; Lu ZJ, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00067; Ly-Chatain MH, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00051; Mahony J, 2011, CURR OPIN BIOTECH, V22, P157, DOI 10.1016/j.copbio.2010.10.008; Maura D, 2012, ANTIMICROB AGENTS CH, V56, P6235, DOI 10.1128/AAC.00602-12; Mirzaei MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118557; MOBLEY HLT, 1990, INFECT IMMUN, V58, P1281, DOI 10.1128/IAI.58.5.1281-1289.1990; Mulvey MA, 2001, INFECT IMMUN, V69, P4572, DOI 10.1128/IAI.69.7.4572-4579.2001; Murphy J, 2013, J DAIRY SCI, V96, P4945, DOI 10.3168/jds.2013-6748; O'Flaherty S, 2005, J BACTERIOL, V187, P7161, DOI 10.1128/JB.187.20.7161-7164.2005; O'Flynn G, 2004, APPL ENVIRON MICROB, V70, P3417, DOI 10.1128/AEM.70.6.3417-3424.2004; Overbeek R, 2014, NUCLEIC ACIDS RES, V42, pD206, DOI 10.1093/nar/gkt1226; Parasion S, 2014, POL J MICROBIOL, V63, P137; Rahal EA, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00024; Rahmani R, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.17744; Sarker SA, 2012, VIROLOGY, V434, P222, DOI 10.1016/j.virol.2012.09.002; Subramanian S, 2008, INFLAMM BOWEL DIS, V14, P162, DOI 10.1002/ibd.20296; Tang F, 2012, J VIROL, V86, P13871, DOI 10.1128/JVI.02698-12; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; Truncaite L, 2012, ARCH VIROL, V157, P2431, DOI 10.1007/s00705-012-1449-x; Tsonos J, 2014, VET MICROBIOL, V171, P470, DOI 10.1016/j.vetmic.2013.10.021; Tunney MM, 2004, ANTIMICROB AGENTS CH, V48, P1879, DOI 10.1128/AAC.48.5.1879-1881.2004; Viertel TM, 2014, J ANTIMICROB CHEMOTH, V69, P2326, DOI 10.1093/jac/dku173; Wittebole X, 2014, VIRULENCE, V5, P226, DOI 10.4161/viru.25991; Yap ML, 2014, FUTURE MICROBIOL, V9, P1319, DOI 10.2217/fmb.14.91	60	42	44	2	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0156773	10.1371/journal.pone.0156773	http://dx.doi.org/10.1371/journal.pone.0156773			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TW	27280590	Green Published, Green Submitted, gold			2023-01-03	WOS:000377563000046
J	d'Azy, CB; Pereira, B; Naughton, G; Chiambaretta, F; Dutheil, F				d'Azy, Cedric Benoist; Pereira, Bruno; Naughton, Geraldine; Chiambaretta, Frederic; Dutheil, Frederic			Antibioprophylaxis in Prevention of Endophthalmitis in Intravitreal Injection: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							ANTIBIOTIC-PROPHYLAXIS; OCULAR SURFACE; RISK; RESISTANCE	Despite endophthalmitis being the most feared complication, antibioprophylaxis remains controversial in intravitreal injections. Therefore, we conducted a systematic review and meta-analysis on the effects of antibioprophylaxis in intravitreal injections in the prevention of endophthalmitis. The PubMed, Cochrane Library, Embase and Science Direct databases were searched for studies comparing groups with and without antibiotics in intravitreal injection, with the use of the following keywords: "antibiotic*", "endophthalmitis" and "intravitreal injection*". To be included, studies needed to specify number of participants and number of endophthalmitis within each group (with and without antibiotics). We conducted meta-analysis on the prevalence of clinical endophthalmitis including both culture-proven and culture negative samples. Nine studies were included. A total of 88 incidences of endophthalmitis were reported from 174,159 injections (0.051% i.e., one incidence of endophthalmitis for 1979 injections). Specifically, 59 incidences of endophthalmitis were reported from 113,530 injections in the group with antibiotics (0.052% or one incidence of endophthalmitis for 1924 injections) and 29 incidences of endophthalmitis from 60,633 injections in the group without antibiotics (0.048% or one endophthalmitis for 2091 injections). Our meta-analysis did not report a significant difference in the prevalence of clinical endophthalimitis between the two groups with and without topical antibiotics: the odds ratio of clinical endophthalimitis was 0.804 (CI95% 0.384-1.682, p = 0.56) for the antibiotic group compared with the group without antibiotics. In conclusion, we performed the first large meta-analysis demonstrating that antibioprophylaxis is not required in intravitreal injections. Strict rules of asepsis remain the only evidence-based prophylaxis of endophthalmitis. The results support initiatives to reduce the global threat of resistance to antibiotics.	[d'Azy, Cedric Benoist; Chiambaretta, Frederic] Univ Hosp Clermont Ferrand CHU, Ophthalmol, Clermont Ferrand, France; [d'Azy, Cedric Benoist; Dutheil, Frederic] Univ Hosp Clermont Ferrand CHU, Prevent & Occupat Med, Clermont Ferrand, France; [Pereira, Bruno] Univ Hosp Clermont Ferrand CHU, Clin Res Direct, Clermont Ferrand, France; [Naughton, Geraldine; Dutheil, Frederic] Australian Catholic Univ, Fac Hlth, Melbourne, Vic, Australia; [Dutheil, Frederic] Univ Blaise Pascal, Clermont Auvergne Univ, Lab Metab Adaptat Exercise Physiol & Pathol Condi, Clermont Ferrand, France; [Dutheil, Frederic] Res Ctr Human Nutr CRNH Auvergne, Clermont Ferrand, France; [Dutheil, Frederic] Univ Clermont Auvergne, CNRS, UMR Physiol & Psychosocial Stress 6024, LAPSCO, Clermont Ferrand, France	CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Clermont Ferrand; Australian Catholic University; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA)	Dutheil, F (corresponding author), Univ Hosp Clermont Ferrand CHU, Prevent & Occupat Med, Clermont Ferrand, France.; Dutheil, F (corresponding author), Australian Catholic Univ, Fac Hlth, Melbourne, Vic, Australia.; Dutheil, F (corresponding author), Univ Blaise Pascal, Clermont Auvergne Univ, Lab Metab Adaptat Exercise Physiol & Pathol Condi, Clermont Ferrand, France.; Dutheil, F (corresponding author), Res Ctr Human Nutr CRNH Auvergne, Clermont Ferrand, France.; Dutheil, F (corresponding author), Univ Clermont Auvergne, CNRS, UMR Physiol & Psychosocial Stress 6024, LAPSCO, Clermont Ferrand, France.	frederic.dutheil@acu.edu.au	Dutheil, Frederic/O-9707-2014; Naughton, Geraldine/M-4094-2017	Dutheil, Frederic/0000-0002-1468-6029; Pereira, Bruno/0000-0003-3778-7161; Naughton, Geraldine/0000-0002-0534-1627	University Hospital of Clermont-Ferrand, France	University Hospital of Clermont-Ferrand, France	This study was funded by the University Hospital of Clermont-Ferrand, France.	Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399; Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f; Bhavsar AR, 2015, RETINA-J RET VIT DIS, V35, P783, DOI 10.1097/IAE.0000000000000392; Bhavsar AR, 2012, ARCH OPHTHALMOL-CHIC, V130, P809, DOI 10.1001/archophthalmol.2012.227; Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304; Bodaghi B, 2012, J FR OPHTALMOL, V35, P69, DOI 10.1016/j.jfo.2011.11.005; Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014; Cochereau I, 2013, J FR OPHTALMOL, V36, P72, DOI 10.1016/j.jfo.2012.10.001; Costello P, 2006, RETINA-J RET VIT DIS, V26, P191, DOI 10.1097/00006982-200602000-00012; da Costa BR, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000048; De Caro JJ, 2008, RETINA-J RET VIT DIS, V28, P877, DOI 10.1097/IAE.0b013e31816b3180; de Kaspar HM, 2001, OPHTHALMOLOGY, V108, P470, DOI 10.1016/S0161-6420(00)00545-5; Dossarps D, 2015, AM J OPHTHALMOL, V160, P17, DOI 10.1016/j.ajo.2015.04.013; Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08; ISENBERG SJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P1340, DOI 10.1001/archopht.1985.01050090092039; Kim SJ, 2011, OPHTHALMOLOGY, V118, P1358, DOI 10.1016/j.ophtha.2010.12.014; Kim SJ, 2010, OPHTHALMOLOGY, V117, P2372, DOI 10.1016/j.ophtha.2010.03.034; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4; Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027; Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4; Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024; Pachuo M, 2015, PAK J OPHTALMOL, V31; Park Y, 2013, J OCUL PHARMACOL TH, V29, P900, DOI 10.1089/jop.2013.0052; Ramel JC, 2014, J FR OPHTALMOL, V37, P273, DOI 10.1016/j.jfo.2014.01.003; Sigford DK, 2015, CLIN OPHTHALMOL, V9, P773, DOI 10.2147/OPTH.S77067; Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037; Stranak Z, 2014, Cesk Slov Oftalmol, V70, P184; Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1; Wykoff CC, 2011, AM J OPHTHALMOL, V152, P717, DOI 10.1016/j.ajo.2011.07.002; Yin VT, 2013, JAMA OPHTHALMOL, V131, P456, DOI 10.1001/jamaophthalmol.2013.2379	31	40	41	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2016	11	6							e0156431	10.1371/journal.pone.0156431	http://dx.doi.org/10.1371/journal.pone.0156431			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN8ZV	27257676	Green Submitted, Green Published, gold			2023-01-03	WOS:000377369700065
J	Jansen, J; Naganathan, V; Carter, SM; McLachlan, AJ; Nickel, B; Irwig, L; Bonner, C; Doust, J; Colvin, J; Heaney, A; Turner, R; McCaffery, K				Jansen, Jesse; Naganathan, Vasi; Carter, Stacy M.; McLachlan, Andrew J.; Nickel, Brooke; Irwig, Les; Bonner, Carissa; Doust, Jenny; Colvin, Jim; Heaney, Aine; Turner, Robin; McCaffery, Kirsten			Too much medicine in older people? Deprescribing through shared decision making	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ADULTS; POLYPHARMACY; MEDICATION; HEALTH; INFORMATION; PERCEPTIONS; COMMUNICATION; ILLNESS; TIME; PARTICIPATION		[Jansen, Jesse; Nickel, Brooke; Irwig, Les; Bonner, Carissa; McCaffery, Kirsten] Univ Sydney, Sydney Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia; [Jansen, Jesse; Nickel, Brooke; Bonner, Carissa; McCaffery, Kirsten] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW 2006, Australia; [Naganathan, Vasi; McLachlan, Andrew J.] Univ Sydney, Concord Hosp, Ageing & Alzheimers Inst, Ctr Educ & Res Ageing, Sydney, NSW 2006, Australia; [Carter, Stacy M.] Univ Sydney, Eth & Law Med, Ctr Values, Sydney, NSW 2006, Australia; [McLachlan, Andrew J.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Doust, Jenny] Bond Univ, Ctr Res Evidence Based Practice, Southport, Qld 4229, Australia; [Colvin, Jim] Hlth Consumers New South Wales, Sydney, NSW, Australia; [Heaney, Aine] NPS MedicineWise, Surry Hills, NSW, Australia; [Turner, Robin] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia	University of Sydney; University of Sydney; Concord Repatriation General Hospital; University of Sydney; University of Sydney; University of Sydney; Bond University; University of New South Wales Sydney	Jansen, J (corresponding author), Univ Sydney, Sydney Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia.; Jansen, J (corresponding author), Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW 2006, Australia.	jesse.jansen@sydney.edu.au	Doust, Jenny/AGI-8773-2022; Carter, Stacy/A-6544-2011; Nickel, Brooke/I-1667-2019; McCaffery, Kirsten/K-7945-2019	Doust, Jenny/0000-0002-4024-9308; Carter, Stacy/0000-0003-2617-8694; Nickel, Brooke/0000-0002-8100-4278; McCaffery, Kirsten/0000-0003-2696-5006; Naganathan, Vasikaran/0000-0001-7243-0796; Bonner, Carissa/0000-0002-4797-6460; McLachlan, Andrew/0000-0003-4674-0242				Anderson K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006544; Anthierens S, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-65; Belcher VN, 2006, J GEN INTERN MED, V21, P298, DOI 10.1111/j.1525-1497.2006.00329.x; Bynum JPW, 2014, MED DECIS MAKING, V34, P216, DOI 10.1177/0272989X13508008; Chewning B, 2012, PATIENT EDUC COUNS, V86, P9, DOI 10.1016/j.pec.2011.02.004; Declercq T, 2013, COCHRANE DB SYST REV, V3; Duerden M, 2013, POLYPHARMACY AND MED; Dumbreck S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h949; Fagerlin A, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S8; Fawzi W, 2012, INT PSYCHOGERIATR, V24, P159, DOI 10.1017/S1041610211001049; Flynn KE, 2007, J GERONTOL B-PSYCHOL, V62, pP261, DOI 10.1093/geronb/62.5.P261; Fried TR, 2007, J AM GERIATR SOC, V55, P1007, DOI 10.1111/j.1532-5415.2007.01232.x; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Fried TR, 2003, J AM GERIATR SOC, V51, P1398, DOI 10.1046/j.1532-5415.2003.51457.x; Fuller R, 2001, AGE AGEING, V30, P473, DOI 10.1093/ageing/30.6.473; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Hanoch Y, 2007, HUM DEV, V50, P333, DOI 10.1159/000109835; Hibbard JH, 2002, HEALTH SERV RES, V37, P291, DOI 10.1111/1475-6773.024; Hibbard JH, 2003, ANNU REV PUBL HEALTH, V24, P413, DOI 10.1146/annurev.publhealth.24.100901.141005; Hilmer SN, 2009, CLIN PHARMACOL THER, V85, P86, DOI 10.1038/clpt.2008.224; Hilmer SN, 2007, FUND CLIN PHARMACOL, V21, P217, DOI 10.1111/j.1472-8206.2007.00473.x; Hoffmann TC, 2015, JAMA INTERN MED, V175, P274, DOI 10.1001/jamainternmed.2014.6016; Iyer S, 2008, DRUG AGING, V25, P1021, DOI 10.2165/0002512-200825120-00004; KAHNEMAN D, 1991, J ECON PERSPECT, V5, P193, DOI 10.1257/jep.5.1.193; Kutner JS, 2015, JAMA INTERN MED, V175, P691, DOI 10.1001/jamainternmed.2015.0289; Laidsaar-Powell RC, 2013, PATIENT EDUC COUNS, V91, P3, DOI 10.1016/j.pec.2012.11.007; Lau DT, 2008, DRUG AGING, V25, P1061, DOI 10.2165/0002512-200825120-00007; Le Couteur D, 2011, AUST PRESCR, V34, P182; Levinson W, 2005, J GEN INTERN MED, V20, P531, DOI 10.1111/j.1525-1497.2005.04101.x; Linsky A, 2015, PATIENT EDUC COUNS, V98, P220, DOI 10.1016/j.pec.2014.11.010; Lockenhoff CE, 2004, J PERS, V72, P1395, DOI 10.1111/j.1467-6494.2004.00301.x; Mata R, 2007, PSYCHOL AGING, V22, P796, DOI 10.1037/0882-7974.22.4.796; Moen J, 2010, J EVAL CLIN PRACT, V16, P69, DOI 10.1111/j.1365-2753.2008.01116.x; Moen J, 2009, PATIENT EDUC COUNS, V74, P135, DOI 10.1016/j.pec.2008.08.019; Moynihan R, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3502; Moynihan R, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5184; National Stakeholders' Meeting, 2015, QUALITY USE OF MEDIC; Peters E, 2007, PERSPECT PSYCHOL SCI, V2, P1, DOI 10.1111/j.1745-6916.2007.00025.x; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Politi MC, 2007, MED DECIS MAKING, V27, P681, DOI 10.1177/0272989x07307270; Reed AE, 2008, PSYCHOL AGING, V23, P671, DOI 10.1037/a0012772; Reeve E, 2014, BRIT J CLIN PHARMACO, V78, P738, DOI 10.1111/bcp.12386; Reeve E, 2013, J AM GERIATR SOC, V61, P1508, DOI 10.1111/jgs.12418; RIGBY D, 2010, AUST J PHARM, V91, P38; Salkeld G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/bmj.320.7231.341; Schnittker J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084933; Schuling J, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-56; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Shah BM, 2012, CLIN GERIATR MED, V28, P173, DOI 10.1016/j.cger.2012.01.002; SPRANCA M, 1991, J EXP SOC PSYCHOL, V27, P76, DOI 10.1016/0022-1031(91)90011-T; Stacey D., 2014, COCHRANE DB SYST REV, V4, pCD001431, DOI [10.1002/14651858.CD001431.pub4, 10.1002/14651858.CD001431.pub5, DOI 10.1002/14651858.CD001431.PUB5, DOI 10.1002/14651858.CD001431.PUB4]; Stacey D, 2010, PATIENT EDUC COUNS, V80, P164, DOI 10.1016/j.pec.2009.10.015; Straand J, 2001, FAM PRACT, V18, P597, DOI 10.1093/fampra/18.6.597; Tannenbaum C, 2014, JAMA INTERN MED; Towle A, 1999, BRIT MED J, V319, P766, DOI 10.1136/bmj.319.7212.766; van der Cammen TJM, 2014, AGE AGEING, V43, P20, DOI 10.1093/ageing/aft166; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966	57	160	162	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2016	353								i2893	10.1136/bmj.i2893	http://dx.doi.org/10.1136/bmj.i2893			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DO0PG	27260319	Green Published			2023-01-03	WOS:000377480200003
J	Gotts, JE; Matthay, MA				Gotts, Jeffrey E.; Matthay, Michael A.			Sepsis: pathophysiology and clinical management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; ACUTE LUNG INJURY; SYSTEMIC INFLAMMATORY RESPONSE; GOAL-DIRECTED RESUSCITATION; TUMOR-NECROSIS-FACTOR; LONG-TERM MORTALITY; SEPTIC SHOCK; DOUBLE-BLIND	Sepsis, severe sepsis, and septic shock represent increasingly severe systemic inflammatory responses to infection. Sepsis is common in the aging population, and it disproportionately affects patients with cancer and underlying immunosuppression. In its most severe form, sepsis causes multiple organ dysfunction that can produce a state of chronic critical illness characterized by severe immune dysfunction and catabolism. Much has been learnt about the pathogenesis of sepsis at the molecular, cell, and intact organ level. Despite uncertainties in hemodynamic management and several treatments that have failed in clinical trials, investigational therapies increasingly target sepsis induced organ and immune dysfunction. Outcomes in sepsis have greatly improved overall, probably because of an enhanced focus on early diagnosis and fluid resuscitation, the rapid delivery of effective antibiotics, and other improvements in supportive care for critically ill patients. These improvements include lung protective ventilation, more judicious use of blood products, and strategies to reduce nosocomial infections.	[Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anesthesia, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Matthay, MA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.	Michael.matthay@ucsf.edu						Abraham E, 2016, JAMA-J AM MED ASSOC, V315, P757, DOI 10.1001/jama.2016.0290; Adrie C, 2007, CHEST, V132, P1786, DOI 10.1378/chest.07-0420; Afshari A, 2007, BMJ-BRIT MED J, V335, P1248, DOI 10.1136/bmj.39398.682500.25; Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Alobaidi R, 2015, SEMIN NEPHROL, V35, P2, DOI 10.1016/j.semnephrol.2015.01.002; Angele MK, 2014, VIRULENCE, V5, P12, DOI 10.4161/viru.26982; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2000, JAMA-J AM MED ASSOC, V283, P1723, DOI 10.1001/jama.283.13.1723; Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206; Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; Barnato AE, 2008, AM J RESP CRIT CARE, V177, P279, DOI 10.1164/rccm.200703-480OC; Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z; Bello S, 2014, CHEST, V146, P1029, DOI 10.1378/chest.13-2853; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bernik TR, 2002, J VASC SURG, V36, P1231, DOI 10.1067/mva.2002.129643; Bjelakovic G., 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd007470.pub3, DOI 10.1002/14651858.CD007470.PUB3, 10.1002/14651858.CD007470.pub3]; Blair LJ, 2016, SURG ENDOSC, V30, P1287, DOI 10.1007/s00464-015-4349-9; Bochud PY, 2008, NEW ENGL J MED, V359, P1766, DOI 10.1056/NEJMoa0802629; BONE RC, 1992, CRIT CARE MED, V20, P724, DOI 10.1097/00003246-199206000-00002; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Borthwick EMJ, 2013, COCHRANE DB SYST REV, V1, DOI [10.1002/14651858.CD008075, DOI 10.1002/14651858.CD0080750.PUB2]; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; Cabrera-Perez J, 2014, J LEUKOCYTE BIOL, V96, P767, DOI 10.1189/jlb.5MR0114-067R; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Calfee CS, 2015, CRIT CARE MED, V43, P1790, DOI 10.1097/CCM.0000000000001089; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Churpek MM, 2015, AM J RESP CRIT CARE, V192, P958, DOI 10.1164/rccm.201502-0275OC; Clark MF, 2006, INTENS CARE MED, V32, P1706, DOI 10.1007/s00134-006-0327-y; De Backer D, 2012, CRIT CARE MED, V40, P725, DOI 10.1097/CCM.0b013e31823778ee; De Backer D, 2010, CURR OPIN CRIT CARE, V16, P250, DOI 10.1097/MCC.0b013e3283383621; de Haan K, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0660-4; De Waele J, 2014, BMC INFECT DIS, V14, DOI [10.1186/1471-2334-14-193, 10.1186/1471-2334-14-420]; Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Deutschman CS, 2014, IMMUNITY, V40, P464, DOI 10.1016/j.immuni.2014.04.001; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P763, DOI 10.1097/01.CCM.0000256726.80998.BF; Drazen JM, 2012, NEW ENGL J MED, V367, P863, DOI 10.1056/NEJMe1209433; Drewry AM, 2014, SHOCK, V42, P383, DOI 10.1097/SHK.0000000000000234; DUNN DL, 1991, CHEST, V100, pS164, DOI 10.1378/chest.100.3_Supplement.164S; Efron PA, 2015, J LEUKOCYTE BIOL, V98, P945, DOI 10.1189/jlb.5MR0315-127R; Eichacker PQ, 2006, NEW ENGL J MED, V355, P1640, DOI 10.1056/NEJMp068197; Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Esposito S, 2014, EUR J INTERN MED, V25, P203, DOI 10.1016/j.ejim.2013.12.004; Fernandez JF, 2012, CHEST, V142, P231, DOI 10.1378/chest.11-2420; Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330; Ferwerda B, 2007, P NATL ACAD SCI USA, V104, P16645, DOI 10.1073/pnas.0704828104; Ferwerda B, 2009, P NATL ACAD SCI USA, V106, P10272, DOI 10.1073/pnas.0811273106; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Fink MP, 2014, NAT REV DRUG DISCOV, V13, P741, DOI 10.1038/nrd4368; Fink Mitchell P, 2003, Curr Opin Crit Care, V9, P143, DOI 10.1097/00075198-200304000-00011; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Fraser GL, 2013, CRIT CARE MED, V41, pS30, DOI 10.1097/CCM.0b013e3182a16898; Fullerton JN, 2013, J PATHOL, V231, P8, DOI 10.1002/path.4232; Funk DJ, 2013, CRIT CARE MED, V41, P573, DOI 10.1097/CCM.0b013e31827bfc25; Galiczewski JM, 2016, INTENS CRIT CARE NUR, V32, P1, DOI 10.1016/j.iccn.2015.08.007; Garcia-Alvarez M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0503-3; Garcia-Vidal C, 2010, THORAX, V65, P77, DOI 10.1136/thx.2009.123612; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Georges S, 2013, EPIDEMIOL INFECT, V141, P1787, DOI 10.1017/S0950268813000083; Greenfield Neal, 2012, Hosp Pract (1995), V40, P147, DOI 10.3810/hp.2012.04.980; Gustot T, 2014, LIVER INT, V34, P1496, DOI 10.1111/liv.12520; Hanberger H, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-513; Hanberger H, 2011, INT J ANTIMICROB AG, V38, P331, DOI 10.1016/j.ijantimicag.2011.05.013; Harrison DA, 2006, CRIT CARE, V10, DOI 10.1186/cc4854; Hartl WH, 2014, NUTRITION, V30, P261, DOI 10.1016/j.nut.2013.07.019; Hartman ME, 2013, PEDIATR CRIT CARE ME, V14, P686, DOI 10.1097/PCC.0b013e3182917fad; Hassoun HT, 2001, SHOCK, V15, P1, DOI 10.1097/00024382-200115010-00001; Havel C, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003709.pub3; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Henckaerts L, 2009, CRIT CARE MED, V37, P192, DOI 10.1097/CCM.0b013e31819263d8; Henriksen DP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124838; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Ishikawa K, 2010, CONTRIB NEPHROL, V165, P18, DOI 10.1159/000313740; Jaimes F, 2009, CRIT CARE MED, V37, P1185, DOI 10.1097/CCM.0b013e31819c06bc; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Kamisoglu K, 2013, SHOCK, V40, P519, DOI 10.1097/SHK.0000000000000063; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kett DH, 2011, CRIT CARE MED, V39, P665, DOI 10.1097/CCM.0b013e318206c1ca; KIMCHI A, 1984, J AM COLL CARDIOL, V4, P945, DOI 10.1016/S0735-1097(84)80055-8; Koh IHJ, 2010, SHOCK, V34, P27, DOI 10.1097/SHK.0b013e3181e7e80c; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Koretz RL, 2007, AM J GASTROENTEROL, V102, P412, DOI 10.1111/j.1572-0241.2006.01024.x; Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Lemay AC, 2014, AM J MED SCI, V347, P282, DOI 10.1097/MAJ.0b013e318295a147; Levi M, 2013, MINERVA ANESTESIOL, V79, P294; Levi M, 2001, J CRIT CARE, V16, P167, DOI 10.1053/jcrc.2001.30666; Levy BD, 2014, ANNU REV PHYSIOL, V76, P467, DOI 10.1146/annurev-physiol-021113-170408; Levy MM, 2010, CRIT CARE MED, V38, P367, DOI 10.1097/CCM.0b013e3181cb0cdc; Levy MM, 2001, INTENS CARE MED, V29, P530, DOI DOI 10.1007/S00134-003-1662-X; Liu KD, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0022-z; Lombardo E, 2015, WORLD J STEM CELLS, V7, P368, DOI 10.4252/wjsc.v7.i2.368; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007; Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Martinod K, 2014, BLOOD, V123, P2768, DOI 10.1182/blood-2013-10-463646; Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331; Mayr FB, 2010, JAMA-J AM MED ASSOC, V303, P2495, DOI 10.1001/jama.2010.851; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; Mehta D, 2014, AM J PHYSIOL-LUNG C, V307, pL924, DOI 10.1152/ajplung.00318.2014; Meisel C, 2009, AM J RESP CRIT CARE, V180, P640, DOI 10.1164/rccm.200903-0363OC; Meyer NJ, 2015, CRIT CARE MED, V43, P242, DOI 10.1097/CCM.0000000000000664; Meziani F, 2010, CRIT CARE, V14, DOI 10.1186/cc9231; Moine P, 2004, SHOCK, V22, P297, DOI 10.1097/01.shk.0000140663.80530.73; Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Munford RS, 2006, ANNU REV PATHOL-MECH, V1, P467, DOI 10.1146/annurev.pathol.1.110304.100200; Nakada TA, 2015, CRIT CARE MED, V43, P101, DOI 10.1097/CCM.0000000000000604; Nelson JE, 2010, AM J RESP CRIT CARE, V182, P446, DOI 10.1164/rccm.201002-0210CI; Netea MG, 2011, NEW ENGL J MED, V364, P60, DOI 10.1056/NEJMra1001976; O'Brien JM, 2007, CRIT CARE MED, V35, P345, DOI 10.1097/01.CCM.0000254340.91644.B2; Obaro SK, 1996, BMJ-BRIT MED J, V312, P1521, DOI 10.1136/bmj.312.7045.1521; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194; Ortiz-Pomales YT, 2013, BURNS, V39, P68, DOI 10.1016/j.burns.2012.04.004; Osuchowski MF, 2014, SHOCK, V41, P463, DOI 10.1097/SHK.0000000000000153; Otto GP, 2011, CRIT CARE, V15, DOI 10.1186/cc10332; Panacek EA, 2004, CRIT CARE MED, V32, P2173, DOI 10.1097/01.CCM.0000145229.59014.6c; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; Patel A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4561; Patel GP, 2012, AM J RESP CRIT CARE, V185, P133, DOI 10.1164/rccm.201011-1897CI; Payen D, 2009, CRIT CARE MED, V37, P803, DOI 10.1097/CCM.0b013e3181962316; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Persichini R, 2012, CRIT CARE MED, V40, P3146, DOI 10.1097/CCM.0b013e318260c6c3; Plantinga TS, 2012, J INFECT DIS, V205, P934, DOI 10.1093/infdis/jir867; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Prowle JR, 2015, SEMIN NEPHROL, V35, P64, DOI 10.1016/j.semnephrol.2015.01.007; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Qiu P, 2013, CRIT CARE MED, V41, P2419, DOI 10.1097/CCM.0b013e3182982add; Rabuel C, 2006, INTENS CARE MED, V32, P799, DOI 10.1007/s00134-006-0142-5; Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290; Rautanen A, 2015, LANCET RESP MED, V3, P53, DOI 10.1016/S2213-2600(14)70290-5; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Ronco JJ, 1996, CRIT CARE CLIN, V12, P645, DOI 10.1016/S0749-0704(05)70268-2; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; Root RK, 2003, CRIT CARE MED, V31, P367, DOI 10.1097/01.CCM.0000048629.32625.5D; Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014; Sakr Y, 2013, CRIT CARE, V17, DOI 10.1186/cc12570; Schmid-Schonbein GW, 2014, ANN BIOMED ENG, V42, P405, DOI 10.1007/s10439-013-0891-6; Schramm P, 2012, CRIT CARE, V16, DOI 10.1186/cc11665; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schulte W, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/165974; SCHUMER W, 1976, ANN SURG, V184, P333, DOI 10.1097/00000658-197609000-00011; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Serhan CN, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016311; Shapiro NI, 2005, ANN EMERG MED, V45, P524, DOI 10.1016/j.annemergmed.2004.12.006; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Shi ZD, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008367.pub2; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Singer M, 2014, VIRULENCE, V5, P66, DOI 10.4161/viru.26907; Sivapalan P, 2015, CRIT CARE MED, V43, P2030, DOI 10.1097/CCM.0000000000001179; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Sterling SA, 2015, CRIT CARE MED, V43, P1907, DOI 10.1097/CCM.0000000000001142; Takasu O, 2013, AM J RESP CRIT CARE, V187, P509, DOI 10.1164/rccm.201211-1983OC; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; Tang BM, 2010, CRIT CARE, V14, DOI 10.1186/cc9392; Tolsma V, 2014, CHEST, V146, P1205, DOI 10.1378/chest.13-2618; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Turan A, 2011, ANESTHESIOLOGY, V114, P837, DOI 10.1097/ALN.0b013e318210f560; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; Van der Graaf CAA, 2006, EUR CYTOKINE NETW, V17, P29; van Gestel A, 2004, CRIT CARE, V8, pR153, DOI 10.1186/cc2858; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; de Oliveira FSV, 2015, J CRIT CARE, V30, P97, DOI 10.1016/j.jcrc.2014.09.002; Vincent JL, 2013, LANCET, V381, P774, DOI 10.1016/S0140-6736(12)61815-7; Vincent JL, 2011, CRIT CARE NURS CLIN, V23, P29, DOI 10.1016/j.ccell.2010.12.002; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Waechter J, 2014, CRIT CARE MED, V42, P2158, DOI 10.1097/CCM.0000000000000520; Walley KR, 2015, AM J RESP CRIT CARE, V192, P1275, DOI 10.1164/rccm.201505-0876CI; Walton AH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098819; Wan L, 2008, CRIT CARE MED, V36, pS198, DOI 10.1097/CCM.0b013e318168ccd5; Wang HE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048307; Ward PA, 2009, J CELL MOL MED, V13, P4154, DOI 10.1111/j.1582-4934.2009.00893.x; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Weiss SL, 2015, AM J RESP CRIT CARE, V191, P1147, DOI 10.1164/rccm.201412-2323OC; Wichmann MW, 2000, INTENS CARE MED, V26, P167, DOI 10.1007/s001340050041; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Williams MD, 2004, CRIT CARE, V8, pR291, DOI 10.1186/cc2893; WOLINSKY H, 1980, CIRC RES, V47, P301, DOI 10.1161/01.RES.47.3.301; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602; Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Ziaja M, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0383-y; Zuber B, 2012, CRIT CARE MED, V40, P55, DOI 10.1097/CCM.0b013e31822d74ba	217	463	505	10	207	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 23	2016	353								i1585	10.1136/bmj.i1585	http://dx.doi.org/10.1136/bmj.i1585			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN3BM	27217054				2023-01-03	WOS:000376937200001
J	Kamat, AM; Hahn, NM; Efstathiou, JA; Lerner, SP; Malmstrom, PU; Choi, W; Guo, CC; Lotan, Y; Kassouf, W				Kamat, Ashish M.; Hahn, Noah M.; Efstathiou, Jason A.; Lerner, Seth P.; Malmstrom, Per-Uno; Choi, Woonyoung; Guo, Charles C.; Lotan, Yair; Kassouf, Wassim			Bladder cancer	LANCET			English	Review							TRANSITIONAL-CELL-CARCINOMA; BACILLUS-CALMETTE-GUERIN; LONG-TERM OUTCOMES; INVASIVE UROTHELIAL CARCINOMA; COMBINED-MODALITY THERAPY; PHASE-III TRIAL; PERIOPERATIVE BLOOD-TRANSFUSION; EAU INTERNATIONAL CONSULTATION; CISPLATIN-BASED CHEMOTHERAPY; GEMCITABINE PLUS CISPLATIN	Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.	[Kamat, Ashish M.; Choi, Woonyoung] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Guo, Charles C.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Hahn, Noah M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Hahn, Noah M.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; [Efstathiou, Jason A.] Harvard Med Sch, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA USA; [Lerner, Seth P.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; [Malmstrom, Per-Uno] Uppsala Univ, Urol, Dept Urol Surg, Uppsala, Sweden; [Lotan, Yair] Univ Texas Southwestern, Dept Urol, Dallas, TX USA; [Kassouf, Wassim] McGill Univ, Dept Surg, Ctr Hlth, Montreal, PQ, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Baylor College of Medicine; Uppsala University; University of Texas System; University of Texas Southwestern Medical Center Dallas; McGill University	Kamat, AM (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	akamat@mdanderson.org			Theralase; Sanofi; Taris; Spectrum Pharmaceuticals; MDxHealth; Heat Biologics; Photocure; Telesta Therapeutics; Merck; Abbott Molecular; FKD; Pacific Edge; BioCancell; Vaxxion; UroGen; Telesta; Sitka; Neucleixx; Bladder Cancer Journal; Ferring; ENDO Pharmaceuticals; Viventia; Roche/Genentech; Genome DX; Abbott; Cepheid; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Theralase; Sanofi; Taris; Spectrum Pharmaceuticals; MDxHealth; Heat Biologics; Photocure; Telesta Therapeutics; Merck(Merck & Company); Abbott Molecular; FKD; Pacific Edge; BioCancell; Vaxxion; UroGen; Telesta; Sitka; Neucleixx; Bladder Cancer Journal; Ferring(Ferring Pharmaceuticals); ENDO Pharmaceuticals; Viventia; Roche/Genentech(Roche HoldingGenentech); Genome DX; Abbott(Abbott Laboratories); Cepheid; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	AMK reports consulting fees from Theralase, Sanofi, Taris, Spectrum Pharmaceuticals, and MDxHealth; reports research support from Heat Biologics, Photocure, Telesta Therapeutics, Merck, Abbott Molecular, FKD, and Pacific Edge; and has a patent pending for cytokine assay for response to intravesical therapy (CYPRIT) for the University of Texas. NMH reports consulting for Merck, Oncogenex, and Bristol-Myers Squibb, and research funding to institution from Novartis, Genentech, Merck, Oncogenex, Mirati Therapeutics, and Acerta Pharma, outside the submitted work. JAE reports consulting for Medivation and Astellas. SPL reports consulting fees from BioCancell, Vaxxion, UroGen, Telesta, Sitka, Neucleixx, Taris, Bladder Cancer Journal, and Ferring and grants from ENDO Pharmaceuticals, FKD, Viventia, Roche/Genentech, and Genome DX, during the conduct of the study. P-UM reports speaker fees from Medac GmbH and scientific advisory from Photocure ASA, and APIM Therapeutics AS, outside the submitted work. WC has a patent pending for methods of characterising and treating molecular subset of muscle-invasive bladder cancer. YL reports grants from Abbott, Cepheid, and MDxHealth and grants and personal fees from Pacific Edge, during the conduct of the study; and grants from genomedx and grants and personal fees from photocure, outside the submitted work. CCG and WK declare no competing interests.	Abd el-Latif A, 2013, J UROLOGY, V189, P1263, DOI 10.1016/j.juro.2012.10.054; Advanced Bladder Cancer ( ABC), 2005, EUR UROL, V48, P202, DOI [DOI 10.1016/J.EURUR0.2005.04.006, DOI 10.1016/j.eururo.2005.04.006]; Aine M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10957; Allory Y, 2014, EUR UROL, V65, P360, DOI 10.1016/j.eururo.2013.08.052; American Cancer Society, 2015, CANC FACTS FIG 2015; Amin MB, 2013, EUR UROL, V63, P16, DOI 10.1016/j.eururo.2012.09.063; Amin MB, 2009, MODERN PATHOL, V22, pS96, DOI 10.1038/modpathol.2009.26; Apolo AB, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.2_suppl.367; Arends TJH, 2016, EUR UROL, V69, P1046, DOI 10.1016/j.eururo.2016.01.006; Aziz A, 2014, EUR UROL, V66, P156, DOI 10.1016/j.eururo.2013.12.018; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; Balbas-Martinez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799; Bangma CH, 2013, EUR UROL, V64, P41, DOI 10.1016/j.eururo.2013.02.036; Baumann BC, 2013, INT J RADIAT ONCOL, V85, P363, DOI 10.1016/j.ijrobp.2012.03.061; Bellmunt J, 2009, J CLIN ONCOL, V27, P4454, DOI 10.1200/JCO.2008.20.5534; Biton A, 2014, CELL REP, V9, P1235, DOI 10.1016/j.celrep.2014.10.035; Blacks PC, 2009, UROL ONCOL-SEMIN ORI, V27, P3, DOI 10.1016/j.urolonc.2007.07.010; Bochner BH, 2015, EUR UROL, V67, P1042, DOI 10.1016/j.eururo.2014.11.043; Bochner BH, 2004, J UROLOGY, V172, P1286, DOI 10.1097/01.ju.0000137817.56888.d1; Bono AV, 2005, EUR UROL, V48, P189, DOI 10.1016/j.eururo.2005.04.005; Brausi M, 2014, EUR UROL, V65, P69, DOI 10.1016/j.eururo.2013.07.021; Burger M, 2008, EUR UROL, V54, P835, DOI 10.1016/j.eururo.2007.12.026; Burger M, 2013, EUR UROL, V64, P846, DOI 10.1016/j.eururo.2013.03.059; Cambier S, 2016, EUR UROL, V69, P60, DOI 10.1016/j.eururo.2015.06.045; CAREL RS, 1987, CLIN CHEM, V33, P2106; Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Chamie K, 2012, CANCER-AM CANCER SOC, V118, P1412, DOI 10.1002/cncr.26402; Chen ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047199; Cheng L, 2012, HUM PATHOL, V43, P2097, DOI 10.1016/j.humpath.2012.01.008; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Chou R, 2015, ANN INTERN MED, V163, P922, DOI 10.7326/M15-0997; Choudhury A, 2011, J CLIN ONCOL, V29, P733, DOI 10.1200/JCO.2010.31.5721; Choudhury A, 2010, CANCER RES, V70, P7017, DOI 10.1158/0008-5472.CAN-10-1202; Choueiri TK, 2014, J CLIN ONCOL, V32, P1889, DOI 10.1200/JCO.2013.52.4785; Christodouleas JP, 2014, CANCER-AM CANCER SOC, V120, P1272, DOI 10.1002/cncr.28544; Clark PE, 2013, J NATL COMPR CANC NE, V11, P446, DOI 10.6004/jnccn.2013.0059; Comperat E, 2010, PATHOLOGY, V42, P650, DOI 10.3109/00313025.2010.522173; Culp SH, 2014, J UROLOGY, V191, P40, DOI 10.1016/j.juro.2013.07.061; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Daneshmand S, 2014, NAT REV UROL, V11, P589, DOI 10.1038/nrurol.2014.245; Dash A, 2008, CANCER-AM CANCER SOC, V113, P2471, DOI 10.1002/cncr.23848; Dayyani F, 2013, J UROLOGY, V189, P1656, DOI 10.1016/j.juro.2012.11.084; De Santis M, 2012, J CLIN ONCOL, V30, P191, DOI 10.1200/JCO.2011.37.3571; Dhar NB, 2008, J UROLOGY, V179, P873, DOI 10.1016/j.juro.2007.10.076; Di Stasi SM, 2006, LANCET ONCOL, V7, P43, DOI 10.1016/S1470-2045(05)70472-1; Dinney CPN, 2004, CANCER CELL, V6, P111, DOI 10.1016/j.ccr.2004.08.002; Divrik RT, 2006, J UROLOGY, V175, P1641, DOI 10.1016/S0022-5347(05)01002-5; Donat SM, 2009, EUR UROL, V55, P177, DOI 10.1016/j.eururo.2008.07.018; Edge SB, 2010, AJCC CANC STAGING MA, P497; Efstathiou JA, 2015, BLADDER PRESERVATION; Efstathiou JA, 2012, EUR UROL, V61, P705, DOI 10.1016/j.eururo.2011.11.010; Efstathiou JA, 2009, J CLIN ONCOL, V27, P4055, DOI 10.1200/JCO.2008.19.5776; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Eswara JR, 2012, J UROLOGY, V187, P463, DOI 10.1016/j.juro.2011.09.159; Fritsche HM, 2012, VIRCHOWS ARCH, V461, P655, DOI 10.1007/s00428-012-1328-6; Gakis G, 2013, EUR UROL, V63, P45, DOI 10.1016/j.eururo.2012.08.009; Galsky MD, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.2_suppl.357; Gangkak G, 2015, J UROLOGY, V194, P852, DOI 10.1016/j.juro.2015.02.2950; Giacalone NJ, 2015, INT J RADIAT ONCOL, V93, pS22, DOI 10.1016/j.ijrobp.2015.07.058; Gogna NK, 2006, RADIOTHER ONCOL, V81, P9, DOI 10.1016/j.radonc.2006.09.001; Gontero P, 2015, EUR UROL, V67, P74, DOI 10.1016/j.eururo.2014.06.040; Gordetsky J, 2014, UROLOGY, V84, P619, DOI 10.1016/j.urology.2014.05.037; Gospodarowicz M K, 1991, Clin Oncol (R Coll Radiol), V3, P155, DOI 10.1016/S0936-6555(05)81190-2; Griffiths G, 2011, J CLIN ONCOL, V29, P2171, DOI 10.1200/JCO.2010.32.3139; Groenendijk FH, 2016, EUR UROL, V69, P384, DOI 10.1016/j.eururo.2015.01.014; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Guevara A, 2010, J UROLOGY, V183, P2161, DOI 10.1016/j.juro.2010.02.026; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Hall MC, 2007, J UROLOGY, V178, P2314, DOI 10.1016/j.juro.2007.09.003; Hansel DE, 2013, UROLOGY, V81, P1123, DOI 10.1016/j.urology.2013.01.027; Hansel DE, 2013, EUR UROL, V63, P321, DOI 10.1016/j.eururo.2012.10.008; Harland SJ, 2007, J UROLOGY, V178, P807, DOI 10.1016/j.juro.2007.05.024; Helenius M, 2015, SCAND J UROL, V49, P377, DOI 10.3109/21681805.2015.1026937; Herr HW, 1999, J UROLOGY, V162, P74, DOI 10.1097/00005392-199907000-00018; Huncharek M, 2000, J CLIN EPIDEMIOL, V53, P676, DOI 10.1016/S0895-4356(99)00203-6; Hurst CD, 2014, EUR UROL, V65, P367, DOI 10.1016/j.eururo.2013.08.057; James ND, 2012, NEW ENGL J MED, V366, P1477, DOI 10.1056/NEJMoa1106106; Jancke G, 2011, SCAND J UROL NEPHROL, V45, P388, DOI 10.3109/00365599.2011.590995; Jani AB, 2015, HEMATOL ONCOL CLIN N, V29, P289, DOI 10.1016/j.hoc.2014.10.004; Jarow J, 2015, BLADDER CANCER, V1, P133, DOI 10.3233/BLC-150016; Jones R, 2007, BMJ-BRIT MED J, V334, P1040, DOI 10.1136/bmj.39171.637106.AE; Kaasinen E, 2002, EUR UROL, V42, P167, DOI 10.1016/S0302-2838(02)00260-9; Kamat AM, 2007, CANCER, V110, P62, DOI 10.1002/cncr.22756; Kamat AM, 2016, J CLIN ONCOL, V34, P1935, DOI 10.1200/JCO.2015.64.4070; Kamat AM, 2016, BJU INT, V117, P754, DOI 10.1111/bju.13186; Kamat AM, 2016, EUR UROL, V69, P197, DOI 10.1016/j.eururo.2015.06.023; Kamat AM, 2015, NAT REV UROL, V12, P225, DOI 10.1038/nrurol.2015.58; Kamat AM, 2014, J UROLOGY, V192, P305, DOI 10.1016/j.juro.2014.02.2573; Kamat AM, 2014, EUR UROL, V65, P267, DOI 10.1016/j.eururo.2013.10.016; Kamat AM, 2012, J UROLOGY, V187, P862, DOI 10.1016/j.juro.2011.10.144; Kassouf W, 2008, J UROLOGY, V180, P164, DOI 10.1016/j.juro.2008.03.037; Kessler TM, 2005, UROL CLIN N AM, V32, P165, DOI 10.1016/j.ucl.2005.02.005; Khan MS, 2016, EUR UROL, V69, P613, DOI 10.1016/j.eururo.2015.07.038; Kim J, 2015, CLIN CANCER RES, V21, P4514, DOI 10.1158/1078-0432.CCR-14-1215; Krogsboll L T, 2015, COCHRANE DB SYST REV, V1; Kurpad R, 2015, J SURG ONCOL, V112, P728, DOI 10.1002/jso.24009; Lamm D, 2014, J UROLOGY, V191, P20, DOI 10.1016/j.juro.2013.07.102; Lee JY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1571-8; Leissner J, 2000, BJU INT, V85, P817, DOI 10.1046/j.1464-410x.2000.00614.x; Leow JJ, 2014, EUR UROL, V66, P42, DOI 10.1016/j.eururo.2013.08.033; Lerner SP, 2015, BLADDER CANCER, V1, P29, DOI 10.3233/BLC-159002; Li W, 2014, AM J CLIN PATHOL, V142, P864, DOI 10.1309/AJCP1J0JPJBPSUXF; Liang Y, 2014, HUM PATHOL, V45, P1466, DOI 10.1016/j.humpath.2014.02.023; Linder BJ, 2013, J UROLOGY, V189, P1670, DOI 10.1016/j.juro.2012.11.006; Linder BJ, 2013, EUR UROL, V63, P839, DOI 10.1016/j.eururo.2013.01.004; Beltran AL, 2014, VIRCHOWS ARCH, V465, P199, DOI 10.1007/s00428-014-1601-y; Lopez-Beltran A, 2006, HUM PATHOL, V37, P1371, DOI 10.1016/j.humpath.2006.05.009; Lopez-Beltran ASG, 2004, WHO CLASSIFICATION T, P89; LOPEZBELTRAN A, 1988, HISTOL HISTOPATHOL, V3, P63; Lotan TL, 2009, AM J SURG PATHOL, V33, P1037, DOI 10.1097/PAS.0b013e3181962dcd; Lotan Y, 2003, UROLOGY, V61, P109, DOI 10.1016/S0090-4295(02)02136-2; Lynch SP, 2013, EUR UROL, V64, P307, DOI 10.1016/j.eururo.2012.04.020; MacLennan GT, 2007, EUR UROL, V51, P889, DOI 10.1016/j.eururo.2006.10.037; Mak KS, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.319; Mak RH, 2014, J CLIN ONCOL, V32, P3801, DOI 10.1200/JCO.2014.57.5548; Malmstrom PU, 2009, EUR UROL, V56, P247, DOI 10.1016/j.eururo.2009.04.038; MANSSON A, 1993, SCAND J UROL NEPHROL, V27, P363, DOI 10.3109/00365599309180448; MARTIN JE, 1989, J CLIN PATHOL, V42, P250, DOI 10.1136/jcp.42.3.250; Martin-Doyle W, 2015, J CLIN ONCOL, V33, P643, DOI 10.1200/JCO.2014.57.6967; McConkey DJ, 2016, EUR UROL, V69, P855, DOI 10.1016/j.eururo.2015.08.034; McConkey DJ, 2015, HEMATOL ONCOL CLIN N, V29, P377, DOI 10.1016/j.hoc.2014.11.003; McConkey DJ, 2014, EUR UROL, V66, P609, DOI 10.1016/j.eururo.2014.05.006; Mitin T, 2013, LANCET ONCOL, V14, P863, DOI 10.1016/S1470-2045(13)70255-9; Miyamoto H, 2010, AM J SURG PATHOL, V34, P418, DOI 10.1097/PAS.0b013e3181ce5066; Moch H., 2016, WHO CLASSIFICATION T, P77; Morgan TM, 2013, UROL ONCOL-SEMIN ORI, V31, P871, DOI 10.1016/j.urolonc.2011.07.012; Mostofi FK, 1973, HISTOLOGICAL TYPING; Mostofi FK, 1999, WHO INT HISTOLOGICAL, P1; Murphy WM, 2002, J UROLOGY, V168, P968, DOI 10.1016/S0022-5347(05)64553-3; National Comprehensive Cancer Network, 2016, NAT COMPR CANC NETW; Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024; Paner GP, 2010, AM J SURG PATHOL, V34, P792, DOI 10.1097/PAS.0b013e3181da7650; Pesch B, 2011, BJU INT, V108, P546, DOI 10.1111/j.1464-410X.2010.09971.x; Pettus JA, 2008, EUR UROL, V53, P370, DOI 10.1016/j.eururo.2007.07.031; Plimack ER, 2015, EUR UROL, V68, P959, DOI 10.1016/j.eururo.2015.07.009; Plimack ER, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4502; Plimack ER, 2014, J CLIN ONCOL, V32, P1895, DOI 10.1200/JCO.2013.53.2465; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; QUILTY PM, 1986, BRIT J UROL, V58, P147, DOI 10.1111/j.1464-410X.1986.tb09015.x; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Reuter VE, 2006, UROLOGY, V67, P11, DOI 10.1016/j.urology.2006.01.037; Ricardo-Gonzalez RR, 2012, J UROLOGY, V187, P852, DOI 10.1016/j.juro.2011.10.145; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Roth B, 2010, EUR UROL, V57, P205, DOI 10.1016/j.eururo.2009.10.026; Samaratunga H, 2002, UROLOGY, V60, P315, DOI 10.1016/S0090-4295(02)01705-3; Sanchez A, 2015, J UROLOGY, V193, pE298, DOI 10.1016/j.juro.2015.02.1134; Satkunasivam R, 2016, BJU INT, V117, P463, DOI 10.1111/bju.13081; Schlomer BJ, 2010, J UROLOGY, V183, P62, DOI 10.1016/j.juro.2009.08.157; Schmitz-Drager BJ, 2015, UROL INT, V94, P1, DOI 10.1159/000369357; Segal R, 2012, BJU INT, V109, P1026, DOI 10.1111/j.1464-410X.2011.10462.x; Sfakianos JP, 2014, J UROLOGY, V191, P341, DOI 10.1016/j.juro.2013.08.022; Shah RB, 2013, UROL ONCOL-SEMIN ORI, V31, P1650, DOI 10.1016/j.urolonc.2012.04.009; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shen SS, 2006, HUM PATHOL, V37, P726, DOI 10.1016/j.humpath.2006.01.027; Shin K, 2014, NAT CELL BIOL, V16, P469, DOI 10.1038/ncb2956; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Smith ND, 2015, BJU INT, V115, P198, DOI 10.1111/bju.12699; Solomon DA, 2013, NAT GENET, V45, P1428, DOI 10.1038/ng.2800; Steiner H, 2008, BJU INT, V102, P291, DOI 10.1111/j.1464-410X.2008.07596.x; Sternberg CN, 2001, J CLIN ONCOL, V19, P2638, DOI 10.1200/JCO.2001.19.10.2638; Sternberg CN, 2015, LANCET ONCOL, V16, P76, DOI 10.1016/S1470-2045(14)71160-X; Sylvester RJ, 2016, EUR UROL, V69, P231, DOI 10.1016/j.eururo.2015.05.050; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Sylvester RJ, 2005, J UROLOGY, V174, P86, DOI 10.1097/01.ju.0000162059.64886.1c; Theodorescu D, 2014, EUR UROL, V65, P370, DOI 10.1016/j.eururo.2013.10.019; Tuna B, 2011, VIRCHOWS ARCH, V458, P659, DOI 10.1007/s00428-011-1072-3; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; van Kessel KEM, 2015, NAT REV UROL, V12, P681, DOI 10.1038/nrurol.2015.231; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; von Rundstedt FC, 2015, J UROLOGY, V193, P58, DOI 10.1016/j.juro.2014.07.114; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weiss C, 2006, J CLIN ONCOL, V24, P2318, DOI 10.1200/JCO.2006.05.8149; Willis D, 2015, HEMATOL ONCOL CLIN N, V29, P237, DOI 10.1016/j.hoc.2014.10.011; Willis DL, 2015, J UROLOGY, V193, P1129, DOI 10.1016/j.juro.2014.09.092; Witjes JA, 2014, EUR UROL, V65, P778, DOI 10.1016/j.eururo.2013.11.046; Xylinas E, 2014, UROL ONCOL-SEMIN ORI, V32, P222, DOI 10.1016/j.urolonc.2013.06.001; Zheng CJ, 2012, BJU INT, V110, pE680, DOI 10.1111/j.1464-410X.2012.11500.x; Zietman AL, 2003, J UROLOGY, V170, P1772, DOI 10.1097/01.ju.0000093721.23249.c3	179	705	722	17	196	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	2016	388	10061					2796	2810		10.1016/S0140-6736(16)30512-8	http://dx.doi.org/10.1016/S0140-6736(16)30512-8			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EE5FB	27345655				2023-01-03	WOS:000389629800031
J	Amundsen, CL; Richter, HE; Menefee, SA; Komesu, YM; Arya, LA; Gregory, T; Myers, DL; Zyczynski, HM; Vasavada, S; Nolen, TL; Wallace, D; Meikle, SF				Amundsen, Cindy L.; Richter, Holly E.; Menefee, Shawn A.; Komesu, Yuko M.; Arya, Lily A.; Gregory, Thomas; Myers, Deborah L.; Zyczynski, Halina M.; Vasavada, Sandip; Nolen, Tracy L.; Wallace, Dennis; Meikle, Susan F.		Pelvic Floor Disorders Network	OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BOTULINUM-TOXIN-A; IDIOPATHIC DETRUSOR OVERACTIVITY; NERVE-STIMULATION; ADVERSE EVENTS; BLADDER; QUESTIONNAIRE; IMPLANTATION; VALIDATION; INJECTIONS; EFFICACY	IMPORTANCE Women with refractory urgency urinary incontinence are treated with sacral neuromodulation and onabotulinumtoxinA with limited comparative information. OBJECTIVE To assess whether onabotulinumtoxinA is superior to sacral neuromodulation in controlling refractory episodes of urgency urinary incontinence. DESIGN, SETTING, AND PARTICIPANTS Multicenter open-label randomized trial (February 2012-January 2015) at 9 US medical centers involving 381 women with refractory urgency urinary incontinence. INTERVENTIONS Cystoscopic intradetrusor injection of 200 U of onabotulinumtoxinA (n = 192) or sacral neuromodulation (n = 189). MAIN OUTCOMES AND MEASURES Primary outcome, change from baseline mean number of daily urgency urinary incontinence episodes over 6 months, was measured with monthly 3-day diaries. Secondary outcomes included change from baseline in urinary symptom scores in the Overactive Bladder Questionnaire Short Form (SF); range, 0-100, higher scores indicating worse symptoms; Overactive Bladder Satisfaction questionnaire; range, 0-100; includes 5 subscales, higher scores indicating better satisfaction; and adverse events. RESULTS Of the 364 women (mean [SD] age, 63.0 [11.6] years) in the intention-to-treat population, 190 women in the onabotulinumtoxinA group had a greater reduction in 6-month mean number of episodes of urgency incontinence per day than did the 174 in the sacral neuromodulation group (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.13 to 1.14; P =.01). Participants treated with onabotulinumtoxinA showed greater improvement in the Overactive Bladder Questionnaire SF for symptom bother (-46.7 vs -38.6; mean difference, 8.1; 95% CI, 3.0 to 13.3; P =.002); treatment satisfaction (67.7 vs 59.8; mean difference, 7.8; 95% CI, 1.6 to 14.1; P =.01) and treatment endorsement (78.1 vs 67.6; mean difference; 10.4, 95% CI, 4.3 to 16.5; P <.001) than treatment with sacral neuromodulation. There were no differences in convenience (67.6 vs 70.2; mean difference, -2.5; 95% CI, -8.1 to 3.0; P =.36), adverse effects (88.4 vs 85.1; mean difference, 3.3; 95% CI, -1.9 to 8.5; P =.22), and treatment preference (92.% vs 89%; risk difference, -3%; 95% CI, -16% to 10%; P =.49). Urinary tract infections were more frequent in the onabotulinumtoxinA group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P <.001). The need for self-catheterization was 8% and 2% at 1 and 6 months in the onabotulinumtoxinA group. Neuromodulation device revisions and removals occurred in 3%. CONCLUSIONS AND RELEVANCE Amongwomen with refractory urgency urinary incontinence, treatment with onabotulinumtoxinA compared with sacral neuromodulation resulted in a small daily improvement in episodes that although statistically significant is of uncertain clinical importance. In addition, it resulted in a higher risk of urinary tract infections and need for transient self-catheterizations.	[Amundsen, Cindy L.] Duke Univ, Dept Obstet & Gynecol, 5324 McFarland Dr,Ste 310, Durham, NC 27707 USA; [Richter, Holly E.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; [Menefee, Shawn A.] Kaiser Permanente San Diego, Dept Obstet & Gynecol, San Diego, CA USA; [Komesu, Yuko M.] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA; [Arya, Lily A.] Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; [Gregory, Thomas] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; [Myers, Deborah L.] Brown Univ, Dept Obstet & Gynecol, Providence, RI 02912 USA; [Zyczynski, Halina M.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Vasavada, Sandip] Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA; [Nolen, Tracy L.; Wallace, Dennis] RTI Int, Social Stat & Environm Sci, Res Triangle Pk, NC USA; [Meikle, Susan F.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA	Duke University; University of Alabama System; University of Alabama Birmingham; Kaiser Permanente; University of New Mexico; University of Pennsylvania; Oregon Health & Science University; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Amundsen, CL (corresponding author), Duke Univ, Dept Obstet & Gynecol, 5324 McFarland Dr,Ste 310, Durham, NC 27707 USA.	cindy.amundsen@duke.edu	Wallace, Dennis/AAR-7005-2021	Richter, Holly E/0000-0001-7741-5771; Nolen, Tracy/0000-0003-2512-343X	Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIH Office of Research on Women's Health at National Institutes of Health 3316 [U01 HD41249U10, HD41261U10 HD41267, U10 HD54215U10-HD41261-11, U10-HD069013, U10-HD054214-06, U10-HD054215-06, U10-HD041267-12, U10-HD069025-01, U10-HD069010, U10-HD054136, U10-HD054241, U10-HD041250-11]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD041267, UG1HD069006, UG1HD041261, U24HD069031, UG1HD041267] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH Office of Research on Women's Health at National Institutes of Health 3316; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women's Health at National Institutes of Health 3316 (U01 HD41249U10, HD41261U10 HD41267, U10 HD54215U10-HD41261-11, U10-HD069013, U10-HD054214-06, U10-HD054215-06, U10-HD041267-12, U10-HD069025-01, U10-HD069010, U10-HD054136, U10-HD054241, and U10-HD041250-11).	Amundsen CL, 2014, CONTEMP CLIN TRIALS, V37, P272, DOI 10.1016/j.cct.2014.01.009; Blandon RE, 2008, BJU INT, V101, P1119, DOI 10.1111/j.1464-410X.2007.07426.x; Borawski KM, 2007, NEUROUROL URODYNAM, V26, P14, DOI 10.1002/nau.20332; Coyne KS, 2006, J UROLOGY, V176, P627, DOI 10.1016/j.juro.2006.03.088; Coyne KS, 2014, J MANAGE CARE PHARM, V20, P130, DOI 10.18553/jmcp.2014.20.2.130; Coyne KS, 2009, NEUROUROL URODYNAM, V28, P969, DOI 10.1002/nau.20705; Dmochowski R, 2010, J UROLOGY, V184, P2416, DOI 10.1016/j.juro.2010.08.021; Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006; HARTMANN KE, 2009, EVID REP TECHNOL ASS, P94; Herbison GP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004202.pub2; Kuo HC, 2006, UROLOGY, V68, P993, DOI 10.1016/j.urology.2006.05.054; Kuo HC, 2007, J UROLOGY, V178, P1359, DOI 10.1016/j.juro.2007.05.136; Margolis MK, 2009, NEUROUROL URODYNAM, V28, P416, DOI 10.1002/nau.20672; Sahai A, 2010, UROLOGY, V75, P552, DOI 10.1016/j.urology.2009.05.097; Sandvik H, 2000, NEUROUROL URODYNAM, V19, P137, DOI 10.1002/(SICI)1520-6777(2000)19:2<137::AID-NAU4>3.0.CO;2-G; Schmidt RA, 1999, J UROLOGY, V162, P352, DOI 10.1016/S0022-5347(05)68558-8; Siddiqui NY, 2010, NEUROUROL URODYNAM, V29, pS18, DOI 10.1002/nau.20786; Siegel S, 2015, NEUROUROL URODYNAM, V34, P224, DOI 10.1002/nau.22544; Tincello DG, 2012, EUR UROL, V62, P507, DOI 10.1016/j.eururo.2011.12.056; UEBERSAX JS, 1995, NEUROUROL URODYNAM, V14, P131, DOI 10.1002/nau.1930140206; Van Voskuilen AC, 2007, BJU INT, V99, P107, DOI 10.1111/j.1464-410X.2006.06508.x; Visco AG, 2012, NEW ENGL J MED, V367, P1803, DOI 10.1056/NEJMoa1208872; Yalcin I, 2003, AM J OBSTET GYNECOL, V189, P98, DOI 10.1067/mob.2003.379	23	128	131	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2016	316	13					1366	1374		10.1001/jama.2016.14617	http://dx.doi.org/10.1001/jama.2016.14617			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DX7TC	27701661	Green Accepted			2023-01-03	WOS:000384591300017
J	Fanucchi, L; Lofwall, MR				Fanucchi, Laura; Lofwall, Michelle R.			Putting Parity into Practice - Integrating Opioid-Use Disorder Treatment into the Hospital Setting	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL		[Fanucchi, Laura] Univ Kentucky, Coll Med, Ctr Hlth Serv Res, Lexington, KY 40506 USA; [Lofwall, Michelle R.] Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky	Fanucchi, L (corresponding author), Univ Kentucky, Coll Med, Ctr Hlth Serv Res, Lexington, KY 40506 USA.							D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Ronan MV, 2016, HEALTH AFFAIR, V35, P832, DOI 10.1377/hlthaff.2015.1424; Shrestha NK, 2015, ANN THORAC SURG, V100, P875, DOI 10.1016/j.athoracsur.2015.03.019; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780	5	37	37	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2016	375	9					811	813		10.1056/NEJMp1606157	http://dx.doi.org/10.1056/NEJMp1606157			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU9HA	27579631	Green Published, Bronze			2023-01-03	WOS:000382526000002
J	Freedhoff, Y; Hall, KD				Freedhoff, Yoni; Hall, Kevin D.			Weight loss diet studies: we need help not hype	LANCET			English	Editorial Material							ADHERENCE; ADULTS		[Freedhoff, Yoni] Bariatr Med Inst, Ottawa, ON, Canada; [Hall, Kevin D.] NIDDK, Integrat Physiol Sect, Lab Biol Modeling, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hall, KD (corresponding author), NIDDK, Integrat Physiol Sect, Lab Biol Modeling, Bethesda, MD 20892 USA.	kevinh@niddk.nih.gov	Hall, Kevin/F-2383-2010	Hall, Kevin/0000-0003-4062-3133	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK013036, ZIADK013037] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bray MS, 2016, OBESITY, V24, P14, DOI 10.1002/oby.21381; Das SK, 2007, AM J CLIN NUTR, V85, P1023, DOI 10.1093/ajcn/85.4.1023; Dhurandhar NV, 2015, INT J OBESITY, V39, P1109, DOI 10.1038/ijo.2014.199; Foster GD, 1997, J CONSULT CLIN PSYCH, V65, P79, DOI 10.1037/0022-006X.65.1.79; Fothergill E, 2016, OBESITY, V24, P1612, DOI 10.1002/oby.21538; Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017; Greenberg I, 2009, J AM COLL NUTR, V28, P159, DOI 10.1080/07315724.2009.10719767; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; MacLean PS, 2015, OBESITY, V23, P7, DOI 10.1002/oby.20967; Polidori D, OBESITY SIL IN PRESS; Sanghvi A, 2015, AM J CLIN NUTR, V102, P353, DOI 10.3945/ajcn.115.111070; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Tobias DK, 2015, LANCET DIABETES ENDO, V3, P968, DOI 10.1016/S2213-8587(15)00367-8	13	31	31	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	2016	388	10047					849	851		10.1016/S0140-6736(16)31338-1	http://dx.doi.org/10.1016/S0140-6736(16)31338-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU0RI	27597452				2023-01-03	WOS:000381911800008
J	Laurencet, ME; Girardin, F; Rigamonti, F; Bevand, A; Meyer, P; Carballo, D; Roffi, M; Noble, S; Mach, F; Gencer, B				Laurencet, Marie-Eva; Girardin, Francois; Rigamonti, Fabio; Bevand, Anne; Meyer, Philippe; Carballo, David; Roffi, Marco; Noble, Stephane; Mach, Francois; Gencer, Baris			Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; RANDOMIZED-TRIAL; PRIMARY PCI; INTERVENTION; GUIDELINES; MANAGEMENT	Introduction Length of hospital stay (LHS) is an indicator of clinical effectiveness. Early hospital discharge (<= 72 hours) is recommended in patients with acute coronary syndromes (ACS) at low risk of complications, but reasons for prolonged LHS poorly reported. Methods We collected data of ACS patients hospitalized at the Geneva University Hospitals from 1st July 2013 to 30th June 2015 and used the Zwolle index score to identify patients at low risk (<= 3 points). We assessed the proportion of eligible patients who were successfully discharged within 72 hours and the reasons for prolonged LHS. Outcomes were defined as adherence to recommended therapies, major adverse events at 30 days and patients' satisfaction using a Likert-scale patient-reported questionnaire. Results Among 370 patients with ACS, 255 (68.9%) were at low-risk of complications but only 128 (50.2%) were eligible for early discharge, because of other clinical reasons for prolonged LHS (e. g. staged coronary revascularization, cardiac monitoring) in 127 patients (49.8%). Of the latter, only 45 (35.2%) benefitted from an early discharge. Reasons for delay in discharge in the remaining 83 patients (51.2%) were mainly due to delays in additional investigations, titration of medical therapy, admission or discharge during weekends. In the early discharge group, at 30 days, only one patient (2.2%) had an adverse event (minor bleeding), 97% of patients were satisfied by the medical care. Conclusion Early discharge was successfully achieved in one third of eligible ACS patients at low risk of complications and appeared sufficiently safe while being overall appreciated by the patients.	[Laurencet, Marie-Eva] Univ Hosp Geneva, Dept Med, Div Internal Med, Geneva, Switzerland; [Girardin, Francois] Univ Hosp Geneva, Dept Anesthesiol Clin Pharmacol & Toxicol Intens, Div Clin Pharmacol & Toxicol, Geneva, Switzerland; [Girardin, Francois] Univ Geneva, Geneva, Switzerland; [Girardin, Francois] Univ Hosp Geneva, Med Direct, Geneva, Switzerland; [Rigamonti, Fabio; Bevand, Anne; Meyer, Philippe; Carballo, David; Roffi, Marco; Noble, Stephane; Mach, Francois; Gencer, Baris] Univ Hosp Geneva, Dept Med, Div Cardiol, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Gencer, B (corresponding author), Univ Hosp Geneva, Dept Med, Div Cardiol, Geneva, Switzerland.	baris.gencer@hcuge.ch	Girardin, Francois/F-5443-2017; Gencer, Baris/AAO-2305-2020; Meyer, Philippe/HHC-0770-2022	Girardin, Francois/0000-0002-0842-927X; Gencer, Baris/0000-0002-8954-9694	Geneva University Hospitals [RD 12-II-2012]; Swiss National Science Foundation [SPUM 33CM30124112, SPUM 33CM30-140 336]; de Reuter Foundation; Gerbex-Bourget Foundation; Swiss Heart Foundation; Schmidheiny Foundation	Geneva University Hospitals; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); de Reuter Foundation; Gerbex-Bourget Foundation; Swiss Heart Foundation; Schmidheiny Foundation	The work was supported by the Geneva University Hospitals, (P, RD 12-II-2012) Swiss National Science Foundation (SPUM 33CM30124112 and SPUM 33CM30-140 336, Inflammation and acute coronary syndromes (ACS) - Novel strategies for prevention and clinical management), de Reuter Foundation, Gerbex-Bourget Foundation. B.G.'s research is supported by grants from the Geneva University Hospitals, Swiss Heart Foundation, de Reuter Foundation, Gerbex-Bourget Foundation and Schmidheiny Foundation. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Auer R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093147; Aujesky D, 2011, LANCET, V378, P41, DOI 10.1016/S0140-6736(11)60824-6; Azzalini L, 2015, CARDIOLOGY, V130, P120, DOI 10.1159/000368890; Barchielli A, 2007, INT J CARDIOL, V114, P57, DOI 10.1016/j.ijcard.2006.01.006; Busato A, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-31; De Luca G, 2004, CIRCULATION, V109, P2737, DOI 10.1161/01.CIR.0000131765.73959.87; Di Mario Carlo, 2004, Int J Cardiovasc Intervent, V6, P128; Gaudenzi Baris G F, 2013, J CLIN TRIALS, V3; Gencer B, 2015, ATHEROSCLEROSIS, V239, P118, DOI 10.1016/j.atherosclerosis.2014.12.049; Gencer B, 2015, EUR J INTERN MED, V26, P56, DOI 10.1016/j.ejim.2014.12.014; Jirmar R, 2008, INT HEART J, V49, P653, DOI 10.1536/ihj.49.653; Jones DA, 2012, HEART, V98, P1722, DOI 10.1136/heartjnl-2012-302414; Kelly DJ, 2013, EUROINTERVENTION, V8, P1190, DOI 10.4244/EIJV8I10A183; Kociol RD, 2012, JAMA-J AM MED ASSOC, V307, P66, DOI 10.1001/jama.2011.1926; Kotowycz MA, 2010, AM HEART J, V159, P117, DOI 10.1016/j.ahj.2009.10.024; Laarman GJ, 2010, HEART, V96, P584, DOI 10.1136/hrt.2009.171363; Melberg T, 2015, EUR J PREV CARDIOL, V22, P1427, DOI 10.1177/2047487314559276; Politi L, 2010, HEART, V96, P662, DOI 10.1136/hrt.2009.177162; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Spencer FA, 2004, ARCH INTERN MED, V164, P733, DOI 10.1001/archinte.164.7.733; Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215; Wald DS, 2013, NEW ENGL J MED, V369, P1115, DOI 10.1056/NEJMoa1305520	23	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2016	11	8							e0161493	10.1371/journal.pone.0161493	http://dx.doi.org/10.1371/journal.pone.0161493			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT8TR	27551861	Green Published, gold, Green Submitted			2023-01-03	WOS:000381768800045
J	Golay, P; Basterrechea, L; Conus, P; Bonsack, C				Golay, Philippe; Basterrechea, Louis; Conus, Philippe; Bonsack, Charles			Internal and Predictive Validity of the French Health of the Nation Outcome Scales: Need for Future Directions	PLOS ONE			English	Article							HONOS; UTILITY; VERSION	The Health of the Nation Outcome Scales (HoNOS) is a widely used measure of health and social functioning of people with mental illness. The goals of this study were to verify the internal validity of the one factor and several four-factor scoring structures and to evaluate the predictive validity of HoNOS items with regards to duration of hospitalization, probability of readmission in the following year and time before readmission. 6175 hospital stays at the department of psychiatry of Lausanne University Hospital were screened and the first HoNOS of each patient was taken into account (N = 2722). Data were analyzed through Confirmatory Factor Analysis (CFA) and the predictive validity of HoNOS items was evaluated with two approaches: item level regressions and latent class analysis (LCA). CFA indicated that the suggested factor structures were not supported by the data. Predictive validity of the 12 items was weak but LCA revealed five distinct and meaningful profiles that were related to length of stay or readmission. HoNOS may be more adapted to the evaluation of patients case-mix rather than to the individual level and concepts such as predictive validity may be more appropriate than internal validity to guide its use.	[Golay, Philippe; Basterrechea, Louis; Conus, Philippe; Bonsack, Charles] Lausanne Univ Hosp CHUV, Dept Psychiat, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Golay, P (corresponding author), Lausanne Univ Hosp CHUV, Dept Psychiat, Lausanne, Switzerland.	Philippe.golay@chuv.ch	Golay, Philippe/GMX-4576-2022; Golay, Philippe/L-6973-2016	Golay, Philippe/0000-0002-2273-6241; Golay, Philippe/0000-0002-2273-6241; Conus, Philippe/0000-0002-5832-1910				Andreas S, 2010, INT J METH PSYCH RES, V19, P50, DOI 10.1002/mpr.305; Asparouhov T, 2014, STRUCT EQU MODELING, V21, P329, DOI 10.1080/10705511.2014.915181; Bech P, 2006, ACTA PSYCHIAT SCAND, V113, P485, DOI 10.1111/j.1600-0447.2005.00693.x; Bisson J, 2004, RAPPORT DE RECHERCHE, P1; Bonsack C, 2002, HEALTH OF NATION OUT, P483; Boot B, 1997, BRIT J PSYCHIAT, V171, P242, DOI 10.1192/bjp.171.3.242; Burns A, 1999, BRIT J PSYCHIAT, V174, P424, DOI 10.1192/bjp.174.5.424; Chin W.W., 1998, MIS QUART, V22, P7, DOI DOI 10.2307/249674; Cieza A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132410; Eagar K, 2005, AUST NZ J PSYCHIAT, V39, P713, DOI 10.1111/j.1440-1614.2005.01655.x; Furr RM, 2013, PSYCHOMETRICS AN INT; Gavin H, 2008, UNDERSTANDING RESEAR; Goldney RD, 1998, AUST NZ J PSYCHIAT, V32, P199, DOI 10.3109/00048679809062729; Gowers SG, 1999, BRIT J PSYCHIAT, V174, P413, DOI 10.1192/bjp.174.5.413; HAYWOOD TW, 1995, AM J PSYCHIAT, V152, P856; Hope JD, 1998, SCHIZOPHR RES, V29, P9, DOI 10.1016/S0920-9964(97)88307-7; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Lanza ST, 2013, STRUCT EQU MODELING, V20, P361, DOI 10.1080/10705511.2013.797816; Lauzon S, 2001, CAN J PSYCHIAT, V46, P841, DOI 10.1177/070674370104600908; Lovaglio PG, 2012, QUAL LIFE RES, V21, P1643, DOI 10.1007/s11136-011-0071-9; Muncer S, 2016, AUSTRALAS PSYCHIATRY; Muncer SJ, 2016, PERS INDIV DIFFER, V94, P272, DOI 10.1016/j.paid.2016.01.051; Muthen B.O., 2004, MPLUS TECHNICAL APPE; Newnham EA, 2009, J MENT HEALTH, V18, P326, DOI 10.1080/09638230802522486; Parker G, 2002, INT J SOC PSYCHIATR, V48, P11, DOI 10.1177/002076402128783046; Pirkis Jane, 2005, Aust New Zealand Health Policy, V2, P8, DOI 10.1186/1743-8462-2-8; Pirkis Jane E, 2005, Health Qual Life Outcomes, V3, P76, DOI 10.1186/1477-7525-3-76; Prowse L, 2009, AUST HEALTH REV, V33, P13, DOI 10.1071/AH090013; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Speak B, 2012, FINAL REPORT; Speak BL, 2015, INT J HEALTH CARE Q, V28, P115, DOI 10.1108/IJHCQA-08-2013-0096; Speak BL, 2016, INTERNATIONAL JOURNA; Trauer T., 1999, J MENTAL HLTH, V8, P499, DOI [DOI 10.1080/09638239917193, 10.1080/09638239917193]; Veerbeek MA, 2013, INT J NURS STUD, V50, P1711, DOI 10.1016/j.ijnurstu.2013.05.004; Wing JK, 1998, BRIT J PSYCHIAT, V172, P11, DOI 10.1192/bjp.172.1.11; Wolff J, 2015, BMC PSYCHIATRY, V15, P1; Yu CY, 2002, EVALUATING CUTOFF CR	37	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2016	11	8							e0160360	10.1371/journal.pone.0160360	http://dx.doi.org/10.1371/journal.pone.0160360			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DS9NS	27483015	Green Published, gold			2023-01-03	WOS:000381110700039
J	Jimenez, S; Gascon, S; Luquin, A; Laguna, M; Ancin-Azpilicueta, C; Rodriguez-Yoldi, MJ				Jimenez, Sandra; Gascon, Sonia; Luquin, Asuncion; Laguna, Mariano; Ancin-Azpilicueta, Carmen; Rodriguez-Yoldi, Maria Jesus			Rosa canina Extracts Have Antiproliferative and Antioxidant Effects on Caco-2 Human Colon Cancer	PLOS ONE			English	Article							PLANT POLYPHENOLS; FREE-RADICALS; CELL-CYCLE; IN-VITRO; APOPTOSIS; L.; DISEASE; CYTOTOXICITY; DERIVATIVES; MECHANISMS	The in vitro antiproliferative and antioxidant effects of different fractions of Rosa canina hips on human colon cancer cell lines (Caco-2) was studied. The compounds tested were total extract (fraction 1), vitamin C (fraction 2), neutral polyphenols (fraction 3) and acidic polyphenols (fraction 4). All the extracts showed high cytotoxicity after 72 h, both low and high concentrations. The flow cytometric analysis revealed that all the fractions produce disturbances in the cell cycle resulting in a concomitant cell death by an apoptotic pathway. Changes in the redox status of Caco-2 cells in response to Rosa canina hips were determined. Cells were exposed to hydrogen peroxide in presence of plant fractions and the production of Reactive Oxygen Species (ROS) was significantly decreased. Therefore, our data demonstrate that rosehip extracts are a powerful antioxidant that produces an antiproliferative effect in Caco-2 cells. Therefore, these results predict a promising future for Rosa canina as a therapeutic agent. Thus, this natural plant could be an effective component of functional foods addressed towards colorectal carcinoma.	[Jimenez, Sandra; Luquin, Asuncion; Ancin-Azpilicueta, Carmen] Univ Publ Navarra, Dept Appl Chem, Pamplona, Spain; [Gascon, Sonia; Rodriguez-Yoldi, Maria Jesus] Univ Zaragoza, Dept Physiol & Pharmacol, CIBERobn, IA2,IIS Aragon,Vet Fac, Zaragoza, Spain; [Laguna, Mariano] Univ Zaragoza, CSIC, Dept Inorgan Chem, Inst Chem Syntheses & Homogeneous Catalysis, Zaragoza, Spain	Universidad Publica de Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC-UZA - Instituto de Sintesis Quimica y Catalisis Homogenea (ISQCH); University of Zaragoza	Ancin-Azpilicueta, C (corresponding author), Univ Publ Navarra, Dept Appl Chem, Pamplona, Spain.; Rodriguez-Yoldi, MJ (corresponding author), Univ Zaragoza, Dept Physiol & Pharmacol, CIBERobn, IA2,IIS Aragon,Vet Fac, Zaragoza, Spain.	ancin@unavarra.es; mjrodyol@unizar.es	Ancín-Azpilicueta, Carmen/M-5632-2018	Ancín-Azpilicueta, Carmen/0000-0001-7690-3204; Luquin, Asuncion/0000-0002-2264-5956	Ministry of Science and Innovation [SAF2013-41651]; CIBER (Centros de Investigacion Biomedica en Red) Sub-program (CIBERobn) by the Instituto de Salud Carlos III [CB06/03/1012]; Proyecto ELENA [EFA 220/11 ELENA]	Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CIBER (Centros de Investigacion Biomedica en Red) Sub-program (CIBERobn) by the Instituto de Salud Carlos III; Proyecto ELENA	This study was supported by the projects: the Ministry of Science and Innovation (SAF2013-41651), founds from Aragon Regional Government (A-32) and CIBER (Centros de Investigacion Biomedica en Red) Sub-program (CIBERobn, CB06/03/1012,) by the Instituto de Salud Carlos III and Proyecto ELENA, EFA 220/11 ELENA. Authors would like also to acknowledge AVANZARE for their collaboration in this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGULLO G, 1994, CANCER LETT, V87, P55, DOI 10.1016/0304-3835(94)90409-X; Al-Gubory KH, 2010, INT J BIOCHEM CELL B, V42, P1634, DOI 10.1016/j.biocel.2010.06.001; Alshikh N, 2015, J FUNCT FOODS, V18, P1022, DOI 10.1016/j.jff.2015.05.018; Beattie J, 2005, CURR NUTR FOOD SCI, V1, P71, DOI 10.2174/1573401052953294; Cano A, 1998, PHYTOCHEM ANALYSIS, V9, P196, DOI 10.1002/(SICI)1099-1565(199807/08)9:4&lt;196::AID-PCA395&gt;3.0.CO;2-W; Carocho M, 2016, FOOD CHEM, V207, P51, DOI 10.1016/j.foodchem.2016.03.085; CHANTRET I, 1994, J CELL SCI, V107, P213; Charles DJ, 2013, ANTIOXIDANT PROPERTI, P39; Chrubasik JE, 2007, PHYTOTHER RES, V21, P675, DOI 10.1002/ptr.2142; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Demir N, 2014, LWT-FOOD SCI TECHNOL, V57, P126, DOI 10.1016/j.lwt.2013.12.038; Duthie GG, 2000, NUTR RES REV, V13, P79, DOI 10.1079/095442200108729016; Dzialo M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020160; Ferreira ICFR, 2009, CURR MED CHEM, V16, P1543, DOI 10.2174/092986709787909587; Gallaher DD, 2013, NUTR PREVENTION TREA, P697; Garcia-Alonso J, 2006, FOOD RES INT, V39, P982, DOI 10.1016/j.foodres.2006.07.001; Garcia-Moreno E, 2013, ORGANOMETALLICS, V32, P3710, DOI 10.1021/om400340a; Guimaraes R, 2010, J AGR FOOD CHEM, V58, P6277, DOI 10.1021/jf101394w; Guo XD, 2013, MOL NUTR FOOD RES, V57, P1037, DOI 10.1002/mnfr.201200569; Hu XL, 2010, BIOCHEM BIOPH RES CO, V398, P62, DOI 10.1016/j.bbrc.2010.06.033; Jain SK, 2013, J NAT PROD, V76, P1724, DOI 10.1021/np400433g; Janeiro P, 2004, ANAL CHIM ACTA, V518, P109, DOI 10.1016/j.aca.2004.05.038; Larsen E, 2003, J NAT PROD, V66, P994, DOI 10.1021/np0300636; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Li Q, 2014, MOLECULES, V19, P19036, DOI 10.3390/molecules191119036; Li Y., 2012, FOOD SCI HUM WELL, V1, P19, DOI [10.1016/j.fshw.2012.08.002, DOI 10.1016/J.FSHW.2012.08.002]; Liu RH, 2004, J NUTR, V134, p3479S, DOI 10.1093/jn/134.12.3479S; Lopez V, 2010, PHYTOTHER RES, V24, P869, DOI 10.1002/ptr.3037; Montero P, 2016, LWT-FOOD SCI TECHNOL, V70, P229, DOI 10.1016/j.lwt.2016.02.040; Nybom H, 2015, ACTA HORTIC, V1064, P137; Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498; Piazzon A, 2012, J AGR FOOD CHEM, V60, P12312, DOI 10.1021/jf304076z; Rechner AR, 2002, FREE RADICAL BIO MED, V33, P220, DOI 10.1016/S0891-5849(02)00877-8; Ruiz-Leal M, 2004, MAR ENVIRON RES, V58, P631, DOI 10.1016/j.marenvres.2004.03.054; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Schieber A, 2003, J AGR FOOD CHEM, V51, P5006, DOI 10.1021/jf030218f; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Serrano J, 2007, FOOD RES INT, V40, P15, DOI 10.1016/j.foodres.2006.07.010; Shahidi F, 2015, J FUNCT FOODS, V18, P820, DOI 10.1016/j.jff.2015.06.018; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Stralsjo L, 2003, J AGR FOOD CHEM, V51, P4291, DOI 10.1021/jf034208q; Taleb-Senouci D, 2009, PHYTOMEDICINE, V16, P623, DOI 10.1016/j.phymed.2008.12.004; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tumbas VT, 2012, J SCI FOOD AGR, V92, P1273, DOI 10.1002/jsfa.4695; Turkben C, 2010, J FOOD AGRIC ENVIRON, V8, P26; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wenzel H, 2000, CANCER RES, V60, P3823; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; Yang J, 2009, J AGR FOOD CHEM, V57, P8581, DOI 10.1021/jf8039796; Zaletok S., 2015, Experimental Oncology, V37, P262	51	60	60	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2016	11	7							e0159136	10.1371/journal.pone.0159136	http://dx.doi.org/10.1371/journal.pone.0159136			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IL	27467555	Green Published, gold			2023-01-03	WOS:000381516100019
J	Ok, E; Asci, G; Chazot, C; Ozkahya, M; Mees, EJD				Ok, Ercan; Asci, Gulay; Chazot, Charles; Ozkahya, Mehmet; Mees, Evert J. Dorhout			Controversies and problems of volume control and hypertension in haemodialysis	LANCET			English	Article							BLOOD-PRESSURE CONTROL; DIALYSATE SODIUM PRESCRIPTION; LEFT-VENTRICULAR HYPERTROPHY; STAGE RENAL-DISEASE; INFERIOR VENA-CAVA; CARDIOVASCULAR EVENTS; MORTALITY RISK; DRY-WEIGHT; FREQUENT HEMODIALYSIS; RECEPTOR BLOCKADE	Extracellular volume overload and hypertension are important contributors to the high risk of cardiovascular mortality in patients undergoing haemodialysis. Hypertension is present in more than 90% of patients at the initiation of haemodialysis and persists in more than two-thirds, despite use of several antihypertensive medications. High blood pressure is a risk factor for the development of left ventricular hypertrophy, heart failure, and mortality, although there are controversies with some study findings showing poor survival with low-but not high-blood pressure. The most frequent cause of hypertension in patients undergoing haemodialysis is volume overload, which is associated with poor cardiovascular outcomes itself independent of blood pressure. Although antihypertensive medications might not be successful to control blood pressure, extracellular volume reduction by persistent ultrafiltration and dietary salt restriction can produce favourable results with good blood pressure control. More frequent or longer haemodialysis can facilitate volume and blood pressure control. However, successful volume and blood pressure control is also possible in patients undergoing conventional haemodialysis.	[Ok, Ercan; Asci, Gulay; Ozkahya, Mehmet] Ege Univ, Sch Med, Div Nephrol, Izmir, Turkey; [Chazot, Charles] NephroCare Tassin Charcot, Sainte Foy Les Lyon, France; [Mees, Evert J. Dorhout] Univ Utrecht, NL-3508 TC Utrecht, Netherlands	Ege University; Utrecht University	Ok, E (corresponding author), Ege Univ, Sch Med, Internal Med, Div Nephrol, TR-35100 Bornova, Turkey.	ercan.ok@ege.edu.tr	asci, gulay/B-9067-2018					Agarwal R, 2003, AM J MED, V115, P291, DOI 10.1016/S0002-9343(03)00366-8; Agarwal R, 2010, NEPHROL DIAL TRANSPL, V25, P3355, DOI 10.1093/ndt/gfq210; Agarwal R, 2010, HYPERTENSION, V56, P512, DOI 10.1161/HYPERTENSIONAHA.110.154815; Agarwal R, 2010, HYPERTENSION, V55, P762, DOI 10.1161/HYPERTENSIONAHA.109.144899; Agarwal R, 2009, HYPERTENSION, V53, P500, DOI 10.1161/HYPERTENSIONAHA.108.125674; Arneson TJ, 2010, CLIN J AM SOC NEPHRO, V5, P1054, DOI 10.2215/CJN.00340110; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Braam B, 2011, HYPERTENSION CARDIOV; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P914, DOI 10.2215/CJN.03900808; Charra B, 1996, NEPHROL DIAL TRANSPL, V11, P16; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; Charra B, 1998, AM J KIDNEY DIS, V32, P720, DOI 10.1016/S0272-6386(98)70147-7; Charra Bernard, 2007, Hemodial Int, V11, P21, DOI 10.1111/j.1542-4758.2007.00148.x; CHAZOT C, 1995, NEPHROL DIAL TRANSPL, V10, P831; CHERIEX EC, 1989, NEPHROL DIAL TRANSPL, V4, P563; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Chou KJ, 2006, KIDNEY INT, V69, P1833, DOI 10.1038/sj.ki.5000266; Cice G, 2010, J AM COLL CARDIOL, V56, P1701, DOI 10.1016/j.jacc.2010.03.105; CIRIT M, 1995, NEPHROL DIAL TRANSPL, V10, P1417; Cirit M, 1998, NEPHROL DIAL TRANSPL, V13, P389, DOI 10.1093/oxfordjournals.ndt.a027835; Conlon PJ, 1996, J AM SOC NEPHROL, V7, P2658; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Curatola G, 2011, J NEPHROL, V24, P465, DOI 10.5301/JN.2011.7735; CURTIS JR, 1969, Q J MED, V38, P49; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; De Lima JJG, 2001, NEPHROL DIAL TRANSPL, V16, P793, DOI 10.1093/ndt/16.4.793; de Paula FM, 2004, KIDNEY INT, V66, P1232, DOI 10.1111/j.1523-1755.2004.00876.x; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; Erdem Y, 2010, BLOOD PRESSURE, V19, P313, DOI 10.3109/08037051003802541; Flythe JE, 2011, KIDNEY INT, V79, P250, DOI 10.1038/ki.2010.383; Foley RN, 2002, KIDNEY INT, V62, P1784, DOI 10.1046/j.1523-1755.2002.00636.x; Foley RN, 1996, KIDNEY INT, V49, P1379, DOI 10.1038/ki.1996.194; Gunal AI, 2002, J NEPHROL, V15, P42; GUYTON AC, 1992, HYPERTENSION, V19, pI2, DOI 10.1161/01.HYP.19.1_Suppl.I2; Guyton AC, 1980, ARTERIAL PRESSURE HY; HARNETT JD, 1995, KIDNEY INT, V47, P884, DOI 10.1038/ki.1995.132; Heerspink HL, 2009, LANCET, V373, P1009, DOI 10.1016/S0140-6736(09)60212-9; Inrig JK, 2009, AM J KIDNEY DIS, V54, P881, DOI 10.1053/j.ajkd.2009.05.012; Iseki K, 2013, NEPHROL DIAL TRANSPL, V28, P1579, DOI 10.1093/ndt/gfs590; Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Katzarski KS, 1999, NEPHROL DIAL TRANSPL, V14, P369, DOI 10.1093/ndt/14.2.369; Katzarski KS, 1997, AM J KIDNEY DIS, V30, P459, DOI 10.1016/S0272-6386(97)90302-4; Kayikcioglu M, 2009, NEPHROL DIAL TRANSPL, V24, P956, DOI 10.1093/ndt/gfn599; Kaysen GA, 2012, KIDNEY INT, V82, P90, DOI 10.1038/ki.2012.75; KOOMANS HA, 1982, HYPERTENSION, V4, P190, DOI 10.1161/01.HYP.4.2.190; KOOMANS HA, 1984, KIDNEY INT, V26, P848, DOI 10.1038/ki.1984.227; Laurent G, 1998, NEPHROL DIAL TRANSPL, V13, P125, DOI 10.1093/ndt/13.suppl_6.125; Laurent G, 1997, NEPHROL DIAL TRANSPL, V12, P1104, DOI 10.1093/ndt/12.6.1104; Levin NW, 2010, KIDNEY INT, V77, P273, DOI 10.1038/ki.2009.469; Lopes AA, 2009, NEPHROL DIAL TRANSPL, V24, P2809, DOI 10.1093/ndt/gfp212; Lynn KL, 2002, KIDNEY INT, V62, P2281, DOI 10.1046/j.1523-1755.2002.00685.x; Mazzuchi N, 2000, KIDNEY INT, V58, P2147; Mc Causland FR, 2012, KIDNEY INT, V82, P204, DOI 10.1038/ki.2012.42; Merchant A, 2015, J AM SOC HYPERTENS, V9, P275, DOI 10.1016/j.jash.2015.01.011; Ok E, 2013, NEPHROL DIAL TRANSPL, V28, P192, DOI 10.1093/ndt/gfs407; Ozdogan O, 2010, AM HEART J, V159, P1089, DOI 10.1016/j.ahj.2010.03.020; Ozkahya M, 1999, AM J KIDNEY DIS, V34, P218, DOI 10.1016/S0272-6386(99)70346-X; Ozkahya M, 2002, J NEPHROL, V15, P655; Ozkahya M, 1998, NEPHROL DIAL TRANSPL, V13, P1489, DOI 10.1093/ndt/13.6.1489; Ozkahya M, 2006, NEPHROL DIAL TRANSPL, V21, P3506, DOI 10.1093/ndt/gfl487; Paoletti E, 2004, NEPHROL DIAL TRANSPL, V19, P1829, DOI 10.1093/ndt/gfh288; Penne EL, 2011, BLOOD PURIFICAT, V31, P86, DOI 10.1159/000321851; Peters CD, 2014, KIDNEY INT, V86, P625, DOI 10.1038/ki.2014.69; Raimann JG, 2015, NEPHROL DIAL TRAN S3, V30, pii276; Robinson BM, 2012, KIDNEY INT, V82, P570, DOI 10.1038/ki.2012.136; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Salem MM, 1999, NEPHROL DIAL TRANSPL, V14, P125, DOI 10.1093/ndt/14.1.125; Salem MM, 1996, AM J KIDNEY DIS, V28, P737, DOI 10.1016/S0272-6386(96)90257-7; Santos SFF, 2008, CLIN J AM SOC NEPHRO, V3, P522, DOI 10.2215/CJN.03360807; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P114; SELLARS L, 1979, BMJ-BRIT MED J, V1, P520, DOI 10.1136/bmj.1.6162.520; Sinha AD, 2010, HYPERTENSION, V55, P305, DOI 10.1161/HYPERTENSIONAHA.109.143974; Stidley CA, 2006, J AM SOC NEPHROL, V17, P513, DOI 10.1681/ASN.2004110921; Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P689, DOI 10.1053/j.ajkd.2011.12.020; Tai DJ, 2010, CLIN J AM SOC NEPHRO, V5, P623, DOI 10.2215/CJN.07831109; Takahashi A, 2006, NEPHROL DIAL TRANSPL, V21, P2507, DOI 10.1093/ndt/gfl293; Tomson CRV, 2001, NEPHROL DIAL TRANSPL, V16, P1538, DOI 10.1093/ndt/16.8.1538; Toz Huseyin, 2007, Hemodial Int, V11, P46; Tozawa M, 2002, KIDNEY INT, V61, P717, DOI 10.1046/j.1523-1755.2002.00173.x; Tripepi G, 2009, HYPERTENSION, V54, P818, DOI 10.1161/HYPERTENSIONAHA.109.136804; Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4; Twardowski ZJ, 2008, HEMODIAL INT, V12, P412, DOI 10.1111/j.1542-4758.2008.00304.x; VERTES V, 1969, NEW ENGL J MED, V280, P978, DOI 10.1056/NEJM196905012801802; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Zager PG, 1998, KIDNEY INT, V54, P561, DOI 10.1046/j.1523-1755.1998.00005.x; Zannad F, 2006, KIDNEY INT, V70, P1318, DOI 10.1038/sj.ki.5001657; Zoccali C, 2013, J AM SOC NEPHROL, V24, P639, DOI 10.1681/ASN.2012100990	91	41	46	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	2016	388	10041					285	293		10.1016/S0140-6736(16)30389-0	http://dx.doi.org/10.1016/S0140-6736(16)30389-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DR2LN	27226131				2023-01-03	WOS:000379736100033
J	Casarett, D; Teno, J				Casarett, David; Teno, Joan			Why Population Health and Palliative Care Need Each Other	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Casarett, David] Univ Penn, Perelman Sch Med, Dept Med, 3615 Chestnut St, Philadelphia, PA 19119 USA; [Teno, Joan] Univ Washington, Cambia Palliat Care Ctr Excellence, Div Gerontol & Geriatr, Seattle, WA 98195 USA	University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle	Casarett, D (corresponding author), Univ Penn, Perelman Sch Med, 3615 Chestnut St, Philadelphia, PA 19119 USA.	casarett@mail.med.upenn.edu						Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Grad FP, 2002, B WORLD HEALTH ORGAN, V80, P981; Kindig D, 2003, AM J PUBLIC HEALTH, V93, P380, DOI 10.2105/AJPH.93.3.380; Kindig D., 2015, HLTH AFFAIRS BL 0406; Krumholz HM, 2015, JAMA-J AM MED ASSOC, V314, P355, DOI 10.1001/jama.2015.8035; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Washington AE, 2016, JAMA-J AM MED ASSOC, V315, P459, DOI 10.1001/jama.2015.18550	7	9	9	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2016	316	1					27	28		10.1001/jama.2016.5961	http://dx.doi.org/10.1001/jama.2016.5961			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DQ2MY	27257779				2023-01-03	WOS:000379037600011
J	Emanuel, EJ; Onwuteaka-Philipsen, BD; Urwin, JW; Cohen, J				Emanuel, Ezekiel J.; Onwuteaka-Philipsen, Bregje D.; Urwin, John W.; Cohen, Joachim			Attitudes and Practices of Euthanasia and Physician-Assisted Suicide in the United States, Canada, and Europe	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE DECISIONS; CARE PROFESSIONALS; MEDICAL DECISIONS; POSTMORTEM SURVEY; CANCER-PATIENTS; OREGON DEATH; END; NETHERLANDS; EXPERIENCES; BELGIUM	IMPORTANCE The increasing legalization of euthanasia and physician-assisted suicide worldwide makes it important to understand related attitudes and practices. OBJECTIVE To review the legal status of euthanasia and physician-assisted suicide and the available data on attitudes and practices. EVIDENCE REVIEW Polling data and published surveys of the public and physicians, official state and country databases, interview studies with physicians, and death certificate studies (the Netherlands and Belgium) were reviewed for the period 1947 to 2016. FINDINGS Currently, euthanasia or physician-assisted suicide can be legally practiced in the Netherlands, Belgium, Luxembourg, Colombia, and Canada (Quebec since 2014, nationally as of June 2016). Physician-assisted suicide, excluding euthanasia, is legal in 5 US states (Oregon, Washington, Montana, Vermont, and California) and Switzerland. Public support for euthanasia and physician-assisted suicide in the United States has plateaued since the 1990s (range, 47%-69%). In Western Europe, an increasing and strong public support for euthanasia and physician-assisted suicide has been reported; in Central and Eastern Europe, support is decreasing. In the United States, less than 20% of physicians report having received requests for euthanasia or physician-assisted suicide, and 5% or less have complied. In Oregon and Washington state, less than 1% of licensed physicians write prescriptions for physician-assisted suicide per year. In the Netherlands and Belgium, about half or more of physicians reported ever having received a request; 60% of Dutch physicians have ever granted such requests. Between 0.3% to 4.6% of all deaths are reported as euthanasia or physician-assisted suicide in jurisdictions where they are legal. The frequency of these deaths increased after legalization. More than 70% of cases involved patients with cancer. Typical patients are older, white, and well-educated. Pain is mostly not reported as the primary motivation. A large portion of patients receiving physician-assisted suicide in Oregon and Washington reported being enrolled in hospice or palliative care, as did patients in Belgium. In no jurisdiction was there evidence that vulnerable patients have been receiving euthanasia or physician-assisted suicide at rates higher than those in the general population. CONCLUSIONS AND RELEVANCE Euthanasia and physician-assisted suicide are increasingly being legalized, remain relatively rare, and primarily involve patients with cancer. Existing data do not indicate widespread abuse of these practices.	[Emanuel, Ezekiel J.; Urwin, John W.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,Blockley Hall,11th & 14th Floors, Philadelphia, PA 19104 USA; [Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Canc Ctr Amsterdam, Amsterdam, Netherlands; [Cohen, Joachim] VUB, End Life Care Res Grp, Brussels, Belgium; [Cohen, Joachim] Univ Ghent, Brussels, Belgium	University of Pennsylvania; Pennsylvania Medicine; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Brussel; Ghent University	Emanuel, EJ (corresponding author), Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,Blockley Hall,11th & 14th Floors, Philadelphia, PA 19104 USA.	MEHPchair@upenn.edu	Cohen, Joachim/B-6803-2008	Cohen, Joachim/0000-0002-7224-9476; Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248				[Anonymous], 2014, BBC; [Anonymous], 2005, TIJDSCHRIFT NATL RAA, V109, P7; [Anonymous], 2002, ETHICAL PERSPECT, V9, P182, DOI DOI 10.2143/EP.9.2.503856; [Anonymous], 2014, AM END EUTH AND LIF; [Anonymous], 2015, GEN SOC SURV 1972 20; [Anonymous], 2015, SBS; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Battin MP, 2007, J MED ETHICS, V33, P591, DOI 10.1136/jme.2007.022335; BATTIN MP, 1995, ACAD MED, V70, P583; Board of the Royal Dutch Medical Association, 1984, MED CONTACT, V39, P990; Bolt EE, 2015, J MED ETHICS, V41, P592, DOI 10.1136/medethics-2014-102150; Bosshard G, 2012, Praxis (Bern 1994), V101, P183, DOI 10.1024/1661-8157/a000828; Bosshard G, 2003, SWISS MED WKLY, V133, P310; Bosshard G, 2016, JAMA INTERN MED, V176, P555, DOI 10.1001/jamainternmed.2015.7676; Brauer S, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14142; Brinkman-Stoppelenburg A, 2015, SUPPORT CARE CANCER, V23, P2899, DOI 10.1007/s00520-015-2655-3; Buiting H, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-18; Chambaere K, 2015, NEW ENGL J MED, V372, P1179, DOI 10.1056/NEJMc1414527; Chambaere K, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1055; Chambaere K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-299; Cohen J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-307; Cohen J, 2014, INT J PUBLIC HEALTH, V59, P143, DOI 10.1007/s00038-013-0461-6; Cohen J, 2013, EUR J PUBLIC HEALTH, V23, P378, DOI 10.1093/eurpub/cks186; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Colbert JA, 2013, NEW ENGL J MED, V368, pE12, DOI 10.1056/NEJMclde1301407; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; Dierickx S, 2015, JAMA INTERN MED, V175, P1703, DOI 10.1001/jamainternmed.2015.3982; Dobscha Steven K, 2004, J Palliat Med, V7, P451, DOI 10.1089/1096621041349374; Drum CE, 2010, DISABIL HEALTH J, V3, P3, DOI 10.1016/j.dhjo.2009.10.001; Dutch Ministry of Security and Justice and the Dutch Ministry of Health Welfare and Sport, 2007, STAATSCOURANT, V51, P8; Dyer O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4481; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Espino DV, 2010, J AM GERIATR SOC, V58, P1370, DOI 10.1111/j.1532-5415.2010.02910.x; Federal Statistical Office, 2012, CAUS DEATH STAT 2009; Fischer S, 2009, SWISS MED WKLY, V139, P333, DOI smw-12614; Ganzini L, 2002, NEW ENGL J MED, V347, P582, DOI 10.1056/NEJMsa020562; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Gielen J, 2008, J PALLIAT CARE, V24, P173, DOI 10.1177/082585970802400307; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Hilden JM, 2001, J CLIN ONCOL, V19, P205, DOI 10.1200/JCO.2001.19.1.205; Hurst SA, 2003, BRIT MED J, V326, P271, DOI 10.1136/bmj.326.7383.271; Kane L., 2014, MEDSCAPE ETHICS RE 1; Kim SYH, 2016, JAMA PSYCHIAT, V73, P362, DOI 10.1001/jamapsychiatry.2015.2887; Kissane DW, 1998, LANCET, V352, P1097, DOI 10.1016/S0140-6736(98)05406-3; Kouwenhoven PSC, 2014, EUR J GEN PRACT, V20, P25, DOI 10.3109/13814788.2013.813014; Kouwenhoven PSC, 2013, PALLIATIVE MED, V27, P273, DOI 10.1177/0269216312448507; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; Lee W, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-2; Legemaate J, 2012, HAGUE ZONMW, V84; Legemaate J, 2013, EUR J HEALTH LAW, V20, P451, DOI 10.1163/15718093-12341298; Lerner BH, 2015, JAMA INTERN MED, V175, P1640, DOI 10.1001/jamainternmed.2015.4086; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Loefmark R, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-4; Louhiala P, 2006, J MED ETHICS, V32, P627, DOI 10.1136/jme.2006.016246; Mason B., 2015, ALLOW ME DIE; McCarthy J., 2014, 7 10 AM BACK EUTHANA; McCormack R, 2012, PALLIATIVE MED, V26, P23, DOI 10.1177/0269216311397688; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Muller-Busch H C, 2004, Med Health Care Philos, V7, P333; Onwuteaka-Philipsen B, 2012, 2 EVALUATION EUTHANA; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Oregon Public Health Division, 2016, OR RES DEATHS AG GRO; Parpa Efi, 2006, Am J Hosp Palliat Care, V23, P297, DOI 10.1177/1049909106290247; Parpa E, 2010, HEALTH POLICY, V97, P160, DOI 10.1016/j.healthpol.2010.04.008; Pennec S, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-25; Peretti-Watel P, 2003, J PALLIATIVE CARE, V19, P271, DOI 10.1177/082585970301900409; Pew Research Center, 2013, VIEWS END OF LIF MED; Pousset G, 2010, ARCH PEDIAT ADOL MED, V164, P547, DOI 10.1001/archpediatrics.2010.59; Regional Euthanasia Control Committees, 2015, ANN REP 2002 2015; Rich BA, 2002, PAIN MED, V3, P353, DOI 10.1046/j.1526-4637.2002.02056.x; Rich P., 2014, PHYS PERSPECTIVE END; Rietjens JAC, 2014, JAMA-J AM MED ASSOC, V312, P1258, DOI 10.1001/jama.2014.9876; Schaus Valerie, 2015, J Pharm Belg, P4; Schmidt TA, 1996, ACAD EMERG MED, V3, P938, DOI 10.1111/j.1553-2712.1996.tb03323.x; Seale C, 2009, PALLIATIVE MED, V23, P198, DOI 10.1177/0269216308102042; Smets T, 2011, J PAIN SYMPTOM MANAG, V41, P580, DOI 10.1016/j.jpainsymman.2010.05.015; Smets T, 2010, MED CARE, V48, P187, DOI 10.1097/MLR.0b013e3181bd4dde; Smith KA, 2015, J PAIN SYMPTOM MANAG, V49, P555, DOI 10.1016/j.jpainsymman.2014.06.010; Statistics Belgium, 2016, NUMB DEATHS BELG 200; Statistics Netherlands, 2016, DEC GEND AG; Steck N, 2014, INT J EPIDEMIOL, V43, P614, DOI 10.1093/ije/dyu010; Steck N, 2013, MED CARE, V51, P938, DOI 10.1097/MLR.0b013e3182a0f427; Suarez-Almazor ME, 2002, J CLIN ONCOL, V20, P2134, DOI 10.1200/JCO.2002.08.025; ten Cate K, 2015, J MED ETHICS, V41, P795, DOI 10.1136/medethics-2014-102562; Tomlinson E, 2015, INT J GERIATR PSYCH, V30, P10, DOI 10.1002/gps.4169; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Lee ML, 2005, J CLIN ONCOL, V23, P6607, DOI 10.1200/JCO.2005.14.308; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Van Wesemael Y, 2011, J PAIN SYMPTOM MANAG, V42, P721, DOI 10.1016/j.jpainsymman.2011.02.011; Van Wesemael Y, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-220; Van Wesemael Y, 2009, HEALTH SERV RES, V44, P2180, DOI 10.1111/j.1475-6773.2009.01042.x; Verhagen E, 2005, NEW ENGL J MED, V352, P959, DOI 10.1056/NEJMp058026; Vrakking AM, 2005, LANCET, V365, P1329, DOI 10.1016/S0140-6736(05)61030-6; Washington State Department of Health, 2016, VIT STAT DAT DEATH T; Weide MCJV, 2005, ARCH INTERN MED, V165, P1698, DOI 10.1001/archinte.165.15.1698; Willems DL, 2000, ARCH INTERN MED, V160, P63, DOI 10.1001/archinte.160.1.63; Yun YH, 2011, CAN MED ASSOC J, V183, pE673, DOI 10.1503/cmaj.110020; Ziegler S, 2007, BMJ-BRIT MED J, V334, P295, DOI 10.1136/bmj.39100.417072.BE	102	346	351	40	359	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2016	316	1					79	90		10.1001/jama.2016.8499	http://dx.doi.org/10.1001/jama.2016.8499			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DQ2MY	27380345				2023-01-03	WOS:000379037600021
J	Davis, MM; Gebremariam, A; Ayanian, JZ				Davis, Matthew M.; Gebremariam, Achamyeleh; Ayanian, John Z.			Changes in Insurance Coverage Among Hospitalized Nonelderly Adults After Medicaid Expansion in Michigan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Davis, Matthew M.; Ayanian, John Z.] Univ Michigan, Inst Healthcare Policy & Innovat, 300 NIB,6A18, Ann Arbor, MI 48109 USA; [Gebremariam, Achamyeleh] Univ Michigan Hlth Syst, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Davis, MM (corresponding author), Univ Michigan, Inst Healthcare Policy & Innovat, 300 NIB,6A18, Ann Arbor, MI 48109 USA.	mattdav@med.umich.edu						Ayanian JZ, 2013, NEW ENGL J MED, V369, P1773, DOI 10.1056/NEJMp1310910; DeLeire T, IMPACT INSURANCE EXP; Deloitte Development, COMM KENT MED EXP RE; Nikpay S, 2016, HEALTH AFFAIR, V35, P106, DOI 10.1377/hlthaff.2015.1144; State Health Reform Assistance Network, IMP MED EXP UNC CAR	5	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2016	315	23					2617	2618		10.1001/jama.2016.6303	http://dx.doi.org/10.1001/jama.2016.6303			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DP2GQ	27327805	Bronze			2023-01-03	WOS:000378306700025
J	Czyzewska, U; Siemionow, K; Zareba, I; Miltyk, W				Czyzewska, Urszula; Siemionow, Katarzyna; Zareba, Ilona; Miltyk, Wojciech			Proapoptotic Activity of Propolis and Their Components on Human Tongue Squamous Cell Carcinoma Cell Line (CAL-27)	PLOS ONE			English	Article							ORAL-CANCER; CHEMICAL-COMPOSITION; MASS-SPECTROMETRY; TEA POLYPHENOLS; CAFFEIC ACID; COLON-CANCER; NECK-CANCER; IN-VITRO; APOPTOSIS; FLAVONOIDS	Propolis has been used since ancient times in folk medicine. It is a popular medicine possessing a broad spectrum of biological activities. This material is one of the richest sources of polyphenolic compounds such as flavonoids and phenolic acids. The ethanolic extract of propolis (EEP) evokes antibacterial, antiviral, antifungal and anticancer properties. Due to pharmacological properties it is used in the commercial production of nutritional supplements. In this study, gas chromatography coupled with mass spectrometry (GC-MS) was used to quantify main polyphenols in EEPs. The effect of EEPs, individual EEPs components (chrysin, galangin, pinocembrin, caffeic acid, p-coumaric acid, ferulic acid) and their mixture on viability of human tongue squamous cell carcinoma cell line (CAL-27) as well as the molecular mechanisms of the process were examined. The results of MTTs assay demonstrated that EEP, polyphenols and mixture of polyphenolic compounds were cytotoxic for CAL-27 cells in a dose dependent manner. The mechanism of cytotoxicity induced by these components undergoes through apoptosis as detected by flow cytometry. The ethanolic extracts of propolis activated caspases -3, -8, -9. Mixture of polyphenols was found as the most potent inducer of apoptosis thorough both intrinsic and extrinsic pathway. Therefore, we suggest that anticancer properties of propolis is related to synergistic activity of its main components.	[Czyzewska, Urszula; Siemionow, Katarzyna; Miltyk, Wojciech] Med Univ Bialystok, Dept Pharmaceut Anal, Bialystok, Poland; [Zareba, Ilona] Med Univ Bialystok, Dept Med Chem, Bialystok, Poland	Medical University of Bialystok; Medical University of Bialystok	Czyzewska, U (corresponding author), Med Univ Bialystok, Dept Pharmaceut Anal, Bialystok, Poland.	urszula.czyzewska@umb.edu.pl	Frazao, Maria/O-4407-2016; Miltyk, Wojciech/P-6937-2018; Zareba, Ilona/T-6930-2018	Miltyk, Wojciech/0000-0001-5150-6093; Zareba, Ilona/0000-0002-7934-6973	Medical University of Bialystok as part of the OP DEP [POPW.01.03.00-20-008/09]; Medical University of Bialystok, Poland (KNOW) [124/KNOW/15]	Medical University of Bialystok as part of the OP DEP; Medical University of Bialystok, Poland (KNOW)	This study was conducted with the use of equipment purchased by Medical University of Bialystok as part of the OP DEP 2007-2013, Priority Axis I.3, contract No. POPW.01.03.00-20-008/09 and financially supported by the Medical University of Bialystok, Poland (KNOW Project No. 124/KNOW/15). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Cancer Society, 2015, CANC FACTS FIG 2015; [Anonymous], CANC POL 2012; Bankova VS, 2000, APIDOLOGIE, V31, P3, DOI 10.1051/apido:2000102; Barlak Y, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-74; Barnes L, 2005, PATHLOGY GENETICS HE; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chang YC, 2012, J AGR FOOD CHEM, V60, P8395, DOI 10.1021/jf302223g; Chen ZY, 2013, BANGL J PHARMACOL, V8, P255, DOI 10.3329/bjp.v8i3.14795; Czyzewska U, 2015, J MED FOOD, V18, P584, DOI 10.1089/jmf.2014.0069; Watanabe MAE, 2011, J PHARM PHARMACOL, V63, P1378, DOI 10.1111/j.2042-7158.2011.01331.x; Fan MJ, 2015, NUTR CANCER, V67, P327, DOI 10.1080/01635581.2015.990576; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Galeone C, 2015, INT J CANCER, V136, P904, DOI 10.1002/ijc.29044; Gardana C, 2007, J PHARMACEUT BIOMED, V45, P390, DOI 10.1016/j.jpba.2007.06.022; Gazzani G, 2012, CURR OPIN BIOTECH, V23, P153, DOI 10.1016/j.copbio.2011.09.003; Gomez-Caravaca AM, 2006, J PHARMACEUT BIOMED, V41, P1220, DOI 10.1016/j.jpba.2006.03.002; Guo SJ, 2011, ADV BIOM ENG, P98; Hashim YZHY, 2008, INT J CANCER, V122, P495, DOI 10.1002/ijc.23148; Iriti M, 2013, NUTRIENTS, V5, P2564, DOI 10.3390/nu5072564; Kademani D, 2007, MAYO CLIN PROC, V82, P878, DOI 10.4065/82.7.878; Kasala ER, 2015, TOXICOL LETT, V233, P214, DOI 10.1016/j.toxlet.2015.01.008; Kim JW, 2010, CANCER PREV RES, V3, P900, DOI 10.1158/1940-6207.CAPR-09-0131; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Kubina R, 2015, ADV CLIN EXP MED, V24, P203, DOI 10.17219/acem/31792; Kuntz S, 1999, EUR J NUTR, V38, P133, DOI 10.1007/s003940050054; Lin CL, 2012, INT J MOL SCI, V13, P6236, DOI 10.3390/ijms13056236; Lin J.-K., 2006, FLAVONOIDS NUTRACEUT; Mangalath U, 2014, J INT SOC PREV COMMU, V4, pS131, DOI 10.4103/2231-0762.149018; Markiewicz-Zukowska R, 2012, ADV MED SCI-POLAND, V57, P208, DOI 10.2478/v10039-012-0042-6; Prasad NR, 2011, MOL CELL BIOCHEM, V349, P11, DOI 10.1007/s11010-010-0655-7; Premratanachai Pongsathon, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P337, DOI 10.12980/APJTB.4.2014C1262; Rasul A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/379850; Roleira FMF, 2015, FOOD CHEM, V183, P235, DOI 10.1016/j.foodchem.2015.03.039; Sawicka D, 2012, FOLIA HISTOCHEM CYTO, V50, P25, DOI [10.5603/FHC.2012.0004, 10.2478/18693]; Sforcin JM, 2011, J ETHNOPHARMACOL, V133, P253, DOI 10.1016/j.jep.2010.10.032; Toreti VC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/697390; Torkin R, 2005, MOL CANCER THER, V4, P1; Turan I, 2015, TROP J PHARM RES, V14, P777, DOI 10.4314/tjpr.v14i5.5; Walle T, 2007, BIOCHEM PHARMACOL, V73, P1288, DOI 10.1016/j.bcp.2006.12.028	39	23	23	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2016	11	6							e0157091	10.1371/journal.pone.0157091	http://dx.doi.org/10.1371/journal.pone.0157091			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DO1TW	27281369	gold, Green Published, Green Submitted			2023-01-03	WOS:000377563000082
J	Zhang, WZ; Lu, JY; Chen, JZ; Zhai, TT; Huang, BT; Li, DR; Chen, CZ				Zhang, Wu-Zhe; Lu, Jia-Yang; Chen, Jian-Zhou; Zhai, Tian-Tian; Huang, Bao-Tian; Li, De-Rui; Chen, Chuang-Zhen			A Dosimetric Study of Using Fixed-Jaw Volumetric Modulated Arc Therapy for the Treatment of Nasopharyngeal Carcinoma with Cervical Lymph Node Metastasis	PLOS ONE			English	Article							RADIOTHERAPY; TOMOTHERAPY; IMRT	Purpose To study the dosimetric difference between fixed-jaw volumetric modulated radiotherapy (FJ-VMAT) and large-field volumetric modulated radiotherapy (LF-VMAT) for nasopharyngeal carcinoma (NPC) with cervical lymph node metastasis. Methods Computed tomography (CT) datasets of 10 NPC patients undergoing chemoradiotherapy were used to generate LF-VMAT and FJ-VMAT plans in the Eclipse version 10.0 treatment planning system. These two kinds of plans were then compared with respect to planning-target-volume (PTV) coverage, conformity index (CI), homogeneity index (HI), organ-at-risk sparing, monitor units (MUs) and treatment time (TT). Results The FJ-VMAT plans provided lower D-2% of PGTVnd (PTV of lymph nodes), PTV1 (high-risk PTV) and PTV2 (low-risk PTV) than did the LF-VMAT plans, whereas no significant differences were observed in PGTVnx (PTV of primary nasopharyngeal tumor). The FJ-VMAT plans provided lower doses delivered to the planning organ at risk (OAR) volumes (PRVs) of both brainstem and spinal cord, both parotid glands and normal tissue than did the LF-VMAT plans, whereas no significant differences were observed with respect to the oral cavity and larynx. The MUs of the FJ-VMAT plans (683 +/- 87) were increased by 22% +/- 12% compared with the LF-VMAT plans (559 +/- 62). In terms of the TT, no significant difference was found between the two kinds of plans. Conclusions FJ-VMAT was similar or slightly superior to LF-VMAT in terms of PTV coverage and was significantly superior in terms of OAR sparing, at the expense of increased MUs.	[Zhang, Wu-Zhe; Lu, Jia-Yang; Chen, Jian-Zhou; Zhai, Tian-Tian; Huang, Bao-Tian; Li, De-Rui; Chen, Chuang-Zhen] Shantou Univ, Coll Med, Canc Hosp, Dept Radiat Oncol, Shantou, Guangdong, Peoples R China	Shantou University	Chen, CZ (corresponding author), Shantou Univ, Coll Med, Canc Hosp, Dept Radiat Oncol, Shantou, Guangdong, Peoples R China.	stccz@139.com	Chen, Jianzhou/AAW-1443-2021		Shantou University Medical College Clinical Research Enhancement Initiative [201424]; Shantou Medical Science and Technology Planning Project [(2015) 123]	Shantou University Medical College Clinical Research Enhancement Initiative; Shantou Medical Science and Technology Planning Project	This work was sponsored by Shantou University Medical College Clinical Research Enhancement Initiative (Grant No. 201424) and Shantou Medical Science and Technology Planning Project [Grant No. (2015) 123]. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen JY, 2014, MED DOSIM, V39, P325, DOI 10.1016/j.meddos.2014.05.006; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Huang B, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20140183; Lee FKH, 2014, MED DOSIM, V39, P44, DOI 10.1016/j.meddos.2013.09.004; Lee TF, 2008, RADIOTHER ONCOL, V89, P89, DOI 10.1016/j.radonc.2008.05.010; Lu SH, 2012, RADIOTHER ONCOL, V104, P324, DOI 10.1016/j.radonc.2011.11.017; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Srivastava SP, 2011, MED DOSIM, V36, P6, DOI 10.1016/j.meddos.2009.10.002; Vanetti E, 2009, RADIOTHER ONCOL, V92, P111, DOI 10.1016/j.radonc.2008.12.008; Verbakel WFAR, 2009, INT J RADIAT ONCOL, V74, P252, DOI 10.1016/j.ijrobp.2008.12.033; White P, 2013, J RADIAT RES, V54, P532, DOI 10.1093/jrr/rrs111	11	4	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2016	11	5							e0156675	10.1371/journal.pone.0156675	http://dx.doi.org/10.1371/journal.pone.0156675			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN2GV	27231871	Green Submitted, gold, Green Published			2023-01-03	WOS:000376883000052
J	Oliver, D				Oliver, David			More older patients are stuck in hospitals	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Healthwatch England, 2015, SPEC INQ SAF HOM WHA; House of Commons Committee of Public Accounts, 2016, SUST FIN PERF AC HOS; Humphries R, 2015, HLTH SERV J; Kings Fund, 2015, SOC CAR BUDG CUTS DA; National Audit Office, 2016, HC18 SESS 2016 17; *NHS BENCHM, 2015, OLD PEOPL AC CAR SET; NHS Benchmarking, 2015, NAT AUD INT CAR SUMM; NHS Confederation, 2010, DEAL DOWNT US EV; Thompson J, 2015, KINGS FUND BLOG 1109	9	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2016	353								i2948	10.1136/bmj.i2948	http://dx.doi.org/10.1136/bmj.i2948			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN3CL	27230037	Bronze, Green Published			2023-01-03	WOS:000376939900004
